<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70717" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12481210</article-id><article-id pub-id-type="pmcid-ver">PMC12481210.1</article-id><article-id pub-id-type="pmcaid">12481210</article-id><article-id pub-id-type="pmcaiid">12481210</article-id><article-id pub-id-type="pmid">41025379</article-id><article-id pub-id-type="doi">10.1002/alz.70717</article-id><article-id pub-id-type="publisher-id">ALZ70717</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Plasma p&#8208;tau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer's disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinic</article-title><alt-title alt-title-type="left-running-head">ERATNE <sc>et&#160;al</sc>.</alt-title></title-group><contrib-group><contrib id="alz70717-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Eratne</surname><given-names initials="D">Dhamidhu</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3226-7645</contrib-id><xref rid="alz70717-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70717-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>deratne@unimelb.edu.au</email></address></contrib><contrib id="alz70717-cr-0002" contrib-type="author"><name name-style="western"><surname>Kang</surname><given-names initials="M">Matthew</given-names></name><xref rid="alz70717-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70717-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70717-cr-0003" contrib-type="author"><name name-style="western"><surname>Malpas</surname><given-names initials="CB">Charles B</given-names></name><xref rid="alz70717-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz70717-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70717-cr-0004" contrib-type="author"><name name-style="western"><surname>Dang</surname><given-names initials="C">Christa</given-names></name><xref rid="alz70717-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="alz70717-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="alz70717-cr-0005" contrib-type="author"><name name-style="western"><surname>Lewis</surname><given-names initials="C">Courtney</given-names></name><xref rid="alz70717-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="alz70717-cr-0006" contrib-type="author"><name name-style="western"><surname>Bhalala</surname><given-names initials="OG">Oneil G</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4412-7009</contrib-id><xref rid="alz70717-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="alz70717-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="alz70717-cr-0007" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="QX">Qiao&#8208;Xin</given-names></name><xref rid="alz70717-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="alz70717-cr-0008" contrib-type="author"><name name-style="western"><surname>Collins</surname><given-names initials="S">Steven</given-names></name><xref rid="alz70717-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="alz70717-cr-0009" contrib-type="author"><name name-style="western"><surname>Masters</surname><given-names initials="CL">Colin L</given-names></name><xref rid="alz70717-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="alz70717-cr-0010" contrib-type="author"><name name-style="western"><surname>Loi</surname><given-names initials="SM">Samantha M</given-names></name><xref rid="alz70717-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70717-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70717-cr-0011" contrib-type="author"><name name-style="western"><surname>Santillo</surname><given-names initials="AF">Alexander F</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9717-0820</contrib-id><xref rid="alz70717-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="alz70717-cr-0012" contrib-type="author"><name name-style="western"><surname>Blennow</surname><given-names initials="K">Kaj</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1890-4193</contrib-id><xref rid="alz70717-aff-0012" ref-type="aff">
<sup>12</sup>
</xref><xref rid="alz70717-aff-0013" ref-type="aff">
<sup>13</sup>
</xref><xref rid="alz70717-aff-0014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib id="alz70717-cr-0013" contrib-type="author"><name name-style="western"><surname>Zetterberg</surname><given-names initials="H">Henrik</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3930-4354</contrib-id><xref rid="alz70717-aff-0013" ref-type="aff">
<sup>13</sup>
</xref><xref rid="alz70717-aff-0015" ref-type="aff">
<sup>15</sup>
</xref><xref rid="alz70717-aff-0016" ref-type="aff">
<sup>16</sup>
</xref><xref rid="alz70717-aff-0017" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib id="alz70717-cr-0014" contrib-type="author"><name name-style="western"><surname>Velakoulis</surname><given-names initials="D">Dennis</given-names></name><xref rid="alz70717-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70717-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70717-cr-0015" contrib-type="author"><collab collab-type="authors">And The MiND Study Group</collab></contrib></contrib-group><aff id="alz70717-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Neuropsychiatry Centre</named-content>
<institution>Royal Melbourne Hospital</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz70717-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry</named-content>
<institution>University of Melbourne</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz70717-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine (Royal Melbourne Hospital)</named-content>
<institution>University of Melbourne</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz70717-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Melbourne School of Psychological Sciences</named-content>
<institution>University of Melbourne</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz70717-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>National Ageing Research Institute</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz70717-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of General Practice</named-content>
<institution>University of Melbourne Victoria</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz70717-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Institute of Health and Wellbeing</named-content>
<institution>Federation University</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz70717-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Royal Melbourne Hospital</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz70717-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Genetics and Gene Regulation Division</named-content>
<institution>The Walter and Eliza Hall Institute of Medical Research</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz70717-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">National Dementia Diagnostics Laboratory</named-content>
<institution>The Florey</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="alz70717-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Clinical Memory Research Unit</named-content>
<named-content content-type="organisation-division">Department of Clinical Sciences</named-content>
<named-content content-type="organisation-division">Faculty of Medicine</named-content>
<institution>Lund University</institution>
<city>Lund</city>
<country country="SE">Sweden</country>
</aff><aff id="alz70717-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Institute. of Neuroscience and Physiology</named-content>
<institution>University of Gothenburg</institution>
<city>M&#246;lndal</city>
<country country="SE">Sweden</country>
</aff><aff id="alz70717-aff-0013">
<label>
<sup>13</sup>
</label>
<named-content content-type="organisation-division">Clinical Neurochemistry Laboratory</named-content>
<institution>Sahlgrenska University Hospital</institution>
<city>M&#246;lndal</city>
<country country="SE">Sweden</country>
</aff><aff id="alz70717-aff-0014">
<label>
<sup>14</sup>
</label>
<named-content content-type="organisation-division">Neurodegenerative Disorder Research Center</named-content>
<named-content content-type="organisation-division">Division of Life Sciences and Medicine</named-content>
<named-content content-type="organisation-division">and Department of Neurology</named-content>
<named-content content-type="organisation-division">Institute on Aging and Brain Disorders</named-content>
<institution>University of Science and Technology of China and First Affiliated Hospital of USTC</institution>
<city>Hefei</city>
<named-content content-type="country-part">Anhui</named-content>
<country country="CN">P.R. China</country>
</aff><aff id="alz70717-aff-0015">
<label>
<sup>15</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry and Neurochemistry</named-content>
<named-content content-type="organisation-division">Institute of Neuroscience and Physiology</named-content>
<institution>the Sahlgrenska Academy at the University of Gothenburg</institution>
<city>M&#246;lndal</city>
<country country="SE">Sweden</country>
</aff><aff id="alz70717-aff-0016">
<label>
<sup>16</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology and Laboratory Medicine</named-content>
<named-content content-type="organisation-division">University of Wisconsin School of Medicine and Public Health</named-content>
<institution>University of Wisconsin&#8208;Madison</institution>
<city>Madison</city>
<named-content content-type="country-part">Wisconsin</named-content>
<country country="US">USA</country>
</aff><aff id="alz70717-aff-0017">
<label>
<sup>17</sup>
</label>
<named-content content-type="organisation-division">Wisconsin Alzheimer's Disease Research Center</named-content>
<named-content content-type="organisation-division">University of Wisconsin School of Medicine and Public Health</named-content>
<institution>University of Wisconsin&#8208;Madison</institution>
<city>Madison</city>
<named-content content-type="country-part">Wisconsin</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Dhamidhu Eratne, Neuropsychiatry Centre, The Royal Melbourne Hospital, 300 Grattan St, Parkville VIC, Melbourne, Australia.<break/> Email: <email>deratne@unimelb.edu.au</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="80">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70717</elocation-id><history><date date-type="rev-recd"><day>18</day><month>8</month><year>2025</year></date><date date-type="received"><day>10</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 09:26:11.207"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70717.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70717.pdf"/><abstract><title>Abstract</title><sec id="alz70717-sec-0010"><title>INTRODUCTION</title><p>Plasma biomarkers offer promise for improving the diagnosis of Alzheimer's disease (AD) and differentiating AD and other neurodegenerative disorders (NDs) like frontotemporal dementia (FTD) from primary psychiatric disorders (PPDs), particularly in younger patients.</p></sec><sec id="alz70717-sec-0020"><title>METHODS</title><p>In this prospective study, we investigated plasma phosphorylated tau 217 (p&#8208;tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) in 341 unselected participants from a neuropsychiatry memory clinic, including AD (<italic toggle="yes">n</italic>&#160;=&#160;40), behavioral variant FTD (bvFTD) (<italic toggle="yes">n</italic>&#160;=&#160;15), PPD (<italic toggle="yes">n</italic>&#160;=&#160;69), other NDs, and controls.</p></sec><sec id="alz70717-sec-0030"><title>RESULTS</title><p>Plasma p&#8208;tau217 showed strong diagnostic performance for distinguishing AD from bvFTD (96% accuracy) and PPD (93% accuracy). NfL best distinguished all NDs from PPD, while GFAP did not bring additional value. Biomarker profiles using predefined cut&#8208;offs and age&#8208;adjusted z&#8208;scores further clarified group differences.</p></sec><sec id="alz70717-sec-0040"><title>DISCUSSION</title><p>Plasma p&#8208;tau217 and NfL have strong diagnostic utility in real&#8208;world, diagnostically complex cohorts. These findings support implementation of scalable blood&#8208;based biomarkers to improve early and accurate diagnosis in memory clinical settings.</p></sec><sec id="alz70717-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70717-list-0001"><list-item><p>Plasma p&#8208;tau217 was significantly elevated in AD compared to other disorders.</p></list-item><list-item><p>P&#8208;tau217 distinguished AD from bvFTD with high accuracy.</p></list-item><list-item><p>P&#8208;tau217 distinguished AD from PPDs with high accuracy.</p></list-item><list-item><p>NfL/p&#8208;tau217 ratio and GFAP added limited diagnostic value compared to p&#8208;tau217 and NfL.</p></list-item><list-item><p>Findings support blood biomarkers in younger, real&#8208;world clinical cohorts.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70717-kwd-0001">age&#8208;adjusted reference ranges</kwd><kwd id="alz70717-kwd-0002">Alzheimer's disease</kwd><kwd id="alz70717-kwd-0003">blood&#8208;based biomarkers</kwd><kwd id="alz70717-kwd-0004">diagnostic accuracy</kwd><kwd id="alz70717-kwd-0005">frontotemporal dementia</kwd><kwd id="alz70717-kwd-0006">GFAP</kwd><kwd id="alz70717-kwd-0007">memory clinic</kwd><kwd id="alz70717-kwd-0008">neurodegeneration</kwd><kwd id="alz70717-kwd-0009">neurofilament light chain</kwd><kwd id="alz70717-kwd-0010">plasma biomarkers</kwd><kwd id="alz70717-kwd-0011">primary psychiatric disorders</kwd><kwd id="alz70717-kwd-0012">prospective cohort</kwd><kwd id="alz70717-kwd-0013">psychiatric misdiagnosis</kwd><kwd id="alz70717-kwd-0014">p&#8208;tau217</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Swedish Research</institution></institution-wrap></funding-source><award-id>2017&#8208;00915</award-id><award-id>2022&#8208;00732</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Swedish Alzheimer Foundation</institution></institution-wrap></funding-source><award-id>AF&#8208;930351</award-id><award-id>AF&#8208;939721</award-id><award-id>AF&#8208;968270</award-id><award-id>AF&#8208;994551</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Hj&#228;rnfonden, Sweden</institution></institution-wrap></funding-source><award-id>ALZ2022&#8208;0006</award-id><award-id>FO2024&#8208;0048&#8208;TK&#8208;130</award-id><award-id>FO2024&#8208;0048&#8208;HK&#8208;24</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>ALF agreement</institution></institution-wrap></funding-source><award-id>ALFGBG&#8208;965240</award-id><award-id>ALFGBG&#8208;1006418</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>European Union Joint Programme for Neurodegenerative Disorders</institution></institution-wrap></funding-source><award-id>JPND2019&#8208;466&#8208;236</award-id></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>Alzheimer's Association 2021 Zenith Award</institution></institution-wrap></funding-source><award-id>ZEN&#8208;21&#8208;848495</award-id></award-group><award-group id="funding-0007"><funding-source><institution-wrap><institution>Alzheimer's Association 2022&#8208;2025</institution></institution-wrap></funding-source><award-id>SG&#8208;23&#8208;1038904 QC</award-id></award-group><award-group id="funding-0008"><funding-source><institution-wrap><institution>the Swedish Research Council</institution></institution-wrap></funding-source><award-id>2023&#8208;00356</award-id><award-id>2022&#8208;01018</award-id><award-id>2019&#8208;02397</award-id></award-group><award-group id="funding-0009"><funding-source><institution-wrap><institution>European Union's Horizon Europe</institution></institution-wrap></funding-source><award-id>101053962</award-id></award-group><award-group id="funding-0010"><funding-source><institution-wrap><institution>Swedish State Support for Clinical Research</institution></institution-wrap></funding-source><award-id>ALFGBG&#8208;71320</award-id></award-group><award-group id="funding-0011"><funding-source><institution-wrap><institution>Alzheimer Drug Discovery Foundation (ADDF)</institution></institution-wrap></funding-source><award-id>201809&#8208;2016862</award-id></award-group><award-group id="funding-0012"><funding-source><institution-wrap><institution>AD Strategic Fund and the Alzheimer's Association</institution></institution-wrap></funding-source><award-id>ADSF&#8208;21&#8208;831376&#8208;C</award-id><award-id>ADSF&#8208;21&#8208;831381&#8208;C</award-id><award-id>ADSF&#8208;21&#8208;831377&#8208;C</award-id><award-id>ADSF&#8208;24&#8208;1284328&#8208;C</award-id></award-group><award-group id="funding-0013"><funding-source><institution-wrap><institution>European Union's Horizon Europe Research and Innovation Programme</institution></institution-wrap></funding-source></award-group><award-group id="funding-0014"><funding-source><institution-wrap><institution>NEuroBioStand</institution></institution-wrap></funding-source><award-id>22HLT07</award-id></award-group><award-group id="funding-0015"><funding-source><institution-wrap><institution>Erling&#8211;Persson Family Foundation</institution></institution-wrap></funding-source><award-id>FO2022&#8208;0270</award-id></award-group><award-group id="funding-0016"><funding-source><institution-wrap><institution>European Union's Horizon 2020</institution></institution-wrap></funding-source><award-id>860197</award-id></award-group><award-group id="funding-0017"><funding-source><institution-wrap><institution>European Union Joint Programme&#8211;Neurodegenerative Disease Research</institution></institution-wrap></funding-source><award-id>JPND2021&#8208;00694</award-id></award-group><award-group id="funding-0018"><funding-source><institution-wrap><institution>UK Dementia Research Institute</institution><institution-id institution-id-type="doi">10.13039/501100017510</institution-id></institution-wrap></funding-source><award-id>UKDRI&#8208;1003</award-id></award-group><award-group id="funding-0019"><funding-source><institution-wrap><institution>AFS</institution></institution-wrap></funding-source><award-id>ALF 2022 YF 0017</award-id></award-group></funding-group><counts><fig-count count="6"/><table-count count="1"/><page-count count="15"/><word-count count="8202"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:30.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70717-cite-0001"><string-name name-style="western"><surname>Eratne</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Malpas</surname><given-names>CB</given-names></string-name>, et&#160;al. <article-title>Plasma p&#8208;tau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer's disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinic</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70717</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70717</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz70717-sec-0060"><label>1</label><title>BACKGROUND</title><p>Blood&#8208;based biomarkers show great potential to transform diagnosis and clinical care of patients presenting with cognitive, psychiatric, and neurological symptoms. Their potential includes improving early and accurate diagnosis of Alzheimer's disease (AD) and resolving real&#8208;world diagnostic challenges, such as distinguishing AD from other neurodegenerative disorders (NDs) like behavioral variant frontotemporal dementia (bvFTD) and from common mimics such as primary psychiatric disorders (PPDs).<xref rid="alz70717-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70717-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70717-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70717-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70717-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="alz70717-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Early, accurate diagnosis is increasingly important with the emergence of disease&#8208;specific treatments, such as monoclonal antibodies targeting amyloid beta.</p><p>Two of the most promising biomarkers are plasma phosphorylated tau 217 (p&#8208;tau217) and neurofilament light chain (NfL) protein. P&#8208;tau217 shows strong diagnostic performance and specificity to distinguish AD from non&#8208;AD disorders (including non&#8208;AD dementias and PPD).<xref rid="alz70717-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="alz70717-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz70717-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="alz70717-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Within AD and control cohorts, plasma levels of p&#8208;tau217 correlate with tau positron emission tomography (PET) pathology<xref rid="alz70717-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> and tangle load at autopsy<xref rid="alz70717-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> and are elevated in disorders with tangles but without amyloid plaques,<xref rid="alz70717-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> supporting its reflection of tau phosphorylation and pathology. NfL, a non&#8208;specific marker of neurodegeneration and acute neuronal injury, particularly in long myelinated axons, distinguishes neurodegenerative disorders (NDs) from ND mimics, including PPDs and non&#8208;NDs,<xref rid="alz70717-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70717-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70717-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70717-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> and has utility in clinical settings.<xref rid="alz70717-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70717-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="alz70717-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="alz70717-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70717-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Glial fibrillary acidic protein (GFAP), a marker of astrocytic activation and neuroinflammation, is an additional biomarker of interest in a range of disorders.<xref rid="alz70717-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70717-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="alz70717-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="alz70717-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="alz70717-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="alz70717-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="alz70717-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70717-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> However, the utility of GFAP for the clinical differentiation between AD, non&#8208;AD NDs, and PPDs, especially when compared to p&#8208;tau217 and NfL is not yet clear.</p><p>We previously published diagnostic performance, cut&#8208;offs, and reference ranges for plasma p&#8208;tau217 and NfL,<xref rid="alz70717-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70717-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70717-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70717-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="alz70717-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="alz70717-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> but we have not investigated their combined use. Furthermore, while we and others have published data showing the superiority of NfL compared to GFAP to distinguish bvFTD from PPDs,<xref rid="alz70717-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="alz70717-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> we have not yet investigated all three, p&#8208;tau217, NfL, and GFAP, in a younger real&#8208;world clinical neuropsychiatric cohort with diverse NDs and PPDs. Some studies have investigated combinations of these markers. Benussi et&#160;al. investigated NfL, p&#8208;tau217, NfL/p&#8208;tau217 ratios, and other biomarkers in 374 participants (97 AD, 278 FTD).<xref rid="alz70717-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> They found strong diagnostic performance of p&#8208;tau217 and slightly superior performance of NfL/p&#8208;tau217 to distinguish between AD and FTD. However, they lacked a PPD group, which is critical to appreciate the use of biomarkers for bvFTD diagnosis. Rousset et&#160;al. assessed p&#8208;tau217 and NfL in an unselected memory clinic cohort, showing strong utility of p&#8208;tau217 for AD diagnosis and describing biomarker profiles (high/low p&#8208;tau217 and NfL) across clinical groups.<xref rid="alz70717-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> To our knowledge, no study to date has jointly investigated p&#8208;tau217, NfL, GFAP, and biomarker profiles, with a specific focus on AD, bvFTD, PPD, in younger people, where differential diagnoses, diagnostic uncertainty, misdiagnosis, and delay are greater.<xref rid="alz70717-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70717-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="alz70717-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="alz70717-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Further research is needed to properly establish the roles of single and combination biomarkers in real&#8208;world clinical settings with diverse neuropsychiatric cohorts.</p><p>The primary aim of this study was to compare levels and diagnostic performances of plasma p&#8208;tau217, NfL, NfL/p&#8208;tau217 ratio, and GFAP for distinguishing between AD, bvFTD, and PPDs. We hypothesized that combining p&#8208;tau217 and NfL would improve diagnostic accuracy compared to either alone. We also aimed to describe p&#8208;tau217/NfL biomarker profiles of AD pathology and neuronal injury (e.g., low AD/low neuronal injury, high AD/high neuronal injury) in an unselected population of patients from a neuropsychiatry memory clinic. We focused on p&#8208;tau217 and NfL using our previously described cut&#8208;off for plasma p&#8208;tau217<xref rid="alz70717-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> and age&#8208;adjusted <italic toggle="yes">z</italic>&#8208;score reference range models for plasma NfL.<xref rid="alz70717-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="alz70717-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> We wanted to explore whether GFAP could improve any distinctions, for example, between bvFTD and PPDs. Although some studies reported age&#8208;binned reference ranges for GFAP in serum<xref rid="alz70717-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> and plasma,<xref rid="alz70717-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> we are unaware of any studies that have described GFAP reference ranges using continuous modeling to derive precise age&#8208;adjusted percentiles and <italic toggle="yes">z</italic>&#8208;scores, as we did for NfL. As an exploratory aim, we applied a novel <italic toggle="yes">z</italic>&#8208;score model for plasma GFAP to define biomarker profiles reflecting AD pathology, neuronal injury, and neuroinflammation (p&#8208;tau217/NfL/GFAP).</p></sec><sec id="alz70717-sec-0070"><label>2</label><title>METHODS</title><p>The current study included participants prospectively recruited between June 2019 and April 2023 who had provided a blood sample for biomarker analysis. This is a follow&#8208;up to our previous study cohort in which we investigated plasma and cerebrospinal fluid (CSF) NfL.<xref rid="alz70717-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> In the current study, we included participants who had plasma p&#8208;tau217, NfL, and GFAP biomarker results available. In the current study the focus was on AD, bvFTD, and PPD diagnostic groups, with comparator groups being control participants and other NDs (both described in the previous study). Data were available in the current study for additional comparator groups (not previously described): people with mild cognitive impairment (MCI) and people with presymptomatic genetic NDs. The bvFTD group included patients meeting diagnostic criteria for possible bvFTD. The participants in this study did not overlap with our previous study on NfL and GFAP in bvFTD, mood, and psychotic disorders.<xref rid="alz70717-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70717-sec-0080"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70717-list-0002"><list-item><p>
<bold>Systematic review</bold>: We reviewed the PubMed literature on plasma p&#8208;tau217, NfL, and GFAP in AD, FTD, and PPDs. Although several studies support the individual diagnostic value of p&#8208;tau217 and NfL, few examined all three biomarkers together in real&#8208;world, diagnostically heterogeneous clinical cohorts, including PPDs.</p></list-item><list-item><p>
<bold>Interpretation</bold>: This prospective study demonstrates the strong diagnostic performance of plasma p&#8208;tau217 in distinguishing AD from FTD and PPDs and other non&#8208;AD disorders and confirms NfL as a useful marker of neurodegeneration. GFAP added limited value. These findings add to growing evidence on the clinical application of blood&#8208;based biomarkers in younger and diagnostically complex populations.</p></list-item><list-item><p>
<bold>Future directions</bold>: Future research should validate these findings in larger, more diverse cohorts, develop multimodal diagnostic algorithms, and evaluate the clinical utility and cost&#8208;effectiveness of implementing blood biomarker testing in psychiatric, primary care, and memory clinic settings.</p></list-item></list>
</p></sec></boxed-text><p>Participants were recruited from the Neuropsychiatry Centre at The Royal Melbourne Hospital, a quaternary service receiving referrals for diagnostically complex cases from primary care and other specialist services within Australia. Patients, as part of routine clinical care through the Neuropsychiatry Centre, received comprehensive multidisciplinary assessments and multimodal investigations, including CSF AD biomarker analysis, with gold standard consensus diagnosis based on established diagnostic criteria, as previously described in detail.<xref rid="alz70717-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70717-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70717-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Diagnostic group categorization was determined based on the most recent diagnosis, at longitudinal follow&#8208;up, based on established diagnostic criteria, blinded to plasma biomarker levels, as previously described.<xref rid="alz70717-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70717-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70717-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Control participants were people recruited from the community. Cognitive screening data are still being collected and not yet available for this study; however, no control participants had symptoms or diagnoses of neurological or NDs and no active psychiatric symptoms or conditions.</p><p>EDTA plasma samples were collected during patients&#8217; diagnostic work&#8208;up and at first visit for community controls. Samples were stored at &#8722;80&#176;C. Plasma NfL and GFAP were measured using N2PB kits on a Quanterix Single molecule array (Simoa) HD&#8208;X analyzer, according to the manufacturer's instructions (Quanterix Corp., Billerica, MA, USA). Plasma p&#8208;tau217 was measured using an in&#8208;house University of Gothenburg (UGOT) p&#8208;tau217 assay, as previously described in detail.<xref rid="alz70717-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> The measurements were performed in one round of experiments using one batch of reagents by analysts blinded to clinical data and diagnoses, thereby reducing potential batch effects.</p><p>This study, part of the Markers in Neuropsychiatric Disorders Study (The MiND Study, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://themindstudy.org" ext-link-type="uri">https://themindstudy.org</ext-link>), was approved by the human research ethics committee at Melbourne Health (2016.038, 2017.090, 2018.371, 2020.142).</p><sec id="alz70717-sec-0090"><label>2.1</label><title>Statistical analyses</title><p>Statistical analyses were performed using R version 4.5.0 (2025&#8208;04&#8208;11). Biomarker levels in different groups were compared using standardized bootstrapped general linear models (GLMs), with age at blood sample and sex as additional covariates. Receiver operating characteristic (ROC) curve analyses were then performed to investigate diagnostic utility between different combinations of groups. Bootstrapped differences in area under the curve (AUC) were used to compare ROC curves. Optimal cut&#8208;offs were selected based on Youden's <italic toggle="yes">J</italic> statistic. Additional diagnostic test parameters were computed: positive and negative likelihood ratios, positive and negative predictive values, overall accuracy, and diagnostic odds ratio. Additional sensitivity analyses were performed: excluding extreme outliers, excluding patients with Creutzfeldt&#8211;Jakob disease (CJD), and performing all GLMs with weight included as a covariate. As results were similar, the results excluding weight and including outliers and patients with CJD were presented to maximize the sample sizes for analyses and presented results (since not all participants had weight data).</p><p>We focused on describing p&#8208;tau217 and NfL biomarker profiles. These were low p&#8208;tau217/low NfL (a low AD pathology and low neuronal injury profile &#8211; a &#8220;normal&#8221; profile) and abnormal profiles: low p&#8208;tau217/high NfL (low AD pathology but elevated neuronal injury), high p&#8208;tau217/low NfL (AD pathology but low neuronal injury), and high p&#8208;tau217/high NfL (high AD pathology and high neuronal injury). Plasma p&#8208;tau217 and NfL biomarker levels were dichotomized in to &#8220;high&#8221; and &#8220;low&#8221; based on our previously published data and cut&#8208;offs that used the same assays.<xref rid="alz70717-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70717-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> For p&#8208;tau217, we used a cut&#8208;off of 2.35, which was optimal at distinguishing AD from non&#8208;AD, as previously described and published.<xref rid="alz70717-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> For plasma NfL, given the strong non&#8208;linear association with age, we used age&#8208;based percentiles and <italic toggle="yes">z</italic>&#8208;scores derived from the generalized additive models for location, scale, and shape (GAMLSS) model of a large reference control cohort that we developed, previously described and published,<xref rid="alz70717-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> defining the 95th percentile as the cut&#8208;off between high and low. For this study, we created a novel age&#8208;adjusted GFAP reference range model using (GAMLSS) using this study's control group. This allowed us to derive precise age&#8208;based percentiles and <italic toggle="yes">z</italic>&#8208;scores and thus more precise categorization, again given the significant strong and non&#8208;linear association with age compared to coarse age&#8208;binned cut&#8208;offs. The 95th percentile was defined as the cut&#8208;off for high and low GFAP levels.</p></sec></sec><sec id="alz70717-sec-0100"><label>3</label><title>RESULTS</title><p>The final cohort consisted of 341 participants: 40 with AD (median age 62 years, 53% female), 15 with bvFTD (median age 57 years, 27% female), and 69 with PPDs (median age 55 years, 48% female). There were 119 controls (median age 63, 74% female), and in the additional comparator groups: 67 with other NDs, 13 with MCI, and 18 with presymptomatic genetic NDs (see Table&#160;<xref rid="alz70717-tbl-0001" ref-type="table">1</xref> for full details).</p><table-wrap position="float" id="alz70717-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Study cohort details and biomarker levels.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>
</th><th align="left" rowspan="1" colspan="1">
<p>AD</p>
<p>
<italic toggle="yes">N</italic> = 40<xref rid="alz70717-tbl1-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</p>
</th><th align="left" rowspan="1" colspan="1">
<p>bvFTD</p>
<p>
<italic toggle="yes">N</italic> = 15<xref rid="alz70717-tbl1-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</p>
</th><th align="left" rowspan="1" colspan="1">
<p>PPD</p>
<p>
<italic toggle="yes">N</italic> = 69<xref rid="alz70717-tbl1-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Control</p>
<p>
<italic toggle="yes">N</italic> = 119<xref rid="alz70717-tbl1-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Other ND</p>
<p>
<italic toggle="yes">N</italic> = 67<xref rid="alz70717-tbl1-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</p>
</th><th align="left" rowspan="1" colspan="1">
<p>MCI</p>
<p>
<italic toggle="yes">N</italic> = 13<xref rid="alz70717-tbl1-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Presymptomatic genetic ND</p>
<p>
<italic toggle="yes">N</italic> = 18<xref rid="alz70717-tbl1-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</p>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">341</td><td align="char" rowspan="1" colspan="1">62 (58, 65)</td><td align="char" rowspan="1" colspan="1">57 (56, 62)</td><td align="char" rowspan="1" colspan="1">55 (45, 62)</td><td align="char" rowspan="1" colspan="1">63 (55, 70)</td><td align="char" rowspan="1" colspan="1">61 (45, 67)</td><td align="char" rowspan="1" colspan="1">65 (56, 67)</td><td align="char" rowspan="1" colspan="1">51 (43, 62)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1">341</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">21/40 (53%)</td><td align="char" rowspan="1" colspan="1">4/15 (27%)</td><td align="char" rowspan="1" colspan="1">33/69 (48%)</td><td align="char" rowspan="1" colspan="1">88/119 (74%)</td><td align="char" rowspan="1" colspan="1">29/67 (43%)</td><td align="char" rowspan="1" colspan="1">3/13 (23%)</td><td align="char" rowspan="1" colspan="1">13/18 (72%)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">19/40 (48%)</td><td align="char" rowspan="1" colspan="1">11/15 (73%)</td><td align="char" rowspan="1" colspan="1">36/69 (52%)</td><td align="char" rowspan="1" colspan="1">31/119 (26%)</td><td align="char" rowspan="1" colspan="1">38/67 (57%)</td><td align="char" rowspan="1" colspan="1">10/13 (77%)</td><td align="char" rowspan="1" colspan="1">5/18 (28%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight</td><td align="left" rowspan="1" colspan="1">270</td><td align="char" rowspan="1" colspan="1">73 (59, 83)</td><td align="char" rowspan="1" colspan="1">84 (63, 101)</td><td align="char" rowspan="1" colspan="1">84 (73, 99)</td><td align="char" rowspan="1" colspan="1">75 (65, 85)</td><td align="char" rowspan="1" colspan="1">75 (65, 88)</td><td align="char" rowspan="1" colspan="1">84 (78, 90)</td><td align="char" rowspan="1" colspan="1">79 (70, 98)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Unknown</td><td align="left" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1">15</td><td align="char" rowspan="1" colspan="1">2</td><td align="char" rowspan="1" colspan="1">14</td><td align="char" rowspan="1" colspan="1">16</td><td align="char" rowspan="1" colspan="1">12</td><td align="char" rowspan="1" colspan="1">4</td><td align="char" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">p&#8208;tau217</td><td align="left" rowspan="1" colspan="1">341</td><td align="char" rowspan="1" colspan="1">3.63 (2.90, 4.41)</td><td align="char" rowspan="1" colspan="1">1.07 (0.72, 1.50)</td><td align="char" rowspan="1" colspan="1">0.92 (0.58, 1.32)</td><td align="char" rowspan="1" colspan="1">0.91 (0.65, 1.31)</td><td align="char" rowspan="1" colspan="1">1.11 (0.69, 1.68)</td><td align="char" rowspan="1" colspan="1">1.04 (0.78, 1.40)</td><td align="char" rowspan="1" colspan="1">0.83 (0.65, 1.25)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nfl</td><td align="left" rowspan="1" colspan="1">341</td><td align="char" rowspan="1" colspan="1">24 (18, 28)</td><td align="char" rowspan="1" colspan="1">21 (12, 55)</td><td align="char" rowspan="1" colspan="1">11 (8, 13)</td><td align="char" rowspan="1" colspan="1">12 (9, 17)</td><td align="char" rowspan="1" colspan="1">29 (16, 42)</td><td align="char" rowspan="1" colspan="1">15 (13, 20)</td><td align="char" rowspan="1" colspan="1">12 (10, 19)</td></tr><tr><td align="left" rowspan="1" colspan="1">NfL/p&#8208;tau217 ratio</td><td align="left" rowspan="1" colspan="1">341</td><td align="char" rowspan="1" colspan="1">7 (5, 9)</td><td align="char" rowspan="1" colspan="1">25 (10, 48)</td><td align="char" rowspan="1" colspan="1">12 (9, 20)</td><td align="char" rowspan="1" colspan="1">13 (9, 22)</td><td align="char" rowspan="1" colspan="1">24 (11, 47)</td><td align="char" rowspan="1" colspan="1">16 (12, 27)</td><td align="char" rowspan="1" colspan="1">14 (11, 27)</td></tr><tr><td align="left" rowspan="1" colspan="1">GFAP</td><td align="left" rowspan="1" colspan="1">341</td><td align="char" rowspan="1" colspan="1">212 (151, 305)</td><td align="char" rowspan="1" colspan="1">79 (53, 192)</td><td align="char" rowspan="1" colspan="1">86 (56, 117)</td><td align="char" rowspan="1" colspan="1">115 (89, 177)</td><td align="char" rowspan="1" colspan="1">132 (77, 216)</td><td align="char" rowspan="1" colspan="1">144 (86, 174)</td><td align="char" rowspan="1" colspan="1">97 (61, 125)</td></tr><tr><td align="left" rowspan="1" colspan="1">log p&#8208;tau217</td><td align="left" rowspan="1" colspan="1">341</td><td align="char" rowspan="1" colspan="1">0.56 (0.46, 0.64)</td><td align="char" rowspan="1" colspan="1">0.03 (&#8722;0.14, 0.18)</td><td align="char" rowspan="1" colspan="1">&#8722;0.04 (&#8722;0.24, 0.12)</td><td align="char" rowspan="1" colspan="1">&#8722;0.04 (&#8722;0.19, 0.12)</td><td align="char" rowspan="1" colspan="1">0.05 (&#8722;0.16, 0.23)</td><td align="char" rowspan="1" colspan="1">0.02 (&#8722;0.11, 0.15)</td><td align="char" rowspan="1" colspan="1">&#8722;0.08 (&#8722;0.19, 0.10)</td></tr><tr><td align="left" rowspan="1" colspan="1">log NfL</td><td align="left" rowspan="1" colspan="1">341</td><td align="char" rowspan="1" colspan="1">1.38 (1.25, 1.45)</td><td align="char" rowspan="1" colspan="1">1.31 (1.08, 1.74)</td><td align="char" rowspan="1" colspan="1">1.02 (0.90, 1.11)</td><td align="char" rowspan="1" colspan="1">1.09 (0.94, 1.24)</td><td align="char" rowspan="1" colspan="1">1.46 (1.20, 1.62)</td><td align="char" rowspan="1" colspan="1">1.19 (1.11, 1.30)</td><td align="char" rowspan="1" colspan="1">1.06 (0.99, 1.27)</td></tr><tr><td align="left" rowspan="1" colspan="1">log GFAP</td><td align="left" rowspan="1" colspan="1">341</td><td align="char" rowspan="1" colspan="1">2.33 (2.18, 2.48)</td><td align="char" rowspan="1" colspan="1">1.90 (1.72, 2.28)</td><td align="char" rowspan="1" colspan="1">1.93 (1.75, 2.07)</td><td align="char" rowspan="1" colspan="1">2.06 (1.95, 2.25)</td><td align="char" rowspan="1" colspan="1">2.12 (1.88, 2.33)</td><td align="char" rowspan="1" colspan="1">2.16 (1.93, 2.24)</td><td align="char" rowspan="1" colspan="1">1.99 (1.78, 2.10)</td></tr></tbody></table><table-wrap-foot><fn id="alz70717-tbl1-note-0001"><p><bold>
<sup>Abbreviations:</sup>
:</bold>AD, Alzheimer's disease; bvFTD, behavioral variant frontotemporal dementia; GFAP, glial fibrillary acidic protein; MCI, mild cognitive impairment; NfL, neurofilament light chain; ND, neurodegenerative disorder; PPD, primary psychiatric disorder; p&#8208;tau217, phosphorylated tau 217</p></fn><fn id="alz70717-tbl1-note-0002"><label>
<sup>a</sup>
</label><p>Median (Q1, Q3); <italic toggle="yes">n</italic>/<italic toggle="yes">N</italic> (%).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>PPDs consisted of major depressive disorder (MDD, <italic toggle="yes">n</italic>&#160;=&#160;21), bipolar disorder (<italic toggle="yes">n</italic>&#160;=&#160;6), functional neurological/cognitive disorder (<italic toggle="yes">n</italic>&#160;=&#160;8), schizophrenia spectrum disorder (<italic toggle="yes">n</italic>&#160;=&#160;16), bvFTD &#8220;phenocopy&#8221; syndrome (<italic toggle="yes">n</italic>&#160;=&#160;2), and other PPDs (<italic toggle="yes">n</italic>&#160;=&#160;16, which included anxiety, personality, obsessive&#8208;compulsive, post&#8208;traumatic stress, and undifferentiated psychiatric disorders).</p><p>Other NDs consisted of CJD (<italic toggle="yes">n</italic>&#160;=&#160;2), dementia with Lewy bodies (<italic toggle="yes">n</italic>&#160;=&#160;5), dementia not otherwise specified (<italic toggle="yes">n</italic>&#160;=&#160;6), Huntington's disease (HD, <italic toggle="yes">n</italic>&#160;=&#160;15), mixed AD/vascular (<italic toggle="yes">n</italic>&#160;=&#160;3), substance&#8208;related cognitive impairment/dementia (<italic toggle="yes">n</italic>&#160;=&#160;2), vascular dementia (<italic toggle="yes">n</italic>&#160;=&#160;5), and a range of other NDs (<italic toggle="yes">n</italic>&#160;=&#160;29, which included autoimmune encephalitis, cerebral amyloid angiopathy, corticobasal syndrome, central nervous system vasculitis, Down syndrome, Fahr disease, metabolic disorders, Niemann&#8211;Pick Type C, Parkinson's disease, and cerebellar degenerative disorder). The presymptomatic genetic ND group consisted of AD (<italic toggle="yes">PSEN1</italic>, <italic toggle="yes">n</italic>&#160;=&#160;2), genetic CJD (<italic toggle="yes">n</italic>&#160;=&#160;6), HD (<italic toggle="yes">n</italic>&#160;=&#160;6), CADASIL (<italic toggle="yes">n</italic>&#160;=&#160;1), bvFTD (<italic toggle="yes">C9orf72</italic>
<italic toggle="yes">n</italic>&#160;=&#160;1 and <italic toggle="yes">GRN</italic>
<italic toggle="yes">n</italic>&#160;=&#160;2).</p><p>CSF biomarker analysis, including AD proteins CSF AB42 and p&#8208;tau181 (Supporting Information Table <xref rid="alz70717-supinfo-0001" ref-type="">1</xref>), was conducted on 80 patients. Briefly, 27/40 (68%) of AD patients had CSF AD biomarkers. Most (18/27, 67%) had a CSF AD biomarker profile consistent with AD, as defined by an amyloid&#8208;positive, p&#8208;tau&#8208;positive (A+T+) profile, categorized using established cut&#8208;offs, as described in our previous study.<xref rid="alz70717-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Other profiles in the AD group were 8/27 with A+T&#8722; and 1/27 with A&#8722;T+. Two patients with AD had amyloid PET (but not CSF), and both were positive for amyloid plaques. Further information, including phenotype information for AD, are in the Supporting Information Tables <xref rid="alz70717-supinfo-0001" ref-type="">1</xref> and 2. Forty&#8208;seven percent (7/15) of bvFTD patients had CSF AD biomarkers (none with an A+T+ profile, 4/7 with A&#8722;T&#8722;, and 3/7 with A+T&#8722;). None of the patients in the other groups who had CSF AD biomarkers (20 in the PPD group, 21 in other NDs, and five MCI) had A+T+ profiles (further details in Supporting Information Tables <xref rid="alz70717-supinfo-0001" ref-type="">1</xref> and <xref rid="alz70717-supinfo-0001" ref-type="">2</xref>).</p><sec id="alz70717-sec-0110"><label>3.1</label><title>Levels of plasma p&#8208;tau217, NfL, NfL/p&#8208;tau217 ratio, GFAP, in AD, bvFTD, and PPD</title><sec id="alz70717-sec-0120"><label>3.1.1</label><title>Plasma p&#8208;tau 217</title><p>As demonstrated in Table&#160;<xref rid="alz70717-tbl-0001" ref-type="table">1</xref> and Figure&#160;<xref rid="alz70717-fig-0001" ref-type="fig">1</xref>, plasma p&#8208;tau217 levels were significantly elevated in AD compared to bvFTD (standardized bootstrapped GLM with age and sex as additional covariates; <italic toggle="yes">&#946;</italic>&#160;=&#160;1.30, 95% CI: [0.71, 1.73], <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), and AD compared to PPDs (<italic toggle="yes">&#946;</italic>&#160;=&#160;1.59 [1.34, 1.80], <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). Levels were also elevated in AD compared to the other groups (controls, Other NDs, MCI, and Presymptomatic ND, and all <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001).</p><fig position="float" fig-type="FIGURE" id="alz70717-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Plasma p&#8208;tau217, NfL, NfL/p&#8208;tau217 ratio, and GFAP levels, in AD, bvFTD, PPDs, controls, and other comparator groups. Plasma p&#8208;tau217 levels were significantly elevated in AD compared to all other disorders and controls. To improve readability, seven outliers were not displayed in plot B for NfL (two for AD [141 and 294 pg/mL], two bvFTD [101 and 214 pg/mL], three other NDs [106, 352, and 1154 pg/mL]), and six in plot C for NfL/p&#8208;tau217 ratio (one bvFTD [143], two controls [699, 772], three other NDs [190, 198, and 604]). Dashed red lines&#160;=&#160;predefined optimal cut&#8208;offs from our previous studies, for p&#8208;tau217 (2.35pg/mL). AD, Alzheimer's disease; bvFTD, behavioral variant frontotemporal dementia; GFAP, glial fibrillary acidic protein; ND, neurodegenerative disorder; NfL, neurofilament light chain; PPD, primary psychiatric disorder; p&#8208;tau217, phosphorylated tau 217.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70717-g002.jpg"/></fig></sec><sec id="alz70717-sec-0130"><label>3.1.2</label><title>Plasma NfL</title><p>Plasma NfL was elevated in AD compared to PPD (<italic toggle="yes">&#946;</italic>&#160;=&#160;0.87 [0.59, 1.13], <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), but not for AD compared to bvFTD (<italic toggle="yes">&#946;</italic>&#160;=&#160;&#8722;0.10 [&#8722;0.82, 0.58], <italic toggle="yes">p</italic>&#160;=&#160;0.788). There were no significant differences in plasma NfL levels across the ND groups (AD, bvFTD, Other NDs, all <italic toggle="yes">p</italic>&#160;&gt;&#160;0.05). Levels were also similar between PPDs, control, MCI, and presymptomatic ND groups.</p></sec><sec id="alz70717-sec-0140"><label>3.1.3</label><title>Plasma NfL/p&#8208;tau217 ratio</title><p>The plasma NfL/p&#8208;tau217 ratio was reduced in AD compared to bvFTD (<italic toggle="yes">&#946;</italic>&#160;=&#160;&#8722;1.57 [&#8722;2.16, &#8722;0.94], <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) and PPD (<italic toggle="yes">&#946;</italic>&#160;=&#160;&#8722;0.99 [&#8722;0.58, &#8722;1.34], <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). The ratio was also lower in AD compared to all the other groups (controls, Other NDs, MCI, Presymptomatic NDs, and all <italic toggle="yes">p</italic>&#160;&lt;&#160;0.002).</p></sec><sec id="alz70717-sec-0150"><label>3.1.4</label><title>Plasma GFAP</title><p>GFAP levels were elevated in AD compared to bvFTD (<italic toggle="yes">&#946;</italic>&#160;=&#160;0.80 [0.23, 1.39], <italic toggle="yes">p</italic>&#160;=&#160;0.010), and PPD (<italic toggle="yes">&#946;</italic>&#160;=&#160;0.82 [0.36, 1.21], <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). GFAP levels were also elevated in AD compared to some other groups (controls, MCI, Presymptomatic ND, all <italic toggle="yes">p</italic>&#160;&lt;&#160;0.038), but not between AD and other NDs (<italic toggle="yes">p</italic>&#160;=&#160;0.108).</p></sec></sec><sec id="alz70717-sec-0160"><label>3.2</label><title>Biomarker diagnostic performance to distinguish AD from PPDs, AD from bvFTD, and bvFTD from PPD</title><sec id="alz70717-sec-0170"><label>3.2.1</label><title>Distinguishing AD from PPDs</title><p>P&#8208;tau217 demonstrated the strongest diagnostic performance to distinguish AD from PPDs, as demonstrated in Figure&#160;<xref rid="alz70717-fig-0002" ref-type="fig">2</xref> and Supporting Information Table <xref rid="alz70717-supinfo-0001" ref-type="">3</xref>. P&#8208;tau217 had an AUC of 0.97, outperforming NfL, NfL/p&#8208;tau217 ratio, and GFAP (AUCs 0.89, 0.77, 0.86 respectively; AUC differences all <italic toggle="yes">p</italic>&#160;&lt;&#160;0.016). P&#8208;tau217 had the highest accuracy (93%), specificity (91%), and sensitivity (95%), at an optimal cut&#8208;off of 1.84pg/mL. Further details of all diagnostic performance metrics are available in Supporting Information Table <xref rid="alz70717-supinfo-0001" ref-type="">3</xref>.</p><fig position="float" fig-type="FIGURE" id="alz70717-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>ROC analyses for diagnostic performance of plasma p&#8208;tau217, NfL, NfL/p&#8208;tau217 ratio, and GFAP. Plasma p&#8208;tau217 had the very strong diagnostic performance for AD versus PPD, AD versus bvFTD, AD versus non&#8208;AD, AD versus controls, outperforming other biomarkers and the NfL/p&#8208;tau217 ratio. NfL's diagnostic performance was for bvFTD versus PPD and all NDs versus PPDs. AD, Alzheimer's disease; bvFTD, behavioral variant frontotemporal dementia; GFAP, glial fibrillary acidic protein; NfL, neurofilament light chain; PPD, primary psychiatric disorder; p&#8208;tau217, phosphorylated tau 217; ROC, receiver operating characteristic.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70717-g003.jpg"/></fig></sec><sec id="alz70717-sec-0180"><label>3.2.2</label><title>Distinguishing AD from bvFTD</title><p>To distinguish AD from bvFTD, p&#8208;tau217 once again demonstrated the highest AUC (0.93) and the strongest diagnostic performance (93% specificity, 98% sensitivity, 96% accuracy, and cut&#8208;off 1.64) compared to the other biomarkers. NfL did not have significant diagnostic performance to distinguish AD from bvFTD (AUC 0.51 [0.30, 0.74]). The AUC difference was not statistically different between p&#8208;tau217 and the NfL/p&#8208;tau217 ratio (AUC 0.88, AUC difference <italic toggle="yes">p&#160;</italic>=&#160;0.509) or GFAP (AUC 0.77, AUC difference <italic toggle="yes">p</italic>&#160;=&#160;0.10). However, compared to p&#8208;tau217, both the ratio and GFAP demonstrated poorer specificity (87% and 67%, respectively), sensitivity (80% and 85%), and accuracy (82% and 80%) and much lower diagnostic odds ratios (26 and 11.33, vs p&#8208;tau217's 546).</p></sec><sec id="alz70717-sec-0190"><label>3.2.3</label><title>Distinguishing AD from non&#8208;AD disorders</title><p>P&#8208;tau217 demonstrated high diagnostic performance to distinguish AD from other non&#8208;AD disorders (consisting of bvFTD, PPDs, Other NDs), with an AUC of 0.94. It was superior to NfL, NfL/p&#8208;tau217 (all <italic toggle="yes">p</italic> &#8804; 0.001) and had 88% specificity, 93% sensitivity, 90% accuracy, and a cut&#8208;off of 2.19.</p><p>P&#8208;tau217 demonstrated very strong diagnostic performance to distinguish AD from controls (AUC 0.98, 96% specificity, and 93% sensitivity).</p></sec><sec id="alz70717-sec-0200"><label>3.2.4</label><title>Distinguishing bvFTD from PPD</title><p>To distinguish bvFTD from PPD, NfL had the highest AUC (0.78) and strongest diagnostic performance (81% specificity, 67% sensitivity, 79% accuracy, and cut&#8208;off 15.15pg/mL), although the AUC difference between NfL and NfL/p&#8208;tau217 ratio was not significant (<italic toggle="yes">p</italic>&#160;=&#160;0.14). P&#8208;tau217 and GFAP had no diagnostic utility (AUC confidence intervals both crossed 0.50).</p></sec></sec><sec id="alz70717-sec-0210"><label>3.3</label><title>Biomarker diagnostic performance to distinguish all NDs from PPDs</title><p>As a follow&#8208;on from our previous studies that focused on NfL in distinguishing NDs from PPDs, we investigated the ability of p&#8208;tau217 and GFAP to distinguish NDs as a group from PPDs. We created an &#8220;all NDs&#8221; group by combining AD, bvFTD, and Other NDs. NfL demonstrated the highest AUC (0.87) and strongest diagnostic performance (81% specificity, 85% sensitivity, 84% accuracy, and cut&#8208;off 14.35) to distinguish All NDs from PPDs, significantly outperforming GFAP (AUC 0.73, AUC difference <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001) and p&#8208;tau217 (AUC 0.72, AUC difference <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). The NfL/p&#8208;tau217 ratio did not have diagnostic utility for All NDs versus PPDs (AUC confidence interval crossed 0.50).xxx</p></sec><sec id="alz70717-sec-0220"><label>3.4</label><title>Biomarker profiles in diagnostic groups</title><sec id="alz70717-sec-0230"><label>3.4.1</label><title>AD pathology/neuronal injury (P&#8208;tau217/NfL) biomarker profiles</title><p>We described p&#8208;tau217 and NfL biomarker profiles in the diagnostic groups, using our previously described cutoff for plasma p&#8208;tau217, and age&#8208;adjusted percentiles model for NfL.<xref rid="alz70717-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70717-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</p><p>As demonstrated in Figure&#160;<xref rid="alz70717-fig-0003" ref-type="fig">3</xref>, the high p&#8208;tau217 profiles were most commonly seen in AD (total 88% of AD, 60% high p&#8208;tau217/high NfL, and 28% high p&#8208;tau217/low NfL biomarker profiles). By comparison less than 10% of each of the other groups exhibited high p&#8208;tau217 profile. bvFTD only had 7% with high p&#8208;tau217 profiles (all high p&#8208;tau217/high NfL), PPD only 6% (3% high p&#8208;tau217/high NfL, 3% high p&#8208;tau217/low NfL), controls only 3% (all high p&#8208;tau217/low NfL), and MCI and presymptomatic ND 8% and 6% respectively. Other NDs had 13% with high p&#8208;tau217 profiles (10% high p&#8208;tau217/high NfL, 3% high p&#8208;tau217/low NfL).</p><fig position="float" fig-type="FIGURE" id="alz70717-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>P&#8208;tau217 and NfL biomarker profiles, classified based on previously described cut&#8208;offs, in different diagnostic groups. NfL, neurofilament light chain; p&#8208;tau217, phosphorylated tau 217.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70717-g001.jpg"/></fig><p>68% of AD had high NfL profiles (high p&#8208;tau217/high NfL, low p&#8208;tau217/high NfL), and AD had the lowest proportion of &#8220;normal&#8221; (low p&#8208;tau217/low NfL) profiles. For bvFTD on the other hand, only 53% had high NfL profiles, and the remaining 47% had low p&#8208;tau217/low NfL profiles. Most PPD had a normal profile (72%), with 25% showing high NfL profiles. Looking at individual PPD (details in Supporting Information Figures <xref rid="alz70717-supinfo-0001" ref-type="">1</xref> and <xref rid="alz70717-supinfo-0001" ref-type="">2</xref>), there was a greater proportion of patients with high NfL profiles in schizophrenia (37%) and Other PPD (33%), compared to other groups (MDD 19%, FND 12.5%, BPAD 0%), although these exploratory findings should be interpreted with caution given the small sub&#8208;group numbers. 83% of controls had a normal profile, and only 14% having high NfL profiles. Other ND had the highest proportions of high NfL levels (74%, 64% low p&#8208;tau217/high NfL, and 10% high p&#8208;tau217/high NfL). Most participants in MCI, and Presymptomatic ND had low p&#8208;tau217/low NfL profiles (72%, 77%, and 67%, respectively), similar to PPD and controls.</p><p>These findings are further demonstrated in Figure&#160;<xref rid="alz70717-fig-0004" ref-type="fig">4</xref>, a plot for different diagnostic groups of log p&#8208;tau217 versus NfL age&#8208;adjusted z&#8208;score, and distributions. The scatter plot and distributions demonstrate that almost all AD patients had elevated p&#8208;tau217 levels and high p&#8208;tau217/high NfL profiles (most in upper right in scatter plot), as compared to non&#8208;AD disorders, where almost all had low p&#8208;tau217 levels. Most NDs had high NfL levels (most in lower right in scatter plot), compared to a small proportion of PPDs and controls (most in lower left in scatter plot).</p><fig position="float" fig-type="FIGURE" id="alz70717-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>P&#8208;tau217 and NfL levels and distributions in study cohort. The scatter plot and distributions demonstrate that almost all AD patients had elevated p&#8208;tau217 levels and high p&#8208;tau217/high NfL profiles, and compared to non&#8208;AD disorders where almost all had low p&#8208;tau217 levels. Most ND had high NfL levels, compared to a small proportion of PPD and controls. Dashed red lines&#160;=&#160;predefined optimal cut&#8208;offs from our previous studies, for p&#8208;tau217 (log10 of 2.35pg/mL) and age&#8208;adjusted NfL (<italic toggle="yes">z</italic>&#8208;score of 1.645 or 95th percentile). AD, Alzheimer's disease; NfL, neurofilament light chain; p&#8208;tau217, phosphorylated tau 217; PPD, primary psychiatric disorder.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="ALZ-21-e70717-g006.jpg"/></fig></sec><sec id="alz70717-sec-0240"><label>3.4.2</label><title>AD pathology/neuronal injury/neuroinflammation (p&#8208;tau217/NfL/GFAP) biomarker profiles</title><p>As an exploratory aim, we developed a novel GAMLSS age&#8208;based model for plasma GFAP to derive percentiles and <italic toggle="yes">z</italic>&#8208;scores, based on our control group. As demonstrated in Figure&#160;<xref rid="alz70717-fig-0005" ref-type="fig">5</xref>, this shows a similar non&#8208;linear association with age and a U&#8208;shaped pattern similar to the found in other studies.<xref rid="alz70717-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="alz70717-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> This enabled complex p&#8208;tau217/NfL/GFAP (AD pathology/neuronal injury/neuroinflammation) biomarker profiling, which is demonstrated in Figure&#160;<xref rid="alz70717-fig-0006" ref-type="fig">6</xref>. Inclusion of GFAP to create this three&#8208;biomarker profile resulted in some differences compared to p&#8208;tau217/NfL only profiling. The proportion of &#8220;normal&#8221; profiles using three biomarkers (i.e., low p&#8208;tau217/low NfL/low GFAP) was slightly lower in bvFTD (40%, compared to 47% low p&#8208;tau217/low NfL profiles). The proportion of normal p&#8208;tau217/NfL/GFAP profiles in PPDs and controls were similar to proportions of normal p&#8208;tau217/NfL profiles. Looking at individual PPDs (details in Supporting Information Figures <xref rid="alz70717-supinfo-0001" ref-type="">1</xref> and <xref rid="alz70717-supinfo-0001" ref-type="">2</xref>), high GFAP profiles did not appear to be different between groups, although these findings should once again be interpreted with caution given the small subgroup numbers.</p><fig position="float" fig-type="FIGURE" id="alz70717-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Plasma GFAP percentiles derived from generalized additive models for location, scale, and shape, based on this study's control group. Two extreme outliers were excluded for modeling (GFAP levels&#160;&gt;&#160;400 pg/mL, aged 52 and 63), given the disproportionate influence they would have with the relatively small sample size. GFAP, glial fibrillary acidic protein.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="ALZ-21-e70717-g004.jpg"/></fig><fig position="float" fig-type="FIGURE" id="alz70717-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>P&#8208;tau217, NfL, and GFAP biomarker profiles in diagnostic groups. GFAP, glial fibrillary acidic protein; NfL, neurofilament light chain; p&#8208;tau217, phosphorylated tau 217.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="ALZ-21-e70717-g005.jpg"/></fig><p>We performed some additional exploratory analyses. To investigate whether there were differences in levels of severity and biomarkers between AD and bvFTD, we first compared MMSE scores between these two groups (calculated from total scores on the Neuropsychiatry Unit Cognitive Assessment Tool (NUCOG), the cognitive screening instrument used in the Neuropsychiatry Centre).<xref rid="alz70717-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> MMSE scores were not statistically different (median [interquartile range, IQR]: 21.9 [16.5 to 24.9] for AD vs 23.4 [20.9 to 25.0] for bvFTD, <italic toggle="yes">p</italic>&#160;=&#160;0.093), Supporting Information Table&#160;<xref rid="alz70717-supinfo-0001" ref-type="">1</xref>. Next, we ran GLMs exploring whether diagnosis of AD or bvFTD, MMSE, and diagnosis &#215; MMSE interaction influenced NfL levels, adjusting for age and sex. Diagnosis (<italic toggle="yes">p</italic>&#160;=&#160;0.394), MMSE (<italic toggle="yes">p</italic>&#160;=&#160;0.700), and the interaction term (<italic toggle="yes">p</italic>&#160;=&#160;0.634) were all non&#8208;significant. Taken together, these findings indicate that the higher proportion of &#8220;high NfL&#8221; profiles in AD was unlikely to be explained by more advanced cognitive impairment compared to bvFTD. Finally, we investigated for any associations between biomarkers and cognitive impairment in AD. In AD cases only, higher plasma NfL showed a trend toward association with lower MMSE, in GLMs also adjusting for age and sex, but it was not statistically significant (<italic toggle="yes">p</italic>&#160;=&#160;0.076). No significant associations were observed in AD between MMSE scores and plasma p&#8208;tau217 (<italic toggle="yes">p</italic>&#160;=&#160;0.928) and GFAP (<italic toggle="yes">p</italic>&#160;=&#160;0.614). These suggest that within our AD group, biomarker levels did not significantly vary with the degree of cognitive impairment.</p></sec></sec></sec><sec id="alz70717-sec-0250"><label>4</label><title>DISCUSSION</title><p>We investigated multiple biomarkers in an unselected real&#8208;world clinical cohort of younger participants seen in a neuropsychiatry memory clinic, focusing on AD, bvFTD, and PPDs. The main findings were as follows: (1) very strong diagnostic performance of plasma p&#8208;tau217 to distinguish AD from bvFTD, and AD from PPDs; (2) superior performance of p&#8208;tau217 for AD diagnosis on its own, compared to NfL/p&#8208;tau217 ratio, NfL, and GFAP; (3) strongest performance of NfL for distinguishing bvFTD from PPDs, and all NDs from PPDs, consistent with previous studies.<xref rid="alz70717-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="alz70717-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> This adds important further evidence to the limited literature so far on roles for different biomarkers in a real&#8208;world clinical cohort, with p&#8208;tau217 being a very sensitive and specific test for AD and NfL having the strongest diagnostic performance to distinguish neurodegeneration from PPDs/non&#8208;NDs, with little role for GFAP in any of these distinctions. The key strengths of this study included a real&#8208;world, unselected diverse, clinical, and younger cohort &#8211; a relatively underinvestigated group. Establishing the role for these biomarkers in younger people, who face greater rates of misdiagnosis and diagnostic uncertainty, is important for increasing clinical and research access, where arguably the clinical, treatment, and broader psychosocial benefits could be greater.</p><p>This study builds on our previous work on p&#8208;tau217,<xref rid="alz70717-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> providing further evidence of very strong diagnostic performance for some of the most common diagnostic distinctions, distinguishing AD from bvFTD, and AD from PPDs. We saw very high specificity and sensitivity (91% and 95%), establishing a role for such an accurate test (93%) in younger people. We found no benefit of NfL/p&#8208;tau217 ratio over p&#8208;tau217 alone in terms of improving the distinction between AD and bvFTD, and bvFTD from PPD, in contrast to Benussi et&#160;al.<xref rid="alz70717-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> This difference in their study was slight and may reflect their older cohort and greater FTD sample sizes. Although there has been interest in GFAP assisting with AD versus non&#8208;AD and ND versus PPD/non&#8208;ND distinctions, we found little to no utility for GFAP. Importantly, while different p&#8208;tau217 assays correlate well with each other, they have not been standardized with each other and thus differ in absolute concentrations.<xref rid="alz70717-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Assay standardization projects are under way; however, at present cut points must be regarded as assay&#8208;specific and, on the very safe side, as lab&#8208;specific.</p><p>An additional strength of the study was defining and describing biomarker profiles using previously published cut&#8208;offs and reference ranges.<xref rid="alz70717-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70717-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="alz70717-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Although the previous p&#8208;tau217 study and cut&#8208;off had some overlap with this study cohort, a new separate analysis of AD versus controls in this study yielded a very similar cut&#8208;off of (2.18 pg/mL, Supporting Information Table <xref rid="alz70717-supinfo-0001" ref-type="">3</xref>). The NfL reference range was from a completely independent, large reference cohort.<xref rid="alz70717-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="alz70717-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> We found higher p&#8208;tau217 diagnostic performance (AUC 0.97 for AD vs PPD, and 0.98 for AD vs controls, sensitivities and specificities, and accuracies&#160;&gt; 90%), compared to Rousset et&#160;al. (AUCs approximately 0.78 to 0.81 depending on the group being compared to AD),<xref rid="alz70717-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> and we also found greater proportions of high p&#8208;tau217/high NfL and high p&#8208;tau217/low NfL profiles in our AD group. Our findings may reflect our younger AD group (median 62 years of age vs 66). Although most patients with PPDs had low p&#8208;tau217/low NfL profiles, there were still a number with other profiles, including 25% with high NfL. This builds on numerous other studies that demonstrated that, although very elevated NfL levels are rarely seen in PPDs, slightly elevated levels can be seen in numerous PPDs, and PPDs cannot be assumed to be equivalent to controls/non&#8208;neurological controls.<xref rid="alz70717-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70717-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70717-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70717-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="alz70717-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="alz70717-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="alz70717-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> Although some interesting patterns could be observed between individual PPDs (Supporting Information Figures&#160;<xref rid="alz70717-supinfo-0001" ref-type="">1</xref> and <xref rid="alz70717-supinfo-0001" ref-type="">2</xref>), any confident interpretations are limited by the small sample sizes, and deeper investigations in larger cohorts are warranted.</p><p>Among AD, bvFTD, and other ND, we found the greatest proportion (47%) of &#8220;normal&#8221; AD/neuronal injury biomarker profile (Low p&#8208;tau217/Low NfL) in bvFTD. This was reduced slightly when considering &#8220;normal&#8221; AD/neuronal injury/neuroinflammation (low p&#8208;tau217/low NfL/low GFAP) profile (40%). This could reflect issues previously described with NfL technical/analytical/reference range issues<xref rid="alz70717-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70717-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> or, more likely, highlights greater complexity and clinical and biomarker heterogeneity, seen in bvFTD.<xref rid="alz70717-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> Although p&#8208;tau217 can accurately distinguish frontal AD from bvFTD, and NfL has strong diagnostic performance for bvFTD versus PPDs at group levels, our findings suggest that many individuals with bvFTD would still have non&#8208;diagnostic biomarker levels and profiles. We found weaker diagnostic performance of NfL for bvFTD versus PPD distinction in this study compared to one of our previous studies that compared bvFTD to PPD<xref rid="alz70717-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> and other studies.<xref rid="alz70717-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> Patients in this study were from within the same unselected clinical cohort, whereas those other studies had patients from separate clinics/cohorts. Therefore, differences in diagnostic performance most likely reflect differences in cohorts, with the present study reflecting the performance, and limitations and ongoing challenges, in a real&#8208;world, unselected clinical cohort. Studies are needed and under way to more deeply understand this discordance in larger groups of people with bvFTD in real&#8208;world clinical cohorts, including multimodal neuroimaging, clinical, multi&#8208;omic, and genomic data, to ultimately improve upon single diagnostic biomarker performance for more accurate diagnosis of bvFTD. Describing biomarker profiles were secondary, exploratory aims of this study. A limitation was binary/dichotomous &#8220;low&#8221;/&#8220;high&#8221; classification. Binary classification loses important nuance in interpreting an individual level (e.g., an individual with level 1% below the binary cut&#8208;off or 95th percentile, and someone with a level 50% below the cut&#8208;off or 95th percentile, would both be classified as &#8220;low&#8221;). Unfortunately, small sample sizes prevented more nuanced categorization (e.g., &#8220;high,&#8221; &#8220;low,&#8221; and &#8220;borderline&#8221;).</p><p>There was a very high p&#8208;tau217 outlier in the bvFTD group. They had a complex history, initially diagnosed with AD based on memory impairment and neuroimaging. They subsequently developed significant personality and behavior change and eventually developed motor neuron disease (MND). At that point, the diagnosis was revised to bvFTD&#8208;MND. Notably, their blood sample and biomarker level was prior to MND onset. Their elevated p&#8208;tau217 level possibly reflected skeletal muscle source of p&#8208;tau217,<xref rid="alz70717-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> or it could suggest that they were unfortunate to have multiple pathologies, such as AD, as well as MND, and possibly FTD. Unfortunately, this patient did not have genetic testing, CSF AD protein analysis, or amyloid PET. It is possible that blood&#8208;based biomarkers could help improve not only accurate AD diagnosis but also identification of cases of multiple co&#8208;pathologies, especially important for older people, where co&#8208;pathology is more common, and in this era of increasingly available disease&#8208;specific treatments.<xref rid="alz70717-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>
</p><p>The study's limitations include the single&#8208;center, cross&#8208;sectional design, relatively small FTD subgroup, and small AD variant subgroups preventing deeper analyses, a lack of gold standard reference tests for AD (CSF AD proteins and amyloid PET) for all participants, reliance on diagnostic categorization based on gold standard clinical diagnoses over biomarker profiles (and thus the range of CSF profiles, such as an A&#8722;T+ CSF profile for one patient with an AD diagnosis, although their CSF AB42 was borderline), and lack of genetic or <italic toggle="yes">post mortem</italic> diagnostic confirmation. Additional exploratory analyses indicated that cognitive severity did not differ significantly between AD and bvFTD and was not significantly associated with plasma biomarkers within AD, suggesting that observed biomarker patterns were unlikely to be driven by disease stage; however, these findings need to be interpreted with caution given the small sample sizes. Other NDs, MCI, and presymptomatic genetic NDs were included as comparator groups for secondary/exploratory/descriptive analyses, but their small sample sizes limited further in&#8208;depth analyses or interpretations. While all cases had systematic longitudinal diagnostic data collection, it was beyond the scope of this study to systematically review all cases with discordant biomarkers (e.g., high NfL in PPD), for reasons of discordance and potential misclassification. Such detailed investigations will be required in future studies. Our control group relied on self&#8208;reports since cognitive screening data on controls were not available for this study. While we could not completely rule out the possibility of some control participants with MCI due to this significant limitation, the relatively younger age, narrow range, and mainly normal biomarker levels in this group suggest that this is very unlikely to be a significant issue. We developed a novel GAMLSS plasma GFAP model. While we found a U&#8208;shaped curve (higher levels in younger people, lower in midlife, then increasing again with age), similar to other studies,<xref rid="alz70717-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="alz70717-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> our model was based on a relatively small number of individuals and therefore should be interpreted with caution. Studies are under way aiming to replicate this study's findings and to investigate the incremental validity of multiple biomarkers in a larger sample size, including imaging and other multi&#8208;omic data, and in different clinical settings.</p><p>This study adds important evidence for the very strong diagnostic performance of p&#8208;tau217 to distinguish AD from bvFTD and PPDs and identified important future research needs to improve bvFTD diagnosis. The strength and simplicity of single blood&#8208;based biomarkers for AD diagnosis are particularly important in the era of increasing availability of anti&#8208;amyloid and other disease&#8208;specific treatments for AD. Ongoing further research will further establish the role of p&#8208;tau217 and NfL in precision diagnostic algorithms to reduce misdiagnosis and diagnostic delay and improve clinical and research outcomes.</p></sec><sec sec-type="COI-statement" id="alz70717-sec-0270"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare no conflicts of interest. Author disclosures are available in the <xref rid="alz70717-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="alz70717-sec-0280"><title>DECLARATION OF INTERESTS AND FINANCIAL DISCLOSURES</title><p>KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, Beckman&#8208;Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sunbird Bio, Sanofi, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai, and Roche Diagnostics; and is a co&#8208;founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp &amp; Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD; is a co&#8208;founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program; and is a shareholder of MicThera (outside submitted work). The other authors have nothing to disclose.</p></sec><sec id="alz70717-sec-0290"><title>CONSENT STATEMENT</title><p>All human subjects provided informed consent.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70717-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70717-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70717-s002.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70717-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70717-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70717-sec-0260"><title>ACKNOWLEDGMENTS</title><p>The authors would like to thank all the patients, participants, and their families for their participation. KB is supported by the Swedish Research Council (2017&#8208;00915 and 2022&#8208;00732), the Swedish Alzheimer Foundation (AF&#8208;930351, AF&#8208;939721, AF&#8208;968270, and AF&#8208;994551), Hj&#228;rnfonden, Sweden (ALZ2022&#8208;0006, FO2024&#8208;0048&#8208;TK&#8208;130, and FO2024&#8208;0048&#8208;HK&#8208;24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (ALFGBG&#8208;965240 and ALFGBG&#8208;1006418), the European Union Joint Programme for Neurodegenerative Disorders (JPND2019&#8208;466&#8208;236), the Alzheimer's Association 2021 Zenith Award (ZEN&#8208;21&#8208;848495), the Alzheimer's Association 2022&#8208;2025 Grant (SG&#8208;23&#8208;1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen R&#246;nstr&#246;ms Stiftelse, Stockholm, Sweden, and an anonymous philanthropist and donor. HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (2023&#8208;00356, 2022&#8208;01018, and 2019&#8208;02397), the European Union's Horizon Europe research and innovation programme under Grant Agreement 101053962, Swedish State Support for Clinical Research (ALFGBG&#8208;71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (201809&#8208;2016862), the AD Strategic Fund and the Alzheimer's Association (ADSF&#8208;21&#8208;831376&#8208;C, ADSF&#8208;21&#8208;831381&#8208;C, ADSF&#8208;21&#8208;831377&#8208;C, and ADSF&#8208;24&#8208;1284328&#8208;C), the European Partnership on Metrology, co&#8208;financed by the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, 22HLT07), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling&#8211;Persson Family Foundation, Familjen R&#246;nstr&#246;ms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen f&#246;r Gamla Tj&#228;narinnor, Hj&#228;rnfonden, Sweden (FO2022&#8208;0270), the European Union's Horizon 2020 research and innovation programme under the Marie Sk&#322;odowska&#8208;Curie Grant Agreement 860197 (MIRIADE), the European Union Joint Programme&#8211;Neurodegenerative Disease Research (JPND2021&#8208;00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI&#8208;1003), and an anonymous donor. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. AFS is primarily funded by the Swedish federal government under the ALF agreement (ALF 2022 YF 0017) and The &#197;ke Wiberg Foundation.</p><p>Open access publishing facilitated by The University of Melbourne, as part of the Wiley &#8208; The University of Melbourne agreement via the Council of Australian University Librarians.</p></ack><ref-list id="alz70717-bibl-0001"><title>REFERENCES</title><ref id="alz70717-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70717-cite-0002"><string-name name-style="western"><surname>Loi</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Eratne</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Santillo</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Velakoulis</surname><given-names>D</given-names></string-name>. <article-title>Biofluid biomarkers in distinguishing young&#8208;onset dementia from primary psychiatric disorders</article-title>. <source>Curr Opin Psychiatry</source>. <year>2025</year>;<volume>38</volume>:<fpage>134</fpage>&#8208;<lpage>143</lpage>. doi:<pub-id pub-id-type="doi">10.1097/YCO.0000000000000979</pub-id><pub-id pub-id-type="pmid">39887317</pub-id></mixed-citation></ref><ref id="alz70717-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70717-cite-0003"><string-name name-style="western"><surname>Arslan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></string-name>. <article-title>Neurofilament light chain as neuronal injury marker&#8212;what is needed to facilitate implementation in clinical laboratory practice?</article-title>. <source>Clin Chem Lab Med</source>. <year>2023</year>;<volume>61</volume>:<fpage>1140</fpage>&#8208;<lpage>1149</lpage>. doi:<pub-id pub-id-type="doi">10.1515/cclm-2023-0036</pub-id><pub-id pub-id-type="pmid">36880940</pub-id></mixed-citation></ref><ref id="alz70717-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70717-cite-0004"><string-name name-style="western"><surname>Bavato</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Barro</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Schnider</surname><given-names>LK</given-names></string-name>, et&#160;al. <article-title>Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls</article-title>. <source>Mol Psychiatry</source>. <year>2024</year>;<volume>29</volume>:<fpage>2543</fpage>&#8208;<lpage>2559</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41380-024-02524-6</pub-id><pub-id pub-id-type="pmid">38503931</pub-id><pub-id pub-id-type="pmcid">PMC11412913</pub-id></mixed-citation></ref><ref id="alz70717-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70717-cite-0005"><string-name name-style="western"><surname>Bavato</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Seifritz</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Quednow</surname><given-names>BB</given-names></string-name>. <article-title>The multifaceted role of neurofilament light chain protein: emerging opportunities in primary psychiatric conditions</article-title>. <source>Brain</source>. <year>2024</year>;<volume>147</volume>:<fpage>e5</fpage>&#8208;<lpage>6</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awad281</pub-id><pub-id pub-id-type="pmid">37615305</pub-id></mixed-citation></ref><ref id="alz70717-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70717-cite-0006"><string-name name-style="western"><surname>Abu&#8208;Rumeileh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Abdelhak</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Foschi</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>The multifaceted role of neurofilament light chain protein in non&#8208;primary neurological diseases</article-title>. <source>Brain</source>. <year>2023</year>;<volume>146</volume>:<fpage>421</fpage>&#8208;<lpage>437</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awac328</pub-id><pub-id pub-id-type="pmid">36083979</pub-id><pub-id pub-id-type="pmcid">PMC9494370</pub-id></mixed-citation></ref><ref id="alz70717-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70717-cite-0007"><string-name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Verberk</surname><given-names>IMW</given-names></string-name>, <string-name name-style="western"><surname>Thijssen</surname><given-names>EH</given-names></string-name>, et&#160;al. <article-title>Blood&#8208;based biomarkers for Alzheimer's disease: towards clinical implementation</article-title>. <source>Lancet Neurol</source>. <year>2021</year>:<fpage>66</fpage>&#8208;<lpage>77</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(21)00361-6</pub-id><pub-id pub-id-type="pmid">34838239</pub-id></mixed-citation></ref><ref id="alz70717-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70717-cite-0008"><string-name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Warmenhoven</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Anastasi</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>Plasma phospho&#8208;tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform</article-title>. <source>Nat Med</source>. <year>2025</year>; <volume>31</volume>:<fpage>2036</fpage>&#8211;<lpage>2043</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-025-03622-w</pub-id><pub-id pub-id-type="pmid">40205199</pub-id><pub-id pub-id-type="pmcid">PMC12176611</pub-id></mixed-citation></ref><ref id="alz70717-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70717-cite-0009"><string-name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Brum</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Di Molfetta</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology</article-title>. <source>JAMA Neurol</source>. <year>2024</year>;<volume>81</volume>:<fpage>255</fpage>&#8208;<lpage>263</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2023.5319</pub-id><pub-id pub-id-type="pmid">38252443</pub-id><pub-id pub-id-type="pmcid">PMC10804282</pub-id></mixed-citation></ref><ref id="alz70717-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70717-cite-0010"><string-name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Keshavan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brum</surname><given-names>WS</given-names></string-name>, et&#160;al. <article-title>The Alzheimer's association global biomarker standardization consortium (GBSC) plasma phospho&#8208;tau round robin study</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e14508</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/alz.14508</pub-id><pub-id pub-id-type="pmid">39907496</pub-id><pub-id pub-id-type="pmcid">PMC11851162</pub-id></mixed-citation></ref><ref id="alz70717-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70717-cite-0011"><string-name name-style="western"><surname>Eratne</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q&#8208;X</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Strong diagnostic performance of plasma ptau217 for CSF biomarker&#8208;defined young&#8208;onset Alzheimer disease in a diagnostically heterogeneous clinical cohort</article-title>. <source>J Neurol</source>. <year>2024</year>;<volume>272</volume>:<fpage>25</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s00415-024-12732-3</pub-id><pub-id pub-id-type="pmid">39666133</pub-id></mixed-citation></ref><ref id="alz70717-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70717-cite-0012"><string-name name-style="western"><surname>Therriault</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Pola</surname><given-names>I</given-names></string-name>, et&#160;al. <article-title>Comparison of two plasma p&#8208;tau217 assays to detect and monitor Alzheimer's pathology</article-title>. <source>EBioMedicine</source>. <year>2024</year>;<volume>102</volume>:<elocation-id>105046</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.ebiom.2024.105046</pub-id><pub-id pub-id-type="pmid">38471397</pub-id><pub-id pub-id-type="pmcid">PMC10943661</pub-id></mixed-citation></ref><ref id="alz70717-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70717-cite-0013"><string-name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Quiroz</surname><given-names>YT</given-names></string-name>, et&#160;al. <article-title>Discriminative accuracy of plasma phospho&#8208;tau217 for Alzheimer disease versus other neurodegenerative disorders</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>324</volume>:<fpage>772</fpage>&#8208;<lpage>781</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.12134</pub-id><pub-id pub-id-type="pmid">32722745</pub-id><pub-id pub-id-type="pmcid">PMC7388060</pub-id></mixed-citation></ref><ref id="alz70717-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70717-cite-0014"><string-name name-style="western"><surname>Gonzalez&#8208;Ortiz</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Karikari</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Taylor&#8208;Te Vruchte</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Plasma phosphorylated&#8208;tau217 is increased in Niemann&#8208;Pick disease type C</article-title>. <source>Brain Commun</source>. <year>2024</year>;<volume>6</volume>:<elocation-id>fcae375</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/braincomms/fcae375</pub-id><pub-id pub-id-type="pmid">39502943</pub-id><pub-id pub-id-type="pmcid">PMC11535543</pub-id></mixed-citation></ref><ref id="alz70717-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70717-cite-0015"><string-name name-style="western"><surname>Eratne</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>MJY</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Plasma and CSF neurofilament light chain distinguish neurodegenerative from primary psychiatric conditions in a clinical setting</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>:<fpage>7989</fpage>&#8208;<lpage>8001</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.14278</pub-id><pub-id pub-id-type="pmid">39369278</pub-id><pub-id pub-id-type="pmcid">PMC11567869</pub-id></mixed-citation></ref><ref id="alz70717-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70717-cite-0016"><string-name name-style="western"><surname>Katisko</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Cajanus</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>J&#228;&#228;skel&#228;inen</surname><given-names>O</given-names></string-name>, et&#160;al. <article-title>Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders</article-title>. <source>J. Neurol</source>. <year>2020</year>;<volume>267</volume>:<fpage>162</fpage>&#8208;<lpage>167</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00415-019-09567-8</pub-id><pub-id pub-id-type="pmid">31595378</pub-id><pub-id pub-id-type="pmcid">PMC6954884</pub-id></mixed-citation></ref><ref id="alz70717-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70717-cite-0017"><string-name name-style="western"><surname>G&#246;tze</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Vrillon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bouaziz&#8208;Amar</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Plasma neurofilament light chain in memory clinic practice: evidence from a real&#8208;life study</article-title>. <source>Neurobiol Dis</source>. <year>2023</year>;<volume>176</volume>:<elocation-id>105937</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.nbd.2022.105937</pub-id><pub-id pub-id-type="pmid">36462720</pub-id></mixed-citation></ref><ref id="alz70717-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70717-cite-0018"><string-name name-style="western"><surname>Rousset</surname><given-names>RZ</given-names></string-name>, <string-name name-style="western"><surname>Claessen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>van Harten</surname><given-names>AC</given-names></string-name>, et&#160;al. <article-title>Performance of plasma p&#8208;tau217 and NfL in an unselected memory clinic setting</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2024</year>;<volume>16</volume>:<elocation-id>e70003</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/dad2.70003</pub-id><pub-id pub-id-type="pmid">39583647</pub-id><pub-id pub-id-type="pmcid">PMC11584915</pub-id></mixed-citation></ref><ref id="alz70717-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70717-cite-0019"><string-name name-style="western"><surname>Eratne</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Loi</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q&#8208;X</given-names></string-name>, et&#160;al. <article-title>Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>18</volume>:<fpage>2218</fpage>&#8208;<lpage>2233</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.12549</pub-id><pub-id pub-id-type="pmid">35102694</pub-id></mixed-citation></ref><ref id="alz70717-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70717-cite-0020"><string-name name-style="western"><surname>Eratne</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Loi</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Walia</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: a &#8220;C&#8208;reactive protein&#8221; for psychiatrists and neurologists?</article-title>. <source>Aust N Z J Psychiatry</source>. <year>2020</year>;<volume>54</volume>:<fpage>57</fpage>&#8208;<lpage>67</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0004867419857811</pub-id><pub-id pub-id-type="pmid">31220922</pub-id></mixed-citation></ref><ref id="alz70717-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70717-cite-0021"><string-name name-style="western"><surname>Verberk</surname><given-names>IMW</given-names></string-name>, <string-name name-style="western"><surname>Laarhuis</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>van den Bosch</surname><given-names>KA</given-names></string-name>, et&#160;al. <article-title>Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic&#8208;based cohort study</article-title>. <source>The Lancet Healthy Longevity</source>. <year>2021</year>;<volume>2</volume>:<fpage>e87</fpage>&#8208;<lpage>95</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2666-7568(20)30061-1</pub-id><pub-id pub-id-type="pmid">36098162</pub-id></mixed-citation></ref><ref id="alz70717-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70717-cite-0022"><string-name name-style="western"><surname>Katisko</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Cajanus</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Huber</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2021</year>;<volume>92</volume>:<fpage>1305</fpage>&#8208;<lpage>1312</lpage>. doi:<pub-id pub-id-type="doi">10.1136/jnnp-2021-326487</pub-id><pub-id pub-id-type="pmid">34187866</pub-id></mixed-citation></ref><ref id="alz70717-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70717-cite-0023"><string-name name-style="western"><surname>Chatterjee</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Pedrini</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Doecke</surname><given-names>JD</given-names></string-name>, et&#160;al. <article-title>Plasma A&#946;42/40 ratio, p&#8208;tau181, GFAP, and NfL across the Alzheimer's disease continuum: a cross&#8208;sectional and longitudinal study in the AIBL cohort</article-title>. <source>Alzheimer's &amp; Dementia</source>. <year>2023</year>;<volume>19</volume>:<fpage>1117</fpage>&#8208;<lpage>1134</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.12724</pub-id><pub-id pub-id-type="pmid">36574591</pub-id></mixed-citation></ref><ref id="alz70717-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70717-cite-0024"><string-name name-style="western"><surname>Chatterjee</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Pedrini</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></string-name>, et&#160;al. <article-title>Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>18</volume>:<fpage>1141</fpage>&#8208;<lpage>1154</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.12447</pub-id><pub-id pub-id-type="pmid">34494715</pub-id></mixed-citation></ref><ref id="alz70717-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70717-cite-0025"><string-name name-style="western"><surname>Baiardi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Quadalti</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mammana</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Diagnostic value of plasma p&#8208;tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias</article-title>. <source>Alzheimers Res Ther</source>. <year>2022</year>;<volume>14</volume>:<fpage>153</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13195-022-01093-6</pub-id><pub-id pub-id-type="pmid">36221099</pub-id><pub-id pub-id-type="pmcid">PMC9555092</pub-id></mixed-citation></ref><ref id="alz70717-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70717-cite-0026"><string-name name-style="western"><surname>Kang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Grewal</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Eratne</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Neurofilament light and glial fibrillary acidic protein in mood and anxiety disorders: a systematic review and meta&#8208;analysis</article-title>. <source>Brain Behav Immun</source>. <year>2025</year>;<volume>123</volume>:<fpage>1091</fpage>&#8208;<lpage>1102</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbi.2024.11.001</pub-id><pub-id pub-id-type="pmid">39510417</pub-id></mixed-citation></ref><ref id="alz70717-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70717-cite-0027"><string-name name-style="western"><surname>Kang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Eratne</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dean</surname><given-names>O</given-names></string-name>, et&#160;al. <article-title>Plasma Glial fibrillary acidic protein and neurofilament light are elevated in bipolar depression: evidence for neuroprogression and astrogliosis</article-title>. <source>Bipolar Disord</source>. <year>2025</year>;<volume>27</volume>(<issue>5</issue>):<fpage>379</fpage>&#8208;<lpage>388</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bdi.70029</pub-id><pub-id pub-id-type="pmid">40265626</pub-id><pub-id pub-id-type="pmcid">PMC12397446</pub-id></mixed-citation></ref><ref id="alz70717-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70717-cite-0028"><string-name name-style="western"><surname>Eratne</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Malpas</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders</article-title>. <source>Aust N Z J Psychiatry</source>. <year>2024</year>;<volume>58</volume>:<fpage>70</fpage>&#8208;<lpage>81</lpage>. doi:<pub-id pub-id-type="doi">10.1177/00048674231187312</pub-id><pub-id pub-id-type="pmid">37477141</pub-id></mixed-citation></ref><ref id="alz70717-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70717-cite-0029"><string-name name-style="western"><surname>Kang</surname><given-names>MJY</given-names></string-name>, <string-name name-style="western"><surname>Eratne</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dobson</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Cerebrospinal fluid neurofilament light predicts longitudinal diagnostic change in patients with psychiatric and neurodegenerative disorders</article-title>. <source>Acta Neuropsychiatr</source>. <year>2024</year>;<volume>36</volume>:<fpage>17</fpage>&#8208;<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.1017/neu.2023.25</pub-id><pub-id pub-id-type="pmid">37114460</pub-id></mixed-citation></ref><ref id="alz70717-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70717-cite-0030"><string-name name-style="western"><surname>Bhalala</surname><given-names>OG</given-names></string-name>, <string-name name-style="western"><surname>Beamish</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Eratne</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Blood biomarker profiles in young&#8208;onset neurocognitive disorders: a cohort study</article-title>. <source>Aust N Z J Psychiatry</source>. <year>2025</year>;<volume>59</volume>:<fpage>378</fpage>&#8208;<lpage>388</lpage>. doi:<pub-id pub-id-type="doi">10.1177/00048674241312805</pub-id><pub-id pub-id-type="pmid">39825484</pub-id><pub-id pub-id-type="pmcid">PMC11924289</pub-id></mixed-citation></ref><ref id="alz70717-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70717-cite-0031"><string-name name-style="western"><surname>Eratne</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>MJY</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Plasma neurofilament light outperforms glial fibrillary acidic protein in differentiating behavioural variant frontotemporal dementia from primary psychiatric disorders</article-title>. <source>J Neurol Sci</source>. <year>2024</year>;<volume>467</volume>:<elocation-id>123291</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.jns.2024.123291</pub-id><pub-id pub-id-type="pmid">39577322</pub-id></mixed-citation></ref><ref id="alz70717-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70717-cite-0032"><string-name name-style="western"><surname>de Boer</surname><given-names>SCM</given-names></string-name>, <string-name name-style="western"><surname>Fenoglio</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Arighi</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Serum neurofilament light is superior to glial fibrillary acidic protein to distinguish sporadic frontotemporal dementia from late&#8208;onset primary psychiatric disorders: a retrospective DIPPA&#8208;FTD study</article-title>. <source>BMJ Neurol Open</source>. <year>2025</year>;<volume>7</volume>:<elocation-id>e001007</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmjno-2024-001007</pub-id><pub-id pub-id-type="pmcid">PMC12142094</pub-id><pub-id pub-id-type="pmid">40486666</pub-id></mixed-citation></ref><ref id="alz70717-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70717-cite-0033"><string-name name-style="western"><surname>Benussi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Huber</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Plasma p&#8208;tau217 and neurofilament/p&#8208;tau217 ratio in differentiating Alzheimer's disease from syndromes associated with frontotemporal lobar degeneration</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e14482</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/alz.14482</pub-id><pub-id pub-id-type="pmid">39776166</pub-id><pub-id pub-id-type="pmcid">PMC11848195</pub-id></mixed-citation></ref><ref id="alz70717-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70717-cite-0034"><string-name name-style="western"><surname>Loi</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Cations</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Velakoulis</surname><given-names>D</given-names></string-name>. <article-title>Young&#8208;onset dementia diagnosis, management and care: a narrative review</article-title>. <source>Medical Journal of Australia</source>. <year>2023</year>;<volume>218</volume>:<fpage>182</fpage>&#8208;<lpage>189</lpage>. doi:<pub-id pub-id-type="doi">10.5694/mja2.51849</pub-id><pub-id pub-id-type="pmid">36807325</pub-id><pub-id pub-id-type="pmcid">PMC10952480</pub-id></mixed-citation></ref><ref id="alz70717-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70717-cite-0035"><string-name name-style="western"><surname>Tsoukra</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Velakoulis</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wibawa</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>The Diagnostic challenge of young&#8208;onset dementia syndromes and primary psychiatric diseases: results From a retrospective 20&#8208;year cross&#8208;sectional study</article-title>. <source>J Neuropsychiatry Clin Neurosci</source>. <year>2022</year>;<volume>34</volume>:<fpage>44</fpage>&#8208;<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.neuropsych.20100266</pub-id><pub-id pub-id-type="pmid">34538074</pub-id></mixed-citation></ref><ref id="alz70717-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70717-cite-0036"><string-name name-style="western"><surname>Loi</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Goh</surname><given-names>AMY</given-names></string-name>, <string-name name-style="western"><surname>Mocellin</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Time to diagnosis in younger&#8208;onset dementia and the impact of a specialist diagnostic service</article-title>. <source>Int Psychogeriatr</source>. <year>2022</year>;<volume>34</volume>:<fpage>367</fpage>&#8208;<lpage>375</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S1041610220001489</pub-id><pub-id pub-id-type="pmid">32854788</pub-id></mixed-citation></ref><ref id="alz70717-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70717-cite-0037"><string-name name-style="western"><surname>Tybirk</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hviid</surname><given-names>CVB</given-names></string-name>, <string-name name-style="western"><surname>Knudsen</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Parkner</surname><given-names>T</given-names></string-name>. <article-title>Serum GFAP&#8212;reference interval and preanalytical properties in Danish adults</article-title>. <source>Clin Chem Lab Med</source>. <year>2022</year>;<volume>60</volume>:<fpage>1830</fpage>&#8208;<lpage>1838</lpage>. doi:<pub-id pub-id-type="doi">10.1515/cclm-2022-0646</pub-id><pub-id pub-id-type="pmid">36067832</pub-id></mixed-citation></ref><ref id="alz70717-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz70717-cite-0038"><string-name name-style="western"><surname>Cooper</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Stukas</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ghodsi</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Age specific reference intervals for plasma biomarkers of neurodegeneration and neurotrauma in a Canadian population</article-title>. <source>Clinical Biochemistry</source>. <year>2023</year>;<volume>121&#8208;122</volume>:<elocation-id>110680</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.clinbiochem.2023.110680</pub-id><pub-id pub-id-type="pmid">37884086</pub-id></mixed-citation></ref><ref id="alz70717-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70717-cite-0039"><string-name name-style="western"><surname>Gonzalez&#8208;Ortiz</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>PCL</given-names></string-name>, <string-name name-style="western"><surname>Gonz&#225;lez&#8208;Escalante</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>A novel ultrasensitive assay for plasma p&#8208;tau217: performance in individuals with subjective cognitive decline and early Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>:<fpage>1239</fpage>&#8208;<lpage>1249</lpage>. doi:<pub-id pub-id-type="doi">10.1002/alz.13525</pub-id><pub-id pub-id-type="pmid">37975513</pub-id><pub-id pub-id-type="pmcid">PMC10916963</pub-id></mixed-citation></ref><ref id="alz70717-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz70717-cite-0040"><string-name name-style="western"><surname>Walterfang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Siu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Velakoulis</surname><given-names>D</given-names></string-name>. <article-title>The NUCOG: validity and reliability of a brief cognitive screening tool in neuropsychiatric patients</article-title>. <source>Australian and New Zealand Journal of Psychiatry</source>. <year>2006</year>;<volume>40</volume>:<fpage>995</fpage>&#8208;<lpage>1002</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1440-1614.2006.01923.x</pub-id><pub-id pub-id-type="pmid">17054568</pub-id></mixed-citation></ref><ref id="alz70717-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70717-cite-0041"><string-name name-style="western"><surname>Simr&#233;n</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Andreasson</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Gobom</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5&#8208;90 years</article-title>. <source>Brain Communications</source>. <year>2022</year>;<volume>4</volume>(<issue>4</issue>):<elocation-id>fcac174</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/braincomms/fcac174</pub-id><pub-id pub-id-type="pmid">35865350</pub-id><pub-id pub-id-type="pmcid">PMC9297091</pub-id></mixed-citation></ref><ref id="alz70717-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70717-cite-0042"><string-name name-style="western"><surname>Light</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Rahme</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Clinical accuracy of serum neurofilament light to differentiate frontotemporal dementia from primary psychiatric disorders is age&#8208;dependent</article-title>. <source>Am J Geriatr Psychiatry</source>. <year>2024</year>;<volume>32</volume>:<fpage>988</fpage>&#8208;<lpage>1001</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jagp.2024.03.008</pub-id><pub-id pub-id-type="pmid">38609836</pub-id></mixed-citation></ref><ref id="alz70717-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70717-cite-0043"><string-name name-style="western"><surname>Sotirchos</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>MD</given-names></string-name>, et&#160;al. <article-title>Agreement between published reference resources for neurofilament light chain levels in people with multiple sclerosis</article-title>. <source>Neurology</source>. <year>2023</year>;<volume>101</volume>:<fpage>e2448</fpage>&#8208;<lpage>53</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000207957</pub-id><pub-id pub-id-type="pmid">37816633</pub-id><pub-id pub-id-type="pmcid">PMC10752633</pub-id></mixed-citation></ref><ref id="alz70717-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70717-cite-0044"><string-name name-style="western"><surname>Ducharme</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dols</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Laforce</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders</article-title>. <source>Brain</source>. <year>2020</year>;<volume>143</volume>:<fpage>1632</fpage>&#8208;<lpage>1650</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awaa018</pub-id><pub-id pub-id-type="pmid">32129844</pub-id><pub-id pub-id-type="pmcid">PMC7849953</pub-id></mixed-citation></ref><ref id="alz70717-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70717-cite-0045"><string-name name-style="western"><surname>Abu&#8208;Rumeileh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Scholle</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mensch</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Phosphorylated tau 181 and 217 are elevated in serum and muscle of patients with amyotrophic lateral sclerosis</article-title>. <source>Nat Commun</source>. <year>2025</year>;<volume>16</volume>:<fpage>2019</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-025-57144-7</pub-id><pub-id pub-id-type="pmid">40044663</pub-id><pub-id pub-id-type="pmcid">PMC11882981</pub-id></mixed-citation></ref><ref id="alz70717-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz70717-cite-0046"><string-name name-style="western"><surname>Bhalala</surname><given-names>OG</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Watson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yassi</surname><given-names>N</given-names></string-name>. <article-title>Contextualising the benefits and risks of anti&#8208;amyloid therapy for patients with Alzheimer disease and their care team</article-title>. <source>Med J Aust</source>. <year>2024</year>;<volume>221</volume>:<fpage>78</fpage>&#8208;<lpage>82</lpage>. doi:<pub-id pub-id-type="doi">10.5694/mja2.52359</pub-id><pub-id pub-id-type="pmid">38894659</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Alzheimers Dis Rep</journal-id><journal-id journal-id-type="iso-abbrev">J Alzheimers Dis Rep</journal-id><journal-id journal-id-type="pmc-domain-id">3553</journal-id><journal-id journal-id-type="pmc-domain">jadr</journal-id><journal-id journal-id-type="publisher-id">ALR</journal-id><journal-title-group><journal-title>Journal of Alzheimer's Disease Reports</journal-title></journal-title-group><issn pub-type="epub">2542-4823</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12480830</article-id><article-id pub-id-type="pmcid-ver">PMC12480830.1</article-id><article-id pub-id-type="pmcaid">12480830</article-id><article-id pub-id-type="pmcaiid">12480830</article-id><article-id pub-id-type="pmid">41036470</article-id><article-id pub-id-type="doi">10.1177/25424823251384245</article-id><article-id pub-id-type="publisher-id">10.1177_25424823251384245</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>KIAA0319 modulates Alzheimer's disease risk through PMM2 regulation: Evidence from integrated pQTL-mediation and transcriptomic analyses</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1451-497X</contrib-id><name name-style="western"><surname>Wen</surname><given-names initials="P">Peng</given-names></name><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff1-25424823251384245" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-7430-3891</contrib-id><name name-style="western"><surname>Han</surname><given-names initials="C">Chong</given-names></name><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff2-25424823251384245" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-8400-6885</contrib-id><name name-style="western"><surname>Zhao</surname><given-names initials="H">Hongxin</given-names></name><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="aff3-25424823251384245" ref-type="aff">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-0208-513X</contrib-id><name name-style="western"><surname>Yao</surname><given-names initials="S">Shengtao</given-names></name><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff2-25424823251384245" ref-type="aff">2</xref><xref rid="corresp1-25424823251384245" ref-type="corresp"/><xref rid="corresp1-25424823251384245" ref-type="corresp"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3498-6088</contrib-id><name name-style="western"><surname>Chen</surname><given-names initials="H">Huan</given-names></name><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff4-25424823251384245" ref-type="aff">4</xref><xref rid="corresp2-25424823251384245" ref-type="corresp"/></contrib></contrib-group><aff id="aff1-25424823251384245">
<label>1</label>Department of Neurosurgery, The Third Affiliated Hospital of Zunyi Medical University, The First People's Hospital of Zunyi, Zunyi, China</aff><aff id="aff2-25424823251384245">
<label>2</label>Department of Cerebrovascular Disease, <institution-wrap><institution-id institution-id-type="Ringgold">159358</institution-id><institution content-type="university">Affiliated Hospital of Zunyi Medical University</institution></institution-wrap>, Zunyi, China</aff><aff id="aff3-25424823251384245">
<label>3</label>Department of Neurosurgery, <institution-wrap><institution-id institution-id-type="Ringgold">159358</institution-id><institution content-type="university">Affiliated Hospital of Zunyi Medical University</institution></institution-wrap>, Zunyi, China</aff><aff id="aff4-25424823251384245">
<label>4</label>Department of Clinical Pharmacy, The Third Affiliated Hospital of Zunyi Medical University, The First People's Hospital of Zunyi, Zunyi, China</aff><author-notes><corresp id="corresp1-25424823251384245">Shengtao Yao, Department of Cerebrovascular Disease, Affiliated Hospital of Zunyi Medical University, Zunyi, China. Email: <email>812526064@qq.com</email></corresp><corresp id="corresp2-25424823251384245">Huan Chen, Department of Clinical Pharmacy, The Third Affiliated Hospital of Zunyi Medical University, The First People's Hospital of Zunyi, Zunyi, China. Email: <email>chenhuantry@126.com</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2025</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">482990</issue-id><elocation-id>25424823251384245</elocation-id><history><date date-type="received"><day>10</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 09:25:35.093"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_25424823251384245.pdf"/><abstract><sec><title>Background</title><p>Genome-wide studies have identified multiple risk genes for Alzheimer's disease (AD), yet the causal protein interactions and pathways driving AD pathogenesis remain unclear.</p></sec><sec><title>Objective</title><p>This study aimed to assess the causal relationships between plasma proteins and AD risk, and to delineate protein-mediated regulatory pathways involved in AD pathogenesis.</p></sec><sec><title>Methods</title><p>We assessed the causal relationships between plasma proteins and AD risk using protein quantitative trait loci (pQTL) data from two large-scale resources: the UK Biobank Pharma Proteomics Project (UKB-PPP) and deCODE genetics. These data were integrated with genome-wide association studies (GWAS) on AD. We applied two-sample Mendelian randomization (MR), followed by two-step MR and mediation analyses, to delineate causal regulatory pathways and quantify mediating effects of proteins in AD pathogenesis. To further provide supporting evidence, we analyzed transcriptomic data from postmortem AD brain tissues (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE33000">GSE33000</ext-link>, Gene Expression Omnibus) and conducted differential expression analyses.</p></sec><sec><title>Results</title><p>In the UK Biobank cohort, seven upstream proteins showed causal associations with six downstream proteins in the deCODE cohort, which in turn influenced AD risk through both positive and negative regulatory effects (p&#8201;&lt;&#8201;0.05). Transcriptomic analysis demonstrated significant downregulation of <italic toggle="yes">KIAA0319</italic> in AD patients (p&#8201;&lt;&#8201;0.0001). These findings were consistent with our mediation analysis, which indicated that reduced KIAA0319 expression adversely affected PMM2 and thereby increased AD risk (mediation effect: 13.37%, 95% CI: 1.68%&#8211;25.06%, p&#8201;&lt;&#8201;0.05).</p></sec><sec><title>Conclusions</title><p>This integrative analysis uncovered a novel KIAA0319&#8211;PMM2 regulatory axis implicated in AD pathogenesis. Both proteins represent potential therapeutic targets for future AD interventions.</p></sec></abstract><kwd-group><kwd>Alzheimer's disease</kwd><kwd>KIAA0319</kwd><kwd>Mendelian randomization</kwd><kwd>PMM2</kwd><kwd>pQTL</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts19</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-25424823251384245"><title>Introduction</title><p>Alzheimer's disease (AD), a predominant form of neurodegenerative disorder, accounts for 60%&#8211;80% of global dementia cases.<sup>
<xref rid="bibr1-25424823251384245" ref-type="bibr">1</xref>
</sup> Genetic predisposition and aging have been established as primary risk factors for AD.<sup><xref rid="bibr2-25424823251384245" ref-type="bibr">2</xref><xref rid="bibr3-25424823251384245" ref-type="bibr"/>&#8211;<xref rid="bibr4-25424823251384245" ref-type="bibr">4</xref></sup> Research on its pathological mechanisms has focused predominantly on two hallmark features: amyloid-&#946; (A&#946;) plaque deposition and neurofibrillary tangles.<sup><xref rid="bibr4-25424823251384245" ref-type="bibr">4</xref>,<xref rid="bibr5-25424823251384245" ref-type="bibr">5</xref></sup> Recent studies have revealed multidimensional pathophysiological mechanisms underlying AD, including the A&#946; cascade, aberrant tau protein modifications, and neuroinflammatory activation.<sup>
<xref rid="bibr6-25424823251384245" ref-type="bibr">6</xref>
</sup> However, clinical trials targeting these pathways have repeatedly encountered setbacks,<sup><xref rid="bibr6-25424823251384245" ref-type="bibr">6</xref>,<xref rid="bibr7-25424823251384245" ref-type="bibr">7</xref></sup> underscoring the complexity of disease regulatory networks and the limitations of current therapeutic strategies.<sup>
<xref rid="bibr8-25424823251384245" ref-type="bibr">8</xref>
</sup> Consequently, an in-depth understanding of the molecular mechanisms underlying AD is urgently needed to provide a theoretical foundation for the development of early diagnostic biomarkers and innovative therapies.</p><p>Advances in genetic research have opened new directions for exploring AD pathogenesis. The <italic toggle="yes">APOE4</italic> allele, recognized as the most significant genetic risk factor, accelerates AD progression through dual mechanisms: promoting aberrant A&#946; deposition and tau hyperphosphorylation<sup>
<xref rid="bibr3-25424823251384245" ref-type="bibr">3</xref>
</sup> and exacerbating pathological accumulation via low-density lipoprotein receptor-mediated clearance impairment.<sup><xref rid="bibr9-25424823251384245" ref-type="bibr">9</xref>,<xref rid="bibr10-25424823251384245" ref-type="bibr">10</xref></sup> Furthermore, genome-wide association studies (GWASs) have identified novel risk gene clusters, such as <italic toggle="yes">TREM2</italic>, <italic toggle="yes">CLU</italic>, and <italic toggle="yes">BIN1</italic>, whose functional networks encompass critical pathways, including immune regulation, lipid metabolism, and A&#946; clearance.<sup>
<xref rid="bibr11-25424823251384245" ref-type="bibr">11</xref>
</sup> Notably, GWAS-identified risk genes collaboratively regulate pathological progression through dynamic protein interaction networks. For instance, <italic toggle="yes">APOE4</italic> has been demonstrated to drive the spatial propagation of tau pathology.<sup><xref rid="bibr12-25424823251384245" ref-type="bibr">12</xref>,<xref rid="bibr13-25424823251384245" ref-type="bibr">13</xref></sup> Nevertheless, the current research lacks systematic elucidation of the causal temporality and molecular cascades underlying AD risk protein interactions.</p><p>Mendelian randomization (MR) methodology offers an innovative tool to address this bottleneck. By leveraging genetic variants as instrumental variables, MR enables robust inference of causal associations between exposure factors (e.g., protein expression) and AD risk, circumventing the confounding biases inherent in traditional observational studies.<sup><xref rid="bibr14-25424823251384245" ref-type="bibr">14</xref><xref rid="bibr15-25424823251384245" ref-type="bibr"/>&#8211;<xref rid="bibr16-25424823251384245" ref-type="bibr">16</xref></sup> Furthermore, integration of protein quantitative trait loci (pQTL) data facilitates systematic screening of AD risk genes as well as their downstream functional targets.<sup><xref rid="bibr17-25424823251384245" ref-type="bibr">17</xref>,<xref rid="bibr18-25424823251384245" ref-type="bibr">18</xref></sup></p><p>In this study, two independent European population-based pQTL datasets are innovatively integrated and a two-step MR framework is employed to systematically investigate the causal relationships between upstream regulatory proteins associated with AD and their potential protein mediators, elucidating how they influence disease risk. The aim of this work is to provide novel evidence clarifying specific gene&#8210;protein&#8210;phenotype causal pathways and identify key proteins that may represent promising therapeutic targets.</p></sec><sec sec-type="methods" id="section2-25424823251384245"><title>Methods</title><sec id="section2A-25424823251384245"><title>Study design</title><p>This study adheres to the STROBE-MR guidelines and rigorously complies with the three core assumptions of MR to ensure that instrumental variables (IVs) must (1) exhibit significant associations with exposures, (2) remain unaffected by potential confounders, and (3) influence outcomes exclusively through exposure without involvement in alternative biological pathways or horizontal pleiotropy. The workflow is illustrated in <xref rid="fig1-25424823251384245" ref-type="fig">Figure 1</xref>. Protein levels associated with the UKB pQTL served as exposures, proteins derived from the Icelandic pQTL acted as mediators, and AD was designated as the outcome. Following IV selection, MR analyses were conducted. All the statistical analyses, including MR and MR-PRESSO, were performed using R version 4.4.2 (available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.R-project.org" ext-link-type="uri">http://www.R-project.org</ext-link>).</p><fig position="float" id="fig1-25424823251384245" orientation="portrait"><label>Figure 1.</label><caption><p>Research design pathway.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251384245-fig1.jpg"/></fig></sec><sec id="section2B-25424823251384245"><title>Data sources</title><sec id="section2B1-25424823251384245"><title>UKB-PPP pQTL dataset</title><p>This resource was derived from a large-scale study that integrated plasma proteomics, genetics, and health data from the UK Biobank (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.synapse.org/Synapse:syn51364943/wiki/622119" ext-link-type="uri">https://www.synapse.org/Synapse:syn51364943/wiki/622119</ext-link>). It provides comprehensive pQTL mapping of 2923 plasma proteins across 54,219 participants.<sup>
<xref rid="bibr19-25424823251384245" ref-type="bibr">19</xref>
</sup></p></sec><sec id="section2B2-25424823251384245"><title>Icelandic pQTL dataset</title><p>Obtained from deCODE genetics (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.decode.com/summarydata/" ext-link-type="uri">http://www.decode.com/summarydata/</ext-link>), this dataset contains GWAS associations for plasma protein levels quantified through 4907 aptamers in 35,559 Icelandic individuals.<sup>
<xref rid="bibr20-25424823251384245" ref-type="bibr">20</xref>
</sup></p></sec><sec id="section2B3-25424823251384245"><title>AD GWAS data</title><p>This dataset was accessed from the IEU Open GWAS database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90027001-GCST90028000/GCST90027158/" ext-link-type="uri">http://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90027001-GCST90028000/GCST90027158/</ext-link>) and included 487,511 participants, comprising 39,106 clinically diagnosed AD cases, 46,828 proxy-ADD cases, and 401,577 controls.<sup>
<xref rid="bibr3-25424823251384245" ref-type="bibr">3</xref>
</sup> In this study, the clinically diagnosed AD cases and proxy-ADD cases were combined into the AD case group, while the remaining participants served as the control group.</p></sec></sec><sec id="section2C-25424823251384245"><title>Instrumental variable selection</title><p>To ensure reliable causal inference between UKB-PPP pQTL proteins and AD risk and to characterize Icelandic pQTL proteins as potential mediators, we implemented the following quality control steps for IV selection following best practices outlined in recent high-impact MR studies (<xref rid="fig1-25424823251384245" ref-type="fig">Figure 1</xref>):<sup>
<xref rid="bibr21-25424823251384245" ref-type="bibr">21</xref>
</sup> (1) Significance threshold: single nucleotide polymorphisms (SNPs) significantly associated with protein exposures (p&#8201;&lt;&#8201;5&#8201;&#215;&#8201;10<sup>&#8722;8</sup>) were selected as initial IVs to ensure strong instrument-exposure associations. (2) Linkage disequilibrium (LD) clumping: SNPs were pruned using PLINK with the following parameters: a clumping window of 10,000&#8197;kb and an LD threshold of r&#178;&#8201;&lt;&#8201;0.1, using the 1000 Genomes European population as a reference panel to mitigate bias from correlated variants. (3) Weak IV exclusion: Instruments with F-statistics&#8201;&lt;&#8201;10 were removed to avoid weak instrument bias, with F-statistics calculated as F&#8201;=&#8201;&#946;&#178;/SE&#178; (the squared ratio of the SNP-exposure effect size to its standard error). (4) Allele harmonization: Data harmonization was performed using the harmonise_data() function in the TwoSampleMR R package to ensure consistency of effect alleles between the exposure and outcome datasets. (5) IV quantity control: To ensure reliable causal estimates, we documented the number of IVs used in each MR analysis. While all proteins passing the initial IV selection criteria were included in the primary MR screening, only proteins with &#8805;5 instrumental variables were considered for subsequent mediation analysis to avoid unstable estimates associated with insufficient instruments. Proteins with &lt;5 IVs were retained in the initial screening but excluded from downstream analyses because of potential reliability concerns.</p></sec><sec id="section2D-25424823251384245"><title>MR analysis</title><p>The inverse-variance weighted (IVW) method<sup>
<xref rid="bibr22-25424823251384245" ref-type="bibr">22</xref>
</sup> was employed as the primary analytical approach to investigate (1) causal effects of proteins identified from UKB-PPP pQTLs on AD and (2) causal effects of proteins identified from Icelandic pQTLs on AD. Bonferroni correction was applied to control family-wise error rates, with significance thresholds set as p&#8201;&lt;&#8201;0.05/n (where n represents the number of proteins tested in each dataset). In addition to the primary IVW analysis, we conducted four supplementary MR methods (MR&#8210;Egger, weighted median, weighted mode, and simple mode) as sensitivity analyses. Given the exploratory nature of identifying potential causal associations, we applied a significance threshold of p&#8201;&lt;&#8201;0.05 for these supplementary methods. We considered causal associations robust when supported by at least two MR methods.</p><p>Confounder control and bias assessment: To minimize confounding and assess potential bias, we implemented multiple quality control measures: (1) Steiger filtering was applied using the TwoSampleMR R package, retaining only SNPs with significantly greater variance explained (r&#178;) in the exposure (protein levels) than in the outcome (AD), thus confirming the exposure-to-outcome directionality and addressing potential reverse causality.<sup>
<xref rid="bibr23-25424823251384245" ref-type="bibr">23</xref>
</sup> (2) Horizontal pleiotropy assessment was conducted using MR&#8210;Egger regression (intercept test) and MR-PRESSO to detect and correct for pleiotropic outliers. (3) Heterogeneity evaluation was performed using Cochran's Q test via the mr_heterogeneity_test function. (4) Leave-one-out analysis was systematically performed to assess the robustness of MR results and identify influential instruments by iteratively removing each SNP and recalculating the causal estimate.</p><p>Any analyses exhibiting statistically significant pleiotropy (p&#8201;&lt;&#8201;0.05) or heterogeneity were excluded from further consideration. Sensitivity analyses using multiple MR methods, including IVW, MR&#8210;Egger, and weighted median, were compared to ensure consistency of the results.</p><p>Subsequent MR analyses were conducted to dissect causal relationships between the AD-associated proteins identified from both the UKB-PPP and Icelandic pQTL datasets, as illustrated in <xref rid="fig1-25424823251384245" ref-type="fig">Figure 1</xref>.</p></sec><sec id="section2E-25424823251384245"><title>Mediation analysis</title><p>For proteins identified as potential mediators, we calculated (1) the total effect of UKB-PPP pQTL proteins on Icelandic pQTL proteins (<italic toggle="yes">beta1</italic>) and (2) the total effect of Icelandic pQTL proteins on AD (<italic toggle="yes">beta2</italic>). The mediation effect was computed as <italic toggle="yes">beta12</italic>&#8201;=&#8201;<italic toggle="yes">beta1</italic> * <italic toggle="yes">beta2.</italic><sup>
<xref rid="bibr24-25424823251384245" ref-type="bibr">24</xref>
</sup> The direct effect was derived as <italic toggle="yes">beta_dir</italic>&#8201;=&#8201;<italic toggle="yes">beta_all</italic> - <italic toggle="yes">beta12</italic>, where <italic toggle="yes">beta_all</italic> represents the total effect of UKB-PPP pQTL proteins on AD from our primary MR analysis. The proportion mediated was quantified as <italic toggle="yes">beta12_p</italic>&#8201;=&#8201;<italic toggle="yes">beta12/beta_all</italic>. Statistical significance was defined as p&#8201;&lt;&#8201;0.05 (<xref rid="fig1-25424823251384245" ref-type="fig">Figure 1</xref>).</p></sec><sec id="section2F-25424823251384245"><title>Supporting evidence of mRNA transcript levels</title><p>Transcriptomic data from AD postmortem brain tissues were obtained from the GEO database (accession: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE33000">GSE33000</ext-link>; 310 AD cases, 157 controls).<sup>
<xref rid="bibr25-25424823251384245" ref-type="bibr">25</xref>
</sup> Differential expression analysis was conducted for genes encoding the candidate proteins identified in our MR and mediation analyses. Gene expression data were preprocessed using the limma R package, including averaging of replicate probes and between-array normalization. Differential expression was assessed using the Wilcoxon rank-sum test, with genes considered differentially expressed at a p value&#8201;&lt;&#8201;0.05. Following established MR best practices, genes within the MHC region were excluded from validation because of complex LD structures. The directionality and magnitude of gene expression changes were then compared with the protein-level effects observed in our mediation analysis to assess biological consistency.</p></sec></sec><sec sec-type="results" id="section3-25424823251384245"><title>Results</title><sec id="section3A-25424823251384245"><title>Causal inference between proteins and AD using UKB-PPP pQTL instruments</title><p>After filtering SNPs as IVs, we obtained 2619 molecules from the original 2923 UKB-PPP pQTL molecules and conducted MR analysis using these filtered molecules as exposure factors. To account for multiple testing across 2619 independent MR analyses, we applied a Bonferroni correction with a significance threshold of p&#8201;&lt;&#8201;1.91&#8201;&#215;&#8201;10<sup>&#8722;5</sup> (0.05/2619) for the IVW method results. Following the removal of pleiotropy effects and p value correction from the IVW analysis results, we identified 27 molecules with significant causal associations with AD. These findings suggest potential risk-increasing or protective effects on AD development, with odds ratio (OR) values greater than 1 indicating promoting effects and values less than 1 indicating inhibitory effects (<xref rid="fig2-25424823251384245" ref-type="fig">Figure 2</xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251384245" ext-link-type="uri">Supplemental Table 1</ext-link>). To ensure the robustness of our findings, we conducted four additional MR methods (MR&#8210;Egger, weighted median, weighted mode, and simple mode) as sensitivity analyses. Importantly, all 27 identified molecules were consistently significantly different (p&#8201;&lt;&#8201;0.05) according to at least two MR methods, confirming the reliability of the causal associations (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251384245" ext-link-type="uri">Supplemental Table 1</ext-link>). These 27 causally associated proteins provide important insights into the molecular mechanisms underlying AD pathogenesis and represent potential therapeutic targets.</p><fig position="float" id="fig2-25424823251384245" orientation="portrait"><label>Figure 2.</label><caption><p>Causal effects of UKB-PPP pQTL-identified proteins on Alzheimer&#8217;s disease risk via two-sample Mendelian randomization analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251384245-fig2.jpg"/></fig></sec><sec id="section3B-25424823251384245"><title>Causal inference between proteins and AD using deCODE genetics pQTL instruments</title><p>Similarly, after screening SNPs as IVs, we obtained 4759 molecules from a total of 4907 molecules and performed MR analysis using these pQTL-associated molecules as exposure factors. After removing pleiotropy effects and correcting p values, IVW analysis revealed 30 molecules with significant causal relationships with AD (p&#8201;&lt;&#8201;1.05&#8201;&#215;&#8201;10<sup>&#8722;5</sup>). These results suggest that these molecules potentially influence the development of AD (<xref rid="fig3-25424823251384245" ref-type="fig">Figure 3</xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251384245" ext-link-type="uri">Supplemental Table 2</ext-link>). Sensitivity analyses using four supplementary MR methods confirmed the robustness of these findings, with all 30 identified molecules showing consistently significant results (p&#8201;&lt;&#8201;0.05) in at least two MR methods (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251384245" ext-link-type="uri">Supplemental Table 2</ext-link>). Among the 30 molecules identified, four (APBB2, PPBP, CBX1, and TRH) were supported by fewer than 5 instrumental variables (IVs&#8201;&lt;&#8201;5), which may produce less stable estimates than those with sufficient IVs (&#8805;5). These four molecules are listed in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251384245" ext-link-type="uri">Supplemental Table 2</ext-link> and were excluded from subsequent mediation analyses to ensure the reliability of our main findings. The identification of these 26 proteins with sufficient instrumental variables established a comprehensive pool of potential downstream mediators for investigating the causal pathways through which the UKB-PPP proteins influence AD development.</p><fig position="float" id="fig3-25424823251384245" orientation="portrait"><label>Figure 3.</label><caption><p>Causal effects of deCODE Cohort pQTL-identified proteins on Alzheimer&#8217;s disease risk via two-sample Mendelian randomization analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251384245-fig3.jpg"/></fig></sec><sec id="section3C-25424823251384245"><title>Causal relationships between UKB-PPP pQTLs and deCODE genetics pQTL proteins</title><p>Using the 27 UKB-PPP pQTL protein molecules identified in the preceding analysis as exposure factors and the 30 deCODE genetics pQTL protein molecules as outcomes, we conducted MR analysis. IVW results revealed causal relationships between 12 UKB-PPP pQTL molecules and 20 deCODE genetics pQTL molecules (p&#8201;&lt;&#8201;6.17&#8201;&#215;&#8201;10<sup>&#8722;5</sup>). These findings suggest that the former may influence the expression or activity of the latter (<xref rid="fig4-25424823251384245" ref-type="fig">Figure 4</xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251384245" ext-link-type="uri">Supplemental Table 3</ext-link>). Sensitivity analyses using multiple MR methods demonstrated that except for one molecular pair (LY96 to HDGFRP3, significant only in IVW), all the other identified causal relationships were consistently supported by at least two MR methods (p&#8201;&lt;&#8201;0.05), indicating robust causal evidence (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251384245" ext-link-type="uri">Supplemental Table 3</ext-link>). Among the molecules involved in these causal relationships, HLA-DRA was excluded from transcriptomic analysis because of the complex LD structure within the MHC region, which poses methodological challenges for MR analysis. Additionally, three molecules (APBB2, PPBP, and TRH) with fewer than 5 instrumental variables were also noted but excluded from subsequent mediation analyses to ensure analytical reliability. These exclusions followed established best practices in the field and enhanced the robustness of our findings.</p><fig position="float" id="fig4-25424823251384245" orientation="portrait"><label>Figure 4.</label><caption><p>Causal network among prioritized proteins with effects on Alzheimer&#8217;s disease risk across the UKB-PPP and deCODE Cohorts.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251384245-fig4.jpg"/></fig></sec><sec id="section3D-25424823251384245"><title>Transcriptional supporting evidence and mediation analysis</title><p>The analyses above suggest that 12 UKB-PPP pQTL-associated proteins may indirectly influence AD risk by regulating 17 deCODE genetics pQTL-associated proteins (after methodological exclusions as described above). On the basis of these protein&#8210;protein causal relationships, we conducted a systematic mediation analysis and identified significant regulatory effects of 8 UKB-PPP proteins on 9 deCODE genetics proteins (p&#8201;&lt;&#8201;0.05), with indirect effect proportions (beta12_p) shown in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251384245" ext-link-type="uri">Supplemental Table 4</ext-link>. HLA-DRA was excluded because of MHC region methodological considerations. Seven upstream proteins in the UK Biobank cohort causally influenced six downstream proteins in the deCODE cohort that subsequently modulated AD risk (p&#8201;&lt;&#8201;0.05). The regulatory relationships included both positive regulation (4 pairs: SERPINI2&#8594;CR2, KIAA0319&#8594;PMM2, LILRB5&#8594;FCRL1, RGS8&#8594;SCG3) and negative regulation (3 pairs: MENT&#8594;ARL2, CCL19&#8594;SLC5A5, CD55&#8594;CR2). Among the downstream proteins, five exhibited protective effects against AD (ARL2, SLC5A5, PMM2, FCRL1, and SCG3), while one (CR2) increased AD risk (<xref rid="fig5-25424823251384245" ref-type="fig">Figure 5</xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251384245" ext-link-type="uri">Supplemental Table 4</ext-link>).</p><fig position="float" id="fig5-25424823251384245" orientation="portrait"><label>Figure 5.</label><caption><p>A protein regulatory network linking upstream UKB and downstream deCODE proteins in Alzheimer's disease. The diagram depicts interactions among 7 UKB-derived upstream proteins and 6 deCODE-derived downstream proteins, outlining their collective influence on disease risk.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251384245-fig5.jpg"/></fig><p>To provide supporting evidence for these protein-level findings at the transcriptional level, we analyzed gene expression data for 7 out of 8 genes from the UKB-PPP pQTL (using sample data from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE33000">GSE33000</ext-link>). The results revealed that <italic toggle="yes">KIAA0319</italic> gene expression was significantly lower in AD patients than in controls (p&#8201;&lt;&#8201;0.0001; <xref rid="fig6-25424823251384245" ref-type="fig">Figure 6</xref>). These transcriptional findings align with our protein-level causal effect direction from MR analysis: downregulation of KIAA0319 expression (and its corresponding protein) may indirectly promote AD progression by inhibiting the expression of the PMM2 protein (beta12_p&#8201;=&#8201;13.37%, 95% CI: 1.68%&#8211;25.06%, p&#8201;&lt;&#8201;0.05) (<xref rid="fig7-25424823251384245" ref-type="fig">Figure 7</xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251384245" ext-link-type="uri">Supplemental Tables 4 and 8</ext-link>).</p><fig position="float" id="fig6-25424823251384245" orientation="portrait"><label>Figure 6.</label><caption><p>Significant downregulation of KIAA0319 in Alzheimer&#8217;s disease patients compared to controls (****p&#8201;&lt;&#8201;0.0001).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251384245-fig6.jpg"/></fig><fig position="float" id="fig7-25424823251384245" orientation="portrait"><label>Figure 7.</label><caption><p>PMM2 mediates the effect of KIAA0319 on Alzheimer's disease risk. <italic toggle="yes">beta1</italic> represents the total effect of KIAA0319 on PMM2; <italic toggle="yes">beta2</italic> represents the total effect of PMM2 on AD; <italic toggle="yes">beta</italic>_<italic toggle="yes">all</italic> represents the total effect of KIAA0319 on AD; <italic toggle="yes">beta12</italic> represents the mediating effect of PMM2 on the KIAA0319-AD pathway.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_25424823251384245-fig7.jpg"/></fig><p>To ensure the robustness of these key findings, we conducted comprehensive sensitivity analyses for the KIAA0319-PMM2-AD causal pathway. Multiple MR methods (IVW, MR&#8210;Egger, weighted median, and MR-PRESSO) consistently supported this causal relationship (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251384245" ext-link-type="uri">Supplemental Table 5</ext-link>). Assessment of pleiotropy using the MR&#8210;Egger intercept test revealed no evidence of horizontal pleiotropy (p&#8201;&gt;&#8201;0.05), and heterogeneity analysis revealed no significant heterogeneity among instrumental variables (Cochran's Q test, p&#8201;&gt;&#8201;0.05) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251384245" ext-link-type="uri">Supplemental Tables 6 and 7</ext-link>). Leave-one-out analysis confirmed the stability of the results by demonstrating that no single instrumental variable drove the observed association (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251384245" ext-link-type="uri">Supplemental Figures 1&#8211;3</ext-link> show scatter plots, leave-one-out analysis, funnel plots, and forest plots for the KIAA0319-AD, PMM2-AD, and KIAA0319-PMM2 associations, respectively).</p><p>For the remaining 6 genes corresponding to the UKB-PPP proteins, supportive transcriptional evidence was not obtained from the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE33000">GSE33000</ext-link> dataset (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/25424823251384245" ext-link-type="uri">Supplemental Table 8</ext-link>).</p></sec></sec><sec sec-type="discussion" id="section4-25424823251384245"><title>Discussion</title><p>Proteins encoded by genetic risk loci are being increasingly recognized as pivotal regulators of AD pathogenesis. While prior studies have established canonical pathways such as <italic toggle="yes">APOE4</italic>-driven A&#946; and tau pathology,<sup>
<xref rid="bibr3-25424823251384245" ref-type="bibr">3</xref>
</sup> the systematic identification of upstream&#8211;downstream protein networks remains underexplored. Here, by integrating two independent pQTL datasets with AD GWAS data through a two-sample MR framework, we revealed causal relationships between 7 upstream regulators and 6 downstream targets, forming an AD-associated interaction network. Furthermore, transcriptomic analysis and mediation analysis revealed that KIAA0319 is a key upstream modulator whose downregulation in AD brains may drive disease progression via PMM2 inhibition. Our findings highlight this protein as a newly identified AD risk modulator that acts through PMM2, a pathway not previously implicated in AD pathogenesis.</p><p>The genetic architecture of AD has been extensively characterized,<sup>
<xref rid="bibr2-25424823251384245" ref-type="bibr">2</xref>
</sup> spanning early-onset (e.g., <italic toggle="yes">APP and PSEN1/2</italic>)<sup>
<xref rid="bibr26-25424823251384245" ref-type="bibr">26</xref>
</sup> and late-onset (e.g., <italic toggle="yes">APOE and TREM2</italic>)<sup><xref rid="bibr27-25424823251384245" ref-type="bibr">27</xref><xref rid="bibr28-25424823251384245" ref-type="bibr"/>&#8211;<xref rid="bibr29-25424823251384245" ref-type="bibr">29</xref></sup> loci. Our MR analysis expands this landscape by identifying <italic toggle="yes">KIAA0319</italic> as a putative susceptibility gene. The negative correlation between <italic toggle="yes">KIAA0319</italic> and AD risk aligns with the results of an East Asian GWAS indicating that this gene is involved in depression-cognition-memory phenotypes<sup>
<xref rid="bibr30-25424823251384245" ref-type="bibr">30</xref>
</sup> and with the findings of rodent studies demonstrating its neuroprotective role against astrocytic oxidative stress.<sup>
<xref rid="bibr31-25424823251384245" ref-type="bibr">31</xref>
</sup> Crucially, KIAA0319 mRNA expression was significantly reduced in AD brains (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE33000">GSE33000</ext-link>), reinforcing its disease relevance. Unlike previous MR studies focusing on single pQTL datasets, our dual pQTL integration approach uniquely identified the KIAA0319 protein as an upstream regulator of PMM2, a relationship undetectable in conventional analyses.</p><p>Originally linked to neurodevelopmental disorders,<sup>
<xref rid="bibr32-25424823251384245" ref-type="bibr">32</xref>
</sup> the role of the KIAA0319 protein in neurodegeneration is emerging. Structural studies have characterized its MANSC and polycystic kidney disease domains, which mediate hepatocyte growth factor activation and neuronal migration.<sup><xref rid="bibr33-25424823251384245" ref-type="bibr">33</xref>,<xref rid="bibr34-25424823251384245" ref-type="bibr">34</xref></sup> In their initial characterization, Guo et al. (2004) identified the MANSC domain as a structural feature shared among KIAA0319, HAI-1, and LRP, but its potential role in neurodegenerative diseases remains unclear. Subsequent independent lines of evidence have implicated components of this pathway in AD: HGF levels in cerebrospinal fluid (CSF) increase with age,<sup><xref rid="bibr35-25424823251384245" ref-type="bibr">35</xref>,<xref rid="bibr36-25424823251384245" ref-type="bibr">36</xref></sup> HGF/MET activation demonstrates neuroprotective potential,<sup>
<xref rid="bibr37-25424823251384245" ref-type="bibr">37</xref>
</sup> and HAI-1 (a negative regulator of HGF) is depleted in AD white matter.<sup>
<xref rid="bibr38-25424823251384245" ref-type="bibr">38</xref>
</sup> Additionally, LRP has been formally recognized as an AD risk protein,<sup>
<xref rid="bibr39-25424823251384245" ref-type="bibr">39</xref>
</sup> complementing the aforementioned evidence of HAI-1 dysregulation in AD. While these findings suggest the potential involvement of MANSC domain-containing proteins in AD, direct evidence linking MANSC domains to AD pathogenesis is lacking. Our MR analysis provides the first genetic evidence directly connecting a MANSC-containing protein (KIAA0319) to AD risk. These newly characterized findings substantiate the previously hypothesized role of MANSC domain biology in neurodegeneration and open new avenues for exploring how this structural domain may mediate critical interactions in AD pathogenesis.</p><p>In addition to structural domains, we discovered that the KIAA0319 protein may regulate AD through PMM2-dependent glycosylation pathways. While PMM2 is known to be a rate-limiting enzyme in N-glycosylation,<sup><xref rid="bibr40-25424823251384245" ref-type="bibr">40</xref>,<xref rid="bibr41-25424823251384245" ref-type="bibr">41</xref></sup> our study newly demonstrated its reduced activity downstream of the KIAA0319 protein. Aberrant glycosylation is implicated in tau pathology: hyperphosphorylated tau in AD is associated with defective O-GlcNAcylation,<sup>
<xref rid="bibr42-25424823251384245" ref-type="bibr">42</xref>
</sup> whereas N-glycosylation inhibits aggregation.<sup>
<xref rid="bibr43-25424823251384245" ref-type="bibr">43</xref>
</sup> We propose that KIAA0319 downregulation disrupts PMM2-mediated Tau glycosylation, accelerating neurofibrillary tangle formation.</p><p>Moreover, this newly identified KIAA0319-PMM2 pathway may have broader implications for AD metabolism. While PMM2 mutations have been previously linked to metabolic effects, including impaired sulfonylurea receptor glycosylation<sup>
<xref rid="bibr44-25424823251384245" ref-type="bibr">44</xref>
</sup> and disrupted glucose homeostasis,<sup>
<xref rid="bibr45-25424823251384245" ref-type="bibr">45</xref>
</sup> and AD has been characterized separately as &#8220;type III diabetes&#8221;,<sup>
<xref rid="bibr6-25424823251384245" ref-type="bibr">6</xref>
</sup> the connection between these pathways remains unexplored. Our identification of the role of the KIAA0319-PMM2 protein axis in AD risk suggests a previously unrecognized mechanism that may bridge genetic susceptibility with metabolic dysfunction in AD pathogenesis.</p><p>Furthermore, preclinical studies have revealed that upregulation of miR-592 expression in AD models suppresses KIAA0319 expression, exacerbating oxidative stress in astrocytes, whereas inhibition of miR-592 activity activates the Keap1/Nrf2/ARE pathway to restore the expression of this protein and confer neuroprotection.<sup>
<xref rid="bibr31-25424823251384245" ref-type="bibr">31</xref>
</sup> This mechanistic link between the KIAA0319 protein and oxidative stress resistance aligns with our finding of its downregulation in AD brains and supports the causal relationship we identified, wherein decreased KIAA0319 levels lead to increased AD risk. Thus, this protein may serve as a nexus connecting genetic risk, glycosylation&#8211;metabolic dysfunction, and redox imbalance in AD.</p><p>Targeting the KIAA0319-PMM2 protein axis may offer a novel therapeutic strategy for AD. Simultaneously, addressing proteostatic failure, metabolic dysregulation, and oxidative stress&#8212;the three interconnected hallmarks of AD pathogenesis&#8212;this axis could overcome the limitations of single-mechanism therapies.</p><p>Several limitations of our study should be acknowledged and suggest directions for future research. First, potential sample overlap between our UKB-derived protein exposure data and the AD GWAS (which included UKB participants) may introduce bias, although the extent of overlap remains uncertain given different study designs, phenotyping protocols, and participant subsets within the UKB. Second, while our MR analysis prioritized the KIAA0319-PMM2 protein interaction, transcriptional supporting evidence was obtained only for the KIAA0319 gene. The lack of consistent transcriptional changes in genes may reflect population heterogeneity, tissue-specific regulation (e.g., blood versus brain proteomes), or discordance between transcriptomic and proteomic layers.<sup>
<xref rid="bibr46-25424823251384245" ref-type="bibr">46</xref>
</sup> Our transcriptional analysis using independent US-based AD brain tissue samples from the GEO database partially addresses concerns about population-specific effects and tissue-specific expression patterns, although sample overlap limitations in MR analysis persist. Third, although sensitivity analyses including tests for heterogeneity and horizontal pleiotropy suggested robustness against detectable pleiotropic effects, violations of the InSIDE assumption or subtle undetected pleiotropic pathways could still bias our estimates. Future work should (1) validate MR findings using direct protein abundance measurements in AD brain tissues or CSF samples, (2) confirm PMM2 activity changes in KIAA0319-deficient AD models, (3) define molecular interactions (e.g., co-immunoprecipitation, CRISPR editing), (4) explore tissue-specific pQTLs to address blood&#8210;brain discordance, (5) replicate MR findings using completely independent, non-UKB AD GWAS datasets, and (6) assess glycosylation-dependent Tau aggregation in vivo.</p><sec id="section4A-25424823251384245"><title>Conclusion</title><p>This study identifies a novel regulatory axis between KIAA0319 and PMM2 in AD pathogenesis, which is supported by pQTL and transcriptomic analyses. Our findings establish KIAA0319 as an upstream risk factor that influences AD development through the mediation of PMM2. Both proteins represent potential therapeutic targets in AD, warranting further investigation into their mechanistic interactions and tissue-specific effects.</p></sec></sec><sec sec-type="supplementary-material" id="section5-25424823251384245"><title>Supplemental Material</title><supplementary-material id="suppl1-25424823251384245" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-xlsx-1-alr-10.1177_25424823251384245 - Supplemental material for KIAA0319 modulates Alzheimer's disease risk through PMM2 regulation: Evidence from integrated pQTL-mediation and transcriptomic analyses</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-xlsx-1-alr-10.1177_25424823251384245.xlsx" position="float" orientation="portrait"/><p>Supplemental material, sj-xlsx-1-alr-10.1177_25424823251384245 for KIAA0319 modulates Alzheimer's disease risk through PMM2 regulation: Evidence from integrated pQTL-mediation and transcriptomic analyses by Peng Wen, Chong Han, Hongxin Zhao, Shengtao Yao and Huan Chen in Journal of Alzheimer's Disease Reports</p></supplementary-material><supplementary-material id="suppl2-25424823251384245" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-pdf-2-alr-10.1177_25424823251384245 - Supplemental material for KIAA0319 modulates Alzheimer's disease risk through PMM2 regulation: Evidence from integrated pQTL-mediation and transcriptomic analyses</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-pdf-2-alr-10.1177_25424823251384245.pdf" position="float" orientation="portrait"/><p>Supplemental material, sj-pdf-2-alr-10.1177_25424823251384245 for KIAA0319 modulates Alzheimer's disease risk through PMM2 regulation: Evidence from integrated pQTL-mediation and transcriptomic analyses by Peng Wen, Chong Han, Hongxin Zhao, Shengtao Yao and Huan Chen in Journal of Alzheimer's Disease Reports</p></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>We acknowledge the valuable GWAS and pQTL data made publicly available through databases and previous studies. We thank the original investigators and participants who contributed to these resources. We also appreciate the researchers and individuals who generated and shared the GSE data used in this study.</p></ack><fn-group><fn fn-type="other"><p><bold>ORCID iDs:</bold> Peng Wen <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0003-1451-497X" ext-link-type="uri">https://orcid.org/0000-0003-1451-497X</ext-link></p><p>Chong Han <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0002-7430-3891" ext-link-type="uri">https://orcid.org/0009-0002-7430-3891</ext-link></p><p>Hongxin Zhao <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0001-8400-6885" ext-link-type="uri">https://orcid.org/0009-0001-8400-6885</ext-link></p><p>Shengtao Yao <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0004-0208-513X" ext-link-type="uri">https://orcid.org/0009-0004-0208-513X</ext-link></p><p>Huan Chen <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-3498-6088" ext-link-type="uri">https://orcid.org/0000-0002-3498-6088</ext-link></p></fn><fn fn-type="other"><p><bold>Ethical considerations:</bold> This study used publicly available de-identified data and did not require ethics approval.</p></fn><fn fn-type="con"><p><bold>Author contribution(s):</bold>
<bold>Peng Wen:</bold> Conceptualization; Data curation; Formal analysis; Visualization; Writing &#8211; original draft.</p><p><bold>Chong Han:</bold> Formal analysis; Visualization; Writing &#8211; original draft.</p><p><bold>Hongxin Zhao:</bold> Validation; Writing &#8211; original draft.</p><p><bold>Shengtao Yao:</bold> Investigation; Writing &#8211; review &amp; editing.</p><p><bold>Huan Chen:</bold> Methodology; Supervision; Writing &#8211; review &amp; editing.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors received no financial support for the research, authorship, and/or publication of this article.</p></fn><fn fn-type="COI-statement"><p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="other"><p><bold>Data availability statement:</bold> All data are publicly available from the sources cited in the manuscript.</p></fn><fn fn-type="other"><p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-25424823251384245"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Alzheimer's Association</collab></person-group>. <article-title>2023 Alzheimer's disease facts and figures</article-title>. <source>Alzheimers Dement</source><year>2023</year>; <volume>19</volume>: <fpage>1598</fpage>&#8211;<lpage>1695</lpage>.<pub-id pub-id-type="pmid">36918389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13016</pub-id></mixed-citation></ref><ref id="bibr2-25424823251384245"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatz</surname><given-names>M</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>CA</given-names></name><name name-style="western"><surname>Fratiglioni</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>Role of genes and environments for explaining Alzheimer disease</article-title>. <source>Arch Gen Psychiatry</source><year>2006</year>; <volume>63</volume>: <fpage>168</fpage>&#8211;<lpage>174</lpage>.<pub-id pub-id-type="pmid">16461860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archpsyc.63.2.168</pub-id></mixed-citation></ref><ref id="bibr3-25424823251384245"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellenguez</surname><given-names>C</given-names></name><name name-style="western"><surname>Kucukali</surname><given-names>F</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>IE</given-names></name></person-group>, <etal>et al.</etal><article-title>New insights into the genetic etiology of Alzheimer's disease and related dementias</article-title>. <source>Nat Genet</source><year>2022</year>; <volume>54</volume>: <fpage>412</fpage>&#8211;<lpage>436</lpage>.<pub-id pub-id-type="pmid">35379992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-022-01024-z</pub-id><pub-id pub-id-type="pmcid">PMC9005347</pub-id></mixed-citation></ref><ref id="bibr4-25424823251384245"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name><name name-style="western"><surname>De Strooper</surname><given-names>B</given-names></name><name name-style="western"><surname>Kivipelto</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Alzheimer's disease</article-title>. <source>Lancet</source><year>2021</year>; <volume>397</volume>: <fpage>1577</fpage>&#8211;<lpage>1590</lpage>.<pub-id pub-id-type="pmid">33667416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32205-4</pub-id><pub-id pub-id-type="pmcid">PMC8354300</pub-id></mixed-citation></ref><ref id="bibr5-25424823251384245"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></name><name name-style="western"><surname>Amieva</surname><given-names>H</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name></person-group>, <etal>et al.</etal><article-title>Alzheimer disease</article-title>. <source>Nat Rev Dis Primers</source><year>2021</year>; <volume>7</volume>: <fpage>33</fpage>.<pub-id pub-id-type="pmid">33986301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-021-00269-y</pub-id><pub-id pub-id-type="pmcid">PMC8574196</pub-id></mixed-citation></ref><ref id="bibr6-25424823251384245"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group>. <article-title>Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy</article-title>. <source>Protein Cell</source><year>2025</year>; <volume>16</volume>: <fpage>83</fpage>&#8211;<lpage>120</lpage>.<pub-id pub-id-type="pmid">38733347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/procel/pwae026</pub-id><pub-id pub-id-type="pmcid">PMC11786724</pub-id></mixed-citation></ref><ref id="bibr7-25424823251384245"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egan</surname><given-names>MF</given-names></name><name name-style="western"><surname>Kost</surname><given-names>J</given-names></name><name name-style="western"><surname>Voss</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal><article-title>Randomized trial of verubecestat for prodromal Alzheimer's disease</article-title>. <source>N Engl J Med</source><year>2019</year>; <volume>380</volume>: <fpage>1408</fpage>&#8211;<lpage>1420</lpage>.<pub-id pub-id-type="pmid">30970186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1812840</pub-id><pub-id pub-id-type="pmcid">PMC6776078</pub-id></mixed-citation></ref><ref id="bibr8-25424823251384245"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>JM</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></name></person-group>. <article-title>Alzheimer disease: an update on pathobiology and treatment strategies</article-title>. <source>Cell</source><year>2019</year>; <volume>179</volume>: <fpage>312</fpage>&#8211;<lpage>339</lpage>.<pub-id pub-id-type="pmid">31564456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2019.09.001</pub-id><pub-id pub-id-type="pmcid">PMC6778042</pub-id></mixed-citation></ref><ref id="bibr9-25424823251384245"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deane</surname><given-names>R</given-names></name><name name-style="western"><surname>Sagare</surname><given-names>A</given-names></name><name name-style="western"><surname>Hamm</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Apoe isoform-specific disruption of amyloid beta peptide clearance from mouse brain</article-title>. <source>J Clin Invest</source><year>2008</year>; <volume>118</volume>: <fpage>4002</fpage>&#8211;<lpage>4013</lpage>.<pub-id pub-id-type="pmid">19033669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI36663</pub-id><pub-id pub-id-type="pmcid">PMC2582453</pub-id></mixed-citation></ref><ref id="bibr10-25424823251384245"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verghese</surname><given-names>PB</given-names></name><name name-style="western"><surname>Castellano</surname><given-names>JM</given-names></name><name name-style="western"><surname>Garai</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Apoe influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2013</year>; <volume>110</volume>: <comment>E1807</comment>&#8211;<lpage>E1816</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1220484110</pub-id><pub-id pub-id-type="pmcid">PMC3651443</pub-id><pub-id pub-id-type="pmid">23620513</pub-id></mixed-citation></ref><ref id="bibr11-25424823251384245"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>IE</given-names></name><name name-style="western"><surname>Savage</surname><given-names>JE</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk</article-title>. <source>Nat Genet</source><year>2019</year>; <volume>51</volume>: <fpage>404</fpage>&#8211;<lpage>413</lpage>.<pub-id pub-id-type="pmid">30617256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-018-0311-9</pub-id><pub-id pub-id-type="pmcid">PMC6836675</pub-id></mixed-citation></ref><ref id="bibr12-25424823251384245"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koutsodendris</surname><given-names>N</given-names></name><name name-style="western"><surname>Blumenfeld</surname><given-names>J</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits</article-title>. <source>Nat Aging</source><year>2023</year>; <volume>3</volume>: <fpage>275</fpage>&#8211;<lpage>296</lpage>.<pub-id pub-id-type="pmid">37118426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00368-3</pub-id><pub-id pub-id-type="pmcid">PMC10154214</pub-id></mixed-citation></ref><ref id="bibr13-25424823251384245"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cella</surname><given-names>M</given-names></name><name name-style="western"><surname>Mallinson</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>TREM2 Lipid sensing sustains the microglial response in an Alzheimer's disease model</article-title>. <source>Cell</source><year>2015</year>; <volume>160</volume>: <fpage>1061</fpage>&#8211;<lpage>1071</lpage>.<pub-id pub-id-type="pmid">25728668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.01.049</pub-id><pub-id pub-id-type="pmcid">PMC4477963</pub-id></mixed-citation></ref><ref id="bibr14-25424823251384245"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>X</given-names></name><name name-style="western"><surname>Dou</surname><given-names>M</given-names></name><name name-style="western"><surname>Cao</surname><given-names>B</given-names></name></person-group>, <etal>et al.</etal><article-title>Peripheral level of CD33 and Alzheimer's disease: a bidirectional two-sample Mendelian randomization study</article-title>. <source>Transl Psychiatry</source><year>2022</year>; <volume>12</volume>: <fpage>427</fpage>.<pub-id pub-id-type="pmid">36192375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-022-02205-4</pub-id><pub-id pub-id-type="pmcid">PMC9529877</pub-id></mixed-citation></ref><ref id="bibr15-25424823251384245"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>GD</given-names></name><name name-style="western"><surname>Ebrahim</surname><given-names>S</given-names></name></person-group>. <article-title>Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?</article-title><source>Int J Epidemiol</source><year>2003</year>; <volume>32</volume>: <fpage>1</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">12689998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyg070</pub-id></mixed-citation></ref><ref id="bibr16-25424823251384245"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsson</surname><given-names>SC</given-names></name><name name-style="western"><surname>Butterworth</surname><given-names>AS</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name></person-group>. <article-title>Mendelian randomization for cardiovascular diseases: principles and applications</article-title>. <source>Eur Heart J</source><year>2023</year>; <volume>44</volume>: <fpage>4913</fpage>&#8211;<lpage>4924</lpage>.<pub-id pub-id-type="pmid">37935836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehad736</pub-id><pub-id pub-id-type="pmcid">PMC10719501</pub-id></mixed-citation></ref><ref id="bibr17-25424823251384245"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wingo</surname><given-names>AP</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gerasimov</surname><given-names>ES</given-names></name></person-group>, <etal>et al.</etal><article-title>Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer's disease pathogenesis</article-title>. <source>Nat Genet</source><year>2021</year>; <volume>53</volume>: <fpage>143</fpage>&#8211;<lpage>146</lpage>.<pub-id pub-id-type="pmid">33510477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-020-00773-z</pub-id><pub-id pub-id-type="pmcid">PMC8130821</pub-id></mixed-citation></ref><ref id="bibr18-25424823251384245"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Xi</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Identification of potential therapeutic targets for Alzheimer's disease from the proteomes of plasma and cerebrospinal fluid in a multicenter Mendelian randomization study</article-title>. <source>Int J Biol Macromol</source><year>2025</year>; <volume>294</volume>: <fpage>139394</fpage>.<pub-id pub-id-type="pmid">39755304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2024.139394</pub-id></mixed-citation></ref><ref id="bibr19-25424823251384245"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>BB</given-names></name><name name-style="western"><surname>Chiou</surname><given-names>J</given-names></name><name name-style="western"><surname>Traylor</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Plasma proteomic associations with genetics and health in the UK biobank</article-title>. <source>Nature</source><year>2023</year>; <volume>622</volume>: <fpage>329</fpage>&#8211;<lpage>338</lpage>.<pub-id pub-id-type="pmid">37794186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06592-6</pub-id><pub-id pub-id-type="pmcid">PMC10567551</pub-id></mixed-citation></ref><ref id="bibr20-25424823251384245"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferkingstad</surname><given-names>E</given-names></name><name name-style="western"><surname>Sulem</surname><given-names>P</given-names></name><name name-style="western"><surname>Atlason</surname><given-names>BA</given-names></name></person-group>, <etal>et al.</etal><article-title>Large-scale integration of the plasma proteome with genetics and disease</article-title>. <source>Nat Genet</source><year>2021</year>; <volume>53</volume>: <fpage>1712</fpage>&#8211;<lpage>1721</lpage>.<pub-id pub-id-type="pmid">34857953</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-00978-w</pub-id></mixed-citation></ref><ref id="bibr21-25424823251384245"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Dong</surname><given-names>SS</given-names></name></person-group>, <etal>et al.</etal><article-title>Bidirectional two-sample Mendelian randomization analysis identifies causal associations between relative carbohydrate intake and depression</article-title>. <source>Nat Hum Behav</source><year>2022</year>; <volume>6</volume>: <fpage>1569</fpage>&#8211;<lpage>1576</lpage>.<pub-id pub-id-type="pmid">35851841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41562-022-01412-9</pub-id></mixed-citation></ref><ref id="bibr22-25424823251384245"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name><name name-style="western"><surname>Butterworth</surname><given-names>A</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>SG</given-names></name></person-group>. <article-title>Mendelian randomization analysis with multiple genetic variants using summarized data</article-title>. <source>Genet Epidemiol</source><year>2013</year>; <volume>37</volume>: <fpage>658</fpage>&#8211;<lpage>665</lpage>.<pub-id pub-id-type="pmid">24114802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gepi.21758</pub-id><pub-id pub-id-type="pmcid">PMC4377079</pub-id></mixed-citation></ref><ref id="bibr23-25424823251384245"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemani</surname><given-names>G</given-names></name><name name-style="western"><surname>Tilling</surname><given-names>K</given-names></name><name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name></person-group>. <article-title>Orienting the causal relationship between imprecisely measured traits using GWAS summary data</article-title>. <source>PLoS Genet</source><year>2017</year>; <volume>13</volume>: <comment>e1007081</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1007081</pub-id><pub-id pub-id-type="pmcid">PMC5711033</pub-id><pub-id pub-id-type="pmid">29149188</pub-id></mixed-citation></ref><ref id="bibr24-25424823251384245"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>VanderWeele</surname><given-names>TJ</given-names></name></person-group>. <article-title>Mediation analysis: a practitioner's guide</article-title>. <source>Annu Rev Public Health</source><year>2016</year>; <volume>37</volume>: <fpage>17</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">26653405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-publhealth-032315-021402</pub-id></mixed-citation></ref><ref id="bibr25-25424823251384245"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narayanan</surname><given-names>M</given-names></name><name name-style="western"><surname>Huynh</surname><given-names>JL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Common dysregulation network in the human prefrontal cortex underlies two neurodegenerative diseases</article-title>. <source>Mol Syst Biol</source><year>2014</year>; <volume>10</volume>: <fpage>743</fpage>.<pub-id pub-id-type="pmid">25080494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/msb.20145304</pub-id><pub-id pub-id-type="pmcid">PMC4299500</pub-id></mixed-citation></ref><ref id="bibr26-25424823251384245"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertram</surname><given-names>L</given-names></name><name name-style="western"><surname>Lill</surname><given-names>CM</given-names></name><name name-style="western"><surname>Tanzi</surname><given-names>RE</given-names></name></person-group>. <article-title>The genetics of Alzheimer disease: back to the future</article-title>. <source>Neuron</source><year>2010</year>; <volume>68</volume>: <fpage>270</fpage>&#8211;<lpage>281</lpage>.<pub-id pub-id-type="pmid">20955934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2010.10.013</pub-id></mixed-citation></ref><ref id="bibr27-25424823251384245"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neu</surname><given-names>SC</given-names></name><name name-style="western"><surname>Pa</surname><given-names>J</given-names></name><name name-style="western"><surname>Kukull</surname><given-names>W</given-names></name></person-group>, <etal>et al.</etal><article-title>Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis</article-title>. <source>JAMA Neurol</source><year>2017</year>; <volume>74</volume>: <fpage>1178</fpage>&#8211;<lpage>1189</lpage>.<pub-id pub-id-type="pmid">28846757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2017.2188</pub-id><pub-id pub-id-type="pmcid">PMC5759346</pub-id></mixed-citation></ref><ref id="bibr28-25424823251384245"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerreiro</surname><given-names>R</given-names></name><name name-style="western"><surname>Wojtas</surname><given-names>A</given-names></name><name name-style="western"><surname>Bras</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>TREM2 Variants in Alzheimer's disease</article-title>. <source>N Engl J Med</source><year>2013</year>; <volume>368</volume>: <fpage>117</fpage>&#8211;<lpage>127</lpage>.<pub-id pub-id-type="pmid">23150934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1211851</pub-id><pub-id pub-id-type="pmcid">PMC3631573</pub-id></mixed-citation></ref><ref id="bibr29-25424823251384245"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seshadri</surname><given-names>S</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>AL</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>MA</given-names></name></person-group>, <etal>et al.</etal><article-title>Genome-wide analysis of genetic loci associated with Alzheimer disease</article-title>. <source>JAMA</source><year>2010</year>; <volume>303</volume>: <fpage>1832</fpage>&#8211;<lpage>1840</lpage>.<pub-id pub-id-type="pmid">20460622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2010.574</pub-id><pub-id pub-id-type="pmcid">PMC2989531</pub-id></mixed-citation></ref><ref id="bibr30-25424823251384245"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Multivariate genome-wide association study of depression, cognition, and memory phenotypes and validation analysis identify 12 cross-ethnic variants</article-title>. <source>Transl Psychiatry</source><year>2022</year>; <volume>12</volume>: <fpage>304</fpage>.<pub-id pub-id-type="pmid">35907915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41398-022-02074-x</pub-id><pub-id pub-id-type="pmcid">PMC9338946</pub-id></mixed-citation></ref><ref id="bibr31-25424823251384245"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>GD</given-names></name><name name-style="western"><surname>Li</surname><given-names>ZH</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name></person-group>, <etal>et al.</etal><article-title>microRNA-592 blockade inhibits oxidative stress injury in Alzheimer's disease astrocytes via the KIAA0319-mediated Keap1/Nrf2/ARE signaling pathway</article-title>. <source>Exp Neurol</source><year>2020</year>; <volume>324</volume>: <fpage>113128</fpage>.<pub-id pub-id-type="pmid">31759899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.expneurol.2019.113128</pub-id></mixed-citation></ref><ref id="bibr32-25424823251384245"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGrath</surname><given-names>LM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>SD</given-names></name><name name-style="western"><surname>Pennington</surname><given-names>BF</given-names></name></person-group>. <article-title>Breakthroughs in the search for dyslexia candidate genes</article-title>. <source>Trends Mol Med</source><year>2006</year>; <volume>12</volume>: <fpage>333</fpage>&#8211;<lpage>341</lpage>.<pub-id pub-id-type="pmid">16781891</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2006.05.007</pub-id></mixed-citation></ref><ref id="bibr33-25424823251384245"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>MANSC: a seven-cysteine-containing domain present in animal membrane and extracellular proteins</article-title>. <source>Trends Biochem Sci</source><year>2004</year>; <volume>29</volume>: <fpage>172</fpage>&#8211;<lpage>174</lpage>.<pub-id pub-id-type="pmid">15124631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibs.2004.02.007</pub-id></mixed-citation></ref><ref id="bibr34-25424823251384245"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paracchini</surname><given-names>S</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A</given-names></name><name name-style="western"><surname>Castro</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>The chromosome 6p22 haplotype associated with dyslexia reduces the expression of KIAA0319, a novel gene involved in neuronal migration</article-title>. <source>Hum Mol Genet</source><year>2006</year>; <volume>15</volume>: <fpage>1659</fpage>&#8211;<lpage>1666</lpage>.<pub-id pub-id-type="pmid">16600991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddl089</pub-id></mixed-citation></ref><ref id="bibr35-25424823251384245"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsuboi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kakimoto</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Increased hepatocyte growth factor level in cerebrospinal fluid in Alzheimer's disease</article-title>. <source>Acta Neurol Scand</source><year>2003</year>; <volume>107</volume>: <fpage>81</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">12580855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1034/j.1600-0404.2003.02089.x</pub-id></mixed-citation></ref><ref id="bibr36-25424823251384245"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>L</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name></person-group>, <etal>et al.</etal><article-title>Molecules of senescent glial cells differentiate Alzheimer's disease from ageing</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2023</year>; <volume>94</volume>: <fpage>550</fpage>&#8211;<lpage>559</lpage>.<pub-id pub-id-type="pmid">37012067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2022-330743</pub-id></mixed-citation></ref><ref id="bibr37-25424823251384245"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hua</surname><given-names>X</given-names></name><name name-style="western"><surname>Church</surname><given-names>K</given-names></name><name name-style="western"><surname>Walker</surname><given-names>W</given-names></name></person-group>, <etal>et al.</etal><article-title>Safety, tolerability, pharmacokinetics, and pharmacodynamics of the positive modulator of HGF/MET, fosgonimeton, in healthy volunteers and subjects with Alzheimer's disease: randomized, placebo-controlled, double-blind, phase I clinical trial</article-title>. <source>J Alzheimers Dis</source><year>2022</year>; <volume>86</volume>: <fpage>1399</fpage>&#8211;<lpage>1413</lpage>.<pub-id pub-id-type="pmid">35180125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215511</pub-id><pub-id pub-id-type="pmcid">PMC9108585</pub-id></mixed-citation></ref><ref id="bibr38-25424823251384245"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsujioka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Taguchi</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>White matter astrocytes produce hepatocyte growth factor activator inhibitor in human brain tissues</article-title>. <source>Exp Neurol</source><year>1998</year>; <volume>153</volume>: <fpage>60</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="pmid">9743567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/exnr.1998.6874</pub-id></mixed-citation></ref><ref id="bibr39-25424823251384245"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>SL</given-names></name><name name-style="western"><surname>Ng</surname><given-names>HK</given-names></name><name name-style="western"><surname>Baum</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>Low-density lipoprotein receptor-related protein 8 (apolipoprotein E receptor 2) gene polymorphisms in Alzheimer's disease</article-title>. <source>Neurosci Lett</source><year>2002</year>; <volume>332</volume>: <fpage>216</fpage>&#8211;<lpage>218</lpage>.<pub-id pub-id-type="pmid">12399018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0304-3940(02)00942-4</pub-id></mixed-citation></ref><ref id="bibr40-25424823251384245"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Altassan</surname><given-names>R</given-names></name><name name-style="western"><surname>Peanne</surname><given-names>R</given-names></name><name name-style="western"><surname>Jaeken</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: diagnosis, treatment and follow up</article-title>. <source>J Inherit Metab Dis</source><year>2019</year>; <volume>42</volume>: <fpage>5</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">30740725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jimd.12024</pub-id></mixed-citation></ref><ref id="bibr41-25424823251384245"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cabezas</surname><given-names>OR</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>SE</given-names></name><name name-style="western"><surname>Stanescu</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Polycystic kidney disease with hyperinsulinemic hypoglycemia caused by a promoter mutation in phosphomannomutase 2</article-title>. <source>J Am Soc Nephrol</source><year>2017</year>; <volume>28</volume>: <fpage>2529</fpage>&#8211;<lpage>2539</lpage>.<pub-id pub-id-type="pmid">28373276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2016121312</pub-id><pub-id pub-id-type="pmcid">PMC5533241</pub-id></mixed-citation></ref><ref id="bibr42-25424823251384245"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Tanimukai</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease</article-title>. <source>Brain</source><year>2009</year>; <volume>132</volume>: <fpage>1820</fpage>&#8211;<lpage>1832</lpage>.<pub-id pub-id-type="pmid">19451179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awp099</pub-id><pub-id pub-id-type="pmcid">PMC2702834</pub-id></mixed-citation></ref><ref id="bibr43-25424823251384245"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Losev</surname><given-names>Y</given-names></name><name name-style="western"><surname>Paul</surname><given-names>A</given-names></name><name name-style="western"><surname>Frenkel-Pinter</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Novel model of secreted human tau protein reveals the impact of the abnormal N-glycosylation of tau on its aggregation propensity</article-title>. <source>Sci Rep</source><year>2019</year>; <volume>9</volume>: <fpage>2254</fpage>.<pub-id pub-id-type="pmid">30783169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-39218-x</pub-id><pub-id pub-id-type="pmcid">PMC6381127</pub-id></mixed-citation></ref><ref id="bibr44-25424823251384245"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conti</surname><given-names>LR</given-names></name><name name-style="western"><surname>Radeke</surname><given-names>CM</given-names></name><name name-style="western"><surname>Vandenberg</surname><given-names>CA</given-names></name></person-group>. <article-title>Membrane targeting of ATP-sensitive potassium channel. Effects of glycosylation on surface expression</article-title>. <source>J Biol Chem</source><year>2002</year>; <volume>277</volume>: <fpage>25416</fpage>&#8211;<lpage>25422</lpage>.<pub-id pub-id-type="pmid">11994306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M203109200</pub-id></mixed-citation></ref><ref id="bibr45-25424823251384245"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabi</surname><given-names>SH</given-names></name><name name-style="western"><surname>Alzreqat</surname><given-names>RK</given-names></name><name name-style="western"><surname>Almaaytah</surname><given-names>AM</given-names></name></person-group>, <etal>et al.</etal><article-title>Genetic variations in hyperinsulinemic hypoglycemia: active versus inactive mutations</article-title>. <source>Diabetes Metab Syndr Obes</source><year>2024</year>; <volume>17</volume>: <fpage>4439</fpage>&#8211;<lpage>4452</lpage>.<pub-id pub-id-type="pmid">39619217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DMSO.S482056</pub-id><pub-id pub-id-type="pmcid">PMC11607999</pub-id></mixed-citation></ref><ref id="bibr46-25424823251384245"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Eraslan</surname><given-names>B</given-names></name><name name-style="western"><surname>Wieland</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal><article-title>A deep proteome and transcriptome abundance atlas of 29 healthy human tissues</article-title>. <source>Mol Syst Biol</source><year>2019</year>; <volume>15</volume>: <comment>e8503</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/msb.20188503</pub-id><pub-id pub-id-type="pmcid">PMC6379049</pub-id><pub-id pub-id-type="pmid">30777892</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70749" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12479218</article-id><article-id pub-id-type="pmcid-ver">PMC12479218.1</article-id><article-id pub-id-type="pmcaid">12479218</article-id><article-id pub-id-type="pmcaiid">12479218</article-id><article-id pub-id-type="pmid">41023472</article-id><article-id pub-id-type="doi">10.1002/alz.70749</article-id><article-id pub-id-type="publisher-id">ALZ70749</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Catecholaminergic nucleus integrity and Alzheimer's pathology, symptoms, and progression</article-title><alt-title alt-title-type="left-running-head">DAVID <sc>et&#160;al</sc>.</alt-title></title-group><contrib-group><contrib id="alz70749-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>David</surname><given-names initials="MCB">Michael C. B.</given-names></name><xref rid="alz70749-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70749-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>md2012@ic.ac.uk</email></address></contrib><contrib id="alz70749-cr-0002" contrib-type="author"><name name-style="western"><surname>Kolanko</surname><given-names initials="MA">Magdalena A.</given-names></name><xref rid="alz70749-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70749-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70749-cr-0003" contrib-type="author"><name name-style="western"><surname>Parker</surname><given-names initials="TD">Thomas D.</given-names></name><xref rid="alz70749-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70749-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70749-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70749-cr-0004" contrib-type="author"><name name-style="western"><surname>Nilforooshan</surname><given-names initials="R">Ramin</given-names></name><xref rid="alz70749-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70749-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70749-cr-0005" contrib-type="author"><name name-style="western"><surname>Zimmerman</surname><given-names initials="KA">Karl A.</given-names></name><xref rid="alz70749-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70749-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70749-cr-0006" contrib-type="author"><name name-style="western"><surname>Bonet Olivares</surname><given-names initials="C">Cristina</given-names></name><xref rid="alz70749-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70749-cr-0007" contrib-type="author"><name name-style="western"><surname>Hoang</surname><given-names initials="K">Karen</given-names></name><xref rid="alz70749-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70749-cr-0008" contrib-type="author"><name name-style="western"><surname>Brandt</surname><given-names initials="J">Johanna</given-names></name><xref rid="alz70749-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70749-cr-0009" contrib-type="author"><name name-style="western"><surname>Triantafyllou</surname><given-names initials="C">Charikleia</given-names></name><xref rid="alz70749-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70749-cr-0010" contrib-type="author"><name name-style="western"><surname>Lally</surname><given-names initials="PJ">Peter J.</given-names></name><xref rid="alz70749-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70749-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70749-cr-0011" contrib-type="author"><name name-style="western"><surname>Scott</surname><given-names initials="G">Gregory</given-names></name><xref rid="alz70749-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70749-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70749-cr-0012" contrib-type="author"><collab collab-type="authors">CR&amp;T Group of UKDRI</collab><xref rid="alz70749-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70749-cr-0013" contrib-type="author"><name name-style="western"><surname>Sharp</surname><given-names initials="DJ">David J.</given-names></name><xref rid="alz70749-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70749-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70749-cr-0014" contrib-type="author"><name name-style="western"><surname>Malhotra</surname><given-names initials="PA">Paresh A.</given-names></name><xref rid="alz70749-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70749-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="alz70749-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">UK Dementia Research Institute Care Research and Technology Centre</named-content>
<institution>Imperial College London</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="alz70749-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Imperial College London, Brain Sciences, South Kensington</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="alz70749-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">The Dementia Research Centre, Department of Neurodegenerative Disease</named-content>
<institution>University College London</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="alz70749-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Surrey and Borders Partnership NHS Foundation Trust</institution>
<city>Leatherhead</city>
<named-content content-type="country-part">Surrey</named-content>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Dr. Michael David, Care Research &amp; Technology Centre, UK Dementia Research Institute, 9th Floor, Sir Michael Uren Hub, 86 Wood Ln, London, W12 0BZ, UK.<break/> Email: <email>md2012@ic.ac.uk</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="250">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70749</elocation-id><history><date date-type="rev-recd"><day>01</day><month>9</month><year>2025</year></date><date date-type="received"><day>09</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>02</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 08:25:55.207"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70749.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70749.pdf"/><abstract><title>Abstract</title><sec id="alz70749-sec-0010"><title>BACKGROUND</title><p>The noradrenergic locus coeruleus (LC) accumulates pathology early in Alzheimer's disease (AD), with LC dysfunction contributing to symptoms and disease progression. We investigated LC and substantia nigra (SN) integrity in healthy controls and AD participants.</p></sec><sec id="alz70749-sec-0020"><title>METHODS</title><p>Ninety&#8208;three AD participants and 29 controls underwent neuromelanin magnetic resonance imaging. LC and SN contrast, reflecting nucleus integrity, related to cognitive and neuropsychiatric symptoms, as well as cognitive decline and atrophy rates.</p></sec><sec id="alz70749-sec-0030"><title>RESULTS</title><p>LC &#8211; but not SN &#8211; integrity was reduced in AD versus controls (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.39, <italic toggle="yes">p</italic>&#160;=&#160;0.001) and within AD was associated with global cognition (<italic toggle="yes">b&#160;</italic>=&#160;8.53, <italic toggle="yes">p</italic>&#160;=&#160;0.04) and neuropsychiatric symptoms, accounting for SN. An AD subgroup with reduced SN integrity had worse cognition. LC integrity predicted&#160;plasma phosphorylated tau protein 217 (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.30, <italic toggle="yes">p</italic>&#160;=&#160;0.03). Lower LC and SN integrities were both related to faster cognitive decline (LC: <italic toggle="yes">b&#160;</italic>=&#160;&#8722;4.74, <italic toggle="yes">p</italic>&#160;=&#160;0.048; SN: <italic toggle="yes">b&#160;</italic>=&#160;&#8722;2.27, <italic toggle="yes">p</italic>&#160;=&#160;0.03), accounting for one another.</p></sec><sec id="alz70749-sec-0040"><title>DISCUSSION</title><p>Catecholaminergic nucleus integrity plays an important role in AD. Both systems are relevant to cognitive performance and decline. LC, in particular, relates closely to symptoms, pathology, and rate of progression.</p></sec><sec id="alz70749-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70749-list-0001"><list-item><p>In symptomatic AD, LC integrity reflects cortical AD pathology, measured by pTau217.</p></list-item><list-item><p>LC integrity predicts cognitive function in AD, independent of cortical atrophy.</p></list-item><list-item><p>LC and SN integrity independently relate to attentional performance.</p></list-item><list-item><p>Symptoms of anxiety, depression, and apathy are associated with lower LC integrity.</p></list-item><list-item><p>LC and SN relate to cognitive decline rate and left LC predicts atrophy rate.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70749-kwd-0001">catecholamines</kwd><kwd id="alz70749-kwd-0002">cognition</kwd><kwd id="alz70749-kwd-0003">disease progression</kwd><kwd id="alz70749-kwd-0004">dopamine</kwd><kwd id="alz70749-kwd-0005">locus coeruleus</kwd><kwd id="alz70749-kwd-0006">neuromelanin</kwd><kwd id="alz70749-kwd-0007">neuropsychiatric symptoms</kwd><kwd id="alz70749-kwd-0008">noradrenaline</kwd><kwd id="alz70749-kwd-0009">norepinephrine</kwd><kwd id="alz70749-kwd-0010">substantia nigra</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>the UK DRI</institution></institution-wrap></funding-source><award-id>UKDRI&#8208;7202</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>National Institute for Health and Care Research (NIHR) Advanced Fellow</institution></institution-wrap></funding-source><award-id>NIHR302971</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Alzheimer's Society</institution><institution-id institution-id-type="doi">10.13039/501100000320</institution-id></institution-wrap></funding-source><award-id>608 AS&#8208;CTF&#8208;22&#8208;013</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>LifeArc</institution><institution-id institution-id-type="doi">10.13039/100012357</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>Dementias Platform UK</institution><institution-id institution-id-type="doi">10.13039/501100021686</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>Alzheimer&#8217;s Research UK</institution><institution-id institution-id-type="doi">10.13039/501100002283</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0007"><funding-source><institution-wrap><institution>NIHR Imperial Biomedical Research Centre</institution><institution-id institution-id-type="doi">10.13039/501100013342</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0008"><funding-source><institution-wrap><institution>National Institute for Health and Care Research</institution><institution-id institution-id-type="doi">10.13039/501100000272</institution-id></institution-wrap></funding-source><award-id>NIHR302971</award-id></award-group><award-group id="funding-0009"><funding-source><institution-wrap><institution>Medical Research Council</institution><institution-id institution-id-type="doi">10.13039/501100000265</institution-id></institution-wrap></funding-source><award-id>MR/W016095/1</award-id></award-group></funding-group><counts><fig-count count="7"/><table-count count="1"/><page-count count="19"/><word-count count="11143"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:29.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70749-cite-0001"><string-name name-style="western"><surname>David</surname><given-names>MCB</given-names></string-name>, <string-name name-style="western"><surname>Kolanko</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Parker</surname><given-names>TD</given-names></string-name>, et&#160;al. <article-title>Catecholaminergic nucleus integrity and Alzheimer's pathology, symptoms, and progression</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70749</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70749</pub-id><pub-id pub-id-type="pmid">41023472</pub-id></mixed-citation>
</p><fn-group><fn id="alz70749-note-0001" fn-type="equal"><p>David J. Sharp and Paresh A. Malhotra contributed equally to the study.</p></fn></fn-group></notes></front><body><sec id="alz70749-sec-0060"><label>1</label><title>BACKGROUND</title><p>Wide&#8208;reaching efferents from the pontine locus coeruleus (LC) supply much of the cortex with noradrenaline (or norepinephrine)<xref rid="alz70749-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> &#8211; a key neurotransmitter for cognition and behavior.<xref rid="alz70749-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70749-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="alz70749-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> In Alzheimer's disease (AD), the LC accumulates toxic hyperphosphorylated tau decades before symptoms, leading to neuronal death, reduced integrity,<xref rid="alz70749-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> and symptoms.<xref rid="alz70749-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70749-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
</p><p>The midbrain substantia nigra (SN), the main source of central dopamine (Figure&#160;<xref rid="alz70749-fig-0001" ref-type="fig">1</xref>), is a key pathological locus in Parkinson's disease (PD), but has received less attention in AD. However, Lewy bodies, plus tau aggregates and neuronal loss, have been reported in the SN in AD.<xref rid="alz70749-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="alz70749-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz70749-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Additionally, <italic toggle="yes">post mortem</italic> studies and positron emission tomography (PET) imaging have demonstrated reduced dopaminergic function in AD.<xref rid="alz70749-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70749-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> This is recognized in recent diagnostic criteria, which include &#945;&#8208;synuclein as a common non&#8208;AD co&#8208;pathology.<xref rid="alz70749-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="alz70749-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Sources and biosynthesis of catecholamines. Top left: location and projections of LC (blue) and SN (red). Bottom left: anatomy of nuclei on axial slices through brainstem. Right: biosynthetic pathway of dopamine, noradrenaline, and adrenaline. CA, caudate; LC, locus coeruleus; NA, nucleus accumbens; PU, putamen; SN, substantia nigra; TH, thalamus; VTA, ventral tegmental area.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70749-g006.jpg"/></fig><p>Owing to its small size and deep location, the LC has been challenging to image in vivo with conventional techniques. The development of neuromelanin&#8208;sensitive magnetic resonance imaging (MRI) represents a significant breakthrough. Neuromelanin accumulates over the lifespan in the LC and SN, appearing bright on targeted sequences, allowing accurate segmentation.<xref rid="alz70749-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Importantly, neuromelanin undergoes microglial clearance following cell death, causing signal reduction in neurodegenerative conditions.<xref rid="alz70749-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Reduced LC contrast has been repeatedly demonstrated in AD,<xref rid="alz70749-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70749-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="alz70749-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> as have SN reductions in PD<xref rid="alz70749-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> but not AD.</p><p>LC contrast relates to cognition, particularly memory, in older healthy people,<xref rid="alz70749-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> those with mild cognitive impairment (MCI),<xref rid="alz70749-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> and AD&#8208;mutation carriers.<xref rid="alz70749-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> However, there has been only limited work investigating the relationship between LC contrast and cognitive subdomains in sporadic clinical AD.<xref rid="alz70749-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70749-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="alz70749-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Neuromelanin MRI can quantify integrity in both LC and SN, allowing exploration of their shared and distinct associations with cognition.<xref rid="alz70749-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</p><p>Catecholaminergic control of arousal is also relevant to neuropsychiatric symptomatology.<xref rid="alz70749-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70749-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Importantly, neuropsychiatric symptoms are inadequately addressed by existing therapies.<xref rid="alz70749-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Most notably, anxiety, depression, and apathy are closely associated with arousal and noradrenergic tone (see Brunello et&#160;al.<xref rid="alz70749-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> for review). In one study of AD, lower LC contrast predicted worse neuropsychiatric symptoms, though without accounting for any contribution from the SN.<xref rid="alz70749-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</p><p>LC integrity in AD appears to reflect overall disease state. Reduced LC contrast predicts greater amyloid beta (A&#946;) burden and relates to cortical tau more strongly than A&#946; PET or hippocampal volume do.<xref rid="alz70749-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="alz70749-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="alz70749-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="alz70749-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Recent developments in plasma biomarkers, particularly phosphorylated tau protein 217 (pTau217), offer practical in vivo measures of AD pathology and are strongly associated with amyloid and tau PET tracer uptake.<xref rid="alz70749-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) &#8211; non&#8208;specific markers of neurodegeneration and astrocyte activation, respectively &#8211; are also measurable in plasma.<xref rid="alz70749-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="alz70749-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> Previous work has only explored the relationship between LC contrast and these biomarkers in healthy older adults.<xref rid="alz70749-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="alz70749-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
</p><p>LC integrity may also influence the trajectory of AD.<xref rid="alz70749-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="alz70749-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> There is considerable variability in AD progression rate. Noradrenaline has substantial neuroprotective effects,<xref rid="alz70749-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> including reducing inflammation and excitotoxicity,<xref rid="alz70749-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> and stimulating A&#946; clearance by microglia.<xref rid="alz70749-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> In AD mouse models, LC damage promotes neuroinflammation, A&#946;, and tau pathology.<xref rid="alz70749-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="alz70749-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> Accordingly, across assessment of multiple brainstem nuclei, LC neuronal density was most associated with the rate of age&#8208;related cognitive decline.<xref rid="alz70749-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Lower LC contrast predicts conversion to MCI/AD<xref rid="alz70749-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="alz70749-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> and also a steeper slope of memory decline in mild dementia.<xref rid="alz70749-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Similarly, dopamine enhances A&#946; degradation in mice and therefore dysfunction may exacerbate disease progression.<xref rid="alz70749-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Also, AD patients with parkinsonism show faster cognitive decline.<xref rid="alz70749-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> However, the relationship of LC and SN integrity to disease progression has not been examined at later disease stages.</p><p>We systematically evaluated relationships between catecholamine nucleus integrity, cognitive and neuropsychiatric symptoms, rate of decline, and relevant plasma biomarkers in a cohort of 93 participants with AD and 29 healthy older people. We specifically tested the following hypotheses: (1) LC integrity and SN integrity are independently associated with cognition; (2) lower LC integrity is related to arousal&#8208;related neuropsychiatric symptoms; (3) lower LC integrity correlates with higher plasma pTau217, GFAP, and NFL levels; and (4) LC integrity and SN integrity predict the rate of disease progression measured using longitudinal cognitive testing and atrophy rate.</p></sec><sec id="alz70749-sec-0070"><label>2</label><title>METHODS</title><sec id="alz70749-sec-0080"><label>2.1</label><title>Participants</title><p>AD participants (<italic toggle="yes">N</italic>&#160;=&#160;93) were recruited as part of two studies: (1) &#8220;Minder,&#8221; an ongoing longitudinal community&#8208;based dementia cohort study run by the Care, Research and Technology Centre of the United Kingdom Dementia Research Institute (UK DRI) (<italic toggle="yes">N</italic>&#160;=&#160;38);<xref rid="alz70749-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> and (2) &#8220;Physiological Correlates of Noradrenergic Add&#8208;on Therapy&#8221; (PCNorAD), an experimental medicine add&#8208;on study to the NorAD clinical trial (<italic toggle="yes">N</italic>&#160;=&#160;55).<xref rid="alz70749-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> Participants recruited from NorAD underwent the procedures for this study at least 1 month after completing participation in the trial. Twenty&#8208;nine age&#8208;matched healthy controls (HC) were also recruited as part of PCNorAD.</p><p>All AD participants had a pre&#8208;existing clinical diagnosis of AD that was reviewed in a multidisciplinary team meeting, composed of neurologists, psychiatrists, and neuroradiologists, as part of this study. Diagnosis was confirmed upon review of available clinical and research neuroimaging as well as other investigations including cerebrospinal fluid (CSF) and PET biomarkers. HC were recruited if&#160;&gt;60 years old and with no symptoms of cognitive impairment. All participants were free of major neurological illnesses other than AD.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70749-sec-0090"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70749-list-0002"><list-item><p>
<bold>Systematic review</bold>: PubMed and GoogleScholar literature searches revealed evidence for LC pathology early in AD. The LC's relevance to cognition and progression to AD has mostly been reported in healthy or prodromal cohorts. There is limited work exploring SN integrity in AD. We extended pre&#8208;existing work, examining both nuclei in patients across a range of AD severity.</p></list-item><list-item><p>
<bold>Interpretation</bold>: We demonstrate LC integrity significantly contributes to cognitive and neuropsychiatric symptoms in AD, independently of SN integrity. LC integrity is associated with pathological burden and disease progression, although the integrity of both nuclei relates to attention and cognitive decline rate, independently of each other. Together, these results highlight the influence of noradrenergic function, in particular, on symptoms and disease trajectory.</p></list-item><list-item><p>
<bold>Future directions</bold>: Therapeutic approaches that directly modulate noradrenergic tone and/or protect the integrity of the LC have the potential for symptomatic and possibly disease&#8208;modifying benefit.</p></list-item></list>
</p></sec></boxed-text></sec><sec id="alz70749-sec-0100"><label>2.2</label><title>Ethical approval</title><p>The Minder and PCNorAD studies were<xref rid="alz70749-fig-0001" ref-type="fig">&#8195;</xref> approved by the London&#8208;Surrey Borders Research Ethics Committee (19/LO/0102) and London&#8208;Central&#160;Research Ethics Committee (18/LO/0249), respectively. All participants with the capacity to consent provided written informed consent for participation and for their data to be included. Those without capacity were enrolled in accordance with the Mental Capacity Act (2005) on recommendation of an assigned consultee.</p></sec><sec id="alz70749-sec-0110"><label>2.3</label><title>MRI acquisition</title><p>MRI scans were acquired once for all controls and for AD participants in PCNorAD and approximately annually for AD participants in Minder. For some participants, MRI data from different visits were used for different analyses to meet the specific criteria for each analysis (see below). MRI data were obtained using a Siemens&#160;Verio&#160;3T MRI scanner with a 32&#8208;channel head coil.&#160;Participants underwent a T1&#8208;weighted three&#8208;dimensional magnetization&#8208;prepared rapid acquisition gradient&#8208;echo (3D&#8208;MPRAGE) sequence.</p><p>The parameters were as follows: flip angle&#160;=&#160;9&#176;, echo time (TE)&#160;=&#160;2.98&#160;ms, repetition time (TR)&#160;=&#160;2300&#160;ms, inversion time&#160;=&#160;900&#160;ms, bandwidth&#160;=&#160;240&#160;Hz/pixel, acquisition matrix&#160;=&#160;256 &#215; 240 &#215; 160, voxel size&#160;=&#160;1.0 &#215; 1.0 &#215; 1.0&#160;mm, and GRAPPA acceleration factor&#160;=&#160;2. LC and SN contrast was quantified using the following MRI sequence (3D T2*&#8208;weighted multi&#8208;echo gradient&#8208;echo with a magnetization transfer preparation pulse), which was aligned perpendicularly to the plane of the participant's brainstem based on the sagittal reconstruction from the MPRAGE sequence and used the following parameters: flip angle&#160;=&#160;20&#176;; TE&#160;=&#160;7.5, 15.0, and 22.5&#160;ms; TR&#160;=&#160;62&#160;ms; acquisition matrix&#160;=&#160;384 &#215; 384 &#215; 48; voxel size&#160;=&#160;0.67 &#215; 0.67 &#215; 1.34&#160;mm; bandwidth&#160;=&#160;230&#160;Hz/pixel; GRAPPA acceleration factor&#160;=&#160;2; and slice partial Fourier factor&#160;=&#160;6/8. The first echo time was analyzed.</p></sec><sec id="alz70749-sec-0120"><label>2.4</label><title>MRI analysis</title><sec id="alz70749-sec-0130"><label>2.4.1</label><title>Neuromelanin contrast</title><p>Images were bias corrected using N4BiasFieldCorrection by Advanced Normalization Tools version 2.1. LC contrast was quantified as in David et&#160;al.<xref rid="alz70749-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> (Figure <xref rid="alz70749-supinfo-0001" ref-type="">S1</xref>). Briefly, the LC was manually identified as two hyperintense areas in the pons around the base of the fourth ventricle.<xref rid="alz70749-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> Contrast values were calculated as a ratio between a five&#8208;voxel region on both the left and right against a 7 &#215; 7 voxel square reference region in the nearby pons, using the following equation:<xref rid="alz70749-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>
<disp-formula id="alz70749-disp-0001"><mml:math id="jats-math-1" display="block"><mml:mrow><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>Mean</mml:mi><mml:mspace width="0.33em"/><mml:mi>of</mml:mi><mml:mspace width="0.33em"/><mml:mi>left</mml:mi><mml:mspace width="0.33em"/><mml:mi>and</mml:mi><mml:mspace width="0.33em"/><mml:mi>right</mml:mi><mml:mspace width="0.33em"/><mml:mi>LC</mml:mi><mml:mspace width="0.33em"/><mml:mi>contrast</mml:mi></mml:mrow><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:mspace width="0.33em"/><mml:mrow><mml:mi>Mean</mml:mi><mml:mspace width="0.33em"/><mml:mi>reference</mml:mi><mml:mspace width="0.33em"/><mml:mi>contrast</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>Standard</mml:mi><mml:mspace width="0.33em"/><mml:mi>deviation</mml:mi><mml:mspace width="0.33em"/><mml:mi>of</mml:mi><mml:mspace width="0.33em"/><mml:mi>reference</mml:mi><mml:mspace width="0.33em"/><mml:mi>contrast</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula>
</p><p>This was conducted across five consecutive slices and then averaged to give a single value per side, and the average of the two sides was calculated. We used two independent raters for each scan with an average taken. The ICC between the two raters was very high (0.88 to 0.96). Where there was a large disagreement regarding contrast ratio between raters (&gt;0.45), scans were re&#8208;examined, and a consensus was reached.</p><p>While a manual method was employed for quantification of the LC to prevent the risk of misplacement of regions of interest (ROIs), a semi&#8208;automated method was employed for the quantification of SN contrast (Figure <xref rid="alz70749-supinfo-0001" ref-type="">S2</xref>), owing to its larger size and the existence of established ROI masks.<xref rid="alz70749-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> In addition to these SN region masks, a circular reference region four voxels in diameter and spanning seven consecutive slices in the nearby cerebral peduncle on the left and right, was created. First, a Montreal Neurological Institute (MNI) template image and the bias corrected neuromelanin&#8208;sensitive brainstem slab images were registered to each participant's T1 image using the default antsRegistrationSyNQuick.sh process of rigid, affine, and non&#8208;linear transformations.<xref rid="alz70749-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> Then the transforms from the MNI to T1 registrations were applied to the SN and reference ROIs, after which, the inverse of the transforms from the brainstem slab to T1 registrations was applied to the ROIs to move them to the participant space. The mean and standard deviation of the contrast in the ROIs for each participant was then extracted. Contrast ratios were calculated for the left and right SN region relative to the reference regions using the same formula as for the LC. Ratios were then averaged across sides to give a single SN contrast ratio.</p><p>We also produced a composite metric of LC and SN contrast by dividing each participant's value by the median value in the control group, for LC and SN separately. Given that they are collected using the same sequence, if proved useful, this metric could be easily computed in future clinical and scientific work. These standardized values were then summed to give a &#8220;LCSN&#8221; value representative of the combined contrast in both nuclei.</p></sec><sec id="alz70749-sec-0140"><label>2.4.2</label><title>Gray matter volume and atrophy</title><p>All T1 images underwent brain extraction using HD&#8208;BET<xref rid="alz70749-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> and tissue segmentation using FMRIB&#8217;s Automated Segmentation Tool<xref rid="alz70749-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> to give total gray matter volume and estimated total intracranial volume. Then, for subjects with multiple scans, an established pipeline was used for longitudinal analysis in SPM12 (University College London).<xref rid="alz70749-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> Briefly, T1 images at baseline and follow&#8208;up were segmented into gray matter, white matter, and CSF. Where two follow&#8208;up scans were available, the later of the two was used to maximize reliability of the atrophy rate measure. The segmentations were visually quality checked. Each participant's baseline T1 was iteratively co&#8208;registered to their follow&#8208;up image to produce a midpoint &#8220;participant average&#8208;space&#8221; image, which was also then segmented into the three tissues. The gray matter segmentation was binarized to produce a gray matter specific mask, which was then divided into left and right by the midline. For each participant a three&#8208;dimensional voxel&#8208;wise &#8220;Jacobian determinant&#8221; (JD) map was produced. The JD measures how much a volume changes during a transformation and is applied to serial brain imaging data to show the change in volume between scans as a measure of atrophy rate.<xref rid="alz70749-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> The bilateral, left, and right gray matter masks for each participant were then applied to the JD map. These values were multiplied by 100 to produce percentage change per year.</p></sec></sec><sec id="alz70749-sec-0150"><label>2.5</label><title>Neuropsychological assessment</title><p>For the analysis of rate of cognitive decline, the Alzheimer's Disease Assessment Scale&#8211;Cognitive Subscale (ADAS&#8208;Cog) 14<xref rid="alz70749-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> was used. This is frequently used in assessing changes in cognition over time in AD, particularly in clinical trials. For AD participants in the Minder study, this was performed routinely every 6 months. For PCNorAD participants, this was performed once at the start of the NorAD trial (before starting either drug or placebo) and in a subgroup of participants, at one further time point at least 3 months after the trial. This gave a range of 2 to 7 ADAS&#8208;Cog scores per participant included in this analysis. If multiple scans were available for a given participant, the scan closest to the first ADAS&#8208;Cog was used in the cognitive decline rate analysis. For all participants, this scan fell during, or within 1 year of, the period of longitudinal cognitive testing.</p><p>The Addenbrookes Cognitive Examination&#8208;III (ACE)<xref rid="alz70749-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> was selected as the cross&#8208;sectional measure on the day of MRI scanning as it is quicker and more practical to administer than the ADAS&#8208;Cog. It has the added advantage of providing five cognitive subdomain scores (attention, language, memory, visuospatial ability, and fluency) that can be independently related to imaging markers. By not using the ADAS&#8208;Cog on the day of the MRI scan, it also ensured that Minder participants did not have multiple ADAS&#8208;Cog assessments within a 6&#8208;month period, which would increase the risk of learning effects. If multiple contemporaneous MRI&#8208;ACE timepoints were available, the first was used.</p></sec><sec id="alz70749-sec-0160"><label>2.6</label><title>Neuropsychiatric assessment</title><p>The Neuropsychiatric Inventory (NPI)<xref rid="alz70749-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> was used to assess neuropsychiatric symptoms for the AD participants. Total scores (frequency <mml:math id="jats-math-2" display="inline"><mml:mrow><mml:mo>&#215;</mml:mo></mml:mrow></mml:math> severity) were collected across 12 domains: delusions, hallucinations, agitation, depression, anxiety, elation, apathy, disinhibition, irritability, motor behaviors, sleep, and eating. As there were only a few participants with a score&#160;&gt;&#160;0 for some of the 12 symptoms, participants were simply divided into those with and without symptoms of each domain, based on a total score of&#160;&gt;&#160;0 or 0. LC/SN contrast was compared between the two groups. For each participant, the scan closest to the date of the NPI was used for this analysis, and only those with a scan within a year were included.</p></sec><sec id="alz70749-sec-0170"><label>2.7</label><title>Plasma sample assessment</title><p>Plasma samples were taken on the day of the MRI scan (<italic toggle="yes">N</italic>&#160;=&#160;53), or within 1 year (<italic toggle="yes">N</italic>&#160;=&#160;8). A cannula was first inserted, and then blood was drawn 10 min later with the patient supine, so as to allow for the autonomic response to needle insertion to subside. Participants were asked not to eat or drink at least 1 h before blood sampling and to abstain from caffeine and exercise on the day. Blood samples were collected using ethylenediaminetetraacetic acid&#8208;coated tubes. After 30 to 120&#160;min at room temperature, samples were centrifuged at 2500&#160;g at 4&#176;C for 20&#160;min and frozen at &#8722;80&#176;C. For a subgroup of 37 AD and 24 HC, plasma pTau217, NfL, and GFAP concentration was quantified using the ALZpath pTau217 and Simoa&#8208;Neurology assays (Quanterix, Inc.).</p></sec><sec id="alz70749-sec-0180"><label>2.8</label><title>Statistical analysis</title><p>All analysis was conducted using RStudio (Posit, PBC). Group differences in demographics were compared using <italic toggle="yes">t</italic>&#8208;tests, Wilcoxon tests, and chi&#8208;squared tests as appropriate. Linear mixed&#8208;effects models using contrast measures from multiple timepoints were used to test for group and laterality differences in LC/SN contrast and to test the relationship of the two nuclei with age and with each other, additionally controlling for time from baseline scan, and with participant as a repeated measure term. Linear regression models were used to test the ability of a single LC/SN contrast measure per participant to predict contemporaneous ACE scores, plasma biomarkers, and JD (atrophy rate between the scan used to measure the LC contrast and a subsequent follow&#8208;up scan). For comparing those with and without NPI symptoms for each domain, logistic regression was used. As a further exploratory analysis of the relationship between LC/SN contrast and contemporaneous ACE score, LC/SN values were converted to <italic toggle="yes">z</italic>&#8208;scores relative to controls. <italic toggle="yes">K</italic>&#8208;means clustering was then performed on these values and identified three clusters of patients, as recommended by the elbow method (Figure <xref rid="alz70749-supinfo-0001" ref-type="">S3</xref>). For each outcome (ACE total and subdomain scores), a type III analysis of covariance (ANCOVA) was fitted with cluster as the primary predictor, plus nuisance co&#8208;variates. Post hoc pairwise comparisons between clusters were obtained from estimated marginal means with Tukey adjustment within each outcome. For regression models, age, sex, and AD symptom duration (to account for disease stage), plus education for cognitive outcomes, were included as standard. We did not correct for multiple comparisons across the different ACE and NPI domains, plasma biomarkers, or side (left/right).</p><p>To estimate the annual rate of change in cognition over time, linear mixed&#8208;effects models were employed to calculate individual participants&#8217; rate of change. The equation used was
<disp-formula id="alz70749-disp-0002"><mml:math id="jats-math-3" display="block"><mml:mrow><mml:mrow><mml:mrow><mml:mi>ADAS</mml:mi><mml:mo linebreak="badbreak">&#8722;</mml:mo><mml:mi>Cog</mml:mi></mml:mrow><mml:mo>&#8764;</mml:mo><mml:mi>timefrombaseline</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mi>timefrombaseline</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mi>participant</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>where &#8220;ADAS&#8208;Cog&#8221; represents the score at a particular timepoint and &#8220;timefrombaseline&#8221; represents the time the score was taken relative to that participant's first ADAS&#8208;Cog score. Fixed effects, indicating the average rate of change in ADAS&#8208;Cog scores per year for the entire group, and the random effects, representing the individual variation in the rate of change per year, were extracted. The annual rate of change for each participant was then calculated by summing the fixed, group&#8208;level rate of change and the individual's random slope. This approach enabled modeling of the group&#8208;level trend in cognitive scores while considering the unique trajectory of each participant and their baseline cognitive function. The annual rate of change was then used as the dependent variable in a linear regression model with LC/SN contrast as predictor variable plus nuisance covariates. Additionally, a model was run including pTau217 for the 19 participants with these data available.</p></sec></sec><sec id="alz70749-sec-0190"><label>3</label><title>RESULTS</title><sec id="alz70749-sec-0200"><label>3.1</label><title>Participant characteristics</title><p>In total, 93 AD participants and 29 healthy older controls underwent MRI scanning (Table&#160;<xref rid="alz70749-tbl-0001" ref-type="table">1</xref>). AD had an ACE of 56.3/100&#160;&#177;&#160;17.6 (mean&#160;&#177;&#160;SD), which is considered &#8220;moderate dementia,&#8221;<xref rid="alz70749-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> and had a symptoms duration of 5.2&#160;&#177;&#160;3.2 years (mean&#160;&#177;&#160;SD). Scores for the ACE subdomains in both groups are reported in Table&#160;<xref rid="alz70749-tbl-0001" ref-type="table">1</xref>. A subgroup of AD participants (<italic toggle="yes">N</italic>&#160;=&#160;28) returned for a second scan after approximately a year, with 12 returning for a third scan a year later. On eight occasions (out of 162 scans), brainstem contrast imaging was not acquired as the participant did not tolerate the whole scan. Fourteen brainstem contrast scans could not be analyzed due to artifact, giving a total of 140 analyzable scans.</p><table-wrap position="float" id="alz70749-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Participant demographics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">HC</th><th align="left" rowspan="1" colspan="1">AD</th><th align="left" rowspan="1" colspan="1">Statistic</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total included in analyses</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">93</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age, years, mean (SD)</td><td align="left" rowspan="1" colspan="1">75.6 (6.1)</td><td align="left" rowspan="1" colspan="1">75.0 (8.2)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>&#160;=&#160;&#8722;0.41</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, percentage female</td><td align="left" rowspan="1" colspan="1">48.3</td><td align="left" rowspan="1" colspan="1">54.8</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">&#967;</italic>
<sup>2</sup>&#160;=&#160;0.52</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">ACE total, mean (SD)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#160;=&#160;28, 95.8 (3.6)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>&#160;=&#160;77, 56.3 (17.6)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">W</italic>&#160;=&#160;&#8722;9.5</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Attention</td><td align="left" rowspan="1" colspan="1">17.5 (0.8)</td><td align="left" rowspan="1" colspan="1">10.1 (4.1)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">W</italic>&#160;=&#160;&#8722;91.5</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Fluency</td><td align="left" rowspan="1" colspan="1">12.4 (1.4)</td><td align="left" rowspan="1" colspan="1">6.4 (3.4)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">W</italic>&#160;=&#160;&#8722;93.5</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Language</td><td align="left" rowspan="1" colspan="1">25.6 (0.5)</td><td align="left" rowspan="1" colspan="1">19.1 (5.2)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">W</italic>&#160;=&#160;&#8722;108</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Visuospatial</td><td align="left" rowspan="1" colspan="1">15.5 (0.8)</td><td align="left" rowspan="1" colspan="1">11.3 (4.1)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">W</italic>&#160;=&#160;&#8722;248</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Memory</td><td align="left" rowspan="1" colspan="1">24.7 (1.8)</td><td align="left" rowspan="1" colspan="1">9.4 (5.2)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">W</italic>&#160;=&#160;&#8722;26</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Full&#8208;time education, years, mean (SD)</td><td align="left" rowspan="1" colspan="1">15.1 (3.9)</td><td align="left" rowspan="1" colspan="1">13.7 (3.0)</td><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">W</italic>&#160;=&#160;857.5</td><td align="left" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Dementia symptoms, years, mean (SD)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">5.2 (3.2)</td><td colspan="2" align="left" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn id="alz70749-tbl1-note-0001"><p>
<italic toggle="yes">Note</italic>: Age and years of symptoms at first MRI visit for each participant. <italic toggle="yes">T</italic>&#8208;test, Wilcoxon tests, and chi&#8208;squared tests are used as appropriate. <italic toggle="yes">p</italic> values are uncorrected for multiple comparisons.</p></fn><fn id="alz70749-tbl1-note-0002"><p>Abbreviations: Alzheimer's disease; ACE, Addenbrooke's Cognitive Examination; HC, healthy control; AD, SD, standard deviation.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz70749-sec-0210"><label>3.2</label><title>Effects of AD and age on LC and SN integrity</title><p>Using mixed&#8208;effects models, we compared the contrast in the LC and SN between the AD and control groups. To do this we utilized all analyzable scans (<italic toggle="yes">N</italic>&#160;=&#160;140), including multiple visits from 19 AD participants. There was a significant reduction in LC contrast in AD (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.39, SE&#160;=&#160;0.12, <italic toggle="yes">t</italic>[125.0]&#160;=&#160;3.26, <italic toggle="yes">p</italic>&#160;=&#160;0.001) (Figure&#160;<xref rid="alz70749-fig-0002" ref-type="fig">2A</xref>). There was no significant effect of sex or age on LC contrast. For the SN there was no significant group difference (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.25, SE&#160;=&#160;0.15, <italic toggle="yes">t</italic>[121.7]&#160;=&#160;1.59, <italic toggle="yes">p</italic>&#160;=&#160;0.11) (Figure&#160;<xref rid="alz70749-fig-0002" ref-type="fig">2B</xref>). SN contrast decreased significantly with male sex (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.30, SE&#160;=&#160;0.13, <italic toggle="yes">t</italic>[103.8]&#160;=&#160;&#8722;2.21, <italic toggle="yes">p</italic>&#160;=&#160;0.03) and age (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.02, SE&#160;=&#160;0.01, <italic toggle="yes">t</italic>[93.87]&#160;=&#160;&#8722;2.53, <italic toggle="yes">p</italic>&#160;=&#160;0.01). There was a significant positive relationship between LC and SN contrast (<italic toggle="yes">b&#160;</italic>=&#160;0.35, SE&#160;=&#160;0.11, <italic toggle="yes">t</italic>[132.8]&#160;=&#160;3.23, <italic toggle="yes">p</italic>&#160;=&#160;0.002) but no group interaction (Figure&#160;<xref rid="alz70749-fig-0002" ref-type="fig">2C</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70749-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>LC and SN integrity in AD and healthy aging. Violin plots showing LC (A) and SN (B) contrast by group. Data from all visits plotted, including multiple timepoints for 19 AD participants. Significance shown is the result of linear mixed&#8208;effects models adjusting for covariates. **<italic toggle="yes">p</italic>&#160;&lt;&#160;0.01. (C) Scatter plot showing relationship between LC and SN contrast, split by group. (D and E) Scatter plot showing relationship between LC/SN contrast and age, split by group. (F) Scatter plot showing relationship between LC contrast and ACE, split by group. (G and H) Scatter plots showing LC/SN contrast over time, relative to baseline scan, in AD participants only. Values from same participant joined by gray line. There is no significant group level change over time for either measure. For (A&#8211;F), the shaded error bar shows standard error of the mean. For (C&#8211;F), the line of best fit through the raw data is plotted. AD, Alzheimer's disease (green); HC, healthy control (gold); LC, locus coeruleus; SN, substantia nigra.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70749-g005.jpg"/></fig><p>Contrast was significantly lower on the right side compared to the left for both the LC (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.30, SE&#160;=&#160;0.06, <italic toggle="yes">t</italic>[169.0]&#160;=&#160;&#8722;5.21, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) and SN (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.26, SE&#160;=&#160;0.07, <italic toggle="yes">t</italic>[168.0]&#160;=&#160;&#8722;3.78, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) (Figure <xref rid="alz70749-supinfo-0001" ref-type="">S4</xref>). While neither nucleus showed a side&#8208;by&#8208;group interaction, the group difference between AD and HC was numerically larger for both nuclei for the left (LC: <italic toggle="yes">b&#160;</italic>=&#160;0.46, SE&#160;=&#160;0.14, <italic toggle="yes">t</italic>[119.6]&#160;=&#160;3.27, <italic toggle="yes">p</italic>&#160;=&#160;0.001; SN: <italic toggle="yes">b&#160;</italic>=&#160;0.29, SE&#160;=&#160;0.17, <italic toggle="yes">t</italic>[119.4] = 1.69, <italic toggle="yes">p</italic>&#160;=&#160;0.09) than the right (LC: <italic toggle="yes">b&#160;</italic>=&#160;0.32, SE&#160;=&#160;0.14, <italic toggle="yes">t</italic>[130.1]&#160;=&#160;2.32, <italic toggle="yes">p</italic>&#160;=&#160;0.02; SN: <italic toggle="yes">b&#160;</italic>=&#160;0.21, SE&#160;=&#160;0.18, <italic toggle="yes">t</italic>[131.5] = 1.17, <italic toggle="yes">p</italic>&#160;=&#160;0.24) (Figure <xref rid="alz70749-supinfo-0001" ref-type="">S4</xref>).</p><p>As neuromelanin is known to increase with healthy aging<xref rid="alz70749-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> but decrease in AD, we further explored the effect of aging of LC/SN contrast by looking at the interaction between age and group (Figure&#160;<xref rid="alz70749-fig-0002" ref-type="fig">2D,E</xref>). For the LC there was a significant interaction of age and group (<italic toggle="yes">b&#160;</italic>=&#160;0.05, SE&#160;=&#160;0.02, <italic toggle="yes">t</italic>[121.7]&#160;=&#160;2.52, <italic toggle="yes">p</italic>&#160;=&#160;0.01) driven by a non&#8208;significant trend toward increasing LC contrast with age in HC (<italic toggle="yes">b&#160;</italic>=&#160;0.04, SE&#160;=&#160;0.03, <italic toggle="yes">t</italic>[26]&#160;=&#160;1.590, <italic toggle="yes">p</italic>&#160;=&#160;0.12) and decreasing in AD (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.01, SE&#160;=&#160;0.01, <italic toggle="yes">t</italic>[84.6]&#160;=&#160;&#8722;1.04, <italic toggle="yes">p</italic>&#160;=&#160;0.30). For the SN, there was a stronger interaction (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.03, SE&#160;=&#160;0.01, <italic toggle="yes">t</italic>[89.6]&#160;=&#160;&#8722;3.47, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) due to a borderline significant increase in contrast with age in HC (<italic toggle="yes">b&#160;</italic>=&#160;0.04, SE&#160;=&#160;0.02, <italic toggle="yes">t</italic>[26]&#160;=&#160;1.93, <italic toggle="yes">p</italic>&#160;=&#160;0.06) and a significant decrease in AD (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.03, SE&#160;=&#160;0.01, <italic toggle="yes">t</italic>[69.9]&#160;=&#160;&#8722;3.17, <italic toggle="yes">p</italic>&#160;=&#160;0.002).</p><p>For the 19 AD participants with multiple neuromelanin MRI timepoints (eight with two, 11 with three), there was no significant effect of time from baseline scan on either the LC (<italic toggle="yes">b&#160;</italic>=&#160;0.00, SE&#160;=&#160;0.00, <italic toggle="yes">t</italic>[33.9]&#160;=&#160;0.91, <italic toggle="yes">p</italic>&#160;=&#160;0.37) or SN (<italic toggle="yes">b&#160;</italic>=&#160;0.00, SE&#160;=&#160;0.00, <italic toggle="yes">t</italic>[32.4]&#160;=&#160;&#8722;1.37, <italic toggle="yes">p</italic>&#160;=&#160;0.18), indicating that at the group level, contrast values did not change over time (Figure&#160;<xref rid="alz70749-fig-0002" ref-type="fig">2G,H</xref>).</p></sec><sec id="alz70749-sec-0220"><label>3.3</label><title>Relationship of LC and SN integrity to cognition</title><p>We examined the relationship between LC/SN integrity and cognition in all participants who had same&#8208;day ACE and MRI data (76 AD, 28 HC). Linear regression revealed a significant interaction of group and LC integrity on total ACE (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;10.41, SE&#160;=&#160;5.08, <italic toggle="yes">t</italic>[96]&#160;=&#160;&#8722;2.05, <italic toggle="yes">p</italic>&#160;=&#160;0.04). This was due to a significant positive relationship in AD (<italic toggle="yes">b&#160;</italic>=&#160;9.71, SE&#160;=&#160;4.20, <italic toggle="yes">t</italic>[70]&#160;=&#160;2.31, <italic toggle="yes">p</italic>&#160;=&#160;0.02), and no relationship in the HC (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.22, SE&#160;=&#160;0.91, <italic toggle="yes">t</italic>[23]&#160;=&#160;&#8722;0.25, <italic toggle="yes">p</italic>&#160;=&#160;0.81) (Figure&#160;<xref rid="alz70749-fig-0002" ref-type="fig">2F</xref>). Given LC integrity and cognition were significantly related in the AD group only, we then ran a series of linear regression models to further explore the relationship with cognition in just that group (Figure&#160;<xref rid="alz70749-fig-0003" ref-type="fig">3</xref>, Table <xref rid="alz70749-supinfo-0001" ref-type="">S1</xref>). For each model, the predictor was either LC or SN contrast, or LCSN composite contrast value, and the dependent variable was ACE total or subdomain score. LC showed a significant positive relationship with total ACE score (<italic toggle="yes">b&#160;</italic>=&#160;9.71, SE&#160;=&#160;4.2, <italic toggle="yes">t</italic>[70]&#160;=&#160;2.31, <italic toggle="yes">p</italic>&#160;=&#160;0.02), attention (<italic toggle="yes">b&#160;</italic>=&#160;2.33, SE&#160;=&#160;0.98, <italic toggle="yes">t</italic>[70]&#160;=&#160;2.38, <italic toggle="yes">p</italic>&#160;=&#160;0.02), and visuospatial ability (<italic toggle="yes">b&#160;</italic>=&#160;2.16, SE&#160;=&#160;0.99, <italic toggle="yes">t</italic>[70]&#160;=&#160;2.17, <italic toggle="yes">p</italic>&#160;=&#160;0.03). SN was significantly positively associated with total ACE score (<italic toggle="yes">b&#160;</italic>=&#160;6.38, SE&#160;=&#160;2.85, <italic toggle="yes">t</italic>[70]&#160;=&#160;2.24, <italic toggle="yes">p</italic>&#160;=&#160;0.03) and attention (<italic toggle="yes">b&#160;</italic>=&#160;1.51, SE&#160;=&#160;0.66, <italic toggle="yes">t</italic>[70]&#160;=&#160;2.28, <italic toggle="yes">p</italic>&#160;=&#160;0.03). The LCSN composite was significantly positively associated with scores in attention, language, visuospatial ability, and memory, but not fluency (Figure&#160;<xref rid="alz70749-fig-0003" ref-type="fig">3B</xref>) (see Table <xref rid="alz70749-supinfo-0001" ref-type="">S1</xref> for statistics).</p><fig position="float" fig-type="FIGURE" id="alz70749-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Relationship with ACE total score and subdomain scores. (A) Scatter plots showing relationship with ACE for LC (blue) and SN (brown) contrast in AD, one timepoint per participant. Significant relationships according to linear regression models run separately for each nucleus are shown with a solid line of best fit through the raw data. Shaded error bar shows standard error of the mean. (B) Heatmap showing the <italic toggle="yes">p</italic> values resulting from linear regression models. All models include age, sex, education, and length of symptoms as covariates. The LC (+ SN) column shows the <italic toggle="yes">p</italic> value related to the LC in the model in which both contrast values are included in the same model, and vice versa for SN (+ LC). LCSN is a single composite value derived from both nuclei. <italic toggle="yes">p</italic>&#160;&gt;&#160;0.05 marked in gray. ACE,&#160;Addenbrooke's Cognitive Examination total score; LC,&#160;locus coeruleus; SN,&#160;substantia nigra.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70749-g004.jpg"/></fig><p>As a sensitivity analysis, the preceding models were additionally run with total gray matter volume and estimated total intracranial volume as covariates. Gray matter volume was significantly associated with total ACE and all subdomain scores (except visuospatial ability), when accounting for LC and SN together or when accounting for the LCSN composite. The LC remained significantly associated with ACE score when accounting for SN and gray matter volume (<italic toggle="yes">b&#160;</italic>=&#160;9.78, SE&#160;=&#160;4.21, <italic toggle="yes">t</italic>[54]&#160;=&#160;2.32, <italic toggle="yes">p</italic>&#160;=&#160;0.02), while the associations with attention (<italic toggle="yes">b&#160;</italic>=&#160;1.91, SE&#160;=&#160;1.07, <italic toggle="yes">t</italic>[54]&#160;=&#160;1.78, <italic toggle="yes">p</italic>&#160;=&#160;0.08) and language (<italic toggle="yes">b&#160;</italic>=&#160;2.45, SE&#160;=&#160;1.29, <italic toggle="yes">t</italic>[54]&#160;=&#160;1.9, <italic toggle="yes">p</italic>&#160;=&#160;0.06) were trend level. The SN and LCSN composite were not associated with cognition when accounting for gray matter volume (see Table <xref rid="alz70749-supinfo-0001" ref-type="">S1</xref> for full statistics).</p><p>In a further exploratory analysis, AD participants were grouped into three clusters using <italic toggle="yes">k</italic>&#8208;means, based on their LC and SN values (&#8220;Methods&#8221;) (Figure&#160;<xref rid="alz70749-fig-0004" ref-type="fig">4A,B</xref>). Relative to controls, Cluster 1 showed a moderate reduction in LC contrast (&#8722;0.6 SD) with marked SN reduction (&#8722;2.0 SD); Cluster 2 had a milder LC reduction (&#8722;0.3 SD) and an increase in SN contrast (1.0 SD); Cluster 3 showed moderate LC reduction (&#8722;0.6 SD) with only mild SN reduction (&#8722;0.4 SD). The cognitive scores of each cluster were then compared. Cluster 1 had significantly lower total ACE scores compared to both Clusters 2 (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;18.15, SE&#160;=&#160;5.73, <italic toggle="yes">t</italic>[69]&#160;=&#160;&#8722;3.17, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01) and 3 (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;14.34, SE&#160;=&#160;4.6, <italic toggle="yes">t</italic>[69]&#160;=&#160;&#8722;3.12, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01). Cluster 1 also had significantly lower attention (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;3.79, SE&#160;=&#160;1.37, <italic toggle="yes">t</italic>[69]&#160;=&#160;&#8722;2.76, <italic toggle="yes">p</italic>&#160;=&#160;0.02), language (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;4.44, SE&#160;=&#160;1.78, <italic toggle="yes">t</italic>[69]&#160;=&#160;&#8722;2.5, <italic toggle="yes">p</italic>&#160;=&#160;0.04), and visuospatial ability (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;3.45, SE&#160;=&#160;1.41, <italic toggle="yes">t</italic>[69]&#160;=&#160;&#8722;2.46, <italic toggle="yes">p</italic>&#160;=&#160;0.04) compared to Cluster 2; and significantly lower memory (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;3.57, SE&#160;=&#160;1.41, <italic toggle="yes">t</italic>[69]&#160;=&#160;&#8722;2.54, <italic toggle="yes">p</italic>&#160;=&#160;0.04), fluency (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;3.11, SE&#160;=&#160;0.95, <italic toggle="yes">t</italic>[69]&#160;=&#160;&#8722;3.29, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01), and language (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;3.63, SE&#160;=&#160;1.43, <italic toggle="yes">t</italic>[69]&#160;=&#160;&#8722;2.54, <italic toggle="yes">p</italic>&#160;=&#160;0.03) compared to Cluster 3 (Figure&#160;<xref rid="alz70749-fig-0004" ref-type="fig">4C</xref>). There were no differences between Clusters 2 and 3 (see Table <xref rid="alz70749-supinfo-0001" ref-type="">S2</xref> for full statistics).</p><fig position="float" fig-type="FIGURE" id="alz70749-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Clustering of AD participants and relationships with cognition (A) density plots showing distribution of LC and SN contrast values (converted to <italic toggle="yes">z</italic>&#8208;scores relative to controls) in AD group. (B) Scatter plot showing clusters of AD participants based on their LC/SN contrast values. (C) Box plots showing ACE total and subdomain scores for each AD cluster. Significance shown is the result of analysis of covariance adjusting for covariates. Post hoc Tukey adjustment performed for comparisons between clusters within each ACE domain. *<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, **<italic toggle="yes">p</italic>&#160;&lt;&#160;0.01. ACE, Addenbrooke's Cognitive Examination total score; AD, Alzheimer's disease; LC, locus coeruleus; SN, substantia nigra.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="ALZ-21-e70749-g007.jpg"/></fig></sec><sec id="alz70749-sec-0230"><label>3.4</label><title>Noradrenergic dysfunction and neuropsychiatric symptoms</title><p>We investigated the relationship between LC and SN contrast and NPI scores from 62 AD participants. All NPI assessments were performed within 1 year of the scan with a gap in days of 95&#160;&#177;&#160;125 (mean&#160;&#177;&#160;SD). The participants with symptoms of apathy (<italic toggle="yes">N</italic>&#160;=&#160;22/62, <italic toggle="yes">b&#160;</italic>=&#160;&#8722;2.24, SE&#160;=&#160;0.85, <italic toggle="yes">Z</italic>&#160;=&#160;&#8722;2.63, odds ratio [OR]&#160;=&#160;0.11, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01), anxiety (<italic toggle="yes">N</italic>&#160;=&#160;19/62, <italic toggle="yes">b&#160;</italic>=&#160;&#8722;1.67, SE&#160;=&#160;0.83, <italic toggle="yes">Z</italic>&#160;=&#160;&#8722;2.01, OR&#160;=&#160;0.19, <italic toggle="yes">p</italic>&#160;=&#160;0.04), and depression (<italic toggle="yes">N</italic>&#160;=&#160;29/62, <italic toggle="yes">b&#160;</italic>=&#160;&#8722;1.58, SE&#160;=&#160;0.74, <italic toggle="yes">Z</italic>&#160;=&#160;&#8722;2.13, OR&#160;=&#160;0.21, <italic toggle="yes">p</italic>&#160;=&#160;0.03), all had significantly lower LC contrast than those without (Figure&#160;<xref rid="alz70749-fig-0005" ref-type="fig">5</xref>) (uncorrected for multiple comparisons). All three significant symptom domains remained significant when including SN as a covariate, indicating an independent association of LC contrast. There was no difference in LC contrast between those with and without the other NPI symptoms. SN contrast was not associated with any neuropsychiatric symptoms (Table <xref rid="alz70749-supinfo-0001" ref-type="">S3</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70749-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Using LC contrast to predict neuropsychiatric symptoms. Box plots showing significantly lower LC contrast for participants with versus without NPI score&#160;&gt;&#160;0 for (A) apathy, (B) anxiety, and (C) depression. (D&#8211;L) No difference seen in contrast between those with and without the other symptoms. Significance shown is the result of logistic regression adjusting for covariates. *<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, **<italic toggle="yes">p</italic>&#160;&lt;&#160;0.01. LC, locus coeruleus; NPI, Neuropsychiatric Inventory.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="ALZ-21-e70749-g003.jpg"/></fig></sec><sec id="alz70749-sec-0240"><label>3.5</label><title>Catecholamines and Alzheimer's disease progression</title><sec id="alz70749-sec-0250"><label>3.5.1</label><title>Plasma biomarkers</title><p>Plasma biomarkers were quantified for 37 AD and 24 HC. One further AD participant's GFAP and NfL analysis failed. There was a significant difference between groups, accounting for age and sex, with elevated levels in AD for pTau217 (<italic toggle="yes">b&#160;</italic>=&#160;0.64, SE&#160;=&#160;0.11, <italic toggle="yes">t</italic>[57]&#160;=&#160;6.03, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), GFAP (<italic toggle="yes">b&#160;</italic>=&#160;80.87, SE&#160;=&#160;29.97, <italic toggle="yes">t</italic>[56]&#160;=&#160;2.70, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01), and NfL (<italic toggle="yes">b&#160;</italic>=&#160;13.04, SE&#160;=&#160;3.09, <italic toggle="yes">t</italic>[56]&#160;=&#160;4.21, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) (Figure&#160;<xref rid="alz70749-fig-0006" ref-type="fig">6A&#8211;C</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70749-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>LC and SN integrity and disease progression. (A&#8211;C) Violin plots showing plasma pTau217, GFAP, and NfL by group. (D) Scatter plot showing relationship between plasma pTau217 and ACE, split by group. Shows a significant relationship across all participants, accounting for group, with no group interaction. (E and F) Scatter plot showing relationship between plasma pTau217 and LC contrast, split by group, showing significant relationship in AD but not HC. (D&#8211;F) Lines of best fit plotted through raw data. (G) Timeline of ADAS&#8208;Cog relative to MRI scan used to compare LC contrast against rate of cognitive decline. The red and blue dots represent first and last ADAS&#8208;Cog for each participant, respectively. Solid black vertical line represents the time of the MRI scan. Dashed black vertical line represents 1 year before/after the MRI scan. All scans fell during, or within 1 year of, the period of longitudinal cognitive testing. (H) Line graph representing each participant's ADAS&#8208;Cog scores over time. Baseline taken as date of first ADAS&#8208;Cog. Line color represents LC contrast value for that participant measured on a single MRI scan, with darker color indicating higher contrast. (I) Scatter plot showing LC contrast against annual rate of change in ADAS&#8208;Cog score, with line of best fit through raw data. Panels (J) and (K) are as in (H) and (I) but for SN. Significant <italic toggle="yes">p</italic> values (&lt;&#160;0.05) in bold. All models include age, sex, and length of symptoms as covariates, plus education for cognitive decline. Shaded error bars show standard error of the mean. **<italic toggle="yes">p</italic>&#160;&lt;&#160;0.01, ***<italic toggle="yes">p</italic>&#160;&lt;&#160;0.001. ACE, Addenbrooke's Cognitive Examination; pTau217, phospho&#8208;tau&#8208;217; AD, Alzheimer's disease (green); ADAS&#8211;Cog, Alzheimer's Disease Assessment Scale&#8211;Cognitive; GFAP, glial fibrillary acidic protein; HC, Healthy control (gold); LC, locus coeruleus; NfL, neurofilament light; SN, substantia nigra.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="ALZ-21-e70749-g002.jpg"/></fig><p>There was a significant negative relationship between LC contrast and plasma pTau217 concentration, accounting for length of symptoms (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.30, SE&#160;=&#160;0.14, <italic toggle="yes">t</italic>[54]&#160;=&#160;&#8722;2.22, <italic toggle="yes">p</italic>&#160;=&#160;0.03), with a significant group:LC contrast interaction (<italic toggle="yes">b&#160;</italic>=&#160;0.34, SE&#160;=&#160;0.17, <italic toggle="yes">t</italic>[54]&#160;=&#160;0.17, <italic toggle="yes">p</italic>&#160;=&#160;0.048). This was the result of a significant negative relationship in AD (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.34, SE&#160;=&#160;0.16, <italic toggle="yes">t</italic>[32]&#160;=&#160;&#8722;2.04, <italic toggle="yes">p</italic>&#160;=&#160;0.05) but not HC (<italic toggle="yes">p</italic>&#160;&gt;&#160;0.05) (Figure&#160;<xref rid="alz70749-fig-0006" ref-type="fig">6E,F</xref>). There was a significant negative relationship between ACE and plasma pTau217 concentration (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;8.02, SE&#160;=&#160;3.78, <italic toggle="yes">t</italic>[50]&#160;=&#160;&#8722;2.12, <italic toggle="yes">p</italic>&#160;=&#160;0.04), with no interaction of group (Figure&#160;<xref rid="alz70749-fig-0006" ref-type="fig">6D</xref>). There was no relationship between GFAP or NfL with LC contrast or ACE (all <italic toggle="yes">p</italic>&#160;&gt;&#160;0.05) (Table <xref rid="alz70749-supinfo-0001" ref-type="">S4</xref>).</p><p>There was no relationship of pTau217, GFAP, or NfL with SN contrast (all <italic toggle="yes">p</italic>&#160;&gt;&#160;0.05) (Table <xref rid="alz70749-supinfo-0001" ref-type="">S4</xref>). There was a significant SN:group interaction in predicting GFAP (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;117.33, SE&#160;=&#160;43.17, <italic toggle="yes">t</italic>[53]&#160;=&#160;&#8722;2.72, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01) due to a significant negative relationship in controls (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;90.51, SE&#160;=&#160;41.31, <italic toggle="yes">t</italic>[20] = &#8722;2.19, <italic toggle="yes">p</italic>&#160;=&#160;0.04), but not in AD (<italic toggle="yes">p</italic>&#160;&gt;&#160;0.05).</p></sec><sec id="alz70749-sec-0260"><label>3.5.2</label><title>Cognitive decline rate</title><p>The ADAS&#8208;Cog is typically used to show change in cognition in AD during clinical trials. It was conducted here at multiple timepoints, unrelated to the day of the MRI scanning, as a means of tracking rate of decline. The annual rate of change in ADAS&#8208;Cog score was 9.69&#160;&#177;&#160;5.97 (mean&#160;&#177;&#160;SD; <italic toggle="yes">N</italic>&#160;=&#160;48). LC contrast was significantly associated with cognitive decline rate with a lower contrast associated with a faster decline (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;5.08, SE&#160;=&#160;2.43, <italic toggle="yes">t</italic>[42]&#160;=&#160;&#8722;2.9, <italic toggle="yes">p</italic>&#160;=&#160;0.04) (Figure&#160;<xref rid="alz70749-fig-0006" ref-type="fig">6H,I</xref>). When controlling for pTau217, the result also remained (<italic toggle="yes">N</italic>&#160;=&#160;19, <italic toggle="yes">b&#160;</italic>=&#160;&#8722;7.16, SE&#160;=&#160;3.05, <italic toggle="yes">t</italic>[12]&#160;=&#160;&#8722;2.35, <italic toggle="yes">p</italic>&#160;=&#160;0.04), suggesting that the relationship between LC integrity and disease progression in clinical AD was independent of amyloid burden.</p><p>Lower SN contrast was also associated with faster cognitive decline rate (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;2.4, SE&#160;=&#160;1.06, <italic toggle="yes">t</italic>[42]&#160;=&#160;&#8722;2.27, <italic toggle="yes">p</italic>&#160;=&#160;0.03) (Figure&#160;<xref rid="alz70749-fig-0006" ref-type="fig">6J,K</xref>); however this was not the case when accounting for pTau217 (N&#160;=&#160;19, <italic toggle="yes">b&#160;</italic>=&#160;&#8722;0.18, SE&#160;=&#160;1.73, <italic toggle="yes">t</italic>[12]&#160;=&#160;&#8722;0.11, <italic toggle="yes">p</italic>&#160;=&#160;0.92). When including both SN and LC in the model, they both remained associated with rate of cognitive decline (LC: <italic toggle="yes">b&#160;</italic>=&#160;&#8722;4.74, SE&#160;=&#160;2.33, <italic toggle="yes">t</italic>[41]&#160;=&#160;&#8722;2.04, <italic toggle="yes">p</italic>&#160;=&#160;0.048; SN: <italic toggle="yes">b&#160;</italic>=&#160;&#8722;2.27, SE&#160;=&#160;1.02, <italic toggle="yes">t</italic>[41]&#160;=&#160;&#8722;2.22, <italic toggle="yes">p</italic>&#160;=&#160;0.03). The LCSN composite was a stronger predictor of cognitive decline than the individual nuclei (<italic toggle="yes">b&#160;</italic>=&#160;&#8722;4.57, SE&#160;=&#160;1.56, <italic toggle="yes">t</italic>[42]&#160;=&#160;&#8722;2.93, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.01).</p></sec><sec id="alz70749-sec-0270"><label>3.5.3</label><title>Atrophy rate</title><p>Having established a relationship between contrast in both nuclei and the rate of cognitive decline in AD, we looked at the relationship between nucleus contrast and subsequent atrophy rate (Figure&#160;<xref rid="alz70749-fig-0007" ref-type="fig">7A&#8211;C</xref>). This was done by calculating the JD for the bilateral cortical gray matter, and for the right and left side separately, in 28 AD participants, over 16.43&#160;&#177;&#160;6.96 months (mean&#160;&#177;&#160;SD). The bilateral gray matter JD was &#8722;0.93%&#160;&#177;&#160;1.11 per year, and for the left and right it was &#8722;0.95%&#160;&#177;&#160;1.10 and &#8722;0.91%&#160;&#177;&#160;1.12 per year, respectively (mean&#160;&#177;&#160;SD). There was no difference between sides on <italic toggle="yes">t</italic>&#8208;testing (<italic toggle="yes">p</italic>&#160;&gt;&#160;0.05). The relationship between LC contrast and bilateral gray matter (<italic toggle="yes">b&#160;</italic>=&#160;1.50, SE&#160;=&#160;0.80, <italic toggle="yes">t</italic>[19]&#160;=&#160;1.87, <italic toggle="yes">p</italic>&#160;=&#160;0.08), left gray matter (<italic toggle="yes">b&#160;</italic>=&#160;1.46, SE&#160;=&#160;0.83, <italic toggle="yes">t</italic>[19]&#160;=&#160;1.77, <italic toggle="yes">p</italic>&#160;=&#160;0.09), and right gray matter (<italic toggle="yes">b&#160;</italic>=&#160;1.54, SE&#160;=&#160;0.84, <italic toggle="yes">t</italic>[19]&#160;=&#160;1.83, <italic toggle="yes">p</italic>&#160;=&#160;0.08) JD showed a trend level relationship, that is, a trend to faster volume loss with lower contrast (Figure&#160;<xref rid="alz70749-fig-0007" ref-type="fig">7A,D</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70749-fig-0007" orientation="portrait"><label>FIGURE 7</label><caption><p>LC integrity and atrophy rate. (A&#8211;C) Scatter plots showing bilateral, left, and right LC contrast against bilateral GM JD, with line of best fit through raw data. (D) Table showing estimates and <italic toggle="yes">p</italic> values resulting from linear regression models between LC (above) and SN (below) contrast and cortical gray matter JD in AD participants. GM, gray matter; JD, Jacobian determinant; LC, locus coeruleus; SN, substantia nigra.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="ALZ-21-e70749-g001.jpg"/></fig><p>In a further exploratory analysis, we also looked at the relationship between the contrast in each of the left and right LC and SN nuclei and the JD values. The left LC showed a significant relationship with all three JD measures (bilateral gray matter: <italic toggle="yes">b&#160;</italic>=&#160;1.66, SE&#160;=&#160;0.60, <italic toggle="yes">t</italic>[19]&#160;=&#160;2.78, <italic toggle="yes">p</italic>&#160;=&#160;0.01; left: <italic toggle="yes">b&#160;</italic>=&#160;1.72, SE&#160;=&#160;0.61, <italic toggle="yes">t</italic>[19]&#160;=&#160;2.84, <italic toggle="yes">p</italic>&#160;=&#160;0.01; right: <italic toggle="yes">b&#160;</italic>=&#160;1.61, SE&#160;=&#160;0.64, <italic toggle="yes">t</italic>[19]&#160;=&#160;2.51, <italic toggle="yes">p</italic>&#160;=&#160;0.02) (Figure&#160;<xref rid="alz70749-fig-0007" ref-type="fig">7B,D</xref>). The right LC showed no relationship with JD (Figure&#160;<xref rid="alz70749-fig-0007" ref-type="fig">7C,D</xref>). SN contrast, measured bilaterally or on either side, was not associated with gray matter JD (Figure&#160;<xref rid="alz70749-fig-0007" ref-type="fig">7E</xref>).</p></sec></sec></sec><sec id="alz70749-sec-0280"><label>4</label><title>DISCUSSION</title><p>We found LC nucleus integrity, measured with neuromelanin MRI, was reduced in AD relative to HC, consistent with previous work.<xref rid="alz70749-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70749-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="alz70749-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="alz70749-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> In what we believe is the first application of this method to the SN in clinical AD, there was no group difference. While contrast in both nuclei related to global cognition, when accounting for both, only the LC still did so. LC integrity was lower in participants with apathy, anxiety, and depression symptoms, all of which are associated with noradrenergic function.<xref rid="alz70749-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70749-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> Notably, these analyses accounted for symptom duration, indicating a relationship to LC integrity per se rather than disease stage. LC integrity related to cognition even accounting for total gray matter volume.</p><p>MCI patients usually show deficits in a single cognitive domain, often memory, before the involvement of others.<xref rid="alz70749-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref> Accordingly, LC integrity has predominantly been associated with memory in prodromal/early stages.<xref rid="alz70749-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70749-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="alz70749-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref> In this cohort however, most participants&#8217; disease had progressed to a stage such that they displayed multidomain deficits. This may explain how associations of LC with attention and visuospatial ability were demonstrated here. In fact, both LC and SN integrity were related to attention when accounting for one another. Noradrenergic function is commonly associated with attention,<xref rid="alz70749-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> and implications for AD have been described.<xref rid="alz70749-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> Dopamine is also implicated in attentional control,<xref rid="alz70749-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> specifically via prefrontal D<sub>1</sub> receptors,<xref rid="alz70749-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> and reduced SN contrast is associated with poorer attention and working memory in PD and healthy aging, respectively.<xref rid="alz70749-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70749-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> Interestingly, we found that a combined, equally weighted metric of both nuclei was the strongest predictor of global cognition. Also, a subgroup of AD participants with reduced SN integrity in addition to reduced LC integrity had worse cognition than those in which SN integrity was preserved. Together these findings point to the contribution of disruption to both systems to cognitive dysfunction in AD.</p><p>LC contrast was reduced in patients with symptoms of depression, anxiety, and apathy, when accounting for SN contrast. AD patients with depression have fewer LC neurons<xref rid="alz70749-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> and a 10&#8208; to 20&#8208;fold reduction in cortical noradrenaline.<xref rid="alz70749-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> However, the mechanism underpinning this relationship is unclear and multifactorial.<xref rid="alz70749-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Specific neuropsychiatric symptoms are not present in all patients, and a recent meta&#8208;analysis concluded that antidepressants are ineffective in dementia, likely due to the diversity of mechanisms.<xref rid="alz70749-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> Better understanding of individual pathophysiology and targeting of subgroups likely to benefit from specific treatments is warranted.<xref rid="alz70749-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>
</p><p>Apathy occurs in half of AD patients.<xref rid="alz70749-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Like depression, the cause is complex and likely secondary to both subcortical and cortical pathology, with both catecholaminergic systems implicated.<xref rid="alz70749-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref> Previous studies related LC MRI and dopaminergic SPECT imaging to apathy in PD and AD.<xref rid="alz70749-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="alz70749-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref>, <xref rid="alz70749-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref>, <xref rid="alz70749-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> Symptom and mechanistic variability between individuals again highlight the need for biomarker&#8208;led approaches. Unlike depression, meta&#8208;analysis evidence shows a positive effect of noradrenergic drugs on apathy in AD,<xref rid="alz70749-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> perhaps due to the dual dopaminergic&#8208;noradrenergic action of some drugs.<xref rid="alz70749-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref>
</p><p>Previous work showed that pTau217 &#8211; a marker of amyloid and tau pathology<xref rid="alz70749-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> &#8211; related to LC contrast in healthy older adults (not replicated here). Here, AD patients with lower LC integrity had higher pTau217. Because this holds when accounting for symptom duration, both biomarkers may reflect the variability in pathological burden between patients, rather than merely disease stage.<xref rid="alz70749-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> This association was unique to pTau217; we did not see one with NfL or GFAP, both of which are sensitive but not specific to AD.<xref rid="alz70749-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="alz70749-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
</p><p>We also found a relationship between LC integrity and rate of cognitive decline and gray matter atrophy. AD is heterogenous, resulting in variable disease courses.<xref rid="alz70749-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70749-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref> Multiple fluid and imaging biomarkers predict progression to AD from preclinical states, including LC contrast.<xref rid="alz70749-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="alz70749-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>, <xref rid="alz70749-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref>, <xref rid="alz70749-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> The relationship of LC integrity to rate of cognitive decline was independent of pTau217. This suggests it is not merely a corollary of cortical pathological burden but in fact drives disease progression independently. This was not true of the SN, for which the relationship between integrity and cognitive decline rate was not independent of pTau217.</p><p>Given extensive evidence for noradrenaline's neuroprotective effects, these results linking LC integrity to disease progression suggest a causal relationship. To summarize evidence reviewed elsewhere,<xref rid="alz70749-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> noradrenergic loss induces proinflammatory cytokines (e.g., IL&#8208;1&#946;, TNF&#8208;&#945;, and IL&#8208;6) &#8211; largely via &#946;&#8208;adrenergic receptors and cAMP pathways.<xref rid="alz70749-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref>, <xref rid="alz70749-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> Also, noradrenaline reduces microglial A&#946; clearance.<xref rid="alz70749-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref>, <xref rid="alz70749-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> Interestingly, noradrenaline's neuroprotective effects are particularly prominent in the SN&#8211;dopaminergic system.<xref rid="alz70749-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref> Long&#8208;term noradrenergic denervation reduces the number of SN dopaminergic neurons and affects behavioral function in rats,<xref rid="alz70749-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> while noradrenaline depletion inhibits recovery of lesioned dopaminergic neurons.<xref rid="alz70749-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref> Therefore, loss of the neuroprotective effects of noradrenaline may lead to dopaminergic dysfunction, exacerbating symptoms.</p><p>This evidence evokes the possibility that therapeutically increasing noradrenergic tone may have neuroprotective, even disease&#8208;modifying, effects. In a recent trial testing the potential AD&#8208;modifying effects of the noradrenaline reuptake inhibitor atomoxetine, CSF total tau and pTau181 were reduced, while temporal lobe metabolism increased versus placebo.<xref rid="alz70749-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref> There was no effect on cognition or atrophy, perhaps as trial duration was only 6 months. Alongside anti&#8208;amyloid therapies, drugs promoting tau removal are being trialed.<xref rid="alz70749-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref> If effective in slowing or even reversing LC damage and restoring noradrenergic function, these therapies may generate a neuroprotective positive feedback loop.</p><p>The LC integrity&#8211;cognition relationship may actually be bidirectional. It is believed that mental stimulation is protective against later&#8208;life decline. In 2013, Robertson proposed that noradrenaline is key in mediating this cognitive reserve.<xref rid="alz70749-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref> Lifestyle factors that contribute to cognitive reserve stimulate noradrenergic activity, which Robertson claimed provides benefit through compensation and/or modification. In healthy people, established proxies of reserve relate to LC contrast.<xref rid="alz70749-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref> Also, LC tangle density is associated with lower social activity independent of amyloid and tau burden, and its relationship with cognition is partially mediated by reduced social activity.<xref rid="alz70749-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref> Cognitive reserve may not only protect against developing AD but also influence the disease course. LC integrity, as a biological marker of cognitive reserve, may protect against progression, even in symptomatic AD.</p><p>It is unclear why left LC was more strongly associated with atrophy. Although there are functional differences between left and right LC,<xref rid="alz70749-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref> projections from both are contra&#8208; and ipsilateral,<xref rid="alz70749-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref> and left LC does not accrue more tau or neuronal loss in AD.<xref rid="alz70749-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref> We note that Siemens scanners (used here) systematically produce higher left&#8208;sided contrast.<xref rid="alz70749-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> It is therefore possible that the stronger results relating to the left here (and elsewhere<xref rid="alz70749-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>) are due to higher contrast providing a better signal&#8208;to&#8208;noise ratio, as evidenced by the larger group difference seen on the left.</p><p>Unlike the LC&#8211;noradrenergic system, the extent of group&#8208;level SN changes in AD remains unclear. Our null result may reflect insufficient statistical power, particularly if only a subgroup is affected.<xref rid="alz70749-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz70749-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> This is reflected in the clustering analysis in which three subgroups of patients were identified. Each subgroup had similarly reduced LC integrity, but mildly increased, mildly decreased, or markedly decreased SN integrity, relative to controls. As a consequence, the spread of SN values relative to controls was considerably wider than for the LC (Figure&#160;<xref rid="alz70749-fig-0004" ref-type="fig">4A</xref>), perhaps reflecting the inconsistent presence of pathology in the SN, relative to the LC. Additionally, SN&#8208;dopaminergic pathology in AD may not result in sufficient SN cell death to reduce neuromelanin contrast.<xref rid="alz70749-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Recent neuropathology work identified multiple mechanisms underlying the selective vulnerability of LC versus SN neurons, especially in early disease.<xref rid="alz70749-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref> In particular, LC's elevated cholesterol demand may cause inadvertent uptake of toxic A&#946;. Nevertheless, while in health SN neuromelanin accumulates with age, we showed a negative relationship with age in AD. This interaction of age and disease suggests accelerated cell death in AD (Figure&#160;<xref rid="alz70749-fig-0002" ref-type="fig">2E</xref>).</p><p>Compared to cognitive decline, the lack of predictive value of the SN for subsequent atrophy rate highlights that the association between atrophy and cognition is not absolute. Axonal injury and pathological burden &#8211; leading to network disruption and synaptic dysfunction &#8211; represent alternative factors that may show a closer temporal relationship to cognitive changes than atrophy.<xref rid="alz70749-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref> Cognitive reserve also explains the non&#8208;linear association between neurodegeneration and symptoms to some degree. It may also be that dopamine does not have the same neuroprotective effect and is therefore not a factor in the rate of neuronal loss.</p><p>Our work had the following methodological limitations. The methods of extracting contrast ratio values for the LC and SN were different. We used a semi&#8208;automated method for the SN to avoid rater bias, in line with prior work.<xref rid="alz70749-bib-0087" ref-type="bibr">
<sup>87</sup>
</xref>, <xref rid="alz70749-bib-0088" ref-type="bibr">
<sup>88</sup>
</xref>, <xref rid="alz70749-bib-0089" ref-type="bibr">
<sup>89</sup>
</xref>, <xref rid="alz70749-bib-0090" ref-type="bibr">
<sup>90</sup>
</xref> For the LC, we used manual segmentation because its much smaller size,<xref rid="alz70749-bib-0091" ref-type="bibr">
<sup>91</sup>
</xref>, <xref rid="alz70749-bib-0092" ref-type="bibr">
<sup>92</sup>
</xref> especially in neurodegenerative populations, makes automated alignment less reliable than the SN.<xref rid="alz70749-bib-0093" ref-type="bibr">
<sup>93</sup>
</xref> This is consistent with most clinical AD studies.<xref rid="alz70749-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70749-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="alz70749-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="alz70749-bib-0094" ref-type="bibr">
<sup>94</sup>
</xref> Importantly, however, it should be noted that the imaging sequence and equation used to calculate contrast ratio for both nuclei were identical. Second, to fully elucidate the specific contribution of both neuromodulatory systems to cognitive subdomains, more detailed cognitive assessment tools could be used.<xref rid="alz70749-bib-0095" ref-type="bibr">
<sup>95</sup>
</xref> Third, our follow&#8208;up period may have been too short to detect individual changes in LC contrast, previously observed over 2.5 years.<xref rid="alz70749-bib-0096" ref-type="bibr">
<sup>96</sup>
</xref> Fourth, regarding analysis of nuclei integrity in relation to rate of cognitive decline, the scans were not aligned to the first cognitive test. This single, cross&#8208;sectional measure was related to concurrent rate of decline but cannot be said to have definitively shown prospective predictive utility.</p><p>In conclusion, we conducted a multifaceted study of LC and SN integrity in relation to cognitive and neuropsychiatric symptoms in AD. Extending previous literature, we examined catecholaminergic function across a range of disease severity. LC integrity was reduced at the group level. Overall, there was no group difference in SN integrity, although both nuclei may be affected in a subgroup of AD. Both nuclei were related to attentional performance when accounting for one another. Further, LC integrity related to pTau217, confirming its relevance throughout the disease course. LC integrity not only reflects broader pathological burden but also predicts cognitive decline and, using the left side, the rate of gray matter atrophy. Given known neuroprotective effects of noradrenaline, our results suggest that LC dysfunction &#8211; more so than, and when controlling for, SN &#8211; accelerates the disease. Therefore, therapeutic modulation and/or protection of the noradrenergic system may be disease modifying.<xref rid="alz70749-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref>
</p></sec><sec sec-type="COI-statement" id="alz70749-sec-0300"><title>CONFLICT OF INTEREST STATEMENT</title><p>Paresh A. Malhotra is lead for a NIHR&#8208;funded trial with drug/placebo provided by Takeda Pharmaceuticals and sits on the Data Monitoring Committee for a trial carried out by Johnson &amp; Johnson. He is vice chair of the Alzheimer's Society Research Strategy Council and NIHR Specialty Lead for Dementia and Neurodegeneration, Research Delivery Network. He is also an independent member of a data monitoring committee. All other authors have nothing to disclose. Author disclosures are available in the <xref rid="alz70749-supinfo-0001" ref-type="">Supporting Information</xref>.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70749-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70749-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70749-s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70749-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70749-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70749-sec-0290"><title>ACKNOWLEDGMENTS</title><p>Members of the CR&amp;T Group of the UK DRI group can be found in the appendix. We would like to acknowledge our colleagues Pedro Vicente and Dr. Albert Busza in the imaging facility for their skill and patience in assisting with the MRI data acquisition for this study. This work is supported by the UK DRI (Grant Reference UKDRI&#8208;7202) through UK DRI Ltd., principally funded by the Medical Research Council (MRC), and additional funding partner Alzheimer's Society. Michael C. B. David is a Clinical Research Training Fellow funded by the MRC (Grant Reference: MR/W016095/1). Gregory Scott, National Institute for Health and Care Research (NIHR) Advanced Fellow (Grant Reference: NIHR302971), is funded by the NIHR for this research project. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS, or the UK Department of Health and Social Care. Magdalena A. Kolanko is supported by a personal research fellowship from Alzheimer's Society (Grant Reference: 608, AS&#8208;CTF&#8208;22&#8208;013). Thomas D. Parker is supported by a NIHR lectureship. Paresh A. Malhotra receives research funding from Lifearc, NIHR, MRC, Dementias Platform UK, Alzheimer's Research UK, the Football Association, FIFA, and Alzheimer's Society. Infrastructure support for this research was provided by the NIHR Imperial Biomedical Research Centre (BRC).</p></ack><sec sec-type="data-availability" id="alz70749-sec-0320"><title>DATA AVAILABILITY STATEMENT</title><p>The Minder and PCNorAD studies were approved by the London&#8208;Surrey Borders Research Ethics Committee (19/LO/0102) and London&#8208;Central&#160;Research Ethics Committee (18/LO/0249), respectively. All participants with the capacity to consent provided written informed consent for participation and for their data to be included. Those without capacity were enrolled in accordance with the Mental Capacity Act (2005) on recommendation of an assigned consultee. Data are available from the corresponding author upon reasonable request.</p></sec><ref-list id="alz70749-bibl-0001"><title>REFERENCES</title><ref id="alz70749-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70749-cite-0002"><string-name name-style="western"><surname>Schwarz</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>L</given-names></string-name>. <article-title>Organization of the locus coeruleus&#8208;norepinephrine system</article-title>. <source>Curr Biol</source>. <year>2015</year>;<volume>25</volume>(<issue>21</issue>):<fpage>R1051</fpage>&#8211;<lpage>R1056</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cub.2015.09.039</pub-id><pub-id pub-id-type="pmid">26528750</pub-id></mixed-citation></ref><ref id="alz70749-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70749-cite-0003"><string-name name-style="western"><surname>Sara</surname><given-names>SJ</given-names></string-name>. <article-title>The locus coeruleus and noradrenergic modulation of cognition</article-title>. <source>Nat Rev Neurosci</source>. <year>2009</year>;<volume>10</volume>(<issue>3</issue>):<fpage>211</fpage>&#8211;<lpage>223</lpage>.<pub-id pub-id-type="pmid">19190638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn2573</pub-id></mixed-citation></ref><ref id="alz70749-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70749-cite-0004"><string-name name-style="western"><surname>Berridge</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Waterhouse</surname><given-names>BD</given-names></string-name>. <article-title>The locus coeruleus&#8208;noradrenergic system: modulation of behavioral state and state&#8208;dependent cognitive processes</article-title>. <source>Brain Res Rev</source>. <year>2003</year>;<volume>42</volume>(<issue>1</issue>):<fpage>33</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">12668290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0165-0173(03)00143-7</pub-id></mixed-citation></ref><ref id="alz70749-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70749-cite-0005"><string-name name-style="western"><surname>Brunello</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Blier</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Judd</surname><given-names>LL</given-names></string-name>, et&#160;al. <article-title>Noradrenaline in mood and anxiety disorders: basic and clinical studies</article-title>. <source>Int Clin Psychopharmacol</source>. <year>2003</year>;<volume>18</volume>(<issue>4</issue>):<fpage>191</fpage>&#8211;<lpage>202</lpage>.<pub-id pub-id-type="pmid">12817153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00004850-200307000-00001</pub-id></mixed-citation></ref><ref id="alz70749-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70749-cite-0006"><string-name name-style="western"><surname>Weinshenker</surname><given-names>D</given-names></string-name>. <article-title>Long road to ruin: noradrenergic dysfunction in neurodegenerative disease</article-title>. <source>Trends Neurosci</source>. <year>2018</year>;<volume>41</volume>(<issue>4</issue>):<fpage>211</fpage>&#8211;<lpage>223</lpage>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ovidsp.ovid.com/ovidweb.cgi?T=JS%26PAGE=reference%26D=med15%26NEWS=N%26AN=29475564" ext-link-type="uri">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D&amp;med15&amp;NEWS=N&amp;AN=29475564</ext-link><pub-id pub-id-type="pmid">29475564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tins.2018.01.010</pub-id><pub-id pub-id-type="pmcid">PMC5878728</pub-id></mixed-citation></ref><ref id="alz70749-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70749-cite-0007"><string-name name-style="western"><surname>Holland</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Robbins</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Rowe</surname><given-names>JB</given-names></string-name>. <article-title>The role of noradrenaline in cognition and cognitive disorders</article-title>. <source>Brain</source>. <year>2021</year>;<volume>144</volume>(<issue>8</issue>):<fpage>2243</fpage>&#8211;<lpage>2256</lpage>.<pub-id pub-id-type="pmid">33725122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awab111</pub-id><pub-id pub-id-type="pmcid">PMC8418349</pub-id></mixed-citation></ref><ref id="alz70749-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70749-cite-0008"><string-name name-style="western"><surname>Burns</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Galvin</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Roe</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>McKeel</surname><given-names>DW</given-names></string-name>. <article-title>The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs</article-title>. <source>Neurology</source>. <year>2005</year>;<volume>64</volume>(<issue>8</issue>):<fpage>1397</fpage>&#8211;<lpage>1403</lpage>.<pub-id pub-id-type="pmid">15851730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.WNL.0000158423.05224.7F</pub-id></mixed-citation></ref><ref id="alz70749-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70749-cite-0009"><string-name name-style="western"><surname>Gibb</surname><given-names>WRG</given-names></string-name>, <string-name name-style="western"><surname>Mountjoy</surname><given-names>CQ</given-names></string-name>, <string-name name-style="western"><surname>Mann</surname><given-names>DMA</given-names></string-name>, <string-name name-style="western"><surname>Lees</surname><given-names>AJ</given-names></string-name>. <article-title>The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>1989</year>;<volume>52</volume>(<issue>2</issue>):<fpage>193</fpage>&#8211;<lpage>200</lpage>.<pub-id pub-id-type="pmid">2539435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.52.2.193</pub-id><pub-id pub-id-type="pmcid">PMC1032505</pub-id></mixed-citation></ref><ref id="alz70749-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70749-cite-0010"><string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Bienias</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Gilley</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Kvarnberg</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Mufson</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>. <article-title>Improved detection of substantia nigra pathology in Alzheimer's disease</article-title>. <source>J Histochem Cytochem</source>. <year>2002</year>;<volume>50</volume>(<issue>1</issue>):<fpage>99</fpage>&#8211;<lpage>106</lpage>.<pub-id pub-id-type="pmid">11748299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/002215540205000111</pub-id></mixed-citation></ref><ref id="alz70749-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70749-cite-0011"><string-name name-style="western"><surname>Aral</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kosaka</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Iizuka</surname><given-names>R</given-names></string-name>. <article-title>Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer&#8208;type dementia</article-title>. <source>J Neurochem</source>. <year>1984</year>;<volume>43</volume>(<issue>2</issue>):<fpage>388</fpage>&#8211;<lpage>393</lpage>.<pub-id pub-id-type="pmid">6204013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1471-4159.1984.tb00913.x</pub-id></mixed-citation></ref><ref id="alz70749-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70749-cite-0012"><string-name name-style="western"><surname>Rinne</surname><given-names>JO</given-names></string-name>, <string-name name-style="western"><surname>Sahlberg</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Routtinen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Nagren</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lehikoinen</surname><given-names>P</given-names></string-name>. <article-title>Striatal uptake of the dopamine reuptake ligand [llC]P&#8208;CFT is reduced in Alzheimer's disease assessed by positron emission tomography</article-title>. <source>Neurology</source>. <year>1998</year>;<volume>50</volume>:<fpage>152</fpage>&#8211;<lpage>156</lpage>.<pub-id pub-id-type="pmid">9443472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.50.1.152</pub-id></mixed-citation></ref><ref id="alz70749-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70749-cite-0013"><string-name name-style="western"><surname>Jack</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Andrews</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Beach</surname><given-names>TG</given-names></string-name>, et&#160;al. <article-title>Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup</article-title>. <source>Alzheimer's Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>8</issue>):<fpage>5143</fpage>&#8211;<lpage>5169</lpage>.<pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></mixed-citation></ref><ref id="alz70749-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70749-cite-0014"><string-name name-style="western"><surname>Trujillo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Aumann</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Claassen</surname><given-names>DO</given-names></string-name>. <article-title>Neuromelanin&#8208;sensitive MRI as a promising biomarker of catecholamine function</article-title>. <source>Brain</source>. <year>2023</year>;<volume>147</volume>(<issue>2</issue>):<fpage>337</fpage>&#8211;<lpage>351</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awad300</pub-id><pub-id pub-id-type="pmcid">PMC10834262</pub-id><pub-id pub-id-type="pmid">37669320</pub-id></mixed-citation></ref><ref id="alz70749-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70749-cite-0015"><string-name name-style="western"><surname>Sulzer</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Cassidy</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Horga</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease</article-title>. <source>NPJ Parkinsons Dis</source>. <year>2018</year>;<volume>4</volume>(<issue>1</issue>):<fpage>11</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41531-018-0047-3</pub-id><pub-id pub-id-type="pmid">29644335</pub-id><pub-id pub-id-type="pmcid">PMC5893576</pub-id></mixed-citation></ref><ref id="alz70749-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70749-cite-0016"><string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Decreased locus coeruleus signal associated with Alzheimer's disease based on neuromelanin&#8208;sensitive magnetic resonance imaging technique</article-title>. <source>Front Neurosci</source>. <year>2022</year>;<volume>16</volume>(<issue>October</issue>):<fpage>1</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2022.1014485</pub-id><pub-id pub-id-type="pmcid">PMC9580271</pub-id><pub-id pub-id-type="pmid">36278009</pub-id></mixed-citation></ref><ref id="alz70749-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70749-cite-0017"><string-name name-style="western"><surname>Takahashi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shibata</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sasaki</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Detection of changes in the locus coeruleus in patients with mild cognitive impairment and Alzheimer's disease: high&#8208;resolution fast spin&#8208;echo T1&#8208;weighted imaging</article-title>. <source>Geriatr Gerontol Int</source>. <year>2015</year>;<volume>15</volume>(<issue>3</issue>):<fpage>334</fpage>&#8211;<lpage>340</lpage>.<pub-id pub-id-type="pmid">24661561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ggi.12280</pub-id><pub-id pub-id-type="pmcid">PMC4405055</pub-id></mixed-citation></ref><ref id="alz70749-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70749-cite-0018"><string-name name-style="western"><surname>Cassidy</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Therriault</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pascoal</surname><given-names>TA</given-names></string-name>, et&#160;al. <article-title>Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease</article-title>. <source>Neuropsychopharmacology</source>. <year>2022</year>;<volume>47</volume>(<issue>5</issue>):<fpage>1128</fpage>&#8211;<lpage>1136</lpage>.<pub-id pub-id-type="pmid">35177805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41386-022-01293-6</pub-id><pub-id pub-id-type="pmcid">PMC8938499</pub-id></mixed-citation></ref><ref id="alz70749-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70749-cite-0019"><string-name name-style="western"><surname>Cho</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Bae</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JM</given-names></string-name>, et&#160;al. <article-title>Diagnostic performance of neuromelanin&#8208;sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta&#8208;analysis</article-title>. <source>Eur Radiol</source>. <year>2021</year>;<volume>31</volume>(<issue>3</issue>):<fpage>1268</fpage>&#8211;<lpage>1280</lpage>.<pub-id pub-id-type="pmid">32886201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-020-07240-7</pub-id></mixed-citation></ref><ref id="alz70749-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70749-cite-0020"><string-name name-style="western"><surname>Dahl</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Bachman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dutt</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>The integrity of dopaminergic and noradrenergic brain regions is associated with different aspects of late&#8208;life memory performance</article-title>. <source>Nat Aging</source>. <year>2023</year>;<volume>3</volume>(<issue>9</issue>):<fpage>1128</fpage>&#8208;<lpage>1143</lpage>. 148.<pub-id pub-id-type="pmid">37653256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00469-z</pub-id><pub-id pub-id-type="pmcid">PMC10501910</pub-id></mixed-citation></ref><ref id="alz70749-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70749-cite-0021"><string-name name-style="western"><surname>Elman</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Eglit</surname><given-names>GML</given-names></string-name>, <string-name name-style="western"><surname>Gustavson</surname><given-names>DE</given-names></string-name>, et&#160;al. <article-title>MRI&#8208;assessed locus coeruleus integrity is heritable and associated with multiple cognitive domains, mild cognitive impairment, and daytime dysfunction</article-title>. <source>Alzheimers Dement</source>. <year>2021</year>;<volume>17</volume>(<issue>6</issue>):<fpage>1017</fpage>&#8211;<lpage>1025</lpage>.<pub-id pub-id-type="pmid">33580733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12261</pub-id><pub-id pub-id-type="pmcid">PMC8248066</pub-id></mixed-citation></ref><ref id="alz70749-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70749-cite-0022"><string-name name-style="western"><surname>Dahl</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Mather</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Werkle&#8208;Bergner</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Locus coeruleus integrity is related to tau burden and memory loss in autosomal&#8208;dominant Alzheimer's disease</article-title>. <source>Neurobiol Aging</source>. <year>2022</year>;<volume>112</volume>:<fpage>39</fpage>&#8211;<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2021.11.006</pub-id><pub-id pub-id-type="pmid">35045380</pub-id><pub-id pub-id-type="pmcid">PMC8976827</pub-id></mixed-citation></ref><ref id="alz70749-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70749-cite-0023"><string-name name-style="western"><surname>Hou</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Beardmore</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Holmes</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Osmond</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Darekar</surname><given-names>A</given-names></string-name>. <article-title>A case&#8208;control study of the locus coeruleus degeneration in Alzheimer's disease</article-title>. <source>Eur Neuropsychopharmacol</source>. <year>2021</year>;<volume>43</volume>:<fpage>153</fpage>&#8211;<lpage>159</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.euroneuro.2020.12.013</pub-id><pub-id pub-id-type="pmid">33431221</pub-id></mixed-citation></ref><ref id="alz70749-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70749-cite-0024"><string-name name-style="western"><surname>Galgani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lombardo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Martini</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Magnetic resonance imaging locus coeruleus abnormality in amnestic mild cognitive impairment is associated with future progression to dementia</article-title>. <source>Eur J Neurol</source>. <year>2023</year>;<volume>30</volume>(<issue>1</issue>):<fpage>32</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">36086917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.15556</pub-id><pub-id pub-id-type="pmcid">PMC10092028</pub-id></mixed-citation></ref><ref id="alz70749-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70749-cite-0025"><string-name name-style="western"><surname>Robbins</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Arnsten</surname><given-names>AFT</given-names></string-name>. <article-title>The neuropsychopharmacology of fronto&#8208;executive function: monoaminergic modulation</article-title>. <source>Annu Rev Neurosci</source>. <year>2009</year>;<volume>32</volume>:<fpage>267</fpage>&#8211;<lpage>287</lpage>.<pub-id pub-id-type="pmid">19555290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.neuro.051508.135535</pub-id><pub-id pub-id-type="pmcid">PMC2863127</pub-id></mixed-citation></ref><ref id="alz70749-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70749-cite-0026"><string-name name-style="western"><surname>Clement</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wiborg</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Asuni</surname><given-names>AA</given-names></string-name>. <article-title>Steps towards developing effective treatments for neuropsychiatric disturbances in Alzheimer's disease: insights from preclinical models, clinical data, and future directions</article-title>. <source>Front Aging Neurosci</source>. <year>2020</year>;<volume>12</volume>:<fpage>56</fpage>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/journals/aging-neuroscience" ext-link-type="uri">https://www.frontiersin.org/journals/aging&#8208;neuroscience</ext-link><pub-id pub-id-type="pmid">32210790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2020.00056</pub-id><pub-id pub-id-type="pmcid">PMC7068814</pub-id></mixed-citation></ref><ref id="alz70749-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70749-cite-0027"><string-name name-style="western"><surname>Falg&#224;s</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez&#8208;millan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bosch</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Locus coeruleus integrity and neuropsychiatric symptoms in a cohort of early&#8208; and late&#8208;onset Alzheimer&#8217; s disease</article-title>. <source>Alzheimer's Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>9</issue>):<fpage>6351</fpage>&#8211;<lpage>6364</lpage>. (February):1&#8208;14.<pub-id pub-id-type="pmid">39051173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14131</pub-id><pub-id pub-id-type="pmcid">PMC11497680</pub-id></mixed-citation></ref><ref id="alz70749-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70749-cite-0028"><string-name name-style="western"><surname>Jacobs</surname><given-names>HIL</given-names></string-name>, <string-name name-style="western"><surname>Becker</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Kwong</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline</article-title>. <source>Sci Transl Med</source>. <year>2021</year>;<volume>13</volume>(<issue>612</issue>):<elocation-id>eabj2511</elocation-id>.<pub-id pub-id-type="pmid">34550726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.abj2511</pub-id><pub-id pub-id-type="pmcid">PMC8641759</pub-id></mixed-citation></ref><ref id="alz70749-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70749-cite-0029"><string-name name-style="western"><surname>Engels&#8208;Dom&#237;nguez</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Riphagen</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Van Egroo</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Lower locus coeruleus integrity signals elevated entorhinal tau and clinical progression in asymptomatic older individuals</article-title>. <source>Ann Neurol</source>. <year>2024</year>;<volume>96</volume>(<issue>4</issue>):<fpage>650</fpage>&#8211;<lpage>661</lpage>.<pub-id pub-id-type="pmid">39007398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.27022</pub-id><pub-id pub-id-type="pmcid">PMC11534559</pub-id></mixed-citation></ref><ref id="alz70749-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70749-cite-0030"><string-name name-style="western"><surname>Bueichek&#250;</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Diez</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>CM</given-names></string-name>, et&#160;al. <article-title>Spatiotemporal patterns of locus coeruleus integrity predict cortical tau and cognition</article-title>. <source>Nat Aging</source>. <year>2024</year>;<volume>4</volume>(<issue>5</issue>):<fpage>625</fpage>&#8211;<lpage>637</lpage>.<pub-id pub-id-type="pmid">38664576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-024-00626-y</pub-id><pub-id pub-id-type="pmcid">PMC11108787</pub-id></mixed-citation></ref><ref id="alz70749-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70749-cite-0031"><string-name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Brum</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Di Molfetta</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology</article-title>. <source>JAMA Neurol</source>. <year>2024</year>;<volume>81</volume>(<issue>3</issue>):<fpage>255</fpage>&#8211;<lpage>263</lpage>.<pub-id pub-id-type="pmid">38252443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2023.5319</pub-id><pub-id pub-id-type="pmcid">PMC10804282</pub-id></mixed-citation></ref><ref id="alz70749-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70749-cite-0032"><string-name name-style="western"><surname>Khalil</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Otto</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Neurofilaments as biomarkers in neurological disorders</article-title>. <source>Nat Rev Neurol</source>. <year>2018</year>;<volume>14</volume>(<issue>10</issue>):<fpage>577</fpage>&#8211;<lpage>589</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41582-018-0058-z</pub-id><pub-id pub-id-type="pmid">30171200</pub-id></mixed-citation></ref><ref id="alz70749-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70749-cite-0033"><string-name name-style="western"><surname>Abdelhak</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Foschi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Abu&#8208;Rumeileh</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Blood GFAP as an emerging biomarker in brain and spinal cord disorders</article-title>. <source>Nat Rev Neurol</source>. <year>2022</year>;<volume>18</volume>(<issue>3</issue>):<fpage>158</fpage>&#8211;<lpage>172</lpage>.<pub-id pub-id-type="pmid">35115728</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-021-00616-3</pub-id></mixed-citation></ref><ref id="alz70749-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70749-cite-0034"><string-name name-style="western"><surname>Van Egroo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Riphagen</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></string-name>, et&#160;al. <article-title>Ultra&#8208;high field imaging, plasma markers and autopsy data uncover a specific rostral locus coeruleus vulnerability to hyperphosphorylated tau</article-title>. <source>Mol Psychiatry</source>. <year>2023</year>;<volume>28</volume>(<issue>6</issue>):<fpage>2412</fpage>&#8211;<lpage>2422</lpage>.<pub-id pub-id-type="pmid">37020050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-023-02041-y</pub-id><pub-id pub-id-type="pmcid">PMC10073793</pub-id></mixed-citation></ref><ref id="alz70749-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70749-cite-0035"><string-name name-style="western"><surname>Beckers</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Van Egroo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></string-name>, et&#160;al. <article-title>Microstructural associations between locus coeruleus, cortical, and subcortical regions are modulated by astrocyte reactivity: a 7T MRI adult lifespan study</article-title>. <source>Cerebral Cortex</source>. <year>2024</year>;<volume>34</volume>(<issue>6</issue>):<elocation-id>bhae261</elocation-id>.<pub-id pub-id-type="pmid">38904081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhae261</pub-id><pub-id pub-id-type="pmcid">PMC11190376</pub-id></mixed-citation></ref><ref id="alz70749-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70749-cite-0036"><string-name name-style="western"><surname>Mather</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Harley</surname><given-names>CW</given-names></string-name>. <article-title>The locus coeruleus: essential for maintaining cognitive function and the aging brain</article-title>. <source>Trends Cogn Sci</source>. <year>2016</year>;<volume>20</volume>(<issue>3</issue>):<fpage>214</fpage>&#8211;<lpage>226</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tics.2016.01.001</pub-id><pub-id pub-id-type="pmid">26895736</pub-id><pub-id pub-id-type="pmcid">PMC4761411</pub-id></mixed-citation></ref><ref id="alz70749-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70749-cite-0037"><string-name name-style="western"><surname>Heneka</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Nadrigny</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Regen</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2010</year>;<volume>107</volume>(<issue>13</issue>):<fpage>6058</fpage>&#8211;<lpage>6063</lpage>.<pub-id pub-id-type="pmid">20231476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0909586107</pub-id><pub-id pub-id-type="pmcid">PMC2851853</pub-id></mixed-citation></ref><ref id="alz70749-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz70749-cite-0038"><string-name name-style="western"><surname>Jardanhazi&#8208;Kurutz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kummer</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Terwel</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Vogel</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Thiele</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Heneka</surname><given-names>MT</given-names></string-name>. <article-title>Distinct adrenergic system changes and neuroinflammation in response to induced locus coeruleus degeneration in APP/PS1 transgenic mice</article-title>. <source>Neuroscience</source>. <year>2011</year>;<volume>176</volume>:<fpage>396</fpage>&#8211;<lpage>407</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.11.052</pub-id><pub-id pub-id-type="pmid">21129451</pub-id></mixed-citation></ref><ref id="alz70749-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70749-cite-0039"><string-name name-style="western"><surname>Kalinin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gavrilyuk</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Polak</surname><given-names>PE</given-names></string-name>, et&#160;al. <article-title>Noradrenaline deficiency in brain increases beta&#8208;amyloid plaque burden in an animal model of Alzheimer's disease</article-title>. <source>Neurobiol Aging</source>. <year>2007</year>;<volume>28</volume>(<issue>8</issue>):<fpage>1206</fpage>&#8211;<lpage>1214</lpage>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ovidsp.ovid.com/ovidweb.cgi?T=JS%26PAGE=reference%26D=med6%26NEWS=N%26AN=16837104" ext-link-type="uri">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=med6&amp;NEWS=N&amp;AN=16837104</ext-link><pub-id pub-id-type="pmid">16837104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2006.06.003</pub-id></mixed-citation></ref><ref id="alz70749-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz70749-cite-0040"><string-name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Nag</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></string-name>, et&#160;al. <article-title>Neural reserve, neuronal density in the locus coeruleus, and cognitive decline</article-title>. <source>Neurology</source>. <year>2013</year>;<volume>80</volume>(<issue>13</issue>):<fpage>1202</fpage>&#8211;<lpage>1208</lpage>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ovidsp.ovid.com/ovidweb.cgi?T=JS%26PAGE=reference%26D=med10%26NEWS=N%26AN=23486878" ext-link-type="uri">http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=med10&amp;NEWS=N&amp;AN=23486878</ext-link><pub-id pub-id-type="pmid">23486878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182897103</pub-id><pub-id pub-id-type="pmcid">PMC3691778</pub-id></mixed-citation></ref><ref id="alz70749-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70749-cite-0041"><string-name name-style="western"><surname>Watamura</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kakiya</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Fujioka</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>The dopaminergic system promotes neprilysin&#8208;mediated degradation of amyloid&#8208;&#946; in the brain</article-title>. <source>Sci Signal</source>. <year>2024</year>;<volume>17</volume>(<issue>848</issue>):<fpage>1</fpage>&#8211;<lpage>12</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scisignal.adk1822</pub-id><pub-id pub-id-type="pmid">39106321</pub-id></mixed-citation></ref><ref id="alz70749-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70749-cite-0042"><string-name name-style="western"><surname>Wilson</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Gilley</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Beckett</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Evans</surname><given-names>DA</given-names></string-name>. <article-title>Progression of parkinsonism and loss of cognitive function in Alzheimer disease</article-title>. <source>Arch Neurol</source>. <year>2000</year>;<volume>57</volume>(<issue>6</issue>):<fpage>855</fpage>&#8211;<lpage>860</lpage>.<pub-id pub-id-type="pmid">10867783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.57.6.855</pub-id></mixed-citation></ref><ref id="alz70749-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70749-cite-0043"><string-name name-style="western"><surname>David</surname><given-names>MCB</given-names></string-name>, <string-name name-style="western"><surname>Kolanko</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Del Giovane</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Remote monitoring of physiology in people living with dementia&#160;: an Observational Cohort Study Corresponding</article-title>. <source>JMIR Aging</source>. <year>2023</year>;<volume>6</volume>:<elocation-id>e43777</elocation-id>.<pub-id pub-id-type="pmid">36892931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/43777</pub-id><pub-id pub-id-type="pmcid">PMC10037178</pub-id></mixed-citation></ref><ref id="alz70749-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70749-cite-0044"><string-name name-style="western"><surname>Hoang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Watt</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Golemme</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Noradrenergic add&#8208;on therapy with extended&#8208;release guanfacine in Alzheimer's disease: study protocol for a randomised clinical trial (NorAD) and COVID&#8208;19 amendments</article-title>. <source>Trials</source>. <year>2022</year>;<volume>23</volume>(<issue>1</issue>):<fpage>623</fpage>. In submission.<pub-id pub-id-type="pmid">35915506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13063-022-06190-3</pub-id><pub-id pub-id-type="pmcid">PMC9340683</pub-id></mixed-citation></ref><ref id="alz70749-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70749-cite-0045"><string-name name-style="western"><surname>David</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Mallas</surname><given-names>E&#8208;J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>LM</given-names></string-name>, et&#160;al. <article-title>Pupil&#8208;linked arousal, cortical activity, and cognition in Alzheimer's disease</article-title>. <source>Brain Commun</source>. <year>2025</year>;<volume>7</volume>(<issue>4</issue>):<elocation-id>fcaf236</elocation-id>.<pub-id pub-id-type="pmid">40697964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcaf236</pub-id><pub-id pub-id-type="pmcid">PMC12280328</pub-id></mixed-citation></ref><ref id="alz70749-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz70749-cite-0046"><string-name name-style="western"><surname>Ye</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Rua</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>O'Callaghan</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>An in vivo probabilistic atlas of the human locus coeruleus at ultra&#8208;high field</article-title>. <source>Neuroimage</source>. <year>2021</year>;<volume>225</volume>(<issue>October 2020</issue>):<elocation-id>117487</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.neuroimage.2020.117487</pub-id><pub-id pub-id-type="pmid">33164875</pub-id><pub-id pub-id-type="pmcid">PMC7779564</pub-id></mixed-citation></ref><ref id="alz70749-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz70749-cite-0047"><string-name name-style="western"><surname>Safai</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Prasad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chougule</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Saini</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pal</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Ingalhalikar</surname><given-names>M</given-names></string-name>. <article-title>Microstructural abnormalities of substantia nigra in Parkinson's disease: a neuromelanin sensitive MRI atlas based study</article-title>. <source>Hum Brain Mapp</source>. <year>2020</year>;<volume>41</volume>(<issue>5</issue>):<fpage>1323</fpage>&#8211;<lpage>1333</lpage>.<pub-id pub-id-type="pmid">31778276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.24878</pub-id><pub-id pub-id-type="pmcid">PMC7267920</pub-id></mixed-citation></ref><ref id="alz70749-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="alz70749-cite-0048"><string-name name-style="western"><surname>Avants</surname><given-names>BB</given-names></string-name>, <string-name name-style="western"><surname>Tustison</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cook</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Klein</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gee</surname><given-names>JC</given-names></string-name>. <article-title>A reproducible evaluation of ANTs similarity metric performance in brain image registration</article-title>. <source>Neuroimage</source>. <year>2011</year>;<volume>54</volume>(<issue>3</issue>):<fpage>2033</fpage>&#8211;<lpage>2044</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.09.025</pub-id><pub-id pub-id-type="pmid">20851191</pub-id><pub-id pub-id-type="pmcid">PMC3065962</pub-id></mixed-citation></ref><ref id="alz70749-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="alz70749-cite-0049"><string-name name-style="western"><surname>Isensee</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Schell</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pflueger</surname><given-names>I</given-names></string-name>, et&#160;al. <article-title>Automated brain extraction of multisequence MRI using artificial neural networks</article-title>. <source>Hum Brain Mapp</source>. <year>2019</year>;<volume>40</volume>(<issue>17</issue>):<fpage>4952</fpage>&#8211;<lpage>4964</lpage>.<pub-id pub-id-type="pmid">31403237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.24750</pub-id><pub-id pub-id-type="pmcid">PMC6865732</pub-id></mixed-citation></ref><ref id="alz70749-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="alz70749-cite-0050"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Brady</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>S</given-names></string-name>. <article-title>Segmentation of brain MR images through a hidden Markov random field model and the expectation&#8208;maximization algorithm</article-title>. <source>IEEE Trans Med Imaging</source>. <year>2001</year>;<volume>20</volume>(<issue>1</issue>):<fpage>45</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">11293691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/42.906424</pub-id></mixed-citation></ref><ref id="alz70749-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="alz70749-cite-0051"><string-name name-style="western"><surname>Ashburner</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ridgway</surname><given-names>GR</given-names></string-name>. <article-title>Symmetric diffeomorphic modeling of longitudinal structural MRI</article-title>. <source>Front Neurosci</source>. <year>2013</year>;<volume>6</volume>(<issue>FEB</issue>):<fpage>1</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2012.00197</pub-id><pub-id pub-id-type="pmcid">PMC3564017</pub-id><pub-id pub-id-type="pmid">23386806</pub-id></mixed-citation></ref><ref id="alz70749-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="alz70749-cite-0052"><string-name name-style="western"><surname>Mohs</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname><given-names>RC</given-names></string-name>, et&#160;al. <article-title>Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's disease assessment scale that broaden tts scope</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>1997</year>;<volume>11</volume>(<issue>2</issue>):<fpage>S13</fpage>&#8211;<lpage>S21</lpage>.<pub-id pub-id-type="pmid">9236948</pub-id></mixed-citation></ref><ref id="alz70749-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="alz70749-cite-0053"><string-name name-style="western"><surname>Mathuranath</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Nestor</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Berrios</surname><given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Rakowicz</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Hodges</surname><given-names>JR</given-names></string-name>. <article-title>A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia</article-title>. <source>Neurology</source>. <year>2000</year>;<volume>55</volume>:<fpage>1613</fpage>&#8211;<lpage>1620</lpage>.<pub-id pub-id-type="pmid">11113213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000434309.85312.19</pub-id></mixed-citation></ref><ref id="alz70749-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="alz70749-cite-0054"><string-name name-style="western"><surname>Cummings</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Mega</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Rosenberg&#8208;Thompson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Carusi</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gornbein</surname><given-names>J</given-names></string-name>. <article-title>The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia</article-title>. <source>Neurology</source>. <year>1994</year>;<volume>44</volume>:<fpage>2308</fpage>&#8211;<lpage>2314</lpage>.<pub-id pub-id-type="pmid">7991117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.44.12.2308</pub-id></mixed-citation></ref><ref id="alz70749-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="alz70749-cite-0055"><string-name name-style="western"><surname>McCarthy</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rubinsztein</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lowry</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Cut&#8208;off scores for mild and moderate dementia on the Addenbrooke's Cognitive Examination&#8208;III and the Mini&#8208;Addenbrooke's Cognitive Examination compared with the Mini&#8208;Mental State Examination</article-title>. <source>BJPsych Bull</source>. <year>2024</year>;<volume>48</volume>(<issue>1</issue>):<fpage>12</fpage>&#8211;<lpage>18</lpage>.<pub-id pub-id-type="pmid">37272617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1192/bjb.2023.27</pub-id><pub-id pub-id-type="pmcid">PMC10801363</pub-id></mixed-citation></ref><ref id="alz70749-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="alz70749-cite-0056"><string-name name-style="western"><surname>Costello</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Roiser</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Howard</surname><given-names>R</given-names></string-name>. <article-title>Antidepressant medications in dementia: evidence and potential mechanisms of treatment&#8208;resistance</article-title>. <source>Psychol Med</source>. <year>2023</year>;<volume>53</volume>(<issue>3</issue>):<fpage>654</fpage>&#8211;<lpage>667</lpage>. 1&#8208;14.<pub-id pub-id-type="pmid">36621964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S003329172200397X</pub-id><pub-id pub-id-type="pmcid">PMC9976038</pub-id></mixed-citation></ref><ref id="alz70749-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="alz70749-cite-0057"><string-name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Waring</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Ivnik</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Tangalos</surname><given-names>EG</given-names></string-name>, <string-name name-style="western"><surname>Kokmen</surname><given-names>E</given-names></string-name>. <article-title>Mild cognitive impairment clinical characterization and outcome Ronald</article-title>. <source>Arch Neurol</source>. <year>1999</year>;<volume>56</volume>(<issue>3</issue>):<fpage>303</fpage>&#8211;<lpage>309</lpage>.<pub-id pub-id-type="pmid">10190820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.56.3.303</pub-id></mixed-citation></ref><ref id="alz70749-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="alz70749-cite-0058"><string-name name-style="western"><surname>H&#228;mmerer</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Callaghan</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Hopkins</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Locus coeruleus integrity in old age is selectively related to memories linked with salient negative events</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2018</year>;<volume>115</volume>(<issue>9</issue>):<fpage>2228</fpage>&#8211;<lpage>2233</lpage>.<pub-id pub-id-type="pmid">29440429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1712268115</pub-id><pub-id pub-id-type="pmcid">PMC5834676</pub-id></mixed-citation></ref><ref id="alz70749-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="alz70749-cite-0059"><string-name name-style="western"><surname>Malhotra</surname><given-names>PA</given-names></string-name>. <article-title>Impairments of attention in Alzheimer's disease</article-title>. <source>Curr Opin Psychol</source>. <year>2019</year>;<volume>29</volume>:<fpage>41</fpage>&#8211;<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.copsyc.2018.11.002</pub-id><pub-id pub-id-type="pmid">30496975</pub-id></mixed-citation></ref><ref id="alz70749-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="alz70749-cite-0060"><string-name name-style="western"><surname>Chudasama</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Robbins</surname><given-names>TW</given-names></string-name>. <article-title>Dopaminergic modulation of visual attention and working memory in the rodent prefrontal cortex</article-title>. <source>Neuropsychopharmacology</source>. <year>2004</year>;<volume>29</volume>(<issue>9</issue>):<fpage>1628</fpage>&#8211;<lpage>1636</lpage>.<pub-id pub-id-type="pmid">15138446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.npp.1300490</pub-id></mixed-citation></ref><ref id="alz70749-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="alz70749-cite-0061"><string-name name-style="western"><surname>Biondetti</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gaurav</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yahia&#8208;Cherif</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease</article-title>. <source>Brain</source>. <year>2020</year>;<volume>143</volume>(<issue>9</issue>):<fpage>2757</fpage>&#8211;<lpage>2770</lpage>.<pub-id pub-id-type="pmid">32856056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awaa216</pub-id></mixed-citation></ref><ref id="alz70749-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="alz70749-cite-0062"><string-name name-style="western"><surname>F&#246;rstl</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Levy</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Burns</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Luthert</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Cairns</surname><given-names>N</given-names></string-name>. <article-title>Disproportionate loss of noradrenergic and cholinergic neurons as cause of depression in Alzheimer's disease&#8212;A hypothesis</article-title>. <source>Pharmacopsychiatry</source>. <year>1994</year>;<volume>27</volume>:<fpage>11</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-2007-1014267</pub-id><pub-id pub-id-type="pmid">8159776</pub-id></mixed-citation></ref><ref id="alz70749-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="alz70749-cite-0063"><string-name name-style="western"><surname>Zubenko</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Kopp</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Moossy</surname><given-names>J</given-names></string-name>. <article-title>Neurochemical correlates of major depression in primary dementia</article-title>. <source>Arch Neurol</source>. <year>1990</year>;<volume>47</volume>(<issue>2</issue>):<fpage>209</fpage>&#8211;<lpage>214</lpage>.<pub-id pub-id-type="pmid">1689144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.1990.00530020117023</pub-id></mixed-citation></ref><ref id="alz70749-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="alz70749-cite-0064"><string-name name-style="western"><surname>Husain</surname><given-names>M</given-names></string-name>. <article-title>Noradrenergic therapies for apathy in Alzheimer's disease?</article-title><source>J Neurol Neurosurg Psychiatry</source>. <year>2022</year>;<volume>94</volume>(<issue>2</issue>):<fpage>93</fpage>.<pub-id pub-id-type="pmid">36600570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2022-330824</pub-id><pub-id pub-id-type="pmcid">PMC9872223</pub-id></mixed-citation></ref><ref id="alz70749-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="alz70749-cite-0065"><string-name name-style="western"><surname>Ye</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>O'Callaghan</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rua</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Locus coeruleus integrity from 7 T MRI relates to apathy and cognition in Parkinsonian disorders</article-title>. <source>Mov Disord</source>. <year>2022</year>;<volume>37</volume>(<issue>8</issue>):<fpage>1663</fpage>&#8211;<lpage>1672</lpage>.<pub-id pub-id-type="pmid">35576973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.29072</pub-id><pub-id pub-id-type="pmcid">PMC9541468</pub-id></mixed-citation></ref><ref id="alz70749-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="alz70749-cite-0066"><string-name name-style="western"><surname>Laurencin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Lancelot</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Brosse</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Noradrenergic alterations in Parkinson's disease: a combined 11C&#8208;yohimbine PET/neuromelanin MRI study</article-title>. <source>Brain</source>. <year>2023</year>;<volume>147</volume>(<issue>4</issue>):<fpage>1377</fpage>&#8211;<lpage>1388</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awad338</pub-id><pub-id pub-id-type="pmcid">PMC10994534</pub-id><pub-id pub-id-type="pmid">37787503</pub-id></mixed-citation></ref><ref id="alz70749-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="alz70749-cite-0067"><string-name name-style="western"><surname>Udo</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hashimoto</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Toyonaga</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Apathy in Alzheimer's disease correlates with the dopamine transporter level in the Caudate Nuclei</article-title>. <source>Dement Geriatr Cogn Dis Extra</source>. <year>2020</year>;<volume>10</volume>(<issue>2</issue>):<fpage>86</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">33082772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000509278</pub-id><pub-id pub-id-type="pmcid">PMC7548940</pub-id></mixed-citation></ref><ref id="alz70749-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="alz70749-cite-0068"><string-name name-style="western"><surname>David</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Del Giovane</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>KY</given-names></string-name>, et&#160;al. <article-title>Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer's disease: systematic review and meta&#8208;analysis</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2022</year>:<fpage>1</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2022-329136</pub-id><pub-id pub-id-type="pmcid">PMC9484390</pub-id><pub-id pub-id-type="pmid">35790417</pub-id></mixed-citation></ref><ref id="alz70749-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="alz70749-cite-0069"><string-name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Schonhaut</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Sch&#246;ll</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease</article-title>. <source>Brain</source>. <year>2016</year>;<volume>139</volume>(<issue>5</issue>):<fpage>1551</fpage>&#8211;<lpage>1567</lpage>.<pub-id pub-id-type="pmid">26962052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aww027</pub-id><pub-id pub-id-type="pmcid">PMC5006248</pub-id></mixed-citation></ref><ref id="alz70749-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="alz70749-cite-0070"><string-name name-style="western"><surname>Yakoub</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gonzalez&#8208;ortiz</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></string-name>, et&#160;al. <article-title>Plasma p&#8208;tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10&#8208;year window</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>;<volume>21</volume>(<issue>2</issue>):<elocation-id>e14537</elocation-id>.<pub-id pub-id-type="pmid">40008832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14537</pub-id><pub-id pub-id-type="pmcid">PMC11863240</pub-id></mixed-citation></ref><ref id="alz70749-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="alz70749-cite-0071"><string-name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pichet Binette</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Groot</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Amyloid and tau PET&#8208;positive cognitively unimpaired individuals are at high risk for future cognitive decline</article-title>. <source>Nat Med</source>. <year>2022</year>;<volume>28</volume>(<issue>11</issue>):<fpage>2381</fpage>&#8211;<lpage>2387</lpage>.<pub-id pub-id-type="pmid">36357681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-02049-x</pub-id><pub-id pub-id-type="pmcid">PMC9671808</pub-id></mixed-citation></ref><ref id="alz70749-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="alz70749-cite-0072"><string-name name-style="western"><surname>Hansson</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Seibyl</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Stomrud</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>CSF biomarkers of Alzheimer's disease concord with amyloid&#8208;&#946; PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts</article-title>. <source>Alzheimer's Dement</source>. <year>2018</year>;<volume>14</volume>(<issue>11</issue>):<fpage>1470</fpage>&#8211;<lpage>1481</lpage>.<pub-id pub-id-type="pmid">29499171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.01.010</pub-id><pub-id pub-id-type="pmcid">PMC6119541</pub-id></mixed-citation></ref><ref id="alz70749-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="alz70749-cite-0073"><string-name name-style="western"><surname>Matchett</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Grinberg</surname><given-names>LT</given-names></string-name>, <string-name name-style="western"><surname>Theofilas</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>ME</given-names></string-name>. <article-title>The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer's disease</article-title>. <source>Acta Neuropathol</source>. <year>2021</year>;<volume>141</volume>(<issue>5</issue>):<fpage>631</fpage>&#8211;<lpage>650</lpage>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://link.springer.de/link/service/journals/00401/index.htm" ext-link-type="uri">http://link.springer.de/link/service/journals/00401/index.htm</ext-link><pub-id pub-id-type="pmid">33427939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-020-02248-1</pub-id><pub-id pub-id-type="pmcid">PMC8043919</pub-id></mixed-citation></ref><ref id="alz70749-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="alz70749-cite-0074"><string-name name-style="western"><surname>Mercan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Heneka</surname><given-names>MT</given-names></string-name>. <article-title>The contribution of the locus coeruleus&#8211;Noradrenaline system degeneration during the progression of Alzheimer's disease</article-title>. <source>Biology (Basel)</source>. <year>2022</year>;<volume>11</volume>(<issue>12</issue>):<fpage>1822</fpage>.<pub-id pub-id-type="pmid">36552331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biology11121822</pub-id><pub-id pub-id-type="pmcid">PMC9775634</pub-id></mixed-citation></ref><ref id="alz70749-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="alz70749-cite-0075"><string-name name-style="western"><surname>Paredes&#8208;Rodriguez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Vegas&#8208;Suarez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Morera&#8208;Herreras</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Miguelez</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>De Deurwaerdere</surname><given-names>P</given-names></string-name>. <article-title>The noradrenergic system in Parkinson's disease</article-title>. <source>Front Pharmacol</source>. <year>2020</year>;<volume>11</volume>:<fpage>435</fpage>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.frontiersin.org/Pharmacology" ext-link-type="uri">http://www.frontiersin.org/Pharmacology</ext-link><pub-id pub-id-type="pmid">32322208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2020.00435</pub-id><pub-id pub-id-type="pmcid">PMC7157437</pub-id></mixed-citation></ref><ref id="alz70749-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="alz70749-cite-0076"><string-name name-style="western"><surname>af Bjerk&#233;n</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Stenmark Persson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Barkander</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Noradrenaline is crucial for the substantia nigra dopaminergic cell maintenance</article-title>. <source>Neurochem Int</source>. <year>2019</year>;<volume>131</volume>(<issue>September</issue>):<elocation-id>104551</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.neuint.2019.104551</pub-id><pub-id pub-id-type="pmid">31542295</pub-id></mixed-citation></ref><ref id="alz70749-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="alz70749-cite-0077"><string-name name-style="western"><surname>Yao</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Lesion of the locus coeruleus aggravates dopaminergic neuron degeneration by modulating microglial function in mouse models of Parkinson's disease</article-title>. <source>Brain Res</source>. <year>2015</year>;<volume>1625</volume>:<fpage>255</fpage>&#8211;<lpage>274</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.brainres.2015.08.032</pub-id><pub-id pub-id-type="pmid">26342895</pub-id></mixed-citation></ref><ref id="alz70749-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="alz70749-cite-0078"><string-name name-style="western"><surname>Levey</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment</article-title>. <source>Brain</source>. <year>2022</year>;<volume>145</volume>(<issue>6</issue>):<fpage>1924</fpage>&#8211;<lpage>1938</lpage>.<pub-id pub-id-type="pmid">34919634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awab452</pub-id><pub-id pub-id-type="pmcid">PMC9630662</pub-id></mixed-citation></ref><ref id="alz70749-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="alz70749-cite-0079"><string-name name-style="western"><surname>Mummery</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>B&#246;rjesson&#8208;Hanson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Blackburn</surname><given-names>DJ</given-names></string-name>, et&#160;al. <article-title>Tau&#8208;targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo&#8208;controlled trial</article-title>. <source>Nat Med</source>. <year>2023</year>;<volume>29</volume>(<issue>6</issue>):<fpage>1437</fpage>&#8211;<lpage>1447</lpage>.<pub-id pub-id-type="pmid">37095250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-023-02326-3</pub-id><pub-id pub-id-type="pmcid">PMC10287562</pub-id></mixed-citation></ref><ref id="alz70749-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="alz70749-cite-0080"><string-name name-style="western"><surname>Robertson</surname><given-names>IH</given-names></string-name>. <article-title>A noradrenergic theory of cognitive reserve: implications for Alzheimer's disease</article-title>. <source>Neurobiol Aging</source>. <year>2013</year>;<volume>34</volume>(<issue>1</issue>):<fpage>298</fpage>&#8211;<lpage>308</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2012.05.019</pub-id><pub-id pub-id-type="pmid">22743090</pub-id></mixed-citation></ref><ref id="alz70749-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="alz70749-cite-0081"><string-name name-style="western"><surname>Clewett</surname><given-names>DV</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>TH</given-names></string-name>, <string-name name-style="western"><surname>Greening</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ponzio</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Margalit</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mather</surname><given-names>M</given-names></string-name>. <article-title>Neuromelanin marks the spot: identifying a locus coeruleus biomarker of cognitive reserve in healthy aging</article-title>. <source>Neurobiol Aging</source>. <year>2016</year>;<volume>37</volume>:<fpage>117</fpage>&#8211;<lpage>126</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2015.09.019</pub-id><pub-id pub-id-type="pmid">26521135</pub-id><pub-id pub-id-type="pmcid">PMC5134892</pub-id></mixed-citation></ref><ref id="alz70749-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="alz70749-cite-0082"><string-name name-style="western"><surname>Zide</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Donovan</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nag</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Jacobs</surname><given-names>HIL</given-names></string-name>. <article-title>Social activity mediates locus coeruleus tangle&#8208;related cognition in older adults</article-title>. <source>Mol Psychiatry</source>. <year>2024</year>;<volume>29</volume>:<fpage>2001</fpage>&#8211;<lpage>2008</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41380-024-02467-y</pub-id><pub-id pub-id-type="pmid">38355788</pub-id><pub-id pub-id-type="pmcid">PMC11408254</pub-id></mixed-citation></ref><ref id="alz70749-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="alz70749-cite-0083"><string-name name-style="western"><surname>Jacobs</surname><given-names>HIL</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller&#8208;Ehrenberg</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Priovoulos</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Roebroeck</surname><given-names>A</given-names></string-name>. <article-title>Curvilinear locus coeruleus functional connectivity trajectories over the adult lifespan: a 7T MRI study</article-title>. <source>Neurobiol Aging</source>. <year>2018</year>;<volume>69</volume>:<fpage>167</fpage>&#8211;<lpage>176</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.05.021</pub-id><pub-id pub-id-type="pmid">29908415</pub-id></mixed-citation></ref><ref id="alz70749-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="alz70749-cite-0084"><string-name name-style="western"><surname>Ad&#232;r</surname><given-names>J&#8208;P</given-names></string-name>, <string-name name-style="western"><surname>Room</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Postema</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Korf</surname><given-names>J</given-names></string-name>. <article-title>Bilaterally diverging axon collaterals and contralateral projections from rat locus coeruleus neurons, demonstrated by fluorescent retrograde double labeling and norepinephrine metabolism</article-title>. <source>J Neural Transm</source>. <year>1980</year>;<volume>49</volume>:<fpage>207</fpage>&#8211;<lpage>218</lpage>.<pub-id pub-id-type="pmid">6162001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF01252126</pub-id></mixed-citation></ref><ref id="alz70749-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="alz70749-cite-0085"><string-name name-style="western"><surname>Beckers</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Riphagen</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Van Egroo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Jacobs</surname><given-names>HIL</given-names></string-name>. <article-title>Sparse asymmetry in locus coeruleus pathology in Alzheimer's disease</article-title>. <source>J Alzheimer's Dis</source>. <year>2024</year>;<volume>99</volume>(<issue>1</issue>):<fpage>105</fpage>&#8211;<lpage>111</lpage>.<pub-id pub-id-type="pmid">38607758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-231328</pub-id><pub-id pub-id-type="pmcid">PMC11091606</pub-id></mixed-citation></ref><ref id="alz70749-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="alz70749-cite-0086"><string-name name-style="western"><surname>Ehrenberg</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Sant</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>FL</given-names></string-name>, et&#160;al. <article-title>Pathways underlying selective neuronal vulnerability in Alzheimer&#8217; s disease&#160;: contrasting the vulnerable locus coeruleus to the resilient substantia nigra</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>(<issue>3</issue>):<elocation-id>e70087</elocation-id>. 1&#8208;16.<pub-id pub-id-type="pmid">40135662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.70087</pub-id><pub-id pub-id-type="pmcid">PMC11938114</pub-id></mixed-citation></ref><ref id="alz70749-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="alz70749-cite-0087"><string-name name-style="western"><surname>Svenningsson</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Stomrud</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hansson</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></string-name>. <article-title>Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy</article-title>. <source>Alzheimer's Res Ther</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.1186/s13195-022-01081-w</pub-id><pub-id pub-id-type="pmid">36192766</pub-id><pub-id pub-id-type="pmcid">PMC9531524</pub-id></mixed-citation></ref><ref id="alz70749-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="alz70749-cite-0088"><string-name name-style="western"><surname>Fabbri</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Reim&#227;o</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Carvalho</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Substantia Nigra neuromelanin as an imaging biomarker of disease progression in Parkinson's disease</article-title>. <source>J Parkinsons Dis</source>. <year>2017</year>;<volume>7</volume>(<issue>3</issue>):<fpage>491</fpage>&#8211;<lpage>501</lpage>.<pub-id pub-id-type="pmid">28671143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JPD-171135</pub-id></mixed-citation></ref><ref id="alz70749-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="alz70749-cite-0089"><string-name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Watanabe</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tanaka</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Comprehensive MRI quantification of the substantia nigra pars compacta in Parkinson's disease</article-title>. <source>Eur J Radiol</source>. <year>2018</year>;<volume>109</volume>(<issue>June</issue>):<fpage>48</fpage>&#8211;<lpage>56</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejrad.2018.06.024</pub-id><pub-id pub-id-type="pmid">30527311</pub-id></mixed-citation></ref><ref id="alz70749-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="alz70749-cite-0090"><string-name name-style="western"><surname>Zupan</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>&#352;uput</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pirto&#353;ek</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Vovk</surname><given-names>A</given-names></string-name>. <article-title>Semi&#8208;automatic signature&#8208;based segmentation method for quantification of neuromelanin in substantia Nigra</article-title>. <source>Brain Sci</source>. <year>2019</year>;<volume>9</volume>(<issue>12</issue>):<fpage>335</fpage>.<pub-id pub-id-type="pmid">31766668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci9120335</pub-id><pub-id pub-id-type="pmcid">PMC6956028</pub-id></mixed-citation></ref><ref id="alz70749-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="alz70749-cite-0091"><string-name name-style="western"><surname>Tupe&#8208;Waghmare</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Rajan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Prasad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Saini</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pal</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Ingalhalikar</surname><given-names>M</given-names></string-name>. <article-title>Radiomics on routine T1&#8208;weighted MRI can delineate Parkinson's disease from multiple system atrophy and progressive supranuclear palsy</article-title>. <source>Eur Radiol</source>. <year>2021</year>;<volume>31</volume>(<issue>11</issue>):<fpage>8218</fpage>&#8211;<lpage>8227</lpage>.<pub-id pub-id-type="pmid">33945022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00330-021-07979-7</pub-id></mixed-citation></ref><ref id="alz70749-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="alz70749-cite-0092"><string-name name-style="western"><surname>Fernandes</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Regala</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Correia</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Gon&#231;alves&#8208;Ferreira</surname><given-names>AJ</given-names></string-name>. <article-title>The human locus coeruleus 3&#8208;D stereotactic anatomy</article-title>. <source>Surg Radiol Anat</source>. <year>2012</year>;<volume>34</volume>(<issue>10</issue>):<fpage>879</fpage>&#8211;<lpage>885</lpage>.<pub-id pub-id-type="pmid">22638719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00276-012-0979-y</pub-id></mixed-citation></ref><ref id="alz70749-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="alz70749-cite-0093"><string-name name-style="western"><surname>Massey</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Miranda</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Al&#8208;Helli</surname><given-names>O</given-names></string-name>, et&#160;al. <article-title>9.4 T MR microscopy of the substantia nigra with pathological validation in controls and disease</article-title>. <source>Neuroimage Clin</source>. <year>2017</year>;<volume>13</volume>:<fpage>154</fpage>&#8211;<lpage>163</lpage>.<pub-id pub-id-type="pmid">27981030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2016.11.015</pub-id><pub-id pub-id-type="pmcid">PMC5144755</pub-id></mixed-citation></ref><ref id="alz70749-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="alz70749-cite-0094"><string-name name-style="western"><surname>Castellanos</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Fern&#225;ndez&#8208;Seara</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Lorenzo&#8208;Betancor</surname><given-names>O</given-names></string-name>, et&#160;al. <article-title>Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease</article-title>. <source>Mov Disord</source>. <year>2015</year>;<volume>30</volume>(<issue>7</issue>):<fpage>945</fpage>&#8211;<lpage>952</lpage>.<pub-id pub-id-type="pmid">25772492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.26201</pub-id></mixed-citation></ref><ref id="alz70749-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="alz70749-cite-0095"><string-name name-style="western"><surname>Betts</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Cardenas&#8208;Blanco</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kanowski</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Locus coeruleus MRI contrast is reduced in Alzheimer's disease dementia and correlates with CSF A&#946; levels</article-title>. <source>Alzheimer's Dement</source>. <year>2019</year>;<volume>11</volume>:<fpage>281</fpage>&#8211;<lpage>285</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadm.2019.02.001</pub-id><pub-id pub-id-type="pmcid">PMC6439222</pub-id><pub-id pub-id-type="pmid">30976648</pub-id></mixed-citation></ref><ref id="alz70749-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="alz70749-cite-0096"><string-name name-style="western"><surname>De Giovane</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Giunchiglia</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>Z</given-names></string-name>, et&#160;al. <article-title>Remote cognitive tests predict neurodegenerative biomarkers in the insight 46 cohort</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>(<issue>2</issue>):<elocation-id>e14572</elocation-id>.<pub-id pub-id-type="pmid">39936232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14572</pub-id><pub-id pub-id-type="pmcid">PMC11815243</pub-id></mixed-citation></ref><ref id="alz70749-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="alz70749-cite-0097"><string-name name-style="western"><surname>Galgani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lombardo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Frijia</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>The degeneration of locus coeruleus occurring during Alzheimer's disease clinical progression: a neuroimaging follow&#8208;up investigation</article-title>. <source>Brain Struct Funct</source>. <year>2024</year>;<volume>229</volume>(<issue>5</issue>):<fpage>1317</fpage>&#8208;<lpage>1325</lpage>.<pub-id pub-id-type="pmid">38625557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00429-024-02797-1</pub-id><pub-id pub-id-type="pmcid">PMC11147916</pub-id></mixed-citation></ref></ref-list><app-group><app id="alz70749-app-0001" content-type="APPENDIX"><sec id="alz70749-sec-0330"><label>1</label><p>
<bold>&#160;Acknowledgement list for collaborators from the UK Dementia Research Institute (UK DRI) Care Research &amp; Technology (CR&amp;T) Centre publications using the MINDER core data set</bold>
</p><p>
<bold>Leadership and Management Infrastructure</bold>:</p><p>Centre Director: Professor David Sharp</p><p>Centre and Research Commercialisation Manager: Danielle Wilson</p><p>Health and Social Care Lead: Sarah Daniels</p><p>Clinical Lead: Professor Ramin Nilforooshan</p><p>General Practice Lead: Dr. David Wingfield</p><p>Human&#8208;Centred Design Lead: Matthew Harrison</p><p>Movement Data and Living Lab Lead: Dr. Shlomi Haar</p><p>Data Science Lead: Nora Joby</p><p>Scientific Project Manager: Dr. Mara Golemme</p><p>Scientific Project Manager: Dr. Stephanie Lietz</p><p>Scientific Project Manager Dr. Margherita Tecilla</p><p>
<bold>Group Leaders</bold>: Professor David Sharp, Professor Payam Barnaghi, Professor Paul Freemont, Professor Ravi Vaidyanathan, Professor Tim Constandinou, Dr. Gregory Scott, Imperial College London</p><p>Professor Derk&#8208;Jan Dijk, University of Surrey, Guildford, United Kingdom.</p><p>
<bold>Emerging Leaders</bold>: Dr. Shlomi Haar and Dr. Pete Lally</p><p>
<bold>Associate Members</bold>: Professor Paresh Malhotra, Dame Professor Louise Robinson and Professor Adam Hampshire</p><p>
<bold>Groups: Behaviour and Cognition led by Prof David Sharp</bold>
</p><p>Affiliation: Imperial College London, Brain Sciences</p><p>Michael David</p><p>Martina Del Giovane</p><p>Neil Graham</p><p>Magdalena Kolanko</p><p>Helen Lai</p><p>Lucia M Li</p><p>Mark Crook Rumsey</p><p>Emma Jane Mallas</p><p>Alina&#8208;Irina Serban</p><p>Eyal Soreq</p><p>Abidemi Otaiku</p><p>Megan ParkinsonThomas Parker</p><p>Success Fabusoro</p><p>Emily Beal</p><p>Julian Jeyasingh Jacob</p><p>Gaia Frigerio</p><p>Anastasia Mirza&#8208;Davies</p><p>Ethan de Villiers</p><p>
<bold>Bioelectronic Systems led by Professor Timothy Constandinou</bold>
</p><p>Affiliation: Imperial College London, Electronic Engineering Alan Bannon</p><p>Danilo Mandic</p><p>Ziwei Chen</p><p>Charalambos Hadjipanayi</p><p>Ghena Hammour</p><p>Bryan Hsieh</p><p>Amir Nassibi</p><p>Adrien Rapeaux</p><p>Ian Williams</p><p>Maowen Yin</p><p>Niro Yogendran</p><p>
<bold>Robotics and AI interfaces led by Professor Ravi Vaidyanathan</bold>
</p><p>Affiliation: Imperial College London, Mechanical Engineering</p><p>Maria Lima</p><p>Alina&#8208;Irina Serban</p><p>Ting Su</p><p>Melanie Jouaiti</p><p>Maitreyee Wairagkar</p><p>Carlos Sebastian Castillo</p><p>Panipat Wattansiri</p><p>Thomas Martineau</p><p>Mayue Shi</p><p>Tianbo Xu</p><p>Alejandro Valdunciel</p><p>Reneira Seeamber</p><p>Annika Guez</p><p>Zehao Liu</p><p>Saksham Dhawan</p><p>
<bold>Machine intelligence led by Professor Payam Barnaghi</bold>
</p><p>Affiliation: Imperial College London, Brain Sciences</p><p>Nan Fletcher&#8208;Lloyd</p><p>Samaneh Kouchaki</p><p>Alexander Capstick</p><p>Chloe Walsh</p><p>Louise Rigny</p><p>Ruxandra Mihai</p><p>Marirena Bafaloukou</p><p>Jin Cui</p><p>Ann&#8208;Kathrin Schalkamp</p><p>Yu Chen</p><p>Tianyu Cui</p><p>Nivedita Bijlani</p><p>
<bold>Point of care Diagnostics led by Professor Paul Freemont</bold>
</p><p>Affiliation: Imperial College London, Infectious Disease</p><p>Michael Crone</p><p>Kirsten Jensen</p><p>Martin Tran</p><p>Thomas Adam</p><p>Raphaella Jackson</p><p>Alexander Webb</p><p>David Wingfield</p><p>
<bold>Sleep and Circadian led by Professor Derk Jan Dijk</bold>
</p><p>Affiliation: University of Surrey, The Surrey Sleep Research Centre as part of the School of Biosciences</p><p>Anne C Skeldon</p><p>Kevin Wells</p><p>Ullrich Bartsch</p><p>Ciro Della Monica</p><p>Kiran K G Ravindran</p><p>Victoria L Revell</p><p>Hana Hassanin</p><p>James Woolley</p><p>Iris Wood&#8208;Campar</p><p>Sarmad Al Gawwam</p><p>Aravind Kumar Kamaraj</p><p>Marta Pineda Messina</p><p>
<bold>Brain and movement led by Dr. Shlomi Haar</bold>
</p><p>Affiliation: Imperial College London, Brain SciencesNathan Steadman</p><p>Federico Nardi</p><p>Cosima Graef</p><p>Alena Kutuzova</p><p>Assaf Touboul</p><p>Nicolas Calvo Peiro</p><p>Jenna Yun</p><p>Sean Carr</p><p>Uri Rosenblum&#8208;Belzer</p><p>
<bold>Groups: Computational Neurology led by Dr. Gregory Scott</bold>
</p><p>Affiliation: Imperial College London, Brain Sciences</p><p>Adela Desowska</p><p>Anastasia Gailly de Taurines</p><p>Ruxandra Mihai</p><p>Nina Moutonnet</p><p>
<bold>Helix Centre: Human Centred Design led by Matthew Harrison</bold>
</p><p>Affiliation: Imperial College London, Helix Centre and The Royal College of Art</p><p>Matthew Harrison</p><p>Sophie Horrocks</p><p>Victoria Simpson</p><p>Brian Quan</p><p>
<bold>Software engineering team</bold>
</p><p>Affiliation: Imperial College London, Brain Sciences</p><p>Mark Woodbridge</p><p>Anna Joffe</p><p>Ethan de Villiers</p><p>Amer Marzuki</p><p>Ramsheed Abdul Rahim</p><p>
<bold>Site Investigators and Key Personnel</bold>:</p><p>
<bold>Name and Affiliation: Surrey and Borders Partnership NHS Foundation Trust (Site and Sponsor)</bold>
</p><p>Chief Investigator: Professor Ramin Nilforooshan</p><p>Research and Development Managers: Jessica True, Olga Balazikova</p><p>Research Co&#8208;ordinator: Chloe Walsh</p><p>Clinical Monitoring Team: Nicole Whitethread, Matthew Purnell, Vaiva Zarombaite, Lucy Copps, Olivia Knight, Gaganpreet Bangar, Sumit Dey, Chelsea Mukonda, Jessica Hine, Luke Mallon, Saijal Jhala, Oliver Sargentoni, Amy Alves, Mahan Heydari</p><p>
<bold>Name and Affiliation: Hammersmith and Fulham Partnership</bold>
</p><p>Principal Investigator: Dr. David Wingfield</p><p>Research Nurse / Paramedic: Monica Morim</p><p>Clinical Studies Officers/Research Technicians: Anesha Patel, Ruby Lyall, Sanara Raza, Success Fabusoro, Gaia Frigerio, Maria Rasulo, Catalina Chavarro Novoa, Martynas Stonkus, Prital Patel, Zara Prem</p><p>Research Allied Healthcare Professionals: Naomi Hassim, Pippa Kirby</p><p>London Borough of Hammersmith and Fulham Support: Assistive Technology: John Patterson Business Development: Mike Law</p><p>Social Services OT: Andy Kenny</p><p>
<bold>Name: Minder Digitally Enabled Care for Dementia (MinderCare)</bold>
</p><p>Affiliation: Imperial College Healthcare NHS Trust, Imperial College London</p><p>Principal Investigator: Professor David Sharp</p><p>Co&#8208;Investigators (not listed elsewhere) James Bird, Sarah Pearse</p><p>MinderCare Clinical Team: Joanna James, Janibo Amade Cassimo, Aglaja Dar, Pandora Wright, Lucia Li, Anastasia Mirza&#8208;Davies, Julian Jeyasingh Jacobs, Zinca Zecevic, Sarah Daniels, David Wingfield</p><p>Research Technicians: Success Fabusoro, Gaia Frigerio, Maria Rasulo, Catalina Chavarro Novoa, Emma Burroughs</p></sec></app></app-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Hosp Pharm</journal-id><journal-id journal-id-type="iso-abbrev">Hosp Pharm</journal-id><journal-id journal-id-type="pmc-domain-id">2261</journal-id><journal-id journal-id-type="pmc-domain">hosppharm</journal-id><journal-id journal-id-type="publisher-id">HPX</journal-id><journal-title-group><journal-title>Hospital Pharmacy</journal-title></journal-title-group><issn pub-type="ppub">0018-5787</issn><issn pub-type="epub">1945-1253</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11418606</article-id><article-id pub-id-type="pmcid-ver">PMC11418606.1</article-id><article-id pub-id-type="pmcaid">11418606</article-id><article-id pub-id-type="pmcaiid">11418606</article-id><article-id pub-id-type="pmid">39318742</article-id><article-id pub-id-type="doi">10.1177/00185787231185869</article-id><article-id pub-id-type="publisher-id">10.1177_00185787231185869</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Fms</subject></subj-group></article-categories><title-group><article-title>Lecanemab</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5114-6067</contrib-id><name name-style="western"><surname>Levien</surname><given-names initials="TL">Terri L.</given-names></name><xref rid="aff1-00185787231185869" ref-type="aff">1</xref><xref rid="corresp1-00185787231185869" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4605-3357</contrib-id><name name-style="western"><surname>Baker</surname><given-names initials="DE">Danial E.</given-names></name><xref rid="aff1-00185787231185869" ref-type="aff">1</xref></contrib></contrib-group><aff id="aff1-00185787231185869"><label>1</label>Washington State University, Spokane, WA, USA</aff><author-notes><corresp id="corresp1-00185787231185869">Terri L. Levien, Pharmacotherapy Department, College of Pharmacy and Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls Blvd, Spokane, WA 99202-2131, USA. Email: <email>levient@wsu.edu</email></corresp><fn fn-type="COI-statement"><p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn></author-notes><pub-date pub-type="epub"><day>11</day><month>7</month><year>2023</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2024</year></pub-date><volume>59</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">471294</issue-id><fpage>519</fpage><lpage>528</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-released-under-embargo"><date><day>24</day><month>09</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 00:25:23.493"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_00185787231185869.pdf"/><abstract><p>Each month, subscribers to <italic toggle="yes">The Formulary Monograph Service</italic> receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy &amp; Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of <italic toggle="yes">The Formulary, Hospital Pharmacy</italic> publishes selected reviews in this column. For more information about <italic toggle="yes">The Formulary Monograph Service</italic>, contact Wolters Kluwer customer service at 866-397-3433.</p></abstract><kwd-group><kwd>drug information</kwd><kwd>formulary management/P &amp; T</kwd><kwd>neurology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">eBioMedicine</journal-id><journal-id journal-id-type="iso-abbrev">EBioMedicine</journal-id><journal-id journal-id-type="pmc-domain-id">2749</journal-id><journal-id journal-id-type="pmc-domain">ebiom</journal-id><journal-title-group><journal-title>eBioMedicine</journal-title></journal-title-group><issn pub-type="epub">2352-3964</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12481106</article-id><article-id pub-id-type="pmcid-ver">PMC12481106.1</article-id><article-id pub-id-type="pmcaid">12481106</article-id><article-id pub-id-type="pmcaiid">12481106</article-id><article-id pub-id-type="pmid">40972226</article-id><article-id pub-id-type="doi">10.1016/j.ebiom.2025.105940</article-id><article-id pub-id-type="pii">S2352-3964(25)00384-6</article-id><article-id pub-id-type="publisher-id">105940</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Sol</surname><given-names initials="O">Olivier</given-names></name><email>olivier.sol@acimmune.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Mermoud</surname><given-names initials="J">Julien</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Hallikainen</surname><given-names initials="M">Merja</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Kurl</surname><given-names initials="S">Sudhir</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Rinne</surname><given-names initials="J">Juha</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Dautzenberg</surname><given-names initials="P">Paul</given-names></name><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Vijverberg</surname><given-names initials="EGB">Everard G.B.</given-names></name><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Mummery</surname><given-names initials="C">Catherine</given-names></name><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>B&#246;rjesson-Hanson</surname><given-names initials="A">Anne</given-names></name><xref rid="aff8" ref-type="aff">h</xref><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Jonsson</surname><given-names initials="M">Michael</given-names></name><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Ritchie</surname><given-names initials="C">Craig</given-names></name><xref rid="aff11" ref-type="aff">k</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>Pennington</surname><given-names initials="C">Catherine</given-names></name><xref rid="aff11" ref-type="aff">k</xref></contrib><contrib contrib-type="author" id="au13"><name name-style="western"><surname>Vukicevic</surname><given-names initials="M">Marija</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au14"><name name-style="western"><surname>Gollwitzer</surname><given-names initials="E">Eva</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au15"><name name-style="western"><surname>Fiorini</surname><given-names initials="E">Emma</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au16"><name name-style="western"><surname>Hickman</surname><given-names initials="DT">David T.</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au17"><name name-style="western"><surname>Hliva</surname><given-names initials="V">Val&#233;rie</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au18"><name name-style="western"><surname>Gray</surname><given-names initials="J">Julian</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au19"><name name-style="western"><surname>Gerasymchuk</surname><given-names initials="V">Viktoriia</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au20"><name name-style="western"><surname>Wagg</surname><given-names initials="J">Jonathan</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au21"><name name-style="western"><surname>Fournier</surname><given-names initials="N">Nicolas</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au22"><name name-style="western"><surname>L&#234;</surname><given-names initials="B">B&#233;n&#233;dicte</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au23"><name name-style="western"><surname>Kezic</surname><given-names initials="I">Iva</given-names></name><xref rid="aff12" ref-type="aff">l</xref></contrib><contrib contrib-type="author" id="au24"><name name-style="western"><surname>Steukers</surname><given-names initials="L">Lennert</given-names></name><xref rid="aff12" ref-type="aff">l</xref></contrib><contrib contrib-type="author" id="au25"><name name-style="western"><surname>Triana-Baltzer</surname><given-names initials="G">Gallen</given-names></name><xref rid="aff13" ref-type="aff">m</xref></contrib><contrib contrib-type="author" id="au26"><name name-style="western"><surname>Theunis</surname><given-names initials="C">Clara</given-names></name><xref rid="aff12" ref-type="aff">l</xref></contrib><contrib contrib-type="author" id="au27"><name name-style="western"><surname>Streffer</surname><given-names initials="J">Johannes</given-names></name><xref rid="aff14" ref-type="aff">n</xref></contrib><contrib contrib-type="author" id="au28"><name name-style="western"><surname>Kosco-Vilbois</surname><given-names initials="M">Marie</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au29"><name name-style="western"><surname>Pfeifer</surname><given-names initials="A">Andrea</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au30"><name name-style="western"><surname>Scheltens</surname><given-names initials="P">Philip</given-names></name><xref rid="aff6" ref-type="aff">f</xref></contrib><aff id="aff1"><label>a</label>AC Immune SA, Lausanne, Switzerland</aff><aff id="aff2"><label>b</label>University of Eastern Finland, School of Medicine, Kuopio, Finland</aff><aff id="aff3"><label>c</label>Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland</aff><aff id="aff4"><label>d</label>Clinical Research Services Turku (CRST), Turku, Finland</aff><aff id="aff5"><label>e</label>Brain Research Center, Center Den Bosch, Den Bosch, Netherlands</aff><aff id="aff6"><label>f</label>Amsterdam UMC, Amsterdam, Netherlands</aff><aff id="aff7"><label>g</label>University College London, London, UK</aff><aff id="aff8"><label>h</label>Karolinska Institute, Stockholm, Sweden</aff><aff id="aff9"><label>i</label>Karolinska University Hospital, Stockholm, Sweden</aff><aff id="aff10"><label>j</label>Sahlgrenska University Hospital, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden</aff><aff id="aff11"><label>k</label>University of Edinburgh, Edinburgh, UK</aff><aff id="aff12"><label>l</label>Johnson &amp; Johnson Innovative Medicine, Beerse, Belgium</aff><aff id="aff13"><label>m</label>Johnson &amp; Johnson Innovative Medicine, San Diego, CA, USA</aff><aff id="aff14"><label>n</label>Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author. <email>olivier.sol@acimmune.com</email></corresp></author-notes><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>18</day><month>9</month><year>2025</year></pub-date><volume>120</volume><issue-id pub-id-type="pmc-issue-id">497285</issue-id><elocation-id>105940</elocation-id><history><date date-type="received"><day>20</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>4</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>4</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 09:26:11.207"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 AC Immune SA; Johnson@Johnson Innovative Medicine</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><title>Summary</title><sec><title>Background</title><p>Active immunotherapies targeting C-terminal phosphorylated Tau species have the potential to efficiently reduce Tau spreading. ACI-35.030, a SupraAntigen&#174;-based liposome, and JACI-35.054, a CRM197 carrier-protein conjugate, share the same immunogenic pTau sequence and were assessed to determine the best formulation for preferential activation of B cells specific to pathological Tau forms.</p></sec><sec><title>Methods</title><p>Individuals with early AD were enrolled in this randomised, double-blind, placebo-controlled study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04445831" id="intref0010">NCT04445831</ext-link>). Participants were randomly assigned to 2 cohorts (ACI-35.030 at 300, 900, 1800 &#956;g or placebo; and JACI-35.054 at 15, 60 &#956;g or placebo) and received 4 intramuscular injections over 48 weeks, followed up to week 74. Participants receiving at least one dose of study drug were included in the intention-to-treat analysis. The primary objectives were safety, tolerability and immunogenicity.</p></sec><sec><title>Findings</title><p>Among the 57 randomised participants, 41 were assigned to the ACI-35.030 cohort and 16 to the JACI-35.054 cohort. The most frequent adverse events observed consistently in both active groups were injection site reactions (16.7%&#8211;100%) and headaches (16.7%&#8211;50%). No relevant MRI findings and no adverse events leading to study discontinuation were reported. ACI-35.030 required only one injection to induce anti-pTau IgG titres in all participants and consistently boosted levels with subsequent immunisations. JACI-35.054 raised a strong but more heterogenous anti-pTau IgG response and required multiple administrations to reach consistent titres in all participants. ACI-35.030 induced a robust polyclonal antibody response binding enriched PHF from AD brain tissue while concurrently sparing the response to non-phosphorylated Tau. A post-hoc statistical analysis revealed statistically significant differences between some randomised actively treated groups and the pooled placebo group on plasma pTau217 and brain-derived Tau changes from baseline.</p></sec><sec><title>Interpretation</title><p>ACI-35.030 and JACI-35.054 were well tolerated. ACI-35.030 induced a more rapid and sustained antibody response selective to p-Tau species with evidence of altering AD-related plasma biomarkers and was selected for testing in the ongoing Phase 2b trial.</p></sec><sec><title>Funding</title><p><funding-source id="gs1">AC Immune SA</funding-source> and <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100005565</institution-id><institution>Johnson &amp; Johnson Innovative Medicine</institution></institution-wrap></funding-source>.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Alzheimer's disease</kwd><kwd>Active immunotherapy</kwd><kwd>Vaccine</kwd><kwd>Tau</kwd><kwd>phosphoTau</kwd><kwd>Paired helical filament</kwd><kwd>Immunogenicity</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="p0010">
<boxed-text id="dtbox1" position="float" orientation="portrait"><caption><title>Research in context</title></caption><sec id="dtbox1sec1"><title>Evidence before this study</title><p id="p0015">ACI-35.030 and JACI-35.054 are modifications of a first-generation active immunotherapy formulation, ACI-35, comprised of the same phosphorylated Tau peptide antigen and monosphosphoryl lipid A (MPLA) adjuvant embedded in a liposome. ACI-35 was investigated in a Phase 1 clinical trial (Study ACI-35-1201) where it was found to be safe and well tolerated. Although antibody responses were generated at all tested doses after the first immunisation, sustained anti-pTau antibody responses were not observed with subsequent injections of this first-generation formulation (data on file). ACI-35.030 and JACI-35.054 were, therefore, designed to retain the good safety profile of ACI-35 while improving immunogenicity, notably to maintain specific anti-pTau titres over time. A search in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov" id="intref0015">clinicaltrials.gov</ext-link> and PubMed using the following key words, &#8220;Tau vaccine&#8221;, &#8220;Tau active immunotherapy&#8221;, and &#8220;Alzheimer&#8221; was performed on 11 February 2025. Apart from ACI-35.030 and JACI-35.054 that were assessed in our study, AADVac1 was the only other anti-Tau active immunotherapy with published results from clinical trials. There was no evidence of any completed late-stage trial with anti-Tau-targeting immunotherapies or antisense oligonucleotides in Alzheimer's disease or with other tauopathies, which demonstrate that anti-Tau therapies are still currently in an early stage of clinical development.</p></sec><sec id="dtbox1sec2"><title>Added value of this study</title><p id="p0020">ACI-35.030 and JACI-35.054 are active immunotherapies being developed for the treatment of Alzheimer's Disease (AD). ACI-35.030 and JACI-35.054 are designed to stimulate the immune system of individuals with AD to produce antibodies against specific phosphorylated Tau species. Antibodies induced by treatment with ACI-35.030 and JACI-35.054 are aimed to inhibit tau spreading by targeting and clearing extracellular pathological tau species and consequently preventing their uptake by, and the induction of intracellular tau aggregation in, nearby brain healthy neurons. In this study, both tested active immunotherapies induced robust antibody responses against the immunogen peptide and pathological Tau species. The two compounds were observed to be different in the profile and magnitude of the generated antibody titres. ACI-35.030, derived from the SupraAntigen&#174; liposome&#8211;based platform, induced an early and strong polyclonal antibody response that matured toward, and was mainly oriented and maintained against, key pathological forms of Tau. These pathological species are believed to drive Tau pathology in AD. In contrast, JACI-35.054, a CRM197 carrier-protein conjugate, triggered a more progressive and heterogenous antibody response and was less specifically oriented toward pathological Tau species. The safety and tolerability of these two active immunotherapies were good. This study has demonstrated that two different anti-Tau active immunotherapy formulations sharing the same immunogen can induce a differential effect in antibody response in humans. It also provides evidence that anti-Tau active immunotherapies in the clinical setting can generate an antibody response against the pathological form of the endogenous brain Tau (paired helical filament, PHF). Post-hoc analyses performed in the participating individuals showed statistically significant differences in changes from baseline of plasma pTau217 and brain-derived Tau at different timepoints between some of the actively treated groups and a pooled placebo group. These data, generated in a limited number of participants, will need to be replicated in a broader population. To date, only one other anti-Tau active immunotherapy, AADvac1, comprising tau peptide 294&#8211;305/4R coupled to Keyhole Limpet Haemocyanin and formulated with aluminium hydroxide, has published Phase 2 clinical data, in 196 participants with mild AD. This active immunotherapy targets the microtubule binding region, the main region involved in Tau aggregation. AADVac1 induced IgG titres against its immunogenic peptide, while no data on antibody titres against PHF were reported. This active immunotherapy was safe and well tolerated and over the 24-month treatment period showed a statistically significant reduction in plasma neurofilament light chain (NfL) level compared to placebo. Post-hoc analyses using a prediction model to identify the subgroup of participants likely to be A+/T+ (n = 91) revealed favourable trends in treatment effects on clinical measures of CDR-SB and ADCS-MCI-ADL.</p></sec><sec id="dtbox1sec3"><title>Implications of all the available evidence</title><p id="p0025">Our clinical study demonstrates a potent polyclonal antibody response that matures and is maintained against key pathological forms of Tau in response to active immunotherapy. These results support the continued development of the SupraAntigen&#174; liposome-based active immunotherapy, ACI-35.030 (JNJ-64042056). This study drug is now being assessed in the Phase 2b Re&#964;ain trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT06544616" id="intref0020">NCT06544616</ext-link>) enrolling participants with preclinical AD with the aim to arrest Tau pathology propagation, thus contributing to delaying, or potentially preventing, cognitive decline.</p></sec></boxed-text>
</p><sec id="sec1"><title>Introduction</title><p id="p0030">Due to the complexity of the disease, understanding Alzheimer's disease (AD) pathophysiology well enough to find effective, meaningful treatments has only recently witnessed therapeutic breakthroughs with certain amyloid targeting, disease modifying monoclonal antibodies (mAbs).<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref> These results have provided insights into the cascade hypothesis that begins with amyloid beta (A&#946;) accumulation, followed by Tau aggregation, spreading and ultimately neurodegeneration and cognitive impairment.<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> Diagnostic criteria and staging of AD have been recently updated.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> In the Phase 3 CLARITY AD trial with lecanemab, clinical decline measured by using CDR-SB in individuals with early AD was found to be reduced by 27% in the treated group, compared to placebo after 18 months.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Data from the TRAILBLAZER-ALZ 2 trial with donanemab, also conducted in an early AD population, significantly lowered amyloid plaque burden, as measured with PET-scan, and slowed clinical progression especially in participants with low/medium brain Tau burden.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> While these anti-amyloid mAbs are currently approved in several countries, it still leaves a continued unmet need for new treatments to further prevent or slow disease progression, notably in individuals with preclinical AD.<xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref> In AD, cognitive decline correlates with the burden of pathological Tau inclusions, species that are prone to seeded aggregation and extracellular spreading.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Aberrant hyperphosphorylation of Tau results in aggregation into PHF, the major component of neurofibrillary tangles (NFT). More precisely, the spread of NFTs across interconnected brain regions correlates with cognitive decline and disease progression.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> As pathological Tau species are released from neurons in which Tau aggregation has been initiated, immunotherapies using antibodies specifically binding in the interstitial fluid to pathological forms of Tau, that are closely related to PHF, may offer promise as treatments by impeding the spread of Tau pathology.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> While various Tau-targeting mAb-based therapies are currently being studied in early stages of AD, active immunotherapies are highly attractive to pursue, as immunisation offers several distinct advantages. Active immunotherapies instruct the immune system to defend itself against pathological immunogens. Post dosing, a natural and long-lasting polyclonal antibody response against a pathological target is generated. The maintenance of the antibody response can be achieved with less frequent doses as compared to mAbs, and as the protective antibodies are generated by the immune system, anti-drug antibodies, commonly observed with mAbs, are absent.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> Yet the most highly differentiating feature is the mechanism to instruct/inform, via an active process of affinity maturation, the evolution of the antibodies toward the endogenous pathological form driving disease within each person. This maturation enhances the ability to protect against the disease caused by the pathological Tau species spreading within an individual. Thus, in order to achieve a protective antibody response to the immunising peptide (i.e., pTau) as well as to promote evolution to the endogenous pathological species (represented by PHF enriched from AD brain&#8211;ePHF) within an individual with AD, the design of active immunotherapy required considerable forethought. Although safety, immunogenicity and efficacy can be established using laboratory animals, the ultimate goal is to observe these features in humans who are part of a vulnerable population.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Therefore, in this trial, two active immunotherapy formulations, ACI-35.030 and JACI-35.054, were evaluated for safety, tolerability, and immunogenicity. Both contained the same phospho-Tau peptide from the C-terminal region of the Tau protein (Tau393-408 [pS396/pS404]), considered a relevant phosphorylated region related to AD pathology and abundantly present on PHF.<xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref> The formulations differed in the structural element used to present the phospho-Tau peptide to the immune system and the selection of adjuvants, key drivers of successful active immunotherapies. Therefore, different doses of the two formulations were individually assessed in non-human primates, in order to define an optimal range for each immunotherapy to be evaluated in humans. According to regulatory authority guidelines, the initial dose in humans was low and less immunogenic, followed by increasing doses, up to a maximal dose allowed by the format of the carrier. Here we present safety and immunogenicity data of both active immunotherapies along with the observed effects on fluid biomarkers, imaging parameters and clinical endpoints across all participants.</p></sec><sec id="sec2"><title>Methods</title><sec id="sec2.1"><title>Formulations of ACI-35.030 and JACI-35.054 active immunotherapies and placebo</title><p id="p0035">The liposome-based active immunotherapy formulation, ACI-35.030, presents a phosphorylated Tau (pTau) peptide, Tau393-408 (phosphorylated at Serine 396 and 404), double-lipidated to enable insertion at both the N-and C-terminal ends through Lys(palmitoyl). In addition, universal T-cell epitopes derived from PADRE (Pan DR-binding epitope; universal synthetic T-cell peptide) and Tetanus toxin are encapsulated or associated with the liposome while the two adjuvants, MPLA (3D-(6-acyl)-PHAD&#174;) and CpG7909-cholesterol, are incorporated onto the liposomal surface. The carrier-based active immunotherapy formulation, JACI-35.054, presents the same immunogenic pTau peptide but without lipidation, as it is instead covalently linked to the common carrier protein, CRM197, then mixed with aluminium hydroxide and CpG7909 as adjuvants prior to administration. Both active immunotherapy approaches (liposome versus carrier-based) were chosen as they are well-known to enhance the immunogenicity to antigenic peptides.<xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref> Studies in nonclinical species (i.e., adult wildtype mice and nonhuman primates) were performed in order to determine the optimal formulation and dose level to achieve the best anti-pTau IgG response elicited by each formulation. The dose range of the final formulations used in this trial was determined from these nonclinical data. The appearance of the two active immunotherapy formulations and of the placebo (phosphate-buffered saline (PBS) solution) differed. To prevent unblinding of the patient and any blinded site staff, dedicated unblinded persons at the site pharmacy level were in charge of the preparation of allocated study drug using syringes wrapped in a coloured label.</p></sec><sec id="sec2.2"><title>Study design</title><p id="p0040">This Phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study was designed to evaluate the safety, tolerability and immunogenicity of different doses, regimens and combinations of ACI-35.030 and JACI-35.054 in early AD. The Phase 1b part of the study assessed immunogenicity, tolerability and safety, while the Phase 2a part was intended to provide a preliminary assessment of effects on biomarkers. Outpatients took part in the study between 13 August 2019 (first participant first visit) and 5 September 2023 (last participant last visit) in 9 clinical sites in Finland, Netherlands, United Kingdom and Sweden. The study protocol was reviewed and approved by health authorities, respectively by the Medicines Agency (ID KLnro 30/2019) in Finland, by the Medicines and Healthcare products Regulatory Agency (ID CTA 41996/0004/001-0001) in the UK, by the Medical Products Agency (ID 5.1-2020-37457) in Sweden and by the Medicines Evaluation Board Agency under the Ministry of Health, Welfare and Sport (ID NL69383.000.19) in the Netherlands. The study was initially registered in EudraCT (2015-000630-30) and the public registry onderzoekmetmensen.nl on 18 April 2019, and in research summaries pages of the UK Health Research Authority website. To facilitate broader public access, as phase 1 trials were not made publicly available in EudraCT registry, the trial was subsequently registered on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="intref0025">ClinicalTrials.gov</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04445831" id="intref0030">NCT04445831</ext-link>) on 22 June 2020.</p></sec><sec id="sec2.3"><title>Ethics</title><p id="p0045">The study protocol and key study documents were reviewed and approved respectively by the Ethics Committees of the participating countries, respectively the Committee on Medical Research Ethics (ID 29/06.00.01/2019) in Finland, the West of Scotland Research Ethics Committee (ID 19/WS/0056) in the UK, the Ethical Review Authority (ID 2020-01470) in Sweden, and the Central Committee for Research involving Human subjects (ID CCMO19.0508/JvG/cb/69383) in the Netherlands. All study participants and their caregivers provided written informed consent before any study procedures.</p></sec><sec id="sec2.4"><title>Participants</title><p id="p0050">Participants had to meet the following main inclusion criteria: 50-75 years-old, male or female, diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD according to NIA-AA criteria, Clinical Dementia Rating scale (CDR) global score of 0.5 or 1, Mini-Mental State Examination (MMSE) &#8805;22, abnormal level of CSF amyloid beta (A&#946;) 42 consistent with AD pathology as per laboratory threshold, no intake of marketed treatment for AD or on stable dose of acetylcholinesterase inhibitor and/or memantine for at least 3 months prior to baseline. No particular guidance was given to study sites for the selection of participants according to sex, gender, race and ethnicity and these parameters were collected according to usual local site practice. The main exclusionary selection criteria were recent participation in previous clinical trials for AD and/or for neurological disorders, positive anti-nuclear antibodies (ANA) titres at a dilution &#8805;1/160, current or past history of autoimmune disease, use of immunosuppressive drugs or systemic steroids, any significant medical conditions which could confound the assessment of safety or immunogenicity. Details on eligibility criteria are listed in the protocol.</p></sec><sec id="sec2.5"><title>Randomisation and masking</title><p id="p0055">A randomisation list enabling study treatment allocation was computed by an Interactive Response Technology system using individual medication codes provided by the investigational drug product supplier. The study medication was labelled with the corresponding medication number. The blinded site staff used the IRT system to randomise eligible participants to a study subcohort and to assign study treatment. The randomisation block size of 4 with an active:placebo ratio of 3:1 was used in each study subcohort. Study participants, site personnel and sponsor were blinded to treatment.</p></sec><sec id="sec2.6"><title>Procedures</title><p id="p0060">The initial screening period of up to 42 days was followed by a treatment period of 50 weeks with study drug intramuscular administration in the deltoid muscle at weeks 0, 8, 24, and 48. A 24-week follow-up period up to week 74 completed the study. Participants were kept under clinical observation for 24 h after the first injection and for 4 h after the subsequent study drug administrations. A safety assessment by phone call was also performed 48&#8211;72 h after each immunisation. In each subcohort, the first dosing of the first 4 participants had to be performed 48&#8211;72 h after the safety assessment of the previous participant. Recording of adverse events and of concomitant medications were performed at all study visits. Clinical and neurological examinations and routine laboratory evaluations were performed during on-site visits, as per study protocol. Dose escalation was permitted once all participants in one dose-level subcohort had received the second injection of study drug and after review of interim safety and tolerability data by the independent Data Safety Monitoring Board. ACI-35.030 was sequentially assessed at doses of 300 &#956;g (subcohort 1.1), 900 &#956;g (subcohort 1.2), and 1800 &#956;g (subcohort 1.3), while JACI-35.054 was tested at doses of 15 &#956;g (subcohort 2.1) and 60 &#956;g (subcohort 2.2). Both ACI-35.030 and JACI-35.054 cohorts were conducted independently from each other. Although the ACI-35.030 cohort was started before the JACI-35.054 cohort, the screening periods between cohort 1 (13 August 2019&#8211;22 February 2022) and cohort 2 (28 July 2020 and 26 August 2021) were globally overlapping, thus allowing to group participants on placebo for the analyses. The design of cohorts and subcohorts and study schedule are presented in <xref rid="tbl1" ref-type="table">Table 1</xref>. During the treatment period, study visits at the centres were organised the days of, and two weeks after each immunisation, and an additional visit was also to be performed at week 36. Visits at weeks 67 and 74 (last study visit) were performed during the follow-up period. During each study visit, blood samples were measured for antibody titres against Tau species and safety measures were assessed. Lumbar punctures were performed at screening, weeks 26 and 50 to assess fluid biomarkers and routine cytology and biochemistry. Brain MRIs were planned at baseline, two weeks after the second and subsequent injections and at week 74. For cognitive and clinical assessments, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Clinical Dementia Rating scale - Sum of Boxes (CDR-SB) and Columbia-Suicide Severity Rating Scale (C-SSRS) were performed at screening, weeks 0, 26, 50, and 74. The Neuropsychiatric Inventory (NPI) was performed at the same timepoints as the other scales from week 0 onwards. During the study, additional study visits were conducted at weeks 15, 20, 31, and 42 to assess more closely the kinetics of plasma biomarkers and antibody titres. Of note, due to the COVID-19 pandemic and travel restrictions, immunisations at week 24 were not performed in 7 of 8 participants from Finland in subcohort 1.1.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Study cohort profile and administration schedule.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="4" colspan="1">Cohort</th><th rowspan="4" colspan="1">Subcohort</th><th rowspan="4" colspan="1">IP</th><th rowspan="4" colspan="1">Dose (&#956;g)</th><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">Screening<hr/></th><th colspan="13" rowspan="1">Treatment<hr/></th><th colspan="2" rowspan="1">Follow-up<hr/></th></tr><tr><th colspan="1" rowspan="1">Visit</th><th colspan="1" rowspan="1">S</th><th colspan="1" rowspan="1">V1</th><th colspan="1" rowspan="1">V2</th><th colspan="1" rowspan="1">V3</th><th colspan="1" rowspan="1">V4</th><th colspan="1" rowspan="1">V4.1</th><th colspan="1" rowspan="1">V4.2</th><th colspan="1" rowspan="1">V5</th><th colspan="1" rowspan="1">V6</th><th colspan="1" rowspan="1">V6.1</th><th colspan="1" rowspan="1">V7</th><th colspan="1" rowspan="1">V7.1</th><th colspan="1" rowspan="1">V8</th><th colspan="1" rowspan="1">V9</th><th colspan="1" rowspan="1">V10</th><th colspan="1" rowspan="1">V11</th></tr><tr><th colspan="1" rowspan="1">Week</th><th colspan="1" rowspan="1">&#8722;6 to &#8764;0</th><th colspan="1" rowspan="1">0</th><th colspan="1" rowspan="1">2</th><th colspan="1" rowspan="1">8</th><th colspan="1" rowspan="1">10</th><th colspan="1" rowspan="1">15</th><th colspan="1" rowspan="1">20</th><th colspan="1" rowspan="1">24</th><th colspan="1" rowspan="1">26</th><th colspan="1" rowspan="1">31</th><th colspan="1" rowspan="1">36</th><th colspan="1" rowspan="1">42</th><th colspan="1" rowspan="1">48</th><th colspan="1" rowspan="1">50</th><th colspan="1" rowspan="1">67</th><th colspan="1" rowspan="1">74</th></tr><tr><th colspan="1" rowspan="1">N</th><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1"/></tr></thead><tbody><tr><td rowspan="6" colspan="1">1</td><td align="char" rowspan="2" colspan="1">1.1</td><td colspan="1" rowspan="1">ACE-35.030</td><td align="char" colspan="1" rowspan="1">300</td><td align="char" colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Placebo</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td align="char" rowspan="2" colspan="1">1.2</td><td colspan="1" rowspan="1">ACE-35.030</td><td align="char" colspan="1" rowspan="1">900</td><td align="char" colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Placebo</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td align="char" rowspan="2" colspan="1">1.3</td><td colspan="1" rowspan="1">ACE-35.030</td><td align="char" colspan="1" rowspan="1">1800</td><td align="char" colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Placebo</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td rowspan="4" colspan="1">2</td><td align="char" rowspan="2" colspan="1">2.1</td><td colspan="1" rowspan="1">JACI-35.054</td><td align="char" colspan="1" rowspan="1">15</td><td align="char" colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Placebo</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td align="char" rowspan="2" colspan="1">2.2</td><td colspan="1" rowspan="1">JACI-35.054</td><td align="char" colspan="1" rowspan="1">60</td><td align="char" colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Placebo</td><td colspan="1" rowspan="1">&#8211;</td><td align="char" colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8593;</td><td colspan="1" rowspan="1">CSF</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>&#8593;: IP Injection. CSF: Cerebrospinal Fluid collection. IP: Investigational Product. N: number of study participants. S: screening. V: visit. Cohort 1 placebo group: N = 10. Cohort 2 placebo group: N = 4. Pooled placebo group (cohort 1 placebo + cohort 2 placebo): N = 14. Blood was collected at each visit. Safety phone calls (not depicted on this table) took place 48&#8211;72 h after each IP administration. During the study, additional study visits V4.1, V4.2, V6.1, and V7.1 were conducted at weeks 15, 20, 31, and 42, respectively, to assess more closely the kinetics of plasma biomarkers and antibody titres.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.7"><title>Study objectives and endpoints</title><p id="p0065">The primary objectives were to assess the safety and tolerability of the study active immunotherapies and their immunogenicity to generate an anti-pTau and anti-ePHF IgG responses. The primary endpoints for the safety and tolerability were respectively the collection of adverse events, immediate and delayed reactogenicity, suicidal ideation, behaviour, cognitive and functional assessments also intended to assess safety, vital signs, MRI imaging, electrocardiogram, routine haematology and biochemistry, measure of autoimmune antibodies including anti-dsDNA antibodies in blood; inflammatory markers in blood and CSF. The primary endpoint for immunogenicity was the measure of anti-pTau IgG titres in serum. The secondary outcome measures were intended to assess additional immunogenicity of the active immunotherapies, i.e., anti-Tau IgG and IgM responses. The planned secondary endpoints were the measures of anti-Tau IgG, anti-pTau and anti-Tau IgM titres in serum and the determination of the IgG response profile by avidity testing. The latter was only partially performed due to technical reasons and therefore no conclusion could be drawn on this dataset. Exploratory objectives were to evaluate effects on AD-related fluid biomarkers, inflammatory cytokines, additional immune response components (i.e., antibodies against other study treatment components, namely T50, a universal T-cell epitope contained in ACI-35.030; and CRM, the carrier protein used in JACI-35.054; functional capacity of active immunotherapy-induced antibodies) and behaviour, cognitive and functional performance.</p></sec><sec id="sec2.8"><title>Statistical analysis</title><p id="p0070">Statistical analyses were performed by ICON, except dedicated interim analyses performed in collaboration with Johnson &amp; Johnson Innovative Medicine and a post-hoc statistical analysis performed by AC Immune. All analyses and tabulations of data were performed using SAS&#174; version 9.4 or higher. The post-hoc analyses and all longitudinal plots were generated by AC Immune using the R-statistical programming language (Version 4.3.3). Missing data were excluded from the analyses and no missing data imputation was carried out. Descriptive summaries were tabulated by treatment group, with placebo groups separated by cohort (placebo in cohorts 1 and 2) or pooled across cohorts (Pooled placebo). Categorical data were presented using counts and percentages, with the number of participants in each category as the denominator for percentages. Continuous data were summarised using descriptive statistics. The enrolled population comprised all participants who signed the informed consent form. Baseline characteristics and primary, secondary, and exploratory endpoints were presented using the Intention-to-Treat (ITT)/safety population which consisted of all randomised participants receiving at least one dose of study drug. The Per Protocol (PP) population included participants from the ITT population without any important protocol deviations that could have significantly affected the completeness, accuracy, and/or reliability of the study data. Adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 26.1. The antibody response data for primary, secondary, and exploratory endpoints were presented using descriptive statistics of absolute values and changes from baseline. Predefined semi-blinded interim analyses of the antibody response and of safety/tolerability were performed in randomised participants at specific timepoints. The semi-blinded procedure (recoding of participant identifiers) enabled individual interim data review per treatment group without unblinding a participant's individual identifier. The number of participants in each subcohort (n = 8; 6 on active treatment and 2 on placebo) was considered appropriate to evaluate the preliminary antibody response, safety and tolerability. Up to 16 additional participants could be randomised in subcohort(s) showing a more robust antibody response to get a better appreciation of immunogenicity and safety. The decision was taken to expose additional participants to ACI-35.030 900 &#956;g (n = 19, ITT) within the expanded sub-cohort 1.2 (n = 25, ITT). More details on statistical analysis methods can be found in the <xref rid="appsec1" ref-type="sec">Supplementary Section</xref>.</p></sec><sec id="sec2.9"><title>Role of the funding source</title><p id="p0075">The sponsor of the study, AC Immune SA, participated in study design, study conduct, data collection, analysis and interpretation, clinical study report and writing, review, and approval of the manuscript. All authors had full access to the data, participated in the development and review of the manuscript, took full responsibility for the content and approved the manuscript for submission for publication. Johnson &amp; Johnson Innovative Medicine provided support notably for interim data analyses, generating data on some fluid biomarkers and affiliated coauthors participating in the data interpretation and manuscript review and approval.</p></sec></sec><sec id="sec3"><title>Results</title><p id="p0080">Participants were recruited between 13 August 2019 and 22 February 2022. Among the 79 screened participants, 57 were randomised, 41 participants (male/female: 21/20; mean age: 67.1 (&#177;5.49)) in cohort 1 received either ACI-35.030 or placebo and 16 participants (male/female: 6/10; mean age: 65.6 (&#177;5.73)) in cohort 2 received either JACI-35.054 or placebo. Details on the trial profile are provided in <xref rid="fig1" ref-type="fig">Fig. 1</xref>. All randomised participants with early AD received at least one dose of study drug and were included in the Safety/ITT population. In cohort 1, 37/41 (90.2%) participants entered the follow-up period, and 32/41 (78%) were included in the PP population. In cohort 2, all 16 participants entered the follow-up period, and 15/16 (93.8%) were included in the PP population. All participants were white. Mean baseline MMSE total scores were respectively 26.3 (&#177;2.29) and 26.3 (&#177;2.93) in cohorts 1 and 2. Most participants had a CDR-global score of 0.5 at baseline, 36/41 (87.8%) and 14/16 (87.5%) in cohorts 1 and 2, respectively. Standard of care treatment for AD, i.e., acetylcholinesterase inhibitors and/or memantine, was prescribed in 32/41 (78%) participants in cohort 1 and in 12/16 (75%) in cohort 2. Comprehensive demographics and baseline characteristics are shown in <xref rid="tbl2" ref-type="table">Table 2</xref>. Overall, in cohort 1, 2/41 (4.9%) participants received only two injections, 7/41 (17.1%) received three injections and 32/41 (78.0%) participants received the planned four injections of study drug. All participants received four injections in cohort 2. No death was reported, and no adverse event (AE) led to discontinuation of study treatment or of the study. There were no notable differences in the incidence of treatment-emergent adverse events (TEAEs) in ACI-35.030 active treatment groups, i.e., 6/6 (100%) participants in 300 &#956;g and 1800 &#956;g cohorts, 17/19 (89.5%) participants in 900 &#956;g subcohort, and 8/10 (80.0%) participants in placebo subcohort. TEAEs were mostly mild or moderate in severity. Nine serious adverse events (SAEs) were reported in six participants (2/6 participants (33.3%) in ACI-35.030 300 &#956;g cohort, 2/19 (10.5%) in 900 &#956;g cohort, and 2/6 (33.3%) in 1800 &#956;g cohort), as shown in <xref rid="tbl3" ref-type="table">Table 3</xref>. There was no pattern to the SAEs observed, and all were considered as unlikely related to the study treatment, except for the SAEs of injection site rash and dizziness reported in one participant in the ACI-35.030 900 &#956;g treatment group, which were considered as probably and possibly related to study treatment, respectively. As shown in <xref rid="tbl4" ref-type="table">Table 4</xref>, the most frequent adverse events which occurred more commonly on active treatment compared to placebo were injection site reactions (ISRs). They were reported in cohort 1 on one or more occasions in 2/6 participants (33.3%) at the 300 &#956;g dose, 14/19 (73.7%) at the 900 &#956;g dose and 6/6 (100%) at the 1800 &#956;g dose, with no episode reported with placebo. ISRs were mild to moderate in severity except in two cases in which the reactions were rated as severe due to the magnitude of the area of redness; in all cases the reactions were self-limiting. Headache was more commonly observed at the 900 and 1800 &#956;g dose levels (4/19 participants (21.1%) and 3/6 participants (50%), respectively), compared to the 300 &#956;g dose and concurrent placebo subcohorts, in which no episode occurred. In cohort 2, all participants on active and placebo treatment reported TEAEs that were mostly mild or moderate in severity. One SAE was observed on placebo treatment. The commonest adverse events occurring in a dose dependent manner in the active treatment arms and not on placebo were ISRs, being reported in 1/6 participants (16.7%) in the 15 &#956;g dose group and in 2/6 participants (33.3%) in the 60 &#956;g dose group. There were no clinically meaningful changes in vital signs, ECGs, haematology, biochemistry, and urinalysis parameters during the study. Elevations of anti-dsDNA antibody titres (&gt;15 IU/mL) were observed in 2/6 (33.3%), 10/19 (52.6%), and 2/6 (33.3%) participants treated with ACI-35.030 300 &#956;g, 900 &#956;g, and 1800 &#956;g, respectively, when measured using a standard enzyme-linked immunoassay. When measured using a more specific Farr radioimmunoassay, the titres were slightly and transiently above the normal range in two participants treated with ACI-35.030 900 &#956;g during the follow-up period, without any related symptoms. No ANA titres were above the 1:160 threshold, except transiently at week 67 in one participant, in whom the Farr assay was normal. No clinically relevant MRI changes or new lesions on MRI scans were observed. In cohort 1, two asymptomatic incidental microhaemorrhages (ARIA-H) were detected in one participant treated with ACI-35.030 900 &#956;g at week 74, while in cohort 2, two new asymptomatic microhaemorrhages were noted in two participants, i.e., one treated with JACI-35.054 60 &#956;g at week 50 and the second one on placebo at week 74. The lists of SAEs and of most frequent TEAEs reported in &#8805;20% of participants per group are reported in <xref rid="tbl3" ref-type="table">Tables 3</xref> and <xref rid="tbl4" ref-type="table">4</xref>. T-cell activation and inflammatory cytokines were not measured in the absence of related safety concerns. Overall, no clinically relevant safety and tolerability observations were reported at any doses in participants exposed to the two active immunotherapies. Immunogenicity of the active immunotherapies was assessed using three parameters: the antibody response to the immunogen, i.e., anti-pTau peptide IgG titres, the development of antibodies to brain-derived pathological Tau, i.e., anti-ePHF IgG titres, and the response to the non-phosphorylated version of the immunogen, here designated as anti-Tau IgG titres. Geometric means of the anti-pTau, anti-ePHF, and anti-Tau IgG responses with the two active immunotherapies are presented in <xref rid="fig2" ref-type="fig">Fig. 2</xref>. Tabulations of corresponding fold-changes from baseline for anti-pTau (<xref rid="appsec1" ref-type="sec">Table S1</xref>), anti-ePHF (<xref rid="appsec1" ref-type="sec">Table S2</xref>), and anti-Tau IgG (<xref rid="appsec1" ref-type="sec">Table S3</xref>), and responder rates (based on analytical thresholds for the respective assays) for the same parameters (<xref rid="appsec1" ref-type="sec">Tables S4&#8211;S6</xref>, respectively) are provided in the <xref rid="appsec1" ref-type="sec">Supplementary Material</xref>. For the immunogen, anti-pTau IgG responses were observed after the first injection of ACI-35.030. All participants at all dose-levels were considered anti-pTau IgG responders at 2 weeks post treatment, and these rates were maintained between 94 and 100% until week 74 in the two high-dose cohorts. The transient decrease in responder rates observed with the low 300 &#956;g dose at weeks 36 and 48 is likely explained by the absence of study drug administration at week 24 in 5/6 Finnish participants due to the Covid-19 pandemic. With JACI-35.054, a 100% anti-pTau IgG response was observed after the second injection at week 10 with both dose levels and was maintained until study end. Four participants from the pooled placebo group had anti-pTau IgG titres slightly above the responder threshold at sporadic timepoints due to some variability inherent to the assay. The majority of participants (66.7%&#8211;73.7%) generated an anti-ePHF IgG response against brain-derived pathological Tau after the first administration of ACI-35.030, observed at all doses at week 2. With additional treatments, the anti-ePHF IgG levels increased with responder rates ranging from 25% to 100% across the different dose-levels. The anti-ePHF IgG titres increased in all active groups after each injection with a slower rate of decline between dosing intervals than was observed with anti-pTau IgG titres. In particular, the responder rate at the mid-dose of 900 &#956;g ranged from 70.6% to 94.7% at any timepoints until study end. For JACI-35.054, two administrations were required to observe a robust responder rate of anti-ePHF IgG titres ranging from 50% to 100% up to study end at both doses. Anti-ePHF IgG titres increased after each following administration in both JACI-35.054 treatment groups, with a subsequent consistent rate of decline after each consecutive immunisation. No apparent dose effect was observed between the two doses. No rise of anti-ePHF IgG titres was observed with placebo. Overall, the 900 &#956;g dose of ACI-35.030 demonstrated a stronger and earlier (73.7% responder rate at week 2), more stable and sustained capacity (responder rate was constantly above 70% at all time points) to evolve the antibody response over time toward the endogenous pathological Tau (ePHF) present in the brain of participants with AD. A key element to compare and appreciate the value of immunotherapies was to also evaluate the level of the antibody response generated to the non-pathological form of Tau. While such anti-Tau IgG were observed with ACI-35.030 at week 2 in all active dose groups, these titres quickly decreased and were not maintained, nor boosted, with additional treatments in any ACI-35.030 treatment group. In contrast, with JACI-35.054, such anti-Tau IgG were measured after the second treatment at week 10 and found to have increased after each subsequent administration at either dose level, especially the low dose. Furthermore, the anti-Tau IgG responder rates were maintained at 100% in both JACI-35.054 doses at all measured timepoints from week 10 to 74. No increase of anti-Tau IgG titres and no responders were observed with placebo. Taken together, these results differentiate the two active immunotherapies, as ACI-35.030 demonstrated the ability to evolve the antibody response away from the non-phosphorylated Tau and to maintain the preference of the antibody repertoire toward binding the phosphorylated Tau species. Another differentiating feature between these active immunotherapies was the induction of anti-pTau IgM titres. While anti-pTau IgM responses were observed after the first injection of ACI-35.030, no noteworthy absolute values over time in anti-pTau IgM titres were observed with JACI-35.054 throughout the study (<xref rid="appsec1" ref-type="sec">Supplementary Material, Figures S1 and S2</xref>, respectively). The profile of the anti-pTau IgM titres post ACI-35.030 were consistent, demonstrating a slight increase after each subsequent injection in the active treatment groups, yet an overall decrease in IgM titres over the study. The antibody response against other study drug components, specifically CRM and T50, can be found in the <xref rid="appsec1" ref-type="sec">Supplementary Material</xref> (<xref rid="appsec1" ref-type="sec">Figures S3 and S4</xref>, respectively). A panel of exploratory fluid biomarkers (plasma and CSF biomarkers), clinical assessments, as well as volumetric MRI analyses were performed, although the study was not powered to detect statistical changes of the different treatment groups or placebo (<xref rid="appsec1" ref-type="sec">Supplementary Material, Figures S5&#8211;S20</xref>, inclusively for plasma fluid biomarkers; <xref rid="appsec1" ref-type="sec">Figures S21&#8211;S40</xref>, inclusively for CSF fluid biomarkers; <xref rid="appsec1" ref-type="sec">Figures S41&#8211;S50</xref>, <xref rid="appsec1" ref-type="sec">Table S7</xref> for C-SSRS, inclusively for clinical assessments and <xref rid="appsec1" ref-type="sec">Figures S51&#8211;S56</xref>, inclusively for volumetric MRI analyses). Of these exploratory endpoints, plasma levels of brain-derived (BD)-Tau, a recently identified biomarker that selectively binds to CNS tau isoforms, and pTau217, which has demonstrated specific detection of AD-associated amyloid and tau pathology, provided further data that differentiated the two active immunotherapies (<xref rid="fig3" ref-type="fig">Fig. 3</xref>).<xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref> A post-hoc analysis showed that the change from baseline of BD-Tau plasma levels with ACI-35.030 treatment, when compared to the corresponding changes from baseline for the pooled placebo group, reached nominal significance at weeks 50, 67, and 74 for the 900 &#956;g dose and at weeks 42, 67, and 74 for the 1800 &#956;g dose (<xref rid="fig3" ref-type="fig">Fig. 3</xref> and <xref rid="tbl5" ref-type="table">Table 5</xref>). In contrast, treatment with JACI-35.054 compared to placebo reached significance only at the higher dose and only at one time point, i.e., week 20. For plasma pTau217, post-hoc analysis of the change from baseline with ACI-35.030 treatment, when compared to the corresponding change from baseline for the pooled placebo group, was nominally significant at weeks 31, 36, and 74 for the 900 &#956;g dose and 10, 15, and 36 for the 1800 &#956;g dose (<xref rid="fig3" ref-type="fig">Fig. 3</xref> and <xref rid="tbl6" ref-type="table">Table 6</xref>). Again, in contrast, treatment with JACI-35.054 reached significance for a decrease in plasma pTau217 only at the higher dose and at only at one time point, i.e., week 10. For the other plasma biomarkers (i.e., pTau181, Amyloid-beta 1-42, 1-40 and 1-42/1-40 ratio, NfL, GFAP, YKL-40), as well as CSF biomarkers (i.e., pTau181, pTau217, Tau, Amyloid-beta 1-42, 1-40 and 1-42/1-40 ratio, NfL, GFAP, YKL-40, neurogranin), no consistent differences were observed with ACI-35.030 and JACI-35.054, as compared to placebo, except for a dose-independent increase of plasma pTau181 observed with the latter (<xref rid="appsec1" ref-type="sec">Supplemental Material, Figures S5 and S6</xref>). A higher rate of whole brain volume loss and ventricular volume increase compared to placebo was observed at the 1800 &#956;g dose of ACI-35.030 (<xref rid="appsec1" ref-type="sec">Supplemental Material, Figures S51 and S55</xref>, respectively). Numerically greater hippocampal volume loss compared to placebo was observed only at 900 &#956;g of ACI-35.030 and 60 &#956;g dose of JACI-35.054 but with error bars overlapping with those on placebo (<xref rid="appsec1" ref-type="sec">Supplemental Material, Figures S53 and S54</xref>, respectively). Given the low power for these endpoints, no conclusions regarding effects on brain volume can be drawn. As anticipated, based on the limited number of participants, the clinical exploratory endpoints did not reveal particular differences in CDR-SB, CDR global score, RBANS or NPI scores across the different study groups (<xref rid="appsec1" ref-type="sec">Supplemental Material, Figures S41 and S42</xref> for CDR-SB; <xref rid="appsec1" ref-type="sec">Figures S43 and S44</xref> for CDR global score; <xref rid="appsec1" ref-type="sec">Figures S45&#8211;S48</xref> for RBANS; and <xref rid="appsec1" ref-type="sec">Figures S49 and S50</xref> for NPI). Likewise, no notable differences were evident in the C-SSRS, specifically in the frequency of suicidal ideation and whether or not subjects exhibited suicidal behaviour across study groups (<xref rid="appsec1" ref-type="sec">Supplemental Material, Table S7</xref>).<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p><bold>Trial profile.</bold><sup>1</sup>A participant was considered to have completed the study treatment if he or she had reached the end of the treatment period (Visit 9 Week 50) and had received all planned injections (4 successive IM immunisations with IP). <sup>2</sup>A participant was considered to have not completed the study treatment if he or she had reached the end of the treatment period (Visit 9 Week 50) and had not received all planned IP injections. <sup>3</sup>Participants discontinuing study due to participant withdrawal are the same participants who discontinued IP. <sup>4</sup>A participant was considered to have completed the study if he or she had completed the safety follow-up period. eCRF = electronic case report form; IM = intramuscular; IP = investigational product.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Demographic and baseline characteristics (intention-to-treat population).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="6" rowspan="1">Cohort 1 with ACI-35.030<hr/></th></tr><tr><th colspan="1" rowspan="1">Characteristic</th><th colspan="1" rowspan="1">ACI-35.030 300 &#956;g (N = 6)</th><th colspan="1" rowspan="1">ACI-35.030 900 &#956;g (N = 19)</th><th colspan="1" rowspan="1">ACI-35.030 1800 &#956;g (N = 6)</th><th colspan="1" rowspan="1">Cohort 1 placebo (N = 10)</th><th colspan="1" rowspan="1">Total (N = 41)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Sex [n (%)]</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td colspan="1" rowspan="1">4 (66.7)</td><td colspan="1" rowspan="1">9 (47.4)</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">5 (50.0)</td><td colspan="1" rowspan="1">20 (48.8)</td></tr><tr><td colspan="1" rowspan="1">&#160;Male</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">10 (52.6)</td><td colspan="1" rowspan="1">4 (66.7)</td><td colspan="1" rowspan="1">5 (50.0)</td><td colspan="1" rowspan="1">21 (51.2)</td></tr><tr><td colspan="1" rowspan="1">Race [n (%)]</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;White</td><td colspan="1" rowspan="1">6 (100)</td><td colspan="1" rowspan="1">19 (100)</td><td colspan="1" rowspan="1">6 (100)</td><td colspan="1" rowspan="1">10 (100)</td><td colspan="1" rowspan="1">41 (100)</td></tr><tr><td colspan="1" rowspan="1">Age (years)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;n</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">41</td></tr><tr><td colspan="1" rowspan="1">&#160;Mean (SD)</td><td colspan="1" rowspan="1">65.5 (5.01)</td><td colspan="1" rowspan="1">68.0 (6.29)</td><td colspan="1" rowspan="1">64.7 (4.63)</td><td colspan="1" rowspan="1">67.7 (4.60)</td><td colspan="1" rowspan="1">67.1 (5.49)</td></tr><tr><td colspan="1" rowspan="1">&#160;Median (min, max)</td><td colspan="1" rowspan="1">64.5 (61, 75)</td><td colspan="1" rowspan="1">71.0 (51, 75)</td><td colspan="1" rowspan="1">66.5 (56, 68)</td><td colspan="1" rowspan="1">69.0 (60, 75)</td><td colspan="1" rowspan="1">67.0 (51, 75)</td></tr><tr><td colspan="1" rowspan="1">&#160;Q1, Q3</td><td colspan="1" rowspan="1">62.0, 66.0</td><td colspan="1" rowspan="1">63.0, 73.0</td><td colspan="1" rowspan="1">63.0, 68.0</td><td colspan="1" rowspan="1">66.0, 70.0</td><td colspan="1" rowspan="1">63.0, 71.0</td></tr><tr><td colspan="1" rowspan="1">BMI (kg/m<sup>2</sup>)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;n</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">41</td></tr><tr><td colspan="1" rowspan="1">&#160;Mean (SD)</td><td colspan="1" rowspan="1">26.4 (3.08)</td><td colspan="1" rowspan="1">24.6 (3.46)</td><td colspan="1" rowspan="1">27.8 (7.08)</td><td colspan="1" rowspan="1">25.1 (2.25)</td><td colspan="1" rowspan="1">25.5 (3.91)</td></tr><tr><td colspan="1" rowspan="1">&#160;Median (min, max)</td><td colspan="1" rowspan="1">26.8 (22, 30)</td><td colspan="1" rowspan="1">24.3 (19, 35)</td><td colspan="1" rowspan="1">25.8 (22, 40)</td><td colspan="1" rowspan="1">25.0 (22, 30)</td><td colspan="1" rowspan="1">24.7 (19, 40)</td></tr><tr><td colspan="1" rowspan="1">&#160;Q1, Q3</td><td colspan="1" rowspan="1">24.0, 28.7</td><td colspan="1" rowspan="1">22.1, 26.1</td><td colspan="1" rowspan="1">22.3, 31.1</td><td colspan="1" rowspan="1">24.2, 26.0</td><td colspan="1" rowspan="1">23.1, 26.8</td></tr><tr><td colspan="1" rowspan="1">Time since initial diagnosis of AD (years)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;n</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">41</td></tr><tr><td colspan="1" rowspan="1">&#160;Mean (SD)</td><td colspan="1" rowspan="1">1.2 (0.98)</td><td colspan="1" rowspan="1">1.2 (0.71)</td><td colspan="1" rowspan="1">2.0 (1.10)</td><td colspan="1" rowspan="1">1.9 (2.42)</td><td colspan="1" rowspan="1">1.5 (1.40)</td></tr><tr><td colspan="1" rowspan="1">&#160;Median (min, max)</td><td colspan="1" rowspan="1">1.5 (0, 2)</td><td colspan="1" rowspan="1">1.0 (0, 3)</td><td colspan="1" rowspan="1">2.0 (1, 4)</td><td colspan="1" rowspan="1">1.0 (0, 8)</td><td colspan="1" rowspan="1">1.0 (0, 8)</td></tr><tr><td colspan="1" rowspan="1">&#160;Q1, Q3</td><td colspan="1" rowspan="1">0.0, 2.0</td><td colspan="1" rowspan="1">1.0, 2.0</td><td colspan="1" rowspan="1">1.0, 2.0</td><td colspan="1" rowspan="1">1.0, 2.0</td><td colspan="1" rowspan="1">1.0, 2.0</td></tr><tr><td colspan="1" rowspan="1">MMSE<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;n</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">41</td></tr><tr><td colspan="1" rowspan="1">&#160;Mean (SD)</td><td colspan="1" rowspan="1">27.5 (0.84)</td><td colspan="1" rowspan="1">26.1 (2.02)</td><td colspan="1" rowspan="1">26.0 (2.68)</td><td colspan="1" rowspan="1">26.1 (3.11)</td><td colspan="1" rowspan="1">26.3 (2.29)</td></tr><tr><td colspan="1" rowspan="1">&#160;Median (min, max)</td><td colspan="1" rowspan="1">27.0 (27, 29)</td><td colspan="1" rowspan="1">26.0 (22, 29)</td><td colspan="1" rowspan="1">26.0 (23, 29)</td><td colspan="1" rowspan="1">26.0 (22, 30)</td><td colspan="1" rowspan="1">27.0 (22, 30)</td></tr><tr><td colspan="1" rowspan="1">&#160;Q1, Q3</td><td colspan="1" rowspan="1">27.0, 28.0</td><td colspan="1" rowspan="1">25.0, 28.0</td><td colspan="1" rowspan="1">23.0, 29.0</td><td colspan="1" rowspan="1">23.0, 29.0</td><td colspan="1" rowspan="1">25.0, 28.0</td></tr><tr><td colspan="1" rowspan="1">CDR baseline global score [n (%)]</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;0.5</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">17 (89.5)</td><td colspan="1" rowspan="1">5 (83.3)</td><td colspan="1" rowspan="1">7 (70.0)</td><td colspan="1" rowspan="1">29 (70.7)</td></tr><tr><td colspan="1" rowspan="1">&#160;1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2 (10.5)</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">1 (10.0)</td><td colspan="1" rowspan="1">4 (9.8)</td></tr><tr><td colspan="1" rowspan="1">&#160;Missing<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td colspan="1" rowspan="1">6 (100)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2 (20.0)</td><td colspan="1" rowspan="1">8 (19.5)</td></tr><tr><td colspan="1" rowspan="1">Number (%) of participants with any prior concomitant medications [n (%)]</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Acetylcholinesterase inhibitors</td><td colspan="1" rowspan="1">5 (83.3)</td><td colspan="1" rowspan="1">9 (47.4)</td><td colspan="1" rowspan="1">3 (50.0)</td><td colspan="1" rowspan="1">5 (50.0)</td><td colspan="1" rowspan="1">22 (53.7)</td></tr><tr><td colspan="1" rowspan="1">&#160;Memantine</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">1 (10.0)</td><td colspan="1" rowspan="1">3 (7.3)</td></tr><tr><td colspan="1" rowspan="1">&#160;Acetylcholinesterase inhibitors and memantine</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">4 (21.1)</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">2 (20.0)</td><td colspan="1" rowspan="1">7 (17.1)</td></tr><tr><td colspan="1" rowspan="1">&#160;Neither acetylcholinesterase inhibitors nor memantine</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">5 (26.3)</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">2 (20.0)</td><td colspan="1" rowspan="1">9 (22.0)</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">APOE</italic> genotype at screening</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;E2/E3</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2 (4.9)</td></tr><tr><td colspan="1" rowspan="1">&#160;E3/E3</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">5 (26.3)</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">3 (30.0)</td><td colspan="1" rowspan="1">11 (26.8)</td></tr><tr><td colspan="1" rowspan="1">&#160;E3/E4</td><td colspan="1" rowspan="1">3 (50.0)</td><td colspan="1" rowspan="1">8 (42.1)</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">1 (10.0)</td><td colspan="1" rowspan="1">14 (34.1)</td></tr><tr><td colspan="1" rowspan="1">&#160;E4/E4</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">5 (26.3)</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">6 (60.0)</td><td colspan="1" rowspan="1">13 (31.7)</td></tr><tr><td colspan="1" rowspan="1">&#160;Missing</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="5" rowspan="1">Cohort 2 with JACI-35.054<hr/></th></tr><tr><th colspan="1" rowspan="1">Characteristic</th><th colspan="1" rowspan="1">JACI-35.054 15 &#956;g (N = 6)</th><th colspan="1" rowspan="1">JACI-35.054 60 &#956;g (N = 6)</th><th colspan="1" rowspan="1">Cohort 2 placebo (N = 4)</th><th colspan="1" rowspan="1">Total (N = 16)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Sex [n (%)]</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td colspan="1" rowspan="1">3 (50.0)</td><td colspan="1" rowspan="1">3 (50.0)</td><td colspan="1" rowspan="1">4 (100)</td><td colspan="1" rowspan="1">10 (62.5)</td></tr><tr><td colspan="1" rowspan="1">&#160;Male</td><td colspan="1" rowspan="1">3 (50.0)</td><td colspan="1" rowspan="1">3 (50.0)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">6 (37.5)</td></tr><tr><td colspan="1" rowspan="1">Race [n (%)]</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;White</td><td colspan="1" rowspan="1">6 (100)</td><td colspan="1" rowspan="1">6 (100)</td><td colspan="1" rowspan="1">4 (100)</td><td colspan="1" rowspan="1">16 (100)</td></tr><tr><td colspan="1" rowspan="1">Age (years)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;n</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">16</td></tr><tr><td colspan="1" rowspan="1">&#160;Mean (SD)</td><td colspan="1" rowspan="1">66.7 (6.22)</td><td colspan="1" rowspan="1">63.0 (4.77)</td><td colspan="1" rowspan="1">68.0 (6.16)</td><td colspan="1" rowspan="1">65.6 (5.73)</td></tr><tr><td colspan="1" rowspan="1">&#160;Median (min, max)</td><td colspan="1" rowspan="1">67.0 (56, 73)</td><td colspan="1" rowspan="1">62.0 (58, 72)</td><td colspan="1" rowspan="1">68.5 (60, 75)</td><td colspan="1" rowspan="1">65.0 (56, 75)</td></tr><tr><td colspan="1" rowspan="1">&#160;Q1, Q3</td><td colspan="1" rowspan="1">65.0, 72.0</td><td colspan="1" rowspan="1">61.1, 63.0</td><td colspan="1" rowspan="1">64.0, 72.0</td><td colspan="1" rowspan="1">61.1, 70.5</td></tr><tr><td colspan="1" rowspan="1">BMI (kg/m<sup>2</sup>)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;n</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">16</td></tr><tr><td colspan="1" rowspan="1">&#160;Mean (SD)</td><td colspan="1" rowspan="1">23.2 (3.75)</td><td colspan="1" rowspan="1">26.6 (4.35)</td><td colspan="1" rowspan="1">25.4 (4.31)</td><td colspan="1" rowspan="1">25.0 (4.15)</td></tr><tr><td colspan="1" rowspan="1">&#160;Median (min, max)</td><td colspan="1" rowspan="1">23.4 (19, 28)</td><td colspan="1" rowspan="1">26.5 (21, 32)</td><td colspan="1" rowspan="1">26.2 (20, 30)</td><td colspan="1" rowspan="1">25.6 (19, 32)</td></tr><tr><td colspan="1" rowspan="1">&#160;Q1, Q3</td><td colspan="1" rowspan="1">19.0, 25.8</td><td colspan="1" rowspan="1">22.3, 31.1</td><td colspan="1" rowspan="1">22.4, 28.4</td><td colspan="1" rowspan="1">21.8, 27.6</td></tr><tr><td colspan="1" rowspan="1">Time since initial diagnosis of AD (years)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;n</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">16</td></tr><tr><td colspan="1" rowspan="1">&#160;Mean (SD)</td><td colspan="1" rowspan="1">0.7 (0.82)</td><td colspan="1" rowspan="1">3.0 (4.05)</td><td colspan="1" rowspan="1">2.3 (3.20)</td><td colspan="1" rowspan="1">1.9 (2.98)</td></tr><tr><td colspan="1" rowspan="1">&#160;Median (min, max)</td><td colspan="1" rowspan="1">0.5 (0, 2)</td><td colspan="1" rowspan="1">1.5 (0, 11)</td><td colspan="1" rowspan="1">1.0 (0, 7)</td><td colspan="1" rowspan="1">1.0 (0, 11)</td></tr><tr><td colspan="1" rowspan="1">&#160;Q1, Q3</td><td colspan="1" rowspan="1">0.0, 1.0</td><td colspan="1" rowspan="1">1.0, 3.0</td><td colspan="1" rowspan="1">0.6, 4.0</td><td colspan="1" rowspan="1">0.0, 2.0</td></tr><tr><td colspan="1" rowspan="1">MMSE<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;n</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">16</td></tr><tr><td colspan="1" rowspan="1">&#160;Mean (SD)</td><td colspan="1" rowspan="1">28.0 (1.55)</td><td colspan="1" rowspan="1">25.7 (3.61)</td><td colspan="1" rowspan="1">24.5 (2.52)</td><td colspan="1" rowspan="1">26.3 (2.93)</td></tr><tr><td colspan="1" rowspan="1">&#160;Median (min, max)</td><td colspan="1" rowspan="1">28.0 (26, 30)</td><td colspan="1" rowspan="1">24.5 (22, 30)</td><td colspan="1" rowspan="1">24.0 (22, 28)</td><td colspan="1" rowspan="1">26.5 (22, 30)</td></tr><tr><td colspan="1" rowspan="1">&#160;Q1, Q3</td><td colspan="1" rowspan="1">27.0, 29.0</td><td colspan="1" rowspan="1">23.0, 30.0</td><td colspan="1" rowspan="1">23.0, 26.0</td><td colspan="1" rowspan="1">23.5, 29.0</td></tr><tr><td colspan="1" rowspan="1">CDR baseline global score [n (%)]</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;0.5</td><td colspan="1" rowspan="1">6 (100)</td><td colspan="1" rowspan="1">5 (83.3)</td><td colspan="1" rowspan="1">3 (75.0)</td><td colspan="1" rowspan="1">14 (87.5)</td></tr><tr><td colspan="1" rowspan="1">&#160;1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">1 (25.0)</td><td colspan="1" rowspan="1">2 (12.5)</td></tr><tr><td colspan="1" rowspan="1">&#160;Missing</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Number (%) of participants with any prior concomitant medications [n (%)]</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Acetylcholinesterase inhibitors</td><td colspan="1" rowspan="1">3 (50.0)</td><td colspan="1" rowspan="1">4 (66.7)</td><td colspan="1" rowspan="1">2 (50.0)</td><td colspan="1" rowspan="1">9 (56.3)</td></tr><tr><td colspan="1" rowspan="1">&#160;Memantine</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">1 (25.0)</td><td colspan="1" rowspan="1">2 (12.5)</td></tr><tr><td colspan="1" rowspan="1">&#160;Acetylcholinesterase inhibitors and memantine</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (25.0)</td><td colspan="1" rowspan="1">1 (6.3)</td></tr><tr><td colspan="1" rowspan="1">&#160;Neither acetylcholinesterase inhibitors nor memantine</td><td colspan="1" rowspan="1">3 (50.0)</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">4 (25.0)</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">APOE</italic> genotype at screening</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;E3/E4</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">2 (50.0)</td><td colspan="1" rowspan="1">6 (37.5)</td></tr><tr><td colspan="1" rowspan="1">&#160;E4/E4</td><td colspan="1" rowspan="1">3 (50.0)</td><td colspan="1" rowspan="1">4 (66.7)</td><td colspan="1" rowspan="1">2 (50.0)</td><td colspan="1" rowspan="1">9 (56.3)</td></tr><tr><td colspan="1" rowspan="1">&#160;Missing</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (6.3)</td></tr></tbody></table><table-wrap-foot><fn><p>APOE = apolipoprotein E gene; BMI = body mass index; n = number of participants; Q1/Q3 = first/third quartile; SD = standard deviation.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fna"><label>a</label><p id="ntpara0010">CDR global score was evaluated at screening but recorded in the database only after the corresponding protocol amendment implementation. All 6 participants on ACI-35.030 300 &#956;g (subcohort 1.1) had a CDR Global score of 0.5, while the 2 placebo participants from that sub-cohort had CDR global scores of 0.5 and 1, respectively.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnb"><label>b</label><p id="ntpara0011">MMSE is presented as the total score.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>Serious treatment-emergent adverse events by system organ class and preferred term (safety population).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="7" rowspan="1">Cohort 1 with ACI-35.030<hr/></th></tr><tr><th colspan="1" rowspan="1">SOC<break/>PT [n (%)]</th><th colspan="1" rowspan="1">ACI-35.030 300 &#956;g (N = 6)</th><th colspan="1" rowspan="1">ACI-35.030 900 &#956;g (N = 19)</th><th colspan="1" rowspan="1">ACI-35.030 1800 &#956;g (N = 6)</th><th colspan="1" rowspan="1">Cohort 1 placebo (N = 10)</th><th colspan="1" rowspan="1">Pooled placebo (N = 14)</th><th colspan="1" rowspan="1">Total (N = 41)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Any serious TEAEs</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">2 (10.5)</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (7.1)</td><td colspan="1" rowspan="1">6 (14.6)</td></tr><tr><td colspan="1" rowspan="1">Infections and infestations</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2 (4.9)</td></tr><tr><td colspan="1" rowspan="1">&#160;Diverticulitis</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">&#160;Hemorrhagic fever with renal syndrome</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">Cardiac disorders</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">&#160;Sinus node dysfunction</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">Gastrointestinal disorders</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">&#160;Diverticulum</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">General disorders and administration site conditions</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">&#160;Injection site rash</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">Injury, poisoning, and procedural complications</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">&#160;Post-traumatic pain</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">Nervous system disorders</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">&#160;Dizziness</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (5.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">Vascular disorders</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">&#160;Aneurysm thrombosis</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">&#160;Peripheral artery aneurysm</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (2.4)</td></tr><tr><td colspan="1" rowspan="1">Musculoskeletal and connective tissue disorders</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (7.1)</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">&#160;Intervertebral disc protrusion</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (7.1)</td><td colspan="1" rowspan="1">0</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="6" rowspan="1">Cohort 2 with JACI-35.054<hr/></th></tr><tr><th colspan="1" rowspan="1">SOC<break/>PT [n (%)]</th><th colspan="1" rowspan="1">JACI-35.054 15 &#956;g (N = 6)</th><th colspan="1" rowspan="1">JACI-35.054 60 &#956;g (N = 6)</th><th colspan="1" rowspan="1">Cohort 2 placebo (N = 4)</th><th colspan="1" rowspan="1">Pooled placebo (N = 14)</th><th colspan="1" rowspan="1">Total (N = 16)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Any serious TEAEs</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (25.0)</td><td colspan="1" rowspan="1">1 (7.1)</td><td colspan="1" rowspan="1">1 (6.3)</td></tr><tr><td colspan="1" rowspan="1">Musculoskeletal and connective tissue disorders</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (25.0)</td><td colspan="1" rowspan="1">1 (7.1)</td><td colspan="1" rowspan="1">1 (6.3)</td></tr><tr><td colspan="1" rowspan="1">&#160;Intervertebral disc protrusion</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (25.0)</td><td colspan="1" rowspan="1">1 (7.1)</td><td colspan="1" rowspan="1">1 (6.3)</td></tr></tbody></table><table-wrap-foot><fn id="tspara0035"><p>n = Number of participants; PT = preferred term; SOC = system organ class.</p></fn><fn id="tspara0040"><p>For each SOC and PT, participants are included only once.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl4" orientation="portrait"><label>Table 4</label><caption><p>Most frequent (&#8805;20% of the participants in any active treatment group) treatment-emergent adverse events by preferred term (safety population).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="7" rowspan="1">Cohort 1 with ACI-35.030<hr/></th></tr><tr><th colspan="1" rowspan="1">PT [n (%)]</th><th colspan="1" rowspan="1">ACI-35.030 300 &#956;g (N = 6)</th><th colspan="1" rowspan="1">ACI-35.030 900 &#956;g (N = 19)</th><th colspan="1" rowspan="1">ACI-35.030 1800 &#956;g (N = 6)</th><th colspan="1" rowspan="1">Cohort 1 placebo (N = 10)</th><th colspan="1" rowspan="1">Pooled placebo (N = 14)</th><th colspan="1" rowspan="1">Total (N = 41)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Injection site reaction</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">14 (73.7)</td><td colspan="1" rowspan="1">6 (100.0)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">22 (53.7)</td></tr><tr><td colspan="1" rowspan="1">COVID-19</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">7 (36.8)</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">3 (30.0)</td><td colspan="1" rowspan="1">4 (28.6)</td><td colspan="1" rowspan="1">12 (29.3)</td></tr><tr><td colspan="1" rowspan="1">Fatigue</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">4 (21.1)</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">2 (20.0)</td><td colspan="1" rowspan="1">2 (14.3)</td><td colspan="1" rowspan="1">7 (17.1)</td></tr><tr><td colspan="1" rowspan="1">Headache</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">4 (21.1)</td><td colspan="1" rowspan="1">3 (50.0)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1 (7.1)</td><td colspan="1" rowspan="1">7 (17.1)</td></tr><tr><td colspan="1" rowspan="1">Nasopharyngitis</td><td colspan="1" rowspan="1">3 (50.0)</td><td colspan="1" rowspan="1">2 (10.5)</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">1 (10.0)</td><td colspan="1" rowspan="1">2 (14.3)</td><td colspan="1" rowspan="1">7 (17.1)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="6" rowspan="1">Cohort 2 with JACI-35.054<hr/></th></tr><tr><th colspan="1" rowspan="1">PT [n (%)]</th><th colspan="1" rowspan="1">JACI-35.054 15 &#956;g (N = 6)</th><th colspan="1" rowspan="1">JACI-35.054 60 &#956;g (N = 6)</th><th colspan="1" rowspan="1">Cohort 2 placebo (N = 4)</th><th colspan="1" rowspan="1">Pooled placebo (N = 14)</th><th colspan="1" rowspan="1">Total (N = 16)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Headache</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">1 (25.0)</td><td colspan="1" rowspan="1">1 (7.1)</td><td colspan="1" rowspan="1">4 (25.0)</td></tr><tr><td colspan="1" rowspan="1">Injection site reaction</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">3 (18.8)</td></tr><tr><td colspan="1" rowspan="1">Malaise</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">1 (16.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">3 (18.8)</td></tr><tr><td colspan="1" rowspan="1">Pyrexia</td><td colspan="1" rowspan="1">3 (50.0)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">3 (18.8)</td></tr><tr><td colspan="1" rowspan="1">Epistaxis</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2 (12.5)</td></tr><tr><td colspan="1" rowspan="1">Myalgia</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2 (12.5)</td></tr><tr><td colspan="1" rowspan="1">Ventricular extrasystoles</td><td colspan="1" rowspan="1">2 (33.3)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2 (12.5)</td></tr></tbody></table><table-wrap-foot><fn id="tspara0050"><p>n = number of participants; PT = preferred term.</p></fn><fn id="tspara0055"><p>For each PT, participants are included only once.</p></fn></table-wrap-foot></table-wrap><fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>Geometric mean of the anti-pTau, anti-ePHF, and anti-Tau IgG responses with active immunotherapies.</bold> Plots of the geometric mean of anti-pTau (<bold>a, b</bold>), anti-ePHF (<bold>c, d</bold>), and anti-Tau IgG (<bold>e, f</bold>) responses versus nominal study visit time (in weeks) for active immunotherapy with ACI-35.030 (<bold>a, c, e</bold>) or JACI-35.054 (<bold>b, d, f</bold>). Error bars denote standard errors of the geometric means. Geometric means and standard errors are plotted by study arm and nominal study visit time. Sample sizes for plotted geometric means and standard errors are tabulated below each graph. The four vertical arrows at the top of each graph denote nominal study visit times for administration of ACI-35.030 or JACI-35.054.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig><fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><bold>Arithmetic mean change from baseline of plasma pTau217 and plasma brain derived (BD) Tau with active immunotherapy.</bold> Plots of the mean change from baseline of plasma pTau217 (<bold>a, b</bold>) and plasma brain derived (BD) Tau (<bold>c, d</bold>) concentrations (pg/mL) versus nominal study visit time (in weeks) for active immunotherapy with ACI-35.030 (<bold>a, c</bold>) or JACI-35.054 (<bold>b, d</bold>). Error bars denote standard errors of the means. Means and standard errors are plotted by study arm and nominal study visit time. Sample sizes for plotted means and standard errors are tabulated below each graph. Stars denote a statistically significant (p &lt; 0.05) difference from placebo group based on the post-hoc statistical analysis (Linear Mixed Model analysis, contrasts using Satterthwaite's degrees of freedom; see <xref rid="appsec1" ref-type="sec">Supplementary Material</xref> for full details). The four vertical arrows at the top of each graph denote nominal study visit times for administration of ACI-35.030 or JACI-35.054.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig><table-wrap position="float" id="tbl5" orientation="portrait"><label>Table 5</label><caption><p>Tabulation of post-hoc statistical analysis results comparing changes from baseline of plasma brain derived (BD) Tau in active treatment study arms (ACI-35.030 or JACI-35.054) versus corresponding changes in the pooled placebo study arm.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Week</th><th colspan="1" rowspan="1">Group</th><th colspan="1" rowspan="1">Change from baseline<break/>LS<xref rid="tbl5fna" ref-type="table-fn">a</xref> mean (95% CI<xref rid="tbl5fnb" ref-type="table-fn">b</xref>)</th><th colspan="1" rowspan="1">Change from baseline<break/>LS mean expressed as % relative to baseline</th><th colspan="1" rowspan="1">Difference from placebo (95% CI)</th><th colspan="1" rowspan="1">p-value<xref rid="tbl5fnc" ref-type="table-fn">c</xref></th></tr></thead><tbody><tr><td rowspan="3" colspan="1">42</td><td colspan="1" rowspan="1">Pooled placebo</td><td align="char" colspan="1" rowspan="1">0.22 (&#8722;0.83 to 1.27)</td><td align="char" colspan="1" rowspan="1">4.0%</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">ACI-35.030 900 &#956;g</td><td align="char" colspan="1" rowspan="1">1.57 (0.62&#8211;2.51)</td><td align="char" colspan="1" rowspan="1">28.5%</td><td align="char" colspan="1" rowspan="1">1.35 (&#8722;0.07 to 2.76)</td><td align="char" colspan="1" rowspan="1">0.0625</td></tr><tr><td colspan="1" rowspan="1">ACI-35.030 1800 &#956;g</td><td align="char" colspan="1" rowspan="1">2.21 (0.77&#8211;3.66)</td><td align="char" colspan="1" rowspan="1">37.3%</td><td align="char" colspan="1" rowspan="1">1.99 (0.20&#8211;3.78)</td><td align="char" colspan="1" rowspan="1">0.0291</td></tr><tr><td rowspan="3" colspan="1">50</td><td colspan="1" rowspan="1">Pooled placebo</td><td align="char" colspan="1" rowspan="1">0.16 (&#8722;0.78 to 1.10)</td><td align="char" colspan="1" rowspan="1">2.9%</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">ACI-35.030 900 &#956;g</td><td align="char" colspan="1" rowspan="1">1.59 (0.77&#8211;2.41)</td><td align="char" colspan="1" rowspan="1">28.8%</td><td align="char" colspan="1" rowspan="1">1.43 (0.18&#8211;2.68)</td><td align="char" colspan="1" rowspan="1">0.0250</td></tr><tr><td colspan="1" rowspan="1">ACI-35.030 1800 &#956;g</td><td align="char" colspan="1" rowspan="1">1.86 (0.33&#8211;3.40)</td><td align="char" colspan="1" rowspan="1">31.4%</td><td align="char" colspan="1" rowspan="1">1.71 (&#8722;0.09 to 3.50)</td><td align="char" colspan="1" rowspan="1">0.0625</td></tr><tr><td rowspan="3" colspan="1">67</td><td colspan="1" rowspan="1">Pooled placebo</td><td align="char" colspan="1" rowspan="1">&#8722;0.00 (&#8722;0.94 to 0.94)</td><td colspan="1" rowspan="1">0%</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">ACI-35.030 900 &#956;g</td><td align="char" colspan="1" rowspan="1">1.36 (0.53&#8211;2.20)</td><td align="char" colspan="1" rowspan="1">24.7%</td><td align="char" colspan="1" rowspan="1">1.37 (0.11&#8211;2.62)</td><td align="char" colspan="1" rowspan="1">0.0332</td></tr><tr><td colspan="1" rowspan="1">ACI-35.030 1800 &#956;g</td><td align="char" colspan="1" rowspan="1">2.16 (0.63&#8211;3.70)</td><td align="char" colspan="1" rowspan="1">36.5%</td><td align="char" colspan="1" rowspan="1">2.17 (0.37&#8211;3.96)</td><td align="char" colspan="1" rowspan="1">0.0183</td></tr><tr><td rowspan="3" colspan="1">74</td><td colspan="1" rowspan="1">Pooled placebo</td><td align="char" colspan="1" rowspan="1">0.45 (&#8722;0.48 to 1.39)</td><td align="char" colspan="1" rowspan="1">8.3%</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">ACI-35.030 900 &#956;g</td><td align="char" colspan="1" rowspan="1">1.98 (1.15&#8211;2.82)</td><td align="char" colspan="1" rowspan="1">35.9%</td><td align="char" colspan="1" rowspan="1">1.53 (0.27&#8211;2.79)</td><td align="char" colspan="1" rowspan="1">0.0175</td></tr><tr><td colspan="1" rowspan="1">ACI-35.030 1800 &#956;g</td><td align="char" colspan="1" rowspan="1">2.31 (0.78&#8211;3.84)</td><td align="char" colspan="1" rowspan="1">30.0%</td><td align="char" colspan="1" rowspan="1">1.86 (0.06&#8211;3.65)</td><td align="char" colspan="1" rowspan="1">0.0430</td></tr><tr><td rowspan="3" colspan="1">20</td><td colspan="1" rowspan="1">Pooled placebo</td><td align="char" colspan="1" rowspan="1">&#8722;0.06 (&#8722;1.39 to 1.26)</td><td align="char" colspan="1" rowspan="1">&#8722;1.1%</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">JACI-35.054 15 &#956;g</td><td colspan="1" rowspan="1">Non estimated</td><td colspan="1" rowspan="1">Non estimated</td><td colspan="1" rowspan="1">Non estimated</td><td colspan="1" rowspan="1">&#8211;</td></tr><tr><td colspan="1" rowspan="1">JACI-35.054 60 &#956;g</td><td align="char" colspan="1" rowspan="1">2.43 (0.78&#8211;4.07)</td><td align="char" colspan="1" rowspan="1">39.8%</td><td align="char" colspan="1" rowspan="1">2.49 (0.37&#8211;4.61)</td><td align="char" colspan="1" rowspan="1">0.0219</td></tr></tbody></table><table-wrap-foot><fn id="tbl5fna"><label>a</label><p id="ntpara0015">Least Squares.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fnb"><label>b</label><p id="ntpara0020">Confidence Interval.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl5fnc"><label>c</label><p id="ntpara0025">Linear Mixed Model with baseline and treatment arm&#8727;visit as fixed factors, participant ID as random factor, Satterthwaite's method for degrees of freedom, uncorrected p-values.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl6" orientation="portrait"><label>Table 6</label><caption><p>Tabulation of post-hoc statistical analysis results comparing changes from baseline of plasma pTau217 in active treatment study arms (ACI-35.030 or JACI-35.054) versus corresponding changes in the pooled placebo study arm.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Week</th><th colspan="1" rowspan="1">Group</th><th colspan="1" rowspan="1">Change from baseline<break/>LS<xref rid="tbl6fna" ref-type="table-fn">a</xref> mean (95% CI<xref rid="tbl6fnb" ref-type="table-fn">b</xref>)</th><th colspan="1" rowspan="1">Change from baseline<break/>LS mean expressed as % relative to baseline</th><th colspan="1" rowspan="1">Difference from placebo (95% CI)</th><th colspan="1" rowspan="1">p-value<xref rid="tbl6fnc" ref-type="table-fn">c</xref></th></tr></thead><tbody><tr><td rowspan="3" colspan="1">10</td><td colspan="1" rowspan="1">Pooled placebo</td><td align="char" colspan="1" rowspan="1">0.0025 (&#8722;0.0155 to 0.0205)</td><td align="char" colspan="1" rowspan="1">2.1%</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">ACI-35.030 900 &#956;g</td><td align="char" colspan="1" rowspan="1">&#8722;0.0173 (&#8722;0.0328 to &#8722;0.0019)</td><td align="char" colspan="1" rowspan="1">&#8722;11.5%</td><td align="char" colspan="1" rowspan="1">&#8722;0.0198 (&#8722;0.0438 to 0.0041)</td><td align="char" colspan="1" rowspan="1">0.1036</td></tr><tr><td colspan="1" rowspan="1">ACI-35.030 1800 &#956;g</td><td align="char" colspan="1" rowspan="1">&#8722;0.0345 (&#8722;0.0652 to &#8722;0.0038)</td><td align="char" colspan="1" rowspan="1">&#8722;18.5%</td><td align="char" colspan="1" rowspan="1">&#8722;0.0370 (&#8722;0.0731 to &#8722;0.0010)</td><td align="char" colspan="1" rowspan="1">0.0443</td></tr><tr><td rowspan="3" colspan="1">15</td><td colspan="1" rowspan="1">Pooled placebo</td><td align="char" colspan="1" rowspan="1">0.0049 (&#8722;0.0162 to 0.0261)</td><td align="char" colspan="1" rowspan="1">4.2%</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">ACI-35.030 900 &#956;g</td><td align="char" colspan="1" rowspan="1">&#8722;0.0206 (&#8722;0.0377 to &#8722;0.0034)</td><td align="char" colspan="1" rowspan="1">&#8722;13.6%</td><td align="char" colspan="1" rowspan="1">&#8722;0.0256 (&#8722;0.0530 to 0.0019)</td><td align="char" colspan="1" rowspan="1">0.0675</td></tr><tr><td colspan="1" rowspan="1">ACI-35.030 1800 &#956;g</td><td align="char" colspan="1" rowspan="1">&#8722;0.0555 (&#8722;0.0879 to &#8722;0.0231)</td><td align="char" colspan="1" rowspan="1">&#8722;29.8%</td><td align="char" colspan="1" rowspan="1">&#8722;0.0605 (&#8722;0.0997 to &#8722;0.0213)</td><td align="char" colspan="1" rowspan="1">0.0027</td></tr><tr><td rowspan="3" colspan="1">31</td><td colspan="1" rowspan="1">Pooled placebo</td><td align="char" colspan="1" rowspan="1">0.0006 (&#8722;0.0198 to 0.0209)</td><td align="char" colspan="1" rowspan="1">0.5%</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">ACI-35.030 900 &#956;g</td><td align="char" colspan="1" rowspan="1">&#8722;0.0292 (&#8722;0.0468 to &#8722;0.0117)</td><td align="char" colspan="1" rowspan="1">&#8722;19.3%</td><td align="char" colspan="1" rowspan="1">&#8722;0.0298 (&#8722;0.0569 to &#8722;0.0027)</td><td align="char" colspan="1" rowspan="1">0.0311</td></tr><tr><td colspan="1" rowspan="1">ACI-35.030 1800 &#956;g</td><td align="char" colspan="1" rowspan="1">&#8722;0.0170 (&#8722;0.0495 to 0.0154)</td><td align="char" colspan="1" rowspan="1">&#8722;9.1%</td><td align="char" colspan="1" rowspan="1">&#8722;0.0176 (&#8722;0.0563 to 0.0211)</td><td align="char" colspan="1" rowspan="1">0.3717</td></tr><tr><td rowspan="3" colspan="1">36</td><td colspan="1" rowspan="1">Pooled placebo</td><td align="char" colspan="1" rowspan="1">0.0012 (&#8722;0.0168 to 0.0192)</td><td align="char" colspan="1" rowspan="1">1.0%</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">ACI-35.030 900 &#956;g</td><td align="char" colspan="1" rowspan="1">&#8722;0.0263 (&#8722;0.0419 to &#8722;0.0106)</td><td align="char" colspan="1" rowspan="1">&#8722;17.4%</td><td align="char" colspan="1" rowspan="1">&#8722;0.0274 (&#8722;0.0516 to &#8722;0.0034)</td><td align="char" colspan="1" rowspan="1">0.0257</td></tr><tr><td colspan="1" rowspan="1">ACI-35.030 1800 &#956;g</td><td align="char" colspan="1" rowspan="1">&#8722;0.0367 (&#8722;0.0674 to &#8722;0.0060)</td><td align="char" colspan="1" rowspan="1">&#8722;19.7%</td><td align="char" colspan="1" rowspan="1">&#8722;0.0379 (&#8722;0.0740 to &#8722;0.0019)</td><td align="char" colspan="1" rowspan="1">0.0394</td></tr><tr><td rowspan="3" colspan="1">74</td><td colspan="1" rowspan="1">Pooled placebo</td><td align="char" colspan="1" rowspan="1">0.0159 (&#8722;0.0021 to 0.0339)</td><td align="char" colspan="1" rowspan="1">13.5%</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">ACI-35.030 900 &#956;g</td><td align="char" colspan="1" rowspan="1">&#8722;0.0087 (&#8722;0.0246 to 0.0072)</td><td align="char" colspan="1" rowspan="1">&#8722;5.8%</td><td align="char" colspan="1" rowspan="1">&#8722;0.0246 (&#8722;0.0488 to &#8722;0.0003)</td><td align="char" colspan="1" rowspan="1">0.0469</td></tr><tr><td colspan="1" rowspan="1">ACI-35.030 1800 &#956;g</td><td align="char" colspan="1" rowspan="1">0.0129 (&#8722;0.0178 to 0.0436)</td><td align="char" colspan="1" rowspan="1">6.9%</td><td align="char" colspan="1" rowspan="1">&#8722;0.0030 (&#8722;0.0390 to 0.0331)</td><td align="char" colspan="1" rowspan="1">0.8707</td></tr><tr><td rowspan="3" colspan="1">10</td><td colspan="1" rowspan="1">Pooled placebo</td><td align="char" colspan="1" rowspan="1">0.0063 (&#8722;0.0123 to 0.0250)</td><td align="char" colspan="1" rowspan="1">5.3%</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">JACI-35.054 15 &#956;g</td><td align="char" colspan="1" rowspan="1">0.0212 (&#8722;0.0070 to 0.0495)</td><td align="char" colspan="1" rowspan="1">13.8%</td><td align="char" colspan="1" rowspan="1">0.0149 (&#8722;0.0192 to 0.0490)</td><td align="char" colspan="1" rowspan="1">0.3868</td></tr><tr><td colspan="1" rowspan="1">JACI-35.054 60 &#956;g</td><td align="char" colspan="1" rowspan="1">&#8722;0.0296 (&#8722;0.0581 to &#8722;0.0011)</td><td align="char" colspan="1" rowspan="1">&#8722;17.9%</td><td align="char" colspan="1" rowspan="1">&#8722;0.0359 (&#8722;0.0704 to &#8722;0.0015)</td><td align="char" colspan="1" rowspan="1">0.0411</td></tr></tbody></table><table-wrap-foot><fn id="tbl6fna"><label>a</label><p id="ntpara0030">Least Squares.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl6fnb"><label>b</label><p id="ntpara0035">Confidence Interval.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl6fnc"><label>c</label><p id="ntpara0040">Linear Mixed Model with baseline and treatment arm&#8727;visit as fixed factors, participant ID as random factor, Satterthwaite's method for degrees of freedom, uncorrected p-values.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec4"><title>Discussion</title><p id="p0085">This study shows that active anti-Tau immunotherapies can safely induce the immune system of participants with early AD aged 50&#8211;75 years to produce and maintain antibodies targeting phosphorylated Tau. Moreover, dependent on the active immunotherapy formulation, a different polyclonal anti-Tau antibody response profile developed, despite using the same phospho-Tau peptide. While the two active immunotherapies generated robust titres against pathological Tau species, ACI-35.030 showed an earlier antibody response more specifically directed against phosphorylated Tau species compared to non-phosphorylated Tau, and a sustained and stable response against ePHF, which represents the endogenous pathological Tau in AD pathology. This process of antibody maturation is well established in humans and is fundamental for successfully fighting infectious agents. However, this has not been reported to date with another anti-Tau active immunotherapy, AADVac1, which has an immunogen covering the N-terminal cysteinylated tau 294&#8211;305/4R region and showed preliminary evidence of slowing of neurodegeneration using plasma NfL, a non-specific fluid biomarker, and of AD-related decline in an post-hoc analysis from one clinical trial conducted in 196 participants with mild AD.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> The fast onset of the targeted response, the high responder rate and the boosting of antibody breadth toward pathological Tau reflects the capacity of ACI-35.030 to harness the adaptability of our immune system to extend its reach, aimed at eliminating pathological Tau variants. Safety and tolerability, the other primary outcomes of the study were good with both active immunotherapies, with no participants withdrawing from the study due to adverse events. The most consistently observed adverse events, commonly reported with active immunisation, were headaches and local injection site reactions. They occurred in a dose-dependent manner, were generally mild to moderate in severity and were self-limiting. The numerous measures of fluid-based biomarkers gave two notable outcomes. Using the immunoassay that selectively measures brain-derived Tau (BD-Tau) in blood, a significant accumulation was observed with the 2 highest treatment doses of ACI-35.030.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> Moreover, on average, plasma BD-Tau levels remained constant post the last dosing at 48 weeks until the final analysis at 74 weeks. As the epitopes recognised by the ACI-35.030-induced antibodies do not interfere in the BD-Tau assay, the increase of plasma BD-Tau levels observed with ACI-35.030 immunisation, as compared to placebo, suggests stabilisation in the plasma via antibody-target engagement with these Tau variants. In contrast, plasma pTau217, a biomarker for detecting AD pathology and predicting future development of AD dementia, decreased in a dose-dependent manner post treatment with ACI-35.030, which could indicate a pharmacodynamic effect.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> These results may reflect that as the antibody response matures within each participant post-treatment with ACI-35.030, the antibody repertoire binds more effectively to the Tau species measured in the BD-Tau assay. The relevance of these observations needs to be confirmed in larger cohorts. In this study, ACI-35.030, derived from the SupraAntigen&#174; liposome&#8211;based platform, induced a strong polyclonal antibody response that matured and was maintained against key pathological forms of Tau believed to drive Tau aggregation and AD. JACI-35.054, a CRM197 carrier-protein conjugate, triggered a more heterogenous antibody response, with high responder rates, that was less selective for pathological Tau species. Thus, based on a faster and more stable antibody response, which is selective for and maturing against the endogenous pathological form of Tau, i.e., ePHF, the active immunotherapy, ACI-35.030, was selected for further development. As compared to mAbs, less frequent dosing is required to maintain titres, and efficacy-modifying anti-drug antibodies are absent. Based on the fact that ACI-35.030 (JNJ-64042056) was well tolerated at all tested doses and induced a fast and selective response against endogenous pathological Tau, this SupraAntigen&#174;-based active immunotherapy is in progress into the next phase of clinical development. The remarkably limited screen failure rate (22/79; &#8764;28%) observed may be explained by the very careful identification of participants selected in centres highly experienced in the conduct of early-stage AD studies. The study sites were not given any specific guidelines regarding the preselection or selection of participants and conducted recruitment in accordance with their local rules. This early-stage study by its nature, has certain limitations, notably it was not powered to investigate the effects of study drug on biomarkers, vMRI and on clinical endpoints. Consequently, the lack of statistical significance in this context does not exclude a potential effect. Brain Tau-PET imaging was not performed, precluding the assessment of the polyclonal antibody response against pathological Tau species needed to prevent or inhibit brain Tau spreading. In this early phase study, the treatment period was also limited, thus preventing measurement of the long-term antibody response and pharmacodynamic effects of the study treatment. Based on the limited number of participants, all of whom were white, the influence of sex, gender, race and ethnicity could not be adequately studied nor could the influence of socioeconomic factors be assessed. This will be addressed in larger studies, with efforts including community engagement to ensure a representative and diverse population for this purpose. The study data has shown that injection site reactions were observed exclusively in participants receiving active study treatments. While this observation was unlikely to induce a potential risk of unblinding during the course of this early-phase study, this possibility should be appropriately controlled in subsequent clinical phases by using an adjuvanted placebo formulation able to induce such local reactions while preserving the safety of participants. The phase 2b Retain study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT06544616" id="intref0035">NCT06544616</ext-link>) that is currently ongoing in study population with preclinical AD has been designed to address the above-mentioned points.</p></sec><sec id="sec5"><title>Contributors</title><p id="p0090">OS, JG, JS, and AP defined the overall study design, endpoints and study population with the support of PS, who was the international coordinating investigator. JW and NF took part in the statistical analysis plans and in interim and final study analyses with the support of IK, LS, and GTB for interim analyses. JM, BL, and VH were responsible for clinical operation-related activities during the study conduct. Safety data monitoring was ensured by JG and VG with the support of OS. MV, EG, EF, DTH, CT, GTB, MKV, and AP took part in the selection of antibody titres and fluid biomarker assays and in the analysis of related interim and final dataset. MH, SK, JR, PD, EGBV, CM, ABH, MJ, CR, and CP were principal investigators at the different study sites where study participants were screened and randomised. All authors from AC Immune SA and Johnson &amp; Johnson Innovative Medicine took part in the final data analysis and reviewed the clinical study report. All authors had full access to all data in the study, approved the final manuscript and had final responsibility for the decision to submit for publication. All or part of the underlying data were verified by OS, JM, MV, VG, EG, JG, JW, NF, LS, GTB, MKV, and PS.</p></sec><sec id="sec6"><title>Data sharing statement</title><p id="p0095">AC Immune SA and Johnson &amp; Johnson Innovative Medicine are making provisions to grant access to group-level data (analysis datasets) only in this early phase clinical trial in order to enhance public health and advance science. Qualified researchers who engage in rigorous independent scientific research may be given data access after review and approval of research proposal, Statistical Analysis Plan (SAP) and execution of a Data Use Agreement. Other information such as study protocol and statistical analysis plan can be accessed at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov" id="intref0040">clinicaltrials.gov</ext-link> and in <xref rid="appsec1" ref-type="sec">Supplementary Material</xref>. One study participant did not consent to the storage and further use of samples for future research.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of interests</title><p id="p0100">OS, JM, MV, EG, EF, DTH, VH, VG, JW, NF, BL, MKV, and AP, who is the CEO, are full-time employees and shareholders of AC Immune SA. JS was a full-time employee and shareholder of AC Immune SA at the time of study conduct. JG received consulting fees as a clinical advisor of AC Immune SA. IK is a full-time employee and shareholder of Johnson &amp; Johnson Innovative Medicine, she is also the co-holder of patent JPI6073USPSP2. LS is a full-time employee and shareholder of Johnson &amp; Johnson Innovative Medicine, he is also the co-holder of patents JPl6059OMPCT1 and JPl6073USPSP2. GTB is a full-time employee and shareholder of Johnson &amp; Johnson Innovative Medicine, he is also the co-holder of patents JAB6123USPSP2, JAB7064USPSP2, JAB7165USPSP2, and JAB721SUSPSP2. CT is a full-time employee and shareholder of Johnson &amp; Johnson Innovative Medicine, she is also the co-holder of patents PCT/US2022/074902 and PCT/US2024/052885. JR was study investigator and fees related to the conduct of the study were paid to his institution, he had also academic research grants from Sigrid Juselius Foundation that were received by his institution and also from the Finnish Governmental Research Funding (VTR) that were received by Turku University Hospital. MH, SK, PD, EGBV, and ABH were study investigators and fees related to the conduct of the study were paid to their respective institutions. MJ was study investigator and fees related to the conduct of the study were paid to his institution, he received compensation for advisory board attendance with Biogen, Eli Lilly, Eisai, and BioArctic. CM was study investigator and fees related to the conduct of the study were paid to her institution, she was granted award for investigator led trial of ultrafast MRI in dementia with Biogen, she received compensation for advisory board attendance with Roche, Eli Lilly, Eisai, Novartis, Neurimmune, MSD, and GSK, she received honorarium for lecturing at sponsored symposium with Eli Lilly and Eisai, she received payments from Biogen, Eisai, Roche, and Alector for travel and accommodation for advisory board meetings held at different scientific conferences, she received compensation as DSMB chair from Imperial and Immunobrain, and she is also Director of NIHR UK Dementia Trials Network. CR was study investigator and fees related to the conduct of the study were paid to his institution, he is also the Founder, CEO, and majority shareholder of Scottish Brain Sciences, he received consulting fees from Biogen, Eisai, MSD, Actinogen, Roche, Eli Lilly, and Novo Nordisk, he received payment or honoraria for lectures and presentations from Roche, Eisai, and Eli Lilly, and he also received compensation from Novo Nordisk for advisory board attendance. CP was study investigator and fees related to the conduct of the study were paid to her institutions. PS is Professor Emeritus at Amsterdam UMC, is a DSMB member at Immunobrain Checkpoint and at Johnson &amp; Johnson Innovative Medicine, is a co-chair at the steering committee of EVOKES studies at Novo-Nordisk, is a full-time employee of EQT Life Sciences and, as the ACI-35-1802 study coordinating investigator, he received consulting fees that were paid to Amsterdam UMC.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>van Dyck</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Lecanemab in early Alzheimer's disease</article-title><source>N Engl J Med</source><volume>388</volume><issue>1</issue><year>2023</year><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">36449413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2212948</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Sims</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>C.D.</given-names></name><etal/></person-group><article-title>Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial</article-title><source>JAMA</source><volume>330</volume><issue>6</issue><year>2023</year><fpage>512</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">37459141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.13239</pub-id><pub-id pub-id-type="pmcid">PMC10352931</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Budd Haeberlein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Two randomized phase 3 studies of aducanumab in early Alzheimer's disease</article-title><source>J Prev Alzheimers Dis</source><volume>9</volume><issue>2</issue><year>2022</year><fpage>197</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">35542991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14283/jpad.2022.30</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W.J.</given-names></name><etal/></person-group><article-title>Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers</article-title><source>Lancet Neurol</source><volume>12</volume><issue>2</issue><year>2013</year><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">23332364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(12)70291-0</pub-id><pub-id pub-id-type="pmcid">PMC3622225</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Wiste</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>S.D.</given-names></name><etal/></person-group><article-title>Defining imaging biomarker cut points for brain aging and Alzheimer's disease</article-title><source>Alzheimers Dement</source><volume>13</volume><issue>3</issue><year>2017</year><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">27697430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2016.08.005</pub-id><pub-id pub-id-type="pmcid">PMC5344738</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>B.B.</given-names></name><etal/></person-group><article-title>Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages</article-title><source>Brain</source><volume>139</volume><issue>5</issue><year>2016</year><fpage>1539</fpage><lpage>1550</lpage><pub-id pub-id-type="pmid">26936940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aww023</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pichet Binette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Groot</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline</article-title><source>Nat Med</source><volume>28</volume><year>2022</year><fpage>2381</fpage><lpage>2387</lpage><pub-id pub-id-type="pmid">36357681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-02049-x</pub-id><pub-id pub-id-type="pmcid">PMC9671808</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T.G.</given-names></name><etal/></person-group><article-title>Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup</article-title><source>Alzheimers Dement</source><volume>20</volume><issue>8</issue><year>2024</year><fpage>5143</fpage><lpage>5169</lpage><pub-id pub-id-type="doi">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Hampel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Elhage</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Apostolova</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Nicoll</surname><given-names>J.A.R.</given-names></name><name name-style="western"><surname>Atri</surname><given-names>A.</given-names></name></person-group><article-title>Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics</article-title><source>Brain</source><volume>146</volume><issue>11</issue><year>2023</year><fpage>4414</fpage><lpage>4424</lpage><pub-id pub-id-type="pmid">37280110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awad188</pub-id><pub-id pub-id-type="pmcid">PMC10629981</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Withington</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>R.S.</given-names></name></person-group><article-title>Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer's disease</article-title><source>Front Neurol</source><volume>13</volume><year>2022</year><object-id pub-id-type="publisher-id">862369</object-id><pub-id pub-id-type="doi">10.3389/fneur.2022.862369</pub-id><pub-id pub-id-type="pmcid">PMC8985815</pub-id><pub-id pub-id-type="pmid">35401412</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Rafii</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P.S.</given-names></name></person-group><article-title>Detection and treatment of Alzheimer's disease in its preclinical stage</article-title><source>Nat Aging</source><volume>3</volume><issue>5</issue><year>2023</year><fpage>520</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">37202518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00410-4</pub-id><pub-id pub-id-type="pmcid">PMC11110912</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Tanner</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Iaccarino</surname><given-names>L.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease</article-title><source>Brain</source><volume>145</volume><issue>12</issue><year>2022</year><fpage>4489</fpage><lpage>4505</lpage><pub-id pub-id-type="pmid">35762829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awac229</pub-id><pub-id pub-id-type="pmcid">PMC10200306</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Pichet Binette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Franzmeier</surname><given-names>N.</given-names></name><name name-style="western"><surname>Spotorno</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease</article-title><source>Nat Commun</source><volume>13</volume><issue>1</issue><year>2022</year><object-id pub-id-type="publisher-id">6635</object-id><pub-id pub-id-type="doi">10.1038/s41467-022-34129-4</pub-id><pub-id pub-id-type="pmcid">PMC9636262</pub-id><pub-id pub-id-type="pmid">36333294</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Santa-Maria</surname><given-names>I.</given-names></name><name name-style="western"><surname>Varghese</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ksiezak-Reding</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dzhun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pasinetti</surname><given-names>G.M.</given-names></name></person-group><article-title>Paired Helical Filaments from Alzheimer Disease brain induce intracellular accumulation of Tau protein in aggresomes</article-title><source>J Biol Chem</source><volume>287</volume><issue>24</issue><year>2012</year><fpage>20522</fpage><lpage>20533</lpage><pub-id pub-id-type="pmid">22496370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M111.323279</pub-id><pub-id pub-id-type="pmcid">PMC3370237</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jacks</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.I.</given-names></name></person-group><article-title>Propagation of Tau misfolding from the outside to the inside of a cell</article-title><source>J Biol Chem</source><volume>284</volume><issue>19</issue><year>2009</year><fpage>12845</fpage><lpage>12852</lpage><pub-id pub-id-type="pmid">19282288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M808759200</pub-id><pub-id pub-id-type="pmcid">PMC2676015</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>B.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.I.</given-names></name></person-group><article-title>Prion-like mechanisms in neurodegenerative diseases</article-title><source>Nat Rev Neurosci</source><volume>11</volume><issue>3</issue><year>2010</year><fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">20029438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn2786</pub-id><pub-id pub-id-type="pmcid">PMC3648341</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Gueorguieva</surname><given-names>I.</given-names></name><name name-style="western"><surname>Willis</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Chua</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease</article-title><source>Clin Pharmacol Ther</source><volume>113</volume><issue>6</issue><year>2023</year><fpage>1258</fpage><lpage>1267</lpage><pub-id pub-id-type="pmid">36805552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2875</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Theunis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Crespo-Biel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gafner</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Efficacy and safety of A liposome-based vaccine against protein Tau, assessed in Tau.P301L mice that model tauopathy</article-title><source>PLoS One</source><volume>8</volume><issue>8</issue><year>2013</year><object-id pub-id-type="publisher-id">e72301</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0072301</pub-id><pub-id pub-id-type="pmcid">PMC3747157</pub-id><pub-id pub-id-type="pmid">23977276</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Wegmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Biernat</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mandelkow</surname><given-names>E.</given-names></name></person-group><article-title>A current view on Tau protein phosphorylation in Alzheimer's disease</article-title><source>Curr Opin Neurobiol</source><volume>69</volume><year>2021</year><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">33892381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.conb.2021.03.003</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Bramblett</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Goedert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jakes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Merrick</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>V.M.</given-names></name></person-group><article-title>Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding</article-title><source>Neuron</source><volume>10</volume><issue>6</issue><year>1993</year><fpage>1089</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(93)90057-x</pub-id><pub-id pub-id-type="pmid">8318230</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Mondrag&#243;n-Rodr&#237;guez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>G.</given-names></name><name name-style="western"><surname>Luna-Mu&#241;oz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Acevedo-Aquino</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>S.</given-names></name></person-group><article-title>Phosphorylation of tau protein at sites Ser (396-404) is one of the earliest events in Alzheimer's disease and Down syndrome</article-title><source>Neuropathol Appl Neurobiol</source><volume>40</volume><issue>2</issue><year>2014</year><fpage>121</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1111/nan.12084</pub-id><pub-id pub-id-type="pmid">24033439</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Prokop</surname><given-names>S.</given-names></name><name name-style="western"><surname>Giasson</surname><given-names>B.I.</given-names></name></person-group><article-title>&#8220;Don't Phos Over Tau&#8221;: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies</article-title><source>Mol Neurodegener</source><volume>16</volume><issue>1</issue><year>2021</year><fpage>37</fpage><pub-id pub-id-type="doi">10.1186/s13024-021-00460-5</pub-id><pub-id pub-id-type="pmid">34090488</pub-id><pub-id pub-id-type="pmcid">PMC8180161</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Budzynski</surname><given-names>W.</given-names></name><name name-style="western"><surname>Koganty</surname><given-names>R.R.</given-names></name><etal/></person-group><article-title>Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses</article-title><source>Bioconjug Chem</source><volume>9</volume><issue>4</issue><year>1998</year><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">9667946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bc970183n</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Bakouche</surname><given-names>O.</given-names></name><name name-style="western"><surname>Gerlier</surname><given-names>D.</given-names></name></person-group><article-title>Enhancement of immunogenicity of tumour virus antigen by liposomes: the effect of lipid composition</article-title><source>Immunology</source><volume>58</volume><issue>3</issue><year>1986</year><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="pmid">3733150</pub-id><pub-id pub-id-type="pmcid">PMC1453458</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Vingtdeux</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chandakkar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Acker</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>P.</given-names></name><name name-style="western"><surname>Marambaud</surname><given-names>P.</given-names></name></person-group><article-title>A modification-specific peptide-based immunization approach using CRM197 carrier protein: development of a selective vaccine against pyroglutamate A&#946; peptides</article-title><source>Mol Med</source><volume>22</volume><year>2016</year><fpage>841</fpage><lpage>849</lpage><pub-id pub-id-type="pmid">27900387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2119/molmed.2016.00218</pub-id><pub-id pub-id-type="pmcid">PMC5263057</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Pichichero</surname><given-names>M.E.</given-names></name></person-group><article-title>Protein carriers of conjugate vaccines: characteristics, development, and clinical trials</article-title><source>Hum Vaccin Immunother</source><volume>9</volume><issue>12</issue><year>2013</year><fpage>2505</fpage><lpage>2523</lpage><pub-id pub-id-type="pmid">23955057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.26109</pub-id><pub-id pub-id-type="pmcid">PMC4162048</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Ortiz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Turton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kac</surname><given-names>P.R.</given-names></name><etal/></person-group><article-title>Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration</article-title><source>Brain</source><volume>146</volume><issue>3</issue><year>2023</year><fpage>1152</fpage><lpage>1165</lpage><pub-id pub-id-type="pmid">36572122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awac407</pub-id><pub-id pub-id-type="pmcid">PMC9976981</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Mattsson-Carlgren</surname><given-names>N.</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Palmqvist</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease</article-title><source>Brain</source><volume>143</volume><issue>11</issue><year>2020</year><fpage>3234</fpage><lpage>3241</lpage><pub-id pub-id-type="pmid">33068398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awaa286</pub-id><pub-id pub-id-type="pmcid">PMC7719022</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Palmqvist</surname><given-names>S.</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S.</given-names></name><name name-style="western"><surname>Quiroz</surname><given-names>Y.T.</given-names></name><etal/></person-group><article-title>Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders</article-title><source>JAMA</source><volume>324</volume><issue>8</issue><year>2020</year><fpage>772</fpage><lpage>781</lpage><pub-id pub-id-type="pmid">32722745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.12134</pub-id><pub-id pub-id-type="pmcid">PMC7388060</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Novak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kovacech</surname><given-names>B.</given-names></name><name name-style="western"><surname>Katina</surname><given-names>S.</given-names></name><etal/></person-group><article-title>ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease</article-title><source>Nat Aging</source><volume>1</volume><year>2021</year><fpage>521</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">37117834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-021-00070-2</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Cullen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Novak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tosun</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the &#8220;ADAMANT&#8221; randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial</article-title><source>EBioMedicine</source><volume>99</volume><year>2024</year><object-id pub-id-type="publisher-id">104923</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2023.104923</pub-id><pub-id pub-id-type="pmcid">PMC10733085</pub-id><pub-id pub-id-type="pmid">38101301</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0110">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Supplementary Materials</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc2" position="float" orientation="portrait"><caption><title>Clinical Study Protocol</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc2.pdf" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc3" position="float" orientation="portrait"><caption><title>Statistical Analysis Plan</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc3.pdf" position="float" orientation="portrait"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc4" position="float" orientation="portrait"><caption><title>Author Statement ICJME Transfer Form</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc4.pdf" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0105">We thank all the participants, families, caregivers, and study staff members of study sites. We thank also all employees of AC Immune SA members and of Johnson &amp; Johnson Innovative Medicine who contributed in the study, especially Nicolas Sanchez who contributed to post-hoc analyses and to the preparation of tables and graphs, Lingjue Li who was involved in the data analysis, Tricia Thornton-wells who provided input in the review of the manuscript, Sabrina El Bachiri and the biostatistics team at Johnson &amp; Johnson who generated additional immunogenicity and safety outputs for interim analyses, the personnel of the clinical CRO and of all other vendors who took part in the study from its initiation until clinical study report finalization. This trial was funded by <funding-source id="gs3">AC Immune SA</funding-source> and <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/100005565</institution-id><institution>Johnson &amp; Johnson Innovative Medicine</institution></institution-wrap></funding-source>.</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0115">Supplementary data related to this article can be found at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.ebiom.2025.105940" id="intref0045">https://doi.org/10.1016/j.ebiom.2025.105940</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biochem</journal-id><journal-id journal-id-type="iso-abbrev">J Biochem</journal-id><journal-id journal-id-type="pmc-domain-id">1232</journal-id><journal-id journal-id-type="pmc-domain">jb</journal-id><journal-id journal-id-type="publisher-id">jbchem</journal-id><journal-title-group><journal-title>Journal of Biochemistry</journal-title></journal-title-group><issn pub-type="ppub">0021-924X</issn><issn pub-type="epub">1756-2651</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12480741</article-id><article-id pub-id-type="pmcid-ver">PMC12480741.1</article-id><article-id pub-id-type="pmcaid">12480741</article-id><article-id pub-id-type="pmcaiid">12480741</article-id><article-id pub-id-type="pmid">40631620</article-id><article-id pub-id-type="doi">10.1093/jb/mvaf043</article-id><article-id pub-id-type="publisher-id">mvaf043</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Regular Paper</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/SCI00980</subject></subj-group></article-categories><title-group><article-title>UNC5B is an isoform-dependent target for ectodomain shedding</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Sugimoto</surname><given-names initials="K">Kotaro</given-names></name><aff>
<institution>Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University</institution>, 1-1-1 Nojihigashi, Kusatsu, <addr-line>Shiga 525-8577</addr-line>, <country country="JP">Japan</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Watabe</surname><given-names initials="E">Eichi</given-names></name><aff>
<institution>Medical Research Institute, Tokyo Medical and Dental University</institution>, 1-5-45 Yushima, Bunkyo-ku, <addr-line>Tokyo 113-8510</addr-line>, <country country="JP">Japan</country></aff><aff>
<institution>Business Development Department, Digital Healthcare Division, Hitachi Ltd. Healthcare Innovation Division</institution>, 1-17-1 Toranomon, Minato-ku, <addr-line>Tokyo 105-6412</addr-line>, <country country="JP">Japan</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Takuma</surname><given-names initials="M">Mio</given-names></name><aff>
<institution>Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University</institution>, 1-1-1 Nojihigashi, Kusatsu, <addr-line>Shiga 525-8577</addr-line>, <country country="JP">Japan</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nagahara</surname><given-names initials="K">Kaname</given-names></name><aff>
<institution>Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University</institution>, 1-1-1 Nojihigashi, Kusatsu, <addr-line>Shiga 525-8577</addr-line>, <country country="JP">Japan</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sawano</surname><given-names initials="T">Toshinori</given-names></name><aff>
<institution>Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University</institution>, 1-1-1 Nojihigashi, Kusatsu, <addr-line>Shiga 525-8577</addr-line>, <country country="JP">Japan</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kajita</surname><given-names initials="M">Mihoko</given-names></name><aff>
<institution>Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University</institution>, 1-1-1 Nojihigashi, Kusatsu, <addr-line>Shiga 525-8577</addr-line>, <country country="JP">Japan</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Takagi</surname><given-names initials="J">Junichi</given-names></name><aff>
<institution>Institute for Protein Research, Osaka University</institution>, 3-2 Yamadaoka, Suita, <addr-line>Osaka 565-0871</addr-line>, <country country="JP">Japan</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kuroyanagi</surname><given-names initials="H">Hidehito</given-names></name><aff>
<institution>Medical Research Institute, Tokyo Medical and Dental University</institution>, 1-5-45 Yushima, Bunkyo-ku, <addr-line>Tokyo 113-8510</addr-line>, <country country="JP">Japan</country></aff><aff>
<institution>Department of Biochemistry, Graduate School of Medicine, University of the Ryukyus</institution>, 1076 Kiyuna, Ginowan, <addr-line>Okinawa 901-2725</addr-line>, <country country="JP">Japan</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1563-1134</contrib-id><name name-style="western"><surname>Shirakabe</surname><given-names initials="K">Kyoko</given-names></name><aff>
<institution>Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University</institution>, 1-1-1 Nojihigashi, Kusatsu, <addr-line>Shiga 525-8577</addr-line>, <country country="JP">Japan</country></aff><aff>
<institution>Ritsumeikan Global Innovation Research Organization, Ritsumeikan University</institution>, <addr-line>1-1-1 Nojihigashi, Kusatsu, Shiga 525-8577</addr-line>, <country country="JP">Japan</country></aff><xref rid="cor1" ref-type="corresp"/></contrib></contrib-group><author-notes><corresp id="cor1">Kyoko Shirakabe, Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu, Shiga 525-8577, Japan. Tel./Fax: +81-77-561-2725, email: <email>kshira@fc.ritsumei.ac.jp</email></corresp></author-notes><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-07-09"><day>09</day><month>7</month><year>2025</year></pub-date><volume>178</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">497962</issue-id><fpage>267</fpage><lpage>275</lpage><history><date date-type="received"><day>27</day><month>2</month><year>2025</year></date><date date-type="rev-request"><day>09</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>03</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 14:25:41.837"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press on behalf of the Japanese Biochemical Society.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="mvaf043.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mvaf043.pdf"/><abstract><title>Abstract</title><p>Ectodomain shedding (shedding) is a processing mechanism that cleaves the juxtamembrane region of membrane proteins and solubilizes almost the entire extracellular domain. Shedding irreversibly regulates the localization and function of membrane proteins; however, its physiological role is not fully understood. Previously, we showed that the shedding susceptibility of multiple membrane proteins is altered by skipping or inclusion of skipping exon(s) that encode their juxtamembrane region. In this study, we screened the skipping exon encoding the juxtamembrane region of membrane proteins and found that the shedding susceptibility of UNC5B, a Netrin-1 receptor, is altered by skipping or inclusion of the skipping exon encoding its juxtamembrane region. These results raise the possibility that the biological phenomena involving UNC5B, including neural circuit formation, angiogenesis and cancer development, are regulated by shedding in a splice isoform-dependent manner.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p>
<fig position="float" id="ga1" orientation="portrait"><label>Graphical Abstract</label><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="mvaf043ga.jpg"/></fig>
</p></abstract><kwd-group><kwd>alternative splicing</kwd><kwd>ectodomain shedding</kwd><kwd>skipping exon</kwd><kwd>transmembrane domain</kwd><kwd>UNC5B</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution content-type="funder-name">Astellas Foundation for Research on Metabolic Disorders</institution><institution-id institution-id-type="DOI">10.13039/501100007263</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution content-type="funder-name">Naito Foundation</institution><institution-id institution-id-type="DOI">10.13039/100007428</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution content-type="funder-name">Takeda Science Foundation</institution><institution-id institution-id-type="DOI">10.13039/100007449</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution content-type="funder-name">JSPS KAKENHI</institution></institution-wrap></funding-source><award-id>JP18K06911</award-id></award-group></funding-group><counts><page-count count="9"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Ectodomain shedding, hereafter referred to as shedding, is a processing mechanism in which transmembrane (TM) proteins are cleaved at their juxtamembrane region, and almost the entire extracellular domain is solubilized (<xref rid="ref1" ref-type="bibr">1</xref>). Shedding is mainly executed by a disintegrin and metalloprotease (ADAM) family membrane-anchored metalloproteases (<xref rid="ref2" ref-type="bibr">2</xref>, <xref rid="ref3" ref-type="bibr">3</xref>), which convert a single membrane protein into a soluble extracellular domain that are released extracellularly and a membrane-anchored protein with almost no extracellular domain. Many of the membrane-anchored shedding products undergo intramembrane processing executed by &#947;-secretase (<xref rid="ref4" ref-type="bibr">4</xref>), which can only cleave membrane proteins with almost no extracellular domain, and the resulting products are released both intra- and extracellularly. In other words, shedding is a rate-limiting step in the two-step processing of membrane proteins that irreversibly converts a membrane protein into multiple soluble proteins with different cellular localizations. To date, membrane proteins with various functions, such as growth factors, inflammatory cytokines, their receptors and adhesion molecules, have been reported to undergo shedding (<xref rid="ref1" ref-type="bibr">1&#8211;3</xref>), and their functions are thought to be regulated by the two-step processing; however, the physiological role played by this processing is not fully understood.</p><p>To gain a better understanding of the role of membrane protein processing, we developed a screening system for targets of metalloprotease-dependent shedding (<xref rid="ref5" ref-type="bibr">5</xref>, <xref rid="ref6" ref-type="bibr">6</xref>), as shedding is the rate-limiting step of the processing. We screened a macrophage cell line stimulated with an endotoxin and identified multiple membrane proteins as shedding targets (<xref rid="ref6" ref-type="bibr">6</xref>). Through analysis of the identified shedding targets, we found that the shedding susceptibility of three of them, cell adhesion molecule 1 (CADM1), signal-regulatory protein alpha (SIRP&#945;) and activated leukocyte cell adhesion molecule (ALCAM), is regulated by post-transcriptional modification, alternative splicing (<xref rid="ref6" ref-type="bibr">6</xref>, <xref rid="ref7" ref-type="bibr">7</xref>). Both shedding-susceptible and shedding-resistant isoforms are generated by alternative splicing of their genes. Among them, the shedding susceptibilities of CADM1 and ALCAM, two immunoglobulin superfamily adhesion molecules, are altered by skipping or inclusion of single skipping exon encoding the extracellular juxtamembrane region, which is less than 3% of the full-length protein (<xref rid="ref6" ref-type="bibr">6</xref>, <xref rid="ref7" ref-type="bibr">7</xref>). These results not only indicate that the shedding susceptibility of these membrane proteins is precisely regulated by alternative splicing but also raise the possibility that alternative splicing regulates the shedding susceptibility of other membrane proteins.</p><p>To verify whether there are other membrane proteins whose shedding susceptibility is regulated by alternative splicing, we screened skipping exons that encode the juxtamembrane region of type I TM proteins. By examining the identified skipping exons, we found that UNC5B, a Netrin-1 receptor (<xref rid="ref8" ref-type="bibr">8</xref>), is an isoform-dependent shedding target, although its shedding has not been previously reported. These results suggest that the function of UNC5B, assumed to be involved in neural circuit formation, angiogenesis and cancer development (<xref rid="ref9" ref-type="bibr">9&#8211;12</xref>), is regulated by shedding in a splice isoform-dependent manner.</p><sec id="sec1"><title>Materials and Methods</title><sec id="sec2"><title>Screening of skipping exons encoding juxtamembrane region of type I TM proteins</title><p>GTF annotation files for the RefSeq genes were downloaded from the UCSC Genome Browser (<xref rid="ref13" ref-type="bibr">13</xref>). We used versions 109.20211119 for hg38 (human) and 109.20201027 for mm39 (mouse). To focus only on protein-coding genes, we filtered the GTF files to include only genes containing &#8216;NM&#8217; or &#8216;XM&#8217; transcripts. Next, we ran SUPPA v2.3 (<xref rid="ref14" ref-type="bibr">14</xref>) using the command &#8216;python suppa.py generateEvents -i input.gtf -o output -e [SE,SS,MX,RI,FL] -f ioe&#8217; to generate alternative splicing events.</p><p>Bed files for TM domains and signal peptides were downloaded from the UniProt FTP server (<xref rid="ref15" ref-type="bibr">15</xref>). Both hg38 and mm39 used the version released in 2022_05. The exon-TM domain overlaps and relationships between the generated alternative splicing exons were obtained using bedtools v2.31.1 (<xref rid="ref16" ref-type="bibr">16</xref>). Overlapping exons were identified using the &#8216;intersect&#8217; command in bedtools, whereas adjacent exons were identified using the &#8216;closest&#8217; command. We then filtered for cases in which the upstream exon adjacent to the TM domain was labelled as skipping exon. Additionally, only genes with a single TM domain and signal peptide at the N-terminus were classified as type I TM proteins. For gene duplication checks, mouse homologs of the screened genes in hg38 were obtained using homologene (<xref rid="ref17" ref-type="bibr">17</xref>) and compared with the results from mm39. All filtering and analyses were performed using bedtools v2.31.1 (<xref rid="ref16" ref-type="bibr">16</xref>) and custom in-house R scripts.</p></sec><sec id="sec3"><title>Enrichment analysis</title><p>Pathway enrichment analysis was conducted using Enrichr (<xref rid="ref18" ref-type="bibr">18</xref>). Background was defined as the complete set of type I TM protein genes filtered using the methods described above. From the Reactome 2022 (<xref rid="ref19" ref-type="bibr">19</xref>) results, the top 10 terms (<italic toggle="yes">P</italic>-value &lt;0.01) were used to create bubble plots using ggplot2 with custom in-house R scripts.</p></sec><sec id="sec4"><title>Cell line, transfection and sample preparation for western blotting</title><p>Chinese hamster ovary (CHO) cells were cultured in alpha-MEM supplemented with 10% fetal bovine serum (FBS) and antibiotics. Wild-type and ADAM17<sup>&#8722;/&#8722;</sup> mouse embryonic fibrobrasts (MEFs) (<xref rid="ref20" ref-type="bibr">20</xref>) were kindly provided by Dr. Keisuke Horiuchi (National Defense Medical College Hospital, Saitama, Japan) and cultured in Dulbecco&#8217;s modified Eagle medium (DMEM) supplemented with 10% FBS and antibiotics. Transfection was performed using PEI-MAX (Polysciences, Warrington, PA, USA) for CHO cells and NEPA21 (NEPA GENE, Chiba, Japan) for MEFs. For western blotting, cell extracts and proteins from the culture supernatants were prepared as previously described (<xref rid="ref5" ref-type="bibr">5</xref>). All western blotting were performed at least three times, and one representative data are shown. The amount of soluble extracellular domain in the culture supernatant was quantified using Image Studio (LI-COR, Lincoln, NE, USA).</p></sec><sec id="sec5"><title>Antibodies, chemicals, expression plasmids and siRNAs</title><p>Antibodies were purchased from Promega (anti-HaloTag, G9211; Madison, WI, USA), Fujifilm Wako (anti-PA tag, NZ-1; Tokyo, Japan), Santa Cruz Biotechnology (anti-&#946;-actin, sc-81,178; Santa Cruz, CA, USA), and Abcam (anti-ADAM10, ab39177; anti-ADAM17, ab39162; Cambridge, MA, USA). TPA and DAPT were purchased from Sigma-Aldrich (St. Louis, MO, USA). BB94 was purchased from Selleck Chemicals (Houston, TX, USA). Bortezomib was purchased from Cell Signaling Technology (Danvers, MA, USA). The coding sequences of human long AXL (#105932) and murine long UNC5B (#72195) were purchased from Addgene (Cambridge, MA, USA). Splice isoforms and substitution mutants were constructed using a PCR-based method. The cytoplasmic PA-tag was attached to the C-terminus of UNC5B isoforms using PCR. The coding sequences of UNC5B and AXL were subcloned into an N-terminally-Halo-tagged-type I TM protein expressing plasmid (<xref rid="ref21" ref-type="bibr">21</xref>) after the removal of their signal sequences (Met<sup>1</sup>-Ala<sup>26</sup> and Met<sup>1</sup>-Met<sup>25</sup>, respectively) using PCR. siRNAs (ADAM10, s61946; ADAM17, s61958) were purchased from Thermo Fisher Scientific (Waltham, MA, USA).</p></sec><sec id="sec6"><title>Cell surface staining of halo-tagged proteins</title><p>CHO cells expressing N-terminally Halo-tagged UNC5B isoforms and a red fluorescent protein (DsRed) were stained with a cell-impermeable HaloTag Alexa Fluor 488 ligand (Promega) according to the manufacturer&#8217;s instructions. Fluorescence images were captured using an APX100 Digital Imaging System (Evident, Tokyo, Japan).</p></sec><sec id="sec7"><title>Identification of shedding cleavage site of long UNC5B</title><p>CHO cells expressing N-terminally Halo-tagged and C-terminally PA-tagged long UNC5B were treated with 200&#160;ng/ml TPA and 10&#160;&#956;M DAPT for 3&#160;h and extracted in RIPA buffer (20&#160;mM Tris&#8211;HCl (pH&#160;7.4), 150&#160;mM NaCl, 2&#160;mM EDTA, 1% NP20, 0.1% SDS) supplemented with a protease inhibitor mixture (Sigma-Aldrich) and 10&#160;&#956;m BB94. The extract was incubated with anti-PA tag antibody beads (Fujifilm Wako) at 4&#176;C overnight, washed with RIPA buffer, and eluted via boiling in sample buffer (56.25&#160;mM Tris&#8211;HCl (pH&#160;6.8), 1.8% SDS, 40&#160;mM DTT, 9% glycerol). The eluted proteins were separated using SDS-PAGE, blotted onto a PVDF membrane and stained with Coomassie Blue. The approximately 65-kDa membrane-anchored shedding product of UNC5B was excised and subjected to automated Edman degradation using a protein sequencer PPSQ-53A (Shimadzu, Kyoto, Japan).</p></sec></sec><sec id="sec8"><title>Results</title><sec id="sec9"><title>Screening of skipping exons encoding juxtamembrane region of type I TM proteins</title><p>To comprehensively explore membrane proteins whose shedding susceptibility may be regulated by alternative splicing, we screened publicly available data (<xref rid="f1" ref-type="fig">Fig. 1A</xref>). First, we listed the alternative splicing events for human and mouse protein-coding genes registered in RefSeq using SUPPA2 (<xref rid="ref14" ref-type="bibr">14</xref>). This resulted in the identification of 98,975/66,620 alternative splicing events from 19,545/22,173 genes and 138,947/102,245 transcripts in the human/mouse genome (hg38/mm39). Among the alternative splicing events identified, the percentage of skipping exons was high in both human and mouse genomes (<xref rid="sup1" ref-type="supplementary-material">Fig. S1A</xref>). We then marked TM exons encoding TM domains registered in UniProt (<xref rid="ref15" ref-type="bibr">15</xref>) and checked whether these TM exons, as well as the immediately upstream and downstream exons, were subject to alternative splicing. We found that alternative splicing events were most frequent in the exons immediately upstream of TM exons (<xref rid="sup1" ref-type="supplementary-material">Fig. S1B</xref>). From these &#8216;TM domain-associated alternative splicing events&#8217;, we decided to focus on the skipping exons immediately upstream of the TM exons of type I TM proteins based on the following rationale.</p><fig position="float" id="f1" orientation="portrait"><label>Fig. 1</label><caption><p>Screening of skipping exons encoding juxtamembrane region of TM proteins. (A) An overview of the screening for the candidates for alternative splicing-regulated shedding targets. The number of genes, transcripts, alternative splicing events and skipping exons corresponding to each filtering step is shown. Numbers for human (hg38) and mouse (mm39) are listed separately, divided by a slash. In the gene structure diagram, TM domains are shown in light blue, and skipping exon is shown in light green. (B) Venn diagram of the skipping exons identified in humans (hg38) and mice (mm39). The homologs identified in both humans and mice on homologene is shown in overlapping. (C) Enrichment analysis of the identified candidates for alternative splicing-regulated shedding target genes using all type I TM protein genes as the background. The top 10 enriched pathway terms in Reactome 2022 are plotted. The <italic toggle="yes">x</italic>-axis and colour represent the <italic toggle="yes">P</italic>-value, and the size of the dots reflects the number of genes associated with each term.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="mvaf043f1.jpg"/></fig><p>Our previous proteomic screening of shedding targets revealed that 88.9% of the identified proteins were type I TM proteins (<xref rid="ref6" ref-type="bibr">6</xref>). Similarly, secretome analysis showed that 87.3% of the proteins secreted in a metalloprotease-dependent manner were type I TM proteins (<xref rid="ref22" ref-type="bibr">22</xref>). In addition, 71.3% of the shedding targets registered in SheddomeDB (<xref rid="ref23" ref-type="bibr">23</xref>), a semi-automatically curated database based on publications, were type I TM proteins. Taken together, we concluded that the majority of shedding targets are type I TM proteins.</p><p>Regarding the position of the shedding cleavage sites, in the above-mentioned secretome analysis, metalloprotease-dependent cleavage sites were mainly located within 200 amino acids from the TM domain (<xref rid="ref22" ref-type="bibr">22</xref>). In SheddomeDB (<xref rid="ref23" ref-type="bibr">23</xref>), 1,160 of the 1,344 cleavage sites (86.3%) of the human shedding targets were located upstream of the TM domain (<xref rid="sup1" ref-type="supplementary-material">Fig. S1C</xref>), half of which were within 199 amino acid residues (<xref rid="sup1" ref-type="supplementary-material">Fig. S1D</xref>). A similar trend was observed in mice (<xref rid="sup1" ref-type="supplementary-material">Fig. S1C</xref> and <xref rid="sup1" ref-type="supplementary-material">D</xref>). Furthermore, in humans, half of the cleavage sites nearest to the TM domain are located within 45 amino acids (<xref rid="sup1" ref-type="supplementary-material">Fig. S1D</xref>). These observations suggest that shedding cleavage sites are generally close to the TM domain; thus, we focused on the exons immediately upstream of the TM exons of type I TM protein genes. Furthermore, among the multiple types of alternative splicing events, we focused on skipping exons, which occur most frequently in exons immediately upstream of TM exons (<xref rid="sup1" ref-type="supplementary-material">Fig. S1B</xref>) and is thought to affect the structure of proteins by inserting or deleting a certain length of the amino acid sequence.</p><p>We screened for skipping exons immediately upstream of the TM exons of type I TM protein genes, which have a signal sequence and one TM domain in UniProt, and obtained 174 and 105 skipping exons from the human and mouse genomes, respectively (<xref rid="f1" ref-type="fig">Fig. 1A</xref>, <xref rid="sup1" ref-type="supplementary-material">Table S1A</xref> and <xref rid="sup1" ref-type="supplementary-material">B</xref>). Among these, 40 skipping exons were identified in both the human and mouse genomes (<xref rid="f1" ref-type="fig">Fig. 1B</xref>). The genes containing identified skipping exons included not only CADM1 and ALCAM (<xref rid="ref6" ref-type="bibr">6</xref>, <xref rid="ref7" ref-type="bibr">7</xref>), but also well-known shedding target genes, ERBB2, NTRK2, NRP1 and IL6R (<xref rid="ref1" ref-type="bibr">1</xref>, <xref rid="ref3" ref-type="bibr">3</xref>, <xref rid="ref24" ref-type="bibr">24</xref>, <xref rid="ref25" ref-type="bibr">25</xref>), suggesting that this screening is suitable for clarifying the relationship between shedding susceptibility and alternative splicing. All extracted exons, genes, proteins and the corresponding SheddomeDB entries are summarized in <xref rid="sup1" ref-type="supplementary-material">Table S1A</xref> and <xref rid="sup1" ref-type="supplementary-material">B</xref>.</p><p>Next, to characterize the identified genes, candidates for alternative splicing-regulated shedding targets, we performed enrichment analysis using Enrichr (<xref rid="ref18" ref-type="bibr">18</xref>), with all type I TM protein genes as the background, across various pathway databases. To date, nearly half of the FDA-approved cancer biomarkers are known to be shedding targets (<xref rid="ref26" ref-type="bibr">26</xref>). Our screening also identified notable cancer-related genes such as ERBB2, ERBB4, NTRK2, NTRK3, FGFR2 and FGFR3 (<xref rid="ref27" ref-type="bibr">27</xref>). Reactome (<xref rid="ref19" ref-type="bibr">19</xref>) showed enrichment for pathways associated with cancer, including &#8216;MAPK Family Signalling Cascades&#8217; and &#8216;Signalling By Receptor Tyrosine Kinases&#8217; (<xref rid="f1" ref-type="fig">Fig. 1C</xref>). Immune-related pathways, such as &#8216;immune system&#8217;, and neural differentiation-related pathways &#8216;axon guidance&#8217; and &#8216;nervous system development&#8217; were also enriched (<xref rid="f1" ref-type="fig">Fig. 1C</xref>). Shedding plays a crucial role in immune regulation (<xref rid="ref28" ref-type="bibr">28</xref>), and our screening identified important immune-related genes such as IL6R, IL2RA and TLR4. Additionally, several genes related to axon guidance, such as NRP1, NRP2, UNC5B and UNC5C (<xref rid="ref29" ref-type="bibr">29</xref>) have been identified, suggesting a potential link between neural differentiation and alternative splicing-regulated shedding.</p></sec><sec id="sec10"><title>Splice isoforms of UNC5B, but not those of AXL, have different susceptibilities to shedding</title><p>To examine whether splice isoforms generated by skipping or inclusion of identified skipping exons have different shedding susceptibilities, we selected skipping exons for analysis according to the following criteria: (i) identified in both humans and mice. (ii) Less than 40 bases in length, similar to skipping exons of CADM1 and ALCAM (33 and 39 bases, respectively). (iii) No other alternative splicing events were listed on UniProt. As a result, the skipping exons of three membrane proteins were selected: AXL, a tyrosine kinase receptor (<xref rid="ref30" ref-type="bibr">30</xref>); UNC5B, a netrin receptor (<xref rid="ref10" ref-type="bibr">10</xref>); and PTPRA, a tyrosine phosphatase receptor (<xref rid="ref31" ref-type="bibr">31</xref>). When the amino acid sequences of their juxtamembrane regions were compared, only PTPRA isoforms contained many <italic toggle="yes">O</italic>-glycosylatable amino acids that could interfere with shedding (<xref rid="ref6" ref-type="bibr">6</xref>) (<xref rid="sup1" ref-type="supplementary-material">Figs S1E</xref> and <xref rid="f3" ref-type="fig">3B</xref>); thus, we focused on AXL and UNC5B for the analysis. As shown in <xref rid="f2" ref-type="fig">Fig. 2A</xref>, the skipping exons of both AXL and UNC5B (27 and 33 bases, respectively) encode the stalk region between the extracellular domain structure and the TM domain. The coding sequences of both human long AXL and mouse long UNC5B were purchased, and those of their short isoforms were constructed using a PCR-based method. N-terminally Halo-tagged AXL and UNC5B isoforms were expressed in CHO cells, which were treated with or without 12-<italic toggle="yes">O</italic>-tetradecanoylphorbol 13-acetate (TPA), a strong shedding inducer (<xref rid="ref1" ref-type="bibr">1</xref>). The cell extracts and culture supernatants were subjected to western blotting using an anti-Halo antibody. The Halo-tagged soluble extracellular domain of AXL was almost equally released into the culture supernatant from cells expressing the long or short isoforms in a TPA-dependent manner (<xref rid="f2" ref-type="fig">Fig. 2B</xref>). In contrast, the soluble extracellular domain of UNC5B was released only from cells expressing the long UNC5B, and not from cells expressing the short UNC5B (<xref rid="f2" ref-type="fig">Fig. 2B</xref>). Release of the extracellular domain of long UNC5B was potentiated by TPA (<xref rid="f2" ref-type="fig">Fig. 2B</xref> and <xref rid="f2" ref-type="fig">C</xref>) and completely inhibited by the metalloprotease inhibitor BB94 (<xref rid="f2" ref-type="fig">Fig. 2C</xref>). These results indicate that the two UNC5B isoforms have different susceptibilities to metalloprotease-mediated shedding.</p><fig position="float" id="f2" orientation="portrait"><label>Fig. 2</label><caption><p>Two UNC5B isoforms have different susceptibility to shedding. (A) Schematic diagrams of molecular structure of splice isoforms of human AXL and mouse UNC5B. Exons are indicated by black rectangles and alternative exon are coloured in red. SP, signal peptide; Ig, immunoglobulin-like domain; FN III, fibronectin type III domain; TM, transmembrane domain; Kinase, tyrosine kinase domain; TSP, thrombospondin type 1 domain; ZU5, ZU5 domain; UPA, UPA domain; DD, Death domain. (B) CHO cells expressing N-terminally Halo-tagged splice isoforms of human AXL and mouse UNC5B were treated with or without 200&#160;ng/ml TPA for 60&#160;min, and cell extracts and culture supernatants were subjected to western blotting using anti-Halo antibody. The mean values of soluble extracellular domain quantities in three independent experiments are shown with SD. Asterisk indicates the statistical significance (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) as calculated using the Student&#8217;s <italic toggle="yes">t</italic>-test. NS means not significant. (C) CHO cells expressing Halo-tagged long UNC5B were treated with or without 200&#160;ng/ml TPA and/or 10&#160;&#956;M BB94 for 60&#160;min, and cell extracts and culture supernatants were subjected to western blotting. The mean values of soluble extracellular domain quantities in three independent experiments are shown with SD. Asterisk indicates the statistical significance (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) as calculated using the Student&#8217;s <italic toggle="yes">t</italic>-test. (D) CHO cells expressing Halo-tagged UNC5B isoforms were stained using cell-impermeable HaloTag ligand (Halo ligand). Transfected cells were indicated as DsRed-positive cells (DsRed). Bar, 20&#160;&#956;m.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="mvaf043f2.jpg"/></fig><p>As shedding often occurs at the cell surface, we investigated the cell surface localization of the two UNC5B isoforms. Staining of cells expressing N-terminally Halo-tagged long or short UNC5B with a membrane-impermeable Halo-ligand showed that both isoforms were present on the cell surface to the same extent (<xref rid="f2" ref-type="fig">Fig. 2D</xref>). These results suggest that the two UNC5B isoforms differ in their susceptibility to metalloprotease(s).</p></sec><sec id="sec11"><title>Identification of the cleavage site of long UNC5B</title><p>Next, we attempted to determine the shedding cleavage site of the long UNC5B. N-terminal sequencing of the membrane-anchored shedding product is effective for identifying the shedding cleavage site (<xref rid="ref6" ref-type="bibr">6</xref>, <xref rid="ref7" ref-type="bibr">7</xref>, <xref rid="ref32" ref-type="bibr">32</xref>). To detect membrane-anchored shedding product of long UNC5B, C-terminally PA-tagged UNC5B isoforms were expressed in CHO cells, the cells were treated with TPA and DAPT, a &#947;-secretase inhibitor, and cell extracts were subjected to western blotting using an anti-PA antibody. PA-tagged protein corresponding to the membrane-anchored shedding product (approximately 65&#160;kDa) was detected in the extracts of long UNC5B-expressing cells and increased in response to TPA and DAPT (<xref rid="f3" ref-type="fig">Fig. 3A</xref>, black triangle). This protein was barely detected in the extracts of short UNC5B-expressing cells (<xref rid="f3" ref-type="fig">Fig. 3A</xref>), indicating that it was a membrane-anchored shedding product of long UNC5B. Edman degradation assay of this protein showed that the N-terminal sequence was Asp-Pro-Lys-Ser, indicating that long UNC5B was cleaved between asparagine 361 and aspartic acid 362 (<xref rid="f3" ref-type="fig">Fig. 3B</xref>, arrowhead).</p><fig position="float" id="f3" orientation="portrait"><label>Fig. 3</label><caption><p>Investigation of the shedding cleavage site and sheddase of long UNC5B. (A) CHO cells expressing N-terminally Halo-tagged and cytoplasmic PA-tagged long or short UNC5B were treated with or without 200&#160;ng/ml TPA and/or 10&#160;&#956;M DAPT for 60&#160;min, and cell extracts and culture supernatants were subjected to western blotting using indicated antibodies. Black triangle indicates the approximately 65&#160;kDa membrane-anchored shedding product. (B) The amino acid sequences of juxtamembrane region of UNC5B isoforms. The amino acids encoded by the skipping exon are shown in red, and the amino acids of the TSP type 1 domain are shown in light blue. An arrowhead indicates the shedding cleavage site of long UNC5B. (C) MEF cells transfected with siRNAs and/or Halo-tagged long UNC5B expressing vector as indicated were treated with or without TPA, and cell extracts and culture supernatants were subjected to western blotting using indicated antibodies. The mean values of soluble extracellular domain quantities in three independent experiments are shown with SD. NS means not significant. (D) Wild-type and ADAM17<sup>&#8722;/&#8722;</sup> MEFs transfected with Halo-tagged long UNC5B expressing vector were treated with or without TPA, and cell extracts and culture supernatants were subjected to western blotting using indicated antibodies. The mean values of soluble extracellular domain quantities in three independent experiments are shown with SD. Asterisk indicates the statistical significance (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) as calculated using the Student&#8217;s <italic toggle="yes">t</italic>-test. (E) CHO cells expressing Halo-tagged long UNC5B mutants were treated with TPA for 60&#160;min, and cell extracts and culture supernatants were subjected to western blotting. The amino acid sequences of substitution mutants are indicated above. The mean values of soluble extracellular domain quantities in three independent experiments are shown with SD. Asterisk indicates the statistical significance (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) as calculated using the Student&#8217;s <italic toggle="yes">t</italic>-test. (F) CHO cells expressing N-terminally Halo-tagged and cytoplasmic PA-tagged long UNC5B were treated with 200&#160;ng/ml TPA and/or 1&#160;&#956;M bortezomib for 60&#160;min, and cell extracts and culture supernatants were subjected to western blotting. Black and white triangles indicate the membrane-anchored shedding product and &#947;-fragment of long UNC5B, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="mvaf043f3.jpg"/></fig></sec><sec id="sec12"><title>Investigation of the responsible sheddase of long UNC5B</title><p>Because shedding is mainly executed by two ADAM metalloproteases, ADAM10 and ADAM17 (<xref rid="ref1" ref-type="bibr">1&#8211;3</xref>), we examined whether these ADAMs were responsible for the shedding of long UNC5B. Silencing using the siRNA of ADAM10 did not substantially inhibit the shedding of long UNC5B in mouse embryonic fibroblasts (MEFs), whereas that of ADAM17 tended to inhibit it (<xref rid="f3" ref-type="fig">Fig. 3C</xref>). To further confirm the involvement of ADAM17, we used ADAM17 knockout MEFs (<xref rid="ref20" ref-type="bibr">20</xref>). In ADAM17 knockout MEFs, TPA-dependent shedding of long UNC5B was observed, but its extent was reduced compared to that of wild-type MEFs (<xref rid="f3" ref-type="fig">Fig. 3D</xref>). These results suggest that ADAM17, rather than ADAM10, is partially involved in the shedding of long UNC5B.</p></sec><sec id="sec13"><title>Construction of shedding resistant mutant of long UNC5B</title><p>We have previously shown that a cluster of negatively charged amino acids located around the cleavage site interfere with shedding (<xref rid="ref7" ref-type="bibr">7</xref>). Therefore, we constructed substitution mutants of long UNC5B and examined their susceptibility to shedding. Substitutions of the four amino acids bracketing the identified cleavage site with negatively charged amino acids only partially attenuated the shedding of long UNC5B (<xref rid="f3" ref-type="fig">Fig. 3E</xref>, EDDD), whereas substitutions of the six amino acids almost completely attenuated (<xref rid="f3" ref-type="fig">Fig. 3E</xref>, DEDDDE). These results show that negatively charged amino acids can inhibit the shedding of long UNC5B and indicate the reliability of the identified shedding cleavage site.</p></sec><sec id="sec14"><title>Detection of UNC5B fragment generated by &#947;-secretase cleavage</title><p>The inhibition of &#947;-secretase resulted in the accumulation of membrane-anchored shedding product of long UNC5B (<xref rid="f3" ref-type="fig">Fig. 3A</xref>), suggesting that the product is processed by &#947;-secretase and the entire cytoplasmic domain (&#947;-fragment) is released as in the case of the Notch receptor (<xref rid="ref33" ref-type="bibr">33</xref>). To detect the &#947;-fragment of UNC5B, we used the proteasome inhibitor, bortezomib, because the &#947;-fragment of Neogenin has been reported to increase upon proteasome inhibition (<xref rid="ref34" ref-type="bibr">34</xref>). CHO cells expressing C-terminally PA-tagged long UNC5B were treated with TPA and bortezomib, and cell extracts were subjected to western blotting using anti-PA antibody. PA-tagged protein smaller than membrane-anchored shedding product was detected in the extracts of cells treated with both TPA and bortezomib (<xref rid="f3" ref-type="fig">Fig. 3F</xref>, white triangle). This protein was hardly detected in the extract of cells treated with TPA or bortezomib alone. These results suggest that it is a &#947;-fragment of UNC5B.</p></sec></sec><sec id="sec15"><title>Discussion</title><p>In the present study, we identified UNC5B as an isoform-dependent target for shedding. To the best of our knowledge, this is the first report on the shedding of UNC5B and provides useful insights into the function of UNC5B. UNC5B is a receptor for Netrin-1 that has been identified as a neuronal axon guidance factor (<xref rid="ref8" ref-type="bibr">8</xref>) and is assumed to play an important role in not only neural circuit formation but also angiogenesis and cancer development (<xref rid="ref9" ref-type="bibr">9&#8211;12</xref>). This study suggests that these phenomena may be regulated by the shedding of UNC5B. The long UNC5B coding sequence purchased from Addgene was cloned from mouse retinal cDNA (<xref rid="ref35" ref-type="bibr">35</xref>), suggesting that long UNC5B is sufficiently expressed in the retina, a neural tissue. In addition, RT-PCR using primers flanking exon 8 demonstrated that long UNC5B mRNA was expressed in adult mouse cerebellum at nearly the same level as short UNC5B mRNA (data not shown). These results suggest that shedding-susceptible long UNC5B is expressed in neural tissue and that UNC5B shedding may occur. UNC5B is also known to be a &#8216;dependence receptor&#8217;, which actively induces apoptosis in the &#8216;absence&#8217; of the corresponding ligand, Netrin-1 (<xref rid="ref36" ref-type="bibr">36</xref>). Recently, it has been reported that the UNC5B isoforms have different inducibilities of apoptosis; long UNC5B induces apoptosis only in the absence of Netrin-1, whereas short UNC5B induces apoptosis both in the presence and absence of Netrin-1 (<xref rid="ref37" ref-type="bibr">37</xref>). The functional differences between UNC5B isoforms may be due to the differences in their shedding susceptibility. The report that the shedding-resistant short UNC5B does not respond to Netrin-1 suggests that shedding of UNC5B might be necessary to respond to Netrin-1. Many of the membrane proteins that undergo shedding are further processed by &#947;-secretase, resulting in the release of the &#947;-fragment, which contains the entire cytoplasmic domain, into the cytoplasm. In this study, we identified a protein presumed to be the &#947;-fragment of long UNC5B, which accumulates only when shedding is activated and proteasome is inhibited. It has been reported that the &#947;-fragments of Notch and Neogenin receptors translocate to the nucleus and regulate transcription (<xref rid="ref33" ref-type="bibr">33</xref>, <xref rid="ref34" ref-type="bibr">34</xref>). We would like to investigate whether the &#947;-fragment of UNC5B translocates to the nucleus and regulates transcription in our future studies. Unfortunately, because of the absence of antibodies that recognize the extracellular domain of UNC5B, we have not yet succeeded in observing the shedding of endogenous UNC5B. Whether or not endogenous UNC5B is subject to shedding, and if so, whether the shedding is affected by the extracellular environment, such as the presence of Netrin-1, and what functions the processing products perform, are all questions that future research needs to address.</p><p>The skipping exon of UNC5B encodes the juxtamembrane region, which corresponds to approximately 1% of the full-length protein, indicating the accuracy of the regulatory mechanism of shedding susceptibility. By analyzing the shedding of CADM1 and ALCAM isoforms, we hypothesized that shedding susceptibility is determined by unfavourable factors for sheddases such as <italic toggle="yes">O</italic>-glycans and negatively charged amino acids (<xref rid="ref6" ref-type="bibr">6</xref>, <xref rid="ref7" ref-type="bibr">7</xref>). Our hypothesis was that sheddase tends to cleave at a certain distance from the cell surface and that only membrane proteins with no unfavourable factors around there are susceptible to shedding. In the case of long UNC5B, the shedding cleavage site is located 16 amino acids from the cell surface, and short UNC5B has a TSP type 1 domain at that position. We believe that this study supports our hypothesis and proposes &#8216;domain structure&#8217; as a new unfavourable factor for sheddases.</p><p>The expression ratio of UNC5B isoforms differs depending on the cell type and developmental stage (<xref rid="ref37" ref-type="bibr">37</xref>); thus, even if cells express UNC5B, the responsiveness to Netrin-1 can be altered by alternative splicing. Netrin-1 expression is upregulated in various cancers (<xref rid="ref11" ref-type="bibr">11</xref>, <xref rid="ref12" ref-type="bibr">12</xref>), and cancer therapy using an anti-Netrin-1 neutralizing antibody, which blocks the interaction between Netrin-1 and UNC5B, has been developed, and its efficacy has been verified (<xref rid="ref38" ref-type="bibr">38</xref>, <xref rid="ref39" ref-type="bibr">39</xref>). If this therapy is only effective in cancers expressing shedding-susceptible, Netrin-1-responsive UNC5B, the released extracellular domain of UNC5B could be used as a marker to predict the efficacy of this therapy.</p><p>In this study, we revealed that ADAM17 is partially responsible for shedding of long UNC5B. Shedding of long UNC5B was completely inhibited using metalloprotease inhibitor but not completely inhibited in ADAM17 knockout MEFs, suggesting that metalloproteinases other than ADAM17 also contribute to the shedding of long UNC5B. It is difficult to identify the responsible metalloproteases from the cleavage sequence of long UNC5B because many metalloproteases lack a consensus sequence for cleavage (<xref rid="ref40" ref-type="bibr">40</xref>). Experiments using MEFs lacking metalloproteases may make it possible to identify the responsible metalloproteases in future.</p><p>In this study, we only analyzed the skipping exons of AXL and UNC5B among many identified alternative exons; these skipping exons are less than 40 bases in length. As skipping or inclusion of skipping exons of SIRP&#945;, which are more than 300 bases in length, generates SIRP&#945; isoforms with different shedding susceptibilities (<xref rid="ref6" ref-type="bibr">6</xref>), additional alternative splicing-regulated shedding targets should exist in our list. We argue that the discovery of additional isoform-dependent targets for shedding is a future challenge and that it would be informative to analyze the alternative splicing events of membrane proteins in relation to their susceptibility to shedding.</p></sec><sec sec-type="supplementary-material" id="sec16"><title>Supplementary Data</title><p>
<xref rid="sup1" ref-type="supplementary-material">Supplementary Data</xref> are available at <italic toggle="yes">JB</italic> Online.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>Web_Material_mvaf043</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="web_material_mvaf043.zip" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="mvaf043-ack"><title>Acknowledgements</title><p>We thank Mr. Naoki Matsuda and Mr. Yuta Kawai for technical assistance. The authors used DeepL for the Japanese&#8211;English translation. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication. We thank Editage (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.editage.jp" ext-link-type="uri">www.editage.jp</ext-link>) for English language editing.</p></ack><sec id="sec17"><title>Funding</title><p>This work was financially supported by JSPS KAKENHI (JP18K06911 (to K.S.)), Takeda Science Foundation (to K.S.), Naito Foundation (to K.S.) and a research grant from the Astellas Foundation for Research on Metabolic Disorders (to K.S.).</p></sec><sec sec-type="COI-statement" id="sec18"><title>Conflict of Interest</title><p>The authors declare no conflict of interest. E.W. is employed by Hitachi Ltd., which had no role in the design and execution of this study, the interpretation of its findings or the writing of this manuscript.</p></sec><sec id="sec19"><title>Author Contributions</title><p>K.S., E.W., M.T. and M.K. performed the experiments and data analysis. J.T., H.K. and K.S. designed the experiments. K.S. wrote the manuscript. All authors reviewed and approved the final version of the manuscript.</p></sec><ref-list id="bib1"><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lichtenthaler</surname>, <given-names>S.F.</given-names></string-name>, <string-name name-style="western"><surname>Lemberg</surname>, <given-names>M.K.</given-names></string-name>, and <string-name name-style="western"><surname>Fluhrer</surname>, <given-names>R.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Proteolytic ectodomain shedding of membrane proteins in mammals-hardware, concepts, and recent developments</article-title>. <source>EMBO J.</source> &#160;<volume>37</volume>, e99456<pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.201899456</pub-id><pub-id pub-id-type="pmcid">PMC6068445</pub-id><pub-id pub-id-type="pmid">29976761</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blobel</surname>, <given-names>C.P.</given-names></string-name></person-group> (<year>2005</year>) <article-title>ADAMs: key components in EGFR signalling and development</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> &#160;<volume>6</volume>, <fpage>32</fpage>&#8211;<lpage>43</lpage><pub-id pub-id-type="pmid">15688065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm1548</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reiss</surname>, <given-names>K.</given-names></string-name> and <string-name name-style="western"><surname>Saftig</surname>, <given-names>P.</given-names></string-name></person-group> (<year>2009</year>) <article-title>The "a disintegrin and metalloprotease" (ADAM) family of sheddases: physiological and cellular functions</article-title>. <source>Semin. Cell Dev. Biol.</source> &#160;<volume>20</volume>, <fpage>126</fpage>&#8211;<lpage>137</lpage><pub-id pub-id-type="pmid">19049889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcdb.2008.11.002</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>De Strooper</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Iwatsubo</surname>, <given-names>T.</given-names></string-name>, and <string-name name-style="western"><surname>Wolfe</surname>, <given-names>M.S.</given-names></string-name></person-group> (<year>2012</year>) <article-title>Presenilins and &#947;-secretase: structure, function, and role in Alzheimer disease</article-title>. <source>Cold Spring Harb. Perspect. Med.</source> &#160;<volume>2</volume>, <fpage>a006304</fpage><pub-id pub-id-type="pmid">22315713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a006304</pub-id><pub-id pub-id-type="pmcid">PMC3253024</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shirakabe</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Hattori</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Seiki</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Koyasu</surname>, <given-names>S.</given-names></string-name>, and <string-name name-style="western"><surname>Okada</surname>, <given-names>Y.</given-names></string-name></person-group> (<year>2011</year>) <article-title>VIP36 protein is a target of ectodomain shedding and regulates phagocytosis in macrophage raw 264.7 cells</article-title>. <source>J. Biol. Chem.</source> &#160;<volume>286</volume>, <fpage>43154</fpage>&#8211;<lpage>43163</lpage><pub-id pub-id-type="pmid">22016386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M111.275586</pub-id><pub-id pub-id-type="pmcid">PMC3234858</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shirakabe</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Omura</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Shibagaki</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Mihara</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Homma</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Yoshimura</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Murakami</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Takagi</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Hattori</surname>, <given-names>S.</given-names></string-name>, and <string-name name-style="western"><surname>Ogawa</surname>, <given-names>Y.</given-names></string-name></person-group> (<year>2017</year>) <article-title>Mechanistic insights into ectodomain shedding: susceptibility of CADM1 adhesion molecule is determined by alternative splicing and O-glycosylation</article-title>. <source>Sci. Rep.</source> &#160;<volume>7</volume>, <fpage>46174</fpage><pub-id pub-id-type="pmid">28393893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep46174</pub-id><pub-id pub-id-type="pmcid">PMC5385562</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iwagishi</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Tanaka</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Seto</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Takagi</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Norioka</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Ueyama</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Kawamura</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Takagi</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Ogawa</surname>, <given-names>Y.</given-names></string-name>, and <string-name name-style="western"><surname>Shirakabe</surname>, <given-names>K.</given-names></string-name></person-group> (<year>2020</year>) <article-title>Negatively charged amino acids in the stalk region of membrane proteins reduce ectodomain shedding</article-title>. <source>J. Biol. Chem.</source> &#160;<volume>295</volume>, <fpage>12343</fpage>&#8211;<lpage>12352</lpage><pub-id pub-id-type="pmid">32580944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.RA120.013758</pub-id><pub-id pub-id-type="pmcid">PMC7458810</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Leonardo</surname>, <given-names>E.D.</given-names></string-name>, <string-name name-style="western"><surname>Hinck</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Masu</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Keino-Masu</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Ackerman</surname>, <given-names>S.L.</given-names></string-name>, and <string-name name-style="western"><surname>Tessier-Lavigne</surname>, <given-names>M.</given-names></string-name></person-group> (<year>1997</year>) <article-title>Vertebrate homologues of C. Elegans UNC-5 are candidate netrin receptors</article-title>. <source>Nature.</source> &#160;<volume>386</volume>, <fpage>833</fpage>&#8211;<lpage>838</lpage><pub-id pub-id-type="pmid">9126742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/386833a0</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><surname>Le Noble</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname>, <given-names>Q.</given-names></string-name>, <string-name name-style="western"><surname>De Lafarge</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Sugiyama</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Br&#233;ant</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Claes</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>De Smet</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname>, <given-names>J.L.</given-names></string-name>, <string-name name-style="western"><surname>Autiero</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Carmeliet</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Tessier-Lavigne</surname>, <given-names>M.</given-names></string-name>, and <string-name name-style="western"><surname>Eichmann</surname>, <given-names>A.</given-names></string-name></person-group> (<year>2004</year>) <article-title>The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system</article-title>. <source>Nature.</source> &#160;<volume>432</volume>, <fpage>179</fpage>&#8211;<lpage>186</lpage><pub-id pub-id-type="pmid">15510105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature03080</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname>, <given-names>K.L.W.</given-names></string-name>, <string-name name-style="western"><surname>Correia</surname>, <given-names>J.P.</given-names></string-name>, and <string-name name-style="western"><surname>Kennedy</surname>, <given-names>T.E.</given-names></string-name></person-group> (<year>2011</year>) <article-title>Netrins: versatile extracellular cues with diverse functions</article-title>. <source>Development.</source> &#160;<volume>138</volume>, <fpage>2153</fpage>&#8211;<lpage>2169</lpage><pub-id pub-id-type="pmid">21558366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dev.044529</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mehlen</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Delloye-Bourgeois</surname>, <given-names>C.</given-names></string-name>, and <string-name name-style="western"><surname>Chedotal</surname>, <given-names>A.</given-names></string-name></person-group> (<year>2011</year>) <article-title>Novel roles for slits and netrins: axon guidance cues as anticancer targets?</article-title> &#160;<source>Nat. Rev. Cancer</source> &#160;<volume>11</volume>, <fpage>188</fpage>&#8211;<lpage>197</lpage><pub-id pub-id-type="pmid">21326323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc3005</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nakayama</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Kusumoto</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Nakahara</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Fujiwara</surname>, <given-names>A.</given-names></string-name>, and <string-name name-style="western"><surname>Higashiyama</surname>, <given-names>S.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Semaphorin 3F and Netrin-1: the novel function as a regulator of tumor microenvironment</article-title>. <source>Front. Physiol.</source> &#160;<volume>9</volume>, <fpage>1662</fpage><pub-id pub-id-type="pmid">30532711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2018.01662</pub-id><pub-id pub-id-type="pmcid">PMC6265511</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raney</surname>, <given-names>B.J.</given-names></string-name>, <string-name name-style="western"><surname>Barber</surname>, <given-names>G.P.</given-names></string-name>, <string-name name-style="western"><surname>Benet-Pag&#232;s</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Casper</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Clawson</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Cline</surname>, <given-names>M.S.</given-names></string-name>, <string-name name-style="western"><surname>Diekhans</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Navarro Gonzalez</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Hickey</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Hinrichs</surname>, <given-names>A.S.</given-names></string-name>, <string-name name-style="western"><surname>Kuhn</surname>, <given-names>R.M.</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>, <given-names>B.T.</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>, <given-names>C.M.</given-names></string-name>, <string-name name-style="western"><surname>Le Mercier</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Miga</surname>, <given-names>K.H.</given-names></string-name>, <string-name name-style="western"><surname>Nassar</surname>, <given-names>L.R.</given-names></string-name>, <string-name name-style="western"><surname>Nejad</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Paten</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Perez</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Schmelter</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Speir</surname>, <given-names>M.L.</given-names></string-name>, <string-name name-style="western"><surname>Wick</surname>, <given-names>B.D.</given-names></string-name>, <string-name name-style="western"><surname>Zweig</surname>, <given-names>A.S.</given-names></string-name>, <string-name name-style="western"><surname>Haussler</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Kent</surname>, <given-names>W.J.</given-names></string-name>, and <string-name name-style="western"><surname>Haeussler</surname>, <given-names>M.</given-names></string-name></person-group> (<year>2024</year>) <article-title>The UCSC genome browser database: 2024 update</article-title>. <source>Nucleic Acids Res.</source> &#160;<volume>52</volume>, <fpage>D1082</fpage>&#8211;<lpage>d1088</lpage><pub-id pub-id-type="pmid">37953330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkad987</pub-id><pub-id pub-id-type="pmcid">PMC10767968</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Trincado</surname>, <given-names>J.L.</given-names></string-name>, <string-name name-style="western"><surname>Entizne</surname>, <given-names>J.C.</given-names></string-name>, <string-name name-style="western"><surname>Hysenaj</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Skalic</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Elliott</surname>, <given-names>D.J.</given-names></string-name>, and <string-name name-style="western"><surname>Eyras</surname>, <given-names>E.</given-names></string-name></person-group> (<year>2018</year>) <article-title>SUPPA2: fast, accurate, and uncertainty-aware differential splicing analysis across multiple conditions</article-title>. <source>Genome Biol.</source> &#160;<volume>19</volume>, <fpage>40</fpage><pub-id pub-id-type="pmid">29571299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-018-1417-1</pub-id><pub-id pub-id-type="pmcid">PMC5866513</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The UniProt Consortium</collab></person-group> (<year>2023</year>) <article-title>UniProt: the universal protein knowledgebase in 2023</article-title>. <source>Nucleic Acids Res.</source> &#160;<volume>51</volume>, <fpage>D523</fpage>&#8211;<lpage>d531</lpage><pub-id pub-id-type="pmid">36408920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkac1052</pub-id><pub-id pub-id-type="pmcid">PMC9825514</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Quinlan</surname>, <given-names>A.R.</given-names></string-name> and <string-name name-style="western"><surname>Hall</surname>, <given-names>I.M.</given-names></string-name></person-group> (<year>2010</year>) <article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title>. <source>Bioinformatics.</source> &#160;<volume>26</volume>, <fpage>841</fpage>&#8211;<lpage>842</lpage><pub-id pub-id-type="pmid">20110278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btq033</pub-id><pub-id pub-id-type="pmcid">PMC2832824</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>NCBI Resource Coordinators</collab></person-group> (<year>2018</year>) <article-title>Database resources of the National Center for biotechnology information</article-title>. <source>Nucleic Acids Res.</source> &#160;<volume>46</volume>, <fpage>D8</fpage>&#8211;<lpage>d13</lpage><pub-id pub-id-type="pmid">29140470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkx1095</pub-id><pub-id pub-id-type="pmcid">PMC5753372</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xie</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><surname>Bailey</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Kuleshov</surname>, <given-names>M.V.</given-names></string-name>, <string-name name-style="western"><surname>Clarke</surname>, <given-names>D.J.B.</given-names></string-name>, <string-name name-style="western"><surname>Evangelista</surname>, <given-names>J.E.</given-names></string-name>, <string-name name-style="western"><surname>Jenkins</surname>, <given-names>S.L.</given-names></string-name>, <string-name name-style="western"><surname>Lachmann</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Wojciechowicz</surname>, <given-names>M.L.</given-names></string-name>, <string-name name-style="western"><surname>Kropiwnicki</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Jagodnik</surname>, <given-names>K.M.</given-names></string-name>, <string-name name-style="western"><surname>Jeon</surname>, <given-names>M.</given-names></string-name>, and <string-name name-style="western"><surname>Ma'ayan</surname>, <given-names>A.</given-names></string-name></person-group> (<year>2021</year>) <article-title>Gene set knowledge discovery with Enrichr</article-title>. <source>Curr Protoc.</source> &#160;<volume>1</volume>, <fpage>e90</fpage><pub-id pub-id-type="pmid">33780170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpz1.90</pub-id><pub-id pub-id-type="pmcid">PMC8152575</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gillespie</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Jassal</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Stephan</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Milacic</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Rothfels</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Senff-Ribeiro</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Griss</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Sevilla</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Matthews</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Varusai</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Ragueneau</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Haider</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>May</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Shamovsky</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Weiser</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Brunson</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Sanati</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Beckman</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Shao</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><surname>Fabregat</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Sidiropoulos</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Murillo</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Viteri</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Cook</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Shorser</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Bader</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Demir</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Sander</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Haw</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Hermjakob</surname>, <given-names>H.</given-names></string-name>, and <string-name name-style="western"><surname>D'Eustachio</surname>, <given-names>P.</given-names></string-name></person-group> (<year>2022</year>) <article-title>The reactome pathway knowledgebase 2022</article-title>. <source>Nucleic Acids Res.</source> &#160;<volume>50</volume>, <fpage>D687</fpage>&#8211;<lpage>d692</lpage><pub-id pub-id-type="pmid">34788843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkab1028</pub-id><pub-id pub-id-type="pmcid">PMC8689983</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Horiuchi</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Kimura</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Miyamoto</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Takaishi</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Okada</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Toyama</surname>, <given-names>Y.</given-names></string-name>, and <string-name name-style="western"><surname>Blobel</surname>, <given-names>C.P.</given-names></string-name></person-group> (<year>2007</year>) <article-title>Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock</article-title>. <source>J. Immunol.</source> &#160;<volume>179</volume>, <fpage>2686</fpage>&#8211;<lpage>2689</lpage><pub-id pub-id-type="pmid">17709479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.179.5.2686</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shirakabe</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Shibagaki</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Yoshimura</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Koyasu</surname>, <given-names>S.</given-names></string-name>, and <string-name name-style="western"><surname>Hattori</surname>, <given-names>S.</given-names></string-name></person-group> (<year>2014</year>) <article-title>A proteomic approach for the elucidation of the specificity of ectodomain shedding</article-title>. <source>J. Proteome</source> &#160;<volume>98</volume>, <fpage>233</fpage>&#8211;<lpage>243</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jprot.2014.01.012</pub-id><pub-id pub-id-type="pmid">24456812</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tsumagari</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname>, <given-names>C.H.</given-names></string-name>, and <string-name name-style="western"><surname>Ishihama</surname>, <given-names>Y.</given-names></string-name></person-group> (<year>2021</year>) <article-title>Exploring the landscape of ectodomain shedding by quantitative protein terminomics</article-title>. <source>iScience.</source> &#160;<volume>24</volume>, <fpage>102259</fpage><pub-id pub-id-type="pmid">33796845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2021.102259</pub-id><pub-id pub-id-type="pmcid">PMC7995609</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname>, <given-names>W.Y.</given-names></string-name> and <string-name name-style="western"><surname>Wu</surname>, <given-names>K.P.</given-names></string-name></person-group> (<year>2023</year>) <article-title>SheddomeDB 2023: a revision of an Ectodomain shedding database based on a comprehensive literature review and online resources</article-title>. <source>J. Proteome Res.</source> &#160;<volume>22</volume>, <fpage>2570</fpage>&#8211;<lpage>2576</lpage><pub-id pub-id-type="pmid">37458416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jproteome.3c00001</pub-id><pub-id pub-id-type="pmcid">PMC10407926</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Swendeman</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Mendelson</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Weskamp</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Horiuchi</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Deutsch</surname>, <given-names>U.</given-names></string-name>, <string-name name-style="western"><surname>Scherle</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Hooper</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Rafii</surname>, <given-names>S.</given-names></string-name>, and <string-name name-style="western"><surname>Blobel</surname>, <given-names>C.P.</given-names></string-name></person-group> (<year>2008</year>) <article-title>VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling</article-title>. <source>Circ. Res.</source> &#160;<volume>103</volume>, <fpage>916</fpage>&#8211;<lpage>918</lpage><pub-id pub-id-type="pmid">18818406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.108.184416</pub-id><pub-id pub-id-type="pmcid">PMC2574836</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kreitman</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Noronha</surname>, <given-names>A.</given-names></string-name>, and <string-name name-style="western"><surname>Yarden</surname>, <given-names>Y.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Irreversible modifications of receptor tyrosine kinases</article-title>. <source>FEBS Lett.</source> &#160;<volume>592</volume>, <fpage>2199</fpage>&#8211;<lpage>2212</lpage><pub-id pub-id-type="pmid">29790151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1873-3468.13095</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>J&#248;rgensen</surname>, <given-names>J.T.</given-names></string-name></person-group> (<year>2021</year>) <article-title>The current landscape of the FDA approved companion diagnostics</article-title>. <source>Transl. Oncol.</source> &#160;<volume>14</volume>, <fpage>101063</fpage><pub-id pub-id-type="pmid">33714919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tranon.2021.101063</pub-id><pub-id pub-id-type="pmcid">PMC7957094</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lemmon</surname>, <given-names>M.A.</given-names></string-name> and <string-name name-style="western"><surname>Schlessinger</surname>, <given-names>J.</given-names></string-name></person-group> (<year>2010</year>) <article-title>Cell signaling by receptor tyrosine kinases</article-title>. <source>Cell.</source> &#160;<volume>141</volume>, <fpage>1117</fpage>&#8211;<lpage>1134</lpage><pub-id pub-id-type="pmid">20602996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2010.06.011</pub-id><pub-id pub-id-type="pmcid">PMC2914105</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khokha</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Murthy</surname>, <given-names>A.</given-names></string-name>, and <string-name name-style="western"><surname>Weiss</surname>, <given-names>A.</given-names></string-name></person-group> (<year>2013</year>) <article-title>Metalloproteinases and their natural inhibitors in inflammation and immunity</article-title>. <source>Nat Rev Immunol.</source> &#160;<volume>13</volume>, <fpage>649</fpage>&#8211;<lpage>665</lpage><pub-id pub-id-type="pmid">23969736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3499</pub-id></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dickson</surname>, <given-names>B.J.</given-names></string-name></person-group> (<year>2002</year>) <article-title>Molecular mechanisms of axon guidance</article-title>. <source>Science.</source> &#160;<volume>298</volume>, <fpage>1959</fpage>&#8211;<lpage>1964</lpage><pub-id pub-id-type="pmid">12471249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1072165</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lemke</surname>, <given-names>G.</given-names></string-name></person-group> (<year>2017</year>) <article-title>Phosphatidylserine is the signal for TAM receptors and their ligands</article-title>. <source>Trends Biochem. Sci.</source> &#160;<volume>42</volume>, <fpage>738</fpage>&#8211;<lpage>748</lpage><pub-id pub-id-type="pmid">28734578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibs.2017.06.004</pub-id><pub-id pub-id-type="pmcid">PMC5600686</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tonks</surname>, <given-names>N.K.</given-names></string-name></person-group> (<year>2006</year>) <article-title>Protein tyrosine phosphatases: from genes, to function, to disease</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> &#160;<volume>7</volume>, <fpage>833</fpage>&#8211;<lpage>846</lpage><pub-id pub-id-type="pmid">17057753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrm2039</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hua</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><surname>Watanabe</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Fukunaga</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Matsui</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Matsuoka</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Yamaguchi</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Tanabe</surname>, <given-names>S.Y.</given-names></string-name>, <string-name name-style="western"><surname>Yamamoto</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Tamura-Kawakami</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Takagi</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Kajita</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Futai</surname>, <given-names>E.</given-names></string-name>, and <string-name name-style="western"><surname>Shirakabe</surname>, <given-names>K.</given-names></string-name></person-group> (<year>2024</year>) <article-title>C-terminal amino acids in the type I transmembrane domain of L-type lectin VIP36 affect &#947;-secretase susceptibility</article-title>. <source>Biochem. Biophys. Res. Commun.</source> &#160;<volume>696</volume>, <fpage>149504</fpage><pub-id pub-id-type="pmid">38219489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2024.149504</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sprinzak</surname>, <given-names>D.</given-names></string-name> and <string-name name-style="western"><surname>Blacklow</surname>, <given-names>S.C.</given-names></string-name></person-group> (<year>2021</year>) <article-title>Biophysics of notch signaling</article-title>. <source>Annu. Rev. Biophys.</source> &#160;<volume>50</volume>, <fpage>157</fpage>&#8211;<lpage>189</lpage><pub-id pub-id-type="pmid">33534608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-biophys-101920-082204</pub-id><pub-id pub-id-type="pmcid">PMC8105286</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Goldschneider</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Rama</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Guix</surname>, <given-names>C.</given-names></string-name>, and <string-name name-style="western"><surname>Mehlen</surname>, <given-names>P.</given-names></string-name></person-group> (<year>2008</year>) <article-title>The neogenin intracellular domain regulates gene transcription via nuclear translocation</article-title>. <source>Mol. Cell. Biol.</source> &#160;<volume>28</volume>, <fpage>4068</fpage>&#8211;<lpage>4079</lpage><pub-id pub-id-type="pmid">18391016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/MCB.02114-07</pub-id><pub-id pub-id-type="pmcid">PMC2423113</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Visser</surname>, <given-names>J.J.</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Perry</surname>, <given-names>S.C.</given-names></string-name>, <string-name name-style="western"><surname>Chastain</surname>, <given-names>A.B.</given-names></string-name>, <string-name name-style="western"><surname>Parsa</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Masri</surname>, <given-names>S.S.</given-names></string-name>, <string-name name-style="western"><surname>Ray</surname>, <given-names>T.A.</given-names></string-name>, <string-name name-style="western"><surname>Kay</surname>, <given-names>J.N.</given-names></string-name>, and <string-name name-style="western"><surname>Wojtowicz</surname>, <given-names>W.M.</given-names></string-name></person-group> (<year>2015</year>) <article-title>An extracellular biochemical screen reveals that FLRTs and Unc5s mediate neuronal subtype recognition in the retina</article-title>. <source>Elife.</source> &#160;<volume>4</volume>, <fpage>e08149</fpage><pub-id pub-id-type="pmid">26633812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.08149</pub-id><pub-id pub-id-type="pmcid">PMC4737655</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brisset</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Grandin</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Bernet</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Mehlen</surname>, <given-names>P.</given-names></string-name>, and <string-name name-style="western"><surname>Hollande</surname>, <given-names>F.</given-names></string-name></person-group> (<year>2021</year>) <article-title>Dependence receptors: new targets for cancer therapy</article-title>. <source>EMBO Mol Med.</source> &#160;<volume>13</volume>, <fpage>e14495</fpage><pub-id pub-id-type="pmid">34542930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.202114495</pub-id><pub-id pub-id-type="pmcid">PMC8573599</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pradella</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Deflorian</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Pezzotta</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Di Matteo</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Belloni</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Campolungo</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Paradisi</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Bugatti</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Vermi</surname>, <given-names>W.</given-names></string-name>, <string-name name-style="western"><surname>Campioni</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Chiapparino</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Scietti</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Forneris</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Giampietro</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Volf</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Rehman</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Zacchigna</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Paronetto</surname>, <given-names>M.P.</given-names></string-name>, <string-name name-style="western"><surname>Pistocchi</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Eichmann</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Mehlen</surname>, <given-names>P.</given-names></string-name>, and <string-name name-style="western"><surname>Ghigna</surname>, <given-names>C.</given-names></string-name></person-group> (<year>2021</year>) <article-title>A ligand-insensitive UNC5B splicing isoform regulates angiogenesis by promoting apoptosis</article-title>. <source>Nat. Commun.</source> &#160;<volume>12</volume>, <fpage>4872</fpage><pub-id pub-id-type="pmid">34381052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-24998-6</pub-id><pub-id pub-id-type="pmcid">PMC8358048</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lengrand</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Pastushenko</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><surname>Vanuytven</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Song</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Venet</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Sarate</surname>, <given-names>R.M.</given-names></string-name>, <string-name name-style="western"><surname>Bellina</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Moers</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Boinet</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Sifrim</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Rama</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Ducarouge</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Van Herck</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Dubois</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Scozzaro</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Lemaire</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Gieskes</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Bonni</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Collin</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Braissand</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Allard</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Zindy</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Decaestecker</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Sotiriou</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Salmon</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><surname>Mehlen</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Voet</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Bernet</surname>, <given-names>A.</given-names></string-name>, and <string-name name-style="western"><surname>Blanpain</surname>, <given-names>C.</given-names></string-name></person-group> (<year>2023</year>) <article-title>Pharmacological targeting of netrin-1 inhibits EMT in cancer</article-title>. <source>Nature.</source> &#160;<volume>620</volume>, <fpage>402</fpage>&#8211;<lpage>408</lpage><pub-id pub-id-type="pmid">37532929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06372-2</pub-id><pub-id pub-id-type="pmcid">PMC7615210</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cassier</surname>, <given-names>P.A.</given-names></string-name>, <string-name name-style="western"><surname>Navaridas</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Bellina</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Rama</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Ducarouge</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Hernandez-Vargas</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Delord</surname>, <given-names>J.P.</given-names></string-name>, <string-name name-style="western"><surname>Lengrand</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Paradisi</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Fattet</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Garin</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Gheit</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Dalban</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Pastushenko</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><surname>Neves</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Jelin</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Gadot</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Braissand</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Leon</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Degletagne</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Matias-Guiu</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><surname>Devouassoux-Shisheboran</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Mery-Lamarche</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Allard</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Zindy</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Decaestecker</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Salmon</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><surname>Perol</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Dolcet</surname>, <given-names>X.</given-names></string-name>, <string-name name-style="western"><surname>Ray-Coquard</surname>, <given-names>I.</given-names></string-name>, <string-name name-style="western"><surname>Blanpain</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Bernet</surname>, <given-names>A.</given-names></string-name>, and <string-name name-style="western"><surname>Mehlen</surname>, <given-names>P.</given-names></string-name></person-group> (<year>2023</year>) <article-title>Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer</article-title>. <source>Nature.</source> &#160;<volume>620</volume>, <fpage>409</fpage>&#8211;<lpage>416</lpage><pub-id pub-id-type="pmid">37532934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06367-z</pub-id><pub-id pub-id-type="pmcid">PMC10412451</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hey</surname>, <given-names>S.</given-names></string-name> and <string-name name-style="western"><surname>Linder</surname>, <given-names>S.</given-names></string-name></person-group> (<year>2024</year>) <article-title>Matrix metalloproteinases at a glance</article-title>. <source>J. Cell Sci.</source> &#160;<volume>137</volume>, jcs261898<pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/jcs.261898</pub-id><pub-id pub-id-type="pmid">38236162</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">AJNR Am J Neuroradiol</journal-id><journal-id journal-id-type="iso-abbrev">AJNR Am J Neuroradiol</journal-id><journal-id journal-id-type="pmc-domain-id">3743</journal-id><journal-id journal-id-type="pmc-domain">ajnr</journal-id><journal-id journal-id-type="publisher-id">AJNR</journal-id><journal-title-group><journal-title>AJNR: American Journal of Neuroradiology</journal-title></journal-title-group><issn pub-type="ppub">0195-6108</issn><issn pub-type="epub">1936-959X</issn><publisher><publisher-name>American Society of Neuroradiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11448992</article-id><article-id pub-id-type="pmcid-ver">PMC11448992.1</article-id><article-id pub-id-type="pmcaid">11448992</article-id><article-id pub-id-type="pmcaiid">11448992</article-id><article-id pub-id-type="pmid">38866432</article-id><article-id pub-id-type="doi">10.3174/ajnr.A8372</article-id><article-id pub-id-type="publisher-id">23-01121</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Neurodegenerative Disorder Imaging</subject></subj-group><subj-group subj-group-type="heading"><subject>Artificial Intelligence</subject></subj-group></article-categories><title-group><article-title>MRI-Based Prediction of Clinical Improvement after Ventricular Shunt Placement for Normal Pressure Hydrocephalus: Development and Evaluation of an Integrated Multisequence Machine Learning Algorithm</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6282-828X</contrib-id><name name-style="western"><surname>Leary</surname><given-names initials="OP">Owen P.</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhong</surname><given-names initials="Z">Zhusi</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-6195-1786</contrib-id><name name-style="western"><surname>Bi</surname><given-names initials="L">Lulu</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiao</surname><given-names initials="Z">Zhicheng</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dai</surname><given-names initials="YW">Yu-Wei</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ma</surname><given-names initials="K">Kevin</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0117-2405</contrib-id><name name-style="western"><surname>Sayied</surname><given-names initials="S">Shanzeh</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7013-4301</contrib-id><name name-style="western"><surname>Kargilis</surname><given-names initials="D">Daniel</given-names></name><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5433-4925</contrib-id><name name-style="western"><surname>Imami</surname><given-names initials="M">Maliha</given-names></name><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5214-1898</contrib-id><name name-style="western"><surname>Zhao</surname><given-names initials="LM">Lin-Mei</given-names></name><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2181-9889</contrib-id><name name-style="western"><surname>Feng</surname><given-names initials="X">Xue</given-names></name><xref rid="aff7" ref-type="aff">g</xref><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Riccardello</surname><given-names initials="G">Gerald</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Collins</surname><given-names initials="S">Scott</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Svokos</surname><given-names initials="K">Konstantina</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9464-1551</contrib-id><name name-style="western"><surname>Moghekar</surname><given-names initials="A">Abhay</given-names></name><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="L">Li</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bai</surname><given-names initials="H">Harrison</given-names></name><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9894-7723</contrib-id><name name-style="western"><surname>Klinge</surname><given-names initials="PM">Petra M.</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0594-1542</contrib-id><name name-style="western"><surname>Boxerman</surname><given-names initials="JL">Jerrold L.</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><aff id="aff1"><sup>a</sup>From the Department of Neurosurgery (O.P.L., K.M., S.S., K.S., P.M.K.), Brown University Warren Alpert Medical School, Providence, Rhode Island</aff><aff id="aff2"><sup>b</sup>Department of Diagnostic Imaging (Z.Z., L.B., Z.J., G.R., S.C., J.L.B.), Brown University Warren Alpert Medical School, Providence, Rhode Island</aff><aff id="aff3"><sup>c</sup>School of Electronic Engineering (Z.Z.), Xidian University, Xi&#8217;an, China</aff><aff id="aff4"><sup>d</sup>Department of Neurology (Y.-W.D., L.Y.), The Second Xiangya Hospital, Central South University, Hunan, China</aff><aff id="aff5"><sup>e</sup>Department of Radiology (D.K., M.I., L.-M.Z., H.B.), Johns Hopkins University School of Medicine, Baltimore, Maryland</aff><aff id="aff6"><sup>f</sup>Columbia University Vagelos College of Physicians and Surgeons (K.M.), New York, New York</aff><aff id="aff7"><sup>g</sup>Carina Medical (X.F.), Lexington, Kentucky</aff><aff id="aff8"><sup>h</sup>Department of Biomedical Engineering (X.F.), University of Virginia, Charlottesville, Virginia</aff><aff id="aff9"><sup>i</sup>Department of Neurology (A.M.), Johns Hopkins University School of Medicine, Baltimore, Maryland</aff></contrib-group><author-notes><corresp>Please address correspondence to Owen P. Leary, <addr-line>BS, Warren Alpert Medical School of Brown University, Department of Neurosurgery, Rhode Island Hospital, APC Building, Floor 6, 593 Eddy St, Providence RI 02903</addr-line>; e-mail:&#8194;<email>owen_leary@brown.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2024</year></pub-date><volume>45</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">472108</issue-id><fpage>1536</fpage><lpage>1544</lpage><history><date date-type="received"><day>2</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>5</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-released-under-embargo"><date><day>04</day><month>10</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 00:25:23.493"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by American Journal of Neuroradiology</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>American Journal of Neuroradiology</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="zj41536.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="AN-AJNR240229.pdf"/><abstract><sec><title>BACKGROUND AND PURPOSE:</title><p>Symptoms of normal pressure hydrocephalus (NPH) are sometimes refractory to shunt placement, with limited ability to predict improvement for individual patients. We evaluated an MRI-based artificial intelligence method to predict postshunt NPH symptom improvement.</p></sec><sec><title>MATERIALS AND METHODS:</title><p>Patients with NPH who underwent MRI before shunt placement at a single center (2014&#8211;2021) were identified. Twelve-month postshunt improvement in mRS, incontinence, gait, and cognition were retrospectively abstracted from clinical documentation. 3D deep residual neural networks were built on skull-stripped T2-weighted and FLAIR images. Predictions based on both sequences were fused by additional network layers. Patients from 2014&#8211;2019 were used for parameter optimization, while those from 2020&#8211;2021 were used for testing. Models were validated on an external validation data set from a second institution (<italic toggle="yes">n</italic> = 33).</p></sec><sec><title>RESULTS:</title><p>Of 249 patients, <italic toggle="yes">n</italic> = 201 and <italic toggle="yes">n</italic> = 185 were included in the T2-based and FLAIR-based models according to imaging availability. The combination of T2-weighted and FLAIR sequences offered the best performance in mRS and gait improvement predictions relative to models trained on imaging acquired by using only 1 sequence, with area under the receiver operating characteristic (AUROC) values of 0.7395 [0.5765&#8211;0.9024] for mRS and 0.8816 [0.8030&#8211;0.9602] for gait. For urinary incontinence and cognition, combined model performances on predicting outcomes were similar to FLAIR-only performance, with AUROC values of 0.7874 [0.6845&#8211;0.8903] and 0.7230 [0.5600&#8211;0.8859].</p></sec><sec><title>CONCLUSIONS:</title><p>Application of a combined algorithm by using both T2-weighted and FLAIR sequences offered the best image-based prediction of postshunt symptom improvement, particularly for gait and overall function in terms of mRS.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-id journal-id-type="pmc-domain-id">943</journal-id><journal-id journal-id-type="pmc-domain">alzreth</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12482320</article-id><article-id pub-id-type="pmcid-ver">PMC12482320.1</article-id><article-id pub-id-type="pmcaid">12482320</article-id><article-id pub-id-type="pmcaiid">12482320</article-id><article-id pub-id-type="pmid">41029412</article-id><article-id pub-id-type="doi">10.1186/s13195-025-01858-9</article-id><article-id pub-id-type="publisher-id">1858</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Cerebral amyloid-&#946;, glucose metabolism and hippocampal volume in major depression with and without suspected non-Alzheimer pathophysiology (SNAP)</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="MJ">Min-Jung</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hsiao</surname><given-names initials="IT">Ing-Tsung</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="KJ">Kun-Ju</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="YM">Yi-Ming</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wu</surname><given-names initials="KY">Kuan-Yi</given-names></name><address><email>kuanyiwu1@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00d80zx46</institution-id><institution-id institution-id-type="GRID">grid.145695.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 0922</institution-id><institution>Department of Psychiatry, </institution><institution>Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, </institution></institution-wrap>5 Fu-Hsing Street, Guishan, Tao-Yuan, Taiwan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02verss31</institution-id><institution-id institution-id-type="GRID">grid.413801.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0711 0593</institution-id><institution>Department of Nuclear Medicine and Center for Advanced Molecular Imaging and Translation, </institution><institution>Chang Gung Memorial Hospital, </institution></institution-wrap>Tao-Yuan, Taiwan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00d80zx46</institution-id><institution-id institution-id-type="GRID">grid.145695.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 0922</institution-id><institution>Department of Medical Imaging and Radiological Sciences and Healthy Aging Research Center, </institution><institution>Chang Gung University, </institution></institution-wrap>Tao-Yuan, Taiwan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02verss31</institution-id><institution-id institution-id-type="GRID">grid.413801.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0711 0593</institution-id><institution>Neuroscience Research Center, </institution><institution>Chang Gung Memorial Hospital, Linkou Medical Center, </institution></institution-wrap>Tao-Yuan, Taiwan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02verss31</institution-id><institution-id institution-id-type="GRID">grid.413801.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0711 0593</institution-id><institution>Department of Radiology, </institution><institution>Chang Gung Memorial Hospital, </institution></institution-wrap>Taoyuan, Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">478170</issue-id><elocation-id>207</elocation-id><history><date date-type="received"><day>8</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>1</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 13:25:38.967"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13195_2025_Article_1858.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Major depressive disorder (MDD) can encompass suspected non-Alzheimer&#8217;s disease pathophysiology (SNAP), characterized by negative cerebral Amyloid-&#946; (A&#946;) and positive neurodegeneration (ND) biomarkers. Relationships among cerebral A&#946; deposition, glucose metabolism, and hippocampal volume in SNAP and non-SNAP MDD groups remain unclear.</p></sec><sec><title>Methods</title><p id="Par2">We conducted cross-sectional analyses of 136 MDD patients (enrolment age&#8201;&#8805;&#8201;50 years), classified into SNAP (<italic toggle="yes">n</italic>&#8201;=&#8201;71) and non-SNAP (<italic toggle="yes">n</italic>&#8201;=&#8201;65) groups. Dual-phase <sup>18</sup>F-florbetapir (AV45) PET/MR scans provided early-phase (as a proxy for glucose metabolism) and late-phase (reflecting A&#946; deposition) images. Bilateral adjusted hippocampal volume (HVa) was measured using MRI. Partial correlations and multiple regression analyses examined the associations among A&#946; deposition, metabolism, HVa, and depression-related variables.</p></sec><sec><title>Results</title><p id="Par3">In the non-SNAP MDD, greater A&#946; deposition was associated with reduced glucose metabolism and smaller HVa, while HVa positively correlated with metabolism. Glucose metabolism partially mediated the relationship between A&#946; deposition and both hippocampal atrophy and cognition function. In the SNAP MDD group, lower A&#946; deposition was associated with lower glucose metabolism. While more lifetime depressive episodes were related to smaller HVa, depression severity showed a positive correlation with HVa. Additional subgroup analyses stratified by age and A&#946;/ND status were also conducted.</p></sec><sec><title>Conclusions</title><p id="Par4">These findings suggest distinct biological patterns in SNAP and non-SNAP MDD. Age- and biomarker (A&#946;/ND)-stratified analyses yielded consistent A&#946;&#8211;metabolism&#8211;atrophy profiles; however, the biomarker-stratified results should be interpreted with caution due to limited sample sizes. Notably, the non-SNAP group comprises biologically heterogeneous subgroups, which may obscure important distinctions and limit the interpretability of pooled findings. These results underscore the need for subgroup-specific approaches to better elucidate the pathophysiology of MDD.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13195-025-01858-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Suspected non-Alzheimer pathophysiology (SNAP)</kwd><kwd>Major depressive disorder (MDD)</kwd><kwd>Amyloid-&#946; (A&#946;)</kwd><kwd><sup>18</sup>F-florbetapir (AV45/Amyvid)</kwd><kwd>Glucose metabolism</kwd><kwd>Hippocampal atrophy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Late-life depression is a complex condition marked by both depressed mood and impaired cognitive function, that often presents significant challenges in both diagnosis and treatment [<xref ref-type="bibr" rid="CR1">1</xref>]. A subset of these patients appears to overlap biologically with Alzheimer&#8217;s disease (AD) or other type dementia [<xref ref-type="bibr" rid="CR2">2</xref>], necessitating a clearer view of shared versus distinct mechanisms.</p><p id="Par6">The National Institute on Aging and Alzheimer&#8217;s Association (NIA-AA) proposed a biomarker-based &#8220;ATN&#8221; (Amyloid/Tau/Neurodegeneration) research framework for AD research [<xref ref-type="bibr" rid="CR3">3</xref>]. While late-life depression can be a standalone condition, there is growing evidence to suggest that it may also manifest as an early indicator of underlying neurodegenerative processes. Our previous study [<xref ref-type="bibr" rid="CR4">4</xref>] found increased cerebral A&#946; deposition in late-life major depressive disorder (MDD), whereas Mackin et al. examined late-life depression and reported lower cortical A&#946; deposition than in non-depressed controls [<xref ref-type="bibr" rid="CR5">5</xref>]. Recent research continues to debate the interactions between late-life depression and AD or non-AD pathologies. For instance, Xu et al. [<xref ref-type="bibr" rid="CR6">6</xref>] found that cerebrospinal fluid A&#946; may not only directly contribute to cognitive decline but also magnify the influence of even mild depressive symptoms on cognition in older adults without dementia. Conversely, Mackin et al. [<xref ref-type="bibr" rid="CR5">5</xref>] demonstrated that late-life depression is associated with lower cortical A&#946;, implying that cognitive deficits may arise from factors such as cerebral blood flow or glucose metabolism rather than amyloid pathology. Such variability likely reflects the marked heterogeneity within late-life depression, which encompasses subgroups with distinct pathophysiological features.</p><p id="Par7">Suspected non-Alzheimer disease pathophysiology (SNAP) is characterized by negative amyloid-&#946; (A&#946;-) but positive neurodegeneration (ND+) markers. Hippocampal atrophy and glucose hypometabolism within AD-vulnerable regions are widely adopted as ND biomarkers [<xref ref-type="bibr" rid="CR7">7</xref>&#8211;<xref ref-type="bibr" rid="CR10">10</xref>]. Several studies have demonstrated the relationship between depression, brain atrophy, and hypometabolism in depressed subjects, suggesting significant associations between depression and reductions in gray matter volume, particularly in the hippocampus and prefrontal regions [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. These structural changes affect cognitive impairments in depressed patients.&#8203; Furthermore, longitudinal data indicate that smaller hippocampal volume in late-life depression showed a greater likelihood of converting to dementia [<xref ref-type="bibr" rid="CR13">13</xref>]. Cerebral blood flow and glucose metabolism deficits in frontal regions appear a consistent finding [<xref ref-type="bibr" rid="CR14">14</xref>]. Our previous study [<xref ref-type="bibr" rid="CR15">15</xref>] revealed that a substantial proportion of MDD patients met the criteria of SNAP, exhibiting pronounced cerebral atrophy and hypometabolism.</p><p id="Par8">This study aims to elucidate the relationships among cerebral A&#946; deposition, glucose metabolism, hippocampal volume and depression in MDD patients by separating SNAP and non-SNAP subgroups, investigating explanatory variables of cognitive function (MMSE scores), and exploring potential mediation effects within these relationships.</p></sec><sec id="Sec2"><title>Methods and materials</title><sec id="Sec3"><title>Study participants and ethics</title><p id="Par9">The participants in this research were drawn from a longitudinal clinical cohort study initiated in 2011 at the geriatric psychiatry center of Chang Gung Memorial Hospital (CGMH). The study aimed to explore cerebral A&#946; deposition in individuals with non-dementia MDD. Each MDD patient underwent evaluation for the presence of major depressive episodes according to DSM-IV criteria (later DSM-5 from 2016 onwards) through both a clinical structured interview and a review of their medical records [<xref ref-type="bibr" rid="CR16">16</xref>]. Furthermore, the study sought to delineate the lifetime trajectory of major depression, encompassing factors such as age of onset, number of episodes, and duration since the first episode.</p><p id="Par10">All MDD participants, aged&#8201;&#8805;&#8201;50 years, were free from neurological conditions affecting brain structure (e.g., complete stroke, traumatic head injury, epilepsy), unstable medical conditions involving major organs, and current or recent alcohol or substance abuse. None met the NIA-AA criteria for Alzheimer&#8217;s dementia [<xref ref-type="bibr" rid="CR3">3</xref>] or the DSM-5 criteria for any form of dementia (American Psychiatric Association, 2013). Eligibility criteria required completion of an AV45 PET scan, brain MRI, and MMSE assessment. From July 2014 to June 2020, a total of 161 MDD patients were consecutively enrolled. Twenty-five subjects were excluded due to incomplete AV45 PET/MR scans. Thus, the prospective, cross-sectional study comprised 136 MDD subjects for subsequent analysis. Written informed consent was obtained from all subjects, and the study protocol was approved by the Institutional Review Boards of the Ministry of Health and Welfare and Chang Gung Medical Center. This study adhered to the ethical standards of national and institutional committees on human experimentation and the 2013 revision of the 1975 Helsinki Declaration.</p></sec><sec id="Sec4"><title>Magnetic resonance imaging acquisition and data preprocessing</title><p id="Par11">T1-weighted MRI was performed for all subjects using a 3T Siemens Magnetom TIM Trio scanner on a PET/MR system (Siemens Medical Solutions, Malvern, PA, United States). An acquisition protocol using the following parameters with a sagittal T1-weighted magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence was applied: Repetition Time (TR)/Echo Time (TE)&#8201;=&#8201;2,600/3.12 ms, TI&#8201;=&#8201;900 ms, flip angle&#8201;=&#8201;13, voxel size&#8201;=&#8201;0.5&#160;mm 0.5&#160;mm 1.1&#160;mm. Structural scans were processed using FreeSurfer version 7.1 image analysis software for total bilateral hippocampal and intracranial volumes [<xref ref-type="bibr" rid="CR17">17</xref>]. The total bilateral hippocampal volume adjusted by the estimated total intracranial volume was measured to obtain the adjusted hippocampal volume (HVa), as described in our previous study [<xref ref-type="bibr" rid="CR15">15</xref>], to reduce inter-subject variability.</p></sec><sec id="Sec5"><title>Positron emission tomography imaging acquisition and data preprocessing</title><p id="Par12">Radiosynthesis of AV45 and amyloid PET data acquisition followed the same procedures as previously described [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. During the study, two sets of images were obtained through dual-phase dynamic PET protocol using a single Biograph mMR PET/MR System after intravenous injection of 380&#8201;&#177;&#8201;5 MBq AV45. The dual-phase dynamic PET protocol consisted of (1) early phase: five 1-min scans obtained at 1&#8211;6&#160;min post-injection (pAV45 imaging), and (2) late phase: ten 1-min scans obtained at 50&#8211;60&#160;min post-injection (AV45 imaging) [<xref ref-type="bibr" rid="CR18">18</xref>]. The 3D OSEM PET reconstruction algorithm (3 iterations, 21 subsets; Gaussian filter: 2&#160;mm; zoom: 3) with MR-based attenuation correction, scatter and random corrections was applied to obtain PET images with a matrix size of 344&#8201;&#215;&#8201;344&#8201;&#215;&#8201;127 and a voxel size of 0.83&#8201;&#215;&#8201;0.83&#8201;&#215;&#8201;2.03 mm<sup>3</sup>, which corresponded to the image sampling grid.</p><p id="Par13">PET imaging data were processed and analyzed using PMOD image analysis software, version 3.2 (PMOD Technologies Ltd, Zurich, Switzerland). Both the pAV45 and AV45 images were coregistered with the corresponding T1-weighted MR images. Individual PET images were spatially normalized to the Montreal Neurological Institute (MNI) MRI template. A global meta-volume of interest (VOI) modified using the automated anatomical labelling (AAL) atlas including seven cortical regions of frontal, temporal, parietal, precuneus, anterior and posterior cingulate, and occipital was applied to both normalized pAV45 and AV45 images. The whole cerebellum was used as the reference region to calculate the standardized uptake value ratio (SUVR) for both pAV45 and AV45 images. The global AV45 and pAV45 index were calculated as the mean SUVR from all cortical VOIs. Further details can be found in the previously described methods [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p></sec><sec id="Sec6"><title>SNAP definition</title><p id="Par14">SNAP is defined according to 2018 NIA-AA research framework [<xref ref-type="bibr" rid="CR3">3</xref>]. SNAP pertains to individuals displaying neurodegenerative biomarkers, such as evidence of neuronal injury or neurodegeneration, without significant A&#946; accumulation. This classification differentiates SNAP from Alzheimer&#8217;s disease, highlighting other neurodegenerative processes that may lead to cognitive decline without A&#946; pathology&#8203;.</p><p id="Par15">The method for determining the cut-off point to classify amyloid-negative (A&#946;-) MDD subjects has been previously described [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. We utilized a global AV45 SUVR threshold of 1.286 to define amyloid positivity. Furthermore, an experienced nuclear physician, blinded to clinical data and imaging quantitative analysis, confirmed a negative visual score for AV45 PET. Hippocampal atrophy and glucose hypometabolism within AD-vulnerable regions are commonly adopted as neurodegeneration (ND) biomarkers [<xref ref-type="bibr" rid="CR8">8</xref>], although specific markers may vary across studies [<xref ref-type="bibr" rid="CR20">20</xref>]. Methods and results for determining the HVa cut-off point and the AD t-sum score of FDG-PET reflecting glucose hypometabolism within AD-vulnerable regions have been previously detailed [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par16">Given the high correlation between pAV45 and FDG-PET, pAV45 can serve as an indicator of hypometabolism [<xref ref-type="bibr" rid="CR18">18</xref>]. Therefore, we used whole brain pAV45 index to represent hypometabolism instead of the AD t-sum score of FDG-PET. The method for determining the cut-off point for the pAV45 index is described in the Supplement. Participants were classified as neurodegeneration-positive (ND+) if they were positive for either HVa or the pAV45 index, using cut-off values of 6,879&#160;mm&#179; for HVa and 0.985 for the pAV45 SUVR.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par17">Demographic and clinical data are presented as means&#8201;&#177;&#8201;SD for continuous variables or as absolute numbers with proportions for categorical variables. Group comparisons of continuous variables between non-SNAP and SNAP MDD patients were conducted using t-tests, while categorical data were analyzed with the chi-square (X&#178;) test. To examine the relationships among global AV45 SUVR, pAV45 index, and adjusted hippocampal volume (HVa), partial correlation analyses using Pearson&#8217;s method were conducted, adjusting for age, gender, and years of education. Additional partial correlation analyses were performed to assess associations between depression-related variables and neuroimaging biomarkers. To account for multiple comparisons, the False Discovery Rate (FDR) procedure was applied to partial correlation results [<xref ref-type="bibr" rid="CR21">21</xref>]. Multiple regression analyses were performed to examine associations between global cognition (MMSE scores) and imaging A&#946; biomarkers. Each model included global AV45 SUVR, pAV45 index, and HVa as variables of interest, with age, gender, and years of education as covariates, and the MMSE score as the dependent variable. Statistical analyses were conducted using IBM SPSS version 25.0 (IBM Corp., Armonk, NY, United States), with a significance level set at <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05.</p><p id="Par18">For the mediation analyses, we utilized the PROCESS macro v4.2 in SPSS. To estimate the (in)direct and total effects, bias-corrected bootstrapping with 5000 replications and a 95% confidence interval (CI) was performed. Given the robust associations observed between AV45 SUVR, pAV45 index, and HVa in the non-SNAP MDD group, we first tested the model: AV45 (A&#946;) &#8594; pAV45 (metabolism) &#8594; HVa (atrophy). Subsequently, we proposed a serial mediation model: AV45 (A&#946;) &#8594; pAV45 (metabolism) &#8594; HVa (atrophy) &#8594; MMSE (cognition). In the path analyses, pAV45 (metabolism) and/or HVa (atrophy) were examined as mediators. Age, education, and gender were included as covariates and were regressed on the mediators and the outcome simultaneously.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Characteristics of study population</title><p id="Par19">The study included 136 MDD participants, comprising 71 (53%) SNAP MDD and 65 (47%) non-SNAP MDD cases. Among non-SNAP MDD patients, 47 were A&#946;&#8201;&#8722;&#8201;ND&#8722;, 7 were A&#946;&#8201;+&#8201;ND&#8722;, and 11 were A&#946;&#8201;+&#8201;ND+. Due to the small sample sizes of A&#946;&#8201;+&#8201;ND&#8201;&#8722;&#8201;and A&#946;&#8201;+&#8201;ND&#8201;+&#8201;subgroups, these were combined with A&#946;&#8201;&#8722;&#8201;ND&#8201;&#8722;&#8201;under the non-SNAP MDD classification. Demographic and clinical characteristics are summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>, with A&#946;/ND subgroup details in Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>. At baseline, there were no significant differences between groups in gender, education, and MMSE scores. However, the SNAP MDD group had a higher mean age and significantly decreased global AV45 and pAV45 indices compared to non-SNAP MDD patients. Both groups had comparable HAM-D scores and clinical depressive features (age at onset, disease duration, and depressive episodes). Notably, the SNAP MDD group exhibited significantly lower global AV45 compared to the A&#946;&#8201;&#8722;&#8201;ND&#8201;&#8722;&#8201;MDD group (t&#8201;=&#8201;4.979, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p><p id="Par20">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographic and clinical characteristics of the MDD, non-SNAP MDD, and SNAP MDD patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Characteristic</th><th align="left" colspan="1" rowspan="1">MDD</th><th align="left" colspan="1" rowspan="1">non-SNAP MDD</th><th align="left" colspan="1" rowspan="1">SNAP MDD</th></tr><tr><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;136</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;65</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;71</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">63.19&#8201;&#177;&#8201;7.43</td><td align="left" colspan="1" rowspan="1">61.82&#8201;&#177;&#8201;6.74</td><td align="left" colspan="1" rowspan="1">64.44&#8201;&#177;&#8201;7.86*</td></tr><tr><td align="left" colspan="1" rowspan="1">Age range (years)</td><td align="left" colspan="1" rowspan="1">50&#8211;80</td><td align="left" colspan="1" rowspan="1">50&#8211;76</td><td align="left" colspan="1" rowspan="1">51&#8211;80</td></tr><tr><td align="left" colspan="1" rowspan="1">Female gender, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">112 (82.4)</td><td align="left" colspan="1" rowspan="1">57 (87.7)</td><td align="left" colspan="1" rowspan="1">55 (77.5)</td></tr><tr><td align="left" colspan="2" rowspan="1">Education (years)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">8.64&#8201;&#177;&#8201;4.18</td><td align="left" colspan="1" rowspan="1">8.18&#8201;&#177;&#8201;4.00</td><td align="left" colspan="1" rowspan="1">9.06&#8201;&#177;&#8201;4.31</td></tr><tr><td align="left" colspan="1" rowspan="1">Global AV45</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">1.17&#8201;&#177;&#8201;0.16</td><td align="left" colspan="1" rowspan="1">1.25&#8201;&#177;&#8201;0.18</td><td align="left" colspan="1" rowspan="1">1.10&#8201;&#177;&#8201;0.09**</td></tr><tr><td align="left" colspan="1" rowspan="1">pAV45 index</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">0.97&#8201;&#177;&#8201;0.69</td><td align="left" colspan="1" rowspan="1">1.01&#8201;&#177;&#8201;0.06</td><td align="left" colspan="1" rowspan="1">0.93&#8201;&#177;&#8201;0.05**</td></tr><tr><td align="left" colspan="1" rowspan="1">HVa (mm<sup>3</sup>)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">7881.58&#8201;&#177;&#8201;833.50</td><td align="left" colspan="1" rowspan="1">8037.55&#8201;&#177;&#8201;840.34</td><td align="left" colspan="1" rowspan="1">7738.78&#8201;&#177;&#8201;903.58*</td></tr><tr><td align="left" colspan="1" rowspan="1">MMSE</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">25.01&#8201;&#177;&#8201;3.92</td><td align="left" colspan="1" rowspan="1">25.00&#8201;&#177;&#8201;3.89</td><td align="left" colspan="1" rowspan="1">25.01&#8201;&#177;&#8201;3.98</td></tr><tr><td align="left" colspan="1" rowspan="1">CDR 0.5, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">95 (69.9)</td><td align="left" colspan="1" rowspan="1">39 (60.0)</td><td align="left" colspan="1" rowspan="1">56 (78.9)*</td></tr><tr><td align="left" colspan="1" rowspan="1">HAM-D</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">9.85&#8201;&#177;&#8201;5.90</td><td align="left" colspan="1" rowspan="1">9.43&#8201;&#177;&#8201;5.54</td><td align="left" colspan="1" rowspan="1">10.23&#8201;&#177;&#8201;6.24</td></tr><tr><td align="left" colspan="2" rowspan="1">Age at onset (years)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">52.67&#8201;&#177;&#8201;12.72</td><td align="left" colspan="1" rowspan="1">50.65&#8201;&#177;&#8201;12.24</td><td align="left" colspan="1" rowspan="1">54.52&#8201;&#177;&#8201;12.96</td></tr><tr><td align="left" colspan="3" rowspan="1">Duration since onset of depression (years)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">10.70&#8201;&#177;&#8201;9.78</td><td align="left" colspan="1" rowspan="1">10.97&#8201;&#177;&#8201;9.83</td><td align="left" colspan="1" rowspan="1">10.45&#8201;&#177;&#8201;9.80</td></tr><tr><td align="left" colspan="2" rowspan="1">Number of depressive episodes</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">2.40&#8201;&#177;&#8201;2.08</td><td align="left" colspan="1" rowspan="1">2.37&#8201;&#177;&#8201;1.91</td><td align="left" colspan="1" rowspan="1">2.42&#8201;&#177;&#8201;2.23</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: MDD, major depressive disorder; SNAP, suspected non-Alzheimer&#8217;s disease pathophysiology; Global AV45, late-phase <sup>18</sup>F-florbetapir PET scan for A&#946;; pAV45, early-phase <sup>18</sup>F-florbetapir PET scan for metabolism; HAM-D, 17-item Hamilton Depression Rating Scale; MMSE, Mini Mental Status Examination; CDR, Clinical Dementia Rating; HVa, adjusted hippocampal volume</p><p><italic toggle="yes">p</italic> values denote the significance of differences among the non-SNAP MDD and SNAP MDD groups using the t-test (continuous variables) or the chi-square (X&#178;) test (categorical variables). *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>Associations between global AV45, HVa and pAV45</title><p id="Par21">Initially, we explored the correlation between global AV45, HVa and pAV45 across the entire cohort of MDD patients, depicted in Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1</xref>. Further subgroup analyses of non-SNAP MDD and SNAP MDD (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a) revealed distinct patterns. In the non-SNAP MDD group, AV45 showed negative correlations with HVa (<italic toggle="yes">r</italic> = &#8722;&#8201;0.62, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and pAV45 (<italic toggle="yes">r</italic> = &#8722;&#8201;0.51, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and a more robust positive correlation was observed between HVa and pAV45 (<italic toggle="yes">r</italic>&#8201;=&#8201;0.55, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), compared to the overall MDD cohort. In contrast, the SNAP MDD group demonstrated a significant positive correlation between AV45 and pAV45 (<italic toggle="yes">r</italic>&#8201;=&#8201;0.39, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), while the correlations between AV45 and HVa and between HVa and pAV45 were not statistically significant, as shown in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par22">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>(<bold>a</bold>) Correlations among global AV45, HVa and pAV45 in the SNAP MDD and non-SNAP MDD groups. (<bold>b</bold>) Correlations within the non-SNAP MDD group, further divided into A&#946;&#8201;&#8722;&#8201;ND&#8722; (<italic toggle="yes">n</italic>&#8201;=&#8201;47) and A&#946;&#8201;+&#8201;ND&#8722;/A&#946;&#8201;+&#8201;ND+ (<italic toggle="yes">n</italic>&#8201;=&#8201;18) subgroups. Abbreviations: MDD, major depressive disorder; SNAP, suspected non-Alzheimer&#8217;s disease pathophysiology; AV45, late-phase <sup>18</sup>F-florbetapir PET scan for A&#946;; pAV45, early-phase <sup>18</sup>F-florbetapir PET scan for metabolism, HVa, adjusted hippocampal volume</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e696" position="float" orientation="portrait" xlink:href="13195_2025_1858_Fig1_HTML.jpg"/></fig>
</p><p id="Par23">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Association between global AV45, pAV45 index and HVa among MDD, non-SNAP MDD, and SNAP MDD group</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="2" rowspan="1">MDD<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;136)</th><th align="left" colspan="2" rowspan="1">non-SNAP MDD<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;65)</th><th align="left" colspan="2" rowspan="1">SNAP MDD<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;71)</th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Partial correlation</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th><th align="left" colspan="1" rowspan="1">Partial correlation</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th><th align="left" colspan="1" rowspan="1">Partial correlation</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">AV45 and pAV45 index</td><td align="left" colspan="1" rowspan="1">0.13</td><td align="left" colspan="1" rowspan="1">0.153</td><td align="left" colspan="1" rowspan="1">-0.51</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">0.39</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">AV45 and HVa</td><td align="left" colspan="1" rowspan="1">-0.2</td><td align="left" colspan="1" rowspan="1">0.022</td><td align="left" colspan="1" rowspan="1">-0.62</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">0.18</td><td align="left" colspan="1" rowspan="1">0.133</td></tr><tr><td align="left" colspan="1" rowspan="1">pAV45 index and HVa</td><td align="left" colspan="1" rowspan="1">0.33</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">0.55</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">0.09</td><td align="left" colspan="1" rowspan="1">0.446</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: MDD, major depressive disorder; SNAP, suspected non-Alzheimer&#8217;s disease pathophysiology; AV45, late-phase <sup>18</sup>F-florbetapir PET scan for A&#946;; pAV45, early-phase <sup>18</sup>F-florbetapir PET scan for metabolism; HVa, adjusted hippocampal volume</p><p>Partial correlations were calculated using Pearson correlation analyses, adjusted for age, gender, and years of education</p></table-wrap-foot></table-wrap>
</p><p id="Par24">From a pathophysiological perspective, we further subdivided the non-SNAP MDD group into two biologically distinct subgroups: A&#946;&#8201;&#8722;&#8201;ND&#8722; (<italic toggle="yes">n</italic>&#8201;=&#8201;47) and A&#946;&#8201;+&#8201;ND&#8722;/A&#946;&#8201;+&#8201;ND+ (<italic toggle="yes">n</italic>&#8201;=&#8201;18). In the A&#946;&#8201;+&#8201;ND&#8722;/A&#946;&#8201;+&#8201;ND&#8201;+&#8201;subgroup, partial correlation analyses revealed a strong negative correlation between AV45 and HVa (<italic toggle="yes">r</italic>&#8201;=&#8201;&#8722;&#8201;0.798, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), as well as a significant positive correlation between HVa and pAV45 (<italic toggle="yes">r</italic>&#8201;=&#8201;0.701, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002). In contrast, the A&#946;&#8201;&#8722;&#8201;ND&#8201;&#8722;&#8201;subgroup showed no significant correlations among these variables (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>b; Supplementary Table <xref rid="MOESM1" ref-type="media">S2</xref>). Corresponding scatter plots for these subgroups are presented in Supplementary Fig. <xref rid="MOESM1" ref-type="media">S2</xref>.</p><p id="Par25">To examine whether the main findings varied by age, we stratified participants into mid-life (&lt;&#8201;60 years) and late-life (&#8805;&#8201;60 years) MDD groups (Supplementary Table <xref rid="MOESM1" ref-type="media">S3</xref>). In the &#8805;&#8201;60 years non-SNAP MDD group, partial correlation analyses revealed significant negative correlations between AV45 and HVa (<italic toggle="yes">r</italic>&#8201;=&#8201;&#8722;&#8201;0.608, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and between AV45 and pAV45 (<italic toggle="yes">r</italic>&#8201;=&#8201;&#8722;&#8201;0.442, <italic toggle="yes">p</italic>&#8201;=&#8201;0.008), as well as a positive correlation between HVa and pAV45 (<italic toggle="yes">r</italic>&#8201;=&#8201;0.534, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001). In the &#8805;&#8201;60 years SNAP MDD group, a significant positive correlation was observed between AV45 and pAV45 (<italic toggle="yes">r</italic>&#8201;=&#8201;0.383, <italic toggle="yes">p</italic>&#8201;=&#8201;0.009). Similarly, in the &lt;&#8201;60 years non-SNAP MDD group, AV45 was negatively correlated with both HVa (<italic toggle="yes">r</italic>&#8201;=&#8201;&#8722;&#8201;0.663, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and pAV45 (<italic toggle="yes">r</italic>&#8201;=&#8201;&#8722;&#8201;0.684, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), while a positive correlation was found between HVa and pAV45 (<italic toggle="yes">r</italic>&#8201;=&#8201;0.580, <italic toggle="yes">p</italic>&#8201;=&#8201;0.003). In the &lt;&#8201;60 years SNAP MDD group, HVa and pAV45 also showed a positive correlation (<italic toggle="yes">r</italic>&#8201;=&#8201;0.520, <italic toggle="yes">p</italic>&#8201;=&#8201;0.022), as shown in Supplementary Fig. <xref rid="MOESM1" ref-type="media">S3</xref>. These associations remained consistent after applying FDR correction for multiple comparisons, as detailed in the Supplement.</p></sec><sec id="Sec11"><title>Correlation between depression variables and neuroimaging biomarkers</title><p id="Par26">In the SNAP MDD group, lifetime major depressive episodes showed a negative correlation with HVa (<italic toggle="yes">r</italic> = -0.262, <italic toggle="yes">p</italic>&#8201;=&#8201;0.031), whereas HAM-D scores were positively correlated with HVa (<italic toggle="yes">r</italic>&#8201;=&#8201;0.262, <italic toggle="yes">p</italic>&#8201;=&#8201;0.035) after adjusting for age, gender, and years of education (Supplementary Table <xref rid="MOESM1" ref-type="media">S4</xref>). In the A&#946;&#8201;+&#8201;ND&#8201;+&#8201;subgroup (<italic toggle="yes">n</italic>&#8201;=&#8201;11), HAM-D scores were positively correlated with AV45 (<italic toggle="yes">r</italic>&#8201;=&#8201;0.682, <italic toggle="yes">p</italic>&#8201;=&#8201;0.043). Subgroup analyses for the non-SNAP MDD group are detailed in Supplementary Table <xref rid="MOESM1" ref-type="media">S5</xref>.</p><p id="Par27">Age-stratified analyses revealed consistent patterns: HAM-D scores were positively correlated with HVa in the &#8805;&#8201;60 years MDD (<italic toggle="yes">r</italic>&#8201;=&#8201;0.292, <italic toggle="yes">p</italic>&#8201;=&#8201;0.007) and in &#8805;&#8201;60 years SNAP MDD groups (<italic toggle="yes">r</italic>&#8201;=&#8201;0.495, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), while the number of depressive episodes were negatively correlated with HVa (<italic toggle="yes">r</italic> = -0.311, <italic toggle="yes">p</italic>&#8201;=&#8201;0.035) in the &#8805;&#8201;60 years SNAP MDD group (Supplementary Table <xref rid="MOESM1" ref-type="media">S6</xref>). After applying FDR correction for multiple comparison, only the positive correlation between HAM-D and HVa remained significant in the &#8805;&#8201;60 years MDD and the &#8805;&#8201;60 years SNAP MDD groups (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S4</xref>).</p></sec><sec id="Sec12"><title>Mediation analysis of pAV45 on the AV45-HVa relationship in non-SNAP MDD patients</title><p id="Par28">Mediation analysis revealed a significant total effect of AV45 on HVa (&#946; = &#8722;0.607, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), which included both the direct effect (&#946; = -0.449, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) and the indirect effect via pAV45. Specifically, the indirect path AV45 &#8594; pAV45 &#8594; HVa was also significant (&#946; = &#8722;0.158, 95% CI [&#8722;&#8201;0.322, &#8722;&#8201;0.020]; Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a), indicating that glucose metabolism partially mediated the association between amyloid burden and hippocampal atrophy. Moderation analyses using AV45 and pAV45 as moderators yielded non-significant results. Due to the limited sample size in the A&#946;&#8201;+&#8201;ND&#8722;/A&#946;&#8201;+&#8201;ND&#8201;+&#8201;subgroup, further moderated mediation models for stratified-analyses could not be reliably conducted.</p><p id="Par29">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>(<bold>a</bold>) pAV45 index are partially mediating the association between global A&#946; deposition and HVa atrophy in the non-SNAP MDD patients. (<bold>b</bold>) pAV45 index are partially mediating the association between global A&#946; deposition and MMSE scores in the non-SNAP MDD patients. Bias-corrected bootstrapping with 5000 replications and a 95% confidence interval (CI) was performed to estimate the indirect effects. Abbreviations: MDD, major depressive disorder; SNAP, suspected non-Alzheimer&#8217;s disease pathophysiology; AV45, late-phase <sup>18</sup>F-florbetapir PET scan for A&#946;; pAV45, early-phase <sup>18</sup>F-florbetapir PET scan for metabolism, HVa, adjusted hippocampal volume</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e995" position="float" orientation="portrait" xlink:href="13195_2025_1858_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec13"><title>Associations with global cognitive function (MMSE Scores)</title><p id="Par30">We conducted multiple regression analyses to investigate the effects of AV45, HVa, and pAV45 on MMSE scores, accounting for age, gender, and education (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). For the overall MDD group, higher global AV45 levels were significantly associated with lower MMSE scores (&#946; = -0.25, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), while greater glucose metabolism, as indicated by pAV45, was positively associated with cognitive performance (&#946;&#8201;=&#8201;0.26, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). HVa showed only a marginal association with MMSE (&#946;&#8201;=&#8201;0.15, <italic toggle="yes">p</italic>&#8201;=&#8201;0.05). In the non-SNAP MDD group, the associations became even more pronounced: global AV45 (&#946; = -0.33, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and pAV45 (&#946;&#8201;=&#8201;0.29, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) remained significantly linked to MMSE scores, while hippocampal volume was not significantly associated (&#946;&#8201;=&#8201;0.12, <italic toggle="yes">p</italic>&#8201;=&#8201;0.248). The model demonstrated a high explanatory power (R&#178; = 0.76, F-test&#8201;&lt;&#8201;0.001). In contrast, in the SNAP MDD subgroup, none of the imaging biomarkers &#8212; AV45 (&#946;&#8201;=&#8201;0.08), HVa (&#946;&#8201;=&#8201;0.06), or pAV45 (&#946;&#8201;=&#8201;0.06) &#8212; showed significant associations with MMSE scores. Analyses restricted to the &#8805;&#8201;60 years MDD groups yielded consistent results (Supplementary Table <xref rid="MOESM1" ref-type="media">S7</xref>).</p><p id="Par31">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Regression estimates for global AV45, pAV45 and HVa indices in relation to MMSE scores</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Explanatory variables</th><th align="left" colspan="2" rowspan="1">MDD<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;136)</th><th align="left" colspan="2" rowspan="1">non-SNAP MDD<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;65)</th><th align="left" colspan="2" rowspan="1">SNAP MDD<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;71)</th><th align="left" colspan="1" rowspan="1"/></tr><tr><th align="left" colspan="1" rowspan="1">&#946;</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" colspan="1" rowspan="1">&#946;</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" colspan="1" rowspan="1">&#946;</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" colspan="1" rowspan="1"/></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">global AV45</td><td align="left" colspan="1" rowspan="1">-0.25</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">-0.33</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">0.08</td><td align="left" colspan="1" rowspan="1">0.41</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">pAV45 index</td><td align="left" colspan="1" rowspan="1">0.26</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">0.29</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">0.06</td><td align="left" colspan="1" rowspan="1">0.56</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="2" rowspan="1">HVa</td><td align="left" colspan="1" rowspan="1">0.15</td><td align="left" colspan="1" rowspan="1">0.05</td><td align="left" colspan="1" rowspan="1">0.12</td><td align="left" colspan="1" rowspan="1">0.248</td><td align="left" colspan="1" rowspan="1">0.06</td><td align="left" colspan="1" rowspan="1">0.61</td></tr><tr><td align="left" colspan="1" rowspan="1">R<sup>2</sup></td><td align="left" colspan="2" rowspan="1">0.56</td><td align="left" colspan="2" rowspan="1">0.76</td><td align="left" colspan="2" rowspan="1">0.49</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Abbreviations; MDD, major depressive disorder; SNAP, suspected non-Alzheimer&#8217;s disease pathophysiology, Global AV45, late-phase <sup>18</sup>F-florbetapir PET scan for A&#946;; pAV45, early-phase <sup>18</sup>F-florbetapir PET scan for metabolism; HVa, adjusted hippocampal volume</p><p>Models were adjusted by age, gender, and education for multiple regression analysis</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec14"><title>Mediation analysis on the AV45-MMSE relationship in non-SNAP MDD patients</title><p id="Par32">Mediation analysis revealed a significant indirect effect of AV45 through the pathway &#8216;AV45&#8594; pAV45 index &#8594; MMSE&#8217; (&#946; = -0.161&#8201;&#177;&#8201;0.75, 95% CI [-0.333, -0.36]). The total indirect effect was &#946; = -0.231&#8201;&#177;&#8201;0.96, 95% CI [-0.439, -0.58], as illustrated in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref> (b). Additionally, we also tested AV45, pAV45 and HVa as potential moderators in the &#8216;A&#946; &#8594; cognition&#8217; pathway, but these were found to be non-significant.</p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par33">In this study, we investigated the relationships among cerebral A&#946; deposition, glucose metabolism and hippocampal volume in a characterized cohort of MDD patients, including subgroup analyses of SNAP and non-SNAP classifications. We further conducted age-stratified analyses (&lt;&#8201;60 vs. &#8805;60 years) and biologically based stratification within the non-SNAP group (A&#946;&#8201;&#8722;&#8201;ND&#8201;&#8722;&#8201;vs. A&#946;&#8201;+&#8201;ND&#8722;/A&#946;&#8201;+&#8201;ND+). Additionally, we examined the associations of these imaging biomarkers with global cognitive function (MMSE) and explored potential mediation effects.</p><p id="Par34">In the overall MDD cohort, scatter plots of A&#946; versus hippocampal volume and A&#946; versus glucose metabolism displayed an inverted-V pattern. Subgroup analyses revealed distinct association patterns, which remained consistent across both &lt;&#8201;60 and &#8805;&#8201;60 years age strata. We also examined the relationships between depression-related clinical variables and imaging biomarkers. To account for multiple comparisons, the FDR procedure was applied.</p><sec id="Sec16"><title>Importance of distinguishing between SNAP and Non-SNAP MDD groups</title><p id="Par35">Several studies have reported no consistent association between amyloid burden and hippocampal volume across the spectrum from normal cognition to dementia [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], and similar null findings have been observed in late-life depression [<xref ref-type="bibr" rid="CR24">24</xref>]. Our cohort exhibited a wide range of A&#946; deposition (Supplementary Fig. <xref rid="MOESM1" ref-type="media">S1</xref>), suggesting the presence of biologically heterogeneous subgroups with distinct underlying pathophysiological mechanisms. This pattern mirrors the heterogeneity described by Nolan et al. in their structural MRI review in MDD aged 18&#8211;85 years [<xref ref-type="bibr" rid="CR25">25</xref>]. While our study encompassed both mid-life and late-life MDD populations, age-stratified analyses yielded results consistent with the overall findings, supporting the robustness of our conclusions. This highlights the necessity of subgroup-specific analyses to avoid obscuring meaningful associations and to guide more targeted diagnostic or therapeutic approaches.</p><p id="Par36">Our study included 136 MDD participants, with 71 (53%) cases meeting SNAP criteria. This proportion is comparable to our earlier research [<xref ref-type="bibr" rid="CR15">15</xref>] and to Mackin et al.&#8217;s Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) Depression Project, in which late-life depression patients showed lower A&#946; deposition than non-depressed peers [<xref ref-type="bibr" rid="CR5">5</xref>]. Converging evidence across studies indicates that both the hippocampus and amygdala are smaller in individuals with depression [<xref ref-type="bibr" rid="CR25">25</xref>], suggesting the involvement of heterogeneous underlying mechanisms. Therefore, distinguishing between SNAP and non-SNAP MDD groups is crucial for understanding the heterogeneous neurobiological mechanisms underlying late-life depression. Our findings demonstrate that these subgroups exhibit distinct patterns of association among amyloid burden, neurodegeneration, and cognitive function.</p></sec><sec id="Sec17"><title>Opposing A&#946;&#8211;metabolism patterns in non-SNAP and SNAP MDD groups</title><p id="Par37">Among non&#8209;SNAP MDD patients, greater A&#946; deposition correlated with cerebral hypometabolism, echoing the findings of Tondo et al., who reported distinct hypometabolic patterns in A&#946;-positive individuals with subjective cognitive decline or pre-MCI during the preclinical stage of dementia [<xref ref-type="bibr" rid="CR26">26</xref>]. By contrast, SNAP MDD exhibited a positive association between A&#946; deposition and metabolism, a pattern that was consistently observed across both age strata. Additionally, the SNAP MDD showed significantly lower levels of A&#946; deposition compared to the A&#946;&#8201;&#8722;&#8201;ND&#8201;&#8722;&#8201;MDD group. Notably, extremely low A&#946; levels in this group were linked to cerebral hypometabolism, aligning with our previous observation that markedly reduced A&#946; can coexist with significant metabolic decline [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. These opposing patterns support an amyloid driven pathway in the non-SNAP MDD group, while highlighting an amyloid-independent trajectory in SNAP MDD [<xref ref-type="bibr" rid="CR27">27</xref>].</p></sec><sec id="Sec18"><title>Associations between depression and imaging biomarkers</title><p id="Par38">In the SNAP group, the number of lifetime depressive episodes was inversely associated with hippocampal volume, a pattern that was also evident in the &#8805;&#8201;60 years MDD subgroup. Such volume loss may be partly attributable to stress-related neurotoxicity, potentially driven by chronic HPA axis activation in recurrent depression [<xref ref-type="bibr" rid="CR28">28</xref>&#8211;<xref ref-type="bibr" rid="CR31">31</xref>]. By contrast, in the non-SNAP MDD group, hippocampal atrophy was associated with cerebral A&#946; deposition, aligning with the amyloid&#8211;depression hypothesis that late-onset depression may signal prodromal amyloid pathology [<xref ref-type="bibr" rid="CR32">32</xref>&#8211;<xref ref-type="bibr" rid="CR34">34</xref>]. This link was also suggested by a positive correlation between HAM-D scores and A&#946; deposition in the A&#946;&#8201;+&#8201;ND&#8201;+&#8201;subgroup. (Supplementary Table <xref rid="MOESM1" ref-type="media">S5</xref>). The pronounced atrophy observed in the SNAP MDD may involve mechanisms beyond stress neurotoxicity. One possibility is TDP-43 proteinopathy, characteristic of limbic-predominant age-related TDP-43 encephalopathy (LATE), which leads to severe hippocampal sclerosis and may occur independently of amyloid pathology [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Interestingly, depression severity was positively correlated with hippocampal volume in this group. This may suggest that repeated depressive episodes and cross-sectional depression severity exert distinct influences on hippocampal volume. Notably, these findings drawn from marginal or exploratory results should be interpreted with caution, and should be validated with larger sample sizes and longitudinal data.</p></sec><sec id="Sec19"><title>Mediation analysis of pAV45 on the AV45-HVa relationship in non-SNAP MDD patients</title><p id="Par39">Cerebral hypoperfusion, commonly observed in aging populations, is linked to cognitive decline and reduced hippocampal volume [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Previous studies have shown that amyloid-positive individuals with late-life depression continue to exhibit smaller hippocampal volumes [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. In our non-SNAP MDD group, A&#946; deposition may contribute to hippocampal atrophy both directly and indirectly by reducing cerebral glucose metabolism, which in turn further exacerbates hippocampal volume loss. This pathway of the &#8216;A&#946; &#8594; hypometabolism &#8594; atrophy&#8217; aligns with the NIA-AA AD continuum of A&#946; cascades [<xref ref-type="bibr" rid="CR3">3</xref>]. Notably, further mediation analyses in the A&#946;&#8201;+&#8201;ND&#8722;/A&#946;&#8201;+&#8201;ND&#8201;+&#8201;subgroup could not be conducted limited to small sample sizes.</p></sec><sec id="Sec20"><title>Imaging biomarkers and MMSE scores</title><p id="Par40">Cognitive impairment is prevalent among individuals with late-life depression and frequently persists even improvement of depression. In our study, A&#946; and hypometabolism were significantly associated with MMSE scores in the overall MDD and non-SNAP MDD groups, but not in SNAP MDD subjects. Notably, hippocampal atrophy was not independently associated with MMSE scores after adjusting for A&#946;, metabolism, age, gender and education in any group subset, while most previous studies have linked hippocampal atrophy to cognitive impairments in depressed individuals. The discrepancy may be attributed to the inclusion of additional variables that more strongly influence MMSE scores, particularly in the non-SNAP MDD subgroup. Consequently, in our regression model (R&#178; &gt;0.7), the effect of hippocampal atrophy on cognitive performance appeared to be attenuated by the influence of other dominant factors. These results remained consistent when analyses were stratified to the &#8805;&#8201;60 years MDD subgroup.</p></sec><sec id="Sec21"><title>Mediation analysis on the AV45-MMSE relationship in non-SNAP MDD patients</title><p id="Par41">Wang et al. [<xref ref-type="bibr" rid="CR41">41</xref>]. found that a more rapid increase in Geriatric Depression Scale (GDS) scores was linked to accelerated cognitive decline and a higher likelihood of progressing to MCI or AD in cognitively normal participants. Additionally, changes in GDS rates were significantly correlated with A&#946; deposition and cerebral glucose metabolism. In our study, HAM-D scores and clinical depressive features were not correlated with MMSE in any group after controlling for covariates. This discrepancy may be attributed to the use of cross-sectional HAM-D scores rather than longitudinal measures of depressive symptom changes. Additionally, differences in study populations and cognitive assessment tools may also contribute to the observed variation [<xref ref-type="bibr" rid="CR41">41</xref>]. Our mediation analysis revealed that hypometabolism accounted for most of the indirect effect between A&#946; and cognition. Notably, the indirect effects of the &#8216;A&#946;&#8594;hippocampal volume&#8594;MMSE&#8217; and &#8216;A&#946;&#8594;metabolism&#8594;hippocampal volume&#8594;MMSE&#8217; pathways were non-significant, in contrast to previous studies suggesting that hippocampal atrophy in MDD is associated with an increased risk of cognitive decline [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Our findings indicate that, in this subgroup, metabolic dysfunction may play a more central role than structural atrophy in linking amyloid burden to cognitive impairment.</p></sec><sec id="Sec22"><title>Limitations</title><p id="Par42">This study has several limitations. First, the A&#946;&#8201;+&#8201;ND- and A&#946;&#8201;+&#8201;ND&#8201;+&#8201;MDD subgroups were small (<italic toggle="yes">n</italic>&#8201;=&#8201;18). This limitation stems from our focus on non-demented MDD individuals, which naturally resulted in fewer cases with amyloid positivity. Consequently, we were obliged to merge A&#946;-positive cases with the A&#946;-ND-MDD group in mediation analyses, potentially introducing heterogeneity and limiting the precision of interpretation. Future work will require larger, homogeneous samples of amyloid-positive MDD to validate these exploratory findings. Second, while all participants were &#8805;&#8201;50 years of age, the cohort spans both mid-life and late-life stages of MDD. Although age-stratified results mirrored the overall pattern, caution is warranted when generalizing these findings to cohorts strictly defined as late-life depression. Third, The absence of a non-depressed control group limits direct comparison with normative ageing or neurodegenerative trajectories. Demographically matched non-depressed controls will be essential in future work. Fourth, the choice of ND biomarkers may have influenced our findings. While atrophy and hypometabolism are commonly acknowledged as ND biomarkers [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR43">43</xref>], the lack of measurement standards and appropriate cut-off points may have led to misclassification of subjects at the margins [<xref ref-type="bibr" rid="CR15">15</xref>]. Fifth, the absence of tau PET imaging and tau-related biofluid biomarkers limited our ability to perform a comprehensive subgroup analysis and to explore tau&#8217;s role in the ATN hypothesis of the AD continuum. Sixth, lifetime MDD history was obtained retrospectively and is vulnerable to recall bias, which makes it difficult to precisely assess cumulative effects of depressive episodes and treatments over time. Seventh, as a cross-sectional study, causal relationships cannot be inferred, and temporal sequences cannot be established; longitudinal multimodal imaging and cognitive follow-up are required. Eighth, this study focused on global AV45 and pAV45 SUVRs and did not examine small anatomical subregions such as the hippocampus individually. Therefore, partial volume correction techniques were not applied in the current analysis. Future studies may benefit from incorporating such corrections to improve the accuracy of measurements in smaller brain regions. Finally, the study&#8217;s sample, drawn from clinical settings, may limit the generalizability of the findings, necessitating further validation in diverse populations. Despite these constraints, the consistency of our findings across age and biomarker strata provides a strong basis for larger, prospective studies to refine the neurobiological classification of SNAP and non-SNAP MDD.</p></sec></sec><sec id="Sec23"><title>Conclusion</title><p id="Par43">MDD is inherently heterogeneous. Our subgroup analyses demonstrate that non-SNAP and SNAP MDD display distinct A&#946;&#8211;metabolism&#8211;atrophy profiles, each with different implications for cognitive decline. The core A&#946;&#8211;metabolism&#8211;atrophy relationship remained consistent across age (mid-life and late-life) and biomarker (A&#946;/ND status) MDD subgroups. These divergent neurobiological pathways provide a strong foundation for designing subgroup-tailored, longitudinal, and multimodal studies in major depression.</p></sec><sec id="Sec24" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="13195_2025_1858_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Avid Radiopharmaceuticals Inc. (Philadelphia, PA, USA) for providing the precursor for the preparation of <sup>18</sup>F-florbetapir. We also thank the Center for Advanced Molecular Imaging and Translation, Chang Gung Memorial Hospital, Linkou, for technical support.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All the authors contributed to the manuscript preparation. I.T.H. recruited subjects and co-designed the research framework. K.J.L. designed and supervised the methodology. K.Y.W. wrote the final version of the manuscript and supervised the whole project. M.J.W. prepared the tables and drafted the manuscript. Y.M.W. prepared the figures and participated in the data analysis. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was carried out with financial support from the National Science and Technology Council, Taiwan (111-2314-B-182&#160;A-022-MY2, 113-2314-B-182-042-MY2, and 114-2314-B-182-043), and grants from the Research Fund of Chang Gung Memorial Hospital (CPRPG3M0081, CPRPG3M0082, CPRPG3N0041, CPRPG3N0042, CMRPD1H0391-3, BMRP488, CORPG3J0342, CMRPG3J0371, and CMRPG3J0361).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par44">The study involving human participants was reviewed and approved by the Institutional Review Boards of the Ministry of Health and Welfare and Chang Gung Medical Center. All participants provided their written informed consents to participate in this study.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par45">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par46">The authors declare no competing interests.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>A&#946;</term><def><p id="Par47">Amyloid-&#946;</p></def></def-item><def-item><term>AD</term><def><p id="Par48">Alzheimer&#8217;s disease</p></def></def-item><def-item><term>CDR</term><def><p id="Par49">Clinical Dementia Rating</p></def></def-item><def-item><term>Global AV45</term><def><p id="Par50">Gloabl 18&#160;F-florbetapir AV45 PET/MR scan late phase for A&#946; deposition</p></def></def-item><def-item><term>HAM-D</term><def><p id="Par51">17-item Hamilton Depression Rating Scale</p></def></def-item><def-item><term>HVa</term><def><p id="Par52">Adjusted hippocampal volume</p></def></def-item><def-item><term>MCI</term><def><p id="Par53">Mild cognitive impairment</p></def></def-item><def-item><term>MDD</term><def><p id="Par54">Major depressive disorder</p></def></def-item><def-item><term>MMSE</term><def><p id="Par55">Mini Mental Status Examination</p></def></def-item><def-item><term>ND</term><def><p id="Par56">Neurodegeneration</p></def></def-item><def-item><term>NIA-AA</term><def><p id="Par57">National Institute on Aging and Alzheimer&#8217;s Association</p></def></def-item><def-item><term>pAV45 index</term><def><p id="Par58">18&#160;F-florbetapir (AV45) PET/MR scan early phase for glucose metabolism</p></def></def-item><def-item><term>SNAP</term><def><p id="Par59">Suspected non-Alzheimer&#8217;s disease pathophysiology</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steffens</surname><given-names>DC</given-names></name></person-group><article-title>Late-Life depression, antidepressant treatment, and cognition: the short haul and the long haul</article-title><source>Am J Psychiatry</source><year>2024</year><volume>181</volume><issue>3</issue><fpage>183</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">38425257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.20231022</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Steffens DC. Late-Life depression, antidepressant treatment, and cognition: the short haul and the long haul. Am J Psychiatry. 2024;181(3):183&#8211;5.<pub-id pub-id-type="pmid">38425257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.20231022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jellinger</surname><given-names>KA</given-names></name></person-group><article-title>The heterogeneity of late-life depression and its pathobiology: a brain network dysfunction disorder</article-title><source>J Neural Transm (Vienna)</source><year>2023</year><volume>130</volume><issue>8</issue><fpage>1057</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">37145167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00702-023-02648-z</pub-id><pub-id pub-id-type="pmcid">PMC10162005</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Jellinger KA. The heterogeneity of late-life depression and its pathobiology: a brain network dysfunction disorder. J Neural Transm (Vienna). 2023;130(8):1057&#8211;76.<pub-id pub-id-type="pmid">37145167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00702-023-02648-z</pub-id><pub-id pub-id-type="pmcid">PMC10162005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>MC</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>B</given-names></name><name name-style="western"><surname>Haeberlein</surname><given-names>SB</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W</given-names></name><name name-style="western"><surname>Jessen</surname><given-names>F</given-names></name><name name-style="western"><surname>Karlawish</surname><given-names>J</given-names></name><etal/></person-group><article-title>NIA-AA research framework: toward a biological definition of alzheimer&#8217;s disease</article-title><source>Alzheimers Dement</source><year>2018</year><volume>14</volume><issue>4</issue><fpage>535</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al. NIA-AA research framework: toward a biological definition of alzheimer&#8217;s disease. Alzheimers Dement. 2018;14(4):535&#8211;62.<pub-id pub-id-type="pmid">29653606</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>KY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CH</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>IT</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CP</given-names></name><name name-style="western"><surname>Yen</surname><given-names>TC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>KJ</given-names></name></person-group><article-title>Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2016</year><volume>43</volume><issue>6</issue><fpage>1067</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">26739329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-015-3291-3</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Wu KY, Liu CY, Chen CS, Chen CH, Hsiao IT, Hsieh CJ, Lee CP, Yen TC, Lin KJ. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study. Eur J Nucl Med Mol Imaging. 2016;43(6):1067&#8211;76.<pub-id pub-id-type="pmid">26739329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-015-3291-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackin</surname><given-names>RS</given-names></name><name name-style="western"><surname>Insel</surname><given-names>PS</given-names></name><name name-style="western"><surname>Landau</surname><given-names>S</given-names></name><name name-style="western"><surname>Bickford</surname><given-names>D</given-names></name><name name-style="western"><surname>Morin</surname><given-names>R</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>E</given-names></name><name name-style="western"><surname>Tosun</surname><given-names>D</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Butters</surname><given-names>M</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Late-Life depression is associated with reduced cortical amyloid burden: findings from the alzheimer&#8217;s disease neuroimaging initiative depression project</article-title><source>Biol Psychiatry</source><year>2021</year><volume>89</volume><issue>8</issue><fpage>757</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">32980132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2020.06.017</pub-id><pub-id pub-id-type="pmcid">PMC10165941</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Mackin RS, Insel PS, Landau S, Bickford D, Morin R, Rhodes E, Tosun D, Rosen HJ, Butters M, Aisen P, et al. Late-Life depression is associated with reduced cortical amyloid burden: findings from the alzheimer&#8217;s disease neuroimaging initiative depression project. Biol Psychiatry. 2021;89(8):757&#8211;65.<pub-id pub-id-type="pmid">32980132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2020.06.017</pub-id><pub-id pub-id-type="pmcid">PMC10165941</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W</given-names></name><name name-style="western"><surname>Shen</surname><given-names>XN</given-names></name><name name-style="western"><surname>Bi</surname><given-names>YL</given-names></name><name name-style="western"><surname>Ma</surname><given-names>YH</given-names></name><name name-style="western"><surname>Li</surname><given-names>JQ</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>JT</given-names></name><name name-style="western"><surname>Initia</surname><given-names>ADN</given-names></name></person-group><article-title>Amyloid pathologies modulate the associations of minimal depressive symptoms with cognitive impairments in older adults without dementia</article-title><source>Biol Psychiatry</source><year>2021</year><volume>89</volume><issue>8</issue><fpage>766</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">32980133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2020.07.004</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Xu W, Feng W, Shen XN, Bi YL, Ma YH, Li JQ, Dong Q, Tan L, Yu JT, Initia ADN. Amyloid pathologies modulate the associations of minimal depressive symptoms with cognitive impairments in older adults without dementia. Biol Psychiatry. 2021;89(8):766&#8211;75.<pub-id pub-id-type="pmid">32980133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopsych.2020.07.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>KY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>YM</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CS</given-names></name><name name-style="western"><surname>Yen</surname><given-names>TC</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>IT</given-names></name></person-group><article-title>Decreased cerebral Amyloid-beta depositions in patients with a lifetime history of major depression with suspected Non-Alzheimer pathophysiology</article-title><source>Front Aging Neurosci</source><year>2022</year><volume>14</volume><fpage>857940</fpage><pub-id pub-id-type="pmid">35721010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.857940</pub-id><pub-id pub-id-type="pmcid">PMC9204309</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Wu KY, Lin KJ, Chen CH, Liu CY, Wu YM, Chen CS, Yen TC, Hsiao IT. Decreased cerebral Amyloid-beta depositions in patients with a lifetime history of major depression with suspected Non-Alzheimer pathophysiology. Front Aging Neurosci. 2022;14:857940.<pub-id pub-id-type="pmid">35721010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.857940</pub-id><pub-id pub-id-type="pmcid">PMC9204309</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>SD</given-names></name><name name-style="western"><surname>Wiste</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Vemuri</surname><given-names>P</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>V</given-names></name><name name-style="western"><surname>Kantarci</surname><given-names>K</given-names></name><name name-style="western"><surname>Gunter</surname><given-names>JL</given-names></name><name name-style="western"><surname>Senjem</surname><given-names>ML</given-names></name><name name-style="western"><surname>Ivnik</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>An operational approach to National Institute on Aging-Alzheimer&#8217;s association criteria for preclinical alzheimer disease</article-title><source>Ann Neurol</source><year>2012</year><volume>71</volume><issue>6</issue><fpage>765</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">22488240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.22628</pub-id><pub-id pub-id-type="pmcid">PMC3586223</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Jack CR Jr., Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, et al. An operational approach to National Institute on Aging-Alzheimer&#8217;s association criteria for preclinical alzheimer disease. Ann Neurol. 2012;71(6):765&#8211;75.<pub-id pub-id-type="pmid">22488240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.22628</pub-id><pub-id pub-id-type="pmcid">PMC3586223</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caroli</surname><given-names>A</given-names></name><name name-style="western"><surname>Prestia</surname><given-names>A</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>S</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>C</given-names></name><name name-style="western"><surname>van der Flier</surname><given-names>WM</given-names></name><name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></name><name name-style="western"><surname>Van Berckel</surname><given-names>B</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>C</given-names></name><name name-style="western"><surname>Wall</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression</article-title><source>Neurology</source><year>2015</year><volume>84</volume><issue>5</issue><fpage>508</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">25568301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000001209</pub-id><pub-id pub-id-type="pmcid">PMC4336071</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen C, Wall AE, et al. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology. 2015;84(5):508&#8211;15.<pub-id pub-id-type="pmid">25568301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000001209</pub-id><pub-id pub-id-type="pmcid">PMC4336071</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mormino</surname><given-names>EC</given-names></name><name name-style="western"><surname>Papp</surname><given-names>KV</given-names></name><name name-style="western"><surname>Rentz</surname><given-names>DM</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>AP</given-names></name><name name-style="western"><surname>LaPoint</surname><given-names>M</given-names></name><name name-style="western"><surname>Amariglio</surname><given-names>R</given-names></name><name name-style="western"><surname>Hanseeuw</surname><given-names>B</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>GA</given-names></name><name name-style="western"><surname>Hedden</surname><given-names>T</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Heterogeneity in suspected Non-Alzheimer disease pathophysiology among clinically normal older individuals</article-title><source>JAMA Neurol</source><year>2016</year><volume>73</volume><issue>10</issue><fpage>1185</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">27548655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2016.2237</pub-id><pub-id pub-id-type="pmcid">PMC5266522</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Mormino EC, Papp KV, Rentz DM, Schultz AP, LaPoint M, Amariglio R, Hanseeuw B, Marshall GA, Hedden T, Johnson KA, et al. Heterogeneity in suspected Non-Alzheimer disease pathophysiology among clinically normal older individuals. JAMA Neurol. 2016;73(10):1185&#8211;91.<pub-id pub-id-type="pmid">27548655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2016.2237</pub-id><pub-id pub-id-type="pmcid">PMC5266522</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dean</surname><given-names>J</given-names></name><name name-style="western"><surname>Keshavan</surname><given-names>M</given-names></name></person-group><article-title>The neurobiology of depression: an integrated view</article-title><source>Asian J Psychiatr</source><year>2017</year><volume>27</volume><fpage>101</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">28558878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajp.2017.01.025</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Dean J, Keshavan M. The neurobiology of depression: an integrated view. Asian J Psychiatr. 2017;27:101&#8211;11.<pub-id pub-id-type="pmid">28558878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajp.2017.01.025</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geraets</surname><given-names>AFJ</given-names></name><name name-style="western"><surname>Schram</surname><given-names>MT</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>JFA</given-names></name><name name-style="western"><surname>Koster</surname><given-names>A</given-names></name><name name-style="western"><surname>Dagnelie</surname><given-names>PC</given-names></name><name name-style="western"><surname>van Greevenbroek</surname><given-names>MMJ</given-names></name><name name-style="western"><surname>Stehouwer</surname><given-names>CDA</given-names></name><name name-style="western"><surname>Verhey</surname><given-names>FRJ</given-names></name><name name-style="western"><surname>K&#246;hler</surname><given-names>S</given-names></name></person-group><article-title>The relation of depression with structural brain abnormalities and cognitive functioning: the Maastricht study</article-title><source>Psychol Med</source><year>2021</year><volume>52</volume><issue>15</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">33634767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0033291721000222</pub-id><pub-id pub-id-type="pmcid">PMC9772903</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Geraets AFJ, Schram MT, Jansen JFA, Koster A, Dagnelie PC, van Greevenbroek MMJ, Stehouwer CDA, Verhey FRJ, K&#246;hler S. The relation of depression with structural brain abnormalities and cognitive functioning: the Maastricht study. Psychol Med. 2021;52(15):1&#8211;10.<pub-id pub-id-type="pmid">33634767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0033291721000222</pub-id><pub-id pub-id-type="pmcid">PMC9772903</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steffens</surname><given-names>DC</given-names></name><name name-style="western"><surname>McQuoid</surname><given-names>DR</given-names></name><name name-style="western"><surname>Payne</surname><given-names>ME</given-names></name><name name-style="western"><surname>Potter</surname><given-names>GG</given-names></name></person-group><article-title>Change in hippocampal volume on magnetic resonance imaging and cognitive decline among older depressed and nondepressed subjects in the neurocognitive outcomes of depression in the elderly study</article-title><source>Am J Geriatric Psychiatry</source><year>2011</year><volume>19</volume><issue>1</issue><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JGP.0b013e3181d6c245</pub-id><pub-id pub-id-type="pmcid">PMC3010251</pub-id><pub-id pub-id-type="pmid">20808107</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Steffens DC, McQuoid DR, Payne ME, Potter GG. Change in hippocampal volume on magnetic resonance imaging and cognitive decline among older depressed and nondepressed subjects in the neurocognitive outcomes of depression in the elderly study. Am J Geriatric Psychiatry. 2011;19(1):4&#8211;12.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JGP.0b013e3181d6c245</pub-id><pub-id pub-id-type="pmcid">PMC3010251</pub-id><pub-id pub-id-type="pmid">20808107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colloby</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Firbank</surname><given-names>MJ</given-names></name><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Vasudev</surname><given-names>A</given-names></name><name name-style="western"><surname>Parry</surname><given-names>SW</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>JT</given-names></name></person-group><article-title>Regional cerebral blood flow in late-life depression: arterial spin labelling magnetic resonance study</article-title><source>Br J Psychiatry</source><year>2012</year><volume>200</volume><issue>2</issue><fpage>150</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">22194184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1192/bjp.bp.111.092387</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Colloby SJ, Firbank MJ, He J, Thomas AJ, Vasudev A, Parry SW, O&#8217;Brien JT. Regional cerebral blood flow in late-life depression: arterial spin labelling magnetic resonance study. Br J Psychiatry. 2012;200(2):150&#8211;5.<pub-id pub-id-type="pmid">22194184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1192/bjp.bp.111.092387</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>KY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CS</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CY</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SY</given-names></name><name name-style="western"><surname>Yen</surname><given-names>TC</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>IT</given-names></name></person-group><article-title>Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: evidence of cerebral amyloidosis and hippocampal atrophy</article-title><source>Brain Behav</source><year>2018</year><volume>8</volume><issue>7</issue><fpage>e01016</fpage><pub-id pub-id-type="pmid">29927088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/brb3.1016</pub-id><pub-id pub-id-type="pmcid">PMC6043710</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Wu KY, Lin KJ, Chen CH, Chen CS, Liu CY, Huang SY, Yen TC, Hsiao IT. Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: evidence of cerebral amyloidosis and hippocampal atrophy. Brain Behav. 2018;8(7):e01016.<pub-id pub-id-type="pmid">29927088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/brb3.1016</pub-id><pub-id pub-id-type="pmcid">PMC6043710</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">First MB. Structured clinical interview for the DSM (SCID). <italic toggle="yes">The encyclopedia of clinical psychology</italic> 2014:1&#8211;6.</mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dale</surname><given-names>AM</given-names></name><name name-style="western"><surname>Fischl</surname><given-names>B</given-names></name><name name-style="western"><surname>Sereno</surname><given-names>MI</given-names></name></person-group><article-title>Cortical surface-based analysis. I. Segmentation and surface reconstruction</article-title><source>NeuroImage</source><year>1999</year><volume>9</volume><issue>2</issue><fpage>179</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">9931268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/nimg.1998.0395</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. NeuroImage. 1999;9(2):179&#8211;94.<pub-id pub-id-type="pmid">9931268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/nimg.1998.0395</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>IT</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>JL</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Huang</surname><given-names>KL</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Wey</surname><given-names>SP</given-names></name><name name-style="western"><surname>Yen</surname><given-names>TC</given-names></name></person-group><article-title>Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in alzheimer&#8217;s disease and mild cognitive impairment</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2016</year><volume>43</volume><issue>7</issue><fpage>1304</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">27003417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-016-3359-8</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Lin KJ, Hsiao IT, Hsu JL, Huang CC, Huang KL, Hsieh CJ, Wey SP, Yen TC. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in alzheimer&#8217;s disease and mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2016;43(7):1304&#8211;14.<pub-id pub-id-type="pmid">27003417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-016-3359-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>KY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CH</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>YM</given-names></name><name name-style="western"><surname>Yen</surname><given-names>TC</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>IT</given-names></name></person-group><article-title>Atrophy, hypometabolism and implication regarding pathology in late-life major depression with suspected non-alzheimer pathophysiology (SNAP)</article-title><source>Biomed J</source><year>2023</year><volume>46</volume><issue>6</issue><fpage>100589</fpage><pub-id pub-id-type="pmid">36914051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bj.2023.03.002</pub-id><pub-id pub-id-type="pmcid">PMC10749882</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Wu KY, Lin KJ, Chen CH, Liu CY, Wu YM, Yen TC, Hsiao IT. Atrophy, hypometabolism and implication regarding pathology in late-life major depression with suspected non-alzheimer pathophysiology (SNAP). Biomed J. 2023;46(6):100589.<pub-id pub-id-type="pmid">36914051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bj.2023.03.002</pub-id><pub-id pub-id-type="pmcid">PMC10749882</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></name><name name-style="western"><surname>Chetelat</surname><given-names>G</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>D</given-names></name><name name-style="western"><surname>Fagan</surname><given-names>AM</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>GB</given-names></name><name name-style="western"><surname>Jagust</surname><given-names>W</given-names></name><name name-style="western"><surname>Mormino</surname><given-names>EC</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>RC</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Suspected non-Alzheimer disease pathophysiology&#8211;concept and controversy</article-title><source>Nat Rev Neurol</source><year>2016</year><volume>12</volume><issue>2</issue><fpage>117</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">26782335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2015.251</pub-id><pub-id pub-id-type="pmcid">PMC4784257</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Jack CR Jr., Knopman DS, Chetelat G, Dickson D, Fagan AM, Frisoni GB, Jagust W, Mormino EC, Petersen RC, Sperling RA, et al. Suspected non-Alzheimer disease pathophysiology&#8211;concept and controversy. Nat Rev Neurol. 2016;12(2):117&#8211;24.<pub-id pub-id-type="pmid">26782335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2015.251</pub-id><pub-id pub-id-type="pmcid">PMC4784257</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benjamini</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><article-title>Controlling the false discovery rate: A practical and powerful approach to multiple testing</article-title><source>J Royal Stat Soc Ser B (Methodological)</source><year>1995</year><volume>57</volume><issue>1</issue><fpage>289</fpage><lpage>300</lpage></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Stat Soc Ser B (Methodological). 1995;57(1):289&#8211;300.</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haller</surname><given-names>S</given-names></name><name name-style="western"><surname>Montandon</surname><given-names>ML</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>C</given-names></name><name name-style="western"><surname>Garibotto</surname><given-names>V</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>FR</given-names></name><name name-style="western"><surname>Giannakopoulos</surname><given-names>P</given-names></name></person-group><article-title>Hippocampal volume loss, brain amyloid accumulation, and APOE status in cognitively intact elderly subjects</article-title><source>Neurodegener Dis</source><year>2019</year><volume>19</volume><issue>3&#8211;4</issue><fpage>139</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">31846965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000504302</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Haller S, Montandon ML, Rodriguez C, Garibotto V, Herrmann FR, Giannakopoulos P. Hippocampal volume loss, brain amyloid accumulation, and APOE status in cognitively intact elderly subjects. Neurodegener Dis. 2019;19(3&#8211;4):139&#8211;47.<pub-id pub-id-type="pmid">31846965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000504302</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trzepacz</surname><given-names>PT</given-names></name><name name-style="western"><surname>Hochstetler</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P</given-names></name><name name-style="western"><surname>Castelluccio</surname><given-names>P</given-names></name><name name-style="western"><surname>Witte</surname><given-names>MM</given-names></name><name name-style="western"><surname>Dell&#8217;Agnello</surname><given-names>G</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>EK</given-names></name></person-group><article-title>Relationship of hippocampal volume to amyloid burden across diagnostic stages of alzheimer&#8217;s disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2016</year><volume>41</volume><issue>1&#8211;2</issue><fpage>68</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">26625159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000441351</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Trzepacz PT, Hochstetler H, Yu P, Castelluccio P, Witte MM, Dell&#8217;Agnello G, Degenhardt EK. Relationship of hippocampal volume to amyloid burden across diagnostic stages of alzheimer&#8217;s disease. Dement Geriatr Cogn Disord. 2016;41(1&#8211;2):68&#8211;79.<pub-id pub-id-type="pmid">26625159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000441351</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Winter</surname><given-names>FL</given-names></name><name name-style="western"><surname>Emsell</surname><given-names>L</given-names></name><name name-style="western"><surname>Bouckaert</surname><given-names>F</given-names></name><name name-style="western"><surname>Claes</surname><given-names>L</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S</given-names></name><name name-style="western"><surname>Farrar</surname><given-names>G</given-names></name><name name-style="western"><surname>Billiet</surname><given-names>T</given-names></name><name name-style="western"><surname>Evers</surname><given-names>S</given-names></name><name name-style="western"><surname>Van den Stock</surname><given-names>J</given-names></name><name name-style="western"><surname>Sienaert</surname><given-names>P</given-names></name><etal/></person-group><article-title>No association of lower hippocampal volume with alzheimer&#8217;s disease pathology in Late-Life depression</article-title><source>Am J Psychiatry</source><year>2017</year><volume>174</volume><issue>3</issue><fpage>237</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">27539488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.2016.16030319</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">De Winter FL, Emsell L, Bouckaert F, Claes L, Jain S, Farrar G, Billiet T, Evers S, Van den Stock J, Sienaert P, et al. No association of lower hippocampal volume with alzheimer&#8217;s disease pathology in Late-Life depression. Am J Psychiatry. 2017;174(3):237&#8211;45.<pub-id pub-id-type="pmid">27539488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.2016.16030319</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nolan</surname><given-names>M</given-names></name><name name-style="western"><surname>Roman</surname><given-names>E</given-names></name><name name-style="western"><surname>Nasa</surname><given-names>A</given-names></name><name name-style="western"><surname>Levins</surname><given-names>KJ</given-names></name><name name-style="western"><surname>O&#8217;Hanlon</surname><given-names>E</given-names></name><name name-style="western"><surname>O&#8217;Keane</surname><given-names>V</given-names></name><name name-style="western"><surname>Willian Roddy</surname><given-names>D</given-names></name></person-group><article-title>Hippocampal and amygdalar volume changes in major depressive disorder: A targeted review and focus on stress</article-title><source>Chronic Stress (Thousand Oaks)</source><year>2020</year><volume>4</volume><fpage>2470547020944553</fpage><pub-id pub-id-type="pmid">33015518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2470547020944553</pub-id><pub-id pub-id-type="pmcid">PMC7513405</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Nolan M, Roman E, Nasa A, Levins KJ, O&#8217;Hanlon E, O&#8217;Keane V, Willian Roddy D. Hippocampal and amygdalar volume changes in major depressive disorder: A targeted review and focus on stress. Chronic Stress (Thousand Oaks). 2020;4:2470547020944553.<pub-id pub-id-type="pmid">33015518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2470547020944553</pub-id><pub-id pub-id-type="pmcid">PMC7513405</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tondo</surname><given-names>G</given-names></name><name name-style="western"><surname>Boccalini</surname><given-names>C</given-names></name><name name-style="western"><surname>Vanoli</surname><given-names>EG</given-names></name><name name-style="western"><surname>Presotto</surname><given-names>L</given-names></name><name name-style="western"><surname>Muscio</surname><given-names>C</given-names></name><name name-style="western"><surname>Ciullo</surname><given-names>V</given-names></name><name name-style="western"><surname>Banaj</surname><given-names>N</given-names></name><name name-style="western"><surname>Piras</surname><given-names>F</given-names></name><name name-style="western"><surname>Filippini</surname><given-names>G</given-names></name><name name-style="western"><surname>Tiraboschi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Brain metabolism and amyloid load in individuals with subjective cognitive decline or Pre-Mild cognitive impairment</article-title><source>Neurology</source><year>2022</year><volume>99</volume><issue>3</issue><fpage>e258</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">35487700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000200351</pub-id><pub-id pub-id-type="pmcid">PMC9302934</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Tondo G, Boccalini C, Vanoli EG, Presotto L, Muscio C, Ciullo V, Banaj N, Piras F, Filippini G, Tiraboschi P, et al. Brain metabolism and amyloid load in individuals with subjective cognitive decline or Pre-Mild cognitive impairment. Neurology. 2022;99(3):e258&#8211;69.<pub-id pub-id-type="pmid">35487700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000200351</pub-id><pub-id pub-id-type="pmcid">PMC9302934</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>J</given-names></name></person-group><article-title>The amyloid hypothesis of alzheimer&#8217;s disease at 25 years</article-title><source>EMBO Mol Med</source><year>2016</year><volume>8</volume><issue>6</issue><fpage>595</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">27025652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.201606210</pub-id><pub-id pub-id-type="pmcid">PMC4888851</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Selkoe DJ, Hardy J. The amyloid hypothesis of alzheimer&#8217;s disease at 25 years. EMBO Mol Med. 2016;8(6):595&#8211;608.<pub-id pub-id-type="pmid">27025652</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.201606210</pub-id><pub-id pub-id-type="pmcid">PMC4888851</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheline</surname><given-names>YI</given-names></name></person-group><article-title>Neuroimaging studies of mood disorder effects on the brain</article-title><source>Biol Psychiatry</source><year>2003</year><volume>54</volume><issue>3</issue><fpage>338</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">12893109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-3223(03)00347-0</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Sheline YI. Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry. 2003;54(3):338&#8211;52.<pub-id pub-id-type="pmid">12893109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-3223(03)00347-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Videbech</surname><given-names>P</given-names></name><name name-style="western"><surname>Ravnkilde</surname><given-names>B</given-names></name></person-group><article-title>Hippocampal volume and depression: a meta-analysis of MRI studies</article-title><source>Am J Psychiatry</source><year>2004</year><volume>161</volume><issue>11</issue><fpage>1957</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">15514393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.161.11.1957</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry. 2004;161(11):1957&#8211;66.<pub-id pub-id-type="pmid">15514393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.161.11.1957</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arborelius</surname><given-names>L</given-names></name><name name-style="western"><surname>Owens</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Plotsky</surname><given-names>PM</given-names></name><name name-style="western"><surname>Nemeroff</surname><given-names>CB</given-names></name></person-group><article-title>The role of corticotropin-releasing factor in depression and anxiety disorders</article-title><source>J Endocrinol</source><year>1999</year><volume>160</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">9854171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1677/joe.0.1600001</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999;160(1):1&#8211;12.<pub-id pub-id-type="pmid">9854171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1677/joe.0.1600001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McEwen</surname><given-names>BS</given-names></name></person-group><article-title>Effects of adverse experiences for brain structure and function</article-title><source>Biol Psychiatry</source><year>2000</year><volume>48</volume><issue>8</issue><fpage>721</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">11063969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-3223(00)00964-1</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">McEwen BS. Effects of adverse experiences for brain structure and function. Biol Psychiatry. 2000;48(8):721&#8211;31.<pub-id pub-id-type="pmid">11063969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-3223(00)00964-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donovan</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Locascio</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>GA</given-names></name><name name-style="western"><surname>Gatchel</surname><given-names>J</given-names></name><name name-style="western"><surname>Hanseeuw</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Rentz</surname><given-names>DM</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>KA</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>RA</given-names></name></person-group><article-title>Harvard aging brain S: longitudinal association of amyloid beta and Anxious-Depressive symptoms in cognitively normal older adults</article-title><source>Am J Psychiatry</source><year>2018</year><volume>175</volume><issue>6</issue><fpage>530</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">29325447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.2017.17040442</pub-id><pub-id pub-id-type="pmcid">PMC5988933</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Donovan NJ, Locascio JJ, Marshall GA, Gatchel J, Hanseeuw BJ, Rentz DM, Johnson KA, Sperling RA. Harvard aging brain S: longitudinal association of amyloid beta and Anxious-Depressive symptoms in cognitively normal older adults. Am J Psychiatry. 2018;175(6):530&#8211;7.<pub-id pub-id-type="pmid">29325447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ajp.2017.17040442</pub-id><pub-id pub-id-type="pmcid">PMC5988933</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linnemann</surname><given-names>C</given-names></name><name name-style="western"><surname>Lang</surname><given-names>UE</given-names></name></person-group><article-title>Pathways connecting Late-Life depression and dementia</article-title><source>Front Pharmacol</source><year>2020</year><volume>11</volume><fpage>279</fpage><pub-id pub-id-type="pmid">32231570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2020.00279</pub-id><pub-id pub-id-type="pmcid">PMC7083108</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Linnemann C, Lang UE. Pathways connecting Late-Life depression and dementia. Front Pharmacol. 2020;11:279.<pub-id pub-id-type="pmid">32231570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2020.00279</pub-id><pub-id pub-id-type="pmcid">PMC7083108</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrington</surname><given-names>KD</given-names></name><name name-style="western"><surname>Gould</surname><given-names>E</given-names></name><name name-style="western"><surname>Lim</surname><given-names>YY</given-names></name><name name-style="western"><surname>Ames</surname><given-names>D</given-names></name><name name-style="western"><surname>Pietrzak</surname><given-names>RH</given-names></name><name name-style="western"><surname>Rembach</surname><given-names>A</given-names></name><name name-style="western"><surname>Rainey-Smith</surname><given-names>S</given-names></name><name name-style="western"><surname>Martins</surname><given-names>RN</given-names></name><name name-style="western"><surname>Salvado</surname><given-names>O</given-names></name><name name-style="western"><surname>Villemagne</surname><given-names>VL</given-names></name><etal/></person-group><article-title>Amyloid burden and incident depressive symptoms in cognitively normal older adults</article-title><source>Int J Geriatr Psychiatry</source><year>2017</year><volume>32</volume><issue>4</issue><fpage>455</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">27114112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.4489</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Harrington KD, Gould E, Lim YY, Ames D, Pietrzak RH, Rembach A, Rainey-Smith S, Martins RN, Salvado O, Villemagne VL, et al. Amyloid burden and incident depressive symptoms in cognitively normal older adults. Int J Geriatr Psychiatry. 2017;32(4):455&#8211;63.<pub-id pub-id-type="pmid">27114112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.4489</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>PT</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>DW</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>JQ</given-names></name><name name-style="western"><surname>Jack</surname><given-names>CR</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></name><name name-style="western"><surname>Arfanakis</surname><given-names>K</given-names></name><name name-style="western"><surname>Rademakers</surname><given-names>R</given-names></name><name name-style="western"><surname>Alafuzoff</surname><given-names>I</given-names></name><name name-style="western"><surname>Attems</surname><given-names>J</given-names></name><name name-style="western"><surname>Brayne</surname><given-names>C</given-names></name><etal/></person-group><article-title>Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report</article-title><source>Brain</source><year>2019</year><volume>142</volume><issue>6</issue><fpage>1503</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">31039256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awz099</pub-id><pub-id pub-id-type="pmcid">PMC6536849</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503&#8211;27.<pub-id pub-id-type="pmid">31039256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awz099</pub-id><pub-id pub-id-type="pmcid">PMC6536849</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>PA</given-names></name><name name-style="western"><surname>Dawe</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></name><name name-style="western"><surname>Arfanakis</surname><given-names>K</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>JA</given-names></name></person-group><article-title>Contribution of TDP and hippocampal sclerosis to hippocampal volume loss in older-old persons</article-title><source>Neurology</source><year>2020</year><volume>94</volume><issue>2</issue><fpage>e142</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">31757868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000008679</pub-id><pub-id pub-id-type="pmcid">PMC6988988</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Yu L, Boyle PA, Dawe RJ, Bennett DA, Arfanakis K, Schneider JA. Contribution of TDP and hippocampal sclerosis to hippocampal volume loss in older-old persons. Neurology. 2020;94(2):e142&#8211;52.<pub-id pub-id-type="pmid">31757868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000008679</pub-id><pub-id pub-id-type="pmcid">PMC6988988</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolters</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Zonneveld</surname><given-names>HI</given-names></name><name name-style="western"><surname>Hofman</surname><given-names>A</given-names></name><name name-style="western"><surname>van der Lugt</surname><given-names>A</given-names></name><name name-style="western"><surname>Koudstaal</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Vernooij</surname><given-names>MW</given-names></name><name name-style="western"><surname>Ikram</surname><given-names>MA</given-names></name></person-group><article-title>Heart-Brain connection collaborative research G: cerebral perfusion and the risk of dementia: A Population-Based study</article-title><source>Circulation</source><year>2017</year><volume>136</volume><issue>8</issue><fpage>719</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">28588075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.117.027448</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Wolters FJ, Zonneveld HI, Hofman A, van der Lugt A, Koudstaal PJ, Vernooij MW, Ikram MA. Heart-Brain connection collaborative research G: cerebral perfusion and the risk of dementia: A Population-Based study. Circulation. 2017;136(8):719&#8211;28.<pub-id pub-id-type="pmid">28588075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.117.027448</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caroli</surname><given-names>A</given-names></name><name name-style="western"><surname>Testa</surname><given-names>C</given-names></name><name name-style="western"><surname>Geroldi</surname><given-names>C</given-names></name><name name-style="western"><surname>Nobili</surname><given-names>F</given-names></name><name name-style="western"><surname>Guerra</surname><given-names>UP</given-names></name><name name-style="western"><surname>Bonetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>GB</given-names></name></person-group><article-title>Brain perfusion correlates of medial Temporal lobe atrophy and white matter hyperintensities in mild cognitive impairment</article-title><source>J Neurol</source><year>2007</year><volume>254</volume><issue>8</issue><fpage>1000</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17375260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-006-0498-z</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Caroli A, Testa C, Geroldi C, Nobili F, Guerra UP, Bonetti M, Frisoni GB. Brain perfusion correlates of medial Temporal lobe atrophy and white matter hyperintensities in mild cognitive impairment. J Neurol. 2007;254(8):1000&#8211;8.<pub-id pub-id-type="pmid">17375260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-006-0498-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JE</given-names></name><name name-style="western"><surname>Byun</surname><given-names>MS</given-names></name><name name-style="western"><surname>Yi</surname><given-names>D</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Byeon</surname><given-names>G</given-names></name><name name-style="western"><surname>Jung</surname><given-names>G</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YK</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>DY</given-names></name></person-group><article-title>Depression accelerates longitudinal progression of hippocampal atrophy and cognitive decline in preclinical alzheimer&#8217;s disease: neuropsychiatry and behavioral neurology/neuropsychiatry</article-title><source>Alzheimer&#8217;s Dement</source><year>2020</year><volume>16</volume><fpage>e041089</fpage></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Park JE, Byun MS, Yi D, Lee JH, Byeon G, Jung G, Lee JY, Kim YK, Sohn CH, Lee DY. Depression accelerates longitudinal progression of hippocampal atrophy and cognitive decline in preclinical alzheimer&#8217;s disease: neuropsychiatry and behavioral neurology/neuropsychiatry. Alzheimer&#8217;s Dement. 2020;16:e041089.</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackin</surname><given-names>RS</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>E</given-names></name><name name-style="western"><surname>Kassel</surname><given-names>M</given-names></name><name name-style="western"><surname>Kryza-Lacombe</surname><given-names>M</given-names></name><name name-style="western"><surname>Burns</surname><given-names>E</given-names></name><name name-style="western"><surname>Bickford</surname><given-names>D</given-names></name><name name-style="western"><surname>Morin</surname><given-names>R</given-names></name><name name-style="western"><surname>Tosun</surname><given-names>D</given-names></name><name name-style="western"><surname>Landau</surname><given-names>S</given-names></name><name name-style="western"><surname>Butters</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Cortico-limbic volume abnormalities in late life depression are distinct from &#946; amyloid and white matter pathologies</article-title><source>Mol Psychiatry</source><year>2025</year><volume>30</volume><issue>4</issue><fpage>1267</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">39511448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-024-02677-4</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Mackin RS, Rhodes E, Kassel M, Kryza-Lacombe M, Burns E, Bickford D, Morin R, Tosun D, Landau S, Butters MA, et al. Cortico-limbic volume abnormalities in late life depression are distinct from &#946; amyloid and white matter pathologies. Mol Psychiatry. 2025;30(4):1267&#8211;76.<pub-id pub-id-type="pmid">39511448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-024-02677-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>ZT</given-names></name><name name-style="western"><surname>Shen</surname><given-names>XN</given-names></name><name name-style="western"><surname>Ma</surname><given-names>YH</given-names></name><name name-style="western"><surname>Ou</surname><given-names>YN</given-names></name><name name-style="western"><surname>Dong</surname><given-names>PQ</given-names></name><name name-style="western"><surname>Tan</surname><given-names>PL</given-names></name><name name-style="western"><surname>Yu</surname><given-names>PJ</given-names></name></person-group><article-title>Associations of the rate of change in geriatric depression scale with amyloid and cerebral glucose metabolism in cognitively normal older adults: A longitudinal study</article-title><source>J Affect Disord</source><year>2021</year><volume>280</volume><issue>Pt A</issue><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">33202341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2020.10.078</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Wang ZT, Shen XN, Ma YH, Ou YN, Dong PQ, Tan PL, Yu PJ. Associations of the rate of change in geriatric depression scale with amyloid and cerebral glucose metabolism in cognitively normal older adults: A longitudinal study. J Affect Disord. 2021;280(Pt A):77&#8211;84.<pub-id pub-id-type="pmid">33202341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2020.10.078</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slavin</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Sandstrom</surname><given-names>CK</given-names></name><name name-style="western"><surname>Tran</surname><given-names>TT</given-names></name><name name-style="western"><surname>Doraiswamy</surname><given-names>PM</given-names></name><name name-style="western"><surname>Petrella</surname><given-names>JR</given-names></name></person-group><article-title>Hippocampal volume and the Mini-Mental state examination in the diagnosis of amnestic mild cognitive impairment</article-title><source>AJR Am J Roentgenol</source><year>2007</year><volume>188</volume><issue>5</issue><fpage>1404</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">17449789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2214/AJR.06.1052</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Slavin MJ, Sandstrom CK, Tran TT, Doraiswamy PM, Petrella JR. Hippocampal volume and the Mini-Mental state examination in the diagnosis of amnestic mild cognitive impairment. AJR Am J Roentgenol. 2007;188(5):1404&#8211;10.<pub-id pub-id-type="pmid">17449789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2214/AJR.06.1052</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>M</given-names></name></person-group><article-title>[Suspected Non-Alzheimer&#8217;s disease pathophysiology (SNAP) and its pathological backgrounds in the diagnosis of preclinical and clinical alzheimer&#8217;s disease]</article-title><source>Brain Nerve</source><year>2018</year><volume>70</volume><issue>1</issue><fpage>59</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">29348375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.11477/mf.1416200951</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Yamada M. [Suspected Non-Alzheimer&#8217;s disease pathophysiology (SNAP) and its pathological backgrounds in the diagnosis of preclinical and clinical alzheimer&#8217;s disease]. Brain Nerve. 2018;70(1):59&#8211;71.<pub-id pub-id-type="pmid">29348375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.11477/mf.1416200951</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="pmc-domain-id">1609</journal-id><journal-id journal-id-type="pmc-domain">bmjo</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12481332</article-id><article-id pub-id-type="pmcid-ver">PMC12481332.1</article-id><article-id pub-id-type="pmcaid">12481332</article-id><article-id pub-id-type="pmcaiid">12481332</article-id><article-id pub-id-type="pmid">41022443</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2024-092459</article-id><article-id pub-id-type="publisher-id">bmjopen-2024-092459</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Health Informatics</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1702</subject><subject>1506</subject></subj-group></article-categories><title-group><article-title>Dementia-related volumetric assessments in neuroradiology reports: a natural language processing-based study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0008-1948-657X</contrib-id><name name-style="western"><surname>Mayers</surname><given-names initials="AJ">Adam John</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Roberts</surname><given-names initials="A">Angus</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7977-1948</contrib-id><name name-style="western"><surname>Venkataraman</surname><given-names initials="AV">Ashwin V</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Booth</surname><given-names initials="C">Christopher</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stewart</surname><given-names initials="R">Robert</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><aff id="aff1"><label>1</label><institution>King&#8217;s College London, Institute of Psychiatry Psychology &amp; Neuroscience</institution>, <addr-line content-type="city">London</addr-line>, <country>UK</country></aff><aff id="aff2"><label>2</label><institution>Guy's and St Thomas&#8217; NHS Foundation Trust</institution>, <addr-line content-type="city">London</addr-line>, <country>UK</country></aff><aff id="aff3"><label>3</label><institution>South London and Maudsley NHS Foundation Trust</institution>, <addr-line content-type="city">London</addr-line>, <country>UK</country></aff></contrib-group><author-notes><fn><p><bold>Supplemental material:</bold> Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></fn><fn fn-type="COI-statement" id="fn4"><p>None declared.</p></fn><corresp id="cor1">Dr Adam John Mayers; <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="adam.mayers@nhs.net">adam.mayers@nhs.net</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>28</day><month>9</month><year>2025</year></pub-date><volume>15</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496158</issue-id><elocation-id>e092459</elocation-id><history><date date-type="received"><day>14</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>04</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 00:25:23.493"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bmjopen-15-9.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="bmjopen-15-9.pdf"/><abstract><sec><title> ABSTRACT</title></sec><sec><title>Objectives</title><p>Structural MRI of the brain is routinely performed on patients referred to memory clinics; however, resulting radiology reports, including volumetric assessments, are conventionally stored as unstructured free text. We sought to use natural language processing (NLP) to extract text relating to intracranial volumetric assessment from brain MRI text reports to enhance routine data availability for research purposes.</p></sec><sec><title>Setting</title><p>Electronic records from a large mental healthcare provider serving a geographic catchment of 1.3&#8201;million residents in four boroughs of south London, UK.</p></sec><sec><title>Design</title><p>A corpus of 4007 de-identified brain MRI reports from patients referred to memory assessment services. An NLP algorithm was developed, using a span categorisation approach, to extract six binary (presence/absence) categories from the text reports: (i) global volume loss, (ii) hippocampal/medial temporal lobe volume loss and (iii) other lobar/regional volume loss. Distributions of these categories were evaluated.</p></sec><sec><title>Results</title><p>The overall F1 score for the six categories was 0.89 (precision 0.92, recall 0.86), with the following precision/recall for each category: presence of global volume loss 0.95/0.95, absence of global volume loss 0.94/0.77, presence of regional volume loss 0.80/0.58, absence of regional volume loss 0.91/0.93, presence of hippocampal volume loss 0.90/0.88, and absence of hippocampal volume loss 0.94/0.92.</p></sec><sec><title>Conclusions</title><p>These results support the feasibility and accuracy of using NLP techniques to extract volumetric assessments from radiology reports, and the potential for automated generation of novel meta-data from dementia assessments in electronic health records.</p></sec></abstract><kwd-group><kwd>Feasibility Studies</kwd><kwd>Natural Language Processing</kwd><kwd>Magnetic resonance imaging</kwd><kwd>RADIOLOGY &amp; IMAGING</kwd><kwd>Dementia</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>King&#8217;s College London</institution></institution-wrap></funding-source></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>National Institute for Health Research (NIHR)</institution></institution-wrap></funding-source></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Applied Research Collaboration South London</institution></institution-wrap></funding-source></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>NIHR</institution></institution-wrap></funding-source></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>King&#8217;s College Hospital NHS Foundation Trust</institution></institution-wrap></funding-source></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/W014386</award-id><award-id>MR/Z504816/1</award-id></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100031401</institution-id><institution>UK Prevention Research Partnership</institution></institution-wrap></funding-source><award-id>MR-VO49879/1</award-id></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Brain</institution></institution-wrap></funding-source></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>NIHR Maudsley Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust</institution></institution-wrap></funding-source></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009362</institution-id><institution>South London and Maudsley NHS Foundation Trust</institution></institution-wrap></funding-source></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100019418</institution-id><institution>NIHR Maudsley Biomedical Research Centre</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Strengths and limitations of this study</title></caption><list list-type="bullet" list-content="ul"><list-item><p>To our knowledge, there has been no prior published research on the automated extraction of terms relating specifically to volumetric assessments from brain MRI reports.</p></list-item><list-item><p>This study uses natural language processing to extract mentions of dementia-related volumetric assessments from brain MRI reports which would not be feasible in a large dataset.</p></list-item><list-item><p>Reports are from patients referred for imaging from a single healthcare provider and the reports will have been written by a comparatively small number of neuroradiologists although over a long time period (13 years).</p></list-item><list-item><p>The majority of the reports are addressing the same clinical question and the model would not be generalisable to other radiology reports.</p></list-item><list-item><p>The model does not seek to capture longitudinal or comparative data. Some of the reports only mentioned that there was no progressive atrophy, implying a consideration of previous reports, and there was no means to evaluate what this meant for the scan in question.</p></list-item></list></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><sec id="s1-1"><title>Background</title><p> Brain MRI scans are performed on many patients being evaluated for a dementia diagnosis. The radiology report forms an important part of the patient health record, with the radiologist conventionally composing a free text document describing their findings following their interpretation of the images. In the context of dementia, this report is likely to include mentions of the presence or absence of generalised, regional or more specific focal areas of volume loss, as these findings in conjunction with the clinical picture help to guide diagnosis. For example, the presence of hippocampal atrophy is an important finding in the context of suspected Alzheimer&#8217;s type dementia,<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> as is the regional vulnerability to neurodegeneration across a variety of different dementia-related processes.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> Electronic health records (EHRs) provide important opportunities for research using large historic cohorts, although research questions are limited by the availability of data in a structured format for analysis. Extracting mentions of intracranial volumes from the radiology report would allow structured data to be generated and used for cohort assembly and analysis for downstream research.</p></sec><sec id="s1-2"><title>Natural language processing in radiology</title><p>Natural language processing (NLP) harnesses computational techniques to scrutinise both written and spoken language. Supervised approaches include rule based and/or machine learning based strategies, where the latter involve the deployment of methods such as deep learning and necessitate large volumes of data for training, validation and testing. The implementation of EHRs has made large volumes of digital data readily available for the application of NLP techniques, and these are increasingly being used within medicine with a wide variety of applications.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> This includes implementation within the field of radiology, with multiple systematic reviews demonstrating increasing usage of NLP techniques.<xref rid="R4" ref-type="bibr">4</xref><xref rid="R6" ref-type="bibr">6</xref> Applications include diagnostic surveillance, cohort building for research studies, query-based case retrieval, quality assurance, clinical support<xref rid="R7" ref-type="bibr"><sup>7</sup></xref> and automated protocolling.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref></p></sec><sec id="s1-3"><title>Natural language processing in neuroimaging and dementia</title><p>Even within neuroradiology, there are a large number of uses for NLP, such as extraction from reports of any mentions of ischaemic stroke and their acuity/location<xref rid="R9" ref-type="bibr"><sup>9</sup></xref>, detection of white matter hyperintensities and silent brain infarcts,<xref rid="R10" ref-type="bibr"><sup>10</sup></xref> or more broad detection of stroke, haemorrhage, tumour and atrophy.<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> In the dementia field, machine learning techniques have been used to model the progression of Alzheimer&#8217;s disease,<xref rid="R12" ref-type="bibr"><sup>12 13</sup></xref> and more specifically, NLP techniques have been applied to several areas including diagnosis from speech<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> or extracting symptomology from the clinical record.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref></p><p>To our knowledge, there are currently no papers focussing on the automated extraction of terms relating to volumetric assessments, as would be of particular use in a dementia context. We therefore sought to develop an automated method for labelling and extracting dementia-related volumetric assessments from neuroimaging reports in a large EHR database using machine learning techniques. We evaluated the performance of our method on a dataset of MRI reports from patients referred for imaging from memory clinic and compared it with manual review of original text.</p></sec></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>Corpus selection and preprocessing: the South London and Maudsley mental health case register</title><p>The South London and Maudsley NHS Foundation Trust (SLaM) provides mental health and dementia care services to around 1.3&#8201;million residents in its geographic catchment of four south London boroughs (Lambeth, Southwark, Lewisham and Croydon). SLaM adopted EHRs across all of its services in 2006. In 2007&#8211;2008, the Clinical Record Interactive Search (CRIS) application was developed with funding from the British National Institute for Health Research.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> CRIS generates a research database containing pseudonymised versions of de-identified patient records on more than 250&#8201;000 patients and 3.5&#8201;million documents. Since its development, the data have been substantially enhanced through external linkages and NLP.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> CRIS and associated data resources have received ethical approval for secondary analyses (Oxford Research Ethics Committee C, reference 23/SC/0257).</p><p>A total of 5672 radiology events were extracted from the radiology information system data for patients referred from memory assessment services between 5 August 2008 and 25 October 2021. After the exclusion of events where there was no associated report (ie, where the event was cancelled, the patient did not attend or there was no image acquisition for another reason), there were 4007 free text records. The total number of words in the corpus was 280&#8201;621 over 19&#8201;304 sentences, with a mean of 14.5 words per sentence. The mean number of words per report was 68 (median=61), with a report length ranging from 1 to 373 words (<xref rid="F1" ref-type="fig">figure 1</xref>).</p><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><title>Distribution of length of report in words.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bmjopen-15-9-g001.jpg"/></fig></sec><sec id="s2-2"><title>Technique</title><p>A span categorisation technique was used rather than a named entity recognition approach. Span categorisation<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> involves labelling a collection of contiguous tokens (span) as belonging to category, where any span can have an arbitrary number of labels, including those that are nested or overlapping. This is in contrast to labelling individual tokens as belonging to a particularly named entity (as in Named Entity Recognition approaches, or NER). There are a number of advantages to a span categorisation approach for this specific task. First, the terms of interest in these types of reports are often overlapping (eg, &#8216;no lobar, regional, or hippocampal volume loss&#8217;) and a span categorisation approach allows multilabel classification at a token level meaning that overlapping or nested terms of interest can be represented easily. Second, the mentions of volumetric assessment are generally longer than would be considered as a single named entity (eg, &#8216;severe bilateral hippocampal and medial temporal lobe volume loss&#8217;) and as such do not have as clear token boundaries as would be required for a named entity recognition approach. Third, negation statements are also frequently distant from the term itself (including within a preceding sentence), which is more challenging for named entity recognition approaches. Finally, it allows broad inclusion within categories (eg, all other named areas of the brain that are not the hippocampus) that would be challenging to encompass with an NER approach.</p><p>We identified three key types of volume loss that were relevant to this use case&#8212;generalised atrophy, medial temporal lobe/hippocampal atrophy and other areas of regional atrophy. While the &#8216;regional&#8217; category could be subdivided further (eg, &#8216;frontal volume loss&#8217;, &#8216;parietal volume loss&#8217;), the negation of volume loss was usually documented as &#8216;no regional or lobar atrophy&#8217;, and therefore, it was decided to model the simpler absence vs presence of regional volume loss. While this could have been modelled as absence of regional volume loss vs <italic toggle="yes">n</italic> categories of regional volume loss (where <italic toggle="yes">n</italic> is an arbitrary list of brain regions), the list of regions would be difficult to decide on without first reading the entire dataset, and increasing the number of categories increases the challenge of the annotation task and reduces the number of instances of each category in the dataset.</p><p>Therefore, six target categories were proposed:</p><list list-type="bullet" list-content="ul"><list-item><p>Global volume loss&#8212;present.</p></list-item><list-item><p>Global volume loss&#8212;absent.</p></list-item><list-item><p>Regional volume loss&#8212;present.</p></list-item><list-item><p>Regional volume loss&#8212;absent.</p></list-item><list-item><p>Hippocampal volume loss&#8212;present.</p></list-item><list-item><p>Hippocampal volume loss&#8212;absent.</p></list-item></list></sec><sec id="s2-3"><title>Annotation and description of labelled spans</title><p>The guidelines for annotation were written following examination of approximately 500 randomly selected reports. Generally, the annotated span would include any laterality or descriptor of severity (eg, &#8216;severe bilateral hippocampal volume loss&#8217;) and was based only on what could be taken as objective from the report. In cases where a finding was related to a patient&#8217;s age (which was neither known to the model nor the annotator), this qualifying language was excluded and only the phrase which could be taken as objective was annotated. As an example, &#8216;global volume loss in keeping with the patient&#8217;s age&#8217; would have &#8216;global volume loss&#8217; categorised as such. However, &#8216;brain volume is normal for the patient&#8217;s age&#8217; would have &#8216;brain volume is normal&#8217; categorised as such. The annotation guidelines are supplied as <xref rid="SM1" ref-type="supplementary-material">online supplemental material</xref>.</p><p>The annotation was performed using the prodigy software library.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> Both annotators were senior clinical radiology registrars. Inter-annotator agreement was calculated using the F1 measure, that is, assuming one annotator was the &#8216;gold standard&#8217; and measuring the other annotator&#8217;s performance against this. This approach was used as Cohen&#8217;s kappa (the standard inter-annotator agreement used for classification tasks) does not function well in this instance, as the vast majority of tokens in the dataset are not labelled at all, resulting in a very unbalanced dataset and artificially inflating the level of kappa agreement.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> Inter-annotator agreement using exact matches (ie, the presence of a span, its label, and both the start and end tokens) was 0.61 (95% CI 0.59 to 0.63). Using a relaxed definition of a match, as in Wang <italic toggle="yes">et al</italic><xref rid="R21" ref-type="bibr"><sup>21</sup></xref> (ie, the presence of a span, its label and at least overlapping token boundaries), this rose to 0.83 (0.82&#8211;0.85).</p><p>Following annotation of the full 4007 reports, 9154 total span examples were generated. Each category contained between 951 and 2165 examples, and span length ranged from 1 to 22 tokens with a median span length of 6. Distributions are visualised in <xref rid="F2" ref-type="fig">figure 2</xref>.</p><fig position="float" id="F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><title>Distribution of lengths of labelled spans, per span category.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bmjopen-15-9-g002.jpg"/></fig><p>Both span and boundary distinctiveness values were obtained using the spaCy library which calculates the Kullback&#8211;Leibler divergence of the span and boundary tokens in comparison to the remainder of the text.<xref rid="R22" ref-type="bibr"><sup>22</sup></xref> Average span distinctiveness and boundary distinctiveness were 1.84 and 1.42 respectively, with some variability between the different categories (<xref rid="T1" ref-type="table">table 1</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Average span length, span distinctiveness and boundary distinctiveness per category</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1">Category</th><th valign="bottom" rowspan="1" colspan="1">Average span length</th><th valign="bottom" rowspan="1" colspan="1">Span distinctiveness</th><th valign="bottom" rowspan="1" colspan="1">Boundary distinctiveness</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Global volume loss&#8212;present</td><td align="left" valign="top" rowspan="1" colspan="1">4.71</td><td align="left" valign="top" rowspan="1" colspan="1">1.91</td><td align="left" valign="top" rowspan="1" colspan="1">1.33</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Global volume loss&#8212;absent</td><td align="left" valign="top" rowspan="1" colspan="1">5.89</td><td align="left" valign="top" rowspan="1" colspan="1">1.87</td><td align="left" valign="top" rowspan="1" colspan="1">1.76</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Regional volume loss&#8212;present</td><td align="left" valign="top" rowspan="1" colspan="1">6.48</td><td align="left" valign="top" rowspan="1" colspan="1">1.38</td><td align="left" valign="top" rowspan="1" colspan="1">1.20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Regional volume loss&#8212;absent</td><td align="left" valign="top" rowspan="1" colspan="1">5.21</td><td align="left" valign="top" rowspan="1" colspan="1">2.23</td><td align="left" valign="top" rowspan="1" colspan="1">1.59</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hippocampal volume loss&#8212;present</td><td align="left" valign="top" rowspan="1" colspan="1">5.88</td><td align="left" valign="top" rowspan="1" colspan="1">1.65</td><td align="left" valign="top" rowspan="1" colspan="1">1.27</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hippocampal volume loss&#8212;absent</td><td align="left" valign="top" rowspan="1" colspan="1">6.37</td><td align="left" valign="top" rowspan="1" colspan="1">2.04</td><td align="left" valign="top" rowspan="1" colspan="1">1.63</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weighted average</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>5.62</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.84</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>1.42</bold>
</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1" fn-type="other"><p>Bold values are the weighted average of the rows above.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-4"><title>Internal report inconsistency</title><p>As data are labelled at a word/token level, it is possible for a report to contain &#8216;contradictory&#8217; labels. For some instances, this is appropriate: for example, both &#8216;left hippocampal atrophy&#8217; and &#8216;right hippocampus is normal&#8217; can appear within the same report. However, there can also be genuine inconsistencies within the report for example, both &#8216;no lobar or regional atrophy&#8217; and &#8216;there is generalised widening of the parietal sulci&#8217;. However, this reflects a degree of inconsistency in the initial report rather than an error in the labelling. The overall number of reports containing conflicting labels, however, was small (141 reports, 3.5%) and this issue was not considered further in any analysis and these reports were not excluded.</p></sec><sec id="s2-5"><title>Model development</title><p>The 4007 total annotated reports were then subdivided, with 80% (3206 reports) being used for model development and 20% (801) being kept as a separate holdout test set. The spaCy Python library was used for model development of the algorithm.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref> K-fold cross-validation with five folds was implemented<xref rid="R24" ref-type="bibr"><sup>24</sup></xref> to evaluate model performance for the purposes of base model selection and for further hyperparameter tuning.</p><p>The model was initially trained on each of spaCy&#8217;s publicly available English language pipelines (both convolutional neural networks and transformer architectures), including those trained on general web text as well as those from the scispacy library trained on a scientific corpus. The best performing model with default parameters was the transformer model trained on general web text (&#8216;en_core_web_trf&#8217;<xref rid="R25" ref-type="bibr"><sup>25</sup></xref>), and this was used as the basis for further model development. The pipeline consisted only of the tokenisation, transformer and span categorisation components (&#8216;spancat&#8217;, which itself contains the suggester function for candidate spans, and a labeller that predicts zero or more labels for per candidate span). Including other pipeline components such as part of speech tagging, parsing and other available pipeline components did not improve performance and increased both resource usage and training time. After base architecture selection, hyperparameter tuning was performed (please see GitHub for spaCy configuration files<xref rid="R24" ref-type="bibr"><sup>24</sup></xref>).</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>Against the holdout test set, the model&#8217;s F1 score averaged over all six categories was 0.89, with precision of 0.92 (95% CI 0.90 to 0.93) and recall of 0.86 (95% CI 0.84 to 0.87). Performance varied across the categories, with five of the categories in the 0.85&#8211;0.95 range, and regional volume loss being a relative outlier with F1 score of 0.68 (<xref rid="T2" ref-type="table">table 2</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><title>Precision, recall and F1 score for each span category</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1">Category</th><th valign="bottom" rowspan="1" colspan="1">Precision (95%&#8201;CI)</th><th valign="bottom" rowspan="1" colspan="1">Recall (95%&#8201;CI)</th><th valign="bottom" rowspan="1" colspan="1">F1 score</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1">Global volume loss&#8212;present</td><td valign="top" align="char" rowspan="1" colspan="1">0.95 (0.93 to 0.97)</td><td valign="top" align="char" rowspan="1" colspan="1">0.95 (0.92 to 0.97)</td><td valign="top" align="char" rowspan="1" colspan="1">0.95</td></tr><tr><td valign="top" rowspan="1" colspan="1">Global volume loss&#8212;absent</td><td valign="top" align="char" rowspan="1" colspan="1">0.94 (0.90 to 0.97)</td><td valign="top" align="char" rowspan="1" colspan="1">0.77 (0.70 to 0.82)</td><td valign="top" align="char" rowspan="1" colspan="1">0.85</td></tr><tr><td valign="top" rowspan="1" colspan="1">Regional volume loss&#8212;present</td><td valign="top" align="char" rowspan="1" colspan="1">0.80 (0.74 to 0.85)</td><td valign="top" align="char" rowspan="1" colspan="1">0.58 (0.52 to 0.65)</td><td valign="top" align="char" rowspan="1" colspan="1">0.68</td></tr><tr><td valign="top" rowspan="1" colspan="1">Regional volume loss&#8212;absent</td><td valign="top" align="char" rowspan="1" colspan="1">0.91 (0.88 to 0.94)</td><td valign="top" align="char" rowspan="1" colspan="1">0.93 (0.90 to 0.95)</td><td valign="top" align="char" rowspan="1" colspan="1">0.92</td></tr><tr><td valign="top" rowspan="1" colspan="1">Hippocampal volume loss&#8212;present</td><td valign="top" align="char" rowspan="1" colspan="1">0.90 (0.87 to 0.93)</td><td valign="top" align="char" rowspan="1" colspan="1">0.88 (0.85 to 0.91)</td><td valign="top" align="char" rowspan="1" colspan="1">0.89</td></tr><tr><td valign="top" rowspan="1" colspan="1">Hippocampal volume loss&#8212;absent</td><td valign="top" align="char" rowspan="1" colspan="1">0.94 (0.90 to 0.97)</td><td valign="top" align="char" rowspan="1" colspan="1">0.92 (0.88 to 0.95)</td><td valign="top" align="char" rowspan="1" colspan="1">0.93</td></tr></tbody></table></table-wrap><sec id="s3-1"><title>Inferred prevalence of specific types of atrophy</title><p>By using the presence of at least one instance of a span category to label the whole report, we can infer the reported prevalence of each type of atrophy in the cohort (<xref rid="T3" ref-type="table">table 3</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><title>Total number of reports containing at least one instance of a span category, and as a percentage of the whole cohort</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1">Category</th><th valign="bottom" rowspan="1" colspan="1">Total</th><th valign="bottom" rowspan="1" colspan="1">Prevalence</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Global volume loss&#8212;present</td><td valign="top" align="left" rowspan="1" colspan="1">1852</td><td valign="top" align="left" rowspan="1" colspan="1">46.2%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Global volume loss&#8212;absent</td><td valign="top" align="left" rowspan="1" colspan="1">955</td><td valign="top" align="left" rowspan="1" colspan="1">23.8%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Regional volume loss&#8212;present</td><td valign="top" align="left" rowspan="1" colspan="1">952</td><td valign="top" align="left" rowspan="1" colspan="1">23.8%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Regional volume loss&#8212;absent</td><td valign="top" align="left" rowspan="1" colspan="1">1607</td><td valign="top" align="left" rowspan="1" colspan="1">40.1%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hippocampal volume loss&#8212;present</td><td valign="top" align="left" rowspan="1" colspan="1">1488</td><td valign="top" align="left" rowspan="1" colspan="1">37.1%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hippocampal volume loss&#8212;absent</td><td valign="top" align="left" rowspan="1" colspan="1">975</td><td valign="top" align="left" rowspan="1" colspan="1">24.3%</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>We developed an application capable of extracting mentions of volumetric assessment from radiologist&#8217;s unstructured plain text brain MRI reports, to enable enrichment of routinely collected data for use in research. The algorithm was able to perform this task at good levels of accuracy against manually annotated source text, with an overall F score of 0.89, and a precision and recall of 0.92 and 0.86 respectively. The best performing category was the &#8216;global volume loss &#8211; present&#8217; category (F1 score of 0.95), likely a function of both number of occurrences (this was the category with the most examples) and more stereotyped phrasing.</p><p>The algorithm relatively underperforms on the &#8216;regional volume loss - present&#8217; category (F1 score of 0.68). This is somewhat expected given the underlying problem; if regional volume loss is present, then any anatomical term may be mentioned. This inherently makes this category much more heterogeneous in comparison to mentions of generalised volume loss or hippocampal volume loss, both of which need a much smaller vocabulary to describe. If regional volume loss is absent, then this similarly can only be described in a much more limited number of ways than its presence. This is in part reflected in the data, with the &#8216;regional volume loss &#8211; present&#8217; category having the broadest range of span length (2&#8211;22) and the lowest span distinctiveness (1.38).</p><sec id="s4-1"><title>Strengths and limitations</title><p>To our knowledge, there has been no published research on the automated extraction of terms relating specifically to volumetric assessments from brain MRI reports, as would be of particular use in a dementia context. We accurately extracted these terms using a model trained on a moderately sized dataset (more than 3200 radiologist-labelled reports out of the full annotated dataset of 4007). This model can now be used to extract these measures on a population-level basis and be used for cohort identification and comparison with other measures from age to performance on cognitive testing. Additionally, this model has demonstrated that this approach could be easily used to develop similar algorithms for different clinical problems with the appropriate labelled text.</p><p>Limitations include the use of reports from patients referred for imaging from a single healthcare provider; therefore, the reports will have been written by a comparatively small number of subspecialised neuroradiologists. This may have limited the variety of reports and writing styles that were available to train and validate algorithm and its generalisability clearly requires wider evaluation. On the other hand, the reports were drawn from a long time period (13 years), increasing the potential heterogeneity of raters. The model is also limited in only having been trained on text written in English. Similarly, the overwhelming majority of the reports are addressing the same clinical question. Radiology reports may differ in style dependent on the clinical question and therefore, using the algorithm on both a more generalised or on a different patient population (eg, all outpatient scans, or patients referred from an epilepsy or stroke clinic) would need further evaluation, as the relevant terms of interest may not appear in the report even if present. For example, the radiologist may be less likely to specifically mention the size of the hippocampi for a patient referred from an epilepsy service. This is not necessarily a weakness of the model itself but a limit to its application that needs to be considered in future usage. A further limitation of the model is that it does not seek to capture longitudinal or comparative data. Some of the reports only mentioned that there was no progressive atrophy, implying a consideration of previous reports, and there was no means to evaluate what this meant for the scan in question. Again, this limitation in applicability would need to be considered if the model was used as part of longitudinal research into mild cognitive impairment progression, or evolution of dementia symptoms over time.</p></sec></sec><sec sec-type="conclusions" id="s5"><title>Conclusion</title><p>These results support the feasibility and accuracy of natural language processing applied to routine radiology reports and the potential for automated generation of novel meta-data from dementia assessments in electronic health records. This approach is planned to be implemented as part of routine data processing within the CRIS application for future research.</p></sec><sec sec-type="supplementary-material" id="s6"><title>Supplementary material</title><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/bmjopen-2024-092459</object-id><label>online supplemental material 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bmjopen-15-9-s001.docx" id="d67e661" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> RS is part-funded by: (i) the NIHR Maudsley Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust and King&#8217;s College London; (ii) the National Institute for Health Research (NIHR) Applied Research Collaboration South London (NIHR ARC South London) at King&#8217;s College Hospital NHS Foundation Trust; (iii) UKRI &#8211; Medical Research Council through the DATAMIND HDR UK Mental Health Data Hub (MRC reference: MR/W014386); (iv) the UK Prevention Research Partnership (Violence, Health and Society; MR-VO49879/1), an initiative funded by UK Research and Innovation Councils, the Department of Health and Social Care (England) and the UK devolved administrations, and leading health research charities. AR is part-funded by: (i) UKRI &#8211; Medical Research Council through the DATAMIND HDR UK Mental Health Data Hub (MRC reference: MR/Z504816/1); (ii) the UK Prevention Research Partnership (Violence, Health and Society; MR-VO49879/1), an initiative funded by UK Research and Innovation Councils, the Department of Health and Social Care (England) and the UK devolved administrations, and leading health research charities. AVV is funded by the National Institute for Health Research (NIHR) as NIHR Clinical Lecturer and supported by the NIHR Maudsley Biomedical Research Centre and NIHR HealthTech Research Centre in Brain Health at King&#8217;s College London and South London and Maudsley NHS Foundation Trust. The funders did not influence the results/outcomes of the study despite author affiliations with the funder.</p></fn><fn fn-type="other"><p>Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1136/bmjopen-2024-092459" ext-link-type="uri">https://doi.org/10.1136/bmjopen-2024-092459</ext-link>).</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Ethics approval:</bold> This study involves human participants and was approved by South Central &#8211; Oxford C Research Ethics Committee 23/SC/0257. The CRIS database has received ethical approval for secondary analysis (Oxford Research Ethics Committee, reference 18/SC/0372).</p></fn><fn fn-type="other"><p><bold>Patient and public involvement:</bold> Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion</article-title><source>Lancet Neurol</source><year>2002</year><volume>1</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/s1474-4422(02)00002-9</pub-id><pub-id pub-id-type="pmid">12849541</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>PNE</given-names></name><name name-style="western"><surname>Estarellas</surname><given-names>M</given-names></name><name name-style="western"><surname>Coomans</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Imaging biomarkers in neurodegeneration: current and future practices</article-title><source><italic toggle="yes">Alz Res Therapy</italic></source><year>2020</year><volume>12</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1186/s13195-020-00612-7</pub-id><pub-id pub-id-type="pmcid">PMC7187531</pub-id><pub-id pub-id-type="pmid">32340618</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Systematic Evaluation of Research Progress on Natural Language Processing in Medicine Over the Past 20 Years: Bibliometric Study on PubMed</article-title><source>J Med Internet Res</source><year>2020</year><volume>22</volume><elocation-id>e16816</elocation-id><pub-id pub-id-type="doi">10.2196/16816</pub-id><pub-id pub-id-type="pmid">32012074</pub-id><pub-id pub-id-type="pmcid">PMC7005695</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casey</surname><given-names>A</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>E</given-names></name><name name-style="western"><surname>Poon</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>A systematic review of natural language processing applied to radiology reports</article-title><source>BMC Med Inform Decis Mak</source><year>2021</year><volume>21</volume><elocation-id>179</elocation-id><pub-id pub-id-type="doi">10.1186/s12911-021-01533-7</pub-id><pub-id pub-id-type="pmid">34082729</pub-id><pub-id pub-id-type="pmcid">PMC8176715</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>JW</given-names></name><name name-style="western"><surname>Chong</surname><given-names>JJR</given-names></name></person-group><article-title>Review of Natural Language Processing in Radiology</article-title><source>Neuroimaging Clin N Am</source><year>2020</year><volume>30</volume><fpage>447</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.nic.2020.08.001</pub-id><pub-id pub-id-type="pmid">33038995</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pons</surname><given-names>E</given-names></name><name name-style="western"><surname>Braun</surname><given-names>LMM</given-names></name><name name-style="western"><surname>Hunink</surname><given-names>MGM</given-names></name><etal>et al</etal></person-group><article-title>Natural Language Processing in Radiology: A Systematic Review</article-title><source>Radiology</source><year>2016</year><volume>279</volume><fpage>329</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1148/radiol.16142770</pub-id><pub-id pub-id-type="pmid">27089187</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linna</surname><given-names>N</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>CE</given-names></name></person-group><article-title>Applications of natural language processing in radiology: A systematic review</article-title><source>Int J Med Inform</source><year>2022</year><volume>163</volume><fpage>104779</fpage><pub-id pub-id-type="doi">10.1016/j.ijmedinf.2022.104779</pub-id><pub-id pub-id-type="pmid">35533413</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chillakuru</surname><given-names>YR</given-names></name><name name-style="western"><surname>Munjal</surname><given-names>S</given-names></name><name name-style="western"><surname>Laguna</surname><given-names>B</given-names></name><etal>et al</etal></person-group><article-title>Development and web deployment of an automated neuroradiology MRI protocoling tool with natural language processing</article-title><source>BMC Med Inform Decis Mak</source><year>2021</year><volume>21</volume><fpage>213</fpage><pub-id pub-id-type="doi">10.1186/s12911-021-01574-y</pub-id><pub-id pub-id-type="pmid">34253196</pub-id><pub-id pub-id-type="pmcid">PMC8276477</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Orfanoudaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Machine learning and natural language processing methods to identify ischemic stroke, acuity and location from radiology reports</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0234908</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0234908</pub-id><pub-id pub-id-type="pmid">32559211</pub-id><pub-id pub-id-type="pmcid">PMC7304623</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>LY</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S</given-names></name><name name-style="western"><surname>Luetmer</surname><given-names>PH</given-names></name><etal>et al</etal></person-group><article-title>Agreement between neuroimages and reports for natural language processing-based detection of silent brain infarcts and white matter disease</article-title><source>BMC Neurol</source><year>2021</year><volume>21</volume><fpage>189</fpage><pub-id pub-id-type="doi">10.1186/s12883-021-02221-9</pub-id><pub-id pub-id-type="pmid">33975556</pub-id><pub-id pub-id-type="pmcid">PMC8111708</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alex</surname><given-names>B</given-names></name><name name-style="western"><surname>Grover</surname><given-names>C</given-names></name><name name-style="western"><surname>Tobin</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Text mining brain imaging reports</article-title><source>J Biomed Semantics</source><year>2019</year><volume>10</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/s13326-019-0211-7</pub-id><pub-id pub-id-type="pmid">31711539</pub-id><pub-id pub-id-type="pmcid">PMC6849161</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Oh</surname><given-names>I</given-names></name><name name-style="western"><surname>Schindler</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Machine learning for modeling the progression of Alzheimer disease dementia using clinical data: a systematic literature review</article-title><source>JAMIA Open</source><year>2021</year><volume>4</volume><elocation-id>ooab052</elocation-id><pub-id pub-id-type="doi">10.1093/jamiaopen/ooab052</pub-id><pub-id pub-id-type="pmid">34350389</pub-id><pub-id pub-id-type="pmcid">PMC8327375</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="preprint"><person-group person-group-type="author"><name name-style="western"><surname>Venkataraman</surname><given-names>AV</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>C</given-names></name><name name-style="western"><surname>Rittman</surname><given-names>T</given-names></name></person-group><article-title>Automated brain image analysis in dementia using artificial intelligence: a roadmap for the development of clinical tools</article-title><source>Open Science Framework</source><comment>Preprint</comment><year>2023</year><pub-id pub-id-type="doi">10.31219/osf.io/myuq7</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Searle</surname><given-names>T</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>Z</given-names></name><name name-style="western"><surname>Dobson</surname><given-names>R</given-names></name></person-group><article-title>Comparing natural language processing techniques for Alzheimer&#8217;s dementia prediction in spontaneous speech</article-title><source>arXiv</source><year>2020</year><pub-id pub-id-type="doi">10.48550/arXiv.2006.07358</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Topaz</surname><given-names>M</given-names></name><name name-style="western"><surname>Adams</surname><given-names>V</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Free-Text Documentation of Dementia Symptoms in Home Healthcare: A Natural Language Processing Study</article-title><source>Gerontol Geriatr Med</source><year>2020</year><volume>6</volume><elocation-id>2333721420959861</elocation-id><pub-id pub-id-type="doi">10.1177/2333721420959861</pub-id><pub-id pub-id-type="pmid">33029550</pub-id><pub-id pub-id-type="pmcid">PMC7520927</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>R</given-names></name><name name-style="western"><surname>Soremekun</surname><given-names>M</given-names></name><name name-style="western"><surname>Perera</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data</article-title><source>BMC Psychiatry</source><year>2009</year><volume>9</volume><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1186/1471-244X-9-51</pub-id><pub-id pub-id-type="pmid">19674459</pub-id><pub-id pub-id-type="pmcid">PMC2736946</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perera</surname><given-names>G</given-names></name><name name-style="western"><surname>Broadbent</surname><given-names>M</given-names></name><name name-style="western"><surname>Callard</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource</article-title><source>BMJ Open</source><year>2016</year><volume>6</volume><elocation-id>e008721</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2015-008721</pub-id><pub-id pub-id-type="pmcid">PMC4785292</pub-id><pub-id pub-id-type="pmid">26932138</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Schmuhl</surname><given-names>E</given-names></name><name name-style="western"><surname>Miranda</surname><given-names>L</given-names></name><name name-style="western"><surname>K&#225;d&#225;r</surname><given-names>&#193;</given-names></name><etal>et al</etal></person-group><article-title>Spancat: a new approach for span labelling</article-title><year>2022</year><comment>Available</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://explosion.ai/blog/spancat" ext-link-type="uri">https://explosion.ai/blog/spancat</ext-link></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Montani</surname><given-names>I</given-names></name><name name-style="western"><surname>Honnibal</surname><given-names>M</given-names></name></person-group><part-title>Prodigy: a modern and scriptable annotation tool for creating training data for machine learning models</part-title><source>Prodigy. Explosion</source><comment>Available</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://prodi.gy/" ext-link-type="uri">https://prodi.gy/</ext-link></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Deleger</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lingren</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Building gold standard corpora for medical natural language processing tasks</article-title><conf-name>AMIA Annual Symposium Proceedings, Vol. 2012</conf-name><year>2012</year><fpage>144</fpage><pub-id pub-id-type="pmcid">PMC3540456</pub-id><pub-id pub-id-type="pmid">23304283</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>R</given-names></name><name name-style="western"><surname>Alachram</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>NERO: a biomedical named-entity (recognition) ontology with a large, annotated corpus reveals meaningful associations through text embedding</article-title><source>NPJ Syst Biol Appl</source><year>2021</year><volume>7</volume><elocation-id>38</elocation-id><pub-id pub-id-type="doi">10.1038/s41540-021-00200-x</pub-id><pub-id pub-id-type="pmid">34671039</pub-id><pub-id pub-id-type="pmcid">PMC8528865</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papay</surname><given-names>S</given-names></name><name name-style="western"><surname>Klinger</surname><given-names>R</given-names></name><name name-style="western"><surname>Pad&#243;</surname><given-names>S</given-names></name></person-group><article-title>Dissecting span identification tasks with performance prediction</article-title><source>arXiv</source><year>2020</year><pub-id pub-id-type="doi">10.48550/arXiv.2010.02587</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="report"><person-group person-group-type="author"><name name-style="western"><surname>Honnibal</surname><given-names>M</given-names></name><name name-style="western"><surname>Montani</surname><given-names>I</given-names></name><name name-style="western"><surname>Van Landeghem</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>spaCy: industrial-strength natural language processing in python</article-title><year>2020</year><comment>Available</comment><pub-id pub-id-type="doi">10.5281/zenodo.1212303</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Mayers</surname><given-names>A</given-names></name></person-group><article-title>Brain mri nlp (version 1.0.0) [computer software]</article-title><year>2025</year><comment>Available</comment><pub-id pub-id-type="doi">10.5281/zenodo.15790492</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="webpage"><article-title>Spacy &#8211; available trained pipelines for English</article-title><year>2025</year><comment>Available</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://spacy.io/models/en#en_core_web_trf" ext-link-type="uri">https://spacy.io/models/en#en_core_web_trf</ext-link><comment>Accessed</comment><date-in-citation>02-Jul-2025</date-in-citation></element-citation></ref></ref-list><sec sec-type="data-availability"><title>Data availability statement</title><p>No data are available.</p></sec></back><sub-article id="sub-article1" article-type="aggregated-review-documents"><front-stub><title-group><article-title>Review Process File</article-title></title-group><pub-date pub-type="epub"><day>28</day><month>09</month><year>2025</year></pub-date></front-stub><body><fig id="d67e1295" position="anchor" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bmjopen-2024-092459.reviewer_comments.pdf" position="float" orientation="portrait"/></fig></body></sub-article></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70748" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12481214</article-id><article-id pub-id-type="pmcid-ver">PMC12481214.1</article-id><article-id pub-id-type="pmcaid">12481214</article-id><article-id pub-id-type="pmcaiid">12481214</article-id><article-id pub-id-type="pmid">41025328</article-id><article-id pub-id-type="doi">10.1002/alz.70748</article-id><article-id pub-id-type="publisher-id">ALZ70748</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Modeling presynaptic inhibition by the amyloid precursor protein demonstrates one potential mechanism for preventing runaway synaptic modification in Alzheimer's disease</article-title><alt-title alt-title-type="left-running-head">BARBER <sc>et&#160;al</sc>.</alt-title></title-group><contrib-group><contrib id="alz70748-cr-0001" contrib-type="author"><name name-style="western"><surname>Barber</surname><given-names initials="D">Dylan</given-names></name><xref rid="alz70748-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70748-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70748-cr-0002" contrib-type="author" corresp="yes"><name name-style="western"><surname>Hasselmo</surname><given-names initials="ME">Michael E.</given-names></name><xref rid="alz70748-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>hasselmo@bu.edu</email></address></contrib><contrib id="alz70748-cr-0003" contrib-type="author" corresp="yes"><name name-style="western"><surname>Rice</surname><given-names initials="HC">Heather C.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5818-4338</contrib-id><xref rid="alz70748-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70748-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70748-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="alz70748-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><address><email>heather-rice@omrf.org</email></address></contrib></contrib-group><aff id="alz70748-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Aging &amp; Metabolism Research Program</named-content>
<institution>Oklahoma Medical Research Foundation</institution>
<city>Oklahoma City</city>
<named-content content-type="country-part">Oklahoma</named-content>
<country country="US">USA</country>
</aff><aff id="alz70748-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Program in Neuroscience</named-content>
<institution>University of Oklahoma Health Sciences Center</institution>
<city>Oklahoma City</city>
<named-content content-type="country-part">Oklahoma</named-content>
<country country="US">USA</country>
</aff><aff id="alz70748-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Center for Systems Neuroscience</named-content>
<institution>Boston University</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz70748-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Physiology and Biochemistry</named-content>
<institution>University of Oklahoma Health Sciences Center</institution>
<city>Oklahoma City</city>
<named-content content-type="country-part">Oklahoma</named-content>
<country country="US">USA</country>
</aff><aff id="alz70748-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Center for Geroscience and Healthy Brain Aging</named-content>
<institution>University of Oklahoma Health Sciences Center</institution>
<city>Oklahoma City</city>
<named-content content-type="country-part">Oklahoma</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Michael E. Hasselmo, Center for Systems Neuroscience, Boston University, Boston, MA, USA.<break/> Email: <email>hasselmo@bu.edu</email><break/>Dr. Heather C. Rice, Aging &amp; Metabolism Research Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA.<break/> Email: <email>heather-rice@omrf.org</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="280">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70748</elocation-id><history><date date-type="rev-recd"><day>20</day><month>5</month><year>2025</year></date><date date-type="received"><day>20</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>02</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 00:25:23.493"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70748.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70748.pdf"/><abstract><title>Abstract</title><sec id="alz70748-sec-0010"><title>INTRODUCTION</title><p>Previous simulations of Hebbian associative memory models inspired the malignant synaptic growth hypothesis of Alzheimer's disease (AD), which suggests that cognitive impairments arise due to runaway synaptic modification resulting from poor separation between encoding and retrieval.</p></sec><sec id="alz70748-sec-0020"><title>METHODS</title><p>We computationally model presynaptic inhibition by the recently identified interaction of soluble amyloid precursor protein alpha (sAPP&#945;) with <italic toggle="yes">&#947;</italic>&#8208;aminobutyric acid type B receptor (GABA<sub>B</sub>R) as one potential biological mechanism that can enhance separation between encoding and retrieval.</p></sec><sec id="alz70748-sec-0030"><title>RESULTS</title><p>Simulations predict that the dual effect of sAPP&#945; on long&#8208;term potentiation and presynaptic inhibition of glutamatergic synapses maintains effective associative memory function and prevents runaway synaptic modification. Moreover, computational modeling predicts that sAPP&#945;, which interacts with the 1a isoform of GABA<sub>B</sub>R, is more effective than the GABA<sub>B</sub>R agonist baclofen at stabilizing associative memory.</p></sec><sec id="alz70748-sec-0040"><title>DISCUSSION</title><p>Molecular mechanisms that enhance presynaptic inhibition, such as sAPP&#945;&#8208;GABA<sub>B</sub>R1a signaling, are potential therapeutic targets for preventing cognitive impairments in AD.</p></sec><sec id="alz70748-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70748-list-0001"><list-item><p>Computational modeling of Hebbian associative memory provides a framework for understanding the functional basis of Alzheimer's disease.</p></list-item><list-item><p>Soluble amyloid precursor protein (sAPP&#945;) presynaptic activation of &#947;&#8208;aminobutyric acid B (GABA<sub>B</sub>) receptors prevents runaway synaptic modification in associative memory models.</p></list-item><list-item><p>sAPP&#945; is more effective than baclofen at stabilizing associative memory.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70748-kwd-0001">amyloid precursor protein</kwd><kwd id="alz70748-kwd-0002">associative memory</kwd><kwd id="alz70748-kwd-0003">GABA receptors</kwd><kwd id="alz70748-kwd-0004">presynaptic inhibition</kwd><kwd id="alz70748-kwd-0005">runaway synaptic modification</kwd></kwd-group><counts><fig-count count="7"/><table-count count="0"/><page-count count="18"/><word-count count="12129"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:30.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70748-cite-0001"><string-name name-style="western"><surname>Barber</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hasselmo</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Rice</surname><given-names>HC</given-names></string-name>. <article-title>Modeling presynaptic inhibition by the amyloid precursor protein demonstrates one potential mechanism for preventing runaway synaptic modification in Alzheimer's disease</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70748</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70748</pub-id><pub-id pub-id-type="pmid">41025328</pub-id><pub-id pub-id-type="pmcid">PMC12481214</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz70748-sec-0060"><label>1</label><title>BACKGROUND</title><p>Prominent hypotheses of Alzheimer's disease (AD) center on molecular pathways such as amyloid and tau. However, the malignant synaptic growth hypothesis<xref rid="alz70748-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70748-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70748-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> proposes that AD arises from an imbalance of synaptic strengthening, leading to runaway synaptic modification (RSM; malignant synaptic growth) that exacerbates amyloid and tau pathologies. The imbalance could arise from variations in molecular mechanisms for associative memory function in cortical structures<xref rid="alz70748-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70748-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="alz70748-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> that regulate the separation of encoding and retrieval. Here, encoding refers to the <italic toggle="yes">N</italic>&#8208;methyl&#8208;<sc>d</sc>&#8208;aspartate (NMDA)&#8211;dependent process of synaptic modification to store novel memories, and retrieval refers to the spread of activity via glutamate release at modified synapses to recall previously stored memories. Malignant synaptic growth is typically prevented in associative memory models such as Hopfield networks<xref rid="alz70748-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="alz70748-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz70748-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="alz70748-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70748-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> by complete separation of encoding and retrieval.<xref rid="alz70748-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="alz70748-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz70748-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="alz70748-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70748-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> However, because glutamate release is necessary for both memory retrieval and encoding via NMDA&#8208;dependent synaptic modification, the overlap of encoding and retrieval is inevitable in biological circuits. The mathematical models presented here show how variation of molecular pathways that regulate the separation of encoding and retrieval can allow malignant synaptic growth that increases both the total number of synapses and the total strength of individual synapses.<xref rid="alz70748-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70748-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70748-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70748-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> These models can account for the initial appearance of AD tangle pathology in the hippocampus and entorhinal cortex,<xref rid="alz70748-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70748-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> the dysfunction of synapses in the hippocampus,<xref rid="alz70748-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="alz70748-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> the evidence of functional magnetic resonance imaging (fMRI) hyperactivation in the hippocampus in early AD,<xref rid="alz70748-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70748-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="alz70748-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="alz70748-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="alz70748-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> and the spread of disease pathology along pathways associated with memory consolidation.<xref rid="alz70748-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p><p>A number of molecular mechanisms can mediate the separation of encoding and retrieval through presynaptic inhibition, including activation of muscarinic acetylcholine receptors,<xref rid="alz70748-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> &#947;&#8208;aminobutyric acid receptors (GABA<sub>B</sub>Rs),<xref rid="alz70748-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> and metabotropic glutamate receptors (mGluRs). The balance can also be influenced by amyloid beta (A&#946;) regulation of synaptic plasticity. Moreover, runaway synaptic transmission can be prevented by mechanisms of homeostatic plasticity, including physical synapse remodeling, presynaptic regulation of release mechanisms, regulation of synaptic &#945;&#8208;amino&#8208;3&#8208;hydroxy&#8208;5&#8208;methyl&#8208;4&#8208;isoxazolepropionic acid receptor (AMPA) and NMDA receptors, and G protein&#8211;coupled receptors (GPCRs; including GABA<sub>B</sub>R).<xref rid="alz70748-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="alz70748-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="alz70748-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="alz70748-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="alz70748-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="alz70748-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="alz70748-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="alz70748-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> This article focuses on sAPP&#945;&#8208;GABA<sub>B</sub>R1a signaling<xref rid="alz70748-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="alz70748-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> as one mechanism that might contribute to prevention of RSM (Figure&#160;<xref rid="alz70748-fig-0001" ref-type="fig">1</xref>). This consideration is particularly critical, as amyloid precursor protein (APP)&#8211;targeting small interfering RNA (siRNA) therapeutics are currently undergoing clinical evaluation for the treatment of AD and cerebral amyloid angiopathy (CAA).<xref rid="alz70748-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="alz70748-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Proposed model of the protective role of soluble APP alpha (sAPP&#945;) signaling on brain networks and memory function. Our model proposes that an increase of sAPP&#945; secretion stimulated by neuronal activity contributes to learning and memory. sAPP&#945; increases both long term potentiation (LTP) and presynaptic inhibition (PreInhib). The GABA<sub>B</sub> receptor subunit 1a (GABA<sub>B</sub>R1a) mediates the effects of sAPP on presynaptic inhibition. Models of Hebbian associative learning indicate that this combined function of sAPP can increase network stability and increase memory recall performance by reducing interference between encoding and retrieval. Created in BioRender. Barber, D. (2025) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com/l41i127" ext-link-type="uri">https://BioRender.com/l41i127</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70748-g002.jpg"/></fig><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70748-sec-0070"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70748-list-0002"><list-item><p>
<bold>Systematic review</bold>: The authors reviewed the literature related to two main topics: (1) the application of Hebbian associative memory models to understand Alzheimer's disease (AD) pathophysiology and (2) the physiological function of amyloid precursor protein (APP) and its potential protective effects on AD pathophysiology.</p></list-item><list-item><p>
<bold>Interpretation</bold>: Multidisciplinary integration of computational neuroscience to model molecular experimental data led to a novel hypothesis for the protective effects of APP in AD.</p></list-item><list-item><p>
<bold>Future directions</bold>: Future studies should be aimed at empirically testing soluble APP (sAPP&#945;)presynaptic activation of &#947;&#8208;aminobutyric acid B (GABA<sub>B</sub>) receptors in the context of AD and its comparison to baclofen. The study also supports the development of isoform&#8208;specific modulators of GABA<sub>B</sub> receptors as a therapeutic strategy in AD as an important future direction.</p></list-item></list>
</p></sec></boxed-text><p>Amyloid precursor protein (or APP) is a type I transmembrane protein that undergoes sequential proteolytic processing to generate<xref rid="alz70748-fig-0001" ref-type="fig">&#8195;</xref> multiple peptides, including A&#946;, the primary constituent of amyloid plaques found in AD brains. The normal function of APP promotes learning<xref rid="alz70748-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="alz70748-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>, <xref rid="alz70748-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> and regulates both encoding via enhancing long&#8208;term potentiation (LTP)<xref rid="alz70748-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="alz70748-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> and retrieval via regulation of presynaptic inhibition.<xref rid="alz70748-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> The soluble APP ectodomains (sAPP), which are generated during the initial cleavage event by &#945;&#8208; or &#946;&#8208; secretases, appear to mediate these functions of APP, and could switch the network between encoding (when sAPP enhances LTP and causes presynaptic inhibition) and retrieval (when APP has not been cleaved).</p><p>Studies have addressed the functional role of sAPP&#945;. In slices, sAPP&#945; reduces synaptic activity and enhances the LTP of glutamatergic synapses,<xref rid="alz70748-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="alz70748-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>, <xref rid="alz70748-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="alz70748-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> potentially via nicotinic acetylcholine receptor 7 signaling and calcium permeable AMPA receptor recruitment.<xref rid="alz70748-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>, <xref rid="alz70748-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> sAPP&#945; also regulates dendritic spine density.<xref rid="alz70748-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> sAPP&#945; rescues defects in LTP and spatial learning<xref rid="alz70748-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>, <xref rid="alz70748-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="alz70748-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> in App knockout mice. GABA<sub>B</sub>R1a has been shown to bind the APP ectodomain<xref rid="alz70748-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="alz70748-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> and mediate the effects of sAPP on presynaptic inhibition of glutamate release.<xref rid="alz70748-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="alz70748-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> The specific mechanisms mediating the functional effects of this interaction are still under active investigation. These mechanisms may not stimulate canonical GABA<sub>B</sub>R signaling<xref rid="alz70748-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>; however, this is still being investigated. In these studies,<xref rid="alz70748-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="alz70748-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="alz70748-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> the APP extracellular domain was found to specifically bind the 1a isoform of the GABA<sub>B</sub>R, whereas current GABA<sub>B</sub>R agonists, such as baclofen target both 1A and 1B isoforms.</p><p>We employed a standard Hebbian associative memory model to address the:
<list list-type="order" id="alz70748-list-0003"><list-item><p>relationship between an increase in both LTP and presynaptic inhibition of glutamatergic synapses by sAPP&#945;;</p></list-item><list-item><p>potential protective role of sAPP&#945;&#8208;GABA<sub>B</sub>R1a signaling on brain networks in AD;</p></list-item><list-item><p>potential therapeutic implications of GABA<sub>B</sub>R1a&#8208;specific modulation as compared to non&#8211;isoform&#8208;specific modulation of GABA<sub>B</sub>R signaling;</p></list-item><list-item><p>potential detrimental impacts of reducing APP expression by RNA interference (RNAi) as a treatment for AD.</p></list-item></list>
</p></sec><sec id="alz70748-sec-0080"><label>2</label><title>METHODS</title><sec id="alz70748-sec-0090"><label>2.1</label><title>Small circuit example</title><sec id="alz70748-sec-0100"><label>2.1.1</label><title>Associative memory model description of the physiological effects of sAPP&#945;&#8208;GABA<sub>B</sub>R1a binding</title><p>Memory models commonly focus on the formation of associations between different elements of a stored episodic memory (Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2A</xref>). One might form an association between a face and a place, for example, when forming the episodic memory of meeting a new colleague at a reception. Standard models of associative memory link patterns of neural activity, represented by a series of vectors in one population (i.e., the input layer) to patterns of neural activity, also represented as vectors, in another population (i.e., the output layer). Note that these vectors are not orthogonal (they contain overlapping active elements). The storage of correlated patterns has been known as an issue for the capacity of Hopfield networks,<xref rid="alz70748-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="alz70748-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> which can be reduced by learning rules that decrease correlations, but here we focus on the breakdown of function enhanced by correlations.</p><fig position="float" fig-type="FIGURE" id="alz70748-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Models of Hebbian associative memory show effective function with separation of encoding and retrieval and undesired synaptic growth without this separation. (A) In the first event, one population of activated neurons (left blue circles) responds to a sensory input representing a face and a place associated with the memory. Another output population (right blue circles) responds to the input in corresponding manner. (B) During encoding, Hebbian synaptic modification (encoding LTP) strengthens synapses between the activated neurons (thick blue lines). (C) The input layer of neurons receives activity corresponding to Face 1 associated with Place 1. This spreads across the matrix (blue lines). (D) The input of Face 1 evokes the full memory encoded earlier in Step B in the output layer due to the recently modified synapses. (E) The same pattern of strengthened synapses (blue lines) can be represented by pink shaded squares in a matrix of connections. (F&#8211;J) With separation of encoding and retrieval, the input of a consecutive overlapping Event 2 activates neurons (green circles) that have overlap of Place 1 being associated with a novel face 2. (F) With separation of encoding and retrieval, encoding activity only activates the neurons getting direct input (green circles). (G) This encoding activity causes strengthening (LTP) of only the desired synapses (green lines), with no undesired strengthening. (H) The input layer receives activity corresponding to Face 2 that was associated with Place 1. (I) The full memory of Face 2 and Place 1 encoded from Step G is recalled without interference. (J) The three new strengthened synapses are shown as pink squares. (K) Without separation between encoding and retrieval, encoding activity with retrieval involves neurons getting direct input (green circles) and spreading of retrieval activity across a previously strengthened synapse (red line and orange circle). (L) This mixed postsynaptic activity causes strengthening (LTP) of not only the new association (thick green lines) but also additional undesired synapses (orange dashed line). (M) The input layer receives activity corresponding to Face 2. (N) The memory evoked by retrieval includes not only the correct memory (green) but also interference from activation of the postsynaptic neuron previously associated with Face 1 (orange). (O) The undesired synapse appears as a pink square in Column F2, Row F1. (P) For Event 3, without separation of encoding and retrieval, encoding activity with retrieval spreads to both of the previous memories (red lines and orange circles). (Q) This additional activity causes LTP of the new association (purple lines) to include two undesired synapses being strengthened (orange dashed lines). (R) The input layer receives activity corresponding to only Place 2. (S) The memory recalled in the output layer now includes even more interference from both Face 1 and Place 1 due to undesired modification from Event 2. (T) The map of the modified synapses now reflects the additional undesired synapses as pink squares in Column P2, Row F1, and Column P2, Row P1. This shows the undesired synaptic growth associated with interference from retrieval during encoding. LTP, long term potentiation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70748-g003.jpg"/></fig><p>The associative memory is formed by a pattern of synapses <italic toggle="yes">W</italic> between the two populations. Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2A</xref> shows an example of associative memory connectivity for a single episode regarding a face and a place.</p><p>The mathematical description here first shows the breakdown in function using equations that are standard components of associative memory models with Hebbian modification.<xref rid="alz70748-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="alz70748-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz70748-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="alz70748-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70748-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> The later equations then add parameters that reflect the stabilizing physiological effects of molecular pathways that regulate synaptic modification and synaptic transmission.<xref rid="alz70748-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70748-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70748-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> The equations effectively address the associative memory function used in most models of the hippocampal formation,<xref rid="alz70748-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70748-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="alz70748-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> although this associative memory model is very simple relative to the data showing detailed physiological differences between different anatomic subregions and sublayers of the hippocampus.<xref rid="alz70748-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>, <xref rid="alz70748-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> More elaborate models of hippocampus have used ionic conductances to simulate spiking dynamics, but usually still rely on the same functional elements of associative memory with Hebbian synaptic modification for encoding and completion of memories<xref rid="alz70748-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> and Hebbian spike timing dependent plasticity (STDP) for the encoding and replay of encoded sequences.<xref rid="alz70748-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>
</p><p>Most associative memory models encode new associations between patterns by using the Hebb rule, which causes a change in the strength of a matrix of synaptic weights <italic toggle="yes">W</italic> between neurons in the population (thick blue lines in Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2B</xref>). This synaptic matrix is modified based on a vector <italic toggle="yes">p</italic>, representing the array of activity in a first population of presynaptic neurons, and the vector <italic toggle="yes">r</italic>, representing the array of activity across a second population of postsynaptic neurons. (In associative memory models, the postsynaptic activity vector <italic toggle="yes">r</italic> is driven by a separate input vector <italic toggle="yes">q</italic> to the postsynaptic neurons). The Hebb rule for modification of synaptic weights results in the pattern of connectivity shown in Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2B</xref>, and the matrix or map of connectivity shown in Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2E</xref>. Mathematically, this corresponds to the creation of this matrix from the outer product of the presynaptic pattern <italic toggle="yes">p</italic> and the postsynaptic pattern <italic toggle="yes">r</italic>, as&#160;represented by the following equation (where a vector transpose is indicated by T):
<disp-formula id="alz70748-disp-0001"><label>(1)</label><mml:math id="jats-math-1" display="block"><mml:mrow><mml:mrow><mml:mspace width="0.33em"/><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo linebreak="badbreak">=</mml:mo><mml:mi>r</mml:mi><mml:msup><mml:mi>p</mml:mi><mml:mi>T</mml:mi></mml:msup></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>
<italic toggle="yes">r</italic>&#160;=&#160;pattern of postsynaptic neuron activation;</p><p>
<italic toggle="yes">p</italic>&#160;=&#160;pattern of presynaptic neuron;</p><p>
<italic toggle="yes">W</italic>&#160;=&#160;weights of synaptic association matrix.</p><p>After encoding, the associative memory model can retrieve the association with corresponding input. A portion of the presynaptic activity pattern in the first population <italic toggle="yes">p</italic> is activated by sensory input from the outside world (e.g. face 1 in Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2C</xref>) and acts as a cue for the retrieval of the memory by the spread across strengthened synapses (thick blue lines) to activate postsynaptic neurons that represent the retrieval of the previously encoded memory (face 1 and place 1 in (Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2D</xref>). Additional memories can be encoded even with overlapping associations (Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2F</xref>), but this requires separation of encoding and retrieval. For example, Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2F</xref> shows how input corresponding to the place encoded in the memory in Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2A</xref> could spread activity across the strengthened synapses (thick blue lines) to activate postsynaptic neurons that represent the retrieval of the memory previously encoded, but in this example this retrieval is not allowed during the encoding step (Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2G</xref>) so that the new encoded association can be retrieved without interference (Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2H</xref>,<xref rid="alz70748-fig-0002" ref-type="fig">I</xref>).</p><p>In the equations, this retrieval process is represented by the vector of activity <italic toggle="yes">p</italic> being multiplied by the matrix of synaptic weights <italic toggle="yes">W</italic> to generate a vector of postsynaptic activity <italic toggle="yes">r</italic>. Thus, the retrieval process is described by the equation:
<disp-formula id="alz70748-disp-0002"><label>(2)</label><mml:math id="jats-math-2" display="block"><mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mo linebreak="badbreak">=</mml:mo><mml:mi>W</mml:mi><mml:mi>p</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>q</mml:mi></mml:mrow></mml:mrow></mml:math></disp-formula>where <italic toggle="yes">r</italic> is a vector representing the activity of all the neurons in the postsynaptic population. The population <italic toggle="yes">r</italic> receives the spread of activity across the matrix of synapses <italic toggle="yes">W</italic> that are multiplied by the presynaptic activity <italic toggle="yes">p</italic> (e.g., representing the current input cues for the memory). The population <italic toggle="yes">r</italic> also receives the direct postsynaptic input <italic toggle="yes">q</italic> representing current input. Associative memory function requires that at least a subset of synapses have different external sources for presynaptic and postsynaptic input. Standard models of the hippocampal formation<xref rid="alz70748-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70748-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="alz70748-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="alz70748-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70748-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref> focus on associations formed at modifiable synapses between neurons in the hippocampus, which are not the predominant influence on postsynaptic activity during encoding.<xref rid="alz70748-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> In these models, the direct external input driving postsynaptic activation would be synaptic input from the entorhinal cortex or dentate gyrus.</p><p>Equations&#160;<xref rid="alz70748-disp-0001" ref-type="disp-formula">1</xref> and&#160;<xref rid="alz70748-disp-0002" ref-type="disp-formula">2</xref> are the standard equations for associative memory in numerous models. However, the network described by these equations is unstable and sensitive to interference between memories.<xref rid="alz70748-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70748-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Most associative memory models avoid this instability and interference by ignoring synaptic transmission during Hebbian synaptic modification, but here we focus on instability as an important property. The instability can be seen by combining the equations by replacing <italic toggle="yes">r</italic> in Equation&#160;<xref rid="alz70748-disp-0001" ref-type="disp-formula">1</xref> with <italic toggle="yes">r</italic> from Equation&#160;<xref rid="alz70748-disp-0002" ref-type="disp-formula">2</xref>; this results in the following equation:<disp-formula id="alz70748-disp-0003"><label>(3)</label><mml:math id="jats-math-3" display="block"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo linebreak="badbreak">=</mml:mo><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mi>W</mml:mi><mml:mi>p</mml:mi><mml:mo>+</mml:mo><mml:mi>q</mml:mi></mml:mrow></mml:mfenced><mml:mspace width="0.33em"/><mml:msup><mml:mi>p</mml:mi><mml:mi>T</mml:mi></mml:msup></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>The instability of this equation is shown in Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2K&#8211;O</xref>. The figure shows that retrieval of a previous associative memory can influence the synaptic modification process during the encoding of a new overlapping associative memory. In this example, Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2K</xref> shows the case of a new episode that involves a single point of overlap in the presynaptic input with a previously encoded memory (the place). For example, you meet a second colleague at the same place where you met the first colleague. The overlap results in spread across previously strengthened synapses (thick blues lines, with the specific synapse involved in retrieval marked by the red line in Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2K</xref>). Thus, the same place can cause retrieval of the face from Memory 1 (orange circle in Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2K</xref>). This causes strengthening of additional incorrect synapses from the face&#160;in Memory 2 to the face&#160;in Memory 1, as shown by the orange line in Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2L</xref>. This problem becomes compounded further when learning another episode in succession in which there is one or more overlapping events with any previously encoded memories, as shown in Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2P&#8211;T</xref>. This eventually results in a weight matrix <italic toggle="yes">W</italic> that cannot discern any previously encoded memories from one another, with this problem resulting in unnecessary and undesired strengthening of many additional synapses.</p><p>The instability of the equation can also be shown by solving Equation&#160;<xref rid="alz70748-disp-0003" ref-type="disp-formula">3</xref> as a first&#8208;order differential equation for input patterns <italic toggle="yes">p</italic> and <italic toggle="yes">q</italic> to compute the change in synaptic strength over time. This yields a solution that grows linearly with presynaptic activity <italic toggle="yes">p</italic> and direct post&#8208;synaptic activity <italic toggle="yes">q</italic>, but also grows exponentially with presynaptic activity <italic toggle="yes">p</italic>:<disp-formula id="alz70748-disp-0004"><label>(4)</label><mml:math id="jats-math-4" display="block"><mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mspace width="0.33em"/><mml:mfenced open="(" close=")"><mml:mi>t</mml:mi></mml:mfenced><mml:mo linebreak="badbreak">=</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:msup><mml:mi>p</mml:mi><mml:mi>T</mml:mi></mml:msup></mml:mrow></mml:msup><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>q</mml:mi><mml:msup><mml:mi>p</mml:mi><mml:mi>T</mml:mi></mml:msup></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>Note that this exponential growth concerns not only the growth in strength of individual synapses, but also the spread of undesired growth to synapses that should have no growth (orange lines weights in Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2L</xref>, <xref rid="alz70748-fig-0002" ref-type="fig">Q</xref>), even if individual synapses are not allowed to grow beyond a certain maximum value. The exponential growth of synaptic weight in this equation demonstrates one major driving force that is proposed to underlie the pathology of early AD. This erroneous modification involves more than just excitotoxicity because it concerns increased synaptic modification at early stages rather than just increased neural activity. However, in some cases it could have the side effect of excitotoxicity depending on how synaptic growth influences activity among particular subsets of neurons.</p><p>The solution to Equation&#160;<xref rid="alz70748-disp-0003" ref-type="disp-formula">3</xref> can be made more stable by adding features that correspond to mechanisms that regulate biological synaptic transmission and synaptic modification. For example, as shown in Figure&#160;<xref rid="alz70748-fig-0003" ref-type="fig">3D</xref>, presynaptic inhibition of synaptic transmission during synaptic modification can prevent the exponential growth. This can provide stability in the equation by reducing the influence of prior weight <italic toggle="yes">W</italic> on synaptic modification. Abstract models of associative memory commonly avoid the instability using implementations of the equations that simply ignore retrieval during the encoding of new associations.<xref rid="alz70748-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="alz70748-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70748-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70748-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> Thus, stability of associative memory function could be obtained by ensuring that synaptic modification is combined with presynaptic inhibition of synaptic transmission during synaptic modification. Studies implementing optogenetic manipulations of LTP and long&#8208;term depression (LTD) have demonstrated that the hippocampus can be programmed using simple Hebbian learning driven by LTP<xref rid="alz70748-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>, <xref rid="alz70748-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref>, <xref rid="alz70748-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> resulting in the creation and ablation of synthetic memories in mice. It is necessary to provide biological mechanisms that ensure that the induction of these functional synaptic modifications does not lead to the instability innate in Hebbian learning. Physiologically, this could be obtained by secretion of sAPP&#945; causing an encoding phase that includes both enhancement of LTP (encouraging modification for encoding of memories) and presynaptic inhibition of synaptic transmission via presynaptic GABA<sub>B</sub>R1a receptors, whereas less secretion of sAPP&#945; would correspond to the retrieval phase.</p><fig position="float" fig-type="FIGURE" id="alz70748-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Presynaptic inhibition due to the activation of GABA<sub>B</sub>Rs by sAPP&#945; prevents interference during encoding between overlapping associations. (A) In the first event, one population of activated neurons (left blue circles) responds to a sensory input representing a face and a place associated with the memory, and this also activates the output population (right blue circles). (B) During encoding, Hebbian synaptic modification strengthens synapses between the activated neurons (blue lines) and leads to an increase in sAPP&#945; secretion at those synapses. (C) The same pattern of strengthened synapses can be represented by pink&#8208;shaded squares in a matrix of connections. (D) Now, in a consecutive overlapping Event 2, in which the activated neurons (green circles) have overlap in the same place being associated with a novel face, this overlap no longer causes undesired retrieval due to GABA<sub>B</sub>R&#8208;mediated presynaptic inhibition by sAPP&#945; at the previously modified synapses. (E,F) This results in Encoding LTP strengthening only desired new synapses (green in E, pink in F). (G) Event 3 input only activates neurons receiving direct input (violet circles). Due to sAPP&#945; presynaptic inhibition of prior retrieval, the Hebbian modification only strengthens desired synapses (violet lines in H, pink&#8208;shaded squares in I).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70748-g004.jpg"/></fig><p>Recently, the capacity of classical Hopfield networks has been increased by the use of modern Hopfield networks.<xref rid="alz70748-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref>, <xref rid="alz70748-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref> These networks do not define a synaptic weight matrix as in classical Hopfield networks, but instead define an energy function and an associated activation function (update rule). Thus it is difficult to directly map these new networks to actual biological synapses and synaptic modification rules. However, the energy functions in those models appear to implicitly define synaptic interactions as the sum of a function of the dot product of every stored pattern with the state pattern, which does not take into account their sequential dynamics of retrieval that would require the implementation of their update rule/activation function separately for each stored pattern. Thus the new models make the same assumption of encoding as a separate process from retrieval as in the original Hopfield networks.</p></sec><sec id="alz70748-sec-0110"><label>2.1.2</label><title>Stabilizing the Hebbian learning equation</title><p>The stability of associative memory can be evaluated mathematically for conditions when encoding and retrieval are not assumed to be completely separated. This could be useful for understanding the interaction of disparate physiological effects that include presynaptic inhibition as well as the regulation of synaptic modification (both potentiation and depression). These effects involve different molecular pathways, but might all converge on the enzymatic processing of APP by both &#945;&#8208; and &#946;&#8208;secretase pathways; so the equation could provide a unified vision of the functional role of APP processing on synaptic modification and network stability. The point is to demonstrate that sAPP&#945; can cause effects that shift dynamics between encoding and retrieval, so that the network maintains better associative memory function. In this equation for stability of associative memory,<xref rid="alz70748-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> the influence of molecular factors (<italic toggle="yes">&#964;</italic>) on synaptic modification, the influences (<italic toggle="yes">Z</italic>) on postsynaptic activity, and the effect of transmission across synapses <italic toggle="yes">W</italic> can be combined into a single equation:
<disp-formula id="alz70748-disp-0005"><label>(5)</label><mml:math id="jats-math-5" display="block"><mml:mrow><mml:mrow><mml:mi>&#964;</mml:mi><mml:mspace width="0.33em"/><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo linebreak="badbreak">=</mml:mo><mml:mi>W</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>Z</mml:mi></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>Using the standard solution for an inhomogeneous first&#8208;order differential equation, this yields the solution:
<disp-formula id="alz70748-disp-0006"><label>(6)</label><mml:math id="jats-math-6" display="block"><mml:mrow><mml:mrow><mml:mi>W</mml:mi><mml:mspace width="0.33em"/><mml:mfenced open="(" close=")"><mml:mi>t</mml:mi></mml:mfenced><mml:mo linebreak="badbreak">=</mml:mo><mml:mi>W</mml:mi><mml:mfenced open="(" close=")"><mml:mn>0</mml:mn></mml:mfenced><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>/</mml:mo><mml:mi>&#964;</mml:mi></mml:mrow></mml:msup><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>Z</mml:mi><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>/</mml:mo><mml:mi>&#964;</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>This corresponds to the solution for a standard nonhomogeneous first&#8208;order equation<xref rid="alz70748-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref> as described with the following structure and solution:
<disp-formula id="alz70748-disp-0007"><mml:math id="jats-math-7" display="block"><mml:mrow><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>A</mml:mi><mml:mfrac><mml:mrow><mml:mi>df</mml:mi><mml:mfenced open="(" close=")"><mml:mi>x</mml:mi></mml:mfenced></mml:mrow><mml:mi>dx</mml:mi></mml:mfrac><mml:mspace width="0.33em"/></mml:mrow></mml:mtd><mml:mtd><mml:mo>+</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mspace width="0.33em"/><mml:mi>Bf</mml:mi><mml:mspace width="0.33em"/><mml:mfenced open="(" close=")"><mml:mi>x</mml:mi></mml:mfenced><mml:mo linebreak="badbreak">+</mml:mo><mml:mi>C</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:mn>0</mml:mn><mml:mspace width="0.33em"/><mml:mi>with</mml:mi><mml:mspace width="0.33em"/><mml:mi>solution</mml:mi><mml:mspace width="0.33em"/><mml:mi>f</mml:mi><mml:mspace width="0.33em"/><mml:mfenced open="(" close=")"><mml:mi>x</mml:mi></mml:mfenced></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo linebreak="badbreak">=</mml:mo><mml:mi>f</mml:mi><mml:mfenced open="(" close=")"><mml:mn>0</mml:mn></mml:mfenced><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mfenced separators="" open="(" close=")"><mml:mfrac><mml:mi>B</mml:mi><mml:mi>A</mml:mi></mml:mfrac></mml:mfenced><mml:mi>x</mml:mi></mml:mrow></mml:msup><mml:mo linebreak="goodbreak">+</mml:mo><mml:mfenced separators="" open="(" close=")"><mml:mfrac><mml:mi>C</mml:mi><mml:mi>B</mml:mi></mml:mfrac></mml:mfenced><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mfenced separators="" open="(" close=")"><mml:mfrac><mml:mi>B</mml:mi><mml:mi>A</mml:mi></mml:mfrac></mml:mfenced><mml:mi>x</mml:mi></mml:mrow></mml:msup><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula>
</p><p>This equation can grow to a stable asymptote when 1/<italic toggle="yes">&#964;</italic> is negative or will show exponential growth when 1/<italic toggle="yes">&#964;</italic> is positive. The values from the previously presented Equation&#160;<xref rid="alz70748-disp-0003" ref-type="disp-formula">3</xref> are <italic toggle="yes">Z</italic>&#160;=&#160;qp<sup>T</sup>, and 1/<italic toggle="yes">&#964;</italic>&#160;=&#160;pp<sup>T</sup>, but these components can be expanded to consider other molecular and physiological features influencing synaptic function. For example, Equation&#160;<xref rid="alz70748-disp-0003" ref-type="disp-formula">3</xref> can be expanded to include a range of physiological parameters in the following form:
<disp-formula id="alz70748-disp-0008"><label>(7)</label><mml:math id="jats-math-8" display="block"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>W</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo linebreak="badbreak">=</mml:mo><mml:mi>&#951;</mml:mi><mml:mi>q</mml:mi><mml:msup><mml:mi>p</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mspace width="0.33em"/><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:mi>H</mml:mi><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:mi mathvariant="normal">&#937;</mml:mi><mml:mo linebreak="goodbreak">+</mml:mo><mml:mi>W</mml:mi><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:mi>&#968;</mml:mi></mml:mrow></mml:mfenced><mml:mi>&#951;</mml:mi><mml:mi>p</mml:mi><mml:msup><mml:mi>p</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:mi>&#956;</mml:mi><mml:msup><mml:mi>p</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mo>&#8722;</mml:mo><mml:mi>&#947;</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>This equation includes parameters that are modulated by sAPP&#945; or other modulators during an encoding phase but not during subsequent retrieval. These include the parameter <italic toggle="yes">&#968;</italic>, which reflects the magnitude of presynaptic inhibition of synaptic transmission during learning, <italic toggle="yes">&#956;</italic> for magnitude of synaptic decay dependent on presynaptic activity, <italic toggle="yes">&#947;</italic> for magnitude of synaptic decay that depends only on current strength, and <italic toggle="yes">&#951;</italic> for the learning rate that characterizes the magnitude of change dependent on presynaptic activity. <italic toggle="yes">H</italic> represents postsynaptic inhibition and &#937; represents a postsynaptic activity threshold for synaptic modification.</p><p>Separating out the components of this equation gives:
<disp-formula id="alz70748-disp-0009"><label>(8)</label><mml:math id="jats-math-9" display="block"><mml:mrow><mml:mrow><mml:mi>Z</mml:mi><mml:mo linebreak="badbreak">=</mml:mo><mml:mi>&#951;</mml:mi><mml:mi>q</mml:mi><mml:msup><mml:mi>p</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:mi>H</mml:mi><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:mi mathvariant="normal">&#937;</mml:mi></mml:mrow></mml:mrow></mml:math></disp-formula>and
<disp-formula id="alz70748-disp-0010"><label>(9)</label><mml:math id="jats-math-10" display="block"><mml:mrow><mml:mrow><mml:mi>&#964;</mml:mi><mml:mo linebreak="badbreak">=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mfenced separators="" open="[" close="]"><mml:mrow><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:mi>&#968;</mml:mi></mml:mrow></mml:mfenced><mml:mi>&#951;</mml:mi><mml:mi>p</mml:mi><mml:msup><mml:mi>p</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:mi>&#956;</mml:mi><mml:msup><mml:mi>p</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:mo>&#8722;</mml:mo><mml:mi>&#947;</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>The 1/<italic toggle="yes">&#964;</italic> parameter describes the time course of exponential growth of synaptic strength. Exponential growth can be prevented if the parameter <italic toggle="yes">&#968;</italic> reduces <italic toggle="yes">W</italic> to zero during encoding. For example, if sAPP&#945;&#8208;GABA<sub>B</sub>R1a presynaptic inhibition (which corresponds to <italic toggle="yes">&#968;</italic> in the equation) causes sufficient presynaptic inhibition of synaptic transmission during encoding, this prevents exponential growth, as shown in Figure&#160;<xref rid="alz70748-fig-0003" ref-type="fig">3</xref>. (An interesting property of this mathematical analysis is that the presynaptic inhibition of synaptic transmission by GABA<sub>B</sub>R or m4 muscarinic receptors is mathematically equivalent to gated decay of synaptic strength based on both presynaptic and postsynaptic activity.)</p><p>The exponential growth can also be slowed by causing LTD based on current weights (corresponding to the decay of weight in proportion to the constants <italic toggle="yes">&#947;</italic> and <italic toggle="yes">&#956;</italic>). The learning rate parameter <italic toggle="yes">&#951;</italic> could correspond to the role of sAPP&#945; in forming synapses or enhancing synapse strength, whereas the A&#946; generated by the &#946;&#8208;secretase pathway might regulate the synaptic decay parameters <italic toggle="yes">&#947;</italic> and <italic toggle="yes">&#956;</italic> involved in breaking down synapses.</p><p>Equations <xref rid="alz70748-disp-0008" ref-type="disp-formula">7</xref> to&#160;<xref rid="alz70748-disp-0010" ref-type="disp-formula">9</xref> predicts how mutations that affect the physiological function of APP and APP secretion could influence the rate of progression of AD. Mutations that impair the presynaptic inhibition by sAPP&#945; or the LTD due to A&#946; should result in a more rapid time course of progression. Mutations that enhance presynaptic inhibition should result in a slower time course or absence of disease.</p></sec></sec><sec id="alz70748-sec-0120"><label>2.2</label><title>Large&#8208;scale simulations</title><p>Simulations in MATLAB tested the basic associative memory function illustrated in Figures&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2</xref> and&#160;<xref rid="alz70748-fig-0003" ref-type="fig">3</xref> using the expanded versions of Equations&#160;<xref rid="alz70748-disp-0003" ref-type="disp-formula">3</xref> and&#160;<xref rid="alz70748-disp-0004" ref-type="disp-formula">4</xref> (i.e. equation <xref rid="alz70748-disp-0008" ref-type="disp-formula">7</xref>), but with larger populations of neurons (i.e., larger vectors of presynaptic and postsynaptic activity) and multiple different vectors. In the simulations, each association involves external input that activates 6 of the 100&#8211;200 neurons in the presynaptic population of neurons to represent features of an episodic memory. These are associated with direct postsynaptic input that activates 6 of the 100&#8211;200 neurons in the postsynaptic population of neurons. In Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4</xref>, 20 new associations are stored, and each new input pattern overlaps with the previous association by one element.</p><fig position="float" fig-type="FIGURE" id="alz70748-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>The combination of sAPP&#945;&#8208;mediated effects on both long&#8208;term potentiation and presynaptic inhibition stabilize Hebbian associative memory in simulation. (A) Sample of memory training patterns generated to test the network recall accuracy of each iteration of the network. The <italic toggle="yes">x</italic>&#8208;axis corresponds to different patterns (pattern #) shown at different time points. Rows on the <italic toggle="yes">y</italic>&#8208;axis indicate different neurons (neuron #) active in each input pattern (red indicates activity). (B) These two rows show simulated weight matrices resulting after training on the full set of patterns with different parameters. Pink and red indicate strength of synaptic weights. The percent values show magnitude of effects of sAPP&#945; on long&#8208;term potentiation (LTP) and presynaptic inhibition (PreInhib) that were increased in strength to illustrate the effects on runaway synaptic modification (RSM). (B1). Weight matrices for 0% PreInhib, with LTP strength increased from 0% to 90%. At 0% LTP, no weight changes occur and no memories are stored. With 30% LTP, only weak memories are stored (pink line along diagonal). With 60% LTP, weak memories are stored with interference from adjacent memories (broad line on diagonal). With 90% LTP strength and 0% PreInhib, the traditional Hebbian network dynamics lead to RSM, which strengthens synapses linking new memories to many previously presented memories (due to RSM, red squares representing synapses fill the upper right diagonal of the square matrix). (B2) Matrices for LTP set at 100% with increases in sAPP&#945;&#8208;mediated PreInhib from 0% to 90%. On the left, LTP at 100% and PreInhib at 0% result in massive RSM, maximally strengthening synapses between current memory and all previous memories (red values for all the undesired weights in upper right of square matrix). As %PreInhib increases to 30%, 60%, and 90%, the retrieval of old memories during encoding is reduced, and the matrix of red synaptic connections contains less and less undesired synapses between the elements of each association (fewer red squares in upper right diagonal of square matrix). The combined effects of sAPP&#945; on LTP and PreInhib stabilize the learning of the basic Hebbian network. (C) Quantification of the recall performance for different values of increased LTP and PreInhib. On the left side with PreInhib of 0%, increased LTP causes interference that reduces recall performance to negative values. On the right side, with PreInhib at 90%, as LTP increases, the performance gets better (reaching over 0.8) and gets closer to perfect recall (1.0). (D) Quantification of memory retrieval performance for 0% PreInhib across increasing numbers of memories. 0% LTP results in no memory storage and 0% performance (gray circles). Performance is slightly better for low levels of LTP (30%, pink circles), but drops off quickly as LTP increases further due to RSM (going to negative values for red circles for 60% LTP and dark red circles for 90% LTP). (E) Performance for 100% LTP and PreInhib at 0% shows a sharp decrease in recall performance (gray circles). Performance gets better for larger values of PreInhib until showing best performance for PreInhib of 90% (dark red line above 0.8 performance for all memories). LTP, long&#8208;term potentiation; RSM, runaway synaptic modification.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="ALZ-21-e70748-g001.jpg"/></fig><p>The postsynaptic population activity is computed according to Equation&#160;<xref rid="alz70748-disp-0002" ref-type="disp-formula">2</xref> to incorporate both the external input pattern and the retrieval that would occur in the network. The synapses are then strengthened according to Equation&#160;<xref rid="alz70748-disp-0003" ref-type="disp-formula">3</xref>. As an additional component, to show that RSM is due to interference causing a spread of synaptic weight through the network, rather than allowing unlimited strengthening of individual weights, the model was simulated with a limit on synaptic weights of 1.01. Despite this limit on weight, the network still exhibits RSM, as shown in the large&#8208;scale simulations.</p></sec></sec><sec id="alz70748-sec-0130"><label>3</label><title>RESULTS</title><sec id="alz70748-sec-0140"><label>3.1</label><title>sAPP&#945; activation of presynaptic GABA<sub>B</sub>Rs prevents RSM</title><p>Using the above&#8208;described methods, the phenomenon of RSM summarized in Figures&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2</xref> and&#160;<xref rid="alz70748-fig-0003" ref-type="fig">3</xref> was simulated with sequential learning of a much larger number of overlapping associations, each with six input landmarks and six individual events. Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4A</xref> shows how each new input vector (pattern # on <italic toggle="yes">x</italic>&#8208;axis) activates a sequential set of neurons (neuron # on <italic toggle="yes">y</italic>&#8208;axis) with one overlapping element with the preceding input vector, similar to the simple example in Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2</xref>. The small and uniform number of inputs was selected to allow visualization. The simulations shown in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B,C</xref> model the biological components during encoding that include effects of sAPP&#945; on synaptic modification<xref rid="alz70748-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="alz70748-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>, <xref rid="alz70748-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="alz70748-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>, <xref rid="alz70748-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="alz70748-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> and presynaptic inhibition of glutamatergic synaptic transmission by sAPP&#945;,<xref rid="alz70748-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> whereas they test performance in a retrieval phase with weaker effects of sAPP&#945;. Data show that LTP is enhanced by sAPP&#945;, which also simultaneously causes presynaptic inhibition of synaptic transmission via GABA<sub>B</sub>R. We first describe an introductory overview of the simulations in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4</xref>, and we then describe them in detail. Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B1</xref> shows that the enhancement of LTP can provide increases in encoding of individual memories, but this can also cause a breakdown in function termed runaway synaptic modification (or RSM) for higher values of LTP (i.e., 90%). Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B2</xref> starts with LTP at 100% and shows that the addition of stronger presynaptic inhibition prevents RSM even when LTP is strong. Thus, combining the two biological effects of sAPP&#945; during encoding results in a more stable memory function of the network as tested by performance with retrieval dynamics without sAPP&#945;, as shown for 90% presynaptic inhibition and 100% LTP in the right&#8208;hand panel of Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B2</xref>. After encoding, the matrix of synaptic connectivity shown in the right&#8208;hand panel of Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B2</xref> with higher levels of sAPP&#8208;GABA<sub>B</sub>R1a modulation strengthens the relevant memory synapses on the diagonal, similar to what was shown in Figure&#160;<xref rid="alz70748-fig-0003" ref-type="fig">3F</xref>, which shows strengthening only along the diagonal of groups of four synapses between the elements of each association.</p><p>To describe the same effects in the figure in more detail, the row of synaptic matrices in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B1</xref> shows how the function of the associative memory network breaks down for overlapping memories when Hebbian synaptic modification is applied at different strengths (0%&#8211;90%) with the absence of the presynaptic inhibition of synaptic transmission (PreInhib&#160;=&#160;0%) during synaptic modification (Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B1</xref>). For LTP&#160;=&#160;0%, there is no strengthening and no memories are stored. This appears as an absence of red squares in the left panel of Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B1</xref>. For LTP&#160;=&#160;30%, there is weak strengthening of synapses, shown as a pink diagonal. For LTP&#160;=&#160;60%, the network shows interference between memories that appears as a widening of the distribution of weights along the diagonal, indicating that each memory is interfering with the preceding memories. For LTP&#160;=&#160;90%, the buildup of interference due to retrieval of previous associations during learning of new associations causes RSM. This results in the strengthening of many additional synapses that results in modification (red) of almost all of the synapses in the upper right section of the matrix. The matrix of connectivity has the same form as shown Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2T</xref>, showing that strengthening of undesired synapses continues during subsequent associations and results in synaptic strengthening that links the elements of each new memory to almost every previously stored memory. Simply stated, the effect of interference during learning can be powerful and widespread, affecting an enormous number of additional synapses. The right panel shows bad memory retrieval performance as described later for Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4D</xref>.</p><p>In contrast, Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B2</xref> shows that increases in presynaptic inhibition (PreInhib) can prevent RSM. The left panel of Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B2</xref> shows the synaptic matrix after learning with LTP at 100%, but PreInhib at 0%. This shows extreme RSM that modifies weights between every new memory and all the previously stored memories (solid red in upper right). The large difference in sum of synaptic weights with RSM occurs despite the fact that each individual weight in the matrix is only allowed to grow to 1.01 in the simulation. In contrast to the left panel, the subsequent panels show that even with LTP kept at 100%, larger amounts of presynaptic inhibition prevent this RSM, with weaker interference at PreInhib&#160;=&#160;30% and 60% and no interference or RSM at PreInhib&#160;= 90%. This last panel on the right panel of Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B2</xref> shows that LTP&#160;=&#160;100% and PreInhib&#160;=&#160;90% allows strong memory weights (dark red along the diagonal) but prevents interference and RSM (no weights in upper right). This is similar to the example of how presynaptic inhibition prevents excess synaptic strengthening in Figure&#160;<xref rid="alz70748-fig-0003" ref-type="fig">3I</xref>. This right panel also corresponds to the best retrieval performance across memories shown in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4E</xref> and described next.</p><p>The memory performance was tested by evaluating the accuracy of memory retrieval by the network when given only two random input cues (active presynaptic neurons) for each memory and using feedback inhibition to set a threshold so that six postsynaptic neurons are activated each time during retrieval. The memory retrieval performance is shown on the <italic toggle="yes">y&#8208;</italic>axis in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4C</xref> for different levels of presynaptic inhibition (<italic toggle="yes">x</italic>&#8208;axis) and for different strengths of LTP (gray to red curves). Similarly, the memory performance is shown on the <italic toggle="yes">y</italic>&#8208;axis in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4D,E</xref> as the number of memories increases on the <italic toggle="yes">x</italic>&#8208;axis. As an overview, Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4D</xref> shows performance when PreInhib&#160;=&#160;0% and LTP is increased to different values (gray&#160;=&#160;0% LTP and red&#160;=&#160;90% LTP). Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4E</xref> shows performance when LTP&#160;=&#160;100% and PreInhib is increased (gray&#160;=&#160;0% PreInhib and red&#160;=&#160;90% PreInhib).</p><p>To provide a more detailed description, Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4D</xref> tests performance for the matrices shown in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B1</xref> and shows that when presynaptic inhibition is absent (PreInhib&#160;=&#160;0%), network function breaks down with higher values of synaptic modification (LTP). Setting the synaptic modification learning rate (LTP) to 0% results in no strengthening for any memory, and the memory retrieval performance remains at zero for all memories (gray line in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4D</xref>). With an increase in LTP to 30%, there is some strengthening of synapses and memories are encoded weakly, resulting in performance that stays at a low level (pink line in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4D</xref>). For LTP&#160;=&#160;60%, there is more strengthening, but the strengthened synapses for each association cause more retrieval of previous memories during new encoding. As described in Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2</xref>, this results in interference that strengthens additional undesired synapses in the weight matrix (Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B1</xref>), and during memory retrieval testing this results in retrieval of undesired components of previous patterns. This causes performance to fall below zero for more than three memories (red line for LTP&#160;=&#160;60%). Finally, for LTP&#160;=&#160;90%, the strong retrieval of previously stored memories during encoding causes extensive strengthening of undesired synapses, forming associations with previous memories, which causes RSM and quickly causes a rapid collapse of memory performance (dark red line that drops rapidly to negative values in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4D</xref>).</p><p>Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4E</xref> shows the performance for the matrices shown in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B2</xref>, in which the synaptic modification learning rate (LTP) was kept at 100% and we tested different values of presynaptic inhibition (PreInhib&#160;=&#160;0%&#8211;90%). As a summary of this figure, the memory performance stabilizes when simulations were performed with the addition of higher values of presynaptic inhibition of synaptic transmission by GABA<sub>B</sub>R1aRs, as shown by the memory performance above 0.8 for PreInhib&#160;=&#160;90% in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4E</xref>. Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4E</xref> shows that with LTP&#160;=&#160;100% and presynaptic inhibition (PreInhib) at 0%, the performance drops rapidly (gray line in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4E</xref>) because each memory cue retrieves interference from all previously stored memories, due to the undesired synaptic weights filling the upper right diagonal of weights in the connectivity matrix in the left panel in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B2</xref>. In contrast, encoding with presynaptic inhibition by sAPP&#945; causes strengthening of only desired synapses in proportion to the number of stored memories and the number of additional synapses strengthened for each new memory (Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B2</xref>). As shown in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4E</xref>, presynaptic inhibition by sAPP&#945;&#8208;GABA<sub>B</sub>R1a with values of 60%&#8211;90% prevents interference from prior retrieval during encoding. With PreInhib&#160;=&#160;60%, the interference is weaker and performance increases to values above zero, as shown by the red line staying above zero in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4E</xref>. With PreInhib&#160;=&#160;90%, there is no interference during learning; therefore, the memory performance during retrieval shows better stability, with the dark red line showing performance above 0.8 for 20 stored memories. (Note that this function could continue for larger numbers of stored memories, and larger memory capacities can also be obtained with changes in other parameters including sparseness of network storage.)</p></sec><sec id="alz70748-sec-0150"><label>3.2</label><title>sAPP&#945; is more effective than baclofen at stabilizing associative memory in associative memory models</title><p>The 1a isoform of GABA<sub>B</sub>R is predominantly localized to presynaptic compartments, where it inhibits glutamate release; whereas, the 1b isoform is predominantly localized to postsynaptic compartments, where it mediates postsynaptic inhibition.<xref rid="alz70748-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> Although sAPP&#945; specifically interacts with GABA<sub>B</sub>R1a, baclofen is a non&#8208;specific agonist of both 1a&#8208; and 1b&#8208;containing GABA<sub>B</sub>R heterodimers. Therefore, we sought to compare the effectiveness of sAPP&#945; and baclofen on stabilizing associative memory. We first confirmed that the properties of the GABA<sub>B</sub>R1a&#8208;dependent effects of sAPP&#945; on presynaptic inhibition were preserved in the expanded Hebbian Equations (<xref rid="alz70748-disp-0008" ref-type="disp-formula">7</xref> to <xref rid="alz70748-disp-0010" ref-type="disp-formula">9</xref>&#160;). With high levels of LTP (100%), both encoding and memory recall performance are stabilized by sAPP&#945;&#8208;mediated presynaptic inhibition at 60% (strong dark red line on diagonal of the right&#8208;hand figure in Figure&#160;<xref rid="alz70748-fig-0005" ref-type="fig">5A</xref>, similar to the right panel in Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B2</xref>). This resulted in strong performance (the dark red line over 80% in Figure&#160;<xref rid="alz70748-fig-0005" ref-type="fig">5B</xref>, similar to Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4E</xref>). We then tested the effects of postsynaptic inhibition alone to model the effects of R1b on the baseline instability of the Hebb learning dynamic (Figure&#160;<xref rid="alz70748-fig-0005" ref-type="fig">5C</xref>). With low values of postsynaptic inhibition (0% or 30%), the underlying instability remained, leading to RSM. For higher levels of postsynaptic inhibition (60%), the reduction of activity during encoding prevented RSM from occurring (right panel in Figure&#160;<xref rid="alz70748-fig-0005" ref-type="fig">5C</xref>). However, this resulted in insufficient synaptic modification (weaker pink line on diagonal) and poor (near zero) memory recall performance (dark red line at zero in Figure&#160;<xref rid="alz70748-fig-0005" ref-type="fig">5D</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70748-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>sAPP&#945; is more effective than baclofen at stabilizing associative memory in associative memory models. (A,C,E) Sample networks generated using an expanded Hebbian learning algorithm with LTP at 100% and different activation of subtypes of GABA<sub>B</sub>Rs. (A) Synaptic matrix shown after encoding with increasing levels (0%, 30%, 60%) of sAPP&#945;&#8208;mediated activation of GABA<sub>B</sub>R1a. (C) Matrix after encoding with increasing activation (0%, 30%, 60%) of GABA<sub>B</sub>R1b. (E) Matrix after encoding with baclofen&#8208;mediated activation of both GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b (at 0%, 30%, or 60%). Each of these interventions stabilizes networks as shown by transition from many undesired strengthened synapses (red) in upper right of square matrix for 0%, to only strengthened synapses on the diagonal for 60%. However, performance is best for selective sAPP&#945; activation of GABA<sub>B</sub>R1a (A), in contrast with GABA<sub>B</sub>R1b (C) or baclofen&#8208;mediated activation of both GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b (E), in which the synapses at 60% are strengthened less (lighter pink) due to postsynaptic inhibition from GABA<sub>B</sub>R1b activation resulting in a weak association matrix (maximum value of 0.4) with a narrow window of baclofen efficacy. (B,D,F). Quantification of memory performance over increasing number of memories (<italic toggle="yes">x</italic>&#8208;axis) with different circles indicating increasing levels (0%&#8211;80%) of sAPP&#945;&#8208;mediated activation of (B) GABA<sub>B</sub>R1a, (D) activation of GABA<sub>B</sub>R1b (D), or (F) baclofen&#8208;mediated activation of both GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b. (B) Memory recall performance was optimal (near 1.0) with sAPP&#8208;mediated activation of GABA<sub>B</sub>R1a (dark red circles near 1.0 in figure (B). (D) This contrasts with recall performance that is poor for only increased activation of GABA<sub>B</sub>R1b postsynaptic inhibition (dark red circles at 0.0 for most increasing number). (F) This also contrasts with lower performance for baclofen&#8208;mediated activation of both GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b which is better for intermediate values but not high values.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="ALZ-21-e70748-g007.jpg"/></fig><p>We modeled the effects of baclofen on both 1a&#8208; and 1b&#8208;containing GABA<sub>B</sub>R heterodimers by modeling simultaneous changes in both presynaptic and postsynaptic inhibition using the weight matrix update functions described in Equations&#160;<xref rid="alz70748-disp-0008" ref-type="disp-formula">(7)</xref>, <xref rid="alz70748-disp-0009" ref-type="disp-formula">(8)</xref>, <xref rid="alz70748-disp-0010" ref-type="disp-formula">(9)</xref> (Figure&#160;<xref rid="alz70748-fig-0005" ref-type="fig">5E</xref>). At weak pre&#8208; and post&#8208;synaptic inhibition (e.g., 30%), there is some weakening of the encoding of previous memories (Figure&#160;<xref rid="alz70748-fig-0005" ref-type="fig">5E</xref>, middle panel) but relatively stable recall performance (near 1) (Figure&#160;<xref rid="alz70748-fig-0005" ref-type="fig">5F</xref>, red line). Simulations with a combination of strong pre&#8208; and post&#8208;synaptic inhibition (e.g., 60%) could prevent RSM (Figure&#160;<xref rid="alz70748-fig-0005" ref-type="fig">5E</xref>, right panel), but this resulted in insufficient synaptic modification (pink line) and poor (near 0) memory recall performance (Figure&#160;<xref rid="alz70748-fig-0005" ref-type="fig">5F</xref>, dark red line for 60%, although note that lower levels have better performance). Together, these results suggest that sAPP&#945; is more effective than baclofen at stabilizing associative memory and may help explain the limited success of baclofen as a treatment strategy for AD and other neurodegenerative diseases.</p></sec><sec id="alz70748-sec-0160"><label>3.3</label><title>With random selection of memory activity, presynaptic inhibition by sAPP&#945;&#8208;GABA<sub>B</sub>R1a signaling prevents RSM</title><p>For clarity of illustration, the simulations in the previous figures employ artificial patterns of memories, with each new memory of six elements containing one overlap with the previous memory and five new elements in numerical order. This was done as the simplest way to illustrate the build&#8208;up of RSM. In Figure&#160;<xref rid="alz70748-fig-0006" ref-type="fig">6</xref>, the six presynaptic and postsynaptic active input elements are chosen randomly with a uniform distribution, so that the overlap and its frequency is random.</p><fig position="float" fig-type="FIGURE" id="alz70748-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>sAPP&#945; prevents runaway synaptic modification in models of random memories. Larger sample networks (400&#160;&#215;&#160;400 neurons) were generated to test the effects of sAPP&#945;&#8208;mediated activation of GABA<sub>B</sub>R1a with randomly distributed memory patterns and LTP at 100%. (A) Without sAPP&#945;&#8208;mediated PreInhib (0%), the 100% LTP induced synaptic modification that resulted in RSM (many small red squares that are mostly undesired synapses). (B) Strong sAPP&#945;&#8208;mediated PreInhib (90%) prevents RSM (reduction in non&#8208;specific synaptic growth). The synaptic matrix shows only the desired synapses necessary for associative memory (fewer small red squares). (C) Quantification of memory performance across sequential encoding of 80 random memories. Recall performance is strongest when sAPP&#945;&#8208;mediated presynaptic inhibition (PreInhib) is 50% (dark red circles), allowing excellent recall for a few stored memories and decaying gradually due to gradually increasing overlap of the random memories. In contrast, lower levels of sAPP&#945; allow more interference during encoding, leading to steep losses in memory function due to recall intrusions (e.g., gray circles at 0%). RSM, runaway synaptic modification.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="ALZ-21-e70748-g006.jpg"/></fig><p>RSM builds up in the same way if memories with six active elements are randomly added to the network, as shown in Figure&#160;<xref rid="alz70748-fig-0006" ref-type="fig">6A</xref>, which shows the same analysis for memories in which the six active elements are selected at random with random amounts of overlap across the entire bank of training data. Here we can again demonstrate the benefits of stabilizing Hebbian learning via presynaptic inhibition though sAPP&#945;&#8208;GABA<sub>B</sub>R1a activity. The high amounts of presynaptic inhibition by sAPP&#945;&#8208;GABA<sub>B</sub>R1a result in improved encoding (Figure&#160;<xref rid="alz70748-fig-0006" ref-type="fig">6B</xref>) and improved memory performance (Figure&#160;<xref rid="alz70748-fig-0006" ref-type="fig">6C</xref>).</p></sec><sec id="alz70748-sec-0170"><label>3.4</label><title>sAPP&#945;&#160;prevents RSM without leading to insufficient modification</title><p>To summarize the effects of sAPP&#945; and baclofen on synaptic modification in our models, we have categorized the sum of synaptic weights in the sample networks into three bins: stable (linear growth of synaptic weight and number), runaway (exponential growth of synaptic weight and number), and insufficient (insufficient growth of synaptic weight and number to achieve recall), across a range of tested strengths. Without presynaptic inhibition (PreInhib&#160;=&#160;0%), LTP (over a range of 0%&#8211;100%) produces RSM in 100% of the strengths tested (Figure&#160;<xref rid="alz70748-fig-0007" ref-type="fig">7A</xref>, left).</p><fig position="float" fig-type="FIGURE" id="alz70748-fig-0007" orientation="portrait"><label>FIGURE 7</label><caption><p>Summary of the protective role of sAPP&#945; on network stability. The effects of presynaptic inhibition are categorized into three unique bins based on the associated changes to the sum of synaptic weights of the sample network. Runaway synaptic modification (RSM; red) is defined by an exponential increase in synaptic weight per memory encoded. Stable (green) is defined by a linear increase in synaptic weight per memory encoded. Insufficient (blue) is defined by an increase in weight insufficient to evoke recall. (A) (Left): The results of LTP (over a range of 0%&#8211;100%) without presynaptic inhibition (PreInhib&#160;=&#160;0%) gives RSM in all cases (red). (A) (Right): This contrasts with LTP (100%) with presynaptic inhibition (0%&#8211;100%), which gives many conditions that show stable memory function (green). (B) (Left): LTP at 100% with GABA<sub>B</sub>R1a stimulation (PreInhib&#160;=&#160;0%&#8211;100%, PostInhib&#160;=&#160;0%) gives mostly stable memory function (green). (B) (Middle): In contrast, LTP at 100% with GABA<sub>B</sub>R1b stimulation alone (PreInhib&#160;=&#160;0%, PostInhib&#160;=&#160;0%&#8211;100%) gives mostly insufficient (blue) or RSM (red) and only some stable memory function (green). (B) (Right): LTP at 100% with both GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b stimulation (PreInhib&#160;=&#160;0%&#8211;100%, PostInhib&#160;=&#160;0%&#8211;100%) gives mostly insufficient memory (blue) with smaller amounts of stable memory function (green) and some RSM (red). These results are a summary of the total sum of synaptic weights across 100 sequential 40 memory simulations regarding each of the five parameters. LTP, long&#8208;term potentiation; RSM, runaway synaptic modification.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="ALZ-21-e70748-g005.jpg"/></fig><p>When GABA<sub>B</sub>R1a&#8208;sAPP&#945; signaling is modeled (PreInhib tested over a range of 0%&#8211;100%) under conditions of high synaptic modification (LTP&#160;=&#160;100%), RSM is observed in 24% of the tested strengths (red), with the remaining being stable (green, 68%) (Figure&#160;<xref rid="alz70748-fig-0007" ref-type="fig">7A</xref>, right; <xref rid="alz70748-fig-0007" ref-type="fig">7B</xref> left). If instead of presynaptic inhibition by GABA<sub>B</sub>R1a, postsynaptic inhibition by GABA<sub>B</sub>R1b is modeled under conditions of high synaptic modification (LTP&#160;=&#160;100%, PreInhib&#160;=&#160;0%, PostInhib&#160;=&#160;0%&#8211;100%), similar percentages of RSMs are obtained (38%); however, only 18% of the strengths tested led to stable synaptic modification (green) with the emergence of insufficient synaptic modification (blue, 46%) (Figure&#160;<xref rid="alz70748-fig-0007" ref-type="fig">7B</xref>, middle). When baclofen was modeled by combining the activation of both GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b (LTP&#160;=&#160;100%, PreInhib&#160;=&#160;0%&#8211;100%, PostInhib&#160;=&#160;0%&#8211;100%) (Figure&#160;<xref rid="alz70748-fig-0007" ref-type="fig">7B</xref> right), stable synaptic modification was observed in 32% of the ranges tested (green), runaway in 22% (red), and insufficient in 46% (blue). Together, these results highlight that sAPP&#945; and baclofen can both prevent RSM; however, baclofen does so at the expense of causing insufficient synaptic modification.</p></sec></sec><sec id="alz70748-sec-0180"><label>4</label><title>DISCUSSION</title><sec id="alz70748-sec-0190"><label>4.1</label><title>A protective role of sAPP&#945; in Alzheimer's disease</title><p>Our simulations demonstrate how sAPP&#945; could be one of many possible mechanisms for preventing a proposed breakdown of synaptic homeostasis in AD. A protective role of sAPP&#945; is supported by experimental studies showing that sAPP&#945; can improve cognitive outcomes in AD mouse models.<xref rid="alz70748-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>, <xref rid="alz70748-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>, <xref rid="alz70748-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> Although human biomarker studies for sAPP&#945; and sAPP&#946; have been variable in their directionality, they suggest that levels of sAPP&#945; and sAPP&#946; may be dysregulated in AD.<xref rid="alz70748-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref>, <xref rid="alz70748-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref>, <xref rid="alz70748-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref> In addition, functional ADAM10 secretase levels are disturbed in AD<xref rid="alz70748-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> and point mutations in ADAM10 have been identified to increase AD susceptibility,<xref rid="alz70748-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref> further implicating changes to sAPP&#945; in AD. GABA<sub>B</sub>R protein expression is altered in mouse models of AD, further linking the synaptic effects of APP to severity and onset of disease.<xref rid="alz70748-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> Enhancing sAPP&#945; has long been proposed as a strategy to protect against AD<xref rid="alz70748-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>; however, recent clinical trials have administered siRNAs that target APP as a strategy to reduce A&#946; production to treat AD.<xref rid="alz70748-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> Thus, it is critical to consider the potential consequences of targeting APP and its fragments in AD.</p><p>Figures&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2</xref>, <xref rid="alz70748-fig-0003" ref-type="fig">3</xref>, <xref rid="alz70748-fig-0004" ref-type="fig">4</xref>, <xref rid="alz70748-fig-0005" ref-type="fig">5</xref>, <xref rid="alz70748-fig-0006" ref-type="fig">6</xref> show how Hebbian associative memory function in standard models can be stabilized by &#945;&#8208;secretase production of sAPP&#945;&#160;that causes presynaptic inhibition of glutamate release via activation of GABA<sub>B</sub>Rs<xref rid="alz70748-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="alz70748-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> and also enhances synaptic modification (LTP) of glutamatergic synapses.<xref rid="alz70748-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="alz70748-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> This dual function of sAPP&#945; prevents the retrieval of previously encoded episodic memories from interfering with the encoding of new episodic memories. Simulations show that insufficient presynaptic inhibition allows RSM to spread through the network (e.g., Figure&#160;<xref rid="alz70748-fig-0002" ref-type="fig">2T</xref> and Figure&#160;<xref rid="alz70748-fig-0004" ref-type="fig">4B</xref>), which the malignant synaptic growth hypothesis<xref rid="alz70748-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70748-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70748-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> suggests is a functional cause of AD. Associative memories such as Hopfield networks have long been employed in modeling the hippocampus and other cortical structures,<xref rid="alz70748-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70748-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>, <xref rid="alz70748-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref>, <xref rid="alz70748-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref>, <xref rid="alz70748-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref> which informed our choice to use such a model.<xref rid="alz70748-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>, <xref rid="alz70748-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref>, <xref rid="alz70748-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref>
</p><p>These findings could be tested experimentally in AD mouse models by cannula injection of sAPP&#945; or the short peptides composed of the binding region of APP to the GABA<sub>B</sub>R, which mimics its function.<xref rid="alz70748-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> These studies could test for improved performance in one&#8208;shot behavioral tests such as delayed non&#8208;match to position in a Morris water maze<xref rid="alz70748-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref> or in other task designs that specifically include proactive interference.<xref rid="alz70748-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref>, <xref rid="alz70748-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref> It is predicted that increasing sAPP&#945;&#8208;GABA<sub>B</sub>R1a signaling will rescue or delay cognitive deficits in AD mouse models.</p></sec><sec id="alz70748-sec-0200"><label>4.2</label><title>RSM causes hyperactivation</title><p>Previous simulations of the model presented here indicate that RSM would be accompanied by hyperactivation in affected brain regions.<xref rid="alz70748-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70748-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70748-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> This prediction is supported by functional magnetic resonance imaging (fMRI) studies in humans with mild cognitive impairment showing increased activity in hippocampus during memory encoding<xref rid="alz70748-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70748-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref> and in young adults with the mutation that causes AD.<xref rid="alz70748-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> The hippocampal hyperactivation correlates with the appearance of amyloid plaques.<xref rid="alz70748-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref> The hyperactivation also appears in cortical regions called the default network.<xref rid="alz70748-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref> In addition, RSM could also contribute to the increased propensity for seizures observed in AD.<xref rid="alz70748-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref>, <xref rid="alz70748-bib-0087" ref-type="bibr">
<sup>87</sup>
</xref>
</p><p>Our modeling proposes that APP, by influencing both presynaptic inhibition and LTP, functions as a homeostatic mechanism consistent with a broader perspective on homeostatic plasticity in AD.<xref rid="alz70748-bib-0088" ref-type="bibr">
<sup>88</sup>
</xref> There are a number of homeostatic synaptic mechanisms that contribute to the separation of encoding and retrieval by which existing modifications on different time frames contribute to conversion of novel stimuli into more robust semantic representations while not resulting in RSM.<xref rid="alz70748-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>, <xref rid="alz70748-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> These mechanisms of homeostatic plasticity have been identified to converge on a number of shared molecular processes, such as regulation of AMPA receptor recruitment to the postsynaptic density.<xref rid="alz70748-bib-0089" ref-type="bibr">
<sup>89</sup>
</xref> Hebbian plasticity may require mechanisms of homeostatic plasticity for stability,<xref rid="alz70748-bib-0090" ref-type="bibr">
<sup>90</sup>
</xref> resulting a balanced system wherein perturbances to either homeostatic mechanisms or Hebbian mechanisms could result in unstable growth (RSM), or unreliable neural encoding.<xref rid="alz70748-bib-0091" ref-type="bibr">
<sup>91</sup>
</xref> It should be noted that certain activation states, like hyperactivity, limit the efficacy of homeostatic plasticity.<xref rid="alz70748-bib-0092" ref-type="bibr">
<sup>92</sup>
</xref> Signaling by sAPP is one candidate mechanism that may help regulate malignant synaptic growth in AD. Note that hyperactivation is here proposed to be caused by RSM but can also contribute to the excess synaptic modification. Previous papers about this model<xref rid="alz70748-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> have proposed that oligomeric A&#946; inhibition of LTP<xref rid="alz70748-bib-0093" ref-type="bibr">
<sup>93</sup>
</xref>, <xref rid="alz70748-bib-0094" ref-type="bibr">
<sup>94</sup>
</xref>, <xref rid="alz70748-bib-0095" ref-type="bibr">
<sup>95</sup>
</xref> might be a homeostatic mechanism in which A&#946; normally acts to reduce RSM, rather than A&#946; being only a pathological neurotoxic mechanism. Our model confirms that reducing the learning rate <italic toggle="yes">&#951;</italic> greatly slows the progression of RSM. However, it has also been shown that endogenously produced A&#946;&#160;enhances evoked neurotransmitter release,<xref rid="alz70748-bib-0096" ref-type="bibr">
<sup>96</sup>
</xref> which directly opposes the GABA<sub>B</sub>R&#8208;mediated effects of sAPP&#945; on neurotransmitter release. Thus, sAPP&#945; could be acting to counterbalance these effects of A&#946;. The majority of the hyperactivation correlating with amyloid appearance has also been shown in Alzheimer's model mice,<xref rid="alz70748-bib-0097" ref-type="bibr">
<sup>97</sup>
</xref>, <xref rid="alz70748-bib-0098" ref-type="bibr">
<sup>98</sup>
</xref>, <xref rid="alz70748-bib-0099" ref-type="bibr">
<sup>99</sup>
</xref> but has been attributed to blockade of glutamate reuptake<xref rid="alz70748-bib-0100" ref-type="bibr">
<sup>100</sup>
</xref> rather than RSM.</p></sec><sec id="alz70748-sec-0210"><label>4.3</label><title>Implications for pharmacological treatments</title><p>Modeling the role of presynaptic inhibition in preventing the induction of AD suggests specific approaches for pharmacological treatment. Deficits in associative memory are among the first identified in AD patient populations.<xref rid="alz70748-bib-0101" ref-type="bibr">
<sup>101</sup>
</xref>, <xref rid="alz70748-bib-0102" ref-type="bibr">
<sup>102</sup>
</xref> Malignant synaptic growth would result in both retrograde and anterograde amnesia for recent episodic memories. Autobiographical memories integrate semantic memories and highly consolidated episodic memories that may have undergone more pattern separation that makes them more robust to interference, which could explain why they are lost at a later stage in AD. The therapeutic benefit of increasing presynaptic inhibition through molecular interactors like sAPP&#945; in early AD would be a reduction or slowing of the progressive memory dysfunction.</p><p>Previously<xref rid="alz70748-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> it was proposed that AD could be slowed by enhancing selective presynaptic inhibition with agonists of the M4 muscarinic receptor.<xref rid="alz70748-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70748-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> This could also be done via the presynaptic inhibition of glutamatergic synaptic transmission by presynaptically located GABA<sub>B</sub>R,<xref rid="alz70748-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> similar to muscarinic receptors.<xref rid="alz70748-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70748-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> Presynaptic inhibition by GABA<sub>B</sub>R shows a selective effect on glutamatergic synaptic transmission at recurrent synapses but not afferent input synapses in the hippocampus<xref rid="alz70748-bib-0103" ref-type="bibr">
<sup>103</sup>
</xref>, <xref rid="alz70748-bib-0104" ref-type="bibr">
<sup>104</sup>
</xref> and piriform cortex.<xref rid="alz70748-bib-0105" ref-type="bibr">
<sup>105</sup>
</xref> Presynaptic inhibition by GABA<sub>B</sub>R was proposed previously to prevent interference from prior retrieval during encoding based on enhanced LTP,<xref rid="alz70748-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="alz70748-bib-0106" ref-type="bibr">
<sup>106</sup>
</xref> similar to the recently described dual effects of sAPP&#945; that are modeled here.</p><p>Baclofen, an agonist of both 1a and 1b isoforms of GABA<sub>B</sub>R, has been proposed as a treatment for AD.<xref rid="alz70748-bib-0107" ref-type="bibr">
<sup>107</sup>
</xref> However, here we propose that specifically activating the 1a isoform of GABA<sub>B</sub>R, would more effectively reduce the progression of RSM in AD than a non&#8208;specific agonist. The discoveries that GABA<sub>B</sub>R1a is transported with APP<xref rid="alz70748-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> and activated by sAPP&#945;<xref rid="alz70748-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> provides a target for the development of therapeutic strategies for modulating GABA<sub>B</sub>R1a&#8208;specific signaling. The identification of short (&lt;17amino acid) peptides within sAPP&#945; that are sufficient to bind GABA<sub>B</sub>R1a and mimic the effects of sAPP&#945; on GABA<sub>B</sub>R1a provides a potential basis for the development of a GABA<sub>B</sub>R1a isoform&#8211;specific agonist.</p><p>Treatment could utilize activation of M4 muscarinic cholinergic receptors that cause presynaptic inhibition selectively at excitatory feedback glutamatergic synapses in the cortex,<xref rid="alz70748-bib-0108" ref-type="bibr">
<sup>108</sup>
</xref>, <xref rid="alz70748-bib-0109" ref-type="bibr">
<sup>109</sup>
</xref> whereas afferent input synapses show much weaker muscarinic presynaptic inhibition. The same synapses that show presynaptic inhibition also show strong Hebbian LTP in the hippocampus<xref rid="alz70748-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70748-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> and the piriform cortex.<xref rid="alz70748-bib-0110" ref-type="bibr">
<sup>110</sup>
</xref> This is consistent with the anatomic distribution of M4 receptor labeling.<xref rid="alz70748-bib-0111" ref-type="bibr">
<sup>111</sup>
</xref>, <xref rid="alz70748-bib-0112" ref-type="bibr">
<sup>112</sup>
</xref> Enhancement of presynaptic inhibition could utilize selective M4 receptor agonists and allosteric modulators.<xref rid="alz70748-bib-0113" ref-type="bibr">
<sup>113</sup>
</xref>, <xref rid="alz70748-bib-0114" ref-type="bibr">
<sup>114</sup>
</xref> Modeling shows that the blockade of presynaptic inhibition by the muscarinic antagonist scopolamine should enhance proactive interference,<xref rid="alz70748-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> and this was supported by behavioral data on the effects of scopolamine in humans.<xref rid="alz70748-bib-0115" ref-type="bibr">
<sup>115</sup>
</xref> These previous models also showed how cholinergic modulation could be activated selectively for novel stimuli, based on a mismatch computed in region CA1 between current sensory input from the entorhinal cortex and retrieval from region CA3. These studies were cited in a later report that used the same mechanism for selective modification of synapses without synaptic transmission when there was a mismatch, allowing novelty&#8208;facilitated Hebbian modification while blocking retrieval dynamics.<xref rid="alz70748-bib-0116" ref-type="bibr">
<sup>116</sup>
</xref> APP could allow an additional type of novelty&#8208;facilitated modification, in which synapses that have not been recently modified (and therefore have more APP available for &#945;&#8208;secretase splicing) might be more accessible for modification.</p><p>M4 receptor activators have been proposed as a treatment for hyperactivity observed in AD.<xref rid="alz70748-bib-0117" ref-type="bibr">
<sup>117</sup>
</xref> Treatment by selective M4 drugs for slowing progression would be most effective at an early stage of the disease before tangles have developed. Another possible pharmacological approach could address the role of Group 1 mGluRs in regulating LTD to counteract the mechanism of RSM. MgluR5, which is predominantly postsynaptically localized, has also been proposed as a therapeutic target in AD.<xref rid="alz70748-bib-0118" ref-type="bibr">
<sup>118</sup>
</xref> It possesses a kinetic profile similar to that of GABA<sub>B</sub>R but differs in the heterodimer assembly speed and surface retention.<xref rid="alz70748-bib-0119" ref-type="bibr">
<sup>119</sup>
</xref>
</p><p>Several characteristics of sAPP&#945; position it as a particularly interesting candidate molecule to target therapeutically in AD. sAPP&#945; as a shed extracellular domain would be expected to have slower turnover rates as a ligand at the synapse than classic neurotransmitters, such as GABA, glutamate, or acetylcholine. sAPP&#945; is also of high therapeutic relevance because (1) it is an 1a&#8208;isoform&#8208;specific GABA<sub>B</sub>R ligand and (2) it is derived from the same precursor protein that leads to A&#946; found in amyloid plaques associated with AD.</p></sec><sec id="alz70748-sec-0220"><label>4.4</label><title>Summary</title><p>This model shows how cortical memory function could be stabilized by a secreted form of APP (sAPP&#945;) that causes both presynaptic inhibition of glutamate release via activation of GABA<sub>B</sub> receptors<xref rid="alz70748-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> and enhancement of LTP.<xref rid="alz70748-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> This joint function of sAPP can prevent RSM that could underlie AD. Moreover, modeling suggests that sAPP, which interacts with the 1a isoform of GABA<sub>B</sub>R, more effectively stabilizes associative memory than the non&#8208;specific agonist baclofen. Together, these results support enhancing the sAPP&#8208;GABA<sub>B</sub>R1a signaling pathway as a potential therapeutic strategy for preventing cognitive impairment in AD. These findings also suggest caution in approaches that aim to reduce APP levels for the treatment of AD.</p></sec></sec><sec sec-type="COI-statement" id="alz70748-sec-0240"><title>CONFLICT OF INTEREST STATEMENT</title><p>H.C.R. is an inventor on a patent on the APP&#8208;GABABR interaction that is owned by VIB (Flemish Institute of Biotechnology)&#160;and the KU Leuven: Patent no. WO2018015296A1, &#8220;Therapeutic agents for neurological and psychiatric disorders.&#8221; D.B. and M.E.H do not have any conflicts of interest to disclose. Any author disclosures are available in the <xref rid="alz70748-supinfo-0001" ref-type="">Supporting Information</xref>.</p></sec><sec id="alz70748-sec-0250"><title>CONSENT STATEMENT</title><p>Human subjects were not used in this study.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70748-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70748-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70748-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70748-sec-0230"><title>ACKNOWLEDGMENTS</title><p>This work is supported by the National Institutes of Health, grant numbers R01 MH120073, and R35 GM142726.</p></ack><ref-list id="alz70748-bibl-0001"><title>REFERENCES</title><ref id="alz70748-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70748-cite-0002"><string-name name-style="western"><surname>Hasselmo</surname><given-names>ME</given-names></string-name>. <article-title>Runaway synaptic modification in models of cortex: implications for Alzheimer's disease</article-title>. <source>Neural Networks</source>. <year>1994</year>;<volume>7</volume>:<fpage>13</fpage>&#8208;<lpage>40</lpage>.</mixed-citation></ref><ref id="alz70748-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70748-cite-0003"><string-name name-style="western"><surname>Newman</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Shay</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Hasselmo</surname><given-names>ME</given-names></string-name>. <article-title>Malignant synaptic growth and Alzheimer's disease</article-title>. <source>Future Neurol</source>. <year>2012</year>;<volume>7</volume>:<fpage>557</fpage>&#8208;<lpage>571</lpage>.<pub-id pub-id-type="pmid">23420180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fnl.12.47</pub-id><pub-id pub-id-type="pmcid">PMC3571723</pub-id></mixed-citation></ref><ref id="alz70748-bib-0003"><label>3</label><mixed-citation publication-type="book" id="alz70748-cite-0004"><string-name name-style="western"><surname>Hasselmo</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Wyble</surname><given-names>BP</given-names></string-name>. <part-title>Does the spread of Alzheimer's disease neuropathology involve the mechanisms of consolidation?</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Reggia</surname><given-names>J</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Berndt</surname><given-names>R</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Ruppin</surname><given-names>E</given-names></string-name></person-group>, eds. <source>Neural Modeling of Brain and Cognitive Disorders</source>. <publisher-name>World Scientific Publishing</publisher-name>; <year>1996</year>.</mixed-citation></ref><ref id="alz70748-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70748-cite-0005"><string-name name-style="western"><surname>McNaughton</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>RGM</given-names></string-name>. <article-title>Hippocampal synaptic enhancement and information storage within a distributed memory system</article-title>. <source>Trends Neurosci</source>. <year>1987</year>;<volume>10</volume>:<fpage>408</fpage>&#8208;<lpage>415</lpage>.</mixed-citation></ref><ref id="alz70748-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70748-cite-0006"><string-name name-style="western"><surname>Hasselmo</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Wyble</surname><given-names>BP</given-names></string-name>. <article-title>Free recall and recognition in a network model of the hippocampus: simulating effects of scopolamine on human memory function</article-title>. <source>Behav Brain Res</source>. <year>1997</year>;<volume>89</volume>:<fpage>1</fpage>&#8208;<lpage>34</lpage>.<pub-id pub-id-type="pmid">9475612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0166-4328(97)00048-x</pub-id></mixed-citation></ref><ref id="alz70748-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70748-cite-0007"><string-name name-style="western"><surname>Norman</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>O'Reilly</surname><given-names>RC</given-names></string-name>. <article-title>Modeling hippocampal and neocortical contributions to recognition memory: a complementary&#8208;learning&#8208;systems approach</article-title>. <source>Psychol Rev</source>. <year>2003</year>;<volume>110</volume>:<fpage>611</fpage>&#8208;<lpage>646</lpage>.<pub-id pub-id-type="pmid">14599236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/0033-295X.110.4.611</pub-id></mixed-citation></ref><ref id="alz70748-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70748-cite-0008"><string-name name-style="western"><surname>Hopfield</surname><given-names>JJ</given-names></string-name>. <article-title>Neurons with graded response have collective computational properties like those of two&#8208;state neurons</article-title>. <source>Proc Natl Acad Sci</source>. <year>1984</year>;<volume>81</volume>:<fpage>3088</fpage>&#8208;<lpage>3092</lpage>.<pub-id pub-id-type="pmid">6587342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.81.10.3088</pub-id><pub-id pub-id-type="pmcid">PMC345226</pub-id></mixed-citation></ref><ref id="alz70748-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70748-cite-0009"><string-name name-style="western"><surname>Kohonen</surname><given-names>T</given-names></string-name>. <article-title>Correlation matrix memories</article-title>. <source>IEEE Trans Computers</source>. <year>1972</year>;<volume>C&#8208;21</volume>:<fpage>353</fpage>&#8208;<lpage>359</lpage>.</mixed-citation></ref><ref id="alz70748-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70748-cite-0010"><string-name name-style="western"><surname>Anderson</surname><given-names>JA</given-names></string-name>. <article-title>A simple neural network generating an interactive memory</article-title>. <source>Math Biosci</source>. <year>1972</year>;<volume>14</volume>:<fpage>197</fpage>&#8208;<lpage>220</lpage>.</mixed-citation></ref><ref id="alz70748-bib-0010"><label>10</label><mixed-citation publication-type="book" id="alz70748-cite-0011"><string-name name-style="western"><surname>Amit</surname><given-names>DJ</given-names></string-name>. <source>Modeling BRAIN function: The World of Attractor Neural Networks</source>. <publisher-name>Cambridge Univ. Press</publisher-name>; <year>1988</year>.</mixed-citation></ref><ref id="alz70748-bib-0011"><label>11</label><mixed-citation publication-type="book" id="alz70748-cite-0012"><string-name name-style="western"><surname>Kohonen</surname><given-names>T</given-names></string-name>. <source>Self&#8208;Organization and Associative Memory</source>. <publisher-name>Springer&#8208;Verlag</publisher-name>; <year>1984</year>.</mixed-citation></ref><ref id="alz70748-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70748-cite-0013"><string-name name-style="western"><surname>Hasselmo</surname><given-names>ME</given-names></string-name>. <article-title>A computational model of the progression of Alzheimer's disease</article-title>. <source>MD Comput</source>. <year>1997</year>;<volume>14</volume>:<fpage>181</fpage>&#8208;<lpage>191</lpage>.<pub-id pub-id-type="pmid">9151508</pub-id></mixed-citation></ref><ref id="alz70748-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70748-cite-0014"><string-name name-style="western"><surname>Hasselmo</surname><given-names>ME</given-names></string-name>. <article-title>Acetylcholine and learning in a cortical associative memory</article-title>. <source>Neural Comp</source>. <year>1993</year>;<volume>5</volume>:<fpage>32</fpage>&#8208;<lpage>44</lpage>.</mixed-citation></ref><ref id="alz70748-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70748-cite-0015"><string-name name-style="western"><surname>Greenstein&#8208;Messica</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ruppin</surname><given-names>E</given-names></string-name>. <article-title>Synaptic runaway in associative networks and the pathogenesis of schizophrenia</article-title>. <source>Neural Comput</source>. <year>1998</year>;<volume>10</volume>:<fpage>451</fpage>&#8208;<lpage>465</lpage>.<pub-id pub-id-type="pmid">9472490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1162/089976698300017836</pub-id></mixed-citation></ref><ref id="alz70748-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70748-cite-0016"><string-name name-style="western"><surname>Braak</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Braak</surname><given-names>E</given-names></string-name>. <article-title>Neuropathological staging of Alzheimer&#8208;related changes</article-title>. <source>Acta Neuropathol</source>. <year>1991</year>;<volume>82</volume>:<fpage>239</fpage>&#8208;<lpage>259</lpage>.<pub-id pub-id-type="pmid">1759558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00308809</pub-id></mixed-citation></ref><ref id="alz70748-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70748-cite-0017"><string-name name-style="western"><surname>Arriagada</surname><given-names>PV</given-names></string-name>, <string-name name-style="western"><surname>Growdon</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Hedley&#8208;Whyte</surname><given-names>ET</given-names></string-name>, <string-name name-style="western"><surname>Hyman</surname><given-names>BT</given-names></string-name>. <article-title>Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease</article-title>. <source>Neurol</source>. <year>1992</year>;<volume>42</volume>:<fpage>631</fpage>&#8208;<lpage>639</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.42.3.631</pub-id><pub-id pub-id-type="pmid">1549228</pub-id></mixed-citation></ref><ref id="alz70748-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70748-cite-0018"><string-name name-style="western"><surname>Purro</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Dickins</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Salinas</surname><given-names>PC</given-names></string-name>. <article-title>The secreted Wnt antagonist Dickkopf&#8208;1 is required for amyloid beta&#8208;mediated synaptic loss</article-title>. <source>J Neurosci</source>. <year>2012</year>;<volume>32</volume>:<fpage>3492</fpage>&#8208;<lpage>3498</lpage>.<pub-id pub-id-type="pmid">22399772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.4562-11.2012</pub-id><pub-id pub-id-type="pmcid">PMC6621056</pub-id></mixed-citation></ref><ref id="alz70748-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70748-cite-0019"><string-name name-style="western"><surname>Scheff</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Price</surname><given-names>D</given-names></string-name>. <article-title>Alzheimer's disease&#8208;related alterations in synaptic density: neocortex and hippocampus</article-title>. <source>J Alzheimer's Dis</source>. <year>2006</year>;<volume>9</volume>:<fpage>101</fpage>&#8208;<lpage>115</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/jad-2006-9s312</pub-id><pub-id pub-id-type="pmid">16914849</pub-id></mixed-citation></ref><ref id="alz70748-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70748-cite-0020"><string-name name-style="western"><surname>Dickerson</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Salat</surname><given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Bates</surname><given-names>JF</given-names></string-name>, et&#160;al. <article-title>Medial temporal lobe function and structure in mild cognitive impairment</article-title>. <source>Ann Neurol</source>. <year>2004</year>;<volume>56</volume>:<fpage>27</fpage>&#8208;<lpage>35</lpage>.<pub-id pub-id-type="pmid">15236399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.20163</pub-id><pub-id pub-id-type="pmcid">PMC4335689</pub-id></mixed-citation></ref><ref id="alz70748-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70748-cite-0021"><string-name name-style="western"><surname>Quiroz</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Budson</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Celone</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease</article-title>. <source>Ann Neurol</source>. <year>2010</year>;<volume>68</volume>:<fpage>865</fpage>&#8208;<lpage>875</lpage>.<pub-id pub-id-type="pmid">21194156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.22105</pub-id><pub-id pub-id-type="pmcid">PMC3175143</pub-id></mixed-citation></ref><ref id="alz70748-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70748-cite-0022"><string-name name-style="western"><surname>Dickerson</surname><given-names>BC</given-names></string-name>, <string-name name-style="western"><surname>Salat</surname><given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Greve</surname><given-names>DN</given-names></string-name>, et&#160;al. <article-title>Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD</article-title>. <source>Neurology</source>. <year>2005</year>;<volume>65</volume>:<fpage>404</fpage>&#8208;<lpage>411</lpage>.<pub-id pub-id-type="pmid">16087905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000171450.97464.49</pub-id><pub-id pub-id-type="pmcid">PMC4335677</pub-id></mixed-citation></ref><ref id="alz70748-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70748-cite-0023"><string-name name-style="western"><surname>Hamalainen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pihlajamaki</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tanila</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Increased fMRI responses during encoding in mild cognitive impairment</article-title>. <source>Neurobiol Aging</source>. <year>2007</year>;<volume>28</volume>:<fpage>1889</fpage>&#8208;<lpage>1903</lpage>.<pub-id pub-id-type="pmid">16997428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2006.08.008</pub-id></mixed-citation></ref><ref id="alz70748-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70748-cite-0024"><string-name name-style="western"><surname>Park</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kohl</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Kwag</surname><given-names>J</given-names></string-name>. <article-title>Memory encoding and retrieval by retrosplenial parvalbumin interneurons are impaired in Alzheimer's disease model mice</article-title>. <source>Curr Biol</source>. <year>2024</year>;<volume>34</volume>:<fpage>434</fpage>&#8208;<lpage>443</lpage>.<pub-id pub-id-type="pmid">38157861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cub.2023.12.014</pub-id></mixed-citation></ref><ref id="alz70748-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70748-cite-0025"><string-name name-style="western"><surname>Maass</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Berron</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Harrison</surname><given-names>TM</given-names></string-name>, et&#160;al. <article-title>Alzheimer's pathology targets distinct memory networks in the ageing brain</article-title>. <source>Brain</source>. <year>2019</year>;<volume>142</volume>:<fpage>2492</fpage>&#8208;<lpage>2509</lpage>.<pub-id pub-id-type="pmid">31199481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awz154</pub-id><pub-id pub-id-type="pmcid">PMC6658874</pub-id></mixed-citation></ref><ref id="alz70748-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70748-cite-0026"><string-name name-style="western"><surname>Hasselmo</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Schnell</surname><given-names>E</given-names></string-name>. <article-title>Laminar selectivity of the cholinergic suppression of synaptic transmission in rat hippocampal region CA1: computational modeling and brain slice physiology</article-title>. <source>J Neurosci</source>. <year>1994</year>;<volume>14</volume>:<fpage>3898</fpage>&#8208;<lpage>3914</lpage>.<pub-id pub-id-type="pmid">8207494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.14-06-03898.1994</pub-id><pub-id pub-id-type="pmcid">PMC6576918</pub-id></mixed-citation></ref><ref id="alz70748-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70748-cite-0027"><string-name name-style="western"><surname>Molyneaux</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Hasselmo</surname><given-names>ME</given-names></string-name>. <article-title>GABA(B) presynaptic inhibition has an in vivo time constant sufficiently rapid to allow modulation at theta frequency</article-title>. <source>J Neurophysiol</source>. <year>2002</year>;<volume>87</volume>:<fpage>1196</fpage>&#8208;<lpage>1205</lpage>.<pub-id pub-id-type="pmid">11877493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/jn.00077.2001</pub-id></mixed-citation></ref><ref id="alz70748-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70748-cite-0028"><string-name name-style="western"><surname>Seol</surname><given-names>GH</given-names></string-name>, <string-name name-style="western"><surname>Ziburkus</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Neuromodulators control the polarity of spike&#8208;timing&#8208;dependent synaptic plasticity</article-title>. <source>Neuron</source>. <year>2007</year>;<volume>55</volume>:<fpage>919</fpage>&#8208;<lpage>929</lpage>.<pub-id pub-id-type="pmid">17880895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2007.08.013</pub-id><pub-id pub-id-type="pmcid">PMC2756178</pub-id></mixed-citation></ref><ref id="alz70748-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70748-cite-0029"><string-name name-style="western"><surname>Vertkin</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Styr</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Slomowitz</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>GABAB receptor deficiency causes failure of neuronal homeostasis in hippocampal networks</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2015</year>;<volume>112</volume>:<fpage>E3291</fpage>&#8208;<lpage>E3299</lpage>.<pub-id pub-id-type="pmid">26056260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1424810112</pub-id><pub-id pub-id-type="pmcid">PMC4485096</pub-id></mixed-citation></ref><ref id="alz70748-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70748-cite-0030"><string-name name-style="western"><surname>Huang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Trevino</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Pull&#8208;push neuromodulation of LTP and LTD enables bidirectional experience&#8208;induced synaptic scaling in visual cortex</article-title>. <source>Neuron</source>. <year>2012</year>;<volume>73</volume>:<fpage>497</fpage>&#8208;<lpage>510</lpage>.<pub-id pub-id-type="pmid">22325202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2011.11.023</pub-id><pub-id pub-id-type="pmcid">PMC3373163</pub-id></mixed-citation></ref><ref id="alz70748-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70748-cite-0031"><string-name name-style="western"><surname>Guo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>de Pasquale</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Dark exposure extends the integration window for spike&#8208;timing&#8208;dependent plasticity</article-title>. <source>J Neurosci</source>. <year>2012</year>;<volume>32</volume>:<fpage>15027</fpage>&#8208;<lpage>15035</lpage>.<pub-id pub-id-type="pmid">23100424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2545-12.2012</pub-id><pub-id pub-id-type="pmcid">PMC3496177</pub-id></mixed-citation></ref><ref id="alz70748-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70748-cite-0032"><string-name name-style="western"><surname>Chipman</surname><given-names>PH</given-names></string-name>, <string-name name-style="western"><surname>Fetter</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Panzera</surname><given-names>LC</given-names></string-name>, et&#160;al. <article-title>NMDAR&#8208;dependent presynaptic homeostasis in adult hippocampus: synapse growth and cross&#8208;modal inhibitory plasticity</article-title>. <source>Neuron</source>. <year>2022</year>;<volume>110</volume>:<fpage>3302</fpage>&#8208;<lpage>3317</lpage>.<pub-id pub-id-type="pmid">36070750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2022.08.014</pub-id><pub-id pub-id-type="pmcid">PMC9588671</pub-id></mixed-citation></ref><ref id="alz70748-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70748-cite-0033"><string-name name-style="western"><surname>Turrigiano</surname><given-names>G</given-names></string-name>. <article-title>Homeostatic signaling: the positive side of negative feedback</article-title>. <source>Curr Opin Neurobiol</source>. <year>2007</year>;<volume>17</volume>:<fpage>318</fpage>&#8208;<lpage>324</lpage>.<pub-id pub-id-type="pmid">17451937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.conb.2007.04.004</pub-id></mixed-citation></ref><ref id="alz70748-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70748-cite-0034"><string-name name-style="western"><surname>Turrigiano</surname><given-names>GG</given-names></string-name>. <article-title>The self&#8208;tuning neuron: synaptic scaling of excitatory synapses</article-title>. <source>Cell</source>. <year>2008</year>;<volume>135</volume>:<fpage>422</fpage>&#8208;<lpage>435</lpage>.<pub-id pub-id-type="pmid">18984155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2008.10.008</pub-id><pub-id pub-id-type="pmcid">PMC2834419</pub-id></mixed-citation></ref><ref id="alz70748-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70748-cite-0035"><string-name name-style="western"><surname>Davis</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller</surname><given-names>M</given-names></string-name>. <article-title>Homeostatic control of presynaptic neurotransmitter release</article-title>. <source>Annu Rev Physiol</source>. <year>2015</year>;<volume>77</volume>:<fpage>251</fpage>&#8208;<lpage>270</lpage>.<pub-id pub-id-type="pmid">25386989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-physiol-021014-071740</pub-id></mixed-citation></ref><ref id="alz70748-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70748-cite-0036"><string-name name-style="western"><surname>Rice</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>de Malmazet</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Schreurs</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Secreted amyloid&#8208;beta precursor protein functions as a GABABR1a ligand to modulate synaptic transmission</article-title>. <source>Science</source>. <year>2019</year>;<volume>363</volume>:<elocation-id>eaao4827</elocation-id>.<pub-id pub-id-type="pmid">30630900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aao4827</pub-id><pub-id pub-id-type="pmcid">PMC6366617</pub-id></mixed-citation></ref><ref id="alz70748-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70748-cite-0037"><string-name name-style="western"><surname>Dinamarca</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Raveh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Complex formation of APP with GABAB receptors links axonal trafficking to amyloidogenic processing</article-title>. <source>Nat Commun</source>. <year>2019</year>;<volume>10</volume>:<fpage>1331</fpage>.<pub-id pub-id-type="pmid">30902970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-09164-3</pub-id><pub-id pub-id-type="pmcid">PMC6430795</pub-id></mixed-citation></ref><ref id="alz70748-bib-0037"><label>37</label><mixed-citation publication-type="miscellaneous" id="alz70748-cite-0038"><article-title>A Study to Evaluate the Safety and Tolerability of ALN&#8208;APP in Patients With EOAD</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05231785" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT05231785</ext-link></mixed-citation></ref><ref id="alz70748-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70748-cite-0039"><string-name name-style="western"><surname>Dawson</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Seabrook</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Age&#8208;related cognitive deficits, impaired long&#8208;term potentiation and reduction in synaptic marker density in mice lacking the beta&#8208;amyloid precursor protein</article-title>. <source>Neuroscience</source>. <year>1999</year>;<volume>90</volume>:<fpage>1</fpage>&#8208;<lpage>13</lpage>.<pub-id pub-id-type="pmid">10188929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0306-4522(98)00410-2</pub-id></mixed-citation></ref><ref id="alz70748-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz70748-cite-0040"><string-name name-style="western"><surname>Steubler</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Erdinger</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Back</surname><given-names>MK</given-names></string-name>, et&#160;al. <article-title>Loss of all three APP family members during development impairs synaptic function and plasticity, disrupts learning, and causes an autism&#8208;like phenotype</article-title>. <source>Embo j</source>. <year>2021</year>;<volume>40</volume>:<elocation-id>e107471</elocation-id>.<pub-id pub-id-type="pmid">34008862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.2020107471</pub-id><pub-id pub-id-type="pmcid">PMC8204861</pub-id></mixed-citation></ref><ref id="alz70748-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70748-cite-0041"><string-name name-style="western"><surname>M&#252;ller</surname><given-names>UC</given-names></string-name>, <string-name name-style="western"><surname>Deller</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Korte</surname><given-names>M</given-names></string-name>. <article-title>Not just amyloid: physiological functions of the amyloid precursor protein family</article-title>. <source>Nat Rev Neurosci</source>. <year>2017</year>;<volume>18</volume>:<fpage>281</fpage>&#8208;<lpage>298</lpage>.<pub-id pub-id-type="pmid">28360418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn.2017.29</pub-id></mixed-citation></ref><ref id="alz70748-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70748-cite-0042"><string-name name-style="western"><surname>Taylor</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Ireland</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Ballagh</surname><given-names>I</given-names></string-name>, et&#160;al. <article-title>Endogenous secreted amyloid precursor protein&#8208;alpha regulates hippocampal NMDA receptor function, long&#8208;term potentiation and spatial memory</article-title>. <source>Neurobiol Dis</source>. <year>2008</year>;<volume>31</volume>:<fpage>250</fpage>&#8208;<lpage>260</lpage>.<pub-id pub-id-type="pmid">18585048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nbd.2008.04.011</pub-id></mixed-citation></ref><ref id="alz70748-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70748-cite-0043"><string-name name-style="western"><surname>Richter</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Ludewig</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Winschel</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Distinct in vivo roles of secreted APP ectodomain variants APPsalpha and APPsbeta in regulation of spine density, synaptic plasticity, and cognition</article-title>. <source>EMBO J</source>. <year>2018</year>;<volume>37</volume>:<elocation-id>e98335</elocation-id>.<pub-id pub-id-type="pmid">29661886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.201798335</pub-id><pub-id pub-id-type="pmcid">PMC5983155</pub-id></mixed-citation></ref><ref id="alz70748-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70748-cite-0044"><string-name name-style="western"><surname>Furukawa</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Barger</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Blalock</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Mattson</surname><given-names>MP</given-names></string-name>. <article-title>Activation of K+ channels and suppression of neuronal activity by secreted beta&#8208;amyloid&#8208;precursor protein</article-title>. <source>Nature</source>. <year>1996</year>;<volume>379</volume>:<fpage>74</fpage>&#8208;<lpage>78</lpage>.<pub-id pub-id-type="pmid">8538744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/379074a0</pub-id></mixed-citation></ref><ref id="alz70748-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70748-cite-0045"><string-name name-style="western"><surname>Ishida</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Furukawa</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Keller</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Mattson</surname><given-names>MP</given-names></string-name>. <article-title>Secreted form of beta&#8208;amyloid precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP in hippocampal slices</article-title>. <source>Neuroreport</source>. <year>1997</year>;<volume>8</volume>:<fpage>2133</fpage>&#8208;<lpage>2137</lpage>.<pub-id pub-id-type="pmid">9243598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00001756-199707070-00009</pub-id></mixed-citation></ref><ref id="alz70748-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz70748-cite-0046"><string-name name-style="western"><surname>Xiong</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>OD</given-names></string-name>, <string-name name-style="western"><surname>Peppercorn</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ohline</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Tate</surname><given-names>WP</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname><given-names>WC</given-names></string-name>. <article-title>Secreted amyloid precursor protein&#8208;alpha can restore novel object location memory and hippocampal LTP in aged rats</article-title>. <source>Neurobiol Learn Mem</source>. <year>2017</year>;<volume>138</volume>:<fpage>291</fpage>&#8208;<lpage>299</lpage>.<pub-id pub-id-type="pmid">27521248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nlm.2016.08.002</pub-id></mixed-citation></ref><ref id="alz70748-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz70748-cite-0047"><string-name name-style="western"><surname>Richter</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Ludewig</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Winschel</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Distinct in vivo roles of secreted APP ectodomain variants APPs&#945; and APPs&#946; in regulation of spine density, synaptic plasticity, and cognition</article-title>. <source>Embo j</source>. <year>2018</year>;<volume>37</volume>(<issue>11</issue>):<elocation-id>e98335</elocation-id>.<pub-id pub-id-type="pmid">29661886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.201798335</pub-id><pub-id pub-id-type="pmcid">PMC5983155</pub-id></mixed-citation></ref><ref id="alz70748-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="alz70748-cite-0048"><string-name name-style="western"><surname>Livingstone</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Elder</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Secreted amyloid precursor protein&#8208;alpha enhances LTP through the synthesis and trafficking of Ca(2+)&#8208;permeable AMPA receptors</article-title>. <source>Front Mol Neurosci</source>. <year>2021</year>;<volume>14</volume>:<elocation-id>660208</elocation-id>.<pub-id pub-id-type="pmid">33867938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnmol.2021.660208</pub-id><pub-id pub-id-type="pmcid">PMC8047154</pub-id></mixed-citation></ref><ref id="alz70748-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="alz70748-cite-0049"><string-name name-style="western"><surname>Ring</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Weyer</surname><given-names>SW</given-names></string-name>, <string-name name-style="western"><surname>Kilian</surname><given-names>SB</given-names></string-name>, et&#160;al. <article-title>The secreted beta&#8208;amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP&#8208;deficient mice</article-title>. <source>J Neurosci</source>. <year>2007</year>;<volume>27</volume>:<fpage>7817</fpage>&#8208;<lpage>7826</lpage>.<pub-id pub-id-type="pmid">17634375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.1026-07.2007</pub-id><pub-id pub-id-type="pmcid">PMC6672885</pub-id></mixed-citation></ref><ref id="alz70748-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="alz70748-cite-0050"><string-name name-style="western"><surname>Hick</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Herrmann</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Weyer</surname><given-names>SW</given-names></string-name>, et&#160;al. <article-title>Acute function of secreted amyloid precursor protein fragment APPs&#945; in synaptic plasticity</article-title>. <source>Acta Neuropathol</source>. <year>2015</year>;<volume>129</volume>:<fpage>21</fpage>&#8208;<lpage>37</lpage>.<pub-id pub-id-type="pmid">25432317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-014-1368-x</pub-id></mixed-citation></ref><ref id="alz70748-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="alz70748-cite-0051"><string-name name-style="western"><surname>Rem</surname><given-names>PD</given-names></string-name>, <string-name name-style="western"><surname>Sereikaite</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Fernandez&#8208;Fernandez</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Soluble amyloid&#8208;beta precursor peptide does not regulate GABA(B) receptor activity</article-title>. <source>Elife</source>. <year>2023</year>;<volume>12</volume>(<issue>4</issue>):<fpage>505</fpage>&#8208;<lpage>508</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.82082</pub-id><pub-id pub-id-type="pmcid">PMC9917443</pub-id><pub-id pub-id-type="pmid">36688536</pub-id></mixed-citation></ref><ref id="alz70748-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="alz70748-cite-0052"><string-name name-style="western"><surname>Agliari</surname><given-names>EBA</given-names></string-name>, <string-name name-style="western"><surname>De Antoni</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Galluzzi</surname><given-names>A</given-names></string-name>. <article-title>Parallel retrieval of correlated patterns: from Hopfield networks to Boltzmann machines</article-title>. <source>Neural Netw</source>. <year>2013</year>:<fpage>52</fpage>&#8208;<lpage>63</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neunet.2012.11.010</pub-id><pub-id pub-id-type="pmid">23246601</pub-id></mixed-citation></ref><ref id="alz70748-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="alz70748-cite-0053"><string-name name-style="western"><surname>L&#246;we</surname><given-names>M</given-names></string-name>. <article-title>On the storage capacity of Hopfield models with correlated patterns</article-title>. <source>Ann Appl Probab</source>. <year>1998</year>;<volume>8</volume>:<fpage>1216</fpage>&#8208;<lpage>1250</lpage>.</mixed-citation></ref><ref id="alz70748-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="alz70748-cite-0054"><string-name name-style="western"><surname>Gava</surname><given-names>GP</given-names></string-name>, <string-name name-style="western"><surname>McHugh</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Lefevre</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Integrating new memories into the hippocampal network activity space</article-title>. <source>Nat Neurosci</source>. <year>2021</year>;<volume>24</volume>:<fpage>326</fpage>&#8208;<lpage>330</lpage>.<pub-id pub-id-type="pmid">33603228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-021-00804-w</pub-id><pub-id pub-id-type="pmcid">PMC7116855</pub-id></mixed-citation></ref><ref id="alz70748-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="alz70748-cite-0055"><string-name name-style="western"><surname>Gava</surname><given-names>GPLL</given-names></string-name>, <string-name name-style="western"><surname>Broadbelt</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>McHugh</surname><given-names>SB</given-names></string-name>, et&#160;al. <article-title>Organizing the coactivity structure of the hippocampus from robust to flexible memory</article-title>. <source>Science</source>. <year>2024</year>;<volume>385</volume>:<fpage>1120</fpage>&#8208;<lpage>1127</lpage>.<pub-id pub-id-type="pmid">39236189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.adk9611</pub-id><pub-id pub-id-type="pmcid">PMC7616439</pub-id></mixed-citation></ref><ref id="alz70748-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="alz70748-cite-0056"><string-name name-style="western"><surname>Menschik</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Finkel</surname><given-names>L</given-names></string-name>. <article-title>Neuromodulatory control of hippocampal function: towards a model of Alzheimer's disease</article-title>. <source>Artif Intell Med</source>. <year>1998</year>;<volume>13</volume>:<fpage>99</fpage>&#8208;<lpage>121</lpage>.<pub-id pub-id-type="pmid">9654381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0933-3657(98)00006-2</pub-id></mixed-citation></ref><ref id="alz70748-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="alz70748-cite-0057"><string-name name-style="western"><surname>Malerba</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bazhenov</surname><given-names>M</given-names></string-name>. <article-title>Circuit mechanisms of hippocampal reactivation during sleep</article-title>. <source>Neurobiol Learn Mem</source>. <year>2019</year>;<volume>160</volume>:<fpage>98</fpage>&#8208;<lpage>107</lpage>.<pub-id pub-id-type="pmid">29723670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nlm.2018.04.018</pub-id><pub-id pub-id-type="pmcid">PMC6649660</pub-id></mixed-citation></ref><ref id="alz70748-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="alz70748-cite-0058"><string-name name-style="western"><surname>Treves</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rolls</surname><given-names>E</given-names></string-name>. <article-title>Computational constraints suggest the need for two distinct input systems to the hippocampal CA3 network</article-title>. <source>Hippocampus</source>. <year>1992</year>;<volume>2</volume>:<fpage>189</fpage>&#8208;<lpage>199</lpage>.<pub-id pub-id-type="pmid">1308182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hipo.450020209</pub-id></mixed-citation></ref><ref id="alz70748-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="alz70748-cite-0059"><string-name name-style="western"><surname>Hasselmo</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Schnell</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Barkai</surname><given-names>E</given-names></string-name>. <article-title>Dynamics of learning and recall at excitatory recurrent synapses and cholinergic modulation in rat hippocampal region CA3</article-title>. <source>J Neurosci: Offic J Soc Neurosci</source>. <year>1995</year>;<volume>15</volume>:<fpage>5249</fpage>&#8208;<lpage>5262</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.15-07-05249.1995</pub-id><pub-id pub-id-type="pmcid">PMC6577857</pub-id><pub-id pub-id-type="pmid">7623149</pub-id></mixed-citation></ref><ref id="alz70748-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="alz70748-cite-0060"><string-name name-style="western"><surname>Hopfield</surname><given-names>JJ</given-names></string-name>. <article-title>Neural networks and physical systems with emergent collective computational abilities</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1982</year>;<volume>79</volume>:<fpage>2554</fpage>&#8208;<lpage>2558</lpage>.<pub-id pub-id-type="pmid">6953413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.79.8.2554</pub-id><pub-id pub-id-type="pmcid">PMC346238</pub-id></mixed-citation></ref><ref id="alz70748-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="alz70748-cite-0061"><string-name name-style="western"><surname>Robinson</surname><given-names>NTM</given-names></string-name>, <string-name name-style="western"><surname>Descamps</surname><given-names>LAL</given-names></string-name>, <string-name name-style="western"><surname>Russell</surname><given-names>LE</given-names></string-name>, et&#160;al. <article-title>Targeted activation of hippocampal place cells drives memory&#8208;guided spatial behavior</article-title>. <source>Cell</source>. <year>2020</year>;<volume>183</volume>:<fpage>1586</fpage>&#8208;<lpage>1599</lpage>. e10.<pub-id pub-id-type="pmid">33159859</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.09.061</pub-id><pub-id pub-id-type="pmcid">PMC7754708</pub-id></mixed-citation></ref><ref id="alz70748-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="alz70748-cite-0062"><string-name name-style="western"><surname>Ramirez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>PA</given-names></string-name>, et&#160;al. <article-title>Creating a false memory in the hippocampus</article-title>. <source>Science</source>. <year>2013</year>;<volume>341</volume>:<fpage>387</fpage>&#8208;<lpage>391</lpage>.<pub-id pub-id-type="pmid">23888038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1239073</pub-id></mixed-citation></ref><ref id="alz70748-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="alz70748-cite-0063"><string-name name-style="western"><surname>Carrillo&#8208;Reid</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Akrouh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yuste</surname><given-names>R</given-names></string-name>. <article-title>Controlling visually guided behavior by holographic recalling of cortical ensembles</article-title>. <source>Cell</source>. <year>2019</year>;<volume>178</volume>:<fpage>447</fpage>&#8208;<lpage>457</lpage>. e5.<pub-id pub-id-type="pmid">31257030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2019.05.045</pub-id><pub-id pub-id-type="pmcid">PMC6747687</pub-id></mixed-citation></ref><ref id="alz70748-bib-0063"><label>63</label><mixed-citation publication-type="book" id="alz70748-cite-0064"><string-name name-style="western"><surname>Krotov</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hopfield</surname><given-names>JJ</given-names></string-name>. <part-title>Dense associative memory for pattern recognition</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Lee NS</surname><given-names>DD</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Luxburg</surname><given-names>UV</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Guyon</surname><given-names>I</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Garnett</surname><given-names>R</given-names></string-name></person-group>, eds. <source>Advances in Neural Information Processing Systems</source>. <publisher-name>Curran.: Red Hook</publisher-name>; <year>2016</year>:<fpage>1172</fpage>&#8208;<lpage>1180</lpage>.</mixed-citation></ref><ref id="alz70748-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="alz70748-cite-0065"><string-name name-style="western"><surname>Ramsauer</surname><given-names>HSB</given-names></string-name>, <string-name name-style="western"><surname>Lehner</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Seidl</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Hopfield networks is all you need</article-title>. <source>Int Conf Learn Represent</source>. 20212021.</mixed-citation></ref><ref id="alz70748-bib-0065"><label>65</label><mixed-citation publication-type="miscellaneous" id="alz70748-cite-0066"><string-name name-style="western"><surname>Nave</surname><given-names>CR</given-names></string-name>, <article-title>First order non&#8208;homogeneous differential equation</article-title>. <year>2000</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://hyperphysics.phy-astr.gsu.edu/hbase/Math/deinhom.html" ext-link-type="uri">hyperphysics.phy&#8208;astr.gsu.edu/hbase/Math/deinhom.html</ext-link></mixed-citation></ref><ref id="alz70748-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="alz70748-cite-0067"><string-name name-style="western"><surname>Vigot</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Barbieri</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Brauner&#8208;Osborne</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Differential compartmentalization and distinct functions of GABAB receptor variants</article-title>. <source>Neuron</source>. <year>2006</year>;<volume>50</volume>:<fpage>589</fpage>&#8208;<lpage>601</lpage>.<pub-id pub-id-type="pmid">16701209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2006.04.014</pub-id><pub-id pub-id-type="pmcid">PMC3531664</pub-id></mixed-citation></ref><ref id="alz70748-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="alz70748-cite-0068"><string-name name-style="western"><surname>Bold</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Baltissen</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ludewig</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>APPs&#945; rescues Tau&#8208;induced synaptic pathology</article-title>. <source>J Neurosci</source>. <year>2022</year>;<volume>42</volume>:<fpage>5782</fpage>&#8208;<lpage>5802</lpage>.<pub-id pub-id-type="pmid">35667850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.2200-21.2022</pub-id><pub-id pub-id-type="pmcid">PMC9302470</pub-id></mixed-citation></ref><ref id="alz70748-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="alz70748-cite-0069"><string-name name-style="western"><surname>Fol</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Braudeau</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ludewig</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Viral gene transfer of APPs&#945; rescues synaptic failure in an Alzheimer's disease mouse model</article-title>. <source>Acta Neuropathol</source>. <year>2016</year>;<volume>131</volume>:<fpage>247</fpage>&#8208;<lpage>266</lpage>.<pub-id pub-id-type="pmid">26538149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-015-1498-9</pub-id></mixed-citation></ref><ref id="alz70748-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="alz70748-cite-0070"><string-name name-style="western"><surname>Mockett</surname><given-names>BG</given-names></string-name>, <string-name name-style="western"><surname>Richter</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>M&#252;ller</surname><given-names>UC</given-names></string-name>. <article-title>Therapeutic potential of secreted amyloid precursor protein APPs&#945;</article-title>. <source>Front Mol Neurosci</source>. <year>2017</year>;<volume>10</volume>:<fpage>30</fpage>.<pub-id pub-id-type="pmid">28223920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnmol.2017.00030</pub-id><pub-id pub-id-type="pmcid">PMC5293819</pub-id></mixed-citation></ref><ref id="alz70748-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="alz70748-cite-0071"><string-name name-style="western"><surname>Sennvik</surname><given-names>KF</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Blomberg</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wahlund</surname><given-names>LO</given-names></string-name>, <string-name name-style="western"><surname>Winblad</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Benedikz</surname><given-names>E</given-names></string-name>. <article-title>Levels of alpha&#8208; and &#946;&#8208;secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients</article-title>. <source>Neurosci. Lett</source>. <year>2000</year>;<volume>278</volume>:<fpage>169</fpage>&#8208;<lpage>172</lpage>.<pub-id pub-id-type="pmid">10653020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0304-3940(99)00929-5</pub-id></mixed-citation></ref><ref id="alz70748-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="alz70748-cite-0072"><string-name name-style="western"><surname>Araki</surname><given-names>WKK</given-names></string-name>, <string-name name-style="western"><surname>Hattori</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tsukamoto</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Soluble APP&#8208;&#945; and APP&#8208;&#946; in cerebrospinal fluid as potential biomarkers for differential diagnosis of mild cognitive impairment</article-title>. <source>Aging Clin Exp Res</source>. <year>2021</year>;<volume>34</volume>:<fpage>341</fpage>&#8208;<lpage>347</lpage>.<pub-id pub-id-type="pmid">34283410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-021-01935-7</pub-id></mixed-citation></ref><ref id="alz70748-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="alz70748-cite-0073"><string-name name-style="western"><surname>Papaliagkas</surname><given-names>VKK</given-names></string-name>, <string-name name-style="western"><surname>Vareltzis</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Moraitou</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Papamitsou</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Chatzidimitriou</surname><given-names>M</given-names></string-name>. <article-title>CSF biomarkers in the early diagnosis of mild cognitive impairment and Alzheimer's disease</article-title>. <source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>:<fpage>8976</fpage>.<pub-id pub-id-type="pmid">37240322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24108976</pub-id><pub-id pub-id-type="pmcid">PMC10218948</pub-id></mixed-citation></ref><ref id="alz70748-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="alz70748-cite-0074"><string-name name-style="western"><surname>Pereira Vatanabe</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Peron</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mantellatto Grigoli</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>ADAM10 Plasma and CSF levels are increased in mild Alzheimer's disease</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>:<fpage>2416</fpage>.<pub-id pub-id-type="pmid">33670873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22052416</pub-id><pub-id pub-id-type="pmcid">PMC7957802</pub-id></mixed-citation></ref><ref id="alz70748-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="alz70748-cite-0075"><string-name name-style="western"><surname>Kim</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Suh</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Romano</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Potential late&#8208;onset Alzheimer's disease&#8208;associated mutations in the ADAM10 gene attenuate alpha&#8208;secretase activity</article-title>. <source>Hum Mol Genet</source>. <year>2009</year>;<volume>18</volume>:<fpage>3987</fpage>&#8208;<lpage>3996</lpage>.<pub-id pub-id-type="pmid">19608551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/hmg/ddp323</pub-id><pub-id pub-id-type="pmcid">PMC2748890</pub-id></mixed-citation></ref><ref id="alz70748-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="alz70748-cite-0076"><string-name name-style="western"><surname>Salazar</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Leisgang</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Ortiz</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Murtishaw</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Kinney</surname><given-names>JW</given-names></string-name>. <article-title>Alterations of GABA B receptors in the APP/PS1 mouse model of Alzheimer's disease</article-title>. <source>Neurobiol Aging</source>. <year>2021</year>;<volume>97</volume>:<fpage>129</fpage>&#8208;<lpage>143</lpage>.<pub-id pub-id-type="pmid">33232936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2020.10.013</pub-id></mixed-citation></ref><ref id="alz70748-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="alz70748-cite-0077"><string-name name-style="western"><surname>Chandra</surname><given-names>SSS</given-names></string-name>, <string-name name-style="western"><surname>Chaudhuri</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fiete</surname><given-names>I</given-names></string-name>. <article-title>Episodic and associative memory from spatial scaffolds in the hippocampus</article-title>. <source>Nature</source>. <year>2025</year>;<volume>638</volume>:<fpage>739</fpage>&#8208;<lpage>751</lpage>.<pub-id pub-id-type="pmid">39814883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-08392-y</pub-id></mixed-citation></ref><ref id="alz70748-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="alz70748-cite-0078"><string-name name-style="western"><surname>Pilly</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Howard</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Bhattacharyya</surname><given-names>R</given-names></string-name>. <article-title>Modeling contextual modulation of memory associations in the hippocampus</article-title>. <source>Front Hum Neurosci</source>. <year>2018</year>;<volume>12</volume>:<fpage>442</fpage>.<pub-id pub-id-type="pmid">30473660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnhum.2018.00442</pub-id><pub-id pub-id-type="pmcid">PMC6237880</pub-id></mixed-citation></ref><ref id="alz70748-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="alz70748-cite-0079"><string-name name-style="western"><surname>Kaneki</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Araki</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Tsukada</surname><given-names>M</given-names></string-name>. <article-title>Dual synaptic plasticity in the hippocampus: Hebbian and spatiotemporal learning dynamics</article-title>. <source>Cogn Neurodyn</source>. <year>2009</year>;<volume>3</volume>:<fpage>153</fpage>&#8208;<lpage>163</lpage>.<pub-id pub-id-type="pmid">19034691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11571-008-9071-z</pub-id><pub-id pub-id-type="pmcid">PMC2678199</pub-id></mixed-citation></ref><ref id="alz70748-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="alz70748-cite-0080"><string-name name-style="western"><surname>Nabavi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Proulx</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Tsien</surname><given-names>RY</given-names></string-name>, <string-name name-style="western"><surname>Malinow</surname><given-names>R</given-names></string-name>. <article-title>Engineering a memory with LTD and LTP</article-title>. <source>Nature</source>. <year>2014</year>;<volume>511</volume>:<fpage>348</fpage>&#8208;<lpage>352</lpage>.<pub-id pub-id-type="pmid">24896183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature13294</pub-id><pub-id pub-id-type="pmcid">PMC4210354</pub-id></mixed-citation></ref><ref id="alz70748-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="alz70748-cite-0081"><string-name name-style="western"><surname>Nakazawa</surname><given-names>KSL</given-names></string-name>, <string-name name-style="western"><surname>Quirk</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Rondi&#8208;Reig</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Tonegawa</surname><given-names>S</given-names></string-name>. <article-title>Hippocampal CA3 NMDA receptors are crucial for memory acquisition of one&#8208;time experience</article-title>. <source>Neuron</source>. <year>2003</year>;<volume>38</volume>:<fpage>305</fpage>&#8208;<lpage>315</lpage>.<pub-id pub-id-type="pmid">12718863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0896-6273(03)00165-x</pub-id></mixed-citation></ref><ref id="alz70748-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="alz70748-cite-0082"><string-name name-style="western"><surname>Roberts</surname><given-names>WAMH</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Macpherson</surname><given-names>K</given-names></string-name>. <article-title>Release from proactive interference in rat spatial working memory</article-title>. <source>Learn Behav</source>. <year>2017</year>;<volume>45</volume>:<fpage>263</fpage>&#8208;<lpage>275</lpage>.<pub-id pub-id-type="pmid">28364365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3758/s13420-017-0263-4</pub-id></mixed-citation></ref><ref id="alz70748-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="alz70748-cite-0083"><string-name name-style="western"><surname>Chan</surname><given-names>MEM</given-names></string-name>, <string-name name-style="western"><surname>Sanderson</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Easton</surname><given-names>A</given-names></string-name>. <article-title>Continual trials spontaneous recognition tasks in mice: reducing animal numbers and improving our understanding of the mechanisms underlying memory</article-title>. <source>Front Behav Neurosci</source>. <year>2018</year>;<volume>12</volume>:<fpage>214</fpage>.<pub-id pub-id-type="pmid">30271334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnbeh.2018.00214</pub-id><pub-id pub-id-type="pmcid">PMC6146106</pub-id></mixed-citation></ref><ref id="alz70748-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="alz70748-cite-0084"><string-name name-style="western"><surname>Bakker</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Krauss</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Albert</surname><given-names>MS</given-names></string-name>, et&#160;al. <article-title>Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment</article-title>. <source>Neuron</source>. <year>2012</year>;<volume>74</volume>:<fpage>467</fpage>&#8208;<lpage>474</lpage>.<pub-id pub-id-type="pmid">22578498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2012.03.023</pub-id><pub-id pub-id-type="pmcid">PMC3351697</pub-id></mixed-citation></ref><ref id="alz70748-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="alz70748-cite-0085"><string-name name-style="western"><surname>Leal</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Landau</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Jagust</surname><given-names>WJ</given-names></string-name>. <article-title>Hippocampal activation is associated with longitudinal amyloid accumulation and cognitive decline</article-title>. <source>eLife</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e22978</elocation-id>.<pub-id pub-id-type="pmid">28177283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.22978</pub-id><pub-id pub-id-type="pmcid">PMC5325620</pub-id></mixed-citation></ref><ref id="alz70748-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="alz70748-cite-0086"><string-name name-style="western"><surname>Sperling</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>LaViolette</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>O'Keefe</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Amyloid deposition is associated with impaired default network function in older persons without dementia</article-title>. <source>Neuron</source>. <year>2009</year>;<volume>63</volume>:<fpage>178</fpage>&#8208;<lpage>188</lpage>.<pub-id pub-id-type="pmid">19640477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2009.07.003</pub-id><pub-id pub-id-type="pmcid">PMC2738994</pub-id></mixed-citation></ref><ref id="alz70748-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="alz70748-cite-0087"><string-name name-style="western"><surname>Vossel</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Tartaglia</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Nygaard</surname><given-names>HB</given-names></string-name>, <string-name name-style="western"><surname>Zeman</surname><given-names>AZ</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>BL</given-names></string-name>. <article-title>Epileptic activity in Alzheimer's disease: causes and clinical relevance</article-title>. <source>Lancet</source>. <year>2017</year>;<volume>16</volume>:<fpage>311</fpage>&#8208;<lpage>322</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(17)30044-3</pub-id><pub-id pub-id-type="pmcid">PMC5973551</pub-id><pub-id pub-id-type="pmid">28327340</pub-id></mixed-citation></ref><ref id="alz70748-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="alz70748-cite-0088"><string-name name-style="western"><surname>Scharfman</surname><given-names>HE</given-names></string-name>. <article-title>Alzheimer's disease and epilepsy: insight from animal models</article-title>. <source>Future Neurology</source>. <year>2012</year>;<volume>7</volume>:<fpage>177</fpage>&#8208;<lpage>192</lpage>.<pub-id pub-id-type="pmid">22723738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fnl.12.8</pub-id><pub-id pub-id-type="pmcid">PMC3378058</pub-id></mixed-citation></ref><ref id="alz70748-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="alz70748-cite-0089"><string-name name-style="western"><surname>Styr</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Slutsky</surname><given-names>I</given-names></string-name>. <article-title>Imbalance between firing homeostasis and synaptic plasticity drives early&#8208;phase Alzheimer's disease</article-title>. <source>Nat Neurosci</source>. <year>2018</year>;<volume>21</volume>:<fpage>463</fpage>&#8208;<lpage>473</lpage>.<pub-id pub-id-type="pmid">29403035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41593-018-0080-x</pub-id><pub-id pub-id-type="pmcid">PMC6533171</pub-id></mixed-citation></ref><ref id="alz70748-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="alz70748-cite-0090"><string-name name-style="western"><surname>Arendt</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jurado</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Malenka</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Sudhof</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>. <article-title>Retinoic acid and LTP recruit postsynaptic AMPA receptors using distinct SNARE&#8208;dependent mechanisms</article-title>. <source>Neuron</source>. <year>2015</year>;<volume>86</volume>:<fpage>442</fpage>&#8208;<lpage>456</lpage>.<pub-id pub-id-type="pmid">25843403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2015.03.009</pub-id><pub-id pub-id-type="pmcid">PMC4578641</pub-id></mixed-citation></ref><ref id="alz70748-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="alz70748-cite-0091"><string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>. <article-title>Homeostatic synaptic plasticity as a metaplasticity mechanism&#8212;a molecular and cellular perspective</article-title>. <source>Curr Opin Neurobiol</source>. <year>2019</year>;<volume>54</volume>:<fpage>44</fpage>&#8208;<lpage>53</lpage>.<pub-id pub-id-type="pmid">30212714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.conb.2018.08.010</pub-id><pub-id pub-id-type="pmcid">PMC6361678</pub-id></mixed-citation></ref><ref id="alz70748-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="alz70748-cite-0092"><string-name name-style="western"><surname>Rozenfeld</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ehmann</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Manoim</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Kittel</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Parnas</surname><given-names>M</given-names></string-name>. <article-title>Homeostatic synaptic plasticity rescues neural coding reliability</article-title>. <source>Nat Commun</source>. <year>2023</year>;<volume>14</volume>:<fpage>2993</fpage>.<pub-id pub-id-type="pmid">37225688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-38575-6</pub-id><pub-id pub-id-type="pmcid">PMC10209050</pub-id></mixed-citation></ref><ref id="alz70748-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="alz70748-cite-0093"><string-name name-style="western"><surname>Jeanne</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>RI</given-names></string-name>. <article-title>Convergence, divergence, and reconvergence in a feedforward network improves neural speed and accuracy</article-title>. <source>Neuron</source>. <year>2015</year>;<volume>88</volume>:<fpage>1014</fpage>&#8208;<lpage>1026</lpage>.<pub-id pub-id-type="pmid">26586183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2015.10.018</pub-id><pub-id pub-id-type="pmcid">PMC5488793</pub-id></mixed-citation></ref><ref id="alz70748-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="alz70748-cite-0094"><string-name name-style="western"><surname>Shankar</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mehta</surname><given-names>TH</given-names></string-name>, et&#160;al. <article-title>Amyloid&#8208;beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory</article-title>. <source>Nat Med</source>. <year>2008</year>;<volume>14</volume>:<fpage>837</fpage>&#8208;<lpage>842</lpage>.<pub-id pub-id-type="pmid">18568035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1782</pub-id><pub-id pub-id-type="pmcid">PMC2772133</pub-id></mixed-citation></ref><ref id="alz70748-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="alz70748-cite-0095"><string-name name-style="western"><surname>Li</surname><given-names>SJM</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ostaszewski</surname><given-names>BL</given-names></string-name>. <article-title>Selkoe DJ. Decoding the synaptic dysfunction of bioactive human AD brain soluble A&#946; to inspire novel therapeutic avenues for Alzheimer's disease</article-title>. <source>Acta Neuropathol Commun</source>. <year>2018</year>;<volume>8</volume>:<fpage>121</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-018-0626-x</pub-id><pub-id pub-id-type="pmcid">PMC6225562</pub-id><pub-id pub-id-type="pmid">30409172</pub-id></mixed-citation></ref><ref id="alz70748-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="alz70748-cite-0096"><string-name name-style="western"><surname>Walsh</surname><given-names>DMKI</given-names></string-name>, <string-name name-style="western"><surname>Fadeeva</surname><given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Cullen</surname><given-names>WK</given-names></string-name>, et&#160;al. <article-title>Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long&#8208;term potentiation in vivo</article-title>. <source>Nature</source>. <year>2002</year>;<volume>416</volume>:<fpage>535</fpage>&#8208;<lpage>539</lpage>.<pub-id pub-id-type="pmid">11932745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/416535a</pub-id></mixed-citation></ref><ref id="alz70748-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="alz70748-cite-0097"><string-name name-style="western"><surname>Abramov</surname><given-names>EDI</given-names></string-name>, <string-name name-style="western"><surname>Fogel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ciccotosto</surname><given-names>GD</given-names></string-name>, <string-name name-style="western"><surname>Ruff</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Slutsky</surname><given-names>I</given-names></string-name>. <article-title>Amyloid&#8208;&#946; as a positive endogenous regulator of release probability at hippocampal synapses</article-title>. <source>Nat Neurosci</source>. <year>2009</year>;<volume>12</volume>:<fpage>1567</fpage>&#8208;<lpage>1576</lpage>.<pub-id pub-id-type="pmid">19935655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.2433</pub-id></mixed-citation></ref><ref id="alz70748-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="alz70748-cite-0098"><string-name name-style="western"><surname>Grienberger</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rochefort</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Adelsberger</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease</article-title>. <source>Nature Commun</source>. <year>2012</year>;<volume>3</volume>:<fpage>774</fpage>.<pub-id pub-id-type="pmid">22491322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms1783</pub-id><pub-id pub-id-type="pmcid">PMC3337977</pub-id></mixed-citation></ref><ref id="alz70748-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="alz70748-cite-0099"><string-name name-style="western"><surname>Harris</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Wolf</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>De Strooper</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Busche</surname><given-names>MA</given-names></string-name>. <article-title>Tipping the Scales: peptide&#8208;Dependent Dysregulation of Neural Circuit Dynamics in Alzheimer's Disease</article-title>. <source>Neuron</source>. <year>2020</year>;<volume>107</volume>:<fpage>417</fpage>&#8208;<lpage>435</lpage>.<pub-id pub-id-type="pmid">32579881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2020.06.005</pub-id></mixed-citation></ref><ref id="alz70748-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="alz70748-cite-0100"><string-name name-style="western"><surname>Busche</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Henning</surname><given-names>HA</given-names></string-name>, et&#160;al. <article-title>Critical role of soluble amyloid&#8208;beta for early hippocampal hyperactivity in a mouse model of Alzheimer's disease</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2012</year>;<volume>109</volume>:<fpage>8740</fpage>&#8208;<lpage>8745</lpage>.<pub-id pub-id-type="pmid">22592800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1206171109</pub-id><pub-id pub-id-type="pmcid">PMC3365221</pub-id></mixed-citation></ref><ref id="alz70748-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="alz70748-cite-0101"><string-name name-style="western"><surname>Zott</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Simon</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>A vicious cycle of amyloid beta&#8208;dependent neuronal hyperactivation</article-title>. <source>Science</source>. <year>2019</year>;<volume>365</volume>:<fpage>559</fpage>&#8208;<lpage>565</lpage>.<pub-id pub-id-type="pmid">31395777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aay0198</pub-id><pub-id pub-id-type="pmcid">PMC6690382</pub-id></mixed-citation></ref><ref id="alz70748-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="alz70748-cite-0102"><string-name name-style="western"><surname>Bastin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bahri</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Mievis</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>Associative memory and its cerebral correlates in Alzheimer's disease: evidence for distinct deficits of relational and conjunctive memory</article-title>. <source>Neuropsychologia</source>. <year>2014</year>;<volume>63</volume>:<fpage>99</fpage>&#8208;<lpage>106</lpage>.<pub-id pub-id-type="pmid">25172390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuropsychologia.2014.08.023</pub-id><pub-id pub-id-type="pmcid">PMC4194129</pub-id></mixed-citation></ref><ref id="alz70748-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="alz70748-cite-0103"><string-name name-style="western"><surname>Polcher</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Frommann</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Koppara</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wolfsgruber</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jessen</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wagner</surname><given-names>M</given-names></string-name>. <article-title>Face&#8208;name associative recognition deficits in subjective cognitive decline and mild cognitive impairment</article-title>. <source>J Alzheimers Dis</source>. <year>2017</year>;<volume>56</volume>:<fpage>1185</fpage>&#8208;<lpage>1196</lpage>.<pub-id pub-id-type="pmid">28106560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-160637</pub-id></mixed-citation></ref><ref id="alz70748-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="alz70748-cite-0104"><string-name name-style="western"><surname>Ault</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Nadler</surname><given-names>JV</given-names></string-name>. <article-title>Baclofen selectively inhibits transmission at synapses made by axons of CA3 pyramidal cells in the hippocampal slice</article-title>. <source>J Pharmacol Experiment Therapeut</source>. <year>1982</year>;<volume>223</volume>:<fpage>291</fpage>&#8208;<lpage>297</lpage>.<pub-id pub-id-type="pmid">6290635</pub-id></mixed-citation></ref><ref id="alz70748-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="alz70748-cite-0105"><string-name name-style="western"><surname>Lanthorn</surname><given-names>TH</given-names></string-name>, <string-name name-style="western"><surname>Cotman</surname><given-names>CW</given-names></string-name>. <article-title>Baclofen selectively inhibits excitatory synaptic transmission in the hippocampus</article-title>. <source>Brain Res</source>. <year>1981</year>;<volume>225</volume>:<fpage>171</fpage>&#8208;<lpage>178</lpage>.<pub-id pub-id-type="pmid">6271336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-8993(81)90326-7</pub-id></mixed-citation></ref><ref id="alz70748-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="alz70748-cite-0106"><string-name name-style="western"><surname>Tang</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Hasselmo</surname><given-names>ME</given-names></string-name>. <article-title>Selective suppression of intrinsic but not afferent fiber synaptic transmission by baclofen in the piriform (olfactory) cortex</article-title>. <source>Brain Res</source>. <year>1994</year>;<volume>659</volume>:<fpage>75</fpage>&#8208;<lpage>81</lpage>.<pub-id pub-id-type="pmid">7820683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0006-8993(94)90865-6</pub-id></mixed-citation></ref><ref id="alz70748-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="alz70748-cite-0107"><string-name name-style="western"><surname>Hasselmo</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Fehlau</surname><given-names>BP</given-names></string-name>. <article-title>Differences in time course of ACh and GABA modulation of excitatory synaptic potentials in slices of rat hippocampus</article-title>. <source>J Neurophysiol</source>. <year>2001</year>;<volume>86</volume>:<fpage>1792</fpage>&#8208;<lpage>1802</lpage>.<pub-id pub-id-type="pmid">11600640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/jn.2001.86.4.1792</pub-id></mixed-citation></ref><ref id="alz70748-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="alz70748-cite-0108"><string-name name-style="western"><surname>Chumakov</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Nabirotchkin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cholet</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy</article-title>. <source>Scientific Reports</source>. <year>2015</year>;<volume>5</volume>:<fpage>7608</fpage>.<pub-id pub-id-type="pmid">25566747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep07608</pub-id><pub-id pub-id-type="pmcid">PMC5378993</pub-id></mixed-citation></ref><ref id="alz70748-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="alz70748-cite-0109"><string-name name-style="western"><surname>Dasari</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gulledge</surname><given-names>AT</given-names></string-name>. <article-title>M1 and M4 receptors modulate hippocampal pyramidal neurons</article-title>. <source>J Neurophysiol</source>. <year>2011</year>;<volume>105</volume>:<fpage>779</fpage>&#8208;<lpage>792</lpage>.<pub-id pub-id-type="pmid">21160001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/jn.00686.2010</pub-id><pub-id pub-id-type="pmcid">PMC3059175</pub-id></mixed-citation></ref><ref id="alz70748-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="alz70748-cite-0110"><string-name name-style="western"><surname>Thorn</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Popiolek</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stark</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Edgerton</surname><given-names>JR</given-names></string-name>. <article-title>Effects of M1 and M4 activation on excitatory synaptic transmission in CA1</article-title>. <source>Hippocampus</source>. <year>2017</year>;<volume>27</volume>:<fpage>794</fpage>&#8208;<lpage>810</lpage>.<pub-id pub-id-type="pmid">28422371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hipo.22732</pub-id><pub-id pub-id-type="pmcid">PMC5573954</pub-id></mixed-citation></ref><ref id="alz70748-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="alz70748-cite-0111"><string-name name-style="western"><surname>Hasselmo</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Bower</surname><given-names>JM</given-names></string-name>. <article-title>Cholinergic suppression specific to intrinsic not afferent fiber synapses in rat piriform (olfactory) cortex</article-title>. <source>J Neurophysiol</source>. <year>1992</year>;<volume>67</volume>:<fpage>1222</fpage>&#8208;<lpage>1229</lpage>.<pub-id pub-id-type="pmid">1597708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/jn.1992.67.5.1222</pub-id></mixed-citation></ref><ref id="alz70748-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="alz70748-cite-0112"><string-name name-style="western"><surname>Levey</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Edmunds</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Koliatsos</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Wiley</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Heilman</surname><given-names>CJ</given-names></string-name>. <article-title>Expression of m1&#8208;m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation</article-title>. <source>J Neurosci</source>. <year>1995</year>;<volume>15</volume>:<fpage>4077</fpage>&#8208;<lpage>4092</lpage>.<pub-id pub-id-type="pmid">7751967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.15-05-04077.1995</pub-id><pub-id pub-id-type="pmcid">PMC6578239</pub-id></mixed-citation></ref><ref id="alz70748-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="alz70748-cite-0113"><string-name name-style="western"><surname>Rouse</surname><given-names>ST</given-names></string-name>, <string-name name-style="western"><surname>Gilmor</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Levey</surname><given-names>AI</given-names></string-name>. <article-title>Differential presynaptic and postsynaptic expression of m1&#8208;m4 muscarinic acetylcholine receptors at the perforant pathway/granule cell synapse</article-title>. <source>Neuroscience</source>. <year>1998</year>;<volume>86</volume>:<fpage>221</fpage>&#8208;<lpage>232</lpage>.<pub-id pub-id-type="pmid">9692756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0306-4522(97)00681-7</pub-id></mixed-citation></ref><ref id="alz70748-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="alz70748-cite-0114"><string-name name-style="western"><surname>Shirey</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Orton</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission</article-title>. <source>Nat Chem Biol</source>. <year>2008</year>;<volume>4</volume>:<fpage>42</fpage>&#8208;<lpage>50</lpage>.<pub-id pub-id-type="pmid">18059262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchembio.2007.55</pub-id></mixed-citation></ref><ref id="alz70748-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="alz70748-cite-0115"><string-name name-style="western"><surname>Kennedy</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Bridges</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Gentry</surname><given-names>PR</given-names></string-name>, et&#160;al. <article-title>Synthesis and structure&#8208;activity relationships of allosteric potentiators of the m(4) muscarinic acetylcholine receptor</article-title>. <source>ChemMedChem</source>. <year>2009</year>;<volume>4</volume>:<fpage>1600</fpage>&#8208;<lpage>1607</lpage>.<pub-id pub-id-type="pmid">19705385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cmdc.200900231</pub-id><pub-id pub-id-type="pmcid">PMC2887613</pub-id></mixed-citation></ref><ref id="alz70748-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="alz70748-cite-0116"><string-name name-style="western"><surname>Atri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sherman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Norman</surname><given-names>KA</given-names></string-name>, et&#160;al. <article-title>Blockade of central cholinergic receptors impairs new learning and increases proactive interference in a word paired&#8208;associate memory task</article-title>. <source>Behav Neurosci</source>. <year>2004</year>;<volume>118</volume>:<fpage>223</fpage>&#8208;<lpage>236</lpage>.<pub-id pub-id-type="pmid">14979800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/0735-7044.118.1.223</pub-id></mixed-citation></ref><ref id="alz70748-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="alz70748-cite-0117"><string-name name-style="western"><surname>Blumenfeld</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Preminger</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sagi</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tsodyks</surname><given-names>M</given-names></string-name>. <article-title>Dynamics of memory representations in networks with novelty&#8208;facilitated synaptic plasticity</article-title>. <source>Neuron</source>. <year>2006</year>;<volume>52</volume>:<fpage>383</fpage>&#8208;<lpage>394</lpage>.<pub-id pub-id-type="pmid">17046699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2006.08.016</pub-id></mixed-citation></ref><ref id="alz70748-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="alz70748-cite-0118"><string-name name-style="western"><surname>Popiolek</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mandelblat&#8208;Cerf</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>In vivo modulation of hippocampal excitability by M4 muscarinic acetylcholine receptor activator: implications for treatment of Alzheimer's disease and Schizophrenic patients</article-title>. <source>ACS Chem Neurosci</source>. <year>2019</year>;<volume>10</volume>:<fpage>1091</fpage>&#8208;<lpage>1098</lpage>.<pub-id pub-id-type="pmid">30335349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschemneuro.8b00496</pub-id></mixed-citation></ref><ref id="alz70748-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="alz70748-cite-0119"><string-name name-style="western"><surname>Hamilton</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vasefi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vander Tuin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>McQuaid</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Anisman</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ferguson</surname><given-names>SS</given-names></string-name>. <article-title>Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an Alzheimer disease mouse model</article-title>. <source>Cell Rep</source>. <year>2016</year>;<volume>15</volume>:<fpage>1859</fpage>&#8208;<lpage>1865</lpage>.<pub-id pub-id-type="pmid">27210751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2016.04.077</pub-id></mixed-citation></ref><ref id="alz70748-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="alz70748-cite-0120"><string-name name-style="western"><surname>Kukaj</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sattler</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zimmer</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Schmauder</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Benndorf</surname><given-names>K</given-names></string-name>. <article-title>Kinetic fingerprinting of metabotropic glutamate receptors</article-title>. <source>Commun Biol</source>. <year>2023</year>;<volume>6</volume>:<fpage>104</fpage>.<pub-id pub-id-type="pmid">36707695</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-023-04468-z</pub-id><pub-id pub-id-type="pmcid">PMC9883448</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Digit Health</journal-id><journal-id journal-id-type="iso-abbrev">Digit Health</journal-id><journal-id journal-id-type="pmc-domain-id">3398</journal-id><journal-id journal-id-type="pmc-domain">dghealth</journal-id><journal-id journal-id-type="publisher-id">DHJ</journal-id><journal-title-group><journal-title>Digital Health</journal-title></journal-title-group><issn pub-type="epub">2055-2076</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12480803</article-id><article-id pub-id-type="pmcid-ver">PMC12480803.1</article-id><article-id pub-id-type="pmcaid">12480803</article-id><article-id pub-id-type="pmcaiid">12480803</article-id><article-id pub-id-type="pmid">41036435</article-id><article-id pub-id-type="doi">10.1177/20552076251380065</article-id><article-id pub-id-type="publisher-id">10.1177_20552076251380065</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Protocol</subject></subj-group></article-categories><title-group><article-title>Identifying digital phenotypes of risk for Alzheimer's disease and related dementia among Hispanic/Latino persons living in the United States: A protocol for a prospective quantitative study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Moore</surname><given-names initials="RC">Raeanne C.</given-names></name><xref rid="aff1-20552076251380065" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-9307-7623</contrib-id><name name-style="western"><surname>Nakahira</surname><given-names initials="S">Shay</given-names></name><xref rid="aff1-20552076251380065" ref-type="aff">1</xref><xref rid="aff2-20552076251380065" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3678-5888</contrib-id><name name-style="western"><surname>Gallo</surname><given-names initials="LC">Linda C.</given-names></name><xref rid="aff3-20552076251380065" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7964-7808</contrib-id><name name-style="western"><surname>Demos</surname><given-names initials="AP">Alexander P.</given-names></name><xref rid="aff4-20552076251380065" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sundermann</surname><given-names initials="EE">E. E.</given-names></name><xref rid="aff1-20552076251380065" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Galasko</surname><given-names initials="D">Douglas</given-names></name><xref rid="aff5-20552076251380065" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Delano-Wood</surname><given-names initials="L">Lisa</given-names></name><xref rid="aff1-20552076251380065" ref-type="aff">1</xref><xref rid="aff6-20552076251380065" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Perez</surname><given-names initials="M">Martha</given-names></name><xref rid="aff1-20552076251380065" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-3863-0972</contrib-id><name name-style="western"><surname>Betancourt</surname><given-names initials="LR">Luis Ricardo</given-names></name><xref rid="aff1-20552076251380065" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Churchill</surname><given-names initials="EG">Emma G.</given-names></name><xref rid="aff1-20552076251380065" ref-type="aff">1</xref><xref rid="aff7-20552076251380065" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Portillo</surname><given-names initials="K">Kassandra</given-names></name><xref rid="aff1-20552076251380065" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-2276-3003</contrib-id><name name-style="western"><surname>Rocha</surname><given-names initials="P">Perla</given-names></name><xref rid="aff3-20552076251380065" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mendoza</surname><given-names initials="P">Paulina</given-names></name><xref rid="aff3-20552076251380065" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0004-6706-8883</contrib-id><name name-style="western"><surname>Scandalis</surname><given-names initials="L">Lina</given-names></name><xref rid="aff8-20552076251380065" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Daly</surname><given-names initials="R">Rebecca</given-names></name><xref rid="aff1-20552076251380065" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2249-6628</contrib-id><name name-style="western"><surname>Marquine</surname><given-names initials="MJ">Mar&#237;a J.</given-names></name><xref rid="aff9-20552076251380065" ref-type="aff">9</xref><xref rid="aff10-20552076251380065" ref-type="aff">10</xref><xref rid="corresp1-20552076251380065" ref-type="corresp"/></contrib></contrib-group><aff id="aff1-20552076251380065">
<label>1</label>Department of Psychiatry, <institution-wrap><institution-id institution-id-type="Ringgold">8784</institution-id><institution content-type="university">University of California San Diego</institution></institution-wrap>, San Diego, CA, USA</aff><aff id="aff2-20552076251380065">
<label>2</label>John A. Burns School of Medicine, <institution-wrap><institution-id institution-id-type="Ringgold">3949</institution-id><institution content-type="university">University of Hawai&#8217;i at Manoa</institution></institution-wrap>, Honolulu, HI, USA</aff><aff id="aff3-20552076251380065">
<label>3</label>Department of Psychology, College of Sciences, <institution-wrap><institution-id institution-id-type="Ringgold">7117</institution-id><institution content-type="university">San Diego State University</institution></institution-wrap>, San Diego, CA, USA</aff><aff id="aff4-20552076251380065">
<label>4</label>Department of Psychology, <institution-wrap><institution-id institution-id-type="Ringgold">14681</institution-id><institution content-type="university">University of Illinois Chicago</institution></institution-wrap>, Chicago, IL, USA</aff><aff id="aff5-20552076251380065">
<label>5</label>Department of Neurosciences, <institution-wrap><institution-id institution-id-type="Ringgold">8784</institution-id><institution content-type="university">University of California San Diego</institution></institution-wrap>, San Diego, CA, USA</aff><aff id="aff6-20552076251380065">
<label>6</label>VA San Diego Healthcare System, San Diego, CA, USA</aff><aff id="aff7-20552076251380065">
<label>7</label>University of Central Florida, Orlando, FL, USA</aff><aff id="aff8-20552076251380065">
<label>8</label>Department of Medicine, <institution-wrap><institution-id institution-id-type="Ringgold">8784</institution-id><institution content-type="university">University of California San Diego</institution></institution-wrap>, San Diego, CA, USA</aff><aff id="aff9-20552076251380065">
<label>9</label>Department of Medicine, Duke University, Durham, NC, USA</aff><aff id="aff10-20552076251380065">
<label>10</label>Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA</aff><author-notes><corresp id="corresp1-20552076251380065">Mar&#237;a J Marquine, Duke University School of Medicine, Box 3003, DUMC, Durham, NC 27710, USA. 
Email: <email>maria.marquine@duke.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2025</year></pub-date><volume>11</volume><issue-id pub-id-type="pmc-issue-id">478303</issue-id><elocation-id>20552076251380065</elocation-id><history><date date-type="received"><day>25</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 09:25:35.093"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd, unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NoDerivs 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>) which permits any use, reproduction and distribution of the work as published without adaptation or alteration, provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_20552076251380065.pdf"/><abstract><sec><title>Objective</title><p>Hispanic/Latino/a/x (hereafter Latino) persons living in the U.S. are at increased risk for Alzheimer's disease and related dementias (ADRD) compared to non-Latino Whites. Early detection of preclinical changes is crucial. The SALUD-Tech study aims to identify digital behavioral markers&#8212;&#8220;digital signatures&#8221;&#8212;of ADRD risk in diverse middle-aged and older Latinos using passive data from smartphones and smartwatches.</p></sec><sec><title>Methods</title><p>Participants include Latino adults aged 50&#8211;70 years living in southern California, with varying degrees of ADRD risk as defined by the presence of mild cognitive impairment and cardiovascular disease risk. Data collection began in April 2022 and will continue through 2026. Participants complete comprehensive laboratory assessments (neurobehavioral, medical, sociocultural, and psychiatric assessments). High-frequency data on sensors, keyboard dynamics, and phone use activity are collected for 30 days following the baseline visit. A subset of study participants completes 18- and 36-month longitudinal assessments; these participants are selected based on risk profiles and retention likelihood. All data are securely encrypted, de-identified, and collected respecting participant privacy and consent in accordance with ethical standards. Data analysis involves integrating multimodal data streams using machine learning to identify behavioral patterns associated with early cognitive decline.</p></sec><sec><title>Results</title><p>We anticipate 300 participants will be enrolled in the study. Study results will be published in peer-reviewed scientific journals.</p></sec><sec><title>Discussion</title><p>Early detection of ADRD risk using smartphone and wearable data could help reduce disparities by providing a low-cost, accessible tool. Ultimately, this approach may be integrated into clinical care to enable earlier interventions and reduce healthcare costs.</p></sec></abstract><kwd-group><kwd>Neurocognitive disorder</kwd><kwd>cognitive decline</kwd><kwd>wearable electronic devices</kwd><kwd>smartphone</kwd><kwd>geographic information system</kwd><kwd>remote sensing technology</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-20552076251380065"><funding-source id="funding1-20552076251380065"><institution-wrap><institution>National Institute on Aging</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000049</institution-id></institution-wrap></funding-source><award-id rid="funding1-20552076251380065">K24AG075240</award-id><award-id rid="funding1-20552076251380065">R01AG070956</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts19</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="section1-20552076251380065"><title>Introduction</title><p>Alzheimer's disease (AD) is a progressive neurodegenerative disorder that poses a significant health challenge worldwide.<sup>
<xref rid="bibr1-20552076251380065" ref-type="bibr">1</xref>
</sup> Hispanic/Latino/a/x (hereafter Latino) persons living in the United States are at increased risk for mild cognitive impairment (MCI) and Alzheimer's Disease and Related Dementias (ADRDs) compared to non-Latino White persons.<sup><xref rid="bibr2-20552076251380065" ref-type="bibr">2</xref><xref rid="bibr3-20552076251380065" ref-type="bibr"/>&#8211;<xref rid="bibr4-20552076251380065" ref-type="bibr">4</xref></sup> The number of Latino adults with AD is expected to increase to 3.5 million by 2060,<sup>
<xref rid="bibr5-20552076251380065" ref-type="bibr">5</xref>
</sup> which represents a growth of 832% relative to 2012.<sup>
<xref rid="bibr5-20552076251380065" ref-type="bibr">5</xref>
</sup> Yet, Latino persons continue to be underrepresented in research studies, with a median of 2% of participants in clinical research funded by the National Institute on Aging self-identifying as Latino in 2023.<sup>
<xref rid="bibr6-20552076251380065" ref-type="bibr">6</xref>
</sup></p><p>Alzheimer's disease&#8211;related brain changes can begin&#8201;&#8805;&#8201;20 years before clinical symptoms occur, and the likelihood of staving off anatomic and physiologic changes decreases dramatically with disease advancement.<sup><xref rid="bibr7-20552076251380065" ref-type="bibr">7</xref>,<xref rid="bibr8-20552076251380065" ref-type="bibr">8</xref></sup> Early disease risk detection is crucial to maximize the impact of interventions, particularly as new pathology-modifying therapies emerge.<sup><xref rid="bibr9-20552076251380065" ref-type="bibr">9</xref><xref rid="bibr10-20552076251380065" ref-type="bibr"/><xref rid="bibr11-20552076251380065" ref-type="bibr"/>&#8211;<xref rid="bibr12-20552076251380065" ref-type="bibr">12</xref></sup> This is especially important for Latino persons, who generally experience an earlier onset of AD symptoms,<sup><xref rid="bibr13-20552076251380065" ref-type="bibr">13</xref><xref rid="bibr14-20552076251380065" ref-type="bibr"/><xref rid="bibr15-20552076251380065" ref-type="bibr"/>&#8211;<xref rid="bibr16-20552076251380065" ref-type="bibr">16</xref></sup> and are diagnosed at more advanced stages<sup>
<xref rid="bibr16-20552076251380065" ref-type="bibr">16</xref>
</sup> compared to other ethnic groups. While there has been increased focus on the use of biological markers for early detection of AD,<sup>
<xref rid="bibr17-20552076251380065" ref-type="bibr">17</xref>
</sup> research on these biomarkers among the U.S. Latino population has greatly lagged behind that of the majority non-Latino White population.<sup>
<xref rid="bibr18-20552076251380065" ref-type="bibr">18</xref>
</sup></p><p>Emerging research suggests digital markers can identify individuals at risk for developing ADRD.<sup><xref rid="bibr19-20552076251380065" ref-type="bibr">19</xref><xref rid="bibr20-20552076251380065" ref-type="bibr"/><xref rid="bibr21-20552076251380065" ref-type="bibr"/><xref rid="bibr22-20552076251380065" ref-type="bibr"/><xref rid="bibr23-20552076251380065" ref-type="bibr"/><xref rid="bibr24-20552076251380065" ref-type="bibr"/>&#8211;<xref rid="bibr25-20552076251380065" ref-type="bibr">25</xref></sup> Digital health technologies offer a passive and continuous way to gather data on behavioral changes affected early in ADRDs (e.g., physical activity, sleep, language). The passive and continuous nature of data collection that digital health technologies allow presents a unique and innovative opportunity to detect ADRD risk at scale in a timely, accessible, and economical manner.<sup>
<xref rid="bibr20-20552076251380065" ref-type="bibr">20</xref>
</sup> However, we also recognize that passive data collection raises important ethical considerations, including privacy concerns and potential participant discomfort with continuous monitoring&#8212;issues that are essential to address as the field continues to evolve. The development of potentially impactful digital health solutions for early ADRD detection must not leave behind underserved and higher-risk segments of the U.S. population. Including Latino persons early in the development of digital signatures of ADRD will ensure applicability and optimization for the early detection and monitoring of ADRD in this population, while helping to combat the unequal burden of ADRD among Latino persons.</p><p>The SALUD-Tech study aims to identify digital phenotypes of risk for ADRD among middle-aged and older Latino persons, with a focus on vascular contributions to dementia, given the disproportionate impact of cerebrovascular disease risk in this group.<sup><xref rid="bibr15-20552076251380065" ref-type="bibr">15</xref>,<xref rid="bibr26-20552076251380065" ref-type="bibr">26</xref><xref rid="bibr27-20552076251380065" ref-type="bibr"/><xref rid="bibr28-20552076251380065" ref-type="bibr"/><xref rid="bibr29-20552076251380065" ref-type="bibr"/><xref rid="bibr30-20552076251380065" ref-type="bibr"/>&#8211;<xref rid="bibr31-20552076251380065" ref-type="bibr">31</xref></sup> Guided by the NIA Health Disparities Research Framework,<sup>
<xref rid="bibr32-20552076251380065" ref-type="bibr">32</xref>
</sup> and recognizing the multifactorial nature of ADRD risk among Latino persons, the study captures multiple behavioral features linked to ADRD risk via passive and unobtrusive data collection methods in the real world. The passive data streams included in this study were selected based on a review of the digital phenotyping literature available at the time the grant was written in 2020.<sup><xref rid="bibr19-20552076251380065" ref-type="bibr">19</xref>,<xref rid="bibr20-20552076251380065" ref-type="bibr">20</xref>,<xref rid="bibr23-20552076251380065" ref-type="bibr">23</xref><xref rid="bibr24-20552076251380065" ref-type="bibr"/>&#8211;<xref rid="bibr25-20552076251380065" ref-type="bibr">25</xref></sup> Selection criteria prioritized data streams that could be collected using widely available consumer-grade devices and ensuring an unobtrusive approach conducive to continuous data collection in everyday life. Additionally, the selected streams targeted behavioral domains known to be risk factors for ADRD among Latinos, specifically physical activity, sleep, motor movements, geolocation, and social activity. We chose not to include active digital data collection (e.g., mobile cognitive tests, speech samples) in this study to minimize participant burden and maximize adoption of the technology in underrepresented populations. Given well-established sex differences in ADRD and in the behavioral features that are captured in SALUD-Tech,<sup><xref rid="bibr33-20552076251380065" ref-type="bibr">33</xref><xref rid="bibr34-20552076251380065" ref-type="bibr"/><xref rid="bibr35-20552076251380065" ref-type="bibr"/><xref rid="bibr36-20552076251380065" ref-type="bibr"/><xref rid="bibr37-20552076251380065" ref-type="bibr"/><xref rid="bibr38-20552076251380065" ref-type="bibr"/><xref rid="bibr39-20552076251380065" ref-type="bibr"/><xref rid="bibr40-20552076251380065" ref-type="bibr"/><xref rid="bibr41-20552076251380065" ref-type="bibr"/><xref rid="bibr42-20552076251380065" ref-type="bibr"/><xref rid="bibr43-20552076251380065" ref-type="bibr"/><xref rid="bibr44-20552076251380065" ref-type="bibr"/>&#8211;<xref rid="bibr45-20552076251380065" ref-type="bibr">45</xref></sup> the study is investigating sex differences in the digital signatures of ADRD among older Latino persons. Considering the heterogeneity within the Latino population in the U.S.,<sup>
<xref rid="bibr46-20552076251380065" ref-type="bibr">46</xref>
</sup> SALUD-Tech is also examining whether sociocultural factors (e.g., language use/bilingualism, acculturation, socioeconomic status) impact or modify digital signatures of ADRD risk. Lastly, this study is investigating digital phenotypes of longitudinal neurocognitive change at 18- and 36-months in an exploratory fashion in a subset of Latino persons with and without ADRD risk. Ultimately, the goal is to develop a cost-effective, user-friendly solution for the early detection and monitoring of ADRD among Latino persons, via the identification of culturally relevant digital signatures of ADRD risk in this group.</p></sec><sec sec-type="methods" id="section2-20552076251380065"><title>Methods</title><sec id="section2A-20552076251380065"><title>Design</title><p>The SALUD-Tech study uses a combined cross-sectional and longitudinal design to identify digital phenotypes of risk for ADRD among middle-aged and older Latino persons living in Southern California. The cross-sectional aspect of the study involves the examination of 300 Latino persons aged 50&#8211;70 years, with varied degrees of ADRD risk, as defined by the presence/absence of cardiovascular disease (CVD) risk and MCI. Apolipoprotein E (APOE) &#949;4 and plasma-based AD are also considered for further classification of ADRD risk. During in-person baseline visits, participants complete comprehensive neuropsychological and neuromedical evaluations, and assessments of culturally relevant factors. During this visit, participants are provided with a Fitbit Versa 2 or 4 device and assisted with installing apps on their personal smartphones. High-frequency data on sensors, keyboard dynamics, and phone use activity are collected continuously over 30 days following the study visit in participants&#8217; natural environments. A subset of participants is followed longitudinally with lab-based assessments at 18- and 36-month post-baseline visit. In-person study visits are conducted at the University of California San Diego (UCSD) La Jolla campus, the San Diego State University South Bay Latino Research Center (SBLRC) in Chula Vista, CA or at participants&#8217; homes.</p></sec><sec id="section2B-20552076251380065"><title>Ethics and institutional review board</title><p>All study-related procedures have been reviewed and are overseen by the UCSD Institutional Review Board (Protocol 803609). The most commonly expected risks of the study are feeling stressed or uncomfortable about answering some of the questions, pain or bruising from the blood draw, and mild discomfort when wearing a smartwatch. The most serious risk may include accidental disclosure of genetic information. Multiple provisions are in place to prevent this loss of confidentiality and minimize other risks. While there is no direct benefit to participants, the new knowledge gained regarding the identification of ADRD risk among Latino persons may help others in the future. While not a benefit, participants will receive a small incentive for participating in the study (up to $175 for baseline data, up to $20 for 18-month follow-up data, and up to $55 for 36-month follow-up data). Participants can also obtain results from their cognitive and blood-based metabolic markers data.</p></sec><sec id="section2C-20552076251380065"><title>Study population inclusion and exclusion criteria</title><p>The target sample at baseline is 300 adults ages 50&#8211;70 years old who self-identify as Latino with and without MCI and CVD risk as follows: 1) with MCI and CVD risk (MCI+/CVD+); 2) cognitively normal with CVD risk (MCI-/CVD+), 3) with MCI but no CVD risk (MCI+/CVD-), and 4) cognitively normal without CVD risk (MCI-/CVD-). Additional inclusion criteria include: participants may be monolingual in English or Spanish or bilingual (Spanish/English), able to provide informed consent to participate in research, and smartphone ownership. We anticipate most participants will be of Mexican heritage, but we do not exclude participants based on Latino background. Participants are excluded if they have a history of psychotic disorder, notable neurological confounds (e.g., loss of consciousness for more than 30&#8197;min, history of brain hemorrhage, brain surgery, diagnosis of seizures, clinical stroke, multiple sclerosis, or dementia), inability to text on a smartphone, and notable alcohol or substance use (10-item Alcohol Use Disorders Identification Test [AUDIT] Total Score &gt;16 or Drug Abuse Screen Test [DAST] total score &gt;6). For the longitudinal aspect of the study, we prioritize inviting participants with (MCI+/CVD+) or without (MCI-/CVD-) ADRD risk at baseline and who were responsive to the study protocol during the baseline assessment (e.g., completed all lab visit assessments; complied with at least 70% of the digital data on at least three data streams) to participate, with a target sample of 90 participants at 18-month and 36-month follow-up.</p><sec id="section2D1-20552076251380065"><title>Culturally relevant considerations</title><p>Study procedures follow a culturally informed approach. Our study team includes several bilingual/bicultural members, including one Multiple Principal Investigator (MJM) and all study staff who had participant contact via recruitment efforts or data collection. Study visits are conducted in Spanish or English based on participants&#8217; primary language, determined via methods used in prior studies.<sup>
<xref rid="bibr47-20552076251380065" ref-type="bibr">47</xref>
</sup> These methods include a validated algorithm based on a brief measure assessing participant's language preference, fluency, and use in daily life<sup>
<xref rid="bibr48-20552076251380065" ref-type="bibr">48</xref>
</sup> and confirmed via performance-based measures of fluency in English<sup>
<xref rid="bibr49-20552076251380065" ref-type="bibr">49</xref>
</sup> and Spanish.<sup>
<xref rid="bibr50-20552076251380065" ref-type="bibr">50</xref>
</sup> We have implemented several strategies to reduce practical barriers to research participation including: a testing site in a community with high Latino representation; home visits when needed; study visits during weekends and after regular working hours; transportation to/from study visits; meals during visits; childcare reimbursement; compensation for time and effort; and return of study results. Based on a comprehensive literature review, we identified the most appropriate assessment instruments for middle-age and older Latino persons. We chose those with available English and Spanish versions and strong psychometric properties for Latino persons.</p></sec><sec id="section2D2-20552076251380065"><title>Recruitment and retention</title><p>Recruitment activities occur in San Diego County (California). Recruitment efforts leverage an NIH-funded longitudinal observational cohort study of Latino persons (R01MD013502), an existing participant pool at the San Diego State University SBLRC, and other participant registries at UCSD. Bilingual study staff reach out to participants in these cohort studies who had previously provided consent to be contacted for future studies via telephone and provide an overview of the study using a low-literacy recruitment script. Building on years of experience fostering trust in the local Latino community, we also recruit new participants, with a focus on persons residing in Latino neighborhoods in southern San Diego County, CA. Activities for recruitment of new participants include presentations to community organizations that serve the older adult Latino community, participation in health events, flyer distribution, establishing a formal partnership with a promotora de salud, referrals from current participants, and mailings to Latino neighborhoods. Recruitment materials were codeveloped in English and Spanish, utilizing plain language and considering cultural appropriateness.</p><p>To ensure evidence-based retention efforts for the duration of the study we will: 1) form a direct relationship with each study participant, 2) call and check-in with participants during the first three days and every two weeks of the digital data collection period, and 3) encourage participants to let us know when their contact information changes and do periodic checks on the accuracy of the records. We will make reminder calls to participants one week, then again one day, prior to their follow-up visit. In addition, our team utilizes participant retention methods based on previously published principles, including: 1) informing individuals that they will be followed up for the duration of the study; and 2) obtaining permission at the time of entry to allow follow-up through other contacts (e.g., family members, trusted confidants).</p></sec></sec><sec id="section2D-20552076251380065"><title>Instruments</title><p>The corresponding author can be contacted to request a complete packet and references of all study measures that are not proprietary.</p><sec id="section2D3-20552076251380065"><title>Laboratory assessments</title><sec id="section2D3A-20552076251380065"><title>Neurobehavioral assessments</title><p>Neurocognitive function is assessed via a comprehensive neuropsychological assessment battery, which measures seven ability domains (<xref rid="table1-20552076251380065" ref-type="table">Table 1</xref>). All tests are available in English and Spanish and have demographically adjusted normative data for Latino populations. All tests are completed at the baseline and 36-month visits, and a subset at the 18-month visits (noted in <xref rid="table1-20552076251380065" ref-type="table">Table 1</xref>). The neurobehavioral assessment includes also self-report measures of current problems with instrumental activities of daily living<sup>
<xref rid="bibr8-20552076251380065" ref-type="bibr">8</xref>
</sup> and self-report of cognitive symptoms.<sup>
<xref rid="bibr51-20552076251380065" ref-type="bibr">51</xref>
</sup></p><table-wrap position="float" id="table1-20552076251380065" orientation="portrait"><label>Table 1.</label><caption><p>Comprehensive neuropsychological test battery.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_20552076251380065-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Neurocognitive domain</th><th align="left" rowspan="1" colspan="1">Cognitive test (score)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Learning</td><td rowspan="1" colspan="1">Hopkins Verbal Learning Test-Revised (Total Recall)*(53)<break/>Brief Visuospatial Memory Test-Revised (Total Recall)(53)<break/>UDSv3 Craft Story (Immediate Verbatim)(52)</td></tr><tr><td rowspan="1" colspan="1">Delayed Recall</td><td rowspan="1" colspan="1">Hopkins Verbal Learning Test-Revised (Delayed Recall)*(53)<break/>Brief Visuospatial Memory Test-Revised (Delayed Recall)(53)<break/>UDSv3 Craft Story (Delay Verbatim)(52)</td></tr><tr><td rowspan="1" colspan="1">Language/Verbal Fluency</td><td rowspan="1" colspan="1">UDSv3 Animal Naming (Total Score in 60 s)*(52)<break/>UDSv3 Phonemic Fluency (P Spanish and F English Total Score)*(52)<break/>UDSv3 Multilingual Naming Test (MINT Total Score)(52)</td></tr><tr><td rowspan="1" colspan="1">Attention/Working Memory</td><td rowspan="1" colspan="1">UDSv3 Digit Span Forward (Total Correct)*(52)<break/>UDSv3 Digit Span Backwards (Total Correct)*(52)</td></tr><tr><td rowspan="1" colspan="1">Processing Speed</td><td rowspan="1" colspan="1">WAIS-III Digit Symbol (Total Score)(55)<break/>WAIS-III Symbol Search (Total Score)(55)<break/>UDSv3 Trail Making Test A (Time in s)*(52)</td></tr><tr><td rowspan="1" colspan="1">Executive Functioning</td><td rowspan="1" colspan="1">Wisconsin Card Sorting Test-64 (Perseverative Responses and Total Errors)(54)<break/>UDSv3 Trail Making Test B (Time in s)*(52)</td></tr><tr><td rowspan="1" colspan="1">Visual-Spatial Skills</td><td rowspan="1" colspan="1">UDSv3 Benson Complex Figure Copy (Total Score)(52)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-20552076251380065"><p><italic toggle="yes">Note.</italic> All tests are administered at baseline and 36 months. *Tests administered at 18 months.</p></fn><fn id="table-fn2-20552076251380065"><p>UDSv3: Uniform Data Set-Version 3; WAIS: Wechsler Adult Intelligence Scale.</p></fn></table-wrap-foot></table-wrap><p>Neurocognitive data will be utilized to compute three types of <italic toggle="yes">outcomes</italic>: 1) <italic toggle="yes">Cross-sectional continuous neurocognitive performance:</italic> Raw test scores for each test are converted into demographically adjusted T-scores (age, education, gender).<sup><xref rid="bibr52-20552076251380065" ref-type="bibr">52</xref><xref rid="bibr53-20552076251380065" ref-type="bibr"/><xref rid="bibr54-20552076251380065" ref-type="bibr"/>&#8211;<xref rid="bibr55-20552076251380065" ref-type="bibr">55</xref></sup> Adjusted T-scores are averaged to compute global and domain T-scores.<sup>
<xref rid="bibr18-20552076251380065" ref-type="bibr">18</xref>
</sup> 2) <italic toggle="yes">Diagnosis of MCI</italic>. Objective presence of MCI is determined via Jak/Bondi diagnostic criteria.<sup>
<xref rid="bibr56-20552076251380065" ref-type="bibr">56</xref>
</sup> Per these criteria, MCI is defined by impairment in at least one cognitive domain. Domain impairment is quantified by scores of &gt;1SD below the normative mean on at least two tests within the domain. 3) <italic toggle="yes">Longitudinal neurocognitive change</italic> will be analyzed utilizing cognitive T-scores at baseline, 18 months and 36 months.<sup>
<xref rid="bibr57-20552076251380065" ref-type="bibr">57</xref>
</sup></p></sec><sec id="section2D3B-20552076251380065"><title>Neuromedical assessments</title><p>The neuromedical exam at baseline consists of medical and medication history, anthropomorphic and vital signs measurements, assessment of physical function via the Short Physical Performance Battery,<sup>
<xref rid="bibr6-20552076251380065" ref-type="bibr">6</xref>
</sup> and a fasting blood draw. Cardiovascular disease risk factors are based on established criteria: 1) diabetes mellitus (fasting plasma glucose &#8805;126 mg/dL, an HbA1c&#8201;&#8805;&#8201;6.5%, and/or use of antihyperglycemic medications)<sup>
<xref rid="bibr58-20552076251380065" ref-type="bibr">58</xref>
</sup>; 2) hypercholesterolemia and dyslipidemia (total cholesterol &#8805;240 mg/dL, LDL cholesterol &#8805;160 mg/dL, or HDL cholesterol &lt;40 mg/dL [for persons with and without diabetes] or on cholesterol-lowering medication)<sup>
<xref rid="bibr59-20552076251380065" ref-type="bibr">59</xref>
</sup>; 3) hypertension (systolic blood pressure &#8805;140 mm Hg, diastolic blood pressure &#8805;90 mm Hg, or on antihypertensive medication)<sup>
<xref rid="bibr60-20552076251380065" ref-type="bibr">60</xref>
</sup>; 4) current cigarette smoking; and 5) obesity (BMI of &#8805;30.0).<sup>
<xref rid="bibr61-20552076251380065" ref-type="bibr">61</xref>
</sup> Cardiovascular disease risk burden is defined by the count of CVD risk factors based on prior research.<sup>
<xref rid="bibr30-20552076251380065" ref-type="bibr">30</xref>
</sup> An adverse CVD risk profile is defined by the presence of 2+ CVD risk factors based on findings showing a significant link between a similar CVD risk burden and cognitive function in Latino persons.<sup>
<xref rid="bibr62-20552076251380065" ref-type="bibr">62</xref>
</sup> We also genotype APOE and will consider it in secondary analyses for the determination of ADRD risk along with plasma-based biomarkers known to be important in the expression and evolution of AD (phosphorylated-tau [p-tau181]; neurofilament light [Nfl]).<sup><xref rid="bibr63-20552076251380065" ref-type="bibr">63</xref>,<xref rid="bibr64-20552076251380065" ref-type="bibr">64</xref></sup> We are also storing plasma to allow for new assays. A subset of the neuromedical assessments are administered at follow-up visits, including updates on medical and medication history, and anthropomorphic and vital signs measurements.</p></sec><sec id="section2D3C-20552076251380065"><title>Culturally relevant factors</title><p>Acculturation is assessed via self-report<sup>
<xref rid="bibr65-20552076251380065" ref-type="bibr">65</xref>
</sup> and bilingualism via self-report<sup>
<xref rid="bibr66-20552076251380065" ref-type="bibr">66</xref>
</sup> and performance-based measures.<sup><xref rid="bibr67-20552076251380065" ref-type="bibr">67</xref><xref rid="bibr68-20552076251380065" ref-type="bibr"/>&#8211;<xref rid="bibr69-20552076251380065" ref-type="bibr">69</xref></sup> Participants also complete a self-report sociodemographic questionnaire that collects information on place of birth, time in the US, quality of education (educational setting and resources), income, and characteristics of the childhood environment, among others.<sup>
<xref rid="bibr70-20552076251380065" ref-type="bibr">70</xref>
</sup> Data on all sociocultural factors are collected at baseline, and those that might change over time (e.g., income) are also measured at longitudinal visits.</p></sec><sec id="section2D3D-20552076251380065"><title>Psychiatric and substance use characteristics</title><p>Psychiatric symptoms and substances are assessed via the Patient Health Questionnaire-9 (PHQ-9),<sup>
<xref rid="bibr71-20552076251380065" ref-type="bibr">71</xref>
</sup> the Generalized Anxiety Disorder &#8211; 7 item,<sup>
<xref rid="bibr72-20552076251380065" ref-type="bibr">72</xref>
</sup> the NIH Toolbox Emotion Battery,<sup><xref rid="bibr73-20552076251380065" ref-type="bibr">73</xref>,<xref rid="bibr74-20552076251380065" ref-type="bibr">74</xref></sup> and the AUDIT.<sup>
<xref rid="bibr75-20552076251380065" ref-type="bibr">75</xref>
</sup> All psychiatric and substance use assessments are administered at baseline, and the PHQ-9 and GAD are repeated at follow-up assessments. The Life Events Scale<sup>
<xref rid="bibr76-20552076251380065" ref-type="bibr">76</xref>
</sup> is also administered in follow-up visits to capture major life events over the past year.</p></sec></sec><sec id="section2D4-20552076251380065"><title>Digital phenotyping data</title><p>Descriptions of the digital data collected are provided below and summarized in <xref rid="table2-20552076251380065" ref-type="table">Table 2</xref> and include keystroke metadata, sleep, physical activity, geolocation, and phone use activity. Participants use their own smartphones for the study, and Fitbit Versa 2 or 4 watches are provided to collect sleep and physical activity data over 30 days post baseline laboratory visit.</p><table-wrap position="float" id="table2-20552076251380065" orientation="portrait"><label>Table 2.</label><caption><p>Summary of digital data collected.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_20552076251380065-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Data source</th><th align="left" rowspan="1" colspan="1">Data processing</th><th align="left" rowspan="1" colspan="1">Off the shelf features and established metrics</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">GPS and GIS data</td><td rowspan="1" colspan="1">PALMS processing</td><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Time spent at home</p></list-item><list-item><p>Distance from home</p></list-item><list-item><p>Total walking distance</p></list-item><list-item><p>Neighborhood characteristics</p></list-item></list>
</td></tr><tr><td rowspan="1" colspan="1">Keyboard Typing Patterns</td><td rowspan="1" colspan="1">KeyWise processing</td><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Typing speed variability</p></list-item><list-item><p>Average interkey delay</p></list-item><list-item><p>Backspace usage</p></list-item><list-item><p>Circadian rhythms</p></list-item><list-item><p>accelerometer during typing</p></list-item></list>
</td></tr><tr><td rowspan="1" colspan="1">Wrist-worn accelerometer</td><td rowspan="1" colspan="1">TLBC processing</td><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Step count</p></list-item><list-item><p>Distance</p></list-item><list-item><p>Overall physical activity</p></list-item><list-item><p>Total sleep time</p></list-item><list-item><p>Sleep efficiency</p></list-item></list>
</td></tr><tr><td rowspan="1" colspan="1">Social Activity</td><td rowspan="1" colspan="1">No preprocessing</td><td rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Average screen time</p></list-item><list-item><p>Variability in screen time</p></list-item><list-item><p>Most used apps</p></list-item><list-item><p>Categories of apps used</p></list-item></list>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn3-20552076251380065"><p><italic toggle="yes">Note.</italic> GPS: Global Positioning System; GIS: Geographic Information System; PALMS: Personal Activity and Location Measurement System; TLBC: Two-Level Behavior Classification.</p></fn></table-wrap-foot></table-wrap><sec id="section2D4A-20552076251380065"><title>Keystroke data</title><p>Participants install the KeyWise AI keyboard extension (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://keywise.tech/" ext-link-type="uri">https://keywise.tech/</ext-link>) on their personal Android or iPhone smartphones, which replaces the standard smartphone keyboard. This keyboard passively collects typing metadata (e.g., time between keypresses, backspace usage, accelerometer during typing) without capturing content, ensuring user privacy. Deidentified data are automatically uploaded to a password-protected AWS cloud server, with no data stored on the device. KeyWise ensures that no personally identifying information is stored with the data. The raw metadata and derived metrics, including average interkey delay, typing speed variability, backspace usage, and circadian rhythms, will be used in analyses.</p></sec><sec id="section2D4B-20552076251380065"><title>Sleep and physical activity</title><p>Sleep and physical activity are measured objectively using the wrist-worn Fitbit Versa 2 or 4, and participants are asked to wear the device for 24&#8197;h/day (except when charging) on their nondominant wrist for the 30-day home assessment period (and the two additional 30-day assessment bursts in the subsample completing longitudinal visits). Indicators for physical activity analyses will be averaged at the day level and include distance traveled, step count, and overall activity, and indicators for sleep analyses will include total sleep time and sleep efficiency.</p></sec><sec id="section2D4C-20552076251380065"><title>Geolocation</title><p>As another potential objective indicator of ADRD risk, a continuous series of location-based data are obtained using the built-in GPS on participants&#8217; smartphones and will be analyzed to generate representations of the participants and their surrounding environments (e.g., time spent at-home/not-at-home). We use the GPS logger app for Android devices and MyTracks app for iOS devices to collect the GPS data. Indicators for analyses include time spent at home, distance from home, neighborhood characteristics, and total distance traveled in a day.</p><p>Further, when these locations are analyzed with the background Geographic Information Systems (GIS) layers using methods such as spatial overlay, we can quantify the neighborhood characteristics that participants are exposed to. Environment will be quantified through two composite indexes of GIS data: physical/built or structural and sociocultural. The index will be created using summed z-scores of a number of features, and a final total environmental disadvantage index from both variables will be created. <italic toggle="yes">Physical/built</italic> or structural disadvantage will be compiled from walkability,<sup>
<xref rid="bibr77-20552076251380065" ref-type="bibr">77</xref>
</sup> recreation,<sup>
<xref rid="bibr78-20552076251380065" ref-type="bibr">78</xref>
</sup> built food environment,<sup>
<xref rid="bibr79-20552076251380065" ref-type="bibr">79</xref>
</sup> transit, road safety, and green space (NDVI index).<sup>
<xref rid="bibr80-20552076251380065" ref-type="bibr">80</xref>
</sup>
<italic toggle="yes">Sociocultural</italic> disadvantage will be compiled with measures of diversity,<sup>
<xref rid="bibr81-20552076251380065" ref-type="bibr">81</xref>
</sup> language, economy,<sup>
<xref rid="bibr82-20552076251380065" ref-type="bibr">82</xref>
</sup> and crime.<sup>
<xref rid="bibr83-20552076251380065" ref-type="bibr">83</xref>
</sup> We will also explore environmental hazards by examining air, noise, and light pollution, as well as water quality.</p></sec><sec id="section2D4D-20552076251380065"><title>Social activity</title><p>Communication patterns and social dynamics are quantified by phone use activity (aka &#8220;screen time&#8221;), such as time spent in messaging/social media apps and time spent talking on the phone. To obtain these data, participants send daily screenshots of their prior day screen time activity to the study team. Indicators for analyses will include mean screen time, daily variability in screen time, top apps used (quantified into categories such as social media, communication, games, and utilities), and time spent in various activities.</p></sec></sec></sec><sec id="section2E-20552076251380065"><title>Data analysis plan</title><sec id="section2E1-20552076251380065"><title>Feature engineering overview</title><p>We will use a combination of existing features provided by industry partners (e.g., robust statistics metrics previously used to predict age and smartphone usage),<sup>
<xref rid="bibr84-20552076251380065" ref-type="bibr">84</xref>
</sup> and we will engineer additional features using nonlinear dynamical systems methods developed to study intrasubject variability dynamics over time (e.g., recurrence quantification<sup>
<xref rid="bibr85-20552076251380065" ref-type="bibr">85</xref>
</sup> and multiscalar entropy analysis<sup>
<xref rid="bibr86-20552076251380065" ref-type="bibr">86</xref>
</sup>) as well as traditional time-series methods. Intrasubject variability will provide interpretable features that may be indicative of subtle differences due to MCI and/or CVD risk.</p><p>Using the keystroke data as an example, an outline of the specific features we aim to extract to demonstrate the potential richness and predictive power of digital phenotypes is as follows. We plan to extract a comprehensive suite of keystroke and session-level features from each individual's daily typing data. Specifically, we will quantify interkey timing metrics&#8212;such as the median, harmonic mean, 95th percentile, root mean square of successive differences, and median absolute deviation of alphanumeric-to-alphanumeric intervals, as well as session characteristics such as median and mean session length and total typing duration per day. We will also capture error-related behaviors (e.g., backspace and autocorrect event rates) and derive variability and complexity indices (e.g., multiscale entropy of interkey intervals).</p><p>Prior research indicates that these measures predict both demographic and cognitive signal: typing speed can predict chronological age,<sup>
<xref rid="bibr87-20552076251380065" ref-type="bibr">87</xref>
</sup> while entropy-based variability in keypress timing correlates with planning performance on the Tower of London task.<sup>
<xref rid="bibr88-20552076251380065" ref-type="bibr">88</xref>
</sup> Furthermore, within-subject fluctuations in daily typing speed have been shown to track trail-making task performance and depressive symptom severity.<sup><xref rid="bibr89-20552076251380065" ref-type="bibr">89</xref>,<xref rid="bibr90-20552076251380065" ref-type="bibr">90</xref></sup> In work currently in review on younger adults (ages 21&#8211;40), we derived 39 keyboard-dynamics features and used principal component analysis to reveal that the first component (overall typing speed) and second component (usage patterns such as pause behavior) each significantly predict fluid cognition (NIH Toolbox composite) and TMT-B completion time.<sup>
<xref rid="bibr91-20552076251380065" ref-type="bibr">91</xref>
</sup> For the current sample, we will extend this approach by incorporating pause-based features&#8212;capturing intrasession idle durations&#8212;to enhance sensitivity to fine-grained changes in processing speed and attentional control.</p><p>Lastly, we will use artificial neural networks, specifically a deep learning method that combines convolutional neural networks (CNNs) and long short-term memory networks (LSTMs) called CNN-LSTMs. It will extract features from the individual data streams to examine hidden markers that are predictive of the dependent variables. Such models can automatically &#8220;featurize&#8221; the raw data, including temporal patterns, during the end-to-end training process.<sup>
<xref rid="bibr92-20552076251380065" ref-type="bibr">92</xref>
</sup> To reduce the risk of overfitting, we will regularize the model aggressively and explore unsupervised pretraining to learn the lower layers of the CNN features.</p></sec><sec id="section2E2-20552076251380065"><title>Feature engineering analyses</title><p>For feature extraction from the passive metrics, the goal is to develop stable parameter estimation of the intrasubject variability using both standard and ML approaches. Standard approaches to capture intrasubject variability involve tools from dynamical systems (complex systems tools), such as entropy-based methods for physiological time series methods, and have been used successfully in bipolar disorder to predict changes in mood self-report,<sup>
<xref rid="bibr93-20552076251380065" ref-type="bibr">93</xref>
</sup> motor activity,<sup>
<xref rid="bibr94-20552076251380065" ref-type="bibr">94</xref>
</sup> motor activity in depression,<sup>
<xref rid="bibr95-20552076251380065" ref-type="bibr">95</xref>
</sup> and a range of other physiological disorders such as heart disease.<sup>
<xref rid="bibr96-20552076251380065" ref-type="bibr">96</xref>
</sup> Multiscalar entropy analysis<sup>
<xref rid="bibr97-20552076251380065" ref-type="bibr">97</xref>
</sup> will be applied to measure intrasubject variance, and our own simulations show we need to at least 3000 data points to achieve stable estimates. For keystroke metadata, we can safely assume 300 keystrokes/day &#215; 30 days&#8201;=&#8201;9000 keystrokes/person. For GPS/GIS data, the polling rate is 12 times an hour &#215; 24&#8197;h &#215; 30 days&#8201;=&#8201;8640 data points. For the other metrics of intrasubject variance where the time-series is shorter (e.g., gait speed/day, sleep/night), we will use recurrence quantification analysis, another complex systems tool for nonlinear time-series data. Recurrence quantification analysis can be understood as the generalized autocorrelation function and allows the detection of deterministic elements of a signal what might look stochastic in nature<sup>
<xref rid="bibr98-20552076251380065" ref-type="bibr">98</xref>
</sup> and has been successfully applied to EEG,<sup>
<xref rid="bibr99-20552076251380065" ref-type="bibr">99</xref>
</sup> heart rate variability,<sup>
<xref rid="bibr100-20552076251380065" ref-type="bibr">100</xref>
</sup> and postural sway.<sup>
<xref rid="bibr101-20552076251380065" ref-type="bibr">101</xref>
</sup> Recurrence quantification analysis produces several metrics (including entropy) from nonlinear time series, such as where in time the person is repeating patterns and how stable patterns are in time.</p></sec><sec id="section2E3-20552076251380065"><title>Machine learning and statistical analyses</title><p>Alzheimer's Disease and Related Dementias risk groups (MCI+/-, CVD+/-) will be predicted from data obtained via passive digital measures collected over 30 days. Digital features from the passive metrics (both standard and machine-learned) will be entered into ML methods designed for high-dimensional multivariate predictors in small sample sizes for cognitive T-scores and CVD risk.<sup>
<xref rid="bibr102-20552076251380065" ref-type="bibr">102</xref>
</sup> Interactions with sex and with language use and other sociocultural factors will also be examined. LASSO will select the most impactful passive digital features while limiting model complexity (help prevent overfitting), maintaining type I error levels in a small sample relative to the number of parameters.<sup>
<xref rid="bibr103-20552076251380065" ref-type="bibr">103</xref>
</sup> XGBoost,<sup>
<xref rid="bibr104-20552076251380065" ref-type="bibr">104</xref>
</sup> a method that incorporates pruning and regularization methods (like LASSO), will help assess the importance of individual features. For the classification of ADRD risk group, modern ML classifiers will be used with standard metrics to assess model fit (i.e., raw accuracy, area under the ROC, specificity sensitivity, and precision). Predictors will be tested stepwise to improve interpretability. The specific algorithms selected will depend on a balance of power relative to underlying assumptions<sup><xref rid="bibr105-20552076251380065" ref-type="bibr">105</xref>,<xref rid="bibr106-20552076251380065" ref-type="bibr">106</xref></sup> that are met with an emphasis on model interpretability (e.g., QDA, random forest, XGBoost). To guard against overfitting in all our machine-learning models, we will first set aside 20% of subjects (stratified by group) for a final hold-out validation. Within the remaining 80%, we will perform k-fold cross-validation (e.g., k&#8201;=&#8201;10), monitoring variability in balanced accuracy and F1-score across folds. To reduce feature-space complexity, we will preselect predictors informed by prior literature and, where necessary, apply dimensionality reduction (e.g., PCA, T-SNE). For our CNN-LSTM pipelines, we will additionally withhold 50% of each individual's time-series streams (Fitbit, GPS, KeyWise, screen time) during training, and employ dropout and regularization (e.g., L&#8322; weight-decay) in the convolutional and recurrent layers. Finally, we will evaluate generalization performance on the 20% subject hold-out set mentioned above.</p><p>The specific cross-validation technique will depend on algorithm selection (e.g., leave-one-out, K-fold, or bootstrapping).<sup>
<xref rid="bibr107-20552076251380065" ref-type="bibr">107</xref>
</sup> To assess individual feature importance SHAP (SHapley Additive exPlantations) values will be extracted. To balance type I and II error rate and control for multiple testing, we will use an optimal alpha strategy (a&#8201;=&#8201;.05 to .005) depending on whether the question at hand is a main hypothesis or exploratory and relative analysis being conducted (e.g., ML analysis, classical or robust parametric and nonparametric statistics), and how the <italic toggle="yes">p</italic>-values are derived for the specific algorithm tested (e.g., classical, Bayesian, or bootstrapped). We will use Holm&#8211;Bonferroni adjustments for &#8804;5 tests<sup>
<xref rid="bibr108-20552076251380065" ref-type="bibr">108</xref>
</sup> and false discovery rate methods for &gt;6 tests.<sup>
<xref rid="bibr109-20552076251380065" ref-type="bibr">109</xref>
</sup> When dependent outcome measures are correlated, corrections will be calculated based on the effective number of independent tests.<sup>
<xref rid="bibr110-20552076251380065" ref-type="bibr">110</xref>
</sup> For the longitudinal exploratory aim, generalized linear mixed-effect models<sup>
<xref rid="bibr111-20552076251380065" ref-type="bibr">111</xref>
</sup> will model neurocognitive change and its association with changes in digital data features over time.<sup>
<xref rid="bibr112-20552076251380065" ref-type="bibr">112</xref>
</sup> The variable selection methods above will be used to explore which features are the most impactful.<sup>
<xref rid="bibr113-20552076251380065" ref-type="bibr">113</xref>
</sup> Finally, we will explore the standard feature importance analysis method of drop-feature evaluation, an ablation analysis where we withhold a subset of features at a time and rebuild the models.</p></sec><sec id="section2E4-20552076251380065"><title>Sample size and power analyses</title><p>We conducted a sensitivity analysis to determine the minimum effect sizes detectable in our study, using a multiple regression sensitivity analysis. Drawing on previous studies with passive metrics, we anticipate identifying 18&#8211;20 passive features relevant to the primary study aim. With 20 predictors, we estimated small-to-medium effect sizes between individual predictors and cognition T-scores, achieving a power of 0.80 with Cohen's <italic toggle="yes">f</italic><sup>2</sup> = 0.026 (Cohen's <italic toggle="yes">d</italic>&#8201;=&#8201;0.32; <italic toggle="yes">R</italic>&#178; = 0.025) and a power of 0.95 with Cohen's <italic toggle="yes">f</italic><sup>2</sup> = 0.044 (Cohen's <italic toggle="yes">d</italic>&#8201;=&#8201;0.42; <italic toggle="yes">R</italic><sup>2</sup> = 0.042). For the examination of sex, language use, and other sociocultural factors, we will also explore the smallest effect size necessary for accurate participant classification into predefined groups using logistic regression, the oldest and most conservative method, assuming moderate intercorrelation among normally distributed predictors (<italic toggle="yes">R</italic><sup>2</sup> = 0.30): a power of 0.80 analysis resulted in an odds ratio of 1.49 or Cohen's <italic toggle="yes">d</italic>&#8201;=&#8201;0.22, and a power of 0.95 resulted in an odds ratio of 1.69 or Cohen's <italic toggle="yes">d</italic>&#8201;=&#8201;0.29. These results indicate adequate power to detect small-to-medium effect sizes.</p></sec></sec></sec><sec sec-type="results" id="section3-20552076251380065"><title>Results</title><p>Enrollment of participants for the baseline assessments started in April 2022 and is expected to be completed by April 2025. As of March 2025, 297 individuals have completed these first-round assessments. The first round of 18-month follow-up assessments occurred in July 2023. Study results will be published in peer-reviewed scientific journals in a timely fashion at completion of data collection. We intend to publish all deidentified datasets, code, and models we create on a publicly accessible project webpage hosted on GitHub. We will also release the raw data files from which we created our unlabeled data on the repository.</p></sec><sec sec-type="discussion" id="section4-20552076251380065"><title>Discussion</title><p>There is a pressing need to develop tools to detect the earliest manifestations of ADRD, particularly in Latino persons. A variety of behavioral changes can reveal risk for ADRD, and mobile technologies offer ways to unobtrusively collect, track, and analyze these behaviors as a person engages in their daily life. Projects worldwide are emerging to take advantage of the large amounts of data collected via these mobile technologies.<sup><xref rid="bibr114-20552076251380065" ref-type="bibr">114</xref>,<xref rid="bibr115-20552076251380065" ref-type="bibr">115</xref></sup> The digital signatures captured through the SALUD-Tech study hold the potential to provide insights into patterns of behavior changes in a well-characterized cohort of Latino persons living in the U.S. with varying risk for developing ADRD. Importantly, the study aims to examine how heterogeneity within Latino persons might impact digital signatures of risk for ADRD.</p><p>The identification of culturally relevant digital phenotypes of ADRD specific to the Latino population is crucial for the accurate detection of ADRD risk in this group. Behavior is culturally dependent, and thus, it is imperative that culture is carefully considered in the examination of digital signatures of ADRD. Seminal ADRD research has historically been conducted in primarily non-Hispanic White samples, contributing to a poor understanding of the nature of ADRD among Latino persons and resulting in a skewed understanding of ADRDs. By including Latino persons early in the development of digital signatures, we strive to ensure applicability and optimization for the early detection of ADRD. Further, the utilization of passive data collection methods could mitigate many challenges of traditional neurobehavioral assessment methods to detect preclinical ADRD and provide a powerful tool to identify ADRD early with minimal burden to Latino persons. Such tools can immediately advance ADRD disparities science by providing a low-cost, low-burden risk detection tool for research, and facilitate improved understanding of ADRD risk factors and disease progression.</p><p>Findings from the SALUD-Tech study might also contribute to the diagnosis of ADRD in Latino persons in clinical settings. Given barriers to preclinical assessments, incorporating digital health technologies into routine healthcare practices may provide a strategy for early identification. Tools developed via the SALUD-Tech study could ultimately be incorporated into clinical care, providing opportunities for timely disease detection and intervention. Addressing ADRD disparities through research that prioritizes the inclusion and lived experiences of Latino persons can help promote equitable access to resources and care.</p><p>Limitations of the current study include the relatively short follow-up period (3 years) in only a subset of participants. To mitigate this limitation, we selected &#8220;no-risk&#8221; and &#8220;high-risk&#8221; groups for developing ADRD for the longitudinal follow-up visits. This approach increases the likelihood of observing greater cognitive decline within the study period in our high-risk group and enhances our ability to compare the trajectories of the two groups. We also chose to study an &#8220;at-risk&#8221; group instead of persons with notable ADRD symptoms, as the goal is to identify subtle behavioral changes in daily life as early indicators of ADRD risk. These digital markers likely differ between persons with subclinical disease burden and those with dementia, given functional impairments in this latter group that impact activities of daily living and often require caregiver assistance. In future work, we plan to continue following this cohort, as well as other at-risk groups, to evaluate digital signatures of long-term trajectories of cognitive and brain changes, and onset of ADRD. Also, given the geographical region in which the study is being conducted (southern California), we expect a majority of our sample will be of Mexican background, which is the largest Hispanic heritage group in the U.S. Yet, findings from the present study might not generalize to persons from other Latino backgrounds and living in other regions of the country. Future multisite studies including Latino persons from other U.S. regions and heritages (e.g., Puerto Rican, Cuban, Salvadoran populations), with associated cultural, educational, and other differences, will be key in determining the generalizability of our findings to Latino persons in the U.S. more broadly and ensuring that digital signatures of ADRD accurately reflect the heterogeneous Latino U.S. population. Lastly, as is the case with several digital health studies, there is the potential for selection bias due to differences in digital literacy and access to technology among participants. In the present study, we provide wearables to participants which might minimize this bias to some extent. We also record reasons for exclusion, including not owning a smartphone, which will help determine the extent to which smartphone ownership was a deterrence to study participation. It is important for future studies to continue considering strategies to further minimize potential biases and ensure that the digital data captured is representative of the broader Latino population.</p></sec><sec id="section5-20552076251380065"><title>Conclusion</title><p>Ultimately, this study has the potential to make a meaningful contribution to clinical practice and health policy, especially for underserved populations. By using passive mobile sensing and machine learning, it aims to identify early signs of ADRD risk in a way that is unobtrusive and affordable, which is criteria for timely intervention. If successful, this approach could help clinicians monitor at-risk individuals more easily and support earlier interventions. The tools developed through this work could also inform policies around integrating digital health strategies into routine care, helping to improve early detection and reduce health disparities in Hispanic/Latino communities.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors thank all participants for the time spent participating in this study, and students who assisted with data processing and entry.</p></ack><fn-group><fn fn-type="other"><p><bold>ORCID iDs:</bold> Shay Nakahira <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0002-9307-7623" ext-link-type="uri">https://orcid.org/0009-0002-9307-7623</ext-link></p><p>Linda C Gallo <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0002-3678-5888" ext-link-type="uri">https://orcid.org/0000-0002-3678-5888</ext-link></p><p>Alexander P Demos <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0001-7964-7808" ext-link-type="uri">https://orcid.org/0000-0001-7964-7808</ext-link></p><p>Luis Ricardo Betancourt <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0003-3863-0972" ext-link-type="uri">https://orcid.org/0009-0003-3863-0972</ext-link></p><p>Perla Rocha <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0005-2276-3003" ext-link-type="uri">https://orcid.org/0009-0005-2276-3003</ext-link></p><p>Lina Scandalis <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0009-0004-6706-8883" ext-link-type="uri">https://orcid.org/0009-0004-6706-8883</ext-link></p><p>Mar&#237;a J Marquine <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0003-2249-6628" ext-link-type="uri">https://orcid.org/0000-0003-2249-6628</ext-link></p></fn><fn fn-type="other"><p><bold>Ethical approval:</bold> All study procedures and protocols were in accordance with the Declaration of Helsinki and were approved by the University of California San Diego Institutional Review Board (Protocol 803609).</p></fn><fn fn-type="other"><p><bold>Contributorship:</bold> RCM and MJM co-led the conception and design of the work, as well as the acquisition, analysis, and interpretation of data for the work; drafted part of the initial work and revised other sections; provided final approval of the version to be published; and are accountable for all aspects of the work. LCG, EES, APD, DG, and LD-W contributed to the design of the work and funding acquisition for this study, interpretation of data, revising this draft and its final approval, and are accountable for all aspects of the work. SN, EGC, PM-M, and RD contributed to revising this draft and its final approval and are accountable for all aspects of the work. MEPL, LRB, and PR contributed to the overall study recruitment efforts and acquisition of data by actively participating in the collection process, ensuring adherence to protocol, revising this draft and its final approval, and are accountable for all aspects of the work. KP and LS contributed to the data acquisition and completion of preanalytical phase of blood specimen collection, including standard processing and preparation for the analytical phase of the APOE genotyping, revising this draft and its final approval, and are accountable for all aspects of the work.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by National Institute on Aging grants R01AG070956 to RCM and MJM, and K24AG075240 to MJM.</p></fn><fn fn-type="COI-statement"><p>The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Moore is a co-founder of KeyWise AI and has equity interest. The terms of this arrangement have been reviewed and approved by UC San Diego in accordance with its conflict-of-interest policies. The remaining authors declare that they have no competing interests.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-20552076251380065"><label>1</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>
<italic toggle="yes">Association As</italic>
</collab></person-group>. <comment>Alzheimer&#8217;s Disease Facts and Figures2024 December 26, 2024. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf" ext-link-type="uri">https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf</ext-link></comment>.</mixed-citation></ref><ref id="bibr2-20552076251380065"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>MX</given-names></name><name name-style="western"><surname>Cross</surname><given-names>P</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal><article-title>Incidence of Alzheimer&#8217;s disease in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan</article-title>. <source>Neurology</source><year>2001</year>; <volume>56</volume>: <fpage>49</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">11148235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.56.1.49</pub-id></mixed-citation></ref><ref id="bibr3-20552076251380065"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>HM</given-names></name><name name-style="western"><surname>Tarraf</surname><given-names>W</given-names></name><name name-style="western"><surname>Gouskova</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Neurocognitive function among middle-aged and older Hispanic/Latinos: results from the Hispanic Community Health Study/Study of Latinos</article-title>. <source>Arch Clin Neuropsych</source><year>2015</year>; <volume>30</volume>: <fpage>68</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/arclin/acu066</pub-id><pub-id pub-id-type="pmcid">PMC4351363</pub-id><pub-id pub-id-type="pmid">25451561</pub-id></mixed-citation></ref><ref id="bibr4-20552076251380065"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurland</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Wilder</surname><given-names>DE</given-names></name><name name-style="western"><surname>Lantigua</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Rates of dementia in three ethnoracial groups</article-title>. <source>Int J Geriatr Psych</source><year>1999</year>; <volume>14</volume>: <fpage>481</fpage>&#8211;<lpage>493</lpage>.<pub-id pub-id-type="pmid">10398359</pub-id></mixed-citation></ref><ref id="bibr5-20552076251380065"><label>5</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>USC Edward</surname><given-names>R</given-names></name></person-group>. <comment>Royal Institute on Aging and the Latinos Against Alzheimer&#8217;s Network. Latinos and Alzheimer&#8217;s Disease: New Numbers Behind the Crisis. 2016 January 31, 2019. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.usagainstalzheimers.org/sites/default/files/Latinos-and-AD_USC_UsA2-Impact-Report.pdf" ext-link-type="uri">https://www.usagainstalzheimers.org/sites/default/files/Latinos-and-AD_USC_UsA2-Impact-Report.pdf</ext-link></comment>.</mixed-citation></ref><ref id="bibr6-20552076251380065"><label>6</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>National Institutes of Health</collab></person-group>. <comment>NIH RCDC Inclusion Statistics Report2023 December 18th, 2024. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://report.nih.gov/RISR/#/ic?rcdcCategory=Clinical+Research%2526ic=NIA" ext-link-type="uri">https://report.nih.gov/RISR/#/ic?rcdcCategory=Clinical+Research&amp;ic=NIA</ext-link></comment>.</mixed-citation></ref><ref id="bibr7-20552076251380065"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caselli</surname><given-names>RJLB</given-names></name><name name-style="western"><surname>Dueck</surname><given-names>AC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuropsychological decline up to 20 years before incident mild cognitive impairment</article-title>. <source>Alzheimers Dement</source><year>2020</year>; <volume>16</volume>: <fpage>512</fpage>&#8211;<lpage>523</lpage>.<pub-id pub-id-type="pmid">31787561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2019.09.085</pub-id><pub-id pub-id-type="pmcid">PMC7067658</pub-id></mixed-citation></ref><ref id="bibr8-20552076251380065"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beason-Held</surname><given-names>LL</given-names></name><name name-style="western"><surname>Goh</surname><given-names>JO</given-names></name><name name-style="western"><surname>An</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal><article-title>Changes in brain function occur years before the onset of cognitive impairment</article-title>. <source>J Neurosci</source><year>2013</year>; <volume>33</volume>: <fpage>18008</fpage>&#8211;<lpage>18014</lpage>.<pub-id pub-id-type="pmid">24227712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.1402-13.2013</pub-id><pub-id pub-id-type="pmcid">PMC3828456</pub-id></mixed-citation></ref><ref id="bibr9-20552076251380065"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Posner</surname><given-names>H</given-names></name><name name-style="western"><surname>Curiel</surname><given-names>R</given-names></name><name name-style="western"><surname>Edgar</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Outcome assessment in clinical trials of Alzheimer&#8217;s disease and its precursors: readying for short-term and long-term clinical trial needs</article-title>. <source>Innov Clin Neurosci</source><year>2017</year>; <volume>14</volume>: <fpage>22</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="pmid">28386518</pub-id><pub-id pub-id-type="pmcid">PMC5373792</pub-id></mixed-citation></ref><ref id="bibr10-20552076251380065"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perneczky</surname><given-names>R</given-names></name><name name-style="western"><surname>Dom</surname><given-names>G</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Anti-amyloid antibody treatments for Alzheimer's disease</article-title>. <source>Eur J Neurol</source><year>2024</year>; <volume>31</volume>: <comment>e16049</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.16049</pub-id><pub-id pub-id-type="pmcid">PMC11235913</pub-id><pub-id pub-id-type="pmid">37697714</pub-id></mixed-citation></ref><ref id="bibr11-20552076251380065"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terao</surname><given-names>I</given-names></name><name name-style="western"><surname>Kodama</surname><given-names>W</given-names></name></person-group>. <article-title>Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: a systematic review and network meta-analysis</article-title>. <source>Ageing Res Rev</source><year>2024</year>; <volume>94</volume>: <fpage>102203</fpage>.<pub-id pub-id-type="pmid">38253184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.arr.2024.102203</pub-id></mixed-citation></ref><ref id="bibr12-20552076251380065"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bateman</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>McDade</surname><given-names>EM</given-names></name></person-group>, <etal>et al.</etal><article-title>Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial</article-title>. <source>Lancet Neurol</source><year>2025</year>; <volume>24</volume>(<issue>4</issue>): <fpage>316</fpage>&#8211;<lpage>330</lpage>.<pub-id pub-id-type="pmid">40120616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(25)00024-9</pub-id><pub-id pub-id-type="pmcid">PMC12042767</pub-id></mixed-citation></ref><ref id="bibr13-20552076251380065"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fitten</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Ortiz</surname><given-names>F</given-names></name><name name-style="western"><surname>Fairbanks</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>Younger age of dementia diagnosis in a Hispanic population in southern California</article-title>. <source>Int J Geriatr Psychiatry</source><year>2014</year>; <volume>29</volume>: <fpage>586</fpage>&#8211;<lpage>593</lpage>.<pub-id pub-id-type="pmid">24478258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gps.4040</pub-id><pub-id pub-id-type="pmcid">PMC4013239</pub-id></mixed-citation></ref><ref id="bibr14-20552076251380065"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>CM</given-names></name><name name-style="western"><surname>DeCarli</surname><given-names>C</given-names></name><name name-style="western"><surname>Mungas</surname><given-names>D</given-names></name></person-group>, <etal>et al.</etal><article-title>Earlier onset of Alzheimer disease symptoms in Latino individuals compared with Anglo individuals</article-title>. <source>Arch Neurol</source><year>2005</year>; <volume>62</volume>: <fpage>774</fpage>&#8211;<lpage>778</lpage>.<pub-id pub-id-type="pmid">15883265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.62.5.774</pub-id></mixed-citation></ref><ref id="bibr15-20552076251380065"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'Bryant</surname><given-names>SE</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>L</given-names></name><name name-style="western"><surname>Balldin</surname><given-names>V</given-names></name></person-group>, <etal>et al.</etal><article-title>Characterization of Mexican Americans with mild cognitive impairment and Alzheimer's disease</article-title>. <source>J Alzheimers Dis</source><year>2013</year>; <volume>33</volume>: <fpage>373</fpage>&#8211;<lpage>379</lpage>.<pub-id pub-id-type="pmid">22976076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-2012-121420</pub-id><pub-id pub-id-type="pmcid">PMC3524411</pub-id></mixed-citation></ref><ref id="bibr16-20552076251380065"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'Bryant</surname><given-names>S</given-names></name><name name-style="western"><surname>Humphreys</surname><given-names>J</given-names></name><name name-style="western"><surname>Schiffer</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Presentation of Mexican Americans to a memory disorder clinic</article-title>. <source>J Psychopathol Behav Assess</source><year>2007</year>; <volume>29</volume>: <fpage>137</fpage>&#8211;<lpage>140</lpage>.</mixed-citation></ref><ref id="bibr17-20552076251380065"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack CR</surname><given-names>J</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>JS</given-names></name><name name-style="western"><surname>Beach</surname><given-names>TG</given-names></name></person-group>, <etal>et al.</etal><article-title>Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup</article-title>. <source>Alzheimers Dement</source><year>2024</year>; <volume>20</volume>: <fpage>5143</fpage>&#8211;<lpage>5169</lpage>.<pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></mixed-citation></ref><ref id="bibr18-20552076251380065"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asken</surname><given-names>BM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W-E</given-names></name><name name-style="western"><surname>McFarland</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Plasma Alzheimer's biomarkers and brain amyloid in Hispanic and non-Hispanic older adults</article-title>. <source>Alzheimers Dement</source><year>2024</year>; <volume>20</volume>: <fpage>437</fpage>&#8211;<lpage>446</lpage>.<pub-id pub-id-type="pmid">37671801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13456</pub-id><pub-id pub-id-type="pmcid">PMC10865106</pub-id></mixed-citation></ref><ref id="bibr19-20552076251380065"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stange</surname><given-names>JP</given-names></name><name name-style="western"><surname>Zulueta</surname><given-names>J</given-names></name><name name-style="western"><surname>Langenecker</surname><given-names>SA</given-names></name></person-group>, <etal>et al.</etal><article-title>Let your fingers do the talking: passive typing instability predicts future mood outcomes</article-title>. <source>Bipolar Disord</source><year>2018</year>; <volume>20</volume>: <fpage>285</fpage>&#8211;<lpage>288</lpage>.<pub-id pub-id-type="pmid">29516666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bdi.12637</pub-id><pub-id pub-id-type="pmcid">PMC5940490</pub-id></mixed-citation></ref><ref id="bibr20-20552076251380065"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kourtis</surname><given-names>LC</given-names></name><name name-style="western"><surname>Regele</surname><given-names>OB</given-names></name><name name-style="western"><surname>Wright</surname><given-names>JM</given-names></name></person-group>, <etal>et al.</etal><article-title>Digital biomarkers for Alzheimer's disease: the mobile/wearable devices opportunity</article-title>. <source>NPJ Digit Med</source><year>2019</year>; <volume>2</volume>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-019-0084-2</pub-id><pub-id pub-id-type="pmcid">PMC6526279</pub-id><pub-id pub-id-type="pmid">31119198</pub-id></mixed-citation></ref><ref id="bibr21-20552076251380065"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanderlip</surname><given-names>CR</given-names></name><name name-style="western"><surname>Stark</surname><given-names>CEL</given-names></name><name name-style="western"><surname>Initiative</surname><given-names>l</given-names></name></person-group>. <article-title>Digital cognitive assessments as low-burden markers for predicting future cognitive decline and tau accumulation across the Alzheimer's spectrum</article-title>. <source>Alzheimers Dement</source><year>2024</year>; <volume>20</volume>: <fpage>6881</fpage>&#8211;<lpage>6895</lpage>.<pub-id pub-id-type="pmid">39239892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14154</pub-id><pub-id pub-id-type="pmcid">PMC11485398</pub-id></mixed-citation></ref><ref id="bibr22-20552076251380065"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smagula</surname><given-names>SF</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Krafty</surname><given-names>RT</given-names></name></person-group>, <etal>et al.</etal><article-title>Sleep-wake behaviors associated with cognitive performance in middle-aged participants of the Hispanic Community Health Study/Study of Latinos</article-title>. <source>Sleep Health</source><year>2024</year>; <volume>10</volume>: <fpage>500</fpage>&#8211;<lpage>507</lpage>.<pub-id pub-id-type="pmid">38693044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.sleh.2024.02.002</pub-id><pub-id pub-id-type="pmcid">PMC11309910</pub-id></mixed-citation></ref><ref id="bibr23-20552076251380065"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dagum</surname><given-names>P</given-names></name></person-group>. <article-title>Digital biomarkers of cognitive function</article-title>. <source>NPJ Digit Med</source><year>2018</year>; <volume>1</volume>: <fpage>10</fpage>.<pub-id pub-id-type="pmid">31304295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41746-018-0018-4</pub-id><pub-id pub-id-type="pmcid">PMC6550173</pub-id></mixed-citation></ref><ref id="bibr24-20552076251380065"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Jankovic</surname><given-names>F</given-names></name><name name-style="western"><surname>Marinsek</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Developing measures of cognitive impairment in the real world from consumer-grade multimodal sensor streams</article-title>. <source>Proceedings of the 25th ACM SIGKDD International Conference on Knowledge Discovery &amp; Data Mining; Anchorage, AK, USA: Association for Computing Machinery</source><year>2019</year>: pp.<fpage>2145</fpage>&#8211;<lpage>2155</lpage>.</mixed-citation></ref><ref id="bibr25-20552076251380065"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilmer</surname><given-names>HH</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>LE</given-names></name><name name-style="western"><surname>Chein</surname><given-names>JM</given-names></name></person-group>. <article-title>Smartphones and cognition: a review of research exploring the links between mobile technology habits and cognitive functioning</article-title>. <source>Front Psychol</source><year>2017</year>; <volume>8: 605</volume>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyg.2017.00605</pub-id><pub-id pub-id-type="pmcid">PMC5403814</pub-id><pub-id pub-id-type="pmid">28487665</pub-id></mixed-citation></ref><ref id="bibr26-20552076251380065"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>HM</given-names></name><name name-style="western"><surname>Tarraf</surname><given-names>W</given-names></name><name name-style="western"><surname>Fornage</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>A research framework for cognitive aging and Alzheimer's disease among diverse US Latinos: design and implementation of the Hispanic Community Health Study/Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA)</article-title>. <source>Alzheimers Dement</source><year>2019</year>; <volume>15</volume>: <fpage>1624</fpage>&#8211;<lpage>1632</lpage>.<pub-id pub-id-type="pmid">31759880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2019.08.192</pub-id><pub-id pub-id-type="pmcid">PMC6925624</pub-id></mixed-citation></ref><ref id="bibr27-20552076251380065"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filshtein</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Dugger</surname><given-names>BN</given-names></name><name name-style="western"><surname>Jin</surname><given-names>LW</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuropathological diagnoses of demented Hispanic, black, and non-Hispanic white decedents seen at an Alzheimer's disease center</article-title>. <source>J Alzheimers Dis</source><year>2019</year>; <volume>68</volume>: <fpage>145</fpage>&#8211;<lpage>158</lpage>.<pub-id pub-id-type="pmid">30775996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-180992</pub-id><pub-id pub-id-type="pmcid">PMC7286069</pub-id></mixed-citation></ref><ref id="bibr28-20552076251380065"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haan</surname><given-names>MN</given-names></name><name name-style="western"><surname>Mungas</surname><given-names>DM</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>HM</given-names></name></person-group>, <etal>et al.</etal><article-title>Prevalence of dementia in older Latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors</article-title>. <source>J Am Geriatr Soc</source><year>2003</year>; <volume>51</volume>: <fpage>169</fpage>&#8211;<lpage>177</lpage>.<pub-id pub-id-type="pmid">12558712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1532-5415.2003.51054.x</pub-id></mixed-citation></ref><ref id="bibr29-20552076251380065"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weissberger</surname><given-names>GH</given-names></name><name name-style="western"><surname>Gollan</surname><given-names>TH</given-names></name><name name-style="western"><surname>Bondi</surname><given-names>MW</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuropsychological deficit profiles, vascular risk factors, and neuropathological findings in Hispanic older adults with autopsy-confirmed Alzheimer's disease</article-title>. <source>J Alzheimers Dis</source><year>2019</year>; <volume>67</volume>: <fpage>291</fpage>&#8211;<lpage>302</lpage>.<pub-id pub-id-type="pmid">30636736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-180351</pub-id><pub-id pub-id-type="pmcid">PMC6925532</pub-id></mixed-citation></ref><ref id="bibr30-20552076251380065"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daviglus</surname><given-names>ML</given-names></name><name name-style="western"><surname>Talavera</surname><given-names>GA</given-names></name><name name-style="western"><surname>Aviles-Santa</surname><given-names>ML</given-names></name></person-group>, <etal>et al.</etal><article-title>Prevalence of major cardiovascular risk factors and cardiovascular diseases among Hispanic/Latino individuals of diverse backgrounds in the United States</article-title>. <source>JAMA</source><year>2012</year>; <volume>308</volume>: <fpage>1775</fpage>&#8211;<lpage>1784</lpage>.<pub-id pub-id-type="pmid">23117778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2012.14517</pub-id><pub-id pub-id-type="pmcid">PMC3777250</pub-id></mixed-citation></ref><ref id="bibr31-20552076251380065"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>HM</given-names></name><name name-style="western"><surname>Tarraf</surname><given-names>W</given-names></name><name name-style="western"><surname>Schneiderman</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Prevalence and correlates of mild cognitive impairment among diverse Hispanics/Latinos: study of Latinos-Investigation of Neurocognitive Aging Results</article-title>. <source>Alzheimers Dement</source><year>2019</year>; <volume>15</volume>: <fpage>1507</fpage>&#8211;<lpage>1515</lpage>.<pub-id pub-id-type="pmid">31753701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2019.08.202</pub-id><pub-id pub-id-type="pmcid">PMC7318558</pub-id></mixed-citation></ref><ref id="bibr32-20552076251380065"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>CV</given-names></name><name name-style="western"><surname>Perez-Stable</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>NA</given-names></name></person-group>, <etal>et al.</etal><article-title>The national institute on aging health disparities research framework</article-title>. <source>Ethn Dis</source><year>2015</year>; <volume>25</volume>: <fpage>245</fpage>&#8211;<lpage>254</lpage>.<pub-id pub-id-type="pmid">26675362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18865/ed.25.3.245</pub-id><pub-id pub-id-type="pmcid">PMC4671408</pub-id></mixed-citation></ref><ref id="bibr33-20552076251380065"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farrer</surname><given-names>LA</given-names></name><name name-style="western"><surname>Cupples</surname><given-names>LA</given-names></name><name name-style="western"><surname>Haines</surname><given-names>JL</given-names></name></person-group>, <etal>et al.</etal><article-title>Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium</article-title>. <source>JAMA</source><year>1997</year>; <volume>278</volume>: <fpage>1349</fpage>&#8211;<lpage>1356</lpage>.<pub-id pub-id-type="pmid">9343467</pub-id></mixed-citation></ref><ref id="bibr34-20552076251380065"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nitrini</surname><given-names>R</given-names></name><name name-style="western"><surname>Bottino</surname><given-names>CM</given-names></name><name name-style="western"><surname>Albala</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Prevalence of dementia in Latin America: a collaborative study of population-based cohorts</article-title>. <source>Int Psychogeriatr</source><year>2009</year>; <volume>21</volume>: <fpage>622</fpage>&#8211;<lpage>630</lpage>.<pub-id pub-id-type="pmid">19505354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1041610209009430</pub-id><pub-id pub-id-type="pmcid">PMC8324310</pub-id></mixed-citation></ref><ref id="bibr35-20552076251380065"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilbur</surname><given-names>J</given-names></name><name name-style="western"><surname>Marquez</surname><given-names>DX</given-names></name><name name-style="western"><surname>Fogg</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>The relationship between physical activity and cognition in older latinos</article-title>. <source>J Gerontol B Psychol Sci Soc Sci</source><year>2012</year>; <volume>67</volume>: <fpage>525</fpage>&#8211;<lpage>534</lpage>.<pub-id pub-id-type="pmid">22321957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/geronb/gbr137</pub-id></mixed-citation></ref><ref id="bibr36-20552076251380065"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buracchio</surname><given-names>T</given-names></name><name name-style="western"><surname>Dodge</surname><given-names>HH</given-names></name><name name-style="western"><surname>Howieson</surname><given-names>D</given-names></name></person-group>, <etal>et al.</etal><article-title>The trajectory of gait speed preceding mild cognitive impairment</article-title>. <source>Arch Neurol</source><year>2010</year>; <volume>67</volume>: <fpage>980</fpage>&#8211;<lpage>986</lpage>.<pub-id pub-id-type="pmid">20697049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneurol.2010.159</pub-id><pub-id pub-id-type="pmcid">PMC2921227</pub-id></mixed-citation></ref><ref id="bibr37-20552076251380065"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacAulay</surname><given-names>RK</given-names></name><name name-style="western"><surname>Allaire</surname><given-names>T</given-names></name><name name-style="western"><surname>Brouillette</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Apolipoprotein E genotype linked to spatial gait characteristics: predictors of cognitive dual task gait change</article-title>. <source>PLoS One</source><year>2016</year>; <volume>11</volume>: <comment>e0156732</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0156732</pub-id><pub-id pub-id-type="pmcid">PMC4972432</pub-id><pub-id pub-id-type="pmid">27486898</pub-id></mixed-citation></ref><ref id="bibr38-20552076251380065"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osibogun</surname><given-names>OI</given-names></name><name name-style="western"><surname>Ogunmoroti</surname><given-names>O</given-names></name><name name-style="western"><surname>Benson</surname><given-names>EM</given-names></name></person-group>, <etal>et al.</etal><article-title>Sex differences in the association between ideal cardiovascular health and biomarkers of cardiovascular disease: the multi-ethnic study of atherosclerosis</article-title>. <source>Circulation</source><year>2019</year>; <comment>9(11): e031414</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2019-031414</pub-id><pub-id pub-id-type="pmcid">PMC6886920</pub-id><pub-id pub-id-type="pmid">31772093</pub-id></mixed-citation></ref><ref id="bibr39-20552076251380065"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos</surname><given-names>AR</given-names></name><name name-style="western"><surname>Tarraf</surname><given-names>W</given-names></name><name name-style="western"><surname>Daviglus</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Sleep duration and neurocognitive function in the Hispanic Community Health Study/Study of Latinos</article-title>. <source>Sleep</source><year>2016</year>; <volume>39</volume>: <fpage>1843</fpage>&#8211;<lpage>1851</lpage>.<pub-id pub-id-type="pmid">27450689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5665/sleep.6166</pub-id><pub-id pub-id-type="pmcid">PMC5020366</pub-id></mixed-citation></ref><ref id="bibr40-20552076251380065"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasquez</surname><given-names>E</given-names></name><name name-style="western"><surname>Strizich</surname><given-names>G</given-names></name><name name-style="western"><surname>Isasi</surname><given-names>CR</given-names></name></person-group>, <etal>et al.</etal><article-title>Is there a relationship between accelerometer-assessed physical activity and sedentary behavior and cognitive function in US Hispanic/Latino adults? The Hispanic Community Health Study/Study of Latinos (HCHS/SOL)</article-title>. <source>Prev Med</source><year>2017</year>; <volume>103</volume>: <fpage>43</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">28765082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ypmed.2017.07.024</pub-id><pub-id pub-id-type="pmcid">PMC5798874</pub-id></mixed-citation></ref><ref id="bibr41-20552076251380065"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wennberg</surname><given-names>AMV</given-names></name><name name-style="western"><surname>Lesnick</surname><given-names>TG</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>CG</given-names></name></person-group>, <etal>et al.</etal><article-title>Longitudinal association between brain amyloid-beta and gait in the Mayo Clinic Study of aging</article-title>. <source>J Gerontol A Biol Sci Med Sci</source><year>2018</year>; <volume>73</volume>: <fpage>1244</fpage>&#8211;<lpage>1250</lpage>.<pub-id pub-id-type="pmid">29236984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glx240</pub-id><pub-id pub-id-type="pmcid">PMC6093355</pub-id></mixed-citation></ref><ref id="bibr42-20552076251380065"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gifford</surname><given-names>KA</given-names></name><name name-style="western"><surname>Bell</surname><given-names>SP</given-names></name><name name-style="western"><surname>Liu</surname><given-names>DD</given-names></name></person-group>, <etal>et al.</etal><article-title>Frailty is related to subjective cognitive decline in older women without dementia</article-title>. <source>J Am Geriatr Soc</source><year>2019</year>; <volume>67</volume>: <fpage>1803</fpage>&#8211;<lpage>1811</lpage>.<pub-id pub-id-type="pmid">31095735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgs.15972</pub-id><pub-id pub-id-type="pmcid">PMC6781867</pub-id></mixed-citation></ref><ref id="bibr43-20552076251380065"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sillars</surname><given-names>A</given-names></name><name name-style="western"><surname>Ho</surname><given-names>FK</given-names></name><name name-style="western"><surname>Pell</surname><given-names>GP</given-names></name></person-group>, <etal>et al.</etal><article-title>Sex differences in the association of risk factors for heart failure incidence and mortality</article-title>. <source>Heart</source><year>2020</year>; <volume>106</volume>: <fpage>203</fpage>&#8211;<lpage>212</lpage>.<pub-id pub-id-type="pmid">31366573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/heartjnl-2019-314878</pub-id></mixed-citation></ref><ref id="bibr44-20552076251380065"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlsson</surname><given-names>AC</given-names></name><name name-style="western"><surname>Wandell</surname><given-names>PE</given-names></name><name name-style="western"><surname>de Faire</surname><given-names>U</given-names></name></person-group>, <etal>et al.</etal><article-title>Risk factors associated with newly diagnosed high blood pressure in men and women</article-title>. <source>Am J Hypertens</source><year>2008</year>; <volume>21</volume>: <fpage>771</fpage>&#8211;<lpage>777</lpage>.<pub-id pub-id-type="pmid">18437125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ajh.2008.167</pub-id></mixed-citation></ref><ref id="bibr45-20552076251380065"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yusuf</surname><given-names>S</given-names></name><name name-style="western"><surname>Hawken</surname><given-names>S</given-names></name><name name-style="western"><surname>Ounpuu</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study</article-title>. <source>Lancet</source><year>2004</year>; <volume>364</volume>: <fpage>937</fpage>&#8211;<lpage>952</lpage>.<pub-id pub-id-type="pmid">15364185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(04)17018-9</pub-id></mixed-citation></ref><ref id="bibr46-20552076251380065"><label>46</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Moslimani</surname><given-names>M</given-names></name><name name-style="western"><surname>Bustamante</surname><given-names>L</given-names></name></person-group>. <comment>Facts on Latinos in the U.S.2023 December 26, 2024. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pewresearch.org/race-and-ethnicity/fact-sheet/latinos-in-the-us-fact-sheet/" ext-link-type="uri">https://www.pewresearch.org/race-and-ethnicity/fact-sheet/latinos-in-the-us-fact-sheet/</ext-link></comment>.</mixed-citation></ref><ref id="bibr47-20552076251380065"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marquine</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kamalyan</surname><given-names>L</given-names></name><name name-style="western"><surname>Zlatar</surname><given-names>ZZ</given-names></name></person-group>, <etal>et al.</etal><article-title>Disparities in metabolic syndrome and neurocognitive function among older hispanics/latinos with human immunodeficiency virus</article-title>. <source>AIDS Patient Care STDS</source><year>2024</year>; <volume>38</volume>: <fpage>195</fpage>&#8211;<lpage>205</lpage>.<pub-id pub-id-type="pmid">38662469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/apc.2024.0043</pub-id><pub-id pub-id-type="pmcid">PMC11301713</pub-id></mixed-citation></ref><ref id="bibr48-20552076251380065"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mungas</surname><given-names>D</given-names></name><name name-style="western"><surname>Reed</surname><given-names>BR</given-names></name><name name-style="western"><surname>Crane</surname><given-names>PK</given-names></name></person-group>, <etal>et al.</etal><article-title>Spanish and English Neuropsychological Assessment Scales (SENAS): further development and psychometric characteristics</article-title>. <source>Psychol Assess</source><year>2004</year>; <volume>16</volume>: <fpage>347</fpage>&#8211;<lpage>359</lpage>.<pub-id pub-id-type="pmid">15584794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/1040-3590.16.4.347</pub-id></mixed-citation></ref><ref id="bibr49-20552076251380065"><label>49</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Benton</surname><given-names>AL</given-names></name><name name-style="western"><surname>Hamsher</surname><given-names>K</given-names></name></person-group>. <source>Multilingual aphasia examination</source>. <edition>2nd ed.</edition><publisher-loc>Iowa City</publisher-loc>: <publisher-name>AJA Associates</publisher-name>, <year>1989</year>.</mixed-citation></ref><ref id="bibr50-20552076251380065"><label>50</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Artiola i Fortuny</surname><given-names>L</given-names></name><name name-style="western"><surname>Hermosillo Romo</surname><given-names>D</given-names></name><name name-style="western"><surname>Heaton</surname><given-names>RK</given-names></name></person-group>, <etal>et al.</etal><source>Manual de Normas y Procedimientos para la Bateria Neuropsicologica en Espanol</source>. <publisher-loc>Tucson</publisher-loc>, <publisher-loc>AZ</publisher-loc>: <publisher-name>m Press</publisher-name>, <year>1999</year>.</mixed-citation></ref><ref id="bibr51-20552076251380065"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomaszewski Farias</surname><given-names>S</given-names></name><name name-style="western"><surname>Mungas</surname><given-names>D</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>DJ</given-names></name></person-group>, <etal>et al.</etal><article-title>The measurement of everyday cognition: development and validation of a short form of the everyday cognition scales</article-title>. <source>Alzheimers Dement</source><year>2011</year>; <volume>7</volume>: <fpage>593</fpage>&#8211;<lpage>601</lpage>.<pub-id pub-id-type="pmid">22055976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.02.007</pub-id><pub-id pub-id-type="pmcid">PMC3211103</pub-id></mixed-citation></ref><ref id="bibr52-20552076251380065"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marquine</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Parks</surname><given-names>A</given-names></name><name name-style="western"><surname>Perales-Puchalt</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Demographically-adjusted normative data among Latinos for the version 3 of the Alzheimer's disease centers&#8217; neuropsychological test battery in the uniform data set</article-title>. <source>Alzheimers Dement</source><year>2023</year>; <volume>19</volume>: <fpage>4174</fpage>&#8211;<lpage>4186</lpage>.<pub-id pub-id-type="pmid">37356069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13313</pub-id><pub-id pub-id-type="pmcid">PMC10622863</pub-id></mixed-citation></ref><ref id="bibr53-20552076251380065"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diaz-Santos</surname><given-names>M</given-names></name><name name-style="western"><surname>Suarez</surname><given-names>PA</given-names></name><name name-style="western"><surname>Marquine</surname><given-names>MJ</given-names></name></person-group>, <etal>et al.</etal><article-title>Updated demographically adjusted norms for the Brief Visuospatial Memory Test-revised and Hopkins Verbal Learning Test-revised in Spanish-speakers from the U.S.-Mexico border region: the NP-NUMBRS project</article-title>. <source>Clin Neuropsychol</source><year>2021</year>; <volume>35</volume>: <fpage>374</fpage>&#8211;<lpage>395</lpage>.<pub-id pub-id-type="pmid">33380275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13854046.2020.1861329</pub-id><pub-id pub-id-type="pmcid">PMC8218787</pub-id></mixed-citation></ref><ref id="bibr54-20552076251380065"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marquine</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Yassai-Gonzalez</surname><given-names>D</given-names></name><name name-style="western"><surname>Perez-Tejada</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal><article-title>Demographically adjusted normative data for the Wisconsin Card Sorting Test-64 item: results from the neuropsychological norms for the U.S.-Mexico border region in Spanish (NP-NUMBRS) project</article-title>. <source>Clin Neuropsychol</source><year>2021</year>; <volume>35</volume>: <fpage>339</fpage>&#8211;<lpage>355</lpage>.<pub-id pub-id-type="pmid">31900055</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13854046.2019.1703042</pub-id><pub-id pub-id-type="pmcid">PMC7523029</pub-id></mixed-citation></ref><ref id="bibr55-20552076251380065"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivera Mindt</surname><given-names>M</given-names></name><name name-style="western"><surname>Marquine</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Aghvinian</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Demographically-adjusted norms for the processing speed subtests of the WAIS-III in a Spanish-speaking adult population: results from the neuropsychological norms for the U.S.-Mexico border region in Spanish (NP-NUMBRS) project</article-title>. <source>Clin Neuropsychol</source><year>2021</year>; <volume>35</volume>: <fpage>293</fpage>&#8211;<lpage>307</lpage>.<pub-id pub-id-type="pmid">32233833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13854046.2020.1723707</pub-id><pub-id pub-id-type="pmcid">PMC8186464</pub-id></mixed-citation></ref><ref id="bibr56-20552076251380065"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jak</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Bondi</surname><given-names>MW</given-names></name><name name-style="western"><surname>Delano-Wood</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>Quantification of five neuropsychological approaches to defining mild cognitive impairment</article-title>. <source>Am J Geriatr Psychiatry</source><year>2009</year>; <volume>17</volume>: <fpage>368</fpage>&#8211;<lpage>375</lpage>.<pub-id pub-id-type="pmid">19390294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JGP.0b013e31819431d5</pub-id><pub-id pub-id-type="pmcid">PMC2743175</pub-id></mixed-citation></ref><ref id="bibr57-20552076251380065"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cysique</surname><given-names>LA</given-names></name><name name-style="western"><surname>Franklin</surname><given-names>D</given-names></name><name name-style="western"><surname>Abramson</surname><given-names>I</given-names></name></person-group>, <etal>et al.</etal><article-title>Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change</article-title>. <source>J Clin Exp Neuropsychol</source><year>2011</year>; <volume>33</volume>: <fpage>505</fpage>&#8211;<lpage>522</lpage>.<pub-id pub-id-type="pmid">21391011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13803395.2010.535504</pub-id><pub-id pub-id-type="pmcid">PMC3151558</pub-id></mixed-citation></ref><ref id="bibr58-20552076251380065"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>American Diabetes</surname><given-names>A</given-names></name></person-group>. <article-title>Diagnosis and classification of diabetes mellitus</article-title>. <source>Diabetes Care</source><year>2010</year>; <volume>33</volume>: <comment>S62</comment>&#8211;<lpage>S69</lpage>.</mixed-citation></ref><ref id="bibr59-20552076251380065"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults</collab></person-group>. <article-title>Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)</article-title>. <source>JAMA</source><year>2001</year>; <volume>285</volume>: <fpage>2486</fpage>&#8211;<lpage>2497</lpage>.<pub-id pub-id-type="pmid">11368702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.285.19.2486</pub-id></mixed-citation></ref><ref id="bibr60-20552076251380065"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chobanian</surname><given-names>AV</given-names></name><name name-style="western"><surname>Bakris</surname><given-names>GL</given-names></name><name name-style="western"><surname>Black</surname><given-names>HR</given-names></name></person-group>, <etal>et al.</etal><article-title>Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure</article-title>. <source>Hypertension</source><year>2003</year>; <volume>42</volume>: <fpage>1206</fpage>&#8211;<lpage>1252</lpage>.<pub-id pub-id-type="pmid">14656957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.HYP.0000107251.49515.c2</pub-id></mixed-citation></ref><ref id="bibr61-20552076251380065"><label>61</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>
<italic toggle="yes">National Heart, Lung, and Blood Institute</italic>
</collab></person-group>. <comment>Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report [NIH Publication No. 98-4083].1998. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf" ext-link-type="uri">http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf</ext-link></comment>.</mixed-citation></ref><ref id="bibr62-20552076251380065"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamar</surname><given-names>M</given-names></name><name name-style="western"><surname>Durazo-Arvizu</surname><given-names>RA</given-names></name><name name-style="western"><surname>Sachdeva</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Cardiovascular disease risk factor burden and cognition: implications of ethnic diversity within the Hispanic Community Health Study/Study of Latinos</article-title>. <source>PLoS One</source><year>2019</year>; <volume>14</volume>: <comment>e0215378</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0215378</pub-id><pub-id pub-id-type="pmcid">PMC6476505</pub-id><pub-id pub-id-type="pmid">31009492</pub-id></mixed-citation></ref><ref id="bibr63-20552076251380065"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></name><name name-style="western"><surname>Insel</surname><given-names>PS</given-names></name><name name-style="western"><surname>Stomrud</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal><article-title>Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease</article-title>. <source>EMBO Mol Med</source><year>2019</year>; <volume>11</volume>: <comment>e11170</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.201911170</pub-id><pub-id pub-id-type="pmcid">PMC6895602</pub-id><pub-id pub-id-type="pmid">31709776</pub-id></mixed-citation></ref><ref id="bibr64-20552076251380065"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duering</surname><given-names>M</given-names></name><name name-style="western"><surname>Konieczny</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Tiedt</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal><article-title>Serum neurofilament light chain levels are related to small vessel disease burden</article-title>. <source>J Stroke</source><year>2018</year>; <volume>20</volume>: <fpage>228</fpage>&#8211;<lpage>238</lpage>.<pub-id pub-id-type="pmid">29886723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5853/jos.2017.02565</pub-id><pub-id pub-id-type="pmcid">PMC6007291</pub-id></mixed-citation></ref><ref id="bibr65-20552076251380065"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tropp</surname><given-names>LR</given-names></name><name name-style="western"><surname>Erkut</surname><given-names>S</given-names></name><name name-style="western"><surname>Coll</surname><given-names>CG</given-names></name></person-group>, <etal>et al.</etal><article-title>Psychological acculturation: development of a new measure for Puerto Ricans on the US mainland</article-title>. <source>Educ Psychol Meas</source><year>1999</year>; <volume>59</volume>: <fpage>351</fpage>&#8211;<lpage>367</lpage>.<pub-id pub-id-type="pmid">21415932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/00131649921969794</pub-id><pub-id pub-id-type="pmcid">PMC3057082</pub-id></mixed-citation></ref><ref id="bibr66-20552076251380065"><label>66</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Birdsong</surname><given-names>D</given-names></name><name name-style="western"><surname>Gertken</surname><given-names>LM</given-names></name><name name-style="western"><surname>Amengual</surname><given-names>M</given-names></name></person-group>. <comment>Bilingual Language Profile: An Easy-to-Use Instrument to Assess Bilingualism: COERLL, University of Texas at Austin; 2012. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://sites.la.utexas.edu/bilingual/" ext-link-type="uri">https://sites.la.utexas.edu/bilingual/</ext-link></comment>.</mixed-citation></ref><ref id="bibr67-20552076251380065"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanova</surname><given-names>I</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>DP</given-names></name><name name-style="western"><surname>Gollan</surname><given-names>TH</given-names></name></person-group>. <article-title>The multilingual naming test in Alzheimer's disease: clues to the origin of naming impairments</article-title>. <source>J Int Neuropsychol Soc</source><year>2013</year>; <volume>19</volume>: <fpage>272</fpage>&#8211;<lpage>283</lpage>.<pub-id pub-id-type="pmid">23298442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1355617712001282</pub-id><pub-id pub-id-type="pmcid">PMC4356120</pub-id></mixed-citation></ref><ref id="bibr68-20552076251380065"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stasenko</surname><given-names>A</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>DM</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>DP</given-names></name></person-group>, <etal>et al.</etal><article-title>The multilingual naming test (MINT) as a measure of picture naming ability in Alzheimer's disease</article-title>. <source>J Int Neuropsychol Soc</source><year>2019</year>; <volume>25</volume>: <fpage>821</fpage>&#8211;<lpage>833</lpage>.<pub-id pub-id-type="pmid">31248465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1355617719000560</pub-id><pub-id pub-id-type="pmcid">PMC6757330</pub-id></mixed-citation></ref><ref id="bibr69-20552076251380065"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suarez</surname><given-names>PA</given-names></name><name name-style="western"><surname>Gollan</surname><given-names>TH</given-names></name><name name-style="western"><surname>Heaton</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Second-language fluency predicts native language stroop effects: evidence from Spanish-English bilinguals</article-title>. <source>J Int Neuropsychol Soc</source><year>2014</year>; <volume>20</volume>: <fpage>342</fpage>&#8211;<lpage>348</lpage>.<pub-id pub-id-type="pmid">24622502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1355617714000058</pub-id><pub-id pub-id-type="pmcid">PMC4296729</pub-id></mixed-citation></ref><ref id="bibr70-20552076251380065"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cherner</surname><given-names>M*</given-names></name><name name-style="western"><surname>Marquine</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Umlauf</surname><given-names>AM</given-names></name></person-group>, <etal>et al.</etal><article-title>Neuropsychological Norms for the U.S.-Mexico border region in Spanish (NP-NUMBRS) project: methodology and sample characteristics</article-title>. <source>Clin Neuropsychol</source><year>2021</year>; <volume>35</volume>(<issue>2</issue>): <fpage>235</fpage>&#8211;<lpage>268</lpage>. <comment> *joint first authors</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13854046.2019.1709661</pub-id><pub-id pub-id-type="pmcid">PMC7894577</pub-id><pub-id pub-id-type="pmid">32319851</pub-id></mixed-citation></ref><ref id="bibr71-20552076251380065"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kroenke</surname><given-names>K</given-names></name><name name-style="western"><surname>Spitzer</surname><given-names>RL</given-names></name><name name-style="western"><surname>Williams</surname><given-names>JB</given-names></name></person-group>. <article-title>The PHQ-9: validity of a brief depression severity measure</article-title>. <source>J Gen Intern Med</source><year>2001</year>; <volume>16</volume>: <fpage>606</fpage>&#8211;<lpage>613</lpage>.<pub-id pub-id-type="pmid">11556941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1525-1497.2001.016009606.x</pub-id><pub-id pub-id-type="pmcid">PMC1495268</pub-id></mixed-citation></ref><ref id="bibr72-20552076251380065"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spitzer</surname><given-names>R</given-names></name><name name-style="western"><surname>Kroenke</surname><given-names>K</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>A brief measure for assessing generalized anxiety disorder: the GAD-7</article-title>. <source>Arch Intern Med</source><year>2006</year>; <volume>166</volume>: <fpage>1092</fpage>&#8211;<lpage>1097</lpage>.<pub-id pub-id-type="pmid">16717171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archinte.166.10.1092</pub-id></mixed-citation></ref><ref id="bibr73-20552076251380065"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salsman</surname><given-names>JM</given-names></name><name name-style="western"><surname>Butt</surname><given-names>Z</given-names></name><name name-style="western"><surname>Pilkonis</surname><given-names>PA</given-names></name></person-group>, <etal>et al.</etal><article-title>Emotion assessment using the NIH toolbox</article-title>. <source>Neurology</source><year>2013</year>; <volume>80</volume>: <comment>S76</comment>&#8211;<lpage>S86</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182872e11</pub-id><pub-id pub-id-type="pmcid">PMC3662334</pub-id><pub-id pub-id-type="pmid">23479549</pub-id></mixed-citation></ref><ref id="bibr74-20552076251380065"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babakhanyan</surname><given-names>I</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>B</given-names></name><name name-style="western"><surname>Casaletto</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>National Institutes of Health toolbox emotion battery for English- and Spanish-speaking adults: normative data and factor-based summary scores</article-title>. <source>Patient Relat Outcome Meas</source><year>2018</year>; <volume>9</volume>: <fpage>115</fpage>&#8211;<lpage>127</lpage>.<pub-id pub-id-type="pmid">29588623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/PROM.S151658</pub-id><pub-id pub-id-type="pmcid">PMC5859895</pub-id></mixed-citation></ref><ref id="bibr75-20552076251380065"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saunders</surname><given-names>JB</given-names></name><name name-style="western"><surname>Aasland</surname><given-names>OG</given-names></name><name name-style="western"><surname>Babor</surname><given-names>TF</given-names></name></person-group>, <etal>et al.</etal><article-title>Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption&#8211;II</article-title>. <source>Addiction</source><year>1993</year>; <volume>88</volume>: <fpage>791</fpage>&#8211;<lpage>804</lpage>.<pub-id pub-id-type="pmid">8329970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1360-0443.1993.tb02093.x</pub-id></mixed-citation></ref><ref id="bibr76-20552076251380065"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kershaw</surname><given-names>KN</given-names></name><name name-style="western"><surname>Brenes</surname><given-names>GA</given-names></name><name name-style="western"><surname>Charles</surname><given-names>LE</given-names></name></person-group>, <etal>et al.</etal><article-title>Associations of stressful life events and social strain with incident cardiovascular disease in the women's health initiative</article-title>. <source>J Am Heart Assoc</source><year>2014</year>; <volume>3</volume>: <comment>e000687</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.113.000687</pub-id><pub-id pub-id-type="pmcid">PMC4309050</pub-id><pub-id pub-id-type="pmid">24973226</pub-id></mixed-citation></ref><ref id="bibr77-20552076251380065"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frank</surname><given-names>LD</given-names></name><name name-style="western"><surname>Sallis</surname><given-names>JF</given-names></name><name name-style="western"><surname>Saelens</surname><given-names>BE</given-names></name></person-group>, <etal>et al.</etal><article-title>The development of a walkability index: application to the Neighborhood Quality of Life Study</article-title>. <source>Br J Sports Med</source><year>2010</year>; <volume>44</volume>: <fpage>924</fpage>&#8211;<lpage>933</lpage>.<pub-id pub-id-type="pmid">19406732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bjsm.2009.058701</pub-id></mixed-citation></ref><ref id="bibr78-20552076251380065"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowler</surname><given-names>DE</given-names></name><name name-style="western"><surname>Buyung-Ali</surname><given-names>LM</given-names></name><name name-style="western"><surname>Knight</surname><given-names>TM</given-names></name></person-group>, <etal>et al.</etal><article-title>A systematic review of evidence for the added benefits to health of exposure to natural environments</article-title>. <source>BMC Public Health</source><year>2010</year>; <volume>10</volume>: <fpage>456</fpage>.<pub-id pub-id-type="pmid">20684754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2458-10-456</pub-id><pub-id pub-id-type="pmcid">PMC2924288</pub-id></mixed-citation></ref><ref id="bibr79-20552076251380065"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clary</surname><given-names>C</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sharecka</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal><article-title>Should we use absolute or relative measures when assessing foodscape exposure in relation to fruit and vegetable intake? Evidence from a wide-scale Canadian study</article-title>. <source>Prev Med</source><year>2015</year>; <volume>71</volume>: <fpage>83</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">25481095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ypmed.2014.11.023</pub-id></mixed-citation></ref><ref id="bibr80-20552076251380065"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>P</given-names></name><name name-style="western"><surname>Hart</surname><given-names>JE</given-names></name><name name-style="western"><surname>Banay</surname><given-names>RF</given-names></name></person-group>, <etal>et al.</etal><article-title>Exposure to greenness and mortality in a nationwide prospective cohort study of women</article-title>. <source>Environ Health Perspect</source><year>2016</year>; <volume>124</volume>: <fpage>1344</fpage>&#8211;<lpage>1352</lpage>.<pub-id pub-id-type="pmid">27074702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1289/ehp.1510363</pub-id><pub-id pub-id-type="pmcid">PMC5010419</pub-id></mixed-citation></ref><ref id="bibr81-20552076251380065"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mennis</surname><given-names>J</given-names></name><name name-style="western"><surname>Dayanim</surname><given-names>SL</given-names></name><name name-style="western"><surname>Grunwald</surname><given-names>H</given-names></name></person-group>. <article-title>Neighborhood collective efficacy and dimensions of diversity: a multilevel analysis</article-title>. <source>Environ Plan A Econ Space</source><year>2013</year>; <volume>45</volume>: <fpage>2176</fpage>&#8211;<lpage>2193</lpage>.</mixed-citation></ref><ref id="bibr82-20552076251380065"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malecki</surname><given-names>KC</given-names></name><name name-style="western"><surname>Engelman</surname><given-names>CD</given-names></name><name name-style="western"><surname>Peppard</surname><given-names>PE</given-names></name></person-group>, <etal>et al.</etal><article-title>The Wisconsin Assessment of the Social and Built Environment (WASABE): a multi-dimensional objective audit instrument for examining neighborhood effects on health</article-title>. <source>BMC Public Health</source><year>2014</year>; <volume>14</volume>: <fpage>1165</fpage>.<pub-id pub-id-type="pmid">25391283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2458-14-1165</pub-id><pub-id pub-id-type="pmcid">PMC4289353</pub-id></mixed-citation></ref><ref id="bibr83-20552076251380065"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>AY</given-names></name><name name-style="western"><surname>Zenk</surname><given-names>SN</given-names></name><name name-style="western"><surname>Wilbur</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Effects of perceived and objective neighborhood crime on walking frequency among midlife African American women in a home-based walking intervention</article-title>. <source>J Phys Act Health</source><year>2010</year>; <volume>7</volume>: <fpage>432</fpage>&#8211;<lpage>441</lpage>.<pub-id pub-id-type="pmid">20683084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1123/jpah.7.4.432</pub-id></mixed-citation></ref><ref id="bibr84-20552076251380065"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vesel</surname><given-names>C</given-names></name><name name-style="western"><surname>Rashidisabet</surname><given-names>H</given-names></name><name name-style="western"><surname>Zulueta</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Effects of mood and aging on keystroke dynamics metadata and their diurnal patterns in a large open-science sample: a BiAffect iOS study</article-title>. <source>J Am Med Inform Assoc</source><year>2020</year>; <volume>27</volume>: <fpage>1007</fpage>&#8211;<lpage>1018</lpage>.<pub-id pub-id-type="pmid">32467973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jamia/ocaa057</pub-id><pub-id pub-id-type="pmcid">PMC7647317</pub-id></mixed-citation></ref><ref id="bibr85-20552076251380065"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marwan</surname><given-names>N</given-names></name></person-group>. <article-title>A historical review of recurrence plots</article-title>. <source>Eur Phys J Spec Top</source><year>2008</year>; <volume>164</volume>: <fpage>3</fpage>&#8211;<lpage>12</lpage>.</mixed-citation></ref><ref id="bibr86-20552076251380065"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldberger</surname><given-names>A</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>L</given-names></name></person-group>. <person-group person-group-type="author"><name name-style="western"><surname>Glass</surname><given-names>L</given-names></name></person-group>, <etal>et al</etal>. <article-title>PhysioBank, PhysioToolkit, and PhysioNet: components of a new research resource for complex physiologic signals</article-title>. <source>Circulation</source><year>2020</year>; <volume>101</volume>(<issue>23</issue>): <comment>e215</comment>&#8211;<lpage>e220</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.cir.101.23.e215</pub-id><pub-id pub-id-type="pmid">10851218</pub-id></mixed-citation></ref><ref id="bibr87-20552076251380065"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zulueta</surname><given-names>J</given-names></name><name name-style="western"><surname>Demos</surname><given-names>AP</given-names></name><name name-style="western"><surname>Vesel</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>The effects of bipolar disorder risk on a mobile phone keystroke dynamics based biomarker of brain age</article-title>. <source>Front Psychiatry</source><year>2021</year>; <volume>12</volume>: <fpage>739022</fpage>.<pub-id pub-id-type="pmid">35002792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2021.739022</pub-id><pub-id pub-id-type="pmcid">PMC8727438</pub-id></mixed-citation></ref><ref id="bibr88-20552076251380065"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ajilore</surname><given-names>O</given-names></name><name name-style="western"><surname>Bark</surname><given-names>JS</given-names></name><name name-style="western"><surname>Demos</surname><given-names>AP</given-names></name></person-group>, <etal>et al.</etal><article-title>Assessment of cognitive function in bipolar disorder with passive smartphone keystroke metadata: a BiAffect digital phenotyping study</article-title>. <source>Front Psychiatry</source><year>2025</year>; <volume>16</volume>: <fpage>1430303</fpage>.<pub-id pub-id-type="pmid">40115651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpsyt.2025.1430303</pub-id><pub-id pub-id-type="pmcid">PMC11922855</pub-id></mixed-citation></ref><ref id="bibr89-20552076251380065"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>MK</given-names></name><name name-style="western"><surname>Demos</surname><given-names>AP</given-names></name><name name-style="western"><surname>Zulueta</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Naturalistic smartphone keyboard typing reflects processing speed and executive function</article-title>. <source>Brain Behav</source><year>2021</year>; <volume>11</volume>: <comment>e2363</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/brb3.2363</pub-id><pub-id pub-id-type="pmcid">PMC8613429</pub-id><pub-id pub-id-type="pmid">34612605</pub-id></mixed-citation></ref><ref id="bibr90-20552076251380065"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vesel</surname><given-names>C</given-names></name><name name-style="western"><surname>Rashidisabet</surname><given-names>H</given-names></name><name name-style="western"><surname>Zulueta</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal><article-title>Effects of mood and aging on keystroke dynamics metadata and their diurnal patterns in a large open-science sample: a BiAffect iOS study</article-title>. <source>J Am Med Inform Assoc</source><year>2020</year>; <volume>27</volume>: <fpage>1007</fpage>&#8211;<lpage>1018</lpage>.<pub-id pub-id-type="pmid">32467973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jamia/ocaa057</pub-id><pub-id pub-id-type="pmcid">PMC7647317</pub-id></mixed-citation></ref><ref id="bibr91-20552076251380065"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ning</surname><given-names>E</given-names></name><name name-style="western"><surname>Estabrook</surname><given-names>R</given-names></name><name name-style="western"><surname>Tulabandhula</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal><article-title>Predicting cognitive functioning in mood disorders through smartphone typing dynamics</article-title>. <source>J Psychopathol Clin Sci</source><volume>2025. Advance online publication. https://doi.org/10.1037/abn0001052</volume>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/abn0001052</pub-id><pub-id pub-id-type="pmcid">PMC12412914</pub-id><pub-id pub-id-type="pmid">40906034</pub-id></mixed-citation></ref><ref id="bibr92-20552076251380065"><label>92</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Goodfellow</surname><given-names>I</given-names></name><name name-style="western"><surname>Bengio</surname><given-names>Y</given-names></name><name name-style="western"><surname>Courville</surname><given-names>A</given-names></name></person-group>. <comment>A Deep Learning: An MIT Book. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.deeplearningbook.org/" ext-link-type="uri">https://www.deeplearningbook.org/</ext-link> 2020</comment>.</mixed-citation></ref><ref id="bibr93-20552076251380065"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glenn</surname><given-names>T</given-names></name><name name-style="western"><surname>Whybrow</surname><given-names>PC</given-names></name><name name-style="western"><surname>Rasgon</surname><given-names>N</given-names></name></person-group>, <etal>et al.</etal><article-title>Approximate entropy of self-reported mood prior to episodes in bipolar disorder</article-title>. <source>Bipolar Disord</source><year>2006</year>; <volume>8</volume>: <fpage>424</fpage>&#8211;<lpage>429</lpage>.<pub-id pub-id-type="pmid">17042880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1399-5618.2006.00373.x</pub-id></mixed-citation></ref><ref id="bibr94-20552076251380065"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Indic</surname><given-names>P</given-names></name><name name-style="western"><surname>Salvatore</surname><given-names>P</given-names></name><name name-style="western"><surname>Maggini</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Scaling behavior of human locomotor activity amplitude: association with bipolar disorder</article-title>. <source>PLoS One</source><year>2011</year>; <volume>6</volume>: <comment>e20650</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0020650</pub-id><pub-id pub-id-type="pmcid">PMC3105113</pub-id><pub-id pub-id-type="pmid">21655197</pub-id></mixed-citation></ref><ref id="bibr95-20552076251380065"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauge</surname><given-names>E</given-names></name><name name-style="western"><surname>Berle</surname><given-names>J</given-names></name><name name-style="western"><surname>Oedegaard</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal><article-title>Nonlinear analysis of motor activity shows differences between schizophrenia and depression: a study using Fourier analysis and sample entropy</article-title>. <source>PLoS One</source><year>2011</year>; <volume>6</volume>: <comment>e16291</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0016291</pub-id><pub-id pub-id-type="pmcid">PMC3030566</pub-id><pub-id pub-id-type="pmid">21297977</pub-id></mixed-citation></ref><ref id="bibr96-20552076251380065"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name></person-group>, <etal>et al.</etal><article-title>Multiscale entropy analysis of biological signals: a fundamental bi-scaling law</article-title>. <source>Front Comput Neurosci</source><year>2015</year>; <volume>9</volume>: <fpage>64</fpage>.<pub-id pub-id-type="pmid">26082711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncom.2015.00064</pub-id><pub-id pub-id-type="pmcid">PMC4451367</pub-id></mixed-citation></ref><ref id="bibr97-20552076251380065"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldberger</surname><given-names>AL</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>LA</given-names></name><name name-style="western"><surname>Glass</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal><article-title>Physiobank, PhysioToolkit, and PhysioNet: components of a new research resource for complex physiologic signals</article-title>. <source>Circulation</source><year>2000</year>; <volume>101</volume>: <comment>E215</comment>&#8211;<lpage>E220</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.cir.101.23.e215</pub-id><pub-id pub-id-type="pmid">10851218</pub-id></mixed-citation></ref><ref id="bibr98-20552076251380065"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marwan</surname><given-names>N</given-names></name></person-group>. <article-title>A historical review of recurrence plots</article-title>. <source>Eur Phys J Spec Top</source><year>2008</year>; <volume>164</volume>: <fpage>3</fpage>&#8211;<lpage>12</lpage>.</mixed-citation></ref><ref id="bibr99-20552076251380065"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouyang</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Dang</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal><article-title>Using recurrence plot for determinism analysis of EEG recordings in genetic absence epilepsy rats</article-title>. <source>Clin Neurophysiol</source><year>2008</year>; <volume>119</volume>: <fpage>1747</fpage>&#8211;<lpage>1755</lpage>.<pub-id pub-id-type="pmid">18486542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinph.2008.04.005</pub-id></mixed-citation></ref><ref id="bibr100-20552076251380065"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>N W</surname><given-names>NM</given-names></name><name name-style="western"><surname>A S</surname><given-names>UM</given-names></name><name name-style="western"><surname>K</surname><given-names>J</given-names></name></person-group>. <article-title>Recurrence-plot-based measures of complexity and their application to heart-rate-variability data</article-title>. <source>Phys Rev E</source><year>2002</year>; <volume>66</volume>: <fpage>026702</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1103/PhysRevE.66.026702</pub-id><pub-id pub-id-type="pmid">12241313</pub-id></mixed-citation></ref><ref id="bibr101-20552076251380065"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demos</surname><given-names>AP</given-names></name><name name-style="western"><surname>Chaffin</surname><given-names>R</given-names></name><name name-style="western"><surname>Logan</surname><given-names>T</given-names></name></person-group>. <article-title>Musicians body sway embodies musical structure and expression: a recurrence-based approach</article-title>. <source>Music Sci</source><year>2017</year>; <volume>22</volume>: <fpage>244</fpage>&#8211;<lpage>263</lpage>.</mixed-citation></ref><ref id="bibr102-20552076251380065"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finch</surname><given-names>WH</given-names></name><name name-style="western"><surname>Finch</surname><given-names>MEH</given-names></name></person-group>. <article-title>Multivariate regression with small samples: a comparison of estimation methods</article-title>. <source>Gen Linear Model J</source><year>2017</year>; <volume>43</volume>: <fpage>16</fpage>&#8211;<lpage>30</lpage>.</mixed-citation></ref><ref id="bibr103-20552076251380065"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name></person-group>, <etal>et al.</etal><article-title>Variable selection for distribution-free models for longitudinal zero-inflated count responses</article-title>. <source>Stat Med</source><year>2016</year>; <volume>35</volume>: <fpage>2770</fpage>&#8211;<lpage>2785</lpage>.<pub-id pub-id-type="pmid">26844819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/sim.6892</pub-id></mixed-citation></ref><ref id="bibr104-20552076251380065"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><name name-style="western"><surname>Guestrin</surname><given-names>C</given-names></name></person-group>. <article-title>XGBoost: a scalable tree boosting system</article-title>. <source>In Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining ACM, New York, NY, USA,</source><year>2016</year>: <fpage>785</fpage>&#8211;<lpage>794</lpage>.</mixed-citation></ref><ref id="bibr105-20552076251380065"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Graber</surname><given-names>A</given-names></name><name name-style="western"><surname>McBurney</surname><given-names>RN</given-names></name></person-group>, <etal>et al.</etal><article-title>Sample size and statistical power considerations in high-dimensionality data settings: a comparative study of classification algorithms</article-title>. <source>BMC Bioinform</source><year>2010</year>; <volume>11</volume>: <fpage>447</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2105-11-447</pub-id><pub-id pub-id-type="pmcid">PMC2942858</pub-id><pub-id pub-id-type="pmid">20815881</pub-id></mixed-citation></ref><ref id="bibr106-20552076251380065"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zavorka</surname><given-names>S</given-names></name><name name-style="western"><surname>Perrett</surname><given-names>JJ</given-names></name></person-group>. <article-title>Minimum sample size considerations for two-group linear and quadratic discriminant analysis with rare populations</article-title>. <source>Commun Stat Simul Comput</source><year>2014</year>; <volume>43</volume>: <fpage>1726</fpage>&#8211;<lpage>1739</lpage>.</mixed-citation></ref><ref id="bibr107-20552076251380065"><label>107</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Hastie</surname><given-names>T</given-names></name><name name-style="western"><surname>Tibshirani</surname><given-names>R</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>J</given-names></name></person-group>. <source>The elements of statistical learning: data mining, inference, and prediction</source>. <publisher-loc>New York, NY, USA</publisher-loc>: <publisher-name>Springer Science &amp; Business Media</publisher-name>, <year>2009</year>.</mixed-citation></ref><ref id="bibr108-20552076251380065"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H</surname><given-names>S</given-names></name></person-group>. <article-title>A simple sequentially rejective multiple test procedure</article-title>. <source>Scand J Stat</source><year>1979</year>; <volume>6</volume>: <fpage>65</fpage>&#8211;<lpage>70</lpage>.</mixed-citation></ref><ref id="bibr109-20552076251380065"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benjamini</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hochberg</surname><given-names>Y</given-names></name></person-group>. <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>J R Stat Soc Ser B (Methodol)</source><year>1995</year>; <volume>57</volume>: <fpage>289</fpage>&#8211;<lpage>300</lpage>.</mixed-citation></ref><ref id="bibr110-20552076251380065"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Ji</surname><given-names>L</given-names></name></person-group>. <article-title>Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix</article-title>. <source>Heredity</source><year>2005</year>; <volume>95</volume>: <fpage>221</fpage>&#8211;<lpage>227</lpage>.<pub-id pub-id-type="pmid">16077740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.hdy.6800717</pub-id></mixed-citation></ref><ref id="bibr111-20552076251380065"><label>111</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Singer</surname><given-names>JD</given-names></name><name name-style="western"><surname>Willett</surname><given-names>JB</given-names></name></person-group>. <source>Applied longitudinal data analysis: Modeling change and event occurrence</source>. <publisher-loc>New York</publisher-loc>, <publisher-loc>NY</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>, <year>2003</year>.</mixed-citation></ref><ref id="bibr112-20552076251380065"><label>112</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name><name name-style="western"><surname>He</surname><given-names>H</given-names></name><name name-style="western"><surname>Tu</surname><given-names>XM</given-names></name></person-group>. <source>Applied categorical and count data analysis</source><italic toggle="yes">.</italic><publisher-loc>New York</publisher-loc>, <publisher-loc>NY</publisher-loc>: <publisher-name>Chapman &amp; Hall/CRC</publisher-name>, <year>2012</year>.</mixed-citation></ref><ref id="bibr113-20552076251380065"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>S</given-names></name><name name-style="western"><surname>Scealy</surname><given-names>JL</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>AH</given-names></name></person-group>. <article-title>Model selection in linear mixed models</article-title>. <source>Stat Sci</source><year>2013</year>; <volume>28</volume>: <fpage>135</fpage>&#8211;<lpage>167</lpage>.</mixed-citation></ref><ref id="bibr114-20552076251380065"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piendel</surname><given-names>L</given-names></name><name name-style="western"><surname>Valis</surname><given-names>M</given-names></name><name name-style="western"><surname>Hort</surname><given-names>J</given-names></name></person-group>. <article-title>An update on mobile applications collecting data among subjects with or at risk of Alzheimer's disease</article-title>. <source>Front Aging Neurosci</source><year>2023</year>; <volume>15</volume>: 1134096. doi: 10.3389/fnagi.2023.1134096.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2023.1134096</pub-id><pub-id pub-id-type="pmcid">PMC10267974</pub-id><pub-id pub-id-type="pmid">37323138</pub-id></mixed-citation></ref><ref id="bibr115-20552076251380065"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butler</surname><given-names>PM</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Brown</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal><article-title>Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment</article-title>. <source>Nat Med</source><year>2025</year>; <volume>31</volume>(<issue>3</issue>): <fpage>829</fpage>&#8211;<lpage>839</lpage>.<pub-id pub-id-type="pmid">40038507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-03475-9</pub-id><pub-id pub-id-type="pmcid">PMC11922773</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Acta Neuropathol</journal-id><journal-id journal-id-type="iso-abbrev">Acta Neuropathol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Acta Neuropathologica</journal-title></journal-title-group><issn pub-type="ppub">0001-6322</issn><issn pub-type="epub">1432-0533</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12479634</article-id><article-id pub-id-type="pmcid-ver">PMC12479634.1</article-id><article-id pub-id-type="pmcaid">12479634</article-id><article-id pub-id-type="pmcaiid">12479634</article-id><article-id pub-id-type="pmid">41023457</article-id><article-id pub-id-type="doi">10.1007/s00401-025-02930-2</article-id><article-id pub-id-type="publisher-id">2930</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Reversible tau hyperphosphorylation in hibernation: a blood biomarker and brain tissue study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Brum</surname><given-names initials="WS">Wagner S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Montoliu-Gaya</surname><given-names initials="L">Laia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Brinkmalm</surname><given-names initials="G">Gunnar</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Piotrowska</surname><given-names initials="D">Diana</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Camporesi</surname><given-names initials="E">Elena</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>J&#228;ger</surname><given-names initials="C">Carsten</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Isaksson</surname><given-names initials="HS">Helena S.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Martin</surname><given-names initials="S">Sven</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Kindberg</surname><given-names initials="J">Jonas</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Lantero-Rodriguez</surname><given-names initials="J">Juan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Ferrari-Souza</surname><given-names initials="JP">Jo&#227;o Pedro</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Moscoso</surname><given-names initials="A">Alexis</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Benedet</surname><given-names initials="AL">Andrea L.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Janelidze</surname><given-names initials="S">Shorena</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Gobom</surname><given-names initials="J">Johan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Zetterberg</surname><given-names initials="H">Henrik</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Hansson</surname><given-names initials="O">Oskar</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Zimmer</surname><given-names initials="ER">Eduardo R.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff17">17</xref><xref ref-type="aff" rid="Aff18">18</xref><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Ashton</surname><given-names initials="NJ">Nicholas J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff20">20</xref><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Arendt</surname><given-names initials="T">Thomas</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Lashley</surname><given-names initials="T">Tammaryn</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Stieler</surname><given-names initials="JT">Jens T.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="no"><name name-style="western"><surname>Holzer</surname><given-names initials="M">Max</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Fr&#246;bert</surname><given-names initials="O">Ole</given-names></name><address><email>ole.frobert@regionorebrolan.se</email></address><xref ref-type="aff" rid="Aff22">22</xref><xref ref-type="aff" rid="Aff23">23</xref><xref ref-type="aff" rid="Aff24">24</xref><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Blennow</surname><given-names initials="K">Kaj</given-names></name><address><email>kaj.blennow@neuro.gu.se</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff26">26</xref><xref ref-type="aff" rid="Aff27">27</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01tm6cn81</institution-id><institution-id institution-id-type="GRID">grid.8761.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9919 9582</institution-id><institution>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, </institution><institution>The Sahlgrenska Academy at the University of Gothenburg, </institution></institution-wrap>M&#246;lndal, Sweden </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/041yk2d64</institution-id><institution-id institution-id-type="GRID">grid.8532.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2200 7498</institution-id><institution>Graduate Program in Biological Sciences: Biochemistry, </institution><institution>Universidade Federal Do Rio Grande Do Sul (UFRGS), </institution></institution-wrap>Porto Alegre, Brazil </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03s7gtk40</institution-id><institution-id institution-id-type="GRID">grid.9647.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 7669 9786</institution-id><institution>Paul Flechsig Institute, Centre of Neuropathology and Brain Research, </institution><institution>University of Leipzig Medical Center, </institution></institution-wrap>Leipzig, Germany </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0387jng26</institution-id><institution-id institution-id-type="GRID">grid.419524.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0041 5028</institution-id><institution>Department of Neurophysics, </institution><institution>Max Planck Institute for Human Cognitive and Brain Sciences, </institution></institution-wrap>Leipzig, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05kytsw45</institution-id><institution-id institution-id-type="GRID">grid.15895.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 0738 8966</institution-id><institution>School of Medical Sciences, </institution><institution>&#214;rebro University, </institution></institution-wrap>&#214;rebro, Sweden </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04aha0598</institution-id><institution-id institution-id-type="GRID">grid.420127.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2107 519X</institution-id><institution>Norwegian Institute for Nature Research, </institution></institution-wrap>Trondheim, Norway </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02yy8x990</institution-id><institution-id institution-id-type="GRID">grid.6341.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 8578 2742</institution-id><institution>Department of Wildlife, Fish and Environmental Studies, </institution><institution>Swedish University of Agricultural Sciences, </institution></institution-wrap>Ume&#229;, Sweden </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01an3r305</institution-id><institution-id institution-id-type="GRID">grid.21925.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9000</institution-id><institution>Department of Psychiatry, </institution><institution>University of Pittsburgh, </institution></institution-wrap>Pittsburgh, PA USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n7xcf53</institution-id><institution-id institution-id-type="GRID">grid.488911.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0408 4897</institution-id><institution>Nuclear Medicine Department and Molecular Imaging Group, </institution><institution>Instituto de Investigaci&#243;n Sanitaria de Santiago de Compostela, Traves&#237;a da Choupana S/N, </institution></institution-wrap>Santiago de Compostela, Spain </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/012a77v79</institution-id><institution-id institution-id-type="GRID">grid.4514.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0930 2361</institution-id><institution>Clinical Memory Research Unit, Department of Clinical Sciences Malm&#246;, Faculty of Medicine, </institution><institution>Lund University, </institution></institution-wrap>Lund, Sweden </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution>Department of Neurodegenerative Disease, Queen Square Institute of Neurology, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jx3x895</institution-id><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution>UK Dementia Research Institute, </institution><institution>University College London, </institution></institution-wrap>London, UK </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04vgqjj36</institution-id><institution-id institution-id-type="GRID">grid.1649.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 9445 082X</institution-id><institution>Clinical Neurochemistry Laboratory, </institution><institution>Sahlgrenska University Hospital, </institution></institution-wrap>M&#246;lndal, Sweden </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00q4vv597</institution-id><institution-id institution-id-type="GRID">grid.24515.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1450</institution-id><institution>Hong Kong Center for Neurodegenerative Diseases, </institution></institution-wrap>Clear Water Bay, Hong Kong, China </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01y2jtd41</institution-id><institution-id institution-id-type="GRID">grid.14003.36</institution-id><institution-id institution-id-type="ISNI">0000 0001 2167 3675</institution-id><institution>Wisconsin Alzheimer&#8217;s Disease Research Center, School of Medicine and Public Health, </institution><institution>University of Wisconsin , </institution></institution-wrap>Madison, WI USA </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02z31g829</institution-id><institution-id institution-id-type="GRID">grid.411843.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0623 9987</institution-id><institution>Memory Clinic, </institution><institution>Sk&#229;ne University Hospital, </institution></institution-wrap>Malm&#246;, Sweden </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/041yk2d64</institution-id><institution-id institution-id-type="GRID">grid.8532.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2200 7498</institution-id><institution>Graduate Program in Biological Sciences: Pharmacology and Therapeutics, </institution><institution>UFRGS, </institution></institution-wrap>Porto Alegre, Brazil </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/041yk2d64</institution-id><institution-id institution-id-type="GRID">grid.8532.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2200 7498</institution-id><institution>Department of Pharmacology, </institution><institution>UFRGS, </institution></institution-wrap>Porto Alegre, Brazil </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01pxwe438</institution-id><institution-id institution-id-type="GRID">grid.14709.3b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8649</institution-id><institution>McGill Centre for Studies in Aging, </institution><institution>McGill University, </institution></institution-wrap>Montreal, QC Canada </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/023jwkg52</institution-id><institution>Banner Alzheimer&#8217;s Institute, </institution></institution-wrap>Phoenix, AZ USA </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04gjkkf30</institution-id><institution-id institution-id-type="GRID">grid.414208.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0619 8759</institution-id><institution>Banner Sun Health Research Institute, </institution></institution-wrap>Sun City, AZ USA </aff><aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05kytsw45</institution-id><institution-id institution-id-type="GRID">grid.15895.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 0738 8966</institution-id><institution>Faculty of Health, Department of Cardiology, </institution><institution>&#214;rebro University, </institution></institution-wrap>&#214;rebro, Sweden </aff><aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01aj84f44</institution-id><institution-id institution-id-type="GRID">grid.7048.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 1956 2722</institution-id><institution>Department of Clinical Medicine, Faculty of Health, </institution><institution>Aarhus University, </institution></institution-wrap>Aarhus, Denmark </aff><aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040r8fr65</institution-id><institution-id institution-id-type="GRID">grid.154185.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0512 597X</institution-id><institution>Department of Clinical Pharmacology, </institution><institution>Aarhus University Hospital, </institution></institution-wrap>Aarhus, Denmark </aff><aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040r8fr65</institution-id><institution-id institution-id-type="GRID">grid.154185.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0512 597X</institution-id><institution>Steno Diabetes Center Aarhus, </institution><institution>Aarhus University Hospital, </institution></institution-wrap>Aarhus, Denmark </aff><aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02mh9a093</institution-id><institution-id institution-id-type="GRID">grid.411439.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2150 9058</institution-id><institution>Paris Brain Institute, ICM, Piti&#233;-Salp&#234;tri&#232;re Hospital, Sorbonne University, </institution></institution-wrap>Paris, France </aff><aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04c4dkn09</institution-id><institution-id institution-id-type="GRID">grid.59053.3a</institution-id><institution-id institution-id-type="ISNI">0000000121679639</institution-id><institution>Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, Department of Neurology, Institute On Aging and Brain Disorders, </institution><institution>University of Science and Technology of China and First Affiliated Hospital of USTC, </institution></institution-wrap>Hefei, People&#8217;s Republic of China </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>150</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">497829</issue-id><elocation-id>36</elocation-id><history><date date-type="received"><day>7</day><month>5</month><year>2025</year></date><date date-type="rev-recd"><day>22</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 09:26:11.207"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="401_2025_Article_2930.pdf"/><abstract id="Abs1"><p id="Par1">Tau hyperphosphorylation, a key neuropathological feature of tauopathies such as Alzheimer&#8217;s disease (AD), also occurs physiologically during mammalian hibernation and is fully reversed upon arousal, offering a unique translational model to study tau metabolism. However, limited data exist on insoluble and soluble tau alterations during hibernation and on patterns of tau fragment concentrations in the hibernating mammalian brain. We quantified tau biomarkers in plasma samples from ten free-ranging brown bears (<italic toggle="yes">Ursus arctos</italic>), captured during both their active summer period and hibernation in the winter, using clinically validated immunoassays and immunoprecipitation mass spectrometry (IP-MS) techniques. We also analyzed brain tissue from ten golden Syrian hamsters (<italic toggle="yes">Mesocricetus auratus</italic>) subjected to induced torpor (hibernation) versus euthermic (non-hibernating) states by quantifying multiple phosphorylated and non-phosphorylated tau peptides with an IP-MS method previously applied in human brain tissue. In brown bears, plasma levels of phosphorylated tau (p-tau) biomarkers p-tau181 and p-tau217 significantly increased during hibernation compared to summer (median increases of 362% and 294% by IP-MS, respectively), with similar increases found with immunoassays. Additional plasma p-tau biomarkers associated with AD pathology, including p-tau205 and p-tau231, were also increased during bear hibernation. In hamster brains, p-tau217, and p-tau231 were similarly elevated during torpor, while tau fragments from the microtubule-binding region (MTBR), associated with tangle aggregation, were not increased. In contrast, brain tissue from <italic toggle="yes">n</italic>&#8201;=&#8201;10 AD patients, analyzed with the same IP-MS method, exhibited striking increases in p-tau (~&#8201;50,000% for p-tau217) and MTBR fragments (~&#8201;20,000% for MTBR tau354-369) compared with <italic toggle="yes">n</italic>&#8201;=&#8201;10 human controls. We show that hibernation-linked tau hyperphosphorylation involves some of the same phospho-sites altered in AD, but occurs without MTBR tau aggregation. This highlights hibernation as a reversible, non-pathological model to study tau biology and mechanisms underlying AD due to its reversibility and lack of tau aggregation despite hyperphosphorylation in key AD tau phospho-sites.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00401-025-02930-2.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#8217;s disease</kwd><kwd>Tau</kwd><kwd>Phosphorylated tau</kwd><kwd>Tauopathies</kwd><kwd>Hibernation</kwd><kwd>Plasma biomarkers</kwd><kwd>Neuropathology</kwd></kwd-group><funding-group><award-group><funding-source><institution>University of Gothenburg</institution></funding-source></award-group><open-access><p>Open access funding provided by University of Gothenburg.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">The accumulation of microtubule-associated protein tau (MAPT) in intracellular fibrillary deposits is a neuropathological hallmark of tauopathies [<xref ref-type="bibr" rid="CR1">1</xref>]. In Alzheimer&#8217;s disease (AD), the most prevalent tauopathy, the accumulation of misfolded and hyperphosphorylated tau (p-tau) is associated with the onset and progression of cognitive decline [<xref ref-type="bibr" rid="CR2">2</xref>]. Tau protein undergoes abnormal hyperphosphorylation at multiple sites, forming paired helical filaments that aggregate into neurofibrillary tangles in the cytoplasm, neuropil threads in dendrites, and the neuritic corona of plaques in axons and nerve terminals [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par3">Traditionally, tau pathology could only be confirmed through postmortem neuropathological examination. However, recent advances enable in vivo tracking of tau abnormalities. Positron emission tomography (PET) topographically quantifies brain tau tangles, while biofluid-based biomarkers measure soluble tau and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) and plasma [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par4">The development of plasma biomarkers, particularly p-tau, has transformed AD research, offering robust, minimally invasive tools for disease detection and monitoring [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Plasma p-tau levels predict A&#946;-positivity, correlate with tau deposition assessed by PET or neuropathology, predict cognitive decline, and associate with clinical progression [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Specific plasma p-tau variants (i.e., phosphorylated at different epitopes) may increase distinctly in response to different AD pathophysiological processes, but increases in their levels in AD seem to be associated with the presence of A&#946; pathology [<xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par5">Despite extensive research on tau dysmetabolism in disease, little is known about its alterations under physiological conditions, partly due to the lack of natural models of tau hyperphosphorylation [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Mammalian hibernation, an extreme physiological state enabling animals to endure adverse environmental conditions, has been proposed as such a model [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. During hibernation, synaptic regression occurs alongside reversible PHF-like tau hyperphosphorylation. Upon arousal, hyperphosphorylation reverses as synapses are restored [<xref ref-type="bibr" rid="CR12">12</xref>]. Despite occurring annually during hibernation seasons, reversible tau hyperphosphorylation does not seem to lead to tau tangle aggregation in the brain, as seen in humans with neurodegenerative disorders, nor to be involved with A&#946; plaque deposition [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>]. Instead, it has been proposed as a neuroprotective mechanism to maintain synaptic integrity [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Most studies investigating hibernation-associated tau hyperphosphorylation have employed immunohistochemistry or immunoblotting in brain tissue [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. However, it is not yet well established whether these changes are reflected by changes in soluble p-tau levels. Tau profiling in brain tissue through the use of direct quantification methods, such as mass spectrometry, has also not yet been explored. Here, we evaluated changes in soluble tau during hibernation and active periods in paired samples from hibernating bears, and performed brain tissue tau profiling in golden Syrian hamsters in a laboratory-induced hibernation protocol versus euthermal controls, and also perform brain tissue analysis of patients with AD vs controls to allow for comparisons between hibernation tau profiles and AD.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Free-ranging brown bears</title><p id="Par6">Blood samples were collected from 10 free-ranging sub-adult brown bears (<italic toggle="yes">Ursus arctos</italic>) in the Dalarna and G&#228;vleborg counties in Sweden with animals age ranging from 2 to 3 years. Bears were equipped with very-high-frequency transmitter implants and global positioning system radiocollars, to enable their tracking during the seasons. The animals were captured between February and March during their hibernation period in the winter and then again between May and June for blood sampling during their active period in the summer, with collection years between 2017 and 2020. Bears were immobilized by darting with an anesthetic while hibernating in their den during the winter with a combination of medetomidine, zolazepam, tiletamine, and ketamine [<xref ref-type="bibr" rid="CR16">16</xref>]. In the summer, bears were darted from a helicopter during their active period in their natural habitat, using a combination of medetomidine, zolazepam, and tiletamine [<xref ref-type="bibr" rid="CR16">16</xref>]. While specific collection years vary between each animal, each animal had one blood sample drawn during the summer and the winter from the same year. Blood samples were collected with EDTA tubes, from the jugular vein within 20&#160;min from darting, and centrifuged at 2000&#8201;&#215;&#8201;g for 10&#160;min up to 1&#160;h after sampling, and stored at &#8722;70&#160;&#186;C until further transportation to the Clinical Neurochemistry Laboratory (Sahlgrenska University Hospital, Sweden), where they were stored at &#8722;80&#160;&#186;C. All activities involving animal handling and sampling were carried in compliance with the Swedish laws, under the approval of the Swedish Ethical Committee on Animal Research (C18/15 and C3/16; &#8220;Djuretiska n&#228;mnden, Uppsala, Sweden&#8221;), and studies did not involve endangered or protected species. Field activities were undertaken by personnel of the Scandinavian Brown Bear Research Project (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.brownbearproject.com/">https://www.brownbearproject.com/</ext-link>).</p></sec><sec id="Sec4"><title>Bear plasma tau quantification</title><p id="Par7">At the Clinical Neurochemistry Laboratory (Sahlgrenska University Hospital, Sweden), we performed immunoprecipitation mass spectrometry (IP-MS) detection of phosphorylated and non-phosphorylated tau peptides by making a minor adaptation of a previously validated method to the <italic toggle="yes">Ursus arctos</italic> tau sequence [<xref ref-type="bibr" rid="CR11">11</xref>]. Briefly, to prepare the EDTA plasma samples (1&#160;mL), they were thawed, vortexed for 30&#160;s at 2000&#160;rpm, and centrifuged at 4,000&#8201;&#215;&#8201;g for 10&#160;min. Tau protein extraction was achieved through immunoprecipitation (IP) using Dynabeads M-280 Sheep Anti-Mouse IgG (Thermo Scientific, Cat#11202D), which were cross-linked with antibodies targeting non-phosphorylated tau: HT7 (Thermo Scientific, Cat#MN1000) and BT2 (Thermo Scientific, Cat#MN1010). The IP process was automated using the KingFisher Flex System (Thermo Scientific). Further tau enrichment involved adding 15&#160;&#181;l of 60% perchloric acid (PCA) to the samples. Desalting was carried out with a 96-well SPE plate (Oasis PRiME HLB 96-well &#181;Elution Plate, 3&#160;mg sorbent per well, Waters), followed by speed-vac drying of the samples. For tryptic digestion, the dried samples were resuspended in a trypsin solution (Sequencing grade, Promega) at 0.1&#160;&#181;g per sample (2.5&#160;&#181;g/ml in 50&#160;mM AMBIC) and incubated at 37&#160;&#176;C. After 18&#160;h, the reaction was halted by adding trifluoroacetic acid (TFA) to a final concentration of 0.1%, and the samples were lyophilized and stored at &#8722;20&#160;&#176;C. Before liquid chromatography&#8211;mass spectrometry analysis, the samples were reconstituted in 50&#160;&#181;l of 0.01% TFA and analyzed as singlicates. Mass spectrometry was performed using a hybrid Orbitrap mass spectrometer (Lumos, Thermo Scientific) equipped with an EasySpray nano-ESI ion source. The instrument operated in positive-ion mode with the following parallel reaction monitoring (PRM) scan settings: Activation Type: HCD, Detector Type: Orbitrap, Orbitrap Resolution: 60,000, Scan Range: 250&#8211;1200, RF Lens: 30%, Easy-IC: On, Quadrupole Isolation Window: 0.7&#160;m/z. Parameters for Maximum Injection Time, Normalized AGC Target, optimal collision energy, and FAIMS voltage were determined for each peptide experimentally. Endogenous tryptic peptides targeted are listed in Supplementary Tables <xref rid="MOESM1" ref-type="media">S1</xref> and S2. Notably, the tau sequence in <italic toggle="yes">Ursus arctos</italic> was conserved except for the region containing the p-tau181 peptide. In humans, this sequence is TPPAPKpTPPSSGEPPK, whereas in <italic toggle="yes">Ursus arctos</italic>, it is TTPSPKpTPPGESGK. A heavy-labeled peptide for the bear-specific sequence was designed, and the mass spectrometry parameters were optimized accordingly. LC&#8211;MS data acquisition was conducted using Xcalibur 4.5 and Tune 3.5 software (Thermo Scientific), and data analysis was performed with Skyline software (McCoss Lab, University of Washington). In addition, plasma p-tau181 and p-tau217 were also quantified by research-grade clinically validated immunoassays. Plasma p-tau181 was measured using the Lumipulse plasma p-tau181 assay, developed as a modified version of their FDA-approved Lumipulse G CSF p-Tau181 assay, using the LUMIPULSE G1200, also at the University of Gothenburg [<xref ref-type="bibr" rid="CR17">17</xref>]. Plasma p-tau217 was quantified using immunoassay (developed by Lilly Research laboratories) on the Meso Scale Discovery platform, at the Clinical Memory Research Unit (Lund University, Sweden), and its clinical validation has been previously described [<xref ref-type="bibr" rid="CR18">18</xref>]. Before analyses, plasma samples previously stored at -80 &#186;C freezers were thawed, vortexed and centrifuged at 4000&#8201;&#215;&#8201;g for 10&#160;min. Scientists and technicians were blinded to the subjects&#8217; information, and internal quality controls were used to monitor analyses.</p></sec><sec id="Sec5"><title>Golden Syrian hamsters</title><p id="Par8">We included brain tissue data analyzed from <italic toggle="yes">n</italic>&#8201;=&#8201;10 wild-type golden Syrian hamsters (<italic toggle="yes">Mesocricetus auratus</italic>), with animals that were obtained from Janvier Labs at an age of 35&#160;weeks. Torpor was induced in a dedicated climate chamber at the Paul Flechsig Institute, University of Leipzig according to Oklejewicz et al. [<xref ref-type="bibr" rid="CR19">19</xref>] by exposing the animals to several weeks of short photoperiod as follows: 4&#160;weeks of &#8216;short day&#8217; (8&#160;h light and 16&#160;h darkness) at room temperature (22&#160;&#176;C) followed by continuous dim red light conditions (LED light with a wavelength&#8201;&gt;&#8201;650&#160;nm) and a reduction of the ambient temperature to 5&#8211;6&#160;&#176;C. General locomotor activity was monitored with passive infrared detectors mounted above each cage allowing the discrimination between torpor (periods with&#8201;&gt;&#8201;24&#160;h of inactivity) and euthermic phases [<xref ref-type="bibr" rid="CR19">19</xref>]. Hamsters that completed at least one torpor cycle and were inactive for at least 24&#160;h were referred as to &#8220;torpor&#8221;. Hamsters kept under identical conditions but who did not enter torpor were referred as to &#8220;eutherm&#8221;. Before sacrifice, hibernation state of the animals was confirmed by measurements of body temperature with an IR thermometer, and upon death core, body temperature was determined using thermocouple thermometer with measurements ranging between &#8764;&#8202;7&#160;&#176;C for torpid animals and &#8764;&#8202;35&#160;&#176;C for euthermic hamsters. Five animals were sacrificed during euthermy and five in deep hibernation (torpor). All animals were about 11&#160;months old when they were killed by means of an overdose inhalation of isoflurane (5%) combined with an intraperitoneal injection of 200&#160;mg/kg ketamine, preceding perfusion. After euthanasia, a neocortical brain slice was extracted from each animal. The experiments were approved by the Animal Care and Use Committee of the University of Leipzig (TVV 06/19). They conformed to the European Communities Council Directive (86/609/EEC).</p></sec><sec id="Sec6"><title>Human brain samples</title><p id="Par9">Post-mortem human brain tissue was obtained from the Queen Square Brain Bank for Neurological Disorders (QSBB), Department of Clinical and Movement Neurosciences, University College London (UCL) Queen Square Institute of Neurology. Frontal cortex samples (Brodmann area 9) from individuals with Alzheimer&#8217;s disease (AD; <italic toggle="yes">n</italic>&#8201;=&#8201;10) and age-matched neurologically healthy controls (<italic toggle="yes">n</italic>&#8201;=&#8201;10) were included. All tissue was flash-frozen at&#8201;&#8722;&#8201;80&#160;&#176;C on brass plates immediately upon donation to QSBB and subsequently stored at&#8201;&#8722;&#8201;80&#160;&#176;C until analysis. The neuropathological assessment of AD cases adhered to the 2012 National Institute on Aging-Alzheimer&#8217;s Association (NIA-AA) guidelines, and the clinical diagnosis met National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) criteria for probable AD [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Control donors exhibited no documented neurological disease during life. Use of human tissue followed the ethical principles of the Declaration of Helsinki and was approved by regional ethics committees at UCL and the University of Gothenburg.</p></sec><sec id="Sec7"><title>Brain tissue tau quantification</title><p id="Par10">Neocortical brain tissue samples (mean&#8201;&#177;&#8201;SD tissue weight 243&#8201;&#177;&#8201;22&#160;mg) from the <italic toggle="yes">n</italic>&#8201;=&#8201;10 golden hamsters, <italic toggle="yes">n</italic>&#8201;=&#8201;10 patients with AD, and <italic toggle="yes">n</italic>&#8201;=&#8201;10 control participants were homogenized, and both the soluble [tris(hydroxymethyl)aminomethane (tris)-buffered saline; TBS] and insoluble (sarkosyl insoluble; SI) fractions were extracted, based on a previously described protocol, with further extraction details detailed elsewhere [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Resulting supernatants, containing tau soluble forms and small oligomers, were aliquoted and stored at &#8722;80&#160;&#176;C. We applied our novel technique combining immunoprecipitation and high-resolution mass spectrometry for the simultaneous detection and quantification of several tau peptides in brain tissue in their phosphorylated and non-phosphorylated form. As our plasma IP-MS tau method, the IP-MS technique for tau quantification in brain tissue has been validated against AD and other tauopathies in humans and was previously described in detail [<xref ref-type="bibr" rid="CR24">24</xref>]. In brief, 10 &#181;g of total protein for the TBS and 4.5&#160;&#181;g for the SI homogenates were immunoprecipitated using Dynabeads M-280 Sheep Anti-Mouse IgG (Thermo Scientific, Cat#11202D), conjugated with the HT7 (Thermo Scientific, Cat#MN1000) antibody targeting non-phosphorylated tau (targeting tau at amino acids 159&#8211;163). Ten microlitres of the human [<italic toggle="yes">U</italic>-<sup>15</sup>N]-protein standards mix (containing 400 fmol protein) were added to each sample. The protein standard mix comprises 0N3R, 1N4R, and 2N4R human tau isoforms. Subsequently, samples were washed and eluted using a magnetic particle processor (KingFisher, Thermo Fisher Scientific). The eluates (100&#160;&#181;l of 0.5% formic acid) were dried in a vacuum centrifuge at room temperature and stored at &#8722;80&#160;&#176;C before resuspension in 50&#160;mM AMBIC and overnight (37&#160;&#176;C, light shaking) enzymatic digestion using trypsin (Sequencing grade, Promega) in the amount of 0.1&#160;&#181;g/sample. Additionally, labeled phospho-peptides (100 fmol each) were also added to each sample before trypsinisation. Tryptic peptides were then analyzed using nanoflow (300&#160;nL/min) LC&#8211;MS with a Dionex 3000 system coupled to a hybrid quadrupole-orbitrap Q Exactive instrument (both Thermo Fisher Scientific) set to data-dependent acquisition mode, followed by peptide identification and quantification with PEAKS Xpro (Bioinformatic Solutions) and Skyline software, respectively. As the method was developed for human tau, for the hamster analyses, a minor adaptation of was done to match <italic toggle="yes">Mesocricetus auratus</italic> tau sequence, including modification of a customized database to contain both human and hamster protein sequences for peptide identification as well as adding the required peptides to the quantification scheme. Details of the sequences used for tau identification and quantification can be found in Supplementary Tables S3 and S4.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p id="Par11">Descriptive statistics are summarized with median and interquartile ranges for continuous variables or counts and percentages for categorical variables. For outlier detection, we set a stringent criterion of 15 median absolute deviations (MAD) above the median. Among plasma quantifications, only one outlier observation with 15.2 MAD was detected, for a plasma p-tau217 summer quantification measured with the MSD immunoassay, with this bear&#8217;s results being excluded from analyses only for this assay. In brain tissue analyses, no outliers were observed for human data, and only one outlier was detected for hamsters&#8217; brain tau quantifications, with a high p-tau217 value in the hibernation group in the SI fraction. To evaluate differences in concentrations of bear plasma biomarker levels between the summer and hibernation in the winter, we used the non-parametric Wilcoxon signed-rank test for paired observations. For comparing hamster brain tissue tau levels between euthermy and torpor, we used the Wilcoxon signed-rank test for non-paired observations. To numerically quantify magnitude of differences between hibernation conditions, we computed the percent median change between hibernation (winter for bears, torpor for hamsters) and the reference group (summer for bears, euthermy for hamsters). For visualization, we displayed boxplots with dots corresponding to the individual biomarker values. For bears, for whom paired data were available, individual dots from the same bears linked values from summer and winter. Statistical significance was set at a two-sided alpha of 0.05. No multiple testing correction was carried, and results were interpreted accordingly. All data analyses and visualization was performed using R version 4.2.1 (R Foundation for Statistical Computing; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link>).</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Plasma tau biomarkers in hibernating bears</title><p id="Par12">The bear cohort included 6 females and 4 males, with a median weight of 44.2&#160;kg (IQR, 40.6&#8211;49.2&#160;kg) in summer and 40.5&#160;kg (37.5&#8211;54.0&#160;kg) in winter. Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref> displays tau biomarkers in phosphorylation site order. High increases were observed during hibernation in plasma p-tau181 (IP-MS: median percent-change&#8201;+&#8201;362%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A; IA:&#8201;+&#8201;97%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>B). Plasma p-tau199 and p-tau202, however, did not show significant changes (both <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>C-D). A much less pronounced hibernation-linked increase was observed for p-tau205 (+&#8201;59.5%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.044; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>E), and the p-tau205/tau195-209 ratio was not significantly altered during winter (<italic toggle="yes">p</italic>&#8201;=&#8201;0.43; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>F). Plasma p-tau217 was also greatly increased during hibernation (IP-MS:&#8201;+&#8201;294%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>G; IA:&#8201;+&#8201;52.1%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01; F<xref rid="Fig1" ref-type="fig">i</xref>g.&#160;<xref rid="Fig1" ref-type="fig">1</xref>I), with significant but less pronounced elevations observed for the p-tau217/tau212-221 ratio, also known as %p-tau217 (+&#8201;142%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>H). Plasma p-tau231 levels were moderately increased during hibernation (+&#8201;40.5%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.03; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>J). Interestingly, the non-phosphorylated tau peptides were also substantially increased in the winter compared with summer (tau195-209:&#8201;+&#8201;153%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>K; tau212-221:&#8201;+&#8201;47.2%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.006; Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>L).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Tau plasma biomarker levels during summer and winter in Swedish brown bears. Dots indicate individual data points for biomarker concentrations on the <italic toggle="yes">y</italic>-axis, and gray lines connect observations between summer (blue) and winter (red), which correspond the <italic toggle="yes">x</italic>-axis groups. Within each specific tau biomarker graph, text boxes indicate the median percent change between summer and winter, as well as the <italic toggle="yes">p </italic>value from a paired-sample non-parametric test. All biomarkers are presented in fmol/mL, with the exception of biomarker ratios (*) which are dimensionless. P-tau: phosphorylated tau; IP-MS: immunoprecipitation mass spectrometry; IA: immunoassay</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="401_2025_2930_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec11"><title>Brain tissue tau profiles in hamster hibernation and in Alzheimer&#8217;s disease</title><p id="Par13">To complement our findings, we used an IP-MS method developed for brain tissue tau quantification in 10 golden Syrian hamsters (<italic toggle="yes">Mesocricetus auratus</italic>) under an induced hibernation protocol and in AD patients and controls [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. We quantified the same tau peptides as in plasma (excluding p-tau199, p-tau202, and p-tau/tau ratios) with the addition of two tau microtubule-binding region (MTBR) peptides, and present results in the main text for the SI fraction, which captures the insoluble tau endophenotype.</p><p id="Par14">Hamsters were euthanized during hibernation (torpor, <italic toggle="yes">n</italic>&#8201;=&#8201;5) or euthermy (<italic toggle="yes">n</italic>&#8201;=&#8201;5), and brain tau levels in the SI fraction were compared between groups. Brain p-tau181 levels were slightly higher in the torpor group (median percent difference:&#8201;+&#8201;26.8%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.06, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A), with p-tau205 showing a mild decrease (&#8722;17.4%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.04, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B). P-tau217 exhibited the largest increase (+&#8201;219%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>C), with more modest increases in p-tau231 levels (+&#8201;21.2%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>D). Tau195-209 (&#8722;31.8%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.02, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>E) and tau212-221 (&#8722;17.2%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>F) were significantly reduced in the torpor group. Importantly, MTBR tau fragments were not altered between euthermy and hibernation groups (MTBR tau243-254: &#8722;13.8%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.68, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>G; MTBR tau354-369: &#8722;15.7%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.53, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>H).<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Dots indicate individual data points for tau peptide concentrations in the brain tissue SI fraction for golden Syrian hamsters (panels A&#8211;H) and humans with AD and controls (panels I&#8211;P). On the x-axis, observations are stratified in euthermy (blue) and torpor/hibernation (red) for hamsters and for controls (blue) and AD (red) groups for humans. Within each specific tau biomarker graph, text boxes indicate the median percent difference between euthermy and torpor or controls and AD, as well as the p-value from a non-parametric test. All biomarkers are presented in the light-to-heavy peptide ratio. SI: sarkosyl insoluble; AD: Alzheimer&#8217;s disease; P-tau: phosphorylated tau; IP-MS: immunoprecipitation mass spectrometry; MTBR: microtubule binding region</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="401_2025_2930_Fig2_HTML.jpg"/></fig></p><p id="Par15">To compare tau changes in hamster brain tissue during hibernation with pathological changes in AD, we included a sample of <italic toggle="yes">n</italic>&#8201;=&#8201;10 controls (mean age 78.0&#160;years) and <italic toggle="yes">n</italic>&#8201;=&#8201;10 AD patients (mean age 75.8&#160;years). All AD patients (100%) presented advanced levels of neurofibrillary tangle pathology, presenting at autopsy with Braak stage V-VI, with descriptive information displayed in Supplementary Table S5. When analyzing these same peptides in the SI fraction of AD patient brains compared with controls, results were markedly different from hibernation. All p-tau variants analyzed displayed much more dramatic increases in AD compared with controls, with&#8201;+&#8201;4,549% increases for p-tau181 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0008, F<xref rid="Fig2" ref-type="fig">i</xref>g.&#160;<xref rid="Fig2" ref-type="fig">2</xref>I),&#8201;+&#8201;791% for p-tau205 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.001, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>J),&#8201;+&#8201;50,366% for p-tau217 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0003, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>K), and&#8201;+&#8201;11,405% for p-tau231 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0008, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>L). Tau195-209 was significantly increased in AD (+&#8201;59.1%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.02, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>M), and so was tau212-221 (+&#8201;383%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>N). MTBR tau fragments, a proxy for neurofibrillary tangle presence, were substantially increased in AD, with&#8201;+&#8201;8,579% increases for MTBR tau243-254 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0006, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>O) and&#8201;+&#8201;19,534% increases for MTBR tau354-369 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0003, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>P).</p><p id="Par16">In Supp. Fig. <xref rid="MOESM1" ref-type="media">S1</xref>, results for hamster brain tissue in euthermy and torpor, as well as for controls and AD patients, are displayed for the TBS fraction of brain tissue. For hamsters, TBS results were generally similar to the SI fraction, with more pronounced increases in p-tau217 and also increases in p-tau231 and p-tau181, with no hibernation-linked increases in MTBR peptides and slight reductions in non-phosphorylated tau. For humans, p-tau217 remained substantially increased in the TBS fraction, also showing reductions in non-phosphorylated tau fragments, but MTBR tau fragments, especially MTBR tau354-369, were still increased.</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par17">In this study, we used a targeted IP-MS method to quantify phosphorylated and non-phosphorylated tau peptides in plasma from free-ranging brown bears during summer and hibernation and validated the results in hamster brains during torpor and euthermy. Hibernation-linked increases in plasma levels of p-tau181, p-tau205, p-tau217, and p-tau231, with unchanged p-tau199 and p-tau202 levels, resemble a pattern seen in AD patients [<xref ref-type="bibr" rid="CR11">11</xref>]. We observed the greatest increases in plasma p-tau181 and p-tau217, biomarkers strongly associated with AD neuropathology [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. These findings align with a previous study on hibernating American black bears that reported, with immunoblotting and immunohistochemistry, neuropathological changes in phospho-sites Thr181, Thr205, Thr217, and Thr231 [<xref ref-type="bibr" rid="CR14">14</xref>]. While that study reported Ser202 phosphorylation changes and no total-tau alterations, we did not observe p-tau202 changes and did not measure total-tau. Instead, we measured non-phosphorylated fragments (tau195-209 and tau212-221), which were markedly increased during hibernation. While total-tau, measured by immunoassays, is traditionally considered a marker of neurodegeneration, less evidence is available on mass spectrometry-based techniques quantifying smaller non-phosphorylated fragments. Nevertheless, a recent study shows that tau212-221 measured by MS correlates tightly with total-tau measured by the Lumipulse immunoassay (<italic toggle="yes">r</italic>&#8201;=&#8201;0.99) [<xref ref-type="bibr" rid="CR26">26</xref>], which could explain why we observed increases in tau195-209 and tau212-221 in a similar direction as with their phospho-counterparts, p-tau205 and p-tau217. Given the cleavage peptides undergo before quantification, it is also possible that part of the two non-phosphorylated fragments we measured come from molecules highly phosphorylated at other sites, due to global increases in tau secretion from neurons, a process that may be increased in hibernation. As hibernating animals do not experience neurodegeneration, the observed increases in these non-phosphorylated fragments may reflect hibernation-linked tau processing alterations rather than neurodegeneration [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Additionally, the ratios of p-tau205 and p-tau217 to their non-phosphorylated counterparts did not show greater increases than p-tau variants alone. We interpret the changes in plasma p-tau levels during hibernation as indicative of the tau hyperphosphorylation process reported in hibernating animals. While it could be argued that protein levels are increasing due to the hemoconcentration that occurs during hibernation, the previous work from the Scandinavian Brown Bear Project estimates that hemoconcentration is limited to a 10&#8211;30% magnitude, which would not account for the&#8201;&gt;&#8201;300% increases we found for plasma p-tau181 and p-tau217 [<xref ref-type="bibr" rid="CR27">27</xref>]. Additionally, prominent and consistent cerebral A&#946; deposition has not been robustly documented in hibernating species&#8212;unlike humans where increased p-tau levels are closely associated with A&#946; pathology&#8212;suggesting that hibernation-linked tau hyperphosphorylation occurs independently of A&#946; abnormalities [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par18">Our IP-MS findings on brain tau levels in golden Syrian hamsters during hibernation align with bear plasma results obtained via IP-MS and immunoassays. Brain p-tau181, p-tau217, and p-tau231 levels increased, in varying magnitudes, in the torpor group in both TBS and SI fractions (although p-tau181 not significant in SI), consistent with prior brain tissue studies on small hibernators showing high tau phosphorylation rates via immunohistochemistry and immunoblotting [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>]. Similarly, the observed increases in bear plasma p-tau181 corroborate recent findings in hamsters, where plasma p-tau181 levels were also higher during torpor than arousal when measured with a non-clinically validated biofunctionalization method [<xref ref-type="bibr" rid="CR28">28</xref>]. This converging evidence highlights the importance of evaluating this hibernation-linked hyperphosphorylation through different species, biological matrices, and analytical methods.</p><p id="Par19">These tau phosphorylation changes may, in part, reflect a passive consequence of lowered body temperature. Planel and colleagues previously proposed that tau hyperphosphorylation under hypothermic conditions results from differential temperature sensitivity of kinases and phosphatases, particularly the inhibition of protein phosphatase 2A [<xref ref-type="bibr" rid="CR29">29</xref>]. Our findings are compatible with this mechanism, but also align with results from hibernating mammals suggesting an additional hibernation-state-specific regulatory component. In particular, Stieler et al. demonstrated that although low temperatures facilitate tau phosphorylation, tissue from torpid animals shows enhanced phosphate incorporation compared to euthermic controls at similar temperatures, indicating active, regulated mechanisms beyond temperature alone [<xref ref-type="bibr" rid="CR14">14</xref>]. Thus, hibernation-linked tau phosphorylation likely involves both passive thermodynamic effects and active, reversible processes associated with the hypometabolic state.</p><p id="Par20">It is well established that hibernators do not develop AD-like fibrillar tangle pathology despite seasonal tau hyperphosphorylation [<xref ref-type="bibr" rid="CR1">1</xref>]. While it has been reported aging bears may form pre-tangle tau aggregates, such formations are rare and not observed in all aged bears [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. The MTBR domain of tau is a key component of insoluble neurofibrillary tangles, and has even been proposed as a tangle-specific biomarker in biofluids [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. In brain tissue from AD patients, where tangle pathology is present, MTBR tau fragments showed dramatic increases, compared with controls without AD pathology. In the SI fraction, containing insoluble aggregates, MTBR tau354-369, in particular, was increased by&#8201;~&#8201;20,000% and still showed a&#8201;~&#8201;238% increase in the soluble TBS fraction, highlighting the substantial tangle burden in AD brains. In hibernating hamsters, however, unlike for p-tau variants, brain levels of MTBR tau243-254 and tau354-369 were not increased compared with euthermy in the SI fraction, and even slightly reduced (-6%) in the TBS fraction. This may be further reflective of the fact that hibernation-linked tau hyperphosphorylation does not lead to tau aggregation with neurofibrillary tangle formation. Additionally, recent evidence suggests that p-tau205, measured in plasma or CSF, may be the p-tau variant with the strongest relation to tau tangles [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Interestingly, p-tau205 levels showed no increase in torpor hamster brains, in both SI and TBS fractions, and only modest increases in bear plasma.</p><p id="Par21">Recent work by L&#246;vestam et al. provides compelling evidence that tau hyperphosphorylation at specific residues is sufficient to drive aggregation into Alzheimer-type paired helical filaments. Using 12 phosphomimetic mutations (PAD12) that mimic phosphorylation at sites, including T181, T205, T217, and T231, the authors demonstrated spontaneous in vitro assembly of recombinant full-length tau into filaments structurally indistinguishable from those found in AD brains [<xref ref-type="bibr" rid="CR33">33</xref>]. These findings establish a mechanistic link between site-specific hyperphosphorylation and the adoption of the AD-specific tau folding, suggesting that tau phosphorylation may be a key driver of filament formation. In our hibernating animal models, we observed reversible phosphorylation at several of these same residues without detectable tau aggregation, suggesting that while phosphorylation can be sufficient under defined experimental conditions and likely also in AD, its capacity to trigger filament formation in vivo may still depend on additional factors not present in hibernation, such as the very long duration of asymptomatic and symptomatic duration of AD, altered clearance, or local biochemical milieu.</p><p id="Par22">Beyond the clear differences in changes in MTBR tau fragments in the brains of AD patients vs controls and lack of changes in hibernating hamster brain tissue, magnitudes of brain tissue phosphorylation were also notably distinct in AD. For instance, in the SI fraction, p-tau217 and p-tau231 were increased by&#8201;~&#8201;50,000% in AD vs controls. Even in the TBS fraction, p-tau217 showed an increase of&#8201;~&#8201;400% in AD. In contrast, in hibernating hamster brain tissue, p-tau217 showed increases of&#8201;~&#8201;200% and&#8201;~&#8201;90% in the SI and TBS fractions, respectively, compared with euthermal hamsters. This may underscore a fundamental difference between the regulated, reversible tau phosphorylation observed in hibernation and the pathological tau accumulation and aggregation characteristic of AD. While hamster brain tissue results were remarkably similar between TBS and SI fractions with modest increases in p-tau217 and p-tau231, human results showed much more pronounced increases in all measured tau peptides in SI compared with TBS, possibly suggesting that the shift from soluble phosphorylated tau to insoluble aggregated tau, as observed in AD, does not occur during hibernation. These results, alongside the absence of MTBR tau accumulation in torpor, even in the SI fraction, supports the notion that hibernation-associated hyperphosphorylation does not progress to tangle formation, further suggesting hibernation as a non-pathological model for studying tau biology.</p><p id="Par23">Interestingly, the non-phosphorylated tau195-209 and tau212-221 peptides were decreased by around&#8201;~&#8201;20&#8211;30% in the hamster brain tissue torpor group. This reduction in non-phospho-peptides was also observed for TBS results in AD brains compared with controls. Unlike with plasma levels, which reflect soluble tau processing in a more dynamic way, the direct quantification of tau in the brain tissue may allow for interpreting that these decreases could be at least partly attributed to increases in phosphorylation rates. The reduction in these non-phosphorylated peptides in brain tissue, combined with their increase in blood levels and the slight decreases in non-phosphorylated MTBR tau fragments, may reflect uncharacterized aspects of tau processing during hibernation.</p><p id="Par24">This work is not exempt from limitations, mostly associated with the high complexity of carrying out longitudinal monitoring in free-ranging animals. Our sample size for hibernators (bears: <italic toggle="yes">n</italic>&#8201;=&#8201;10; hamsters: <italic toggle="yes">n</italic>&#8201;=&#8201;10) is relatively small, but similar to that of other studies in the interface between AD pathology and hibernation [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Also, due to ethical considerations and animal welfare, sampling was restricted to plasma and limited to two occasions, preventing us from quantifying tau proteins in the CSF and from conducting a more detailed repeated-measures analysis of p-tau dynamics throughout the year. While older bears may serve as a more suitable model for aging human disease, the sub-adult (2&#8211;3&#160;years old) bears in our study still exhibited marked changes in plasma p-tau levels. Also, studying older free-ranging bears presents significant challenges, including increased potential for comorbidities and, especially, greater risks to the research team. Brain tissue is not collected within the Scandinavian Brown Bear Research Project, preventing neuropathological analyses in bears, and hamster plasma analysis was not possible due to the high-volume needed by the IP-MS plasma method, which is considerably larger than the small volume of blood usually collected from each hamster. When using methods based on centrifugation and relative detergent solubility, it is possible that some degree of cross-contamination may occur across fractions. Thus, we cannot exclude that the low levels measure here in hamster brain may be tau proteins that pelleted or fragments of non-aggregated insoluble tau (previously reported in hibernation), despite not being assembled in AD-like NFTs [<xref ref-type="bibr" rid="CR14">14</xref>]. At the same time, it is evident from the results of our study that the differences for the key p-tau species measured (the best example being pTau217) change in the same direction as in AD and hamster brain in both SI and TBS fractions (as well as AD CSF/plasma from the literature), and even in plasma from hibernating bears. However, other tau variants which would be expected in the presence of NFT pathology, such as the MTBR species and p-tau205, do not change. We understand that this speaks against the fact that cross-contamination could be driving the results, and that there is a consistent between-species consistent biological phenomenon of tau phosphorylation during hibernation.</p><p id="Par25">To the best of our knowledge, our study provides the first evidence that hibernation-linked tau hyperphosphorylation is reflected in increases in plasma p-tau as measured by validated assays, at the same phospho-sites which are increased in AD patients, as well as the first mass-spectrometry characterization of tau processing in brain tissue during hibernation. The pattern of brain and plasma tau levels is consistent with the lack of tangle formation during hibernation. Further translational studies of this phenomenon may provide insights into the biology of p-tau as well as identify novel strategies to prevent p-tau accumulation in the human brain, taking into account the dynamics of both soluble and insoluble tau. Our results also emphasize the need for more research on hibernation as a translational model for advancing our knowledge on aging-related human diseases.</p></sec><sec id="Sec13" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="401_2025_2930_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file1 (DOCX 459 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Wagner S. Brum and Laia Montoliu-Gaya (first authors) have contributed equally to this work.</p></fn><fn><p>Ole Fr&#246;bert and Kaj Blennow (senior authors) have contributed equally.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank all the staff in administrative, technical and veterinary roles working in the Clinical Neurochemistry Laboratory at the University of Gothenburg, the Scandinavian Brown Bear Research Project, and at University of Leipzig. W.S.B. is supported by CAPES (#88887.372371/2019-00 and #88887.596742/2020-00) and Stiftelsen f&#246;r Gamla Tj&#228;narinnor. LMG is supported by the Brightfocus Foundation (A2022015F), the Swedish Dementia Foundation, Gun and Bertil Stohnes Foundation, &#197;hl&#233;n-stifelsen, Alzheimerfonden (AF-968621), and Gamla Tj&#228;narinnor Foundation. G.B. is supported by Cure Alzheimer&#8217;s Fund, Gun and Bertil Stohnes Foundation, &#197;hl&#233;n-stifelsen, and Gamla Tj&#228;narinnor Foundation. D.P. is supported by Cure Alzheimer&#8217;s Fund. E.C. is supported by Cure Alzheimer&#8217;s Fund. KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hj&#228;rnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer&#8217;s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer&#8217;s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen R&#246;nstr&#246;ms Stiftelse, Stockholm, Sweden. Work at Lund University was supported by the European Research Council (ADG-101096455), Alzheimer&#8217;s Association (ZEN24-1069572, SG-23-1061717), GHR Foundation, Swedish Research Council (2022-00775), ERA PerMed (ERAPERMED2021-184), Knut and Alice Wallenberg Foundation (2022-0231), Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson&#8217;s Disease) at Lund University, Swedish Alzheimer Foundation (AF-980907), Swedish Brain Foundation (FO2021-0293), Parkinson Foundation of Sweden (1412/22), Cure Alzheimer&#8217;s Fund, R&#246;nstr&#246;m Family Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Sk&#229;ne University Hospital Foundation (2020-O000028), Regionalt Forskningsst&#246;d (2022-1259), and Swedish federal government under the ALF agreement (2022-Projekt0080). ERZ is supported by CNPq (435642/2018-9; 312410/2018-2; 409066/2022-2; 312306/2021-0; 409595/2023-3), Instituto Serrapilheira (Serra-1912-31365), Brazilian National Institute of Science and Technology in Excitotoxicity and Neuroprotection (465671/2014-4), ARD/FAPERGS (21/2551-0000673-0), and Alzheimer&#8217;s Association [AARGD-21-850670]. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Union&#8217;s Horizon Europe research and innovation programme under Grant Agreement No. 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer&#8217;s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen f&#246;r Gamla Tj&#228;narinnor, Hj&#228;rnfonden, Sweden (#FO2022-0270), the European Union&#8217;s Horizon 2020 Research and Innovation Programme under the Marie Sk&#322;odowska-Curie under Grant Agreement No. 860197 (MIRIADE), the European Union Joint Programme&#8212;Neurodegenerative Disease Research (JPND2021-00694), the UK Dementia Research Institute at UCL (UKDRI-1003), and Cure Alzheimer&#8217;s Fund. TL is supported by Alzheimer&#8217;s Research UK, Alzheimer&#8217;s Society and the Association of Frontotemporal Dementia. The Queen Square Brain Bank is supported by the Reta Lila Weston Institute of Neurological Studies, UCL Queen Square Institute of Neurology.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>WSB, LMG, HZ, NJA, TA, JTS, MH, OF, and KB designed the study. HI, JK, and OF coordinated the collection and handling of bear plasma samples. CJ, SM, TA, JTS, and MH handled hamster animal experiments. TL provided human brain tissue for analyses. WSB, LMG, JLR, SJ, JG, HZ, OH, NJA, and KB conducted plasma biomarker analyses. GB, DP, EC, JLR, and KB conducted brain tissue mass spectrometry analyses. WSB, LMG, GB, JPFS, AM, ALB, HZ, OH, ERZ, NJA, TA, TL, JTS, MH, OF, and KB analyzed and/or interpreted data. WSB, LMG, and KB drafted the initial version of the manuscript. All authors contributed on subsequent versions of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by University of Gothenburg.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analyzed during this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par26">KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2&#160;years, he has received consultancy/speaker fees from AC Immune, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. ERZ has served in the scientific advisory board of Nintx, Novo Nordisk and masima and is a co-founder and a minority shareholder at masima. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2&#160;years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Siemens.</p></notes><notes id="FPar2"><title>Ethics approval</title><p id="Par27">All activities involving animal handling and sampling were carried in compliance with the Swedish laws, under the approval of the Swedish Ethical Committee on Animal Research (C18/15 and C3/16; &#8220;Djuretiska n&#228;mnden, Uppsala, Sweden&#8221;), and studies did not involve endangered or protected species. The experiments with hamsters were approved by the Animal Care and Use Committee of the University of Leipzig (TVV 06/19) and conformed to the European Communities Council Directive (86/609/EEC). Human brain tissues were used in accordance with the Helsinki declaration and the regional ethics committees at UCL.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arendt</surname><given-names>T</given-names></name><name name-style="western"><surname>Stieler</surname><given-names>JT</given-names></name><name name-style="western"><surname>Holzer</surname><given-names>M</given-names></name></person-group><article-title>Tau and tauopathies</article-title><source>Brain Res Bull</source><year>2016</year><volume>126</volume><fpage>238</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2016.08.018</pub-id><pub-id pub-id-type="pmid">27615390</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Arendt T, Stieler JT, Holzer M (2016) Tau and tauopathies. Brain Res Bull 126:238&#8211;292<pub-id pub-id-type="pmid">27615390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainresbull.2016.08.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ballatore</surname><given-names>C</given-names></name><name name-style="western"><surname>Lee</surname><given-names>VMY</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>JQ</given-names></name></person-group><article-title>Tau-mediated neurodegeneration in Alzheimer&#8217;s disease and related disorders</article-title><source>Nat Rev Neurosci</source><year>2007</year><volume>8</volume><issue>9</issue><fpage>663</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1038/nrn2194</pub-id><pub-id pub-id-type="pmid">17684513</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Ballatore C, Lee VMY, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer&#8217;s disease and related disorders. Nat Rev Neurosci 8(9):663&#8211;672<pub-id pub-id-type="pmid">17684513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrn2194</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansson</surname><given-names>O</given-names></name></person-group><article-title>Biomarkers for neurodegenerative diseases</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><issue>6</issue><fpage>954</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01382-x</pub-id><pub-id pub-id-type="pmid">34083813</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27(6):954&#8211;963<pub-id pub-id-type="pmid">34083813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01382-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karikari</surname><given-names>TK</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Brinkmalm</surname><given-names>G</given-names></name><name name-style="western"><surname>Brum</surname><given-names>WS</given-names></name><name name-style="western"><surname>Benedet</surname><given-names>AL</given-names></name><name name-style="western"><surname>Montoliu-Gaya</surname><given-names>L</given-names></name><etal/></person-group><article-title>Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility</article-title><source>Nat Rev Neurol</source><year>2022</year><volume>18</volume><issue>7</issue><fpage>400</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1038/s41582-022-00665-2</pub-id><pub-id pub-id-type="pmid">35585226</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L et al (2022) Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol 18(7):400&#8211;418<pub-id pub-id-type="pmid">35585226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-022-00665-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Therriault</surname><given-names>J</given-names></name><name name-style="western"><surname>Brum</surname><given-names>WS</given-names></name><name name-style="western"><surname>Trudel</surname><given-names>L</given-names></name><name name-style="western"><surname>Macedo</surname><given-names>AC</given-names></name><name name-style="western"><surname>Bitencourt</surname><given-names>FV</given-names></name><name name-style="western"><surname>Martins-Pfeifer</surname><given-names>CC</given-names></name><name name-style="western"><surname>Nakouzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Pola</surname><given-names>I</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M</given-names></name><name name-style="western"><surname>Kac</surname><given-names>PR</given-names></name><name name-style="western"><surname>Real</surname><given-names>AP</given-names></name><name name-style="western"><surname>Witherow</surname><given-names>C</given-names></name><name name-style="western"><surname>Karikari</surname><given-names>TK</given-names></name><name name-style="western"><surname>Moscoso</surname><given-names>A</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>ER</given-names></name><name name-style="western"><surname>Sch&#246;ll</surname><given-names>M</given-names></name><name name-style="western"><surname>Pascoal</surname><given-names>T</given-names></name><name name-style="western"><surname>Benedet</surname><given-names>AL</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Schindler</surname><given-names>SE</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><name name-style="western"><surname>Rosa-Neto</surname><given-names>P</given-names></name></person-group><article-title>Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis</article-title><source>Lancet Neurol</source><year>2025</year><volume>24</volume><issue>9</issue><fpage>740</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(25)00227-3</pub-id><pub-id pub-id-type="pmid">40818474</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Therriault J, Brum WS, Trudel L, Macedo AC, Bitencourt FV, Martins-Pfeifer CC, Nakouzi M, Pola I, Wong M, Kac PR, Real AP, Witherow C, Karikari TK, Moscoso A, Zimmer ER, Sch&#246;ll M, Pascoal T, Benedet AL, Ashton NJ, Schindler SE, Zetterberg H, Blennow K, Rosa-Neto P (2025) Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 24(9), 740&#8211;752. 10.1016/S1474-4422(25)00227-3<pub-id pub-id-type="pmid">40818474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(25)00227-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></name><name name-style="western"><surname>Tideman</surname><given-names>P</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>N</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name><collab>Alzheimer&#8217;s Disease Neuroimaging Initiative</collab><etal/></person-group><article-title>Prediction of future Alzheimer&#8217;s disease dementia using plasma phospho-tau combined with other accessible measures</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><issue>6</issue><fpage>1034</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01348-z</pub-id><pub-id pub-id-type="pmid">34031605</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Alzheimer&#8217;s Disease Neuroimaging Initiative et al (2021) Prediction of future Alzheimer&#8217;s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med 27(6):1034&#8211;1042<pub-id pub-id-type="pmid">34031605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01348-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Therriault</surname><given-names>J</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Pola</surname><given-names>I</given-names></name><name name-style="western"><surname>Triana-Baltzer</surname><given-names>G</given-names></name><name name-style="western"><surname>Brum</surname><given-names>WS</given-names></name><name name-style="western"><surname>Di Molfetta</surname><given-names>G</given-names></name><etal/></person-group><article-title>Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer&#8217;s pathology</article-title><source>EBioMedicine</source><year>2024</year><volume>102</volume><fpage>105046</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2024.105046</pub-id><pub-id pub-id-type="pmid">38471397</pub-id><pub-id pub-id-type="pmcid">PMC10943661</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Therriault J, Ashton NJ, Pola I, Triana-Baltzer G, Brum WS, Di Molfetta G et al (2024) Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer&#8217;s pathology. EBioMedicine 102:105046<pub-id pub-id-type="pmid">38471397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2024.105046</pub-id><pub-id pub-id-type="pmcid">PMC10943661</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Brum</surname><given-names>WS</given-names></name><name name-style="western"><surname>Di Molfetta</surname><given-names>G</given-names></name><name name-style="western"><surname>Benedet</surname><given-names>AL</given-names></name><name name-style="western"><surname>Arslan</surname><given-names>B</given-names></name><name name-style="western"><surname>Jonaitis</surname><given-names>E</given-names></name><etal/></person-group><article-title>Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology</article-title><source>JAMA Neurol</source><year>2024</year><pub-id pub-id-type="doi">10.1001/jamaneurol.2023.5319</pub-id><pub-id pub-id-type="pmid">38252443</pub-id><pub-id pub-id-type="pmcid">PMC10804282</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E et al (2024) Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 10.1001/jamaneurol.2023.5319<pub-id pub-id-type="pmid">38252443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2023.5319</pub-id><pub-id pub-id-type="pmcid">PMC10804282</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></name><name name-style="western"><surname>Mattsson-Carlgren</surname><given-names>N</given-names></name><name name-style="western"><surname>Binette</surname><given-names>AP</given-names></name><name name-style="western"><surname>Strandberg</surname><given-names>O</given-names></name><name name-style="western"><surname>Brum</surname><given-names>WS</given-names></name><etal/></person-group><article-title>Differential roles of A&#946;42/40, p-tau231 and p-tau217 for Alzheimer&#8217;s trial selection and disease monitoring</article-title><source>Nat Med</source><year>2022</year><pub-id pub-id-type="doi">10.1038/s41591-022-02074-w</pub-id><pub-id pub-id-type="pmid">36456833</pub-id><pub-id pub-id-type="pmcid">PMC9800279</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS et al (2022) Differential roles of A&#946;42/40, p-tau231 and p-tau217 for Alzheimer&#8217;s trial selection and disease monitoring. Nat Med. 10.1038/s41591-022-02074-w<pub-id pub-id-type="pmid">36456833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-022-02074-w</pub-id><pub-id pub-id-type="pmcid">PMC9800279</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lantero-Rodriguez</surname><given-names>J</given-names></name><name name-style="western"><surname>Montoliu-Gaya</surname><given-names>L</given-names></name><name name-style="western"><surname>Benedet</surname><given-names>AL</given-names></name><name name-style="western"><surname>Vrillon</surname><given-names>A</given-names></name><name name-style="western"><surname>Dumurgier</surname><given-names>J</given-names></name><name name-style="western"><surname>Cognat</surname><given-names>E</given-names></name><etal/></person-group><article-title>CSF p-tau205: a biomarker of tau pathology in Alzheimer&#8217;s disease</article-title><source>Acta Neuropathol</source><year>2024</year><volume>147</volume><issue>1</issue><fpage>12</fpage><pub-id pub-id-type="doi">10.1007/s00401-023-02659-w</pub-id><pub-id pub-id-type="pmid">38184490</pub-id><pub-id pub-id-type="pmcid">PMC10771353</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Lantero-Rodriguez J, Montoliu-Gaya L, Benedet AL, Vrillon A, Dumurgier J, Cognat E et al (2024) CSF p-tau205: a biomarker of tau pathology in Alzheimer&#8217;s disease. Acta Neuropathol 147(1):12<pub-id pub-id-type="pmid">38184490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-023-02659-w</pub-id><pub-id pub-id-type="pmcid">PMC10771353</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montoliu-Gaya</surname><given-names>L</given-names></name><name name-style="western"><surname>Benedet</surname><given-names>AL</given-names></name><name name-style="western"><surname>Tissot</surname><given-names>C</given-names></name><name name-style="western"><surname>Vrillon</surname><given-names>A</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Brum</surname><given-names>WS</given-names></name><etal/></person-group><article-title>Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies</article-title><source>Nat Aging</source><year>2023</year><volume>27</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00405-1</pub-id><pub-id pub-id-type="pmcid">PMC10275761</pub-id><pub-id pub-id-type="pmid">37198279</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Montoliu-Gaya L, Benedet AL, Tissot C, Vrillon A, Ashton NJ, Brum WS et al (2023) Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nat Aging 27:1&#8211;9<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00405-1</pub-id><pub-id pub-id-type="pmcid">PMC10275761</pub-id><pub-id pub-id-type="pmid">37198279</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arendt</surname><given-names>T</given-names></name><name name-style="western"><surname>Stieler</surname><given-names>J</given-names></name><name name-style="western"><surname>Strijkstra</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hut</surname><given-names>RA</given-names></name><name name-style="western"><surname>R&#252;diger</surname><given-names>J</given-names></name><name name-style="western"><surname>Van der Zee</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals</article-title><source>J Neurosci</source><year>2003</year><volume>23</volume><issue>18</issue><fpage>6972</fpage><lpage>6981</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-18-06972.2003</pub-id><pub-id pub-id-type="pmid">12904458</pub-id><pub-id pub-id-type="pmcid">PMC6740664</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Arendt T, Stieler J, Strijkstra AM, Hut RA, R&#252;diger J, Van der Zee EA et al (2003) Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J Neurosci 23(18):6972&#8211;6981<pub-id pub-id-type="pmid">12904458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.23-18-06972.2003</pub-id><pub-id pub-id-type="pmcid">PMC6740664</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bullmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Feneberg</surname><given-names>E</given-names></name><name name-style="western"><surname>Kretzschmann</surname><given-names>TP</given-names></name><name name-style="western"><surname>Ogunlade</surname><given-names>V</given-names></name><name name-style="western"><surname>Holzer</surname><given-names>M</given-names></name><name name-style="western"><surname>Arendt</surname><given-names>T</given-names></name></person-group><article-title>Hibernation impairs odor discrimination - implications for Alzheimer&#8217;s disease</article-title><source>Front Neuroanat</source><year>2019</year><volume>13</volume><fpage>69</fpage><pub-id pub-id-type="doi">10.3389/fnana.2019.00069</pub-id><pub-id pub-id-type="pmid">31379517</pub-id><pub-id pub-id-type="pmcid">PMC6646461</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Bullmann T, Feneberg E, Kretzschmann TP, Ogunlade V, Holzer M, Arendt T (2019) Hibernation impairs odor discrimination - implications for Alzheimer&#8217;s disease. Front Neuroanat 13:69<pub-id pub-id-type="pmid">31379517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnana.2019.00069</pub-id><pub-id pub-id-type="pmcid">PMC6646461</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stieler</surname><given-names>JT</given-names></name><name name-style="western"><surname>Bullmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Kohl</surname><given-names>F</given-names></name><name name-style="western"><surname>T&#248;ien</surname><given-names>&#216;</given-names></name><name name-style="western"><surname>Br&#252;ckner</surname><given-names>MK</given-names></name><name name-style="western"><surname>H&#228;rtig</surname><given-names>W</given-names></name><etal/></person-group><article-title>The physiological link between metabolic rate depression and Tau phosphorylation in Mammalian hibernation</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><issue>1</issue><fpage>e14530</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0014530</pub-id><pub-id pub-id-type="pmid">21267079</pub-id><pub-id pub-id-type="pmcid">PMC3022585</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Stieler JT, Bullmann T, Kohl F, T&#248;ien &#216;, Br&#252;ckner MK, H&#228;rtig W et al (2011) The physiological link between metabolic rate depression and Tau phosphorylation in Mammalian hibernation. PLoS ONE 6(1):e14530<pub-id pub-id-type="pmid">21267079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0014530</pub-id><pub-id pub-id-type="pmcid">PMC3022585</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#228;rtig</surname><given-names>W</given-names></name><name name-style="western"><surname>Klein</surname><given-names>C</given-names></name><name name-style="western"><surname>Brauer</surname><given-names>K</given-names></name><name name-style="western"><surname>Sch&#252;ppel</surname><given-names>KF</given-names></name><name name-style="western"><surname>Arendt</surname><given-names>T</given-names></name><name name-style="western"><surname>Br&#252;ckner</surname><given-names>G</given-names></name><etal/></person-group><article-title>Abnormally phosphorylated protein tau in the cortex of aged individuals of various mammalian orders</article-title><source>Acta Neuropathol</source><year>2000</year><volume>100</volume><issue>3</issue><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1007/s004010000183</pub-id><pub-id pub-id-type="pmid">10965801</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">H&#228;rtig W, Klein C, Brauer K, Sch&#252;ppel KF, Arendt T, Br&#252;ckner G et al (2000) Abnormally phosphorylated protein tau in the cortex of aged individuals of various mammalian orders. Acta Neuropathol 100(3):305&#8211;312<pub-id pub-id-type="pmid">10965801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s004010000183</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>AL</given-names></name><name name-style="western"><surname>Sahl&#233;n</surname><given-names>V</given-names></name><name name-style="western"><surname>St&#248;en</surname><given-names>OG</given-names></name><name name-style="western"><surname>Fahlman</surname><given-names>&#197;</given-names></name><name name-style="western"><surname>Brunberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Madslien</surname><given-names>K</given-names></name><etal/></person-group><article-title>Capture, anesthesia, and disturbance of free-ranging brown bears (Ursus arctos) during Hibernation</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><issue>7</issue><fpage>e40520</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0040520</pub-id><pub-id pub-id-type="pmid">22815757</pub-id><pub-id pub-id-type="pmcid">PMC3398017</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Evans AL, Sahl&#233;n V, St&#248;en OG, Fahlman &#197;, Brunberg S, Madslien K et al (2012) Capture, anesthesia, and disturbance of free-ranging brown bears (Ursus arctos) during Hibernation. PLoS ONE 7(7):e40520<pub-id pub-id-type="pmid">22815757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0040520</pub-id><pub-id pub-id-type="pmcid">PMC3398017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>EN</given-names></name><name name-style="western"><surname>Young</surname><given-names>CB</given-names></name><name name-style="western"><surname>Ramos Benitez</surname><given-names>J</given-names></name><name name-style="western"><surname>Swarovski</surname><given-names>MS</given-names></name><name name-style="western"><surname>Feinstein</surname><given-names>I</given-names></name><name name-style="western"><surname>Vandijck</surname><given-names>M</given-names></name><etal/></person-group><article-title>Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer&#8217;s disease</article-title><source>Alzheimers Res Ther</source><year>2022</year><volume>14</volume><issue>1</issue><fpage>172</fpage><pub-id pub-id-type="doi">10.1186/s13195-022-01116-2</pub-id><pub-id pub-id-type="pmid">36371232</pub-id><pub-id pub-id-type="pmcid">PMC9652927</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Wilson EN, Young CB, Ramos Benitez J, Swarovski MS, Feinstein I, Vandijck M et al (2022) Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer&#8217;s disease. Alzheimers Res Ther 14(1):172<pub-id pub-id-type="pmid">36371232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-022-01116-2</pub-id><pub-id pub-id-type="pmcid">PMC9652927</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></name><name name-style="western"><surname>Quiroz</surname><given-names>YT</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name><name name-style="western"><surname>Lopera</surname><given-names>F</given-names></name><name name-style="western"><surname>Stomrud</surname><given-names>E</given-names></name><etal/></person-group><article-title>Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders</article-title><source>JAMA</source><year>2020</year><volume>324</volume><issue>8</issue><fpage>772</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.12134</pub-id><pub-id pub-id-type="pmid">32722745</pub-id><pub-id pub-id-type="pmcid">PMC7388060</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E et al (2020) Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324(8):772&#8211;781<pub-id pub-id-type="pmid">32722745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.12134</pub-id><pub-id pub-id-type="pmcid">PMC7388060</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oklejewicz</surname><given-names>M</given-names></name><name name-style="western"><surname>Daan</surname><given-names>S</given-names></name><name name-style="western"><surname>Strijkstra</surname><given-names>AM</given-names></name></person-group><article-title>Temporal organisation of hibernation in wild-type and tau mutant Syrian hamsters</article-title><source>J Comp Physiol B</source><year>2001</year><volume>171</volume><issue>5</issue><fpage>431</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1007/s003600100193</pub-id><pub-id pub-id-type="pmid">11497131</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Oklejewicz M, Daan S, Strijkstra AM (2001) Temporal organisation of hibernation in wild-type and tau mutant Syrian hamsters. J Comp Physiol B 171(5):431&#8211;439<pub-id pub-id-type="pmid">11497131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s003600100193</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKhann</surname><given-names>G</given-names></name><name name-style="western"><surname>Drachman</surname><given-names>D</given-names></name><name name-style="western"><surname>Folstein</surname><given-names>M</given-names></name><name name-style="western"><surname>Katzman</surname><given-names>R</given-names></name><name name-style="western"><surname>Price</surname><given-names>D</given-names></name><name name-style="western"><surname>Stadlan</surname><given-names>EM</given-names></name></person-group><article-title>Clinical diagnosis of Alzheimer&#8217;s disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><issue>7</issue><fpage>939</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1212/WNL.34.7.939</pub-id><pub-id pub-id-type="pmid">6610841</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer&#8217;s disease. Neurology 34(7):939&#8211;939<pub-id pub-id-type="pmid">6610841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.34.7.939</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montine</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Phelps</surname><given-names>CH</given-names></name><name name-style="western"><surname>Beach</surname><given-names>TG</given-names></name><name name-style="western"><surname>Bigio</surname><given-names>EH</given-names></name><name name-style="western"><surname>Cairns</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>DW</given-names></name><etal/></person-group><article-title>National Institute on Aging&#8211;Alzheimer&#8217;s Association guidelines for the neuropathologic assessment of Alzheimer&#8217;s disease: a practical approach</article-title><source>Acta Neuropathol</source><year>2012</year><volume>123</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1007/s00401-011-0910-3</pub-id><pub-id pub-id-type="pmid">22101365</pub-id><pub-id pub-id-type="pmcid">PMC3268003</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on Aging&#8211;Alzheimer&#8217;s Association guidelines for the neuropathologic assessment of Alzheimer&#8217;s disease: a practical approach. Acta Neuropathol 123(1):1&#8211;11<pub-id pub-id-type="pmid">22101365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-011-0910-3</pub-id><pub-id pub-id-type="pmcid">PMC3268003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camporesi</surname><given-names>E</given-names></name><name name-style="western"><surname>Lashley</surname><given-names>T</given-names></name><name name-style="western"><surname>Gobom</surname><given-names>J</given-names></name><name name-style="western"><surname>Lantero-Rodriguez</surname><given-names>J</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>O</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></name><etal/></person-group><article-title>Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers</article-title><source>Acta Neuropathol Commun</source><year>2021</year><volume>9</volume><issue>1</issue><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/s40478-021-01119-4</pub-id><pub-id pub-id-type="pmid">33522967</pub-id><pub-id pub-id-type="pmcid">PMC7852195</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Camporesi E, Lashley T, Gobom J, Lantero-Rodriguez J, Hansson O, Zetterberg H et al (2021) Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. Acta Neuropathol Commun 9(1):19<pub-id pub-id-type="pmid">33522967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40478-021-01119-4</pub-id><pub-id pub-id-type="pmcid">PMC7852195</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahara</surname><given-names>N</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>T</given-names></name></person-group><article-title>Biochemical properties of pathology-related tau species in tauopathy brains: an extraction protocol for tau oligomers and aggregates</article-title><source>Methods Mol Biol</source><year>2018</year><volume>1779</volume><fpage>435</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7816-8_26</pub-id><pub-id pub-id-type="pmid">29886548</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Sahara N, Kimura T (2018) Biochemical properties of pathology-related tau species in tauopathy brains: an extraction protocol for tau oligomers and aggregates. Methods Mol Biol 1779:435&#8211;445<pub-id pub-id-type="pmid">29886548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-7816-8_26</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lantero-Rodriguez</surname><given-names>J</given-names></name><name name-style="western"><surname>Camporesi</surname><given-names>E</given-names></name><name name-style="western"><surname>Montoliu-Gaya</surname><given-names>L</given-names></name><name name-style="western"><surname>Gobom</surname><given-names>J</given-names></name><name name-style="western"><surname>Piotrowska</surname><given-names>D</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tau protein profiling in tauopathies: a human brain study</article-title><source>Mol Neurodegener</source><year>2024</year><volume>19</volume><issue>1</issue><fpage>54</fpage><pub-id pub-id-type="doi">10.1186/s13024-024-00741-9</pub-id><pub-id pub-id-type="pmid">39026372</pub-id><pub-id pub-id-type="pmcid">PMC11264707</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Lantero-Rodriguez J, Camporesi E, Montoliu-Gaya L, Gobom J, Piotrowska D, Olsson M et al (2024) Tau protein profiling in tauopathies: a human brain study. Mol Neurodegener 19(1):54<pub-id pub-id-type="pmid">39026372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-024-00741-9</pub-id><pub-id pub-id-type="pmcid">PMC11264707</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montoliu-Gaya</surname><given-names>L</given-names></name><name name-style="western"><surname>Alosco</surname><given-names>ML</given-names></name><name name-style="western"><surname>Yhang</surname><given-names>E</given-names></name><name name-style="western"><surname>Tripodis</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sconzo</surname><given-names>D</given-names></name><name name-style="western"><surname>Ally</surname><given-names>M</given-names></name><etal/></person-group><article-title>Optimal blood tau species for the detection of Alzheimer&#8217;s disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study</article-title><source>Acta Neuropathol</source><year>2023</year><volume>147</volume><issue>1</issue><fpage>5</fpage><pub-id pub-id-type="doi">10.1007/s00401-023-02660-3</pub-id><pub-id pub-id-type="pmid">38159140</pub-id><pub-id pub-id-type="pmcid">PMC10757700</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Montoliu-Gaya L, Alosco ML, Yhang E, Tripodis Y, Sconzo D, Ally M et al (2023) Optimal blood tau species for the detection of Alzheimer&#8217;s disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study. Acta Neuropathol 147(1):5<pub-id pub-id-type="pmid">38159140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-023-02660-3</pub-id><pub-id pub-id-type="pmcid">PMC10757700</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name></person-group><article-title>Neurodegeneration and acute neuronal injury drastically skew the p-tau217/non-p217 ratio in both CSF and plasma regardless of analytical technique &#8211; a mass spectrometry and Simoa study</article-title><source>Alzheimers Dement</source><year>2025</year><volume>20</volume><issue>Suppl 8</issue><fpage>e094606</fpage></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Blennow K (2025) Neurodegeneration and acute neuronal injury drastically skew the p-tau217/non-p217 ratio in both CSF and plasma regardless of analytical technique &#8211; a mass spectrometry and Simoa study. Alzheimers Dement 20(Suppl 8):e094606</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welinder</surname><given-names>KG</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>R</given-names></name><name name-style="western"><surname>Overgaard</surname><given-names>MT</given-names></name><name name-style="western"><surname>Brohus</surname><given-names>M</given-names></name><name name-style="western"><surname>S&#248;nderk&#230;r</surname><given-names>M</given-names></name><name name-style="western"><surname>von Bergen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Biochemical foundations of health and energy conservation in hibernating free-ranging Subadult Brown Bear Ursus arctos</article-title><source>J Biol Chem</source><year>2016</year><volume>291</volume><issue>43</issue><fpage>22509</fpage><lpage>22523</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.742916</pub-id><pub-id pub-id-type="pmid">27609515</pub-id><pub-id pub-id-type="pmcid">PMC5077189</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Welinder KG, Hansen R, Overgaard MT, Brohus M, S&#248;nderk&#230;r M, von Bergen M et al (2016) Biochemical foundations of health and energy conservation in hibernating free-ranging Subadult Brown Bear Ursus arctos. J Biol Chem 291(43):22509&#8211;22523<pub-id pub-id-type="pmid">27609515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M116.742916</pub-id><pub-id pub-id-type="pmcid">PMC5077189</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le&#243;n-Espinosa</surname><given-names>G</given-names></name><name name-style="western"><surname>Murillo</surname><given-names>AMM</given-names></name><name name-style="western"><surname>Turegano-Lopez</surname><given-names>M</given-names></name><name name-style="western"><surname>DeFelipe</surname><given-names>J</given-names></name><name name-style="western"><surname>Holgado</surname><given-names>M</given-names></name></person-group><article-title>Phosphorylated Tau at T181 accumulates in the serum of hibernating Syrian hamsters and rapidly disappears after arousal</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>20562</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-71481-5</pub-id><pub-id pub-id-type="pmid">39232030</pub-id><pub-id pub-id-type="pmcid">PMC11375040</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Le&#243;n-Espinosa G, Murillo AMM, Turegano-Lopez M, DeFelipe J, Holgado M (2024) Phosphorylated Tau at T181 accumulates in the serum of hibernating Syrian hamsters and rapidly disappears after arousal. Sci Rep 14(1):20562<pub-id pub-id-type="pmid">39232030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-71481-5</pub-id><pub-id pub-id-type="pmcid">PMC11375040</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Planel</surname><given-names>E</given-names></name><name name-style="western"><surname>Miyasaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Launey</surname><given-names>T</given-names></name><name name-style="western"><surname>Chui</surname><given-names>DH</given-names></name><name name-style="western"><surname>Tanemura</surname><given-names>K</given-names></name><name name-style="western"><surname>Sato</surname><given-names>S</given-names></name><etal/></person-group><article-title>Alterations in glucose metabolism induce hypothermia leading to Tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer&#8217;s disease</article-title><source>J Neurosci</source><year>2004</year><volume>24</volume><issue>10</issue><fpage>2401</fpage><lpage>2411</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5561-03.2004</pub-id><pub-id pub-id-type="pmid">15014115</pub-id><pub-id pub-id-type="pmcid">PMC6729502</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S et al (2004) Alterations in glucose metabolism induce hypothermia leading to Tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer&#8217;s disease. J Neurosci 24(10):2401&#8211;2411<pub-id pub-id-type="pmid">15014115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1523/JNEUROSCI.5561-03.2004</pub-id><pub-id pub-id-type="pmcid">PMC6729502</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cork</surname><given-names>LC</given-names></name><name name-style="western"><surname>Powers</surname><given-names>RE</given-names></name><name name-style="western"><surname>Selkoe</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Davies</surname><given-names>P</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Price</surname><given-names>DL</given-names></name></person-group><article-title>Neurofibrillary tangles and senile plaques in aged bears</article-title><source>J Neuropathol Exp Neurol</source><year>1988</year><volume>47</volume><issue>6</issue><fpage>629</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1097/00005072-198811000-00006</pub-id><pub-id pub-id-type="pmid">3171607</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Cork LC, Powers RE, Selkoe DJ, Davies P, Geyer JJ, Price DL (1988) Neurofibrillary tangles and senile plaques in aged bears. J Neuropathol Exp Neurol 47(6):629&#8211;641<pub-id pub-id-type="pmid">3171607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00005072-198811000-00006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fitzpatrick</surname><given-names>AWP</given-names></name><name name-style="western"><surname>Falcon</surname><given-names>B</given-names></name><name name-style="western"><surname>He</surname><given-names>S</given-names></name><name name-style="western"><surname>Murzin</surname><given-names>AG</given-names></name><name name-style="western"><surname>Murshudov</surname><given-names>G</given-names></name><name name-style="western"><surname>Garringer</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Cryo-EM structures of tau filaments from Alzheimer&#8217;s disease</article-title><source>Nature</source><year>2017</year><volume>547</volume><issue>7662</issue><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/nature23002</pub-id><pub-id pub-id-type="pmid">28678775</pub-id><pub-id pub-id-type="pmcid">PMC5552202</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ et al (2017) Cryo-EM structures of tau filaments from Alzheimer&#8217;s disease. Nature 547(7662):185&#8211;190<pub-id pub-id-type="pmid">28678775</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature23002</pub-id><pub-id pub-id-type="pmcid">PMC5552202</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horie</surname><given-names>K</given-names></name><name name-style="western"><surname>Salvad&#243;</surname><given-names>G</given-names></name><name name-style="western"><surname>Barth&#233;lemy</surname><given-names>NR</given-names></name><name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><etal/></person-group><article-title>CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer&#8217;s disease</article-title><source>Nat Med</source><year>2023</year><volume>29</volume><issue>8</issue><fpage>1954</fpage><lpage>1963</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02443-z</pub-id><pub-id pub-id-type="pmid">37443334</pub-id><pub-id pub-id-type="pmcid">PMC10427417</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Horie K, Salvad&#243; G, Barth&#233;lemy NR, Janelidze S, Li Y, He Y et al (2023) CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer&#8217;s disease. Nat Med 29(8):1954&#8211;1963<pub-id pub-id-type="pmid">37443334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-023-02443-z</pub-id><pub-id pub-id-type="pmcid">PMC10427417</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">L&#246;vestam S, Wagstaff JL, Katsinelos T, Freund SM, Goedert M, Scheres SH. Twelve phosphomimetic mutations induce the assembly of recombinant full-length human tau into paired helical filaments. eLife [Internet]. 2025 Jan 16 [cited 2025 July 9];14. Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://elifesciences.org/reviewed-preprints/104778">https://elifesciences.org/reviewed-preprints/104778</ext-link></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">eBioMedicine</journal-id><journal-id journal-id-type="iso-abbrev">EBioMedicine</journal-id><journal-id journal-id-type="pmc-domain-id">2749</journal-id><journal-id journal-id-type="pmc-domain">ebiom</journal-id><journal-title-group><journal-title>eBioMedicine</journal-title></journal-title-group><issn pub-type="epub">2352-3964</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12481134</article-id><article-id pub-id-type="pmcid-ver">PMC12481134.1</article-id><article-id pub-id-type="pmcaid">12481134</article-id><article-id pub-id-type="pmcaiid">12481134</article-id><article-id pub-id-type="pmid">40974909</article-id><article-id pub-id-type="doi">10.1016/j.ebiom.2025.105930</article-id><article-id pub-id-type="pii">S2352-3964(25)00374-3</article-id><article-id pub-id-type="publisher-id">105930</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Comparative analysis of cerebrospinal fluid neurofilament medium, light and heavy chain in neurodegenerative diseases using an in-house assay for the detection of neurofilament medium chain</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Fazeli</surname><given-names initials="B">Badrieh</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Botzenhardt</surname><given-names initials="S">Sara</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Bachhuber</surname><given-names initials="F">Franziska</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Klassen</surname><given-names initials="P">Paula</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Klose</surname><given-names initials="V">Veronika</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Dorst</surname><given-names initials="J">Johannes</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Wiesenfarth</surname><given-names initials="M">Maximilian</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Uzelac</surname><given-names initials="Z">Zeljko</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Jesse</surname><given-names initials="S">Sarah</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Brenner</surname><given-names initials="D">David</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Anderl-Straub</surname><given-names initials="S">Sarah</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>Ludolph</surname><given-names initials="AC">Albert C.</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au13"><name name-style="western"><surname>Otto</surname><given-names initials="M">Markus</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au14"><name name-style="western"><surname>Weishaupt</surname><given-names initials="J">Jochen</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au15"><name name-style="western"><surname>Tumani</surname><given-names initials="H">Hayrettin</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au16"><name name-style="western"><surname>Halbgebauer</surname><given-names initials="S">Steffen</given-names></name><email>steffen.halbgebauer@uni-ulm.de</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><aff id="aff1"><label>a</label>Department of Neurology, Ulm University Hospital, 89081, Ulm, Germany</aff><aff id="aff2"><label>b</label>German Centre for Neurodegenerative Diseases (DZNE e.V.), 89081, Ulm, Germany</aff><aff id="aff3"><label>c</label>Department of Neurology, University Hospital Halle, 06120, Halle (Saale), Germany</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author. Steffen Halbgebauer Department of Neurology, Ulm University Hospital, Oberer Eselsberg 45, 89081, Ulm, Germany. <email>steffen.halbgebauer@uni-ulm.de</email></corresp></author-notes><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>19</day><month>9</month><year>2025</year></pub-date><volume>120</volume><issue-id pub-id-type="pmc-issue-id">497285</issue-id><elocation-id>105930</elocation-id><history><date date-type="received"><day>8</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>1</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 09:26:11.207"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><title>Summary</title><sec><title>Background</title><p>Neurofilaments are key axonal proteins, with neurofilament light (NfL) and heavy (NfH) chain recognised as promising biomarkers for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). However, neurofilament medium chain (NfM) remained previously underexplored due to a lack of quantitative assays. In this study, we developed a sensitive immunoassay to measure NfM in cerebrospinal fluid (CSF) and analysed its levels in ALS, Alzheimer's disease (AD), frontotemporal dementia (FTD), and Lewy body dementia (LBD). Correlations among neurofilaments and their diagnostic performance were also evaluated.</p></sec><sec><title>Methods</title><p>In this study CSF levels of three neurofilament proteins were measured in 305 participants, including patients with ALS (n = 91), AD (n = 59), FTD (n = 38), LBD (n = 18), non-neurodegenerative controls (CTRL, n = 51), and 48 individuals initially evaluated for ALS but ultimately diagnosed with other conditions (CTRL.DD). NfM levels were quantified using a homemade sandwich ELISA, while NfL and NfH were measured using commercialised Ella cartridges.</p></sec><sec><title>Findings</title><p>All three neurofilaments were significantly elevated in ALS compared to CTRL and CTRL.DD groups (p &lt; 0.0001 for both), with NfM and NfL also increased in FTD (p &lt; 0.0001 for both) and AD (NfM, p &lt; 0.0001; NfL, p = 0.0001) compared to CTRL. NfH demonstrated the greatest distinction between ALS and FTD (p &lt; 0.0001). Strong correlations were observed among neurofilament subunits, particularly between NfM and NfL (r = 0.93, 95% CI: 0.91&#8211;0.94, p &lt; 0.0001). All neurofilaments effectively distinguished ALS from CTRL and CTRL.DD, with AUC values ranging from 0.92 to 0.99. NfM and NfL showed high accuracy in differentiating AD (NfM, AUC: 0.91; NfL, AUC: 0.89) and FTD (NfM, AUC: 0.91; NfL, AUC: 0.92) from CTRL, while NfH best separated ALS from FTD (AUC: 0.96).</p></sec><sec><title>Interpretation</title><p>This study provides a quantitative comparison of NfM with NfL and NfH in a neurodegenerative cohort, highlighting its potential diagnostic value. Further research with larger cohorts, longitudinal studies, and investigations into neurofilament distribution in different compartments is needed to clarify the distinct roles of NfM, NfL, and NfH in the diagnosis and treatment of neurological diseases.</p></sec><sec><title>Funding</title><p>The present study was supported by the <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003042</institution-id><institution>Else Kroener-Fresenius Foundation</institution></institution-wrap></funding-source> (2024-EKEA.126) and Chemische Fabrik Karl Bucher GmbH.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Neurofilament medium chain</kwd><kwd>Fluid biomarkers</kwd><kwd>ELISA</kwd><kwd>Alzheimer's diseases</kwd><kwd>Amyotrophic lateral sclerosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="p0010">
<boxed-text id="dtbox1" position="float" orientation="portrait"><caption><title>Research in context</title></caption><sec id="dtbox1sec1"><title>Evidence before this study</title><p id="p0015">Neurofilaments are intermediate filaments found in neurons, which play crucial roles in maintaining neuronal structure and function. Although NfL and NfH have been widely studied in neurodegenerative diseases, NfM has received less attention due to the absence of sensitive quantitative assays. As a result, NfL and NfH are well-established biomarkers for conditions like Alzheimer's disease and amyotrophic lateral sclerosis. In contrast, the diagnostic potential of NfM remains largely unexplored.</p></sec><sec id="dtbox1sec2"><title>Added value of this study</title><p id="p0020">This study introduced a reliable, sensitive immunoassay for detecting NfM in cerebrospinal fluid (CSF), extending research on NfM in neurodegenerative diseases. This provides a quantitative comparison of CSF levels of NfM with NfL and NfH in neurodegenerative diseases. Results demonstrate that NfM, like NfL, is significantly elevated in ALS, FTD, and AD, supporting its diagnostic potential. The strong correlation between NfM and NfL highlights their interconnected roles, while NfH best differentiates ALS from FTD.</p></sec><sec id="dtbox1sec3"><title>Implications of all the available evidence</title><p id="p0025">This study supports NfM potential to improve diagnostic accuracy, particularly in distinguishing ALS, AD, and FTD. Clinically, integrating NfM measurements into biomarker panels may enhance early disease detection and patient stratification. Future research may build on these findings to refine neurofilament-based diagnostic criteria and explore their prognostic value.</p></sec></boxed-text>
</p><sec id="sec1"><title>Introduction</title><p id="p0030">Neurofilaments constitute a family of intermediate filament proteins that are essential for the development, structural integrity, and functional maintenance of axons within both the central and peripheral nervous systems. The main neurofilament subunits are the neurofilament heavy (NfH), neurofilament medium (NfM) and the neurofilament light chain (NfL) as well as &#945;-internexin, and peripherin. These subunits interact to form heteropolymers, which collectively contribute to the organisation and stability of the neuronal cytoskeleton.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Although these subunits share a conserved tripartite structure, they differ markedly in size and in their specific roles within neurofilament assembly and function. NfL, the smallest (68&#8211;70 kDa) and most abundant subunit, forms the core backbone of neurofilaments, providing structural support. Conversely, NfM (145&#8211;160 kDa) and NfH (200&#8211;220 kDa) feature elongated carboxy-terminal tail domains enriched with phosphorylation sites, which extend as side arms that regulate inter-filament spacing and axonal diameter.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref></p><p id="p0035">Neurofilaments, particularly NfL, have emerged as promising biomarkers for a wide range of neurological disorders including neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD). These cytoskeletal proteins, released into cerebrospinal fluid (CSF) and blood upon neuronal damage, serve as sensitive indicators of axonal injury and neurodegeneration.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> NfL and phosphorylated NfH (pNfH) are significantly elevated in ALS,<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref> with NfL extensively studied in AD,<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref> frontotemporal dementia (FTD),<xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref> and Lewy body dementia (LBD),<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> correlating with cognitive decline and neurodegeneration. While numerous studies have explored NfL and pNfH levels in various neurological diseases, research on NfM levels remains limited as so far, no well validated quantitative assays were previously available. However, non-quantitative protein profiling studies have reported elevated NfM levels in patients with ALS and FTD.<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref></p><p id="p0040">In this study we developed a quantitative and highly sensitive immunoassay to measure NfM levels in CSF and subsequently utilise it for the analysis of NfM in the CSF of patients with neurological disorders, including ALS, AD, FTD, and LBD, alongside control cohorts. Additionally, we investigated correlations between NfM, NfL and NfH and employed receiver operating characteristic (ROC) analysis to evaluate and compare their individual discriminating potentials.</p></sec><sec id="sec2"><title>Methods</title><sec id="sec2.1"><title>Ethics</title><p id="p0045">CSF samples were collected at the Department of Neurology, University Hospital of Ulm, Germany, between 2010 and 2021. All participants or their legal representatives gave written informed consent to participate in the study. The study was approved by the Ethics Committee of the University of Ulm (approval number: 20/10) and was conducted in accordance with the Declaration of Helsinki.</p></sec><sec id="sec2.2"><title>Patient selection</title><p id="p0050">The focus of this study was to measure the levels of three neurofilament proteins in the CSF of 305 patients diagnosed with ALS (n = 91), AD (n = 59), FTD (n = 38), LBD (n = 18), and two control groups consisting of (i) individuals initially under suspicion of ALS but finally diagnosed differently (CTRL.DD) (n = 48) (see <xref rid="appsec1" ref-type="sec">Table S1</xref> for diagnoses) and (ii) non-neurodegenerative controls (CTRL) (n = 51).</p><p id="p0055">Patients with ALS met the criteria for definite or probable ALS based on the revised El Escorial criteria.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> They were stratified into two groups&#8212;slow and intermediate-to-fast progressors&#8212;based on their disease progression rate, using a predefined threshold.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref></p><p id="p0060">The diagnosis of AD in patients was established based on the International Working Group 2 criteria.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> This diagnosis was further supported by the analysis of core CSF biomarkers (A: Abeta 42 to 40 ratio, T: phosphorylated tau 181 (pTau181), N: total tau), following the recommendations from the National Institute on Ageing and Alzheimer's Association.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> All patients with AD presented a CSF biomarker profile of A+ T+ N+. The FTD group included 17 patients diagnosed with behavioural variant frontotemporal dementia (bvFTD), along with 21 patients with primary progressive aphasia (PPA) subtypes: 7 with the non-fluent variant (nfvPPA), 7 with the logopenic variant (lvPPA), and 7 with the semantic variant (svPPA). Diagnoses of bvFTD and PPA were made in accordance with accepted international criteria.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref></p><p id="p0065">Among the 18 patients with LBD, 14 were diagnosed with Parkinson's disease (PD) based on the UK Parkinson's Disease Society Brain Bank criteria,<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> while 4 were diagnosed with Parkinson's disease dementia (PDD) based on significant impairment in daily functioning<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> and the clinical criteria for PDD recommended by the Movement Disorder Society.<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref></p><p id="p0070">The CTRL.DD group comprised patients initially suspected of ALS but later diagnosed with other conditions, with their NfL and NfH levels previously assessed by Halbgebauer et al.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> The final diagnoses are detailed in <xref rid="appsec1" ref-type="sec">Table S1</xref> the in <xref rid="appsec1" ref-type="sec">Supplementary Material</xref>.</p><p id="p0075">The CTRL group included control patients with no clinical signs of neurodegeneration. These subjects were initially admitted to the department of neurology due to symptoms such as tension-type headaches, brief sensory disturbances or dizziness. Thorough clinical and radiological examinations ruled out neurodegenerative and neuroinflammatory disorders. Each control participant also underwent a lumbar puncture to rule out possible central nervous system (CNS) inflammation. Evaluation criteria included a normal leukocyte count, preserved blood-CSF barrier function (reflected by a normal CSF albumin-to-serum ratio) and no evidence of intrathecal immunoglobulin synthesis, confirmed by quantitative analysis of IgG, IgA, IgM and oligoclonal IgG bands.</p></sec><sec id="sec2.3"><title>CSF sampling and analysis</title><p id="p0080">CSF samples were obtained by lumbar puncture, centrifuged at 2000 g for 10 min, and the supernatant was aliquoted and stored at &#8722;80 &#176;C.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> To quantify NfL and NfH in CSF samples, commercially available Ella microfluidic kits (Bio-techne, Minneapolis, USA) were used and measurements were performed according to the manufacturer's instructions. Details of the quantification protocol are provided in the <xref rid="appsec1" ref-type="sec">Supplementary Material</xref>. The quantification range for these assays is 2.7&#8211;10,290 pg/mL for NfL and 7.46&#8211;28,480 pg/mL for NfH. CSF NfM levels were measured using an in-house sandwich ELISA assay. All measurements were performed on aliquots subjected to an equal number of freeze&#8211;thaw cycles, ensuring consistency across samples.</p></sec><sec id="sec2.4"><title>Antibodies and recombinant protein</title><p id="p0085">The in-house NfM immunoassay included a mouse monoclonal antibody, clone OTI2C4 (OriGene Cat# <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="CF506794">CF506794</ext-link>, RRID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_3697381" id="intref0010">AB_3697381</ext-link>) against NfM as capture and a mouse monoclonal antibody, clone OTI2G3 (Novus Cat# NBP2-72977, RRID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_3383062" id="intref0015">AB_3383062</ext-link>) as detector. The detector antibody was biotinylated with EZ-Link&#8482; NHS-PEG4-Biotin (Cat. #A39259, Thermo Fisher Scientific, Massachusetts, USA), in a ratio biotin to antibody 40:1 according to the biotinylation protocol provided by Quanterix Corporation (Lexington, Massachusetts, USA). For assay development and antibody affinity screening, human recombinant NfM (Cat. #TP324475, OriGene Technologies, Rockville, MD, USA) was employed.</p></sec><sec id="sec2.5"><title>NfM sandwich ELISA method</title><p id="p0090">Nunc Maxisorp 96-well microtitre plates (Thermo Fisher Scientific, Massachusetts, USA) were coated with 100 &#956;L per well of capture antibody (Cat. #<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="CF506794">CF506794</ext-link>) at a concentration of 3.3 &#956;g/mL in 100 mM bicarbonate-carbonate buffer (pH 9.6) and incubated overnight at 4 &#176;C. Following removal of the coating solution, non-specific binding sites were blocked by adding 300 &#956;L of blocking buffer (1% bovine serum albumin in phosphate-buffered saline (PBS) with 0.05% Tween 20) to each well, followed by incubation at 20 &#176;C for 2 h. CSF samples were diluted 1:4 in blocking buffer, and calibrators were prepared using recombinant NfM (Cat. #TP324475) with concentrations ranging from 125 to 8000 pg/mL. A volume of 100 &#956;L of the diluted CSF samples, blocking buffer as blank, controls and calibrators was added in duplicate and incubated at 30 &#176;C for 1.5 h. The wells were then washed three times with 300 &#956;L of wash buffer (PBS with 0.05% Tween 20) to remove unbound proteins. Subsequently, 100 &#956;L of biotinylated detector antibody (Cat. #NBP2-72977), diluted to 1.32 &#956;g/mL in blocking buffer, was applied to each well and incubated for 1 h at 20 &#176;C. After further washing, 100 &#956;L of avidin/biotin-based peroxidase complexes (A&amp; B solutions, 1:200 each in PBS) (Cat. #PK-6100, Vector Laboratories, California, USA) was added and incubated for 1 h at 20 &#176;C to allow detection. The plate was washed again and 100 &#956;L of 3,3&#8242;,5,5&#8242;-tetramethylbenzidine (Thermo Fisher Scientific, Massachusetts, USA) was added to each well and incubated for 15 min at room temperature in the dark to allow colour development. The reaction was stopped by adding 100 &#956;L of 1 M hydrochloric acid to each well. Absorbance was measured at 450 nm with a reference wavelength of 570 nm. Concentrations were determined from a 4-parameter logistic standard curve.</p></sec><sec id="sec2.6"><title>NfM assay validation</title><p id="p0095">Repeatability was evaluated by measuring eight replicates of a pooled CSF sample along with two individual CSF samples. To assess intermediate precision, four replicates of three individual CSF samples and one pooled sample were measured across three separate runs. The lower limit of quantification (LLOQ) and the limit of detection (LOD) were determined using 16 blank measurements, with the LLOQ calculated as the signal corresponding to 10 standard deviations (SD) above the mean, and the LOD calculated as 3 SD above the mean.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref></p><p id="p0100">The calibrators covered a concentration range of 125&#8211;8000 pg/mL. 5% of the samples measured exceeded the upper limit and their concentration was estimated by extrapolation. All samples were above the LLOQ. To assess parallelism, two endogenous CSF samples were analysed&#8211;one with a high concentration and one with low concentration&#8211;diluted at ratios ranging from 1:2 to 1:8. The back-calculated concentrations from these dilutions were evaluated to determine the minimum required dilution (MRD). This strategy was implemented to minimise matrix effects and ensure accurate quantification of endogenous NfM.</p><p id="p0105">To assess spike and recovery, two CSF samples were diluted at a ratio of 1:4 and divided into three aliquots. Each aliquot was then spiked with NfM-free sample diluent, as well as recombinant NfM protein (Cat. #TP324475) at medium (2000 pg/mL) and low (400 pg/mL) concentrations. The volume of the spiked solution was kept below 10% of the total aliquot volume, and recovery was expressed as a percentage. To evaluate potential cross-reactivity with abundant CSF proteins, serial dilutions of the two CSF samples were spiked with physiological concentrations of human serum albumin (HSA) (200 &#956;g/mL) and a higher concentration of 600 &#956;g/mL, as well as physiological concentrations of immunoglobulin G (IgG) (30 &#956;g/mL) and a higher concentration of 90 &#956;g/mL. NfM levels in these spiked samples were then compared to those in unspiked samples.</p><p id="p0110">To assess potential cross-reactivity with NfL and NfH in an indirect ELISA, recombinant proteins for NfL (Cat. #ab224840, Abcam, Cambridge, UK) and NfH (Cat. #TP313487, OriGene Technologies, Rockville, MD, USA) were coated onto the assay plate, and antibodies were screened for their affinity to these two proteins. Antibodies specific to NfL (Thermo Fisher Scientific Cat# 13-0400, RRID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_2532995" id="intref0020">AB_2532995</ext-link>) and NfH (Proteintech Cat# 18934-1-AP, RRID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.antibodyregistry.org/AB_10640801" id="intref0025">AB_10640801</ext-link>) were used as positive controls. Furthermore, NfL and NfH recombinant proteins were used as samples in NfM homemade sandwich ELISA to further evaluate possible cross-reactivity.</p></sec><sec id="sec2.7"><title>Statistics</title><p id="p0115">Data analysis and visualisation were performed using GraphPad Prism (RRID:<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798" id="intref0030">SCR_002798</ext-link>), version 10.2.2. The Shapiro&#8211;Wilk test was conducted to assess the data distribution. Since the data did not follow a Gaussian distribution, non-parametric tests were applied. Neurofilament concentrations were normalised using Z-scores. To calculate the Z-scores, the absolute values were first log10-transformed, and then the following formula was applied: Z = (X &#8722; &#956;_controls)/&#963;_controls. In this equation, X represents each individual value within the patient cohort, &#956;_controls is the mean value of the control group, and &#963;_controls is the standard deviation of the control group.</p><p id="p0120">Disease progression rate (&#916;FS) in ALS cohort was calculated as: &#916;FS = (48 &#8722; ALSFRS-R at diagnosis)/disease duration in months from symptom onset to diagnosis. Based on established criteria,<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> slow progressors (&#916;FS &#8804; 0.4 points/month) and intermediate-to-fast progressors (&#916;FS &gt; 0.4 points/month) were defined. The prognostic value of neurofilaments in the ALS cohort was further assessed using Kaplan&#8211;Meier analysis. Mann&#8211;Whitney U tests were used to assess significant differences between groups for pairwise comparisons. For comparisons between multiple groups, the Kruskal&#8211;Wallis test followed by Dunn's post-hoc analysis was performed and the adjusted p-values from Dunn's post hoc test were used to determine statistical significance. Effect sizes (r) for pairwise post-hoc comparisons (Dunn's test) were calculated as following; r = Z/&#8730;N, where Z is the z-value from Kruskal&#8211;Wallis analysis and N is the combined sample size of the two groups. Effect sizes were interpreted according to Cohen's criteria (Small: r = 0.10, Medium: r = 0.30, Large: r &#8805; 0.50).<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> Spearman correlation coefficients were calculated to assess the correlations among neurofilament proteins and their association with age. ROC analyses were performed to determine cut-off values, with the optimal threshold selected based on the maximisation of the Youden Index (sensitivity + specificity &#8722; 1). Statistical significance was defined as p &lt; 0.05.</p></sec><sec id="sec2.8"><title>Role of funders</title><p id="p0125">None of the funders had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>Performance of the established ELISA assay for the detection of NfM</title><p id="p0130">The developed assay, targeting full-length recombinant NfM protein, demonstrated intra- and inter-assay variability of 5.5% and 10%, respectively. The LLOQ and LOD of the assay were determined to be 107.7 pg/mL and 23.9 pg/mL, respectively, with no cross-reactivity observed with NfL or NfH (<xref rid="appsec1" ref-type="sec">Supplementary Material</xref>, <xref rid="appsec1" ref-type="sec">Figure S1</xref>). Parallelism experiments indicated a minimum required dilution (MRD) of 1:2; however, CSF samples were diluted 1:4 in subsequent measurements to maximise the number of samples within the range of the calibration curve (<xref rid="appsec1" ref-type="sec">Supplementary Material</xref>, <xref rid="appsec1" ref-type="sec">Figure S2</xref>). Recovery analysis of the recombinant protein spiked at a 1:4 dilution showed a recovery rate of 96%. Stability testing showed that CSF NfM is stable for up to 3 days at room temperature or 4 &#176;C, and up to five freeze&#8211;thaw cycles did not affect measured NfM concentrations, with variability remaining below 20%. No cross-reactivity with human albumin or immunoglobulin G was detected. Further details of assay performance are provided in the <xref rid="appsec1" ref-type="sec">Supplementary Materials</xref>.</p></sec><sec id="sec3.2"><title>Demographic features and neurofilament protein concentrations</title><p id="p0135">The main demographic parameters for each diagnostic group are summarised in <xref rid="tbl1" ref-type="table">Table 1</xref>. No significant difference in age was observed between the groups. There was also no significant difference between neurofilament levels in female and male control patients (NfM (p = 0.83), NfL (p = 0.83), NfH (p = 0.5)). Correlation analysis revealed a strong correlation between NfM concentrations and age in CTRL (r = 0.69 (95% CI: 0.51&#8211;0.81), p &lt; 0.0001), and CTRL.DD (r = 0.77 (95% CI: 0.62&#8211;0.87), p &lt; 0.0001), but not in the patient's cohorts (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). The correlation between age and neurofilament subunits was assessed in the combined control group (CTRL and CTRL.DD), with the results summarised as follows; NfM: (r = 0.73 (95% CI: 0.62&#8211;0.81), p &lt; 0.0001), NfL: (r = 0.69 (95% CI: 0.56&#8211;0.78), p &lt; 0.0001), and NfH: (r = 0.34 (95% CI: 0.14&#8211;0.51), p = 0.0006). Sex-disaggregated demographic and biomarker data are presented in the <xref rid="appsec1" ref-type="sec">Supplementary Material</xref>, <xref rid="appsec1" ref-type="sec">Table S2</xref>.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Demographic data of the diagnostic cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="2" rowspan="1">Control</th><th colspan="1" rowspan="1">ALS</th><th colspan="1" rowspan="1">AD</th><th colspan="4" rowspan="1">FTD</th><th colspan="2" rowspan="1">LBD</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Subgroups</td><td colspan="1" rowspan="1">CTRL</td><td colspan="1" rowspan="1">CTRL.DD</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">bvFTD</td><td colspan="1" rowspan="1">lvPPA</td><td colspan="1" rowspan="1">nfvPPA</td><td colspan="1" rowspan="1">svPPA</td><td colspan="1" rowspan="1">PD</td><td colspan="1" rowspan="1">PDD</td></tr><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">59</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1">female/male<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td colspan="1" rowspan="1">26/25</td><td colspan="1" rowspan="1">15/33</td><td colspan="1" rowspan="1">44/47</td><td colspan="1" rowspan="1">36/23</td><td colspan="1" rowspan="1">4/13</td><td colspan="1" rowspan="1">3/4</td><td colspan="1" rowspan="1">3/4</td><td colspan="1" rowspan="1">2/5</td><td colspan="1" rowspan="1">6/8</td><td colspan="1" rowspan="1">1/3</td></tr><tr><td colspan="1" rowspan="1">Age at LP [year]</td><td colspan="1" rowspan="1">59 (52&#8211;66)</td><td colspan="1" rowspan="1">59 (50&#8211;70)</td><td colspan="1" rowspan="1">64 (55&#8211;74)</td><td colspan="1" rowspan="1">62 (59&#8211;65)</td><td colspan="1" rowspan="1">63 (60&#8211;69)</td><td colspan="1" rowspan="1">71 (62&#8211;73)</td><td colspan="1" rowspan="1">73 (60&#8211;78)</td><td colspan="1" rowspan="1">65 (57&#8211;74)</td><td colspan="1" rowspan="1">66 (60&#8211;71)</td><td colspan="1" rowspan="1">75 (71&#8211;77)</td></tr><tr><td colspan="1" rowspan="1">CSF NfM [pg/mL]</td><td colspan="1" rowspan="1">900 (552&#8211;1304)</td><td colspan="1" rowspan="1">1034 (678&#8211;1989)</td><td colspan="1" rowspan="1">14,425 (6512&#8211;22964)</td><td colspan="1" rowspan="1">4281 (3035&#8211;7470)</td><td colspan="1" rowspan="1">5308 (1432&#8211;18613)</td><td colspan="1" rowspan="1">4590 (2806&#8211;6972)</td><td colspan="1" rowspan="1">14,106 (9380&#8211;22132)</td><td colspan="1" rowspan="1">10,854 (10,311&#8211;16793)</td><td colspan="1" rowspan="1">1883 (1194&#8211;3793)</td><td colspan="1" rowspan="1">3188 (1620&#8211;4337)</td></tr><tr><td colspan="1" rowspan="1">CSF NfL [pg/mL]</td><td colspan="1" rowspan="1">563 (449&#8211;779)</td><td colspan="1" rowspan="1">592 (446&#8211;890)</td><td colspan="1" rowspan="1">6033 (4092&#8211;9207)</td><td colspan="1" rowspan="1">1320 (1044&#8211;1652)</td><td colspan="1" rowspan="1">1528 (1006&#8211;3154)</td><td colspan="1" rowspan="1">1528 (1324&#8211;2208)</td><td colspan="1" rowspan="1">3528 (2440&#8211;5788)</td><td colspan="1" rowspan="1">3272 (2840&#8211;5032)</td><td colspan="1" rowspan="1">966 (589&#8211;1488)</td><td colspan="1" rowspan="1">1626 (1379&#8211;1732)</td></tr><tr><td colspan="1" rowspan="1">CSF NfH [pg/mL]</td><td colspan="1" rowspan="1">756 (412&#8211;1328)</td><td colspan="1" rowspan="1">953 (712&#8211;1302)</td><td colspan="1" rowspan="1">6324 (4137&#8211;9476)</td><td colspan="1" rowspan="1">1044 (800&#8211;1392)</td><td colspan="1" rowspan="1">1084 (726&#8211;2076)</td><td colspan="1" rowspan="1">1500 (1064&#8211;1892)</td><td colspan="1" rowspan="1">1904 (1208&#8211;2236)</td><td colspan="1" rowspan="1">808 (496&#8211;1424)</td><td colspan="1" rowspan="1">1202 (816&#8211;1868)</td><td colspan="1" rowspan="1">2024 (1415&#8211;2270)</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>Data is reported as median (Interquartile range).</p></fn><fn id="tspara0020"><p>Abbreviations: AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; bvFTD, behavioral variant frontotemporal dementia; CTRL, non-neurodegenerative controls; CTRL.DD, control patients with initial diagnostic suspicion of ALS but finally diagnosed with another condition; CSF, cerebrospinal fluid; FTD, frontotemporal dementia; LBD, lewy body dementia; lvPPA, logopenic variant primary progressive aphasia; NfH, neurofilament heavy chain; NfL, neurofilament light chain; NfM, neurofilament medium chain; nfvPPA, non-fluent variant primary progressive aphasia; PD, Parkinson's disease; PDD, Parkinson's disease dementia; svPPA, semantic variant primary progressive aphasia.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0010">Sex information was obtained through self-report from study participants.</p></fn></table-wrap-foot></table-wrap><fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p><bold>Assessment of correlation between CSF NfM and age</bold>. Spearman correlation between CSF NfM and age in each diagnostic cohort is shown in different colours. CTRL (r = 0.69 (95% CI: 0.51&#8211;0.81), p &lt; 0.0001), CTRL.DD (r = 0.77 (95% CI: 0.62&#8211;0.87), p &lt; 0.0001), ALS (r = &#8722;0.22 (95% CI: &#8722;0.42 to &#8722;0.01), p = 0.03), AD (r = &#8722;0.10 (95% CI: &#8722;0.35 to 0.17), p = 0.44), FTD (r = 0.00 (95% CI: &#8722;0.32 to 0.33), p = 0.97), and LBD (r = 0.50 (95% CI: 0.03&#8211;0.79), p = 0.03). AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; CTRL, non-neurodegenerative controls; CTRL.DD, control patients with initial diagnostic suspicion of ALS but finally diagnosed with another condition; CSF, cerebrospinal fluid; FTD, frontotemporal dementia; LBD, Lewy body dementia; NfM, neurofilament medium chain.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec3.3"><title>NfM, NfL and NfH levels in the diagnostic groups</title><p id="p0140">All three neurofilaments showed significantly elevated levels in ALS compared with CTRL (p &lt; 0.0001, NfM: r = 0.90, NfL: r = 1.05, NfH: r = 0.87, large effect) and CTRL.DD (p &lt; 0.0001, NfM: r = 0.85, NfL: r = 1.02, NfH: r = 0.82, large effect) (<xref rid="fig2" ref-type="fig">Fig. 2</xref>a). However, NfM and NfL were significantly increased in FTD vs CTRL (p &lt; 0.0001, NfM: r = 0.71, NfL: r = 0.64, large effect) and AD vs CTRL (NfM: p &lt; 0.0001, r = 0.57, large effect; NfL: p = 0.0001, r = 0.41, moderate effect), whereas NfH values revealed no significant difference. NfH on the other hand displayed the highest difference between ALS and FTD (p &lt; 0.0001, r = 0.60, large effect).<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>Neurofilament proteins in diagnostic groups</bold>. CSF NfM, NfL and NfH concentrations in the diagnostic groups (<bold>a</bold>) and in the extended diagnostic groups (<bold>b</bold>). Statistically significant differences between the patient cohorts and CTRL are indicated with star symbols (&#8727;), while the comparison between patients with ALS and the CTRL.DD cohort is marked with dollar signs ($). Additional significant differences within the diagnostic cohorts are observed with the following p-values; NfM (ALS vs AD: p = 0.0001; ALS vs LBD: p &lt; 0.0001; FTD vs LBD: p = 0.0179), NfL (ALS vs AD: p &lt; 0.0001; ALS vs FTD: p = 0.0016; ALS vs LBD: p &lt; 0.0001), and NfH (ALS vs AD: p &lt; 0.0001; ALS vs FTD: p &lt; 0.0001; ALS vs LBD: p &lt; 0.0001). Displayed are the median concentration, the 25% and 75% percentiles and whiskers from minimum to maximum. Groups were compared by Kruskal&#8211;Wallis test and Dunns post hoc test. (&#8727;p &lt; 0.05; &#8727;&#8727;p &lt; 0.01; &#8727;&#8727;&#8727;p &lt; 0.001; &#8727;&#8727;&#8727;&#8727;p &lt; 0.0001; and $$$$ p &lt; 0.0001). AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; bvFTD, behavioural variant frontotemporal dementia; CTRL, non-neurodegenerative controls; CTRL.DD, control patients with initial diagnostic suspicion of ALS but finally diagnosed with another condition; CSF, cerebrospinal fluid; FTD, frontotemporal dementia; LBD, Lewy body dementia; lvPPA, logopenic variant primary progressive aphasia; NfH, neurofilament heavy chain; NfL, neurofilament light chain; NfM, neurofilament medium chain; nfvPPA, non-fluent variant primary progressive aphasia; PD, Parkinson's disease; PDD, Parkinson's disease dementia; svPPA, semantic variant primary progressive aphasia.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0145">Within the ALS cohort, comparative analysis between slow and intermediate-to-fast progressors revealed significant differences in CSF neurofilament levels (<xref rid="appsec1" ref-type="sec">Supplementary Material</xref>, <xref rid="appsec1" ref-type="sec">Figure S3</xref> and <xref rid="appsec1" ref-type="sec">Table S3</xref>). NfM showed the most statistically significant elevation in concentrations among the intermediate-to-fast progressor group (p = 0.0007). NfL and NfH also displayed statistically significant differences between the groups, albeit with slightly higher p-values (p = 0.0035 and p = 0.0055, respectively). In addition, Kaplan&#8211;Meier survival analyses revealed that higher CSF levels of all three neurofilaments at the time of sample collection were associated with a trend to reduced survival probability (<xref rid="appsec1" ref-type="sec">Supplementary Material</xref>, <xref rid="appsec1" ref-type="sec">Figure S4</xref>).</p><p id="p0150">To further assess differences in neurofilament protein concentrations, we compared the levels across disease subgroups (<xref rid="fig2" ref-type="fig">Fig. 2</xref>b). A pairwise comparison was made within the FTD and LBD subgroups. Significantly lower NfM levels were observed in lvPPA compared to nfvPPA (p = 0.007) and svPPA (p = 0.0023). Similarly, NfL levels were significantly lower in lvPPA compared to nfvPPA (p = 0.007) and svPPA (p = 0.0006). However, no significant differences were found for NfH levels. All three proteins displayed a trend to elevated levels in the PDD group compared to PD, with only NfL levels showing a significant difference (p = 0.034).</p><p id="p0155">Although the absolute values of the three neurofilament proteins are presented in the same graph (<xref rid="fig2" ref-type="fig">Fig. 2</xref>), direct comparison is not possible due to the use of different assays, each calibrated independently. To enable comparison of variations among the proteins, the absolute values were log transformed, and Z-scores were calculated. These normalised data are displayed in <xref rid="fig3" ref-type="fig">Fig. 3</xref>. Additionally, we calculated ratios between different neurofilament proteins and compared these ratios across diagnostic groups; detailed results of these analyses are provided in the <xref rid="appsec1" ref-type="sec">Supplementary Material</xref> (<xref rid="appsec1" ref-type="sec">Figure S5</xref>).<fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><bold>Neurofilament protein comparison using z-scores</bold>. NfL, NfM and NfH levels were normalised using z-scores and visualised in a forest plot layout. The forest plot displays the mean z-scores and corresponding 95% confidence intervals, illustrating the variations in different proteins values within each patient cohort compared to the mean value in the respective control cohort. The NfM values are depicted in green, NfL in blue, and NfH in purple. AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; LBD, Lewy body dementia; NfH, neurofilament heavy chain; NfL, neurofilament light chain; NfM, neurofilament medium chain.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec><sec id="sec3.4"><title>Associations of CSF neurofilaments with each other and ATN scores</title><p id="p0160">In the entire cohort, CSF NfM values showed a stronger correlation with CSF NfL (r = 0.93, 95% CI: 0.91&#8211;0.94, p &lt; 0.0001) (<xref rid="fig4" ref-type="fig">Fig. 4</xref>a), than with CSF NfH (r = 0.68, 95% CI: 0.61&#8211;0.73, p &lt; 0.0001) (<xref rid="fig4" ref-type="fig">Fig. 4</xref>b). A moderate to strong correlation was noted between CSF NfL and CSF NfH (r = 0.78, 95% CI: 0.73&#8211;0.82, p &lt; 0.0001) (<xref rid="fig4" ref-type="fig">Fig. 4</xref>c). Correlation analysis in a subgroup of patients demonstrated a strong and statistically significant correlation between CSF NfM and serum NfL (r = 0.88, 95% CI: 0.84&#8211;0.91, p &lt; 0.0001), as well as a moderate but significant correlation between CSF NfM and serum NfH (r = 0.50, 95% CI: 0.33&#8211;0.64, p &lt; 0.0001) (<xref rid="appsec1" ref-type="sec">Supplementary Material</xref>, <xref rid="appsec1" ref-type="sec">Figure S6</xref>).<fig id="fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p><bold>Correlation analysis between the different neurofilament proteins</bold>. (<bold>a</bold>) Correlation between CSF NfM and NfL (r = 0.93 (95% CI 0.91&#8211;0.94), p &lt; 0.0001) (n = 305). (<bold>b</bold>) Correlation between CSF NfM and NfH (r = 0.68 (95% CI 0.61&#8211;0.73), p &lt; 0.0001) (n = 305). (<bold>c</bold>) Correlation between CSF NfL and NfH (r = 0.78 (95% CI 0.73&#8211;0.82), p &lt; 0.0001) (n = 305). Correlation analysis was performed using Spearman's correlation coefficient. CI, confidence intervals; CSF, cerebrospinal fluid; NfH, neurofilament heavy chain; NfL, neurofilament light chain; NfM, neurofilament medium chain.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p><p id="p0165">Analysis of ATN scores and neurofilament proteins revealed no significant correlation between the amyloid-beta ratio and any neurofilament protein (<xref rid="fig5" ref-type="fig">Fig. 5</xref>a). Among the three neurofilament proteins analysed, NfM demonstrated the strongest and most significant correlations with tau biomarkers. Specifically, NfM levels were strongly correlated with both pTau181 (r = 0.71, 95% CI: 0.55&#8211;0.82, p &lt; 0.0001; <xref rid="fig5" ref-type="fig">Fig. 5</xref>b) and total tau (tTau) (r = 0.77, 95% CI: 0.64&#8211;0.86, p &lt; 0.0001; <xref rid="fig5" ref-type="fig">Fig. 5</xref>c). In contrast, NfL showed only moderate correlations with both pTau181 (r = 0.50 (95% CI 0.27&#8211;0.67), p &lt; 0.0001) and tTau (r = 0.57 (95% CI 0.36&#8211;0.72), p &lt; 0.0001), while no significant correlations were observed between NfH and either tau biomarkers (pTau181: r = &#8722;0.01 (95% CI &#8722;0.27 to 0.25), p = 0.93; tTau: r = 0.01 (95% CI &#8722;0.25 to 0.27), p = 0.93).<fig id="fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p><bold>Correlation analysis between ATN scores and CSF neurofilaments in AD cohort</bold>. (<bold>a</bold>) Correlation between Amyloid beta 42/40 and NfM (r = &#8722;0.11 (95% CI &#8722;0.36 to 0.16), p = 0.40), n = 59), NfL (r = &#8722;0.14 (95% CI &#8722;0.38 to 0.13), p = 0.30), n = 59), NfH (r = &#8722;0.12 (95% CI &#8722;0.37 to 0.15), p = 0.37), n = 59) (<bold>b</bold>) Correlation between pTau181 and NfM (r = 0.71 (95% CI 0.55&#8211;0.82), p &lt; 0.0001), n = 59), NfL (r = 0.50 (95% CI 0.27&#8211;0.67), p &lt; 0.0001), n = 59), NfH (r = &#8722;0.01 (95% CI &#8722;0.27 to 0.25), p = 0.93), n = 59) (<bold>c</bold>) Correlation between Total Tau and NfM (r = 0.77 (95% CI 0.64&#8211;0.86), p &lt; 0.0001), n = 59), NfL (r = 0.57 (95% CI 0.36&#8211;0.72), p &lt; 0.0001), n = 59), NfH (r = 0.01 (95% CI &#8722;0.25 to 0.27), p = 0.93), n = 59). Correlation analysis was performed using Spearman's correlation coefficient. CI, confidence intervals; CSF, cerebrospinal fluid; NfH, neurofilament heavy chain; NfL, neurofilament light chain; NfM, neurofilament medium chain.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p></sec><sec id="sec3.5"><title>Discriminative potential of CSF neurofilament proteins</title><p id="p0170">ROC analysis demonstrated that all three neurofilament proteins could effectively discriminate ALS from the CTRL cohort with an area under the curve (AUC) of 0.95 for NfM, 0.98 for NfL and 0.92 for NfH (<xref rid="fig6" ref-type="fig">Fig. 6</xref>a). Similarly, patients with ALS could be well distinguished from the CTRL.DD cases by NfM (AUC: 0.96), NfL (AUC: 0.99) and NfH (AUC: 0.99) (<xref rid="fig6" ref-type="fig">Fig. 6</xref>b). In addition, NfM and NfL revealed higher accuracy for the discrimination between patients with AD (NfM, AUC: 0.91; NfL, AUC: 0.89) (<xref rid="fig6" ref-type="fig">Fig. 6</xref>c) and FTD (NfM, AUC: 0.91; NfL, AUC: 0.92) (<xref rid="fig6" ref-type="fig">Fig. 6</xref>d) and CTRL cases. For the discrimination between patients with ALS and FTD, NfH showed the best result (AUC: 0.96), followed by NfL (AUC: 0.83) (<xref rid="fig6" ref-type="fig">Fig. 6</xref>e). However, the performance of neurofilament proteins was suboptimal for discriminating between patients with AD and FTD (<xref rid="fig6" ref-type="fig">Fig. 6</xref>f). The optimal cut-off values for each neurofilament, along with corresponding sensitivity, and specificity, are summarised in the <xref rid="appsec1" ref-type="sec">Supplementary Material</xref>, <xref rid="appsec1" ref-type="sec">Table S4</xref>. The combination of neurofilament proteins did not enhance the accuracy of discrimination between patient cohorts (<xref rid="appsec1" ref-type="sec">Supplementary Material</xref>, <xref rid="appsec1" ref-type="sec">Figure S7</xref>).<fig id="fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p><bold>ROC analysis of CSF neurofilament proteins</bold>. The panels show the results of the ROC analyses comparing the levels of three neurofilament proteins in the CSF of the following groups: (<bold>a</bold>) ALS vs CTRL, (<bold>b</bold>) ALS vs CTRL.DD, (<bold>c</bold>) AD vs CTRL, (<bold>d</bold>) FTD vs CTRL, (<bold>e</bold>) ALS vs FTD, and (<bold>f</bold>) AD vs FTD. AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; CI, confidence intervals; CTRL, non-neurodegenerative controls; CTRL.DD, control patients with initial diagnostic suspicion of ALS but finally diagnosed with another condition; CSF, cerebrospinal fluid; FTD, frontotemporal dementia; NfH, neurofilament heavy chain; NfL, neurofilament light chain; NfM, neurofilament medium chain; NfL, neurofilament light chain protein; ROC, receiver operating characteristic.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0175">CSF NfL and NfH are well studied in the literature as axonal damage markers. However, the third neurofilament NfM is lagging behind in terms of available and well validated assays and analyses in neurological diseases. In this study we developed a sensitive sandwich ELISA for the quantification of NfM in CSF and applied it in a comprehensive cohort of neurodegenerative diseases. The technical validation demonstrated an excellent assay performance meeting all relevant technical criteria. Of particular note is the high specificity for NfM with no cross-reactivity to NfL and NfH.</p><p id="p0180">Our study used a validated quantitative assay for NfM and compared CSF levels between NfM, NfL and NfH. As both NfL and NfH correlate significantly with age,<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> we first examined if NfM (and also NfL and NfH) depicts the same association. Confirming the literature NfL and NfH illustrated a positive association with age in the control group which we also detected for NfM. This effect has to be taken into account when analysing patients in different age groups. In our cohort of control and neurodegenerative diseases there was no significant difference in age.</p><p id="p0185">NfM, NfL and NfH on the other hand showed significantly elevated concentrations in ALS compared to control and CTRL.DD cohorts. While elevated levels of NfL and NfH in ALS have been well-documented,<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> quantitative data for NfM has been lacking. Our study supports recent findings demonstrating elevated NfM levels in ALS using a semi-quantitative bead suspension array.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> Our cross-sectional analysis demonstrated that CSF neurofilament levels are significantly associated with disease progression in ALS, particularly NfM showed the strongest elevation in intermediate-to-fast progressors, followed by NfL and NfH. This finding complements previous studies where NfL and pNfH were established as reliable prognostic markers for ALS, correlating with faster progression and shorter survival.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib43" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> Future longitudinal studies are needed to clarify the temporal dynamics and predictive capacity of NfM and to evaluate its utility as a monitoring or pharmacodynamic biomarker in clinical trials.</p><p id="p0190">Furthermore, we could demonstrate a significant elevation of NfM and NfL but not NfH in AD and FTD compared to controls which was in the case of AD most significant for NfM. This finding confirms the literature showing better discriminating potential for NfL than NfH for AD and FTD compared to controls.<xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref>, <xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref> The NfM results now complement these findings. On the other hand, only NfH was elevated in patients with ALS compared to patients with FTD corroborating findings of other studies.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib49" ref-type="bibr"><sup>49</sup></xref><sup>,</sup><xref rid="bib50" ref-type="bibr"><sup>50</sup></xref></p><p id="p0195">One possible explanation might be the underlying structural characteristics of neurofilament subtypes. NfL is the most abundant (neurofilament subunits stoichiometry 7:3:2 (NfL: NfM: NfH))<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> and soluble form and is rapidly released from neurons following axonal injury. In contrast, NfH is larger and distinguished by its heavily phosphorylated tail domain and possibly slower release following injury. As ALS primarily involves degeneration of large motor neurons with high neurofilament concentrations, it results in a marked increase of both NfL and NfH levels in CSF. FTD, on the other hand, mainly affects cortical neurons with smaller axons and lower NfL and NfH content, accounting due to neurofilaments stoichiometry only for an increase in NfL but no significant NfH elevation supporting NfH's relative specificity for ALS.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> In the FTD subgroups, we observed significantly elevated NfM and NfL levels in patients with nfvPPA and svPPA compared to those with bvFTD and lvPPA, a finding previously reported only for NfL.<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref></p><p id="p0200">Taken together, NfM levels in CSF are more comparable to NfL CSF concentrations than to NfH, despite NfM being more closely related to NfH in terms of amino acid sequence, structure and neurofilament assembly.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> This observation is supported by the correlation analysis between the three neurofilaments, which revealed the strongest association between NfL and NfM. In contrast, NfL and NfH showed a moderate to strong association, consistent with findings from previous studies.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib48" ref-type="bibr"><sup>48</sup></xref></p><p id="p0205">Given the prominently elevated NfM levels in the AD cohort, we also analysed its correlation with the CSF ATN biomarkers assessed in these patients. Notably, NfM showed the strongest association with pTau181 and tTau. While the AD group included only 59 patients, limiting definitive conclusions, this finding warrants further investigation of NfM in a larger AD cohort.</p><p id="p0210">NfM showed similar results to NfL and NfH in discriminating between disease and controls. We confirmed recent semi-quantitative analyses showing high AUCs for NfM in discriminating patients with ALS from controls,<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> findings which are also well-documented for NfL and NfH.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib49" ref-type="bibr"><sup>49</sup></xref><sup>,</sup><xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> NfM also exhibited strong discriminatory potential in patients with AD, slightly better than NfL, in differentiating AD from controls.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib53" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> However, NfM did not enhance the diagnostic power of neurofilaments in the neurodegenerative groups tested.</p><p id="p0215">In our study, combining three neurofilament proteins did not improve overall diagnostic performance compared to individual subunits. This likely reflects the shared structural and functional roles of these neurofilaments, which are released during axonal injury and therefore exhibit high intercorrelation. Similar observations have been reported in previous studies, where NfL alone provided strong diagnostic discrimination, while the addition of NfH offered limited incremental value.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> However, specific neurofilament patterns, such as elevated NfH in ALS and increased NfM in AD, may still aid in distinguishing between disease subtypes, suggesting potential value for targeted clinical applications despite the lack of overall diagnostic improvement from combining markers.</p><p id="p0220">The strength of our study lies in the use of a well characterised and validated quantitative immunoassay for detection of NfM in CSF. Furthermore, we evaluated a comprehensive cohort of neurodegenerative diseases, with parallel assessment of NfL and NfH for comparison. However, limitations include the cross-sectional design, which did not allow us to track NfM changes over time, and the relatively small sample sizes in some subgroups.</p><p id="p0225">We present a quantitative comparison of NfM with NfL and NfH in a neurodegenerative cohort, contributing to the existing body of literature on NfL and NfH. Further studies on NfM, especially in FTD and AD with larger patient cohorts, as well as investigations of NfM in neuroinflammatory diseases and in longitudinal studies will provide more insight into its potential value for the (differential-) diagnosis and monitoring of neurological diseases. Additionally, given the apparent differences in the CSF concentration patterns of NfM, NfL and NfH across neurological diseases, studies examining the expression and distribution of these neurofilaments in different brain compartments could help clarify their distinct roles in various neurological disorders.</p></sec><sec id="sec5"><title>Contributors</title><p id="p0230">All authors made significant contributions to the conception and design of the study, and/or the acquisition, analysis, and interpretation of data. Each author has reviewed and approved the final version of the manuscript for submission and accepts responsibility for all aspects of the work, ensuring that any concerns regarding the accuracy or integrity of any part of the study are thoroughly investigated and appropriately addressed.</p><p id="p0235">Conception and design of the study: BF, HT, SH; Sample collection and data management: BF, SB, FB, PK, VK, JD, MW, ZU, SJ, DB, SAS, ACL, MO, JW, HT, SH; Study management and coordination: BF, FB, HT, SH; Statistical methods and analysis: BF, HT, SH; Interpretation of results: BF, MO, HT, SH; Manuscript writing (first draft): BF, SH; Critical revision of the manuscript: BF, SB, FB, PK, VK, JD, MW, ZU, SJ, DB, SAS, ACL, MO, JW, HT, SH.</p><p id="p0240">BF and SH have both directly accessed and verified the underlying data reported in the manuscript.</p></sec><sec id="sec6"><title>Data sharing statement</title><p id="p0245">The data supporting the findings of this study, including anonymised individual-level neurofilament concentrations and clinical group classifications, can be obtained from the corresponding author upon reasonable request (Dr. Steffen Halbgebauer, email: <email>steffen.halbgebauer@uni-ulm.de</email>).</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of interests</title><p id="p0250">HT reports honoraria for acting as a consultant/speaker and/or for attending events sponsored by Alexion, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Diamed, Fresenius, Fujirebio, GlaxoSmithKline, Horizon, Janssen-Cilag, Merck, Novartis, Roche, Sanofi-Genzyme, Siemens, Teva and Viatris. All conflicts are not relevant to the topic of the study. All other authors declare no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Gafson</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Barth&#233;lemy</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Bomont</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Neurofilaments: Neurobiological foundations for biomarker applications</article-title><source>Brain</source><volume>143</volume><year>2020</year><fpage>1975</fpage><lpage>1998</lpage><pub-id pub-id-type="pmid">32408345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awaa098</pub-id><pub-id pub-id-type="pmcid">PMC7363489</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nixon</surname><given-names>R.A.</given-names></name></person-group><article-title>Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies</article-title><source>Front Neurosci</source><volume>15</volume><year>2021</year><object-id pub-id-type="publisher-id">689938</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2021.689938</pub-id><pub-id pub-id-type="pmcid">PMC8503617</pub-id><pub-id pub-id-type="pmid">34646114</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Bavato</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schnider</surname><given-names>L.K.</given-names></name><etal/></person-group><article-title>Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls</article-title><source>Mol Psychiatry</source><volume>29</volume><issue>8</issue><year>2024</year><fpage>2543</fpage><lpage>2559</lpage><pub-id pub-id-type="pmid">38503931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-024-02524-6</pub-id><pub-id pub-id-type="pmcid">PMC11412913</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Veeranna</surname></name><name name-style="western"><surname>Nixon</surname><given-names>R.A.</given-names></name></person-group><article-title>Neurofilaments and neurofilament proteins in health and disease</article-title><source>Cold Spring Harb Perspect Biol</source><volume>9</volume><issue>4</issue><year>2017</year><object-id pub-id-type="publisher-id">a018309</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a018309</pub-id><pub-id pub-id-type="pmcid">PMC5378049</pub-id><pub-id pub-id-type="pmid">28373358</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Hviid</surname><given-names>C.V.B.</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Winther-Larsen</surname><given-names>A.</given-names></name></person-group><article-title>Biological variation of serum neurofilament light chain</article-title><source>Clin Chem Lab Med</source><volume>60</volume><issue>4</issue><year>2022</year><fpage>569</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">33759425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/cclm-2020-1276</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Khalil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Neurofilaments as biomarkers in neurological disorders &#8212; towards clinical application</article-title><source>Nat Reviews Neurology</source><volume>20</volume><year>2024</year><fpage>269</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">38609644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-024-00955-x</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Gendron</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Daughrity</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Heckman</surname><given-names>M.G.</given-names></name><etal/></person-group><article-title>Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis</article-title><source>Ann Neurol</source><volume>82</volume><issue>1</issue><year>2017</year><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">28628244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.24980</pub-id><pub-id pub-id-type="pmcid">PMC5676468</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>B.A.</given-names></name></person-group><article-title>Neurofilaments in disease: what do we know?</article-title><source>Curr Opin Neurobiol</source><volume>61</volume><year>2020</year><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">32151970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.conb.2020.02.001</pub-id><pub-id pub-id-type="pmcid">PMC7198337</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Vidovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lapp</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Comparative analysis of neurofilaments and biomarkers of muscular damage in amyotrophic lateral sclerosis</article-title><source>Brain Commun</source><volume>6</volume><issue>5</issue><year>2024</year><object-id pub-id-type="publisher-id">fcae288</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcae288</pub-id><pub-id pub-id-type="pmcid">PMC11375854</pub-id><pub-id pub-id-type="pmid">39239150</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Behzadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pujol-Calder&#243;n</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tjust</surname><given-names>A.E.</given-names></name><etal/></person-group><article-title>Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics</article-title><source>Sci Rep</source><volume>11</volume><issue>1</issue><year>2021</year><fpage>22128</fpage><pub-id pub-id-type="pmid">34764380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-01499-6</pub-id><pub-id pub-id-type="pmcid">PMC8585882</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Forgrave</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Best</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>DeMarco</surname><given-names>M.L.</given-names></name></person-group><article-title>The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis</article-title><source>Alzheimers Dementia (Amst)</source><volume>11</volume><year>2019</year><fpage>730</fpage><lpage>743</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadm.2019.08.009</pub-id><pub-id pub-id-type="pmcid">PMC6939029</pub-id><pub-id pub-id-type="pmid">31909174</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Halbgebauer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Steinacker</surname><given-names>P.</given-names></name><name name-style="western"><surname>Verde</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>93</volume><issue>1</issue><year>2022</year><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">34417339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2021-327129</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Skillb&#228;ck</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression</article-title><source>JAMA Neurol</source><volume>73</volume><issue>1</issue><year>2016</year><fpage>60</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">26524180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2015.3037</pub-id><pub-id pub-id-type="pmcid">PMC5624219</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Mazzeo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ingannato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giacomucci</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: a cross-sectional and longitudinal study</article-title><source>Eur J Neurol</source><volume>31</volume><issue>1</issue><year>2024</year><object-id pub-id-type="publisher-id">e16089</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.16089</pub-id><pub-id pub-id-type="pmcid">PMC11235835</pub-id><pub-id pub-id-type="pmid">37797300</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Damoiseaux</surname><given-names>J.S.</given-names></name></person-group><article-title>The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease</article-title><source>Brain</source><volume>147</volume><year>2024</year><fpage>12</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">37540027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awad267</pub-id><pub-id pub-id-type="pmcid">PMC11484517</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Karantali</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kazis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chatzikonstantinou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Petridis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mavroudis</surname><given-names>I.</given-names></name></person-group><article-title>The role of neurofilament light chain in frontotemporal dementia: a meta-analysis</article-title><source>Aging Clin Experimental Res</source><volume>33</volume><year>2021</year><fpage>869</fpage><lpage>881</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40520-020-01554-8</pub-id><pub-id pub-id-type="pmid">32306372</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Verde</surname><given-names>F.</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Silani</surname><given-names>V.</given-names></name></person-group><article-title>Neurofilament light chain as biomarker for amyotrophic lateral sclerosis and frontotemporal dementia</article-title><source>Front Neurosci</source><volume>15</volume><year>2021</year><fpage>679199</fpage><pub-id pub-id-type="pmid">34234641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2021.679199</pub-id><pub-id pub-id-type="pmcid">PMC8255624</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Landqvist Wald&#246;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frizell Santillo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Passant</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia</article-title><source>BMC Neurol</source><volume>13</volume><year>2013</year><fpage>54</fpage><pub-id pub-id-type="pmid">23718879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2377-13-54</pub-id><pub-id pub-id-type="pmcid">PMC3671150</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Pilotto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Imarisio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carrarini</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Plasma neurofilament light chain predicts cognitive progression in prodromal and clinical dementia with lewy bodies</article-title><source>J Alzheimers Dis</source><volume>82</volume><issue>3</issue><year>2021</year><fpage>913</fpage><lpage>919</lpage><pub-id pub-id-type="pmid">34151807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-210342</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>G&#246;tze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vrillon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dumurgier</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting study</article-title><source>Alzheimers Res Ther</source><volume>16</volume><issue>1</issue><year>2024</year><fpage>231</fpage><pub-id pub-id-type="pmid">39427171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01593-7</pub-id><pub-id pub-id-type="pmcid">PMC11490051</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Bergstr&#246;m</surname><given-names>S.</given-names></name><name name-style="western"><surname>&#214;ijerstedt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Remnest&#229;l</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study</article-title><source>Mol Neurodegener</source><volume>16</volume><issue>1</issue><year>2021</year><fpage>79</fpage><pub-id pub-id-type="pmid">34838088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-021-00499-4</pub-id><pub-id pub-id-type="pmcid">PMC8626910</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Barschke</surname><given-names>P.</given-names></name><name name-style="western"><surname>Oeckl</surname><given-names>P.</given-names></name><name name-style="western"><surname>Steinacker</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>91</volume><issue>5</issue><year>2020</year><fpage>503</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">32132225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2019-322476</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Remnest&#229;l</surname><given-names>J.</given-names></name><name name-style="western"><surname>&#214;ijerstedt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ullgren</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers</article-title><source>Transl Neurodegener</source><volume>9</volume><issue>1</issue><year>2020</year><fpage>27</fpage><pub-id pub-id-type="pmid">32576262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40035-020-00198-y</pub-id><pub-id pub-id-type="pmcid">PMC7310563</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>H&#228;ggmark</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mohsenchian</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Plasma profiling reveals three proteins associated to amyotrophic lateral sclerosis</article-title><source>Ann Clin Transl Neurol</source><volume>1</volume><issue>8</issue><year>2014</year><fpage>544</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">25356426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.83</pub-id><pub-id pub-id-type="pmcid">PMC4184557</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Zucchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry</article-title><source>J Neurochem</source><volume>146</volume><issue>5</issue><year>2018</year><fpage>631</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">29959860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.14542</pub-id><pub-id pub-id-type="pmcid">PMC6175430</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Oeckl</surname><given-names>P.</given-names></name><name name-style="western"><surname>Weydt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thal</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Weishaupt</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Ludolph</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Otto</surname><given-names>M.</given-names></name></person-group><article-title>Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis</article-title><source>Acta Neuropathol</source><volume>139</volume><issue>1</issue><year>2020</year><fpage>119</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">31701227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-019-02093-x</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Swash</surname><given-names>M.</given-names></name><name name-style="western"><surname>Munsat</surname><given-names>T.L.</given-names></name></person-group><article-title>El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis</article-title><source>Amyotroph Lateral Scler Other Motor Neuron Disord</source><volume>1</volume><issue>5</issue><year>2000</year><fpage>293</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">11464847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/146608200300079536</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Niccolai</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pedone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinelli</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Amyotrophic lateral sclerosis stratification: unveiling patterns with virome, inflammation, and metabolism molecules</article-title><source>J Neurol</source><volume>271</volume><issue>7</issue><year>2024</year><fpage>4310</fpage><lpage>4325</lpage><pub-id pub-id-type="pmid">38644373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-024-12348-7</pub-id><pub-id pub-id-type="pmcid">PMC11233352</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>B.</given-names></name><name name-style="western"><surname>Villain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><etal/></person-group><article-title>Clinical diagnosis of Alzheimer's disease: recommendations of the international working group</article-title><source>Lancet Neurology</source><volume>20</volume><year>2021</year><fpage>484</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">33933186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(21)00066-1</pub-id><pub-id pub-id-type="pmcid">PMC8339877</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><etal/></person-group><article-title>NIA-AA Research Framework: toward a biological definition of Alzheimer's disease</article-title><source>Alzheimers Dementia</source><volume>14</volume><year>2018</year><fpage>535</fpage><lpage>562</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmcid">PMC5958625</pub-id><pub-id pub-id-type="pmid">29653606</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Rascovsky</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia</article-title><source>Brain</source><volume>134</volume><issue>9</issue><year>2011</year><fpage>2456</fpage><lpage>2477</lpage><pub-id pub-id-type="pmid">21810890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awr179</pub-id><pub-id pub-id-type="pmcid">PMC3170532</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="other" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Gorno-Tempini</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Hillis</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Weintraub</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Classification of primary progressive aphasia and its variants</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.neurology.org" id="intref0045">www.neurology.org</ext-link><year>2011</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e31821103e6</pub-id><pub-id pub-id-type="pmcid">PMC3059138</pub-id><pub-id pub-id-type="pmid">21325651</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Kilford</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lees</surname><given-names>A.J.</given-names></name></person-group><article-title>Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>55</volume><issue>3</issue><year>1992</year><fpage>181</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">1564476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.55.3.181</pub-id><pub-id pub-id-type="pmcid">PMC1014720</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="book" id="sref34"><part-title>Diagnostic and statistical manual of mental disorders: primary care version, 4th ed</part-title><source>Diagnostic and statistical manual of mental disorders: primary care version</source><edition>4th ed.</edition><year>1995</year><publisher-name>American Psychiatric Publishing, Inc.</publisher-name><publisher-loc>Arlington, VA, US</publisher-loc><comment>223, xv, 223&#8211;xv</comment></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Emre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aarsland</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Clinical diagnostic criteria for dementia associated with Parkinson's disease</article-title><source>Mov Disord</source><volume>22</volume><year>2007</year><fpage>1689</fpage><lpage>1707</lpage><pub-id pub-id-type="pmid">17542011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mds.21507</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Teunissen</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Petzold</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking</article-title><comment>Available from:</comment><source>Neurology</source><volume>73</volume><issue>22</issue><year>2009</year><fpage>1914</fpage><lpage>1922</lpage><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.neurology.org" id="intref0050">www.neurology.org</ext-link><pub-id pub-id-type="pmid">19949037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3181c47cc2</pub-id><pub-id pub-id-type="pmcid">PMC2839806</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Andreasson</surname><given-names>U.</given-names></name><name name-style="western"><surname>Perret-Liaudet</surname><given-names>A.</given-names></name><name name-style="western"><surname>van Waalwijk van Doorn</surname><given-names>L.J.C.</given-names></name><etal/></person-group><article-title>A practical guide to immunoassay method validation</article-title><source>Front Neurol</source><volume>6</volume><issue>Aug</issue><year>2015</year><fpage>179</fpage><pub-id pub-id-type="pmid">26347708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2015.00179</pub-id><pub-id pub-id-type="pmcid">PMC4541289</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Fritz</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Richler</surname><given-names>J.J.</given-names></name></person-group><article-title>Effect size estimates: current use, calculations, and interpretation</article-title><source>J Exp Psychol Gen</source><volume>141</volume><issue>1</issue><year>2012</year><fpage>2</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">21823805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1037/a0024338</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>S&#248;ndergaard</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gustavsen</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Neurofilament light in serum: reference values and effect of risk factors for multiple sclerosis</article-title><source>Mult Scler Relat Disord</source><volume>92</volume><year>2024</year><object-id pub-id-type="publisher-id">106166</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2024.106166</pub-id><pub-id pub-id-type="pmid">39577300</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Halbgebauer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klose</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fazeli</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Neurofilament light chain reference values in serum and cerebrospinal fluid: a bi-compartmental analysis in neurological diseases</article-title><source>J Neurol</source><volume>272</volume><issue>8</issue><year>2025</year><fpage>535</fpage><pub-id pub-id-type="pmid">40711597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-025-13271-1</pub-id><pub-id pub-id-type="pmcid">PMC12296792</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>David</surname><given-names>M.</given-names></name><name name-style="western"><surname>McCombe</surname><given-names>P.A.</given-names></name></person-group><article-title>Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis</article-title><source>PLoS One</source><volume>11</volume><issue>10</issue><year>2016</year><object-id pub-id-type="publisher-id">e0164625</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0164625</pub-id><pub-id pub-id-type="pmcid">PMC5061412</pub-id><pub-id pub-id-type="pmid">27732645</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Olofsson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bergstr&#246;m</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mravinacov&#225;</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid levels of NfM in relation to NfL and pNfH as prognostic markers in amyotrophic lateral sclerosis</article-title><source>Amyotroph Lateral Scler Frontotemporal Degener</source><volume>26</volume><issue>1&#8211;2</issue><year>2025</year><fpage>113</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">39575564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21678421.2024.2428930</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Gaiani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martinelli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bello</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease</article-title><source>JAMA Neurol</source><volume>74</volume><issue>5</issue><year>2017</year><fpage>525</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2016.5398</pub-id><pub-id pub-id-type="pmid">28264096</pub-id><pub-id pub-id-type="pmcid">PMC5822207</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Petzold</surname><given-names>A.</given-names></name><name name-style="western"><surname>Topping</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>86</volume><issue>5</issue><year>2015</year><fpage>565</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">25009280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2014-307672</pub-id><pub-id pub-id-type="pmcid">PMC4413806</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Brettschneider</surname><given-names>J.</given-names></name><name name-style="western"><surname>Petzold</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sch&#246;ttle</surname><given-names>D.</given-names></name><name name-style="western"><surname>Claus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Riepe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tumani</surname><given-names>H.</given-names></name></person-group><article-title>The neurofilament heavy chain (NfHSMI35) in the cerebrospinal fluid diagnosis of Alzheimer's disease</article-title><source>Dement Geriatr Cogn Disord</source><volume>21</volume><issue>5&#8211;6</issue><year>2006</year><fpage>291</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1159/000091436</pub-id><pub-id pub-id-type="pmid">16484807</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Kester</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Scheffer</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Koel-Simmelink</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers</article-title><source>Neurobiol Aging</source><volume>33</volume><issue>8</issue><year>2012</year><fpage>1591</fpage><lpage>1598</lpage><pub-id pub-id-type="pmid">21741127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2011.05.013</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Kuhle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Regeniter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leppert</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein</article-title><source>J Neuroimmunol</source><volume>220</volume><issue>1&#8211;2</issue><year>2010</year><fpage>114</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">20117845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneuroim.2010.01.004</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Pijnenburg</surname><given-names>Y.A.L.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Schoonenboom</surname><given-names>N.S.M.</given-names></name><etal/></person-group><article-title>CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls</article-title><source>Dement Geriatr Cogn Disord</source><volume>23</volume><issue>4</issue><year>2007</year><fpage>225</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1159/000099473</pub-id><pub-id pub-id-type="pmid">17290105</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Steinacker</surname><given-names>P.</given-names></name><name name-style="western"><surname>Feneberg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Weishaupt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brettschneider</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tumani</surname><given-names>H.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>87</volume><issue>1</issue><year>2016</year><fpage>12</fpage><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://jnnp.bmj.com/content/87/1/12.abstract" id="intref0055">http://jnnp.bmj.com/content/87/1/12.abstract</ext-link><pub-id pub-id-type="pmid">26296871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2015-311387</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Poesen</surname><given-names>K.</given-names></name><name name-style="western"><surname>De Schaepdryver</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stubendorff</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease</article-title><source>Neurology</source><volume>88</volume><issue>24</issue><year>2017</year><fpage>2302</fpage><lpage>2309</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000004029</pub-id><pub-id pub-id-type="pmid">28500227</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Janmey</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Leterrier</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>H.</given-names></name></person-group><article-title>Assembly and structure of neurofilaments</article-title><source>Curr Opin Colloid Interface Sci</source><volume>8</volume><year>2003</year><fpage>40</fpage><lpage>47</lpage></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="other" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Steinacker</surname><given-names>P.</given-names></name><name name-style="western"><surname>Semler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Anderl-Straub</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias</article-title><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.neurology.org" id="intref0060">https://www.neurology.org</ext-link><year>2017</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000003688</pub-id><pub-id pub-id-type="pmid">28179468</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Preische</surname><given-names>O.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Apel</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease</article-title><source>Nat Med</source><volume>25</volume><issue>2</issue><year>2019</year><fpage>277</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">30664784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0304-3</pub-id><pub-id pub-id-type="pmcid">PMC6367005</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Bacioglu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maia</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Preische</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases</article-title><source>Neuron</source><volume>91</volume><issue>1</issue><year>2016</year><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">27292537</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuron.2016.05.018</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Gaetani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Calabresi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Di Filippo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Parnetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zetterberg</surname><given-names>H.</given-names></name></person-group><article-title>Neurofilament light chain as a biomarker in neurological disorders</article-title><source>J Neurol Neurosurg Psychiatry</source><volume>90</volume><issue>8</issue><year>2019</year><fpage>870</fpage><comment>Available from:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://jnnp.bmj.com/content/90/8/870.abstract" id="intref0065">http://jnnp.bmj.com/content/90/8/870.abstract</ext-link><pub-id pub-id-type="pmid">30967444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2018-320106</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0260">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Supplementary Material</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0255">We extend our gratitude to all the patients who participated in this study, to their caregivers, and to the healthcare professionals involved in the care of patients. We also thank the biobank of the Department of Neurology in Ulm (Alice Beer, Sandra H&#252;bsch and Dagmar Schattauer) for their help with providing the samples. The authors appreciate the support of Chemische Fabrik Karl Bucher GmbH and the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003042</institution-id><institution>Else Kroener-Fresenius Foundation</institution></institution-wrap></funding-source>.</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0265">Supplementary data related to this article can be found at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.ebiom.2025.105930" id="intref0040">https://doi.org/10.1016/j.ebiom.2025.105930</ext-link>.</p></fn></fn-group></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="case-report" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Geriatr</journal-id><journal-id journal-id-type="iso-abbrev">BMC Geriatr</journal-id><journal-id journal-id-type="pmc-domain-id">33</journal-id><journal-id journal-id-type="pmc-domain">bmcgeri</journal-id><journal-title-group><journal-title>BMC Geriatrics</journal-title></journal-title-group><issn pub-type="epub">1471-2318</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12481796</article-id><article-id pub-id-type="pmcid-ver">PMC12481796.1</article-id><article-id pub-id-type="pmcaid">12481796</article-id><article-id pub-id-type="pmcaiid">12481796</article-id><article-id pub-id-type="pmid">41023855</article-id><article-id pub-id-type="doi">10.1186/s12877-025-06445-z</article-id><article-id pub-id-type="publisher-id">6445</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Elevated D-dimer levels after lecanemab infusions: a case report</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Zou</surname><given-names initials="M">Ming</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Xu</surname><given-names initials="SS">Shan-Shan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="SG">Shi-Guo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yuan</surname><given-names initials="CX">Cheng-Xiang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="JF">Jie-Fan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhu</surname><given-names initials="JH">Jian-Hong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhang</surname><given-names initials="X">Xiong</given-names></name><address><email>xiongzhang@wmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="JY">Jian-Yong</given-names></name><address><email>wangjianyong2020@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00rd5t069</institution-id><institution-id institution-id-type="GRID">grid.268099.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0348 3990</institution-id><institution>Department of Neurology and Institute of Geriatric Neurology, the Second Affiliated Hospital and Yuying Children&#8217;s Hospital, </institution><institution>Wenzhou Medical University, </institution></institution-wrap>Wenzhou, Zhejiang China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00rd5t069</institution-id><institution-id institution-id-type="GRID">grid.268099.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0348 3990</institution-id><institution>Department of Nuclear Medicine, the Second Affiliated Hospital and Yuying Children&#8217;s Hospital, </institution><institution>Wenzhou Medical University, </institution></institution-wrap>Wenzhou, Zhejiang China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00rd5t069</institution-id><institution-id institution-id-type="GRID">grid.268099.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0348 3990</institution-id><institution>Institute of Nutrition and Diseases and Center for Research, School of Public Health, </institution><institution>Wenzhou Medical University, </institution></institution-wrap>Wenzhou, Zhejiang China </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><issue-id pub-id-type="pmc-issue-id">478199</issue-id><elocation-id>742</elocation-id><history><date date-type="received"><day>6</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 10:25:36.583"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12877_2025_Article_6445.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Lecanemab is a disease-modifying immunotherapy for Alzheimer&#8217;s disease (AD) and has been increasingly prescribed to the patients in the world. It has a definite therapeutic effect in slowing cognitive decline in AD patients, but its adverse drug reactions should not be ignored.</p></sec><sec><title>Case presentation</title><p id="Par2">We reported an 82-year-old Chinese AD patient who developed recurrent D-dimer elevation after lecanemab infusions. His D-dimer levels were positively correlated with activated partial thromboplastin time, C-reactive protein, and neutrophil percentage, but negatively correlated with platelet count.</p></sec><sec><title>Conclusions</title><p id="Par3">Elevated D-dimer levels may be associated with the enhanced phagocytic response to vascular amyloid &#946; upon lecanemab treatment. Our report expands knowledge on lecanemab&#8217;s adverse drug reactions, suggesting that D-dimer levels and potential thromboembolic events should be monitored during treatment.</p></sec><sec><title>Clinical trial number</title><p id="Par4">not applicable.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#8217;s disease</kwd><kwd>Lecanemab</kwd><kwd>D-dimer</kwd><kwd>Amyloid &#946;</kwd><kwd>Adverse drug reactions</kwd></kwd-group><funding-group><award-group><funding-source><institution>Zhejiang Provincial Medical Technology Program</institution></funding-source><award-id>2023RC215</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Jian-Yong</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par9">Alzheimer&#8217;s disease (AD) is the most common neurodegenerative disease with an irreversible course. Lecanemab, which targets directly against amyloid &#946; (A&#946;) protofibrils, is a disease-modifying immunotherapy for AD. It has been shown to slow down the cognitive decline in AD patients, but its adverse drug reactions should not be ignored [<xref ref-type="bibr" rid="CR1">1</xref>]. Herein, we present a case of AD patient who developed recurrent D-dimer elevation after lecanemab infusion. It has not been reported before.</p></sec><sec id="Sec2"><title>Case presentation</title><p id="Par10">The patient was an 82-year-old Chinese man with 15 years of education. His medical history included diabetes and fatty liver. The patient visited the Second Affiliated Hospital of Wenzhou Medical University on August 22, 2024 due to the slowly progressive episodic memory impairment over the past year. No other abnormal signs were found on neurological examination. Blood tests including coagulation indices were within normal range. Magnetic resonance imaging revealed bilateral hippocampal atrophy. No evidence of microhemorrhage was found by susceptibility weighted imaging. Positron emission tomography imaging using 18&#160;F-AV-45 tracer revealed amyloid &#946; plaque deposition in the bilateral frontal, occipital, and temporal lobes. His apolipoprotein E (<italic toggle="yes">APOE</italic>) genotype was &#949;3/&#949;3.</p><p id="Par11">We diagnosed the patient with AD, and prescribed lecanemab infusion semimonthly. The patient received his first infusion of 600&#160;mg lecanemab on November 25, 2024. One day later, the patient developed dizziness, fatigue, and palpitations. Considering that elderly patients are at high risk for cardiovascular/cerebrovascular diseases and thrombotic events, we performed the following tests: head/chest computed tomography, electrocardiogram, cardiac ultrasound, complete blood count, C-reactive protein, troponin, and coagulation indices. We found that his D-dimer was markedly elevated (&gt;&#8201;20&#160;&#181;g/mL), while other parameters showed no significant abnormalities. Further examination revealed no deep vein thrombosis or pulmonary embolism. To prevent other potential thromboembolic events, we treated the patient with 10&#160;mg of rivaroxaban, and his D-dimer level returned to 6.4&#160;&#181;g/mL after one day, so the anticoagulation was discontinued. The patient received the 2nd (600&#160;mg), 3rd (400&#160;mg), 4th (600&#160;mg), 5th (600&#160;mg), and 6th (200&#160;mg) infusions of lecanemab on December 10, 2024, December 25, 2024, January 9, 2025, January 24, 2025, and February 8, 2025 respectively. Prior to the sixth infusion, the patient experienced an accidental fall. Due to concerns about potential additional adverse events, we adjusted the lecanemab dose to 200&#160;mg after discussion with the patient. His D-dimer levels rose sharply within one day after each infusion and returned to baseline within three days (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A). We closely monitored the patient&#8217;s D-dimer levels and thromboembolic events, but rivaroxaban treatment was not administered for these infusions. Meanwhile, we found that the patient&#8217;s D-dimer levels were positively correlated with activated partial thromboplastin time, C-reactive protein, and neutrophil percentage, but negatively correlated with platelet count (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>B). The patient is currently under constant follow-up and lecanemab treatment. No other drug-related adverse effects were observed.</p><p id="Par12">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>D-dimer levels after lecanemab infusions and correlations with other blood parameters. <bold>A</bold>&#160;Levels of D-dimer, CRP, and Neut% during lecanemab infusions. <bold>B</bold> Correlations of D-dimer levels with APTT, CRP, Neut%, and PLT. APTT, activated partial thromboplastin time; CRP, C-reactive protein; Neut%, neutrophil percentage; PLT, platelet number</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e270" position="float" orientation="portrait" xlink:href="12877_2025_6445_Fig1_HTML.jpg"/></fig>
</p><sec id="Sec3"><title>Discussion and conclusions</title><p id="Par13">In this case, the patient exhibited a sharp rise in D-dimer levels following each infusion of lecanemab. In the third infusion, we adjusted the drug dosage to 400&#160;mg due to elevated D-dimer levels following the previous two administrations, and the magnitude of the D-dimer elevation subsequently decreased, suggesting a causal and dose-dependent relationship between lecanemab infusion and D-dimer elevation.</p><p id="Par14">Lecanemab is considered to have an acceptable safety profile. Its most common adverse effects include amyloid-related imaging abnormalities (ARIA)-edema and ARIA-hemorrhage [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. To the best of our knowledge, our case is the first report of lecanemab-associated D-dimer elevation. A previous report found the occurrence of multiple cerebral infarctions in an AD patient following lecanemab administration, but it did not indicate whether this was accompanied by elevated D-dimer levels [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par15">D-dimer is a degradation product of cross-linked fibrin and serves as an effective indicator of blood coagulation and fibrinolysis [<xref ref-type="bibr" rid="CR5">5</xref>]. An elevated D-dimer level suggests potential conditions such as deep vein thrombosis, pulmonary embolism, or aortic dissection. Lecanemab can dissociate the A&#946;/fibrinogen complex [<xref ref-type="bibr" rid="CR6">6</xref>], which likely promotes fibrin degradation and hyperfibrinolysis, leading to the D-dimer release. This could also explain the prolonged activated partial thromboplastin time and decreased platelet count observed in this patient. In addition, the elevated C-reactive protein and neutrophil percentage are likely associated with the enhanced phagocytic response to vascular A&#946; upon lecanemab treatment [<xref ref-type="bibr" rid="CR1">1</xref>]. Indeed, postmortem examinations of patients treated with lecanemab revealed perivascular inflammatory changes in their cerebral vasculature [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. These findings suggest that elevated D-dimer levels may be associated with vasculitis triggered by lecanemab-mediated dissociation of A&#946;/fibrinogen complexes. The potential utility of D-dimer as a predictive biomarker for treatment-emergent vasculitis warrants additional longitudinal studies. What&#8217;s more, lecanemab leads to higher risk of ARIA-edema and ARIA-hemorrhage in patients carrying <italic toggle="yes">APOE</italic> &#949;4 allele [<xref ref-type="bibr" rid="CR2">2</xref>]. It remains to be further determined whether this allele also contributes to the increase in D-dimer.</p><p id="Par16">In conclusion, we herein report a case of D-dimer elevation, a previously unrecognized adverse effect induced by lecanemab infusion. We propose monitoring D-dimer levels and potential thromboembolic events during lecanemab treatment. The potential association between elevated D-dimer levels and lecanemab-induced vasculitis requires further investigation to establish a definitive relationship.</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>A&#946;</term><def><p id="Par5">Amyloid</p></def></def-item><def-item><term>&#946;; AD</term><def><p id="Par6">Alzheimer&#8217;s disease</p></def></def-item><def-item><term>APOE</term><def><p id="Par7">Apolipoprotein E</p></def></def-item><def-item><term>ARIA</term><def><p id="Par8">Amyloid-related imaging abnormalities</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. N</p></fn><fn><p>Ming Zou and Shan-Shan Xu contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors are thankful to their colleagues for the management of the patient and to the patient for participating in this study.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>MZ, S-GZ, C-XY, and J-YW diagnosed the patient and carried out the treatment strategy. S-SX, J-FH, and J-YW acquired and analyzed all the clinical data. J-HZ and J-YW drafted the manuscript. XZ and J-YW supervised the study. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the Zhejiang Provincial Medical Technology Program (2023RC215).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in this published article.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par17">This report was in compliance with the Helsinki Declaration, and was approved by the ethics committee of the Second Affiliated Hospital and Yuying Children&#8217;s Hospital, Wenzhou Medical University.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par18">The patient signed written informed consent.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par19">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>MT</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>D</given-names></name><name name-style="western"><surname>Jessen</surname><given-names>F</given-names></name></person-group><article-title>Passive anti-amyloid beta immunotherapy in alzheimer&#8217;s disease-opportunities and challenges</article-title><source>Lancet</source><year>2024</year><volume>404</volume><fpage>2198</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)01883-X</pub-id><pub-id pub-id-type="pmid">39549715</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Heneka MT, Morgan D, Jessen F. Passive anti-amyloid beta immunotherapy in alzheimer&#8217;s disease-opportunities and challenges. Lancet. 2024;404:2198&#8211;208. 10.1016/S0140-6736(24)01883-X.<pub-id pub-id-type="pmid">39549715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(24)01883-X</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honig</surname><given-names>LS</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>MN</given-names></name><name name-style="western"><surname>van Dyck</surname><given-names>CH</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>RA</given-names></name><name name-style="western"><surname>Hersch</surname><given-names>S</given-names></name><name name-style="western"><surname>Matta</surname><given-names>A</given-names></name><etal/></person-group><article-title>Updated safety results from phase 3 Lecanemab study in early alzheimer&#8217;s disease</article-title><source>Alzheimers Res Ther</source><year>2024</year><volume>16</volume><fpage>105</fpage><pub-id pub-id-type="doi">10.1186/s13195-024-01441-8</pub-id><pub-id pub-id-type="pmid">38730496</pub-id><pub-id pub-id-type="pmcid">PMC11084061</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, et al. Updated safety results from phase 3 Lecanemab study in early alzheimer&#8217;s disease. Alzheimers Res Ther. 2024;16:105. 10.1186/s13195-024-01441-8.<pub-id pub-id-type="pmid">38730496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01441-8</pub-id><pub-id pub-id-type="pmcid">PMC11084061</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Dyck</surname><given-names>CH</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Aisen</surname><given-names>P</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Gee</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lecanemab in early alzheimer&#8217;s disease</article-title><source>N Engl J Med</source><year>2023</year><volume>388</volume><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2212948</pub-id><pub-id pub-id-type="pmid">36449413</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early alzheimer&#8217;s disease. N Engl J Med. 2023;388:9&#8211;21. 10.1056/NEJMoa2212948.<pub-id pub-id-type="pmid">36449413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2212948</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamazaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Sekine</surname><given-names>T</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>S</given-names></name><name name-style="western"><surname>Sohara</surname><given-names>K</given-names></name><name name-style="western"><surname>Sakamaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Nagao</surname><given-names>T</given-names></name><etal/></person-group><article-title>A case of severe ARIA with multiple infarctions and extensive microbleeds following Lecanemab administration</article-title><source>Psychogeriatrics</source><year>2025</year><volume>25</volume><fpage>e13231</fpage><pub-id pub-id-type="doi">10.1111/psyg.13231</pub-id><pub-id pub-id-type="pmid">39694473</pub-id><pub-id pub-id-type="pmcid">PMC11655173</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Yamazaki A, Sekine T, Takahashi S, Sohara K, Sakamaki M, Nagao T, et al. A case of severe ARIA with multiple infarctions and extensive microbleeds following Lecanemab administration. Psychogeriatrics. 2025;25:e13231. 10.1111/psyg.13231.<pub-id pub-id-type="pmid">39694473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/psyg.13231</pub-id><pub-id pub-id-type="pmcid">PMC11655173</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weitz</surname><given-names>JI</given-names></name><name name-style="western"><surname>Fredenburgh</surname><given-names>JC</given-names></name><name name-style="western"><surname>Eikelboom</surname><given-names>JW</given-names></name></person-group><article-title>A test in context: D-Dimer</article-title><source>J Am Coll Cardiol</source><year>2017</year><volume>70</volume><fpage>2411</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2017.09.024</pub-id><pub-id pub-id-type="pmid">29096812</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-Dimer. J Am Coll Cardiol. 2017;70:2411&#8211;20. 10.1016/j.jacc.2017.09.024.<pub-id pub-id-type="pmid">29096812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2017.09.024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>PK</given-names></name><name name-style="western"><surname>Simoes-Pires</surname><given-names>EN</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Torrente</surname><given-names>D</given-names></name><name name-style="western"><surname>Calvano</surname><given-names>M</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><etal/></person-group><article-title>Lecanemab blocks the effects of the abeta/fibrinogen complex on blood clots and synapse toxicity in organotypic culture</article-title><source>Proc Natl Acad Sci U S A</source><year>2024</year><volume>121</volume><fpage>e2314450121</fpage><pub-id pub-id-type="doi">10.1073/pnas.2314450121</pub-id><pub-id pub-id-type="pmid">38621133</pub-id><pub-id pub-id-type="pmcid">PMC11047064</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Singh PK, Simoes-Pires EN, Chen ZL, Torrente D, Calvano M, Sharma A, et al. Lecanemab blocks the effects of the abeta/fibrinogen complex on blood clots and synapse toxicity in organotypic culture. Proc Natl Acad Sci U S A. 2024;121:e2314450121. 10.1073/pnas.2314450121.<pub-id pub-id-type="pmid">38621133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2314450121</pub-id><pub-id pub-id-type="pmcid">PMC11047064</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solopova</surname><given-names>E</given-names></name><name name-style="western"><surname>Romero-Fernandez</surname><given-names>W</given-names></name><name name-style="western"><surname>Harmsen</surname><given-names>H</given-names></name><name name-style="western"><surname>Ventura-Antunes</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E</given-names></name><name name-style="western"><surname>Shostak</surname><given-names>A</given-names></name><etal/></person-group><article-title>Fatal iatrogenic cerebral beta-amyloid-related arteritis in a woman treated with Lecanemab for alzheimer&#8217;s disease</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>8220</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-43933-5</pub-id><pub-id pub-id-type="pmid">38086820</pub-id><pub-id pub-id-type="pmcid">PMC10716177</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Solopova E, Romero-Fernandez W, Harmsen H, Ventura-Antunes L, Wang E, Shostak A, et al. Fatal iatrogenic cerebral beta-amyloid-related arteritis in a woman treated with Lecanemab for alzheimer&#8217;s disease. Nat Commun. 2023;14:8220. 10.1038/s41467-023-43933-5.<pub-id pub-id-type="pmid">38086820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-43933-5</pub-id><pub-id pub-id-type="pmcid">PMC10716177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castellani</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Shanes</surname><given-names>ED</given-names></name><name name-style="western"><surname>McCord</surname><given-names>M</given-names></name><name name-style="western"><surname>Reish</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>ME</given-names></name><name name-style="western"><surname>Mesulam</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Neuropathology of Anti-Amyloid-beta immunotherapy: A case report</article-title><source>J Alzheimers Dis</source><year>2023</year><volume>93</volume><fpage>803</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.3233/JAD-221305</pub-id><pub-id pub-id-type="pmid">37125554</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Castellani RJ, Shanes ED, McCord M, Reish NJ, Flanagan ME, Mesulam MM, et al. Neuropathology of Anti-Amyloid-beta immunotherapy: A case report. J Alzheimers Dis. 2023;93:803&#8211;13. 10.3233/JAD-221305.<pub-id pub-id-type="pmid">37125554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-221305</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Biophys J</journal-id><journal-id journal-id-type="iso-abbrev">Biophys J</journal-id><journal-id journal-id-type="pmc-domain-id">231</journal-id><journal-id journal-id-type="pmc-domain">biophysj</journal-id><journal-title-group><journal-title>Biophysical Journal</journal-title></journal-title-group><issn pub-type="ppub">0006-3495</issn><issn pub-type="epub">1542-0086</issn><publisher><publisher-name>The Biophysical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11480756</article-id><article-id pub-id-type="pmcid-ver">PMC11480756.1</article-id><article-id pub-id-type="pmcaid">11480756</article-id><article-id pub-id-type="pmcaiid">11480756</article-id><article-id pub-id-type="pmid">39091025</article-id><article-id pub-id-type="doi">10.1016/j.bpj.2024.07.040</article-id><article-id pub-id-type="pii">S0006-3495(24)00517-4</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Short-term neural and glial response to mild traumatic brain injury in the hippocampus</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Dougan</surname><given-names initials="CE">Carey E.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Roberts</surname><given-names initials="BL">Brandon L.</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Crosby</surname><given-names initials="AJ">Alfred J.</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Karatsoreos</surname><given-names initials="IN">Ilia N.</given-names></name><email>ikaratsoreos@umass.edu</email><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Peyton</surname><given-names initials="SR">Shelly R.</given-names></name><email>shelly.peyton@tufts.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff7" ref-type="aff">7</xref><xref rid="cor2" ref-type="corresp">&#8727;&#8727;</xref></contrib><aff id="aff1"><label>1</label>Department of Chemical Engineering, University of Massachusetts Amherst, Amherst, Massachusetts</aff><aff id="aff2"><label>2</label>Department of Chemistry and Department of Engineering, Smith College, Northampton, Massachusetts</aff><aff id="aff3"><label>3</label>Neuroscience and Behavior Program, and Department of Psychological and Brain Sciences, University of Massachusetts Amherst, Amherst, Massachusetts</aff><aff id="aff4"><label>4</label>Department of Zoology &amp; Physiology, University of Wyoming, Laramie, Wyoming</aff><aff id="aff5"><label>5</label>Department of Animal Science, University of Wyoming, Laramie, Wyoming</aff><aff id="aff6"><label>6</label>Department of Polymer Science and Engineering, University of Massachusetts Amherst, Amherst, Massachusetts</aff><aff id="aff7"><label>7</label>Department of Biomedical Engineering, Tufts University, Medford, Massachusetts</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author <email>ikaratsoreos@umass.edu</email></corresp><corresp id="cor2"><label>&#8727;&#8727;</label>Corresponding author <email>shelly.peyton@tufts.edu</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>31</day><month>7</month><year>2024</year></pub-date><volume>123</volume><issue>19</issue><issue-id pub-id-type="pmc-issue-id">472872</issue-id><fpage>3346</fpage><lpage>3354</lpage><history><date date-type="received"><day>6</day><month>4</month><year>2024</year></date><date date-type="accepted"><day>29</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-released-under-embargo"><date><day>17</day><month>10</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 13:25:27.360"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 Biophysical Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Biophysical Society</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" xlink:title="research-article" journal-id="bioRxiv" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11014627"><article-title>Acute and Chronic Neural and Glial Response to Mild Traumatic Brain Injury in the Hippocampus</article-title><date><day>2</day><month>4</month><year>2024</year></date><elocation-id>2024.04.01.587620</elocation-id><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.04.01.587620</pub-id><pub-id pub-id-type="pmcid">PMC11014627</pub-id><pub-id pub-id-type="pmid">38617329</pub-id></related-article><abstract id="abs0010"><p>Traumatic brain injury (TBI) is an established risk factor for developing neurodegenerative disease. However, how TBI leads from acute injury to chronic neurodegeneration is limited to postmortem models. There is a lack of connections between in&#160;vitro and in&#160;vivo TBI models that can relate injury forces to both macroscale tissue damage and brain function at the cellular level. Needle-induced cavitation (NIC) is a technique that can produce small cavitation bubbles in soft tissues, which allows us to relate small strains and strain rates in living tissue to ensuing acute cell death, tissue damage, and tissue remodeling. Here, we applied NIC to mouse brain slices to create a new model of TBI with high spatial and temporal resolution. We specifically targeted the hippocampus, which is a brain region critical for learning and memory and an area in which injury causes cognitive pathologies in humans and rodent models. By combining NIC with patch-clamp electrophysiology, we demonstrate that NIC in the cornu ammonis 3 region of the hippocampus dynamically alters synaptic release onto cornu ammonis 1 pyramidal neurons in a cannabinoid 1 receptor-dependent manner. Further, we show that NIC induces an increase in extracellular matrix protein GFAP associated with neural repair that is mitigated by cannabinoid 1 receptor antagonism. Together, these data lay the groundwork for advanced approaches in understanding how TBI impacts neural function at the cellular level and the development of treatments that promote neural repair in response to brain injury.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><notes><p id="misc0010">Editor: Guy Genin.</p></notes></front></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70710" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12479214</article-id><article-id pub-id-type="pmcid-ver">PMC12479214.1</article-id><article-id pub-id-type="pmcaid">12479214</article-id><article-id pub-id-type="pmcaiid">12479214</article-id><article-id pub-id-type="pmid">41023536</article-id><article-id pub-id-type="doi">10.1002/alz.70710</article-id><article-id pub-id-type="publisher-id">ALZ70710</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Associations of neurodegenerative proteins with brain iron deposition and cognition in cerebral small vessel disease: a quantitative susceptibility mapping and plasma biomarker study</article-title><alt-title alt-title-type="left-running-head">CHEN <sc>et&#160;al.</sc></alt-title></title-group><contrib-group><contrib id="alz70710-cr-0001" contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="Y">Yiwen</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-9411-0145</contrib-id><xref rid="alz70710-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70710-cr-0002" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="M">Meng</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8320-5241</contrib-id><xref rid="alz70710-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70710-cr-0003" contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="J">Jing</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9392-6600</contrib-id><xref rid="alz70710-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70710-cr-0004" contrib-type="author"><name name-style="western"><surname>Liang</surname><given-names initials="P">Pengcheng</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-7392-2566</contrib-id><xref rid="alz70710-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70710-cr-0005" contrib-type="author"><name name-style="western"><surname>Cheng</surname><given-names initials="Z">Zhenyu</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-0717-3228</contrib-id><xref rid="alz70710-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70710-cr-0006" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="N">Na</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6191-4760</contrib-id><xref rid="alz70710-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70710-cr-0007" contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="X">Xinyue</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1643-608X</contrib-id><xref rid="alz70710-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70710-cr-0008" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yuanyuan</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0641-8411</contrib-id><xref rid="alz70710-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz70710-cr-0009" contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="N">Nan</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6202-9349</contrib-id><xref rid="alz70710-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70710-cr-0010" contrib-type="author"><name name-style="western"><surname>Che</surname><given-names initials="Y">Yena</given-names></name><xref rid="alz70710-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70710-cr-0011" contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="W">Wenwen</given-names></name><xref rid="alz70710-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="alz70710-cr-0012" contrib-type="author" corresp="yes"><name name-style="western"><surname>Guo</surname><given-names initials="L">Lingfei</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4885-625X</contrib-id><xref rid="alz70710-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>glfsci@163.com</email></address></contrib><contrib id="alz70710-cr-0013" contrib-type="author" corresp="yes"><name name-style="western"><surname>Liang</surname><given-names initials="C">Changhu</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3796-2978</contrib-id><xref rid="alz70710-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>tigerlch@163.com</email></address></contrib></contrib-group><aff id="alz70710-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Key Laboratory of Endocrine Glucose &amp; Lipids Metabolism and Brain Aging, Ministry of Education, Department of Radiology</named-content>
<institution>Shandong Provincial Hospital Affiliated to Shandong First Medical University</institution>
<city>Jinan</city>
<named-content content-type="country-part">Shandong</named-content>
<country country="CN">China</country>
</aff><aff id="alz70710-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Psychiatry and Psychotherapy</named-content>
<institution>Jena University Hospital</institution>
<city>Jena</city>
<named-content content-type="country-part">Thuringia</named-content>
<country country="DE">Germany</country>
</aff><aff id="alz70710-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Radiology</named-content>
<institution>Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University</institution>
<named-content content-type="country-part">Beijing</named-content>
<country country="CN">China</country>
</aff><aff id="alz70710-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">College of Medical Imaging</named-content>
<institution>Binzhou Medical University</institution>
<city>Yantai</city>
<named-content content-type="country-part">Shandong</named-content>
<country country="CN">China</country>
</aff><aff id="alz70710-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Medical Genetics</named-content>
<institution>Shandong Provincial Hospital Affiliated to Shandong First Medical University</institution>
<city>Jinan</city>
<named-content content-type="country-part">Shandong</named-content>
<country country="CN">China</country>
</aff><aff id="alz70710-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Radiology</named-content>
<institution>Wenshang Hospital of Traditional Chinese Medicine</institution>
<city>Jining</city>
<named-content content-type="country-part">Shandong</named-content>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Lingfei Guo and Changhu Liang, Key Laboratory of Endocrine Glucose &amp; Lipids Metabolism and Brain Aging, Ministry of Education, Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jing&#8208;wu Road No. 324, Jinan 250021, China.<break/> Email: <email>glfsci@163.com</email> and <email>tigerlch@163.com</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>21</volume><issue seq="1010">9</issue><issue-id pub-id-type="pmc-issue-id">495846</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.9</issue-id><elocation-id>e70710</elocation-id><history><date date-type="rev-recd"><day>02</day><month>8</month><year>2025</year></date><date date-type="received"><day>04</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 08:25:55.207"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70710.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70710.pdf"/><abstract><title>Abstract</title><sec id="alz70710-sec-0010"><title>INTRODUCTION</title><p>Cerebral small vessel disease (CSVD) is a common neurological disorder with limited pathology on conventional magnetic resonance imaging. This study uses quantitative susceptibility mapping (QSM) to investigate links among brain iron, plasma neurodegenerative proteins, and cognition in CSVD.</p></sec><sec id="alz70710-sec-0020"><title>METHODS</title><p>This study enrolled 319 CSVD patients, grouped into CSVD&#8208;M and CSVD&#8208;S. Plasma proteins were measured in 178 participants, with 80 being followed up after 2 years. QSM&#8208;based voxel&#8208;wise analysis assessed brain iron, CSVD severity, and protein correlations. A cross&#8208;lagged panel model was used to analyze the temporal association between plasma protein levels and brain iron levels.</p></sec><sec id="alz70710-sec-0030"><title>RESULTS</title><p>In CSVD&#8208;S, elevated QSM values in the right Rolandic operculum/superior temporal gyrus negatively correlated with plasma A&#946;42 and executive function. A&#946;42 also negatively correlated with QSM in cortical regions, tied to episodic memory decline. Higher baseline A&#946;40 predicted increased QSM in the left putamen at follow&#8208;up.</p></sec><sec id="alz70710-sec-0040"><title>DISCUSSION</title><p>Plasma A&#946;42 and A&#946;40 may drive brain iron deposition and cognitive impairment in CSVD, serving as potential early biomarkers for disease progression.</p></sec><sec id="alz70710-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70710-list-0001"><list-item><p>QSM reveals brain iron links to A&#946;42, cognition in CSVD.</p></list-item><list-item><p>Plasma A&#946;42 correlates with iron in motor and frontal areas.</p></list-item><list-item><p>High A&#946;40 predicts putamen iron increase in CSVD follow&#8208;up.</p></list-item><list-item><p>Iron deposition is tied to executive, memory deficits in CSVD.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70710-kwd-0001">cerebral small vessel disease</kwd><kwd id="alz70710-kwd-0002">iron</kwd><kwd id="alz70710-kwd-0003">neurodegeneration</kwd><kwd id="alz70710-kwd-0004">quantitative susceptibility mapping</kwd><kwd id="alz70710-kwd-0005">tau</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Natural Science Foundation of China</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id>82272072</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Natural Science Foundation of Shandong Province</institution><institution-id institution-id-type="doi">10.13039/501100007129</institution-id></institution-wrap></funding-source><award-id>ZR2020MH288</award-id><award-id>ZR2024MH026</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Medical and Health Science and Technology Development Project of Shandong Province</institution><institution-id institution-id-type="doi">10.13039/501100019446</institution-id></institution-wrap></funding-source><award-id>202309010560</award-id><award-id>202309010557</award-id><award-id>202409010479</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Technology Development Plan of Jinan</institution></institution-wrap></funding-source><award-id>202328066</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>Shandong Province Medical System Employee Science and Technology Innovation Plan</institution></institution-wrap></funding-source><award-id>SDYWZGKCIH2023034</award-id><award-id>SDYWZGKCJH2024021</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="5"/><page-count count="14"/><word-count count="8207"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:29.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70710-cite-0001"><string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Associations of neurodegenerative proteins with brain iron deposition and cognition in cerebral small vessel disease: a quantitative susceptibility mapping and plasma biomarker study</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70710</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70710</pub-id><pub-id pub-id-type="pmid">41023536</pub-id></mixed-citation>
</p><fn-group><fn id="alz70710-note-0001" fn-type="equal"><p>Yiwen Chen and Meng Li contributed equally to this work and shared the first authorship.</p></fn><fn id="alz70710-note-0002" fn-type="equal"><p>Lingfei Guo and Changhu Liang contributed equally to this work and shared the corresponding author.</p></fn></fn-group></notes></front><body><sec id="alz70710-sec-0060"><label>1</label><title>BACKGROUND</title><p>Cerebral small vessel disease (CSVD) is a common neurological disorder affecting small brain vessels (&lt;&#160;1&#160;mm), contributing to 25% of strokes and 45% of dementias.<xref rid="alz70710-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70710-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70710-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> The diagnosis of CSVD relies on magnetic resonance imaging (MRI) features, including lacunes, white matter hyperintensities (WMHs), cerebral microbleeds (CMBs), and perivascular spaces.<xref rid="alz70710-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> However, the lesions detected by conventional MRI represent only a fraction of the underlying pathological changes in CSVD, necessitating deeper investigation.</p><p>Iron is essential for various neurobiological processes, including DNA synthesis, oxygen transport, myelin formation, mitochondrial function, and neurotransmitter synthesis and metabolism.<xref rid="alz70710-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Excessive iron deposition causes oxidative stress, contributing to neurodegenerative diseases and cognitive impairments.<xref rid="alz70710-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="alz70710-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Brain iron, stored as ferritin and hemosiderin, distorts local fields. Local magnetic field distortions can be detected by typical susceptibility&#8208;weighted imaging (SWI) techniques, including those measuring transverse relaxation rates (R2, R2*, T2, and T2*) and quantitative susceptibility mapping (QSM).<xref rid="alz70710-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Unlike other SWI techniques, QSM precisely quantifies tissue magnetic susceptibility at the voxel level by solving the inverse problem &#8211; specifically, the deconvolution process from the measured magnetic field to the underlying susceptibility sources.<xref rid="alz70710-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz70710-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> This enables an in&#8208;depth investigation of susceptibility changes caused by iron distribution, metabolic oxygen consumption, calcification, demyelination, and other pathophysiological alterations.<xref rid="alz70710-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> A strong linear correlation exists between the susceptibility values of gray matter and chemically measured iron concentrations. This enables susceptibility values to serve as a non&#8208;invasive biomarker for quantifying pathological iron accumulation within brain tissue in patients with neurodegenerative diseases. Consequently, QSM provides crucial technical support for research into the etiology and treatment of neurodegenerative disorders.<xref rid="alz70710-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>Amyloid beta (A&#946;) is a 36&#8208; to 43&#8208;amino&#8208;acid peptide derived from A&#946; precursor protein (APP), expressed mainly in brain neurons and non&#8208;neuronal cells. A&#946;40 is the most abundant, whereas A&#946;42 is widely regarded as the primary protein constituent of amyloid plaques in Alzheimer's disease (AD).<xref rid="alz70710-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70710-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Tau, encoded by the microtubule&#8208;associated protein tau (MAPT) gene located on chromosome 17q21, is a microtubule&#8208;associated protein critical for the assembly and stabilization of microtubules, as well as DNA/RNA protection.<xref rid="alz70710-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70710-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Tau is predominantly expressed in neurons, with lesser expression in astrocytes and oligodendrocytes. In pathological conditions, soluble, unfolded tau undergoes changes influenced by genetic mutations, conformational alterations, and post&#8208;translational modifications (PTMs), rendering it insoluble and leading to its aggregation into paired helical filaments and neurofibrillary tangles (NFTs).<xref rid="alz70710-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Tau phosphorylation has been the most extensively studied and is considered a pivotal event in the pathological aggregation of tau protein.</p><p>Plasma A&#946;42/40 and phosphorylated tau (pTau) exhibit a high degree of consistency with cerebrospinal fluid (CSF) levels, accurately reflecting intracerebral A&#946; plaques and NFTs accumulation.<xref rid="alz70710-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> These biomarkers show high specificity in distinguishing between abnormal and normal A&#946;&#8208;positron emission tomography (PET) statuses,&#160;which are established indicators&#160;for detecting AD.<xref rid="alz70710-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70710-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Although amyloid plaques and NFTs are pathological hallmarks of AD, their presence has also been reported in other conditions, such as Huntington's disease,<xref rid="alz70710-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="alz70710-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Parkinson's disease,<xref rid="alz70710-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="alz70710-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> traumatic brain injury,<xref rid="alz70710-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> and cerebral amyloid angiopathy (CAA).<xref rid="alz70710-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> It suggests that pathological changes and mechanisms associated with A&#946; and tau proteins play significant roles in non&#8208;AD populations as well. Prior research identified correlations between plasma/CSF levels of A&#946; and tau proteins and various imaging markers of CSVD, such as WMHs, CMBs, and lacunes. Furthermore, these protein levels have been closely linked to cognitive function, highlighting their broader relevance in CSVD.<xref rid="alz70710-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70710-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="alz70710-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="alz70710-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p><p>Research on CSVD has largely ignored interactions between neurodegenerative proteins and brain iron levels. This study hypothesizes that, in CSVD, the abnormal aggregation of neurodegenerative proteins may disrupt local iron transport or activate microglia responsible for clearance functions, causing aberrant iron deposition. This may trigger neuronal damage via oxidative stress responses, ultimately mediating cognitive impairment in CSVD patients.<xref rid="alz70710-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="alz70710-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> The present study addresses this hypothesis through the following approaches: (1) voxel&#8208;wise QSM analysis compared QSM values between mild CSVD and severe CSVD groups; (2) voxel&#8208;wise correlation between plasma protein concentrations and QSM values; and (3) longitudinal voxel&#8208;wise QSM changes in a follow&#8208;up cohort, using a cross&#8208;lagged panel model to assess plasma protein&#8208;QSM relationships.</p></sec><sec id="alz70710-sec-0070"><label>2</label><title>MATERIALS AND METHODS</title><sec id="alz70710-sec-0080"><label>2.1</label><title>Participants</title><p>This community&#8208;based cohort study enrolled 319 participants with CSVD from communities surrounding Shandong Provincial Hospital between September 2019 and February 2025. The inclusion criteria for participants were based on the updated Standards for Reporting Vascular Changes on Neuroimaging (STRIVE)<xref rid="alz70710-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>: (1) age &#8805; 40 years; (2) MRI compatibility (no ferromagnetic implants, claustrophobia, or motion artifacts&#160;&gt;&#160;2&#160;mm); (3) psychotropic medication&#8208;free; (4) preserved sensory function.</p><p>The exclusion criteria were as follows: (1) major neuropsychiatric disorders (stroke, traumatic brain injury), neurodegenerative diseases (AD, Parkinson's disease, Huntington's disease), or intracranial lesions; (2) significant organ dysfunction including cardiac, renal, or hepatic impairment; (3) confirmed non&#8208;vascular white matter lesions, include multiple sclerosis, adult leukodystrophy, or metabolic encephalopathy.</p><p>Clinical data, including age, sex, body mass index (BMI), education, and vascular risk factors (hypertension, diabetes, hyperlipidemia, smoking), were systematically recorded. The presence or absence of each vascular risk factor was determined based on participants' self&#8208;reported medical histories, with each factor assigned a binary value (0 or 1). These individual risk factors were subsequently combined to form a composite vascular risk factor score, ranging from 0 to 4.</p></sec><sec id="alz70710-sec-0090"><label>2.2</label><title>Plasma neurodegenerative protein measurement</title><p>Plasma collection for neurodegeneration biomarker assays began in January 2021, involving a subsample of 178 participants. Eighty participants completed a follow&#8208;up assessment 2 years later, with the same protein types and measurement methods applied as at baseline.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70710-sec-0100"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70710-list-0002"><list-item><p>
<bold>Systematic review</bold>: We systematically reviewed all PubMed peer&#8208;reviewed articles on CSVD and plasma neurodegenerative protein biomarkers.&#160;This is the first study&#160;using QSM to examine&#160;cerebral iron deposition &#8211; plasma biomarker relationships&#160;in CSVD. Nevertheless, several recent studies have explored associations between CSVD and plasma biomarkers. All referenced literature is appropriately cited.</p></list-item><list-item><p>
<bold>Interpretation</bold>: This study revealed that in cross&#8208;sectional investigations of CSVD,&#160;iron deposition levels in multiple brain regions demonstrated significant correlations with concentrations of plasma neurodegenerative protein biomarkers and were further associated with domain&#8208;specific cognitive functions. Longitudinal analyses additionally indicated that&#160;baseline plasma A&#946;40 levels could effectively predict future iron deposition changes in the left putamen.</p></list-item><list-item><p>
<bold>Future directions</bold>: Future studies should extend this research by (1)&#160;incorporating novel plasma biomarker panels or establishing more precise quantification methodologies and (2)&#160;combining white matter tractography with QSM&#160;to elucidate white matter integrity &#8211; plasma biomarker pathological relationships.</p></list-item></list>
</p></sec></boxed-text><p>Blood samples (5&#160;mL) were collected via venipuncture into EDTA tubes using a standardized protocol. Samples were centrifuged at 3000&#160;rpm for 15&#160;min. Plasma was separated, aliquoted, and stored at &#8722;20&#176;C for short&#8208;term preservation, followed by long&#8208;term storage at &#8722;70&#176;C. Plasma levels of A&#946;1&#8208;42 and A&#946;1&#8208;40 were measured using human&#8208;specific enzyme&#8208;linked immunosorbent assay (ELISA) kits (Thermo Fisher/Invitrogen, USA). All samples were processed with a single reagent lot according to the manufacturer's protocol to ensure consistency. Total tau, pTau 181, pTau 231, and pTau 217 were analyzed using the same ELISA platform under identical conditions. All tau measurements were performed in the same batch as amyloid biomarkers to maintain analytical uniformity.</p></sec><sec id="alz70710-sec-0110"><label>2.3</label><title>Neuropsychological assessment</title><p>All participants underwent comprehensive cognitive function assessments. The Montreal Cognitive Assessment (MoCA) was used to evaluate global cognitive function. The MoCA is a 30&#8208;point test that covers eight cognitive domains, with higher scores indicating better cognitive performance.<xref rid="alz70710-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> To ensure applicability to the Chinese population, the Beijing version of the MoCA was used in this study.</p><p>The cognitive subdomain assessments included the Auditory Verbal Learning Test (AVLT), Stroop Color and Word Test (SCWT), Trail Making Test (TMT), and Symbol Digit Modalities Test (SDMT). The AVLT is a neuropsychological assessment designed to evaluate episodic memory function. Through auditory&#8208;verbal recall tasks, it comprehensively measures an individual's episodic memory abilities. The Chinese version of the SCWT reflects information processing speed and the ability to resist cognitive interference.<xref rid="alz70710-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Performance was assessed based on the accuracy and timing of verbal responses to colors or words, with higher scores indicating lower cognitive flexibility. TMT evaluates information processing speed, sequencing ability, cognitive flexibility, and visual&#8211;motor coordination.<xref rid="alz70710-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Scores were based on the accuracy and timing of the sorting tasks, with higher scores reflecting slower information processing speed and poorer cognitive flexibility. The SDMT primarily measures information processing speed.<xref rid="alz70710-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Participants were asked to verbally provide the number corresponding to a symbol within 90 s, with the total score reflecting the number of correct responses.</p></sec><sec id="alz70710-sec-0120"><label>2.4</label><title>MRI acquisition</title><p>MRI examinations were conducted using a Siemens MAGNETOM Skyra 3.0T system (Erlangen, Germany) with a 32&#8208;channel head receiver coil. To reduce scanner noise, participants were given foam earplugs. Head motion was minimized using a head restraint system, which included foam padding around the participant's head. The imaging protocol included 3D T1&#8208;magnetization&#8208;prepared rapid gradient echo (MPRAGE)&#160;sequence for structural analysis (repetition time [TR]/echo time [TE]/inversion time [TI]&#160;=&#160;7.3/2.4/900&#160;ms; flip angle 9&#176;; 1&#160;mm<sup>3</sup> isotropic resolution); 3D multi&#8208;echo gradient echo (mGRE)&#160;sequence for QSM reconstruction (TR&#160;=&#160;50&#160;ms; TE/&#916;<italic toggle="yes">TE</italic>&#160;=&#160;6.8/4.1&#160;ms; 10 echoes; 15&#176; flip angle; 1&#215;1&#215;2&#160;mm<sup>3</sup> resolution); T2&#8208;weighted turbo spin echo (T2W), T2&#8208;weighted fluid&#8208;attenuated inversion recovery (FLAIR), diffusion&#8208;weighted imaging (DWI), and susceptibility&#8208;weighted imaging (SWI) sequences were also performed to detect brain abnormalities.</p></sec><sec id="alz70710-sec-0130"><label>2.5</label><title>Neuroimaging biomarker evaluation</title><p>The identification and severity evaluation of imaging biomarkers of CSVD were performed following the updated Standards for Reporting Vascular Changes on Neuroimaging 1(STRIVE&#8208;1).<xref rid="alz70710-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</p><p>A composite CSVD burden score (0 to 4 points) was calculated to assess overall disease severity, as validated for cognitive impairment prediction.<xref rid="alz70710-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> One point was allocated for each of the following: presence of &#8805;1 lacune, presence of &#8805;1 CMB, confluent deep WMH, or periventricular hyperintensities extending into deep white matter, and moderate&#8208;to&#8208;severe enlarged perivascular spaces (PVS)&#160;(&gt;10).</p><p>Based on the total CSVD burden score, participants were stratified into two distinct groups: the&#160;CSVD&#8208;M group&#160;(scores 0 to 1), representing no/mild small vessel disease burden, and the&#160;CSVD&#8208;S group&#160;(scores 2 to 4), indicative of moderate&#8211;severe cerebrovascular pathology.</p></sec><sec id="alz70710-sec-0140"><label>2.6</label><title>QSM reconstruction</title><p>QSM reconstruction was performed using the morphology&#8208;enabled dipole inversion with automatic uniform cerebrospinal fluid zero reference algorithm (MEDI+0) framework on multi&#8208;echo GRE data.<xref rid="alz70710-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> In summary, non&#8208;linear fitting of the multi&#8208;echo data was first conducted to estimate the total magnetic field. The total field was spatially unwrapped using a quality&#8208;guided region&#8208;growing algorithm.<xref rid="alz70710-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> This was followed by background field removal using the projection onto dipole fields (PDF) algorithm to compute the local field.<xref rid="alz70710-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> The local field was then inverted to produce the final susceptibility map. To enhance QSM accuracy and provide an automatic susceptibility reference, structural priors (edges) from the magnitude image, along with a regularization term to enforce uniform CSF susceptibility in the lateral ventricles, were incorporated into the numerical inversion. The CSF mask was generated by thresholding the R2* map derived from the mGRE magnitude data, with voxel connectivity constraints.<xref rid="alz70710-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
</p><p>We initiated our analysis by segmenting the T1&#8208;weighted anatomical images using Statistical Parametric Mapping (SPM12) to obtain gray matter volume images. Concurrently, the QSM images were resampled to match the isotropic resolution (1 &#215; 1 &#215; 1&#160;mm<sup>3</sup>) of the gray matter volume images. Subsequently, a study&#8208;specific brain template was created utilizing the Diffeomorphic Anatomical Registration Through Exponentiated Lie Algebra (DARTEL) toolbox.<xref rid="alz70710-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> The gray matter volume and QSM maps were then normalized into Montreal Neurological Institute (MNI) space and subjected to smoothing with a 3&#8208;mm full&#8208;width at half&#8208;maximum Gaussian kernel, following established protocols.<xref rid="alz70710-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>
</p></sec></sec><sec id="alz70710-sec-0150"><label>3</label><title>STATISTICAL ANALYSES</title><sec id="alz70710-sec-0160"><label>3.1</label><title>Demographic and clinical variable comparisons</title><p>Statistical analysis was performed using SPSS (version 27.0) and R (version 4.2.3). Normality assumptions were verified through Shapiro&#8211;Wilk testing. Between&#8208;group comparisons (CSVD&#8208;M vs CSVD&#8208;S) employed parametric (independent t&#8208;test) or non&#8208;parametric (Mann&#8211;Whitney <italic toggle="yes">U</italic> test) approaches for continuous variables based on distribution characteristics, while categorical variables were analyzed using &#967;<sup>2</sup> or Fisher's exact tests as appropriate. A two&#8208;tailed &#945; level of 0.05 defined statistical significance.</p></sec><sec id="alz70710-sec-0170"><label>3.2</label><title>Voxel&#8208;wise QSM analysis</title><p>Using Statistical Parametric Mapping (SPM12) in the MATLAB R2022b environment, a voxel&#8208;wise two&#8208;sample <italic toggle="yes">t</italic>&#8208;test was conducted within a mask created by the Anatomical Automatic Labeling (AAL) atlas with the cerebellum removed. This analysis compared voxel&#8208;wise QSM values between the CSVD&#8208;M and CSVD&#8208;S groups, with sex, age, and vascular risk factor scores included as covariates.</p><p>Additionally, multiple linear regression was employed to investigate the correlation between voxel&#8208;wise QSM values and concentrations of plasma neurodegenerative proteins (A&#946;40, A&#946;42, pTau231, pTau217, and pTau181), with sex, age, and vascular risk factor scores included as covariates. Analyses were repeated in CSVD&#8208;M and CSVD&#8208;S subgroups. The significance thresholds were set at a voxel&#8208;wise <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001 and a cluster&#8208;wise family&#8208;wise error (FWE)&#8208;corrected <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05, with only clusters exceeding 100 voxels considered significant. Significant clusters were defined as regions of interest (ROIs), and their mean QSM values were extracted for subsequent analyses.</p></sec><sec id="alz70710-sec-0180"><label>3.3</label><title>ROI&#8208;cognitive score association analysis</title><p>
<italic toggle="yes">ROI_diff</italic> was defined as a significant cluster identified through voxel&#8208;wise two&#8208;sample <italic toggle="yes">t</italic>&#8208;test. Spearman rank correlation analysis assessed associations between plasma proteins and QSM values of <italic toggle="yes">ROI_diff</italic>. Variables with uncorrected&#160;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.1 were entered into multivariate stepwise linear regression models, which were adjusted for age, sex, vascular risk factor score, and education years. Stratified subgroup analyses were rigorously performed within the&#160;CSVD&#8208;M&#160;and&#160;CSVD&#8208;S&#160;cohorts.</p><p>Spearman rank correlation analysis was conducted between QSM values of <italic toggle="yes">ROI_diff</italic> and cognitive scores across all participants. Variables with uncorrected&#160;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.1 were incorporated into multivariate stepwise linear regression models, with age, sex, and education years as covariates. This analysis was repeated within the CSVD&#8208;M and CSVD&#8208;S groups.</p><p>Spearman rank correlation analysis was conducted between QSM values of plasma protein&#8208;associated clusters and cognitive scores across all participants. Variables with uncorrected&#160;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.1 were incorporated into multivariate stepwise linear regression models, which were adjusted for age, sex, and education years. Stepwise regression was employed, and multicollinearity was assessed using variance inflation factors (VIF&#160;&lt;&#160;5). Stratified subgroup analyses were systematically performed within the&#160;CSVD&#8208;M&#160;and&#160;CSVD&#8208;S&#160;cohorts.</p></sec><sec id="alz70710-sec-0190"><label>3.4</label><title>Longitudinal voxel&#8208;wise QSM analysis and its association with plasma neurodegenerative protein concentrations</title><p>To investigate the longitudinal association between QSM values and plasma neurodegenerative proteins, this study enrolled 80 CSVD patients, who completed full follow&#8208;up between September 2019 and February 2025, with an average follow&#8208;up duration of 19.95&#160;&#177;&#160;8.80 months. There were 75 CSVD&#8208;M participants and 5 CSVD&#8208;S participants among the 80 CSVD patients. Given the small number of participants in the CSVD&#8208;S group, we only conducted a longitudinal analysis on the subjects from the CSVD&#8208;M group.</p><p>Using SPM12 (in the MATLAB R2022b environment), voxel&#8208;wise paired <italic toggle="yes">t</italic>&#8208;tests were performed on baseline and follow&#8208;up QSM values (corrected at the cluster level with FWE correction, with thresholds set at a voxel&#8208;wise <italic toggle="yes">p&#160;</italic>&lt;&#160;0.001 and cluster size &#8805; 100 contiguous voxels) to identify brain regions with significant QSM changes during the follow&#8208;up period. A cross&#8208;lagged panel model was employed to examine the dynamic associations between the mean QSM values of the cluster and plasma neurodegenerative protein concentrations, adjusting for covariates including age, sex, vascular risk factors, and follow&#8208;up interval (in months).</p></sec></sec><sec id="alz70710-sec-0200"><label>4</label><title>RESULTS</title><sec id="alz70710-sec-0210"><label>4.1</label><title>Missing data analysis</title><p>Among the total cohort of 319 CSVD participants, 178 individuals with measured plasma biomarker levels were included in the plasma biomarker analyses. A comparison between participants&#160;with&#160;plasma biomarker data (<italic toggle="yes">n</italic>&#160;=&#160;178) and those&#160;without&#160;(<italic toggle="yes">n</italic>&#160;=&#160;141) revealed significant differences in several baseline characteristics: those with biomarker data were younger, had higher educational levels and a lower prevalence of hypertension, and demonstrated better global cognitive function (Table <xref rid="alz70710-supinfo-0001" ref-type="">S1</xref>). Furthermore, within the subset of 178 participants with plasma biomarker measurements, 80 completed the follow&#8208;up assessment at 2 years. Participants who returned for follow&#8208;up exhibited higher educational levels and better performance in specific cognitive domains compared to those lost to follow&#8208;up (Table <xref rid="alz70710-supinfo-0001" ref-type="">S2</xref>).</p></sec><sec id="alz70710-sec-0220"><label>4.2</label><title>Characteristics of study participants</title><p>This study enrolled a total of 319 participants with CSVD, comprising 226 CSVD&#8208;M participants and 93 CSVD&#8208;S participants. Among these, 178 participants provided plasma protein samples, with 137 from the CSVD&#8208;M group and 41 from the CSVD&#8208;S group.</p><p>No significant differences were observed between the CSVD&#8208;M and CSVD&#8208;S groups in terms of BMI, hyperlipidemia, and smoking status. However, compared to the CSVD&#8208;M group, the CSVD&#8208;S group was older, had a higher proportion of males, lower educational attainment, and a greater prevalence of hypertension and diabetes (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05). Significant differences were also found between the two groups in the AVLT, MoCA, SCWT, and TMT measurements (Table&#160;<xref rid="alz70710-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="alz70710-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Demographic and clinical data.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">CSVD&#8208;M (226)</th><th align="left" rowspan="1" colspan="1">CSVD&#8208;S (93)</th><th align="left" rowspan="1" colspan="1">T/&#967;2/z value</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td align="left" rowspan="1" colspan="1">57.78&#160;&#177;&#160;8.54</td><td align="left" rowspan="1" colspan="1">65.71&#160;&#177;&#160;6.89</td><td align="char" rowspan="1" colspan="1">&#8722;7.95</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="alz70710-tbl1-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Sex</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1">105 (46.5)</td><td align="char" rowspan="1" colspan="1">56 (60.2)</td><td align="char" rowspan="1" colspan="1">4.45</td><td align="char" rowspan="1" colspan="1">0.035<xref rid="alz70710-tbl1-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="char" rowspan="1" colspan="1">121 (53.5)</td><td align="char" rowspan="1" colspan="1">37 (39.8)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>BMI</bold>
</td><td align="left" rowspan="1" colspan="1">24.35&#160;&#177;&#160;4.22</td><td align="left" rowspan="1" colspan="1">24.92&#160;&#177;&#160;2.77</td><td align="char" rowspan="1" colspan="1">&#8722;1.19</td><td align="char" rowspan="1" colspan="1">0.236<xref rid="alz70710-tbl1-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Education years</bold>
</td><td align="left" rowspan="1" colspan="1">13.11&#160;&#177;&#160;3.45</td><td align="left" rowspan="1" colspan="1">11.48&#160;&#177;&#160;3.12</td><td align="char" rowspan="1" colspan="1">3.93</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="alz70710-tbl1-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Hypertension</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="char" rowspan="1" colspan="1">141 (62.4)</td><td align="char" rowspan="1" colspan="1">24 (26.4)</td><td align="char" rowspan="1" colspan="1">32.29</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="alz70710-tbl1-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1">85 (37.6)</td><td align="char" rowspan="1" colspan="1">67 (73.6)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Diabetes</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="char" rowspan="1" colspan="1">155 (68.9)</td><td align="char" rowspan="1" colspan="1">46 (51.1)</td><td align="char" rowspan="1" colspan="1">8.05</td><td align="char" rowspan="1" colspan="1">0.005<xref rid="alz70710-tbl1-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1">70 (31.1)</td><td align="char" rowspan="1" colspan="1">44 (48.9)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Hyperlipidaemia</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="char" rowspan="1" colspan="1">119 (58.0)</td><td align="char" rowspan="1" colspan="1">43 (47.3)</td><td align="char" rowspan="1" colspan="1">2.55</td><td align="char" rowspan="1" colspan="1">0.111<xref rid="alz70710-tbl1-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1">86 (42.0)</td><td align="char" rowspan="1" colspan="1">48 (52.7)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Smoking</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="char" rowspan="1" colspan="1">176 (78.2)</td><td align="char" rowspan="1" colspan="1">64 (68.8)</td><td align="char" rowspan="1" colspan="1">2.66</td><td align="char" rowspan="1" colspan="1">0.103<xref rid="alz70710-tbl1-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1">49 (21.8)</td><td align="char" rowspan="1" colspan="1">29 (31.2)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td colspan="5" align="left" rowspan="1">
<bold>Vascular risk factor score</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="char" rowspan="1" colspan="1">65 (28.8)</td><td align="char" rowspan="1" colspan="1">8 (8.6)</td><td align="char" rowspan="1" colspan="1">27.7</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="alz70710-tbl1-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1">72 (31.9)</td><td align="char" rowspan="1" colspan="1">26 (28.0)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="char" rowspan="1" colspan="1">56 (24.8)</td><td align="char" rowspan="1" colspan="1">27 (29.0)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="char" rowspan="1" colspan="1">26 (11.5)</td><td align="char" rowspan="1" colspan="1">20 (21.5)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="char" rowspan="1" colspan="1">7 (3.1)</td><td align="char" rowspan="1" colspan="1">12 (12.9)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>AVLT</bold>
</td><td align="char" rowspan="1" colspan="1">60.00 (51.00, 69.00)</td><td align="char" rowspan="1" colspan="1">54.00 (46.00, 63.00)</td><td align="char" rowspan="1" colspan="1">&#8722;3.15</td><td align="char" rowspan="1" colspan="1">0.002<xref rid="alz70710-tbl1-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>MoCA</bold>
</td><td align="char" rowspan="1" colspan="1">27.00 (25.00, 28.00)</td><td align="char" rowspan="1" colspan="1">25.00 (22.00, 27.00)</td><td align="char" rowspan="1" colspan="1">&#8722;5.56</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="alz70710-tbl1-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Stroop1</bold>
</td><td align="char" rowspan="1" colspan="1">23.00 (20.00, 27.00)</td><td align="char" rowspan="1" colspan="1">27.00 (24.00, 33.00)</td><td align="char" rowspan="1" colspan="1">5.54</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="alz70710-tbl1-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Stroop2</bold>
</td><td align="char" rowspan="1" colspan="1">35.00 (30.00, 40.00)</td><td align="char" rowspan="1" colspan="1">41.00 (35.00, 51.00)</td><td align="char" rowspan="1" colspan="1">5.67</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="alz70710-tbl1-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Stroop3</bold>
</td><td align="char" rowspan="1" colspan="1">66.00 (57.00, 80.00)</td><td align="char" rowspan="1" colspan="1">86.00 (67.25, 108.00)</td><td align="char" rowspan="1" colspan="1">6.17</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="alz70710-tbl1-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>SCWT</bold>
</td><td align="char" rowspan="1" colspan="1">120.00 (107.00, 146.00)</td><td align="char" rowspan="1" colspan="1">150.00 (130.25, 188.00)</td><td align="char" rowspan="1" colspan="1">6.37</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="alz70710-tbl1-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TMTA</bold>
</td><td align="char" rowspan="1" colspan="1">50.00 (38.00, 71.00)</td><td align="char" rowspan="1" colspan="1">67.50 (51.25, 95.25)</td><td align="char" rowspan="1" colspan="1">5.02</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="alz70710-tbl1-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TMTB</bold>
</td><td align="char" rowspan="1" colspan="1">140.50 (100.00, 201.77)</td><td align="char" rowspan="1" colspan="1">207.00 (153.25, 294.50)</td><td align="char" rowspan="1" colspan="1">6.38</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="alz70710-tbl1-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TMT (A+B)</bold>
</td><td align="char" rowspan="1" colspan="1">190.50 (140.00, 275.00)</td><td align="char" rowspan="1" colspan="1">263.50 (208.50, 380.25)</td><td align="char" rowspan="1" colspan="1">6.12</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="alz70710-tbl1-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TMT (B</bold>&#8722;<bold>A)</bold>
</td><td align="char" rowspan="1" colspan="1">85.00 (58.00, 137.25)</td><td align="char" rowspan="1" colspan="1">139.50 (89.25, 212.50)</td><td align="char" rowspan="1" colspan="1">5.85</td><td align="char" rowspan="1" colspan="1">&lt;0.001<xref rid="alz70710-tbl1-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="alz70710-tbl1-note-0001"><p>Abbreviations: AVLT, Auditory Verbal Learning Test; CSVD&#8208;M, cerebral small vessel disease participants with no/mild small vessel disease burden (total CSVD burden score&#160;&lt;&#160;2); CSVD&#8208;S, cerebral small vessel disease participants with moderate/severe small vessel disease burden (total CSVD burden score &#8805; 2); MoCA, Montreal Cognitive Assessment; SCWT, Stroop Color and Word Test; SDMT, Symbol Digit Modalities Test; TMT, Trail Making Test.</p></fn><fn id="alz70710-tbl1-note-0002"><label>
<sup>a</sup>
</label><p>Two&#8208;sample <italic toggle="yes">t&#8208;</italic>tests.</p></fn><fn id="alz70710-tbl1-note-0003"><label>
<sup>b</sup>
</label><p>Chi&#8208;squared test.</p></fn><fn id="alz70710-tbl1-note-0004"><label>
<sup>c</sup>
</label><p>Mann&#8211;Whitney <italic toggle="yes">U</italic> test.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="alz70710-sec-0230"><label>5</label><title>RESULTS OF VOXEL&#8208;WISE QSM ANALYSIS</title><sec id="alz70710-sec-0240"><label>5.1</label><title>Voxel&#8208;wise QSM differences in CSVD cohort</title><p>In the CSVD cohort, two&#8208;sample&#160;<italic toggle="yes">t</italic>&#8208;tests adjusted for age, sex, and vascular risk factor scores demonstrated significantly higher QSM values in the CSVD&#8208;S group compared to CSVD&#8208;M within the right Rolandic operculum and right superior temporal gyrus (peak MNI: 43, &#8722;23, 16;&#160;<italic toggle="yes">t</italic>&#160;=&#160;5.06, FWE&#8208;corrected&#160;<italic toggle="yes">p</italic>&#160;=&#160;&lt;&#160;0.001) (Table&#160;<xref rid="alz70710-tbl-0002" ref-type="table">2</xref>, Figure&#160;<xref rid="alz70710-fig-0001" ref-type="fig">1</xref>). No regions exhibited lower QSM values in CSVD&#8208;S relative to CSVD&#8208;M.</p><table-wrap position="float" id="alz70710-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Regions with QSM value differences between every two groups (voxel&#8208;wise <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001 and cluster&#8208;wise FWE&#8208;corrected <italic toggle="yes">p&#160;</italic>&lt;&#160;0.05).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th rowspan="2" align="left" colspan="1">Clusters</th><th rowspan="2" align="left" colspan="1">Cluster size (total voxels)</th><th rowspan="2" align="left" colspan="1">
<italic toggle="yes">t</italic>&#8208;value</th><th rowspan="2" align="left" colspan="1">
<italic toggle="yes">p</italic>
<sub>FWE</sub> value</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Peak MINI coordinates (mm)</th><th rowspan="2" align="left" colspan="1">Brain regions (cluster size)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">X</th><th align="left" rowspan="1" colspan="1">Y</th><th align="left" rowspan="1" colspan="1">Z</th></tr></thead><tbody><tr><td colspan="8" align="left" rowspan="1">CSVD&#8208;M&#160;&lt; CSVD&#8208;S</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">789</td><td align="left" rowspan="1" colspan="1">5.06</td><td align="left" rowspan="1" colspan="1">&lt;0.001</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">&#8722;23</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">
<p>Rolandic_Oper_R (517),</p>
<p>Temporal_Sup_R (154)</p>
</td></tr></tbody></table><table-wrap-foot><fn id="alz70710-tbl2-note-0001"><p>Abbreviations: CSVD&#8208;S, cerebral small vessel disease with moderate&#8211;severe cerebrovascular pathology; FWE, family&#8208;wise error; MNI, Montreal Neurological Institute; QSM, Quantitative Susceptibility Mapping; Rolandic_Oper_R, right Rolandic Operculum; Temporal_Sup_R, right superior temporal gyrus.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><fig position="float" fig-type="FIGURE" id="alz70710-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Regions with QSM value differences between the two groups (voxel&#8208;wise <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001 and cluster&#8208;wise FWE&#8208;corrected <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05). (A) Depicts the cluster with QSM value differences between CSVD&#8208;M and CSVD&#8208;S in sagittal, coronal, and axial planes; Maps are displayed at the <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05 level with the <italic toggle="yes">T</italic>&#8208;values displayed in the color bar. Correction for multiple comparisons was applied with FWE correction. (B) The distribution of the QSM values in the cluster with statistical differences in two&#8208;sample <italic toggle="yes">t</italic> test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70710-g001.jpg"/></fig></sec><sec id="alz70710-sec-0250"><label>5.2</label><title>Voxel&#8208;wise QSM and plasma protein concentration correlations</title><p>Voxel&#8208;wise correlation analyses adjusted for age, sex, and vascular risk factor scores revealed widespread negative associations between mean QSM values and plasma A&#946;42 levels across bilateral supplementary motor areas/paracentral lobules/superior frontal gyri/postcentral gyri, and right precentral (voxel&#8208;wise&#160;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.001, cluster&#8208;level FWE&#8208;corrected&#160;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05) (Table&#160;<xref rid="alz70710-tbl-0003" ref-type="table">3</xref>, Figure <xref rid="alz70710-supinfo-0001" ref-type="">S1</xref>).</p><table-wrap position="float" id="alz70710-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Regions with QSM value significantly associated with plasma neurodegenerative protein in CSVD patients (voxel&#8208;wise <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001 and cluster&#8208;wise FWE&#8208;corrected <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><thead><tr><th rowspan="2" align="left" colspan="1">Groups</th><th rowspan="2" align="left" colspan="1">Variable</th><th rowspan="2" align="left" colspan="1">Clusters</th><th rowspan="2" align="left" colspan="1">Cluster size</th><th rowspan="2" align="left" colspan="1">
<italic toggle="yes">t</italic> value</th><th rowspan="2" align="left" colspan="1">
<italic toggle="yes">p</italic>
<sub>FWE</sub> value</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">Peak MINI coordinates (mm)</th><th align="left" rowspan="2" colspan="1">Brain regions (cluster size)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">X</th><th align="left" rowspan="1" colspan="1">Y</th><th align="left" rowspan="1" colspan="1">Z</th></tr></thead><tbody><tr><td rowspan="2" align="left" colspan="1">
<bold>All</bold>
</td><td rowspan="2" align="left" colspan="1">
<bold>A&#946;42&#8208;negative correlation</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="char" rowspan="1" colspan="1">14746</td><td align="char" rowspan="1" colspan="1">5.481</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1">12</td><td align="char" rowspan="1" colspan="1">&#8722;33</td><td align="char" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1">Supp_Motor_Area_R (5308), Supp_Motor_Area_L (2135), Paracentral_Lobule_R (1501), Paracentral_Lobule_L (1042), Frontal_Sup_Medial_R (999), Frontal_Sup_R (971), Frontal_Sup_L (865), Postcentral_R (733), Precentral_R (315), Postcentral_L (912)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="char" rowspan="1" colspan="1">1330</td><td align="char" rowspan="1" colspan="1">5.076</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1">&#8722;19</td><td align="char" rowspan="1" colspan="1">&#8722;36</td><td align="char" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">Postcentral_L (912)</td></tr><tr><td rowspan="7" align="left" colspan="1">
<bold>CSVD&#8208;M</bold>
</td><td rowspan="5" align="left" colspan="1">
<bold>A&#946;42&#8208;negative correlation</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="char" rowspan="1" colspan="1">1758</td><td align="char" rowspan="1" colspan="1">4.421</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1">10</td><td align="char" rowspan="1" colspan="1">7</td><td align="char" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">Supp_Motor_Area_R (1388), Frontal_Sup_R (244)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="char" rowspan="1" colspan="1">1074</td><td align="char" rowspan="1" colspan="1">5.276</td><td align="char" rowspan="1" colspan="1">0.001</td><td align="char" rowspan="1" colspan="1">13</td><td align="char" rowspan="1" colspan="1">&#8722;33</td><td align="char" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1">Paracentral_Lobule_R (501), Postcentral_R (453)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>3</bold>
</td><td align="char" rowspan="1" colspan="1">1047</td><td align="char" rowspan="1" colspan="1">4.628</td><td align="char" rowspan="1" colspan="1">0.002</td><td align="char" rowspan="1" colspan="1">8</td><td align="char" rowspan="1" colspan="1">&#8722;17</td><td align="char" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">Supp_Motor_Area_R (842)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="char" rowspan="1" colspan="1">947</td><td align="char" rowspan="1" colspan="1">4.121</td><td align="char" rowspan="1" colspan="1">0.003</td><td align="char" rowspan="1" colspan="1">&#8722;3</td><td align="char" rowspan="1" colspan="1">&#8722;11</td><td align="char" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">Supp_Motor_Area_L (674)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>5</bold>
</td><td align="char" rowspan="1" colspan="1">670</td><td align="char" rowspan="1" colspan="1">4.305</td><td align="char" rowspan="1" colspan="1">0.022</td><td align="char" rowspan="1" colspan="1">&#8722;19</td><td align="char" rowspan="1" colspan="1">&#8722;36</td><td align="char" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1">Postcentral_L (536)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Tau&#8208;positive correlation</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="char" rowspan="1" colspan="1">647</td><td align="char" rowspan="1" colspan="1">4.4</td><td align="char" rowspan="1" colspan="1">0.025</td><td align="char" rowspan="1" colspan="1">&#8722;2</td><td align="char" rowspan="1" colspan="1">52</td><td align="char" rowspan="1" colspan="1">&#8722;5</td><td align="left" rowspan="1" colspan="1">Frontal_Med_Orb_L (479)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>pTau181&#8208;positive correlation</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="char" rowspan="1" colspan="1">739</td><td align="char" rowspan="1" colspan="1">4.379</td><td align="char" rowspan="1" colspan="1">0.013</td><td align="char" rowspan="1" colspan="1">3</td><td align="char" rowspan="1" colspan="1">&#8722;10</td><td align="char" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1">Paracentral_Lobule_L (452)</td></tr><tr><td rowspan="3" align="left" colspan="1">
<bold>CSVD&#8208;S</bold>
</td><td rowspan="2" align="left" colspan="1">
<bold>A&#946;42&#8208;negative correlation</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="char" rowspan="1" colspan="1">440</td><td align="char" rowspan="1" colspan="1">4.722</td><td align="char" rowspan="1" colspan="1">0.036</td><td align="char" rowspan="1" colspan="1">&#8722;46</td><td align="char" rowspan="1" colspan="1">12</td><td align="char" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">Frontal_Inf_Oper_L (242)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>2</bold>
</td><td align="char" rowspan="1" colspan="1">610</td><td align="char" rowspan="1" colspan="1">5.026</td><td align="char" rowspan="1" colspan="1">0.006</td><td align="char" rowspan="1" colspan="1">35</td><td align="char" rowspan="1" colspan="1">&#8722;49</td><td align="char" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">Parietal_Inf_R (444)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>pTau217&#8208;positive correlation</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1</bold>
</td><td align="char" rowspan="1" colspan="1">757</td><td align="char" rowspan="1" colspan="1">5.165</td><td align="char" rowspan="1" colspan="1">0.002</td><td align="char" rowspan="1" colspan="1">46</td><td align="char" rowspan="1" colspan="1">11</td><td align="char" rowspan="1" colspan="1">&#8722;1</td><td align="left" rowspan="1" colspan="1">Insula_R (444), Rolandic_Oper_R (200)</td></tr></tbody></table><table-wrap-foot><fn id="alz70710-tbl3-note-0001"><p>Abbreviations: CSVD, cerebral small vessel disease; Inf_Oper, inferior opercular frontal cortex; Frontal_Med_Orb, medial orbital frontal cortex; Frontal_Sup_Medial, superior medial frontal cortex; Frontal_Sup_R, superior frontal gyrus; FWE, family&#8208;wise error; Insula, insular cortex; L, left hemisphere; MNI, Montreal Neurological Institute; Paracentral_Lobule, paracentral lobule; Parietal_Inf, inferior parietal lobule; Postcentral, postcentral gyrus; Precentral, precentral gyrus; QSM, quantitative susceptibility mapping; R, right hemisphere; Rolandic_Oper, Rolandic operculum; Supp_Motor_Area, supplementary motor area.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>In the CSVD&#8208;M subgroup, after adjusting age, sex, and vascular risk factor scores, voxel&#8208;wise correlation analyses revealed (1) negative associations between mean QSM values and plasma A&#946;42 levels across right supplementary motor areas/superior frontal gyri/paracentral lobule/postcentral gyri/supplementary motor areas, left supplementary motor areas/postcentral gyri; (2) positive associations between mean QSM values and plasma tau protein levels in the left medial orbital frontal gyrus; (3) positive associations between mean QSM values and plasma pTau181 protein levels in the left paracentral lobule (Table&#160;<xref rid="alz70710-tbl-0003" ref-type="table">3</xref>, Figure <xref rid="alz70710-supinfo-0001" ref-type="">S1</xref>).</p><p>In the CSVD&#8208;S subgroup, after adjusting for age, sex, and vascular risk factor scores, voxel&#8208;wise correlation analyses revealed (1) negative associations between mean QSM values and plasma A&#946;42 levels across the left inferior frontal operculum/right inferior parietal lobule and (2) positive associations between mean QSM values and plasma PTau217 protein levels in the right insula/right Rolandic operculum. Details of the voxel&#8208;wise correlation analyses between QSM and plasma protein levels are shown in Table&#160;<xref rid="alz70710-tbl-0003" ref-type="table">3</xref> and Figure <xref rid="alz70710-supinfo-0001" ref-type="">S1</xref>.</p></sec></sec><sec id="alz70710-sec-0260"><label>6</label><title>RESULTS OF ROI&#8211;COGNITIVE SCORE ASSOCIATION ANALYSIS</title><sec id="alz70710-sec-0270"><label>6.1</label><title>Relationship between <italic toggle="yes">ROI_diff</italic> QSM values and plasma protein levels</title><p>In the CSVD cohort, Spearman correlation analysis revealed that in the CSVD&#8208;S group, the <italic toggle="yes">ROI_diff</italic> mean QSM values were negatively correlated with plasma A&#946;42 protein concentrations (<italic toggle="yes">r</italic>&#160;=&#160;&#8722;0.455,&#160;<italic toggle="yes">p</italic>&#160;=&#160;0.004). After adjusting for age, sex, vascular risk factor scores, and education years, multiple linear regression confirmed this negative correlation (&#946; [95% confidence interval [CI]&#160;=&#160;&#8722;0.140 (&#8722;0.220,&#8722;0.059),&#160;<italic toggle="yes">p</italic>&#160;=&#160;0.001) (Table <xref rid="alz70710-supinfo-0001" ref-type="">S3</xref>, Figure <xref rid="alz70710-supinfo-0001" ref-type="">S2</xref>). However, no association was observed between the <italic toggle="yes">ROI_diff</italic> mean QSM values and plasma protein concentrations in either the overall population or the CSVD&#8208;M group.</p></sec><sec id="alz70710-sec-0280"><label>6.2</label><title>Relationship between <italic toggle="yes">ROI_diff</italic> QSM values and cognitive performance</title><p>After adjusting for age, sex, and education years, multiple linear regression analyses revealed the following associations:</p><p>All CSVD participants: The <italic toggle="yes">ROI_diff</italic> mean QSM values (CSVD&#8208;M vs CSVD&#8208;S) were positively correlated with SCWT (Stroop3: &#946; [95% CI]&#160;=&#160;0.372 [0.119, 0.624],&#160;<italic toggle="yes">p</italic>&#160;=&#160;0.004) and TMT Part A (TMT&#8208;A: &#946; [95% CI]&#160;=&#160;0.323 (0.063, 0.583),&#160;<italic toggle="yes">p</italic>&#160;=&#160;0.015) (Table&#160;<xref rid="alz70710-tbl-0004" ref-type="table">4</xref>, Figure&#160;<xref rid="alz70710-fig-0002" ref-type="fig">2</xref>);</p><table-wrap position="float" id="alz70710-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Associations between regions with QSM value differences and cognitive function among the two groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Cognition</th><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">&#946; (95% CI)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>&#8208;value</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">R</italic>
<sup>2</sup> of model</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value of model</th></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1">
<bold>ALL</bold>
</td></tr><tr><td rowspan="4" align="left" colspan="1">Stroop3</td><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">0.7 (0.363,1.037)</td><td align="char" rowspan="1" colspan="1">4.088</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1">0.281</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Education</td><td align="char" rowspan="1" colspan="1">&#8722;2.526 (&#8722;3.39, &#8722;1.661)</td><td align="char" rowspan="1" colspan="1">&#8722;5.746</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;11.204 (&#8722;16.597, &#8722;5.811)</td><td align="char" rowspan="1" colspan="1">&#8722;4.088</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ROI_diff</italic>
</td><td align="char" rowspan="1" colspan="1">0.372 (0.119, 0.624)</td><td align="char" rowspan="1" colspan="1">2.899</td><td align="char" rowspan="1" colspan="1">0.004</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td rowspan="4" align="left" colspan="1">TMT&#8208;A</td><td align="left" rowspan="1" colspan="1">Education</td><td align="char" rowspan="1" colspan="1">&#8722;3.436 (&#8722;4.323, &#8722;2.549)</td><td align="char" rowspan="1" colspan="1">&#8722;7.621</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1">0.43</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">1.239 (0.892, 1.587)</td><td align="char" rowspan="1" colspan="1">7.022</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">8.486 (2.935, 14.038)</td><td align="char" rowspan="1" colspan="1">3.008</td><td align="char" rowspan="1" colspan="1">0.003</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ROI_diff</italic>
</td><td align="char" rowspan="1" colspan="1">0.323 (0.063, 0.583)</td><td align="char" rowspan="1" colspan="1">2.443</td><td align="char" rowspan="1" colspan="1">0.015</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td colspan="7" align="left" rowspan="1">
<bold>CSVD&#8208;M</bold>
</td></tr><tr><td rowspan="4" align="left" colspan="1">Stroop3</td><td align="left" rowspan="1" colspan="1">Education</td><td align="char" rowspan="1" colspan="1">&#8722;2.318 (&#8722;3.26, &#8722;1.376)</td><td align="char" rowspan="1" colspan="1">&#8722;4.848</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1">0.242</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">0.607 (0.234, 0.981)</td><td align="char" rowspan="1" colspan="1">3.207</td><td align="char" rowspan="1" colspan="1">0.002</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">&#8722;9.658 (&#8722;15.58, &#8722;3.735)</td><td align="char" rowspan="1" colspan="1">&#8722;3.214</td><td align="char" rowspan="1" colspan="1">0.002</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ROI_diff</italic>
</td><td align="char" rowspan="1" colspan="1">0.301 (0.006, 0.595)</td><td align="char" rowspan="1" colspan="1">2.011</td><td align="char" rowspan="1" colspan="1">0.046</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="alz70710-tbl4-note-0001"><p>Abbreviations: CI, confidence interval; CSVD&#8208;M, cerebral small vessel disease with no/mild small vessel disease burden (total CSVD burden score&#160;&lt;&#160;2); CSVD&#8208;S, cerebral small vessel disease with moderate/severe small vessel disease burden (total CSVD burden score &#8805; 2); QSM, quantitative susceptibility mapping; ROI_diff, regions with QSM value differences between each two groups; Stroop3, Stroop Color and Word Test Part 3; TMT, Trail Making Test.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><fig position="float" fig-type="FIGURE" id="alz70710-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Associations between regions with QSM value differences and cognitive function among the two groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70710-g003.jpg"/></fig><p>CSVD&#8208;M group: The mean QSM values of <italic toggle="yes">ROI_diff</italic> was positively correlated with SCWT (Stroop3: &#946; [95% CI]&#160;=&#160;0.301 (0.006, 0.595),&#160;<italic toggle="yes">p</italic>&#160;=&#160;0.046) (Table&#160;<xref rid="alz70710-tbl-0004" ref-type="table">4</xref>, Figure&#160;<xref rid="alz70710-fig-0002" ref-type="fig">2</xref>).</p></sec><sec id="alz70710-sec-0290"><label>6.3</label><title>Relationship between QSM values in plasma protein concentration&#8208;related clusters and cognitive performance in plasma protein cohort</title><p>In the plasma protein cohort, after adjusting for age, sex, and education years, multiple linear regression analyses revealed the following associations:</p><p>All CSVD participants: Clusters with mean QSM values negatively correlated with plasma A&#946;42 levels exhibited inverse associations with Auditory Verbal Learning Test delayed recall scores (AVLT: &#946; [95% CI]&#160;=&#160;&#8722;0.394 (&#8722;0.625, &#8722;0.163),&#160;<italic toggle="yes">p</italic>&#160;=&#160;0.001) (Table&#160;<xref rid="alz70710-tbl-0005" ref-type="table">5</xref>);</p><table-wrap position="float" id="alz70710-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 5</label><caption><p>Associations between protein&#8208;associated regions and cognitive function among the two groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Cognition</th><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">&#946; (95% CI)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">t&#8208;</italic>value</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" rowspan="1" colspan="1">R<sup>2</sup> of model</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value of model</th></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1">
<bold>ALL</bold>
</td></tr><tr><td rowspan="4" align="left" colspan="1">AVLT</td><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">4.718 (0.966,8.47)</td><td align="char" rowspan="1" colspan="1">2.482</td><td align="char" rowspan="1" colspan="1">0.014</td><td align="char" rowspan="1" colspan="1">0.352</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">&#8722;0.442 (&#8722;0.662, &#8722;0.222)</td><td align="char" rowspan="1" colspan="1">&#8722;3.966</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Education</td><td align="char" rowspan="1" colspan="1">1.347 (0.807, 1.887)</td><td align="char" rowspan="1" colspan="1">4.924</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">A&#946;42_Negative_Cluster1</td><td align="char" rowspan="1" colspan="1">&#8722;0.394 (&#8722;0.625, &#8722;0.163)</td><td align="char" rowspan="1" colspan="1">&#8722;3.366</td><td align="char" rowspan="1" colspan="1">0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td colspan="7" align="left" rowspan="1">
<bold>CSVD&#8208;M</bold>
</td></tr><tr><td rowspan="4" align="left" colspan="1">AVLT</td><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">5.858 (1.611, 10.104)</td><td align="char" rowspan="1" colspan="1">2.729</td><td align="char" rowspan="1" colspan="1">0.007</td><td align="char" rowspan="1" colspan="1">0.399</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">&#8722;0.416 (&#8722;0.671, &#8722;0.161)</td><td align="char" rowspan="1" colspan="1">&#8722;3.231</td><td align="char" rowspan="1" colspan="1">0.002</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Education</td><td align="char" rowspan="1" colspan="1">1.603 (0.999, 2.207)</td><td align="char" rowspan="1" colspan="1">5.252</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">A&#946;42_Negative_Cluster1</td><td align="char" rowspan="1" colspan="1">&#8722;0.43 (&#8722;0.664, &#8722;0.197)</td><td align="char" rowspan="1" colspan="1">&#8722;3.65</td><td align="char" rowspan="1" colspan="1">&lt;0.001</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td colspan="7" align="left" rowspan="1">
<bold>CSVD&#8208;S</bold>
</td></tr><tr><td rowspan="4" align="left" colspan="1">AVLT</td><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1">4.511 (&#8722;2.724, 11.747)</td><td align="char" rowspan="1" colspan="1">1.266</td><td align="char" rowspan="1" colspan="1">0.214</td><td align="char" rowspan="1" colspan="1">0.353</td><td align="char" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="char" rowspan="1" colspan="1">&#8722;0.764 (&#8722;1.269, &#8722;0.26)</td><td align="char" rowspan="1" colspan="1">&#8722;3.074</td><td align="char" rowspan="1" colspan="1">0.004</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Education</td><td align="char" rowspan="1" colspan="1">0.582 (&#8722;0.577, 1.742)</td><td align="char" rowspan="1" colspan="1">1.02</td><td align="char" rowspan="1" colspan="1">0.315</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">A&#946;42_Negative_Cluster2</td><td align="char" rowspan="1" colspan="1">&#8722;0.506 (&#8722;0.834, &#8722;0.178)</td><td align="char" rowspan="1" colspan="1">&#8722;3.136</td><td align="char" rowspan="1" colspan="1">0.003</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="alz70710-tbl5-note-0001"><p>Abbreviations: A&#946;42_Negative_Cluster, clusters with QSM values correlated to plasma A&#946;42 protein; AVLT, auditory verbal learning test; CI, confidence interval; CSVD&#8208;M, cerebral small vessel disease with no/mild small vessel disease burden; CSVD&#8208;S, cerebral small vessel disease with moderate/severe small vessel disease burden.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>CSVD&#8208;M group: Clusters with mean QSM values negatively correlated with plasma A&#946;42 levels exhibited inverse associations with Auditory Verbal Learning Test delayed recall scores (AVLT: &#946; [95% CI]&#160;=&#160;&#8722;0.403 (&#8722;0.664, &#8722;0.197),&#160;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) (Table&#160;<xref rid="alz70710-tbl-0005" ref-type="table">5</xref>);</p><p>CSVD&#8208;S group: Clusters with mean QSM values negatively correlated with plasma A&#946;42 levels were positively correlated to AVLT score (AVLT: &#946; (95% CI)&#160;=&#160;&#8722;0.506 (&#8722;0.834, &#8722;0.178),&#160;<italic toggle="yes">p</italic>&#160;=&#160;0.003) (Table&#160;<xref rid="alz70710-tbl-0005" ref-type="table">5</xref>).</p></sec><sec id="alz70710-sec-0300"><label>6.4</label><title>Longitudinal voxel&#8208;wise QSM analysis and its association with plasma neurodegenerative protein concentrations</title><p>Longitudinal studies indicate that, over approximately 2 years of follow&#8208;up, 75 CSVD&#8208;M patients exhibit a significant increase in QSM values in the left putamen (voxel&#8208;wise&#160;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.001, cluster&#8208;level FWE&#8208;corrected&#160;<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05) (Table <xref rid="alz70710-supinfo-0001" ref-type="">S4</xref>, Figure&#160;<xref rid="alz70710-fig-0003" ref-type="fig">3</xref>). Baseline plasma A&#946;40 concentrations show a positive correlation with QSM values in this region at follow&#8208;up (<italic toggle="yes">p</italic>&#160;=&#160;0.026) (Figure&#160;<xref rid="alz70710-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="alz70710-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Longitudinal voxel&#8208;based QSM analysis and its association with plasma neurodegenerative protein concentrations. (A) QSM voxel&#8208;wise paired <italic toggle="yes">t</italic>&#8208;tests were performed on baseline and follow&#8208;up participants. (B) The cross&#8208;lagged panel models assess associations between the longitudinal cluster QSM and the plasma protein; Time 1, baseline; Time 2, follow&#8208;up. (C) Wilcoxon signed rank test assesses the differences of QSM values between the baseline and follow&#8208;up cluster.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70710-g002.jpg"/></fig></sec></sec><sec id="alz70710-sec-0310"><label>7</label><title>DISCUSSION</title><p>This study is the first to employ QSM voxel&#8208;based analysis to investigate the relationships among plasma neurodegenerative proteins, brain iron, and cognitive function in CSVD, aiming to offer new perspectives for future diagnostic and therapeutic strategies.</p><p>Iron deposits are linked to dysfunctional iron regulatory mechanisms within the brain. The core mechanism underlying CSVD&#8208;related brain injury is diffuse cerebral vascular endothelial dysfunction.<xref rid="alz70710-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> CSVD&#8208;related cerebrovascular endothelial dysfunction increases blood&#8211;brain barrier (BBB) permeability, promoting the accumulation of harmful substances such as iron and hemoglobin, thereby triggering neuroinflammation.<xref rid="alz70710-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>, <xref rid="alz70710-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
</p><p>This study found that elevated QSM values in the right Rolandic operculum and right superior temporal gyrus were negatively correlated with executive function decline in CSVD&#8208;S patients, suggesting that increased iron load may contribute to cognitive impairment, particularly in interference suppression.</p><p>The Rolandic operculum, also known as the subcentral gyrus or central/basal operculum, is a large, highly interconnected structure adjacent to the insula, playing a critical role in sensorimotor function and language processing.<xref rid="alz70710-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> Although current research has not specifically focused on the relationship between CSVD burden and iron deposition in the Rolandic operculum, the stability of this region's function tends to decline as CSVD burden increases. A recent study employing voxel&#8208;based morphometry and amplitude of low&#8208;frequency fluctuations (ALFF) analysis found that the Rolandic operculum in CSVD patients not only underwent volumetric atrophy but also exhibits a compensatory increase in ALFF.<xref rid="alz70710-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> Consequently, the observed increase in iron deposition in the Rolandic operculum may serve as a marker of disease progression in CSVD patients. Future studies are needed to elucidate the mechanisms by which iron accumulation in this region impacts cognitive function in CSVD and to explore its potential as a target for therapeutic intervention.</p><p>In the CSVD&#8208;S population, plasma A&#946;42 protein levels were negatively correlated with QSM values in the right Rolandic operculum/superior temporal gyrus, suggesting that plasma A&#946;42 levels may decrease as CSVD burden increases. A&#946;42 aggregates more rapidly than A&#946;40, potentially rendering it more toxic and making it a primary component of amyloid plaques.<xref rid="alz70710-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Previous studies demonstrated a strong consistency between plasma A&#946;42/40 concentrations and CSF levels. Earlier research also showed that reduced CSF A&#946;42 levels were associated with increased CSVD burden and more severe neurodegeneration.<xref rid="alz70710-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> To date, no studies have explored the relationship between brain iron levels in CSVD and plasma neurodegenerative proteins.</p><p>To investigate the relationship between plasma levels of neurodegenerative proteins (A&#946;40, A&#946;42, pTau231, pTau217, and pTau181) and brain iron in CSVD patients, this study employed voxel&#8208;wise multiple linear regression analysis. The results revealed a negative correlation between plasma A&#946;42 levels and QSM values in specific regions of the frontal and parietal lobes. Furthermore, across the entire study population and the two subgroup, QSM values in these clusters were negatively correlated with AVLT scores, indicating that brain iron deposition in these regions was associated with impaired episodic memory function in CSVD subjects.</p><p>Disruption of brain iron homeostasis is a key factor in A&#946; protein deposition. Elevated intracellular iron levels upregulate APP expression by enhancing iron regulatory protein/iron regulatory element interactions. During iron overload, impaired furin suppresses &#945;&#8208;secretase activity while activating &#946;&#8208;secretase, cleaving the upregulated APP into A&#946;40/42 and accelerating its deposition.<xref rid="alz70710-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> APP stabilizes ferroportin&#8208;1 (FPN1) to promote iron efflux, but under iron overload, excessive consumption of this mechanism impairs iron export, exacerbating deposition.<xref rid="alz70710-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> Soluble A&#946; binds to Fe<sup>3</sup>&#8314; to remove excess iron but is difficult to dissociate; it also promotes the reduction of Fe<sup>3</sup>&#8314; to Fe<sup>2</sup>&#8314;, releasing reactive oxygen species (ROS) and further accelerating A&#946; deposition.<xref rid="alz70710-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> Consequently, in CSVD patients, increased iron accumulation may trigger A&#946;42 deposition, manifesting as reduced A&#946;42 levels in plasma and CSF.</p><p>Local iron deposition may accelerate neuronal death by disrupting protein synthesis or increasing oxidative stress, manifesting as gray matter volume reduction.<xref rid="alz70710-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="alz70710-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> Studies have previously identified atrophy in the frontal and parietal gray matter in CSVD patients with mild cognitive impairment.<xref rid="alz70710-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> Additionally, while univariate correlation analysis indicated that QSM values of plasma A&#946;42 protein&#8208;related clusters were associated with multiple cognitive domains, these associations were attenuated after adjusting for age, sex, and education. Only a negative correlation between QSM values and the AVLT survived, suggesting that brain iron deposition in this region was linked to episodic memory impairment. Prior research noted that, compared to other cognitive domains, amyloid burden exhibits a stronger association with episodic memory.<xref rid="alz70710-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> Notably, voxel&#8208;wise multivariate linear regression revealed no associations between QSM values in temporal/hippocampal regions &#8211; areas of earliest AD involvement &#8211; and plasma A&#946;42 levels. This spatial dissociation suggests distinct patterns of iron&#8208;associated A&#946;42 aggregation in CSVD compared to classic AD pathology.</p><p>Although no association between voxel&#8208;wise QSM values and plasma pTau levels has been observed in the general population, subgroup analyses provide valuable insights. In the CSVD&#8208;M group, the QSM value of the left paracentral lobule positively correlates with plasma pTau181 levels. In the CSVD&#8208;S group, the QSM values of the right insula and right Rolandic operculum positively correlate with plasma pTau217 levels. Previous studies found that increased plasma levels of pTau181 and pTau217 correlated with a greater CSVD burden, including increased WMH volume, as well as a higher number of cerebral microbleeds and lacunes.<xref rid="alz70710-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="alz70710-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> In addition, plasma pTau181 and pTau217 levels reflect underlying tau pathology and amyloid plaque deposition.<xref rid="alz70710-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>, <xref rid="alz70710-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> When local tauopathy and amyloid accumulation occur, misfolded proteins induce neuroinflammation characterized by microglial clustering, iron deposition, and elevated ROS generation.<xref rid="alz70710-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> Subsequent ROS overproduction compromises cerebrovascular endothelial function through diminished nitric oxide (NO) bioavailability alongside enhanced platelet aggregation, leukocyte adhesion, and cellular apoptosis.<xref rid="alz70710-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>The progressive deterioration and dissemination of endothelial dysfunction consequently exacerbates CSVD severity.</p><p>Longitudinal studies indicate that, over approximately 2 years of follow&#8208;up, CSVD patients exhibit a significant increase in QSM values in the left putamen. Baseline plasma A&#946;40 concentrations show a positive correlation with QSM values in this region at follow&#8208;up, suggesting that higher A&#946;40 levels may predict future iron accumulation in the brain. Although cross&#8208;sectional studies have not identified a direct association, longitudinal data support a potential link between A&#946;40 and iron deposition. Mechanistically, elevated A&#946;40 concentrations may reflect more severe amyloid pathology, potentially leading to microglial activation, neuroinflammation, and iron deposition, which could ultimately result in oligodendrocyte damage and vascular endothelial cell injury.<xref rid="alz70710-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>, <xref rid="alz70710-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref> These findings align with previous research, which showed that higher plasma A&#946;40 levels were not only associated with more severe WMH volume, as well as increased numbers of lacunes and microbleeds in the brain, but also with the future progression of these lesions.<xref rid="alz70710-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="alz70710-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref>
</p><p>The primary strengths of this study include the inclusion of a large sample of community&#8208;dwelling CSVD individuals, ensuring a robust sample size; a comprehensive evaluation of neuroimaging, plasma biomarkers, and cognitive function, providing rich multidimensional data; and the adoption of a longitudinal follow&#8208;up design, which enabled the capture of temporal trends in disease progression. Additionally, the neuroimaging and plasma biomarker assessments were blinded to clinical data, minimizing data bias. Most notably, this study is the first to utilize QSM to assess regional iron deposition in CSVD patients, integrating plasma biomarkers and clinical cognitive function to uncover a potential link between iron accumulation and neurodegenerative protein metabolism. This finding enhances our understanding of the pathophysiological mechanisms underlying the onset and progression of CSVD and offers potential targets for future intervention strategies.</p><p>However, this study has several limitations. It did not include a healthy control group, instead categorizing participants into mild and severe CSVD groups based on total small vessel disease burden scores. This approach may underestimate the impact of CSVD on brain iron and plasma proteins due to potentially subtle differences in disease severity between groups. In addition, in the cross&#8208;sectional analysis of plasma biomarkers, the CSVD&#8208;S subgroup (<italic toggle="yes">n&#160;</italic>=&#160;41) had a substantially smaller sample size than the CSVD&#8208;M subgroup (<italic toggle="yes">n&#160;</italic>=&#160;137). This imbalance may reduce statistical sensitivity. As a single&#8208;center study conducted in a hospital&#8208;adjacent community population, sample bias may exist, potentially reducing statistical power. The long&#8208;term follow&#8208;up design resulted in some participants being unable to complete the entire study, which could further compromise the statistical power of the follow&#8208;up analysis. This study did not systematically collect records of participant medication use, including antidiabetic, antihypertensive, antimicrobial, and anti&#8208;inflammatory drugs. These medications may modulate the relationships observed between QSM values and biomarkers of neurodegeneration by counteracting free radical generation, neuroinflammation, A&#946; aggregation, and tau hyperphosphorylation.<xref rid="alz70710-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> While the current study employed rigorously controlled ELISA protocols to measure plasma biomarkers, this method may have limited sensitivity for detecting subtle concentration changes in low&#8208;abundance targets such as A&#946; isoforms and pTau variants (pTau 181/231/217). Emerging platforms (e.g., SIMOA, immunoprecipitation&#8208;mass spectrometry, single&#8208;molecule array and Meso Scale Discovery immunoassay platforms) demonstrate superior performance in quantifying such biomarkers.<xref rid="alz70710-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>, <xref rid="alz70710-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> This study could not adjust for participants' APOE genotype status. Given that APOE status is strongly associated with increased amyloid deposition and impaired clearance, future studies incorporating complete APOE genetic data would facilitate further interpretation of results. The longitudinal analyses in this study primarily reflect iron deposition dynamics in the CSVD&#8208;M subgroup. Definitive conclusions regarding the high&#8208;severity cohort (CSVD&#8208;S) remain limited by its underrepresentation in the follow&#8208;up sample (<italic toggle="yes">n</italic>&#160;=&#160;5). Future investigations should prioritize enlarging the high&#8208;severity subgroup cohort or establishing multicenter collaborations to achieve statistically robust analyses. In addition, recent evidence identifies blood neurofilament light chain (NfL) as a potential biomarker for CSVD burden and progression, mechanistically associated with acute/chronic neuroaxonal injury.<xref rid="alz70710-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> Future studies should incorporate NfL measurements to comprehensively elucidate multidimensional pathological processes in CSVD.</p></sec><sec sec-type="COI-statement" id="alz70710-sec-0330"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare that they have no conflicts of interest. Author disclosures are available in the <xref rid="alz70710-supinfo-0001" ref-type="">supporting information</xref>.</p></sec><sec id="alz70710-sec-0340"><title>CONSENT STATEMENT</title><p>All study procedures were approved by the Ethical Committee of the Institutional Review Board of Shandong Institute of Medical Imaging (2019&#8208;002). Informed consent was obtained from all participants, and the consent forms were securely stored.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70710-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70710-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70710-s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70710-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70710-s004.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70710-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70710-s003.tif" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70710-supitem-0004" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70710-s002.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70710-sec-0320"><title>ACKNOWLEDGMENTS</title><p>The authors express their deepest gratitude to Meng Li for his invaluable assistance in data post&#8208;processing and to Lingfei Guo for his substantial contributions to the manuscript revision. The authors are also immensely grateful to the clinical laboratory physicians for their meticulous work and expertise, which greatly enriched the quality of their study. Their heartfelt appreciation extends to all participants for their enthusiastic support. Finally, the authors sincerely acknowledge the unwavering dedication and hard work of our entire research team throughout this project. This work was funded by the Natural Science Foundation of China, Grant/Award Number: 82272072; Natural Science Foundation of Shandong Province, Grant/Award Numbers: ZR2020MH288, ZR2024MH026; Medical and Health Science and Technology Development Project of Shandong Province, Grant/Award Numbers: 202309010560, 202309010557. 202409010479; Technology Development Plan of Jinan, Grant/Award Number: 202328066; Shandong Province Medical System Employee Science and Technology Innovation Plan, Grant/Award Numbers: SDYWZGKCIH2023034, SDYWZGKCJH2024021.</p></ack><ref-list id="alz70710-bibl-0001"><title>REFERENCES</title><ref id="alz70710-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70710-cite-0002"><string-name name-style="western"><surname>Nam</surname><given-names>K&#8208;W</given-names></string-name>, <string-name name-style="western"><surname>Kwon</surname><given-names>H&#8208;M</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>J&#8208;S</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>M&#8208;K</given-names></string-name>, <string-name name-style="western"><surname>Nam</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>Y&#8208;S</given-names></string-name>. <article-title>The presence and severity of cerebral small vessel disease increases the frequency of stroke in a cohort of patients with large artery occlusive disease</article-title>. <source>PLoS ONE</source>. <year>2017</year>;<volume>12</volume>:<elocation-id>e0184944</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0184944</pub-id><pub-id pub-id-type="pmid">28991905</pub-id><pub-id pub-id-type="pmcid">PMC5633141</pub-id></mixed-citation></ref><ref id="alz70710-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70710-cite-0003"><string-name name-style="western"><surname>Gorelick</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Scuteri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Black</surname><given-names>SE</given-names></string-name>, et&#160;al. <article-title>Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association</article-title>. <source>Stroke</source>. <year>2011</year>;<volume>42</volume>:<fpage>2672</fpage>&#8208;<lpage>2713</lpage>. doi:<pub-id pub-id-type="doi">10.1161/str.0b013e3182299496</pub-id><pub-id pub-id-type="pmid">21778438</pub-id><pub-id pub-id-type="pmcid">PMC3778669</pub-id></mixed-citation></ref><ref id="alz70710-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70710-cite-0004"><string-name name-style="western"><surname>Pantoni</surname><given-names>L</given-names></string-name>. <article-title>Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges</article-title>. <source>The Lancet Neurology</source>. <year>2010</year>;<volume>9</volume>:<fpage>689</fpage>&#8208;<lpage>701</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(10)70104-6</pub-id><pub-id pub-id-type="pmid">20610345</pub-id></mixed-citation></ref><ref id="alz70710-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70710-cite-0005"><string-name name-style="western"><surname>Duering</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Biessels</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Brodtmann</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Neuroimaging standards for research into small vessel disease&#8212;advances since 2013</article-title>. <source>The Lancet Neurology</source>. <year>2023</year>;<volume>22</volume>:<fpage>602</fpage>&#8208;<lpage>618</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(23)00131-X</pub-id><pub-id pub-id-type="pmid">37236211</pub-id></mixed-citation></ref><ref id="alz70710-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70710-cite-0006"><string-name name-style="western"><surname>Ward</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Zucca</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Duyn</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Crichton</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Zecca</surname><given-names>L</given-names></string-name>. <article-title>The role of iron in brain ageing and neurodegenerative disorders</article-title>. <source>The Lancet Neurology</source>. <year>2014</year>;<volume>13</volume>:<fpage>1045</fpage>&#8208;<lpage>1060</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(14)70117-6</pub-id><pub-id pub-id-type="pmid">25231526</pub-id><pub-id pub-id-type="pmcid">PMC5672917</pub-id></mixed-citation></ref><ref id="alz70710-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70710-cite-0007"><string-name name-style="western"><surname>Das</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Raymick</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sarkar</surname><given-names>S</given-names></string-name>. <article-title>Role of metals in Alzheimer's disease</article-title>. <source>Metab Brain Dis</source>. <year>2021</year>;<volume>36</volume>:<fpage>1627</fpage>&#8208;<lpage>1639</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11011-021-00765-w</pub-id><pub-id pub-id-type="pmid">34313926</pub-id></mixed-citation></ref><ref id="alz70710-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70710-cite-0008"><string-name name-style="western"><surname>Reichenbach</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Schweser</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Serres</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Deistung</surname><given-names>A</given-names></string-name>. <article-title>Quantitative Susceptibility Mapping: concepts and applications</article-title>. <source>Clin Neuroradiol</source>. <year>2015</year>;<volume>25</volume>:<fpage>225</fpage>&#8208;<lpage>230</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00062-015-0432-9</pub-id><pub-id pub-id-type="pmid">26198880</pub-id></mixed-citation></ref><ref id="alz70710-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70710-cite-0009"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Spincemaille</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, et&#160;al. <article-title>Clinical quantitative susceptibility mapping (QSM): biometal imaging and its emerging roles in patient care</article-title>. <source>Magnetic Resonance Imaging</source>. <year>2017</year>;<volume>46</volume>:<fpage>951</fpage>&#8208;<lpage>971</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jmri.25693</pub-id><pub-id pub-id-type="pmcid">PMC5592126</pub-id><pub-id pub-id-type="pmid">28295954</pub-id></mixed-citation></ref><ref id="alz70710-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70710-cite-0010"><string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>T</given-names></string-name>. <article-title>Quantitative susceptibility mapping (QSM): decoding <sc>mri</sc> data for a tissue magnetic biomarker</article-title>. <source>Magnetic Resonance in Med</source>. <year>2015</year>;<volume>73</volume>:<fpage>82</fpage>&#8208;<lpage>101</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mrm.25358</pub-id><pub-id pub-id-type="pmcid">PMC4297605</pub-id><pub-id pub-id-type="pmid">25044035</pub-id></mixed-citation></ref><ref id="alz70710-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70710-cite-0011"><string-name name-style="western"><surname>Zheng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Nichol</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>Y&#8208;CN</given-names></string-name>, <string-name name-style="western"><surname>Haacke</surname><given-names>EM</given-names></string-name>. <article-title>Measuring iron in the brain using quantitative susceptibility mapping and x&#8208;ray fluorescence imaging</article-title>. <source>NeuroImage</source>. <year>2013</year>;<volume>78</volume>:<fpage>68</fpage>&#8208;<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.04.022</pub-id><pub-id pub-id-type="pmid">23591072</pub-id><pub-id pub-id-type="pmcid">PMC3843006</pub-id></mixed-citation></ref><ref id="alz70710-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70710-cite-0012"><string-name name-style="western"><surname>Chen</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Amyloid beta: structure, biology and structure&#8208;based therapeutic development</article-title>. <source>Acta Pharmacol Sin</source>. <year>2017</year>;<volume>38</volume>:<fpage>1205</fpage>&#8208;<lpage>1235</lpage>. doi:<pub-id pub-id-type="doi">10.1038/aps.2017.28</pub-id><pub-id pub-id-type="pmid">28713158</pub-id><pub-id pub-id-type="pmcid">PMC5589967</pub-id></mixed-citation></ref><ref id="alz70710-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70710-cite-0013"><string-name name-style="western"><surname>Abyadeh</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Paulo</surname><given-names>JA</given-names></string-name>, et&#160;al. <article-title>Amyloid&#8208;beta and tau protein beyond Alzheimer's disease</article-title>. <source>Neural Regeneration Research</source>. <year>2024</year>;<volume>19</volume>:<fpage>1262</fpage>&#8208;<lpage>1276</lpage>. doi:<pub-id pub-id-type="doi">10.4103/1673-5374.386406</pub-id><pub-id pub-id-type="pmid">37905874</pub-id><pub-id pub-id-type="pmcid">PMC11467936</pub-id></mixed-citation></ref><ref id="alz70710-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70710-cite-0014"><string-name name-style="western"><surname>Violet</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Delattre</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tardivel</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions</article-title>. <source>Front Cell Neurosci</source>. <year>2014</year>;<volume>8</volume>:<fpage>84</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fncel.2014.00084</pub-id><pub-id pub-id-type="pmid">24672431</pub-id><pub-id pub-id-type="pmcid">PMC3957276</pub-id></mixed-citation></ref><ref id="alz70710-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70710-cite-0015"><string-name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Stomrud</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Plasma &#946;&#8208;amyloid in Alzheimer's disease and vascular disease</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<elocation-id>26801</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/srep26801</pub-id><pub-id pub-id-type="pmid">27241045</pub-id><pub-id pub-id-type="pmcid">PMC4886210</pub-id></mixed-citation></ref><ref id="alz70710-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70710-cite-0016"><string-name name-style="western"><surname>Barth&#233;lemy</surname><given-names>NR</given-names></string-name>, <string-name name-style="western"><surname>Salvad&#243;</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Schindler</surname><given-names>SE</given-names></string-name>, et&#160;al. <article-title>Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests</article-title>. <source>Nat Med</source>. <year>2024</year>;<volume>30</volume>:<fpage>1085</fpage>&#8208;<lpage>1095</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-024-02869-z</pub-id><pub-id pub-id-type="pmid">38382645</pub-id><pub-id pub-id-type="pmcid">PMC11031399</pub-id></mixed-citation></ref><ref id="alz70710-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70710-cite-0017"><string-name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Barth&#233;lemy</surname><given-names>NR</given-names></string-name>, <string-name name-style="western"><surname>Salvad&#243;</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Plasma phosphorylated Tau 217 and A&#946;42/40 to predict early brain A&#946; accumulation in people without cognitive impairment</article-title>. <source>JAMA Neurol</source>. <year>2024</year>;<volume>81</volume>:<fpage>947</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2024.2619</pub-id><pub-id pub-id-type="pmid">39068669</pub-id><pub-id pub-id-type="pmcid">PMC11284634</pub-id></mixed-citation></ref><ref id="alz70710-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70710-cite-0018"><string-name name-style="western"><surname>Cisbani</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Maxan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kordower</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Planel</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Freeman</surname><given-names>TB</given-names></string-name>, <string-name name-style="western"><surname>Cicchetti</surname><given-names>F</given-names></string-name>. <article-title>Presence of tau pathology within foetal neural allografts in patients with Huntington's and Parkinson's disease</article-title>. <source>Brain</source>. <year>2017</year>;<volume>140</volume>:<fpage>2982</fpage>&#8208;<lpage>2992</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awx255</pub-id><pub-id pub-id-type="pmid">29069396</pub-id><pub-id pub-id-type="pmcid">PMC5841208</pub-id></mixed-citation></ref><ref id="alz70710-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70710-cite-0019"><string-name name-style="western"><surname>Jellinger</surname><given-names>KA</given-names></string-name>. <article-title>Alzheimer&#8208;type lesions in Huntington's disease</article-title>. <source>J Neural Transmission</source>. <year>1998</year>;<volume>105</volume>:<fpage>787</fpage>&#8208;<lpage>799</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s007020050095</pub-id><pub-id pub-id-type="pmid">9869319</pub-id></mixed-citation></ref><ref id="alz70710-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70710-cite-0020"><string-name name-style="western"><surname>Kotzbauer</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Cairns</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>MC</given-names></string-name>, et&#160;al. <article-title>Pathologic accumulation of &#945;&#8208;Synuclein and A&#946; in Parkinson disease patients with dementia</article-title>. <source>Arch Neurol</source>. <year>2012</year>;<volume>69</volume>:<fpage>1326</fpage>. doi:<pub-id pub-id-type="doi">10.1001/archneurol.2012.1608</pub-id><pub-id pub-id-type="pmid">22825369</pub-id><pub-id pub-id-type="pmcid">PMC3616136</pub-id></mixed-citation></ref><ref id="alz70710-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70710-cite-0021"><string-name name-style="western"><surname>Johnson</surname><given-names>VE</given-names></string-name>, <string-name name-style="western"><surname>Stewart</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>DH</given-names></string-name>. <article-title>Widespread Tau and Amyloid&#8208;Beta pathology many years after a single traumatic brain injury in humans</article-title>. <source>Brain Pathology</source>. <year>2012</year>;<volume>22</volume>:<fpage>142</fpage>&#8208;<lpage>149</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1750-3639.2011.00513.x</pub-id><pub-id pub-id-type="pmid">21714827</pub-id><pub-id pub-id-type="pmcid">PMC3979351</pub-id></mixed-citation></ref><ref id="alz70710-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70710-cite-0022"><string-name name-style="western"><surname>Malhotra</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Theodorou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Katsanos</surname><given-names>AH</given-names></string-name>, et&#160;al. <article-title>Prevalence of clinical and neuroimaging markers in cerebral amyloid angiopathy: a systematic review and meta&#8208;analysis</article-title>. <source>Stroke</source>. <year>2022</year>;<volume>53</volume>:<fpage>1944</fpage>&#8208;<lpage>1953</lpage>. doi:<pub-id pub-id-type="doi">10.1161/STROKEAHA.121.035836</pub-id><pub-id pub-id-type="pmid">35264008</pub-id></mixed-citation></ref><ref id="alz70710-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70710-cite-0023"><string-name name-style="western"><surname>Van Dijk</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Prins</surname><given-names>ND</given-names></string-name>, <string-name name-style="western"><surname>Vermeer</surname><given-names>SE</given-names></string-name>, et&#160;al. <article-title>Plasma amyloid &#946;, apolipoprotein E, lacunar infarcts, and white matter lesions</article-title>. <source>Annals of Neurology</source>. <year>2004</year>;<volume>55</volume>:<fpage>570</fpage>&#8208;<lpage>575</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.20050</pub-id><pub-id pub-id-type="pmid">15048897</pub-id></mixed-citation></ref><ref id="alz70710-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70710-cite-0024"><string-name name-style="western"><surname>Van Leijsen</surname><given-names>EMC</given-names></string-name>, <string-name name-style="western"><surname>Kuiperij</surname><given-names>HB</given-names></string-name>, <string-name name-style="western"><surname>Kersten</surname><given-names>I</given-names></string-name>, et&#160;al. <article-title>Plasma A&#946; (Amyloid&#8208;&#946;) levels and severity and progression of small vessel disease</article-title>. <source>Stroke</source>. <year>2018</year>;<volume>49</volume>:<fpage>884</fpage>&#8208;<lpage>890</lpage>. doi:<pub-id pub-id-type="doi">10.1161/STROKEAHA.117.019810</pub-id><pub-id pub-id-type="pmid">29540613</pub-id></mixed-citation></ref><ref id="alz70710-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70710-cite-0025"><collab collab-type="authors">for the Alzheimer's Disease Neuroimaging Initiative</collab>
, <string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>H&#8208;Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>H</given-names></string-name>, et&#160;al, <collab collab-type="authors">for the Alzheimer's Disease Neuroimaging Initiative</collab>
. <article-title>Cerebral small vessel disease burden predicts neurodegeneration and clinical progression in prodromal Alzheimer's disease</article-title>. <source>JAD</source>. <year>2023</year>;<volume>93</volume>:<fpage>283</fpage>&#8208;<lpage>294</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-221207</pub-id><pub-id pub-id-type="pmid">36970905</pub-id></mixed-citation></ref><ref id="alz70710-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70710-cite-0026"><string-name name-style="western"><surname>Didonna</surname><given-names>A</given-names></string-name>. <article-title>Tau at the interface between neurodegeneration and neuroinflammation</article-title>. <source>Genes Immun</source>. <year>2020</year>;<volume>21</volume>:<fpage>288</fpage>&#8208;<lpage>300</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41435-020-00113-5</pub-id><pub-id pub-id-type="pmid">33011744</pub-id></mixed-citation></ref><ref id="alz70710-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz70710-cite-0027"><string-name name-style="western"><surname>Wang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Rausch</surname><given-names>W&#8208;D</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>X</given-names></string-name>. <article-title>Iron Dyshomeostasis and Ferroptosis: a new Alzheimer's disease hypothesis?</article-title>. <source>Front Aging Neurosci</source>. <year>2022</year>;<volume>14</volume>:<elocation-id>830569</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2022.830569</pub-id><pub-id pub-id-type="pmid">35391749</pub-id><pub-id pub-id-type="pmcid">PMC8981915</pub-id></mixed-citation></ref><ref id="alz70710-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70710-cite-0028"><string-name name-style="western"><surname>Duering</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Biessels</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Brodtmann</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Neuroimaging standards for research into small vessel disease&#8212;advances since 2013</article-title>. <source>The Lancet Neurology</source>;<volume>22</volume>:<fpage>602</fpage>&#8208;<lpage>618</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(23)00131-X</pub-id><pub-id pub-id-type="pmid">37236211</pub-id></mixed-citation></ref><ref id="alz70710-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70710-cite-0029"><string-name name-style="western"><surname>Nasreddine</surname><given-names>ZS</given-names></string-name>, <string-name name-style="western"><surname>Phillips</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>B&#233;dirian</surname><given-names>V</given-names></string-name>, et&#160;al. <article-title>The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment</article-title>. <source>J American Geriatrics Society</source>. <year>2005</year>;<volume>53</volume>:<fpage>695</fpage>&#8208;<lpage>699</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1532-5415.2005.53221.x</pub-id><pub-id pub-id-type="pmid">15817019</pub-id></mixed-citation></ref><ref id="alz70710-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70710-cite-0030"><string-name name-style="western"><surname>Lee</surname><given-names>TMC</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>CCH</given-names></string-name>. <article-title>Stroop interference in Chinese and English</article-title>. <source>J Clin Experiment Neuropsychol</source>. <year>2000</year>;<volume>22</volume>:<fpage>465</fpage>&#8208;<lpage>471</lpage>. doi:<pub-id pub-id-type="doi">10.1076/1380-3395(200008)22:4;1-0;FT465</pub-id><pub-id pub-id-type="pmid">10923056</pub-id></mixed-citation></ref><ref id="alz70710-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70710-cite-0031"><string-name name-style="western"><surname>Bowie</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Harvey</surname><given-names>PD</given-names></string-name>. <article-title>Administration and interpretation of the Trail Making Test</article-title>. <source>Nat Protoc</source>. <year>2006</year>;<volume>1</volume>:<fpage>2277</fpage>&#8208;<lpage>2281</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nprot.2006.390</pub-id><pub-id pub-id-type="pmid">17406468</pub-id></mixed-citation></ref><ref id="alz70710-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70710-cite-0032"><string-name name-style="western"><surname>Silva</surname><given-names>PHR</given-names></string-name>, <string-name name-style="western"><surname>Spedo</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Barreira</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Leoni</surname><given-names>RF</given-names></string-name>. <article-title>Symbol Digit Modalities Test adaptation for magnetic resonance imaging environment: a systematic review and meta&#8208;analysis</article-title>. <source>Multiple Sclerosis and Related Disorders</source>. <year>2018</year>;<volume>20</volume>:<fpage>136</fpage>&#8208;<lpage>143</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.msard.2018.01.014</pub-id><pub-id pub-id-type="pmid">29414287</pub-id></mixed-citation></ref><ref id="alz70710-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70710-cite-0033"><string-name name-style="western"><surname>Klarenbeek</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Van Oostenbrugge</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Rouhl</surname><given-names>RPW</given-names></string-name>, <string-name name-style="western"><surname>Knottnerus</surname><given-names>ILH</given-names></string-name>, <string-name name-style="western"><surname>Staals</surname><given-names>J</given-names></string-name>. <article-title>Ambulatory blood pressure in patients with lacunar stroke: association with total MRI burden of cerebral small vessel disease</article-title>. <source>Stroke</source>. <year>2013</year>;<volume>44</volume>:<fpage>2995</fpage>&#8208;<lpage>2999</lpage>. doi:<pub-id pub-id-type="doi">10.1161/STROKEAHA.113.002545</pub-id><pub-id pub-id-type="pmid">23982717</pub-id></mixed-citation></ref><ref id="alz70710-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70710-cite-0034"><string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Spincemaille</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>. <article-title>MEDI+0: morphology enabled dipole inversion with automatic uniform cerebrospinal fluid zero reference for quantitative susceptibility mapping</article-title>. <source>Magnetic Resonance in Med</source>. <year>2018</year>;<volume>79</volume>:<fpage>2795</fpage>&#8208;<lpage>2803</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mrm.26946</pub-id><pub-id pub-id-type="pmcid">PMC5821583</pub-id><pub-id pub-id-type="pmid">29023982</pub-id></mixed-citation></ref><ref id="alz70710-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70710-cite-0035"><string-name name-style="western"><surname>Cusack</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Papadakis</surname><given-names>N</given-names></string-name>. <article-title>New Robust 3&#8208;D Phase Unwrapping Algorithms: application to magnetic field mapping and Undistorting Echoplanar Images</article-title>. <source>NeuroImage</source>. <year>2002</year>;<volume>16</volume>:<fpage>754</fpage>&#8208;<lpage>764</lpage>. doi:<pub-id pub-id-type="doi">10.1006/nimg.2002.1092</pub-id><pub-id pub-id-type="pmid">12169259</pub-id></mixed-citation></ref><ref id="alz70710-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70710-cite-0036"><string-name name-style="western"><surname>Liu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Khalidov</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>De Rochefort</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>A novel background field removal method for MRI using projection onto dipole fields (PDF)</article-title>. <source>NMR in Biomedicine</source>. <year>2011</year>;<volume>24</volume>:<fpage>1129</fpage>&#8208;<lpage>1136</lpage>. doi:<pub-id pub-id-type="doi">10.1002/nbm.1670</pub-id><pub-id pub-id-type="pmid">21387445</pub-id><pub-id pub-id-type="pmcid">PMC3628923</pub-id></mixed-citation></ref><ref id="alz70710-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70710-cite-0037"><string-name name-style="western"><surname>Ashburner</surname><given-names>J</given-names></string-name>. <article-title>A fast diffeomorphic image registration algorithm</article-title>. <source>Neuroimage</source>. <year>2007</year>;<volume>38</volume>:<fpage>95</fpage>&#8208;<lpage>113</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuroimage.2007.07.007</pub-id><pub-id pub-id-type="pmid">17761438</pub-id></mixed-citation></ref><ref id="alz70710-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz70710-cite-0038"><string-name name-style="western"><surname>Pengas</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>JMS</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>GB</given-names></string-name>, <string-name name-style="western"><surname>Nestor</surname><given-names>PJ</given-names></string-name>. <article-title>Comparative reliability of total intracranial volume estimation methods and the influence of atrophy in a longitudinal semantic dementia cohort</article-title>. <source>J Neuroimaging</source>. <year>2009</year>;<volume>19</volume>:<fpage>37</fpage>&#8208;<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1552-6569.2008.00246.x</pub-id><pub-id pub-id-type="pmid">18494772</pub-id></mixed-citation></ref><ref id="alz70710-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70710-cite-0039"><string-name name-style="western"><surname>Caplan</surname><given-names>LR</given-names></string-name>. <article-title>Lacunar infarction and small vessel disease: pathology and pathophysiology</article-title>. <source>J Stroke</source>. <year>2015</year>;<volume>17</volume>:<elocation-id>2</elocation-id>. doi:<pub-id pub-id-type="doi">10.5853/jos.2015.17.1.2</pub-id><pub-id pub-id-type="pmid">25692102</pub-id><pub-id pub-id-type="pmcid">PMC4325635</pub-id></mixed-citation></ref><ref id="alz70710-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz70710-cite-0040"><string-name name-style="western"><surname>Wardlaw</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dichgans</surname><given-names>M</given-names></string-name>. <article-title>Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging</article-title>. <source>The Lancet Neurology</source>. <year>2013</year>;<volume>12</volume>:<fpage>483</fpage>&#8208;<lpage>497</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(13)70060-7</pub-id><pub-id pub-id-type="pmid">23602162</pub-id><pub-id pub-id-type="pmcid">PMC3836247</pub-id></mixed-citation></ref><ref id="alz70710-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70710-cite-0041"><string-name name-style="western"><surname>Zhang</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Van De Haar</surname><given-names>HJ</given-names></string-name>, et&#160;al. <article-title>Blood&#8211;brain barrier leakage is more widespread in patients with cerebral small vessel disease</article-title>. <source>Neurology</source>. <year>2017</year>;<volume>88</volume>:<fpage>426</fpage>&#8208;<lpage>432</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000003556</pub-id><pub-id pub-id-type="pmid">28031395</pub-id></mixed-citation></ref><ref id="alz70710-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70710-cite-0042"><string-name name-style="western"><surname>Triarhou</surname><given-names>LC</given-names></string-name>. <article-title>Cytoarchitectonics of the Rolandic operculum: morphofunctional ponderings</article-title>. <source>Brain Struct Funct</source>. <year>2021</year>;<volume>226</volume>:<fpage>941</fpage>&#8208;<lpage>950</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00429-021-02258-z</pub-id><pub-id pub-id-type="pmid">33743075</pub-id></mixed-citation></ref><ref id="alz70710-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70710-cite-0043"><string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>T</given-names></string-name>. <article-title>Concurrent brain structural and functional alterations related to cognition in patients with cerebral small vessel disease</article-title>. <source>Neuroradiology</source>. <year>2025</year>;<volume>67</volume>(<issue>4</issue>):<fpage>833</fpage>&#8208;<lpage>844</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00234-025-03557-6</pub-id><pub-id pub-id-type="pmid">39937266</pub-id><pub-id pub-id-type="pmcid">PMC12041081</pub-id></mixed-citation></ref><ref id="alz70710-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70710-cite-0044"><string-name name-style="western"><surname>Yatawara</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ng</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Cristine Guevarra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Yong</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kandiah</surname><given-names>N</given-names></string-name>. <article-title>Small vessel disease and associations with cerebrospinal fluid Amyloid, Tau, and Neurodegeneration (ATN) biomarkers and cognition in young onset dementia</article-title>. <source>Journal of Alzheimer's Disease</source>. <year>2020</year>;<volume>77</volume>:<fpage>1305</fpage>&#8208;<lpage>1314</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-200311</pub-id><pub-id pub-id-type="pmid">32925034</pub-id></mixed-citation></ref><ref id="alz70710-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70710-cite-0045"><string-name name-style="western"><surname>Silvestri</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Camaschella</surname><given-names>C</given-names></string-name>. <article-title>A potential pathogenetic role of iron in Alzheimer's disease</article-title>. <source>J Cellular Molecular Medi</source>. <year>2008</year>;<volume>12</volume>:<fpage>1548</fpage>&#8208;<lpage>1550</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1582-4934.2008.00356.x</pub-id><pub-id pub-id-type="pmcid">PMC3918070</pub-id><pub-id pub-id-type="pmid">18466351</pub-id></mixed-citation></ref><ref id="alz70710-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz70710-cite-0046"><string-name name-style="western"><surname>Greenough</surname><given-names>MA</given-names></string-name>. <article-title>The role of presenilin in protein trafficking and degradation&#8212;implications for metal homeostasis</article-title>. <source>J Mol Neurosci</source>. <year>2016</year>;<volume>60</volume>:<fpage>289</fpage>&#8208;<lpage>297</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12031-016-0826-4</pub-id><pub-id pub-id-type="pmid">27558108</pub-id></mixed-citation></ref><ref id="alz70710-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz70710-cite-0047"><string-name name-style="western"><surname>Ha</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ryu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>CB</given-names></string-name>. <article-title>Metal ions differentially influence the aggregation and deposition of Alzheimer's &#946;&#8208;Amyloid on a solid template</article-title>. <source>Biochemistry</source>. <year>2007</year>;<volume>46</volume>:<fpage>6118</fpage>&#8208;<lpage>6125</lpage>. doi:<pub-id pub-id-type="doi">10.1021/bi7000032</pub-id><pub-id pub-id-type="pmid">17455909</pub-id></mixed-citation></ref><ref id="alz70710-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="alz70710-cite-0048"><string-name name-style="western"><surname>Gaasch</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Lockman</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Geldenhuys</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Allen</surname><given-names>DD</given-names></string-name>, <string-name name-style="western"><surname>Van</surname><given-names>Der</given-names></string-name>, <string-name name-style="western"><surname>Schyf</surname><given-names>CJ</given-names></string-name>. <article-title>Brain iron toxicity: differential Responses of Astrocytes, Neurons, and Endothelial Cells</article-title>. <source>Neurochem Res</source>. <year>2007</year>;<volume>32</volume>:<fpage>1196</fpage>&#8208;<lpage>1208</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11064-007-9290-4</pub-id><pub-id pub-id-type="pmid">17404839</pub-id></mixed-citation></ref><ref id="alz70710-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="alz70710-cite-0049"><string-name name-style="western"><surname>Tian</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>LZ</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>W</given-names></string-name>. <article-title>Progress of ferroptosis in ischemic stroke and therapeutic targets</article-title>. <source>Cell Mol Neurobiol</source>. <year>2024</year>;<volume>44</volume>:<fpage>25</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s10571-024-01457-6</pub-id><pub-id pub-id-type="pmid">38393376</pub-id><pub-id pub-id-type="pmcid">PMC10891262</pub-id></mixed-citation></ref><ref id="alz70710-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="alz70710-cite-0050"><string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Structural changes in the lobar regions of brain in cerebral small&#8208;vessel disease patients with and without cognitive impairment: an MRI&#8208;based study with automated brain volumetry</article-title>. <source>European Journal of Radiology</source>. <year>2020</year>;<volume>126</volume>:<elocation-id>108967</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.ejrad.2020.108967</pub-id><pub-id pub-id-type="pmid">32268244</pub-id></mixed-citation></ref><ref id="alz70710-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="alz70710-cite-0051"><string-name name-style="western"><surname>Hedden</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Younger</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>TA</given-names></string-name>. <article-title>Meta&#8208;analysis of amyloid&#8208;cognition relations in cognitively normal older adults</article-title>. <source>Neurology</source>. <year>2013</year>;<volume>80</volume>:<fpage>1341</fpage>&#8208;<lpage>1348</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0b013e31828ab35d</pub-id><pub-id pub-id-type="pmid">23547267</pub-id><pub-id pub-id-type="pmcid">PMC3656457</pub-id></mixed-citation></ref><ref id="alz70710-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="alz70710-cite-0052"><string-name name-style="western"><surname>Sanchez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Coughlan</surname><given-names>GT</given-names></string-name>, <string-name name-style="western"><surname>Wilkinson</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Association of plasma biomarkers with longitudinal atrophy and microvascular burden on MRI across neurodegenerative and cerebrovascular diseases</article-title>. <source>Neurology</source>. <year>2025</year>;<volume>104</volume>:<elocation-id>e213438</elocation-id>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000213438</pub-id><pub-id pub-id-type="pmid">40063856</pub-id></mixed-citation></ref><ref id="alz70710-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="alz70710-cite-0053"><string-name name-style="western"><surname>Hsieh</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tsai</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Plasma Phosphorylated Tau 217 as a Discriminative Biomarker for Cerebral Amyloid Angiopathy</article-title>. <source>Euro J of Neurology</source>. <year>2025</year>;<volume>32</volume>:<elocation-id>e70066</elocation-id>. doi:<pub-id pub-id-type="doi">10.1111/ene.70066</pub-id><pub-id pub-id-type="pmcid">PMC11795418</pub-id><pub-id pub-id-type="pmid">39907306</pub-id></mixed-citation></ref><ref id="alz70710-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="alz70710-cite-0054"><string-name name-style="western"><surname>Karikari</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Pascoal</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></string-name>, et&#160;al. <article-title>Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts</article-title>. <source>The Lancet Neurology</source>. <year>2020</year>;<volume>19</volume>:<fpage>422</fpage>&#8208;<lpage>433</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(20)30071-5</pub-id><pub-id pub-id-type="pmid">32333900</pub-id></mixed-citation></ref><ref id="alz70710-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="alz70710-cite-0055"><string-name name-style="western"><surname>Thijssen</surname><given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>La Joie</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Strom</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study</article-title>. <source>The Lancet Neurology</source>. <year>2021</year>;<volume>20</volume>:<fpage>739</fpage>&#8208;<lpage>752</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s1474-4422(21)00214-3</pub-id><pub-id pub-id-type="pmid">34418401</pub-id><pub-id pub-id-type="pmcid">PMC8711249</pub-id></mixed-citation></ref><ref id="alz70710-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="alz70710-cite-0056"><string-name name-style="western"><surname>Dusek</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hofer</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Alexander</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Roos</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Aaseth</surname><given-names>JO</given-names></string-name>. <article-title>Cerebral iron deposition in neurodegeneration</article-title>. <source>Biomolecules</source>. <year>2022</year>;<volume>12</volume>:<fpage>714</fpage>. doi:<pub-id pub-id-type="doi">10.3390/biom12050714</pub-id><pub-id pub-id-type="pmid">35625641</pub-id><pub-id pub-id-type="pmcid">PMC9138489</pub-id></mixed-citation></ref><ref id="alz70710-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="alz70710-cite-0057"><string-name name-style="western"><surname>Montezano</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Touyz</surname><given-names>RM</given-names></string-name>. <article-title>Reactive oxygen species and endothelial function &#8211; role of nitric oxide synthase uncoupling and Nox Family Nicotinamide Adenine Dinucleotide Phosphate Oxidases</article-title>. <source>Basic Clin Pharma Tox</source>. <year>2012</year>;<volume>110</volume>:<fpage>87</fpage>&#8208;<lpage>94</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1742-7843.2011.00785.x</pub-id><pub-id pub-id-type="pmid">21883939</pub-id></mixed-citation></ref><ref id="alz70710-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="alz70710-cite-0058"><string-name name-style="western"><surname>Lloret</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Esteve</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lloret</surname><given-names>MA</given-names></string-name>, et&#160;al. <article-title>Is oxidative stress the link between cerebral small vessel disease, sleep disruption, and oligodendrocyte dysfunction in the onset of Alzheimer's disease?</article-title>. <source>Front Physiol</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>708061</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fphys.2021.708061</pub-id><pub-id pub-id-type="pmid">34512381</pub-id><pub-id pub-id-type="pmcid">PMC8424010</pub-id></mixed-citation></ref><ref id="alz70710-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="alz70710-cite-0059"><string-name name-style="western"><surname>Hilal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Akoudad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Van Duijn</surname><given-names>CM</given-names></string-name>, et&#160;al. <article-title>Plasma Amyloid&#8208;&#946; levels, cerebral small vessel disease, and cognition: the Rotterdam Study</article-title>. <source>JAD</source>. <year>2017</year>;<volume>60</volume>:<fpage>977</fpage>&#8208;<lpage>987</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-170458</pub-id><pub-id pub-id-type="pmid">28984600</pub-id></mixed-citation></ref><ref id="alz70710-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="alz70710-cite-0060"><string-name name-style="western"><surname>Pattanaik</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ghose</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pakeeraiah</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Paidesetty</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Prusty</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Sahu</surname><given-names>PK</given-names></string-name>. <article-title>Repurposing drugs: promising therapeutic approach against Alzheimer's disease</article-title>. <source>Ageing Research Reviews</source>. <year>2025</year>;<volume>106</volume>:<elocation-id>102698</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.arr.2025.102698</pub-id><pub-id pub-id-type="pmid">39993451</pub-id></mixed-citation></ref><ref id="alz70710-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="alz70710-cite-0061"><string-name name-style="western"><surname>Song</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lachno</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Hanlon</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>A digital enzyme&#8208;linked immunosorbent assay for ultrasensitive measurement of amyloid&#8208;&#946; 1&#8208;42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics</article-title>. <source>Alz Res Therapy</source>. <year>2016</year>;<volume>8</volume>. doi:<pub-id pub-id-type="doi">10.1186/s13195-016-0225-7</pub-id><pub-id pub-id-type="pmcid">PMC5160015</pub-id><pub-id pub-id-type="pmid">27978855</pub-id></mixed-citation></ref><ref id="alz70710-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="alz70710-cite-0062"><string-name name-style="western"><surname>Chong</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Karikari</surname><given-names>TK</given-names></string-name>, et&#160;al. <article-title>Blood&#8208;based high sensitivity measurements of beta&#8208;amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2021</year>;<volume>92</volume>:<fpage>1231</fpage>&#8208;<lpage>1241</lpage>. doi:<pub-id pub-id-type="doi">10.1136/jnnp-2021-327370</pub-id><pub-id pub-id-type="pmid">34510001</pub-id></mixed-citation></ref><ref id="alz70710-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="alz70710-cite-0063"><string-name name-style="western"><surname>Qu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>C&#8208;C</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>X&#8208;N</given-names></string-name>, et&#160;al. <article-title>Association of plasma Neurofilament Light with small vessel disease burden in nondemented elderly: a Longitudinal Study</article-title>. <source>Stroke</source>. <year>2021</year>;<volume>52</volume>:<fpage>896</fpage>&#8208;<lpage>904</lpage>. doi:<pub-id pub-id-type="doi">10.1161/strokeaha.120.030302</pub-id><pub-id pub-id-type="pmid">33517704</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz70752" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12481164</article-id><article-id pub-id-type="pmcid-ver">PMC12481164.1</article-id><article-id pub-id-type="pmcaid">12481164</article-id><article-id pub-id-type="pmcaiid">12481164</article-id><article-id pub-id-type="pmid">41025225</article-id><article-id pub-id-type="doi">10.1002/alz.70752</article-id><article-id pub-id-type="publisher-id">ALZ70752</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Evidence&#8208;based standardized sample handling protocol for accurate blood&#8208;based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium</article-title><alt-title alt-title-type="left-running-head">VERBERK <sc>et&#160;al</sc>.</alt-title></title-group><contrib-group><contrib id="alz70752-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Verberk</surname><given-names initials="IMW">Inge M. W.</given-names></name><xref rid="alz70752-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>i.verberk@amsterdamumc.nl</email></address></contrib><contrib id="alz70752-cr-0002" contrib-type="author" corresp="yes"><name name-style="western"><surname>Gouda</surname><given-names initials="M">Mariam</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-4187-3131</contrib-id><xref rid="alz70752-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>m.m.t.e.e.gouda@amsterdamumc.nl</email></address></contrib><contrib id="alz70752-cr-0003" contrib-type="author"><name name-style="western"><surname>Antwi&#8208;Berko</surname><given-names initials="D">Daniel</given-names></name><xref rid="alz70752-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70752-cr-0004" contrib-type="author"><name name-style="western"><surname>van Leeuwenstijn</surname><given-names initials="M">Mardou</given-names></name><xref rid="alz70752-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz70752-cr-0005" contrib-type="author"><name name-style="western"><surname>Bongers</surname><given-names initials="B">Bram</given-names></name><xref rid="alz70752-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz70752-cr-0006" contrib-type="author"><name name-style="western"><surname>Houtkamp</surname><given-names initials="IM">Isabel M.</given-names></name><xref rid="alz70752-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz70752-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz70752-cr-0007" contrib-type="author"><name name-style="western"><surname>van der Flier</surname><given-names initials="WM">Wiesje M.</given-names></name><xref rid="alz70752-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="alz70752-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="alz70752-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz70752-cr-0008" contrib-type="author"><name name-style="western"><surname>Janelidze</surname><given-names initials="S">Shorena</given-names></name><xref rid="alz70752-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="alz70752-cr-0009" contrib-type="author"><name name-style="western"><surname>Hansson</surname><given-names initials="O">Oskar</given-names></name><xref rid="alz70752-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="alz70752-cr-0010" contrib-type="author"><name name-style="western"><surname>Bastard</surname><given-names initials="NL">Nathalie Le</given-names></name><xref rid="alz70752-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="alz70752-cr-0011" contrib-type="author"><name name-style="western"><surname>Vandijck</surname><given-names initials="M">Manu</given-names></name><xref rid="alz70752-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="alz70752-cr-0012" contrib-type="author"><name name-style="western"><surname>Hunter</surname><given-names initials="J">Jacob</given-names></name><xref rid="alz70752-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="alz70752-cr-0013" contrib-type="author"><name name-style="western"><surname>Honigberg</surname><given-names initials="L">Lee</given-names></name><xref rid="alz70752-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="alz70752-cr-0014" contrib-type="author"><name name-style="western"><surname>Kirmess</surname><given-names initials="KM">Kristopher M.</given-names></name><xref rid="alz70752-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="alz70752-cr-0015" contrib-type="author"><name name-style="western"><surname>Verghese</surname><given-names initials="PB">Philip B.</given-names></name><xref rid="alz70752-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="alz70752-cr-0016" contrib-type="author"><name name-style="western"><surname>Blennow</surname><given-names initials="K">Kaj</given-names></name><xref rid="alz70752-aff-0010" ref-type="aff">
<sup>10</sup>
</xref><xref rid="alz70752-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="alz70752-cr-0017" contrib-type="author"><name name-style="western"><surname>Zetterberg</surname><given-names initials="H">Henrik</given-names></name><xref rid="alz70752-aff-0010" ref-type="aff">
<sup>10</sup>
</xref><xref rid="alz70752-aff-0011" ref-type="aff">
<sup>11</sup>
</xref><xref rid="alz70752-aff-0012" ref-type="aff">
<sup>12</sup>
</xref><xref rid="alz70752-aff-0013" ref-type="aff">
<sup>13</sup>
</xref><xref rid="alz70752-aff-0014" ref-type="aff">
<sup>14</sup>
</xref><xref rid="alz70752-aff-0015" ref-type="aff">
<sup>15</sup>
</xref><xref rid="alz70752-aff-0016" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib id="alz70752-cr-0018" contrib-type="author"><name name-style="western"><surname>Meyers</surname><given-names initials="EA">Emily A.</given-names></name><xref rid="alz70752-aff-0017" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib id="alz70752-cr-0019" contrib-type="author"><name name-style="western"><surname>Edelmayer</surname><given-names initials="RM">Rebecca M.</given-names></name><xref rid="alz70752-aff-0017" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib id="alz70752-cr-0020" contrib-type="author"><name name-style="western"><surname>Teunissen</surname><given-names initials="C">Charlotte</given-names></name><xref rid="alz70752-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="alz70752-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Neurochemistry Laboratory</named-content>
<named-content content-type="organisation-division">Laboratory Medicine</named-content>
<named-content content-type="organisation-division">Amsterdam UMC</named-content>
<institution>Vrije Universiteit Amsterdam</institution>
<institution>Amsterdam Neuroscience</institution>
<city>Amsterdam</city>
<country country="NL">the Netherlands</country>
</aff><aff id="alz70752-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Alzheimer Center Amsterdam</named-content>
<named-content content-type="organisation-division">Neurology</named-content>
<institution>Vrije Universiteit Amsterdam</institution>
<institution>Amsterdam UMC location VUmc</institution>
<city>Amsterdam</city>
<country country="NL">the Netherlands</country>
</aff><aff id="alz70752-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Computing and Information Sciences</named-content>
<named-content content-type="organisation-division">Department of Biology</named-content>
<named-content content-type="organisation-division">AI Technology for Life</named-content>
<institution>Utrecht University</institution>
<city>Utrecht</city>
<country country="NL">the Netherlands</country>
</aff><aff id="alz70752-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Amsterdam Neuroscience</named-content>
<institution>Neurodegeneration</institution>
<city>Amsterdam</city>
<country country="NL">the Netherlands</country>
</aff><aff id="alz70752-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Epidemiology and Data Science</named-content>
<institution>Vrije Universiteit Amsterdam</institution>
<institution>Amsterdam UMC location VUmc</institution>
<city>Amsterdam</city>
<country country="NL">the Netherlands</country>
</aff><aff id="alz70752-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Sciences</named-content>
<named-content content-type="organisation-division">Clinical Memory Research Unit</named-content>
<institution>Lund University</institution>
<city>Lund</city>
<country country="SE">Sweden</country>
</aff><aff id="alz70752-aff-0007">
<label>
<sup>7</sup>
</label>
<institution>Fuijirebio Europe N.V.</institution>
<city>Ghent</city>
<country country="BE">Belgium</country>
</aff><aff id="alz70752-aff-0008">
<label>
<sup>8</sup>
</label>
<institution>ALZpath</institution>
<city>Carlsbad</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="alz70752-aff-0009">
<label>
<sup>9</sup>
</label>
<institution>C2N Diagnostics LLC</institution>
<city>St Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><aff id="alz70752-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Institute of Neuroscience and Physiology</named-content>
<institution>Sahlgrenska Academy at the University of Gothenburg</institution>
<city>Gothenburg</city>
<country country="SE">Sweden</country>
</aff><aff id="alz70752-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Clinical Neurochemistry Laboratory</named-content>
<institution>Sahlgrenska University Hospital</institution>
<city>M&#246;lndal</city>
<country country="SE">Sweden</country>
</aff><aff id="alz70752-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Department of Neurodegenerative Disease</named-content>
<institution>UCL Institute of Neurology</institution>
<institution>Queen Square</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="alz70752-aff-0013">
<label>
<sup>13</sup>
</label>
<named-content content-type="organisation-division">UK Dementia Research Institute</named-content>
<institution>UCL</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="alz70752-aff-0014">
<label>
<sup>14</sup>
</label>
<named-content content-type="organisation-division">Hong Kong Center for Neurodegenerative Diseases</named-content>
<institution>InnoHK</institution>
<city>Hong Kong</city>
<country country="CN">China</country>
</aff><aff id="alz70752-aff-0015">
<label>
<sup>15</sup>
</label>
<named-content content-type="organisation-division">Wisconsin Alzheimer's Disease Research Center</named-content>
<institution>University of Wisconsin School of Medicine and Public Health</institution>
<institution>University of Wisconsin&#8208;Madison</institution>
<city>Madison</city>
<named-content content-type="country-part">Wisconsin</named-content>
<country country="US">USA</country>
</aff><aff id="alz70752-aff-0016">
<label>
<sup>16</sup>
</label>
<named-content content-type="organisation-division">Centre for Brain Research</named-content>
<institution>Indian Institute of Science</institution>
<city>Bangalore</city>
<country country="IN">India</country>
</aff><aff id="alz70752-aff-0017">
<label>
<sup>17</sup>
</label>
<institution>Alzheimer's Association</institution>
<city>Chicago</city>
<named-content content-type="country-part">Illinois</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Inge M.W. Verberk and Mariam Gouda, Neurochemistry Laboratory, Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.<break/> Email: <email>i.verberk@amsterdamumc.nl</email> and <email>m.m.t.e.e.gouda@amsterdamumc.nl</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><volume>21</volume><issue seq="270">10</issue><issue-id pub-id-type="pmc-issue-id">497699</issue-id><issue-id pub-id-type="doi">10.1002/alz.v21.10</issue-id><elocation-id>e70752</elocation-id><history><date date-type="rev-recd"><day>01</day><month>9</month><year>2025</year></date><date date-type="received"><day>04</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>02</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 00:25:23.493"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-21-e70752.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-21-e70752.pdf"/><abstract><title>Abstract</title><sec id="alz70752-sec-0010"><title>INTRODUCTION</title><p>Blood&#8208;based biomarkers (BBMs) have revolutionized Alzheimer's disease diagnosis and monitoring. Their pre&#8208;analytical stability requires scrutiny. This study assessed pre&#8208;analytical effects to inform a standardized sample handling protocol.</p></sec><sec id="alz70752-sec-0020"><title>METHODS</title><p>Assessed pre&#8208;analytical variations included collection tube type, hemolysis, centrifugation settings, centrifugation/storage delays, tube transfers, and freeze&#8208;thawing (<italic toggle="yes">n</italic>&#160;=&#160;15/experiment). Phosphorylated tau (pTau) isoforms were measured with Simoa, Lumipulse, MesoScale Discovery, and immunoprecipitation&#8208;mass spectrometry. Amyloid&#8208;beta (A&#946;42, A&#946;40), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) protein were measured with Simoa.</p></sec><sec id="alz70752-sec-0030"><title>RESULTS</title><p>All assessed BBM levels varied&#160;by over&#160;10% by collection tube type. A&#946; peptides were the most sensitive, and their levels declined&#160;&gt;by more than&#160;10% under storage and centrifugation delays, more steeply at room temperature (RT) compared with 2&#176;C to 8&#176;C. NfL and GFAP levels increased by more than&#160;10% upon RT/&#8722;20&#176;C storage. pTau isoforms demonstrated stability across most pre&#8208;analytical variations.</p></sec><sec id="alz70752-sec-0040"><title>DISCUSSION</title><p>We established an evidence&#8208;based handling protocol to ensure reliable sample handling for neurological BBMs upon adoption in clinics, trials, and research.</p></sec><sec id="alz70752-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz70752-list-0001"><list-item><p>Sample handling protocols can mitigate pre&#8208;analytical effects on BBM results.</p></list-item><list-item><p>We developed an evidence&#8208;based, expert&#8208;consensus plasma sample handling protocol.</p></list-item><list-item><p>Primary collection tube and delays to centrifuging or freezing impact AD BBMs.</p></list-item><list-item><p>Plasma pTau217 is highly resistant to pre&#8208;analytical sample handling variations.</p></list-item><list-item><p>Plasma A&#946;42 and A&#946;40 were most sensitive to pre&#8208;analytical variations.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz70752-kwd-0001">amyloid beta</kwd><kwd id="alz70752-kwd-0002">glial fibrillary acidic protein</kwd><kwd id="alz70752-kwd-0003">neurofilament light</kwd><kwd id="alz70752-kwd-0004">phosphorylated tau</kwd><kwd id="alz70752-kwd-0005">plasma biomarkers</kwd><kwd id="alz70752-kwd-0006">pre&#8208;analytical variability</kwd><kwd id="alz70752-kwd-0007">pre&#8208;analytics</kwd><kwd id="alz70752-kwd-0008">sample handling</kwd><kwd id="alz70752-kwd-0009">stability</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>research grants of Health Holland and ZonMW</institution></institution-wrap></funding-source></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Pasman Stichting. Research of Alzheimer Center Amsterdam</institution></institution-wrap></funding-source></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Stichting Alzheimer Nederland and Stichting Steun Alzheimercentrum Amsterdam</institution></institution-wrap></funding-source></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Swedish Research Council</institution><institution-id institution-id-type="doi">10.13039/501100004359</institution-id></institution-wrap></funding-source><award-id>2017&#8208;00915</award-id><award-id>2022&#8208;00732</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>Swedish Alzheimer Foundation</institution></institution-wrap></funding-source><award-id>AF&#8208;930351</award-id><award-id>AF&#8208;939721</award-id><award-id>AF&#8208;968270</award-id><award-id>AF&#8208;994551</award-id></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>Hj&#228;rnfonden, Sweden</institution></institution-wrap></funding-source><award-id>ALZ2022&#8208;0006</award-id><award-id>FO2024&#8208;0048&#8208;TK&#8208;130</award-id><award-id>FO2024&#8208;0048&#8208;HK&#8208;24</award-id></award-group><award-group id="funding-0007"><funding-source><institution-wrap><institution>European Union Joint Program for Neurodegenerative Disorders</institution></institution-wrap></funding-source></award-group><award-group id="funding-0008"><funding-source><institution-wrap><institution>Alzheimer's Association 2021 Zenith Award</institution></institution-wrap></funding-source></award-group><award-group id="funding-0009"><funding-source><institution-wrap><institution>La Fondation Recherche Alzheimer (FRA)</institution></institution-wrap></funding-source></award-group><award-group id="funding-0010"><funding-source><institution-wrap><institution>Kirsten and Freddy Johansen Foundation</institution></institution-wrap></funding-source></award-group><award-group id="funding-0011"><funding-source><institution-wrap><institution>Swedish State Support for Clinical Research</institution></institution-wrap></funding-source></award-group><award-group id="funding-0012"><funding-source><institution-wrap><institution>AD Strategic Fund and the Alzheimer's Association</institution></institution-wrap></funding-source><award-id>ADSF&#8208;21&#8208;831376&#8208;C</award-id><award-id>ADSF&#8208;21&#8208;831381&#8208;C</award-id><award-id>ADSF&#8208;21&#8208;831377&#8208;C</award-id><award-id>ADSF&#8208;24&#8208;1284328&#8208;C</award-id></award-group><award-group id="funding-0013"><funding-source><institution-wrap><institution>the European Partnership on Metrology</institution></institution-wrap></funding-source></award-group><award-group id="funding-0014"><funding-source><institution-wrap><institution>Cure Alzheimer's Fund</institution><institution-id institution-id-type="doi">10.13039/100007625</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0015"><funding-source><institution-wrap><institution>Olav Thon Foundation, the Erling&#8208;Persson Family Foundation</institution></institution-wrap></funding-source></award-group><award-group id="funding-0016"><funding-source><institution-wrap><institution>Familjen R&#246;nstr&#246;ms Stiftelse</institution></institution-wrap></funding-source></award-group><award-group id="funding-0017"><funding-source><institution-wrap><institution>Familjen Beiglers Stiftelse</institution></institution-wrap></funding-source></award-group><award-group id="funding-0018"><funding-source><institution-wrap><institution>Stiftelsen f&#246;r Gamla Tj&#228;narinnor</institution><institution-id institution-id-type="doi">10.13039/100010815</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0019"><funding-source><institution-wrap><institution>Marie Sk&#322;odowska&#8208;Curie</institution></institution-wrap></funding-source><award-id>860197</award-id></award-group><award-group id="funding-0020"><funding-source><institution-wrap><institution>European Union Joint Programme &#8211; Neurodegenerative Disease Research</institution></institution-wrap></funding-source><award-id>JPND2021&#8208;00694</award-id></award-group><award-group id="funding-0021"><funding-source><institution-wrap><institution>National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre</institution></institution-wrap></funding-source></award-group><award-group id="funding-0022"><funding-source><institution-wrap><institution>European Commission (Marie Curie International Training Network</institution></institution-wrap></funding-source><award-id>860197 (MIRIADE</award-id><award-id>101119596</award-id></award-group><award-group id="funding-0023"><funding-source><institution-wrap><institution>Innovative Medicines Initiatives 3TR</institution></institution-wrap></funding-source></award-group><award-group id="funding-0024"><funding-source><institution-wrap><institution>(bPRIDE, CCAD), European Partnership on Metrology</institution></institution-wrap></funding-source></award-group><award-group id="funding-0025"><funding-source><institution-wrap><institution>European Union's Horizon Europe Research and Innovation Programme</institution></institution-wrap></funding-source><award-id>101053962</award-id><award-id>101053962</award-id></award-group><award-group id="funding-0026"><funding-source><institution-wrap><institution>the Alzheimer Drug Discovery Foundation</institution></institution-wrap></funding-source><award-id>201809&#8208;2016862</award-id></award-group><award-group id="funding-0027"><funding-source><institution-wrap><institution>Michael J. Fox Foundation</institution><institution-id institution-id-type="doi">10.13039/100000864</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0028"><funding-source><institution-wrap><institution>Health Holland, the Dutch Research Council (ZonMW)</institution></institution-wrap></funding-source></award-group><award-group id="funding-0029"><funding-source><institution-wrap><institution>Alzheimer Drug Discovery Foundation</institution></institution-wrap></funding-source></award-group><award-group id="funding-0030"><funding-source><institution-wrap><institution>Selfridges Group Foundation</institution><institution-id institution-id-type="doi">10.13039/501100022692</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0031"><funding-source><institution-wrap><institution>Alzheimer Netherlands</institution><institution-id institution-id-type="doi">10.13039/501100010969</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0032"><funding-source><institution-wrap><institution>Health Holland</institution></institution-wrap></funding-source></award-group><award-group id="funding-0033"><funding-source><institution-wrap><institution>Topsector Life Sciences &amp; Health</institution></institution-wrap></funding-source><award-id>LSHM20106</award-id></award-group><award-group id="funding-0034"><funding-source><institution-wrap><institution>Dutch National Dementia Strategy</institution></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="0"/><page-count count="16"/><word-count count="9387"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:30.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz70752-cite-0001"><string-name name-style="western"><surname>Verberk</surname><given-names>IMW</given-names></string-name>, <string-name name-style="western"><surname>Gouda</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Antwi&#8208;Berko</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Evidence&#8208;based standardized sample handling protocol for accurate blood&#8208;based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium</article-title>. <source>Alzheimer's Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70752</elocation-id>. <pub-id pub-id-type="doi">10.1002/alz.70752</pub-id><pub-id pub-id-type="pmid">41025225</pub-id><pub-id pub-id-type="pmcid">PMC12481164</pub-id></mixed-citation>
</p><fn-group><fn id="alz70752-note-0001"><p>Inge M. W. Verberk and Mariam Gouda shared first authorship.</p></fn></fn-group></notes></front><body><sec id="alz70752-sec-0060"><label>1</label><title>BACKGROUND</title><p>Blood&#8208;based biomarkers (BBMs) are revolutionizing Alzheimer's disease (AD) research and diagnostics.<xref rid="alz70752-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70752-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> They are minimally invasive, accessible, cost&#8208;effective, sustainable, and potentially reliable alternatives to the current diagnostic biomarker methods: positron emission tomography (PET) scans and cerebrospinal fluid (CSF) biomarker analysis.<xref rid="alz70752-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70752-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> With the introduction of anti&#8208;amyloid disease&#8208;targeting treatments, there is an essential need to incorporate BBMs into clinical practice to meet the increased demand for AD biomarker assessment and monitoring.<xref rid="alz70752-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70752-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>The recently revised AD diagnosis and staging criteria of the Alzheimer's Association workgroup incorporated the following BBMs into their framework: core AD BBMs are amyloid beta1&#8208;42/amyloid beta1&#8208;40 (A&#946;42/A&#946;40) ratio, phosphorylated mid&#8208;region tau (pTau) variants (pTau181, pTau217, pTau231), and pTau/A&#946;42 ratio.<xref rid="alz70752-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> These BBMs reflect amyloid and early tau proteinopathy.<xref rid="alz70752-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Non&#8208;core BBMs neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) reflect neurodegeneration and astrocyte reactivity, which are important pathogenic processes that play a role in AD,<xref rid="alz70752-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> as well as in other neurological diseases (e.g., frontotemporal dementia, multiple sclerosis).<xref rid="alz70752-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="alz70752-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> These core and non&#8208;core BBMs may be used in clinical practice if the plasma assays achieve acceptable performance criteria.<xref rid="alz70752-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="alz70752-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Specifically, plasma pTau217 assays that meet acceptable accuracy standards, potentially in combination with other core or non&#8208;core plasma biomarkers, could be used for the diagnosis of AD.<xref rid="alz70752-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="alz70752-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Numerous studies show that the diagnostic performance of plasma pTau217 might be comparable to that of the gold standard CSF AD biomarkers and amyloid PET.</p><p>The widespread clinical validation and adoption of the AD&#8208;related BBM assays can be hindered by variability in pre&#8208;analytical sample handling, as this can substantially affect BBM levels and consequently their diagnostic accuracy.<xref rid="alz70752-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="alz70752-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> There is considerable variability in sample handling across AD biobank studies.<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Through collaboration with the Alzheimer's Association, we therefore published an initial evidence&#8208;based sample handling protocol to mitigate any pre&#8208;analytical sample handling effect on BBM measurements, which at that time was primarily based on A&#946;42 and A&#946;40 measurement stability.<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Among the AD&#8208;related BBMs previously assessed, A&#946;42 and A&#946;40 measurements appeared most susceptible to sample handling variations, particularly for centrifugation and &#8722;80&#176;C storage delays.<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70752-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70752-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70752-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70752-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70752-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="alz70752-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Specifically, it was found that A&#946;42 and A&#946;40 values decreased&#160;by more than 20% when centrifugation of whole blood or &#8722;80&#176;C freezing of EDTA plasma was delayed by 24&#160;h while tubes were kept at room temperature (RT).<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70752-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> NfL and GFAP appeared only modestly affected by variability in sample handling, as less than 10% change in levels was observed upon centrifugation and storage delays.<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70752-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70752-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70752-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Some studies examined the influence of pre&#8208;analytical sample handling effects on pTau217 and pTau181 measurements<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70752-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70752-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70752-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz70752-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70752-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70752-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> and suggested that measurements of pTau were quite resistant to sample handling variations. However, a cross&#8208;technology and cross&#8208;assay comparative pre&#8208;analytical study comprehensively covering the pre&#8208;analytical phase was still lacking, which is essential to disentangle technical analysis variation from protein measurement (in)stability.<xref rid="alz70752-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</p><p>Supported by the Alzheimer's Association and led by the Global Biomarker Standardization Consortium (GBSC) and the Standardization of Alzheimer's Blood Biomarkers (SABB) workgroup, this study aimed to verify and refine our initially published guideline.<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Specifically, we systematically evaluated the impact of diverse pre&#8208;analytical sample handling variations on key AD BBMs but now with a main focus on pTau, utilizing multiple analytical technologies and pTau assays. In addition, we included samples from both patients with AD and healthy controls (HCs) to cover the broad dynamic range of the BBM assays. Lastly, we extended certain pre&#8208;analytical conditions to more extreme scenarios to capture realistic handling scenarios outside specialized centers in more remote settings. We here present the refined, comprehensive, evidence&#8208;based, and consensus blood sample handling protocol, which mitigates the influence of pre&#8208;analytics on key neurological BBM measurements and their interpretation.</p></sec><sec id="alz70752-sec-0070"><label>2</label><title>METHODS</title><sec id="alz70752-sec-0080"><label>2.1</label><title>Samples and pre&#8208;analytical experiments</title><p>At Amsterdam University Medical Centers (Amsterdam UMC), venous blood samples were obtained from 85 individuals who presented at the outpatient clinic for a blood draw for any disease as controls. In addition, 81 patients with AD&#8208;positive CSF biomarkers or an abnormal amyloid PET scan were prospectively included from the Alzheimer Center Amsterdam. Blood samples obtained from individuals were distributed among 11 pre&#8208;analytical experiments so that a total of 15 individuals per experiment were included, of whom eight were controls and seven were patients with AD. A sample size of <italic toggle="yes">n</italic>&#160;=&#160;15 was previously determined based on paired two one&#8208;sideded equivalence power calculation test, assuming 10% as a relevant change. Blood samples were processed anonymously, and no demographic or clinical information was collected.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz70752-sec-0090"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz70752-list-0002"><list-item><p>
<bold>Systematic review</bold>: We reviewed PubMed literature on the impact of pre&#8208;analytical variations on blood&#8208;based biomarkers (BBMs) in Alzheimer's disease (AD) and neurodegeneration. Existing literature focused on a single analytical platform, investigated a narrow range of pre&#8208;analytical variations, or did not include the most promising AD biomarker, plasma phosphorylated&#8208;tau217. We evaluated the influence of a wide range of pre&#8208;analytical variations across multiple platforms and biomarkers, to establish a technology&#8208;independent, evidence&#8208;based sample handling protocol for reliable BBMs measurement.</p></list-item><list-item><p>
<bold>Interpretation</bold>: Our findings highlighted prominent pre&#8208;analytical variations that require strict standardization, such as primary collection tube used, delays in centrifugation and delays in &#8208;80&#176;C freezing. The most susceptible BBMs were A&#946;42, A&#946;40 and pTau217/A&#946;42 ratio. pTau isoforms, GFAP and NfL were more resistant to sample handling variations.</p></list-item><list-item><p>
<bold>Future directions</bold>: We recommend adoption of the developed pre&#8208;analytical sample handling protocol in clinical and research settings.</p></list-item></list>
</p></sec></boxed-text><p>Pre&#8208;analytical experiments were designed systematically, where each pre&#8208;analytical experiment included one reference condition and two to four different handling conditions compared to the reference. The reference condition was defined as a K<sub>2</sub>EDTA blood sample standing for 30 min at RT, followed by centrifugation for 10 min at 1800 x <italic toggle="yes">g</italic> at RT, after which, without any further delays, plasma was separated from whole blood, aliquoted into screw&#8208;capped polypropylene storage tubes (here: 250&#160;&#181;L aliquots in 0.5&#160;mL Sarstedt tubes), and stored at &#8722;80&#176;C until use. All pre&#8208;analytical experiments and conditions are summarized in Figure&#160;<xref rid="alz70752-fig-0001" ref-type="fig">1</xref>. The hemolysis experiment was based on Delgado's method (strategy 1).<xref rid="alz70752-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> The maximum durations selected for each pre&#8208;analytical condition were based chosen as a continuation of our earlier work<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> and guided by experimental feasibility. The complete pre&#8208;analytical sample set consisted of 720 samples divided over several aliquots per condition and covered the complete blood processing workflow: sampling, centrifugation, pooling, &#8722;80&#176;C freezing, and sample freeze&#8208;thawing.</p><fig position="float" fig-type="FIGURE" id="alz70752-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Overview of the 11 pre&#8208;analytical experiments (<italic toggle="yes">n</italic>&#160;=&#160;15/experiment) performed on fresh blood samples covering the complete blood processing workflow, including sample freeze&#8208;thawing. Each pre&#8208;analytical experiment has a reference condition and two to four experimental pre&#8208;analytical variations. All experiments were performed on K<sub>2</sub>EDTA plasma samples, except experiment 1, which varied the primary blood collection tube. The hemolysis experiment was based on Delgado's method (strategy 1).<xref rid="alz70752-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Note, experiment 11, freeze&#8208;thaw cycles, had only <italic toggle="yes">n</italic>&#160;=&#160;5 for condition +4FT. FT, freeze&#8208;thaw; Hb, hemoglobin; hr, hour; K<sub>2</sub>EDTA, dipotassium ethylenediaminetetraacetic acid; Li, lithium; Na, sodium; RT, room temperature.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-21-e70752-g002.jpg"/></fig><p>This study was performed according to the Declaration of Helsinki and approved by the medical ethics committee of the Amsterdam UMC, location VUmc (approval number: 2019.257&#8208;NL69123.029.19). All individuals agreed to participate in this study by signing an informed consent form to use their blood material for the purpose of the study.</p></sec><sec id="alz70752-sec-0100"><label>2.2</label><title>Sample measurements</title><p>Aliquots of the pre&#8208;analytical sample sets were distributed on dry ice among multiple centers, each utilizing a distinct technology and assay for the BBM measurements. Measurements were performed according to the manufacturer's protocols. Fujirebio measured pTau217 and pTau181 in singulate using the LUMIPULSE G1200 instrument (Fujirebio Europe N.V.; pTau181 was measured in one&#8208;time freeze&#8208;thawed samples). C2N Diagnostics measured pTau217 and non&#8208;pTau217 (npTau217) using their standard operating procedure for the %pTau217 test, employing the immunoprecipitation liquid chromatography&#8211;mass spectrometry (LC&#8208;MS) method, with a sample pre&#8208;dilution step (750&#160;&#181;L sample, 250&#160;&#181;L diluent). %pTau217 was calculated by dividing pTau217 by npTau217 levels (%p&#8208;tau217&#160;=&#160;p&#8208;tau217/np&#8208;tau217 *100). Lund University measured pTau217 using the Eli Lilly assay in duplicate on the MesoScale Discovery (MSD) platform.<xref rid="alz70752-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="alz70752-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> The Neurochemistry Laboratory, Amsterdam UMC, measured pTau217 in duplicate using the ALZpath assay on the Simoa HD&#8208;X analyzer. In addition, to compare the results of this study to the published SABB&#8208;GBSC sample handling procedure,<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> we quantified pTau181 using the commercial pTau181 V2 assay in duplicates (Quanterix, Billerica, USA) and NfL, GFAP, A&#946;42, and A&#946;40 using the commercial Neurology 4&#8208;plex E assay (Quanterix, Billerica, MA, USA) in singulate on the Simoa HD&#8208;X analyzer. The pTau217/A&#946;42 ratio was calculated by dividing the Lumipulse pTau217 levels by the A&#946;42 Simoa levels.</p></sec><sec id="alz70752-sec-0110"><label>2.3</label><title>Data analysis</title><p>Data from both the reference and experimental conditions were excluded if the measurement in the reference condition was below the limit of detection or had a coefficient of variation greater than 20% between duplicates. However, if such issues occurred only in the experimental conditions and not in the reference condition, the values were retained, as they may reflect true pre&#8208;analytical effects rather than analytical variability. Levels of BBMs measured in experimental conditions were normalized to the levels measured in the reference condition as follows: Recovery (%)&#160;=&#160;([experimental condition]/[reference condition])*100. If a&#160;&gt;&#160;&#177;10% change in the median recovery was observed, then the pre&#8208;analytical handling effect was considered relevant.<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> In addition, the statistical significance of differences in experimental conditions compared to the reference condition was assessed using the Wilcoxon signed&#8208;rank exact test. Data were analyzed and visualized using R version 4.3.2.</p></sec><sec id="alz70752-sec-0120"><label>2.4</label><title>Establishment of SOP</title><p>When a pre&#8208;analytical variation condition led to both a relevant change (&gt;&#160;&#177;10% change in recovery) and a statistically significant change (<italic toggle="yes">p</italic>&#160;&lt;&#160;0.05), we deemed this condition to impact the plasma biomarker measurement accuracy. If multiple assays/technologies were used to measure a biomarker, the condition was considered impactful if a relevant and statistically significant change was observed in at least one assay/technology. The impacting conditions were used to define acceptable handling parameters in a draft sample handling procedure, which was subsequently presented to the SABB&#8208;GBSC in an online consensus meeting for finalization. To build consensus, an initial draft of the sample handling protocol, along with supporting data, was shared with members of the GBSC via an online forum. Feedback was requested from both academic and industry representatives and discussed during a virtual workgroup meeting. Suggestions were incorporated into the final protocol when the suggestions were supported by empirical evidence as obtained within this study.</p></sec></sec><sec id="alz70752-sec-0130"><label>3</label><title>RESULTS</title><sec id="alz70752-sec-0140"><label>3.1</label><title>Effect of pre&#8208;analytical variation on pTau levels</title><p>The effects of the 11 pre&#8208;analytical experiments on levels of pTau181, pTau217, and npTau217 measured with Lumipulse, Simoa, MSD, and LC&#8208;MS are presented in Figure&#160;<xref rid="alz70752-fig-0002" ref-type="fig">2</xref> and Supplementary File <xref rid="alz70752-supinfo-0001" ref-type="">1</xref> and are described in detail below.</p><fig position="float" fig-type="FIGURE" id="alz70752-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Recovery% plots visualizing the effect of 11 pre&#8208;analytical variations on pTau181 and pTau217 levels as measured by Lumipulse, Simoa, MSD, and LC&#8208;MS and npTau217 levels, as well as pTau217/npTau217 (%pTau217) ratio as measured by LC&#8208;MS. Levels measured in the experimental condition were normalized to levels measured in the reference conditions, i.e., centrifugation of K<sub>2</sub>EDTA blood tubes at 1800 &#215; <italic toggle="yes">g</italic> at RT after standing at RT for 30 min, followed by plasma separation and aliquoting in low binding polypropylene screw&#8208;capped storage tubes and storage at &#8722;80&#176;C without any delays. Horizontal dashed lines at 90% and 110% represent an allowable 10% change in experimental conditions compared to the reference condition. Box plots represent the median and interquartile range (IQR), whiskers represent the extreme data points that are within 1.5 times the IQR. LC&#8208;MS serum measurements were below the limit of detection for most samples (data not shown). EDTA, ethylene diamine tetraacetic acid; FT, freeze&#8208;thaw; LC&#8208;MS, liquid chromatography&#8208;mass spectrometry; Li&#8208;heparin, lithium&#8208;heparin; MSD, Meso Scale Discovery; Na&#8208;citrate, sodium&#8208;citrate; npTau, non&#8208;phosphorylated tau; pTau, phosphorylated tau; RT, room temperature; Simoa, Single molecule array.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ALZ-21-e70752-g001.jpg"/></fig></sec><sec id="alz70752-sec-0150"><label>3.2</label><title>Effect of primary collection tube</title><p>The type of primary collection tube used for blood withdrawal led to differences in measured levels of pTau181, pTau217, and npTau217 (Figure&#160;<xref rid="alz70752-fig-0002" ref-type="fig">2.1</xref>).</p><p>In serum, pTau181 was consistently measured at lower levels compared to K<sub>2</sub>EDTA plasma (both Lumipulse and Simoa: median recovery&#160;=&#160;&#8722;17%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). For pTau217, a more variable result was obtained. Levels of pTau217 were lower in serum compared to K<sub>2</sub>EDTA plasma when measured with Simoa (&#8722;30%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), higher when measured with MSD (+39%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), and similar when measured with Lumipulse. Note, with LC&#8208;MS no reliable pTau217 and npTau217 results could be obtained in serum (respectively one and three out of 15 serum samples gave results; data not shown).</p><p>In Na&#8208;citrate compared to K<sub>2</sub>EDTA plasma, pTau181 levels were lower when measured with Lumipulse (&#8722;20%, <italic toggle="yes">p</italic>&#160;=&#160;0.001; not significant with Simoa: &#8722;11%, <italic toggle="yes">p</italic>&#160;=&#160;0.277). pTau217 levels were lower when measured with Lumipulse (&#8722;18%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) and MSD (&#8722;15%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) but were similar in Na&#8208;citrate and K<sub>2</sub>EDTA plasma when measured with Simoa and LC&#8208;MS. In addition, LC&#8208;MS npTau217 and %pTau217 were similar in level in Na&#8208;citrate and K<sub>2</sub>EDTA plasma samples.</p><p>In Li&#8208;heparin plasma compared to K<sub>2</sub>EDTA plasma, pTau181 levels were lower when measured with Lumipulse (&#8722;14%, <italic toggle="yes">p</italic>&#160;=&#160;0.02) but higher when measured with Simoa (+14%, <italic toggle="yes">p</italic>&#160;=&#160;0.003). pTau217 levels were similar in Li&#8208;heparin and K<sub>2</sub>EDTA plasma when measured with Lumipulse, MSD, and LC&#8208;MS, but higher when measured with Simoa (+14%, <italic toggle="yes">p</italic>&#160;=&#160;0.021). LC&#8208;MS npTau217 was higher (+17%, <italic toggle="yes">p</italic>&#160;=&#160;0.02) and %pTau217 was lower (&#8722;39%, <italic toggle="yes">p</italic>&#160;=&#160;0.03) in Li&#8208;heparin compared to K<sub>2</sub>EDTA plasma.</p></sec><sec id="alz70752-sec-0160"><label>3.3</label><title>Effect of hemolysis</title><p>Compared to no hemolysis, moderate hemolysis at 100&#160;mg/dL Hb or high hemolysis at 500&#160;mg/dL Hb (Figure&#160;<xref rid="alz70752-fig-0002" ref-type="fig">2.2</xref>) resulted in higher pTau181 levels when measured with Lumipulse (moderate: +11%, high: +28%; both <italic toggle="yes">p</italic>&#160;&lt;&#160;0.04) but not when measured with Simoa. Hemolysis did not alter the pTau217 levels as measured with any of the four technologies, nor did it alter the npTau217 level and %pTau217.</p></sec><sec id="alz70752-sec-0170"><label>3.4</label><title>Effect of centrifugation delays</title><p>Compared to direct processing, when K<sub>2</sub>EDTA tubes were kept at RT prior to centrifugation (Figure&#160;<xref rid="alz70752-fig-0002" ref-type="fig">2.3</xref>), pTau181, pTau217, and npTau217 levels were stable up until the 7&#8208;h timepoint, independent of the assay used. At the 24&#8208; and 72&#8208;h timepoints, pTau217 levels were lower when measured with LC&#8208;MS (&#8722;25%, <italic toggle="yes">p</italic>&#160;=&#160;0.03; 72&#160;h: &#8722;36%, <italic toggle="yes">p</italic>&#160;=&#160;0.02), and pTau181 levels were higher when measured with Lumipulse (+22%, <italic toggle="yes">p</italic>&#160;=&#160;0.01) at the 72&#8208;h timepoint. pTau181 level measured with Simoa and pTau217 levels measured with Lumipulse, Simoa, and MSD were stable up until the 72&#8208;h timepoint (i.e., the last timepoint assessed), as were LC&#8208;MS npTau217 level and %pTau217.</p><p>When the K<sub>2</sub>EDTA tubes were kept in the fridge (2&#176;C&#8211;8&#176;C) prior to centrifugation, plasma pTau181, pTau217, and npTau217 levels were stable up until the 7&#8208;h timepoint, independent of the assay used to measure the levels (Figure&#160;<xref rid="alz70752-fig-0002" ref-type="fig">2.4</xref>). At the 24&#8208;h timepoint, pTau181 levels were higher when measured with Simoa (+13%, <italic toggle="yes">p</italic>&#160;=&#160;0.002; 72&#160;h: +14%, p&#160;=&#160;0.002), and pTau217 levels were higher when measured with MSD (+14%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001; 72&#160;h: +16%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). pTau181 levels measured with Lumipulse and pTau217 levels measured with Lumipulse, Simoa, and LC&#8208;MS were stable up until the 72&#8208;h timepoint (i.e., the last timepoint assessed), as were LC&#8208;MS npTau217 and %pTau217.</p></sec><sec id="alz70752-sec-0180"><label>3.5</label><title>Effect of centrifugation settings</title><p>Varying the centrifugation duration (10 or 30 min) and centrifugation temperature (RT or 4&#176;C) did not impact the measured K<sub>2</sub>EDTA plasma pTau181 and pTau217 levels (Figure&#160;<xref rid="alz70752-fig-0002" ref-type="fig">2.5</xref>). There was one exception of an inconsistent effect of centrifugation setting on pTau181 levels when measured with Lumipulse: Compared to 10 min RT centrifugation, pTau181 was higher with 10&#8208;min 4&#176;C centrifugation (+10%, <italic toggle="yes">p</italic>&#160;=&#160;0.002), similar with 30&#8208;min 4&#176;C centrifugation, and lower with 30&#8208;min RT centrifugation (&#8722;11%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001).</p></sec><sec id="alz70752-sec-0190"><label>3.6</label><title>Effect of transferring plasma to novel tubes</title><p>Compared to no transfers, up to four transfers of K<sub>2</sub>EDTA plasma to fresh polypropylene tubes using fresh polypropylene pipette tips did not alter the measured pTau181, pTau217, and npTau217 levels with any of the assays (Figure&#160;<xref rid="alz70752-fig-0002" ref-type="fig">2.6</xref>).</p></sec><sec id="alz70752-sec-0200"><label>3.7</label><title>Effect of delayed &#8722;80&#176;C freezing of plasma aliquots</title><p>The effect of delayed &#8722;80&#176;C freezing of plasma aliquots after centrifugation while they were kept at RT, in the fridge (2&#176;C to 8&#176;C), or at &#8722;20&#176;C is illustrated in Figures&#160;<xref rid="alz70752-fig-0002" ref-type="fig">2.7, 2.8</xref>, <xref rid="alz70752-fig-0002" ref-type="fig">2.9</xref> and&#160;<xref rid="alz70752-fig-0002" ref-type="fig">2.10</xref>.</p><p>When plasma aliquots were kept at RT after centrifugation pending &#8722;80&#176;C freezing, pTau181 and pTau217 levels remained stable up until the 2&#8208;week timepoint (i.e., the last timepoint assessed), independent of the assay used for the measurements. LC&#8208;MS npTau217 levels were lower at the 2&#8208;week timepoint compared to direct &#8722;80&#176;C freezing (&#8722;17%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), while LC&#8211;MS %pTau217 was not significantly changed at the 2&#8208;week timepoint.</p><p>When plasma aliquots were kept in the fridge pending &#8722;80&#176;C freezing, pTau181 levels remained stable up until the 2&#8208;week timepoint independent of the assay used. For pTau217, levels were higher at the 1&#8208; and 2&#8208;week timepoints when measured with MSD (1&#160;week: +18%; 2 weeks: +19%; both <italic toggle="yes">p</italic>&#160;=&#160;0.001), while they remained stable up until the 2&#8208;week timepoint when measured with Lumipulse, Simoa, or LC&#8208;MS. LC&#8208;MS npTau217 and %pTau217 levels also remained stable up until the 2&#8208;week timepoint.</p><p>Temporary &#8722;20&#176; freezing pending &#8722;80&#176;C storage up to 6 months (2&#160;weeks, 2 months, 6 months; Figure&#160;<xref rid="alz70752-fig-0002" ref-type="fig">2.10</xref>) did not alter the measured levels of pTau181, pTau217, and npTau217, nor %pTau217, independent of the assay used.</p></sec><sec id="alz70752-sec-0210"><label>3.8</label><title>Effect of applying freeze&#8208;thaw (FT) cycles</title><p>Applying up to four additional FT cycles generally did not affect the pTau181, pTau217, and npTau217 levels, nor pTtau217%, with any of the assays (Figure&#160;<xref rid="alz70752-fig-0002" ref-type="fig">2.11</xref>), except there was an inconsistent decrease in pTau217 at +2FT when measured with Lumipulse (&#8722;11%, <italic toggle="yes">p</italic>&#160;=&#160;0.01) and an inconsistent decrease in %pTau217 on LC&#8208;MS at +1FT (+17%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.05), where both were unaffected in the more extreme conditions (up to +4FT).</p></sec><sec id="alz70752-sec-0220"><label>3.9</label><title>Effect of pre&#8208;analytical variations on other blood&#8208;based biomarkers</title><p>The results of the 11 pre&#8208;analytical experiments on A&#946;42, A&#946;40, GFAP, and NfL levels and on the A&#946;42/A&#946;40 and pTau217/A&#946;42 ratios are presented in Figure&#160;<xref rid="alz70752-fig-0003" ref-type="fig">3</xref> and Supplementary File <xref rid="alz70752-supinfo-0001" ref-type="">1</xref> and are described in detail below.</p><fig position="float" fig-type="FIGURE" id="alz70752-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Recovery% plots visualizing the effect of 11 pre&#8208;analytical variations on the levels of A&#946;42, A&#946;40, NfL, GFAP, and A&#946;42/40 and pTau217/A&#946;42 ratios as measured with Simoa HDX (pTau217 in the ratio, measured with Lumipulse). Levels measured in experimental conditions were normalized to levels measured in the reference conditions, i.e., centrifugation of K<sub>2</sub>EDTA blood tubes at 1800 &#215; <italic toggle="yes">g</italic> at RT after standing at RT for 30 min, followed by plasma separation and aliquoting in low binding polypropylene screw&#8208;capped storage tubes and storage at &#8722;80&#176;C without any delays. Horizontal dashed lines at 90% and 110% represent an allowable 10% change in the experimental conditions compared to the reference condition. Box plots represent the median and interquartile range (IQR), whiskers represent the extreme data points that are within 1.5 times the IQR. A&#946;42, beta amyloid protein (1&#8208;42); A&#946;40, beta amyloid protein (1&#8208;40); EDTA, ethylene diamine tetraacetic acid; FT, freeze&#8208;thaw; GFAP, glial fibrillary acidic protein; Li&#8208;heparin, lithium&#8208;heparin; Na&#8208;citrate, sodium&#8208;citrate; NfL, neurofilament light chain; RT, room temperature; Simoa, Single molecule array.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="ALZ-21-e70752-g004.jpg"/></fig></sec><sec id="alz70752-sec-0230"><label>3.10</label><title>Effect of different primary collection tubes</title><p>Similar to results obtained for pTau, measured levels of A&#946;42, A&#946;40, GFAP, and NfL differed depending on the primary collection tube used for blood withdrawal (Figure&#160;<xref rid="alz70752-fig-0003" ref-type="fig">3.1</xref>).</p><p>In serum compared to K<sub>2</sub>EDTA plasma, both A&#946;42 and A&#946;40 were measured at lower levels (&#8722;36% and &#8722;30%, respectively; both <italic toggle="yes">p</italic>&#160;&lt;&#160;0.007). This primary collection tube effect could be mitigated by taking the A&#946;42/A&#946;40 ratio (Recovery%: 97%), but not by taking the pTau217/A&#946;42 ratio (+67%, <italic toggle="yes">p</italic>&#160;=&#160;0.001). GFAP and NfL were significantly higher in serum compared to K<sub>2</sub>EDTA plasma (+11% and +23%, respectively; both <italic toggle="yes">p</italic>&#160;&lt;&#160;0.007). In Na&#8208;citrate compared to K<sub>2</sub>EDTA plasma, all markers were measured at lower levels (range decrease: &#8722;16% (A&#946;42) and &#8722;31% (GFAP); all <italic toggle="yes">p</italic>&#160;&lt;&#160;0.009). Here, using the A&#946;42/A&#946;40 ratio did not mitigate the primary collection tube effect (+13%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), while the pTau217/A&#946;42 ratio did (Recovery%: 105%). In plasma Li&#8208;heparin compared to K<sub>2</sub>EDTA plasma, all markers were measured at higher levels (range increase: +21% (A&#946;40) and +31% (A&#946;42); all <italic toggle="yes">p</italic>&#160;&lt;&#160;0.007). Applying the A&#946;42/A&#946;40 ratio mitigated the primary collection tube effect (Recovery%: 105%), while applying the pTau217/A&#946;42 ratio did not (&#8722;17%, <italic toggle="yes">p</italic>&#160;=&#160;0.02).</p></sec><sec id="alz70752-sec-0240"><label>3.11</label><title>Effect of hemolysis</title><p>Compared to no hemolysis, moderate hemolysis at 100&#160;mg/dL Hb and high hemolysis at 500&#160;mg/dL Hb (Figure&#160;<xref rid="alz70752-fig-0003" ref-type="fig">3.2</xref>) resulted in lower levels of A&#946;42 (moderate: &#8722;10%, high: &#8722;36%; both <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) and A&#946;40 (moderate: &#8722;11%, high: &#8722;42%; both <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). The effect of moderate or high hemolysis was mitigated by taking the A&#946;42/A&#946;40 ratio (Recovery% moderate: 99%, Recovery% high: 104%), but a significant effect of high hemolysis remained visible on the pTau217/A&#946;42 ratio (+65%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). Hemolysis did not alter the measured GFAP and NfL levels.</p></sec><sec id="alz70752-sec-0250"><label>3.12</label><title>Effect of centrifugation delays</title><p>When K<sub>2</sub>EDTA tubes were kept at RT pending centrifugation (Figure&#160;<xref rid="alz70752-fig-0003" ref-type="fig">3.3</xref>), A&#946;42 and A&#946;40 levels were only stable up until the 4&#8208;h centrifugation delay timepoint. Thereafter, a consistent effect was noted on the levels, with more pronounced decreases observed with increasing durations of storage delays (A&#946;42: up to &#8722;80% at the 72&#8208;h timepoint; A&#946;40:, up to &#8722;75% at the 72&#8208;h timepoint; all tested conditions <italic toggle="yes">p</italic>&#160;&lt;&#160;0.02). The effect of delayed centrifugation when the K<sub>2</sub>EDTA tubes were kept at RT could be mitigated by taking the A&#946;42/A&#946;40 ratio (Recovery% at 72&#160;h: &#8722;21%, <italic toggle="yes">p</italic>&#160;=&#160;0.100). The pTau217/A&#946;42 ratio was affected from the 24&#8208;h timepoint onward (24&#160;h: +48%; 72&#160;h: +326%; both: <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001).</p><p>At 2&#176;C to 8&#176;C, the levels of most BBMs appeared more stable than at RT. Precisely, the single A&#946;42 and A&#946;40 levels, as well as the A&#946;42/A&#946;40, and pTau217/A&#946;42 ratios remained stable up until the 24&#8208;h timepoint (Figure&#160;<xref rid="alz70752-fig-0003" ref-type="fig">3.4</xref>) when the K<sub>2</sub>EDTA tubes were kept at 2&#176;C to 8&#176;C (fridge) pending centrifugation. At the 72&#8208;h timepoint, A&#946;42 and A&#946;40 levels were decreased (&#8722;17% and &#8722;19%, respectively, both: <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). The A&#946;42/A&#946;40 ratio was not relevantly affected at the 72&#8208;h timepoint when the K<sub>2</sub>EDTA tubes were kept in the fridge pending centrifugation (Recovery% 107%), but the pTau217/A&#946;42 ratio was (+36%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001).</p><p>GFAP and NfL levels remained stable upon delayed centrifugation, both when the K<sub>2</sub>EDTA tubes were kept at RT and when they were kept in the fridge (2&#176;C to 8&#176;C) pending centrifugation.</p></sec><sec id="alz70752-sec-0260"><label>3.13</label><title>Effect of centrifugation settings</title><p>Varying the centrifugation duration (10 or 30 min) and temperature (RT or 4&#176;C) did not influence the measured levels of A&#946;42, A&#946;40, A&#946;42/A&#946;40 ratio, GFAP, or NfL (Figure&#160;<xref rid="alz70752-fig-0003" ref-type="fig">3.5</xref>). Only an inconstant effect of the 10 min 4&#176;C centrifugation setting compared to 10 min RT centrifugation was observed on the pTau217/A&#946;42 ratio (+15%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001).</p></sec><sec id="alz70752-sec-0270"><label>3.14</label><title>Effect of transferring plasma to novel tubes</title><p>Compared to no transfers, up to four transfers of plasma to fresh polypropylene tubes using fresh polypropylene pipette tips did not alter the measured levels of A&#946;42, A&#946;40, GFAP, or NfL, or the A&#946;42/A&#946;40 ratio (Figure&#160;<xref rid="alz70752-fig-0003" ref-type="fig">3.6</xref>). The pTau217/A&#946;42 ratio was higher in the four&#8208;time transfer condition compared to the no&#8208;transfer condition (+11%, <italic toggle="yes">p</italic>&#160;=&#160;0.003).</p></sec><sec id="alz70752-sec-0280"><label>3.15</label><title>Effect of delayed &#8722;80&#176;C freezing of plasma aliquots after centrifugation</title><p>The effect of delayed &#8722;80&#176;C freezing, during which plasma aliquots are kept at different temperatures (RT, 2&#176;C to 8&#176;C, and &#8722;20&#176;C), is illustrated in Figures&#160;<xref rid="alz70752-fig-0003" ref-type="fig">3.7, 3.8</xref>, <xref rid="alz70752-fig-0003" ref-type="fig">3.9</xref>, and&#160;<xref rid="alz70752-fig-0003" ref-type="fig">3.10</xref>.</p><p>A&#946;42 and A&#946;40 levels remained stable up until the 7&#8208;h timepoint when plasma aliquots were kept at RT pending &#8722;80&#176;C freezing, whereafter levels consistently decreased with increasing &#8722;80&#176;C freezing delays until levels were decreased by 95% (A&#946;42) and 97% (A&#946;40) at the 2&#8208;week timepoint. Although the A&#946;42/A&#946;40 ratio was still unchanged at the 2&#8208;week RT&#8208;condition timepoint (+82%, but <italic toggle="yes">p</italic>&#160;=&#160;0.500), the decreases in the single analyte levels approached 0 pg/mL. At 2&#176;C to 8&#176;C, A&#946;42 and A&#946;40 levels in the plasma aliquots remained stable up until the 24&#8208;h timepoint. After 2 weeks, however, levels were decreased by 48% (A&#946;42; <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) and 54% (A&#946;40; <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). The A&#946;42/A&#946;40 ratio was still unchanged at this 2&#8208;week timepoint (R% +12%, <italic toggle="yes">p</italic>&#160;=&#160;0.451). The pTau217/A&#946;42 ratio was only stable up until the 7&#8208;h timepoint when aliquots were kept at RT pending &#8722;80&#176;C freezing, or up to the 72&#8208;h timepoint when aliquots were kept in the fridge pending &#8722;80&#176;C freezing.</p><p>GFAP and NfL levels remained stable up until the 24&#8208;h timepoint when the plasma aliquots were kept at RT pending &#8722;80&#176;C freezing. At the 72&#8208;h timepoint, levels of both markers were increased (GFAP: +18%, NfL: +11%; both: <italic toggle="yes">p</italic>&#160;&lt;&#160;0.003) and continued to increase up until the 1&#8208;week timepoint (GFAP: 1 week +30%, 2 weeks +34%; NfL: 1 week +31%, 2 weeks +30%; all: <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001). For both GFAP and NfL, levels were measured at similar levels in plasma aliquots that were kept in the fridge pending &#8722;80&#176;C freezing. GFAP was increased relevantly at the 2&#8208;week timepoint (+10%, <italic toggle="yes">p</italic>&#160;=&#160;0.003) and NfL at the 1&#8208;week timepoint (+12%, <italic toggle="yes">p</italic>&#160;=&#160;0.002; 2 weeks: +12%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001).</p><p>Freezing plasma aliquots at &#8722;20&#176;C pending &#8722;80&#176;C storage did not affect the measured levels of A&#946;42 and A&#946;40, or the A&#946;42/A&#946;40 ratio, and pTau217/ A&#946;42 ratios, up until the latest timepoint assessed, 6 months. However, the levels of both GFAP and NfL increased upon temporary &#8722;20&#176;C storage. The levels were unchanged at the 2&#8208;week timepoint, but at the 2&#8208;month timepoint, GFAP levels were increased (+12%, <italic toggle="yes">p</italic>&#160;=&#160;0.002; 6 months: +24%, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001), and at the 6&#8208;month timepoint NfL levels were also increased (+14%, <italic toggle="yes">p</italic>&#160;=&#160;0.003).</p></sec><sec id="alz70752-sec-0290"><label>3.16</label><title>Effect of applying freeze&#8208;thaw cycles</title><p>Applying up to four additional FT cycles did not alter the measured levels of A&#946;42, A&#946;40, and NfL, or the A&#946;42/A&#946;40 and pTau217/A&#946;42 ratios. GFAP was slightly increased at the fourth FT cycle (+13%; no statistical testing was performed for condition 4 (4 FT) because of its limited <italic toggle="yes">n</italic>&#160;=&#160;5; Figure&#160;<xref rid="alz70752-fig-0003" ref-type="fig">3.11</xref>).</p></sec><sec id="alz70752-sec-0300"><label>3.17</label><title>Established workflow</title><p>The presented findings, together with the workgroup's suggestions, are summarized as an evidence&#8208;based, consensus sample handling protocol in Figure&#160;<xref rid="alz70752-fig-0004" ref-type="fig">4</xref>. This protocol visualizes our recommendations for EDTA plasma sample handling to ensure reliable quantification of neurological BBMs upon clinical adoption. The sample handling protocol is presented as a flowchart, in which each step in the pre&#8208;analytical phase is depicted. To mitigate the effects of pre&#8208;analytical variability, each step was tailored to the biomarker that was most susceptible to variation at that step. For the more stable BBMs, the protocol includes <italic toggle="yes">allowed deviations</italic>, reflecting their demonstrated stability under specific handling conditions.</p><fig position="float" fig-type="FIGURE" id="alz70752-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Evidence&#8208;based sample handling protocol for accurate neurological blood&#8208;based biomarker (BBMs) measurement. The flowchart is tailored to mitigate any pre&#8208;analytical effect on the most sensitive neurological biomarker. When measuring a specific marker, more flexibility at certain steps might be possible, which can be derived from the &#8220;allowed deviations&#8221; column. Of note, the advised, optimal sample handling protocol includes a total processing time of less than 2&#160;h. Hemolysis degree can be measured or visually inspected using the color grade presented in the figure or by comparing it to the commonly used hemolysis palettes.<xref rid="alz70752-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> EDTA, ethylene diamine tetraacetic acid; FT, freeze&#8208;thaw; Hb, hemoglobin; max, maximum; RT, room temperature.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="ALZ-21-e70752-g003.jpg"/></fig></sec></sec><sec id="alz70752-sec-0310"><label>4</label><title>DISCUSSION</title><p>In this SABB&#8211;GBSC workgroup study, endorsed by the Alzheimer's Association, we extensively evaluated the impact of pre&#8208;analytical sample handling variations on key neurological plasma markers measured with different technologies and assays, aiming to establish an evidence&#8208;based sample handling protocol that mitigates pre&#8208;analytical effects. We systematically varied conditions spanning the entire pre&#8208;analytical phase, mimicking real&#8208;world laboratory practices. According to our results, critical steps in the pre&#8208;analytical sample handling workflow requiring most strict standardization are the type of primary collection tube used to withdraw blood and delays until centrifugation and &#8722;80&#176;C freezing. We observed that A&#946;42, A&#946;40, and pTau217/A&#946;42 were most sensitive to pre&#8208;analytical sample handling variations. The A&#946;42/40 ratio, pTau217, %pTau217 (LC&#8208;MS), pTau181, GFAP, and NfL showed better stability. We summarized our findings in a sample handling workflow, designed for real&#8208;world feasibility by including controlled flexibility in sample processing without compromising biomarker accuracy. While optimal guidelines<xref rid="alz70752-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="alz70752-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> would limit total collection&#8208;to&#8208;freezer time to 2&#160;h, its feasibility is limited to controlled settings. Decentralized (e.g., general practitioners) and resource&#8208;limited settings (e.g., low/middle&#8208;income countries) require flexibility. Following the key priority of the World Health Organization for global access to AD&#8208;related BBMs for equitable healthcare,<xref rid="alz70752-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> the global feasibility of guidelines is essential.</p><p>Varying the primary collection tube resulted in pronounced differences in BBM levels for all assessed markers, in agreement with previous literature.<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70752-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70752-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70752-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70752-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="alz70752-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="alz70752-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> According to our comparative pTau results, the effect of the primary collection tube on the measured BBM level is assay&#8208;dependent. We also observed this when comparing pre&#8208;analytics on A&#946;42 and A&#946;40 levels measured with various technologies.<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Assay dependency is likely explained by differences in detection methodologies and assay components. Despite differences in measured BBM levels across assays, technologies,<xref rid="alz70752-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="alz70752-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> and sample matrices (serum and different kinds of plasma),<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70752-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70752-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz70752-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70752-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="alz70752-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="alz70752-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="alz70752-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> previous studies reported a similar diagnostic performance of plasma and serum pTau measurements in reflecting amyloid pathology.<xref rid="alz70752-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="alz70752-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="alz70752-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> Nevertheless, upon clinical implementation, we recommend avoiding interchangeable use of different blood sample matrices, since each matrix asks for its own clinical cutoffs and normal reference ranges.</p><p>We recommend centrifuging K<sub>2</sub>EDTA plasma tubes promptly without any delays, but based on our data, a maximum of 4&#8208;h delay is allowed if K<sub>2</sub>EDTA plasma collection tubes are kept at RT or 7&#160;h if they are kept refrigerated. These recommendations were tailored to the most unstable markers before centrifugation, i.e., A&#946;42 and A&#946;40 at RT and pTau181 and pTau217 at 2&#176;C to 8&#176;C. Our findings are consistent with previous studies.<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70752-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="alz70752-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70752-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="alz70752-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Pre&#8208;centrifugation instability of A&#946; might be explained by proteolytic degradation, since supplementing samples with protease inhibitors was shown to extend the stability of A&#946;42 and A&#946;40.<xref rid="alz70752-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Interestingly, adding protease inhibitors did not extend the stability of pTau, NfL, and GFAP,<xref rid="alz70752-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> suggesting that specifically A&#946; measurements are susceptible to protease activity. Proteolytic enzymes such as trypsin primarily target lysine and arginine residues.<xref rid="alz70752-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Since A&#946; proteins contain two lysine and one arginine residue, this might explain their susceptibility to proteolytic degradation. Interestingly, rates of decline over centrifugation delay were relatively similar for the A&#946;42 and A&#946;40 peptides. As a result, the instability of A&#946; can mostly be mitigated by applying the A&#946;42/40 ratio. Note that applying the pTau217/A&#946;42 ratio does not mitigate pre&#8208;analytical effects, because pre&#8208;analytical effects are different for pTau and A&#946;42. While well&#8208;controlled studies showed that this ratio outperformed pTau217 alone as a diagnostic biomarker for AD pathophysiology,<xref rid="alz70752-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="alz70752-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="alz70752-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> its reliability seems to be compromised in real&#8208;world settings without stringent sample handling. It was an unexpected finding that pTau181 and pTau217 levels pre&#8208;centrifugation were stable longer at RT than refrigerated. Pre&#8208;centrifugation instability of pTau seemed, however, assay&#8208;dependent, as is generally the case with most assays; stable levels were measured across the 2&#176;C to 8&#176;C centrifugation delay conditions. The negatively charged phosphate groups as present in pTau proteoforms form salt bridges with the protonated side chains of lysine and arginine residues, obscuring the proteolytic action of proteases.<xref rid="alz70752-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> This might make pTau less prone to proteolytic degradation. Supporting this, earlier pre&#8208;analytical studies that measured both total tau (i.e., a mix of npTau and pTau) and pTau specifically confirmed the higher pre&#8208;analytical stability of pTau compared to total tau measurements.<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70752-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> GFAP and NfL levels were resistant to pre&#8208;centrifugation delays up to 72&#160;h at RT and 2&#176;C to 8&#176;C, in agreement with previous literature.<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70752-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>
</p><p>After centrifugation and plasma separation, longer delays until sample freezing can be allowed. Again, our recommendation is not to introduce any delays at this step, but based on our results, we are able to allow freezing delays of up to 7&#160;h when plasma is kept at RT and up to 24&#160;h when plasma is kept cold. A&#946;42 and A&#946;40 were again the most susceptible markers driving our recommendation. The A&#946;42 and A&#946;40 levels consistently decreased with increasing freezing delays, until almost undetectable levels were reached after 2&#160;weeks at RT. Of note, degradation of A&#946;42 and A&#946;40 is slower in separated plasma compared to whole blood, likely due to the lower concentration of proteolytic enzymes in plasma. The A&#946;42/40 ratio, GFAP, and NfL were stable for up to 24&#160;h at RT and 72&#160;h at 2&#176;C to 8&#176;C. pTau217, %p&#8208;Tau217, and pTau181 remained stable for up to 1&#160;week at RT and up to 72&#160;h at 2&#176;C to 8&#176;C, independent of the assay used. The findings are consistent with previous findings.<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70752-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz70752-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="alz70752-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
</p><p>Other pre&#8208;analytical variations assessed in the current study are sample hemolysis, centrifugation settings, plasma transferring, temporary &#8722;20&#176;C freezing, and freeze&#8208;thawing. Sample hemolysis can occur, for example, due to prolonged tourniquet duration<xref rid="alz70752-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="alz70752-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> and occurs in up to 3.3% of routine blood collections,<xref rid="alz70752-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> and more often in the elderly population.<xref rid="alz70752-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> We found that a moderate degree of hemolysis of 100&#160;mg/dL hemoglobin<xref rid="alz70752-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> already influenced the levels of A&#946;42, A&#946;40, pTau217/A&#946;42, and, to a lesser extent, pTau181. Similar trends were observed in a previous study.<xref rid="alz70752-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> Therefore, moderately hemolyzed samples should be discarded <italic toggle="yes">or</italic> interpreted with caution. Immunoassays may suffer more from hemolysis than MS assays, as antibody&#8208;based assays can cross&#8208;react with free hemoglobin. We recommend discarding samples with a moderate to high hemolysis degree. There was no effect of centrifugation settings on the BBM measurements in our study, so we recommend following standard protocols and/or manufacturer's guidelines. Also, tube transferring had no impact on the assessed BBM levels, suggesting that the assessed proteins in plasma did not adsorb to lab plastics tested here, so no stringent recommendations for this step were made. We noted an impact of &#8722;20&#176;C storage on GFAP and NfL levels, in line with previous work.<xref rid="alz70752-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> GFAP levels were increased at the 2&#8208;month timepoint, and NfL levels were increased at 6 months. For long&#8208;term biobanking, we thus recommend storing samples at &#8722;80&#176;C and avoiding prolonged (&gt;2&#160;weeks) &#8722;20&#176;C storage. Freezing and thawing (up to four times) of plasma samples minimally impacted most BBMs, as reported earlier.<xref rid="alz70752-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz70752-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Only GFAP levels were slightly increased at the fourth FT cycle. Hence, our recommendation is to limit freeze&#8208;thawing of K<sub>2</sub>EDTA plasma samples to two cycles. It is interesting that both GFAP and NfL levels tended to increase at &#8722;20&#176;C storage, with GFAP also showing increases with freeze&#8208;thawing, especially because these were the conditions in which A&#946; and pTau were stable. This suggests that a different mechanism results in protein instability for GFAP and NfL than for A&#946; and pTau. Both GFAP and NfL exhibit structural and conformational flexibility depending on the surrounding matrix and are known to form higher&#8208;order assemblies.<xref rid="alz70752-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="alz70752-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> For example, GFAP adopts an open conformation in artificial CSF compared to PBS due to decreased hydrogen bonding. This might also happen in samples exposed to lower temperature freezing or freeze&#8208;thawing, exposing more epitopes to antibodies, and, hence, increase its measurability with immunoassays.<xref rid="alz70752-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> This hypothesis can be tested with MS&#8208;based experiments.</p><p>A key strength of this study is its extensive evaluation of pre&#8208;analytical factors, encompassing many conditions as they occur in daily practice, and tested on the most promising AD BBMs using both immunoassays and LC&#8208;MS assays. Although some assays exhibited relatively large variability across pre&#8208;analytical conditions, including several assays to test the same biomarker increased the generalizability of our findings. The inclusion of both healthy and AD participants covered the clinically relevant range of biomarker measurements. In addition, we generated consensus among experts in the field, enhancing clinical adoption of the developed guideline. Among our study's limitations are (1) focusing on K<sub>2</sub>EDTA (for a serum&#8208;based protocol, refer to van Lierop et&#160;al.<xref rid="alz70752-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>), (2) inability to simulate all pre&#8208;analytical conditions (e.g., transport), (3) assuming BBM stability at &#8208;80&#176;C without experimental verification, (4) not assessing fresh unfrozen samples, (5) not including demographic and clinical information while not knowing whether those could confound pre&#8208;analytical effects on BBM measurements, and (6) not being able to include all possible pTau assays/technologies due to our limited sample volume per experiment/condition. The establishment of a new biorepository including more handling factors is needed, which also offers the possibility to assess pre&#8208;analytics of novel markers, such as plasma brain derived tau (BD&#8208;tau), eMTBR243&#8208;tau, beta&#8208;synuclein, and SNAP&#8208;25,<xref rid="alz70752-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>, <xref rid="alz70752-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="alz70752-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="alz70752-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> and to include FDA&#8208;approved and/or in vitro diagnositic medical devices regulations (IVDR)&#8208;certified assays for the markers assessed here, once these become available, in addition to exploring whether demographic or clinical variables would modify the magnitude of pre&#8208;analytical effects, and test for longer&#8208;term storage at &#8722;20&#176;C</p><p>To conclude, this study provides an evidence&#8208;based, consensus sample handling protocol that ensures reliable neurological biomarker measurement upon clinical adoption. The protocol has flexibility and can be easily tailored to particular BBMs, addressing the important aspect of global BBM accessibility and healthcare equity. The presented standardized handling protocol will improve BBM reliability for diagnostic, prognostic, and disease monitoring approaches in clinical studies and upon routine clinical implementation.</p></sec><sec sec-type="COI-statement" id="alz70752-sec-0330"><title>CONFLICT OF INTEREST STATEMENT</title><p>M.G., D.A.B., M.vL., B.B., I.H., and S.J. have nothing to disclose. IV has consultancy contracts with Quanterix and Neurogen Biomarking, which are paid directly to her institution. I.V. performs contract research for Nitrase Therapeutics and Roche Diagnostics, which is paid directly to her institution. W.F. has been funded by ZonMW, NWO, EU&#8208;JPND, EU&#8208;IHI, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health Holland, Topsector Life Sciences &amp; Health, stichting Dioraphte, Noaber Foundation, Pieter Houbolt Fonds, Gieskes&#8208;Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, Philips, Biogen MA Inc., Novartis&#8208;NL, Life&#8208;MI, AVID, Roche BV, Lilly Nederland, Fujifilm, Eisai, Combinostics. W.F. holds the Pasman Chair. W.F. is the recipient of ABOARD, which is a public&#8211;private partnership receiving funding from ZonMW (No. 73305095007) and Health Holland, Topsector Life Sciences &amp; Health (PPP&#8208;allowance; No. LSHM20106) and is the recipient of TAP&#8208;dementia (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.tap-dementia.nl" ext-link-type="uri">www.tap&#8208;dementia.nl</ext-link>), receiving funding from ZonMw (No. 10510032120003). TAP&#8208;dementia receives co&#8208;financing from Avid Radiopharmaceuticals, Roche, and Amprion. W.F. is recipient of IHI&#8208;PROMINENT (No. 101112145) and IHI&#8208;AD&#8208;RIDDLE (No. 101132933). PROMINENT and AD&#8208;RIDDLE are supported by the Innovative Health Initiative Joint Undertaking (IHI JU). The JU receives support from the European Union's Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, and Vaccines Europe, with Davos Alzheimer's Collaborative, Combinostics OY, Cambridge Cognition Ltd., C2N Diagnostics LLC, and neotiv GmbH. All funding is paid to her institution. W.F. has been an invited speaker at Biogen MA Inc., Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, and European Brain Council. All funding is paid to her institution. W.F. is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc., Eisai, Eli Lilly, Owkin France, Nationale Nederlanden Ventures. All funding is paid to her institution. W.F. participated in advisory boards of Biogen MA Inc., Roche, and Eli Lilly, is a member of the steering committee of phase 3 EVOKE/EVOKE+ studies (NovoNordisk), and is a member of the steering committee of the phase 3 Trontinemab study (Roche). All funding is paid to her institution. In addition, W.F. is a member of the steering committee of PAVE and Think Brain Health, chair of the Scientific Leadership Group of InRAD, a former associate editor of Alzheimer, Research &amp; Therapy in 2020/2021, associate editor at Brain, and a member of the supervisory board (Raad van Toezicht) of Trimbos Instituut. O.H. is an employee of Lund University and Eli Lilly. N.LB. and M.V. are employees of Fujirebio Europe N.V. J.H. and L.H. are employees and shareholders of ALZpath. K.K. and P.V. are salaried employees at C2N Diagnostics and receive compensation from the company in the form of salary and/or equity. K.B. has served as a consultant and on advisory boards for AbbVie, AC Immune, ALZPath, AriBio, Beckman&#8208;Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd., Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sanofi, and Siemens Healthineers; has served on data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials, and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai, and Roche Diagnostics; and is a co&#8208;founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. H.Z. has served on scientific advisory boards and/or as a consultant for AbbVie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp &amp; Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica A.B., Roche, and WebMD; and is a co&#8208;founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). R.M.E. and E.A.M. are full&#8208;time employees of the Alzheimer's Association. C.E.T. has research contracts with Acumen, ADx Neurosciences, AC&#8208;Immune, Alamar, Aribio, Axon Neurosciences, Beckman&#8208;Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, C2N diagnostics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Instant Nano Biosensors, Merck, Muna, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Toyama, Vaccinex, and Vivoryon. C.E.T. is editor in chief of <italic toggle="yes">Alzheimer Research and Therapy</italic>, serves on the editorial boards of <italic toggle="yes">Molecular Neurodegeneration</italic>, <italic toggle="yes">Alzheimer's &amp; Dementia</italic>, <italic toggle="yes">Neurology: Neuroimmunology &amp; Neuroinflammation</italic>, and <italic toggle="yes">Medidact Neurologie</italic>/Springer, and is a member of the committee to define guidelines for cognitive disturbances and a committee for acute neurology in the Netherlands. C.E.T. has consultancy/speaker contracts for Aribio, Biogen, Beckman&#8208;Coulter, Cognition Therapeutics, Danaher, Eisai, Eli Lilly, Janssen, Merck, Novo Nordisk, Novartis, Olink, Roche, Sanofi, and Veravas. Author disclosures are available in the <xref rid="alz70752-supinfo-0001" ref-type="">Supporting Information</xref>.</p></sec><sec id="alz70752-sec-0340"><title>CONSENT STATEMENT</title><p>All human subjects provided informed consent.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz70752-supinfo-0001" position="float" content-type="local-data" orientation="portrait"/><supplementary-material id="alz70752-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70752-s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz70752-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-21-e70752-s002.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz70752-sec-0320"><title>ACKNOWLEDGMENTS</title><p>We acknowledge all participants who took part in this study. We thank Fujirebio, C2N and Lund University for their contribution to the sample measurements. We thank our active SABB workgroup members Marta del Campo, Anja Schneider, Blaine Roberts, Oliveira Fabricio, Ana Pereira, Joshua Bornhorst, Dhamidhu Eratne, Li Qiao&#8208;Xin, Jonathan Schott, Kaj Blennow, Henrik Zetterberg, Manuel Menendez, Leonidas Chouliaras, Suzanne Schindler, Tony Bannon, Erik Stoops, Eugeen Vanmechelen, Noelia Fandos, Andreas Jeromin, Nathalie Le Bastard, Andrei Popescu, Elisabeth Thijssen, Alexander Jethwa, and Les Shaw for their contributions to the consensus sample handling protocol. We acknowledge the following employees of C2N Diagnostics for their support of this work: Venky Venkatesh, PhD, and John Bui (for samples logistics and C2N data sharing), Matt Meyer, PhD (for plasma test development), Justine Coppinger, MS (for critical review of the manuscript), Stephanie Eastwood, PhD, and Mary Holubasch, MT (for plasma analysis). Figures were created in BioRender. This research is part of the neurodegeneration research program of Amsterdam Neuroscience. This study was conducted with funding from the Alzheimer's Association (SG&#8208;22&#8208;856131&#8208;SABB NEXT). M.G. is supported by this research grant. I.V. is supported by this research grant and by research grants from Health Holland and Amsterdam UMC. I.H. is supported by research grants of Health Holland and ZonMW. The chair of Wiesje van der Flier is supported by the Pasman Stichting. Research of Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting Steun Alzheimercentrum Amsterdam. K.B. is supported by the Swedish Research Council (Nos. 2017&#8208;00915 and 2022&#8208;00732), the Swedish Alzheimer Foundation (Nos. AF&#8208;930351, AF&#8208;939721, AF&#8208;968270, and AF&#8208;994551), Hj&#228;rnfonden, Sweden (Nos. ALZ2022&#8208;0006, FO2024&#8208;0048&#8208;TK&#8208;130, and FO2024&#8208;0048&#8208;HK&#8208;24), the Swedish state under an agreement between the Swedish government and the county councils, the ALF&#8208;agreement (Nos. ALFGBG&#8208;965240 and ALFGBG&#8208;1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019&#8208;466&#8208;236), the Alzheimer's Association 2021 Zenith Award (ZEN&#8208;21&#8208;848495), the Alzheimer's Association 2022&#8208;2025 Grant (SG&#8208;23&#8208;1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen R&#246;nstr&#246;ms Stiftelse, Stockholm, Sweden, and an anonymous philanthropist and donor. H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (Nos. 2023&#8208;00356, 2022&#8208;01018, and 2019&#8208;02397), the European Union's Horizon Europe Research and Innovation Programme under grant agreement (No. 101053962), Swedish State Support for Clinical Research (No. ALFGBG&#8208;71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (No. 201809&#8208;2016862), the AD Strategic Fund and the Alzheimer's Association (Nos. ADSF&#8208;21&#8208;831376&#8208;C, ADSF&#8208;21&#8208;831381&#8208;C, ADSF&#8208;21&#8208;831377&#8208;C, and ADSF&#8208;24&#8208;1284328&#8208;C), the European Partnership on Metrology, co&#8208;financed by the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, No. 22HLT07), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling&#8208;Persson Family Foundation, Familjen R&#246;nstr&#246;ms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen f&#246;r Gamla Tj&#228;narinnor, Hj&#228;rnfonden, Sweden (No. FO2022&#8208;0270), the European Union's Horizon 2020 research and innovation program under the Marie Sk&#322;odowska&#8208;Curie Grant Agreement No. 860197 (MIRIADE), the European Union Joint Programme &#8211; Neurodegenerative Disease Research (JPND2021&#8208;00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI&#8208;1003), and an anonymous donor. Research of CET is supported by the European Commission (Marie Curie International Training Network, Grant Agreement No. 860197 (MIRIADE) and No. 101119596 (TAME), Innovative Medicines Initiatives 3TR (Horizon 2020, grant 831434) EPND (IMI 2 Joint Undertaking (JU), grant 101034344), and JPND (bPRIDE, CCAD), European Partnership on Metrology, co&#8208;financed by the European Union's Horizon Europe Research and Innovation Programme and by the Participating States ((22HLT07 NEuroBioStand), Horizon Europe (PREDICTFTD, 101156175), CANTATE project funded by the Alzheimer Drug Discovery Foundation, Alzheimer's Association, Michael J. Fox Foundation, Health Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery Foundation, Selfridges Group Foundation, Alzheimer Netherlands. C.T. is recipient of ABOARD, which is a public&#8208;private partnership receiving funding from ZonMW (No. 73305095007) and Health Holland, Topsector Life Sciences &amp; Health (PPP&#8208;allowance; No. LSHM20106). C.T. is recipient of TAP&#8208;dementia, a ZonMw funded project (No. 10510032120003) in the context of the Dutch National Dementia Strategy. Alzheimer's Association, grant SG&#8208;22&#8208;856131&#8208;SABB NEXT.</p></ack><ref-list id="alz70752-bibl-0001"><title>REFERENCES</title><ref id="alz70752-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="alz70752-cite-0002"><string-name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Verberk</surname><given-names>IMW</given-names></string-name>, <string-name name-style="western"><surname>Thijssen</surname><given-names>EH</given-names></string-name>, et&#160;al. <article-title>Blood&#8208;based biomarkers for Alzheimer's disease: towards clinical implementation</article-title>. <source>Lancet Neurol</source>. <year>2022</year>;<volume>21</volume>:<fpage>66</fpage>&#8208;<lpage>77</lpage>.<pub-id pub-id-type="pmid">34838239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(21)00361-6</pub-id></mixed-citation></ref><ref id="alz70752-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz70752-cite-0003"><string-name name-style="western"><surname>Jack</surname><given-names>CR</given-names>, <suffix>Jr.</suffix></string-name>., <string-name name-style="western"><surname>Andrews</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Beach</surname><given-names>TG</given-names></string-name>, et&#160;al. <article-title>Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>(<issue>8</issue>):<fpage>5143</fpage>&#8208;<lpage>5169</lpage>.<pub-id pub-id-type="pmid">38934362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13859</pub-id><pub-id pub-id-type="pmcid">PMC11350039</pub-id></mixed-citation></ref><ref id="alz70752-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz70752-cite-0004"><string-name name-style="western"><surname>Hansson</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Blennow</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Dage</surname><given-names>J</given-names></string-name>. <article-title>Blood biomarkers for Alzheimer's disease in clinical practice and trials</article-title>. <source>Nature Aging</source>. <year>2023</year>;<volume>3</volume>:<fpage>506</fpage>&#8208;<lpage>519</lpage>.<pub-id pub-id-type="pmid">37202517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43587-023-00403-3</pub-id><pub-id pub-id-type="pmcid">PMC10979350</pub-id></mixed-citation></ref><ref id="alz70752-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz70752-cite-0005"><string-name name-style="western"><surname>Schindler</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Galasko</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>AC</given-names></string-name>, et&#160;al. <article-title>Acceptable performance of blood biomarker tests of amyloid pathology&#8212;recommendations from the Global CEO Initiative on Alzheimer's Disease</article-title>. <source>Nat Rev Neurol</source>. <year>2024</year>;<volume>20</volume>:<fpage>426</fpage>&#8208;<lpage>439</lpage>.<pub-id pub-id-type="pmid">38866966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-024-00977-5</pub-id></mixed-citation></ref><ref id="alz70752-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz70752-cite-0006"><string-name name-style="western"><surname>Mielke</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ashford</surname><given-names>JW</given-names></string-name>, et&#160;al. <article-title>Recommendations for clinical implementation of blood&#8208;based biomarkers for Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2024</year>;<volume>20</volume>:<fpage>8216</fpage>&#8208;<lpage>8224</lpage>.<pub-id pub-id-type="pmid">39351838</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14184</pub-id><pub-id pub-id-type="pmcid">PMC11567872</pub-id></mixed-citation></ref><ref id="alz70752-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz70752-cite-0007"><string-name name-style="western"><surname>Abdelhak</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Foschi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Abu&#8208;Rumeileh</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Blood GFAP as an emerging biomarker in brain and spinal cord disorders</article-title>. <source>Nat Rev Neuro</source>. <year>2022</year>;<volume>18</volume>:<fpage>158</fpage>&#8208;<lpage>172</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-021-00616-3</pub-id><pub-id pub-id-type="pmid">35115728</pub-id></mixed-citation></ref><ref id="alz70752-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz70752-cite-0008"><string-name name-style="western"><surname>Khalil</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Lehmann</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Neurofilaments as biomarkers in neurological disorders &#8212; towards clinical application</article-title>. <source>Nat Rev Neuro</source>. <year>2024</year>;<volume>20</volume>:<fpage>269</fpage>&#8208;<lpage>287</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-024-00955-x</pub-id><pub-id pub-id-type="pmid">38609644</pub-id></mixed-citation></ref><ref id="alz70752-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz70752-cite-0009"><string-name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Kolster</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Triana&#8208;Baltzer</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zetterberg</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kolb</surname><given-names>HC</given-names></string-name>. <article-title>Plasma p&#8208;tau immunoassays in clinical research for Alzheimer's disease</article-title>. <source>Alzheimer Dement</source>. <year>2025</year>;<volume>21</volume>(<issue>1</issue>):<elocation-id>e14397</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14397</pub-id><pub-id pub-id-type="pmcid">PMC11977406</pub-id><pub-id pub-id-type="pmid">39625101</pub-id></mixed-citation></ref><ref id="alz70752-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz70752-cite-0010"><collab collab-type="authors">Center for Devices and Radiological Health</collab>
. <article-title>FDA clears first blood test used in diagnosing Alzheimer's disease</article-title>. <source>News Release</source>. FDA. <year>2025</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease</ext-link></mixed-citation></ref><ref id="alz70752-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz70752-cite-0011"><string-name name-style="western"><surname>Zeng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sehrawat</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting</article-title>. <source>Mol Neurodegener</source>. <year>2024</year>;<volume>19</volume>:<fpage>40</fpage>.<pub-id pub-id-type="pmid">38750570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-024-00711-1</pub-id><pub-id pub-id-type="pmcid">PMC11095038</pub-id></mixed-citation></ref><ref id="alz70752-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz70752-cite-0012"><string-name name-style="western"><surname>Verberk</surname><given-names>IMW</given-names></string-name>, <string-name name-style="western"><surname>Misdorp</surname><given-names>EO</given-names></string-name>, <string-name name-style="western"><surname>Koelewijn</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Characterization of pre&#8208;analytical sample handling effects on a panel of Alzheimer's disease&#8208;related blood&#8208;based biomarkers: results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>18</volume>:<fpage>1484</fpage>&#8208;<lpage>1497</lpage>.<pub-id pub-id-type="pmid">34845818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12510</pub-id><pub-id pub-id-type="pmcid">PMC9148379</pub-id></mixed-citation></ref><ref id="alz70752-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz70752-cite-0013"><string-name name-style="western"><surname>Kurz</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>St&#246;ckl</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Schrurs</surname><given-names>I</given-names></string-name>, et&#160;al. <article-title>Impact of pre&#8208;analytical sample handling factors on plasma biomarkers of Alzheimer's disease</article-title>. <source>J Neurochem</source>. <year>2023</year>;<volume>165</volume>:<fpage>95</fpage>&#8208;<lpage>105</lpage>.<pub-id pub-id-type="pmid">36625424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.15757</pub-id></mixed-citation></ref><ref id="alz70752-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz70752-cite-0014"><string-name name-style="western"><surname>R&#243;zga</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bittner</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Batrla</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Karl</surname><given-names>J</given-names></string-name>. <article-title>Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2019</year>;<volume>11</volume>:<fpage>291</fpage>&#8208;<lpage>300</lpage>.<pub-id pub-id-type="pmid">30984815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dadm.2019.02.002</pub-id><pub-id pub-id-type="pmcid">PMC6446057</pub-id></mixed-citation></ref><ref id="alz70752-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz70752-cite-0015"><string-name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Su&#225;rez&#8208;Calvet</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Karikari</surname><given-names>TK</given-names></string-name>, et&#160;al. <article-title>Effects of pre&#8208;analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2021</year>;<volume>13</volume>:<elocation-id>e12168</elocation-id>.<pub-id pub-id-type="pmid">34124336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12168</pub-id><pub-id pub-id-type="pmcid">PMC8171159</pub-id></mixed-citation></ref><ref id="alz70752-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz70752-cite-0016"><string-name name-style="western"><surname>Bali</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hansson</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></string-name>. <article-title>Effects of certain pre&#8208;analytical factors on the performance of plasma phospho&#8208;tau217</article-title>. <source>Alzheimers Res Ther</source>. <year>2024</year>;<volume>16</volume>:<fpage>31</fpage>.<pub-id pub-id-type="pmid">38331843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01391-1</pub-id><pub-id pub-id-type="pmcid">PMC10851521</pub-id></mixed-citation></ref><ref id="alz70752-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz70752-cite-0017"><string-name name-style="western"><surname>Mansilla</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Canyelles</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ferrer</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Effects of storage conditions on the stability of blood&#8208;based markers for the diagnosis of Alzheimer's disease</article-title>. <source>Clin Chem Lab Med</source>. <year>2023</year>;<volume>61</volume>:<fpage>1580</fpage>&#8208;<lpage>1589</lpage>.<pub-id pub-id-type="pmid">37083158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/cclm-2023-0245</pub-id></mixed-citation></ref><ref id="alz70752-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz70752-cite-0018"><string-name name-style="western"><surname>Figdore</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Schuder</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Ashrafzadeh&#8208;Kian</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gronquist</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Bornhorst</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Algeciras&#8208;Schimnich</surname><given-names>A</given-names></string-name>. <article-title>Differences in Alzheimer's disease blood biomarker stability: implications for the use of tau/amyloid ratios</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e70173</elocation-id>.<pub-id pub-id-type="pmid">40308118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.70173</pub-id><pub-id pub-id-type="pmcid">PMC12044288</pub-id></mixed-citation></ref><ref id="alz70752-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz70752-cite-0019"><string-name name-style="western"><surname>Sunde</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Alsnes</surname><given-names>IV</given-names></string-name>, <string-name name-style="western"><surname>Aarsland</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2023</year>;<volume>15</volume>:<elocation-id>e12439</elocation-id>.<pub-id pub-id-type="pmid">37192842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12439</pub-id><pub-id pub-id-type="pmcid">PMC10182363</pub-id></mixed-citation></ref><ref id="alz70752-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz70752-cite-0020"><string-name name-style="western"><surname>Panikkar</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Vivek</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Crimmins</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Faul</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Langa</surname><given-names>KM</given-names></string-name>. <article-title>Thyagarajan B. Pre&#8208;analytical variables influencing stability of blood&#8208;based biomarkers of neuropathology</article-title>. <source>J Alzheimers Dis</source>. <year>2023</year>;<volume>95</volume>:<fpage>735</fpage>&#8208;<lpage>748</lpage>.<pub-id pub-id-type="pmid">37574735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-230384</pub-id><pub-id pub-id-type="pmcid">PMC11520930</pub-id></mixed-citation></ref><ref id="alz70752-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz70752-cite-0021"><string-name name-style="western"><surname>Jiang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Lei</surname><given-names>P</given-names></string-name>. <article-title>Head&#8208;to&#8208;Head Comparison of different blood collecting tubes for quantification of Alzheimer's disease biomarkers in plasma</article-title>. <source>Biomolecules</source>. <year>2022</year>;<volume>12</volume>(<issue>9</issue>):<fpage>1194</fpage>.<pub-id pub-id-type="pmid">36139033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom12091194</pub-id><pub-id pub-id-type="pmcid">PMC9496121</pub-id></mixed-citation></ref><ref id="alz70752-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz70752-cite-0022"><string-name name-style="western"><surname>Delgado</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Morell&#8208;Garcia</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bau&#231;a</surname><given-names>JM</given-names></string-name>. <article-title>Hemolysis Interference studies: the particular case of sodium ion</article-title>. <source>Ejifcc</source>. <year>2019</year>;<volume>30</volume>:<fpage>25</fpage>&#8208;<lpage>34</lpage>.<pub-id pub-id-type="pmid">30881272</pub-id><pub-id pub-id-type="pmcid">PMC6416812</pub-id></mixed-citation></ref><ref id="alz70752-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz70752-cite-0023"><string-name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Leuzy</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A&#946;42/A&#946;40 and p&#8208;tau</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>18</volume>:<fpage>283</fpage>&#8208;<lpage>293</lpage>.<pub-id pub-id-type="pmid">34151519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12395</pub-id></mixed-citation></ref><ref id="alz70752-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz70752-cite-0024"><string-name name-style="western"><surname>Palmqvist</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Quiroz</surname><given-names>YT</given-names></string-name>, et&#160;al. <article-title>Discriminative accuracy of plasma phospho&#8208;tau217 for Alzheimer disease vs other neurodegenerative disorders</article-title>. <source>Jama</source>. <year>2020</year>;<volume>324</volume>:<fpage>772</fpage>&#8208;<lpage>781</lpage>.<pub-id pub-id-type="pmid">32722745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.12134</pub-id><pub-id pub-id-type="pmcid">PMC7388060</pub-id></mixed-citation></ref><ref id="alz70752-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="alz70752-cite-0025"><string-name name-style="western"><surname>O'Bryant</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Henriksen</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Guidelines for the standardization of preanalytic variables for blood&#8208;based biomarker studies in Alzheimer's disease research</article-title>. <source>Alzheimers Dement</source>. <year>2015</year>;<volume>11</volume>:<fpage>549</fpage>&#8208;<lpage>560</lpage>.<pub-id pub-id-type="pmid">25282381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2014.08.099</pub-id><pub-id pub-id-type="pmcid">PMC4414664</pub-id></mixed-citation></ref><ref id="alz70752-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="alz70752-cite-0026"><string-name name-style="western"><surname>Redrup</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Igarashi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Schaefgen</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Sample management: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team</article-title>. <source>Aaps j</source>. <year>2016</year>;<volume>18</volume>:<fpage>290</fpage>&#8208;<lpage>293</lpage>.<pub-id pub-id-type="pmid">26821803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-016-9869-2</pub-id><pub-id pub-id-type="pmcid">PMC4779093</pub-id></mixed-citation></ref><ref id="alz70752-bib-0026"><label>26</label><mixed-citation publication-type="book" id="alz70752-cite-0027"><collab collab-type="authors">WHO</collab>
. <source>Preferred Product Characteristics of Blood&#8208;Based Biomarker Diagnostics for Alzheimer Disease</source>. <publisher-name>World Health Organization</publisher-name>; 2024. Licence: CC BY&#8208;NC&#8208;SA 3.0 IGO. <year>2024</year>.</mixed-citation></ref><ref id="alz70752-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz70752-cite-0028"><string-name name-style="western"><surname>Gonzalez&#8208;Ortiz</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Dias</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Turton</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Preanalytical stability of plasma/serum brain&#8208;derived tau</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>:<fpage>4764</fpage>&#8208;<lpage>4770</lpage>.<pub-id pub-id-type="pmid">37232524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13156</pub-id><pub-id pub-id-type="pmcid">PMC10592602</pub-id></mixed-citation></ref><ref id="alz70752-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz70752-cite-0029"><string-name name-style="western"><surname>van Lierop</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Verberk</surname><given-names>IMW</given-names></string-name>, <string-name name-style="western"><surname>van Uffelen</surname><given-names>KWJ</given-names></string-name>, et&#160;al. <article-title>Pre&#8208;analytical stability of serum biomarkers for neurological disease: neurofilament&#8208;light, glial fibrillary acidic protein and contactin&#8208;1</article-title>. <source>Clin Chem Lab Med</source>. <year>2022</year>;<volume>60</volume>:<fpage>842</fpage>&#8208;<lpage>850</lpage>.<pub-id pub-id-type="pmid">35333481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/cclm-2022-0007</pub-id></mixed-citation></ref><ref id="alz70752-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz70752-cite-0030"><string-name name-style="western"><surname>Youssef</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hughes</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>WS</given-names></string-name>, et&#160;al. <article-title>Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting</article-title>. <source>Sci Rep</source>. <year>2023</year>;<volume>13</volume>:<fpage>5217</fpage>.<pub-id pub-id-type="pmid">36997567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-32480-0</pub-id><pub-id pub-id-type="pmcid">PMC10063670</pub-id></mixed-citation></ref><ref id="alz70752-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz70752-cite-0031"><string-name name-style="western"><surname>Pannee</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Korecka</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>The global Alzheimer's Association round robin study on plasma amyloid &#946; methods</article-title>. <source>Alzheimers Dement (Amst)</source>. <year>2021</year>;<volume>13</volume>:<elocation-id>e12242</elocation-id>.<pub-id pub-id-type="pmid">34692980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12242</pub-id><pub-id pub-id-type="pmcid">PMC8515356</pub-id></mixed-citation></ref><ref id="alz70752-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz70752-cite-0032"><string-name name-style="western"><surname>Ashton</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Keshavan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brum</surname><given-names>WS</given-names></string-name>, et&#160;al. <article-title>The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho&#8208;tau Round Robin study</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>;<volume>21</volume>(<issue>2</issue>):<elocation-id>e14508</elocation-id>.<pub-id pub-id-type="pmid">39907496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14508</pub-id><pub-id pub-id-type="pmcid">PMC11851162</pub-id></mixed-citation></ref><ref id="alz70752-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz70752-cite-0033"><string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Albert</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Sehrawat</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Equivalence of plasma and serum for clinical measurement of p&#8208;tau217: comparative analyses of four blood&#8208;based assays</article-title>. <source>J Neurochem</source>. <year>2025</year>;<volume>169</volume>(<issue>7</issue>):<elocation-id>e70114</elocation-id>.<pub-id pub-id-type="pmid">40600294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.70114</pub-id><pub-id pub-id-type="pmcid">PMC12215601</pub-id></mixed-citation></ref><ref id="alz70752-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="alz70752-cite-0034"><string-name name-style="western"><surname>Kac</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Gonzalez&#8208;Ortiz</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Simr&#233;n</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Diagnostic value of serum versus plasma phospho&#8208;tau for Alzheimer's disease</article-title>. <source>Alzheimer Res Ther</source>. <year>2022</year>;<volume>14</volume>:<fpage>65</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-022-01011-w</pub-id><pub-id pub-id-type="pmcid">PMC9097064</pub-id><pub-id pub-id-type="pmid">35545792</pub-id></mixed-citation></ref><ref id="alz70752-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz70752-cite-0035"><string-name name-style="western"><surname>Walter</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wiltfang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vogelgsang</surname><given-names>J</given-names></string-name>. <article-title>Pre&#8208;Analytical sampling and storage conditions of amyloid&#8208;&#946; peptides in venous and capillary blood</article-title>. <source>J Alzheimers Dis</source>. <year>2020</year>;<volume>78</volume>:<fpage>529</fpage>&#8208;<lpage>535</lpage>.<pub-id pub-id-type="pmid">33016918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-200777</pub-id></mixed-citation></ref><ref id="alz70752-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz70752-cite-0036"><string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Diaz</surname><given-names>JL</given-names></string-name>, et&#160;al. <article-title>Effect of blood collection tube containing protease inhibitors on the pre&#8208;analytical stability of Alzheimer's disease plasma biomarkers</article-title>. <source>J Neurochem</source>. <year>2024</year>;<volume>168</volume>(<issue>9</issue>):<fpage>2736</fpage>&#8208;<lpage>2750</lpage>.<pub-id pub-id-type="pmid">38814273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.16130</pub-id><pub-id pub-id-type="pmcid">PMC11449657</pub-id></mixed-citation></ref><ref id="alz70752-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz70752-cite-0037"><string-name name-style="western"><surname>Jambunathan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Galande</surname><given-names>AK</given-names></string-name>. <article-title>Sample collection in clinical proteomics&#8211;proteolytic activity profile of serum and plasma</article-title>. <source>Proteomics Clin Appl</source>. <year>2014</year>;<volume>8</volume>:<fpage>299</fpage>&#8208;<lpage>307</lpage>.<pub-id pub-id-type="pmid">24723329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prca.201300037</pub-id></mixed-citation></ref><ref id="alz70752-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz70752-cite-0038"><string-name name-style="western"><surname>Lehmann</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gabelle</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Duchiron</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Comparative performance of plasma pTau181/A&#946;42, pTau217/A&#946;42 ratios, and individual measurements in detecting brain amyloidosis</article-title>. <source>EBioMedicine</source>. <year>2025</year>;<volume>117</volume>:<elocation-id>105805</elocation-id>.<pub-id pub-id-type="pmid">40513421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2025.105805</pub-id><pub-id pub-id-type="pmcid">PMC12192541</pub-id></mixed-citation></ref><ref id="alz70752-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz70752-cite-0039"><string-name name-style="western"><surname>Arranz</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Rubio&#8208;Guerra</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Diagnostic performance of plasma pTau217, pTau181, A&#946;1&#8208;42 and A&#946;1&#8208;40 in the LUMIPULSE automated platform for the detection of Alzheimer disease</article-title>. <source>Alzheimer Res Ther</source>. <year>2024</year>;<volume>16</volume>:<fpage>139</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-024-01513-9</pub-id><pub-id pub-id-type="pmcid">PMC11200993</pub-id><pub-id pub-id-type="pmid">38926773</pub-id></mixed-citation></ref><ref id="alz70752-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz70752-cite-0040"><string-name name-style="western"><surname>Zhong</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Plasma p&#8208;tau217 and p&#8208;tau217/A&#946;1&#8208;42 are effective biomarkers for identifying CSF&#8208; and PET imaging&#8208;diagnosed Alzheimer's disease: insights for research and clinical practice</article-title>. <source>Alzheimers Dement</source>. <year>2025</year>;<volume>21</volume>:<elocation-id>e14536</elocation-id>.<pub-id pub-id-type="pmid">39887504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.14536</pub-id><pub-id pub-id-type="pmcid">PMC11848202</pub-id></mixed-citation></ref><ref id="alz70752-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz70752-cite-0041"><string-name name-style="western"><surname>Bubis</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Gorshkov</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Gorshkov</surname><given-names>MV</given-names></string-name>, <string-name name-style="western"><surname>Kjeldsen</surname><given-names>F</given-names></string-name>. <article-title>PhosphoShield: improving trypsin digestion of phosphoproteins by shielding the negatively charged phosphate moiety</article-title>. <source>J Am Soc Mass Spectro</source>. <year>2020</year>;<volume>31</volume>:<fpage>2053</fpage>&#8208;<lpage>2060</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jasms.0c00171</pub-id><pub-id pub-id-type="pmid">32840367</pub-id></mixed-citation></ref><ref id="alz70752-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz70752-cite-0042"><string-name name-style="western"><surname>Wollowitz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bijur</surname><given-names>PE</given-names></string-name>, <string-name name-style="western"><surname>Esses</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>John Gallagher</surname><given-names>E</given-names></string-name>. <article-title>Use of butterfly needles to draw blood is independently associated with marked reduction in hemolysis compared to intravenous catheter</article-title>. <source>Acad Emerg Med</source>. <year>2013</year>;<volume>20</volume>:<fpage>1151</fpage>&#8208;<lpage>1155</lpage>.<pub-id pub-id-type="pmid">24238318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acem.12245</pub-id></mixed-citation></ref><ref id="alz70752-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz70752-cite-0043"><string-name name-style="western"><surname>Tanabe</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kyriacou</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Garland</surname><given-names>F</given-names></string-name>. <article-title>Factors affecting the risk of blood bank specimen hemolysis</article-title>. <source>Acad Emerg Med</source>. <year>2003</year>;<volume>10</volume>:<fpage>897</fpage>&#8208;<lpage>900</lpage>.<pub-id pub-id-type="pmid">12896895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1553-2712.2003.tb00637.x</pub-id></mixed-citation></ref><ref id="alz70752-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz70752-cite-0044"><string-name name-style="western"><surname>Wan Azman</surname><given-names>WN</given-names></string-name>, <string-name name-style="western"><surname>Omar</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Koon</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Tuan Ismail</surname><given-names>TS</given-names></string-name>. <article-title>Hemolyzed Specimens: major challenge for identifying and rejecting specimens in clinical laboratories</article-title>. <source>Oman Med J</source>. <year>2019</year>;<volume>34</volume>:<fpage>94</fpage>&#8208;<lpage>98</lpage>.<pub-id pub-id-type="pmid">30918601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5001/omj.2019.19</pub-id><pub-id pub-id-type="pmcid">PMC6425048</pub-id></mixed-citation></ref><ref id="alz70752-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz70752-cite-0045"><string-name name-style="western"><surname>Tian</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Jin</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>The incidence rate and influence factors of hemolysis, lipemia, icterus in fasting serum biochemistry specimens</article-title>. <source>PLoS One</source>. <year>2022</year>;<volume>17</volume>:<elocation-id>e0262748</elocation-id>.<pub-id pub-id-type="pmid">35045128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0262748</pub-id><pub-id pub-id-type="pmcid">PMC8769349</pub-id></mixed-citation></ref><ref id="alz70752-bib-0045"><label>45</label><mixed-citation publication-type="miscellaneous" id="alz70752-cite-0046"><collab collab-type="authors">(CDC) CfDCaP</collab>
. <article-title>Reference tool for hemolysis status</article-title>. U.S. Department of Health &amp; Human Services. <year>2024</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/vector-borne-diseases/php/laboratories/reference-tool-for-hemolysis-status.html" ext-link-type="uri">https://www.cdc.gov/vector&#8208;borne&#8208;diseases/php/laboratories/reference&#8208;tool&#8208;for&#8208;hemolysis&#8208;status.html</ext-link></mixed-citation></ref><ref id="alz70752-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz70752-cite-0047"><string-name name-style="western"><surname>Anwar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Renu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>AK</given-names></string-name>, et&#160;al. <article-title>Impact of hemolysis on the levels of proteins associated with aging and age&#8208;related neurodegenerative diseases in a multicentric clinical research</article-title>. <source>Prac Lab Med</source>. <year>2025</year>;<volume>44</volume>:<elocation-id>e00455</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.plabm.2025.e00455</pub-id><pub-id pub-id-type="pmcid">PMC11791351</pub-id><pub-id pub-id-type="pmid">39906488</pub-id></mixed-citation></ref><ref id="alz70752-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="alz70752-cite-0048"><string-name name-style="western"><surname>Ayele</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Whitehead</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Pascual</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>AD plasma biomarkers are stable for an extended period at &#8722;20&#176;C: implications for resource&#8208;constrained environments</article-title>. <source>medRxiv</source>. <year>2024</year>.</mixed-citation></ref><ref id="alz70752-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="alz70752-cite-0049"><string-name name-style="western"><surname>Gogishvili</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Illes&#8208;Toth</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Hopley</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Teunissen</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Abeln</surname><given-names>S</given-names></string-name>. <article-title>Structural flexibility and heterogeneity of recombinant human glial fibrillary acidic protein (GFAP)</article-title>. <source>Proteins</source>. <year>2024</year>;<volume>92</volume>:<fpage>649</fpage>&#8208;<lpage>664</lpage>.<pub-id pub-id-type="pmid">38149328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/prot.26656</pub-id></mixed-citation></ref><ref id="alz70752-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="alz70752-cite-0050"><string-name name-style="western"><surname>Coppens</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gogishvili</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Faustinelli</surname><given-names>V</given-names></string-name>, et&#160;al. <article-title>Neurofilament light chain under the lens of structural mass spectrometry</article-title>. <source>ACS Chem Neurosci</source>. <year>2025</year>;<volume>16</volume>:<fpage>141</fpage>&#8208;<lpage>151</lpage>.<pub-id pub-id-type="pmid">39746934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschemneuro.4c00526</pub-id><pub-id pub-id-type="pmcid">PMC11740998</pub-id></mixed-citation></ref><ref id="alz70752-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="alz70752-cite-0051"><string-name name-style="western"><surname>Gonzalez&#8208;Ortiz</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Turton</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kac</surname><given-names>PR</given-names></string-name>, et&#160;al. <article-title>Brain&#8208;derived tau: a novel blood&#8208;based biomarker for Alzheimer's disease&#8208;type neurodegeneration</article-title>. <source>Brain</source>. <year>2023</year>;<volume>146</volume>:<fpage>1152</fpage>&#8208;<lpage>1165</lpage>.<pub-id pub-id-type="pmid">36572122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awac407</pub-id><pub-id pub-id-type="pmcid">PMC9976981</pub-id></mixed-citation></ref><ref id="alz70752-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="alz70752-cite-0052"><string-name name-style="western"><surname>Oeckl</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Halbgebauer</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Higher plasma &#946;&#8208;synuclein indicates early synaptic degeneration in Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>:<fpage>5095</fpage>&#8208;<lpage>5102</lpage>.<pub-id pub-id-type="pmid">37186338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.13103</pub-id></mixed-citation></ref><ref id="alz70752-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="alz70752-cite-0053"><string-name name-style="western"><surname>Horie</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Salvad&#243;</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Koppisetti</surname><given-names>RK</given-names></string-name>, et&#160;al. <article-title>Plasma MTBR&#8208;tau243 biomarker identifies tau tangle pathology in Alzheimer's disease</article-title>. <source>Nat Med</source>. <year>2025</year>;<volume>31</volume>:<fpage>2044</fpage>&#8211;<lpage>2053</lpage>.<pub-id pub-id-type="pmid">40164726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-025-03617-7</pub-id><pub-id pub-id-type="pmcid">PMC12176612</pub-id></mixed-citation></ref><ref id="alz70752-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="alz70752-cite-0054"><string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Therriault</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>MS</given-names></string-name>, et&#160;al. <article-title>Cerebrospinal fluid synaptosomal&#8208;associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease</article-title>. <source>Alzheimers Res Ther</source>. <year>2018</year>;<volume>10</volume>:<fpage>80</fpage>.<pub-id pub-id-type="pmid">30115118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13195-018-0407-6</pub-id><pub-id pub-id-type="pmcid">PMC6097333</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neural Eng</journal-id><journal-id journal-id-type="iso-abbrev">J Neural Eng</journal-id><journal-id journal-id-type="pmc-domain-id">3178</journal-id><journal-id journal-id-type="pmc-domain">iopsd</journal-id><journal-id journal-id-type="publisher-id">jne</journal-id><journal-title-group><journal-title>Journal of Neural Engineering</journal-title></journal-title-group><issn pub-type="ppub">1741-2560</issn><issn pub-type="epub">1741-2552</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>IOP Publishing</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12481582</article-id><article-id pub-id-type="pmcid-ver">PMC12481582.1</article-id><article-id pub-id-type="pmcaid">12481582</article-id><article-id pub-id-type="pmcaiid">12481582</article-id><article-id pub-id-type="pmid">40961977</article-id><article-id pub-id-type="doi">10.1088/1741-2552/ae087d</article-id><article-id pub-id-type="publisher-id">jneae087d</article-id><article-id pub-id-type="other">JNE-108628.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Paper</subject></subj-group></article-categories><title-group><article-title>An interpretable generative multimodal neuroimaging-genomics framework for decoding Alzheimer&#8217;s disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0002-7817-7984</contrib-id><name name-style="western"><surname>Dolci</surname><given-names initials="G">Giorgio</given-names></name><xref rid="jneae087daf1" ref-type="aff">1</xref><xref rid="jneae087daf2" ref-type="aff">2</xref><xref rid="jneae087daf3" ref-type="aff">3</xref><xref rid="jneae087dfn3" ref-type="author-notes">*</xref><email>giorgio.dolci@univr.it</email></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7258-1463</contrib-id><name name-style="western"><surname>Cruciani</surname><given-names initials="F">Federica</given-names></name><xref rid="jneae087daf2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-4241-2439</contrib-id><name name-style="western"><surname>Abdur Rahaman</surname><given-names initials="M">Md</given-names></name><xref rid="jneae087daf3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-9223-5314</contrib-id><name name-style="western"><surname>Abrol</surname><given-names initials="A">Anees</given-names></name><xref rid="jneae087daf3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-5059-372X</contrib-id><name name-style="western"><surname>Chen</surname><given-names initials="J">Jiayu</given-names></name><xref rid="jneae087daf3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-1591-4900</contrib-id><name name-style="western"><surname>Fu</surname><given-names initials="Z">Zening</given-names></name><xref rid="jneae087daf3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-4153-3749</contrib-id><name name-style="western"><surname>Boscolo Galazzo</surname><given-names initials="I">Ilaria</given-names></name><xref rid="jneae087daf2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6889-3461</contrib-id><name name-style="western"><surname>Menegaz</surname><given-names initials="G">Gloria</given-names></name><xref rid="jneae087daf2" ref-type="aff">2</xref><xref rid="jneae087dfn1" ref-type="author-notes">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-9058-0747</contrib-id><name name-style="western"><surname>Calhoun</surname><given-names initials="VD">Vince D</given-names></name><xref rid="jneae087daf3" ref-type="aff">3</xref><xref rid="jneae087dfn1" ref-type="author-notes">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><collab>for the Alzheimer&#8217;s Disease Neuroimaging Initiative</collab><xref rid="jneae087dfn2" ref-type="author-notes">
<sup>5</sup>
</xref></contrib><aff id="jneae087daf1">
<label>1</label>Department of Computer Science, <institution>University of Verona</institution>, Verona, <country>Italy</country></aff><aff id="jneae087daf2">
<label>2</label>Department of Engineering for Innovation Medicine, <institution>University of Verona</institution>, Verona, <country>Italy</country></aff><aff id="jneae087daf3">
<label>3</label>Tri-Institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State University, Georgia Institute of Technology, <institution>Emory University</institution>, Atlanta, GA, <country>United States of America</country></aff></contrib-group><author-notes><fn id="jneae087dfn1"><label>4</label><p>V D Calhoun and G Menegaz equally contributed as last authors to this work.</p></fn><fn id="jneae087dfn2"><label>5</label><p>Data used in preparation of this article were obtained from the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf" ext-link-type="uri">http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf</ext-link></p></fn><corresp id="jneae087dfn3"><label>*</label>Author to whom any correspondence should be addressed.</corresp></author-notes><pub-date iso-8601-date="2025-10-01" pub-type="ppub"><day>01</day><month>10</month><year>2025</year></pub-date><pub-date iso-8601-date="2025-09-30" pub-type="epub"><day>30</day><month>9</month><year>2025</year></pub-date><volume>22</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">497985</issue-id><elocation-id content-type="artnum">056021</elocation-id><history><date date-type="received"><day>04</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>26</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>9</month><year>2025</year></date><date date-type="oa-requested"><day>29</day><month>6</month><year>2025</year></date><date date-type="open-access"><day>01</day><month>10</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 10:25:36.583"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by IOP Publishing Ltd</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>
Original content from this work may be used under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 license</ext-link>. Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jne_22_5_056021.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="jne_22_5_056021.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="preprint" xml:lang="en" xlink:title="research-article" journal-id="ArXiv" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11213156"><article-title>AN INTERPRETABLE GENERATIVE MULTIMODAL NEUROIMAGING-GENOMICS FRAMEWORK FOR DECODING ALZHEIMER&#8217;S DISEASE</article-title><date><day>4</day><month>2</month><year>2025</year></date><elocation-id>arXiv:2406.13292v3</elocation-id><source>ArXiv</source><pub-id pub-id-type="pmcid">PMC11213156</pub-id><pub-id pub-id-type="pmid">38947922</pub-id></related-article><abstract abstract-type="standard"><title>Abstract</title><p><italic toggle="yes">Objective.</italic> Alzheimer&#8217;s disease (AD) is the most prevalent form of dementia worldwide, encompassing a prodromal stage known as mild cognitive impairment (MCI), where patients may either progress to AD or remain stable. The objective of the work was to capture structural and functional modulations of brain structure and function relying on multimodal MRI data and single nucleotide polymorphisms, also in case of missing views, with the twofold goal of classifying AD patients versus healthy controls and detecting MCI converters. <italic toggle="yes">Approach.</italic> We propose a multimodal deep learning (DL)-based classification framework where a generative module employing cycle generative adversarial networks was introduced in the latent space for imputing missing data (a common issue of multimodal approaches). Explainable AI method was then used to extract input features&#8217; relevance allowing for post-hoc validation and enhancing the interpretability of the learned representations. <italic toggle="yes">Main results.</italic> Experimental results on two tasks, AD detection and MCI conversion, showed that our framework reached competitive performance in the state-of-the-art with an accuracy of <inline-formula><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.926\pm0.02$\end{document}</tex-math><mml:math id="M2" overflow="scroll"><mml:mrow><mml:mn>0.926</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.02</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn1.jpg"/></alternatives></inline-formula> (CI [0.90, 0.95]) and <inline-formula><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.711\pm0.01$\end{document}</tex-math><mml:math id="M4" overflow="scroll"><mml:mrow><mml:mn>0.711</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn2.jpg"/></alternatives></inline-formula> (CI [0.70, 0.72]) in the two tasks, respectively. The interpretability analysis revealed gray matter modulations in cortical and subcortical brain areas typically associated with AD. Moreover, impairments in sensory-motor and visual resting state networks along the disease continuum, as well as genetic mutations defining biological processes linked to endocytosis, amyloid-beta, and cholesterol, were identified. <italic toggle="yes">Significance.</italic> Our integrative and interpretable DL approach shows promising performance for AD detection and MCI prediction while shedding light on important biological insights.</p></abstract><kwd-group kwd-group-type="author"><kwd>Alzheimer&#8217;s disease</kwd><kwd>generative model</kwd><kwd>imaging-genetics</kwd><kwd>explainable AI</kwd></kwd-group><funding-group><award-group><funding-source>Fondazione CariVerona</funding-source><award-id>2018.0855.2019</award-id></award-group><award-group><funding-source>MIUR</funding-source><award-id>D.M. 737/2021 AI4Health</award-id></award-group><award-group><funding-source><institution-wrap><institution>National Institutes of Health</institution><institution-id institution-id-type="doi">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>RF1AG063153</award-id></award-group><award-group><funding-source><institution-wrap><institution>National Science Foundation</institution><institution-id institution-id-type="doi">10.13039/100000001</institution-id></institution-wrap></funding-source><award-id>#2112455</award-id></award-group></funding-group><counts><page-count count="23"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>crossmark</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="jneae087ds1"><label>1.</label><title>Introduction</title><p>Alzheimer&#8217;s disease (AD) is a chronic neurodegenerative disorder that affects millions of people worldwide (approximately 30&#8201;million in 2015 [<xref rid="jneae087dbib1" ref-type="bibr">1</xref>]. It is the most common cause of cognitive impairment, gradually impacting the activities of a patient&#8217;s daily life. It is characterized by the progressive loss of cognitive and functional abilities, including memory, language, and executive functions [<xref rid="jneae087dbib2" ref-type="bibr">2</xref>], with a temporal progression. Amyloid accumulation represents the first event, followed by tau accumulation, hypometabolism (assessed with positron emission tomography (PET)), atrophy, and cognitive decline [<xref rid="jneae087dbib3" ref-type="bibr">3</xref>, <xref rid="jneae087dbib4" ref-type="bibr">4</xref>]. It is hence evident that the pathology changes of AD actually begin several years before the first clinical symptoms. Therefore, a timely AD diagnosis is highly beneficial for optimizing patient care and enabling appropriate therapeutic interventions. Mild cognitive impairment (MCI) is the intermediate stage from normal cognitive function to AD, hence representing an opportunity for an early targeting of the disease. However, it includes a very heterogeneous class of patients, including subjects that will likely convert to AD, known as MCI converters (MCIc), with an estimated annual conversion rate around the 16.5% [<xref rid="jneae087dbib5" ref-type="bibr">5</xref>], and subjects that remain stable after several years, being part of the MCI non-converters (MCInc) group [<xref rid="jneae087dbib6" ref-type="bibr">6</xref>].</p><p>Among the available neuroimaging technologies, structural magnetic resonance imaging (sMRI) and resting-state functional MRI (rs-fMRI) have provided unprecedented opportunities for deriving biomarkers allowing the early diagnosis of AD. For instance, sMRI is currently a key part of the diagnostic criteria for the differential diagnosis and longitudinal monitoring of patients with dementia, enabling the estimation of brain atrophy. Several studies have consistently observed both global and local atrophic changes in AD, lying along the hippocampal pathway (entorhinal cortex, hippocampus, parahippocampal gyrus, and posterior cingulate cortex) in the early stages of the disease, while atrophy in temporal, parietal and frontal neocortices emerges at later stages being associated with neuronal loss as well as with language, visuospatial and behavioral impairments [<xref rid="jneae087dbib7" ref-type="bibr">7</xref>, <xref rid="jneae087dbib8" ref-type="bibr">8</xref>]. Rs-fMRI, in turn, indirectly measures neural activity by detecting changes in the blood oxygenation level dependent (BOLD) signals, which depend on the neurovascular coupling [<xref rid="jneae087dbib9" ref-type="bibr">9</xref>]. In particular, investigating functional connectivity (FC; inter-regional coupling), functional network connectivity (FNC; inter-network coupling), and functional networks from BOLD rs-fMRI provides a means for understanding the mechanisms and relevance of the functional relationships across brain regions. A growing body of rs-fMRI studies suggests that failure of specific resting-state networks (RSNs) is closely related to AD, with the default-mode network (DM) and the salience network (SN) playing a pivotal role and being disrupted before clinically evident symptoms [<xref rid="jneae087dbib10" ref-type="bibr">10</xref>]. Specific alterations in these functional networks have been reported in AD patients, with prominent FC decreased within the DM and increased FC in the SN [<xref rid="jneae087dbib11" ref-type="bibr">11</xref>, <xref rid="jneae087dbib12" ref-type="bibr">12</xref>]. Moreover, disconnections within and between the different RSNs have been consistently demonstrated, particularly over long connection distances [<xref rid="jneae087dbib13" ref-type="bibr">13</xref>]. All of these factors have contributed to the widespread view of AD as a disconnection syndrome being characterized by a cascading network failure, beginning in the posterior DM and then shifting to other systems containing prominent connectivity hubs, possibly associated with amyloid accumulation [<xref rid="jneae087dbib14" ref-type="bibr">14</xref>]. Moreover, increased evidence supports the view that tau depositions are also related to functional brain architecture and FC changes, supporting the view of transneuronal tau propagation in AD [<xref rid="jneae087dbib15" ref-type="bibr">15</xref>].</p><p>AD also features a strong genetic component. Strategies to extract linked genotype traits are commonly based on single nucleotide polymorphism (SNPs) analysis [<xref rid="jneae087dbib16" ref-type="bibr">16</xref>], representing variations of single nucleotides in DNA sequences that vary from person to person [<xref rid="jneae087dbib16" ref-type="bibr">16</xref>] and are present in at least 1% of the population. Several genome-wide association studies (GWASs) have identified more than 40 AD-associated genes/loci, which are likely to increase the risk of developing the disease [<xref rid="jneae087dbib17" ref-type="bibr">17</xref>&#8211;<xref rid="jneae087dbib19" ref-type="bibr">19</xref>]. Among them, the apolipoprotein E (APOE), in particular the <inline-formula><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\epsilon4$\end{document}</tex-math><mml:math id="M6" overflow="scroll"><mml:mrow><mml:mi>&#1013;</mml:mi><mml:mn>4</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn3.jpg"/></alternatives></inline-formula> allele, PICALM, CLU, ABCA7, and CR1 are the most important genes being associated with AD risk factor or the progression from MCI to AD [<xref rid="jneae087dbib20" ref-type="bibr">20</xref>&#8211;<xref rid="jneae087dbib27" ref-type="bibr">27</xref>].</p><p>This great heterogeneity of available biomarkers offers a unique opportunity to explore various aspects of the disease continuum. Each biomarker provides valuable information about specific characteristics, enabling a multifaceted investigation of AD which calls for methods that can effectively integrate and leverage complementary information. In this regard, artificial intelligence, machine learning (ML) and particularly deep learning (DL), emerge as promising technologies to tackle this complex task. Different ML algorithms have been developed for integrating heterogeneous data, such as canonical correlation analysis, partial least squares, and ensemble methods, e.g. consisting of different support vector machines (SVMs). Even if these methods can perform well in studying neurodegenerative diseases [<xref rid="jneae087dbib28" ref-type="bibr">28</xref>, <xref rid="jneae087dbib29" ref-type="bibr">29</xref>], they have some limitations, such as requiring vectorized input data, hence denaturing the spatial information of 3D volumes (e.g. sMRI or PET 3D images), and potentially being too simple for solving complex tasks. On the other hand, by employing multiple layers of processing, DL models allow extracting progressively higher-level and more informative features from input data, with the option of preserving spatial information, without the need of vectorizing the input features. Moreover, the inclusion of multiple data sources into a single model can uncover complex and deep non-linear associations across the input features from a multimodal perspective [<xref rid="jneae087dbib30" ref-type="bibr">30</xref>]. As a result, multimodality is gaining significant popularity representing the key approach to derive valuable insights into complex and multifaceted neurodegenerative diseases such as AD [<xref rid="jneae087dbib31" ref-type="bibr">31</xref>&#8211;<xref rid="jneae087dbib36" ref-type="bibr">36</xref>]. However, despite the promising foreseen of such an approach, multiple drawbacks are present and represent the focus of the current research. The main concern resides in missing data management. Particularly in the biomedical domain, it is very common to incur in missing values or acquisitions for certain subjects or entire study cohorts due to different reasons, such as missing acquisition, corrupted data, patients dropout from a study [<xref rid="jneae087dbib37" ref-type="bibr">37</xref>], and the requirements of privacy and expensive tests. Additionally, the interpretability of a model&#8217;s predictions is a central characteristic of decision-aiding models, which is still not pervasively addressed. In the past years, many high-performing prediction models have been proposed lacking a clear rationale to be effectively considered for practical use. Strong and validated explanations associated with a given prediction are fundamental for increasing trust in the results as well as for their applicability in a real-world scenario. Innovative and viable missing modality management as well as interpretability are the key attributes that a multimodal model for diagnosis detection should have.</p><p>Diving into missing data management, the simplest and most common solutions consist either in discarding samples with missing modalities, or in filling the missing values with zeros [<xref rid="jneae087dbib38" ref-type="bibr">38</xref>], and computing imputations based on data interpolation [<xref rid="jneae087dbib39" ref-type="bibr">39</xref>]. Such solutions are evidently suboptimal since they could significantly reduce the number of training samples, already small when addressing biomedical-related tasks, or introduce important biases in the data and the model due to the interpolation or the zero filling when a lot of data are missing. Alternative methods to exploit the information of all the available subjects were proposed. Some works employed multi-kernel learning methods for imputing missing data employing different kernel strategies to mix and integrate the heterogeneous modality, while managing missing data [<xref rid="jneae087dbib40" ref-type="bibr">40</xref>&#8211;<xref rid="jneae087dbib42" ref-type="bibr">42</xref>]. A possible approach is the complementation of incomplete data representation, which consists in extracting a latent representation from both the complete and incomplete modalities, avoiding the need for data imputation [<xref rid="jneae087dbib43" ref-type="bibr">43</xref>, <xref rid="jneae087dbib44" ref-type="bibr">44</xref>]. Most recent approaches aim at generating missing data either in the input space [<xref rid="jneae087dbib45" ref-type="bibr">45</xref>&#8211;<xref rid="jneae087dbib47" ref-type="bibr">47</xref>] or in an intermediate latent representation [<xref rid="jneae087dbib48" ref-type="bibr">48</xref>&#8211;<xref rid="jneae087dbib50" ref-type="bibr">50</xref>] relying on generative models such as generative adversarial networks (GANs) [<xref rid="jneae087dbib45" ref-type="bibr">45</xref>, <xref rid="jneae087dbib48" ref-type="bibr">48</xref>, <xref rid="jneae087dbib49" ref-type="bibr">49</xref>, <xref rid="jneae087dbib51" ref-type="bibr">51</xref>&#8211;<xref rid="jneae087dbib54" ref-type="bibr">54</xref>] and their variants, or variational autoencoders [<xref rid="jneae087dbib55" ref-type="bibr">55</xref>]. This last approach has been successfully applied to the AD continuum investigation. It allows the exploitation of the availability of multimodal data for capturing the relationship among different data sources in the latent space, enabling the generation of one modality from another. Generative models, hence, appear as the route to be followed when dealing with missing data. Interestingly, the recently proposed cycle-consistent GANs [<xref rid="jneae087dbib56" ref-type="bibr">56</xref>] have shown impressive results in various knowledge translation tasks since they offer a flexible and effective approach for learning mappings across different domains without relying on paired data.</p><p>Moving to model interpretability, it is well established that with increasing model complexity, interpretability decreases drastically. However, in order to better understand the mechanisms that underlie the AD continuum and allow the models to be applied in clinical and real-life applications, it is vital to understand the reasons behind a certain output. In this case, explainable artificial intelligence (XAI), becomes essential to understand why a given model made a certain prediction. XAI encompasses <italic toggle="yes">post-hoc</italic> methods that allow the assignment of an importance score to each feature, reflecting its role in the classification task. This means finally opening the &#8216;black box&#8217; of complex models hopefully increasing their exploitability in clinical practice. XAI is starting to be applied in multimodal frameworks to study neurodegenerative and psychiatric diseases. Few works could be found adopting simple gradient-based, feature perturbation methods, or attention weights [<xref rid="jneae087dbib32" ref-type="bibr">32</xref>, <xref rid="jneae087dbib45" ref-type="bibr">45</xref>, <xref rid="jneae087dbib52" ref-type="bibr">52</xref>, <xref rid="jneae087dbib57" ref-type="bibr">57</xref>&#8211;<xref rid="jneae087dbib59" ref-type="bibr">59</xref>]. On top of this, another overlooked yet stringent aspect is the strong validation of XAI methods and the obtained explanations. The evaluation of explanation methods is still under-investigated, however, since explainability is meant to increase confidence in AI, it is vital to systematically analyze the obtained results referring also to the prior knowledge derived from the state-of-the-art.</p><p>In this rapidly evolving landscape, where multimodality holds a central role, we aim at shading light on the importance of the complementary information that could be derived from advanced biomarkers such as brain FC and SNPs mutations, together with the well-established brain atrophy measures derived from sMRI, in detecting AD-related modulations. With this purpose, we will present a multimodal framework for AD detection and MCI conversion prediction, which addresses (i) heterogeneous data integration, (ii) missing data management, and (iii) interpretability. Regarding the former, our framework allows the integration of heterogeneous data featuring different dimensionality, e.g. 3D volumes and vectorized data, and nature, meaning from multi-domain, e.g. imaging and genetics. Concerning the second, we propose an approach that allows generating missing modalities in the latent space obtained after input feature reduction, ensuring high accuracy in reconstructing latent features while minimizing computational demands. Moreover, another important aspect of imputing missing data in the latent space relies on the fact that the latent space is lower-dimensional with respect to the input one, thus a simpler task to solve. The goal is to define a framework that can be generalized to any missing modality, without requiring to have at least one specific modality shared by all the subjects in the considered population. Finally, we aimed at emphasizing the interpretability of the proposed framework in order to reinforce its transparency and reliability by conducting an XAI post-hoc interpretability analysis, supplemented by a robust validation step, which enables to precisely discern the contribution of each input feature to the classification of subjects in the AD continuum, thus highlighting relevant phenotypic and genotypic biomarkers for AD.</p></sec><sec id="jneae087ds2"><label>2.</label><title>Materials and methods</title><sec id="jneae087ds2-1"><label>2.1.</label><title>Dataset</title><p>Data used in the preparation of this article were obtained from the AD Neuroimaging Initiative (ADNI) database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://adni.loni.usc.edu/" ext-link-type="uri">https://adni.loni.usc.edu/</ext-link>). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. For up-to-date information, see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.adni-info.org" ext-link-type="uri">www.adni-info.org</ext-link>.</p><p>For each subject, the baseline timepoint was retained for all the selected imaging modalities, that is, sMRI and rs-fMRI. The respective genetic variants (SNPs) were then selected, if available. The final study cohort included 1911 subjects, divided into healthy controls (CN), AD, MCInc, and MCIc. In detail, following the classification available on the ADNI website, an MCI subject was considered as MCIc if dementia was diagnosed at any timepoint after MCI diagnosis. Table <xref rid="jneae087dt1" ref-type="table">1</xref> shows the Task 1 and Task 2 demographic information. For Task 1, the entire cohort, and the subset of individuals sharing both sMRI-fMRI and sMRI-SNPs are highlighted.</p><table-wrap position="float" id="jneae087dt1" orientation="portrait"><label>Table 1.</label><caption id="jneae087dtc1"><p>Demographic information of the CN, AD, MCInc, and MCIc subjects. MCInc and MCIc have the following % of missing SNPs 59.6% and 30.8%, respectively, and the missing fMRI are 60.1% and 92%, respectively. MMSE = mini-mental state examination; wild (W) and mutated (M) alleles in APOE4: 0 = homozygous (W/W), 1 = heterozygous (W/M), 2 = homozygous (M/M).</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th align="center" colspan="6" rowspan="1" valign="bottom">Task 1</th><th align="center" colspan="2" rowspan="1" valign="bottom">Task 2</th></tr><tr><th align="left" colspan="1" rowspan="1" valign="bottom"/><th align="center" colspan="3" rowspan="1" valign="bottom">CN</th><th align="center" colspan="3" rowspan="1" valign="bottom">AD</th><th align="left" colspan="1" rowspan="1" valign="bottom">MCInc</th><th align="left" colspan="1" rowspan="1" valign="bottom">MCIc</th></tr><tr><th align="left" colspan="1" rowspan="1" valign="bottom">Cohorts</th><th align="left" colspan="1" rowspan="1" valign="bottom">All subjects</th><th align="left" colspan="1" rowspan="1" valign="bottom">sMRI-fMRI</th><th align="left" colspan="1" rowspan="1" valign="bottom">sMRI-SNPs</th><th align="left" colspan="1" rowspan="1" valign="bottom">All subjects</th><th align="left" colspan="1" rowspan="1" valign="bottom">sMRI-fMRI</th><th align="left" colspan="1" rowspan="1" valign="bottom">sMRI-SNPs</th><th align="center" colspan="2" rowspan="1" valign="bottom">Only for testing phase</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1" valign="top">Count</td><td align="left" colspan="1" rowspan="1" valign="top">644</td><td align="left" colspan="1" rowspan="1" valign="top">321</td><td align="left" colspan="1" rowspan="1" valign="top">253</td><td align="left" colspan="1" rowspan="1" valign="top">332</td><td align="left" colspan="1" rowspan="1" valign="top">66</td><td align="left" colspan="1" rowspan="1" valign="top">152</td><td align="left" colspan="1" rowspan="1" valign="top">646</td><td align="left" colspan="1" rowspan="1" valign="top">289</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Age (y)</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$73.6 \pm 6.6$\end{document}</tex-math><mml:math id="M8" overflow="scroll"><mml:mrow><mml:mn>73.6</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>6.6</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn4.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$72.4 \pm 7.1$\end{document}</tex-math><mml:math id="M10" overflow="scroll"><mml:mrow><mml:mn>72.4</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>7.1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn5.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$76.4 \pm 5.4$\end{document}</tex-math><mml:math id="M12" overflow="scroll"><mml:mrow><mml:mn>76.4</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>5.4</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn6.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$75.1 \pm 7.9$\end{document}</tex-math><mml:math id="M14" overflow="scroll"><mml:mrow><mml:mn>75.1</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>7.9</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn7.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$74.7 \pm 8.1$\end{document}</tex-math><mml:math id="M16" overflow="scroll"><mml:mrow><mml:mn>74.7</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>8.1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn8.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$75.8 \pm 7.7$\end{document}</tex-math><mml:math id="M18" overflow="scroll"><mml:mrow><mml:mn>75.8</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>7.7</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn9.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$73 \pm 8.5$\end{document}</tex-math><mml:math id="M20" overflow="scroll"><mml:mrow><mml:mn>73</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>8.5</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn10.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$74 \pm 8.5$\end{document}</tex-math><mml:math id="M22" overflow="scroll"><mml:mrow><mml:mn>74</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>8.5</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn11.jpg"/></alternatives>
</inline-formula>
</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Gender (F)</td><td align="left" colspan="1" rowspan="1" valign="top">284 (360)</td><td align="left" colspan="1" rowspan="1" valign="top">117 (204)</td><td align="left" colspan="1" rowspan="1" valign="top">137 (116)</td><td align="left" colspan="1" rowspan="1" valign="top">181 (151)</td><td align="left" colspan="1" rowspan="1" valign="top">35 (31)</td><td align="left" colspan="1" rowspan="1" valign="top">84 (68)</td><td align="left" colspan="1" rowspan="1" valign="top">374 (272)</td><td align="left" colspan="1" rowspan="1" valign="top">172 (117)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">MMSE</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$29.1 \pm 1.1$\end{document}</tex-math><mml:math id="M24" overflow="scroll"><mml:mrow><mml:mn>29.1</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>1.1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn12.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$29.1 \pm 1.2$\end{document}</tex-math><mml:math id="M26" overflow="scroll"><mml:mrow><mml:mn>29.1</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>1.2</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn13.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$29.1 \pm 1.1$\end{document}</tex-math><mml:math id="M28" overflow="scroll"><mml:mrow><mml:mn>29.1</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>1.1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn14.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$23.1 \pm 2.2$\end{document}</tex-math><mml:math id="M30" overflow="scroll"><mml:mrow><mml:mn>23.1</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>2.2</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn15.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$22.6 \pm 2.6$\end{document}</tex-math><mml:math id="M32" overflow="scroll"><mml:mrow><mml:mn>22.6</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>2.6</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn16.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$23.3 \pm 2.0$\end{document}</tex-math><mml:math id="M34" overflow="scroll"><mml:mrow><mml:mn>23.3</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>2.0</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn17.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$27.9 \pm 1.8$\end{document}</tex-math><mml:math id="M36" overflow="scroll"><mml:mrow><mml:mn>27.9</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>1.8</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn18.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$26.9 \pm 1.8$\end{document}</tex-math><mml:math id="M38" overflow="scroll"><mml:mrow><mml:mn>26.9</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>1.8</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn19.jpg"/></alternatives>
</inline-formula>
</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">APOE e4 (<inline-formula><alternatives><tex-math id="M39">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0/1/2$\end{document}</tex-math><mml:math id="M40" overflow="scroll"><mml:mrow><mml:mn>0</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn20.jpg"/></alternatives></inline-formula>)</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M41">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$455/168/21$\end{document}</tex-math><mml:math id="M42" overflow="scroll"><mml:mrow><mml:mn>455</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>168</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>21</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn21.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M43">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$224/87/10$\end{document}</tex-math><mml:math id="M44" overflow="scroll"><mml:mrow><mml:mn>224</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>87</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn22.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M45">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$189/57/7$\end{document}</tex-math><mml:math id="M46" overflow="scroll"><mml:mrow><mml:mn>189</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>57</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn23.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M47">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$109/156/67$\end{document}</tex-math><mml:math id="M48" overflow="scroll"><mml:mrow><mml:mn>109</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>156</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>67</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn24.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M49">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$19/34/13$\end{document}</tex-math><mml:math id="M50" overflow="scroll"><mml:mrow><mml:mn>19</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>34</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>13</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn25.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M51">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$49/76/27$\end{document}</tex-math><mml:math id="M52" overflow="scroll"><mml:mrow><mml:mn>49</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>76</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>27</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn26.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M53">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$377/205/64$\end{document}</tex-math><mml:math id="M54" overflow="scroll"><mml:mrow><mml:mn>377</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>205</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>64</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn27.jpg"/></alternatives>
</inline-formula>
</td><td align="left" colspan="1" rowspan="1" valign="top">
<inline-formula>
<alternatives><tex-math id="M55">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$103/143/43$\end{document}</tex-math><mml:math id="M56" overflow="scroll"><mml:mrow><mml:mn>103</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>143</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>43</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn28.jpg"/></alternatives>
</inline-formula>
</td></tr></tbody></table></table-wrap><p>3D T1-w MRI and rs-fMRI acquisitions were considered as imaging input channels and were acquired with the following sequence parameters: (i) sagittal accelerated MPRAGE, TR/TE = shortest, TI = 900&#8201;ms, flip angle = 9<sup>&#8728;</sup>, Field Of View = 256&#8201;&#215;&#8201;256&#8201;mm<sup>2</sup>, spatial resolution = <inline-formula><alternatives><tex-math id="M57">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$1\times1\times1$\end{document}</tex-math><mml:math id="M58" overflow="scroll"><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#215;</mml:mo><mml:mn>1</mml:mn><mml:mo>&#215;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn29.jpg"/></alternatives></inline-formula>&#8201;mm<sup>3</sup>, slices = <inline-formula><alternatives><tex-math id="M59">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$176-211$\end{document}</tex-math><mml:math id="M60" overflow="scroll"><mml:mrow><mml:mn>176</mml:mn><mml:mo>&#8722;</mml:mo><mml:mn>211</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn30.jpg"/></alternatives></inline-formula>), (ii) rs-fMRI: TR/TE = <inline-formula><alternatives><tex-math id="M61">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$ 3000/30$\end{document}</tex-math><mml:math id="M62" overflow="scroll"><mml:mrow><mml:mn>3000</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>30</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn31.jpg"/></alternatives></inline-formula>&#8201;ms, FA = 90<sup>&#8728;</sup>, FOV = 220&#8201;&#215;&#8201;220&#8201;&#215;&#8201;163&#8201;mm<sup>3</sup>, 3.4&#8201;mm isotropic voxel size. 200 fMRI volumes were acquired in almost all subjects, with minimal variations in a small subset (e.g. 197 or 195 volumes). More details about the data acquisition can be found in [<xref rid="jneae087dbib60" ref-type="bibr">60</xref>]. Concerning the genetic data, DNA samples were genotyped using Illumina Human610-Quad or Illumina HumanOmniExpress BeadChip.</p></sec><sec id="jneae087ds2-2"><label>2.2.</label><title>Preprocessing and feature engineering</title><p>The sMRI volumes preprocessing included tissue segmentation in gray matter (GM), white matter, and cerebrospinal fluid using the modulated normalization algorithm. Only the GM volume was considered for this study, to which a smoothing using a Gaussian kernel (FWHM = 6&#8201;mm) was applied. FWHM of 6&#8201;mm was selected since this value can efficiently reduce random noise and mitigate minor inter-subject anatomical variability, enhancing our ability to detect group-level differences, and to keep the consistency between sMRI and rs-fMRI. The full preprocessed GM volume was used as input for the sMRI channel, resulting in an input size of 121&#8201;&#215;&#8201;145&#8201;&#215;&#8201;121 for each subject. The rs-fMRI data was preprocessed using the statistical parametric mapping toolbox (SPM12, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.fil.ion.ucl.ac.uk/spm/" ext-link-type="uri">http://www.fil.ion.ucl.ac.uk/spm/</ext-link>) including rigid body motion correction to correct subject head motion, slice-timing correction, warping to the standard MNI space using the EPI template, resampling to (3 mm)<sup>3</sup> isotropic voxels, and smoothing using a Gaussian kernel (FWHM = 6&#8201;mm), following the preprocessing proposed in [<xref rid="jneae087dbib61" ref-type="bibr">61</xref>]. Fifty-three independent components (ICs) covering the whole brain were extracted using spatially constrained ICA with the Neuromark_fMRI_1.0 template (available in the GIFT software; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://trendscenter.org/software/gift" ext-link-type="uri">http://trendscenter.org/software/gift</ext-link>). For each subject, a correlation matrix was then created computing the Pearson correlation between the ICs time courses, resulting in a 53&#8201;&#215;&#8201;53 static FNC matrix. This was divided into 7 RSNs, named: (i) sub-cortical network (SC), (ii) auditory network, (iii) sensorimotor network (SM), (iv) visual network (VI), (v) cognitive-control network (CC), (vi) DM network, and (vii) Cerebellar network (CB) (please, refer to supplementary table 5 for more information). The upper triangular matrix was then vectorized, resulting in an input vector of 1378 features for each subject. Quality control of MRI images is detailed in the supplementary materials section &#8216;Materials and Methods&#8217;, subsection &#8216;Preprocessing quality control of MRI&#8217;.</p><p>Moving to the genomics data, pre-imputation QC was performed to remove SNPs with minor allele frequency <inline-formula><alternatives><tex-math id="M63">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$ &lt; 0.05$\end{document}</tex-math><mml:math id="M64" overflow="scroll"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn32.jpg"/></alternatives></inline-formula>, call rate <inline-formula><alternatives><tex-math id="M65">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$ &lt; 0.98$\end{document}</tex-math><mml:math id="M66" overflow="scroll"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>0.98</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn33.jpg"/></alternatives></inline-formula>, and Hardy Weinberg Equilibrium <inline-formula><alternatives><tex-math id="M67">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$ &lt; 10^{-3}$\end{document}</tex-math><mml:math id="M68" overflow="scroll"><mml:mrow><mml:mo>&lt;</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn34.jpg"/></alternatives></inline-formula> (details in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.synapse.org/#!Synapse:syn2290704/wiki/64710" ext-link-type="uri">http://www.synapse.org/#!Synapse:syn2290704/wiki/64710</ext-link>). Imputation was performed with the same reference panel. Only the SNPs with imputation <inline-formula><alternatives><tex-math id="M69">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$r^2 &gt; 0.4$\end{document}</tex-math><mml:math id="M70" overflow="scroll"><mml:mrow><mml:msup><mml:mi>r</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>&gt;</mml:mo><mml:mn>0.4</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn35.jpg"/></alternatives></inline-formula> were included. Linkage disequilibrium-based pruning with <inline-formula><alternatives><tex-math id="M71">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$r^2 = 0.8$\end{document}</tex-math><mml:math id="M72" overflow="scroll"><mml:mrow><mml:msup><mml:mi>r</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mn>0.8</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn36.jpg"/></alternatives></inline-formula> in a window of 50 kb was applied, yielding <inline-formula><alternatives><tex-math id="M73">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$445\,838$\end{document}</tex-math><mml:math id="M74" overflow="scroll"><mml:mrow><mml:mn>445</mml:mn><mml:mstyle scriptlevel="0"/><mml:mn>838</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn37.jpg"/></alternatives></inline-formula> SNPs for further analyses [<xref rid="jneae087dbib62" ref-type="bibr">62</xref>]. A feature selection leveraging on the GWAS on AD conducted by [<xref rid="jneae087dbib17" ref-type="bibr">17</xref>] was carried on to include all the relevant SNPs having GWAS <italic toggle="yes">p</italic>-values less than 1&#215;10<sup>&#8210;4</sup>. A total of 565 SNPs was selected and a value between 0 and 2 was assigned based on the presence of mutated alleles. In detail, defining wild and mutated alleles respectively as W and M, a score of 0 means wild homozygous alleles (W/W), a score of 1 indicates heterozygous alleles (W/M), and a score of 2 defines mutated homozygous alleles (M/M).</p></sec><sec id="jneae087ds2-3"><label>2.3.</label><title>Framework architecture</title><p>The proposed framework builds on our previous work [<xref rid="jneae087dbib35" ref-type="bibr">35</xref>] and employed for addressing two classification tasks: Task 1, CN-AD, and Task 2, MCInc-MCIc, is shown in figure <xref rid="jneae087df1" ref-type="fig">1</xref>. In detail, the architecture for disease detection consists of three modules: (i) <italic toggle="yes">feature reduction module</italic>, which performs a CNN-based feature extraction to derive a lower dimensionality latent space, separately for each input channel; (ii) <italic toggle="yes">Generative module</italic> that, in the eventuality of missing modalities, actuates a generative process in the latent space transferring the knowledge from one domain to another; and (iii) <italic toggle="yes">data fusion &amp; classification module</italic> that fuses the latent features obtained for the three modalities and then performs the classification. Post-hoc interpretability analysis was then carried on in order to retrieve features&#8217; contributions to the classification task. The three modules will be detailed in the following paragraphs.</p><fig position="float" id="jneae087df1" orientation="portrait"><label>Figure 1.</label><caption id="jneae087dfc1"><p>The proposed framework that integrates sMRI, fMRI, and SNPs is articulated in three modules: (i) a feature reduction module where the latent representations are extracted for the input data; (ii) a generative module where, if necessary, the missing modalities are imputed; and (iii) a data fusion &amp; classification module where the latent features are fused and then classified. Finally, <italic toggle="yes">post-hoc</italic> XAI analysis is performed relying on the IG method for feature attribution derivation.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="print-only" content-type="print" id="jneae087df1_eps" position="float" orientation="portrait" xlink:href="jneae087df1.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="web-only" content-type="online" id="jneae087df1_lr" position="float" orientation="portrait" xlink:href="jneae087df1_lr.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="high" id="jneae087df1_hr" position="float" orientation="portrait" xlink:href="jneae087df1_hr.jpg"/></alternatives></fig><sec id="jneae087ds2-3-1"><title>Feature reduction module</title><p>The feature reduction module consists of three different CNNs, one for each input channel, leading to a latent low dimensionality representation consisting of 100 latent features for each channel. The sMRI channel was analyzed through a 3D CNN (sMRI-CNN) defined by six convolutional layers (filter sizes of <inline-formula><alternatives><tex-math id="M75">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$3\times3\times3$\end{document}</tex-math><mml:math id="M76" overflow="scroll"><mml:mrow><mml:mn>3</mml:mn><mml:mo>&#215;</mml:mo><mml:mn>3</mml:mn><mml:mo>&#215;</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn38.jpg"/></alternatives></inline-formula> for the first four convolutional layers and <inline-formula><alternatives><tex-math id="M77">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$2\times2\times2$\end{document}</tex-math><mml:math id="M78" overflow="scroll"><mml:mrow><mml:mn>2</mml:mn><mml:mo>&#215;</mml:mo><mml:mn>2</mml:mn><mml:mo>&#215;</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn39.jpg"/></alternatives></inline-formula> for the last two, number of filters: 64, 64, 64, 128, 128, and 128) and three max-pooling layer, followed by four fully-connected layers (FCLs) (number of nodes: 1536, 768, 384, and 192). The rs-fMRI channel was analyzed through a 1D CNN (rs-fMRI-CNN), consisting of four convolutional layers (filter sizes 5, number of filters: 64, 128, 128, and 128), two max-pooling layers, and two FCLs (number of nodes: 384 and 100). Finally, for genetic data, a 1D CNN (SNPs-CNN) was employed, enclosing three convolutional blocks, each including a sequence of convolutional layers (filter sizes 3, number of filters: 64, 64, and 128), batch-normalization and max-pooling, followed by three FCLs (number of nodes: 1024, 512, and 128). The ReLU activation function was used for all the layers of these three CNNs. Implementation details are summarized in table 1 of the supplementary materials.</p></sec><sec id="jneae087ds2-3-2"><title>Generative module</title><p>The generative module allows imputing the missing modalities in the latent space given the others, when necessary. This task is possible thanks to the injection in the complete framework of four pre-trained generators derived from two different cGANs [<xref rid="jneae087dbib56" ref-type="bibr">56</xref>]. The first, the sMRI-SNPs-cGAN allows imputing the latent genetics features transferring the knowledge from the latent sMRI one and vice-versa, and the second, the sMRI-fMRI-cGAN, transfers the knowledge again from the latent sMRI features to generate the respective rs-fMRI ones, and vice-versa. The scarcity of subjects sharing all modalities impeded the development of an fMRI-SNPs-cGAN model.</p><p>The cGANs were built and trained prior to the full framework. In detail, to obtain the pretrained generators, the first step required to obtain the channels&#8217; latent representations (i.e. the 100 features vector for each modality) needed to subsequently train the cGANs. This was necessary since, as already highlighted, the proposed framework performs the data generation directly in the latent space and not in the original input space. Since the subset of subjects having all three modalities was not numerous enough to train a classification model, two separate bi-modal models were developed, one having sMRI and SNPs (sMRI-SNPs-NN) as input channels and the other having sMRI and rs-fMRI as input channels (sMRI-fMRI-NN). Figure <xref rid="jneae087df2" ref-type="fig">2</xref>(a) shows the schematic representation of the sMRI-fMRI-NN, as a reference example. The feature reduction for each channel and the data fusion &amp; classification modules of these bi-modal models were the same as the ones adopted in the complete framework and described in the previous paragraph. Once the latent vectors were obtained, they were given as input to two cGANs, namely sMRI-fMRI-cGAN and sMRI-SNPs-cGAN, one for each bi-modal model, and hence for each information transfer, from sMRI to rs-fMRI and from sMRI to SNPs, respectively. Figure <xref rid="jneae087df2" ref-type="fig">2</xref>(b) shows the sample sMRI-fMRI-cGAN architecture used to generate sMRI from rs-fMRI and vice-versa. The generators are composed of six FCLs (number of nodes: 256, 512, 512, 1024, 512, and 100) activated by a ReLU activation function. The discriminators consisted of four FCLs (number of nodes: 256, 128, 64, and 1) activated by the LeakyRelu function, alternated with three dropout layers (dropout probability: 0.3). The same architecture was considered for the sMRI-SNPs-cGAN. Implementation details are summarized in table 2 of the supplementary materials.</p><fig position="float" id="jneae087df2" orientation="portrait"><label>Figure 2.</label><caption id="jneae087dfc2"><p>The bi-modal model sMRI-fMRI-NN/cGAN. (a) The sMRI-fMRI-NN is composed of feature reduction and data fusion &amp; classification modules (equal architectures of the full model). (b) After training, the feature reduction module extracts the latent features of both MRI used for training the sMRI-fMRI-cGAN, whose losses are described in (c) and (d).</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="print-only" content-type="print" id="jneae087df2_eps" position="float" orientation="portrait" xlink:href="jneae087df2.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="web-only" content-type="online" id="jneae087df2_lr" position="float" orientation="portrait" xlink:href="jneae087df2_lr.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="high" id="jneae087df2_hr" position="float" orientation="portrait" xlink:href="jneae087df2_hr.jpg"/></alternatives></fig></sec><sec id="jneae087ds2-3-3"><title>Data fusion &amp; classification module</title><p>The data fusion &amp; classification module consists of a fusion layer and a classifier. The latent features obtained either from the data reduction module or the data generation module (for the subjects with missing modalities) are fused through vector concatenation, resulting in 300 features. A multilayer perceptron composed of three FCLs (number of nodes: 150, 75, and 2) activated by the ReLU function was then used for classification. Softmax activated the output layer.</p></sec></sec><sec id="jneae087ds2-4"><label>2.4.</label><title>Training scheme</title><p>Figure <xref rid="jneae087df3" ref-type="fig">3</xref> illustrates the training workflow of the entire framework. As already specified, the training phase was not performed end-to-end but was divided into two steps, each one with end-to-end training, necessary for the correct training of the generation module: (i) Step 1: training of bi-modal models and cGANs, and (ii) Step 2: training of the full framework.</p><fig position="float" id="jneae087df3" orientation="portrait"><label>Figure 3.</label><caption id="jneae087dfc3"><p>The framework training is performed in two steps: Step 1 involves the training of sMRI-fMRI-NN and sMRI-SNPs-NN (Step 1a) and the respective sMRI-fMRI-cGAN and sMRI-SNPs-cGAN (Step 1b); while in Step 2 the multimodal framework is trained.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="print-only" content-type="print" id="jneae087df3_eps" position="float" orientation="portrait" xlink:href="jneae087df3.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="web-only" content-type="online" id="jneae087df3_lr" position="float" orientation="portrait" xlink:href="jneae087df3_lr.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="high" id="jneae087df3_hr" position="float" orientation="portrait" xlink:href="jneae087df3_hr.jpg"/></alternatives></fig><p>Hyperparameter tuning was performed through a grid search. The number of layers, channels, nodes, and the filters&#8217; size were tuned considering the single-modality architectures for the classification (Task 1) before training the multimodal framework.</p><sec id="jneae087ds2-4-1"><title>Training step 1: bi-modal models and cGANs</title><p>In the training Step 1 the two sMRI-fMRI-NN and sMRI-SNPs-NN bi-modal models were trained for the AD versus CN classification (Step 1a, figure <xref rid="jneae087df3" ref-type="fig">3</xref>) in order to subsequently extract the latent features to be fed to the two cGANs, sMRI-fMRI-cGAN and sMRI-SNPs-cGAN (Step 1b, figure <xref rid="jneae087df3" ref-type="fig">3</xref>). More in-depth, the bi-model models and subsequently the cGANs were trained relying on the AD and CN subjects sharing respectively the sMRI and rs-fMRI acquisition and the sMRI and SNPs acquisition, presented in table <xref rid="jneae087dt1" ref-type="table">1</xref>. A 10-folds stratified cross validation (CV) procedure for a total of 40 epochs, Adam optimizer [<xref rid="jneae087dbib63" ref-type="bibr">63</xref>] with a learning rate of 0.0001, and mini-batch technique considering a batch size of 14 and 9 were selected, respectively, for the training of the sMRI-fMRI-NN and the sMRI-SNPs-NN. Weighted cross entropy (CE) was used as the loss function. The sMRI-fMRI-NN and the sMRI-SNPs-NN achieved an average validation accuracy of <inline-formula><alternatives><tex-math id="M79">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.89\pm0.03$\end{document}</tex-math><mml:math id="M80" overflow="scroll"><mml:mrow><mml:mn>0.89</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn40.jpg"/></alternatives></inline-formula> (CI [0.86, 0.91]) and <inline-formula><alternatives><tex-math id="M81">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.864\pm0.03$\end{document}</tex-math><mml:math id="M82" overflow="scroll"><mml:mrow><mml:mn>0.864</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn41.jpg"/></alternatives></inline-formula> (CI [0.82, 0.89]), respectively. The best model in terms of validation accuracy was retained for both the NNs and used to extract the 100 latent features for each subject and for each modality. The newly obtained feature set was used to train the two cGANs. A mini-batch technique, keeping the same subjects in each batch as the bi-modal models, was used for both the sMRI-fMRI-cGAN and the sMRI-SNPs-cGAN training. Adam optimizer with a learning rate of 0.0001 was used to train the generators for a total of 600 epochs. As in [<xref rid="jneae087dbib56" ref-type="bibr">56</xref>], the adversarial losses were considered as optimization targets for each cGAN as in figure <xref rid="jneae087df2" ref-type="fig">2</xref>(c). In detail, considering the sMRI-fMRI-cGAN as reference, given <italic toggle="yes">s</italic> and <italic toggle="yes">f</italic> the latent feature vectors for the sMRI and rs-fMRI, <italic toggle="yes">G</italic><sub><italic toggle="yes">fs</italic></sub> and <italic toggle="yes">G</italic><sub><italic toggle="yes">sf</italic></sub> the generators to obtain <italic toggle="yes">s</italic> from <italic toggle="yes">f</italic> and vice-versa and <italic toggle="yes">D<sub>s</sub></italic> and <italic toggle="yes">D<sub>f</sub></italic> the discriminators to distinguish the <italic toggle="yes">s</italic> from the generated <inline-formula><alternatives><tex-math id="M83">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\hat{s}$\end{document}</tex-math><mml:math id="M84" overflow="scroll"><mml:mrow><mml:mrow><mml:mover><mml:mi>s</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn42.jpg"/></alternatives></inline-formula> and the <italic toggle="yes">f</italic> from the generated <inline-formula><alternatives><tex-math id="M85">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\hat{f}$\end{document}</tex-math><mml:math id="M86" overflow="scroll"><mml:mrow><mml:mrow><mml:mover><mml:mi>f</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn43.jpg"/></alternatives></inline-formula>, respectively, the adversarial loss penalizes the <italic toggle="yes">D<sub>s</sub></italic> and <italic toggle="yes">D<sub>f</sub></italic> errors in discriminating between <inline-formula><alternatives><tex-math id="M87">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\hat{s} = G_{fs}(f)$\end{document}</tex-math><mml:math id="M88" overflow="scroll"><mml:mrow><mml:mrow><mml:mover><mml:mi>s</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>f</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn44.jpg"/></alternatives></inline-formula> and <italic toggle="yes">s</italic>, and <inline-formula><alternatives><tex-math id="M89">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$\hat{f} = G_{sf}(s)$\end{document}</tex-math><mml:math id="M90" overflow="scroll"><mml:mrow><mml:mrow><mml:mover><mml:mi>f</mml:mi><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn45.jpg"/></alternatives></inline-formula> and <italic toggle="yes">f</italic>, respectively. The major issue arising when considering this loss solely is that with a large enough capacity, the generators <italic toggle="yes">G</italic><sub><italic toggle="yes">fs</italic></sub> and <italic toggle="yes">G</italic><sub><italic toggle="yes">sf</italic></sub> can map the same set of input images to any random permutation of images in the target domain (latent features in our case) [<xref rid="jneae087dbib56" ref-type="bibr">56</xref>]. The cycle consistency losses were hence introduced to limit the space of possible mapping functions by also penalizing the difference between <italic toggle="yes">f</italic> and <inline-formula><alternatives><tex-math id="M91">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$G_{sf}(G_{fs}(f))$\end{document}</tex-math><mml:math id="M92" overflow="scroll"><mml:mrow><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>f</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn46.jpg"/></alternatives></inline-formula>, and between <italic toggle="yes">s</italic> and <inline-formula><alternatives><tex-math id="M93">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$G_{fs}(G_{sf}(s))$\end{document}</tex-math><mml:math id="M94" overflow="scroll"><mml:mrow><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>f</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn47.jpg"/></alternatives></inline-formula>, respectively, hence completing the cycle (figure <xref rid="jneae087df2" ref-type="fig">2</xref>(d)). The cycle consistency loss was used in both sMRI-fMRI-cGAN and sMRI-SNPs-cGAN in order to assess the performance of the generators in imputing missing modalities using the mean absolute error (MAE). The four pre-trained generators, two for the sMRI-fMRI-cGAN and two for the sMRI-SNPs-cGAN, were then extracted and injected in the latent space of the proposed multimodal framework for the online generation of the missing modalities during the full framework training.</p></sec><sec id="jneae087ds2-4-2"><title>Training Step 2: full multimodal framework</title><p>The full multimodal framework including the three input channels, sMRI, rs-fMRI, and SNPs, was trained for classification Task 1, AD detection, relying on the complete AD and CN data cohort. Subjects were split into training and testing sets, respectively, including the 80%&#8211;20% of the study cohort. The testing set was kept unseen until the last testing phase. A stratified 10-fold CV procedure was applied to the training set. A mini-batch strategy (12 subjects per batch) was adopted during training. Adam optimizer with a learning rate of 0.0001 was chosen and the model was trained for a total of 70 epochs. Weighted CE was considered as the loss function. During this training phase, the four pre-trained cGAN generators&#8217; weights were kept frozen. Indeed, during backpropagation, only the weights of the feature reduction module and the data fusion and classification module were updated. Additional information about the training procedure is described in the supplementary materials &#8216;Materials and methods&#8217; and subsection &#8216;Training scheme additional information&#8217;.</p><sec id="jneae087ds2-4-2-1"><title>2.4.1. Testing and performance evaluation</title><p>The best model, in terms of validation accuracy, obtained from the CV procedure of training Step 2 was considered for the testing phase for the two classification tasks. The full MCI cohort, never considered during the training phase, hence kept completely unseen by the model, was considered as a testing set for the classification Task 2, MCI conversion prediction. The framework was finally evaluated in terms of accuracy (ACC), precision (PRE), and recall (REC) on both testing sets for the two classification tasks. Five independent runs reshuffling the train and test sets were performed for probing the generalization capabilities of the model, and the average test performance over the different runs was retained.</p></sec></sec></sec><sec id="jneae087ds2-5"><label>2.5.</label><title>Comparison with baseline approaches</title><p>Two baseline methods with two different imputation strategies were implemented for the sake of comparison with the proposed framework in each Task. In detail, an ensemble SVM and an ensemble random forest classifiers with mean and zero imputation strategies were developed on the dataset considered in this study. Similar to the proposed framework, the cohort composed of CN and AD was used to train and test both ensemble models, and then Task 2 (MCI cohort) was employed only in the testing phase as an external test. Additionally, an ablation study has been conducted to assess the ability of the multimodal framework to outperform the single modality and bi-modal models, and to assess the importance of data integration and the generative process, which allows for not discarding individuals with missing data. Five independent runs, as in the proposed method, were performed for all the models to assess the ability to generalize on different testing splits.</p></sec></sec><sec id="jneae087ds3"><label>3.</label><title>Post-hoc interpretability analysis</title><p>The post-hoc interpretability analysis was performed relying on Integrated Gradients (IG) [<xref rid="jneae087dbib64" ref-type="bibr">64</xref>], aiming at obtaining attribution maps describing the relevance of each input feature on the different input channels with respect to the outcome of the model. IG is a baseline attribution method, in the sense that, to obtain feature attributions, IG computes the path integral of the gradients along the straightline path from a given baseline <italic toggle="yes">x</italic>&#8242; to the input <italic toggle="yes">x</italic> [<xref rid="jneae087dbib64" ref-type="bibr">64</xref>] following the equation <disp-formula id="jneae087deqn1"><alternatives><tex-math id="M95">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{align*} \mathrm{IG}_i\left(x\right):: &amp;amp;= \left(x_i-x_{i}^{^{\prime}}\right)\nonumber\\ &amp;amp; \quad \times\int_{\alpha = 0}^{1} \frac{\partial F\left(x^{^{\prime}}_i+\alpha\times\left(x_i-x^{^{\prime}}_i\right)\right)}{\partial x_i}\mathrm{d}\alpha\end{align*}\end{document}</tex-math><mml:math id="M96" display="block" overflow="scroll"><mml:mrow><mml:mtable columnalign="left" displaystyle="true"><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mi>IG</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>x</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>::</mml:mo></mml:mtd><mml:mtd><mml:mi/><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mi>&#8242;</mml:mi></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mstyle scriptlevel="0"/><mml:mo>&#215;</mml:mo><mml:msubsup><mml:mo>&#8747;</mml:mo><mml:mrow><mml:mi>&#945;</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mfrac><mml:mrow><mml:mi>&#8706;</mml:mi><mml:mi>F</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>&#8242;</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>&#945;</mml:mi><mml:mo>&#215;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>&#8242;</mml:mi></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>&#8706;</mml:mi><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mi>&#945;</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jneae087deqn1.jpg"/></alternatives></disp-formula> where <italic toggle="yes">F</italic> is the model and <italic toggle="yes">&#945;</italic> is a factor ranging in [<inline-formula><alternatives><tex-math id="M97">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0,1$\end{document}</tex-math><mml:math id="M98" overflow="scroll"><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn48.jpg"/></alternatives></inline-formula>], determining the step size along the straightline path from <italic toggle="yes">x</italic> to <italic toggle="yes">x</italic>&#8242;. For the proposed model, a triplet of neutral baselines, one for each input data, was selected as follows: 3D zero matrix, 1D zero vector, and 1D Gaussian noise vector for sMRI, rs-fMRI, and SNPs, respectively.</p><p>In our study IG was applied on the testing set of each classification task, resulting in a triplet of attribution maps for sMRI, rs-fMRI, and SNPs lying in the same space as the input data, for each subject and task. The different maps will be referred to as sMRI-IG, fMRI-IG, and SNPs-IG in what follows.</p><sec id="jneae087ds3-1"><label>3.1.</label><title>Neuroimaging</title><p>In order to retain the most relevant features, an initial sMRI-IG map thresholding was applied, selecting only the attribution values exceeding in absolute value the 99.5th percentile of the respective IG values distribution voxelwise. The average sMRI-IG values for 55 cortical and subcortical brain regions based on the Harvard&#8211;Oxford atlas [<xref rid="jneae087dbib65" ref-type="bibr">65</xref>] were then extracted for all the subjects in the testing sets of both classification tasks. Only the regions where at least 99% of the subjects had average values exceeding the percentile threshold were kept for subsequent analysis. For fMRI-IG, only the connections whose attribution scores were in absolute value above the 98th percentile of the respective IG value distribution connection-wise were considered for further analysis. Different thresholds were chosen for the IG maps due to the different input sizes.</p><p>A statistical group-based analysis was then performed considering the attribution maps derived for each class, namely CN, MCInc, MCIc, and AD. Shapiro&#8211;Wilk test of normality was initially performed on the sMRI-IG and fMRI-IG derived features, revealing non-normally distributed values. The non-parametric Kruskal&#8211;Wallis test was hence performed to check the statistical difference across the four classes considered in each feature, derived either from rs-fMRI (most relevant connections resulting from fMRI-IG) or sMRI (most relevant brain regions derived from the sMRI-IG). When significance was found, the pairwise Wilcoxon Rank Sum Test was performed between all the possible pairs of the four considered groups (AD-CN, AD-MCIc, AD-MCInc, CN-MCIc, CN-MCInc, MCIc-MCInc) and adjusted for multiple comparisons with Bonferroni correction.</p><p>The same analysis was performed on the real value of the sMRI and rs-fMRI used as input to the proposed model, thus considering the GM maps and the FC for validating the post-hoc XAI analysis.</p></sec><sec id="jneae087ds3-2"><label>3.2.</label><title>Genetics</title><p>Only the SNPs with attribution greater than the 65th percentile in absolute terms of the SNPs-IG distribution, and those having positive attribution, were kept. The ensemble variant effect predictor tool [<xref rid="jneae087dbib66" ref-type="bibr">66</xref>] was used to annotate the selected SNPs in their corresponding genes, considering the default settings. Enrichment analysis was then performed using the Gene Ontology enrichment analysis tool [<xref rid="jneae087dbib67" ref-type="bibr">67</xref>&#8211;<xref rid="jneae087dbib69" ref-type="bibr">69</xref>] to derive the most important biological processes in which the annotated genes were involved. A background of 334 genes was generated by annotating the 565 SNPs-set used as input data for the model. Bonferroni correction for multiple testing was performed, and both corrected and no corrected <italic toggle="yes">p</italic>-values were reported. The SNPs annotation, as well as the enrichment analysis, was computed only on the classes of patients (AD, MCInc, and MCIc).</p></sec></sec><sec id="jneae087ds4"><label>4.</label><title>Results</title><sec id="jneae087ds4-1"><label>4.1.</label><title>Task 1: AD detection</title><p>The generators for both sMRI-fMRI-cGAN and sMRI-SNPs-cGAN models were tested by computing the MAE across the validation sets to compare the true latent space and the reconstructed one. For the sMRI-fMRI-cGAN, the generators achieved a MAE of <inline-formula><alternatives><tex-math id="M99">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.065\pm0.01$\end{document}</tex-math><mml:math id="M100" overflow="scroll"><mml:mrow><mml:mn>0.065</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn49.jpg"/></alternatives></inline-formula> (CI [0.06, 0.08]) and <inline-formula><alternatives><tex-math id="M101">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.074\pm0.01$\end{document}</tex-math><mml:math id="M102" overflow="scroll"><mml:mrow><mml:mn>0.074</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn50.jpg"/></alternatives></inline-formula> (CI [0.07, 0.09]) for the fMRI and the sMRI modalities, respectively. Meanwhile, the sMRI-SNPs-cGAN generators reached a MAE of <inline-formula><alternatives><tex-math id="M103">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.506\pm0.04$\end{document}</tex-math><mml:math id="M104" overflow="scroll"><mml:mrow><mml:mn>0.506</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.04</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn51.jpg"/></alternatives></inline-formula> (CI [0.48, 0.52]) and <inline-formula><alternatives><tex-math id="M105">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.333\pm0.10$\end{document}</tex-math><mml:math id="M106" overflow="scroll"><mml:mrow><mml:mn>0.333</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.10</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn52.jpg"/></alternatives></inline-formula> (CI [0.30, 0.37]) for SNPs and sMRI data, respectively.</p><p>The proposed framework reached <inline-formula><alternatives><tex-math id="M107">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.926\pm0.02$\end{document}</tex-math><mml:math id="M108" overflow="scroll"><mml:mrow><mml:mn>0.926</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.02</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn53.jpg"/></alternatives></inline-formula> in ACC (CI [0.90, 0.95]), <inline-formula><alternatives><tex-math id="M109">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.910\pm0.05$\end{document}</tex-math><mml:math id="M110" overflow="scroll"><mml:mrow><mml:mn>0.910</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn54.jpg"/></alternatives></inline-formula> in PRE (CI [0.84, 0.98]), and <inline-formula><alternatives><tex-math id="M111">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.876\pm0.03$\end{document}</tex-math><mml:math id="M112" overflow="scroll"><mml:mrow><mml:mn>0.876</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn55.jpg"/></alternatives></inline-formula> in REC (CI [0.84, 0.91]) for the differentiation between AD and CN subjects. Of note, the best model over the five generalization runs reached 0.964 in ACC, 0.984 in PRE, and 0.909 in REC.</p><p>Regarding the comparison with the baseline approaches for Task 1, the SVM with mean and zero imputation strategy achieved average ACCs of <inline-formula><alternatives><tex-math id="M113">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.699\pm0.01$\end{document}</tex-math><mml:math id="M114" overflow="scroll"><mml:mrow><mml:mn>0.699</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn56.jpg"/></alternatives></inline-formula> (CI [0.68, 0.72]) and <inline-formula><alternatives><tex-math id="M115">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.689\pm0.02$\end{document}</tex-math><mml:math id="M116" overflow="scroll"><mml:mrow><mml:mn>0.689</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.02</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn57.jpg"/></alternatives></inline-formula> (CI [0.67, 0.71]), respectively, while the random forest methods with still mean and zero missing data management approaches obtained average ACCs of <inline-formula><alternatives><tex-math id="M117">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.663\pm0.01$\end{document}</tex-math><mml:math id="M118" overflow="scroll"><mml:mrow><mml:mn>0.663</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn58.jpg"/></alternatives></inline-formula> (CI [0.66, 0.67]) and <inline-formula><alternatives><tex-math id="M119">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.663\pm0.01$\end{document}</tex-math><mml:math id="M120" overflow="scroll"><mml:mrow><mml:mn>0.663</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn59.jpg"/></alternatives></inline-formula> (CI [0.66, 0.67]), respectively. The sMRI-CNN, rs-fMRI-CNN, and SNPs-CNN achieved ACCs of <inline-formula><alternatives><tex-math id="M121">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.883\pm0.02$\end{document}</tex-math><mml:math id="M122" overflow="scroll"><mml:mrow><mml:mn>0.883</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.02</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn60.jpg"/></alternatives></inline-formula> (CI [0.85, 0.91]), <inline-formula><alternatives><tex-math id="M123">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.853\pm0.03$\end{document}</tex-math><mml:math id="M124" overflow="scroll"><mml:mrow><mml:mn>0.853</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn61.jpg"/></alternatives></inline-formula> (CI [0.81, 0.90]), and <inline-formula><alternatives><tex-math id="M125">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.514\pm0.05$\end{document}</tex-math><mml:math id="M126" overflow="scroll"><mml:mrow><mml:mn>0.514</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn62.jpg"/></alternatives></inline-formula> (CI [0.45, 0.58]), respectively, in Task 1. The bi-modal models sMRI-fMRI and sMRI-SNPs obtained ACCs of <inline-formula><alternatives><tex-math id="M127">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.890\pm0.03$\end{document}</tex-math><mml:math id="M128" overflow="scroll"><mml:mrow><mml:mn>0.890</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn63.jpg"/></alternatives></inline-formula> [0.86, 0.91], and <inline-formula><alternatives><tex-math id="M129">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.864\pm0.03$\end{document}</tex-math><mml:math id="M130" overflow="scroll"><mml:mrow><mml:mn>0.864</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn64.jpg"/></alternatives></inline-formula> [0.82, 0.89], respectively. The results of the baseline comparisons and the ablation study highlight how our proposed framework outperformed the simplest approaches. More information about the comparison with the baseline methods is reported in the supplementary materials &#8216;Results&#8217; section, &#8216;Classification comparison with baseline approaches&#8217; subsection.</p><sec id="jneae087ds4-1-1"><label>4.1.1.</label><title>Feature relevance</title><p>Figure <xref rid="jneae087df4" ref-type="fig">4</xref> shows the average IG maps obtained for the AD detection task and for each input channel, averaged over the correctly classified subjects per class (test set). The <italic toggle="yes">jet</italic> colorbar was used to highlight the attribution scores, where red and blue correspond to positive and negative attribution values, respectively. In detail, figure <xref rid="jneae087df4" ref-type="fig">4</xref>(A) shows the average sMRI-IG maps for the correctly classified CN and AD patients, overlaid onto the MNI152 template (1.5&#8201;mm). It is evident that the subcortical regions, in particular the hippocampus, are associated with high IG scores in absolute value, with the highest positive (negative) values for CN (AD). Cortical regions generally showed almost null relevance for both the CN and the AD-derived sMRI-IG maps. Of note, higher absolute values were found for the AD maps compared with the CN ones.</p><fig position="float" id="jneae087df4" orientation="portrait"><label>Figure 4.</label><caption id="jneae087dfc4"><p>IG attribution maps for the classification Task 1. These maps are extracted considering only the individuals correctly classified in the testing set, and then averaging across subjects of the same class. Block A. shows relevance maps in terms of IG score for the CN and AD groups, thresholded to retain IG scores exceeding the 99.5th percentile, where for each group and view, five slices are shown in MNI coordinates; Block B. shows the connectograms highlighting the relevant connections between brain regions pairs, keeping only the connections over the 98th percentile; Finally, clock C. shows the SNPs grouped by chromosomes and their corresponding IG scores, highlighting the SNPs with an associated IG score exceeding the 65th percentile. Jet is the colormap used in Blocks A. and B., where red and blue indicate positive and negative IG values, respectively, while green/yellow colors in Block C. were employed only for visualization, distinguishing the SNPs across adjacent chromosomes. IG means integrated gradients, while IC stands for independent component. SM is the sensorimotor network, VI is the visual network, CC is the cognitive control network, DM is the default mode network, and CB is the cerebellum network. L and R are left and right, inf is inferior, ant is anterior, ctx is cortex, sup is superior, and mid is middle.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="print-only" content-type="print" id="jneae087df4_eps" position="float" orientation="portrait" xlink:href="jneae087df4.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="web-only" content-type="online" id="jneae087df4_lr" position="float" orientation="portrait" xlink:href="jneae087df4_lr.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="high" id="jneae087df4_hr" position="float" orientation="portrait" xlink:href="jneae087df4_hr.jpg"/></alternatives></fig><p>Moving to the fMRI-IG qualitative analysis, figure <xref rid="jneae087df4" ref-type="fig">4</xref>(B) shows the average connectograms for CN and AD subjects, including only the connections above the 98th percentile of the relevance distribution. The ICs-brain region correspondences are detailed in supplementary table 5. The most relevant RSNs were the primary information processing-related networks (SM and VI) followed by multisensory integration networks (CC and DM), and cerebellum (CB), showing high relevance for both the CN and the AD-derived fMRI-IG. In particular, the 53% of the most relevant connections for the CN group belong to the SM network, while a percentage of 38% was found for the AD-derived fMRI-IG maps. On the other hand, the VI was highly involved for AD subjects, with the 28% of relevant connections belonging to this RSN, differently from the CN where only 2 VI ICs resulted as relevant. A total of 15 ICs were marked as relevant for both the CN and the AD-derived fMRI-IG, but with an opposite sign. More in detail of the relevant connections between the different ICs, the CN subjects showed positive relevant intra-network connections in the CB and SM RSNs, with particularly high scores for the connections involving the post/paracentral and parietal gyri (ICs <inline-formula><alternatives><tex-math id="M131">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$9,10,11,12,13$\end{document}</tex-math><mml:math id="M132" overflow="scroll"><mml:mrow><mml:mn>9</mml:mn><mml:mo>,</mml:mo><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mn>11</mml:mn><mml:mo>,</mml:mo><mml:mn>12</mml:mn><mml:mo>,</mml:mo><mml:mn>13</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn65.jpg"/></alternatives></inline-formula>). Inter-network positively relevant connections were also found between the SM and the CB, and the SM and the CC RSNs. Only two negative IG scores were instead retrieved, related to an intra-network connection in the VI network and to an inter-network connection between CC and DM. A similar pattern was found for the AD fMRI-IG relevant connections but with generally opposite IG-associated scores. In detail, negative relevance was mainly found for both the intra- and inter-network connections encompassing the SM and CB RSNs, with an intra-connection in SM (ICs 11&#8211;12) showing the highest negative relevance between the same ICs highlighted with the opposite sign in the CN. On the contrary, positive relevance was recorded for the connections between multiple VI ICs, in particular involving right middle occipital gyrus (IC 21) with cuneus (IC 20), inferior occipital gyrus (IC 23), and middle temporal gyrus (IC 25) as well as the inter-network connections VI-DM and CC-DM, with the latter being the most relevant one.</p><p>Finally, concerning the SNPs-IG qualitative analysis, figure <xref rid="jneae087df4" ref-type="fig">4</xref>(C) presents a Manhattan plot including the SNPs with an IG score higher than the 65th percentile in absolute terms, grouped by chromosome. The <italic toggle="yes">y</italic>-axis reports the associated IG score. A complementary trend between the IG values associated with the SNPs was found between the two classes. This was particularly evident for Chr 1, 7, 11, 14, 15, and 19. A generally high involvement of the Chr 7, 8, 11, 14, and 19 was present for both the AD and CN, with the majority of SNPs selected in these Chr showing high IG scores, either positively or negatively. Of interest, the most relevant SNPs, with positive IG were found in Chr 4, 7, and 8 for the CN and in Chr 12 and 14 for the AD. On the contrary, the most negatively relevant SNPs for CN were found in Chr 14 and 19, as opposed to AD where they were mainly in Chr 1, 6, and 7.</p></sec></sec><sec id="jneae087ds4-2"><label>4.2.</label><title>Task 2: MCI conversion prediction</title><p>The MCI prediction task was performed by testing the full MCI cohort on the best model obtained for the AD detection task, for each one of the five independent runs. This allowed to assess its viability in predicting MCI conversion to AD, by correctly stratifying MCIc and MCInc subjects, without being trained for the specific task. This procedure allowed to reach an ACC of <inline-formula><alternatives><tex-math id="M133">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.711\pm0.01$\end{document}</tex-math><mml:math id="M134" overflow="scroll"><mml:mrow><mml:mn>0.711</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn66.jpg"/></alternatives></inline-formula> (CI [0.70, 0.72]), a PRE of <inline-formula><alternatives><tex-math id="M135">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.558\pm0.03$\end{document}</tex-math><mml:math id="M136" overflow="scroll"><mml:mrow><mml:mn>0.558</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn67.jpg"/></alternatives></inline-formula> (CI [0.51, 0.60]), and a REC of <inline-formula><alternatives><tex-math id="M137">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.610\pm0.03$\end{document}</tex-math><mml:math id="M138" overflow="scroll"><mml:mrow><mml:mn>0.610</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn68.jpg"/></alternatives></inline-formula> (CI [0.55, 0.68]) for the differentiation between MCIc and MCInc. Regarding the performance obtained using the best model trained on Task 1, we achieved 0.711 in ACC, 0.612 in PRE, and 0.550 in REC.</p><p>The baseline approaches were tested under the same training strategy as the proposed model also for Task 2, where the SVM with mean and zero imputation strategy obtained ACCs of <inline-formula><alternatives><tex-math id="M139">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.690\pm0.01$\end{document}</tex-math><mml:math id="M140" overflow="scroll"><mml:mrow><mml:mn>0.690</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn69.jpg"/></alternatives></inline-formula> (CI [0.68, 0.70]) and <inline-formula><alternatives><tex-math id="M141">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.688\pm0.01$\end{document}</tex-math><mml:math id="M142" overflow="scroll"><mml:mrow><mml:mn>0.688</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn70.jpg"/></alternatives></inline-formula> (CI [0.68, 0.70]), respectively, and ACCs of <inline-formula><alternatives><tex-math id="M143">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.698\pm0.01$\end{document}</tex-math><mml:math id="M144" overflow="scroll"><mml:mrow><mml:mn>0.698</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn71.jpg"/></alternatives></inline-formula> (CI [0.69, 0.70]) and <inline-formula><alternatives><tex-math id="M145">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.694\pm0.01$\end{document}</tex-math><mml:math id="M146" overflow="scroll"><mml:mrow><mml:mn>0.694</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn72.jpg"/></alternatives></inline-formula> (CI [0.69, 0.69]) for random forest with mean and zero strategies, respectively. The sMRI-CNN, rs-fMRI-CNN, and SNPs-CNN achieved ACCs of <inline-formula><alternatives><tex-math id="M147">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.638\pm0.01$\end{document}</tex-math><mml:math id="M148" overflow="scroll"><mml:mrow><mml:mn>0.638</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn73.jpg"/></alternatives></inline-formula> (CI [0.63, 0.65]), <inline-formula><alternatives><tex-math id="M149">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.692\pm0.03$\end{document}</tex-math><mml:math id="M150" overflow="scroll"><mml:mrow><mml:mn>0.692</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn74.jpg"/></alternatives></inline-formula> (CI [0.64, 0.74]), and <inline-formula><alternatives><tex-math id="M151">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.522\pm0.02$\end{document}</tex-math><mml:math id="M152" overflow="scroll"><mml:mrow><mml:mn>0.522</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.02</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn75.jpg"/></alternatives></inline-formula> (CI [0.50, 0.55]), respectively, in Task 2. The bi-modal models sMRI-fMRI and sMRI-SNPs obtained ACCs of <inline-formula><alternatives><tex-math id="M153">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.753\pm0.12$\end{document}</tex-math><mml:math id="M154" overflow="scroll"><mml:mrow><mml:mn>0.753</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.12</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn76.jpg"/></alternatives></inline-formula> [0.59, 0.91], and <inline-formula><alternatives><tex-math id="M155">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.643\pm0.05$\end{document}</tex-math><mml:math id="M156" overflow="scroll"><mml:mrow><mml:mn>0.643</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn77.jpg"/></alternatives></inline-formula> [0.57, 0.71], respectively. Similarly to Task 1, the multimodal framework outperforms the comparison with the baseline approaches and with the models used in the ablation study, except for the bi-modal model sMRI-fMRI that obtained an improvement of 4.2% in ACC. Additional details related to the comparison are reported in the supplementary materials &#8216;Results&#8217; section, &#8216;Classification comparison with baseline approaches&#8217; subsection.</p><sec id="jneae087ds4-2-1"><label>4.2.1.</label><title>Feature relevance</title><p>In parallel with the results shown for Task 1, figure <xref rid="jneae087df5" ref-type="fig">5</xref> shows a summary of the IG results obtained for the MCI conversion prediction task. The same visualization techniques presented for Task 1 were applied also for this figure. The maps were averaged over the correctly classified subjects for each class, and thresholding was applied to retain only the values above the 99.5th, 98th, and 65th percentile of the relevance distribution, respectively for the sMRI-IG, fMRI-IG, and the SNPs-IG. In detail, figure <xref rid="jneae087df5" ref-type="fig">5</xref>(A) shows the average sMRI-IG maps for the correctly classified MCIc and MCInc patients. Similarly to what was shown for Task 1, the subcortical regions held the highest relevance, with the hippocampus being clearly highlighted as the most important region with positive attributions for MCInc and negative values for MCIc. Cortical regions did not show particular relevance, except for some temporal and occipital areas, which however showed low IG scores.</p><fig position="float" id="jneae087df5" orientation="portrait"><label>Figure 5.</label><caption id="jneae087dfc5"><p>IG attribution maps for the classification Task 2. These maps are extracted considering only the MCInc and MCIc individuals correctly classified in the testing set, and then averaging across subjects of the same class. Block A. shows relevance maps in terms of IG score for the MCInc and MCIc groups, thresholded to retain IG scores exceeding the 99.5th percentile, where for each group and view, five slices are shown in MNI coordinates; Block B. shows the connectograms highlighting the relevant connections between brain regions pairs, keeping only the connections over the 98th percentile; Finally, clock C. shows the SNPs grouped by chromosomes and their corresponding IG scores for both classes, highlighting the SNPs with an associated IG score exceeding the 65th percentile. Jet is the colormap used in Blocks A. and B., where red and blue indicate positive and negative IG values, respectively, while green/yellow colors in Block C. were employed only for visualization, distinguishing the SNPs across adjacent chromosomes. IG means integrated gradients, while IC stands for independent component. SM is the sensorimotor network, VI is the visual network, CC is the cognitive control network, DM is the default mode network, and CB is the cerebellum network. L and R are left and right, inf is inferior, ant is anterior, ctx is cortex, sup is superior, and mid is middle.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="print-only" content-type="print" id="jneae087df5_eps" position="float" orientation="portrait" xlink:href="jneae087df5.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="web-only" content-type="online" id="jneae087df5_lr" position="float" orientation="portrait" xlink:href="jneae087df5_lr.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="high" id="jneae087df5_hr" position="float" orientation="portrait" xlink:href="jneae087df5_hr.jpg"/></alternatives></fig><p>Moving to the fMRI-IG, figure <xref rid="jneae087df5" ref-type="fig">5</xref>(B) shows the averaged connectograms. In accordance with Task 1, the same five RSNs resulted as the most relevant also for the MCI prediction conversion task, namely the SM, VI, CC, DM and CB. The MCInc fMRI-IG showed more involvement of VI (25% of the relevant ICs), compared with the MCIc one (14% of the relevant ICs). On the contrary, the MCIc IG connectome showed a higher number of ICs belonging to the CC network (4 ICs) compared to the two found for the MCInc one. The two connectograms had 11 common connections with opposite trends. More in details of the relevant connections between the different ICs, of interest, the most relevant connections between the ICs in the SM were exactly the same for MCIc and MCInc, with opposite signs, and mainly involved the post/paracentral and parietal gyri (ICs <inline-formula><alternatives><tex-math id="M157">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$9,10,11,12,13$\end{document}</tex-math><mml:math id="M158" overflow="scroll"><mml:mrow><mml:mn>9</mml:mn><mml:mo>,</mml:mo><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mn>11</mml:mn><mml:mo>,</mml:mo><mml:mn>12</mml:mn><mml:mo>,</mml:mo><mml:mn>13</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn78.jpg"/></alternatives></inline-formula>), as for Task 1. Moreover, the fMRI-IG for the MCInc subjects showed positive relevance also for the intra-network connections in the CB, and for the inter-network connections involving CB-SM and CC-SM. On the other hand, negative relevance was found for the intra-network connections in the VI, mainly involving occipital, lingual, calcarine, middle temporal gyri, and cuneus areas (ICs 17&#8211;24, 18&#8211;20, 21&#8211;25, 23&#8211;24), and for the inter-network connections between VI and DM, and CC and DM. A slightly different pattern was found for the MCIc fMRI-IG, whose relevant connections generally had a negative IG-associated score. In detail, intra-network connections with negative scores were found for SM and CB, as already presented, while inter-network negative connections were depicted for VI-CC, VI-DM, and SM-DM. Of interest, negative connections between CC and SM were also retrieved, never reported for the other classes in the study. Positive attribution was found only for an intra-network connection in the VI (ICs 23&#8211;24) and a connection between CC and DM (ICs 28&#8211;45).</p><p>Finally, concerning the SNPs-IG, figure <xref rid="jneae087df5" ref-type="fig">5</xref>(C) presents a Manhattan plot highlighting the SNPs with an IG score higher than the 65th percentile in absolute terms. As expected and as already seen for the other modalities, a complementary trend between the IG values associated with the SNPs was found for the two classes, with positive weights being associated with the MCInc and negative weights associated with the MCIc for the same SNPs and vice-versa. This was particularly evident for Chr 1, 2, 7, 14, 15 and 17. A generally high involvement of the Chr 11 and 17 was present for both the MCIc and MCInc, with the majority of SNPs showing high IG scores. The most relevant SNPs, with positive IG were found in Chr 17 for the MCInc and in Chr 15 for the MCIc. On the contrary, the most negatively relevant SNPs for MCInc were found in Chr 14, 15, and 17, as opposed to the MCIc where they were mainly in Chr 1, 2, and 7.</p></sec></sec><sec id="jneae087ds4-3"><title>4.3. Group-based statistical IG analysis</title><sec id="jneae087ds4-3-1"><title>Neuroimaging modalities</title><p>Figure <xref rid="jneae087df6" ref-type="fig">6</xref>(A) shows the boxplots representing the distribution of the average sMRI-IG values in the most relevant cortical and subcortical brain regions (ROIs), and only those regions where at least the 99% of the subjects had an IG value were retained. The complete acronym list is reported in supplementary table 4. A general agreement between the CN and the MCInc subjects, as well as between the AD and the MCIc patients is evident in all the considered ROIs, with the AD/MCIc subjects showing a generally higher variance. As expected from the qualitative analysis, the Hipp and the Amy resulted as the highest relevant ROIs, as well as the ones showing the highest group distance, with high positive attributions for the CN and the MCInc, and strong negative attributions for the AD and MCIc. Among the other subcortical ROIs, the Acc showed a notable relevance for all the groups, with the MCInc and CN having negative scores and the MCIc and AD positive ones. Cau and Put had an associated high positive relevance score for AD and MCIc, while almost null scores for the other two groups. Interestingly, among the cortical regions, the TOF was the most relevant for both the MCIc and AD (positive IG scores) and the MCInc and CN (negative IG scores). The largest distance between the group IG score distributions was found for PhGa, followed by the TFCp with the AD and MCIc having high negative values. On the contrary, the OFG, the POpC, and the PaGp showed high positive relevance for AD and MCIc patients associated with negative scores for the CN and MCInc. The Kruskal&#8211;Wallis test was performed in order to establish whether differences, separately for each ROI, were significant considering the four groups together. The significant ROIs (all except the Ins and the TP) were further analyzed to investigate the group-related differences through the Wilcoxon Rank Sum test. The most significant differences were found between MCIc and MCInc in the subcortical ROIs, with the lowest <italic toggle="yes">p</italic>-values being recorded for Hipp and Amy. Moreover, significant differences were also recorded for the temporal (PcC, PhGa, PaGp, TFCp) and occipital (TOF, OFG, POpC) cortical regions, with the most significant difference being recorded for PcC and PhGa. A coherent significance pattern was found between the contrasts MCIc-CN, MCInc-AD, and the CN-AD with generally higher <italic toggle="yes">p</italic>-values. Of interest, no statistically significant differences were found in the sMRI-IG score distributions between AD and MCIc patients, except for PcC, TFCp, and POpC, while some significant differences were found between CN and MCInc but with relatively high <italic toggle="yes">p</italic>-values. Supplementary figure 1(A) shows the <italic toggle="yes">p</italic>-values of statistical analysis between groups for each region. A post-hoc validation analysis performed on the values used as input for the model confirmed that the hippocampus and amygdala were some of the most important regions with the highest differences. Additionally, in the real values, a general agreement between CN and MCInc, and AD and MCIc can be observed, similar to that found in the post-hoc XAI analysis. More details about this analysis are reported in figures 2(A) and 3(A) in the supplementary materials.</p><fig position="float" id="jneae087df6" orientation="portrait"><label>Figure 6.</label><caption id="jneae087dfc6"><p>Boxplots showing the distribution of the correctly classified individuals for all four groups, that are CN, AD, MCInc, and MCIc. Block A. shows the most relevant cortical and subcortical brain regions resulting from the sMRI-IG, where only those regions where at least 99% of the subjects had an IG score after thresholding were retained. Block B. shows the most relevant pairs of ICs for both intra- and inter-network connections. IC states for independent component, while IG means integrated gradients.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="print-only" content-type="print" id="jneae087df6_eps" position="float" orientation="portrait" xlink:href="jneae087df6.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="web-only" content-type="online" id="jneae087df6_lr" position="float" orientation="portrait" xlink:href="jneae087df6_lr.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="high" id="jneae087df6_hr" position="float" orientation="portrait" xlink:href="jneae087df6_hr.jpg"/></alternatives></fig><p>Figure <xref rid="jneae087df6" ref-type="fig">6</xref>(B) shows the boxplots of fMRI-IG values for the intra- and inter-connections of the four groups. The same pattern of sMRI regarding the similarity between CN and MCInc, and AD and MCIc has been also highlighted for the rs-fMRI intra- and inter-network connections. Among the intra-network connections, the ones related to the sensorimotor area were the most important, such as IC9-IC10, IC9-IC11, IC11-IC12, and IC12-IC13. Regarding the inter-network connections, they showed generally lower relevance with respect to the intra-network ones. The same statistical analysis was carried out for fMRI-IG, considering all the most relevant connections resulting from the fMRI-IG scores for all the considered classes. The connections between IC18 (VI) - IC14 (SM) and IC44 (DM) - IC17 (VI) did not reach significance at the Kruskal&#8211;Wallis test, therefore they were excluded from the post-hoc analysis. Differently from the sMRI-IG significance pattern, the most significant differences were recorded between the CN-AD and MCInc-AD contrasts, which showed significant differences for almost all the considered connections. In particular, for the MCInc-AD contrast, significant intra-network connections were part of the SM, involving connections in the parietal lobe, and in the VI RSNs. Concerning the inter-network connection, significance was found between ICs in the DM, part of the cingulate gyrus (IC47, IC45), and ICs in the CC or VI RSNs, as well as between ICs in the SM, located in the parietal lobe and ICs in the CC or CB RSNs. MCIc-CN and MCInc-MCIc showed the same significant pattern as the CN-AD contrast, showing generally higher <italic toggle="yes">p</italic>-values. Of interest, as for the sMRI-IG statistical analysis, no significant differences were detected for the contrasts MCIc-AD and MCInc-CN, except for two connections between CB and SM (IC51-IC9 and the IC51-IC12 respectively for the MCInc-CN and the MCIc-AD). Similarly to the sMRI, a post-hoc validation analysis performed on the real values used as input for the model highlighted a general agreement between the XAI attributions and the real values, where the CN and MCInc groups showed a higher functional strength in absolute terms for the different brain connections. Additionally, an agreement across the group distributions in the real values and the XAI attributions was found, where the CN were similar to MCInc, and AD close to the MCIc. More details about this analysis are reported in the supplementary materials figure 2(B). Supplementary table 5 lists the ICs and corresponding brain regions. The Bonferroni-corrected pairwise tests (Wilcoxon rank sum) are reported in supplementary figure 1(B), separately for intra- and inter-network connections, with the <italic toggle="yes">p</italic>-values being represented in logarithmic scale, while supplementary figure 3(B) shows the results related to the analysis conducted on the real values.</p></sec><sec id="jneae087ds4-3-2"><title>Genetic modality</title><p>Figure <xref rid="jneae087df7" ref-type="fig">7</xref> shows the biological processes derived from enrichment analysis for AD, MCIc, and MCInc classes as well as their corresponding raw <italic toggle="yes">p</italic>-values. Only the SNPs having positive attributions higher than the 65th percentile were retained for gene annotation. The left plot of figure <xref rid="jneae087df7" ref-type="fig">7</xref>, regarding AD patients, highlights the four AD-related biological processes that were statistically significant after <italic toggle="yes">p</italic>-value correction, that is: <italic toggle="yes">intracellular transport</italic> (<inline-formula><alternatives><tex-math id="M159">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$p_{\mathrm{bonf}} = 0.0225$\end{document}</tex-math><mml:math id="M160" overflow="scroll"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mrow><mml:mi>bonf</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.0225</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn80.jpg"/></alternatives></inline-formula>), regulation of protein-containing complex assembly (<inline-formula><alternatives><tex-math id="M161">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$p_{\mathrm{bonf}} = 0.0413$\end{document}</tex-math><mml:math id="M162" overflow="scroll"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mrow><mml:mi>bonf</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.0413</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn81.jpg"/></alternatives></inline-formula>), establishment of localization in cell (<inline-formula><alternatives><tex-math id="M163">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$p_{\mathrm{bonf}} = 0.0446$\end{document}</tex-math><mml:math id="M164" overflow="scroll"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mrow><mml:mi>bonf</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.0446</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn82.jpg"/></alternatives></inline-formula>), and cell development (<inline-formula><alternatives><tex-math id="M165">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$p_{\mathrm{bonf}} = 0.0470$\end{document}</tex-math><mml:math id="M166" overflow="scroll"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mrow><mml:mi>bonf</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.0470</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn83.jpg"/></alternatives></inline-formula>). The other AD-related biological processes that emerged involved the endocytosis mechanism, hence processes related to the transport, such as <italic toggle="yes">positive regulation of endocytosis</italic>, <italic toggle="yes">regulation of vesicle-mediated transport</italic>, and <italic toggle="yes">nitrogen compound transport</italic>. Additionally, biological processes related to the membrane and cell organization were detected. Similarly, the central plot, concerning the MCIc-related biological processes, also identifies the endocytosis mechanism, such as <italic toggle="yes">regulation of endocytosis</italic> and <italic toggle="yes">positive regulation of endocytosis</italic>. Of note, one process was related to the amyloid-<italic toggle="yes">&#946;</italic> (A<italic toggle="yes">&#946;</italic>), that was <italic toggle="yes">negative regulation of amyloid precursor protein catabolic process</italic>. Furthermore, important biological processes related to cholesterol, like <italic toggle="yes">sterol transport</italic> and <italic toggle="yes">cholesterol transport</italic>, and processes involving lipids, amide compound, and proteins, were also highlighted. The ten most frequent genes in terms of occurrences in the enriched biological processes for AD and MCIc patients were CLU, APOE, PICALM, APOA2, ABCA7, TREM106B, NECTIN2, TREM2, BIN1, and BLOC1S3. Regarding the MCInc, right plot, two biological processes were related to the T cell, the <italic toggle="yes">T cell activation</italic> and the <italic toggle="yes">T cell differentiation</italic>, while different processes involved the white blood cells and immunity. For this group, the five most frequent genes were FCER1G, ERCC1, CR1, RELB, and ACE. Supplementary tables 7, 8, and 9 provide additional information, such as the most frequent genes, the GO index, and the corresponding <italic toggle="yes">p</italic>-value for each highlighted biological process for AD, MCIc, and MCInc, respectively.</p><fig position="float" id="jneae087df7" orientation="portrait"><label>Figure 7.</label><caption id="jneae087dfc7"><p>The top 15 biological processes from enrichment analysis reported for the patients groups, i.e. AD, MCIc, and MCInc (columns), where each bar represents a biological process. The colorbar represents the <italic toggle="yes">p</italic>-value, dark violet the lowest, while the number of genes involved is reported as the bar height. <inline-formula><alternatives><tex-math id="M167">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$*$\end{document}</tex-math><mml:math id="M168" overflow="scroll"><mml:mrow><mml:mo>&#8727;</mml:mo></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn79.jpg"/></alternatives></inline-formula> indicates biological processes surviving Bonferroni correction.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="print-only" content-type="print" id="jneae087df7_eps" position="float" orientation="portrait" xlink:href="jneae087df7.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="web-only" content-type="online" id="jneae087df7_lr" position="float" orientation="portrait" xlink:href="jneae087df7_lr.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="high" id="jneae087df7_hr" position="float" orientation="portrait" xlink:href="jneae087df7_hr.jpg"/></alternatives></fig></sec></sec></sec><sec id="jneae087ds5"><label>5.</label><title>Discussion</title><p>In this work, we proposed a multimodal generative and interpretable method, which holds the potential of addressing missing data management while focusing on model interpretability. We specifically applied this method to the crucial tasks of segregating AD patients from CN, and assessed its viability in detecting MCI conversion to AD by integrating neuroimaging (sMRI and rs-fMRI) and genetics (SNPs) data. Incomplete data is handled by generating missing modalities in the latent space, obtained after feature reduction. This ensures high accuracy in reconstructing latent features while minimizing computational demands. However, the proposed approach is generalizable to any missing modality, providing a viable and effective solution for overcoming the missing data bottleneck. Furthermore, we conducted a post-hoc interpretability analysis, supplemented by a robust validation step, consolidating the findings&#8217; impact in the field.</p><sec id="jneae087ds5-1"><label>5.1.</label><title>Classification performance and missing data management</title><p>Focusing on Task 1, AD detection, our model reached competitive performance in the state-of-the-art, obtaining an average accuracy of <inline-formula><alternatives><tex-math id="M169">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.926\pm0.02$\end{document}</tex-math><mml:math id="M170" overflow="scroll"><mml:mrow><mml:mn>0.926</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.02</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn84.jpg"/></alternatives></inline-formula> on the testing set, with the best model reaching an accuracy score of 0.964. Noteworthy, this result was achieved on a cohort where only the 6.5% of the subjects had complete data across all three modalities. The proposed framework in the same Task 1 also outperformed the two baseline methods with the two imputation strategies, where they achieved an average accuracy of <inline-formula><alternatives><tex-math id="M171">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.699\pm0.01$\end{document}</tex-math><mml:math id="M172" overflow="scroll"><mml:mrow><mml:mn>0.699</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn85.jpg"/></alternatives></inline-formula> and <inline-formula><alternatives><tex-math id="M173">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.663\pm0.01$\end{document}</tex-math><mml:math id="M174" overflow="scroll"><mml:mrow><mml:mn>0.663</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn86.jpg"/></alternatives></inline-formula> for the ensemble SVM and ensemble random forest with mean imputation strategy, respectively, while accuracies of <inline-formula><alternatives><tex-math id="M175">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.689\pm0.02$\end{document}</tex-math><mml:math id="M176" overflow="scroll"><mml:mrow><mml:mn>0.689</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.02</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn87.jpg"/></alternatives></inline-formula> and <inline-formula><alternatives><tex-math id="M177">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.663\pm0.01$\end{document}</tex-math><mml:math id="M178" overflow="scroll"><mml:mrow><mml:mn>0.663</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn88.jpg"/></alternatives></inline-formula> were obtained using the zero imputation strategy for SVM and random forest, respectively. Regarding the ablation study conducted, we were able to outperform the other simpler methods in comparison with the proposed one. The sMRI-CNN, rs-fMRI-CNN, and SNPs-CNN achieved an average accuracy of <inline-formula><alternatives><tex-math id="M179">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.883\pm0.02$\end{document}</tex-math><mml:math id="M180" overflow="scroll"><mml:mrow><mml:mn>0.883</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.02</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn89.jpg"/></alternatives></inline-formula>, <inline-formula><alternatives><tex-math id="M181">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.853\pm0.03$\end{document}</tex-math><mml:math id="M182" overflow="scroll"><mml:mrow><mml:mn>0.853</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn90.jpg"/></alternatives></inline-formula>, and <inline-formula><alternatives><tex-math id="M183">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.514\pm0.05$\end{document}</tex-math><mml:math id="M184" overflow="scroll"><mml:mrow><mml:mn>0.514</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn91.jpg"/></alternatives></inline-formula>, respectively, while the bi-modal models sMRI-fMRI and sMRI-SNPs obtained an accuracy of <inline-formula><alternatives><tex-math id="M185">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.890\pm0.03$\end{document}</tex-math><mml:math id="M186" overflow="scroll"><mml:mrow><mml:mn>0.890</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn92.jpg"/></alternatives></inline-formula> and <inline-formula><alternatives><tex-math id="M187">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.864\pm0.03$\end{document}</tex-math><mml:math id="M188" overflow="scroll"><mml:mrow><mml:mn>0.864</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.03</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn93.jpg"/></alternatives></inline-formula>, hence highlighting the effectiveness of the multimodal model. Our dataset was constructed considering the subjects having at least the sMRI modality, however, the proposed framework showcases the capability to potentially impute all three modalities by transferring knowledge across domains, not being limited to having at least one acquisition for all the subjects. Indeed, the injection of the pre-trained generators, that is the two cGANs, allows both to impute the missing rs-fMRI or SNPs from the sMRI and the <italic toggle="yes">vice-versa</italic>, meaning that it would allow deriving the missing sMRI from the other two modalities, if needed. This allows relaxing the requirement of having at least one acquisition for all the subjects which is one of the strengths of the proposed model compared with the state-of-the-art.</p><p>Considering the broad literature on the topic, we decided to limit our comparison to studies that dealt with ML/DL approaches in AD but also introduced a generative process and were able to generate missing data, in order to have a fair comparison with our findings/aims. The simplest model, Venugopalan <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib38" ref-type="bibr">38</xref>] proposed a DL-based multimodal method based on sMRI, clinical, and genetics data, excluding features if missing in more than 70% of subjects, and filling the remaining missing data with zeros. Their classification task was different from ours since they included the MCI subjects in a three-class classification problem. While they achieved an accuracy of 0.780 for the classification between CN, MCI, and AD, the accuracy dropped to 0.630 when classifying CN from the full patient cohort using only sMRI and genetics. Moreover, the proposed technique had some drawbacks, mainly linked to the biases introduced in the network, as already discussed. Alternatively, methods to exploit the information of all the available subjects, without explicitly generating the missing modalities, were proposed relying on latent representation learning. Liu <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib43" ref-type="bibr">43</xref>] developed an auto-encoder-based multi-view missing data completion framework using sMRI and FDG-PET ROI-based features. Their method achieved a classification accuracy of 0.836 for classifying CN versus AD, even with 50% missing PET. Similarly, Ye <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib48" ref-type="bibr">48</xref>] proposed a GAN with an attention layer to generate missing FDG-PET from available MRI features, resulting in a classification accuracy of <inline-formula><alternatives><tex-math id="M189">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.914\pm0.19$\end{document}</tex-math><mml:math id="M190" overflow="scroll"><mml:mrow><mml:mn>0.914</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.19</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn94.jpg"/></alternatives></inline-formula>. In the same way, Zhang <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib52" ref-type="bibr">52</xref>] employed a GAN model based on a pyramidal attention mechanism for imputing PET data from sMRI. Then, the generated PET images were fused with the sMRI at pixel-level, and then the same generator used for PET synthesis was employed for feature extraction, extracting a latent representation that fed a dense layer, reaching an accuracy of 0.934. Zhang <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib46" ref-type="bibr">46</xref>] developed a GAN-based model, named BPGAN, for generating FDG-PET data from sMRI. They created a 3D multiple convolution U-Net generator for PET images, and then they fused the sMRI and the synthetic PET volumes concatenating the data at the pixel-level. Finally, they employed a ResNet-18 for classification achieving an accuracy of 0.981 in discriminating AD from CN. Gao <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib45" ref-type="bibr">45</xref>] proposed a multi-level guided GAN and a multimodal transformer (Mul-T) for synthesizing PET and T2-MRI images from sMRI and extracting features for classification from the three modalities, respectively. The MLG-GAN module generated data using voxel-, feature-, and task-level information for a more accurate generation. The Mul-T achieved competitive performance by integrating local and global information from all modalities reaching an accuracy of 0.944. Tu and colleagues [<xref rid="jneae087dbib51" ref-type="bibr">51</xref>] developed a consistent manifold projection GAN (CMPGAN) model for imputing missing PET from sMRI. The CMPGAN integrated a manifold projection operator to map the data in a low dimensional space and a distribution distance measure to ensure that no gradient disappeared during the generator training, hence creating more reliable data. Then, a multilevel multimodal fusion diagnosis network was developed to diagnose AD by fusing together the synthetic PET and sMRI images. They obtained a final performance in CN versus AD of <inline-formula><alternatives><tex-math id="M191">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.980\pm0.003$\end{document}</tex-math><mml:math id="M192" overflow="scroll"><mml:mrow><mml:mn>0.980</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.003</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn95.jpg"/></alternatives></inline-formula>. Finally, Gao and colleagues [<xref rid="jneae087dbib49" ref-type="bibr">49</xref>] presented a task-induced pyramid and attention GAN to generate missing FDG-PET data from sMRI, achieving an accuracy of 0.927. Moreover, it still lacked the ability to reconstruct sMRI from FDG-PET data. While these approaches demonstrated excellent results, their framework was limited in handling arbitrary missing modalities.</p><p>As mentioned before, the trained model performance was subsequently assessed on Task 2. Only the 7% of the dataset shared all the modalities, making it a challenging scenario. Nevertheless, our framework achieved an average accuracy of <inline-formula><alternatives><tex-math id="M193">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.711\pm0.01$\end{document}</tex-math><mml:math id="M194" overflow="scroll"><mml:mrow><mml:mn>0.711</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn96.jpg"/></alternatives></inline-formula> for the independent test sets. Although it did not outperform methods specifically trained on this particular task, it demonstrated competitive results. Other approaches have focused on different input data and missing data management to solve this task. For instance, Ritter <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib39" ref-type="bibr">39</xref>] proposed simple ML methods with tabular features and limited imputation techniques, achieving an accuracy of 0.670 to stratify MCI subjects. Cai <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib47" ref-type="bibr">47</xref>] used a GAN to impute missing PET images from sMRI scans, achieving an accuracy of 0.657 for discriminating MCInc vs MCIc patients. Furthermore, Zhou <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib50" ref-type="bibr">50</xref>] proposed a framework for projecting original features into a latent representation, resulting in an accuracy of 0.743 in case of missing the 51% of PET data. Gao <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib49" ref-type="bibr">49</xref>] applied the approach already discussed also to address the classification Task 2, reaching an accuracy score of 0.753. Gao <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib45" ref-type="bibr">45</xref>] employed the same framework described in Task 1 of the MCI conversion task. They initially pretrained the models on AD detection, and then they refined the weights on the MCI task, obtaining a final accuracy of 0.778. Similarly, Tu <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib51" ref-type="bibr">51</xref>] trained and tested their model described for Task 1 in Task 2. They achieved an accuracy of <inline-formula><alternatives><tex-math id="M195">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
$0.923\pm0.01$\end{document}</tex-math><mml:math id="M196" overflow="scroll"><mml:mrow><mml:mn>0.923</mml:mn><mml:mo>&#177;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jneae087dieqn97.jpg"/></alternatives></inline-formula> in the MCI conversion task.</p><p>Despite the promising results obtained by the state-of-the-art generative models for missing data imputation, it is essential to acknowledge their shared limitation: they all relied on having sMRI as a prerequisite to impute PET data, and very few included genetics, T2-MRI, or rs-fMRI information in their analyses, which have instead been demonstrated as relevant biomarkers for AD [<xref rid="jneae087dbib10" ref-type="bibr">10</xref>, <xref rid="jneae087dbib15" ref-type="bibr">15</xref>]. In contrast, our framework does not necessitate a shared modality across all subjects. The exploitation of two cGANs during the generation phase enables to produce the missing latent rs-fMRI and/or SNPs from sMRI. In addition, this process is applicable bidirectionally, allowing the generation of sMRI latent features from either SNPs or rs-fMRI as well. The versatility of this approach opens the way to its generalization to additional modalities through training distinct cGANs and integrating the resulting generators into the complete classification framework. Furthermore, our model&#8217;s performance confirms that generative models allow to obtain realistic data and learn nonlinear mappings across the different acquisitions, achieving competitive prediction accuracy also with a substantial proportion of missing modalities. Supplementary table 10 shows the performance of the proposed model compared with the state-of-the-art competitors allowing multimodality and missing data management for both Task 1 and Task 2.</p></sec><sec id="jneae087ds5-2"><label>5.2.</label><title>Interpretability analyses</title><p>Interpretability analysis was performed relying on IG, followed by group-based statistical analysis for the sake of validation. More in detail, for each input modality and each task, relevance maps were extracted and analyzed from a qualitative and quantitative point of view. Interestingly, among the state-of-the-art methods for multimodal AD or MCI conversion detection, only a few works introduced interpretability analysis. Ye <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib48" ref-type="bibr">48</xref>] relied on an attention layer in their generation module for obtaining the feature importance. Venugopalan <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib38" ref-type="bibr">38</xref>] proposed an occlusion-based approach to extract the feature relevance. They found that some cortical regions and the limbic area, including changes in the hippocampus, were relevant for their model. Additionally, they found that some chromosomes, e.g. the 1, 4, 5, 10, and 19, were particularly important. These results were in line with our findings, where subcortical regions were important for the final predictions, as well as chromosomes 1, 4, and 19. Zhou <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib50" ref-type="bibr">50</xref>] exploited the weights learned for their latent representation learning to derive the input features&#8217; importance. They detected the hippocampus as an important region for both sMRI and PET. Additionally, the amygdala and globus were relevant for sMRI, while the precuneus and gyrus for the PET. Similarly, our model found the hippocampus and other subcortical regions important. Zhang <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib52" ref-type="bibr">52</xref>] employed 3D Grad-CAM for extracting the most relevant regions from the fused MRI-PET images that were of interest for their model, highlighting higher importance in GM areas. While Gao <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib45" ref-type="bibr">45</xref>] extracted the spatial attention maps from the attention mechanism. They found that different AD-related regions were highlighted in sMRI, such as the temporal lobe, corpus callosum, and parahippocampal gyrus. For the T2, the found areas were the lateral ventricles and the cingulate gyrus. Finally, the regions shown by PET were the cingulate gyrus, cuneus, and occipital lobe. In general, these works found brain regions, such as the hippocampus and amygdala, as the most important among the others, which was in line with our findings. In our results, the interpretability analysis revealed similarities between the MCIc and the AD phenotypes, as well as between the MCInc and CN, while highlighting significant differences between the CN and AD, as expected, but also between MCIc and MCInc which are of high interest since they would allow to identify early AD biomarkers.</p><p>Regarding the sMRI data, our findings highlighted that sub-cortical regions carried more informative and relevant information for the final classification compared to cortical areas. The hippocampus resulted as the most critical region for all classes under analysis, alongside the amygdala. In AD and MCIc patients, such regions exhibited negative attribution values, suggesting a decrease in GM probability, as opposed to positive values in CN and MCInc subjects. Of interest, the most significant differences in the relevance assigned to such regions were found between MCIc and MCInc. These findings were in line with the well-known literature and established hallmarks of AD. Indeed, the pathological process initially affects the hippocampus and amygdala before extending to other nearby structures [<xref rid="jneae087dbib70" ref-type="bibr">70</xref>, <xref rid="jneae087dbib71" ref-type="bibr">71</xref>]. Focusing on MCI, Liu and collegaues [<xref rid="jneae087dbib72" ref-type="bibr">72</xref>] demonstrated that MCIc patients exhibited higher atrophy in the hippocampus and amygdala compared to MCInc and CN subjects, which aligns well with our findings. Regarding the caudate region, Sodums and Bohbot [<xref rid="jneae087dbib73" ref-type="bibr">73</xref>] and Persson <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib74" ref-type="bibr">74</xref>] highlighted a negative correlation between caudate and hippocampus volumes in healthy subjects, and, in addition, the second work also showed that patients with AD and non-specified dementia have a larger caudate volume compared to non-dementia subjects. However, this is still debated in literature with other works suggesting that the caudate is susceptible to atrophy, resulting in a reduction of the GM volume of this region in AD patients [<xref rid="jneae087dbib75" ref-type="bibr">75</xref>&#8211;<xref rid="jneae087dbib77" ref-type="bibr">77</xref>]. The cortical areas had a generally lower relevance to the classification for all the phenotypes. The parahippocampal gyrus (anterior division) and the occipital fusiform gyrus showed the highest attribution scores, with positive values assigned to CN. This was in line with Wang <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib78" ref-type="bibr">78</xref>] and Liu <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib72" ref-type="bibr">72</xref>] findings which revealed smaller volumes in the anterior parahippocampal area in AD, MCIc, and MCInc subjects compared to CN individuals. Additionally, Dai <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib79" ref-type="bibr">79</xref>] highlighted the importance of the occipital fusiform gyrus for AD classification. As for the other relevant brain regions, the precuneus and fusiform cortices showed a reduction of the GM volume in our results, coherent with what is known from the literature [<xref rid="jneae087dbib80" ref-type="bibr">80</xref>&#8211;<xref rid="jneae087dbib82" ref-type="bibr">82</xref>]. Overall, our findings on sMRI revealed that the relevance scores were sensible to an increase in neurodegeneration in some focal brain areas in AD and MCIc compared with CN and MCInc, which aligns well with the literature findings.</p><p>Based on rs-fMRI attributions, five functional RSNs emerged as highly relevant for the final classification of both tasks, namely SM, DM, CB, VI, and CC. The DM has a central role in information integration and processing, and its involvement in AD is well-known in the current literature, with several studies consistently demonstrating that this is the first RSN to be affected by abnormal protein aggregation [<xref rid="jneae087dbib14" ref-type="bibr">14</xref>, <xref rid="jneae087dbib83" ref-type="bibr">83</xref>]. In our results, we did not retrieve intra-network connections in the DM mode. However, for the MCIc subjects, a negative relevance score, suggesting a decreased FC, was found for inter-network connections between DM and visual/sensorimotor areas (DM-VI, DM-SM), while a positive inter-network connection was highlighted between DM and CC. Conversely, AD subjects revealed a positive relevance for a few connections between the DM and VI and between the DM and the CC, while one negative connection was found between DM and SM. These patterns are not commonly reported in the literature but deserve further investigation since they could represent compensation connectivity patterns. Among the other RSNs, the SM was the most present and relevant, showing negative relevance scores for AD and MCIc for both the intra-connections, involving post/para central and partial gyri, and inter-connections with the other relevant RSNs. On the contrary, for the CN and, importantly, for the MCInc, the SM showed positive relevance, leading to significant differences for both intra- and inter-network connections with the most severe groups (AD and MCIc). The lowest <italic toggle="yes">p</italic>-values were found when comparing MCInc vs AD as well as CN vs AD over the different SM intra-network connections. Inter- and intra-network SM connections were indeed demonstrated to be affected by the AD pathology, generally showing an overall decreased connectivity in the later stages of the disease [<xref rid="jneae087dbib83" ref-type="bibr">83</xref>&#8211;<xref rid="jneae087dbib85" ref-type="bibr">85</xref>]. Moreover, Albers <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib86" ref-type="bibr">86</xref>] showed that many pyramidal and extrapyramidal motor impairments affect a substantial portion of AD patients, even at an early stage of the disease, and progressively worsen along with cognitive impairment, reflecting a possible decreased connectivity in the SM network. Interestingly, the VI RSN was involved in the classification of the different AD stages. In detail, positive relevance was assigned to AD subjects in both intra- and inter-connections (VI-DM and VI-CC), while a different pattern was found for MCInc, which showed negative relevance in almost the same ICs. Of note, the MCIc did not show high involvement of the VI intra-connections, while few negative inter-connections were found between VI and the other relevant RSN (SM, CC, and DM). This revealed another difference between AD and its prodromal stages, indicating a decrease in VI connectivity in the MCI stage, particularly evident for the MCInc, which then converts into hyperconnectivity in the most severe stage, full-blown dementia. The damage in VI due to AD was previously discussed by Zhan <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib83" ref-type="bibr">83</xref>]. In detail, Albers <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib86" ref-type="bibr">86</xref>] found that subgroups of AD patients have concomitant eye diseases, and some visual functions are impaired, which could be caused by impairments in the VI RSN. Moreover, recent studies demonstrated a hyperconnectivity pattern in the most severe stages of the disease present in the VI network [<xref rid="jneae087dbib87" ref-type="bibr">87</xref>]. Hence, further investigation would be needed to elucidate the involvement of VI RSN in the AD continuum.</p><p>Regarding the genetics impact, the significant biological processes for MCInc, MCIc, and AD were derived from the genes annotated starting from the most significant SNPs resulting from the interpretability analysis on the two tasks. Biological processes related to the regulation of endocytosis were found both in AD and MCIc. Previous studies highlighted how endocytosis is strongly related to AD [<xref rid="jneae087dbib88" ref-type="bibr">88</xref>]. Endocytosis is a pathway that, with all the components, proteins, and membrane organization and modulations related to it, plays an important role in AD pathology since it is involved in the trafficking and clearance of A<italic toggle="yes">&#946;</italic> proteins [<xref rid="jneae087dbib88" ref-type="bibr">88</xref>]. Moreover, particularly in MCIc, we found biological processes related to cholesterol, like <italic toggle="yes">cholesterol transport</italic> and <italic toggle="yes">sterol transport</italic>, which, on a deeper analysis, were shown as possibly being associated with the AD continuum [<xref rid="jneae087dbib88" ref-type="bibr">88</xref>]. Excess cholesterol deposit in the brain was demonstrated to be related to an increase of A<italic toggle="yes">&#946;</italic> plaques and amyloid cascade leading to synaptic plasticity annihilation and promotion of tau phosphorylation, hence contributing to the risk of AD pathogenesis, possibly in an early phase [<xref rid="jneae087dbib89" ref-type="bibr">89</xref>, <xref rid="jneae087dbib90" ref-type="bibr">90</xref>]. Additionally, for the MCIc individuals, a biological process related to A<italic toggle="yes">&#946;</italic> was highlighted, the <italic toggle="yes">negative regulation of amyloid precursor protein catabolic process</italic> that is related to AD [<xref rid="jneae087dbib91" ref-type="bibr">91</xref>, <xref rid="jneae087dbib92" ref-type="bibr">92</xref>]. In relation to A<italic toggle="yes">&#946;</italic> proteins, some biological pathways related to the regulation of amide were found in MCIc individuals. A previous study found that fatty acid amides were strongly associated with A<italic toggle="yes">&#946;</italic> and the hippocampal volume [<xref rid="jneae087dbib93" ref-type="bibr">93</xref>]. Regarding the particular genes, APOE, CLU, PICALM, APOA2, ABCA7, and BIN1 were among the most frequent in the biological processes. They all have a relevant impact in the development of AD [<xref rid="jneae087dbib59" ref-type="bibr">59</xref>, <xref rid="jneae087dbib94" ref-type="bibr">94</xref>, <xref rid="jneae087dbib95" ref-type="bibr">95</xref>]. In particular, APOE is notably the major risk factor of AD [<xref rid="jneae087dbib94" ref-type="bibr">94</xref>, <xref rid="jneae087dbib96" ref-type="bibr">96</xref>] and is mainly expressed in both the brain and the liver. More in-depth, the ApolipoproteinE is a ligand receptor-mediated endocytosis of lipoprotein particles [<xref rid="jneae087dbib96" ref-type="bibr">96</xref>] and is the major cholesterol transport and other lipids in the brain [<xref rid="jneae087dbib97" ref-type="bibr">97</xref>, <xref rid="jneae087dbib98" ref-type="bibr">98</xref>]. This gene is hence strongly related to one of the most important biomarkers for AD, namely A<italic toggle="yes">&#946;</italic> plaques containing A<italic toggle="yes">&#946;</italic> peptides and the neurofibrillary tangles containing hyperphosphorylated tau proteins [<xref rid="jneae087dbib99" ref-type="bibr">99</xref>]. TREM2 is another gene-coding protein with a key role in AD progression, and the rare variant of TREM2 R47H has a high-risk factor for AD comparable to the strongest biomarker APOE. TREM2 is a transmembrane receptor on the microglia that, in the condition of A<italic toggle="yes">&#946;</italic> aggregation, rapidly migrates closer to the aggregation, transforming them and promoting the phagocytosis and clearance of A<italic toggle="yes">&#946;</italic> formation. Hence, one of the roles of TREM2 is the regulation of microglia recruitment closer to A<italic toggle="yes">&#946;</italic> formations for the uptake and degradation of them [<xref rid="jneae087dbib100" ref-type="bibr">100</xref>]. ABCA7 is one of the most important risk genes for AD [<xref rid="jneae087dbib27" ref-type="bibr">27</xref>] that mainly regulates the processes related to cholesterol and the processing of A<italic toggle="yes">&#946;</italic> proteins [<xref rid="jneae087dbib101" ref-type="bibr">101</xref>]. ABCA7-expressed proteins have a relevant role in the control of cholesterol metabolism, and then the cholesterol has a strong influence in the regulation of A<italic toggle="yes">&#946;</italic> synthesis [<xref rid="jneae087dbib101" ref-type="bibr">101</xref>, <xref rid="jneae087dbib102" ref-type="bibr">102</xref>]. Additionally, some studies reported also that different variants of ABCA7 are associated with an increase of A<italic toggle="yes">&#946;</italic> deposition in MCI patients rather than AD [<xref rid="jneae087dbib103" ref-type="bibr">103</xref>]. Similarly, APOA2 is strictly related to cholesterol and HDL since it transports the cholesterol to the liver and is an important component for the formation of HDL [<xref rid="jneae087dbib95" ref-type="bibr">95</xref>]. As for the other relevant genes, PICALM is involved in endocytic-related processes, suited for the production, modulation, and clearance of A<italic toggle="yes">&#946;</italic> complexes [<xref rid="jneae087dbib23" ref-type="bibr">23</xref>, <xref rid="jneae087dbib88" ref-type="bibr">88</xref>]. Also, for this gene, interactions with APOE have been demonstrated [<xref rid="jneae087dbib24" ref-type="bibr">24</xref>]. Along with PICALM, the CLU variant was identified as an important biomarker for AD [<xref rid="jneae087dbib25" ref-type="bibr">25</xref>] since it is implicated in white matter integrity, membrane recycling, and lipid transportation [<xref rid="jneae087dbib104" ref-type="bibr">104</xref>]. Finally, Yu <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib105" ref-type="bibr">105</xref>] and Chapuis <italic toggle="yes">et al</italic> [<xref rid="jneae087dbib106" ref-type="bibr">106</xref>] found that BIN1 is a gene strictly related to A<italic toggle="yes">&#946;</italic> and <italic toggle="yes">&#964;</italic> pathologies, and presumably regulates the APOE [<xref rid="jneae087dbib94" ref-type="bibr">94</xref>], hence assuming high relevance in AD.</p></sec><sec id="jneae087ds5-3"><label>5.3.</label><title>Main contributions and outcomes</title><p>We proposed an interpretable, flexible, and generative framework for multimodal AD detection and MCI conversion prediction. The main contributions of this work are as follows: (i) reaching the state-of-the-art of multimodal and generative models in the classification of CN vs AD; (ii) reaching competitive performance in the segregation of MCInc/MCIc phenotypes using a pretrained framework; (iii) managing missing data introducing a generation module in the latent space for generating data in a low dimensional space simplifying the generative task and reducing the computational cost, and allowing to impute missing modalities relaxing the constraint of having at least one modality shared by the whole cohort, and (iv) proposing an interpretability analysis based on IG for extracting biological information.</p><p>The complementary analysis of three different input modalities allowed to uncover the disease signatures at multiple levels of analysis, providing complementary yet interdependent information. Besides some results being in agreement with what is known from the literature, providing evidence of the trustability of the outcomes of the proposed analysis, other findings suggest the involvement of additional mechanisms that could contribute to elucidate the mechanisms underlying the pathogenesis and progression of the disease and would deserve further investigation.</p><p>The main findings concern the presence of atrophy, particularly involving the hippocampus in later stages (MCIc and AD), that is well known in the literature, FNC modulation, particularly in the information processing-related RSN (SM and VI) as well as SNPs mutations in phenotype-specific genes. Regarding FNC, for SM negative relevance scores were recorded, hence suggesting a decreased inter- and intra-connectivity, in both the MCIc and the AD stages, while for VI a different pattern was observed for MCInc/MCIc/AD subjects. In particular, negative attributions were recorded in the MCInc stage, with reduced relevance in the MCIc, while positive attribution values characterized the AD, suggesting a compensation mechanism leading to a hyperconnectivity in such RSN in the later stages of the disease. Such brain modulations were present along with the mutation of relevant SNPs linked to the involvement of different biological processes related to endocytosis, cell and membrane transportation and organization, amyloid and cholesterol regulation for the AD and MCIc subjects, while mostly related to the T cell processes, white blood cells, and immune response pathways for the MCInc.</p><sec id="jneae087ds5-3-1"><label>5.3.1.</label><title>Limitations and future works</title><p>In what follows, the main open issues will be briefly summarized, paving the way for further research. First, related to the model generalizability, since ADNI has some specific inclusion and exclusion criteria, more investigation could be conducted for observing the performance and effects of the proposed framework with other datasets and cohorts. Concerning the MCI task, in this work, our aim was to test the model generalizability by straightforwardly testing it on the MCI cohort. Training and fine-tuning on the specific task would allow obtaining better classification results and will be the object of future analysis. Being the model intrinsically multimodal and easily flexible, additional channels could be included, such as the clinical information and PET imaging, which have been demonstrated to be highly discriminative for the disease [<xref rid="jneae087dbib4" ref-type="bibr">4</xref>], as well as advanced structural connectivity metrics derived from diffusion MRI which could help to shed light on early disease signatures. On top of this, it would be interesting to explore different phenotype stratification tasks, either proposing a multiclass classification or defining biologically homogeneous groups following the A/T/N (amyloid, tau, neurodegeneration) system which has been attracting increasing attention in recent years [<xref rid="jneae087dbib107" ref-type="bibr">107</xref>]. For the generative part, a possible limitation could derive from the fact that the generative models were trained on a population with different demographic information, e.g. age and sex, with respect to the multimodal framework, thus possibly introducing some approximation in the generated features. Finally, concerning the interpretability analysis, further investigation of the visual network in rs-fMRI in the four groups could be carried out in order to assess for any compensatory effects that the MCI and AD patients can have with respect to the control individuals. This could help to better understand AD and have a wider perspective on its mechanisms. Then, we strongly point toward deeper exploitation of XAI methods to open the way to not yet studied associations or mechanisms that are captured by the model. The next step would be the post-hoc validation of the XAI outcomes pursuing the robustness, reliability, and trustfulness of the interpretability analysis outcomes. Last but not least, the analysis of the associations between the different input features would support the interpretation of the results as well as further analysis for elucidating causal relations across the investigated underlying mechanisms.</p></sec></sec></sec><sec id="jneae087ds6"><label>6.</label><title>Conclusions</title><p>In this work, we presented a multimodal, flexible, generative, and interpretable DL-based framework for AD detection and MCI conversion classification. Neuroimaging (structural and functional features) and genetics data were used to address these classification tasks. The generation of missing modalities in the latent space using four pre-trained generators of two different cGANs allowed to obtain competitive classification performance in both tasks. The application of an interpretability method yielded our model to be interpretable, extracting the relevance of each input feature and revealing the most important ones for each class, highlighting disease structural, functional, and genetic signatures and opening the way to further analyses.</p></sec></body><back><ack><title>Acknowledgments</title><p>Data collection and sharing for this project was funded by ADNI (NIH Grant U01 AG024904) and DOD ADNI (DOD Award Number W81XWH-12-2-0012). ADNI is funded by the NIA, the NIBIB, and through generous contributions from the following: AbbVie, Alzheimer&#8217;s Association; Alzheimer&#8217;s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research &amp; Development, LLC.; Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC.; Lumosity; Lundbeck; Merck &amp; Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The CIHR is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the FNIH (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.fnih.org" ext-link-type="uri">www.fnih.org</ext-link>). The grantee organization is the NCIRE, and the study is coordinated by the Alzheimer&#8217;s Therapeutic Research Institute at USC. ADNI data are disseminated by the Laboratory for Neuro Imaging at USC.</p><p>The study was also funded by NIH grants RF1AG063153, R01AG090597, and R01AG073949, and NSF grant #2112455, as well as Ministero dell&#8217;Universit&#224; e della Ricerca (Bando PRIN 2022, &#8220;AI4BRAVE: AI for modeling of the Brain-Heart Axis in aging&#8221; project-reference code 202292PHR2), the Ministero dell&#8217;Istruzione e del Merito (MIUR D.M. 737/2021, &#8220;AI4Health: empowering neurosciences with eXplainable AI methods&#8221; project), and FSE project ANTIAGING: &#8220;Artificial intelligence for healthy aging&#8221; (project-reference code B31J23000910002).</p></ack><sec sec-type="data-availability" id="jneae087ds7"><title>Data availability statement</title><p>The data used in this work were collected by ADNI (url{<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://adni.loni.usc.edu/" ext-link-type="uri">https://adni.loni.usc.edu/</ext-link>}), and they are publicly available after request on the ADNI website.</p></sec><sec sec-type="COI-statement" id="jneae087ds8"><title>Conflict of interest</title><p>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec><ref-list content-type="numerical"><title>References</title><ref id="jneae087dbib1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vos</surname><given-names>T</given-names></name><etal>et al</etal></person-group><year>2016</year><article-title>Global, regional and national incidence, prevalence and years lived with disability for 310 diseases and injuries, 1990&#8211;2015: a systematic analysis for the global burden of disease study 2015</article-title><source>Lancet</source><volume>388</volume><fpage>1545</fpage><lpage>602</lpage><page-range>1545&#8211;602</page-range><pub-id pub-id-type="doi">10.1016/S0140-6736(16)31678-6</pub-id><pub-id pub-id-type="pmid">27733282</pub-id><pub-id pub-id-type="pmcid">PMC5055577</pub-id></element-citation></ref><ref id="jneae087dbib2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robinson-Lane</surname><given-names>S G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name></person-group><year>2020</year><article-title>Inclusive support: addressing the needs of black family caregivers of persons with dementia: dementia care research (research projects; nonpharmacological)/family/lay caregiving</article-title><source>Alzheimer&#8217;s Dement.</source><volume>16</volume><elocation-id content-type="artnum">e046712</elocation-id><pub-id pub-id-type="doi">10.1002/alz.046712</pub-id></element-citation></ref><ref id="jneae087dbib3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breijyeh</surname><given-names>Z</given-names></name><name name-style="western"><surname>Karaman</surname><given-names>R</given-names></name></person-group><year>2020</year><article-title>Comprehensive review on alzheimer&#8217;s disease: causes and treatment</article-title><source>Molecules</source><volume>25</volume><fpage>5789</fpage><pub-id pub-id-type="doi">10.3390/molecules25245789</pub-id><pub-id pub-id-type="pmid">33302541</pub-id><pub-id pub-id-type="pmcid">PMC7764106</pub-id></element-citation></ref><ref id="jneae087dbib4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knopman</surname><given-names>D S</given-names></name><name name-style="western"><surname>Amieva</surname><given-names>H</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>R C</given-names></name><name name-style="western"><surname>Ch&#233;telat</surname><given-names>G</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D M</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B T</given-names></name><name name-style="western"><surname>Nixon</surname><given-names>R A</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D T</given-names></name></person-group><year>2021</year><article-title>Alzheimer disease</article-title><source>Nat. Rev. Dis. Primers</source><volume>7</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1038/s41572-021-00269-y</pub-id><pub-id pub-id-type="pmid">33986301</pub-id><pub-id pub-id-type="pmcid">PMC8574196</pub-id></element-citation></ref><ref id="jneae087dbib5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>R C</given-names></name><etal>et al</etal></person-group><year>2010</year><article-title>Alzheimer&#8217;s disease neuroimaging initiative (ADNI): clinical characterization</article-title><source>Neurology</source><volume>74</volume><fpage>201</fpage><lpage>9</lpage><page-range>201&#8211;9</page-range><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181cb3e25</pub-id><pub-id pub-id-type="pmid">20042704</pub-id><pub-id pub-id-type="pmcid">PMC2809036</pub-id></element-citation></ref><ref id="jneae087dbib6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamel</surname><given-names>R</given-names></name><etal>et al</etal></person-group><year>2015</year><article-title>The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study</article-title><source>Psychol. Med.</source><volume>45</volume><fpage>1509</fpage><lpage>19</lpage><page-range>1509&#8211;19</page-range><pub-id pub-id-type="doi">10.1017/S0033291714002645</pub-id><pub-id pub-id-type="pmid">25407094</pub-id></element-citation></ref><ref id="jneae087dbib7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frisoni</surname><given-names>G B</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N C</given-names></name><name name-style="western"><surname>Jack Jr</surname><given-names>C R</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P M</given-names></name></person-group><year>2010</year><article-title>The clinical use of structural MRI in Alzheimer disease</article-title><source>Nat. Rev. Neurol.</source><volume>6</volume><fpage>67</fpage><lpage>77</lpage><page-range>67&#8211;77</page-range><pub-id pub-id-type="doi">10.1038/nrneurol.2009.215</pub-id><pub-id pub-id-type="pmid">20139996</pub-id><pub-id pub-id-type="pmcid">PMC2938772</pub-id></element-citation></ref><ref id="jneae087dbib8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braskie</surname><given-names>M N</given-names></name><name name-style="western"><surname>Toga</surname><given-names>A W</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P M</given-names></name><name name-style="western"><surname>Perry</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M A</given-names></name><name name-style="western"><surname>Sorensen</surname><given-names>A</given-names></name><name name-style="western"><surname>Avila</surname><given-names>J</given-names></name></person-group><year>2013</year><article-title>Recent advances in imaging Alzheimer&#8217;s disease</article-title><source>J. Alzheimer&#8217;s Disease</source><volume>33</volume><fpage>S313</fpage><lpage>27</lpage><page-range>S313&#8211;27</page-range><pub-id pub-id-type="doi">10.3233/JAD-2012-129016</pub-id><pub-id pub-id-type="pmid">22672880</pub-id><pub-id pub-id-type="pmcid">PMC4110110</pub-id></element-citation></ref><ref id="jneae087dbib9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>K A</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N C</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>R A</given-names></name><name name-style="western"><surname>Klunk</surname><given-names>W E</given-names></name></person-group><year>2012</year><article-title>Brain imaging in Alzheimer disease</article-title><source>Cold Spring Harb. Perspect. Med.</source><volume>2</volume><elocation-id content-type="artnum">a006213</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a006213</pub-id><pub-id pub-id-type="pmid">22474610</pub-id><pub-id pub-id-type="pmcid">PMC3312396</pub-id></element-citation></ref><ref id="jneae087dbib10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pini</surname><given-names>L</given-names></name><name name-style="western"><surname>Wennberg</surname><given-names>A M</given-names></name><name name-style="western"><surname>Salvalaggio</surname><given-names>A</given-names></name><name name-style="western"><surname>Vallesi</surname><given-names>A</given-names></name><name name-style="western"><surname>Pievani</surname><given-names>M</given-names></name><name name-style="western"><surname>Corbetta</surname><given-names>M</given-names></name></person-group><year>2021</year><article-title>Breakdown of specific functional brain networks in clinical variants of Alzheimer&#8217;s disease</article-title><source>Ageing Res. Rev.</source><volume>72</volume><elocation-id content-type="artnum">101482</elocation-id><pub-id pub-id-type="doi">10.1016/j.arr.2021.101482</pub-id><pub-id pub-id-type="pmid">34606986</pub-id></element-citation></ref><ref id="jneae087dbib11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Greicius</surname><given-names>M D</given-names></name><name name-style="western"><surname>Gennatas</surname><given-names>E D</given-names></name><name name-style="western"><surname>Growdon</surname><given-names>M E</given-names></name><name name-style="western"><surname>Jang</surname><given-names>J Y</given-names></name><name name-style="western"><surname>Rabinovici</surname><given-names>G D</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>J H</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>M</given-names></name><name name-style="western"><surname>Miller</surname><given-names>B L</given-names></name><name name-style="western"><surname>Seeley</surname><given-names>W W</given-names></name></person-group><year>2010</year><article-title>Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer&#8217;s disease</article-title><source>Brain</source><volume>133</volume><fpage>1352</fpage><lpage>67</lpage><page-range>1352&#8211;67</page-range><pub-id pub-id-type="doi">10.1093/brain/awq075</pub-id><pub-id pub-id-type="pmid">20410145</pub-id><pub-id pub-id-type="pmcid">PMC2912696</pub-id></element-citation></ref><ref id="jneae087dbib12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Celone</surname><given-names>K A</given-names></name><etal>et al</etal></person-group><year>2006</year><article-title>Alterations in memory networks in mild cognitive impairment and Alzheimer&#8217;s disease: an independent component analysis</article-title><source>J. Neurosci.</source><volume>26</volume><fpage>10222</fpage><lpage>31</lpage><page-range>10222&#8211;31</page-range><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2250-06.2006</pub-id><pub-id pub-id-type="pmid">17021177</pub-id><pub-id pub-id-type="pmcid">PMC6674636</pub-id></element-citation></ref><ref id="jneae087dbib13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Alexander-Bloch</surname><given-names>A F</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T</given-names></name><name name-style="western"><surname>Bullmore</surname><given-names>E</given-names></name></person-group><year>2014</year><article-title>Impaired long distance functional connectivity and weighted network architecture in Alzheimer&#8217;s disease</article-title><source>Cerebral Cortex</source><volume>24</volume><fpage>1422</fpage><lpage>35</lpage><page-range>1422&#8211;35</page-range><pub-id pub-id-type="doi">10.1093/cercor/bhs410</pub-id><pub-id pub-id-type="pmid">23314940</pub-id><pub-id pub-id-type="pmcid">PMC4215108</pub-id></element-citation></ref><ref id="jneae087dbib14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>D T</given-names></name><name name-style="western"><surname>Knopman</surname><given-names>D S</given-names></name><name name-style="western"><surname>Gunter</surname><given-names>J L</given-names></name><name name-style="western"><surname>Graff-Radford</surname><given-names>J</given-names></name><name name-style="western"><surname>Vemuri</surname><given-names>P</given-names></name><name name-style="western"><surname>Boeve</surname><given-names>B F</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>R C</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>M W</given-names></name><name name-style="western"><surname>Jack Jr</surname><given-names>C R</given-names></name></person-group><year>2016</year><article-title>Cascading network failure across the Alzheimer&#8217;s disease spectrum</article-title><source>Brain</source><volume>139</volume><fpage>547</fpage><lpage>62</lpage><page-range>547&#8211;62</page-range><pub-id pub-id-type="doi">10.1093/brain/awv338</pub-id><pub-id pub-id-type="pmid">26586695</pub-id><pub-id pub-id-type="pmcid">PMC4805086</pub-id></element-citation></ref><ref id="jneae087dbib15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franzmeier</surname><given-names>N</given-names></name><name name-style="western"><surname>Neitzel</surname><given-names>J</given-names></name><name name-style="western"><surname>Rubinski</surname><given-names>A</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R</given-names></name><name name-style="western"><surname>Strandberg</surname><given-names>O</given-names></name><name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>O</given-names></name><name name-style="western"><surname>Ewers</surname><given-names>M</given-names></name></person-group><year>2020</year><article-title>Functional brain architecture is associated with the rate of tau accumulation in Alzheimer&#8217;s disease</article-title><source>Nat. Commun.</source><volume>11</volume><fpage>347</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-14159-1</pub-id><pub-id pub-id-type="pmid">31953405</pub-id><pub-id pub-id-type="pmcid">PMC6969065</pub-id></element-citation></ref><ref id="jneae087dbib16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwok</surname><given-names>P-Y</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z</given-names></name></person-group><year>1999</year><article-title>Single nucleotide polymorphism libraries: why and how are we building them?</article-title><source>Mol. Med. Today</source><volume>5</volume><fpage>538</fpage><lpage>43</lpage><page-range>538&#8211;43</page-range><pub-id pub-id-type="doi">10.1016/S1357-4310(99)01601-9</pub-id><pub-id pub-id-type="pmid">10562720</pub-id></element-citation></ref><ref id="jneae087dbib17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wightman</surname><given-names>D P</given-names></name></person-group><year>2021</year><article-title>A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer&#8217;s disease</article-title><source>Nat. Genet.</source><volume>53</volume><fpage>1276</fpage><lpage>82</lpage><page-range>1276&#8211;82</page-range><pub-id pub-id-type="doi">10.1038/s41588-021-00921-z</pub-id><pub-id pub-id-type="pmid">34493870</pub-id><pub-id pub-id-type="pmcid">PMC10243600</pub-id></element-citation></ref><ref id="jneae087dbib18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>J-C</given-names></name><name name-style="western"><surname>Bahrami</surname><given-names>S</given-names></name><name name-style="western"><surname>Holland</surname><given-names>D</given-names></name><name name-style="western"><surname>Rongve</surname><given-names>A</given-names></name><name name-style="western"><surname>B&#246;rte</surname><given-names>S</given-names></name><name name-style="western"><surname>Winsvold</surname><given-names>B S</given-names></name><name name-style="western"><surname>Drange</surname><given-names>O K</given-names></name><name name-style="western"><surname>Martinsen</surname><given-names>A E</given-names></name></person-group><year>2013</year><article-title>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer&#8217;s disease</article-title><source>Nat. Genet.</source><volume>45</volume><fpage>1452</fpage><lpage>8</lpage><page-range>1452&#8211;8</page-range><pub-id pub-id-type="doi">10.1038/s41588-021-00921-z</pub-id><pub-id pub-id-type="pmid">24162737</pub-id><pub-id pub-id-type="pmcid">PMC3896259</pub-id></element-citation></ref><ref id="jneae087dbib19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunkle</surname><given-names>B W</given-names></name><etal>et al</etal></person-group><year>2019</year><article-title>Genetic meta-analysis of diagnosed Alzheimer&#8217;s disease identifies new risk loci and implicates a&#946;, tau, immunity and lipid processing</article-title><source>Nat. Genet.</source><volume>51</volume><fpage>414</fpage><lpage>30</lpage><page-range>414&#8211;30</page-range><pub-id pub-id-type="doi">10.1038/s41588-019-0358-2</pub-id><pub-id pub-id-type="pmid">30820047</pub-id><pub-id pub-id-type="pmcid">PMC6463297</pub-id></element-citation></ref><ref id="jneae087dbib20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winblad</surname><given-names>B</given-names></name><etal>et al</etal></person-group><year>2004</year><article-title>Mild cognitive impairment&#8211;beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment</article-title><source>J. Internal Med.</source><volume>256</volume><fpage>240</fpage><lpage>6</lpage><page-range>240&#8211;6</page-range><pub-id pub-id-type="doi">10.1111/j.1365-2796.2004.01380.x</pub-id><pub-id pub-id-type="pmid">15324367</pub-id></element-citation></ref><ref id="jneae087dbib21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monfared</surname><given-names>A A T</given-names></name><name name-style="western"><surname>Byrnes</surname><given-names>M J</given-names></name><name name-style="western"><surname>White</surname><given-names>L A</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name></person-group><year>2022</year><article-title>Alzheimer&#8217;s disease: epidemiology and clinical progression</article-title><source>Neurol. Therapy</source><volume>11</volume><fpage>553</fpage><lpage>69</lpage><page-range>553&#8211;69</page-range><pub-id pub-id-type="doi">10.1007/s40120-022-00338-8</pub-id><pub-id pub-id-type="pmcid">PMC9095793</pub-id><pub-id pub-id-type="pmid">35286590</pub-id></element-citation></ref><ref id="jneae087dbib22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ungar</surname><given-names>L</given-names></name><name name-style="western"><surname>Altmann</surname><given-names>A</given-names></name><name name-style="western"><surname>Greicius</surname><given-names>M D</given-names></name></person-group><year>2014</year><article-title>Apolipoprotein E, gender and Alzheimer&#8217;s disease: an overlooked, but potent and promising interaction</article-title><source>Brain Imaging Behav.</source><volume>8</volume><fpage>262</fpage><lpage>73</lpage><page-range>262&#8211;73</page-range><pub-id pub-id-type="doi">10.1007/s11682-013-9272-x</pub-id><pub-id pub-id-type="pmid">24293121</pub-id><pub-id pub-id-type="pmcid">PMC4282773</pub-id></element-citation></ref><ref id="jneae087dbib23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J-T</given-names></name></person-group><year>2015</year><article-title>The role of PICALM in Alzheimer&#8217;s disease</article-title><source>Mol. Neurobiol.</source><volume>52</volume><fpage>399</fpage><lpage>413</lpage><page-range>399&#8211;413</page-range><pub-id pub-id-type="doi">10.1007/s12035-014-8878-3</pub-id><pub-id pub-id-type="pmid">25186232</pub-id></element-citation></ref><ref id="jneae087dbib24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jun</surname><given-names>G</given-names></name><etal>et al</etal></person-group><year>2010</year><article-title>Meta-analysis confirms CR1, CLU and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes</article-title><source>Arch. Neurol.</source><volume>67</volume><fpage>1473</fpage><lpage>84</lpage><page-range>1473&#8211;84</page-range><pub-id pub-id-type="doi">10.1001/archneurol.2010.201</pub-id><pub-id pub-id-type="pmid">20697030</pub-id><pub-id pub-id-type="pmcid">PMC3048805</pub-id></element-citation></ref><ref id="jneae087dbib25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harold</surname><given-names>D</given-names></name><etal>et al</etal></person-group><year>2009</year><article-title>Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#8217;s disease</article-title><source>Nat. Genet.</source><volume>41</volume><fpage>1088</fpage><lpage>93</lpage><page-range>1088&#8211;93</page-range><pub-id pub-id-type="doi">10.1038/ng.440</pub-id><pub-id pub-id-type="pmid">19734902</pub-id><pub-id pub-id-type="pmcid">PMC2845877</pub-id></element-citation></ref><ref id="jneae087dbib26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corneveaux</surname><given-names>J J</given-names></name><etal>et al</etal></person-group><year>2010</year><article-title>Association of CR1, CLU and PICALM with Alzheimer&#8217;s disease in a cohort of clinically characterized and neuropathologically verified individuals</article-title><source>Human Mol. Genet.</source><volume>19</volume><fpage>3295</fpage><lpage>301</lpage><page-range>3295&#8211;301</page-range><pub-id pub-id-type="doi">10.1093/hmg/ddq221</pub-id><pub-id pub-id-type="pmid">20534741</pub-id><pub-id pub-id-type="pmcid">PMC2908469</pub-id></element-citation></ref><ref id="jneae087dbib27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Roeck</surname><given-names>A</given-names></name><name name-style="western"><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name name-style="western"><surname>Sleegers</surname><given-names>K</given-names></name></person-group><year>2019</year><article-title>The role of ABCA7 in Alzheimer&#8217;s disease: evidence from genomics, transcriptomics and methylomics</article-title><source>Acta Neuropathologica</source><volume>138</volume><fpage>201</fpage><lpage>20</lpage><page-range>201&#8211;20</page-range><pub-id pub-id-type="doi">10.1007/s00401-019-01994-1</pub-id><pub-id pub-id-type="pmid">30903345</pub-id><pub-id pub-id-type="pmcid">PMC6660495</pub-id></element-citation></ref><ref id="jneae087dbib28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruciani</surname><given-names>F</given-names></name><name name-style="western"><surname>Aparo</surname><given-names>A</given-names></name><name name-style="western"><surname>Brusini</surname><given-names>L</given-names></name><name name-style="western"><surname>Combi</surname><given-names>C</given-names></name><name name-style="western"><surname>Storti</surname><given-names>S F</given-names></name><name name-style="western"><surname>Giugno</surname><given-names>R</given-names></name><name name-style="western"><surname>Menegaz</surname><given-names>G</given-names></name><name name-style="western"><surname>Boscolo Galazzo</surname><given-names>I</given-names></name></person-group><year>2024</year><article-title>Identifying the joint signature of brain atrophy and gene variant scores in Alzheimer&#8217;s disease</article-title><source>J. Biomed. Inform.</source><volume>149</volume><elocation-id content-type="artnum">104569</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbi.2023.104569</pub-id><pub-id pub-id-type="pmid">38104851</pub-id></element-citation></ref><ref id="jneae087dbib29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Risacher</surname><given-names>S L</given-names></name><name name-style="western"><surname>Saykin</surname><given-names>A J</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name></person-group><year>2017</year><article-title>Mining outcome-relevant brain imaging genetic associations via three-way sparse canonical correlation analysis in Alzheimer&#8217;s disease</article-title><source>Sci. Rep.</source><volume>7</volume><elocation-id content-type="artnum">44272</elocation-id><pub-id pub-id-type="doi">10.1038/srep44272</pub-id><pub-id pub-id-type="pmid">28291242</pub-id><pub-id pub-id-type="pmcid">PMC5349597</pub-id></element-citation></ref><ref id="jneae087dbib30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saxe</surname><given-names>A</given-names></name><name name-style="western"><surname>Nelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Summerfield</surname><given-names>C</given-names></name></person-group><year>2021</year><article-title>If deep learning is the answer, what is the question?</article-title><source>Nat. Rev. Neurosci.</source><volume>22</volume><fpage>55</fpage><lpage>67</lpage><page-range>55&#8211;67</page-range><pub-id pub-id-type="doi">10.1038/s41583-020-00395-8</pub-id><pub-id pub-id-type="pmid">33199854</pub-id></element-citation></ref><ref id="jneae087dbib31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelaziz</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Anwaar</surname><given-names>W</given-names></name><name name-style="western"><surname>Elazab</surname><given-names>A</given-names></name></person-group><year>2025</year><article-title>Multi-scale multimodal deep learning framework for Alzheimer&#8217;s disease diagnosis</article-title><source>Comput. Biol. Med.</source><volume>184</volume><elocation-id content-type="artnum">109438</elocation-id><pub-id pub-id-type="doi">10.1016/j.compbiomed.2024.109438</pub-id><pub-id pub-id-type="pmid">39579666</pub-id></element-citation></ref><ref id="jneae087dbib32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolci</surname><given-names>G</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>C A</given-names></name><name name-style="western"><surname>Cruciani</surname><given-names>F</given-names></name><name name-style="western"><surname>Brusini</surname><given-names>L</given-names></name><name name-style="western"><surname>Abrol</surname><given-names>A</given-names></name><name name-style="western"><surname>Galazzo</surname><given-names>I B</given-names></name><name name-style="western"><surname>Menegaz</surname><given-names>G</given-names></name><name name-style="western"><surname>Calhoun</surname><given-names>V D</given-names></name><name name-style="western"><surname>Initiative</surname><given-names>A D N</given-names></name></person-group><year>2024</year><article-title>Multimodal mri accurately identifies amyloid status in unbalanced cohorts in Alzheimer&#8217;s disease continuum</article-title><source>Netw. Neurosci.</source><volume>8</volume><fpage>1</fpage><lpage>21</lpage><page-range>1&#8211;21</page-range><pub-id pub-id-type="doi">10.1162/netn_a_00339</pub-id><pub-id pub-id-type="pmid">40161995</pub-id><pub-id pub-id-type="pmcid">PMC11949592</pub-id></element-citation></ref><ref id="jneae087dbib33"><label>33</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Venkataraman</surname><given-names>A</given-names></name><name name-style="western"><surname>Ghosal</surname><given-names>S</given-names></name></person-group><year>2023</year><article-title>GIRUS-net: a multimodal deep learning model identifying imaging and genetic biomarkers linked to Alzheimer&#8217;s disease severity</article-title><conf-name>2023 45th Annual Int. Conf. of the IEEE Engineering in Medicine &amp; Biology Society (EMBC)</conf-name><publisher-name>IEEE</publisher-name><fpage>1</fpage><lpage>4</lpage><page-range>1&#8211;4</page-range><pub-id pub-id-type="doi">10.1109/EMBC40787.2023.10341000</pub-id><pub-id pub-id-type="pmcid">PMC11005466</pub-id><pub-id pub-id-type="pmid">38083359</pub-id></element-citation></ref><ref id="jneae087dbib34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahaman</surname><given-names>M A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>N</given-names></name><name name-style="western"><surname>Iraji</surname><given-names>A</given-names></name><name name-style="western"><surname>van Erp</surname><given-names>T G</given-names></name><name name-style="western"><surname>Calhoun</surname><given-names>V D</given-names></name></person-group><year>2023</year><article-title>Deep multimodal predictome for studying mental disorders</article-title><source>Human Brain Mapping</source><volume>44</volume><fpage>509</fpage><lpage>22</lpage><page-range>509&#8211;22</page-range><pub-id pub-id-type="doi">10.1002/hbm.26077</pub-id><pub-id pub-id-type="pmid">36574598</pub-id><pub-id pub-id-type="pmcid">PMC9842924</pub-id></element-citation></ref><ref id="jneae087dbib35"><label>35</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Dolci</surname><given-names>G</given-names></name><name name-style="western"><surname>Rahaman</surname><given-names>M A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Duan</surname><given-names>K</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Abrol</surname><given-names>A</given-names></name><name name-style="western"><surname>Menegaz</surname><given-names>G</given-names></name><name name-style="western"><surname>Calhoun</surname><given-names>V D</given-names></name></person-group><year>2022</year><article-title>A deep generative multimodal imaging genomics framework for Alzheimer&#8217;s disease prediction</article-title><conf-name>2022 IEEE 22nd Int. Conf. on Bioinformatics and Bioengineering (BIBE)</conf-name><publisher-name>IEEE</publisher-name><fpage>41</fpage><lpage>44</lpage><page-range>41&#8211;44</page-range><pub-id pub-id-type="doi">10.1109/BIBE55377.2022.00017</pub-id></element-citation></ref><ref id="jneae087dbib36"><label>36</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Abrol</surname><given-names>A</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Calhoun</surname><given-names>V D</given-names></name></person-group><year>2019</year><article-title>Multimodal data fusion of deep learning and dynamic functional connectivity features to predict Alzheimer&#8217;s disease progression</article-title><conf-name>2019 41st Annual Int. Conf. IEEE Engineering in Medicine and Biology Society (EMBC)</conf-name><publisher-name>IEEE</publisher-name><fpage>4409</fpage><lpage>13</lpage><page-range>4409&#8211;13</page-range><pub-id pub-id-type="doi">10.1109/EMBC.2019.8856500</pub-id><pub-id pub-id-type="pmid">31946844</pub-id></element-citation></ref><ref id="jneae087dbib37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Jong</surname><given-names>J</given-names></name><name name-style="western"><surname>Emon</surname><given-names>M A</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P</given-names></name><name name-style="western"><surname>Karki</surname><given-names>R</given-names></name><name name-style="western"><surname>Sood</surname><given-names>M</given-names></name><name name-style="western"><surname>Godard</surname><given-names>P</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>A</given-names></name><name name-style="western"><surname>Vrooman</surname><given-names>H</given-names></name><name name-style="western"><surname>Hofmann-Apitius</surname><given-names>M</given-names></name><name name-style="western"><surname>Fr&#246;hlich</surname><given-names>H</given-names></name></person-group><year>2019</year><article-title>Deep learning for clustering of multivariate clinical patient trajectories with missing values</article-title><source>GigaScience</source><volume>8</volume><fpage>iz134</fpage><pub-id pub-id-type="doi">10.1093/gigascience/giz134</pub-id><pub-id pub-id-type="pmcid">PMC6857688</pub-id><pub-id pub-id-type="pmid">31730697</pub-id></element-citation></ref><ref id="jneae087dbib38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venugopalan</surname><given-names>J</given-names></name><name name-style="western"><surname>Tong</surname><given-names>L</given-names></name><name name-style="western"><surname>Hassanzadeh</surname><given-names>H R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M D</given-names></name></person-group><year>2021</year><article-title>Multimodal deep learning models for early detection of Alzheimer&#8217;s disease stage</article-title><source>Sci. Rep.</source><volume>11</volume><fpage>3254</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-74399-w</pub-id><pub-id pub-id-type="pmid">33547343</pub-id><pub-id pub-id-type="pmcid">PMC7864942</pub-id></element-citation></ref><ref id="jneae087dbib39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritter</surname><given-names>K</given-names></name><etal>et al</etal></person-group><year>2015</year><article-title>Multimodal prediction of conversion to Alzheimer&#8217;s disease based on incomplete biomarkers</article-title><source>Alzheimer&#8217;s Dement.</source><volume>1</volume><fpage>206</fpage><lpage>15</lpage><page-range>206&#8211;15</page-range><pub-id pub-id-type="doi">10.1016/j.dadm.2015.01.006</pub-id><pub-id pub-id-type="pmcid">PMC4877756</pub-id><pub-id pub-id-type="pmid">27239505</pub-id></element-citation></ref><ref id="jneae087dbib40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q</given-names></name><name name-style="western"><surname>Gui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name></person-group><year>2021</year><article-title>Multimodal mr images-based diagnosis of early adolescent attention-deficit/hyperactivity disorder using multiple kernel learning</article-title><source>Front. Neurosci.</source><volume>15</volume><elocation-id content-type="artnum">710133</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2021.710133</pub-id><pub-id pub-id-type="pmid">34594183</pub-id><pub-id pub-id-type="pmcid">PMC8477011</pub-id></element-citation></ref><ref id="jneae087dbib41"><label>41</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Thung</surname><given-names>K-H</given-names></name><name name-style="western"><surname>Adeli</surname><given-names>E</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D</given-names></name></person-group><year>2017</year><article-title>Maximum mean discrepancy based multiple kernel learning for incomplete multimodality neuroimaging data</article-title><conf-name>Int. Conf. on Medical Image Computing and Computer-Assisted Intervention</conf-name><publisher-name>Springer</publisher-name><fpage>72</fpage><lpage>80</lpage><page-range>72&#8211;80</page-range><pub-id pub-id-type="doi">10.1007/978-3-319-66179-7_9</pub-id><pub-id pub-id-type="pmcid">PMC5790115</pub-id><pub-id pub-id-type="pmid">29392246</pub-id></element-citation></ref><ref id="jneae087dbib42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L</given-names></name><name name-style="western"><surname>Fan</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P M</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name></person-group><year>2014</year><article-title>Bi-level multi-source learning for heterogeneous block-wise missing data</article-title><source>NeuroImage</source><volume>102</volume><fpage>192</fpage><lpage>206</lpage><page-range>192&#8211;206</page-range><pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.08.015</pub-id><pub-id pub-id-type="pmid">23988272</pub-id><pub-id pub-id-type="pmcid">PMC3937297</pub-id></element-citation></ref><ref id="jneae087dbib43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Geng</surname><given-names>L</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D</given-names></name></person-group><year>2021</year><article-title>Incomplete multi-modal representation learning for Alzheimer&#8217;s disease diagnosis</article-title><source>Med. Image Anal.</source><volume>69</volume><elocation-id content-type="artnum">101953</elocation-id><pub-id pub-id-type="doi">10.1016/j.media.2020.101953</pub-id><pub-id pub-id-type="pmid">33460880</pub-id></element-citation></ref><ref id="jneae087dbib44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X-F</given-names></name></person-group><year>2019</year><article-title>The emerging roles and therapeutic potential of soluble TREM2 in Alzheimer&#8217;s disease</article-title><source>Front. Aging Neurosci.</source><volume>11</volume><fpage>328</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2019.00328</pub-id><pub-id pub-id-type="pmid">32038221</pub-id><pub-id pub-id-type="pmcid">PMC6988790</pub-id></element-citation></ref><ref id="jneae087dbib45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>F</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name></person-group><year>2023</year><article-title>Multimodal transformer network for incomplete image generation and diagnosis of Alzheimer&#8217;s disease</article-title><source>Comput. Med. Imaging Graph.</source><volume>110</volume><elocation-id content-type="artnum">102303</elocation-id><pub-id pub-id-type="doi">10.1016/j.compmedimag.2023.102303</pub-id><pub-id pub-id-type="pmid">37832503</pub-id></element-citation></ref><ref id="jneae087dbib46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Qing</surname><given-names>L</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name></person-group><year>2022</year><article-title>BPGAN: brain PET synthesis from MRI using generative adversarial network for multi-modal Alzheimer&#8217;s disease diagnosis</article-title><source>Comput. Methods Programs Biomed.</source><volume>217</volume><elocation-id content-type="artnum">106676</elocation-id><pub-id pub-id-type="doi">10.1016/j.cmpb.2022.106676</pub-id><pub-id pub-id-type="pmid">35167997</pub-id></element-citation></ref><ref id="jneae087dbib47"><label>47</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D</given-names></name><name name-style="western"><surname>Ji</surname><given-names>S</given-names></name></person-group><year>2018</year><article-title>Deep adversarial learning for multi-modality missing data completion</article-title><conf-name>Proc. 24th ACM SIGKDD International Conference on Knowledge Discovery &amp; Data Mining</conf-name><fpage>1158</fpage><lpage>66</lpage><page-range>1158&#8211;66</page-range><pub-id pub-id-type="doi">10.1145/3219819.3219963</pub-id></element-citation></ref><ref id="jneae087dbib48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name></person-group><year>2023</year><article-title>Pairwise feature-based generative adversarial network for incomplete multi-modal Alzheimer&#8217;s disease diagnosis</article-title><source>The Visual Computer</source><volume>39</volume><fpage>2235</fpage><lpage>44</lpage><page-range>2235&#8211;44</page-range><pub-id pub-id-type="doi">10.1007/s00371-021-02354-5</pub-id></element-citation></ref><ref id="jneae087dbib49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>F</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name></person-group><year>2021</year><article-title>Task-induced pyramid and attention gan for multimodal brain image imputation and classification in Alzheimer&#8217;s disease</article-title><source>IEEE J. Biomed. Health Inform.</source><volume>26</volume><fpage>36</fpage><lpage>43</lpage><page-range>36&#8211;43</page-range><pub-id pub-id-type="doi">10.1109/JBHI.2021.3097721</pub-id><pub-id pub-id-type="pmid">34280112</pub-id></element-citation></ref><ref id="jneae087dbib50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Thung</surname><given-names>K-H</given-names></name><name name-style="western"><surname>Shen</surname><given-names>D</given-names></name></person-group><year>2019</year><article-title>Latent representation learning for Alzheimer&#8217;s disease diagnosis with incomplete multi-modality neuroimaging and genetic data</article-title><source>IEEE Trans. Med. Imaging</source><volume>38</volume><fpage>2411</fpage><lpage>22</lpage><page-range>2411&#8211;22</page-range><pub-id pub-id-type="doi">10.1109/TMI.2019.2913158</pub-id><pub-id pub-id-type="pmid">31021792</pub-id><pub-id pub-id-type="pmcid">PMC8034601</pub-id></element-citation></ref><ref id="jneae087dbib51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name></person-group><year>2024</year><article-title>Multimodal fusion diagnosis of Alzheimer&#8217;s disease based on FDG-PET generation</article-title><source>Biomed. Signal Process. Control</source><volume>89</volume><elocation-id content-type="artnum">105709</elocation-id><pub-id pub-id-type="doi">10.1016/j.bspc.2023.105709</pub-id></element-citation></ref><ref id="jneae087dbib52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><name name-style="western"><surname>Kong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name><name name-style="western"><surname>Yi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yan</surname><given-names>F</given-names></name></person-group><year>2024</year><article-title>Pyramid-attentive GAN for multimodal brain image complementation in Alzheimer&#8217;s disease classification</article-title><source>Biomed. Signal Process. Control</source><volume>89</volume><elocation-id content-type="artnum">105652</elocation-id><pub-id pub-id-type="doi">10.1016/j.bspc.2023.105652</pub-id></element-citation></ref><ref id="jneae087dbib53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>U</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S-W</given-names></name><name name-style="western"><surname>Jung</surname><given-names>D</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Seo</surname><given-names>S W</given-names></name><name name-style="western"><surname>Seong</surname><given-names>J-K</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>S</given-names></name></person-group><year>2023</year><article-title>Real-world prediction of preclinical Alzheimer&#8217;s disease with a deep generative model</article-title><source>Artif. Intell. Med.</source><volume>144</volume><elocation-id content-type="artnum">102654</elocation-id><pub-id pub-id-type="doi">10.1016/j.artmed.2023.102654</pub-id><pub-id pub-id-type="pmid">37783547</pub-id></element-citation></ref><ref id="jneae087dbib54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodfellow</surname><given-names>I</given-names></name><name name-style="western"><surname>Pouget-Abadie</surname><given-names>J</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><name name-style="western"><surname>Warde-Farley</surname><given-names>D</given-names></name><name name-style="western"><surname>Ozair</surname><given-names>S</given-names></name><name name-style="western"><surname>Courville</surname><given-names>A</given-names></name><name name-style="western"><surname>Bengio</surname><given-names>Y</given-names></name></person-group><year>2020</year><article-title>Generative adversarial networks</article-title><source>Commun. ACM</source><volume>63</volume><fpage>139</fpage><lpage>44</lpage><page-range>139&#8211;44</page-range><pub-id pub-id-type="doi">10.1145/3422622</pub-id></element-citation></ref><ref id="jneae087dbib55"><label>55</label><element-citation publication-type="preprint"><person-group person-group-type="author"><name name-style="western"><surname>Kingma</surname><given-names>D P</given-names></name><name name-style="western"><surname>Welling</surname><given-names>M</given-names></name></person-group><year>2013</year><article-title>Auto-encoding variational bayes</article-title><comment>(arXiv:<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://arxiv.org/abs/1312.6114" ext-link-type="uri">1312.6114</ext-link>)</comment></element-citation></ref><ref id="jneae087dbib56"><label>56</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>J-Y</given-names></name><name name-style="western"><surname>Park</surname><given-names>T</given-names></name><name name-style="western"><surname>Isola</surname><given-names>P</given-names></name><name name-style="western"><surname>Efros</surname><given-names>A A</given-names></name></person-group><year>2017</year><article-title>Unpaired image-to-image translation using cycle-consistent adversarial networks</article-title><conf-name>Proc. IEEE Int. Conf. on Computer Vision</conf-name><fpage>2223</fpage><lpage>32</lpage><page-range>2223&#8211;32</page-range><pub-id pub-id-type="doi">10.1109/ICCV.2017.244</pub-id></element-citation></ref><ref id="jneae087dbib57"><label>57</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Rahaman</surname><given-names>M A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>N</given-names></name><name name-style="western"><surname>Iraji</surname><given-names>A</given-names></name><name name-style="western"><surname>Calhoun</surname><given-names>V D</given-names></name></person-group><year>2021</year><article-title>Multi-modal deep learning of functional and structural neuroimaging and genomic data to predict mental illness</article-title><conf-name>2021 43rd Annual Int. Conf. of the IEEE Engineering in Medicine &amp; Biology Society (EMBC)</conf-name><publisher-name>IEEE</publisher-name><fpage>3267</fpage><lpage>72</lpage><page-range>3267&#8211;72</page-range><pub-id pub-id-type="doi">10.1109/EMBC46164.2021.9630693</pub-id><pub-id pub-id-type="pmid">34891938</pub-id></element-citation></ref><ref id="jneae087dbib58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Sappagh</surname><given-names>S</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>J M</given-names></name><name name-style="western"><surname>Islam</surname><given-names>S</given-names></name><name name-style="western"><surname>Sultan</surname><given-names>A M</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>K S</given-names></name></person-group><year>2021</year><article-title>A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer&#8217;s disease</article-title><source>Sci. Rep.</source><volume>11</volume><fpage>1</fpage><lpage>26</lpage><page-range>1&#8211;26</page-range><pub-id pub-id-type="doi">10.1038/s41598-021-82098-3</pub-id><pub-id pub-id-type="pmid">33514817</pub-id><pub-id pub-id-type="pmcid">PMC7846613</pub-id></element-citation></ref><ref id="jneae087dbib59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y-S</given-names></name><name name-style="western"><surname>Xin</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><year>2017</year><article-title>Analyzing the genes related to Alzheimer&#8217;s disease via a network and pathway-based approach</article-title><source>Alzheimer&#8217;s Res. Therapy</source><volume>9</volume><fpage>1</fpage><lpage>15</lpage><page-range>1&#8211;15</page-range><pub-id pub-id-type="doi">10.1186/s13195-017-0252-z</pub-id><pub-id pub-id-type="pmcid">PMC5406904</pub-id><pub-id pub-id-type="pmid">28446202</pub-id></element-citation></ref><ref id="jneae087dbib60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiner</surname><given-names>M W</given-names></name><etal>et al</etal></person-group><year>2017</year><article-title>The Alzheimer&#8217;s disease neuroimaging initiative 3: continued innovation for clinical trial improvement</article-title><source>Alzheimer&#8217;s Dement.</source><volume>13</volume><fpage>561</fpage><lpage>71</lpage><page-range>561&#8211;71</page-range><pub-id pub-id-type="doi">10.1016/j.jalz.2016.10.006</pub-id><pub-id pub-id-type="pmid">27931796</pub-id><pub-id pub-id-type="pmcid">PMC5536850</pub-id></element-citation></ref><ref id="jneae087dbib61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><year>2020</year><article-title>Neuromark: An automated and adaptive ica based pipeline to identify reproducible fMRI markers of brain disorders</article-title><source>NeuroImage</source><volume>28</volume><elocation-id content-type="artnum">102375</elocation-id><pub-id pub-id-type="doi">10.1016/j.nicl.2020.102375</pub-id><pub-id pub-id-type="pmid">32961402</pub-id><pub-id pub-id-type="pmcid">PMC7509081</pub-id></element-citation></ref><ref id="jneae087dbib62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>I E</given-names></name><etal>et al</etal></person-group><year>2019</year><article-title>Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer&#8217;s disease risk</article-title><source>Nat. Genet.</source><volume>51</volume><fpage>404</fpage><lpage>13</lpage><page-range>404&#8211;13</page-range><pub-id pub-id-type="doi">10.1038/s41588-018-0311-9</pub-id><pub-id pub-id-type="pmid">30617256</pub-id><pub-id pub-id-type="pmcid">PMC6836675</pub-id></element-citation></ref><ref id="jneae087dbib63"><label>63</label><element-citation publication-type="preprint"><person-group person-group-type="author"><name name-style="western"><surname>Kingma</surname><given-names>D P</given-names></name><name name-style="western"><surname>Ba</surname><given-names>J</given-names></name></person-group><year>2014</year><article-title>Adam: a method for stochastic optimization</article-title><comment>(arXiv:<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://arxiv.org/abs/1412.6980" ext-link-type="uri">1412.6980</ext-link>)</comment></element-citation></ref><ref id="jneae087dbib64"><label>64</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Sundararajan</surname><given-names>M</given-names></name><name name-style="western"><surname>Taly</surname><given-names>A</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Q</given-names></name></person-group><year>2017</year><article-title>Axiomatic attribution for deep networks</article-title><conf-name>Int. Conf. on Machine Learning</conf-name><publisher-name>PMLR</publisher-name><fpage>3319</fpage><lpage>28</lpage><page-range>3319&#8211;28</page-range><comment>(available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://proceedings.mlr.press/v70/sundararajan17a/sundararajan17a.pdf" ext-link-type="uri">https://proceedings.mlr.press/v70/sundararajan17a/sundararajan17a.pdf</ext-link>)</comment></element-citation></ref><ref id="jneae087dbib65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desikan</surname><given-names>R S</given-names></name><etal>et al</etal></person-group><year>2006</year><article-title>An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest</article-title><source>NeuroImage</source><volume>31</volume><fpage>968</fpage><lpage>80</lpage><page-range>968&#8211;80</page-range><pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.01.021</pub-id><pub-id pub-id-type="pmid">16530430</pub-id></element-citation></ref><ref id="jneae087dbib66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLaren</surname><given-names>W</given-names></name><name name-style="western"><surname>Gil</surname><given-names>L</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>S E</given-names></name><name name-style="western"><surname>Riat</surname><given-names>H S</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>G R</given-names></name><name name-style="western"><surname>Thormann</surname><given-names>A</given-names></name><name name-style="western"><surname>Flicek</surname><given-names>P</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>F</given-names></name></person-group><year>2016</year><article-title>The ensembl variant effect predictor</article-title><source>Genome Biol.</source><volume>17</volume><fpage>1</fpage><lpage>14</lpage><page-range>1&#8211;14</page-range><pub-id pub-id-type="doi">10.1186/s13059-016-0974-4</pub-id><pub-id pub-id-type="pmid">27268795</pub-id><pub-id pub-id-type="pmcid">PMC4893825</pub-id></element-citation></ref><ref id="jneae087dbib67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashburner</surname><given-names>M</given-names></name><etal>et al</etal></person-group><year>2000</year><article-title>Gene ontology: tool for the unification of biology</article-title><source>Nat. Genet.</source><volume>25</volume><fpage>25</fpage><lpage>29</lpage><page-range>25&#8211;29</page-range><pub-id pub-id-type="doi">10.1038/75556</pub-id><pub-id pub-id-type="pmid">10802651</pub-id><pub-id pub-id-type="pmcid">PMC3037419</pub-id></element-citation></ref><ref id="jneae087dbib68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aleksander</surname><given-names>S A</given-names></name><etal>et al</etal></person-group><year>2023</year><article-title>The gene ontology knowledgebase in 2023</article-title><source>Genetics</source><volume>224</volume><fpage>iyad031</fpage><pub-id pub-id-type="doi">10.1093/genetics/iyad031</pub-id><pub-id pub-id-type="pmid">36866529</pub-id><pub-id pub-id-type="pmcid">PMC10158837</pub-id></element-citation></ref><ref id="jneae087dbib69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>P D</given-names></name><name name-style="western"><surname>Ebert</surname><given-names>D</given-names></name><name name-style="western"><surname>Muruganujan</surname><given-names>A</given-names></name><name name-style="western"><surname>Mushayahama</surname><given-names>T</given-names></name><name name-style="western"><surname>Albou</surname><given-names>L-P</given-names></name><name name-style="western"><surname>Mi</surname><given-names>H</given-names></name></person-group><year>2022</year><article-title>Panther: making genome-scale phylogenetics accessible to all</article-title><source>Protein Sci.</source><volume>31</volume><fpage>8</fpage><lpage>22</lpage><page-range>8&#8211;22</page-range><pub-id pub-id-type="doi">10.1002/pro.4218</pub-id><pub-id pub-id-type="pmid">34717010</pub-id><pub-id pub-id-type="pmcid">PMC8740835</pub-id></element-citation></ref><ref id="jneae087dbib70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehericy</surname><given-names>S</given-names></name><name name-style="western"><surname>Baulac</surname><given-names>M</given-names></name><name name-style="western"><surname>Chiras</surname><given-names>J</given-names></name><name name-style="western"><surname>Pierot</surname><given-names>L</given-names></name><name name-style="western"><surname>Martin</surname><given-names>N</given-names></name><name name-style="western"><surname>Pillon</surname><given-names>B</given-names></name><name name-style="western"><surname>Deweer</surname><given-names>B</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>B</given-names></name><name name-style="western"><surname>Marsault</surname><given-names>C</given-names></name></person-group><year>1994</year><article-title>Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease</article-title><source>Am. J. Neuroradiol.</source><volume>15</volume><fpage>929</fpage><lpage>37</lpage><page-range>929&#8211;37</page-range><pub-id pub-id-type="pmid">8059663</pub-id><pub-id pub-id-type="pmcid">PMC8332162</pub-id></element-citation></ref><ref id="jneae087dbib71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>J</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>J W</given-names></name><name name-style="western"><surname>van de Pol</surname><given-names>L A</given-names></name><name name-style="western"><surname>Loy</surname><given-names>C T</given-names></name><name name-style="western"><surname>Scahill</surname><given-names>R I</given-names></name><name name-style="western"><surname>Frost</surname><given-names>C</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P</given-names></name><name name-style="western"><surname>Fox</surname><given-names>N C</given-names></name></person-group><year>2009</year><article-title>A meta-analysis of hippocampal atrophy rates in Alzheimer&#8217;s disease</article-title><source>Neurobiol. Aging</source><volume>30</volume><fpage>1711</fpage><lpage>23</lpage><page-range>1711&#8211;23</page-range><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2008.01.010</pub-id><pub-id pub-id-type="pmid">18346820</pub-id><pub-id pub-id-type="pmcid">PMC2773132</pub-id></element-citation></ref><ref id="jneae087dbib72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><year>2010</year><article-title>Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer&#8217;s disease</article-title><source>Neurobiol. Aging</source><volume>31</volume><fpage>1375</fpage><lpage>85</lpage><page-range>1375&#8211;85</page-range><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2010.01.022</pub-id><pub-id pub-id-type="pmid">20447732</pub-id></element-citation></ref><ref id="jneae087dbib73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sodums</surname><given-names>D J</given-names></name><name name-style="western"><surname>Bohbot</surname><given-names>V D</given-names></name></person-group><year>2020</year><article-title>Negative correlation between grey matter in the hippocampus and caudate nucleus in healthy aging</article-title><source>Hippocampus</source><volume>30</volume><fpage>892</fpage><lpage>908</lpage><page-range>892&#8211;908</page-range><pub-id pub-id-type="doi">10.1002/hipo.23210</pub-id><pub-id pub-id-type="pmid">32384195</pub-id></element-citation></ref><ref id="jneae087dbib74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Persson</surname><given-names>K</given-names></name><name name-style="western"><surname>Bohbot</surname><given-names>V</given-names></name><name name-style="western"><surname>Bogdanovic</surname><given-names>N</given-names></name><name name-style="western"><surname>Selb&#230;k</surname><given-names>G</given-names></name><name name-style="western"><surname>Br&#230;khus</surname><given-names>A</given-names></name><name name-style="western"><surname>Engedal</surname><given-names>K</given-names></name></person-group><year>2018</year><article-title>Finding of increased caudate nucleus in patients with Alzheimer&#8217;s disease</article-title><source>Acta Neurol. Scand.</source><volume>137</volume><fpage>224</fpage><lpage>32</lpage><page-range>224&#8211;32</page-range><pub-id pub-id-type="doi">10.1111/ane.12800</pub-id><pub-id pub-id-type="pmid">28741672</pub-id></element-citation></ref><ref id="jneae087dbib75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rombouts</surname><given-names>S A</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name><name name-style="western"><surname>Witter</surname><given-names>M P</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name></person-group><year>2000</year><article-title>Unbiased whole-brain analysis of gray matter loss in Alzheimer&#8217;s disease</article-title><source>Neurosci. Lett.</source><volume>285</volume><fpage>231</fpage><lpage>3</lpage><page-range>231&#8211;3</page-range><pub-id pub-id-type="doi">10.1016/S0304-3940(00)01067-3</pub-id><pub-id pub-id-type="pmid">10806328</pub-id></element-citation></ref><ref id="jneae087dbib76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiji</surname><given-names>S</given-names></name><name name-style="western"><surname>Smitha</surname><given-names>K A</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A K</given-names></name><name name-style="western"><surname>Pillai</surname><given-names>V P M</given-names></name><name name-style="western"><surname>Jayasree</surname><given-names>R S</given-names></name></person-group><year>2013</year><article-title>Segmentation and volumetric analysis of the caudate nucleus in Alzheimer&#8217;s disease</article-title><source>Eur. J. Radiol.</source><volume>82</volume><fpage>1525</fpage><lpage>30</lpage><page-range>1525&#8211;30</page-range><pub-id pub-id-type="doi">10.1016/j.ejrad.2013.03.012</pub-id><pub-id pub-id-type="pmid">23664648</pub-id></element-citation></ref><ref id="jneae087dbib77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frisoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Testa</surname><given-names>C</given-names></name><name name-style="western"><surname>Zorzan</surname><given-names>A</given-names></name><name name-style="western"><surname>Sabattoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Beltramello</surname><given-names>A</given-names></name><name name-style="western"><surname>Soininen</surname><given-names>H</given-names></name><name name-style="western"><surname>Laakso</surname><given-names>M</given-names></name></person-group><year>2002</year><article-title>Detection of grey matter loss in mild Alzheimer&#8217;s disease with voxel based morphometry</article-title><source>J. Neurol. Neurosurgery Psychiatry</source><volume>73</volume><fpage>657</fpage><lpage>64</lpage><page-range>657&#8211;64</page-range><pub-id pub-id-type="doi">10.1136/jnnp.73.6.657</pub-id><pub-id pub-id-type="pmcid">PMC1757361</pub-id><pub-id pub-id-type="pmid">12438466</pub-id></element-citation></ref><ref id="jneae087dbib78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W-Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J-T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yin</surname><given-names>R-H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H-F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name><name name-style="western"><surname>Radua</surname><given-names>J</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name></person-group><year>2015</year><article-title>Voxel-based meta-analysis of grey matter changes in Alzheimer&#8217;s disease</article-title><source>Transl. Neurodegeneration</source><volume>4</volume><fpage>1</fpage><lpage>9</lpage><page-range>1&#8211;9</page-range><pub-id pub-id-type="doi">10.1186/s40035-015-0027-z</pub-id><pub-id pub-id-type="pmcid">PMC4381413</pub-id><pub-id pub-id-type="pmid">25834730</pub-id></element-citation></ref><ref id="jneae087dbib79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yan</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xia</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>He</surname><given-names>Y</given-names></name></person-group><year>2012</year><article-title>Discriminative analysis of early Alzheimer&#8217;s disease using multi-modal imaging and multi-level characterization with multi-classifier (m3)</article-title><source>NeuroImage</source><volume>59</volume><fpage>2187</fpage><lpage>95</lpage><page-range>2187&#8211;95</page-range><pub-id pub-id-type="doi">10.1016/j.neuroimage.2011.10.003</pub-id><pub-id pub-id-type="pmid">22008370</pub-id></element-citation></ref><ref id="jneae087dbib80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Apostolova</surname><given-names>L G</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>C A</given-names></name><name name-style="western"><surname>Akopyan</surname><given-names>G G</given-names></name><name name-style="western"><surname>Dutton</surname><given-names>R A</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>K M</given-names></name><name name-style="western"><surname>Toga</surname><given-names>A W</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J L</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>P M</given-names></name></person-group><year>2007</year><article-title>Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease</article-title><source>Arch. Neurol.</source><volume>64</volume><fpage>1489</fpage><lpage>95</lpage><page-range>1489&#8211;95</page-range><pub-id pub-id-type="doi">10.1001/archneur.64.10.1489</pub-id><pub-id pub-id-type="pmid">17923632</pub-id><pub-id pub-id-type="pmcid">PMC3197839</pub-id></element-citation></ref><ref id="jneae087dbib81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karas</surname><given-names>G</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name><name name-style="western"><surname>Rombouts</surname><given-names>S</given-names></name><name name-style="western"><surname>Van Schijndel</surname><given-names>R</given-names></name><name name-style="western"><surname>Klein</surname><given-names>M</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B</given-names></name><name name-style="western"><surname>Flier</surname><given-names>W V D</given-names></name><name name-style="western"><surname>Vrenken</surname><given-names>H</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name></person-group><year>2007</year><article-title>Precuneus atrophy in early-onset Alzheimer&#8217;s disease: a morphometric structural mri study</article-title><source>Neuroradiology</source><volume>49</volume><fpage>967</fpage><lpage>76</lpage><page-range>967&#8211;76</page-range><pub-id pub-id-type="doi">10.1007/s00234-007-0269-2</pub-id><pub-id pub-id-type="pmid">17955233</pub-id></element-citation></ref><ref id="jneae087dbib82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#246;ller</surname><given-names>C</given-names></name><name name-style="western"><surname>Vrenken</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>L</given-names></name><name name-style="western"><surname>Versteeg</surname><given-names>A</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name><name name-style="western"><surname>van der Flier</surname><given-names>W M</given-names></name></person-group><year>2013</year><article-title>Different patterns of gray matter atrophy in early-and late-onset Alzheimer&#8217;s disease</article-title><source>Neurobiol. Aging</source><volume>34</volume><fpage>2014</fpage><lpage>22</lpage><page-range>2014&#8211;22</page-range><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.02.013</pub-id><pub-id pub-id-type="pmid">23561509</pub-id></element-citation></ref><ref id="jneae087dbib83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>An</surname><given-names>N</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Xi</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name></person-group><year>2016</year><article-title>Network-based statistic show aberrant functional connectivity in Alzheimer&#8217;s disease</article-title><source>IEEE J. Sel. Top. Signal Process.</source><volume>10</volume><fpage>1182</fpage><lpage>8</lpage><page-range>1182&#8211;8</page-range><pub-id pub-id-type="doi">10.1109/JSTSP.2016.2600298</pub-id></element-citation></ref><ref id="jneae087dbib84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><etal>et al</etal></person-group><year>2015</year><article-title>Aberrant intra-and inter-network connectivity architectures in Alzheimer&#8217;s disease and mild cognitive impairment</article-title><source>Sci. Rep.</source><volume>5</volume><fpage>1</fpage><lpage>12</lpage><page-range>1&#8211;12</page-range><pub-id pub-id-type="doi">10.1038/srep14824</pub-id><pub-id pub-id-type="pmcid">PMC4594099</pub-id><pub-id pub-id-type="pmid">26439278</pub-id></element-citation></ref><ref id="jneae087dbib85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Damoiseaux</surname><given-names>J S</given-names></name><name name-style="western"><surname>Prater</surname><given-names>K E</given-names></name><name name-style="western"><surname>Miller</surname><given-names>B L</given-names></name><name name-style="western"><surname>Greicius</surname><given-names>M D</given-names></name></person-group><year>2012</year><article-title>Functional connectivity tracks clinical deterioration in Alzheimer&#8217;s disease</article-title><source>Neurobiol. Aging</source><volume>33</volume><fpage>828</fpage><lpage>19</lpage><page-range>828&#8211;19</page-range><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.06.024</pub-id><pub-id pub-id-type="pmcid">PMC3218226</pub-id><pub-id pub-id-type="pmid">21840627</pub-id></element-citation></ref><ref id="jneae087dbib86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albers</surname><given-names>M W</given-names></name><etal>et al</etal></person-group><year>2015</year><article-title>At the interface of sensory and motor dysfunctions and Alzheimer&#8217;s disease</article-title><source>Alzheimer&#8217;s Dement.</source><volume>11</volume><fpage>70</fpage><lpage>98</lpage><page-range>70&#8211;98</page-range><pub-id pub-id-type="doi">10.1016/j.jalz.2014.04.514</pub-id><pub-id pub-id-type="pmid">25022540</pub-id><pub-id pub-id-type="pmcid">PMC4287457</pub-id></element-citation></ref><ref id="jneae087dbib87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penalba-S&#225;nchez</surname><given-names>L</given-names></name><name name-style="western"><surname>Oliveira-Silva</surname><given-names>P</given-names></name><name name-style="western"><surname>Sumich</surname><given-names>A L</given-names></name><name name-style="western"><surname>Cifre</surname><given-names>I</given-names></name></person-group><year>2023</year><article-title>Increased functional connectivity patterns in mild Alzheimer&#8217;s disease: a rsfMRI study</article-title><source>Front. Aging Neurosci.</source><volume>14</volume><elocation-id content-type="artnum">1037347</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2022.1037347</pub-id><pub-id pub-id-type="pmid">36698861</pub-id><pub-id pub-id-type="pmcid">PMC9869068</pub-id></element-citation></ref><ref id="jneae087dbib88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zadka</surname><given-names>L</given-names></name><name name-style="western"><surname>Sochocka</surname><given-names>M</given-names></name><name name-style="western"><surname>Hachiya</surname><given-names>N</given-names></name><name name-style="western"><surname>Chojdak-Lukasiewicz</surname><given-names>J</given-names></name><name name-style="western"><surname>Dziegiel</surname><given-names>P</given-names></name><name name-style="western"><surname>Piasecki</surname><given-names>E</given-names></name><name name-style="western"><surname>Leszek</surname><given-names>J</given-names></name></person-group><year>2024</year><article-title>Endocytosis and Alzheimer&#8217;s disease</article-title><source>Geroscience</source><volume>46</volume><fpage>71</fpage><lpage>85</lpage><page-range>71&#8211;85</page-range><pub-id pub-id-type="doi">10.1007/s11357-023-00923-1</pub-id><pub-id pub-id-type="pmid">37646904</pub-id><pub-id pub-id-type="pmcid">PMC10828383</pub-id></element-citation></ref><ref id="jneae087dbib89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shobab</surname><given-names>L A</given-names></name><name name-style="western"><surname>Hsiung</surname><given-names>G-Y R</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>H H</given-names></name></person-group><year>2005</year><article-title>Cholesterol in Alzheimer&#8217;s disease</article-title><source>Lancet Neurol.</source><volume>4</volume><fpage>841</fpage><lpage>52</lpage><page-range>841&#8211;52</page-range><pub-id pub-id-type="doi">10.1016/S1474-4422(05)70248-9</pub-id><pub-id pub-id-type="pmid">16297842</pub-id></element-citation></ref><ref id="jneae087dbib90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michikawa</surname><given-names>M</given-names></name></person-group><year>2003</year><article-title>The role of cholesterol in pathogenesis of Alzheimer&#8217;s disease: dual metabolic interaction between amyloid &#946;-protein and cholesterol</article-title><source>Mol. Neurobiol.</source><volume>27</volume><fpage>1</fpage><lpage>12</lpage><page-range>1&#8211;12</page-range><pub-id pub-id-type="doi">10.1385/MN:27:1:1</pub-id><pub-id pub-id-type="pmid">12668899</pub-id></element-citation></ref><ref id="jneae087dbib91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dovrolis</surname><given-names>N</given-names></name><name name-style="western"><surname>Nikou</surname><given-names>M</given-names></name><name name-style="western"><surname>Gkrouzoudi</surname><given-names>A</given-names></name><name name-style="western"><surname>Dimitriadis</surname><given-names>N</given-names></name><name name-style="western"><surname>Maroulakou</surname><given-names>I</given-names></name></person-group><year>2022</year><article-title>Unlocking the memory component of Alzheimer&#8217;s disease: biological processes and pathways across brain regions</article-title><source>Biomolecules</source><volume>12</volume><fpage>263</fpage><pub-id pub-id-type="doi">10.3390/biom12020263</pub-id><pub-id pub-id-type="pmid">35204764</pub-id><pub-id pub-id-type="pmcid">PMC8961579</pub-id></element-citation></ref><ref id="jneae087dbib92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mills</surname><given-names>J</given-names></name><name name-style="western"><surname>Reiner</surname><given-names>P B</given-names></name></person-group><year>1999</year><article-title>Regulation of amyloid precursor protein cleavage</article-title><source>J. Neurochem.</source><volume>72</volume><fpage>443</fpage><lpage>60</lpage><page-range>443&#8211;60</page-range><pub-id pub-id-type="doi">10.1046/j.1471-4159.1999.0720443.x</pub-id><pub-id pub-id-type="pmid">9930716</pub-id></element-citation></ref><ref id="jneae087dbib93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>M</given-names></name><etal>et al</etal></person-group><year>2019</year><article-title>Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume and memory in the european medical information framework for Alzheimer&#8217;s disease biomarker discovery cohort</article-title><source>Alzheimer&#8217;s Dement.</source><volume>15</volume><fpage>817</fpage><lpage>27</lpage><page-range>817&#8211;27</page-range><pub-id pub-id-type="doi">10.1016/j.jalz.2019.03.004</pub-id><pub-id pub-id-type="pmid">31078433</pub-id><pub-id pub-id-type="pmcid">PMC6849698</pub-id></element-citation></ref><ref id="jneae087dbib94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name><name name-style="western"><surname>De Strooper</surname><given-names>B</given-names></name><name name-style="western"><surname>Kivipelto</surname><given-names>M</given-names></name><name name-style="western"><surname>Holstege</surname><given-names>H</given-names></name><name name-style="western"><surname>Ch&#233;telat</surname><given-names>G</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>C E</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J</given-names></name><name name-style="western"><surname>van der Flier</surname><given-names>W M</given-names></name></person-group><year>2021</year><article-title>Alzheimer&#8217;s disease</article-title><source>Lancet</source><volume>397</volume><fpage>1577</fpage><lpage>90</lpage><page-range>1577&#8211;90</page-range><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32205-4</pub-id><pub-id pub-id-type="pmid">33667416</pub-id><pub-id pub-id-type="pmcid">PMC8354300</pub-id></element-citation></ref><ref id="jneae087dbib95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z</given-names></name></person-group><year>2015</year><article-title>Serum levels of ApoA1 and ApoA2 are associated with cognitive status in older men</article-title><source>BioMed Res. Int.</source><volume>2015</volume><fpage>1</fpage><lpage>10</lpage><page-range>1&#8211;10</page-range><pub-id pub-id-type="doi">10.1155/2015/481621</pub-id><pub-id pub-id-type="pmcid">PMC4670907</pub-id><pub-id pub-id-type="pmid">26682220</pub-id></element-citation></ref><ref id="jneae087dbib96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Basak</surname><given-names>J M</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D M</given-names></name></person-group><year>2009</year><article-title>The role of apolipoprotein E in Alzheimer&#8217;s disease</article-title><source>Neuron</source><volume>63</volume><fpage>287</fpage><lpage>303</lpage><page-range>287&#8211;303</page-range><pub-id pub-id-type="doi">10.1016/j.neuron.2009.06.026</pub-id><pub-id pub-id-type="pmid">19679070</pub-id><pub-id pub-id-type="pmcid">PMC3044446</pub-id></element-citation></ref><ref id="jneae087dbib97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holtzman</surname><given-names>D M</given-names></name><name name-style="western"><surname>Herz</surname><given-names>J</given-names></name><name name-style="western"><surname>Bu</surname><given-names>G</given-names></name></person-group><year>2012</year><article-title>Apolipoprotein e and apolipoprotein e receptors: normal biology and roles in Alzheimer disease</article-title><source>Cold Spring Harb. Perspect. Med.</source><volume>2</volume><elocation-id content-type="artnum">a006312</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a006312</pub-id><pub-id pub-id-type="pmid">22393530</pub-id><pub-id pub-id-type="pmcid">PMC3282491</pub-id></element-citation></ref><ref id="jneae087dbib98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Kulas</surname><given-names>J A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D M</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>H A</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>S B</given-names></name></person-group><year>2021</year><article-title>Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol</article-title><source>Proc. Natl Acad. Sci.</source><volume>118</volume><elocation-id content-type="artnum">e2102191118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2102191118</pub-id><pub-id pub-id-type="pmid">34385305</pub-id><pub-id pub-id-type="pmcid">PMC8379952</pub-id></element-citation></ref><ref id="jneae087dbib99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>noz</surname><given-names>S S M</given-names></name><name name-style="western"><surname>Garner</surname><given-names>B</given-names></name><name name-style="western"><surname>Ooi</surname><given-names>L</given-names></name></person-group><year>2019</year><article-title>Understanding the role of APOE fragments in Alzheimer&#8217;s disease</article-title><source>Neurochem. Res.</source><volume>44</volume><fpage>1297</fpage><lpage>305</lpage><page-range>1297&#8211;305</page-range><pub-id pub-id-type="doi">10.1007/s11064-018-2629-1</pub-id><pub-id pub-id-type="pmid">30225748</pub-id></element-citation></ref><ref id="jneae087dbib100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>L</given-names></name><etal>et al</etal></person-group><year>2019</year><article-title>Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer&#8217;s disease model</article-title><source>Nat. Commun.</source><volume>10</volume><fpage>1365</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-09118-9</pub-id><pub-id pub-id-type="pmid">30911003</pub-id><pub-id pub-id-type="pmcid">PMC6433910</pub-id></element-citation></ref><ref id="jneae087dbib101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dib</surname><given-names>S</given-names></name><name name-style="western"><surname>Pahnke</surname><given-names>J</given-names></name><name name-style="western"><surname>Gosselet</surname><given-names>F</given-names></name></person-group><year>2021</year><article-title>Role of ABCA7 in human health and in Alzheimer&#8217;s disease</article-title><source>Int. J. Mol. Sci.</source><volume>22</volume><fpage>4603</fpage><pub-id pub-id-type="doi">10.3390/ijms22094603</pub-id><pub-id pub-id-type="pmid">33925691</pub-id><pub-id pub-id-type="pmcid">PMC8124837</pub-id></element-citation></ref><ref id="jneae087dbib102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martins</surname><given-names>I J</given-names></name><name name-style="western"><surname>Berger</surname><given-names>T</given-names></name><name name-style="western"><surname>Sharman</surname><given-names>M J</given-names></name><name name-style="western"><surname>Verdile</surname><given-names>G</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>S J</given-names></name><name name-style="western"><surname>Martins</surname><given-names>R N</given-names></name></person-group><year>2009</year><article-title>Cholesterol metabolism and transport in the pathogenesis of Alzheimer&#8217;s disease</article-title><source>J. Neurochem.</source><volume>111</volume><fpage>1275</fpage><lpage>308</lpage><page-range>1275&#8211;308</page-range><pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06408.x</pub-id><pub-id pub-id-type="pmid">20050287</pub-id></element-citation></ref><ref id="jneae087dbib103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Apostolova</surname><given-names>L G</given-names></name><etal>et al</etal></person-group><year>2018</year><article-title>Associations of the top 20 Alzheimer disease risk variants with brain amyloidosis</article-title><source>JAMA Neurol.</source><volume>75</volume><fpage>328</fpage><lpage>41</lpage><page-range>328&#8211;41</page-range><pub-id pub-id-type="doi">10.1001/jamaneurol.2017.4198</pub-id><pub-id pub-id-type="pmid">29340569</pub-id><pub-id pub-id-type="pmcid">PMC5885860</pub-id></element-citation></ref><ref id="jneae087dbib104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braskie</surname><given-names>M N</given-names></name><etal>et al</etal></person-group><year>2011</year><article-title>Common Alzheimer&#8217;s disease risk variant within the CLU gene affects white matter microstructure in young adults</article-title><source>J. Neurosci.</source><volume>31</volume><fpage>6764</fpage><lpage>70</lpage><page-range>6764&#8211;70</page-range><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5794-10.2011</pub-id><pub-id pub-id-type="pmid">21543606</pub-id><pub-id pub-id-type="pmcid">PMC3176803</pub-id></element-citation></ref><ref id="jneae087dbib105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><etal>et al</etal></person-group><year>2015</year><article-title>Association of brain DNA methylation in SORL1, ABCA7, HLA-DRB5, SLC24A4 and BIN1 with pathological diagnosis of Alzheimer disease</article-title><source>JAMA Neurol.</source><volume>72</volume><fpage>15</fpage><lpage>24</lpage><page-range>15&#8211;24</page-range><pub-id pub-id-type="doi">10.1001/jamaneurol.2014.3049</pub-id><pub-id pub-id-type="pmid">25365775</pub-id><pub-id pub-id-type="pmcid">PMC4344367</pub-id></element-citation></ref><ref id="jneae087dbib106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chapuis</surname><given-names>J</given-names></name><etal>et al</etal></person-group><year>2013</year><article-title>Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology</article-title><source>Mol. Psychiatry</source><volume>18</volume><fpage>1225</fpage><lpage>34</lpage><page-range>1225&#8211;34</page-range><pub-id pub-id-type="doi">10.1038/mp.2013.1</pub-id><pub-id pub-id-type="pmid">23399914</pub-id><pub-id pub-id-type="pmcid">PMC3807661</pub-id></element-citation></ref><ref id="jneae087dbib107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jack</surname><given-names>C R</given-names></name><etal>et al</etal></person-group><year>2016</year><article-title>A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers</article-title><source>Neurology</source><volume>87</volume><fpage>539</fpage><lpage>47</lpage><page-range>539&#8211;47</page-range><pub-id pub-id-type="doi">10.1212/WNL.0000000000002923</pub-id><pub-id pub-id-type="pmid">27371494</pub-id><pub-id pub-id-type="pmcid">PMC4970664</pub-id></element-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Cell Infect Microbiol</journal-id><journal-id journal-id-type="pmc-domain-id">1860</journal-id><journal-id journal-id-type="pmc-domain">fcimb</journal-id><journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Cellular and Infection Microbiology</journal-title></journal-title-group><issn pub-type="epub">2235-2988</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12479512</article-id><article-id pub-id-type="pmcid-ver">PMC12479512.1</article-id><article-id pub-id-type="pmcaid">12479512</article-id><article-id pub-id-type="pmcaiid">12479512</article-id><article-id pub-id-type="pmid">41036228</article-id><article-id pub-id-type="doi">10.3389/fcimb.2025.1659042</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Cellular and Infection Microbiology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Exploring the influence of psychological factors on the comorbidity of dental caries and obesity in adolescents from the perspective of the oral-gut-brain axis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="M">Meng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="X">Xiaopeng</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Y">Yimin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="M">Mingxin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="B">Bairu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="W">Wei</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ma</surname><given-names initials="N">Nan</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2881278/overview"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>He</surname><given-names initials="S">Shili</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="C">Chengyue</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2920172/overview"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Prosthetics, Affiliated Stomatology Hospital of Jinzhou Medical University</institution>, <addr-line>Jinzhou</addr-line>,&#160;<country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Collaborative Innovation Center for Health Promotion of Children and Adolescents of Jinzhou Medical University</institution>, <addr-line>Jinzhou</addr-line>,&#160;<country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Department of Pedodontics, Affiliated Stomatology Hospital of Jinzhou Medical University</institution>, <addr-line>Jinzhou</addr-line>,&#160;<country>China</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>School and Hospital of Stomatology, China Medical University</institution>, <addr-line>Shenyang</addr-line>,&#160;<country>China</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/501284/overview" ext-link-type="uri">Soumyadev Sarkar</ext-link>, Arizona State University, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Maurice H. T. Ling, University of Newcastle, Singapore</p><p>Emiliana D&#8217;Angelo, Universit&#224; della Campania Luigi Vanvitelli, Italy</p></fn><corresp id="fn001">*Correspondence: Chengyue Wang, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:wangcy@jzmu.edu.cn">wangcy@jzmu.edu.cn</email></corresp><fn fn-type="other" id="fn003"><p>&#8224;These authors share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>16</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">481321</issue-id><elocation-id>1659042</elocation-id><history><date date-type="received"><day>03</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-02 09:25:35.093"><day>02</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Wang, Yang, Li, Jiang, Chen, Yang, Ma, He and Wang.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Wang, Yang, Li, Jiang, Chen, Yang, Ma, He and Wang</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcimb-15-1659042.pdf"/><abstract><sec><title>Introduction</title><p>This study investigates how psychological factors influence the comorbidity of dental caries and obesity in adolescents through the oral-gut-brain axis. Adolescence is a critical period for both physical and psychological development, yet dental caries and obesity are prevalent issues that can negatively impact mental health. The study aims to provide insights into the underlying mechanisms and potential prevention and treatment strategies.</p></sec><sec><title>Methods</title><p>An epidemiological survey was conducted on 1,024 students aged 12&#8211;15 from Beizhen No. 1 Junior High School. A total of 90 adolescents were selected for biosample research. The methods used included 16S rRNA gene sequencing, untargeted metabolomics, and SourceTracker analysis to examine oral and gut microbiota and metabolite concentrations.</p></sec><sec><title>Results</title><p>Significant differences in oral and gut microbiota and metabolite concentrations were found among adolescents with different health statuses. Adolescents with caries and obesity showed distinct microbial profiles compared to healthy controls. The study also identified potential oral and gut microbial biomarkers associated with psychological disorders. SourceTracker analysis revealed a higher rate of ectopic colonization of oral microbiota in the intestines of adolescents with caries and obesity.</p></sec><sec><title>Discussion</title><p>The study highlights the roles of the oral-gut and oral-brain axes in the comorbidity of dental caries and obesity among adolescents. The findings suggest that oral and gut microbiota play crucial roles in disease progression, and their imbalances may affect mental health through the oral-gut-brain axis. The results provide a theoretical foundation for developing integrated intervention strategies targeting both oral and systemic health.</p></sec></abstract><kwd-group><kwd>oral-gut-brain axis</kwd><kwd>caries</kwd><kwd>obesity</kwd><kwd>adolescents</kwd><kwd>microbiota</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Department of Education of Liaoning Province
</institution><institution-id institution-id-type="doi">10.13039/501100007620</institution-id></institution-wrap></funding-source></award-group><funding-statement>The author(s) declare financial support was received for the research and/or publication of this article. This work was financially supported by Science and technology innovation team of Liaoning Education Department (LJ222410160037).</funding-statement></funding-group><counts><fig-count count="14"/><table-count count="4"/><equation-count count="0"/><ref-count count="91"/><page-count count="20"/><word-count count="8498"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Oral Microbes and Host</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Adolescence represents a critical developmental window for both physical and psychological maturation; yet the concurrent &#8220;dual epidemic&#8221; of dental caries and obesity now threatens the health of this generation. The World Health Organization (WHO) 2022 report documents a 50&#8211;70% prevalence of permanent-tooth caries among 12- to 15-year-olds (<xref rid="B49" ref-type="bibr">Lobstein et&#160;al., 2015</xref>). According to the World Obesity Atlas 2023 and the 2025 Global Burden of Disease study in The Lancet, obesity prevalence among boys is projected to rise from 10% in 2020 to 20% by 2035, and among girls from 8% to 18% over the same period. The mental health landscape is equally alarming: UNICEF/WHO. State of the World&#8217;s Children 2021: On My Mind&#8212;Promoting, Protecting and Caring for Children&#8217;s Mental Health indicates that approximately 13&#8211;14% of children and adolescents worldwide suffer from psychological disorders, with prevalence rates for anxiety and depression increasing from 3.6% and 1.1% in 10- to 14-year-olds to 4.6% and 2.8% in 15- to 19-year-olds, respectively.</p><p>Dental caries, obesity, and psychological disorders do not occur in isolation; rather, they constitute a &#8220;networked disease complex&#8221; that reciprocally amplifies risk. Poor oral health undermines self-esteem and self-confidence, thereby precipitating anxiety and depression (<xref rid="B41" ref-type="bibr">Kisely et&#160;al., 2015</xref>). Conversely, individuals with compromised mental health&#8212;including severe mental illness, mood disorders, and eating disorders&#8212;often neglect oral hygiene (<xref rid="B42" ref-type="bibr">Kisely et&#160;al., 2016</xref>), which elevates the incidence of dental caries (<xref rid="B28" ref-type="bibr">Folayan et&#160;al., 2018</xref>). Emotional eating and stress-induced bingeing increase the intake of energy-dense foods, promoting obesity (<xref rid="B28" ref-type="bibr">Folayan et&#160;al., 2018</xref>). Obesity, in turn, reduces salivary flow and lowers oral pH, thereby enhancing caries susceptibility (<xref rid="B57" ref-type="bibr">Milaneschi et&#160;al., 2019</xref>). Carious lesions impair masticatory efficiency and nutrient absorption, further disrupting weight control (<xref rid="B18" ref-type="bibr">Chala et&#160;al., 2017</xref>).</p><p>Over the past five years, three converging &#8220;sub-axes&#8221; have provided the most recent empirical foundation for an integrated &#8220;oral&#8211;gut&#8211;brain axis.&#8221;Oral&#8211;gut axis: A systematic review by Yamazaki et&#160;al. demonstrated that periodontal pathogens&#8212;most notably Porphyromonas gingivalis&#8212;can be continuously swallowed with saliva, breach the intestinal barrier, and trigger local dysbiosis and systemic inflammation, thereby establishing the first direct mechanistic link between periodontitis and gut microbial imbalance (<xref rid="B84" ref-type="bibr">Yamazaki, 2023</xref>)Oral&#8211;brain axis: Bowland and Weyrich introduced the conceptual framework of the &#8220;oral&#8211;microbiome&#8211;brain axis,&#8221; emphasizing its relevance to neuropsychiatric disorders (<xref rid="B16" ref-type="bibr">Bowland and Weyrich, 2022</xref>). Dominy et&#160;al. identified P. gingivalis and its gingipains in post-mortem Alzheimer&#8217;s disease (AD) brain tissue, providing direct pathogenic evidence linking oral infection to neurodegeneration (<xref rid="B25" ref-type="bibr">Dominy et&#160;al., 2019</xref>).Gut&#8211;brain axis: Duan and Wu summarized how gut microbiota modulate serotonin (5-HT), brain-derived neurotrophic factor (BDNF), and microglial activity via short-chain fatty acids and tryptophan metabolites, thereby influencing the pathogenesis of depression and Parkinson&#8217;s disease (<xref rid="B26" ref-type="bibr">Duan and Wu, 2024</xref>). Furthermore, Zhang et&#160;al. reported that small-molecule inhibitors targeting oral pathogens can attenuate cerebral &#946;-amyloid deposition, underscoring the therapeutic potential of cross-axis interventions (<xref rid="B90" ref-type="bibr">Zhang et&#160;al., 2023</xref>).</p><p>In summary, dental caries, obesity, and psychological disorders manifest as a syndemic among adolescents, and the emerging concept of the oral&#8211;gut&#8211;brain axis offers a unifying theoretical framework for elucidating their shared mechanistic underpinnings and for developing integrated intervention strategies (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>This figure illustrates the intricate interactions among the oral, gut, and brain axes and their effects on health. Oral microbiota directly associate with brain function through the oral-brain axis, potentially influencing the onset of neuropsychiatric disorders such as depression. Concurrently, oral microbes impact the gut microbiome via the oral-gut axis, subsequently modulating brain function and behavior through the gut-brain axis. Imbalances in oral microbiota (e.g., caries) and gut microbiota (e.g., changes associated with obesity) may affect the levels of neurotransmitters through these axes, thereby playing a role in the development of diseases like depression. This model underscores the dynamic connections among the oral, gut, and brain, highlighting their significance in overall health.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-15-1659042-g001.jpg"><alt-text content-type="machine-generated">Diagram showing the connections between oral, gut, and brain axes. Bacteria types such as Streptococcus and Veillonella are linked to oral health and caries. Gut bacteria like Phocaeicola and Bacteroides impact obesity. The oral-brain axis is associated with depression, involving neurotransmitters like serotonin.</alt-text></graphic></fig></sec><sec sec-type="materials|methods" id="s2"><label>2</label><title>Materials and methods</title><sec id="s2_1"><label>2.1</label><title>Survey subjects</title><p>In September 2024, an epidemiological survey was conducted on 1024 students from the First Junior High School in Beizhen City, Jinzhou City. After questionnaire surveys, physical parameter measurements, and oral examinations, a total of 90 adolescents aged 12&#8211;15 were included in the biological sample study.</p><sec id="s2_1_1"><label>2.1.1</label><title>Sampling strategy and sample size calculation</title><p>This study employed a cross-sectional design with stratified cluster sampling. Fieldwork was conducted in the Beizhen district of Jinzhou City in September 2024. After selecting one fixed-point junior high school, we first stratified students by grade and then randomly selected intact classes within each stratum as primary sampling units.</p><p>Sample size was calculated according to the standard formula for cross-sectional surveys, <italic toggle="yes">N=K &#215; Q/P</italic>, where K=400 when the permissible error is set at 10%. Using the most recent National Oral Health Epidemiological Survey (NOHES), the caries prevalence (P) for 12- and 15-year-olds was reported to be 38.5% and 44.4%, respectively; the larger value (44.4%) was adopted to yield a conservative estimate. This produced a minimum required sample of approximately 501 participants per group. To account for the design effect inherent in cluster sampling and an anticipated 10% non-response rate, the final sample was expanded to 1,024 adolescents, ensuring adequate statistical power and representativeness of the findings.</p></sec><sec id="s2_1_2"><label>2.1.2</label><title>Inclusion criteria for biological sample subjects</title><p>All subjects had not taken antibiotics within 1 month before the examination, had no systemic diseases, no congenital diseases or other diseases (oral mucosal diseases), and did not wear orthodontic appliances in the mouth. This study was approved by the Ethics Committee (Approval Number: JYFELL202409). The children examined obtained the permission of their parents or guardians and signed the informed consent form. A total of 90 participants were enrolled for biological sample collection in this study. The inclusion method is presented in the following <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>:</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Biological sample collection criteria.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Stage</th><th valign="middle" align="left" rowspan="1" colspan="1">Procedure</th><th valign="middle" align="left" rowspan="1" colspan="1">Excluded (n)</th><th valign="middle" align="left" rowspan="1" colspan="1">Remaining (n)</th><th valign="middle" align="left" rowspan="1" colspan="1">Notes</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Total Population</td><td valign="middle" align="left" rowspan="1" colspan="1">Students aged 12-15 from Beizhen No. 1 Middle School</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">1,024</td><td valign="middle" align="left" rowspan="1" colspan="1">Initial survey population</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Stage 1: Screening</td><td valign="middle" align="left" rowspan="1" colspan="1">Excluded: antibiotic/probiotic use (within 1 month), systemic diseases, orthodontic appliances, etc.</td><td valign="middle" align="left" rowspan="1" colspan="1">187</td><td valign="middle" align="left" rowspan="1" colspan="1">837</td><td valign="middle" align="left" rowspan="1" colspan="1">Key exclusion criteria detailed in Section 2.1.2</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Stage 2: Stratification</td><td valign="middle" align="left" rowspan="1" colspan="1">Grouped by health status</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">(criteria in Section 2.4):</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="middle" align="left" rowspan="1" colspan="1">&#8226; HG</td><td valign="middle" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="middle" align="left" rowspan="1" colspan="1">180</td><td valign="middle" align="left" rowspan="1" colspan="1">No caries, obesity, or psychological disorders</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="middle" align="left" rowspan="1" colspan="1">&#8226; COG</td><td valign="middle" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="middle" align="left" rowspan="1" colspan="1">125</td><td valign="middle" align="left" rowspan="1" colspan="1">Diagnosed with both caries and obesity</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="middle" align="left" rowspan="1" colspan="1">&#8226; PDG</td><td valign="middle" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="middle" align="left" rowspan="1" colspan="1">17</td><td valign="middle" align="left" rowspan="1" colspan="1">No caries/obesity; diagnosed with psychological disorders</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="middle" align="left" rowspan="1" colspan="1">&#8226; COPG</td><td valign="middle" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="middle" align="left" rowspan="1" colspan="1">44</td><td valign="middle" align="left" rowspan="1" colspan="1">Diagnosed with caries, obesity, and psychological disorders</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Stage 3: Sampling</td><td valign="middle" align="left" rowspan="1" colspan="1">Each group was randomly selected</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="middle" align="left" rowspan="1" colspan="1">&#8226; The initial plan was 23 cases per group</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Adjusted due to insufficient PDG sample size and depth issues</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="middle" align="left" rowspan="1" colspan="1">&#8226; Supplement to 30 cases per group</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Random number table method</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#8211;</td><td valign="middle" align="left" rowspan="1" colspan="1">&#8226; Remove low quality samples (e.g. DNA extraction failure)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1">Final: 30 per group via random number table</td></tr></tbody></table></table-wrap></sec></sec><sec id="s2_2"><label>2.2</label><title>Research methods</title><sec id="s2_2_1"><label>2.2.1</label><title>Questionnaire survey</title><p>The demographic characteristics of the survey subjects, including the educational level of the parents of the survey subjects, the frequency of tooth brushing, the frequency of sweets and beverages, were collected through one-on-one questionnaire surveys. The International General Health Questionnaire-12 (GHQ-12) was used to assess the mental health status of students.</p></sec><sec id="s2_2_2"><label>2.2.2</label><title>Physical parameter measurement</title><p>Trained medical examiners measured the height, weight, and waist circumference. The height was measured using a metal column height meter, the weight was measured using an electronic weighing scale, and the waist circumference was measured using a non-elastic soft ruler with a minimum scale of 1 mm. The weight was accurate to 0.01 kg, and the height and waist circumference were accurate to 0.1 cm. They were recorded separately, and the body mass index of each survey subject was calculated.</p></sec><sec id="s2_2_3"><label>2.2.3</label><title>Dental caries examination</title><p>Using the methods and standards published by the World Health Organization, professional dentists used disposable oral instruments under a unified artificial light source, used probes and flat mirrors, and used a combination of visual and probing methods to examine and evaluate the dental health status of the survey subjects. A special recorder checked and recorded the caries, loss, and filling of each tooth.</p></sec></sec><sec id="s2_3"><label>2.3</label><title>Diagnostic criteria</title><sec id="s2_3_1"><label>2.3.1</label><title>Psychological disorder</title><p>The GHQ-12 questionnaire consisted of 12 questions, using the Likert 4-point scoring method, with options ranging from 1 point &#8220;never&#8221; to 4 points &#8220;often&#8221;. The score ranged from 12 to 48, and the higher the score, the lower the mental health level. A total score &gt; 27 indicated poor mental health.</p></sec><sec id="s2_3_2"><label>2.3.2</label><title>Dental caries</title><p>(1) Caries-free: No signs of caries and no fillings due to caries.</p><p>(2) Dental Caries: The pits or smooth surfaces of the teeth have softening at the bottom, potential damage to the enamel, or softening of the walls, which are divided into pit and fissure caries and smooth surface caries.</p><p>(3) Filled with Caries: Teeth with permanent fillings and one or more new caries.</p><p>(4) Filled without Caries: Teeth with one or more permanent fillings and no other caries.</p><p>(5) Missing due to Caries: Teeth lost or extracted due to caries.</p></sec><sec id="s2_3_3"><label>2.3.3</label><title>Obesity</title><p>(1) BMI(Body Mass Index): According to the Comprehensive Evaluation of the Development Level of Children and Adolescents (GB/T 31178-2014) standard (<xref rid="B6" ref-type="bibr">Comprehensive evaluation of children and adolescents development, n.d.</xref>), children and adolescents are divided into thin, normal, overweight, and obese. When the BMI of the investigator is less than the &#8220;normal&#8221; threshold point of the corresponding gender and age group, it is considered thin; when the BMI is less than the &#8220;overweight&#8221; threshold point of the corresponding gender and age group, it is considered normal; when the BMI is greater than or equal to the &#8220;overweight&#8221; threshold point of the corresponding gender and age group, it is considered overweight or obese. (BMI=Weight (kg)/[Height (m)]^2).</p><p>(2) Waist Circumference: According to the Screening Threshold for High Waist Circumference in Children and Adolescents aged 7&#8211;18 Years (WS/T 611-2018) (<xref rid="B1" ref-type="bibr">20180704145130574.pdf</xref>), the P90 of waist circumference in different gender and age groups is used as the judgment standard for central obesity.</p></sec></sec><sec id="s2_4"><label>2.4</label><title>Biological sample collection</title><p>All samples were divided into four groups, with 10 samples taken from each group</p><list list-type="order"><list-item><p>Healthy Group (HG)</p></list-item><list-item><p>Caries and Obesity Group (COG)</p></list-item><list-item><p>Psychological Disorders Group (PDG)</p></list-item><list-item><p>Caries, Obesity and Psychological Disorders Group (COPG)</p></list-item></list></sec><sec id="s2_5"><label>2.5</label><title>Statistical methods</title><p>IBM SPSS Statistics 26.0 statistical software was used for data processing and analysis. Quantitative data that conformed to a normal distribution were described using (x&#175; &#177; s), and the t-test was used for comparison between two groups, and analysis of variance was used for comparison between multiple groups. Qualitative data were described using the number of cases (%). The significance level &#945; was set to 0.05 unless otherwise specified.</p><p>A one-way analysis of variance (ANOVA) was performed for each demographic variable (age, sex, BMI, etc.). <xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref> presents the ANOVA results with the total psychological score as the dependent variable and caries status, BMI, age, sex, and comorbidity as independent variables. Participants with caries (n=205) exhibited significantly higher psychological scores than their caries-free counterparts (n=819, p &lt; 0.001). A statistically significant age difference was also observed between the two groups (p=0.009). In contrast, neither BMI (22.15 &#177; 5.19 vs. 21.68 &#177; 5.14) nor sex distribution (1.51 &#177; 0.50 vs. 1.53 &#177; 0.50) differed significantly (p &gt; 0.05). Notably, the caries&#8211;obesity comorbidity showed the most pronounced between-group difference (p &lt; 0.001), indicating that the co-occurrence of caries and obesity may exert an additive effect on psychological distress.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>The aforementioned demographic variables&#8212;age, sex, BMI, and psychological status&#8212;will be included as covariates in subsequent microbiota analyses to control for their potential confounding effects on community structure.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" colspan="5" rowspan="1">Analysis of variance results</th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">Variable</th><th valign="middle" align="center" rowspan="1" colspan="1">Psychological total score evaluation</th><th valign="middle" align="center" rowspan="1" colspan="1">(Average &#177; standard deviation)</th><th valign="middle" align="center" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1">Psychology (<italic toggle="yes">n</italic>=205)</th><th valign="middle" align="center" rowspan="1" colspan="1">Normal (<italic toggle="yes">n</italic>=819)</th><th valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">F</italic>
</th><th valign="middle" align="center" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1">Caries</td><td valign="middle" align="center" rowspan="1" colspan="1">0.74 &#177; 0.44</td><td valign="middle" align="center" rowspan="1" colspan="1">0.60 &#177; 0.49</td><td valign="middle" align="center" rowspan="1" colspan="1">13.773</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000**</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">BMI</td><td valign="middle" align="center" rowspan="1" colspan="1">22.15 &#177; 5.19</td><td valign="middle" align="center" rowspan="1" colspan="1">21.68 &#177; 5.14</td><td valign="middle" align="center" rowspan="1" colspan="1">1.324</td><td valign="middle" align="center" rowspan="1" colspan="1">0.250</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Age</td><td valign="middle" align="center" rowspan="1" colspan="1">13.49 &#177; 0.95</td><td valign="middle" align="center" rowspan="1" colspan="1">13.68 &#177; 0.97</td><td valign="middle" align="center" rowspan="1" colspan="1">6.815</td><td valign="middle" align="center" rowspan="1" colspan="1">0.009**</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">gender</td><td valign="middle" align="center" rowspan="1" colspan="1">1.51 &#177; 0.50</td><td valign="middle" align="center" rowspan="1" colspan="1">1.53 &#177; 0.50</td><td valign="middle" align="center" rowspan="1" colspan="1">0.267</td><td valign="middle" align="center" rowspan="1" colspan="1">0.605</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Caries and obesity are common</td><td valign="middle" align="center" rowspan="1" colspan="1">1.52 &#177; 0.96</td><td valign="middle" align="center" rowspan="1" colspan="1">1.19 &#177; 1.02</td><td valign="middle" align="center" rowspan="1" colspan="1">17.665</td><td valign="middle" align="center" rowspan="1" colspan="1">0.000**</td></tr></tbody></table><table-wrap-foot><fn><p>*p&lt;0.05, **p&lt;0.01.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><sec id="s3_1"><label>3.1</label><title>Basic characteristics</title><p>A total of 1,024 students were enrolled, comprising 483 (47.17%) males and 541 (52.83%) females. The majority were of Manchu ethnicity (n=813, 79.47%), followed by Han (n=197, 19.26%), Mongolian (n=8, 0.78%), and other ethnicities (n=5, 0.49%). Age distribution peaked at 13&#8211;14 years, accounting for 33.01% and 34.96%, respectively, with fewer participants in other age brackets. The overall caries detection rate was 62.50% (n=640). Regarding body-mass index (BMI), 499 participants (48.73%) were classified as having normal weight, 292 (28.52%) as obese, 83 (8.11%) as overweight, and 150 (14.65%) as underweight. Psychological assessment revealed that 819 individuals (79.98%) exhibited normal mental health status, whereas 205 (20.02%) presented with psychological or behavioral disorders (<xref rid="T3" ref-type="table">
<bold>Table&#160;3</bold>
</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table&#160;3</label><caption><p>The aforementioned demographic variables&#8212;age, sex, BMI, and psychological status&#8212;will be included as covariates in subsequent microbiota analyses to control for their potential confounding effects on community structure.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Essential information</th><th valign="middle" align="center" rowspan="1" colspan="1">Classify</th><th valign="middle" align="center" rowspan="1" colspan="1">Number (n)</th><th valign="middle" align="center" rowspan="1" colspan="1">Percentage (%)</th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Han nationality</td><td valign="middle" align="center" rowspan="1" colspan="1">197</td><td valign="middle" align="center" rowspan="1" colspan="1">19.26</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Man nationality</td><td valign="middle" align="center" rowspan="1" colspan="1">813</td><td valign="middle" align="center" rowspan="1" colspan="1">79.47</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Nation</td><td valign="middle" align="center" rowspan="1" colspan="1">Mongolian nationality</td><td valign="middle" align="center" rowspan="1" colspan="1">8</td><td valign="middle" align="center" rowspan="1" colspan="1">0.78</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Other nationality</td><td valign="middle" align="center" rowspan="1" colspan="1">5</td><td valign="middle" align="center" rowspan="1" colspan="1">0.49</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Gender</td><td valign="middle" align="center" rowspan="1" colspan="1">Male</td><td valign="middle" align="center" rowspan="1" colspan="1">483</td><td valign="middle" align="center" rowspan="1" colspan="1">47.17</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Female</td><td valign="middle" align="center" rowspan="1" colspan="1">541</td><td valign="middle" align="center" rowspan="1" colspan="1">52.83</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">11</td><td valign="middle" align="center" rowspan="1" colspan="1">1</td><td valign="middle" align="center" rowspan="1" colspan="1">0.10</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">12</td><td valign="middle" align="center" rowspan="1" colspan="1">122</td><td valign="middle" align="center" rowspan="1" colspan="1">11.91</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">13</td><td valign="middle" align="center" rowspan="1" colspan="1">338</td><td valign="middle" align="center" rowspan="1" colspan="1">33.01</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Age</td><td valign="middle" align="center" rowspan="1" colspan="1">14</td><td valign="middle" align="center" rowspan="1" colspan="1">358</td><td valign="middle" align="center" rowspan="1" colspan="1">34.96</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">15</td><td valign="middle" align="center" rowspan="1" colspan="1">188</td><td valign="middle" align="center" rowspan="1" colspan="1">18.36</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">16</td><td valign="middle" align="center" rowspan="1" colspan="1">17</td><td valign="middle" align="center" rowspan="1" colspan="1">1.66</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">No</td><td valign="middle" align="center" rowspan="1" colspan="1">384</td><td valign="middle" align="center" rowspan="1" colspan="1">37.50</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Caries</td><td valign="middle" align="center" rowspan="1" colspan="1">Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">640</td><td valign="middle" align="center" rowspan="1" colspan="1">62.50</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">marasmus</td><td valign="middle" align="center" rowspan="1" colspan="1">150</td><td valign="middle" align="center" rowspan="1" colspan="1">14.65</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Normal</td><td valign="middle" align="center" rowspan="1" colspan="1">499</td><td valign="middle" align="center" rowspan="1" colspan="1">48.73</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">BMI</td><td valign="middle" align="center" rowspan="1" colspan="1">Overweight</td><td valign="middle" align="center" rowspan="1" colspan="1">83</td><td valign="middle" align="center" rowspan="1" colspan="1">8.11</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">Obesity</td><td valign="middle" align="center" rowspan="1" colspan="1">292</td><td valign="middle" align="center" rowspan="1" colspan="1">28.52</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">evaluation</td><td valign="middle" align="center" rowspan="1" colspan="1">Psychology</td><td valign="middle" align="center" rowspan="1" colspan="1">205</td><td valign="middle" align="center" rowspan="1" colspan="1">20.02</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Psychological</td><td valign="middle" align="center" rowspan="1" colspan="1">Normal</td><td valign="middle" align="center" rowspan="1" colspan="1">819</td><td valign="middle" align="center" rowspan="1" colspan="1">79.98</td></tr><tr><td valign="middle" colspan="2" align="center" rowspan="1">Total</td><td valign="middle" align="center" rowspan="1" colspan="1">1024</td><td valign="middle" align="center" rowspan="1" colspan="1">100.0</td></tr></tbody></table></table-wrap></sec><sec id="s3_2"><label>3.2</label><title>Demographic characteristics of participants providing biological samples</title><p>Of the 1,024 adolescents aged 12&#8211;15 years initially surveyed, four groups were established for biological sampling: the Healthy Group (HG, n=180), the Caries-Obesity Group (COG, n=125), the Psychological Disorders Group (PDG, n=17), and the Comorbid Caries-Obesity-Psychological Disorders Group (COPG, n=44). Mean age ranged from 13.30 to 14.59 years across the groups. BMI analyses revealed that the COG (29.11 kg/m&#178;) and COPG (28.37 kg/m&#178;) exhibited significantly higher values than the HG (19.45 kg/m&#178;) and PDG (19.84 kg/m&#178;), underscoring the co-occurrence of obesity and dental caries. Psychological assessment via the GHQ-12 (higher scores indicate poorer mental health) showed that the PDG (29.53) and COPG (28.95) displayed comparable and markedly elevated scores relative to the HG (17.73) and COG (18.60), thereby validating the diagnostic criteria used to define psychological morbidity in the grouping protocol (<xref rid="T4" ref-type="table">
<bold>Table&#160;4</bold>
</xref>).</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table&#160;4</label><caption><p>Comparison of average age, BMI, psychological scores, and gender ratios across four groups: Healthy (HG), Caries-Obesity (COG), Psychological Disorders (PDG), and Comorbid Caries-Obesity-Psychological Disorders (COPG).</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Group</th><th valign="middle" align="center" rowspan="1" colspan="1">Number (n)</th><th valign="middle" align="center" rowspan="1" colspan="1">average age</th><th valign="middle" align="center" rowspan="1" colspan="1">BMI average value</th><th valign="middle" align="center" rowspan="1" colspan="1">Psychological average score</th><th valign="middle" align="center" rowspan="1" colspan="1">Gender ratio is male to female</th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1">HG</td><td valign="middle" align="center" rowspan="1" colspan="1">180</td><td valign="middle" align="center" rowspan="1" colspan="1">14.33</td><td valign="middle" align="center" rowspan="1" colspan="1">19.45</td><td valign="middle" align="center" rowspan="1" colspan="1">17.73</td><td valign="middle" align="center" rowspan="1" colspan="1">81/99</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">COG</td><td valign="middle" align="center" rowspan="1" colspan="1">125</td><td valign="middle" align="center" rowspan="1" colspan="1">13.58</td><td valign="middle" align="center" rowspan="1" colspan="1">29.11</td><td valign="middle" align="center" rowspan="1" colspan="1">18.6</td><td valign="middle" align="center" rowspan="1" colspan="1">78/47</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">PDG</td><td valign="middle" align="center" rowspan="1" colspan="1">17</td><td valign="middle" align="center" rowspan="1" colspan="1">14.59</td><td valign="middle" align="center" rowspan="1" colspan="1">19.84</td><td valign="middle" align="center" rowspan="1" colspan="1">29.53</td><td valign="middle" align="center" rowspan="1" colspan="1">9/8</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">COPG</td><td valign="middle" align="center" rowspan="1" colspan="1">44</td><td valign="middle" align="center" rowspan="1" colspan="1">13.30</td><td valign="middle" align="center" rowspan="1" colspan="1">28.37</td><td valign="middle" align="center" rowspan="1" colspan="1">28.95</td><td valign="middle" align="center" rowspan="1" colspan="1">25/19</td></tr></tbody></table></table-wrap></sec><sec id="s3_3"><label>3.3</label><title>Sequencing information</title><p>All microbiota analyses were adjusted for age, sex, BMI, and psychological score to ensure that observed microbial differences are attributable to disease status rather than demographic characteristics.</p><p>90 samples were divided into three groups, all samples were sequenced by Illumina platform, the results are as follows:</p><list list-type="simple"><list-item><p>Saliva: Among them, all samples in HG, COG and COPG group contained 68543 ASVs (Amplicon Sequence Variant): 354 ASVs in HG and COG group; 192 ASVs in HG and COPG group; 210 ASVs in COG and COPG group; ASVs 2982 unique to HG group; ASVs 5407 unique to COG group; and ASVs 2371 unique to COPG group (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2A</bold>
</xref>).</p></list-item><list-item><p>Feces: All samples in HG, COG and COPG group contained 49126 ASVs: 116 ASVs in HG and COG group; 88 ASVs in HG and COPG group; 161 ASVs in COG and COPG group; ASVs 1753 unique to HG group; ASVs 2926 unique to COG group; ASVs 2372 unique to COPG group (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2B</bold>
</xref>).</p></list-item></list><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>
<bold>(A, B)</bold> Venn diagram illustrating the overlap and unique classifications among COG, HG, and COPG.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-15-1659042-g002.jpg"><alt-text content-type="machine-generated">Two Venn diagrams comparing gene expressions. The left diagram shows overlaps among COPG, COG, and HG, with numbers indicating specific gene counts: COPG (2371), COG (5407), HG (2982), and overlaps like 785 between all three. The right diagram displays similar overlaps among COG, COPG, and HG, with counts: COG (2926), COPG (2372), HG (1753), and 373 in the center overlap.</alt-text></graphic></fig></sec><sec id="s3_4"><label>3.4</label><title>Relative abundance of species at the phylum level</title><sec id="s3_4_1"><label>3.4.1</label><title>Saliva</title><p>The top five most abundant phyla in the saliva were selected, namely Firmicutes, Proteobacteria, Bacteroidota, and Actinobacteriota (<xref rid="f3" ref-type="fig">
<bold>Figure&#160;3A</bold>
</xref>). Compared with the HG group, the COG group exhibited higher relative abundance of Firmicutes, Bacteroidota, and Actinobacteriota, while the relative abundance of Proteobacteria was lower. In comparison with the COG group, the COPG group showed higher relative abundance of Firmicutes and Proteobacteria, and lower relative abundance of Bacteroidota and Actinobacteriota.</p><fig position="float" id="f3" orientation="portrait"><label>Figure&#160;3</label><caption><p>
<bold>(A, B)</bold> Relative abundance of bacterial phyla across different samples at the phylum level.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-15-1659042-g003.jpg"><alt-text content-type="machine-generated">Stacked bar charts show the relative abundance of various bacterial groups across three samples: HG, COD, and COPD. Each color represents a different bacterial group, indicated in the legend.</alt-text></graphic></fig></sec><sec id="s3_4_2"><label>3.4.2</label><title>Feces</title><p>The top five most abundant phyla in fecal samples were selected, namely Bacteroidota, Firmicutes, Actinobacteriota, and Proteobacteria, and a bar chart of their relative abundance was generated (<xref rid="f3" ref-type="fig">
<bold>Figure&#160;3B</bold>
</xref>). Compared with the HG group, the COG group exhibited higher relative abundance of Firmicutes and Proteobacteria, while the relative abundance of Bacteroidota and Actinobacteriota was lower. In comparison with the COG group, the COPG group showed higher relative abundance of Bacteroidota, Actinobacteriota, and Proteobacteria, and lower relative abundance of Firmicutes.</p></sec></sec><sec id="s3_5"><label>3.5</label><title>Relative abundance of species at the genus level</title><sec id="s3_5_1"><label>3.5.1</label><title>Saliva</title><p>The most abundant genera were selected based on their relative abundance, and a bar chart of their abundance was generated (<xref rid="f4" ref-type="fig">
<bold>Figure&#160;4A</bold>
</xref>). Compared with the HG group, the COG group exhibited higher relative abundance of Veillonella, Prevotella, and Rothia, while the relative abundance of Streptococcus, Neisseria, Staphylococcus, and Haemophilus was lower. In comparison with the COG group, the COPG group showed higher relative abundance of Streptococcus, Neisseria, Staphylococcus, and Haemophilus, and lower relative abundance of Veillonella and Prevotella.</p><fig position="float" id="f4" orientation="portrait"><label>Figure&#160;4</label><caption><p>
<bold>(A, B)</bold> Relative abundance of bacterial phyla across different samples at the genus level.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-15-1659042-g004.jpg"><alt-text content-type="machine-generated">Two stacked bar charts display the relative abundance of various bacterial genera across samples labeled HC, COD, and COPG. The colors represent different genera, such as Streptococcus and Neisseria. The y-axis indicates relative abundance in percentage, and the second chart includes additional genera like Propionibacterium and Pseudomonas.</alt-text></graphic></fig></sec><sec id="s3_5_2"><label>3.5.2</label><title>Feces</title><p>The most abundant genera in fecal samples were selected based on their relative abundance, and a bar chart of their abundance was generated (<xref rid="f4" ref-type="fig">
<bold>Figure&#160;4B</bold>
</xref>). Compared with the HG group, the COG group exhibited higher relative abundance of Prevotella, Faecalibacterium, and Bifidobacterium, while the relative abundance of Phocaeicola and Megamonas was lower. In comparison with the COG group, the COPG group showed higher relative abundance of Bacteroides and Bifidobacterium, and lower relative abundance of Phocaeicola, Prevotella, and Faecalibacterium.</p></sec></sec><sec id="s3_6"><label>3.6</label><title>&#945;-diversity analysis</title><p>&#945;-diversity is an analysis of microbial diversity in community ecology, reflecting the distribution and differences of microbial communities (<xref rid="B58" ref-type="bibr">Miller et&#160;al., 2016</xref>).</p><p>Oral microbiota &#945;-diversity analysis (<xref rid="f5" ref-type="fig">
<bold>Figure&#160;5A</bold>
</xref>) revealed that the Simpson index in the COG group was significantly higher than that in the HG and COPG groups (P &lt; 0.05). The Pielou_c and Shannon indices in the COPG group were significantly lower than those in the HG and COG groups (P &lt; 0.05). Additionally, the Faith_pd index in the HG group was significantly lower than that in the COG and COPG groups (P &lt; 0.05).</p><fig position="float" id="f5" orientation="portrait"><label>Figure&#160;5</label><caption><p>
<bold>(A&#8211;D)</bold> Alpha-diversity analysis of oral and gut microbiota across different groups. All p-values were adjusted using the Benjamini&#8211;Hochberg FDR method; q &lt; 0.05 was considered significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-15-1659042-g005.jpg"><alt-text content-type="machine-generated">Box plots comparing different metrics across three groups: HG (red), CDG (blue), and CDPG (green). Metrics include Chao1, Good's coverage, Simpson, Pielou_e, Faith_pd, Shannon, and Observed_species with corresponding p-values above each plot.</alt-text></graphic></fig><p>Gut microbiota &#945;-diversity analysis (<xref rid="f5" ref-type="fig">
<bold>Figure&#160;5B</bold>
</xref>) showed that the Chao1, Simpson, and Observed species indices in the HG group were lower than those in the COG and COPG groups, although the differences were not statistically significant (P &gt; 0.05). This indicates that there were no significant differences in the species diversity and richness of the gut microbiota among the groups.</p></sec><sec id="s3_7"><label>3.7</label><title>&#946;-diversity analysis</title><p>&#946;-diversity is used to measure the similarity or difference among communities of different samples (<xref rid="B65" ref-type="bibr">Paudel et&#160;al., 2022</xref>).</p><p>The &#946;-diversity differences among groups in saliva samples were assessed using Principal Coordinates Analysis (PCoA) methods (<xref rid="f6" ref-type="fig">
<bold>Figures&#160;6A, B</bold>
</xref>). To account for multiple comparisons, the p-values were adjusted using the Benjamini&#8211;Hochberg False Discovery Rate (FDR) method. The adjusted results indicated that the differences in microbial composition among the three groups (saliva and fecal samples) were significantly greater than the within-group differences, with all adjusted p-values being statistically significant (q &lt; 0.05). This suggests that the oral and gut microbiota of healthy individuals, adolescents with dental caries and obesity, and those with psychological disorders exhibit distinct similarities and differences.</p><fig position="float" id="f6" orientation="portrait"><label>Figure&#160;6</label><caption><p>
<bold>(A, B)</bold> Beta-diversity analysis of oral and gut microbiota across different groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-15-1659042-g006.jpg"><alt-text content-type="machine-generated">Two scatter plots with ellipses show principal coordinate analysis (PCoA) of different groups. The left plot displays clusters labeled COPG (red), HG (blue), and CDG (green) along PCo1 (20.2%) and PCo2 (12.3%). The right plot shows overlapping clusters along PCo1 (11.3%) and PCo2 (8%). Each group is represented by colored dots, with ellipses indicating confidence intervals.</alt-text></graphic></fig></sec><sec id="s3_8"><label>3.8</label><title>Analysis of microbial species differences</title><p>LEFSe analysis (<xref rid="f7" ref-type="fig">
<bold>Figures&#160;7A, B</bold>
</xref>) was conducted to validate the differences in microbial species and identify potential oral and gut microbial biomarkers. To control for multiple comparisons, the p-values were adjusted using the Benjamini&#8211;Hochberg False Discovery Rate (FDR) method. Compared among the three groups, 114 species in the oral microbiota and 63 species in the gut microbiota exhibited significant differences (LDA &gt; 2, q &lt; 0.05).</p><fig position="float" id="f7" orientation="portrait"><label>Figure&#160;7</label><caption><p>
<bold>(A, B)</bold> LEfSe, analysis of microbial species differences among three groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-15-1659042-g007.jpg"><alt-text content-type="machine-generated">Two circular cladograms display taxonomic relationships among microbial taxa, with colored sections representing different groups: COG0032 in red, COG0457 in blue, and R1 in green. Labels list specific taxa corresponding to the colored sections.</alt-text></graphic></fig><p>In the oral microbiota, the HG group showed higher relative abundance of Neisseria and Porphyromonas. In contrast, the COG group exhibited significantly increased relative abundance of Fusobacterium, Rothia, and Prevotella. The COPG group had higher relative abundance of Streptococcus and Veillonella compared to the other groups.</p><p>In the gut microbiota, the HG group exhibited significantly higher relative abundance of Bacilli and Erysipelotrichaceae. The COG group had higher relative abundance of Firmicutes and Clostridia. These differentially abundant microbial taxa may play unique functional roles within their respective groups.</p></sec><sec id="s3_9"><label>3.9</label><title>SourceTracker analysis</title><p>To further investigate whether there is ectopic colonization of oral microbiota in the intestines of patients with dental caries and obesity, we employed the SourceTracker method for analysis(<xref rid="f8" ref-type="fig">
<bold>Figure&#160;8A, B</bold>
</xref>). The results demonstrated that nearly 44.88% of the Prevotella in the intestines of our experimental subjects originated from ectopic colonization of oral microbiota, which was higher than the nearly 100% result observed in the healthy population in this study.</p><fig position="float" id="f8" orientation="portrait"><label>Figure&#160;8</label><caption><p>
<bold>(A, B)</bold> SourceTracker analysis of ectopic colonization of oral microbiota in the intestines. These findings suggest that patients with dental caries and obesity have a higher rate of ectopic colonization of oral microbiota in their intestines compared to healthy individuals, which may have implications for understanding the microbial imbalances associated with these conditions.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-15-1659042-g008.jpg"><alt-text content-type="machine-generated">Two pie charts are shown. The left chart is divided into red, labeled &#8220;alive&#8221; at 44.88 percent, and gray, labeled &#8220;unknown&#8221; at 55.12 percent. The right chart is entirely gray, labeled &#8220;100 percent."</alt-text></graphic></fig></sec><sec id="s3_10"><label>3.10</label><title>Untargeted metabolomics analysis</title><p>This study conducted a comprehensive identification and quantitative analysis of metabolites in intestinal samples using untargeted metabolomics. Quality control (QC) analysis ensured the reliability and stability of the experimental data. The total ion chromatogram (TIC) of QC samples showed that the response intensity and retention time of each chromatographic peak were largely overlapping, indicating minimal variation caused by instrument error. The Pearson correlation coefficients between QC samples were all greater than 0.9, demonstrating excellent experimental reproducibility (<xref rid="f9" ref-type="fig">
<bold>Figures&#160;9A&#8211;D</bold>
</xref>).</p><fig position="float" id="f9" orientation="portrait"><label>Figure&#160;9</label><caption><p>
<bold>(A&#8211;D)</bold> Untargeted metabolomics analysis and quality control assessment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-15-1659042-g009.jpg"><alt-text content-type="machine-generated">Two pairs of chromatograms and correlation matrices are shown. The chromatograms display Total Ion Chromatograms (TIC) with intensity over retention time, labeled as QC1 to QC4. Adjacent matrices indicate correlation coefficients, showing perfect correlations with a value of 1.00 across the diagonal and scatter plots in other cells.</alt-text></graphic></fig><p>In the fecal sample comparison between the COG and COPG groups, significant differences in metabolite profiles were observed, with 12 metabolites upregulated and 22 downregulated in the COPG group compared to the COG group. To account for multiple comparisons, the p-values were adjusted using the Benjamini&#8211;Hochberg False Discovery Rate (FDR) method. Oleamide was found to be significantly lower in the COPG group than in the COG group (q &lt; 0.05). In contrast, testosterone enanthate, imidazolepropionic acid, and pyrrolidine were significantly elevated in the COPG group (q &lt; 0.05) (<xref rid="f10" ref-type="fig">
<bold>Figures&#160;10A&#8211;F</bold>
</xref>).</p><fig position="float" id="f10" orientation="portrait"><label>Figure&#160;10</label><caption><p>
<bold>(A&#8211;F)</bold> Metabolite profile differences between COG and COPG groups in fecal samples.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-15-1659042-g010.jpg"><alt-text content-type="machine-generated">Six-panel graphic with various data visualizations. Top left: Volcano plot with points colored by gene expression changes (blue for downregulated, grey for no difference, red for upregulated). Top middle: Bar graph comparing two conditions, CCPG and reference, in red and blue. Top right and bottom panels: Bar charts measuring different variables like Obsolete, Toudoana position, Cribroherozine, and Pyxialon, comparing groups COPG and COG in red and blue with error bars indicating variability.</alt-text></graphic></fig><p>In the comparison of saliva samples between the HG and PDG groups, significant differences in metabolite profiles were observed, with 21 metabolites upregulated and 13 downregulated in the PDG group compared to the HG group. To account for multiple comparisons, the p-values were adjusted using the Benjamini&#8211;Hochberg False Discovery Rate (FDR) method. Specifically, Glu-His-Lys (glutamine-histidine-lysine) and Huperzine B were found to be significantly lower in the PDG group than in the HG group (q &lt; 0.05). In contrast, brucine, 4-oxo-L-proline, and adenine were significantly higher in the PDG group compared to the HG group (q &lt; 0.05) (<xref rid="f11" ref-type="fig">
<bold>Figures&#160;11A&#8211;G</bold>
</xref>).</p><fig position="float" id="f11" orientation="portrait"><label>Figure&#160;11</label><caption><p>
<bold>(A&#8211;G)</bold> Metabolite profile differences between HG and PDG groups in saliva samples.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-15-1659042-g011.jpg"><alt-text content-type="machine-generated">A collage of seven charts. The top left shows a scatter plot with points marked as &#8220;Down,&#8221; &#8220;NoDiff,&#8221; and &#8220;Up,&#8221; colored blue, grey, and red. The top middle chart is a bar graph comparing two categories, shaded red and blue. The remaining five are bar graphs comparing two groups labeled PDG and HG in red and blue, depicting values with error bars for variables like &#8220;glycerol-3-ph,&#8221; &#8220;Hypoxanthine B,&#8221; &#8220;Ureidoprop,&#8221; &#8220;3-Ureido-propionate,&#8221; and &#8220;Allantoate.&#8221; Each chart has separate scales and labels.</alt-text></graphic></fig></sec><sec id="s3_11"><label>3.11</label><title>16S rRNA gene sequencing combined with non-targeted metagenomics analysis</title><p>In the integrated analysis of 16S rRNA gene sequencing and non-targeted metabolomics between the dental caries-obesity group and the dental caries-obesity-mental disorder group, a connection between microorganisms and metabolites associated with psychological issues was identified:</p></sec></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><sec id="s4_1"><label>4.1</label><title>Oral microbiome characteristics of the adolescent caries-obesity-psychological disorder triad</title><p>The oral cavity, as the initial part of the digestive tract communicating with the external environment, serves as the entry point for microorganisms into the human body, including bacteria, fungi, viruses, mycoplasmas, and other biological entities. The oral microbiota represents one of the most diverse and unique microbial communities in the human body, constituting the second most complex microbial ecosystem after the digestive system microbiota (<xref rid="B4" ref-type="bibr">Al Bataineh et&#160;al., 2022</xref>). Saliva samples, being readily obtainable, effectively represent microbial community information from various oral sites (<xref rid="B45" ref-type="bibr">Leake et&#160;al., 2016</xref>; <xref rid="B78" ref-type="bibr">Soriano-Lerma et&#160;al., 2020</xref>) and are widely utilized in oral microbial ecology research (<xref rid="B38" ref-type="bibr">Kaczor-Urbanowicz et&#160;al., 2017</xref>; <xref rid="B15" ref-type="bibr">Borkent et&#160;al., 2020</xref>). Next-generation sequencing (NGS) technology has emerged as a powerful tool for understanding the oral microbiome in health and disease states (<xref rid="B37" ref-type="bibr">Johansson et&#160;al., 2016</xref>; <xref rid="B5" ref-type="bibr">Al-Hebshi et&#160;al., 2019</xref>). By targeting one or more hypervariable regions of the 16S rRNA gene, this method characterizes microbial communities, as these variable regions serve as effective markers for identifying bacterial taxa in samples. In recent years, this approach has been extensively applied in studies investigating cariogenic microbial communities (<xref rid="B53" ref-type="bibr">Magana et&#160;al., 2018</xref>), enhancing our understanding of microbial factors associated with dental caries. Dental caries arises from the interplay among oral microorganisms, host factors, dietary components, and temporal influences (<xref rid="B67" ref-type="bibr">Pitts et&#160;al., 2021</xref>; <xref rid="B77" ref-type="bibr">Song et&#160;al., 2024</xref>), with oral microbiota playing a pivotal role in caries initiation and progression. While the potential connections between caries and systemic health remain underexplored (<xref rid="B19" ref-type="bibr">Chapple et&#160;al., 2017</xref>), current evidence suggests a stronger association between obesity and caries compared to other systemic conditions (<xref rid="B74" ref-type="bibr">Sabharwal et&#160;al., 2021</xref>). Our research group has previously demonstrated a positive correlation between caries prevalence and obesity. Obesity, a complex metabolic disease, has been linked to the oral microbiota. Recent studies have uncovered potential connections between them. The oral microbiota in obese individuals has been shown to change, which may promote systemic inflammation and metabolic disruption. The oral microbiota can influence the host&#8217;s metabolism through various mechanisms, such as producing short-chain fatty acids (SCFAs) and regulating immune responses. A 2025 study investigated the effect of orally administered probiotics on weight and found that certain probiotics could significantly reduce the weight and visceral fat levels of obese patients, indicating that the oral microbiota may play a role in weight management (<xref rid="B33" ref-type="bibr">Guo et&#160;al., 2025</xref>). Moreover, studies have shown that the composition of the oral microbiota can affect the gut microbiota, which in turn impacts metabolic health. For example, specific oral bacteria, such as Prevotella, have been associated with obesity-related changes in the gut microbiota. These findings highlight the importance of considering the oral microbiota in research on obesity and its related metabolic diseases. Concurrently, mental health issues exhibit high prevalence among adolescents (<xref rid="B32" ref-type="bibr">Gulliver et&#160;al., 2010</xref>; <xref rid="B33" ref-type="bibr">Guo et&#160;al., 2025</xref>), affecting approximately 10&#8211;20% of children and adolescents worldwide (<xref rid="B39" ref-type="bibr">Kieling et&#160;al., 2011</xref>; <xref rid="B2" ref-type="bibr">Aarons et&#160;al., 2019</xref>). The role of the oral microbiome in mental health has recently been appreciated within the proposed oral-brain axis. A 2024 study published in Nature found that periodontitis, a chronic bacterial infection, is associated with mental disorders such as depression and anxiety (<xref rid="B54" ref-type="bibr">Malan-M&#252;ller et&#160;al., 2024</xref>). This suggests the existence of an &#8220;oral-brain axis&#8221; and highlights the potential role of the oral microbiome in mental health.</p><p>In the oral microbiota of this study, adolescents with caries and obesity showed distinct microbial profiles compared to healthy controls at the phylum level: higher relative abundances of Firmicutes, Bacteroidota, and Actinobacteriota, and lower relative abundance of Proteobacteria, consistent with findings by Agnello et&#160;al (<xref rid="B7" ref-type="bibr">Advances in research on oral microecology and caries prevention, n.d.</xref>; <xref rid="B3" ref-type="bibr">Agnello et&#160;al., 2017</xref>; <xref rid="B23" ref-type="bibr">De Lemos et&#160;al., 2024</xref>). At the genus level, increased relative abundances of Veillonella, Prevotella, and Rothia were observed, while Streptococcus, Neisseria, Staphylococcus, and Haemophilus exhibited reduced abundances. Multiple studies (<xref rid="B56" ref-type="bibr">Mashima and Nakazawa, 2014</xref>; <xref rid="B24" ref-type="bibr">Do et&#160;al., 2015</xref>; <xref rid="B48" ref-type="bibr">Liu et&#160;al., 2020</xref>; <xref rid="B44" ref-type="bibr">Korona-Glowniak et&#160;al., 2021</xref>)have identified strong associations of Veillonella, Prevotella, and Streptococcus with dental caries. Notably, statistical analyses of Prevotella abundance in prior studies revealed its dominance in Western populations&#8217; oral microbiota, with high-fiber diets and obesity linked to its enrichment (<xref rid="B79" ref-type="bibr">Tett et&#160;al., 2021</xref>). The reduced relative abundance of Streptococcus in the COG group may be attributed to the altered dietary habits and lifestyle in obese individuals, which may lead to changes in saliva composition, such as variations in nutrient content, and alterations in saliva flow rate. These changes may create an environment unfavorable for the growth and colonization of Streptococcus, thereby reducing its relative abundance. While some studies associate Neisseria with caries (<xref rid="B91" ref-type="bibr">Zheng et&#160;al., 2018</xref>), others report its prominence in caries-free groups (<xref rid="B73" ref-type="bibr">Richards et&#160;al., 2017</xref>). Baker et&#160;al (<xref rid="B12" ref-type="bibr">Baker et&#160;al., 2021</xref>), using next-generation whole-genome sequencing to compare salivary microbiota in American children (&gt;3 years old) with and without caries, observed higher abundances of Neisseria and Haemophilus in caries-free groups, aligning with the findings of this study.</p><p>In adolescents with psychological disorders compared to psychologically normal individuals at the phylum level, Firmicutes and Proteobacteria exhibited higher relative abundances, while Bacteroidota and Actinobacteriota showed lower abundances. The reduced abundance of Actinobacteriota was associated with anxiety states and cortisol levels in adolescents (<xref rid="B75" ref-type="bibr">Simpson et&#160;al., 2020</xref>), potentially serving as a marker of hypothalamic-pituitary-adrenal (HPA) axis hyperactivity, a common feature in the pathophysiology of depression. At the genus level, Streptococcus, Neisseria, Staphylococcus, and Haemophilus displayed higher relative abundances, whereas Veillonella and Prevotella demonstrated lower abundances. The observed associations between these microbial taxa and psychological disorders align with findings from studies by Yolken R et&#160;al (<xref rid="B69" ref-type="bibr">Prato et&#160;al., 2021</xref>; <xref rid="B82" ref-type="bibr">Wingfield et&#160;al., 2021</xref>; <xref rid="B89" ref-type="bibr">Yolken et&#160;al., 2021</xref>; <xref rid="B4" ref-type="bibr">Al Bataineh et&#160;al., 2022</xref>).</p><p>The results of alpha diversity analysis align with findings from Liu et&#160;al (<xref rid="B47" ref-type="bibr">Liu et&#160;al., 2019</xref>), a phenomenon potentially associated with oral microbial dysbiosis. According to the &#8220;ecological plaque hypothesis,&#8221; oral microbiota maintains equilibrium under healthy conditions, but alterations in the oral environment disrupt this balance, driving the transition of symbiotic microbial communities into pathogenic biofilms, ultimately leading to dysbiosis and caries development (<xref rid="B7" ref-type="bibr">Advances in research on oral microecology and caries prevention, n.d.</xref>). Beta diversity analysis revealed significant differences in oral microbiota between healthy individuals and adolescents with caries-obesity or psychological disorders, underscoring the critical role of oral microbial communities in both oral and systemic health. Concurrently, LefSe results demonstrated distinct compositional differences in salivary microbial communities across groups, likely attributable to specific oral health statuses or lifestyle factors within each cohort. In the COPG group, enriched Streptococcus and Veillonella genera&#8212;early colonizers and typical symbionts in the oral cavity&#8212;jointly participate in the formation of early-stage biofilms. Extensive research indicates that dysbiosis of Streptococcus and Veillonella is not only closely linked to oral diseases such as caries and periodontitis but may also breach gastrointestinal barriers for distal colonization, emerging as novel potential biomarkers for predicting the onset, progression, and prognosis of various systemic diseases.</p></sec><sec id="s4_2"><label>4.2</label><title>Characteristics of the gut microbiome in adolescents with the caries-obesity-psychological disorders triad</title><p>The gut microbiota is one of the most complex and diverse microbial communities in the human body, with its diversity even surpassing that of the oral microbiota, making it the most diverse among human microbial communities (<xref rid="B46" ref-type="bibr">Li et&#160;al., 2024</xref>). These microbes, including bacteria, fungi, viruses, and archaea, form a complex ecosystem that plays a crucial role in human digestion, immunity, and metabolism. Notably, B. acidifaciens, typically associated with the gut microbiota, has also been found to play a role in the oral microbiota of children with severe dental caries, indicating a possible link between gut and oral microbiota in the development of dental caries (<xref rid="B27" ref-type="bibr">Eriksen et&#160;al., 2024</xref>). Another study highlighted that children with poor oral hygiene and high caries rates showed an increased abundance of specific bacterial phyla and genera, which may disrupt the balance of the gut microbiota and affect systemic health (<xref rid="B72" ref-type="bibr">Ribeiro and Paster, 2023</xref>). Numerous studies comparing the gut microbiota of overweight and normal-weight children through 16S rRNA gene sequencing have found significant differences in microbial diversity and composition between the two groups (<xref rid="B63" ref-type="bibr">Pan and Jiao, 2024</xref>). Moreover, there is also a certain relationship between the gut microbiota and mood disorders, with research indicating that the relative abundance of certain bacteria changes in individuals with depression (<xref rid="B55" ref-type="bibr">Marano et&#160;al., 2025</xref>).</p><p>In the gut microbiota at the phylum level, adolescents with caries and obesity exhibited an elevated Firmicutes/Bacteroidota (F/B) ratio&#8212;characterized by increased Firmicutes and decreased Bacteroidota &#8212;a critical alteration implicated in the pathogenesis of obesity and related metabolic complications (<xref rid="B30" ref-type="bibr">Gallardo-Becerra et&#160;al., 2020</xref>). Concurrently, the reduced relative abundance of Actinobacteriota aligns with findings from Roc&#237;o et&#160;al (<xref rid="B71" ref-type="bibr">Quiroga et&#160;al., 2020</xref>), further supporting the strong association between gut microbial shifts and the caries-obesity phenotype. Notably, adolescents with caries, obesity, and psychological disorders demonstrated distinct microbial profiles compared to their psychologically normal counterparts with obesity: lower Firmicutes abundance and higher relative abundances of Bacteroidota, Actinobacteriota, and Proteobacteria, consistent with studies by Huang, Plaza-D&#237;az J, and colleagues (<xref rid="B35" ref-type="bibr">Huang et&#160;al., 2018</xref>; <xref rid="B36" ref-type="bibr">Jiang et&#160;al., 2018</xref>; <xref rid="B68" ref-type="bibr">Plaza-D&#237;az et&#160;al., 2019</xref>).</p><p>At the genus level, adolescents with caries and obesity showed higher relative abundances of Prevotella, Faecalibacterium, and Bifidobacterium, in agreement with findings by Moran-Ramos S et&#160;al (<xref rid="B59" ref-type="bibr">Moran-Ramos et&#160;al., 2023</xref>), alongside reduced abundances of Faecalibacterium and Megamonas. In contrast, those with psychological disorders displayed elevated Bacteroides and Bifidobacterium abundances but lower Faecalibacterium, Prevotella, and Faecalibacterium levels. These observations align with prior studies reporting reduced Prevotella abundance during depressive states (<xref rid="B76" ref-type="bibr">Simpson et&#160;al., 2021</xref>) and diminished Faecalibacterium levels in individuals with anxiety, depression, bipolar disorder, psychosis, and schizophrenia (<xref rid="B60" ref-type="bibr">Nikolova et&#160;al., 2021</xref>).</p><p>Alpha Diversity Analysis: The observed differences lacked statistical significance, which partially aligns with findings from (<xref rid="B66" ref-type="bibr">Pinart et&#160;al., 2021</xref>). This meta-analysis incorporated 32 cross-sectional studies evaluating gut microbial composition in obese and non-obese adults via high-throughput sequencing. Among these, 7 out of 22 studies reported no significant differences in alpha diversity. This phenomenon may be attributed to similarities in dietary patterns and habits among study participants, leading to consistent nutrient availability for gut microbiota. Such uniformity likely provides comparable ecological niches for microbial taxa, promoting stable microbial community diversity and minimizing alpha diversity variations.</p></sec><sec id="s4_3"><label>4.3</label><title>Microbiota-gut-brain axis</title><p>Communication between the gut and brain is bidirectional, involving multiple pathways such as neural, endocrine, and immune mechanisms (<xref rid="f12" ref-type="fig">
<bold>Figure 12</bold>
</xref>). The microbiota and its derived metabolites act as critical regulators in gut-brain signaling, leading to the concept of the microbiota-gut-brain (MGB) axis (<xref rid="B21" ref-type="bibr">Cryan and Dinan, 2012</xref>). The gut-brain axis, a bidirectional communication system between the gut and the central nervous system mediated via neural, endocrine, and immune pathways, has emerged as a pivotal framework for studying interactions between gut microbes and neurological functions in recent years (<xref rid="B21" ref-type="bibr">Cryan and Dinan, 2012</xref>).</p><fig position="float" id="f12" orientation="portrait"><label>Figure&#160;12</label><caption><p>Interactions between gut microbiota and host health. This schematic diagram illustrates the complex interactions between gut microbiota and host health, highlighting the potential roles of various microbial metabolites in influencing neurological and metabolic conditions.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-15-1659042-g012.jpg"><alt-text content-type="machine-generated">Illustration depicting the gut-brain axis. The human silhouette shows the brain and intestines connected. Gut microbiota influence 5-HT, 2-AG, GABA, and AEA, impacting depression. SCFAs, bile acids, and LPS affect obesity.</alt-text></graphic></fig><p>Analysis of fecal samples from the COG and COPG groups revealed significant alterations in multiple metabolite levels, which may exert broad effects on brain function via the gut-brain axis. Oleamide, which exhibits antidepressant-like properties in rat models, modulates neurotransmitter systems (e.g., 5-HT and GABA), and its decreased levels may impair mood regulation (<xref rid="B14" ref-type="bibr">Boger et&#160;al., 1998</xref>; <xref rid="B31" ref-type="bibr">Ge et&#160;al., 2015</xref>). Additionally, a Japanese study reported psychological changes, such as emotional instability, in some transgender males undergoing gender-affirming hormone therapy with testosterone enanthate, suggesting its potential influence on mood regulation via neuroendocrine pathways (<xref rid="B40" ref-type="bibr">Kirisawa et&#160;al., 2021</xref>). Imidazolepropionic acid, a histidine-derived microbial metabolite, may participate in neurological regulation by affecting neuroinflammation and neuronal function in the brain (<xref rid="B17" ref-type="bibr">Caradonna et&#160;al., 2024</xref>). Pyrrolidine, through its substituted derivatives, enhances 5-HT1A receptor potency by approximately 12-fold, indicating its potential role in modulating neurotransmitter system activity via 5-HT1A receptor regulation (<xref rid="B81" ref-type="bibr">Warren et&#160;al., 2024</xref>).</p><p>These findings further support the hypothesis that gut microbial metabolites may regulate brain function via the HPA axis (<xref rid="B29" ref-type="bibr">Foster and McVey Neufeld, 2013</xref>) and influence neuroinflammation, neurotransmitter systems, and mood regulation through the gut-brain axis, thereby exerting broad impacts on cerebral function. The results provide novel insights into the interactions between gut microbiota and the nervous system, suggesting that microbial metabolites could serve as potential therapeutic targets for future neuropsychiatric interventions.</p><p>Gln-Trp (Glutamine-Tryptophan): Tryptophan, a precursor to the neurotransmitter serotonin (5-hydroxytryptamine), is crucial for regulating emotions, sleep, and appetite. Glutamine, involved in various metabolic processes and important in the nervous system, associates with psychological factors through substance metabolism and neurotransmitter synthesis.</p><p>(2Z)-2-Benzylidenesuccinic Acid: As a phthalate compound, it is prevalent in daily life and may disrupt the endocrine system. Some studies indicate that exposure to phthalates is linked to neurological abnormalities, anxiety, and depression. A U.S. study measured phthalate metabolites in the urine of 153 pregnant women and found that higher mono-isobutyl phthalate levels in boys&#8217; urine were associated with increased scores for inattention, rule-breaking, aggression, and conduct problems. Higher MBzP levels correlated with elevated scores for defiant behavior and conduct problems in boys.</p><p>Gln-Trp was positively correlated with Pseudoxanthomonas, suggesting Pseudoxanthomonas might influence psychological disorders. Conversely, Limivivens, Paraprevotella, Acetatifactor, and Eubacterium showed negative correlations, indicating their abundance might link to psychological issues. Notably, Paraprevotella, part of the Prevotellaceae family, warrants further attention.</p></sec><sec id="s4_4"><label>4.4</label><title>Oral-brain axis</title><p>The mechanisms linking oral microbiota and the brain (termed the &#8220;oral-brain axis&#8221;) remain largely unexplored (<xref rid="B87" ref-type="bibr">Yano et&#160;al., 2015</xref>; <xref rid="B80" ref-type="bibr">Valles-Colomer et&#160;al., 2019</xref>). However, recent studies have proposed several potential routes through which oral bacteria may reach the brain and influence neuroimmune activity and inflammation (<xref rid="B62" ref-type="bibr">Olsen and Hicks, 2020</xref>). For instance, routine dental procedures such as flossing, brushing, and professional cleanings may introduce oral bacteria into the bloodstream, causing bacteremia (<xref rid="B61" ref-type="bibr">Olsen, 2008</xref>). Certain microbes might subsequently traverse the blood-brain barrier. Additionally, altered blood-brain barrier permeability could expose the brain to bacterial metabolites, triggering inflammatory responses that disrupt central nervous system function and contribute to psychological disorders such as anxiety and depression (<xref rid="f13" ref-type="fig">
<bold>Figure 13</bold>
</xref>).</p><fig position="float" id="f13" orientation="portrait"><label>Figure&#160;13</label><caption><p>Schematic representation of the oral-brain axis. This schematic serves as a conceptual framework for understanding the complex interactions that may occur between oral microbiota, oral health conditions, and brain health, including the potential impact on cognitive functions and neurological disorders.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-15-1659042-g013.jpg"><alt-text content-type="machine-generated">Illustration of a human profile showing the connection between the mouth and brain. An arrow indicates the pathway from the mouth to the brain. The brain and oral cavity are highlighted.</alt-text></graphic></fig><p>Analysis of differential metabolites in salivary samples from the HG and PDG groups revealed significant alterations in multiple metabolite levels. Notably, the glutamine-histidine-lysine (Glu-His-Lys) tripeptide, composed of three amino acids, exhibited notable changes. Glutamate (Glu), a critical excitatory neurotransmitter in the brain, is essential for normal cognitive functions such as learning, memory, and attention. However, imbalanced glutamate levels are strongly associated with the pathogenesis of psychiatric disorders (<xref rid="B11" ref-type="bibr">The structure, function and role in neuropsychiatric disorders of glutamate transporters, n.d.</xref>), where excessive concentrations may contribute to depression, anxiety, and schizophrenia. Magnetic resonance spectroscopy (MRS) studies further highlight glutamate&#8217;s potential role in conditions like depression and schizophrenia through quantitative measurements of its cerebral concentrations (<xref rid="B10" ref-type="bibr">The role of the glutamate system in mental disorders: Based on magnetic resonance spectroscopy imaging technology, n.d.</xref>). Histidine (His), a precursor of histamine, serves as both a neurotransmitter and neuromodulator in the brain, regulating sleep-wake cycles, feeding behavior, and learning (<xref rid="B51" ref-type="bibr">Ma et&#160;al., 2023</xref>). Clinical and experimental studies have elucidated histamine&#8217;s role in neuropsychiatric disorders (<xref rid="B20" ref-type="bibr">Cheng et&#160;al., 2021</xref>). Specifically, histamine binds to inhibitory receptors on murine serotonergic neurons, directly suppressing serotonin (5-hydroxytryptamine, 5-HT) release&#8212;a key molecule in mood regulation (<xref rid="B34" ref-type="bibr">Hersey et&#160;al., 2021</xref>). Reduced serotonin levels are closely linked to adverse psychological states such as depression and anxiety. Lysine (Lys), an essential amino acid involved in protein synthesis, also contributes to serotonin production (<xref rid="B86" ref-type="bibr">Yang et&#160;al., 2018</xref>). By enhancing serotonin availability, lysine may modulate mood regulation and potentially alleviate anxiety symptoms. Additionally, Huperzine B&#8212;a natural alkaloid derived from Huperzia species&#8212;exhibits potent acetylcholinesterase (AChE) inhibitory activity, demonstrating therapeutic potential for Alzheimer&#8217;s disease (<xref rid="B43" ref-type="bibr">Kn&#246;lker, 2013</xref>). This suggests its applicability in managing psychological disorders associated with cholinergic dysfunction, such as Alzheimer&#8217;s disease.</p><p>Brucine intoxication may increase neuroexcitability, leading to muscle spasms and seizures, symptoms potentially linked to psychological states such as anxiety and tension (<xref rid="B50" ref-type="bibr">Lu et&#160;al., 2020</xref>). Direct associations between 4-Oxo-L-proline and psychological disorders remain understudied; however, its parent compound, L-proline, has been extensively investigated for its role in the nervous system and the relationship between its metabolic abnormalities and psychiatric conditions. Elevated concentrations of L-proline derivatives may exert toxic effects on the nervous system, such as inducing seizures or impairing normal neuronal function (<xref rid="B22" ref-type="bibr">Das et&#160;al., 2025</xref>). Studies have highlighted the role of proline metabolism in neuronal activity, suggesting that its dysregulation may contribute to neurological dysfunction (<xref rid="B88" ref-type="bibr">Yao and Han, 2022</xref>), thereby increasing susceptibility to neuropsychiatric disorders, including depression and anxiety. Adenine, a key component of purine metabolism, produces adenosine as a metabolite that plays a vital regulatory role in the nervous system. Research indicates that adenosine and its receptors (particularly the A2A subtype) are critically involved in mood regulation and mood disorders. In individuals with depression, adenosine metabolism may be disrupted, and the activity of its receptors (e.g., A2A) is closely associated with emotional behaviors (<xref rid="B70" ref-type="bibr">Qi et&#160;al., 2025</xref>).</p><p>In summary, the interaction between oral microbiota and the brain (termed the &#8220;oral-brain axis&#8221;) may play a significant role in mental health. Oral bacteria and their metabolites can influence the central nervous system through multiple pathways, including direct penetration of the blood-brain barrier, activation of immune responses, or signal transmission via neural routes. Dysbiosis of the oral microbiota is closely associated with psychiatric disorders such as anxiety and depression, highlighting oral health as a critical determinant of mental well-being. These insights not only deepen our understanding of the oral-brain axis but may also inform novel strategies for clinical interventions targeting psychiatric conditions.</p></sec><sec id="s4_5"><label>4.5</label><title>Oral-gut axis</title><p>The oral-gut barrier, primarily shaped by the physical distance between the oral cavity and gut as well as differences in their chemical environments, allows each niche to harbor distinct microbial communities (<xref rid="B65" ref-type="bibr">Paudel et&#160;al., 2022</xref>). A substantial number of oral bacteria are swallowed in saliva, but the low pH of gastric acid creates harsh chemical conditions that prevent many oral bacteria from colonizing the gut (<xref rid="f14" ref-type="fig">
<bold>Figure 14</bold>
</xref>). However, various factors, including disease, medication, and aging, may facilitate ectopic colonization of oral bacteria in the gut (<xref rid="B64" ref-type="bibr">Park et&#160;al., 2021</xref>). Oral bacteria can translocate to the gut and alter gut microbiota composition. The linkage between oral pathogenic bacteria and gut microbiota may be mediated via the &#8220;oral-gut axis,&#8221; wherein oral bacteria migrate through saliva swallowing from the oropharynx or oral digestive sites and ectopically colonize the gut, triggering inflammatory responses (<xref rid="B52" ref-type="bibr">MaChado et&#160;al., 2021</xref>). This process may disrupt the normal equilibrium of gut microbiota, leading to gut microbial dysbiosis (<xref rid="B13" ref-type="bibr">Bao et&#160;al., 2022</xref>; <xref rid="B83" ref-type="bibr">Wu et&#160;al., 2022</xref>). Additionally, these translocated bacteria may modify oral microbial composition during oral transit before entering the gastrointestinal tract. These findings suggest a bidirectional communication between altered microbial communities in the oral and gut ecosystems, influencing both niches (<xref rid="B64" ref-type="bibr">Park et&#160;al., 2021</xref>).</p><fig position="float" id="f14" orientation="portrait"><label>Figure&#160;14</label><caption><p>Schematic representation of the oral-gut axis and its impact on health. This schematic highlights the importance of maintaining a healthy oral and gut microbiota to prevent dental diseases and metabolic disorders, emphasizing the role of the oral-gut axis in overall health.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcimb-15-1659042-g014.jpg"><alt-text content-type="machine-generated">Diagram showing the relationship between oral and gut health. On the left, healthy status includes non-cariogenic bacteria in the mouth and normal gut microbiota. On the right, unhealthy status features cariogenic bacteria leading to dental caries and abnormal gut microbiota contributing to obesity. The oral-gut axis connects these elements.</alt-text></graphic></fig><p>In this experiment, SourceTracker analysis targeting the genus Prevotella was performed on samples from the HG and COG groups. The results showed that the transmission effect in the COG group was significantly greater than that in the HG group, further confirming the role of the &#8220;oral-gut axis&#8221; in disease development. Specifically, the migration of Prevotella from the oral cavity to the gut was more pronounced in the COG group, indicating that in the comorbidity of dental caries and obesity, the oral-gut barrier is altered, making it easier for oral bacteria to colonize the gut. Prevotella is a common oral bacterium, Gram-negative and anaerobic, and is widely found in the human oral cavity, gastrointestinal tract, and urogenital tract (<xref rid="B9" ref-type="bibr">Research progress on Prevotella copri in the gut and its association with inflammatory diseases, n.d.</xref>). Studies have shown that Prevotella can migrate from the oral cavity to the gut via the oral-gut axis and colonize the gut, potentially triggering inflammatory responses, disrupting gut barrier function, and leading to systemic inflammation and metabolic disorders (<xref rid="B85" ref-type="bibr">Yamazaki and Kamada, 2024</xref>). This migration and colonization may affect the host&#8217;s health through various mechanisms.</p></sec></sec><sec sec-type="conclusions" id="s5"><label>5</label><title>Conclusion</title><p>This study explored the impact of psychological factors on adolescent caries-obesity comorbidity from the &#8220;oral-gut-brain axis,&#8221; yielding key conclusions:</p><list list-type="order"><list-item><p>A complex interrelation exists among adolescent caries, obesity, and psychological disorders, forming a health problem network.</p></list-item><list-item><p>Oral and gut microbiota play crucial roles in the development of these conditions. 16S rRNA sequencing revealed significant differences in oral and gut microbiota at phylum and genus levels among adolescents in different health states, with microbial diversity and composition closely linked to health.</p></list-item><list-item><p>Non-targeted metabolomics showed significant metabolite changes between groups, suggesting oral and gut microbial metabolites may influence brain function via the &#8220;gut-brain axis&#8221; and &#8220;oral-brain axis,&#8221; potentially impacting neuropsychiatric diseases.</p></list-item><list-item><p>Source tracker analysis confirmed the &#8220;oral-gut axis&#8221; role in disease, with oral bacteria from caries-obesity patients colonizing the gut and influencing its microbiota, contributing to disease development.</p></list-item></list></sec></body><back><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The data presented in the study are deposited in the NCBI repository, accession number PRJNA1305107\MTBLS12873.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement </title><p>The studies involving humans were approved by Ethics Committee of the Scientific Research Department, Affiliated Stomatology Hospital of Jinzhou Medical University, Jinzhou City, Liaoning Province, China. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants&#8217; legal guardians/next of kin.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>MW: Formal Analysis, Visualization, Software, Project administration, Writing &#8211; original draft, Data curation, Investigation, Conceptualization, Methodology, Validation, Supervision, Writing &#8211; review &amp; editing. XY: Data curation, Writing &#8211; review &amp; editing, Investigation, Formal Analysis, Validation. YL: Formal Analysis, Software, Conceptualization, Investigation, Writing &#8211; review &amp; editing. MJ: Writing &#8211; review &amp; editing, Project administration, Formal Analysis. BC: Methodology, Writing &#8211; review &amp; editing, Validation. WY: Conceptualization, Writing &#8211; review &amp; editing, Methodology. NM: Project administration, Writing &#8211; review &amp; editing, Validation. SH: Writing &#8211; review &amp; editing, Visualization. CW: Supervision, Methodology, Writing &#8211; review &amp; editing, Resources, Funding acquisition.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s11"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p><p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>20180704145130574.pdf</collab></person-group> (<year>n.d.</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.nhc.gov.cn/ewebeditor/uploadfile/2018/07/20180704145130574.pdf">http://www.nhc.gov.cn/ewebeditor/uploadfile/2018/07/20180704145130574.pdf</uri> (Accessed <date-in-citation content-type="access-date">April 9, 2025</date-in-citation>).</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aarons</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Seijo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Green</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Moullin</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Hasson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Von Thiele Schwarz</surname><given-names>U.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Fostering international collaboration in implementation science and research: a concept mapping exploratory study</article-title>. <source>BMC Res. Notes</source><volume>12</volume>, <fpage>778</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13104-019-4800-4</pub-id>, PMID: <pub-id pub-id-type="pmid">31783912</pub-id><pub-id pub-id-type="pmcid">PMC6883596</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agnello</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mittermuller</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chaichanasakul Tran</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Microbiome associated with severe caries in Canadian first nations children</article-title>. <source>J. Dent. Res.</source><volume>96</volume>, <fpage>1378</fpage>&#8211;<lpage>1385</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1177/0022034517718819</pub-id>, PMID: <pub-id pub-id-type="pmid">28709393</pub-id><pub-id pub-id-type="pmcid">PMC5652857</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Bataineh</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>K&#252;nstner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dash</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Abdulsalam</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Al-Kayyali</surname><given-names>R. Z.A.</given-names></name><name name-style="western"><surname>Adi</surname><given-names>M. B.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Altered composition of the oral microbiota in depression among cigarette smokers: A pilot study</article-title>. <source>Front. Psychiatry</source><volume>13</volume>, <elocation-id>902433</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fpsyt.2022.902433</pub-id>, PMID: <pub-id pub-id-type="pmid">35928781</pub-id><pub-id pub-id-type="pmcid">PMC9343996</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Hebshi</surname><given-names>N. N.</given-names></name><name name-style="western"><surname>Baraniya</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>J.</given-names></name><name name-style="western"><surname>Puri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tellez</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Metagenome sequencing-based strain-level and functional characterization of supragingival microbiome associated with dental caries in children</article-title>. <source>J. Oral. Microbiol.</source><volume>11</volume>, <fpage>1557986</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/20002297.2018.1557986</pub-id>, PMID: <pub-id pub-id-type="pmid">30671194</pub-id><pub-id pub-id-type="pmcid">PMC6327923</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="webpage"><source>Comprehensive evaluation of children and adolescents development</source> (<year>n.d.</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.nhc.gov.cn/wjw/pqt/201504/3661756c241b46329dbc6ad73eba0bd1.shtml">http://www.nhc.gov.cn/wjw/pqt/201504/3661756c241b46329dbc6ad73eba0bd1.shtml</uri>(Accessed <date-in-citation content-type="access-date">April 9, 2025</date-in-citation>).</mixed-citation></ref><ref id="B7"><mixed-citation publication-type="webpage"><source>Advances in research on oral microecology and caries prevention</source> (<year>n.d.</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://kns.cnki.net/kcms2/article/abstract?v=uXGtp3S0eCAk7If9PQMD_dpfCkp5XSGuoHnlsBE_lghMarzv5ViR8_XgfDt0623zyHhm0_8GoKPf9n0zHoBBW8_A8k-cq9WBekOSZlYjcaOEgMjKKpTVTMa9K3UpizNV8i1pv0579GXs46ptZWtAe961lOXFt6Ksm-_hszKs10ntQSWm-7qQGA==&amp;uniplatform=NZKPT&amp;language=CHS">https://kns.cnki.net/kcms2/article/abstract?v=uXGtp3S0eCAk7If9PQMD_dpfCkp5XSGuoHnlsBE_lghMarzv5ViR8_XgfDt0623zyHhm0_8GoKPf9n0zHoBBW8_A8k-cq9WBekOSZlYjcaOEgMjKKpTVTMa9K3UpizNV8i1pv0579GXs46ptZWtAe961lOXFt6Ksm-_hszKs10ntQSWm-7qQGA==&amp;uniplatform=NZKPT&amp;language=CHS</uri>(Accessed <date-in-citation content-type="access-date">April 9, 2025</date-in-citation>).</mixed-citation></ref><ref id="B8"><mixed-citation publication-type="webpage"><source>Study on the structure of oral microbiota in children with dental caries based on high-throughput sequencing technology</source> (<year>n.d.</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://kns.cnki.net/kcms2/article/abstract?v=uXGtp3S0eCA_ngkbmBHWeiDLSuYztaJVhcKWIBhajUb1CHLd-QKJgk8nfEY7bIA9yPW2zXRiYHpABq6kqdz207bRclFHjnBnmjOlhz2cGjuC3V3ns2-CZRJwFevHf8PAsIFoNGJMdQoNdWnsVrFTSo_lhStXYb6uxd0MddFYJrjCrk-YiJzVag==&amp;uniplatform=NZKPT&amp;language=CHS">https://kns.cnki.net/kcms2/article/abstract?v=uXGtp3S0eCA_ngkbmBHWeiDLSuYztaJVhcKWIBhajUb1CHLd-QKJgk8nfEY7bIA9yPW2zXRiYHpABq6kqdz207bRclFHjnBnmjOlhz2cGjuC3V3ns2-CZRJwFevHf8PAsIFoNGJMdQoNdWnsVrFTSo_lhStXYb6uxd0MddFYJrjCrk-YiJzVag==&amp;uniplatform=NZKPT&amp;language=CHS</uri>(Accessed <date-in-citation content-type="access-date">April 9, 2025</date-in-citation>).</mixed-citation></ref><ref id="B9"><mixed-citation publication-type="webpage"><source>Research progress on Prevotella copri in the gut and its association with inflammatory diseases</source> (<year>n.d.</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://kns.cnki.net/kcms2/article/abstract?v=uXGtp3S0eCD2d-Jr6xJ5xOoRPPsw3-dOovvDmynaXTqJ3CkRpkCacPQA25QgQcbg3ijHzqEvWF-h1usFoTzxZhpgDiF064JVHyP2b28NYYlriWjXN7lReO8soi1MS0amdMZCJ1dIAOSxgmJzTZpKn0rmL4LaFJMSoWRysUNkyJs7uJovRdZyiA==&amp;uniplatform=NZKPT&amp;language=CHS">https://kns.cnki.net/kcms2/article/abstract?v=uXGtp3S0eCD2d-Jr6xJ5xOoRPPsw3-dOovvDmynaXTqJ3CkRpkCacPQA25QgQcbg3ijHzqEvWF-h1usFoTzxZhpgDiF064JVHyP2b28NYYlriWjXN7lReO8soi1MS0amdMZCJ1dIAOSxgmJzTZpKn0rmL4LaFJMSoWRysUNkyJs7uJovRdZyiA==&amp;uniplatform=NZKPT&amp;language=CHS</uri>(Accessed <date-in-citation content-type="access-date">April 9, 2025</date-in-citation>).</mixed-citation></ref><ref id="B10"><mixed-citation publication-type="webpage"><source>The role of the glutamate system in mental disorders: Based on magnetic resonance spectroscopy imaging technology</source> (<year>n.d.</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://kns.cnki.net/kcms2/article/abstract?v=uXGtp3S0eCDb-Aoz-Yw1kKTLwNfApQtUzPrC2AE9ySYsewJdzag6MTTNoaL0SkQCrCAQTOeObwwumhyLm-aoDr4d1IrjDyMmUxgfyChOX3Dfr-ej9HyLSPVOH_EoY-U2PrDRIt3xxyeW4_3fztdrH1l8Xfi3FnbdWQlbydNx1ThxByT5-0gteg==&amp;uniplatform=NZKPT&amp;language=CHS">https://kns.cnki.net/kcms2/article/abstract?v=uXGtp3S0eCDb-Aoz-Yw1kKTLwNfApQtUzPrC2AE9ySYsewJdzag6MTTNoaL0SkQCrCAQTOeObwwumhyLm-aoDr4d1IrjDyMmUxgfyChOX3Dfr-ej9HyLSPVOH_EoY-U2PrDRIt3xxyeW4_3fztdrH1l8Xfi3FnbdWQlbydNx1ThxByT5-0gteg==&amp;uniplatform=NZKPT&amp;language=CHS</uri> (Accessed <date-in-citation content-type="access-date">April 9, 2025</date-in-citation>).</mixed-citation></ref><ref id="B11"><mixed-citation publication-type="webpage"><source>The structure, function and role in neuropsychiatric disorders of glutamate transporters</source> (<year>n.d.</year>). Available at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://kns.cnki.net/kcms2/article/abstract?v=uXGtp3S0eCD1caR2fN9YQrPzoIs5-En0Pkh8vVpPtqjO_XuB_9iao-vvHdszR2fgE-2vZUzTrMY9mzmu-uC9j1laYTQ8AdxjjxVUGuvcAT3Kpls4CbOLdxK1Hya_SXQmEHTMwKautezUpocr_BuZqS8hYwT7Ixpe2_v6x-sRlNWaOMjJMarRcA==&amp;uniplatform=NZKPT&amp;language=CHS">https://kns.cnki.net/kcms2/article/abstract?v=uXGtp3S0eCD1caR2fN9YQrPzoIs5-En0Pkh8vVpPtqjO_XuB_9iao-vvHdszR2fgE-2vZUzTrMY9mzmu-uC9j1laYTQ8AdxjjxVUGuvcAT3Kpls4CbOLdxK1Hya_SXQmEHTMwKautezUpocr_BuZqS8hYwT7Ixpe2_v6x-sRlNWaOMjJMarRcA==&amp;uniplatform=NZKPT&amp;language=CHS</uri> (Accessed <date-in-citation content-type="access-date">April 9, 2025</date-in-citation>).</mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Dinis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Deep metagenomics examines the oral microbiome during dental caries, revealing novel taxa and co-occurrences with host molecules</article-title>. <source>Genome Res.</source><volume>31</volume>, <fpage>64</fpage>&#8211;<lpage>74</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1101/gr.265645.120</pub-id>, PMID: <pub-id pub-id-type="pmid">33239396</pub-id><pub-id pub-id-type="pmcid">PMC7849383</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Periodontitis may induce gut microbiota dysbiosis via salivary microbiota</article-title>. <source>Int. J. Oral. Sci.</source><volume>14</volume>, <fpage>32</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41368-022-00183-3</pub-id>, PMID: <pub-id pub-id-type="pmid">35732628</pub-id><pub-id pub-id-type="pmcid">PMC9217941</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boger</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Henriksen</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Cravatt</surname><given-names>B. F.</given-names></name></person-group> (<year>1998</year>). <article-title>Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules</article-title>. <source>Curr. Pharm. Des.</source><volume>4</volume>, <fpage>303</fpage>&#8211;<lpage>314</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.2174/138161280404221010152220</pub-id>, PMID: <pub-id pub-id-type="pmid">10197045</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borkent</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reardon</surname><given-names>R. J. M.</given-names></name><name name-style="western"><surname>McLACHLAN</surname><given-names>G.</given-names></name><name name-style="western"><surname>Glendinning</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>P. M.</given-names></name></person-group> (<year>2020</year>). <article-title>A microbiome analysis of equine peripheral dental caries using next generation sequencing</article-title>. <source>Equine Veterinary J.</source><volume>52</volume>, <fpage>67</fpage>&#8211;<lpage>75</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/evj.13126</pub-id>, PMID: <pub-id pub-id-type="pmid">31006119</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowland</surname><given-names>G. B.</given-names></name><name name-style="western"><surname>Weyrich</surname><given-names>L. S.</given-names></name></person-group> (<year>2022</year>). <article-title>The oral-microbiome-brain axis and neuropsychiatric disorders: an anthropological perspective</article-title>. <source>Front. Psychiatry</source><volume>13</volume>, <elocation-id>810008</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fpsyt.2022.810008</pub-id>, PMID: <pub-id pub-id-type="pmid">35432038</pub-id><pub-id pub-id-type="pmcid">PMC9005879</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caradonna</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nemni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bifone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gandolfo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Costantino</surname><given-names>L.</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>The brain&#8211;gut axis, an important player in alzheimer and Parkinson disease: A narrative review</article-title>. <source>JCM</source><volume>13</volume>, <fpage>4130</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/jcm13144130</pub-id>, PMID: <pub-id pub-id-type="pmid">39064171</pub-id><pub-id pub-id-type="pmcid">PMC11278248</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chala</surname><given-names>S.</given-names></name><name name-style="western"><surname>El Aidouni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abouqal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Abdallaoui</surname><given-names>F.</given-names></name></person-group> (<year>2017</year>). <article-title>U-shaped association between untreated caries and body mass index in adults at Rabat dental University hospital, Morocco: cross sectional study</article-title>. <source>BMC Res. Notes</source><volume>10</volume>, <fpage>5</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13104-016-2356-0</pub-id>, PMID: <pub-id pub-id-type="pmid">28057060</pub-id><pub-id pub-id-type="pmcid">PMC5217218</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chapple</surname><given-names>I. L. C.</given-names></name><name name-style="western"><surname>Bouchard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cagetti</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Campus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Carra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cocco</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Interaction of lifestyle, behaviour or systemic diseases with dental caries and periodontal diseases: consensus report of group 2 of the joint <sc>EFP</sc>/<sc>ORCA</sc> workshop on the boundaries between caries and periodontal diseases</article-title>. <source>J. Clinic Periodontol.</source><volume>44</volume>, <elocation-id>S42</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1111/jcpe.12685</pub-id>, PMID: <pub-id pub-id-type="pmid">28266114</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name></person-group> (<year>2021</year>). <article-title>The histaminergic system in neuropsychiatric disorders</article-title>. <source>Biomolecules</source><volume>11</volume>, <fpage>1345</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/biom11091345</pub-id>, PMID: <pub-id pub-id-type="pmid">34572558</pub-id><pub-id pub-id-type="pmcid">PMC8467868</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryan</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Dinan</surname><given-names>T. G.</given-names></name></person-group> (<year>2012</year>). <article-title>Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour</article-title>. <source>Nat. Rev. Neurosci.</source><volume>13</volume>, <fpage>701</fpage>&#8211;<lpage>712</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrn3346</pub-id>, PMID: <pub-id pub-id-type="pmid">22968153</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gauthier-Coles</surname><given-names>G.</given-names></name><name name-style="western"><surname>Br&#246;er</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rae</surname><given-names>C. D.</given-names></name></person-group> (<year>2025</year>). <article-title>l-proline alters energy metabolism in brain cortical tissue slices</article-title>. <source>Neurochem. Res.</source><volume>50</volume>, <fpage>16</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s11064-024-04262-1</pub-id>, PMID: <pub-id pub-id-type="pmid">39556274</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Lemos</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Resende</surname><given-names>C. M.M.</given-names></name><name name-style="western"><surname>Campello</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>I. S.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>De Lima</surname><given-names>E. L.S.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Is oral microbiota associated with overweight and obesity in children and adolescents? A systematic review</article-title>. <source>Crit. Rev. Food Sci. Nutr.</source><volume>64</volume>, <fpage>4275</fpage>&#8211;<lpage>4285</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/10408398.2022.2140330</pub-id>, PMID: <pub-id pub-id-type="pmid">36419361</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Do</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sheehy</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Mulli</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>F.</given-names></name><name name-style="western"><surname>Beighton</surname><given-names>D.</given-names></name></person-group> (<year>2015</year>). <article-title>Transcriptomic analysis of three Veillonella spp. present in carious dentine and in the saliva of caries-free individuals</article-title>. <source>Front. Cell. Infect. Microbiol.</source><volume>5</volume>., PMID: <pub-id pub-id-type="pmid">25859434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2015.00025</pub-id><pub-id pub-id-type="pmcid">PMC4374535</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominy</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ermini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Benedyk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marczyk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Konradi</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>
<italic toggle="yes">Porphyromonas gingivalis</italic> in Alzheimer&#8217;s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors</article-title>. <source>Sci. Adv.</source><volume>5</volume>, <elocation-id>eaau3333</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1126/sciadv.aau3333</pub-id>, PMID: <pub-id pub-id-type="pmid">30746447</pub-id><pub-id pub-id-type="pmcid">PMC6357742</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>Z.-M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.-F.</given-names></name></person-group> (<year>2024</year>). <article-title>Role of oral-gut-brain axis in psychiatric and neurological disorders</article-title>. <source>WCJD</source><volume>32</volume>, <fpage>878</fpage>&#8211;<lpage>886</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.11569/wcjd.v32.i12.878</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eriksen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Boustedt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sonne</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Dahlgren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kristiansen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Twetman</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Early life factors and oral microbial signatures define the risk of caries in a Swedish cohort of preschool children</article-title>. <source>Sci. Rep.</source><volume>14</volume>, <fpage>8463</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-024-59126-z</pub-id>, PMID: <pub-id pub-id-type="pmid">38605085</pub-id><pub-id pub-id-type="pmcid">PMC11009336</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folayan</surname><given-names>M. O.</given-names></name><name name-style="western"><surname>Adeniyi</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Oziegbe</surname><given-names>E. O.</given-names></name><name name-style="western"><surname>Fatusi</surname><given-names>A. O.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Integrated oral, mental and sexual health management for adolescents: a call for professional collaboration</article-title>. <source>Int. J. Adolesc. Med. Health</source><volume>30</volume>, <fpage>20160060</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1515/ijamh-2016-0060</pub-id>, PMID: <pub-id pub-id-type="pmid">27505085</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foster</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>McVey Neufeld</surname><given-names>K.-A.</given-names></name></person-group> (<year>2013</year>). <article-title>Gut&#8211;brain axis: how the microbiome influences anxiety and depression</article-title>. <source>Trends Neurosci.</source><volume>36</volume>, <fpage>305</fpage>&#8211;<lpage>312</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.tins.2013.01.005</pub-id>, PMID: <pub-id pub-id-type="pmid">23384445</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallardo-Becerra</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cornejo-Granados</surname><given-names>F.</given-names></name><name name-style="western"><surname>Garc&#237;a-L&#243;pez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Valdez-Lara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bikel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Canizales-Quinteros</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children</article-title>. <source>Microb. Cell Fact</source><volume>19</volume>, <fpage>61</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12934-020-01319-y</pub-id>, PMID: <pub-id pub-id-type="pmid">32143621</pub-id><pub-id pub-id-type="pmcid">PMC7060530</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ge</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.-H.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Differential proteomic analysis of the anti-depressive effects of oleamide in a rat chronic mild stress model of depression</article-title>. <source>Pharmacol. Biochem. Behav.</source><volume>131</volume>, <fpage>77</fpage>&#8211;<lpage>86</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.pbb.2015.01.017</pub-id>, PMID: <pub-id pub-id-type="pmid">25641667</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gulliver</surname><given-names>A.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>H.</given-names></name></person-group> (<year>2010</year>). <article-title>Perceived barriers and facilitators to mental health help-seeking in young people: a systematic review</article-title>. <source>BMC Psychiatry</source><volume>10</volume>, <fpage>113</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/1471-244X-10-113</pub-id>, PMID: <pub-id pub-id-type="pmid">21192795</pub-id><pub-id pub-id-type="pmcid">PMC3022639</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z.</given-names></name></person-group> (<year>2025</year>). <article-title>Effects of oral supplementation of probiotics on body weight and visceral fat in obese patients: a meta-analysis and systematic review</article-title>. <source>Sci. Rep.</source><volume>15</volume>, <fpage>6355</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-025-90820-8</pub-id>, PMID: <pub-id pub-id-type="pmid">39984625</pub-id><pub-id pub-id-type="pmcid">PMC11845779</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hersey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Samaranayake</surname><given-names>S.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Tavakoli</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mena</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nijhout</surname><given-names>H. F.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Inflammation-induced histamine impairs the capacity of escitalopram to increase hippocampal extracellular serotonin</article-title>. <source>J. Neurosci.</source><volume>41</volume>, <fpage>6564</fpage>&#8211;<lpage>6577</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2618-20.2021</pub-id>, PMID: <pub-id pub-id-type="pmid">34083254</pub-id><pub-id pub-id-type="pmcid">PMC8318079</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Holzapfel</surname><given-names>W. H.</given-names></name></person-group> (<year>2018</year>). <article-title>Differences in anxiety levels of various murine models in relation to the gut microbiota composition</article-title>. <source>Biomedicines</source><volume>6</volume>, <fpage>113</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/biomedicines6040113</pub-id>, PMID: <pub-id pub-id-type="pmid">30518033</pub-id><pub-id pub-id-type="pmcid">PMC6315404</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Altered gut microbiota profile in patients with generalized anxiety disorder</article-title>. <source>J. Psychiatr. Res.</source><volume>104</volume>, <fpage>130</fpage>&#8211;<lpage>136</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jpsychires.2018.07.007</pub-id>, PMID: <pub-id pub-id-type="pmid">30029052</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johansson</surname><given-names>I.</given-names></name><name name-style="western"><surname>Witkowska</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kaveh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lif Holgerson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>A. C. R.</given-names></name></person-group> (<year>2016</year>). <article-title>The microbiome in populations with a low and high prevalence of caries</article-title>. <source>J. Dent. Res.</source><volume>95</volume>, <fpage>80</fpage>&#8211;<lpage>86</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1177/0022034515609554</pub-id>, PMID: <pub-id pub-id-type="pmid">26442950</pub-id><pub-id pub-id-type="pmcid">PMC4700664</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaczor-Urbanowicz</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Martin Carreras-Presas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aro</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garcia-Godoy</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>D. T.</given-names></name></person-group> (<year>2017</year>). <article-title>Saliva diagnostics&#8211;Current views and directions</article-title>. <source>Exp. Biol. Med. (Maywood)</source><volume>242</volume>, <fpage>459</fpage>&#8211;<lpage>472</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1177/1535370216681550</pub-id>, PMID: <pub-id pub-id-type="pmid">27903834</pub-id><pub-id pub-id-type="pmcid">PMC5367650</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kieling</surname><given-names>C.</given-names></name><name name-style="western"><surname>Baker-Henningham</surname><given-names>H.</given-names></name><name name-style="western"><surname>Belfer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Conti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ertem</surname><given-names>I.</given-names></name><name name-style="western"><surname>Omigbodun</surname><given-names>O.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Child and adolescent mental health worldwide: evidence for action</article-title>. <source>Lancet</source><volume>378</volume>, <fpage>1515</fpage>&#8211;<lpage>1525</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(11)60827-1</pub-id>, PMID: <pub-id pub-id-type="pmid">22008427</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirisawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ichihara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Morooka</surname><given-names>D.</given-names></name><name name-style="western"><surname>Iyoki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Masumori</surname><given-names>N.</given-names></name></person-group> (<year>2021</year>). <article-title>Physical and psychological effects of gender-affirming hormonal treatment using intramuscular testosterone enanthate in Japanese transgender men</article-title>. <source>Sexual Med.</source><volume>9</volume>, <fpage>100306</fpage>&#8211;<lpage>100306</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.esxm.2020.100306</pub-id>, PMID: <pub-id pub-id-type="pmid">33540366</pub-id><pub-id pub-id-type="pmcid">PMC8072143</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kisely</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baghaie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lalloo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Siskind</surname><given-names>D.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>N. W.</given-names></name></person-group> (<year>2015</year>). <article-title>A systematic review and meta-analysis of the association between poor oral health and severe mental illness</article-title>. <source>Psychosomatic Med.</source><volume>77</volume>, <fpage>83</fpage>&#8211;<lpage>92</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1097/PSY.0000000000000135</pub-id>, PMID: <pub-id pub-id-type="pmid">25526527</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kisely</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sawyer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Siskind</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lalloo</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>The oral health of people with anxiety and depressive disorders&#8211;a systematic review and meta-analysis</article-title>. <source>J. Affect. Disord.</source><volume>200</volume>, <fpage>119</fpage>&#8211;<lpage>132</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jad.2016.04.040</pub-id>, PMID: <pub-id pub-id-type="pmid">27130961</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kn&#246;lker</surname><given-names>H.-J.</given-names></name></person-group> (<year>2013</year>). <source>The Alkaloids</source> (<publisher-loc>San Diego</publisher-loc>: <publisher-name>Academic Press</publisher-name>).</mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korona-Glowniak</surname><given-names>I.</given-names></name><name name-style="western"><surname>Piatek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fornal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lukowiak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gerasymchuk</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kedziora</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Patterns of oral microbiota in patients with apical periodontitis</article-title>. <source>JCM</source><volume>10</volume>, <fpage>2707</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/jcm10122707</pub-id>, PMID: <pub-id pub-id-type="pmid">34205290</pub-id><pub-id pub-id-type="pmcid">PMC8234888</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leake</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Pagni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Falquet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Taroni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Greub</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>The salivary microbiome for differentiating individuals: proof of principle</article-title>. <source>Microbes Infection</source><volume>18</volume>, <fpage>399</fpage>&#8211;<lpage>405</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.micinf.2016.03.011</pub-id>, PMID: <pub-id pub-id-type="pmid">27063111</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stra&#382;ar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>A. M.T.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Lebar</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Gut microbiome and metabolome profiling in Framingham heart study reveals cholesterol-metabolizing bacteria</article-title>. <source>Cell</source><volume>187</volume>, <fpage>1834</fpage>&#8211;<lpage>1852.e19</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2024.03.014</pub-id>, PMID: <pub-id pub-id-type="pmid">38569543</pub-id><pub-id pub-id-type="pmcid">PMC11071153</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.-X.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>X.-X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.-N.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Z.-H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Analysis of salivary microbiome in patients with alzheimer&#8217;s disease</article-title>. <source>JAD</source><volume>72</volume>, <fpage>633</fpage>&#8211;<lpage>640</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.3233/JAD-190587</pub-id>, PMID: <pub-id pub-id-type="pmid">31594229</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>W. R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Structural and functional characteristics of the microbiome in deep-dentin caries</article-title>. <source>J. Dent. Res.</source><volume>99</volume>, <fpage>713</fpage>&#8211;<lpage>720</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1177/0022034520913248</pub-id>, PMID: <pub-id pub-id-type="pmid">32196394</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lobstein</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jackson-Leach</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moodie</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Gortmaker</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Swinburn</surname><given-names>B. A.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Child and adolescent obesity: part of a bigger picture</article-title>. <source>Lancet</source><volume>385</volume>, <fpage>2510</fpage>&#8211;<lpage>2520</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/S0140-6736(14)61746-3</pub-id>, PMID: <pub-id pub-id-type="pmid">25703114</pub-id><pub-id pub-id-type="pmcid">PMC4594797</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.-Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.-J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Brucine: A review of phytochemistry, pharmacology, and toxicology</article-title>. <source>Front. Pharmacol.</source><volume>11</volume>, <elocation-id>377</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fphar.2020.00377</pub-id>, PMID: <pub-id pub-id-type="pmid">32308621</pub-id><pub-id pub-id-type="pmcid">PMC7145893</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>An</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ping</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Histamine H<sub>2</sub> receptor deficit in glutamatergic neurons contributes to the pathogenesis of schizophrenia</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>120</volume>, <elocation-id>e2207003120</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.2207003120</pub-id>, PMID: <pub-id pub-id-type="pmid">36812204</pub-id><pub-id pub-id-type="pmcid">PMC9992765</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MaChado</surname><given-names>V.</given-names></name><name name-style="western"><surname>Botelho</surname><given-names>J.</given-names></name><name name-style="western"><surname>Escalda</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Luthra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mascarenhas</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Serum C-reactive protein and periodontitis: A systematic review and meta-analysis</article-title>. <source>Front. Immunol.</source><volume>12</volume>, <elocation-id>706432</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.706432</pub-id>, PMID: <pub-id pub-id-type="pmid">34394107</pub-id><pub-id pub-id-type="pmcid">PMC8355591</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sereti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ioannidis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Ball</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Magiorkinis</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Options and limitations in clinical investigation of bacterial biofilms</article-title>. <source>Clin. Microbiol. Rev.</source><volume>31</volume>, <fpage>e00084</fpage>&#8211;<lpage>e00016</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CMR.00084-16</pub-id>, PMID: <pub-id pub-id-type="pmid">29618576</pub-id><pub-id pub-id-type="pmcid">PMC6056845</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malan-M&#252;ller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>R.</given-names></name><name name-style="western"><surname>O&#8217;Shea</surname><given-names>E.</given-names></name><name name-style="western"><surname>Montero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Figuero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zorrilla</surname><given-names>I.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Probing the oral-brain connection: oral microbiome patterns in a large community cohort with anxiety, depression, and trauma symptoms, and periodontal outcomes</article-title>. <source>Transl. Psychiatry</source><volume>14</volume>, <fpage>419</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41398-024-03122-4</pub-id>, PMID: <pub-id pub-id-type="pmid">39368974</pub-id><pub-id pub-id-type="pmcid">PMC11455920</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sfratta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Traversi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lisci</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Anesini</surname><given-names>M. B.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Gut microbiota: A new challenge in mood disorder research</article-title>. <source>Life</source><volume>15</volume>, <fpage>593</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/life15040593</pub-id>, PMID: <pub-id pub-id-type="pmid">40283148</pub-id><pub-id pub-id-type="pmcid">PMC12028401</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mashima</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nakazawa</surname><given-names>F.</given-names></name></person-group> (<year>2014</year>). <article-title>The influence of oral Veillonella species on biofilms formed by Streptococcus species</article-title>. <source>Anaerobe</source><volume>28</volume>, <fpage>54</fpage>&#8211;<lpage>61</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.anaerobe.2014.05.003</pub-id>, PMID: <pub-id pub-id-type="pmid">24862495</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milaneschi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>W. K.</given-names></name><name name-style="western"><surname>Van Rossum</surname><given-names>E. F. C.</given-names></name><name name-style="western"><surname>Penninx</surname><given-names>B. W.</given-names></name></person-group> (<year>2019</year>). <article-title>Depression and obesity: evidence of shared biological mechanisms</article-title>. <source>Mol. Psychiatry</source><volume>24</volume>, <fpage>18</fpage>&#8211;<lpage>33</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41380-018-0017-5</pub-id>, PMID: <pub-id pub-id-type="pmid">29453413</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Engen</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Gillevet</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Shaikh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sikaroodi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Forsyth</surname><given-names>C. B.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>Lower neighborhood socioeconomic status associated with reduced diversity of the colonic microbiota in healthy adults</article-title>. <source>PloS One</source><volume>11</volume>, <elocation-id>e0148952</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0148952</pub-id>, PMID: <pub-id pub-id-type="pmid">26859894</pub-id><pub-id pub-id-type="pmcid">PMC4747579</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moran-Ramos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cerqueda&#8208;Garc&#237;a</surname><given-names>D.</given-names></name><name name-style="western"><surname>L&#243;pez&#8208;Contreras</surname><given-names>B.</given-names></name><name name-style="western"><surname>Larrieta&#8208;Carrasco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Villamil&#8208;Ram&#237;rez</surname><given-names>H.</given-names></name><name name-style="western"><surname>Molina&#8208;Cruz</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>A metagenomic study identifies a <italic toggle="yes">Prevotella copri</italic> enriched microbial profile associated with non-alcoholic steatohepatitis in subjects with obesity</article-title>. <source>J. Gastro Hepatol.</source><volume>38</volume>, <fpage>791</fpage>&#8211;<lpage>799</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/jgh.16147</pub-id>, PMID: <pub-id pub-id-type="pmid">36807933</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikolova</surname><given-names>V. L.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M. R.B.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Cleare</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Stone</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Young</surname><given-names>A. H.</given-names></name></person-group> (<year>2021</year>). <article-title>Perturbations in gut microbiota composition in psychiatric disorders: A review and meta-analysis</article-title>. <source>JAMA Psychiatry</source><volume>78</volume>, <fpage>1343</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2021.2573</pub-id>, PMID: <pub-id pub-id-type="pmid">34524405</pub-id><pub-id pub-id-type="pmcid">PMC8444066</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>I.</given-names></name></person-group> (<year>2008</year>). <article-title>Update on bacteraemia related to dental procedures</article-title>. <source>Transfusion Apheresis Sci.</source><volume>39</volume>, <fpage>173</fpage>&#8211;<lpage>178</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.transci.2008.06.008</pub-id>, PMID: <pub-id pub-id-type="pmid">18753008</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>S. D.</given-names></name></person-group> (<year>2020</year>). <article-title>Oral microbiota and autism spectrum disorder (ASD)</article-title>. <source>J. Oral. Microbiol.</source><volume>12</volume>, <fpage>1702806</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/20002297.2019.1702806</pub-id>, PMID: <pub-id pub-id-type="pmid">31893019</pub-id><pub-id pub-id-type="pmcid">PMC6913665</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>F.-Y.</given-names></name></person-group> (<year>2024</year>). <article-title>Link between childhood obesity and gut microbiota</article-title>. <source>World J. Gastroenterol.</source><volume>30</volume>, <fpage>3560</fpage>&#8211;<lpage>3563</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.3748/wjg.v30.i30.3560</pub-id>, PMID: <pub-id pub-id-type="pmid">39193569</pub-id><pub-id pub-id-type="pmcid">PMC11346147</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>B.-O.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ok</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.-K.</given-names></name><name name-style="western"><surname>Chun</surname><given-names>K.-S.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Oral&#8211;gut microbiome axis in gastrointestinal disease and cancer</article-title>. <source>Cancers</source><volume>13</volume>, <fpage>2124</fpage>.<pub-id pub-id-type="pmid">33924899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers13092124</pub-id><pub-id pub-id-type="pmcid">PMC8125773</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paudel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Uehara</surname><given-names>O.</given-names></name><name name-style="western"><surname>Giri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>K.</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kitagawa</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Effect of psychological stress on the oral-gut microbiota and the potential oral-gut-brain axis</article-title>. <source>Japanese Dental Sci. Rev.</source><volume>58</volume>, <fpage>365</fpage>&#8211;<lpage>375</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jdsr.2022.11.003</pub-id>, PMID: <pub-id pub-id-type="pmid">36425317</pub-id><pub-id pub-id-type="pmcid">PMC9678961</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinart</surname><given-names>M.</given-names></name><name name-style="western"><surname>D&#246;tsch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schlicht</surname><given-names>K.</given-names></name><name name-style="western"><surname>Laudes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bouwman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Forslund</surname><given-names>S. K.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Gut microbiome composition in obese and non-obese persons: A systematic review and meta-analysis</article-title>. <source>Nutrients</source><volume>14</volume>, <fpage>12</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/nu14010012</pub-id>, PMID: <pub-id pub-id-type="pmid">35010887</pub-id><pub-id pub-id-type="pmcid">PMC8746372</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitts</surname><given-names>N. B.</given-names></name><name name-style="western"><surname>Twetman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>P. D.</given-names></name></person-group> (<year>2021</year>). <article-title>Understanding dental caries as a non-communicable disease</article-title>. <source>Br. Dent. J.</source><volume>231</volume>, <fpage>749</fpage>&#8211;<lpage>753</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41415-021-3775-4</pub-id>, PMID: <pub-id pub-id-type="pmid">34921271</pub-id><pub-id pub-id-type="pmcid">PMC8683371</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plaza-D&#237;az</surname><given-names>J.</given-names></name><name name-style="western"><surname>G&#243;mez-Fern&#225;ndez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chueca</surname><given-names>N.</given-names></name><name name-style="western"><surname>Torre-Aguilar</surname><given-names>M. J.D.L.</given-names></name><name name-style="western"><surname>Gil</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>Perez-Navero</surname><given-names>J. L.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Autism spectrum disorder (ASD) with and without mental regression is associated with changes in the fecal microbiota</article-title>. <source>Nutrients</source><volume>11</volume>, <fpage>337</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/nu11020337</pub-id>, PMID: <pub-id pub-id-type="pmid">30764497</pub-id><pub-id pub-id-type="pmcid">PMC6412819</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gulisano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scerbo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barone</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vicario</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>Diagnostic approach to pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS): A narrative review of literature data</article-title>. <source>Front. Pediatr.</source><volume>9</volume>, <elocation-id>746639</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fped.2021.746639</pub-id>, PMID: <pub-id pub-id-type="pmid">34778136</pub-id><pub-id pub-id-type="pmcid">PMC8580040</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>N.</given-names></name><etal/></person-group>. (<year>2025</year>). <article-title>Adenosine A2A receptor-mediated interactions between Th1+ T cells and the choroid plexus epithelium via IFN-&#947; signalling control T-Cell infiltration in experimental autoimmune encephalomyelitis</article-title>. <source>Cell Commun. Signal</source><volume>23</volume>, <fpage>94</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12964-025-02100-7</pub-id>, PMID: <pub-id pub-id-type="pmid">39962526</pub-id><pub-id pub-id-type="pmcid">PMC11834559</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quiroga</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nistal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Est&#233;banez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Porras</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ju&#225;rez-Fern&#225;ndez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Fl&#243;rez</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Exercise training modulates the gut microbiota profile and impairs inflammatory signaling pathways in obese children</article-title>. <source>Exp. Mol. Med.</source><volume>52</volume>, <fpage>1048</fpage>&#8211;<lpage>1061</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s12276-020-0459-0</pub-id>, PMID: <pub-id pub-id-type="pmid">32624568</pub-id><pub-id pub-id-type="pmcid">PMC8080668</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribeiro</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Paster</surname><given-names>B. J.</given-names></name></person-group> (<year>2023</year>). <article-title>Dental caries and their microbiomes in children: what do we do now</article-title>? <source>J. Oral. Microbiol.</source><volume>15</volume>, <fpage>2198433</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1080/20002297.2023.2198433</pub-id>, PMID: <pub-id pub-id-type="pmid">37056224</pub-id><pub-id pub-id-type="pmcid">PMC10088930</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richards</surname><given-names>V. P.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Luce</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Bedenbaugh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Burne</surname><given-names>R. A.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Microbiomes of site-specific dental plaques from children with different caries status</article-title>. <source>Infect. Immun.</source><volume>85</volume>, <fpage>e00106</fpage>&#8211;<lpage>e00117</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.00106-17</pub-id>, PMID: <pub-id pub-id-type="pmid">28507066</pub-id><pub-id pub-id-type="pmcid">PMC5520424</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabharwal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stellrecht</surname><given-names>E.</given-names></name><name name-style="western"><surname>Scannapieco</surname><given-names>F. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Associations between dental caries and systemic diseases: a scoping review</article-title>. <source>BMC Oral. Health</source><volume>21</volume>, <fpage>472</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s12903-021-01803-w</pub-id>, PMID: <pub-id pub-id-type="pmid">34563194</pub-id><pub-id pub-id-type="pmcid">PMC8466895</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simpson</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Du Plessis</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Landau</surname><given-names>E. R.</given-names></name><name name-style="western"><surname>Dashper</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>E. C.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Oral microbiome composition, but not diversity, is associated with adolescent anxiety and depression symptoms</article-title>. <source>Physiol. Behav.</source><volume>226</volume>, <fpage>113126</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.physbeh.2020.113126</pub-id>, PMID: <pub-id pub-id-type="pmid">32777312</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simpson</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Diaz-Arteche</surname><given-names>C.</given-names></name><name name-style="western"><surname>Eliby</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>O. S.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Cowan</surname><given-names>C. S.M.</given-names></name></person-group> (<year>2021</year>). <article-title>The gut microbiota in anxiety and depression&#8211;A systematic review</article-title>. <source>Clin. Psychol. Rev.</source><volume>83</volume>, <fpage>101943</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cpr.2020.101943</pub-id>, PMID: <pub-id pub-id-type="pmid">33271426</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group> (<year>2024</year>). <article-title>Developing functional hydrogels for treatment of oral diseases</article-title>. <source>Smart Med.</source><volume>3</volume>, <elocation-id>e20240020</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1002/SMMD.20240020</pub-id>, PMID: <pub-id pub-id-type="pmid">39420948</pub-id><pub-id pub-id-type="pmcid">PMC11425053</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soriano-Lerma</surname><given-names>A.</given-names></name><name name-style="western"><surname>P&#233;rez-Carrasco</surname><given-names>V.</given-names></name><name name-style="western"><surname>S&#225;nchez-Mara&#241;&#243;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ortiz-Gonz&#225;lez</surname><given-names>M.</given-names></name><name name-style="western"><surname>S&#225;nchez-Mart&#237;n</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gij&#243;n</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>Influence of 16S rRNA target region on the outcome of microbiome studies in soil and saliva samples</article-title>. <source>Sci. Rep.</source><volume>10</volume>, <fpage>13637</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-020-70141-8</pub-id>, PMID: <pub-id pub-id-type="pmid">32788589</pub-id><pub-id pub-id-type="pmcid">PMC7423937</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tett</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pasolli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Masetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ercolini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Segata</surname><given-names>N.</given-names></name></person-group> (<year>2021</year>). <article-title>Prevotella diversity, niches and interactions with the human host</article-title>. <source>Nat. Rev. Microbiol.</source><volume>19</volume>, <fpage>585</fpage>&#8211;<lpage>599</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41579-021-00559-y</pub-id>, PMID: <pub-id pub-id-type="pmid">34050328</pub-id><pub-id pub-id-type="pmcid">PMC11290707</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valles-Colomer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Falony</surname><given-names>G.</given-names></name><name name-style="western"><surname>Darzi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tigchelaar</surname><given-names>E. F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tito</surname><given-names>R. Y.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>The neuroactive potential of the human gut microbiota in quality of life and depression</article-title>. <source>Nat. Microbiol.</source><volume>4</volume>, <fpage>623</fpage>&#8211;<lpage>632</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41564-018-0337-x</pub-id>, PMID: <pub-id pub-id-type="pmid">30718848</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warren</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Lankri</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>I. C.</given-names></name><name name-style="western"><surname>Parise</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Kruegel</surname><given-names>A. C.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Structural pharmacology and therapeutic potential of 5-methoxytryptamines</article-title>. <source>Nature</source><volume>630</volume>, <fpage>237</fpage>&#8211;<lpage>246</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41586-024-07403-2</pub-id>, PMID: <pub-id pub-id-type="pmid">38720072</pub-id><pub-id pub-id-type="pmcid">PMC11152992</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wingfield</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lapsley</surname><given-names>C.</given-names></name><name name-style="western"><surname>McDowell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miliotis</surname><given-names>G.</given-names></name><name name-style="western"><surname>McLafferty</surname><given-names>M.</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>S. M.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Variations in the oral microbiome are associated with depression in young adults</article-title>. <source>Sci. Rep.</source><volume>11</volume>, <fpage>15009</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-021-94498-6</pub-id>, PMID: <pub-id pub-id-type="pmid">34294835</pub-id><pub-id pub-id-type="pmcid">PMC8298414</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Alterations and correlations of gut microbiota and fecal metabolome characteristics in experimental periodontitis rats</article-title>. <source>Front. Microbiol.</source><volume>13</volume>, <elocation-id>865191</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fmicb.2022.865191</pub-id>, PMID: <pub-id pub-id-type="pmid">35495729</pub-id><pub-id pub-id-type="pmcid">PMC9048259</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamazaki</surname><given-names>K.</given-names></name></person-group> (<year>2023</year>). <article-title>Oral-gut axis as a novel biological mechanism linking periodontal disease and systemic diseases: A review</article-title>. <source>Japanese Dental Sci. Rev.</source><volume>59</volume>, <fpage>273</fpage>&#8211;<lpage>280</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jdsr.2023.08.003</pub-id>, PMID: <pub-id pub-id-type="pmid">37674899</pub-id><pub-id pub-id-type="pmcid">PMC10477752</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamazaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kamada</surname><given-names>N.</given-names></name></person-group> (<year>2024</year>). <article-title>Exploring the oral-gut linkage: Interrelationship between oral and systemic diseases</article-title>. <source>Mucosal Immunol.</source><volume>17</volume>, <fpage>147</fpage>&#8211;<lpage>153</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.mucimm.2023.11.006</pub-id>, PMID: <pub-id pub-id-type="pmid">38007003</pub-id><pub-id pub-id-type="pmcid">PMC11222583</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Q.-Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D.-S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.-Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.-F.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>M.-H.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>A connection between lysine and serotonin metabolism in rice endosperm</article-title>. <source>Plant Physiol.</source><volume>176</volume>, <fpage>1965</fpage>&#8211;<lpage>1980</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1104/pp.17.01283</pub-id>, PMID: <pub-id pub-id-type="pmid">29363563</pub-id><pub-id pub-id-type="pmcid">PMC5841688</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yano</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>G. P.</given-names></name><name name-style="western"><surname>Shastri</surname><given-names>G. G.</given-names></name><name name-style="western"><surname>Ann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis</article-title>. <source>Cell</source><volume>161</volume>, <fpage>264</fpage>&#8211;<lpage>276</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.cell.2015.02.047</pub-id>, PMID: <pub-id pub-id-type="pmid">25860609</pub-id><pub-id pub-id-type="pmcid">PMC4393509</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.</given-names></name></person-group> (<year>2022</year>). <article-title>Proline metabolism in neurological and psychiatric disorders</article-title>. <source>Mol. Cells</source><volume>45</volume>, <fpage>781</fpage>&#8211;<lpage>788</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.14348/molcells.2022.0115</pub-id>, PMID: <pub-id pub-id-type="pmid">36324271</pub-id><pub-id pub-id-type="pmcid">PMC9676987</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yolken</surname><given-names>R.</given-names></name><name name-style="western"><surname>Prandovszky</surname><given-names>E.</given-names></name><name name-style="western"><surname>Severance</surname><given-names>E. G.</given-names></name><name name-style="western"><surname>Hatfield</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dickerson</surname><given-names>F.</given-names></name></person-group> (<year>2021</year>). <article-title>The oropharyngeal microbiome is altered in individuals with schizophrenia and mania</article-title>. <source>Schizophr. Res.</source><volume>234</volume>, <fpage>51</fpage>&#8211;<lpage>57</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.schres.2020.03.010</pub-id>, PMID: <pub-id pub-id-type="pmid">32334937</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name></person-group> (<year>2023</year>). <article-title>Advances in the prevention and treatment of Alzheimer&#8217;s disease based on oral bacteria</article-title>. <source>Front. Psychiatry</source><volume>14</volume>, <elocation-id>1291455</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fpsyt.2023.1291455</pub-id>, PMID: <pub-id pub-id-type="pmid">38156323</pub-id><pub-id pub-id-type="pmcid">PMC10754487</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2018</year>). <article-title>Comparative analysis of the microbial profiles in supragingival plaque samples obtained from twins with discordant caries phenotypes and their mothers</article-title>. <source>Front. Cell. Infect. Microbiol.</source><volume>8</volume>, <elocation-id>361</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fcimb.2018.00361</pub-id>, PMID: <pub-id pub-id-type="pmid">30460203</pub-id><pub-id pub-id-type="pmcid">PMC6232758</pub-id></mixed-citation></ref></ref-list></back></article><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Biol Chem</journal-id><journal-id journal-id-type="pmc-domain-id">567</journal-id><journal-id journal-id-type="pmc-domain">jbc</journal-id><journal-title-group><journal-title>The Journal of Biological Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0021-9258</issn><issn pub-type="epub">1083-351X</issn><publisher><publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12481917</article-id><article-id pub-id-type="pmcid-ver">PMC12481917.1</article-id><article-id pub-id-type="pmcaid">12481917</article-id><article-id pub-id-type="pmcaiid">12481917</article-id><article-id pub-id-type="pmid">40825507</article-id><article-id pub-id-type="doi">10.1016/j.jbc.2025.110607</article-id><article-id pub-id-type="pii">S0021-9258(25)02458-5</article-id><article-id pub-id-type="publisher-id">110607</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Andrographolide modulates glucose metabolism in visceral adipose tissue in an Alzheimer's disease obese mouse model</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Ormazabal</surname><given-names initials="P">Paulina</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">&#8225;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Gherardelli</surname><given-names initials="C">Camila</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="fn">&#8225;</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Pinto</surname><given-names initials="C">Cristina</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Servili</surname><given-names initials="E">Evrim</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Mendez-Orellana</surname><given-names initials="C">Carolina</given-names></name><xref rid="aff5" ref-type="aff">5</xref><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Wong</surname><given-names initials="GW">G. William</given-names></name><xref rid="aff7" ref-type="aff">7</xref><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Contreras-D&#237;az</surname><given-names initials="R">Roberto</given-names></name><xref rid="aff9" ref-type="aff">9</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Cisternas</surname><given-names initials="P">Pedro</given-names></name><email>pcisternasf@udla.cl</email><xref rid="aff10" ref-type="aff">10</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Inestrosa</surname><given-names initials="NC">Nibaldo C.</given-names></name><email>nibaldo.inestrosa@umag.cl</email><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><aff id="aff1"><label>1</label>Escuela de Obstetricia, Facultad de Ciencias para el Cuidado de la Salud, Universidad San Sebasti&#225;n, Santiago, Chile</aff><aff id="aff2"><label>2</label>Departamento de Biolog&#237;a Celular y Molecular, Facultad de Ciencias Biol&#243;gicas, Pontificia Universidad Cat&#243;lica de Chile, Santiago, Chile</aff><aff id="aff3"><label>3</label>Centro de Excelencia en Biomedicina de Magallanes (CEBIMA), Escuela de Medicina Universidad de Magallanes, Punta Arenas, Chile</aff><aff id="aff4"><label>4</label>Programa de Biolog&#237;a Celular y Molecular, Instituto de Ciencias Biom&#233;dicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile</aff><aff id="aff5"><label>5</label>Health Sciences Department, Faculty of Medicine, Pontificia Universidad Cat&#243;lica de Chile, Santiago, Chile</aff><aff id="aff6"><label>6</label>Regi&#243;n Metropolitana &amp; Radiology Department, Erasmus MC- University Medical Center Rotterdam the Netherlands, Rotterdam, the Netherlands</aff><aff id="aff7"><label>7</label>Department of Physiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</aff><aff id="aff8"><label>8</label>Center for Metabolism and Obesity Research, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</aff><aff id="aff9"><label>9</label>Centro Regional de Investigaci&#243;n y Desarrollo Sustentable de Atacama (CRIDESAT), Universidad de Atacama, Copiap&#243;, Chile</aff><aff id="aff10"><label>10</label>N&#250;cleo de investigaci&#243;n en nutrici&#243;n y ciencias alimentarias (NINCAL), Facultad de Salud y Ciencias sociales, Universidad de las Am&#233;ricas, Santiago, Chile</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>For correspondence: Nibaldo C. Inestrosa; Pedro Cisternas <email>pcisternasf@udla.cl</email><email>nibaldo.inestrosa@umag.cl</email></corresp><fn id="fn1"><label>&#8225;</label><p id="ntpara0010">These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><month>10</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>8</month><year>2025</year></pub-date><volume>301</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">497570</issue-id><elocation-id>110607</elocation-id><history><date date-type="received"><day>3</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>30</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-01 10:25:36.583"><day>01</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Midlife obesity and high adiposity are recognized as risk factors for Alzheimer's disease (AD), with visceral adipose tissue (VAT) playing a central role due to its endocrine and metabolic activity. Disturbances in VAT metabolism and adipokine secretion exacerbate AD pathology. Andrographolide (Andro), known for its anti-diabetic properties, enhances neuronal glucose uptake and alleviates AD pathology. However, its effects on VAT metabolism in AD remain unexplored. This study aimed to investigate the impact of Andro on glucose metabolism in VAT using a high-fat diet (HFD)-induced obesity model in AD mice (APP/PS1). APP/PS1 mice were fed an HFD and received Andro injections (2 mg/kg, three times a week for 16 weeks). VAT samples were analyzed for glucose uptake, glycolytic rate, pentose phosphate flux, ADP-ATP levels, gene expression, and enzymatic activity of glucose metabolic regulators. In APP/PS1 mice, HFD significantly increased glucose uptake and reduced GLUT4 expression in VAT, effects counteracted by Andro (<italic toggle="yes">p</italic> &lt; 0.05). Andro-treated HFD-fed mice exhibited reduced glucose oxidation through glycolysis (<italic toggle="yes">p</italic> &lt; 0.05), leading to decreased ATP production (<italic toggle="yes">p</italic> &lt; 0.05). Andro administration restored the activity of key glycolytic enzymes and mitigated several HFD-induced metabolic alterations (<italic toggle="yes">p</italic> &lt; 0.05). The study reveals significant metabolic changes in the VAT of obese APP/PS1 mice and highlights Andro's potential as a therapeutic agent for addressing VAT impairment induced by obesity in AD.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Alzheimer's disease</kwd><kwd>andrographolide</kwd><kwd>obesity</kwd><kwd>visceral adipose tissue</kwd><kwd>glucose metabolism</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="kwrd0040">A&#946;</term><def><p>amyloid-&#946;</p></def></def-item><def-item><term id="kwrd0050">AD</term><def><p>for Alzheimer's disease</p></def></def-item><def-item><term id="kwrd0060">AMPK</term><def><p>AMP-activated protein kinase</p></def></def-item><def-item><term id="kwrd0070">Andro</term><def><p>Andrographolide</p></def></def-item><def-item><term id="kwrd0080">Cyt</term><def><p>cytochalasin</p></def></def-item><def-item><term id="kwrd0090">G6PDH</term><def><p>glucose-6-phosphate dehydrogenase</p></def></def-item><def-item><term id="kwrd0100">Glut4</term><def><p>glucose transporter 4</p></def></def-item><def-item><term id="kwrd0110">HFD</term><def><p>high-fat diet</p></def></def-item><def-item><term id="kwrd0120">HK</term><def><p>hexokinase</p></def></def-item><def-item><term id="kwrd0130">NCD</term><def><p>normal chow diet</p></def></def-item><def-item><term id="kwrd0140">PFK-1</term><def><p>phosphofructokinase 1</p></def></def-item><def-item><term id="kwrd0150">PPP</term><def><p>Pentose phosphate pathway</p></def></def-item><def-item><term id="kwrd0160">VAD</term><def><p>visceral adipose tissue</p></def></def-item></def-list><notes><p id="misc0010">Reviewed by members of the JBC Editorial Board. Edited by Qi-Qun Tang</p></notes></front><body><p id="p0010">Alzheimer's disease (AD) is the most prevalent senile dementia, marked by a gradual cognitive decline (<xref rid="bib1" ref-type="bibr">1</xref>). AD is defined by extracellular amyloid-&#946; (A&#946;) deposits, known as amyloid plaques, and intracellular accumulations of hyperphosphorylated tau protein (<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>). A reduction in glucose consumption in the brains of patients with AD is observed, even before the appearance of clinical symptoms, and is closely linked to disease progression (<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>). The causes of reduced glucose metabolism remain unclear; however, multiple studies suggest that enhancing glucose uptake could potentially improve memory and cognitive function (<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>).</p><p id="p0015">In recent years, metabolic disorders, such as obesity, diabetes, and hypertension, have emerged as significant risk factors for the development of dementia (<xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>). Among them, obesity has garnered significant attention due to its escalating prevalence, projected to affect around 60% of the global adult population by 2030 according to the World Health Organization (<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>). Epidemiological studies have associated midlife obesity with an elevated risk of developing AD (<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>). Indeed, the accumulation of body fat in the abdominal cavity, primarily composed of visceral adipose tissue (VAT), has been implicated in eliciting inflammatory responses, potentially contributing to the neuroinflammation observed in AD patients (<xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>). Moreover, chronic low-grade inflammation that accompanies an increase in VAT mass has been shown to disrupt the endocrine function of the adipose tissue, resulting in impaired secretion of adipokines, molecules that have been involved in AD pathogenesis (<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>). Interestingly, impaired VAT metabolism and the burden of cerebral A&#946; are correlated (<xref rid="bib27" ref-type="bibr">27</xref>). While the exact connection between obesity, VAT impairment, and AD remains elusive, evidence suggests that obesity-related insulin resistance could be a central contributor (<xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>). Intriguingly, peripheral insulin resistance and type 2 diabetes have been demonstrated to decrease A&#946; clearance, reduce gray matter volume, increase tau deposition, and accelerate cognitive decline in individuals with AD (<xref rid="bib30" ref-type="bibr">30</xref>). Therefore, pharmacological interventions aimed at restoring adipocyte function hold promise as therapeutic strategies to alleviate symptoms associated with AD.</p><p id="p0020">Andrographolide (Andro), a labdane diterpene and the primary active component of <italic toggle="yes">Andrographis paniculata</italic>, exhibits anti-inflammatory, antioxidant, and antidiabetic properties both <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> (<xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>). Importantly, prior studies conducted by our group and others have revealed Andro&#8217;s ability to modulate key metabolic players and restore glucose metabolism in various cell and animal models (<xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref>, <xref rid="bib38" ref-type="bibr">38</xref>). However, it remains unclear whether Andro can also restore the obesity-associated metabolic changes in VAT during AD. Our findings collectively support the use of Andro as a compound able to restore metabolic alterations in the VAT of animals with obesity, positioning it as a potential pharmacological candidate for restoring obesity-induced VAT alterations in AD.</p><sec id="sec1"><title>Results</title><sec id="sec1.1"><title>Andro reduces glucose uptake in VAT of HFD-fed animals</title><p id="p0025">To study the impact of Andro on glucose metabolism in VAT, we subjected four-month-old APP/PS1 animals to two dietary regimens: a normal chow diet (NCD) and a high-fat diet (HFD), both accompanied by 4 months of intraperitoneal Andro injections (<xref rid="fig1" ref-type="fig">Fig. 1</xref><italic toggle="yes">A</italic>). As expected, HFD-fed animals exhibited a significant increase in body weights (<xref rid="fig1" ref-type="fig">Fig. 1</xref><italic toggle="yes">B</italic>). To further characterize the systemic metabolic status of the animals, we evaluated key biochemical parameters in blood samples, including glucose, insulin, triglycerides, cholesterol, and liver enzymes. These data are presented in <xref rid="tbl1" ref-type="table">Table 1</xref>, highlighting the metabolic alterations induced by HFD, and showing that Andro treatment normalizes some of these changes. To assess whether Andro alters VAT's glucose metabolism, we measured glucose uptake (glucose-C<sup>14</sup>) in NCD and HFD-fed animals. Interestingly, HDF resulted in a strong increase in glucose uptake in VAT compared to NCD. In addition, while no differences were observed in the NCD group, Andro significantly reduced glucose uptake in the VAT of HFD-fed animals (<xref rid="fig1" ref-type="fig">Fig. 1</xref><italic toggle="yes">C</italic>). Further analysis of VAT glucose uptake over 180 s revealed that HFD-fed animals exhibited approximately a 40% increase compared to NCD controls at 180 s (<xref rid="fig1" ref-type="fig">Fig. 1</xref>, <italic toggle="yes">D</italic> and <italic toggle="yes">E</italic>). Significantly, Andro administration effectively lowered VAT glucose uptake in HFD-fed animals, reaching similar levels observed in NCD animals. To evaluate the systemic impact of Andro on glucose homeostasis, we performed a glucose tolerance test (GTT) in all experimental groups (<xref rid="fig1" ref-type="fig">Fig. 1</xref><italic toggle="yes">F</italic>). The area under the curve (AUC) analysis revealed a significant increase in glucose intolerance in HFD-fed animals compared to NCD controls. Importantly, Andro treatment significantly reduced the AUC in HFD-fed animals (<xref rid="fig1" ref-type="fig">Fig. 1</xref><italic toggle="yes">G</italic>), indicating a partial improvement in glucose tolerance.<fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p><bold>Andro reduces glucose uptake in VAT of HFD-fed animals.</bold><italic toggle="yes">A</italic>, schematic representation of experimental design. Four-month-old APP/PS1 mice were subjected to two dietary regimens: a normal chow diet (NCD) or a high-fat diet (HFD) and received 4 months of intraperitoneal Andro or saline injections until they were euthanized at 8 weeks of age. <italic toggle="yes">B</italic>, body weights of mice following indicated treatments. One-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. <italic toggle="yes">C</italic>, uptake of D [<sup>14</sup>C] Glucose of VAT measured at 15 s. One-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. <italic toggle="yes">D</italic>, D [<sup>14</sup>C] Glucose uptake kinetic curve of VAT obtained from NCD or HFD-fed animals, in the presence or absence of Andro, measured over 180 s. Two-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. <italic toggle="yes">E</italic>, uptake of D [<sup>14</sup>C] Glucose at 180 s of D. One-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. <italic toggle="yes">F</italic>, glucose tolerance measured over 120 min. <italic toggle="yes">G</italic>, graph depicting the area under the curve (AUC) of F. One-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. Data is represented as the mean values &#177; SD (n = 3&#8211;6 mice).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Metabolic and liver function parameters in APP/PS1 mice under different dietary conditions</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Blood parameters</th><th colspan="1" rowspan="1">NCD</th><th colspan="1" rowspan="1">NCD + Androndro</th><th colspan="1" rowspan="1">HFD</th><th colspan="1" rowspan="1">HFD + Andro</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Glucose (mg/ml)</td><td align="char" colspan="1" rowspan="1">93.2 &#177; 9.2</td><td align="char" colspan="1" rowspan="1">91.3 &#177; 5.8</td><td align="char" colspan="1" rowspan="1">140 &#177; 20.7</td><td align="char" colspan="1" rowspan="1">121.7 &#177; 19.8</td></tr><tr><td colspan="1" rowspan="1">Cholesterol (mg/dl)</td><td align="char" colspan="1" rowspan="1">124.7 &#177; 7.7</td><td align="char" colspan="1" rowspan="1">121 &#177; 11.3</td><td align="char" colspan="1" rowspan="1">191.3 &#177; 15</td><td align="char" colspan="1" rowspan="1">150.2 &#177; 12.8 &#8727;&#8727;&#8727;</td></tr><tr><td colspan="1" rowspan="1">HOMA-IR</td><td align="char" colspan="1" rowspan="1">0.2 &#177; 0.02</td><td align="char" colspan="1" rowspan="1">0.2 &#177; 0.01</td><td align="char" colspan="1" rowspan="1">1.3 &#177; 0.2</td><td align="char" colspan="1" rowspan="1">0.8 &#177; 0.1 &#8727;&#8727;&#8727;</td></tr><tr><td colspan="1" rowspan="1">Triglycerides (mg/dl)</td><td align="char" colspan="1" rowspan="1">87.3 &#177; 7</td><td align="char" colspan="1" rowspan="1">86 &#177; 5.8</td><td align="char" colspan="1" rowspan="1">166.8 &#177; 21.3</td><td align="char" colspan="1" rowspan="1">139.6 &#177; 11.4 &#8727;</td></tr><tr><td colspan="1" rowspan="1">Insulin (mU/L)</td><td align="char" colspan="1" rowspan="1">0.7 &#177; 0.08</td><td align="char" colspan="1" rowspan="1">0.7 &#177; 0.05</td><td align="char" colspan="1" rowspan="1">3.7 &#177; 0.4</td><td align="char" colspan="1" rowspan="1">2.7 &#177; 0.3 &#8727;&#8727;&#8727;</td></tr><tr><td colspan="1" rowspan="1">Alkaline phosphatase (UI/L)</td><td align="char" colspan="1" rowspan="1">74.72 &#177; 16.4</td><td align="char" colspan="1" rowspan="1">92.9 &#177; 12.3</td><td align="char" colspan="1" rowspan="1">85.5 &#177; 13.5</td><td align="char" colspan="1" rowspan="1">84.1 &#177; 12.5</td></tr><tr><td colspan="1" rowspan="1">AST (UI/L)</td><td align="char" colspan="1" rowspan="1">93.3 &#177; 11.3</td><td align="char" colspan="1" rowspan="1">96.4 &#177; 9.4</td><td align="char" colspan="1" rowspan="1">92.5 &#177; 6.8</td><td align="char" colspan="1" rowspan="1">87.7 &#177; 8.1</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>Values are presented as mean &#177; SD for each experimental group: normal chow diet (NCD), NCD + andrographolide (Andro), high-fat diet (HFD), and HFD + Andro. Statistical significance was assessed by one-way ANOVA followed by Bonferroni&#8217;s <italic toggle="yes">post hoc</italic> test.</p></fn><fn id="tspara0020"><p>&#8727;<italic toggle="yes">p</italic> &lt; 0.05, &#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.01, &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.001 vs. HFD group.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec1.2"><title>HFD-induced glycolysis is reversed by Andro, promoting the PPP pathway</title><p id="p0030">Due to the observed effect on glucose metabolism and to further characterize the impact of HFD and Andro on VAT on glucose metabolic pathways, we also investigated the rate of glycolysis in VAT. Our findings revealed a 3.5-fold increase in the rate of glycolysis in the VAT of HFD-fed animals compared to those on the NCD (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic toggle="yes">A</italic>). Notably, this effect was eliminated in animals that received Andro. Subsequently, we measured the activity of hexokinase (HK), an enzyme responsible for catalyzing the initial step in glycolysis. While HK activity showed no differences among the NCD groups, there was a significant increase in the VAT of HFD-fed animals (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic toggle="yes">B</italic>). Interestingly, the Andro administration reduced HK activity within the HFD group to levels even lower than those observed in the VAT of the NCD group. Once inside the cell, glucose can also undergo oxidation <italic toggle="yes">via</italic> the pentose phosphate pathway (PPP). Thus, to measure PPP rates, we administered VAT with 1-<sup>14</sup>C and 6-<sup>14</sup>C glucose and followed the <sup>14</sup>CO<sub>2</sub> release. Our results showed no differences in the rate of glucose metabolized by PPP in NCD animals, independent of the presence of Andro (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic toggle="yes">C</italic>). Conversely, HFD caused a modest, though statistically not significant, reduction in PPP rates compared to NCD groups. Interestingly, this effect was counteracted by the presence of Andro. Given the observed changes in PPP, and to validate our findings, we also measured the activity of glucose-6-phosphate dehydrogenase (G6PDH), a pivotal and rate-limiting enzyme in the PPP. Our results revealed an approximately 0.9-fold increase in G6PDH within the VAT of animals fed with NCD and treated with Andro in comparison to the control group (<xref rid="fig2" ref-type="fig">Fig. 2</xref><italic toggle="yes">D</italic>). Although we noted a substantial reduction in G6PDH activity in the VAT of HFD-fed animals compared to NCD, the presence of Andro did not rescue this effect. Together, our results suggest that HFD enhances glucose utilization in VAT through glycolysis while decreasing PPP activity. Notably, Andro effectively reverses these effects, restoring the metabolic profile.<fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p><bold>HFD promotes glycolysis in VAT and Andro mitigates this effect.</bold><italic toggle="yes">A</italic>, glycolytic rate, measured by <sup>3</sup>H<sub>2</sub>O production, of VAT after indicated treatments. One-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. <italic toggle="yes">B</italic>, hexokinase activity in VAT. One-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. <italic toggle="yes">C</italic>, pentose phosphate flux of VAT, measured by the rate of <sup>14</sup>CO<sub>2</sub> released from [1-<sup>14</sup>C] and [6-<sup>14</sup>C]. One-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. <italic toggle="yes">D</italic>, bar graph of the activity of glucose-6-phosphate dehydrogenase (G6PDH) in VAT. One-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. Data are represented as the mean values &#177; SD (n = 5 mice).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec><sec id="sec1.3"><title>Andro induces a decrease in ATP synthesis in the VAT of HFD-fed mice</title><p id="p0035">Next, to explore the impact of the observed glycolytic changes on ATP synthesis, we assessed ATP concentrations in VAT. Our findings indicated no alterations in ATP levels in the VAT among the NCD groups (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic toggle="yes">A</italic>). However, there was a notable increase in ATP levels in the VAT of HFD-fed mice. Interestingly, the administration of Andro led to a substantial 50% reduction in ATP levels in the VAT of HFD-fed mice, reaching similar levels observed in the NCD group. Next, we evaluated ADP levels and the ATP/ADP ratio to determine whether Andro&#8217;s effect on ATP was attributed to enhanced release or production. In the NCD group, Andro treatment induced a slight, though non-significant reduction in VAT&#8217;s ADP levels compared to the control animals (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic toggle="yes">B</italic>). However, when we compared the untreated NCD and HFD-fed animals, there was a significant decrease in the VAT&#8217;s ADP levels in the latter group. Interestingly, Andro treatment in HFD-fed animals increased the VAT&#8217;s ADP levels by approximately 40%, suggesting that Andro limited the synthesis of ATP in this group. As expected, no significant differences were observed in the ATP/ADP ratio among the NCD groups (<xref rid="fig3" ref-type="fig">Fig. 3</xref><italic toggle="yes">C</italic>). However, the HFD resulted in a threefold increase in the VAT&#8217;s ATP/ADP ratio in untreated animals compared to the Andro-treated group.<fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p><bold>Andro decreases ATP synthesis in VAT of HFD-fed mice.</bold> VAT of mice fed with either NCD or HFD, treated in the presence or absence of Andro, was isolated and (<italic toggle="yes">A</italic>) ATP levels, (<italic toggle="yes">B</italic>) ADP levels, and (<italic toggle="yes">C</italic>) the ATP/ADP ratio was measured accordingly. One-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. Data are represented as the mean values &#177; SD (n = 5 mice).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec><sec id="sec1.4"><title>Andro decreases the activity of glucose metabolic regulators in VAT</title><p id="p0040">To further investigate the impact of Andro on VAT, we also analyzed the activity of key metabolic regulators involved in glucose metabolism. We assessed the activity of phosphofructokinase 1 (PFK-1), AMP-activated protein kinase (AMPK), and pyruvate kinase. No significant differences in PFK-1, AMPK, and pyruvate kinase activities were observed when VAT was treated with Andro in NCD-fed mice compared to the control group (<xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic toggle="yes">A</italic>&#8211;<italic toggle="yes">C</italic>). However, in HFD-fed animals, a substantial increase in all enzymatic activities was noted. Andro treatment led to a significant reduction in PFK-1, AMPK, and pyruvate kinase activities in the VAT of HFD-fed animals (<xref rid="fig4" ref-type="fig">Fig. 4</xref>, <italic toggle="yes">A</italic>&#8211;<italic toggle="yes">C</italic>).<fig id="fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><p><bold>Andro decreases the activity of glucose metabolic regulators in VAT.</bold><italic toggle="yes">A</italic>, quantification of the activity of phosphofructokinase 1 (PFK-1). One-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. <italic toggle="yes">B</italic>, quantification of the concentration of AMP-activated protein kinase (AMPK) phosphorylated at Thr172. One-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. <italic toggle="yes">C</italic>, quantification of the activity of pyruvate kinase of VAT after indicated treatments. One-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. Data are represented as the mean values &#177; SD (n = 5 mice).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="sec1.5"><title>Insulin reduces the effect of Andro on glucose uptake in HFD-fed animals</title><p id="p0045">Next, we then monitored the uptake of glucose using various glucose uptake modulators or inhibitors such as lithium, insulin, cytochalasin (Cyt) B, or Cyt E. Given insulin&#8217;s role in regulating glucose uptake by promoting the glucose transporter 4 (Glut4) translocation to the cell membrane, we next explore the effect of insulin on glucose uptake (<xref rid="bib39" ref-type="bibr">39</xref>). As expected, insulin increased glucose uptake in both NCD-fed mice groups as compared to control NCD groups with no apparent Andro effect (<xref rid="fig5" ref-type="fig">Fig. 5</xref>). Notably, although the uptake of glucose rose significantly in insulin-treated HFD-fed animals, compared to the insulin-treated NCD group, the extent of the effect was similar as in untreated control HFD-fed mice. Importantly, in the presence of insulin, Andro led to a significant 14% decrease in glucose uptake in the HFD-fed mice group compared to control HFD mice. Lithium has been previously demonstrated to act as a stimulator of cerebral glucose metabolism (<xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref>). Thus, we evaluated whether lithium could alter glucose uptake in the VAT of APP/PS1 mice. In accordance with previous results, glucose uptake in the VAT of HFD-fed mice increased by approximately 30% compared to the VAT of the NCD-fed control group. On the other hand, Andro treatment reduced the glucose uptake by approximately 24% compared to the control group of HFD-fed mice. Next, we treated VAT with two inhibitors of actin polymerization, namely Cyt B, a robust inhibitor of glucose transporter, and Cyt E, an analog of Cyt B that does not impede glucose transport. As expected, Cyt B strongly suppressed glucose uptake in all mouse groups and Cyt E resulted in similar glucose uptake levels as in the untreated control conditions.<fig id="fig5" position="float" orientation="portrait"><label>Figure 5</label><caption><p><bold>Andro reduces glucose uptake in the VAT of HFD-fed mice in the presence of insulin and lithium.</bold> VAT obtained from animals fed with either NCD or HFD was treated with insulin, lithium (Li), cytochalasin B (Cyt B), or cytochalasin E (Cyt E), and glucose uptake was measured. Two-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. Data are represented as the mean values &#177; SD (n = 5 mice).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p></sec><sec id="sec1.6"><title>Andro regulates the mRNA expression of different metabolic genes in VAT</title><p id="p0050">Previous studies have shown that Andro alters the expression of various metabolic genes in the brain (<xref rid="bib43" ref-type="bibr">43</xref>). To comprehensively understand the impact of Andro on VAT, we also assessed the expression levels of several genes associated with glucose metabolic activity. First, we measured the expression changes of Glut1, crucial for basal glucose transport, and Glut4, the predominant isoform responsible for insulin-stimulated glucose uptake in adipocytes. Strikingly, Glut1 mRNA expression increased approximately 1-fold in the VAT of HFD-fed animals compared to the NCD control mice group (<xref rid="fig6" ref-type="fig">Fig. 6</xref><italic toggle="yes">A</italic>). However, Andro significantly reduced Glut1 expression in the HFD group. Interestingly, we observed opposite results on Glut4 expression (<xref rid="fig6" ref-type="fig">Fig. 6</xref><italic toggle="yes">B</italic>). Andro treatment in NCD-fed mice led to a &#8764;40% increase in Glut4 mRNA expression, while HFD-fed mice exhibited a significant &#8764;62% decrease compared to control animals. Notably, Andro treatment increased Glut4 expression by &#8764;2.6-fold compared to non-treated HFD-fed mice, reaching levels similar to those of control animals in NCD-fed mice.<fig id="fig6" position="float" orientation="portrait"><label>Figure 6</label><caption><p><bold>Andro regulates the mRNA expression of different metabolic genes in VAT.</bold> The VAT of mice subjected to NCD or HFD in the presence or absence of Andro was isolated and mRNA expression levels of (<italic toggle="yes">A</italic>) glucose transporter (GLUT) 1, (<italic toggle="yes">B</italic>) GLUT4, (<italic toggle="yes">C</italic>) AMP-activated protein kinase (AMPK), (<italic toggle="yes">D</italic>) phosphofructokinase 1 (PFK-1), (<italic toggle="yes">E</italic>) AKT, (<italic toggle="yes">F</italic>) hexokinase, (<italic toggle="yes">G</italic>) pyruvate kinase, (<italic toggle="yes">H</italic>) tumor necrosis factor (TNF)-&#945; and (<italic toggle="yes">I</italic>) acyl-CoA oxidase 1 (ACOX1) were measured. One-way ANOVA followed by Bonferroni's <italic toggle="yes">post hoc</italic> test was performed. Data are represented as the mean values &#177; SD (n = 5 mice).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p><p id="p0055">Subsequently, we examined the effect of Andro on the expression of key metabolic regulators, such as AMPK, PFK-1, Akt, HK, and pyruvate kinase. A slight but significant upregulation of AMPK was observed after Andro treatment in the NCD-fed animals, compared to the untreated animals (<xref rid="fig6" ref-type="fig">Fig. 6</xref><italic toggle="yes">C</italic>). However, the administration of HFD caused no changes in AMPK expression, independent of the presence of Andro. Next, we examined the mRNA expression of PFK-1 and observed no significant differences in animals on the NCD diet upon Andro treatment (<xref rid="fig6" ref-type="fig">Fig. 6</xref><italic toggle="yes">D</italic>). However, mice on the HFD diet exhibited a notable upregulation of PFK-1, which was downregulated by approximately 30% after Andro treatment. Additionally, we measured the expression levels of Akt, an energy sensor that plays a central role in glucose metabolism and is known to be altered in obesity (<xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref>). Abnormal Akt signaling is also associated with insulin resistance, type 2 diabetes, metabolic syndrome, and glucose and lipid metabolism disorders (<xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref>). Our findings showed an Andro-mediated increase in Akt expression in NCD-fed animals (<xref rid="fig6" ref-type="fig">Fig. 6</xref><italic toggle="yes">E</italic>). However, animals on HFD showed a strong downregulation of Akt expression in comparison to the lean animals, an effect that was reversed upon Andro treatment. Finally, we analyzed the expression changes of both hexokinase and pyruvate kinase. We found no significant differences in the expression levels of either gene among the groups (<xref rid="fig6" ref-type="fig">Fig. 6</xref>, <italic toggle="yes">F</italic> and <italic toggle="yes">G</italic>).</p><p id="p0060">In addition to these metabolic regulators, we also evaluated the mRNA expression of tumor necrosis factor alpha (TNF-&#945;), a key pro-inflammatory cytokine associated with metabolic inflammation in adipose tissue (<xref rid="bib47" ref-type="bibr">47</xref>) and acyl-CoA oxidase 1 (ACOX1), a peroxisomal enzyme involved in &#946;-oxidation (<xref rid="bib48" ref-type="bibr">48</xref>), to explore potential changes in inflammatory tone and fatty acid oxidation capacity in VAT. As shown in <xref rid="fig6" ref-type="fig">Figure 6</xref><italic toggle="yes">H</italic>, HFD feeding led to a significant upregulation of TNF-&#945; expression compared to the NCD group, indicating a heightened inflammatory state. Remarkably, Andro treatment significantly reduced TNF-&#945; expression in the HFD group, suggesting an anti-inflammatory effect of the compound in VAT. In contrast, no significant differences in ACOX1 expression were observed among the experimental groups (<xref rid="fig6" ref-type="fig">Fig. 6</xref><italic toggle="yes">I</italic>), suggesting that peroxisomal &#946;-oxidation is not substantially modulated by Andrographolide under the conditions tested.</p></sec></sec><sec id="sec2"><title>Discussion</title><p id="p0065">Obesity and an increase in VAT mass have been linked to cognitive impairment (<xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref>, <xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref>, <xref rid="bib54" ref-type="bibr">54</xref>, <xref rid="bib55" ref-type="bibr">55</xref>). While the precise mechanism remains elusive, accumulating evidence suggests that it may be attributed to the alteration of the adipose tissue-brain axis, involving the dysregulation of adipocyte-derived signaling molecules (<xref rid="bib56" ref-type="bibr">56</xref>, <xref rid="bib57" ref-type="bibr">57</xref>, <xref rid="bib58" ref-type="bibr">58</xref>, <xref rid="bib59" ref-type="bibr">59</xref>). Therefore, the use of pharmacological compounds capable of restoring adipocyte function holds great potential to alleviate AD symptoms (<xref rid="bib60" ref-type="bibr">60</xref>, <xref rid="bib61" ref-type="bibr">61</xref>). In this study, we demonstrate that Andro, a natural anti-diabetic compound known to enhance glucose metabolism in the brain (<xref rid="bib62" ref-type="bibr">62</xref>), successfully mitigated obesity-linked alterations in glucose metabolism in the VAT of APP-PS1 mice. These findings offer evidence supporting the potential therapeutic application of Andro in addressing metabolic dysregulations associated with obesity in AD.</p><p id="p0070">An unexpected finding was the elevated basal glucose uptake levels observed in HFD animals, compared to those on the NCD. This observation aligns with previous studies indicating increased glucose uptake in adipocytes derived from mice with obesity and in patients with diabetes mellitus (<xref rid="bib63" ref-type="bibr">63</xref>, <xref rid="bib64" ref-type="bibr">64</xref>, <xref rid="bib65" ref-type="bibr">65</xref>). Nevertheless, it remains controversial whether obesity alters glucose uptake since insulin resistance is strongly associated with reduced glucose uptake in insulin-responsive tissues (<xref rid="bib28" ref-type="bibr">28</xref>). Indeed, some groups have shown that obesity also inhibits or does not alter glucose uptake in adipose tissue (<xref rid="bib66" ref-type="bibr">66</xref>, <xref rid="bib67" ref-type="bibr">67</xref>). Interestingly, the increase in glucose uptake was also associated with the downregulation of Glut4 expression in HFD mice, whereas Glut1 expression was strongly upregulated. The insulin-regulated Glut4 is the most abundant transporter isoform in adipose tissue, and its expression is downregulated during obesity and type 2 diabetes (<xref rid="bib68" ref-type="bibr">68</xref>, <xref rid="bib69" ref-type="bibr">69</xref>, <xref rid="bib70" ref-type="bibr">70</xref>). Earlier research has also demonstrated impaired translocation and altered distribution of Glut4 in the adipose tissue of mouse models with diabetes (<xref rid="bib71" ref-type="bibr">71</xref>, <xref rid="bib72" ref-type="bibr">72</xref>, <xref rid="bib73" ref-type="bibr">73</xref>). Furthermore, the specific ablation of Glut4 in adipose tissue results in glucose intolerance, hyperinsulinemia, and insulin resistance (<xref rid="bib70" ref-type="bibr">70</xref>). Conversely, mice overexpressing adipose Glut4 exhibit enhanced glucose tolerance (<xref rid="bib74" ref-type="bibr">74</xref>). In contrast to Glut4, we observed a significant upregulation of Glut1 expression in HFD animals. An increase in Glut1 expression and protein levels has been previously reported in adipose tissue from obese mice (<xref rid="bib64" ref-type="bibr">64</xref>, <xref rid="bib75" ref-type="bibr">75</xref>, <xref rid="bib76" ref-type="bibr">76</xref>). Interestingly, despite being less abundant than Glut4 in adipocytes, Glut1 not only responds to insulin but also to a variety of other stimuli, making this protein less susceptible to the effects of diabetes (<xref rid="bib77" ref-type="bibr">77</xref>). Hence, the observed increase in glucose uptake may be caused by Glut1 upregulation or by other Glut members that facilitate glucose uptake in obesity, rather than Glut4 (<xref rid="bib64" ref-type="bibr">64</xref>, <xref rid="bib77" ref-type="bibr">77</xref>). In addition to the alterations in glucose uptake observed in VAT, our data reveal systemic metabolic changes induced by HFD and partially reversed by Andro treatment. Notably, Glut1/4 the ability of Andro to counteract HFD-induced alterations in metabolic parameters supports a systemic improvement in glucose handling. These findings suggest that Andrographolide not only modulates VAT-specific metabolism but also exerts beneficial effects on whole-body glucose homeostasis in APP/PS1 mice with obesity, thereby contributing to an overall improvement in metabolic health. This interpretation is further supported by the improved glucose clearance observed in the GTT, as evidenced by the significantly reduced AUC in Andrographolide-treated HFD-fed animals compared to their untreated counterparts. These findings suggest that Andrographolide improves systemic glucose disposal capacity in the context of diet-induced metabolic dysfunction.</p><p id="p0075">It is noteworthy that HFD stimulated glycolysis and reduced PPP, whereas Andro administration resulted in the opposite effect. Previous studies have indicated that hypoxia, a condition occurring in adipose tissue during obesity, not only increases glucose uptake but also upregulates the expression of various glycolysis-related genes, including Hexokinase and PFK-1 (<xref rid="bib78" ref-type="bibr">78</xref>, <xref rid="bib79" ref-type="bibr">79</xref>). Additionally, exposure of adipocytes to hypoxic conditions raises Glut1 levels and reduces Glut4 expression, potentially compromising insulin sensitivity (<xref rid="bib75" ref-type="bibr">75</xref>, <xref rid="bib80" ref-type="bibr">80</xref>). Further studies evaluating VAT hypoxia in APP-PS1 mice are needed to establish possible causal relationships between this condition and the expression of Glut1/4 and glycolysis-related molecules.</p><p id="p0080">In several AD models, impaired glucose metabolism in the brain has been consistently reported (<xref rid="bib81" ref-type="bibr">81</xref>, <xref rid="bib82" ref-type="bibr">82</xref>). Notably, reduced glucose utilization can be detected as early as 10 to 20 years before clinical symptoms appear (<xref rid="bib83" ref-type="bibr">83</xref>, <xref rid="bib84" ref-type="bibr">84</xref>, <xref rid="bib85" ref-type="bibr">85</xref>). This hypometabolism has been associated with decreased glucose uptake and mitochondrial dysfunction, contributing to the progression of the disease (<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib86" ref-type="bibr">86</xref>). During the early stages of AD, a compensatory upregulation of the PPP has been reported, likely aimed at counteracting oxidative stress. However, as the disease advances, this response becomes insufficient, leading to a simultaneous reduction in both oxidative phosphorylation and PPP activity, thereby exacerbating oxidative damage and neuronal dysfunction (<xref rid="bib87" ref-type="bibr">87</xref>, <xref rid="bib88" ref-type="bibr">88</xref>, <xref rid="bib89" ref-type="bibr">89</xref>, <xref rid="bib90" ref-type="bibr">90</xref>). Importantly, most of the literature on altered glucose metabolism in AD has focused on the brain, with limited information on peripheral tissues such as VAT. The findings reported in our study, namely a decrease in glycolytic flux and a restoration of PPP-related activity in VAT from APP/PS1 mice treated with Andrographolide, suggest that metabolic dysregulation in AD extends beyond the central nervous system. These results emphasize the relevance of further exploring peripheral metabolic pathways in AD to better understand systemic alterations associated with the disease (<xref rid="bib91" ref-type="bibr">91</xref>).</p><p id="p0085">The activation of AMPK, an enzyme that acts as an energy sensor, promotes glucose uptake and the generation of cellular ATP, while reducing ATP consumption (<xref rid="bib92" ref-type="bibr">92</xref>, <xref rid="bib93" ref-type="bibr">93</xref>, <xref rid="bib94" ref-type="bibr">94</xref>). Our findings suggest an increase in activated AMPK, high ATP levels, and an elevated ATP/ADP ratio in HFD-fed animals. This contrasts with previous studies showing HFD decreasing AMPK activity in adipose tissue from various rodent models and individuals with obesity (<xref rid="bib95" ref-type="bibr">95</xref>, <xref rid="bib96" ref-type="bibr">96</xref>, <xref rid="bib97" ref-type="bibr">97</xref>). However, to our knowledge, there are no studies involving the function of AMPK in AD models. Importantly, an increase in AMPK activation in adipose tissue has been shown to protect mice obesity on a HFD by increasing energy expenditure (<xref rid="bib98" ref-type="bibr">98</xref>). Conversely, the lack of AMPK activity in adipose tissue worsens the detrimental effects induced by a HFD and exacerbates insulin resistance (<xref rid="bib99" ref-type="bibr">99</xref>). Thus, the observed increase in AMPK activity in the VAT of HFD-fed animals might arise as a compensatory mechanism to alleviate diet-induced obesity. It is worth noting that leptin and adiponectin, two adipokines known to be altered in obesity, activate AMPK in adipose tissue (<xref rid="bib100" ref-type="bibr">100</xref>, <xref rid="bib101" ref-type="bibr">101</xref>). Therefore, it is possible that the observed activation of AMPK may be influenced by other pathways.</p><p id="p0090">Additionally, ATP has been shown to play a significant proinflammatory role (<xref rid="bib102" ref-type="bibr">102</xref>); the elevated ATP levels observed in the HFD-fed animals might also be linked to a systemic proinflammatory state. However, further studies are needed to determine whether these animals exhibit elevated inflammatory cytokines, as shown in AD-associated neuroinflammation (<xref rid="bib103" ref-type="bibr">103</xref>).</p><p id="p0095">Interestingly, we observed a reduction in glucose uptake in VAT together with reduced blood glucose concentration after Andro treatment. Previous studies conducted by our group and others have demonstrated that Andro promotes glucose uptake in a variety of tissues, including brain, pre- and mature adipocytes (<xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib33" ref-type="bibr">33</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib38" ref-type="bibr">38</xref>, <xref rid="bib62" ref-type="bibr">62</xref>, <xref rid="bib104" ref-type="bibr">104</xref>). Andro has also been shown to lower plasma glucose in diabetic rats, potentially by enhancing glucose uptake in muscle cells (<xref rid="bib105" ref-type="bibr">105</xref>). Thus, the observed decrease in blood glucose levels may be due to increased uptake by other organs. Interestingly, Andro's ability to enhance glucose uptake has mostly been observed in models unrelated to dementia. Therefore, the downregulation of glucose uptake by Andro in VAT from HFD-fed AD animals might be related to alterations caused by AD, such as systemic inflammation (<xref rid="bib106" ref-type="bibr">106</xref>). This could, at least in part, explain the reduced glucose uptake by adipose tissue in response to Andro treatment.</p><p id="p0100">Several studies have suggested that cognitive decline is exacerbated by insulin resistance, leading to a reduction of gray matter volume in several brain regions (<xref rid="bib107" ref-type="bibr">107</xref>). Moreover, dysregulated insulin/insulin-like growth factor signaling and insulin resistance in the central nervous system have been associated with an elevated risk of dementia, including Alzheimer's disease (<xref rid="bib108" ref-type="bibr">108</xref>, <xref rid="bib109" ref-type="bibr">109</xref>, <xref rid="bib110" ref-type="bibr">110</xref>, <xref rid="bib111" ref-type="bibr">111</xref>). On the other hand, the dysregulation of the Akt signaling pathway, which operates downstream of the insulin signaling, has been implicated in altered glucose metabolism, which is a key aspect of obesity-related metabolic dysfunction (<xref rid="bib112" ref-type="bibr">112</xref>, <xref rid="bib113" ref-type="bibr">113</xref>). Notably, Akt plays a crucial role in promoting the translation and translocation of Glut4, thereby enhancing glucose uptake (<xref rid="bib114" ref-type="bibr">114</xref>, <xref rid="bib115" ref-type="bibr">115</xref>). Interestingly, our study revealed a significant reduction in Akt expression, together with a downregulation of Glut4 in mice fed with an HFD. These findings align with existing evidence demonstrating diminished Akt levels in animals exposed to an HFD (<xref rid="bib116" ref-type="bibr">116</xref>).</p><p id="p0105">Consistent with the glucose-related effects observed in VAT, our findings also revealed that Andrographolide significantly reduced the expression of TNF-&#945; in HFD-fed mice. This result supports the anti-inflammatory potential of Andrographolide in adipose tissue, in agreement with previous reports demonstrating its ability to suppress inflammatory mediators in metabolic and neurodegenerative contexts (<xref rid="bib117" ref-type="bibr">117</xref>, <xref rid="bib118" ref-type="bibr">118</xref>). The marked upregulation of TNF-&#945; in adipose tissue during obesity is a well-established marker of adipose tissue dysfunction and insulin resistance (<xref rid="bib119" ref-type="bibr">119</xref>), and its attenuation by Andrographolide may contribute to the observed effects on glucose metabolic regulators in VAT. In contrast, ACOX1 expression remained unchanged among experimental groups, suggesting that Andrographolide&#8217;s metabolic actions in VAT are not mediated by modulation of peroxisomal lipid oxidation at the transcriptional level. Together, these findings indicate that the beneficial effects of Andrographolide on VAT glucose metabolism may be partially attributed to its anti-inflammatory actions, rather than to enhanced lipid catabolism; however, additional studies are necessary to confirm this hypothesis.</p><p id="p0110">Additionally, the inclusion of hepatic enzyme measurements in the current study provides further insight into the systemic metabolic impact of Andrographolide. The absence of significant alterations in these markers across groups suggests that Andrographolide does not induce hepatotoxicity and may preserve liver function under high-fat diet conditions, further supporting its metabolic safety profile.</p><p id="p0115">While our study represents the first exploration of Andro on VAT and its effects on AD, it comes with certain limitations. Although we demonstrated the restoration of adipocyte function after Andro treatment, we did not analyze its effect on AD. In earlier studies, both we and others have highlighted the positive implications of Andro in AD pathology (<xref rid="bib62" ref-type="bibr">62</xref>, <xref rid="bib120" ref-type="bibr">120</xref>, <xref rid="bib121" ref-type="bibr">121</xref>). Moreover, a recent study from our lab focused on the effect of adipokines in HFD-fed APP/PS1 mice. Interestingly, we observed alterations in A&#946; pathology, cognitive functions, and glucose metabolism, among others (<xref rid="bib122" ref-type="bibr">122</xref>). An additional limitation is the lack of a detailed mechanistic understanding of Andro in the VAT. In the brain, we have shown that Andro activates the Wnt signaling pathway by inhibiting glycogen synthase kinase-3&#946; (GSK-3&#946;) (<xref rid="bib123" ref-type="bibr">123</xref>, <xref rid="bib124" ref-type="bibr">124</xref>, <xref rid="bib125" ref-type="bibr">125</xref>). However, its role in the VAT has yet to be elucidated. Thus, future investigations should delve deeper into the molecular mechanisms underlying the effect of Andro, considering its potential in mitigating AD pathology.</p><p id="p0120">Previous studies have shown that Andrographolide can modulate key metabolic signaling pathways in wild-type models, including the activation of Wnt/&#946;-catenin signaling in C57BL/6J mice (<xref rid="bib123" ref-type="bibr">123</xref>) and the stimulation of glucose uptake and AMPK activation in primary hippocampal neurons from neonatal rats (<xref rid="bib36" ref-type="bibr">36</xref>). However, further research is needed to assess its impact on systemic metabolic health under physiological conditions.</p><p id="p0125">Although body weight was not significantly reduced by Andrographolide treatment, our findings suggest that the compound improves glucose metabolism in VAT through tissue-specific actions, independent of overall body weight changes. This interpretation aligns with recent clinical studies showing that metabolic benefits can occur without weight loss, even under stable body weight conditions (<xref rid="bib126" ref-type="bibr">126</xref>). These observations reinforce the notion that adipose tissue functionality, rather than mass alone, may be a critical target in metabolic interventions.</p><p id="p0130">A limitation of our study is the absence of a wild-type (WT) HFD-fed control group, which restricts our ability to fully discriminate between metabolic alterations driven by the APP/PS1 genotype and those induced solely by high-fat diet exposure. Nonetheless, evidence from previous studies in WT animals by Tapia-Rojas <italic toggle="yes">et al.</italic> (<xref rid="bib127" ref-type="bibr">127</xref>) demonstrated that Andrographolide exerts neuroprotective effects in WT mice through inhibition of GSK-3&#946; and activation of the canonical Wnt/&#946;-catenin pathway, a signaling cascade that is also implicated in adipose tissue homeostasis and inflammation. These findings suggest that Andrographolide may modulate metabolic function in a genotype-independent manner, although further studies directly comparing WT and transgenic models are warranted to confirm this hypothesis. In addition, the present study was conducted exclusively in male mice at 4 months of age. While this design minimizes hormonal variability and corresponds to young adulthood, a commonly used time point in metabolic studies, it may limit the generalizability of our findings. Future studies should therefore incorporate both sexes and different age groups to assess the broader translational potential of Andrographolide-based interventions.</p><p id="p0135">In summary, exploring the impact of Andro on adipose tissue metabolism yields promising insights into its potential applications, particularly in the context of AD. The observed improvements in glucose metabolism within VAT suggest a multifaceted impact of Andro on cellular responses. Considering the established connection between metabolic dysregulation, obesity, and the risk of developing AD, interventions that target adipose tissue functionality hold substantial promise. Thus, the dual role of Andro in mitigating both metabolic and neurodegenerative aspects of AD positions it as a valuable pharmacological candidate for further research.</p></sec><sec id="sec3"><title>Experimental procedures</title><sec id="sec3.1"><title>Animals and ethical standards</title><p id="p0140">Male APP/PS1 (RRID: MMRRC_34829-JAX) were used in this study. APP/PS1 animals co-express the Swedish (K594M/N595L) mutation of a chimeric mouse/human APP (Mo/HuAPP695swe) together with the human exon-9-deleted variant of PS1 (<xref rid="bib128" ref-type="bibr">128</xref>, <xref rid="bib129" ref-type="bibr">129</xref>). We divided the animals into four groups with five to six animals in each group (<xref rid="fig1" ref-type="fig">Fig. 1</xref><italic toggle="yes">A</italic>). In the first and second groups, 4-month-old animals were fed with NCD (with 10% energy from fat, #7024, TestDiet) and received intraperitoneal injections of vehicle (saline solution 0.9% NaCl) or Andro (2 mg/kg, #365645, Sigma-Aldrich), respectively (<xref rid="bib123" ref-type="bibr">123</xref>, <xref rid="bib130" ref-type="bibr">130</xref>). The third and fourth groups were fed an HFD, with 45% energy from fat, #58G8, (TestDiet), and received intraperitoneal injections of saline or Andro (2 mg/kg), respectively. Injections of either Andro or saline solution as a vehicle were carried out three times per week for 16 weeks. After treatments, animals were euthanized by decapitation following asphyxiation by isoflurane. After euthanasia, the VAT was removed from the regions around de branches of the superior and inferior mesenteric arteries. All the experiments were normalized by the protein expression of VAT samples. Animals were maintained at the Animal House Facility of the Pontificia Universidad Cat&#243;lica de Chile under a sanitary barrier in ventilated racks and in closed colonies; no sample calculation was performed. We used simple randomization to allocate mice to different cages. Experimental procedures were approved by the Bioethical and Biosafety Committee of the Faculty of Biological Sciences of the Pontificia Universidad Cat&#243;lica de Chile with the ethical approval CBB-158/2014. The inclusion/exclusion criteria for this study were the health of the animals after treatment; in this study, no animals were excluded. Measurements of animal weight, food, and liquid intake were obtained once per week during the treatment.</p></sec><sec id="sec3.2"><title>Biochemical analysis</title><p id="p0145">After treatments, glucose, cholesterol, insulin, triglycerides, alkaline phosphatase, and aspartate aminotransferase (AST) were measured from blood samples obtained from 5 to 6 mice per group. Intracardiac blood was collected before decapitation, after 6 h of fasting. Serum samples were obtained and stored at &#8722;20 &#176;C for later analysis. Glucose levels were measured according to the hexokinase/G-6-PDH method using Architect Analyzer (Abbott Laboratories). Insulin levels were measured <italic toggle="yes">via</italic> chemiluminescence (Beckman Coulter) and cholesterol levels were enzymatically assessed using an Architect c8000 analyzer. HOMA-IR, an insulin resistance index, was calculated using the following formula: HOMA-IR = fasting glucose (mmol/L) &#215; fasting insulin (mU/ml)/22.5. Triglycerides were assessed enzymatically using the Architect c8000 analyzer (Abbott Laboratories). Alkaline phosphatase activity was measured in the stool supernatant using an automatic biochemistry analyzer. For this, 20 &#956;l of supernatant was added to 1 ml of assay buffer containing p-nitrophenyl phosphate (pNPP) as a substrate and incubated for 1 min at 37 &#176;C. The resulting Alkaline phosphatase activity was then quantified by the analyzer, which was previously calibrated with Alkaline phosphatase standards (<xref rid="bib131" ref-type="bibr">131</xref>). AST was measured using an automatic blood chemical analyzer (Hitachi) (<xref rid="bib132" ref-type="bibr">132</xref>). For the GTT, after 30 days of special or standard diet, animals were fasted for 8 h and then received an injection of glucose (1 g/kg b.w., i.p.). Blood glucose was monitored at 20, 30, 60 and 120 min using a glucometer (Accu-Check) on samples collected from the tip of the tail vein. The AUC analysis was calculated using GraphPad software (<xref rid="bib133" ref-type="bibr">133</xref>).</p></sec><sec id="sec3.3"><title>Glucose uptake analysis</title><p id="p0150">The VAT was prepared according to standard procedures. Briefly, VAT samples were washed with washing buffer (15 mM HEPES [#H3375, Sigma Millipore], 135 mM NaCl [#s3014], 5 mM KCl [#P5405], 1.8 mM CaCl<sub>2</sub> [#C1016], and 0.8 mM MgCl<sub>2</sub> [#208337], all from Sigma-Aldrich (St Louis, MO, USA), supplemented with 0.5 mM glucose. The tissue was incubated with 1-1.2mCi D-[1-<sup>14</sup>C] glucose (#NEC043, PerkinElmer, MA, USA) at a final specific activity of 1 to 3 disintegrations/min/pmol (&#8764;1 mCi/mmol), for indicated periods. Glucose uptake was arrested by washing the VAT with ice-cold PBS supplemented with 1 mM HgCl<sub>2</sub> [#203777, Sigma- Aldrich]. The incorporated radioactivity was then quantified by liquid scintillation counting, as previously described by us (<xref rid="bib36" ref-type="bibr">36</xref>). All data were normalized to VAT protein content. When indicated, the VAT was incubated for 30 min with either insulin, Li<sub>2</sub>CO<sub>3</sub> [Li, 10 mM, #554-13-2], Cyt B [20 &#956;M, #C6762], or Cyt E [20 &#956;M, #C2149], reagents from Sigma-Aldrich.</p></sec><sec id="sec3.4"><title>Determination of the glycolytic rate</title><p id="p0155">Glycolytic rates were determined as previously described (<xref rid="bib122" ref-type="bibr">122</xref>). Briefly, VAT was placed in tubes containing 5 mM glucose and then washed twice in Krebs&#8211;Henseleit solution (11 mM Na<sub>2</sub>HPO<sub>4</sub>, 122 mM NaCl, 3.1 mM KCl, 0.4 mM KH<sub>2</sub>PO<sub>4</sub>, 1.2 mM MgSO<sub>4</sub>, and 1.3 mM CaCl<sub>2</sub>, pH 7.4) containing the appropriate concentration of glucose. After equilibration in 0.5 ml of Hank&#8217;s balanced salt solution/glucose [#14025076, Thermo Fisher, MA, USA] at 37 &#176;C for 30 min, 0.5 ml of Hank&#8217;s balanced salt solution containing various concentrations of D-[1-<sup>14</sup>C] glucose (#NEC043, PerkinElmer, MA, USA) was added, with a final specific activity of 1 to 3 disintegrations/min/pmol (&#8764;1 mCi/mmol). A vapor-phase equilibration step was performed by mixing the samples with water, and then the mixture was incubated at 45 &#176;C for 48 h. The <sup>3</sup>H<sub>2</sub>O content in the scintillation mixture was determined by counting over 5 min. We expressed the results in mg of protein per tissue.</p></sec><sec id="sec3.5"><title>Hexokinase activity</title><p id="p0160">To measure the hexokinase activity, the VAT was washed with PBS, treated with trypsin/EDTA, and centrifuged at 500<italic toggle="yes">g</italic> for 5 min at 4 &#176;C. Lysates were then resuspended in isolation medium (250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM DTT, 2 mg/ml aprotinin [#A1153], 1 mg/ml pepstatin A [#77170], and 2 mg/ml leupeptin [#L8511], reagents from Sigma-Aldrich (St Louis, MO, USA), at a 1:3 dilution, sonicated at 4 &#176;C, and then centrifuged at 1500<italic toggle="yes">g</italic> for 5 min at 4 &#176;C. The supernatant fraction was mixed with the reaction medium (25 mM Tris-HCl, 1 mM DTT, 0.5 mM NADP/Na<sup>+</sup>, 2 mM MgCl<sub>2</sub>, 1 mM ATP, 2 U/ml G6PDH, and 10 mM glucose), and incubated at 37 &#176;C for 30 min. The reaction was stopped by the addition of 10% trichloroacetic acid, TCA, [#T6399, Sigma- Aldrich ], and the generation of NADPH was measured at 340 nm (<xref rid="bib10" ref-type="bibr">10</xref>).</p></sec><sec id="sec3.6"><title>Pentose phosphate pathway (PPP) measurement</title><p id="p0165">Glucose oxidation <italic toggle="yes">via</italic> the PPP was measured based on the difference in <sup>14</sup>CO<sub>2</sub> production from D-[1-<sup>14</sup>C] glucose and D-[6-<sup>14</sup>C] glucose, as previously described (<xref rid="bib122" ref-type="bibr">122</xref>). To this end, VAT tissue was washed with ice-cold PBS and kept in O<sub>2</sub>-saturated Krebs Henseleit buffer. Samples were then placed in Erlenmeyer flasks with another 0.5 ml of the Krebs Henseleit solution containing 0.5 mCi D-[1-<sup>14</sup>C] glucose (#NEC043, PerkinElmer, MA, USA) or 2 mCi D-[6-<sup>14</sup>C] glucose (#NEC045, PerkinElmer) and 5.5 mM D-glucose (final concentration). The Erlenmeyer flasks were equipped with a central well containing an Eppendorf tube with 500 &#956;l of benzethonium hydroxide. The flasks were flushed with O<sub>2</sub> for 20 s, sealed with rubber caps, and incubated for 60 min in a 37 &#176;C water bath with shaking. The incubations were stopped by the injection of 0.2 ml of 1.75 M HClO<sub>4</sub> into the main well, and shaking was continued for another 20 min to facilitate the trapping of <sup>14</sup>CO<sub>2</sub> by benzethonium hydroxide. Radioactivity was assayed by liquid scintillation spectrometry.</p></sec><sec id="sec3.7"><title>Determination of G6PDH activity</title><p id="p0170">VAT tissue samples were washed with PBS, collected by trypsinization (0.25% trypsin- 0.2% EDTA (w/v)), and pelleted. The tissue samples were then resuspended in isolation medium (250 mM sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl<sub>2</sub>, 1 mM EDTA, 1 mM DTT, 2 mg/ml aprotinin, 1 mg/ml pepstatin A, and 2 mg/ml leupeptin) at a 1:3 dilution, sonicated at 4 &#176;C, and centrifuged for 5 min at 1500<italic toggle="yes">g</italic> at 4 &#176;C. Subsequently, the supernatant was further separated by centrifugation at 13,000<italic toggle="yes">g</italic> for 30 min at 4 &#176;C. Finally, the G6PDH activity of the supernatant was quantified in a reaction buffer containing 1 mM ATP and 10 mM glucose-6-phosphate (G6P) for 30 min at 37 &#176;C. The reaction was stopped by the addition of 10% TCA. The generation of NADPH was measured at 340 nm, as described previously (<xref rid="bib134" ref-type="bibr">134</xref>).</p></sec><sec id="sec3.8"><title>Quantification of ADP and ATP levels</title><p id="p0175">ATP and ADP levels were measured using an ATP determination kit [#A22066, Invitrogen/Molecular Probes] or an ADP assay Kit [#ab83359, Abcam, Cambridge, United Kingdom], respectively. The ADP/ATP ratio was measured accordingly (<xref rid="bib122" ref-type="bibr">122</xref>).</p></sec><sec id="sec3.9"><title>AMPK, phosphofructokinase-1 (PFK-1), and pyruvate kinase Activity</title><p id="p0180">AMPK activity was measured by ELISA according to the manufacturer&#8217;s instructions [#KHO0651, ThermoFisher Scientific]. PFK-1 activity was measured using a Colorimetric Assay Kit [#K776, BioVision] (<xref rid="bib135" ref-type="bibr">135</xref>). Pyruvate kinase activity was measured using a pyruvate kinase assay kit [#ab83432, Abcam] (<xref rid="bib136" ref-type="bibr">136</xref>, <xref rid="bib137" ref-type="bibr">137</xref>).</p></sec><sec id="sec3.10"><title>Quantitative real-time PCR (qRT-PCR)</title><p id="p0185">RNA was isolated from VAT and reverse transcribed into cDNA [#18091050, Invitrogen]. Quantitative real-time RT&#8211;PCR (qRT&#8211;PCR) was conducted using SYBR master mix [#4368577, ThermoFisher Scientific], with the program recommended by the manufacturer and as published previously (<xref rid="bib138" ref-type="bibr">138</xref>). As a reference, we used the housekeeping gene cyclophilin, and the relative Ct values of each gene were calculated using the delta Ct, in comparison with the control gene. Duplicated control reactions for every sample without reverse transcription were included to ensure that PCR products were not due to the amplification of contaminated genomic DNA. The sets of primers (IDT Integrated DNA Technologies, IA, USA) used are detailed in <xref rid="appsec1" ref-type="sec">Table S1</xref>.</p></sec><sec id="sec3.11"><title>Statistical analysis</title><p id="p0190">All Statistics were performed using the software Prism 9 (GraphPad). The results are expressed as means &#177; standard deviation (SD). Data were analyzed by one or two-way analysis of variance (ANOVA), followed by Bonferroni&#8217;s <italic toggle="yes">post hoc</italic> test; &#8727;<italic toggle="yes">p</italic> &lt; 0.05, &#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.01, and &#8727;&#8727;&#8727;<italic toggle="yes">p</italic> &lt; 0.001 were considered significant. To test the presence of outliers, we used the Prism software; however, no outliers were detected.</p></sec></sec><sec sec-type="data-availability" id="sec4"><title>Data availability</title><p id="p0195">Data will be made available on request.</p></sec><sec sec-type="supplementary-material" id="sec5"><title>Supporting information</title><p id="p0200">This article contains <xref rid="appsec1" ref-type="sec">supporting information</xref>.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Conflict of interest</title><p id="p0205">The authors declare that they do not have any conflicts of interest with the content of this article.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Serrano-Pozo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frosch</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Masliah</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B.T.</given-names></name></person-group><article-title>Neuropathological alterations in Alzheimer disease</article-title><source>Cold Spring Harb Perspect. Med.</source><volume>1</volume><year>2011</year><object-id pub-id-type="publisher-id">a006189</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a006189</pub-id><pub-id pub-id-type="pmcid">PMC3234452</pub-id><pub-id pub-id-type="pmid">22229116</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Henstridge</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Hyman</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Spires-Jones</surname><given-names>T.L.</given-names></name></person-group><article-title>Beyond the neuron&#8211;cellular interactions early in Alzheimer disease pathogenesis</article-title><source>Nat. Rev. Neurosci.</source><year>2019</year><pub-id pub-id-type="doi">10.1038/s41583-018-0113-1</pub-id><pub-id pub-id-type="pmcid">PMC6545070</pub-id><pub-id pub-id-type="pmid">30643230</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Holtzman</surname><given-names>D.M.</given-names></name></person-group><article-title>Alzheimer disease: an update on pathobiology and treatment strategies</article-title><source>Cell</source><volume>179</volume><year>2019</year><fpage>312</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">31564456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2019.09.001</pub-id><pub-id pub-id-type="pmcid">PMC6778042</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Protas</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Langbaum</surname><given-names>J.B.S.</given-names></name><name name-style="western"><surname>Fleisher</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for alzheimer disease</article-title><source>JAMA Neurol.</source><volume>70</volume><year>2013</year><fpage>320</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">23599929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/2013.jamaneurol.286</pub-id><pub-id pub-id-type="pmcid">PMC3745014</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Mosconi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pupi</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Leon</surname><given-names>M.</given-names></name></person-group><article-title>Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer&#8217;s disease</article-title><source>Ann. N. Y. Acad. Sci.</source><volume>1147</volume><year>2008</year><fpage>180</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">19076441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1196/annals.1427.007</pub-id><pub-id pub-id-type="pmcid">PMC2661241</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Willette</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Bendlin</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Starks</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Birdsill</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Christian</surname><given-names>B.T.</given-names></name><etal/></person-group><article-title>Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease</article-title><source>JAMA Neurol.</source><volume>72</volume><year>2015</year><fpage>1013</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">26214150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2015.0613</pub-id><pub-id pub-id-type="pmcid">PMC4570876</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>C.</given-names></name></person-group><article-title>Decoding Alzheimer&#8217;s disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies</article-title><source>Prog. Neurobiol.</source><volume>108</volume><year>2013</year><fpage>21</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">23850509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2013.06.004</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Gejl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brock</surname><given-names>B.</given-names></name><name name-style="western"><surname>Egefjord</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rungby</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gjedde</surname><given-names>A.</given-names></name></person-group><article-title>Blood-brain glucose transfer in Alzheimer&#8217;s disease: effect of GLP-1 analog treatment</article-title><source>Sci. Rep.</source><volume>7</volume><year>2017</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">29235507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-17718-y</pub-id><pub-id pub-id-type="pmcid">PMC5727512</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Niccoli</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cabecinha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tillmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Cardenes</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Increased glucose transport into neurons rescues A&#946; toxicity in Drosophila</article-title><source>Curr. Biol.</source><volume>26</volume><year>2016</year><fpage>2291</fpage><lpage>2300</lpage><pub-id pub-id-type="pmid">27524482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cub.2016.07.017</pub-id><pub-id pub-id-type="pmcid">PMC5026704</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Cisternas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zolezzi</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>V.I.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>N.C.</given-names></name></person-group><article-title>Wnt-induced activation of glucose metabolism mediates the in vivo neuroprotective roles of Wnt signaling in Alzheimer disease</article-title><source>J. Neurochem.</source><volume>149</volume><year>2019</year><fpage>54</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">30300917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.14608</pub-id><pub-id pub-id-type="pmcid">PMC7680578</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Craft</surname><given-names>S.</given-names></name></person-group><article-title>The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged</article-title><source>Arch. Neurol.</source><volume>66</volume><year>2009</year><fpage>300</fpage><lpage>305</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneurol.2009.27</pub-id><pub-id pub-id-type="pmcid">PMC2717716</pub-id><pub-id pub-id-type="pmid">19273747</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Rios</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cisternas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Arrese</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barja</surname><given-names>S.</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>R&#237;os</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Is Alzheimer&#8217;s disease related to metabolic syndrome? A Wnt signaling conundrum</article-title><source>Prog. Neurobiol.</source><volume>121</volume><year>2014</year><fpage>125</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">25084549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pneurobio.2014.07.004</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><collab>NCD Risk Factor Collaboration (NCD-RisC)</collab></person-group><article-title>Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults</article-title><source>Lancet</source><volume>403</volume><year>2024</year><fpage>1027</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">38432237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)02750-2</pub-id><pub-id pub-id-type="pmcid">PMC7615769</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Koliaki</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dalamaga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liatis</surname><given-names>S.</given-names></name></person-group><article-title>Update on the obesity epidemic: after the sudden rise, is the upward trajectory beginning to flatten?</article-title><source>Curr. Obes. Rep.</source><volume>12</volume><year>2023</year><fpage>514</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">37779155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13679-023-00527-y</pub-id><pub-id pub-id-type="pmcid">PMC10748771</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Flores-Cordero</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>P&#233;rez-P&#233;rez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jim&#233;nez-Cortegana</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alba</surname><given-names>G.</given-names></name><name name-style="western"><surname>Flores-Barrag&#225;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>S&#225;nchez-Margalet</surname><given-names>V.</given-names></name></person-group><article-title>Obesity as a risk factor for dementia and alzheimer&#8217;s disease: the role of leptin</article-title><source>Int. J. Mol. Sci.</source><volume>23</volume><year>2022</year><fpage>5202</fpage><pub-id pub-id-type="pmid">35563589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23095202</pub-id><pub-id pub-id-type="pmcid">PMC9099768</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Whitmer</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Gunderson</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Barrett-Connor</surname><given-names>E.</given-names></name><name name-style="western"><surname>Quesenberry</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Yaffe</surname><given-names>K.</given-names></name></person-group><article-title>Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study</article-title><source>Br. Med. J.</source><volume>330</volume><year>2005</year><fpage>1360</fpage><lpage>1362</lpage><pub-id pub-id-type="pmid">15863436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.38446.466238.E0</pub-id><pub-id pub-id-type="pmcid">PMC558283</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Atti</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Gatz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fratiglioni</surname><given-names>L.</given-names></name></person-group><article-title>Midlife overweight and obesity increase late-life dementia risk: a population-based twin study</article-title><source>Neurology</source><volume>76</volume><year>2011</year><fpage>1568</fpage><lpage>1574</lpage><pub-id pub-id-type="pmid">21536637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182190d09</pub-id><pub-id pub-id-type="pmcid">PMC3100125</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Fitzpatrick</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Kuller</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>O.L.</given-names></name><name name-style="western"><surname>Diehr</surname><given-names>P.</given-names></name><name name-style="western"><surname>O&#8217;Meara</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Longstreth</surname><given-names>W.T.</given-names><suffix>Jr.</suffix></name><etal/></person-group><article-title>Midlife and late-life obesity and the risk of dementia: cardiovascular health study</article-title><source>Arch. Neurol.</source><volume>66</volume><year>2009</year><fpage>336</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">19273752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneurol.2008.582</pub-id><pub-id pub-id-type="pmcid">PMC3513375</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Ishii</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iadecola</surname><given-names>C.</given-names></name></person-group><article-title>Adipocyte-derived factors in age-related dementia and their contribution to vascular and Alzheimer pathology</article-title><source>Biochim. Biophys. Acta Mol. Basis Dis.</source><year>2016</year><pub-id pub-id-type="doi">10.1016/j.bbadis.2015.10.029</pub-id><pub-id pub-id-type="pmcid">PMC4821723</pub-id><pub-id pub-id-type="pmid">26546479</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Parimisetty</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dorsemans</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Awada</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ravanan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Diotel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lefebvre d&#8217;Hellencourt</surname><given-names>C.</given-names></name></person-group><article-title>Secret talk between adipose tissue and central nervous system via secreted factors-an emerging frontier in the neurodegenerative research</article-title><source>J. Neuroinflammation</source><year>2016</year><pub-id pub-id-type="doi">10.1186/s12974-016-0530-x</pub-id><pub-id pub-id-type="pmcid">PMC4806498</pub-id><pub-id pub-id-type="pmid">27012931</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Autieri</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Scalia</surname><given-names>R.</given-names></name></person-group><article-title>Adipose tissue inflammation and metabolic dysfunction in obesity</article-title><source>Am. J. Physiol. Cell Physiol.</source><year>2021</year><pub-id pub-id-type="doi">10.1152/ajpcell.00379.2020</pub-id><pub-id pub-id-type="pmcid">PMC8294624</pub-id><pub-id pub-id-type="pmid">33356944</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Kiliaan</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Arnoldussen</surname><given-names>I.A.C.</given-names></name><name name-style="western"><surname>Gustafson</surname><given-names>D.R.</given-names></name></person-group><article-title>Adipokines: a link between obesity and dementia?</article-title><source>Lancet Neurol.</source><volume>13</volume><year>2014</year><fpage>913</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">25142458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(14)70085-7</pub-id><pub-id pub-id-type="pmcid">PMC4228955</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Forny-Germano</surname><given-names>L.</given-names></name><name name-style="western"><surname>De Felice</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Do Nascimento Vieira</surname><given-names>M.N.</given-names></name></person-group><article-title>The role of leptin and adiponectin in obesity-associated cognitive decline and Alzheimer&#8217;s disease</article-title><source>Front. Neurosci.</source><volume>12</volume><year>2019</year><fpage>1027</fpage><pub-id pub-id-type="pmid">30692905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2018.01027</pub-id><pub-id pub-id-type="pmcid">PMC6340072</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Misiak</surname><given-names>B.</given-names></name><name name-style="western"><surname>Leszek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kiejna</surname><given-names>A.</given-names></name></person-group><article-title>Metabolic syndrome, mild cognitive impairment and Alzheimer&#8217;s disease-The emerging role of systemic low-grade inflammation and adiposity</article-title><source>Brain Res. Bull</source><volume>89</volume><year>2012</year><fpage>144</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">22921944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainresbull.2012.08.003</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Ly</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>G.Z.</given-names></name><name name-style="western"><surname>Mian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meysami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Merrill</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Neuroinflammation: a modifiable pathway linking obesity, Alzheimer&#8217;s disease, and depression</article-title><source>Am. J. Geriatr. Psychiatry</source><volume>31</volume><year>2023</year><fpage>853</fpage><lpage>866</lpage><pub-id pub-id-type="pmid">37365110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jagp.2023.06.001</pub-id><pub-id pub-id-type="pmcid">PMC10528955</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>D.Q.C.</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Mesquita</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>K&#246;hler</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Hyphantis</surname><given-names>T.N.</given-names></name><etal/></person-group><article-title>Adipokines as emerging depression biomarkers: a systematic review and meta-analysis</article-title><source>J. Psychiatr. Res.</source><volume>59</volume><year>2014</year><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">25183029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpsychires.2014.08.002</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Won</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.W.</given-names></name></person-group><article-title>Association between visceral adipose tissue metabolism and Alzheimer&#8217;s disease pathology</article-title><source>Metabolites</source><year>2022</year><pub-id pub-id-type="doi">10.3390/metabo12030258</pub-id><pub-id pub-id-type="pmcid">PMC8949138</pub-id><pub-id pub-id-type="pmid">35323701</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Wondmkun</surname><given-names>Y.T.</given-names></name></person-group><article-title>Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications</article-title><source>Diabetes Metab. Syndr. Obes.</source><volume>13</volume><year>2020</year><fpage>3611</fpage><lpage>3616</lpage><pub-id pub-id-type="pmid">33116712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DMSO.S275898</pub-id><pub-id pub-id-type="pmcid">PMC7553667</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Muniesa</surname><given-names>P.</given-names></name><name name-style="western"><surname>M&#225;rtinez-Gonz&#225;lez</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Despr&#233;s</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Matsuzawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Loos</surname><given-names>R.J.F.</given-names></name><etal/></person-group><article-title>Obesity</article-title><source>Nat. Rev. Dis. Primers</source><year>2017</year><pub-id pub-id-type="doi">10.1038/nrdp.2017.34</pub-id><pub-id pub-id-type="pmid">28617414</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Kellar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Craft</surname><given-names>S.</given-names></name></person-group><article-title>Brain insulin resistance in Alzheimer&#8217;s disease and related disorders: mechanisms and therapeutic approaches</article-title><source>Lancet Neurol.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S1474-4422(20)30231-3</pub-id><pub-id pub-id-type="pmcid">PMC9661919</pub-id><pub-id pub-id-type="pmid">32730766</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Lii</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Shie</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.S.</given-names></name><etal/></person-group><article-title>Andrographis paniculata improves insulin resistance in high-fat diet-induced obese mice and TNF&#945;-treated 3T3-L1 adipocytes</article-title><source>Am. J. Chin. Med.</source><volume>48</volume><year>2020</year><fpage>1073</fpage><lpage>1090</lpage><pub-id pub-id-type="pmid">32668968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1142/S0192415X20500524</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>L.T.</given-names></name></person-group><article-title>Antioxidant, antioedema and analgesic activities of Andrographis paniculata extracts and their active constituent andrographolide</article-title><source>Phytother. Res.</source><volume>23</volume><year>2009</year><fpage>958</fpage><lpage>964</lpage><pub-id pub-id-type="pmid">19142986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ptr.2701</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Astuti</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Novitasari</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Tjandrawinata</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nugroho</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Pramono</surname><given-names>S.</given-names></name></person-group><article-title>Anti-diabetic effect of andrographolide from Sambiloto herbs (Andrographis paniculata (Burm.f.) Nees) through the expression of PPAR&#947; and GLUT-4 in adipocytes</article-title><source>Indones J. Biotechnol.</source><volume>27</volume><year>2022</year><fpage>203</fpage><lpage>211</lpage></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Nugroho</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Andrie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Warditiani</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Siswanto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pramono</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lukitaningsih</surname><given-names>E.</given-names></name></person-group><article-title>Antidiabetic and antihiperlipidemic effect of Andrographis paniculata (Burm. f.) Nees and andrographolide in high-fructose-fat-fed rats</article-title><source>Indian J. Pharmacol.</source><volume>44</volume><year>2012</year><fpage>377</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">22701250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0253-7613.96343</pub-id><pub-id pub-id-type="pmcid">PMC3371463</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Burgos</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Alarc&#243;n</surname><given-names>P.</given-names></name><name name-style="western"><surname>Quiroga</surname><given-names>J.</given-names></name><name name-style="western"><surname>Manosalva</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hancke</surname><given-names>J.</given-names></name></person-group><article-title>Andrographolide, an anti-inflammatory multitarget drug: all roads lead to cellular metabolism</article-title><source>Molecules</source><year>2021</year><pub-id pub-id-type="doi">10.3390/MOLECULES26010005</pub-id><pub-id pub-id-type="pmcid">PMC7792620</pub-id><pub-id pub-id-type="pmid">33374961</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Gherardelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cisternas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Guti&#233;rrez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>N.C.</given-names></name></person-group><article-title>Andrographolide restores glucose uptake in rat hippocampal neurons</article-title><source>J. Neurochem.</source><volume>157</volume><year>2021</year><fpage>1222</fpage><lpage>1233</lpage><pub-id pub-id-type="pmid">33124061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.15229</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.-M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name></person-group><article-title>Andrographolide inhibits non-small cell lung cancer cell proliferation through the activation of the mitochondrial apoptosis pathway and by reprogramming host glucose metabolism</article-title><source>Ann. Transl. Med.</source><volume>9</volume><year>2021</year><fpage>1701</fpage><pub-id pub-id-type="pmid">34988210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/atm-21-5975</pub-id><pub-id pub-id-type="pmcid">PMC8667159</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name></person-group><article-title>Andrographolide promotes uptake of glucose and GLUT4 transport through the PKC pathway in L6 cells</article-title><source>Pharmaceuticals</source><year>2022</year><pub-id pub-id-type="doi">10.3390/ph15111346</pub-id><pub-id pub-id-type="pmcid">PMC9698946</pub-id><pub-id pub-id-type="pmid">36355518</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Saltiel</surname><given-names>A.R.</given-names></name></person-group><article-title>Insulin signaling and the regulation of glucose transport</article-title><source>Mol. Med.</source><year>2004</year><pub-id pub-id-type="doi">10.2119/2005-00029.Saltiel</pub-id><pub-id pub-id-type="pmcid">PMC1431367</pub-id><pub-id pub-id-type="pmid">16307172</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Kohno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shiga</surname><given-names>T.</given-names></name><name name-style="western"><surname>Toyomaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kusumi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Matsuyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Inoue</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Effects of lithium on brain glucose metabolism in healthy men</article-title><source>J. Clin. Psychopharmacol.</source><volume>27</volume><year>2007</year><fpage>698</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">18004140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/jcp.0b013e31815a23c2</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Gherardelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cisternas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>N.C.</given-names></name></person-group><article-title>Lithium enhances hippocampal glucose metabolism in an in vitro mice model of Alzheimer&#8217;s disease</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><pub-id pub-id-type="doi">10.3390/ijms23158733</pub-id><pub-id pub-id-type="pmcid">PMC9368914</pub-id><pub-id pub-id-type="pmid">35955868</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Hollander</surname><given-names>E.</given-names></name><name name-style="western"><surname>Buchsbaum</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Haznedar</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Berenguer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Berlin</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Chaplin</surname><given-names>W.</given-names></name><etal/></person-group><article-title>FDG-PET study in pathological gamblers: 1. Lithium increases orbitofrontal, dorsolateral and cingulate metabolism</article-title><source>Neuropsychobiology</source><volume>58</volume><year>2008</year><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">18781089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000154478</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Gherardelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cisternas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vera-Salazar</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Mendez-Orellana</surname><given-names>C.</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>N.C.</given-names></name></person-group><article-title>Age- and sex-associated glucose metabolism decline in a mouse model of Alzheimer&#8217;s disease</article-title><source>J. Alzheimer Dis.</source><volume>87</volume><year>2022</year><fpage>901</fpage><lpage>917</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-215273</pub-id><pub-id pub-id-type="pmid">35404275</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Z.Q.</given-names></name></person-group><article-title>The PI3K/AKT pathway in obesity and type 2 diabetes</article-title><source>Int. J. Biol. Sci.</source><volume>14</volume><year>2018</year><fpage>1483</fpage><lpage>1496</lpage><pub-id pub-id-type="pmid">30263000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijbs.27173</pub-id><pub-id pub-id-type="pmcid">PMC6158718</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Manning</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Toker</surname><given-names>A.</given-names></name></person-group><article-title>AKT/PKB signaling: navigating the network</article-title><source>Cell</source><year>2017</year><pub-id pub-id-type="doi">10.1016/j.cell.2017.04.001</pub-id><pub-id pub-id-type="pmcid">PMC5546324</pub-id><pub-id pub-id-type="pmid">28431241</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J.</given-names></name></person-group><article-title>Akt: a potential drug target for metabolic syndrome</article-title><source>Front. Physiol.</source><year>2022</year><pub-id pub-id-type="doi">10.3389/fphys.2022.822333</pub-id><pub-id pub-id-type="pmcid">PMC8940245</pub-id><pub-id pub-id-type="pmid">35330934</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name></person-group><article-title>Inflammation-mediated metabolic regulation in adipose tissue</article-title><source>Obes. Rev.</source><year>2024</year><pub-id pub-id-type="doi">10.1111/OBR.13724</pub-id><pub-id pub-id-type="pmid">38408757</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>D.</given-names></name><name name-style="western"><surname>He</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mrad</surname><given-names>M.</given-names></name><name name-style="western"><surname>El Daibani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Liver ACOX1 regulates levels of circulating lipids that promote metabolic health through adipose remodeling</article-title><source>Nat. Commun.</source><year>2024</year><pub-id pub-id-type="doi">10.1038/S41467-024-48471-2</pub-id><pub-id pub-id-type="pmcid">PMC11101658</pub-id><pub-id pub-id-type="pmid">38760332</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>O.H.</given-names></name></person-group><article-title>Associations between metabolic syndrome and type of dementia: analysis based on the National Health Insurance Service database of Gangwon province in South Korea</article-title><source>Diabetol. Metab. Syndr.</source><year>2021</year><pub-id pub-id-type="doi">10.1186/s13098-020-00620-5</pub-id><pub-id pub-id-type="pmcid">PMC7789546</pub-id><pub-id pub-id-type="pmid">33407809</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Diehl-Wiesenecker</surname><given-names>E.</given-names></name><name name-style="western"><surname>Von Armin</surname><given-names>C.A.F.</given-names></name><name name-style="western"><surname>Dupuis</surname><given-names>L.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Ludolph</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Kassubek</surname><given-names>J.</given-names></name></person-group><article-title>Adipose tissue distribution in patients with Alzheimer&#8217;s disease: a whole body MRI case-control study</article-title><source>J. Alzheimer&#8217;s Dis.</source><volume>48</volume><year>2015</year><fpage>825</fpage><lpage>832</lpage><pub-id pub-id-type="pmid">26402111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-150426</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Koscik</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Norton</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carlsson</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Hypertension and obesity moderate the relationship between &#946;-amyloid and cognitive decline in midlife</article-title><source>Alzheimer&#8217;s Demen.</source><volume>15</volume><year>2019</year><fpage>418</fpage><lpage>428</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2018.09.008</pub-id><pub-id pub-id-type="pmcid">PMC6408972</pub-id><pub-id pub-id-type="pmid">30367828</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Papachristou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ramsay</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Lennon</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Papacosta</surname><given-names>O.</given-names></name><name name-style="western"><surname>Iliffe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Whincup</surname><given-names>P.H.</given-names></name><etal/></person-group><article-title>The relationships between body composition characteristics and cognitive functioning in a population-based sample of older British men</article-title><source>BMC Geriatr.</source><year>2015</year><pub-id pub-id-type="doi">10.1186/s12877-015-0169-y</pub-id><pub-id pub-id-type="pmcid">PMC4687114</pub-id><pub-id pub-id-type="pmid">26692280</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Nyberg</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Fjell</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Walhovd</surname><given-names>K.B.</given-names></name></person-group><article-title>Level of body fat relates to memory decline and interacts with age in its association with hippocampal and subcortical atrophy</article-title><source>Neurobiol. Aging</source><volume>91</volume><year>2020</year><fpage>112</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">32224068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2019.10.005</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Andrieu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suckling</surname><given-names>J.</given-names></name><name name-style="western"><surname>Evangelou</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Evidence-based prevention of Alzheimer&#8217;s disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><year>2020</year><pub-id pub-id-type="doi">10.1136/jnnp-2019-321913</pub-id><pub-id pub-id-type="pmcid">PMC7569385</pub-id><pub-id pub-id-type="pmid">32690803</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Bracko</surname><given-names>O.</given-names></name><name name-style="western"><surname>Vinarcsik</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Cruz Hern&#225;ndez</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Ruiz-Uribe</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Haft-Javaherian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Falkenhain</surname><given-names>K.</given-names></name><etal/></person-group><article-title>High fat diet worsens Alzheimer&#8217;s disease-related behavioral abnormalities and neuropathology in APP/PS1 mice, but not by synergistically decreasing cerebral blood flow</article-title><source>Sci. Rep.</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41598-020-65908-y</pub-id><pub-id pub-id-type="pmcid">PMC7303150</pub-id><pub-id pub-id-type="pmid">32555372</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>van Galen</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Schrantee</surname><given-names>A.</given-names></name><name name-style="western"><surname>ter Horst</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>la Fleur</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Booij</surname><given-names>J.</given-names></name><name name-style="western"><surname>Constable</surname><given-names>R.T.</given-names></name><etal/></person-group><article-title>Brain responses to nutrients are severely impaired and not reversed by weight loss in humans with obesity: a randomized crossover study</article-title><source>Nat. Metab.</source><volume>5</volume><year>2023</year><fpage>1059</fpage><lpage>1072</lpage><pub-id pub-id-type="pmid">37308722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-023-00816-9</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Fain</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Hiler</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Cheema</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bahouth</surname><given-names>S.W.</given-names></name></person-group><article-title>Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans</article-title><source>Endocrinology</source><volume>145</volume><year>2004</year><fpage>2273</fpage><lpage>2282</lpage><pub-id pub-id-type="pmid">14726444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2003-1336</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Anand</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Friedrich</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Awadalla</surname><given-names>P.</given-names></name><name name-style="western"><surname>Despr&#233;s</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Evaluation of adiposity and cognitive function in adults</article-title><source>JAMA Netw. Open</source><volume>5</volume><year>2022</year><object-id pub-id-type="publisher-id">e2146324</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.46324</pub-id><pub-id pub-id-type="pmcid">PMC8808326</pub-id><pub-id pub-id-type="pmid">35103790</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Oliveras-Ca&#241;ellas</surname><given-names>N.</given-names></name><name name-style="western"><surname>Castells-Nobau</surname><given-names>A.</given-names></name><name name-style="western"><surname>de la Vega-Correa</surname><given-names>L.</given-names></name><name name-style="western"><surname>Latorre-Luque</surname><given-names>J.</given-names></name><name name-style="western"><surname>Motger-Albert&#237;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arnoriaga-Rodriguez</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Adipose tissue coregulates cognitive function</article-title><source>Sci. Adv.</source><year>2023</year><pub-id pub-id-type="doi">10.1126/sciadv.adg4017</pub-id><pub-id pub-id-type="pmcid">PMC10421051</pub-id><pub-id pub-id-type="pmid">37566655</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Michailidis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tata</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Moraitou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kavvadas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Karachrysafi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Papamitsou</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Antidiabetic drugs in the treatment of Alzheimer&#8217;s disease</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><pub-id pub-id-type="doi">10.3390/ijms23094641</pub-id><pub-id pub-id-type="pmcid">PMC9102472</pub-id><pub-id pub-id-type="pmid">35563031</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Boccardi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Murasecco</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mecocci</surname><given-names>P.</given-names></name></person-group><article-title>Diabetes drugs in the fight against Alzheimer&#8217;s disease</article-title><source>Ageing Res. Rev.</source><year>2019</year><pub-id pub-id-type="doi">10.1016/j.arr.2019.100936</pub-id><pub-id pub-id-type="pmid">31330313</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Cisternas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Oliva</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>V.I.</given-names></name><name name-style="western"><surname>Barrera</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>N.C.</given-names></name></person-group><article-title>Presymptomatic treatment with andrographolide improves brain metabolic markers and cognitive behavior in a model of early-onset Alzheimer&#8217;s disease</article-title><source>Front Cell Neurosci.</source><volume>13</volume><year>2019</year><fpage>295</fpage><pub-id pub-id-type="pmid">31379502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2019.00295</pub-id><pub-id pub-id-type="pmcid">PMC6657419</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Czech</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Gitomer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Heinrich</surname><given-names>J.</given-names></name></person-group><article-title>Insulin response in skeletal muscle and fat cells of the genetically obese Zucker rat</article-title><source>Metabolism</source><year>1978</year><pub-id pub-id-type="doi">10.1016/S0026-0495(78)80013-4</pub-id><pub-id pub-id-type="pmid">723645</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Talior</surname><given-names>I.</given-names></name><name name-style="western"><surname>Yarkoni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bashan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Eldar-Finkelman</surname><given-names>H.</given-names></name></person-group><article-title>Increased glucose uptake promotes oxidative stress and PKC-&#948; activation in adipocytes of obese, insulin-resistant mice</article-title><source>Am. J. Physiol. Endocrinol. Metab.</source><volume>285</volume><year>2003</year><fpage>E295</fpage><lpage>E302</lpage><pub-id pub-id-type="pmid">12857675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpendo.00044.2003</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Raineri-Maldonado</surname><given-names>C.</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pories</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Carter-Su</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pilch</surname><given-names>P.F.</given-names></name><etal/></person-group><article-title>Adipose tissue glucose transporters in NIDDM. Decreased levels of muscle/fat isoform</article-title><source>Diabetes</source><volume>40</volume><year>1991</year><fpage>472</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">2010047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diab.40.4.472</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Stolic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hutley</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fielding</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hay</surname><given-names>J.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Glucose uptake and insulin action in human adipose tissue- Influence of BMI, anatomical depot and body fat distribution</article-title><source>Int. J. Obes.</source><volume>26</volume><year>2002</year><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.ijo.0801850</pub-id><pub-id pub-id-type="pmid">11791142</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Molina</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Ciaraldi</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Brady</surname><given-names>D.</given-names></name><name name-style="western"><surname>Olefsky</surname><given-names>J.M.</given-names></name></person-group><article-title>Decreased activation rate of insulin-stimulated glucose transport in adipocytes from obese subjects</article-title><source>Diabetes</source><volume>38</volume><year>1989</year><fpage>991</fpage><lpage>995</lpage><pub-id pub-id-type="pmid">2666204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diab.38.8.991</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Kahn</surname><given-names>B.B.</given-names></name></person-group><article-title>Adipose tissue, inter-organ communication, and the path to type 2 diabetes: the 2016 banting medal for scientific achievement lecture</article-title><source>Diabetes</source><volume>68</volume><year>2019</year><fpage>3</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">30573674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dbi18-0035</pub-id><pub-id pub-id-type="pmcid">PMC6302542</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Hussey</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>McGee</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Garnham</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wentworth</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Jeukendrup</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Hargreaves</surname><given-names>M.</given-names></name></person-group><article-title>Exercise training increases adipose tissue GLUT4 expression in patients with type 2 diabetes</article-title><source>Diabetes Obes. Metab.</source><volume>13</volume><year>2011</year><fpage>959</fpage><lpage>962</lpage><pub-id pub-id-type="pmid">21615668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1463-1326.2011.01426.x</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Abel</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Peroni</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Boss</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hadro</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver</article-title><source>Nature</source><volume>409</volume><year>2001</year><fpage>729</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">11217863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/35055575</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Miura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ishihara</surname><given-names>E.</given-names></name><name name-style="western"><surname>Arai</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>H.</given-names></name><name name-style="western"><surname>Seino</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Impairment of insulin-stimulated GLUT4 translocation in skeletal muscle and adipose tissue in the Tsumura Suzuki obese diabetic mouse: a new genetic animal model of type 2 diabetes</article-title><source>Eur. J. Endocrinol.</source><volume>145</volume><year>2001</year><fpage>785</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">11720905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/eje.0.1450785</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Favaretto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Milan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Collin</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Stasi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Maffei</surname><given-names>P.</given-names></name><etal/></person-group><article-title>GLUT4 defects in adipose tissue are early signs of metabolic alterations in alms1GT/GT, a mouse model for obesity and insulin resistance</article-title><source>PLoS One</source><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0109540</pub-id><pub-id pub-id-type="pmcid">PMC4192353</pub-id><pub-id pub-id-type="pmid">25299671</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Maianu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Keller</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Garvey</surname><given-names>W.T.</given-names></name></person-group><article-title>Adipocytes exhibit abnormal subcellular distribution and translocation of vesicles containing glucose transporter 4 and insulin-regulated aminopeptidase in type 2 diabetes mellitus: implications regarding defects in vesicle trafficking</article-title><source>J. Clin. Endocrinol. Metab.</source><volume>86</volume><year>2001</year><fpage>5450</fpage><lpage>5456</lpage><pub-id pub-id-type="pmid">11701721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jcem.86.11.8053</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Shepherd</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Gnudi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tozzo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Leach</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>B.B.</given-names></name></person-group><article-title>Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue</article-title><source>J. Biol. Chem.</source><volume>268</volume><year>1993</year><fpage>22243</fpage><lpage>22246</lpage><pub-id pub-id-type="pmid">8226728</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name></person-group><article-title>Role of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue</article-title><source>Am. J. Physiol. Endocrinol. Metab.</source><year>2009</year><pub-id pub-id-type="doi">10.1152/ajpendo.90760.2008</pub-id><pub-id pub-id-type="pmcid">PMC2645021</pub-id><pub-id pub-id-type="pmid">19066318</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>B.B.</given-names></name></person-group><article-title>Divergent regulation of the Glut 1 and Glut 4 glucose transporters in isolated adipocytes from Zucker rats</article-title><source>J. Clin. Invest.</source><volume>89</volume><year>1992</year><fpage>1964</fpage><lpage>1973</lpage><pub-id pub-id-type="pmid">1534819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI115804</pub-id><pub-id pub-id-type="pmcid">PMC295898</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Chadt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Hasani</surname><given-names>H.</given-names></name></person-group><article-title>Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease</article-title><source>Pflugers Arch.</source><volume>472</volume><year>2020</year><fpage>1273</fpage><lpage>1298</lpage><pub-id pub-id-type="pmid">32591906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00424-020-02417-x</pub-id><pub-id pub-id-type="pmcid">PMC7462924</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Trayhurn</surname><given-names>P.</given-names></name></person-group><article-title>Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity</article-title><source>Annu. Rev. Nutr.</source><volume>34</volume><year>2014</year><fpage>207</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">24819450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-nutr-071812-161156</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Trayhurn</surname><given-names>P.</given-names></name></person-group><article-title>PCR arrays identify metallothionein-3 as a highly hypoxia-inducible gene in human adipocytes</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>368</volume><year>2008</year><fpage>88</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">18206644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2008.01.036</pub-id><pub-id pub-id-type="pmcid">PMC2635530</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lorente-Cebri&#225;n</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trayhurn</surname><given-names>P.</given-names></name></person-group><article-title>Hypoxia increases expression of selective facilitative glucose transporters (GLUT) and 2-deoxy-d-glucose uptake in human adipocytes</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>361</volume><year>2007</year><fpage>468</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">17658463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2007.07.032</pub-id><pub-id pub-id-type="pmcid">PMC2211375</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Butterfield</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Halliwell</surname><given-names>B.</given-names></name></person-group><article-title>Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease</article-title><source>Nat. Rev. Neurosci.</source><year>2019</year><pub-id pub-id-type="doi">10.1038/s41583-019-0132-6</pub-id><pub-id pub-id-type="pmcid">PMC9382875</pub-id><pub-id pub-id-type="pmid">30737462</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><comment>[preprint]</comment><person-group person-group-type="author"><name name-style="western"><surname>Minhas</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Latif-Hernandez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sugiura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Durairaj</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Uenaka</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Restoring hippocampal glucose metabolism rescues cognition across Alzheimer&#8217;s disease pathologies</article-title><source>bioRxiv</source><year>2024</year><pub-id pub-id-type="doi">10.1101/2024.06.23.598940</pub-id><pub-id pub-id-type="pmcid">PMC12313320</pub-id><pub-id pub-id-type="pmid">39172838</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Mosconi</surname><given-names>L.</given-names></name></person-group><article-title>Glucose metabolism in normal aging and Alzheimer&#8217;s disease: methodological and physiological considerations for PET studies</article-title><source>Clin. Transl. Imaging</source><volume>1</volume><year>2013</year><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40336-013-0026-y</pub-id><pub-id pub-id-type="pmcid">PMC3881550</pub-id><pub-id pub-id-type="pmid">24409422</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Mosconi</surname><given-names>L.</given-names></name></person-group><article-title>Brain glucose metabolism in the early and specific diagnosis of Alzheimer&#8217;s disease: FDG-PET studies in MCI and AD</article-title><source>Eur. J. Nucl. Med. Mol. Imaging</source><volume>32</volume><year>2005</year><fpage>486</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">15747152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-005-1762-7</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>Mosconi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Berti</surname><given-names>V.</given-names></name><name name-style="western"><surname>Glodzik</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pupi</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Santi</surname><given-names>S.</given-names></name><name name-style="western"><surname>de Leon</surname><given-names>M.J.</given-names></name></person-group><article-title>Pre-clinical detection of Alzheimer&#8217;s disease using FDG-PET, with or without amyloid imaging</article-title><source>J. Alzheimer Dis.</source><volume>23</volume><year>2010</year><fpage>843</fpage><lpage>854</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-2010-091504</pub-id><pub-id pub-id-type="pmcid">PMC3038340</pub-id><pub-id pub-id-type="pmid">20182025</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Cisternas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>N.C.</given-names></name></person-group><article-title>Brain glucose metabolism: role of Wnt signaling in the metabolic impairment in Alzheimer&#8217;s disease</article-title><source>Neurosci. Biobehav Rev.</source><volume>80</volume><year>2017</year><fpage>316</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">28624434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neubiorev.2017.06.004</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-rodriguez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bola&#241;os</surname><given-names>J.P.</given-names></name></person-group><article-title>Neurochemistry International Brain energy metabolism in glutamate-receptor activation and excitotoxicity : role for APC/C-Cdh1 in the balance glycolysis/pentose phosphate pathway</article-title><source>Neurochem. Int.</source><volume>62</volume><year>2013</year><fpage>750</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">23416042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuint.2013.02.005</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Bolanos</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>A.</given-names></name></person-group><article-title>The pentose-phosphate pathway in neuronal survival against nitrosative stress</article-title><source>IUBMB Life.</source><volume>62</volume><year>2010</year><fpage>14</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">19937972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/iub.280</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Bola&#241;os</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Delgado-Esteban</surname><given-names>M.</given-names></name><name name-style="western"><surname>Herrero-Mendez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fernandez-Fernandez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>A.</given-names></name></person-group><article-title>Regulation of glycolysis and pentose-phosphate pathway by nitric oxide: impact on neuronal survival</article-title><source>Biochim. Biophys. Acta</source><volume>1777</volume><year>2008</year><fpage>789</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">18455501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbabio.2008.04.011</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Rodriguez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bola&#241;os</surname><given-names>J.P.</given-names></name></person-group><article-title>Underestimation of the pentose-phosphate pathway in intact primary neurons as revealed by metabolic flux analysis</article-title><source>J. Cereb. Blood Flow Metab.</source><volume>33</volume><year>2013</year><fpage>1843</fpage><lpage>1845</lpage><pub-id pub-id-type="pmid">24064491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jcbfm.2013.168</pub-id><pub-id pub-id-type="pmcid">PMC3851909</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Trushina</surname><given-names>E.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease mechanisms in peripheral cells: Promises and challenges</article-title><source>Alzheimer&#8217;s Demen.</source><volume>5</volume><year>2019</year><fpage>652</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trci.2019.06.008</pub-id><pub-id pub-id-type="pmcid">PMC6838468</pub-id><pub-id pub-id-type="pmid">31720366</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Hardie</surname><given-names>D.G.</given-names></name></person-group><article-title>AMP-activated protein kinase-an energy sensor that regulates all aspects of cell function</article-title><source>Genes Dev.</source><year>2011</year><pub-id pub-id-type="doi">10.1101/gad.17420111</pub-id><pub-id pub-id-type="pmcid">PMC3185962</pub-id><pub-id pub-id-type="pmid">21937710</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Mihaylova</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>R.J.</given-names></name></person-group><article-title>The AMP-activated protein kinase (AMPK) signaling pathway coordinates cell growth, autophagy, &amp; metabolism</article-title><source>Nat. Cell Biol.</source><volume>13</volume><year>2011</year><fpage>1016</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">21892142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncb2329</pub-id><pub-id pub-id-type="pmcid">PMC3249400</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Salt</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Connell</surname><given-names>J.M.C.</given-names></name><name name-style="western"><surname>Gould</surname><given-names>G.W.</given-names></name></person-group><article-title>5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR) inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes</article-title><source>Diabetes</source><volume>49</volume><year>2000</year><fpage>1649</fpage><lpage>1656</lpage><pub-id pub-id-type="pmid">11016448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diabetes.49.10.1649</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>Lindholm</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Ertel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Bauwens</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Schmuck</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Mulligan</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Saupe</surname><given-names>K.W.</given-names></name></person-group><article-title>A high-fat diet decreases AMPK activity in multiple tissues in the absence of hyperglycemia or systemic inflammation in rats</article-title><source>J. Physiol. Biochem.</source><volume>69</volume><year>2013</year><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">22941749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13105-012-0199-2</pub-id><pub-id pub-id-type="pmcid">PMC3644018</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>High-fat diet-induced diabetes couples to Alzheimer&#8217;s disease through inflammation-activated C/EBP&#946;/AEP pathway</article-title><source>Mol. Psychiatry</source><volume>27</volume><year>2022</year><fpage>3396</fpage><lpage>3409</lpage><pub-id pub-id-type="pmid">35546632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41380-022-01600-z</pub-id><pub-id pub-id-type="pmcid">PMC10032575</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Gauthier</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Bigornia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mott</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cacicedo</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.J.</given-names></name><etal/></person-group><article-title>Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>404</volume><year>2011</year><fpage>382</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">21130749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2010.11.127</pub-id><pub-id pub-id-type="pmcid">PMC3061625</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Pollard</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>L.</given-names></name><name name-style="western"><surname>Muckett</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Khadayate</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bornot</surname><given-names>A.</given-names></name><name name-style="western"><surname>Clausen</surname><given-names>M.</given-names></name><etal/></person-group><article-title>AMPK activation protects against diet-induced obesity through Ucp1-independent thermogenesis in subcutaneous white adipose tissue</article-title><source>Nat. Metab.</source><year>2019</year><pub-id pub-id-type="doi">10.1038/s42255-019-0036-9</pub-id><pub-id pub-id-type="pmcid">PMC6420092</pub-id><pub-id pub-id-type="pmid">30887000</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Mottillo</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Desjardins</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Crane</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Green</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Ducommun</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Lack of adipocyte AMPK exacerbates insulin resistance and hepatic steatosis through Brown and beige adipose tissue function</article-title><source>Cell Metab.</source><volume>24</volume><year>2016</year><fpage>118</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">27411013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2016.06.006</pub-id><pub-id pub-id-type="pmcid">PMC5239668</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Sell</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dietze-Schroeder</surname><given-names>D.</given-names></name><name name-style="western"><surname>Eckardt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Eckel</surname><given-names>J.</given-names></name></person-group><article-title>Cytokine secretion by human adipocytes is differentially regulated by adiponectin, AICAR, and troglitazone</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>343</volume><year>2006</year><fpage>700</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">16563350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2006.03.010</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Orci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Ravazzola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Montesano</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Rapid transformation of white adipocytes into fat-oxidizing machines</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>101</volume><year>2004</year><fpage>2058</fpage><lpage>2063</lpage><pub-id pub-id-type="pmid">14769942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0308258100</pub-id><pub-id pub-id-type="pmcid">PMC357051</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Cauwels</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rogge</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vandendriessche</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shiva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brouckaert</surname><given-names>P.</given-names></name></person-group><article-title>Extracellular ATP drives systemic inflammation, tissue damage and mortality</article-title><source>Cell Death Dis.</source><year>2014</year><pub-id pub-id-type="doi">10.1038/cddis.2014.70</pub-id><pub-id pub-id-type="pmcid">PMC3973196</pub-id><pub-id pub-id-type="pmid">24603330</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Rani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chawla</surname><given-names>R.</given-names></name></person-group><article-title>Role of pro-inflammatory cytokines in Alzheimer&#8217;s disease and neuroprotective effects of pegylated self-assembled nanoscaffolds</article-title><source>Curr. Res. Pharmacol. Drug Discov.</source><year>2023</year><pub-id pub-id-type="doi">10.1016/j.crphar.2022.100149</pub-id><pub-id pub-id-type="pmcid">PMC9804106</pub-id><pub-id pub-id-type="pmid">36593925</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>Andrographolide attenuates tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes</article-title><source>Mol. Cell Endocrinol.</source><year>2011</year><pub-id pub-id-type="doi">10.1016/j.mce.2010.10.005</pub-id><pub-id pub-id-type="pmid">20943205</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J.T.</given-names></name></person-group><article-title>Antihyperglycemic effect of andrographolide in streptozotocin-induced diabetic rats</article-title><source>Planta Med.</source><volume>69</volume><year>2003</year><fpage>1075</fpage><lpage>1079</lpage><pub-id pub-id-type="pmid">14750020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-2003-45185</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Thakur</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhapola</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sarma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Medhi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>D.H.K.</given-names></name></person-group><article-title>Neuroinflammation in Alzheimer&#8217;s disease: current progress in molecular signaling and therapeutics</article-title><source>Inflammation</source><year>2023</year><pub-id pub-id-type="doi">10.1007/s10753-022-01721-1</pub-id><pub-id pub-id-type="pmid">35986874</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Moderating effect of insulin resistance on the relationship between gray matter volumes and cognitive function</article-title><source>J. Clin. Med.</source><year>2018</year><pub-id pub-id-type="doi">10.3390/jcm7110413</pub-id><pub-id pub-id-type="pmcid">PMC6262494</pub-id><pub-id pub-id-type="pmid">30400348</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Banks</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Owen</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Erickson</surname><given-names>M.A.</given-names></name></person-group><article-title>Insulin in the brain: there and back again</article-title><source>Pharmacol. Ther.</source><year>2012</year><pub-id pub-id-type="doi">10.1016/j.pharmthera.2012.07.006</pub-id><pub-id pub-id-type="pmcid">PMC4134675</pub-id><pub-id pub-id-type="pmid">22820012</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Hierro-Bujalance</surname><given-names>C.</given-names></name><name name-style="western"><surname>del Marco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jos&#233; Ramos-Rodr&#237;guez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Infante-Garcia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bella Gomez-Santos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Herrera</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Cell proliferation and neurogenesis alterations in Alzheimer&#8217;s disease and diabetes mellitus mixed murine models</article-title><source>J. Neurochem.</source><volume>154</volume><year>2020</year><fpage>673</fpage><lpage>692</lpage><pub-id pub-id-type="pmid">32068886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.14987</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>Imamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yanagihara</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Ohyagi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Iinuma</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Yamasaki</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Insulin deficiency promotes formation of toxic amyloid-&#946;42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer&#8217;s disease model</article-title><source>Neurobiol. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.nbd.2020.104739</pub-id><pub-id pub-id-type="pmid">31927145</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Soto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Konishi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>C.R.</given-names></name></person-group><article-title>Insulin signaling in the hippocampus and amygdala regulates metabolism and neurobehavior</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>116</volume><year>2019</year><fpage>6379</fpage><lpage>6384</lpage><pub-id pub-id-type="pmid">30765523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1817391116</pub-id><pub-id pub-id-type="pmcid">PMC6442573</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>S.</given-names></name></person-group><article-title>Decoding insulin resistance and metabolic syndrome for promising therapeutic intervention</article-title><source>J. Endocrinol.</source><year>2014</year><pub-id pub-id-type="doi">10.1530/JOE-13-0584</pub-id><pub-id pub-id-type="pmcid">PMC4068335</pub-id><pub-id pub-id-type="pmid">24431466</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Saltiel</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>C.R.</given-names></name></person-group><article-title>Insulin signalling and the regulation of glucose and lipid metabolism</article-title><source>Nature</source><volume>414</volume><year>2001</year><fpage>799</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">11742412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/414799a</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Osorio-Fuentealba</surname><given-names>C.</given-names></name><name name-style="western"><surname>Contreras-Ferrat</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Altamirano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Espinosa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Electrical stimuli release ATP to increase GLUT4 translocation and glucose uptake via PI3K&#947;-Akt-AS160 in skeletal muscle cells</article-title><source>Diabetes</source><volume>62</volume><year>2013</year><fpage>1519</fpage><lpage>1526</lpage><pub-id pub-id-type="pmid">23274898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db12-1066</pub-id><pub-id pub-id-type="pmcid">PMC3636621</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Ramachandran</surname><given-names>V.</given-names></name><name name-style="western"><surname>Saravanan</surname><given-names>R.</given-names></name></person-group><article-title>Glucose uptake through translocation and activation of GLUT4 in PI3K/Akt signaling pathway by asiatic acid in diabetic rats</article-title><source>Hum. Exp. Toxicol.</source><volume>34</volume><year>2015</year><fpage>884</fpage><lpage>893</lpage><pub-id pub-id-type="pmid">26286522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0960327114561663</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Osqueei</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Mahmoudabadi</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>Bahari</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Meftahi</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Movahedi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Taghipour</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Eryngium billardieri extract affects cardiac gene expression of master regulators of cardiomyaopathy in rats with high fatdiet-induced insulin resistance</article-title><source>Clin. Nutr. ESPEN</source><volume>56</volume><year>2023</year><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">37344084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clnesp.2023.04.016</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Sani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Khatab</surname><given-names>N.I.O.</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Yong</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Basri</surname><given-names>H.</given-names></name><etal/></person-group><article-title>A standardised Andrographis paniculata Burm. Nees aqueous extract prevents Lipopolysaccharide-induced cognitive deficits through suppression of inflammatory cytokines and oxidative stress mediators</article-title><source>J. Adv. Res.</source><volume>16</volume><year>2019</year><fpage>87</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">30899592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jare.2018.11.005</pub-id><pub-id pub-id-type="pmcid">PMC6412812</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q.L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name></person-group><article-title>Neuroprotective effects of andrographolide derivative CX-10 in transient focal ischemia in rat: involvement of Nrf2/AE and TLR/NF-&#954;B signaling</article-title><source>Pharmacol. Res.</source><volume>144</volume><year>2019</year><fpage>227</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">31028905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2019.04.023</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>Hotamisligil</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Shargill</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Spiegelman</surname><given-names>B.M.</given-names></name></person-group><article-title>Adipose expression of tumor necrosis factor-&#945;: Direct role in obesity-linked insulin resistance</article-title><source>Science</source><volume>259</volume><year>1993</year><fpage>87</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">7678183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.7678183</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Rivera</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Lindsay</surname><given-names>C.</given-names></name><name name-style="western"><surname>Codocedo</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Morel</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cisternas</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Andrographolide recovers cognitive impairment in a natural model of Alzheimer&#8217;s disease (Octodon degus)</article-title><source>Neurobiol. Aging</source><volume>46</volume><year>2016</year><fpage>204</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">27505720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2016.06.021</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Arredondo</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Herrera-Soto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mardones</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Varela-Nallar</surname><given-names>L.</given-names></name></person-group><article-title>Andrographolide promotes hippocampal neurogenesis and spatial memory in the APPswe/PS1&#916;E9 mouse model of Alzheimer&#8217;s disease</article-title><source>Sci. Rep.</source><year>2021</year><pub-id pub-id-type="doi">10.1038/s41598-021-01977-x</pub-id><pub-id pub-id-type="pmcid">PMC8616902</pub-id><pub-id pub-id-type="pmid">34824314</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Cisternas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gherardelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mendez-Orellana</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.W.</given-names></name><etal/></person-group><article-title>Adiponectin and resistin modulate the progression of Alzheimer's disease in a metabolic syndrome model</article-title><source>Front Endocrinol (Lausanne)</source><volume>14</volume><year>2023</year><object-id pub-id-type="publisher-id">1237796</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2023.1237796</pub-id><pub-id pub-id-type="pmcid">PMC10507329</pub-id><pub-id pub-id-type="pmid">37732123</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Tapia-Rojas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sch&#252;ller</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lindsay</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Ureta</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Mejias-reyes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hancke</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3&#946;: autoregulation of GSK-3&#946; in vivo</article-title><source>Biochem. J.</source><volume>466</volume><year>2015</year><fpage>415</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">25423492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BJ20140207</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>Serrano</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Tapia-Rojas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carvajal</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Hancke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cerpa</surname><given-names>W.</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>N.C.</given-names></name></person-group><article-title>Andrographolide reduces cognitive impairment in young and mature A&#946;PPswe/PS-1 mice</article-title><source>Mol. Neurodegener.</source><year>2014</year><pub-id pub-id-type="doi">10.1186/1750-1326-9-61</pub-id><pub-id pub-id-type="pmcid">PMC4414355</pub-id><pub-id pub-id-type="pmid">25524173</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Ju</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Andrographolide exerts a neuroprotective effect by regulating the LRP1-mediated PPAR&#947;/NF-&#954;B pathway</article-title><source>Eur. J. Pharmacol.</source><year>2023</year><pub-id pub-id-type="doi">10.1016/j.ejphar.2023.175756</pub-id><pub-id pub-id-type="pmid">37179044</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Ahn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Schleh</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Varshney</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ludzki</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Gillen</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>Exercise training remodels subcutaneous adipose tissue in adults with obesity even without weight loss</article-title><source>J. Physiol.</source><volume>600</volume><year>2022</year><fpage>2127</fpage><lpage>2146</lpage><pub-id pub-id-type="pmid">35249225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1113/JP282371</pub-id><pub-id pub-id-type="pmcid">PMC9058215</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Tapia-rojas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lindsay</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Ureta</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Hancke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3 &#946; : autoregulation of GSK-3 &#946; in vivo</article-title><source>Biochem. J.</source><volume>430</volume><year>2015</year><fpage>415</fpage><lpage>430</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BJ20140207</pub-id><pub-id pub-id-type="pmid">25423492</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Radde</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bolmont</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kaeser</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Coomaraswamy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lindau</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stoltze</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Abeta42-driven cerebral amyloidosis in transgenic</article-title><source>EMBO Rep.</source><volume>7</volume><year>2006</year><fpage>940</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">16906128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.embor.7400784</pub-id><pub-id pub-id-type="pmcid">PMC1559665</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Maia</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Kaeser</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Reichwald</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hruscha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martus</surname><given-names>P.</given-names></name><name name-style="western"><surname>Staufenbiel</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Changes in amyloid-&#946; and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein</article-title><source>Sci. Transl. Med.</source><year>2013</year><pub-id pub-id-type="doi">10.1126/scitranslmed.3006446</pub-id><pub-id pub-id-type="pmid">23863834</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Lindsay</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Zolezzi</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Cisternas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bozinovic</surname><given-names>F.</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>N.C.</given-names></name></person-group><article-title>Andrographolide reduces neuroinflammation and oxidative stress in aged Octodon degus</article-title><source>Mol. Neurobiol.</source><volume>57</volume><year>2020</year><fpage>1131</fpage><lpage>1145</lpage><pub-id pub-id-type="pmid">31701436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-019-01784-6</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Malo</surname><given-names>M.S.</given-names></name></person-group><article-title>A high level of intestinal alkaline phosphatase is protective against type 2 diabetes mellitus irrespective of obesity</article-title><source>EBioMedicine</source><volume>2</volume><year>2015</year><fpage>2016</fpage><lpage>2023</lpage><pub-id pub-id-type="pmid">26844282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2015.11.027</pub-id><pub-id pub-id-type="pmcid">PMC4703762</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Lentjes</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Harff</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Backer</surname><given-names>E.T.</given-names></name></person-group><article-title>Evaluation of the Hitachi 704 automatic analyzer</article-title><source>Clin. Chem.</source><volume>33</volume><year>1987</year><fpage>2089</fpage><lpage>2092</lpage><pub-id pub-id-type="pmid">3677384</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>Salazar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cisternas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Codocedo</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>N.C.</given-names></name></person-group><article-title>Induction of hypothyroidism during early postnatal stages triggers a decrease in cognitive performance by decreasing hippocampal synaptic plasticity</article-title><source>Biochim. Biophys. Acta Mol. Basis Dis.</source><volume>1863</volume><year>2017</year><fpage>870</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">28088629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2017.01.002</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name></person-group><article-title>Purification and kinetic characterization of 6-phosphogluconate dehydrogenase from Schizosaccharomyces pombe</article-title><source>Biochem. Cell Biol.</source><volume>76</volume><year>1998</year><fpage>107</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">10099784</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Thurley</surname><given-names>K.</given-names></name><name name-style="western"><surname>Herbst</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wesener</surname><given-names>F.</given-names></name><name name-style="western"><surname>Koller</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wallach</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Principles for circadian orchestration of metabolic pathways</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2017</year><pub-id pub-id-type="doi">10.1073/pnas.1613103114</pub-id><pub-id pub-id-type="pmcid">PMC5321018</pub-id><pub-id pub-id-type="pmid">28159888</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Das Gupta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shakespear</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Curson</surname><given-names>J.E.B.</given-names></name><name name-style="western"><surname>Murthy</surname><given-names>A.M.V.</given-names></name><name name-style="western"><surname>Iyer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hodson</surname><given-names>M.P.</given-names></name><etal/></person-group><article-title>Class IIa histone deacetylases drive toll-like receptor-inducible glycolysis and macrophage inflammatory responses via pyruvate kinase M2</article-title><source>Cell Rep.</source><volume>30</volume><year>2020</year><fpage>2712</fpage><lpage>2728.e8</lpage><pub-id pub-id-type="pmid">32101747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2020.02.007</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>J.</given-names></name><etal/></person-group><article-title>TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism</article-title><source>Nat. Commun.</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41467-020-15819-3</pub-id><pub-id pub-id-type="pmcid">PMC7170963</pub-id><pub-id pub-id-type="pmid">32312982</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name name-style="western"><surname>Martinez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>V.I.</given-names></name><name name-style="western"><surname>Vio</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Inestrosa</surname><given-names>N.C.</given-names></name></person-group><article-title>Canonical Wnt signaling modulates the expression of pre- and postsynaptic components in different temporal patterns</article-title><source>Mol. Neurobiol.</source><volume>57</volume><year>2020</year><fpage>1389</fpage><lpage>1404</lpage><pub-id pub-id-type="pmid">31745835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-019-01785-5</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supporting information</title><p id="p0220">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Table S1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ack0010"><sec id="sec6"><title>Author contributions</title><p id="p0210">P. O., C. G., R. C-D., P. C., and E. S. writing&#8211;original draft; P. O., N. C. I., and P. C. visualization; P. O., C. G., R. C-D., P. C., and C. M. O. methodology; P. O., C. G., R. C-D., and C. M. O. investigation; P. O., R. C-D., N. C. I., E. S., and C. M. O. funding acquisition; P. O., C. G., R. C-D., and C. P. data curation; C. G., P. C., and G. W. W. validation; C. G., P. C., C. P., C. M. O., and G. W. W. formal analysis; C. G. and P. C. conceptualization; N. C. I. writing&#8211;review &amp; editing; N. C. I., P. C. supervision.</p></sec><sec id="sec7"><title>Funding and additional information</title><p id="p0215">This work was supported by grants from the <funding-source id="gs14">Basal Center of Excellence in Aging and Regeneration</funding-source> (CONICYT-AFB 170005) and &#8220;BIP: 40042452-0 Gobierno Regional de Magallanes y Ant&#225;rtica Chilena-UMAG&#8221; to NI. We also thank the Sociedad Q&#250;&#305;mica y Minera de Chile (SQM) for the special grants &#8220;<funding-source id="gs7">The Role of K+ on Hypertension and Cognition</funding-source>&#8221;, &#8220;<funding-source id="gs9">The Role of Lithium in Human Health and Disease</funding-source>&#8221; to NI, and &#8220;<funding-source id="gs10">Fondo interdisciplina del departamento Ciencias de la salud, P. Universidad Cat&#243;lica de Chile</funding-source>" to CMO, <funding-source id="gs11"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004408</institution-id><institution>Centro Interuniversitario de Envejecimiento Saludable</institution></institution-wrap></funding-source> (CIES), Proyecto CIES 007 to PO, <funding-source id="gs12">FONDECYT Postdoctoral Fellowship</funding-source>
<award-id award-type="grant" rid="gs12">3240187</award-id> to ES and <funding-source id="gs13">FONDECYT Iniciaci&#243;n</funding-source>
<award-id award-type="grant" rid="gs13">11230668</award-id> to RC-D.</p></sec></ack></back></article></pmc-articleset>